PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Peelen, DM; Hoogduijn, MJ; Hesselink, DA; Baan, CC				Peelen, Daphne M.; Hoogduijn, Martin J.; Hesselink, Dennis A.; Baan, Carla C.			Advanced in vitro Research Models to Study the Role of Endothelial Cells in Solid Organ Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						solid organ transplantation; allograft rejection; endothelial cells; organoids; 3D in vitro models; organ-on-a-chip	PLURIPOTENT STEM-CELLS; REGULATORY T-CELLS; ON-A-CHIP; FUNCTIONAL HUMAN LIVER; BLOOD-BRAIN-BARRIER; VASCULAR ENDOTHELIUM; ALLOGRAFT-REJECTION; KIDNEY ORGANOIDS; RENAL-TRANSPLANTATION; LYMPHOCYTE MIGRATION	The endothelium plays a key role in acute and chronic rejection of solid organ transplants. During both processes the endothelium is damaged often with major consequences for organ function. Also, endothelial cells (EC) have antigen-presenting properties and can in this manner initiate and enhance alloreactive immune responses. For decades, knowledge about these roles of EC have been obtained by studying both in vitro and in vivo models. These experimental models poorly imitate the immune response in patients and might explain why the discovery and development of agents that control EC responses is hampered. In recent years, various innovative human 3D in vitro models mimicking in vivo organ structure and function have been developed. These models will extend the knowledge about the diverse roles of EC in allograft rejection and will hopefully lead to discoveries of new targets that are involved in the interactions between the donor organ EC and the recipient's immune system. Moreover, these models can be used to gain a better insight in the mode of action of the currently prescribed immunosuppression and will enhance the development of novel therapeutics aiming to reduce allograft rejection and prolong graft survival.	[Peelen, Daphne M.; Hoogduijn, Martin J.; Hesselink, Dennis A.; Baan, Carla C.] Erasmus Univ, Rotterdam Transplant Grp, Dept Internal Med Nephrol & Transplantat, Med Ctr,Erasmus MC, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Peelen, DM (corresponding author), Erasmus Univ, Rotterdam Transplant Grp, Dept Internal Med Nephrol & Transplantat, Med Ctr,Erasmus MC, Rotterdam, Netherlands.	d.peelen@erasmusmc.nl		Hullegie-Peelen, Daphne/0000-0003-4489-8417; Baan, Carla/0000-0003-2274-2788				Abdelgawad M, 2011, LAB CHIP, V11, P545, DOI 10.1039/c01c00093k; Abrahimi P, 2015, AM J TRANSPLANT, V15, P1748, DOI 10.1111/ajt.13242; Al-Lamki RS, 2008, TRANSPLANTATION, V86, P1340, DOI 10.1097/TP.0b013e3181891d8b; Baan C, 2003, TRANSPLANTATION, V75, P570, DOI 10.1097/01.TP.0000034241.55602.AD; Baudin B, 2007, NAT PROTOC, V2, P481, DOI 10.1038/nprot.2007.54; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Biedermann BC, 1998, J IMMUNOL, V161, P4679; Blaheta RA, 2000, TRANSPLANTATION, V69, P588, DOI 10.1097/00007890-200002270-00021; Blaheta RA, 1998, TRANSPL IMMUNOL, V6, P251, DOI 10.1016/S0966-3274(98)80015-4; Boos CJ, 2006, J AM COLL CARDIOL, V48, P1538, DOI 10.1016/j.jacc.2006.02.078; Brehm MA, 2012, CELL MOL IMMUNOL, V9, P225, DOI 10.1038/cmi.2011.64; Brennan MD, 2014, LAB CHIP, V14, P4305, DOI 10.1039/c4lc00853g; Bruneau S, 2016, PEDIATR NEPHROL, V31, P41, DOI 10.1007/s00467-015-3094-6; Caballero D, 2017, LAB CHIP, V17, P3760, DOI 10.1039/c7lc00574a; Campisi M, 2018, BIOMATERIALS, V180, P117, DOI 10.1016/j.biomaterials.2018.07.014; Canet E, 2012, TRANSPLANTATION, V93, P257, DOI 10.1097/TP.0b013e31823ec0ec; Cao X, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807173; Capla JM, 2006, PLAST RECONSTR SURG, V117, P836, DOI 10.1097/01.prs.0000201459.91559.7f; Cardinal H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01130; Chau L, 2009, LAB CHIP, V9, P1897, DOI 10.1039/b823180j; Chen CC, 2018, J CLIN INVEST, V128, P219, DOI 10.1172/JCI93542; Chen LJ, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11010079; Chen WJ, 2016, ATHEROSCLEROSIS, V244, P108, DOI 10.1016/j.atherosclerosis.2015.11.002; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; Chien S, 2008, ANN BIOMED ENG, V36, P554, DOI 10.1007/s10439-007-9426-3; Choi J, 2004, ANNU REV IMMUNOL, V22, P683, DOI 10.1146/annurev.immunol.22.012703.104639; Chong AS, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015495; Choo JK, 1997, TRANSPLANTATION, V64, P1315, DOI 10.1097/00007890-199711150-00014; Cinamon G, 2001, J LEUKOCYTE BIOL, V69, P860; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Collins AB, 1999, J AM SOC NEPHROL, V10, P2208; Combes AN, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0615-0; Conant CG, 2010, J BIOMOL SCREEN, V15, P102, DOI 10.1177/1087057109353789; Cross AR, 2019, KIDNEY INT, V96, P689, DOI 10.1016/j.kint.2019.04.023; Cross AR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00106; Dehoux JP, 2007, FRONT BIOSCI-LANDMRK, V12, P4864, DOI 10.2741/2434; Delville M, 2019, J AM SOC NEPHROL, V30, P692, DOI 10.1681/ASN.2018080868; Dengler TJ, 2000, J IMMUNOL, V164, P5146, DOI 10.4049/jimmunol.164.10.5146; Denton M D, 2000, Pediatr Transplant, V4, P252, DOI 10.1034/j.1399-3046.2000.00031.x; Denton MD, 1999, J EXP MED, V190, P555, DOI 10.1084/jem.190.4.555; Dragovich MA, 2017, CELL MOL BIOENG, V10, P102, DOI 10.1007/s12195-016-0463-6; Dragun D, 2004, KIDNEY INT, V65, P1076, DOI 10.1111/j.1523-1755.2004.00478.x; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; Farinacci M, 2019, RES PRACT THROMB HAE, V3, P49, DOI 10.1002/rth2.12158; Feletou M, 2011, ENDOTHELIUM-J ENDOTH, DOI DOI 10.4199/C00031ED1V01Y201105ISP019; Franco C, 2012, NATURE, V488, P465, DOI 10.1038/488465a; Fukami N, 2012, TRANSPLANTATION, V93, P364, DOI 10.1097/TP.0b013e3182406a6b; Gaskill C, 2017, PULM CIRC, V7, P108, DOI 10.1177/2045893217702346; Gosselin EA, 2018, NAT MATER, V17, P484, DOI 10.1038/s41563-018-0077-6; Haase K, 2019, ADV SCI, V6, DOI 10.1002/advs.201900878; Hamano K, 1998, EUR SURG RES, V30, P235, DOI 10.1159/000008582; Haramati J, 2007, TRANSPLANTATION, V84, P1364, DOI 10.1097/01.tp.0000289994.13139.f4; Harding A, 2017, STEM CELLS, V35, P909, DOI 10.1002/stem.2577; He SL, 2010, ARTERIOSCL THROM VAS, V30, P2621, DOI 10.1161/ATVBAHA.110.210492; Hogenes M, 2014, TRANSPLANT REV-ORLAN, V28, P103, DOI 10.1016/j.trre.2014.02.002; Homan KA, 2019, NAT METHODS, V16, P255, DOI 10.1038/s41592-019-0325-y; Hu C, 2019, ANALYST, V144, P4461, DOI 10.1039/c9an00421a; HUANG EH, 1994, TRANSPLANTATION, V58, P1216, DOI 10.1097/00007890-199412150-00014; Huang YF, 2005, INT IMMUNOPHARMACOL, V5, P1029, DOI 10.1016/j.intimp.2005.01.015; Huebert RC, 2010, LAB INVEST, V90, P1770, DOI 10.1038/labinvest.2010.132; Jahan B, 2020, STEM CELL RES, V42, DOI 10.1016/j.scr.2019.101685; Jane-wit D, 2013, CIRCULATION, V128, P2504, DOI 10.1161/CIRCULATIONAHA.113.002972; Jassem W, 2003, TRANSPLANTATION, V75, P2001, DOI 10.1097/01.TP.0000061605.30685.03; JEANNET M, 1970, NEW ENGL J MED, V282, P111, DOI 10.1056/NEJM197001152820301; Jourde-Chiche N, 2019, NAT REV NEPHROL, V15, P87, DOI 10.1038/s41581-018-0098-z; Kapessidou Y, 2006, TRANSPLANTATION, V82, P582, DOI 10.1097/01.tp.0000184444.93108.d1; Kariya T, 2016, J GASTROENTEROL, V51, P985, DOI 10.1007/s00535-016-1169-1; Kim J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133880; KINJO T, 1989, CELL TISSUE RES, V256, P27; Kirkiles-Smith NC, 2009, TRANSPLANTATION, V87, P189, DOI 10.1097/TP.0b013e318192e05d; Klingenberg R, 2005, EUR J IMMUNOL, V35, P1712, DOI 10.1002/eji.200425727; Kloc M, 2015, TRANSPLANTATION, V99, P658, DOI 10.1097/TP.0000000000000648; Koenig A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13113-5; Koning M, 2020, CELL MOL LIFE SCI, V77, P2257, DOI 10.1007/s00018-019-03401-0; Koo DDH, 1999, KIDNEY INT, V56, P1551, DOI 10.1046/j.1523-1755.1999.00657.x; Koopmans M, 2006, TRANSPLANTATION, V82, pS25, DOI 10.1097/01.tp.0000231446.41051.98; Kreisel D, 2002, NAT MED, V8, P233, DOI 10.1038/nm0302-233; Kreisel D, 2002, J IMMUNOL, V169, P6154, DOI 10.4049/jimmunol.169.11.6154; Krupnick AS, 2002, TRANSPLANTATION, V74, P871, DOI 10.1097/00007890-200209270-00022; Kuncova-Kallio J., 2006, ENG MED BIOL SOC 200, P2486, DOI DOI 10.1109/IEMBS.2006.260465; Kunitomi A, 2000, J LEUKOCYTE BIOL, V68, P111; Lagaaij EL, 2001, LANCET, V357, P33, DOI 10.1016/S0140-6736(00)03569-8; Lahdou I, 2014, INVEST OPHTH VIS SCI, V55, P1213, DOI 10.1167/iovs.13-11930; LAMBERT PB, 1971, NATURE, V232, P279, DOI 10.1038/232279a0; Lee E, 2018, J MATER CHEM B, V6, P1085, DOI 10.1039/c7tb03239k; Lee MO, 2013, P NATL ACAD SCI USA, V110, pE3281, DOI 10.1073/pnas.1303669110; Li YSJ, 2005, J BIOMECH, V38, P1949, DOI 10.1016/j.jbiomech.2004.09.030; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; Lim WC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00565; Lin NYC, 2019, P NATL ACAD SCI USA, V116, P5399, DOI 10.1073/pnas.1815208116; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lion J, 2016, AM J TRANSPLANT, V16, P1408, DOI 10.1111/ajt.13644; Lion J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01761; Lorber MI, 1999, TRANSPLANTATION, V67, P897, DOI 10.1097/00007890-199903270-00018; Luo CY, 2016, CELL REP, V17, P3369, DOI 10.1016/j.celrep.2016.12.001; Manavalan JS, 2004, INT IMMUNOL, V16, P1055, DOI 10.1093/intimm/dxh107; Martignoni M, 2006, EXPERT OPIN DRUG MET, V2, P875, DOI 10.1517/17425255.2.6.875; Mathur T, 2019, LAB CHIP, V19, P2500, DOI 10.1039/c9lc00469f; McDonald AI, 2018, CELL STEM CELL, V23, P210, DOI 10.1016/j.stem.2018.07.011; Mcginn S, 2004, NEPHROLOGY, V9, P229, DOI 10.1111/j.1440-1797.2004.00254.x; McGuigan AP, 2006, P NATL ACAD SCI USA, V103, P11461, DOI 10.1073/pnas.0602740103; Medina-Leyte DJ, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10030938; Miller PG, 2016, BIOTECHNOL BIOENG, V113, P2213, DOI 10.1002/bit.25989; Miri AK, 2019, BIOFABRICATION, V11, DOI 10.1088/1758-5090/ab2798; MORDENTI J, 1986, J PHARM SCI, V75, P852, DOI 10.1002/jps.2600750906; Muczynski KA, 2003, J AM SOC NEPHROL, V14, P1336, DOI 10.1097/01.ASN.0000061778.08085.9F; Muller WA, 2014, AM J PATHOL, V184, P886, DOI 10.1016/j.ajpath.2013.12.033; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; MURRAY AG, 1994, P NATL ACAD SCI USA, V91, P9146, DOI 10.1073/pnas.91.19.9146; Murray AG, 1998, AM J PATHOL, V153, P627, DOI 10.1016/S0002-9440(10)65604-0; Musah S, 2018, NAT PROTOC, V13, P1662, DOI 10.1038/s41596-018-0007-8; Nankivell BJ, 2010, NEW ENGL J MED, V363, P1451, DOI 10.1056/NEJMra0902927; Nolan DJ, 2013, DEV CELL, V26, P204, DOI 10.1016/j.devcel.2013.06.017; Novak R, 2020, NAT BIOMED ENG, DOI 10.1038/s41551-019-0497-x; Olejarz W, 2014, EUR J CLIN INVEST, V44, P54, DOI 10.1111/eci.12191; Ostrowski MA, 2014, BIOPHYS J, V106, P366, DOI 10.1016/j.bpj.2013.11.4502; Page C, 1994, Transpl Immunol, V2, P342, DOI 10.1016/0966-3274(94)90013-2; PAGE C, 1992, AM J PATHOL, V141, P673; Park D, 2020, TRENDS BIOTECHNOL, V38, P99, DOI 10.1016/j.tibtech.2019.06.006; Park SE, 2019, SCIENCE, V364, P960, DOI 10.1126/science.aaw7894; Peck RW, 2020, CLIN PHARMACOL THER, V107, P181, DOI 10.1002/cpt.1688; Pettinato G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45514-3; Pham MT, 2018, NEUROREPORT, V29, P588, DOI 10.1097/WNR.0000000000001014; Phipson B, 2019, NAT METHODS, V16, P79, DOI 10.1038/s41592-018-0253-2; Pons JA, 2003, TRANSPLANTATION, V75, P1045, DOI 10.1097/01.TP.0000058472.71775.7D; Prasain N, 2014, NAT BIOTECHNOL, V32, P1151, DOI 10.1038/nbt.3048; Price GM, 2010, BIOMATERIALS, V31, P6182, DOI 10.1016/j.biomaterials.2010.04.041; Quadrato G, 2017, NATURE, V545, P48, DOI 10.1038/nature22047; Racape M, 2017, HUM IMMUNOL, V78, P4, DOI 10.1016/j.humimm.2017.06.010; Rahman NA, 2016, BRAIN RES, V1642, P532, DOI 10.1016/j.brainres.2016.04.024; Ricotta D, 2001, CARDIOVASC RES, V49, P440, DOI 10.1016/S0008-6363(00)00258-3; Ronaldson-Bouchard K, 2018, CELL STEM CELL, V22, P310, DOI 10.1016/j.stem.2018.02.011; Rossi G, 2018, NAT REV GENET, V19, P671, DOI 10.1038/s41576-018-0051-9; Roth SJ, 1995, J IMMUNOL METHODS, V188, P97, DOI 10.1016/0022-1759(95)00208-1; Rothermel Annette L., 2004, BMC Immunology, V5, P1; Salvadori Maurizio, 2015, World J Transplant, V5, P52, DOI 10.5500/wjt.v5.i2.52; Satchell SC, 2006, KIDNEY INT, V69, P1633, DOI 10.1038/sj.ki.5000277; SAVAGE COS, 1993, TRANSPLANTATION, V56, P128, DOI 10.1097/00007890-199307000-00024; Schneeberger K, 2017, BIOFABRICATION, V9, DOI 10.1088/1758-5090/aa6121; Schoneberg J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28715-0; Sfriso R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24273-7; Shankar AS, 2019, TRANSPLANTATION, V103, P250, DOI 10.1097/TP.0000000000002547; Shiao SL, 2005, J IMMUNOL, V175, P4886, DOI 10.4049/jimmunol.175.8.4886; Skylar-Scott MA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2459; Soloyan H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67588-0; Springer MS, 2007, BIOL REV, V82, P375, DOI 10.1111/j.1469-185X.2007.00016.x; Strauss O, 2017, SCI REP-UK, V7, DOI 10.1038/srep44356; Suarez Y, 2007, J IMMUNOL, V179, P7488, DOI 10.4049/jimmunol.179.11.7488; Subramanian A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13382-0; Suzuki M, 2010, RHEUMATOL INT, V30, P309, DOI 10.1007/s00296-009-0953-0; Swearengen JR, 2018, ANIM MODEL EXP MED, V1, P100, DOI 10.1002/ame2.12020; Taflin C, 2011, IMMUNOL LETT, V139, P1, DOI 10.1016/j.imlet.2011.04.014; Taflin C, 2011, P NATL ACAD SCI USA, V108, P2891, DOI 10.1073/pnas.1011811108; Takasato M, 2015, NATURE, V526, P564, DOI 10.1038/nature15695; Takebe T, 2014, NAT PROTOC, V9, P396, DOI 10.1038/nprot.2014.020; Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271; Tan PH, 2004, ATHEROSCLEROSIS, V173, P171, DOI 10.1016/j.atherosclerosis.2003.12.011; Tanaka Y, 2005, LIVER TRANSPLANT, V11, P547, DOI 10.1002/lt.20415; Tang MLK, 1997, J IMMUNOL, V158, P5191; Tovar-Lopez F, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00081; Tsai M, 2012, J CLIN INVEST, V122, P408, DOI 10.1172/JCI58753; Valenzuela NM, 2017, TRANSPLANTATION, V101, P1559, DOI 10.1097/TP.0000000000001486; Valujskikh A, 2003, CURR OPIN IMMUNOL, V15, P493, DOI 10.1016/S0952-7915(03)00110-9; Valujskikh A, 2002, NAT IMMUNOL, V3, P844, DOI 10.1038/ni831; van den Berg CW, 2018, STEM CELL REP, V10, P751, DOI 10.1016/j.stemcr.2018.01.041; van Meer BJ, 2017, BIOCHEM BIOPH RES CO, V482, P323, DOI 10.1016/j.bbrc.2016.11.062; van Poelgeest EP, 2005, KIDNEY INT, V68, P847, DOI 10.1111/j.1523-1755.2005.00466.x; Vanhoutte PM, 2010, CARDIOVASC DRUG THER, V24, P299, DOI 10.1007/s10557-010-6257-5; Vedula EM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184330; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908; von Rossum A, 2016, TRANSPLANTATION, V100, P2332, DOI 10.1097/TP.0000000000001227; Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Werner I, 2014, TRANSPL P, V46, P2953, DOI 10.1016/j.transproceed.2014.06.055; Westhofen S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214513; Wu QR, 2020, BIOMED ENG ONLINE, V19, DOI 10.1186/s12938-020-0752-0; Xu W, 2002, TRANSPLANTATION, V74, P1316, DOI 10.1097/00007890-200211150-00020; Yilmaz O, 2019, CLIN KIDNEY J, V12, P611, DOI 10.1093/ckj/sfz042; Yoder MC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006692; Yoder MC, 2015, CURR OPIN HEMATOL, V22, P252, DOI 10.1097/MOH.0000000000000140; Yoshida N, 1997, LIFE SCI, V60, P2341, DOI 10.1016/S0024-3205(97)00290-7; Yu F, 2019, MICROMACHINES-BASEL, V10, DOI 10.3390/mi10030165; Zheng Y, 2012, P NATL ACAD SCI USA, V109, P9342, DOI 10.1073/pnas.1201240109; Zhou MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep31771	184	1	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2021	12								607953	10.3389/fimmu.2021.607953	http://dx.doi.org/10.3389/fimmu.2021.607953			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QP7WO	33664744	Green Published, gold			2022-12-18	WOS:000624043300001
J	Sala, E; Vived, C; Luna, J; Saavedra-Avila, NA; Sengupta, U; Castano, AR; Villar-Pazos, S; Haba, L; Verdaguer, J; Ropero, AB; Stratmann, T; Pizarro, J; Vazquez-Carrera, M; Nadal, A; Lahti, JM; Mora, C				Sala, Ester; Vived, Celia; Luna, Julia; Saavedra-Avila, Noemi Alejandra; Sengupta, Upasana; Castano, A. Raul; Villar-Pazos, Sabrina; Haba, Laura; Verdaguer, Joan; Ropero, Ana B.; Stratmann, Thomas; Pizarro, Javier; Vazquez-Carrera, Manuel; Nadal, Angel; Lahti, Jill M.; Mora, Conchi			CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						apoptosis; beta cell; CDK11; cyclin D3; inflammation; type 1 diabetes; glucose; insulin		Background Pancreatic islets are exposed to strong pro-apoptotic stimuli: inflammation and hyperglycemia, during the progression of the autoimmune diabetes (T1D). We found that the Cdk11(Cyclin Dependent Kinase 11) is downregulated by inflammation in the T1D prone NOD (non-obese diabetic) mouse model. The aim of this study is to determine the role of CDK11 in the pathogenesis of T1D and to assess the hierarchical relationship between CDK11 and Cyclin D3 in beta cell viability, since Cyclin D3, a natural ligand for CDK11, promotes beta cell viability and fitness in front of glucose. Methods We studied T1D pathogenesis in NOD mice hemideficient for CDK11 (N-HTZ), and, in N-HTZ deficient for Cyclin D3 (K11HTZ-D3KO), in comparison to their respective controls (N-WT and K11WT-D3KO). Moreover, we exposed pancreatic islets to either pro-inflammatory cytokines in the presence of increasing glucose concentrations, or Thapsigargin, an Endoplasmic Reticulum (ER)-stress inducing agent, and assessed apoptotic events. The expression of key ER-stress markers (Chop, Atf4 and Bip) was also determined. Results N-HTZ mice were significantly protected against T1D, and NS-HTZ pancreatic islets exhibited an impaired sensitivity to cytokine-induced apoptosis, regardless of glucose concentration. However, thapsigargin-induced apoptosis was not altered. Furthermore, CDK11 hemideficiency did not attenuate the exacerbation of T1D caused by Cyclin D3 deficiency. Conclusions This study is the first to report that CDK11 is repressed in T1D as a protection mechanism against inflammation-induced apoptosis and suggests that CDK11 lies upstream Cyclin D3 signaling. We unveil the CDK11/Cyclin D3 tandem as a new potential intervention target in T1D.	[Sala, Ester; Vived, Celia; Luna, Julia; Saavedra-Avila, Noemi Alejandra; Sengupta, Upasana; Verdaguer, Joan; Mora, Conchi] Univ Lleida, Dept Expt Med, Immunol Unit, Fac Med, Lleida, Spain; [Sala, Ester; Vived, Celia; Luna, Julia; Saavedra-Avila, Noemi Alejandra; Sengupta, Upasana; Verdaguer, Joan; Mora, Conchi] Inst Recerca Biomed Lleida IRBL Leida, Lleida, Spain; [Castano, A. Raul] Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Barcelona, Spain; [Villar-Pazos, Sabrina] Univ Miguel Hernandez, Inst Invest Desarrollo & Innovac Biotecnol Sanit, IDiBE, Elche, Spain; [Villar-Pazos, Sabrina; Lahti, Jill M.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Haba, Laura] Inst Biomed Res August Pi & Sunyer IDIBAPS, Expt Diabet Lab, Barcelona, Spain; [Ropero, Ana B.] Univ Miguel Hernandez, Inst Bioingn, Elche, Spain; [Stratmann, Thomas] Univ Barcelona, Fac Biol, Dept Cell Biol Physiol & Immunol, Barcelona, Spain; [Pizarro, Javier; Vazquez-Carrera, Manuel] Univ Barcelona, Dept Pharmacol Toxicol & Therapeut Chem, Fac Pharm & Food Sci, Barcelona, Spain; [Pizarro, Javier; Vazquez-Carrera, Manuel] Univ Barcelona, Inst Biomed IBUB, Barcelona, Spain; [Vazquez-Carrera, Manuel] Inst Salud Carlos III, Spanish Biomed Res Ctr Diabet & Associated Metab, Madrid, Spain; [Vazquez-Carrera, Manuel] Hosp St Joan de Deu, Pediat Res Inst, Esplugas de Llobregat, Spain; [Nadal, Angel] Univ Miguel Hernandez Elche, Diabet & Associated Metab Disorders CIBERDEM, Elche, Spain	Universitat de Lleida; Autonomous University of Barcelona; Universidad Miguel Hernandez de Elche; St Jude Children's Research Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universidad Miguel Hernandez de Elche; University of Barcelona; University of Barcelona; University of Barcelona; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Universidad Miguel Hernandez de Elche	Mora, C (corresponding author), Univ Lleida, Dept Expt Med, Immunol Unit, Fac Med, Lleida, Spain.; Mora, C (corresponding author), Inst Recerca Biomed Lleida IRBL Leida, Lleida, Spain.	conchi.mora@udl.cat	Mora, Conchi/A-8280-2010; Nadal, Angel/G-6721-2014; Vázquez-Carrera, Manuel/H-2612-2015; B, Ana/AAN-9680-2021; Vived, Celia/K-7646-2017; Castaño, A. Raul/A-5905-2012; ROPERO, ANA B./AAK-8342-2021; Verdaguer Autonell, Joan/A-2059-2010	Mora, Conchi/0000-0002-5644-0537; Nadal, Angel/0000-0003-4178-2152; Vázquez-Carrera, Manuel/0000-0001-7138-8207; Vived, Celia/0000-0002-9522-0860; Castaño, A. Raul/0000-0003-2107-8862; ROPERO, ANA B./0000-0002-6503-7598; Verdaguer Autonell, Joan/0000-0003-1768-9310; Saavedra-Avila, Noemi Alejandra/0000-0003-3064-7254; Stratmann, Thomas/0000-0001-6196-1487	Spanish Ministerio de Economia, Industria y Competitividad Grant [SAF2017-82567-R]; Ministerio de Ciencia y Tecnologia [SAF2008-02536]; Ministerio de Ciencia, Innovacion y Universidades Grant [SAF2014-55077-R, SAF2016-77227-R, SAF2013-45140-R]; 2009 SGR-DGR grant from the Generalitat de Catalunya; University of Lleida [A001E-12132/2009, TR265]; Generalitat Valenciana [PROMETEO/2011/080]; Ministerio de Economia y Competitividad [BFU2011-28358]; University of Lleida; AGAUR predoctoral fellowships from the Generalitat de Catalunya	Spanish Ministerio de Economia, Industria y Competitividad Grant; Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Ministerio de Ciencia, Innovacion y Universidades Grant; 2009 SGR-DGR grant from the Generalitat de Catalunya(Generalitat de Catalunya); University of Lleida; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Ministerio de Economia y Competitividad(Spanish Government); University of Lleida; AGAUR predoctoral fellowships from the Generalitat de Catalunya	This work was supported by the Spanish Ministerio de Economia, Industria y Competitividad Grant SAF2017-82567-R, Ministerio de Ciencia y Tecnologia Grant SAF2008-02536, and, Ministerio de Ciencia, Innovacion y Universidades Grant SAF2014-55077-R (to CM) and SAF2016-77227-R and SAF2013-45140-R (to TS and JV); the 2009 SGR-DGR grant from the Generalitat de Catalunya (to JV and CM) and the TR265 no. A001E-12132/2009 from the University of Lleida (to JV and CM); the Generalitat Valenciana PROMETEO/2011/080 grant; and the Ministerio de Economia y Competitividad BFU2011-28358 grant (to AN). NS-A and CV were recipients of a predoctoral fellowship from the University of Lleida. US, ES, and JL have been granted with AGAUR predoctoral fellowships from the Generalitat de Catalunya. CM and JV are assistant professors of Immunology in the Serra Hunter Program at the University of Lleida and, investigators at the same institution and the Lleida Institute for Biomedical Research Fundacio ' n Pifarre '.	Saavedra-Avila NA, 2014, P NATL ACAD SCI USA, V111, pE3405, DOI 10.1073/pnas.1323236111; Allison J, 2005, J IMMUNOL, V175, P293, DOI 10.4049/jimmunol.175.1.293; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; Chi YY, 2011, J BIOL CHEM, V286, P1748, DOI 10.1074/jbc.M110.107367; Chi YY, 2009, BIOCHEM BIOPH RES CO, V386, P493, DOI 10.1016/j.bbrc.2009.06.061; Cnop M, 2012, TRENDS MOL MED, V18, P59, DOI 10.1016/j.molmed.2011.07.010; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; D'Hertog W, 2007, MOL CELL PROTEOMICS, V6, P2180, DOI 10.1074/mcp.M700085-MCP200; Duan YN, 2010, INFLAMMATION, V33, P189, DOI 10.1007/s10753-009-9173-8; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Feng YM, 2005, BIOCHEM J, V392, P65, DOI 10.1042/BJ20050195; Feng YM, 2004, GENE, V330, P75, DOI 10.1016/j.gene.2004.01.006; Hoorens A, 1999, DIABETOLOGIA, V42, P55, DOI 10.1007/s001250051113; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Hu DL, 2007, J CELL SCI, V120, P2424, DOI 10.1242/jcs.007963; Ji YH, 2008, MOL CELL BIOCHEM, V309, P49, DOI 10.1007/s11010-007-9642-z; Kacheva S, 2011, CYTOKINE, V55, P195, DOI 10.1016/j.cyto.2011.04.002; Kahle A, 2005, GENE, V344, P53, DOI 10.1016/j.gene.2004.10.020; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li LR, 2015, IMMUNOL RES, V62, P198, DOI 10.1007/s12026-015-8651-3; Li TY, 2004, MOL CELL BIOL, V24, P3188, DOI 10.1128/MCB.24.8.3188-3197.2004; Lu J, 2020, FASEB J, V34, P15015, DOI 10.1096/fj.202001218R; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Marhfour I, 2012, DIABETOLOGIA, V55, P2417, DOI 10.1007/s00125-012-2604-3; Marzo N, 2008, J IMMUNOL, V180, P1189, DOI 10.4049/jimmunol.180.2.1189; Meyerovich K, 2016, J MOL ENDOCRINOL, V57, pR1, DOI 10.1530/JME-15-0306; Morita S, 2017, CELL METAB, V25, P883, DOI 10.1016/j.cmet.2017.03.018; O'Brien BA, 2002, DIABETES, V51, P2481, DOI 10.2337/diabetes.51.8.2481; OBrien BA, 1997, DIABETES, V46, P750, DOI 10.2337/diabetes.46.5.750; Oettgen P, 2006, CIRC RES, V99, P1159, DOI 10.1161/01.RES.0000251056.85990.db; Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Sachs NA, 2003, BBA-GEN SUBJECTS, V1624, P98, DOI 10.1016/j.bbagen.2003.10.001; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Shi JQ, 2009, FEBS LETT, V583, P971, DOI 10.1016/j.febslet.2009.02.028; Sreenan S, 1999, DIABETES, V48, P989, DOI 10.2337/diabetes.48.5.989; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; Wagner AM, 2007, DIABETOLOGIA, V50, P676, DOI 10.1007/s00125-006-0556-1; Wang YL, 2009, J BIOCHEM, V145, P331, DOI 10.1093/jb/mvn177; Wilker EW, 2007, NATURE, V446, P329, DOI 10.1038/nature05584; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Yun XJ, 2007, MOL CELL BIOCHEM, V304, P213, DOI 10.1007/s11010-007-9502-x; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	51	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2021	12								634797	10.3389/fimmu.2021.634797	http://dx.doi.org/10.3389/fimmu.2021.634797			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QP9DA	33664748	Green Published, gold			2022-12-18	WOS:000624128000001
J	Foth, S; Volkel, S; Bauersachs, D; Zemlin, M; Skevaki, C				Foth, Svenja; Voelkel, Sara; Bauersachs, Daniel; Zemlin, Michael; Skevaki, Chrysanthi			T Cell Repertoire During Ontogeny and Characteristics in Inflammatory Disorders in Adults and Childhood	FRONTIERS IN IMMUNOLOGY			English	Review						T cell immunity; diversity; clonality; ontogeny; autoimmune disorders; immune deficiencies; allergy; next generation sequencing		Since the first day of life, a newborn has to deal with various pathogens from the environment. While passive immune protection is provided by diaplacental maternal antibodies, the development of cellular immunity is ongoing. A mature immune system should be able not only to defend against pathogens, but should also be able to differentiate between self- and non-self-antigens. Dysregulation in the development of cellular immunity can lead to severe disorders like immunodeficiency, autoimmunity and chronic inflammation. In this review, we explain the role of T cell immunity in antigen detection and summarize the characteristics of a mature TCR repertoire as well as the current state of knowledge about the development of the TCR repertoire in ontogenesis. In addition, methods of assessments are outlined, with a focus on the advantages and disadvantages of advanced methods such as next generation sequencing. Subsequently, we provide an overview of various disorders occuring in early childhood like immunodeficiencies, autoimmunity, allergic diseases and chronic infections and outline known changes in the TCR repertoire. Finally, we summarize the latest findings and discuss current research gaps as well as potential future developments.	[Foth, Svenja; Voelkel, Sara; Bauersachs, Daniel; Skevaki, Chrysanthi] Philipps Univ Marburg, Univ Giessen & Marburg Lung Ctr UGMLC, Inst Lab Med, German Ctr Lung Res DZL, Marburg, Germany; [Zemlin, Michael] Saarland Univ, Med Sch, Dept Gen Pediat & Neonatol, Homburg, Germany	Philipps University Marburg; Universitatsklinikum des Saarlandes	Skevaki, C (corresponding author), Philipps Univ Marburg, Univ Giessen & Marburg Lung Ctr UGMLC, Inst Lab Med, German Ctr Lung Res DZL, Marburg, Germany.	chrysanthi.skevaki@uk-gm.de		Zemlin, Michael/0000-0001-9528-7419	Bundesministerium fur Bildung und Forschung (BMBF), PRIMAL Consortium grant [01GL1746D]; Universities Giessen and Marburg Lung Center (UGMLC); German Center for Lung Research (DZL); Deutsche Forschungsgemeinschaft (DFG) [SFB 1021, KFO 309, SK 317/1-1, 428518790]; Foundation for Pathobiochemistry and Molecular Diagnostics; University Hospital Giessen and Marburg (UKGM)	Bundesministerium fur Bildung und Forschung (BMBF), PRIMAL Consortium grant(Federal Ministry of Education & Research (BMBF)); Universities Giessen and Marburg Lung Center (UGMLC); German Center for Lung Research (DZL); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Foundation for Pathobiochemistry and Molecular Diagnostics; University Hospital Giessen and Marburg (UKGM)	MZ is supported by Bundesministerium fur Bildung und Forschung (BMBF), PRIMAL Consortium grant 01GL1746D. CS is supported by the Universities Giessen and Marburg Lung Center (UGMLC), the German Center for Lung Research (DZL), University Hospital Giessen and Marburg (UKGM) research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft (DFG)-funded SFB 1021 (C04), KFO 309 (P10), and SK 317/1-1 (Project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics.	Albano F, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090836; Sousa ADA, 2016, ANN CLIN TRANSL NEUR, V3, P422, DOI 10.1002/acn3.310; Amariglio N, 2011, J CLIN IMMUNOL, V31, P1021, DOI 10.1007/s10875-011-9580-0; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Attaf M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02539; Attaf M, 2015, CELL MOL IMMUNOL, V12, P391, DOI 10.1038/cmi.2014.134; Barennes P, 2021, NAT BIOTECHNOL, V39, DOI 10.1038/s41587-020-0656-3; Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438; Ben Youssef G, 2018, J EXP MED, V215, P459, DOI 10.1084/jem.20171739; Bousso P, 2000, J IMMUNOL, V165, P760, DOI 10.4049/jimmunol.165.2.760; Bradley P, 2019, ANNU REV IMMUNOL, V37, P547, DOI 10.1146/annurev-immunol-042718-041757; Britanova OV, 2016, J IMMUNOL, V196, P5005, DOI 10.4049/jimmunol.1600005; Cao K, 2020, ALLERGY, V75, P681, DOI 10.1111/all.14014; Cavalcante P, 2010, ANN NEUROL, V67, P726, DOI 10.1002/ana.21902; Chapman CG, 2016, INFLAMM BOWEL DIS, V22, P1275, DOI 10.1097/MIB.0000000000000752; Chen HB, 2012, NAT IMMUNOL, V13, P691, DOI 10.1038/ni.2342; Chen YH, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5727516; Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; Correia-Neves M, 2001, IMMUNITY, V14, P21, DOI 10.1016/S1074-7613(01)00086-3; Cossarizza A, 2017, EUR J IMMUNOL, V47, P1584, DOI 10.1002/eji.201646632; Currier Jeffrey R, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1028s38; De Simone M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01638; de Vries ACH, 2008, LEUKEMIA, V22, P1170, DOI 10.1038/leu.2008.23; Dimova T, 2015, P NATL ACAD SCI USA, V112, pE556, DOI 10.1073/pnas.1412058112; Dokai H, 2007, J NEUROIMMUNOL, V187, P192, DOI 10.1016/j.jneuroim.2007.04.021; Dowd JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064921; Eggesbo LM, 2020, MUCOSAL IMMUNOL, V13, P313, DOI 10.1038/s41385-019-0222-9; Eugster A, 2015, J IMMUNOL, V194, P2531, DOI 10.4049/jimmunol.1403031; Faint JM, 1999, J IMMUNOL METHODS, V225, P53, DOI 10.1016/S0022-1759(99)00027-7; Fazilleau N, 2007, J IMMUNOL, V178, P4865, DOI 10.4049/jimmunol.178.8.4865; Flores-Gonzalez J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228830; Fozza C, 2017, J IMMUNOL METHODS, V440, P1, DOI 10.1016/j.jim.2016.11.001; Gabriel B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48434-4; Gong L, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.03.036; Healy K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061471; Hodges E, 1998, CLIN EXP IMMUNOL, V112, P363; Kircher MF, 2002, J ALLERGY CLIN IMMUN, V109, P517, DOI 10.1067/mai.2002.121945; Klarenbeek PL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002889; Lai CKW, 2009, THORAX, V64, P476, DOI 10.1136/thx.2008.106609; Laitinen OH, 2014, DIABETES, V63, P446, DOI 10.2337/db13-0619; Li HJ, 2012, CELL RES, V22, P33, DOI 10.1038/cr.2012.1; Liu B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.323; Liu Xiao, 2016, PLoS One, V11, pe0152464, DOI 10.1371/journal.pone.0152464; McLean-Tooke A, 2011, SCAND J IMMUNOL, V73, P577, DOI 10.1111/j.1365-3083.2011.02527.x; Michaux H, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00338; Miho E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00224; Mims JW, 2015, INT FORUM ALLERGY RH, V5, pS2, DOI 10.1002/alr.21609; Nielsen SD, 2001, BLOOD, V98, P398, DOI 10.1182/blood.V98.2.398; Papadopoulou M, 2019, J IMMUNOL, V203, P1468, DOI 10.4049/jimmunol.1900592; Pietrzyk JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078585; RAAPHORST FM, 1994, INT IMMUNOL, V6, P1, DOI 10.1093/intimm/6.1.1; Ramesh M, 2017, CLIN IMMUNOL, V178, P1, DOI 10.1016/j.clim.2015.01.002; Ravens S, 2020, P NATL ACAD SCI USA, V117, P18649, DOI 10.1073/pnas.1922588117; Rechavi E, 2017, SEMIN IMMUNOPATHOL, V39, P577, DOI 10.1007/s00281-017-0626-0; Robins HS, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001442; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; Sade K, 2003, ALLERGY, V58, P430, DOI 10.1034/j.1398-9995.2003.00055.x; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SantAngelo DB, 1997, IMMUNITY, V7, P517, DOI 10.1016/S1074-7613(00)80373-8; Saravanarajan K, 2020, GENES IMMUN, V21, P109, DOI 10.1038/s41435-020-0092-x; Schelonka RL, 1998, PEDIATR RES, V43, P396, DOI 10.1203/00006450-199803000-00015; Schober K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061367; Six A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00413; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Thapa DR, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0655-9; Tzifi F, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-33; Unterman A., 2020, A95 NOVEL INSIGHT IP, pA2516; van den Heuvel D, 2016, J INFECT DIS, V213, P233, DOI 10.1093/infdis/jiv369; Vogel AB, 2010, J IMMUNOL, V185, P4824, DOI 10.4049/jimmunol.0903631; Wahlstrom J, 2001, CLIN IMMUNOL, V100, P31, DOI 10.1006/clim.2001.5045; Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107; Warren RL, 2011, GENOME RES, V21, P790, DOI 10.1101/gr.115428.110; Werner L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00109; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Wu JF, 2015, J ALLERGY CLIN IMMUN, V135, P209, DOI 10.1016/j.jaci.2014.06.025; Yao Y, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108621; Yu XM, 2014, J ALLERGY CLIN IMMUN, V133, P1109, DOI 10.1016/j.jaci.2013.11.018; Zemlin M, 2002, IMMUNOL RES, V26, P265, DOI 10.1385/IR:26:1-3:265	79	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2021	11								611573	10.3389/fimmu.2020.611573	http://dx.doi.org/10.3389/fimmu.2020.611573			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QK4JC	33633732	Green Published, gold			2022-12-18	WOS:000620352400001
J	He, JM; Zhao, J; Quan, YH; Hou, XL; Yang, MX; Dong, ZJ				He, Junming; Zhao, Jun; Quan, Yuhe; Hou, Xinlei; Yang, Meixiang; Dong, Zhongjun			Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer (NK) cell; protein kinase B (PKB); phosphoinositide-dependent protein kinase-1 (PDK1); mammalian target of rapamycin complex 2; development; survival		The role of PI3K-mTOR pathway in regulating NK cell development has been widely reported. However, it remains unclear whether NK cell development depends on the protein kinase B (PKB), which links PI3K and mTOR, perhaps due to the potential redundancy of PKB. PKB has two phosphorylation sites, threonine 308 (T308) and serine 473 (S473), which can be phosphorylated by phosphoinositide-dependent protein kinase-1 (PDK1) and mTORC2, respectively. In this study, we established a mouse model in which PKB was inactivated through the deletion of PDK1 and Rictor, a key component of mTORC2, respectively. We found that the single deletion of PDK1 or Rictor could lead to a significant defect in NK cell development, while combined deletion of PDK1 and Rictor severely hindered NK cell development at the early stage. Notably, ectopic expression of myristoylated PKB significantly rescued this defect. In terms of mechanism, in PDK1/Rictor-deficient NK cells, E4BP4, a transcription factor for NK cell development, was less expressed, and the exogenous supply of E4BP4 could alleviate the developmental defect of NK cell in these mice. Besides, overexpression of Bcl-2 also helped the survival of PDK1/Rictor-deficient NK cells, suggesting an anti-apoptotic role of PKB in NK cells. In summary, complete phosphorylation of PKB at T308 and S473 by PDK1 and mTORC2 is necessary for optimal NK cell development, and PKB regulates NK cell development by promoting E4BP4 expression and preventing cell apoptosis.	[He, Junming; Zhao, Jun; Quan, Yuhe; Hou, Xinlei; Dong, Zhongjun] Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China; [He, Junming; Zhao, Jun; Quan, Yuhe; Hou, Xinlei; Dong, Zhongjun] Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China; [Yang, Meixiang] Jinan Univ, Zhuhai Precis Med Ctr, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Guangdong, Peoples R China; [Yang, Meixiang] Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Guangdong, Peoples R China	Tsinghua University; Tsinghua University; Jinan University; Jinan University	Dong, ZJ (corresponding author), Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.; Dong, ZJ (corresponding author), Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.; Yang, MX (corresponding author), Jinan Univ, Zhuhai Precis Med Ctr, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Guangdong, Peoples R China.; Yang, MX (corresponding author), Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Guangdong, Peoples R China.	yangmxqilu@163.com; dongzj@mail.tsinghua.edu.cn			Natural Science Foundation of China [31830027, 81725007, 91942308, 31821003, 81771666, 31700771]; National Key Research & Developmental Program of China [2018YFC1003900]; Natural Science Foundation of Guangdong Province [2019A1515011707]; Guangzhou Science and Technology Project [201707010395]; China Postdoctoral Science Foundation [2020M670296]; Tsinghua-Peking Center for Life Sciences	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research & Developmental Program of China; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Project; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Tsinghua-Peking Center for Life Sciences	Research reported in this publication was supported by the Natural Science Foundation of China (to Z.D, 31830027, 81725007, 91942308, and 31821003; to MY, 81771666; to WX, 31700771), National Key Research & Developmental Program of China (2018YFC1003900), Natural Science Foundation of Guangdong Province (to MY, 2019A1515011707), Guangzhou Science and Technology Project (to MY, 201707010395) and the China Postdoctoral Science Foundation (to JH, 2020M670296). The Dong laboratory was also supported by Tsinghua-Peking Center for Life Sciences.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ali AK, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00355; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Cooper MA, 2002, BLOOD, V100, P3633, DOI 10.1182/blood-2001-12-0293; Guo HL, 2008, J EXP MED, V205, P2419, DOI 10.1084/jem.20072327; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; He JM, 2019, CELL DEATH DIFFER, V26, P1918, DOI 10.1038/s41418-018-0263-8; Kamizono S, 2009, J EXP MED, V206, P2977, DOI 10.1084/jem.20092176; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Luo W, 2019, NAT IMMUNOL, V20, P736, DOI 10.1038/s41590-019-0376-3; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Minagawa M, 2002, J IMMUNOL, V169, P4153, DOI 10.4049/jimmunol.169.8.4153; Parham P, 2018, ANNU REV IMMUNOL, V36, P519, DOI 10.1146/annurev-immunol-042617-053149; Rogel A, 2017, P NATL ACAD SCI USA, V114, pE1178, DOI 10.1073/pnas.1611299114; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Tassi I, 2007, IMMUNITY, V27, P214, DOI 10.1016/j.immuni.2007.07.014; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wang FJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07277-9; Yang C, 2018, ELIFE, V7, DOI 10.7554/eLife.35619; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703; Zhao X, 2014, MOL CELL BIOL, V34, P1966, DOI 10.1128/MCB.00144-14	27	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2021	11								617404	10.3389/fimmu.2020.617404	http://dx.doi.org/10.3389/fimmu.2020.617404			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QK9LU	33633735	Green Published, gold			2022-12-18	WOS:000620700500001
J	Lehmann, AA; Zhang, T; Reche, PA; Lehmann, PV				Lehmann, Alexander A.; Zhang, Ting; Reche, Pedro A.; Lehmann, Paul, V			Discordance Between the Predicted Versus the Actually Recognized CD8+T Cell Epitopes of HCMV pp65 Antigen and Aleatory Epitope Dominance	FRONTIERS IN IMMUNOLOGY			English	Article						epitope prediction; brute force epitope mapping; high throughput; ImmunoSpot; ELISPOT		CD8+ T cell immune monitoring aims at measuring the size and functions of antigen-specific CD8+ T cell populations, thereby providing insights into cell-mediated immunity operational in a test subject. The selection of peptides for ex vivo CD8+ T cell detection is critical because within a complex antigen exists a multitude of potential epitopes that can be presented by HLA class I molecules. Further complicating this task, there is HLA class I polygenism and polymorphism which predisposes CD8+ T cell responses towards individualized epitope recognition profiles. In this study, we compare the actual CD8+ T cell recognition of a well-characterized model antigen, human cytomegalovirus (HCMV) pp65 protein, with its anticipated epitope coverage. Due to the abundance of experimentally defined HLA-A*02:01-restricted pp65 epitopes, and because in silico epitope predictions are most advanced for HLA-A*02:01, we elected to focus on subjects expressing this allele. In each test subject, every possible CD8+ T cell epitope was systematically covered testing 553 individual peptides that walk the sequence of pp65 in steps of single amino acids. Highly individualized CD8+ T cell response profiles with aleatory epitope recognition patterns were observed. No correlation was found between epitopes' ranking on the prediction scale and their actual immune dominance. Collectively, these data suggest that accurate CD8+ T cell immune monitoring may necessitate reliance on agnostic mega peptide pools, or brute force mapping, rather than electing individual peptides as representative epitopes for tetramer and other multimer labeling of surface antigen receptors.	[Lehmann, Alexander A.; Zhang, Ting; Lehmann, Paul, V] Cellular Technol Ltd, Res & Dev, Shaker Hts, OH 44122 USA; [Reche, Pedro A.] Univ Complutense Madrid, Fac Med, Dept Immunol & O2, Lab Inmunomed & Inmunoinformat, Madrid, Spain	Complutense University of Madrid	Lehmann, PV (corresponding author), Cellular Technol Ltd, Res & Dev, Shaker Hts, OH 44122 USA.	paul.lehmann@immunospot.com	Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838	R&D budget of Cellular Technology Limited	R&D budget of Cellular Technology Limited	This study was funded by the R&D budget of Cellular Technology Limited.	Altman John D, 2003, Curr Protoc Immunol, VChapter 17, DOI 10.1002/0471142735.im1703s53; Anthony DD, 2003, METHODS, V29, P260, DOI 10.1016/S1046-2023(02)00348-1; Anton LC, 2014, J LEUKOCYTE BIOL, V95, P551, DOI 10.1189/jlb.1113599; Apetoh L, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998538; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; Desai Dattatraya V, 2014, Methods Mol Biol, V1184, P333, DOI 10.1007/978-1-4939-1115-8_19; Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452; Elkington R, 2003, J VIROL, V77, P5226, DOI 10.1128/JVI.77.9.5226-5240.2003; Fernandes JD, 2020, NAT GENET, V52, P991, DOI 10.1038/s41588-020-0700-8; Godard B, 2004, HUM IMMUNOL, V65, P1307, DOI 10.1016/j.humimm.2004.06.006; Hamel Y, 2003, EUR J IMMUNOL, V33, P760, DOI 10.1002/eji.200323628; Hanley PJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2546; Hanson J, 2018, METHODS MOL BIOL, V1808, P51, DOI 10.1007/978-1-4939-8567-8_5; Hanson J, 2015, CELLS-BASEL, V4, P71, DOI 10.3390/cells4010071; Hesse MD, 2001, J IMMUNOL, V167, P1353, DOI 10.4049/jimmunol.167.3.1353; Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140; Karulin AY, 2015, CELLS-BASEL, V4, P96, DOI 10.3390/cells4010096; Khan N, 2004, J IMMUNOL, V173, P7481, DOI 10.4049/jimmunol.173.12.7481; Khan N, 2007, J IMMUNOL, V178, P4455, DOI 10.4049/jimmunol.178.7.4455; Klinger M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141561; Kondo E, 2004, BLOOD, V103, P630, DOI 10.1182/blood-2003-03-0824; Lacey SF, 2003, HUM IMMUNOL, V64, P440, DOI 10.1016/S0198-8859(03)00028-4; Lee S, 2011, TRANSPL P, V43, P2636, DOI 10.1016/j.transproceed.2011.05.051; Lehmann A., 2020, DECONVOLUTING T CELL, DOI [10.1101/2020.11.29.402677, DOI 10.1101/2020.11.29.402677]; Lehmann PV, 2020, CRIT REV IMMUNOL, V40, P225, DOI 10.1615/CritRevImmunol.2020034838; Lehmann PV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00655; Mei ST, 2020, BRIEF BIOINFORM, V21, P1119, DOI 10.1093/bib/bbz051; Moudgil KD, 1998, J IMMUNOL, V161, P6046; NAGY ZA, 1989, IMMUNOL TODAY, V10, P132, DOI 10.1016/0167-5699(89)90247-8; Nastke MD, 2005, CELL MOL LIFE SCI, V62, P77, DOI 10.1007/s00018-004-4363-x; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Newell EW, 2013, NAT BIOTECHNOL, V31, P623, DOI 10.1038/nbt.2593; Provenzano M, 2009, J CELL MOL MED, V13, P2131, DOI 10.1111/j.1582-4934.2008.00531.x; Qin OY, 2004, EXP GERONTOL, V39, P607, DOI 10.1016/j.exger.2003.11.016; Ramachandran Hari, 2012, Cells, V1, P313, DOI 10.3390/cells1030313; Ravkov EV, 2003, J IMMUNOL, V170, P2461, DOI 10.4049/jimmunol.170.5.2461; Reche PA, 2005, BIOINFORMATICS, V21, P2140, DOI 10.1093/bioinformatics/bti269; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rist M, 2005, EUR J IMMUNOL, V35, P996, DOI 10.1002/eji.200425746; Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010; Schalich J, 2008, BIOL CHEM, V389, P551, DOI 10.1515/BC.2008.065; Schiller A, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6040047; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Solache A, 1999, J IMMUNOL, V163, P5512; Sundararaman S., 2014, J IMMUNOTHER CANCER, V2, pP156, DOI [10.1186/2051-1426-2-S3-P156, DOI 10.1186/2051-1426-2-S3-P156]; Williams TM, 2001, J MOL DIAGN, V3, P98, DOI 10.1016/S1525-1578(10)60658-7; Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005; Zhang SQ, 2018, NAT BIOTECHNOL, V36, P1156, DOI 10.1038/nbt.4282; Zhong J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003256	50	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 9	2021	11								618428	10.3389/fimmu.2020.618428	http://dx.doi.org/10.3389/fimmu.2020.618428			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QK7GB	33633736	gold, Green Published			2022-12-18	WOS:000620549500001
J	Li, RQ; Sun, N; Chen, X; Li, XQ; Zhao, J; Cheng, WP; Hua, H; Fukatsu, M; Mori, H; Takahashi, H; Ohkawara, H; Fukami, M; Okamoto, M; Hamazaki, Y; Zheng, KY; Yang, J; Ikezoe, T				Li, Rongqing; Sun, Na; Chen, Xin; Li, Xueqin; Zhao, Jie; Cheng, Wanpeng; Hua, Hui; Fukatsu, Masahiko; Mori, Hirotaka; Takahashi, Hiroshi; Ohkawara, Hiroshi; Fukami, Miwa; Okamoto, Masatoshi; Hamazaki, Yoichi; Zheng, Kuiyang; Yang, Jing; Ikezoe, Takayuki			JAK2(V617F) Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						glycolysis; PKM1; STAT3; IL-6		A substitution mutation of valine to phenylalanine at codon encoding position 617 of the Janus kinase 2 (JAK2) gene (JAK2(V617F) ) has been detected in myeloid cells of some individuals with higher levels of proinflammatory cytokine production such as interleukin (IL)-6. However, the mechanisms by which JAK2(V617F) mutation mediating those cytokines remain unclear. We, therefore, established JAK2(V617F) -expressing murine macrophages (JAK2(V617F) macrophages) and found that the levels of p-STAT3 were markedly elevated in JAK2(V617F) macrophages in association with an increase in IL-6 production. However, inhibition of STAT3 by C188-9 significantly decreased the production of IL-6. Furthermore, the JAK2(V617F) mutation endowed macrophages with an elevated glycolytic phenotype in parallel with aberrant expression of PKM1. Interestingly, silencing of PKM1 inactivated STAT3 in parallel with reduced IL-6 production. In contrast, ectopic expression of PKM1 elevated IL-6 production via STAT3 activation. Importantly, the JAK2(V617F) mutation contributed to PKM1 protein stabilization via blockade of lysosomal-dependent degradation via chaperone-mediated autophagy (CMA), indicating that the JAK2(V617F) mutation could protect PKM1 from CMA-mediated degradation, leading to activation of STAT3 and promoting IL-6 production.	[Li, Rongqing; Sun, Na; Chen, Xin; Li, Xueqin; Zhao, Jie; Cheng, Wanpeng; Hua, Hui; Zheng, Kuiyang; Yang, Jing] Xuzhou Med Univ, Jiangsu Prov Key Lab Immun & Metab, Xuzhou, Jiangsu, Peoples R China; [Li, Rongqing; Sun, Na; Chen, Xin; Li, Xueqin; Zhao, Jie; Cheng, Wanpeng; Hua, Hui; Zheng, Kuiyang; Yang, Jing] Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Xuzhou, Jiangsu, Peoples R China; [Li, Rongqing; Sun, Na; Fukatsu, Masahiko; Mori, Hirotaka; Takahashi, Hiroshi; Ohkawara, Hiroshi; Fukami, Miwa; Ikezoe, Takayuki] Fukushima Med Univ, Dept Hematol, Fukushima, Japan; [Okamoto, Masatoshi] YUASA Fdn Jusendo Gen Hosp, Dept Hematol, Koriyama, Fukushima, Japan; [Hamazaki, Yoichi] Iwaki City Med Ctr, Dept Hematol, Iwaki, Fukushima, Japan	Xuzhou Medical University; Xuzhou Medical University; Fukushima Medical University	Yang, J (corresponding author), Xuzhou Med Univ, Jiangsu Prov Key Lab Immun & Metab, Xuzhou, Jiangsu, Peoples R China.; Yang, J (corresponding author), Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Xuzhou, Jiangsu, Peoples R China.; Ikezoe, T (corresponding author), Fukushima Med Univ, Dept Hematol, Fukushima, Japan.	jingyang@xzhmu.edu.cn; ikezoet@fmu.ac.jp	Yang, jing/GPF-6220-2022	Yang, jing/0000-0002-2624-5028; Ohkawara, Hiroshi/0000-0002-3129-1977	Jiangsu Distinguished Professorship Program; KAKENHI [18H02844]	Jiangsu Distinguished Professorship Program; KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Jiangsu Distinguished Professorship Program to JY and KAKENHI (18H02844) to TI.	Alves JC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00145; An MX, 2017, J CELL BIOL, V216, P4091, DOI 10.1083/jcb.201701064; Ayanlaja AA, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-019-0485-5; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Demaria Marco, 2012, JAKSTAT, V1, P194, DOI 10.4161/jkst.20662; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Fisher DAC, 2019, LEUKEMIA, V33, P1978, DOI 10.1038/s41375-019-0379-y; Foucar CE, 2017, JAMA-J AM MED ASSOC, V317, P2228, DOI 10.1001/jama.2017.2329; Godfrey AL, 2013, HAEMATOLOGICA, V98, P718, DOI 10.3324/haematol.2012.079129; Goette NP, 2010, CYTOKINE, V51, P67, DOI 10.1016/j.cyto.2010.04.011; Grisouard J, 2015, BLOOD, V125, P2131, DOI 10.1182/blood-2014-08-594572; Hodges VA, 2007, CRIT REV ONCOL HEMAT, V64, P139, DOI 10.1016/j.critrevonc.2007.06.006; Hou PF, 2018, CANCER RES, V78, P387, DOI 10.1158/0008-5472.CAN-17-0883; Hubbi ME, 2013, J BIOL CHEM, V288, P10703, DOI 10.1074/jbc.M112.414771; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Lai HY, 2019, BLOOD ADV, V3, P122, DOI 10.1182/bloodadvances.2018026450; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Moss JWE, 2016, FUTURE MED CHEM, V8, P1317, DOI 10.4155/fmc-2016-0072; Naqvi K, 2019, CANCER-AM CANCER SOC, V125, P2233, DOI 10.1002/cncr.32056; Nosaka M, 2011, J CLIN INVEST, V121, P2911, DOI 10.1172/JCI40782; Obro NF, 2020, HEMASPHERE, V4, DOI 10.1097/HS9.0000000000000371; Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI [10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017]; Sano S, 2019, JACC-BASIC TRANSL SC, V4, P684, DOI 10.1016/j.jacbts.2019.05.013; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schuett H, 2012, ARTERIOSCL THROM VAS, V32, P281, DOI 10.1161/ATVBAHA.111.229435; Seim GL, 2019, NAT METAB, V1, P731, DOI 10.1038/s42255-019-0083-2; Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900; Stunault MI, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/2426138; van de Wetering C, 2020, J IMMUNOL, V204, P763, DOI 10.4049/jimmunol.1901086; Wang W, 2018, CIRC RES, V123, pE35, DOI 10.1161/CIRCRESAHA.118.313283; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Zhang BL, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00835-3	33	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2021	11								589048	10.3389/fimmu.2020.589048	http://dx.doi.org/10.3389/fimmu.2020.589048			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QJ9WR	33628203	gold, Green Published			2022-12-18	WOS:000620034400001
J	Sanchez-Castro, EE; Pajuelo-Reyes, C; Tejedo, R; Soria-Juan, B; Tapia-Limonchi, R; Andreu, E; Hitos, AB; Martin, F; Cahuana, GM; Guerra-Duarte, C; de Assis, TCS; Bedoya, FJ; Soria, B; Chavez-Olortegui, C; Tejedo, JR				Eduardo Sanchez-Castro, E.; Pajuelo-Reyes, Cecilia; Tejedo, Rebeca; Soria-Juan, Barbara; Tapia-Limonchi, Rafael; Andreu, Etelvina; Hitos, Ana B.; Martin, Franz; Cahuana, Gladys M.; Guerra-Duarte, Clara; Silva de Assis, Thamyres C.; Bedoya, Francisco J.; Soria, Bernat; Chavez-Olortegui, Carlos; Tejedo, Juan R.			Mesenchymal Stromal Cell-Based Therapies as Promising Treatments for Muscle Regeneration After Snakebite Envenoming	FRONTIERS IN IMMUNOLOGY			English	Review						advanced therapy medicinal products; mesenchymal stromal cells; snakebite; envenoming; muscle regeneration	PROGENITOR CELLS; MECHANISMS; VENOM	Snakebite envenoming is a global neglected disease with an incidence of up to 2.7 million new cases every year. Although antivenoms are so-far the most effective treatment to reverse the acute systemic effects induced by snakebite envenoming, they have a limited therapeutic potential, being unable to completely neutralize the local venom effects. Local damage, such as dermonecrosis and myonecrosis, can lead to permanent sequelae with physical, social, and psychological implications. The strong inflammatory process induced by snake venoms is associated with poor tissue regeneration, in particular the lack of or reduced skeletal muscle regeneration. Mesenchymal stromal cells (MSCs)-based therapies have shown both anti-inflammatory and pro-regenerative properties. We postulate that using allogeneic MSCs or their cell-free products can induce skeletal muscle regeneration in snakebite victims, improving all the three steps of the skeletal muscle regeneration process, mainly by anti-inflammatory activity, paracrine effects, neovascularization induction, and inhibition of tissue damage, instrumental for microenvironment remodeling and regeneration. Since snakebite envenoming occurs mainly in areas with poor healthcare, we enlist the principles and potential of MSCs-based therapies and discuss regulatory issues, good manufacturing practices, transportation, storage, and related-procedures that could allow the administration of these therapies, looking forward to a safe and cost-effective treatment for a so far unsolved and neglected health problem.	[Eduardo Sanchez-Castro, E.] Univ Nacl Mayor San Marcos, Fac Biol Sci, Lima, Peru; [Pajuelo-Reyes, Cecilia; Tapia-Limonchi, Rafael; Tejedo, Juan R.] Univ Nacl Toribio Rodriguez de Mendoza Amazonas, Inst Trop Dis, Chachapoyas, Peru; [Tejedo, Rebeca] Univ Privada San Juan Bautista, Fac Med, Lima, Peru; [Soria-Juan, Barbara; Martin, Franz; Cahuana, Gladys M.; Bedoya, Francisco J.; Soria, Bernat; Tejedo, Juan R.] Univ Pablo de Olavide, Dept Mol Biol & Biochem Engn, Seville, Spain; [Soria-Juan, Barbara] Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Surg, Unidad Terapias Avanzadas, Madrid, Spain; [Andreu, Etelvina; Soria, Bernat] ISABIAL Hosp Gen & Univ Alicante, Alicante, Spain; [Andreu, Etelvina] Univ Miguel Hernandez, Dept Fis Aplicadas, Alicante, Spain; [Hitos, Ana B.; Martin, Franz; Cahuana, Gladys M.; Bedoya, Francisco J.; Tejedo, Juan R.] Univ Pablo de Olavide, Univ Sevilla, Dept Cell Regenerat & Adv Therapies,CSIC, Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Seville, Spain; [Hitos, Ana B.; Martin, Franz; Bedoya, Francisco J.; Soria, Bernat; Tejedo, Juan R.] Inst Salud Carlos III, Biomed Res Network Diabet & Related Metab Dis CIB, Madrid, Spain; [Guerra-Duarte, Clara] Fundacao Ezequiel Dias, Ctr Res & Dev, Belo Horizonte, MG, Brazil; [Silva de Assis, Thamyres C.; Chavez-Olortegui, Carlos] Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil; [Soria, Bernat] Univ Miguel Hernandez Elche, Inst Bioengn, Alicante, Spain	Universidad Nacional Mayor de San Marcos; Universidad Nacional Toribio Rodriguez De Mendoza De Amazonas; Universidad Privada San Juan Bautista; Universidad Pablo de Olavide; Autonomous University of Madrid; General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Instituto de Salud Carlos III; Universidade Federal de Minas Gerais; Universidad Miguel Hernandez de Elche	Tejedo, JR (corresponding author), Univ Nacl Toribio Rodriguez de Mendoza Amazonas, Inst Trop Dis, Chachapoyas, Peru.; Tejedo, JR (corresponding author), Univ Pablo de Olavide, Dept Mol Biol & Biochem Engn, Seville, Spain.; Chavez-Olortegui, C (corresponding author), Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.	olortegi@icb.ufmg.br; jrtejhua@upo.es	Martin, Franz/K-4197-2014; Andreu, Etelvina/M-1623-2014; Duarte, Clara Guerra/H-1409-2012; Tejedo, Juan R./AAN-8865-2021; Bedoya, Francisco J/R-4871-2018; Hitos, Ana Belén/ABE-3465-2021; Bedoya, Francisco/AAX-8812-2021; Cahuana, Gladys M/R-1789-2018; , Bernat/AAL-6470-2021	Martin, Franz/0000-0002-5745-8704; Andreu, Etelvina/0000-0003-0156-8944; Duarte, Clara Guerra/0000-0002-7698-3811; Tejedo, Juan R./0000-0002-8434-7516; Bedoya, Francisco J/0000-0003-0262-7029; Hitos, Ana Belén/0000-0002-0403-6647; Bedoya, Francisco/0000-0003-0262-7029; Soria, Bernat/0000-0002-2356-0380; Pajuelo Reyes, Cecilia Isabel/0000-0002-7712-4453; de Assis, Thamyres/0000-0001-6276-8929; Tapia-Limonchi, Rafael/0000-0001-7483-1729; Sanchez-Castro, E. Eduardo/0000-0002-2319-5192	University Pablo de Olavide (Sevilla); University Miguel Hernandez (Elche, Alicante); National University Toribio Rodriguez de Mendoza (Chachapoyas, Peru) [09-2019-FONDECYT-BM-INC.INV, JDRF 2-SRA-2019-837-S-B, AVI-GVA COVID-19-68]; Fundacion Andaluza de I+D; Al-Andalus Biopharma Project [FAID-2018-1]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) [406163/20189]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil - CAPES [88881.191812/201801]; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil (FAPEMIG)	University Pablo de Olavide (Sevilla); University Miguel Hernandez (Elche, Alicante); National University Toribio Rodriguez de Mendoza (Chachapoyas, Peru); Fundacion Andaluza de I+D; Al-Andalus Biopharma Project; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil - CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	The authors are supported by the University Pablo de Olavide (Sevilla), the University Miguel Hernandez (Elche, Alicante), National University Toribio Rodriguez de Mendoza (Chachapoyas, Peru) Grants: Contrato No 09-2019-FONDECYT-BM-INC.INV to JRT, JDRF 2-SRA-2019-837-S-B and AVI-GVA COVID-19-68 to BS, Fundacion Andaluza de I+D and Al-Andalus Biopharma Project (FAID-2018-1). The authors CC-O, CG-D, and TCSA were supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) (Process: 406163/20189), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil - CAPES (Program COFECUB Process: 88881.191812/201801) and by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil (FAPEMIG).	Acosta L, 2013, DIABETES, V62, P4266, DOI 10.2337/db13-0896; Alcayaga-Miranda F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00339; Alcayaga-Miranda F, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0013-5; Almada AE, 2016, NAT REV MOL CELL BIO, V17, P267, DOI 10.1038/nrm.2016.7; ARCE V, 1991, INT J EXP PATHOL, V72, P211; Baldo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000727; Bortolotti F, 2015, STEM CELL REP, V4, P332, DOI 10.1016/j.stemcr.2015.01.001; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Calderon HB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00655; Calvete JJ, 2017, BIOCHEM J, V474, P611, DOI 10.1042/BCJ20160577; Ceafalan LC, 2018, CELL ADHES MIGR, V12, P228, DOI 10.1080/19336918.2017.1346774; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chen JF, 2010, J CELL BIOL, V190, P867, DOI 10.1083/jcb.200911036; Chippaux JP, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0127-6; Chippaux JP, 2011, TOXICON, V57, P586, DOI 10.1016/j.toxicon.2010.12.022; Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06-08-0693; Ciciliot S, 2010, CURR PHARM DESIGN, V16, P906, DOI 10.2174/138161210790883453; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Cruz Luzia S, 2009, Ethn Dis, V19, pS1; D'souza N, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0426-0; Dai Y, 2016, IN VITRO CELL DEV-AN, V52, P27, DOI 10.1007/s11626-015-9953-4; De Palma C, 2014, SKELET MUSCLE, V4, DOI 10.1186/s13395-014-0022-6; Demonbreun AR, 2017, CURR OPIN PHARMACOL, V34, P7, DOI 10.1016/j.coph.2017.03.008; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dziki JL, 2018, TISSUE ENG PT A, V24, P34, DOI [10.1089/ten.TEA.2017.0011, 10.1089/ten.tea.2017.0011]; English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56; Escacena Acosta N., 2016, THESIS CABIMER; Escacena N, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/895714; Escalante T, 2011, J PROTEOMICS, V74, P1781, DOI 10.1016/j.jprot.2011.03.026; Feitosa ES, 2015, REV SOC BRAS MED TRO, V48, P34, DOI 10.1590/0037-8682-0105-2013; Ferguson SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19581-x; Fernandez J, 2013, FEBS J, V280, P3878, DOI 10.1111/febs.12386; Fernandez O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195891; Forbes SJ, 2014, NAT MED, V20, P857, DOI 10.1038/nm.3653; Forterre A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084153; Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012; Fry CS, 2017, CELL STEM CELL, V20, P56, DOI 10.1016/j.stem.2016.09.010; Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004; Gold BS, 2002, NEW ENGL J MED, V347, P347, DOI 10.1056/NEJMra013477; Silva LMG, 2018, TOXICON, V152, P23, DOI 10.1016/j.toxicon.2018.07.006; Gutierrez JM, 2005, TOXICON, V45, P997, DOI 10.1016/j.toxicon.2005.02.029; GUTIERREZ JM, 1985, TOXICON, V23, P887, DOI 10.1016/0041-0101(85)90380-0; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; GUTIERREZ JM, 1995, EXP MOL PATHOL, V62, P28, DOI 10.1006/exmp.1995.1004; GUTIERREZ JM, 1984, EXP MOL PATHOL, V40, P367, DOI 10.1016/0014-4800(84)90054-6; Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9; Gutierrez JM, 2006, PLOS MED, V3, P727, DOI 10.1371/journal.pmed.0030150; Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]; Hassanzadeh-Ghassabeh G, 2013, NANOMEDICINE-UK, V8, P1013, DOI [10.2217/NNM.13.86, 10.2217/nnm.13.86]; Hernandez R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019834; Herrera C., 2015, PLOS NEGLECT TROP D, V9, P1; Jing H, 2018, TRANSL RES, V196, P1, DOI 10.1016/j.trsl.2018.01.005; Alcaraz MJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010098; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Kwon SY, 2017, TISSUE ENG REGEN MED, V14, P595, DOI 10.1007/s13770-017-0068-8; Laing GD, 2003, EUR J IMMUNOL, V33, P3458, DOI 10.1002/eji.200324475; Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559; Lam NT, 2020, J MUSCLE RES CELL M, V41, P269, DOI 10.1007/s10974-019-09555-5; Li XJ, 2020, IMMUNOL LETT, V222, P49, DOI 10.1016/j.imlet.2020.03.005; Ling WF, 2014, CANCER RES, V74, P1576, DOI 10.1158/0008-5472.CAN-13-1656; Lo Sicco C, 2017, STEM CELL TRANSL MED, V6, P1018, DOI 10.1002/sctm.16-0363; Lomonte B, 2012, TOXICON, V60, P520, DOI 10.1016/j.toxicon.2012.02.007; Lopez-Beas J, 2020, MED RES REV, V40, P1315, DOI 10.1002/med.21659; Lu HY, 2011, FASEB J, V25, P358, DOI 10.1096/fj.10-171579; Lysaght T, 2017, J BIOETHIC INQ, V14, P261, DOI 10.1007/s11673-017-9776-y; Gutierrez JM, 2007, CURR PHARM DESIGN, V13, P2935, DOI 10.2174/138161207782023784; Gutierrez JM, 2018, TOXINS, V10, DOI 10.3390/toxins10050182; Gutierrez JM, 2017, TOXINS, V9, DOI 10.3390/toxins9050163; Gutierrez JM, 2016, TOXICON, V109, P51, DOI 10.1016/j.toxicon.2015.11.013; Gutierrez JM, 2010, TOXICON, V56, P1223, DOI 10.1016/j.toxicon.2009.11.020; Gutierrez JM, 2010, TOXICON, V55, P166, DOI 10.1016/j.toxicon.2009.08.006; Masucci MT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01146; McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858; McCarthy JJ, 2008, BBA-GENE REGUL MECH, V1779, P682, DOI 10.1016/j.bbagrm.2008.03.001; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Miller KJ, 2000, AM J PHYSIOL-CELL PH, V278, pC174, DOI 10.1152/ajpcell.2000.278.1.C174; Mourikis P, 2016, CELL STEM CELL, V18, P160, DOI 10.1016/j.stem.2016.01.008; Nadur-Andrade N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004998; Nagata Y, 2006, J CELL BIOL, V174, P245, DOI 10.1083/jcb.200605028; Nakamura Y, 2015, FEBS LETT, V589, P1257, DOI 10.1016/j.febslet.2015.03.031; Nederveen JP, 2017, CURR STEM CELL REP, V3, P192, DOI 10.1007/s40778-017-0089-1; Mamede CCN, 2016, TOXICON, V117, P37, DOI 10.1016/j.toxicon.2016.03.006; Ochoa O, 2007, AM J PHYSIOL-REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007; Oustanina S, 2004, EMBO J, V23, P3430, DOI 10.1038/sj.emboj.7600346; Pawitan JA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/965849; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prochazka V, 2010, CELL TRANSPLANT, V19, P1413, DOI 10.3727/096368910X514170; Prochazka V, 2016, CELL TRANSPLANT, V25, P1623, DOI 10.3727/096368915X689767; Rangel J, 2011, CELL BIOCHEM FUNCT, V29, P365, DOI 10.1002/cbf.1758; Ruiz-Salmeron R, 2011, CELL TRANSPLANT, V20, P1629, DOI 10.3727/096368910X0177; Saclier M, 2013, STEM CELLS, V31, P384, DOI 10.1002/stem.1288; Sagaradze G.D., 2018, CELL FREE THERAPEUTI, DOI 10.5772/intechopen.78605; Sagaradze G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071656; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Sanchez-Guijo F, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100454; Sant'Ana Malaque CM., 2017, CRITICAL CARE TOXICO, DOI [10.1007/978-3-319-17900-1_146, DOI 10.1007/978-3-319-17900-1_146]; Saravia-Otten P, 2013, MUSCLE NERVE, V47, P202, DOI 10.1002/mus.23489; Sharma RR, 2014, TRANSFUSION, V54, P1418, DOI 10.1111/trf.12421; Shefer G., 2008, MEDIA, P107; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Slater CR., SKELETAL MUSCLE REPA, V3, DOI [10.1007/978-1-4020-6768-6_14, DOI 10.1007/978-1-4020-6768-6_14]; Campos GRS, 2018, TOXICON, V152, P95, DOI 10.1016/j.toxicon.2018.07.029; Soria-Juan B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01151; Spinazzola JM, 2017, CELL STEM CELL, V20, P1, DOI 10.1016/j.stem.2016.12.009; Szczepiorkowski Z., 2017, PRACTICAL TRANSFUSIO, P429, DOI [10.1002/9781119129431.ch38, DOI 10.1002/9781119129431.CH38]; Takeda S, 2012, BBA-PROTEINS PROTEOM, V1824, P164, DOI 10.1016/j.bbapap.2011.04.009; Tan KZ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/8717694; Tatsumi R, 2006, AM J PHYSIOL-CELL PH, V290, pC1487, DOI 10.1152/ajpcell.00513.2005; Teixeira CFP, 2003, TOXICON, V42, P947, DOI 10.1016/j.toxicon.2003.11.006; Teixeira FG, 2020, NEURAL REGEN RES, V15, P75, DOI 10.4103/1673-5374.264455; Thej C, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0488-3; Tidball JG, 2010, AM J PHYSIOL-REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009; Tidball James G., 2008, V3, P243; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tortoza, 2016, TENDENCIAS CIENTIFIC; Townley-Tilson WHD, 2010, INT J BIOCHEM CELL B, V42, P1252, DOI 10.1016/j.biocel.2009.03.002; Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007; van den Akker F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/181020; Wang GY, 2020, INFLAMMOPHARMACOLOGY, V28, P603, DOI 10.1007/s10787-019-00683-5; Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-19; Warrell, 1996, TOXICON, V34, P144, DOI [10.1016/0041-0101(96)83654-3, DOI 10.1016/0041-0101(96)83654-3]; Williams DJ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007059; Xie B., 2018, STEM CELLS INT, P7528464, DOI [DOI 10.1155/2018/7528464, 10.1155/2018/7528464]; Yang SH, 2009, EXP MOL MED, V41, P315, DOI 10.3858/emm.2009.41.5.035; Young Michael H, 2005, Expert Rev Anti Infect Ther, V3, P279, DOI 10.1586/14787210.3.2.279; Zamuner SR, 2005, TOXICON, V46, P806, DOI 10.1016/j.toxicon.2005.08.011; Zuliani JP, 2020, TOXICON, V187, P188, DOI 10.1016/j.toxicon.2020.09.006	128	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								609961	10.3389/fimmu.2020.609961	http://dx.doi.org/10.3389/fimmu.2020.609961			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0NX	33633730	Green Published, gold			2022-12-18	WOS:000618673300001
J	Kumashie, KG; Cebula, M; Hagedorn, C; Kreppel, F; Pils, MC; Koch-Nolte, F; Rissiek, B; Wirth, D				Kumashie, Kingsley Gideon; Cebula, Marcin; Hagedorn, Claudia; Kreppel, Florian; Pils, Marina C.; Koch-Nolte, Friedrich; Rissiek, Bjorn; Wirth, Dagmar			Improved Functionality of Exhausted Intrahepatic CXCR5+CD8+T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation	FRONTIERS IN IMMUNOLOGY			English	Article						T cell exhaustion; CXCR5+T cells; CpG oligonucleotide; T cell reinvigoration; exhausted stem-like T cells; liver resident T cells; follicular helper-like T cells; liver		Chronic hepatotropic viral infections are characterized by exhausted CD8+ T cells in the presence of cognate antigen in the liver. The impairment of T cell response limits the control of chronic hepatotropic viruses. Immune-modulatory strategies are attractive options to re-invigorate exhausted T cells. However, in hepatotropic viral infections, the knowledge about immune-modulatory effects on the in-situ regulation of exhausted intrahepatic CD8+ T cells is limited. In this study, we elucidated the functional heterogeneity in the pool of exhausted CD8+ T cells in the liver of mice expressing the model antigen Ova in a fraction of hepatocytes. We found a subpopulation of intrahepatic CXCR5+ Ova-specific CD8+ T cells, which are profoundly cytotoxic, exhibiting efficient metabolic functions as well as improved memory recall and self-maintenance. The intrahepatic Ova-specific CXCR5+ CD8+ T cells are possibly tissue resident cells, which may rely largely on OXPHOS and glycolysis to fuel their cellular processes. Importantly, host conditioning with CpG oligonucleotide reinvigorates and promotes exhausted T cell expansion, facilitating complete antigen eradication. The CpG oligonucleotide-mediated reinvigoration may support resident memory T cell formation and the maintenance of CXCR5+ Ova-specific CD8+ T cells in the liver. These findings suggest that CpG oligodinucleotide may preferentially target CXCR5+ CD8+ T cells for expansion to facilitate the revival of exhausted T cells. Thus, therapeutic strategies aiming to expand CXCR5+ CD8+ T cells might provide a novel approach against chronic liver infection.	[Kumashie, Kingsley Gideon; Cebula, Marcin; Wirth, Dagmar] Helmholtz Ctr Infect Res, Model Syst Infect & Immun, Braunschweig, Germany; [Hagedorn, Claudia; Kreppel, Florian] Univ Witten Herdecke, Chair Biochem & Mol Med, Witten, Germany; [Pils, Marina C.] Helmholtz Ctr Infect Res, Mouse Pathol Unit, Braunschweig, Germany; [Koch-Nolte, Friedrich] Univ Med Ctr Hamburg Eppendorf, Inst Immunol, Hamburg, Germany; [Rissiek, Bjorn] Univ Med Ctr Hamburg Eppendorf, Inst Neurol, Hamburg, Germany; [Wirth, Dagmar] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Witten Herdecke University; Helmholtz Association; Helmholtz-Center for Infection Research; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School	Kumashie, KG; Wirth, D (corresponding author), Helmholtz Ctr Infect Res, Model Syst Infect & Immun, Braunschweig, Germany.; Wirth, D (corresponding author), Hannover Med Sch, Inst Expt Hematol, Hannover, Germany.	k.kumashie@uke.de; dagmar.wirth@helmholtz-hzi.de	Cebula, Marcin/ABF-8802-2021; Rissiek, Björn/J-4252-2019	Cebula, Marcin/0000-0003-2649-1269; Rissiek, Björn/0000-0001-5327-5479	Deutsche Forschungsgemeinschaft (DFG) via the Cluster of Excellence ECX62 (REBIRTH - From Regenerative Biology to Reconstructive Therapy)	Deutsche Forschungsgemeinschaft (DFG) via the Cluster of Excellence ECX62 (REBIRTH - From Regenerative Biology to Reconstructive Therapy)(German Research Foundation (DFG))	This work was supported by grants from Deutsche Forschungsgemeinschaft (DFG) via the Cluster of Excellence ECX62 (REBIRTH - From Regenerative Biology to Reconstructive Therapy).	Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Bantug GR, 2018, IMMUNITY, V48, P542, DOI 10.1016/j.immuni.2018.02.012; Bottcher JP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9306; Brown RJP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd3233; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Cebula M, 2017, MOL THER, V25, P2289, DOI 10.1016/j.ymthe.2017.06.018; Cebula M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068720; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen ZY, 2019, IMMUNITY, V51, P840, DOI 10.1016/j.immuni.2019.09.013; Chu FL, 2019, LEUKEMIA, V33, P2640, DOI 10.1038/s41375-019-0464-2; Crispe IN, 2009, ANNU REV IMMUNOL, V27, P147, DOI 10.1146/annurev.immunol.021908.132629; Cui WG, 2010, IMMUNOL REV, V236, P151, DOI 10.1111/j.1600-065X.2010.00926.x; da Silva HB, 2018, NATURE, V559, P264, DOI 10.1038/s41586-018-0282-0; Danilo M, 2018, CELL REP, V22, P2107, DOI 10.1016/j.celrep.2018.01.072; Desdin-Mico G, 2018, MITOCHONDRION, V41, P51, DOI 10.1016/j.mito.2017.10.006; Dorner M, 2011, NATURE, V474, P208, DOI 10.1038/nature10168; Dunn JD, 2015, REDOX BIOL, V6, P472, DOI 10.1016/j.redox.2015.09.005; Esensten JH, 2016, IMMUNITY, V44, P973, DOI 10.1016/j.immuni.2016.04.020; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Geltink RIK, 2017, CELL, V171, P385, DOI 10.1016/j.cell.2017.08.018; Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018; Hashimoto M, 2018, ANNU REV MED, V69, P301, DOI 10.1146/annurev-med-012017-043208; He R, 2016, NATURE, V537, P412, DOI 10.1038/nature19317; Huang LR, 2013, NAT IMMUNOL, V14, P574, DOI 10.1038/ni.2573; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Jiang H, 2017, DNA CELL BIOL, V36, P321, DOI 10.1089/dna.2016.3571; Jin Y, 2017, INT IMMUNOPHARMACOL, V53, P42, DOI 10.1016/j.intimp.2017.10.009; Kamphorst AO, 2017, SCIENCE, V355, P1423, DOI 10.1126/science.aaf0683; Lang PA, 2013, CELL DEATH DIFFER, V20, P649, DOI 10.1038/cdd.2012.167; Leong YA, 2016, NAT IMMUNOL, V17, P1187, DOI 10.1038/ni.3543; Li D, 2009, J BIOL CHEM, V284, P21001, DOI 10.1074/jbc.M109.002865; Li YY, 2020, J HEPATOL, V72, P420, DOI 10.1016/j.jhep.2019.09.031; Mackay LK, 2016, SCIENCE, V352, P459, DOI 10.1126/science.aad2035; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Maini MK, 2019, NAT REV GASTRO HEPAT, V16, P662, DOI 10.1038/s41575-019-0196-9; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; McNamara HA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aaj1996; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704; Mylvaganam GH, 2017, P NATL ACAD SCI USA, V114, P1976, DOI 10.1073/pnas.1621418114; Nicolas W, 2017, PHYSIOL BEHAV, V176, P139, DOI 10.1016/j.physbeh.2017.03.040; Ochel A, 2016, CELL MOL IMMUNOL, V13, P805, DOI 10.1038/cmi.2015.80; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Penaloza-MacMaster P, 2011, J VIROL, V85, P6168, DOI 10.1128/JVI.02205-10; Protzer U, 2012, NAT REV IMMUNOL, V12, P201, DOI 10.1038/nri3169; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Riehn M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01201; Rissiek B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01580; Rissiek B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00204; Sandhu U, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq868; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Schirmbeck R, 2008, MOL THER, V16, P1609, DOI 10.1038/mt.2008.141; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Shi JW, 2018, IMMUNITY, V49, P264, DOI 10.1016/j.immuni.2018.06.012; Steinbach K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02827; Strandt H, 2017, J IMMUNOL, V199, P1626, DOI 10.4049/jimmunol.1602098; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; Wang Y, 2009, J BIOL CHEM, V284, P12645, DOI 10.1074/jbc.M807207200; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wieland D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15050; Wortmann A, 2008, MOL THER, V16, P154, DOI 10.1038/sj.mt.6300306; Wu T, 2016, SCI IMMUNOL, V331, P54, DOI [10.1002/dev.21214.Developmental, DOI 10.1002/DEV.21214.DEVELOPMENTAL]; Wu TQ, 2015, CELL REP, V12, P2099, DOI 10.1016/j.celrep.2015.08.049; Ziegler PK, 2018, CELL, V174, P88, DOI 10.1016/j.cell.2018.05.028	70	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								592328	10.3389/fimmu.2020.592328	http://dx.doi.org/10.3389/fimmu.2020.592328			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0BB	33613516	gold, Green Published			2022-12-18	WOS:000618638900001
J	Sakakura, T				Sakakura, Teruyo			Serendipity; Close Encounter of Tenascin C	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						epithelial-mesenchymal interactions; morphogenesis; mammary gland; cancer; stroma			[Sakakura, Teruyo] Mie Univ, Grad Sch Med, Dept Matrix Biol & Pathol, Tsu, Mie, Japan	Mie University	Sakakura, T (corresponding author), Mie Univ, Grad Sch Med, Dept Matrix Biol & Pathol, Tsu, Mie, Japan.	sakakura@houwakai.or.jp						BOURDON MA, 1983, CANCER RES, V43, P2796; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; GROBSTEIN C, 1953, NATURE, V172, P869, DOI 10.1038/172869a0; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; OIKE Y, 1990, International Journal of Developmental Biology, V34, P309; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAKAKURA T, 1979, DEV BIOL, V72, P201, DOI 10.1016/0012-1606(79)90111-8; SAKAKURA T, 1981, J NATL CANCER I, V66, P953; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; Spemann H, 2001, INT J DEV BIOL, V45, P13	15	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								620182	10.3389/fimmu.2020.620182	http://dx.doi.org/10.3389/fimmu.2020.620182			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0AJ	33613549	Green Published, gold			2022-12-18	WOS:000618637100001
J	Xu, L; Tudor, D; Bomsel, M				Xu, Lin; Tudor, Daniela; Bomsel, Morgane			The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						adjuvant; intra-nasal vaccination route; IgA; mucosa; Th2-cytokine thymic stromal lymphopoietin; HIV-1 gp41; P1; microRNA-4485		Mucosal nasal vaccine development, although ideal to protect from pathogens invading mucosally, is limited by the lack of specific adjuvant. We recently used P1, a conserved region of HIV-1 gp41-envelope glycoprotein, as efficient antigen in a prophylactic HIV-1 mucosal vaccine applied nasally. Herein, P1 immunomodulation properties were assessed on human nasal mucosal models by measuring induction of cytokine and chemokine production, intracellular signaling pathways, mucosal dendritic cell (DC) activation, and T cell proliferation. P1 adjuvant properties were evaluated by quantification of antigen-specific B cell responses against a model antigen in an in vitro immunization model. We now demonstrated that P1 has additional immunological properties. P1 initiates immune responses by inducing nasal epithelial cells to secrete the Th2-cytokine thymic stromal lymphopoietin (TSLP), a described mucosal adjuvant. Secreted TSLP activates, in turn, intracellular calcium flux and PAR-2-associated NFAT signaling pathway regulated by microRNA-4485. Thereafter, P1 induces mucosal dendritic cell maturation, secretion of TSLP in a TSLP-receptor (R)-dependent autocrine loop, but also IL-6, IL-10, IL-8, CCL20, CCL22, and MMP-9, and proliferation of CD4+ T cells. Finally, P1 acts as an adjuvant to stimulate antigen-specific B cell responses in vitro. Overall, P1 is a multi-functional domain with various immuno-modulatory properties. In addition to being a protective vaccine antigen for HIV prevention, P1 acts as adjuvant for other mucosal vaccines able to stimulate humoral and cellular antigen-specific responses.	[Xu, Lin; Tudor, Daniela; Bomsel, Morgane] CNRS UMR 8104, Cochin Inst, Dept Infect Immun & Inflammat, Lab Mucosal Entry HIV 1 & Mucosal Immun, Paris, France; [Xu, Lin; Tudor, Daniela; Bomsel, Morgane] INSEAM U1016, Paris, France; [Xu, Lin; Tudor, Daniela; Bomsel, Morgane] Univ Paris, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Bomsel, M (corresponding author), CNRS UMR 8104, Cochin Inst, Dept Infect Immun & Inflammat, Lab Mucosal Entry HIV 1 & Mucosal Immun, Paris, France.; Bomsel, M (corresponding author), INSEAM U1016, Paris, France.; Bomsel, M (corresponding author), Univ Paris, Paris, France.	morgane.bomsel@inserm.fr	Tudor, Daniela/GSN-1837-2022; Bomsel, Morgane/GSN-1948-2022	Bomsel, Morgane/0000-0002-9577-7474; Tudor, Daniela/0000-0002-8281-4600	Agence Nationale de Recherche sur le SIDA et les Hepatites [AO2015-2-17046]; Fondation pour la Recherche Medicale (Grant : "Equipe FRM") [EQU201903007830]	Agence Nationale de Recherche sur le SIDA et les Hepatites; Fondation pour la Recherche Medicale (Grant : "Equipe FRM")	Agence Nationale de Recherche sur le SIDA et les Hepatites (AO2015-2-17046). Fondation pour la Recherche Medicale (Grant : "Equipe FRM" EQU201903007830).	Alfsen A, 2002, J BIOL CHEM, V277, P25649, DOI 10.1074/jbc.M200554200; Anjuere F, 2003, J IMMUNOL, V170, P1586, DOI 10.4049/jimmunol.170.3.1586; Biton M, 2011, NAT IMMUNOL, V12, P239, DOI 10.1038/ni.1994; Bjerkan L, 2015, MUCOSAL IMMUNOL, V8, P49, DOI 10.1038/mi.2014.41; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; BORREBAECK CAK, 1987, BIOCHEM BIOPH RES CO, V148, P941, DOI 10.1016/S0006-291X(87)80223-1; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x; Brandtzaeg P, 2011, AM J RESP CRIT CARE, V183, P1595, DOI 10.1164/rccm.201011-1783OC; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Conche C, 2009, IMMUNITY, V30, P33, DOI 10.1016/j.immuni.2008.10.020; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dong HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep39559; Duchemin M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00244; Fontenot D, 2009, P NATL ACAD SCI USA, V106, P16776, DOI 10.1073/pnas.0907347106; Fujkuyama Y, 2012, EXPERT REV VACCINES, V11, P367, DOI [10.1586/erv.11.196, 10.1586/ERV.11.196]; George JA, 2017, ONCOTARGET, V8, P106050, DOI 10.18632/oncotarget.22525; Guichard V, 2017, ELIFE, V6, DOI 10.7554/e.Life.27215; Hatayama T, 2018, J IMMUNOL, V200, P2670, DOI 10.4049/jimmunol.1701276; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Jabbal-Gill I, 2010, J DRUG TARGET, V18, P771, DOI 10.3109/1061186X.2010.523790; Johansson EL, 2001, INFECT IMMUN, V69, P7481, DOI 10.1128/IAI.69.12.7481-7486.2001; Joo S, 2017, MUCOSAL IMMUNOL, V10, P901, DOI 10.1038/mi.2016.103; Jung YS, 2007, BIOSCI BIOTECH BIOCH, V71, P1963, DOI 10.1271/bbb.70159; Kamekura R, 2009, CELL TISSUE RES, V338, P283, DOI 10.1007/s00441-009-0855-1; Kelso EB, 2006, J PHARMACOL EXP THER, V316, P1017, DOI 10.1124/jpet.105.093807; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Leroux-Roels G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055438; Magerus-Chatinet A, 2007, VIROLOGY, V362, P67, DOI 10.1016/j.virol.2006.11.035; Meng HX, 2016, TRANSL RES, V176, P1, DOI 10.1016/j.trsl.2016.04.008; Nazli A, 2013, J IMMUNOL, V191, P4246, DOI 10.4049/jimmunol.1301482; Qin T, 2015, VACCINE, V33, P1382, DOI 10.1016/j.vaccine.2015.01.022; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Saghazadeh A, 2017, EXPERT OPIN THER TAR, V21, P415, DOI 10.1080/14728222.2017.1299128; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Smelter D, 2009, FASEB J, V23; Sripada L, 2017, J MOL MED, V95, P641, DOI 10.1007/s00109-017-1517-5; Sun JC, 2014, EMBO J, V33, P1295, DOI 10.1002/embj.201387651; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/jhc.4A6539.2005; Tsilingiri K, 2017, CELL MOL GASTROENTER, V3, P174, DOI 10.1016/j.jcmgh.2017.01.005; Van Roey GA, 2012, EUR J IMMUNOL, V42, P353, DOI 10.1002/eji.201141787; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Wang Q, 2015, J ALLERGY CLIN IMMUN, V135, P781, DOI 10.1016/j.jaci.2014.09.015; Wijkhuisen A, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0253-1; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wygrecka M, 2013, AM J PATHOL, V182, P2094, DOI 10.1016/j.ajpath.2013.02.013; Yeh CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055472; Zaman M, 2013, DRUG DELIV TRANSL RE, V3, P100, DOI 10.1007/s13346-012-0085-z; Zhou Z, 2018, MUCOSAL IMMUNOL, V11, P158, DOI 10.1038/mi.2017.23; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	56	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								599278	10.3389/fimmu.2020.599278	http://dx.doi.org/10.3389/fimmu.2020.599278			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0HN	33613520	Green Published, gold			2022-12-18	WOS:000618656200001
J	Zarinsefat, A; Guerra, JMA; Sigdel, T; Damm, I; Sarwal, R; Chan-on, C; Szabo, G; Aguilar-Frasco, JL; Ixtlapale-Carmona, X; Salinas-Ramos, C; Ramirez-Martinez, L; Ramirez, C; Vilatoba, M; Buenrostro, LEM; Alberu, JM; Sarwal, MM				Zarinsefat, Arya; Arreola Guerra, Jose M.; Sigdel, Tara; Damm, Izabella; Sarwal, Reuben; Chan-on, Chitranon; Szabo, Gyula; Aguilar-Frasco, Jorge L.; Ixtlapale-Carmona, Xicohtencatl; Salinas-Ramos, Carlos; Ramirez-Martinez, Leonardo; Ramirez, Claudio; Vilatoba, Mario; Morales Buenrostro, Luis E.; Alberu, Josefina M.; Sarwal, Minnie M.			Use of the Tissue Common Rejection Module Score in Kidney Transplant as an Objective Measure of Allograft Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplant; acute rejection; biomarkers; transcriptomics; formalin-fixed paraffin-embedded (FFPE); graft inflammation		Long-term kidney transplant (KT) allograft outcomes have not improved as expected despite a better understanding of rejection and improved immunosuppression. Previous work had validated a computed rejection score, the tissue common rejection module (tCRM), measured by amplification-based assessment of 11 genes from formalin-fixed paraffin-embedded (FFPE) biopsy specimens, which allows for quantitative, unbiased assessment of immune injury. We applied tCRM in a prospective trial of 124 KT recipients, and contrasted assessment by tCRM and histology reads from 2 independent pathologists on protocol and cause biopsies post-transplant. Four 10-mu m shaves from FFPE biopsy specimens were used for RNA extraction and amplification by qPCR of the 11 tCRM genes, from which the tCRM score was calculated. Biopsy diagnoses of either acute rejection (AR) or borderline rejection (BL) were considered to have inflammation present, while stable biopsies had no inflammation. Of the 77 biopsies that were read by both pathologists, a total of 40 mismatches in the diagnosis were present. The median tCRM scores for AR, BL, and stable diagnoses were 4.87, 1.85, and 1.27, respectively, with an overall significant difference among all histologic groups (Kruskal-Wallis, p < 0.0001). There were significant differences in tCRM scores between pathologists both finding inflammation vs. disagreement (p = 0.003), and both finding inflammation vs. both finding no inflammation (p < 0.001), along with overall significance between all scores (Kruskal-Wallis, p < 0.001). A logistic regression model predicting graft inflammation using various clinical predictor variables and tCRM revealed the tCRM score as the only significant predictor of graft inflammation (OR: 1.90, 95% CI: 1.40-2.68, p < 0.0001). Accurate, quantitative, and unbiased assessment of rejection of the clinical sample is critical. Given the discrepant diagnoses between pathologists on the same samples, individuals could utilize the tCRM score as a tiebreaker in unclear situations. We propose that the tCRM quantitative score can provide unbiased quantification of graft inflammation, and its rapid evaluation by PCR on the FFPE shave can become a critical adjunct to help drive clinical decision making and immunosuppression delivery.	[Zarinsefat, Arya; Sigdel, Tara; Damm, Izabella; Sarwal, Reuben; Chan-on, Chitranon; Sarwal, Minnie M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Arreola Guerra, Jose M.] Centenario Hosp Miguel Hidalgo, Dept Internal Med, Aguascalientes, Aguascalientes, Mexico; [Szabo, Gyula] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Aguilar-Frasco, Jorge L.; Ixtlapale-Carmona, Xicohtencatl; Salinas-Ramos, Carlos; Ramirez-Martinez, Leonardo; Ramirez, Claudio; Vilatoba, Mario; Morales Buenrostro, Luis E.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Alberu, Josefina M.] Tecnol Monterrey, Escuela Med & Ciencias Salud, Dept Med, Mexico City, DF, Mexico	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Tecnologico de Monterrey	Zarinsefat, A (corresponding author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.	arya.zarinsefat@ucsf.edu		Aguilar Frasco, Jorge L./0000-0001-5314-2887	 [NIH: 5 T32 AI 125222]		AZ was funded by the NIH: 5 T32 AI 125222.	Adamek M, 2016, CLIN CHEM LAB MED, V54, P1147, DOI 10.1515/cclm-2015-0622; Beck J, 2015, TRANSPL P, V47, P2400, DOI 10.1016/j.transproceed.2015.08.035; Beck J, 2013, CLIN CHEM, V59, P1732, DOI 10.1373/clinchem.2013.210328; Bloom RD, 2017, J AM SOC NEPHROL, V28, P2221, DOI 10.1681/ASN.2016091034; Furness PN, 2003, AM J SURG PATHOL, V27, P805, DOI 10.1097/00000478-200306000-00012; Haas M, 2018, AM J TRANSPLANT, V18, P293, DOI 10.1111/ajt.14625; Halloran PF, 2015, CURR OPIN ORGAN TRAN, V20, P359, DOI 10.1097/MOT.0000000000000193; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Khatri P, 2013, J EXP MED, V210, P2205, DOI 10.1084/jem.20122709; Lee Hyeseon, 2017, Genomics & Informatics, V15, P2, DOI 10.5808/GI.2017.15.1.2; Li L, 2012, AM J TRANSPLANT, V12, P2710, DOI 10.1111/j.1600-6143.2012.04253.x; Meier-Kriesche HU, 2001, J AM SOC NEPHROL, V12, P1293, DOI 10.1681/ASN.V1261293; Naesens M, 2011, KIDNEY INT, V80, P1364, DOI 10.1038/ki.2011.245; Oniscu GC, 2005, J AM SOC NEPHROL, V16, P1859, DOI 10.1681/ASN.2004121092; Pineda S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09930-3; Roedder S, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001759; Sacreas A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205107; Sigdel T, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00213; Sigdel TK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220052; Sigdel TK, 2018, KIDNEY INT REP, V3, P722, DOI 10.1016/j.ekir.2018.01.014; Sigdel TK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138133; Veronese FV, 2005, CLIN TRANSPLANT, V19, P518, DOI 10.1111/j.1399-0012.2005.00377.x; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303	23	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								614343	10.3389/fimmu.2020.614343	http://dx.doi.org/10.3389/fimmu.2020.614343			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0BC	33613539	Green Published, gold			2022-12-18	WOS:000618639000001
J	Bi, XW; Jiang, BL; Zhou, JY; Fan, XR; Yan, XT; Liang, JJ; Luo, L; Yin, ZM				Bi, Xiaowen; Jiang, Baolin; Zhou, Jinyi; Fan, Xirui; Yan, Xintong; Liang, Juanjuan; Luo, Lan; Yin, Zhimin			CBP Bromodomain Inhibition Rescues Mice From Lethal Sepsis Through Blocking HMGB1-Mediated Inflammatory Responses	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; CREB binding protein; high mobility group box-1 protein; protein phosphatase 2A; MAPK phosphatase 1		CREB binding protein (CBP), a transcriptional coactivator and acetyltransferase, is involved in the pathogenesis of inflammation-related diseases. High mobility group box-1 protein (HMGB1) is a critical mediator of lethal sepsis, which has prompted investigation for the development of new treatment for inflammation. Here, we report that the potent and selective inhibition of CBP bromodomain by SGC-CBP30 blocks HMGB1-mediated inflammatory responses in vitro and in vivo. Our data suggest that CBP bromodomain inhibition suppresses LPS-induced expression and release of HMGB1, when the inhibitor was given 8 h post LPS stimulation; moreover, CBP bromodomain inhibition attenuated pro-inflammatory activity of HMGB1. Furthermore, our findings provide evidence that SGC-CBP30 down-regulated rhHMGB1-induced activation of MAPKs and NF-kappa B signaling by triggering the reactivation of protein phosphatase 2A (PP2A) and the stabilization of MAPK phosphatase 1 (MKP-1). Collectively, these results suggest that CBP bromodomain could serve as a candidate therapeutic target for the treatment of lethal sepsis via inhibiting LPS-induced expression and release of HMGB1 and suppressing the pro-inflammatory activity of HMGB1.	[Bi, Xiaowen; Jiang, Baolin; Zhou, Jinyi; Fan, Xirui; Yan, Xintong; Liang, Juanjuan; Yin, Zhimin] Nanjing Normal Univ, Jiangsu Prov Key Lab Mol & Med Biotechnol, Coll Life Sci, Nanjing, Peoples R China; [Luo, Lan] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Sch Life Sci, Nanjing, Peoples R China	Nanjing Normal University; Nanjing University	Yin, ZM (corresponding author), Nanjing Normal Univ, Jiangsu Prov Key Lab Mol & Med Biotechnol, Coll Life Sci, Nanjing, Peoples R China.; Luo, L (corresponding author), Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Sch Life Sci, Nanjing, Peoples R China.	lanluo@nju.edu.cn; yinzhimin@njnu.edu.cn			Natural Science Foundation of China [32001023, 81671565, 81771703]; China Postdoctoral Science Foundation [2020T130058ZX]; Priority Academic Program Development of Jiangsu Higher Education Institution (PADD)	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Priority Academic Program Development of Jiangsu Higher Education Institution (PADD)	This work was financially supported by grants from the Natural Science Foundation of China (32001023, 81671565, and 81771703), the China Postdoctoral Science Foundation (2020T130058ZX), the Priority Academic Program Development of Jiangsu Higher Education Institution (PADD).	Andersson U, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00172-4; Andersson U, 2018, EXPERT OPIN THER TAR, V22, P263, DOI 10.1080/14728222.2018.1439924; Andrew RC., 2016, ELIFE, V5, DOI [10.7554/eLife.10483.001, DOI 10.7554/ELIFE.10483.001]; Bi XW, 2019, MOL IMMUNOL, V108, P45, DOI 10.1016/j.molimm.2019.02.008; Chan HM, 2001, J CELL SCI, V114, P2363; Chen HF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112668; Dancy BM, 2015, CHEM REV, V115, P2419, DOI 10.1021/cr500452k; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Fujishima S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0029-y; Gao YG, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02283-2; HADJIMINAS DJ, 1994, SHOCK, V2, P376, DOI 10.1097/00024382-199411000-00013; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Jin LY, 2017, CANCER RES, V77, P5564, DOI 10.1158/0008-5472.CAN-17-0314; Johnson JR, 2006, J INFECT DIS, V194, P71, DOI 10.1086/504921; Keane C, 2011, J INFECTION, V63, pE27, DOI 10.1016/j.jinf.2011.04.058; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Li MJ, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20150239; Lin HY, 2020, CHIN J TRAUMATOL, V23, P190, DOI 10.1016/j.cjtee.2020.06.002; Liu WH, 2013, CELL SIGNAL, V25, P1845, DOI 10.1016/j.cellsig.2013.05.021; Longin S, 2008, EXP CELL RES, V314, P68, DOI 10.1016/j.yexcr.2007.07.030; Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001; Lundback P, 2016, ANTIOXID REDOX SIGN, V24, P605, DOI 10.1089/ars.2014.6039; Moosavi SM, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0637-3; Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992; Pasheva E, 2004, BIOCHEMISTRY-US, V43, P2935, DOI 10.1021/bi035615y; Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Schulte W, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/165974; Sents W, 2013, FEBS J, V280, P644, DOI 10.1111/j.1742-4658.2012.08579.x; Sun L, 2015, BIOMOLECULES, V5, P1284, DOI 10.3390/biom5031284; Ueda T, 2014, CRIT CARE MED, V42, pE288, DOI 10.1097/CCM.0000000000000162; Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031; Wang HC, 2009, SHOCK, V32, P348, DOI 10.1097/SHK.0b013e3181a551bd; Wang YL, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4208; Wu CX, 2012, J SURG RES, V175, P88, DOI 10.1016/j.jss.2011.02.026; Xie SH, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106066; Youn JH, 2008, J IMMUNOL, V180, P5067, DOI 10.4049/jimmunol.180.7.5067; Yu Y, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1857-6; Zhao F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9719647; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794; Zhao Yarong, 2018, Oncotarget, V9, P14959, DOI 10.18632/oncotarget.24127; Zheng HY, 2018, CURR MED SCI, V38, P115, DOI 10.1007/s11596-018-1854-9	45	1	1	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								625542	10.3389/fimmu.2020.625542	http://dx.doi.org/10.3389/fimmu.2020.625542			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH1YY	33603756	Green Published, gold			2022-12-18	WOS:000618075000001
J	Krantsevich, A; Tang, CE; MacCarthy, T				Krantsevich, Artem; Tang, Catherine; MacCarthy, Thomas			Correlations in Somatic Hypermutation Between Sites in IGHV Genes Can Be Explained by Interactions Between AID and/or Pol eta Hotspots	FRONTIERS IN IMMUNOLOGY			English	Article						B cell receptor; activation-induced deaminase; computational immunology; immunoglobulin heavy chain; somatic hypermutation; overlapping hotspots		The somatic hypermutation (SHM) of Immunoglobulin (Ig) genes is a key process during antibody affinity maturation in B cells. The mutagenic enzyme activation induced deaminase (AID) is required for SHM and has a preference for WRC hotspots in DNA. Error-prone repair mechanisms acting downstream of AID introduce further mutations, including DNA polymerase eta (Pol eta), part of the non-canonical mismatch repair pathway (ncMMR), which preferentially generates mutations at WA hotspots. Previously proposed mechanistic models lead to a variety of predictions concerning interactions between hotspots, for example, how mutations in one hotspot will affect another hotspot. Using a large, high-quality, Ig repertoire sequencing dataset, we evaluated pairwise correlations between mutations site-by-site using an unbiased measure similar to mutual information which we termed "mutational association" (MA). Interactions are dominated by relatively strong correlations between nearby sites (short-range MAs), which can be almost entirely explained by interactions between overlapping hotspots for AID and/or Pol eta. We also found relatively weak dependencies between almost all sites throughout each gene (longer-range MAs), although these arise mostly as a statistical consequence of high pairwise mutation frequencies. The dominant short-range interactions are also highest within the most highly mutating IGHV sub-regions, such as the complementarity determining regions (CDRs), where there is a high hotspot density. Our results suggest that the hotspot preferences for AID and Pol eta have themselves evolved to allow for greater interactions between AID and/or Pol eta induced mutations.	[Krantsevich, Artem; Tang, Catherine; MacCarthy, Thomas] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA; [MacCarthy, Thomas] SUNY Stony Brook, Laufer Ctr Phys & Quantitat Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	MacCarthy, T (corresponding author), SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.; MacCarthy, T (corresponding author), SUNY Stony Brook, Laufer Ctr Phys & Quantitat Biol, Stony Brook, NY 11794 USA.	thomas.maccarthy@stonybrook.edu			 [NIH R01AI132507]		This work was supported by grant NIH R01AI132507 to TM. The funders had no role in study design, data collection, and interpretation or the decision to submit the work for publication.	Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Buerstedde JM, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001831; Cui A, 2016, J IMMUNOL, V197, P3566, DOI 10.4049/jimmunol.1502263; Delbos F, 2005, J EXP MED, V201, P1191, DOI 10.1084/jem.20050292; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Feng YQ, 2020, TRENDS IMMUNOL, V41, P586, DOI 10.1016/j.it.2020.04.009; Frieder D, 2009, MOL CELL BIOL, V29, P5148, DOI 10.1128/MCB.00647-09; Han L, 2011, P NATL ACAD SCI USA, V108, P11584, DOI 10.1073/pnas.1018726108; Hoehn KB, 2016, MOL BIOL EVOL, V33, P1147, DOI 10.1093/molbev/msw015; Hoffman PD, 2008, BIOCHEMISTRY-US, V47, P4583, DOI 10.1021/bi701781p; KEHOE JM, 1971, P NATL ACAD SCI USA, V68, P2019, DOI 10.1073/pnas.68.9.2019; Kepler Thomas B, 2013, F1000Res, V2, P103, DOI 10.12688/f1000research.2-103.v1; King JJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00351; Kodgire P, 2012, MOL CELL BIOL, V32, P2030, DOI 10.1128/MCB.06722-11; Mak CH, 2013, J BIOL CHEM, V288, P29786, DOI 10.1074/jbc.M113.506550; Martomo SA, 2005, P NATL ACAD SCI USA, V102, P8656, DOI 10.1073/pnas.0501852102; Mayorov VI, 2005, J IMMUNOL, V174, P7781, DOI 10.4049/jimmunol.174.12.7781; Methot SP, 2017, ADV IMMUNOL, V133, P37, DOI 10.1016/bs.ai.2016.11.002; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Ohm-Laursen L, 2007, J IMMUNOL, V178, P4322, DOI 10.4049/jimmunol.178.7.4322; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Pham P, 2007, DNA REPAIR, V6, P689, DOI 10.1016/j.dnarep.2007.01.001; Pucella JN, 2017, MOL CELL, V67, P355, DOI 10.1016/j.molcel.2017.07.020; Quinlan EM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00077-17; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Refsland EW, 2013, CURR TOP MICROBIOL, V371, P1, DOI 10.1007/978-3-642-37765-5_1; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Schramm CA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01876; Shapiro GS, 1999, J IMMUNOL, V163, P259; Sheng ZZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00537; Slatkin M, 2008, NAT REV GENET, V9, P477, DOI 10.1038/nrg2361; Storb U, 2009, CELL CYCLE, V8, P3097, DOI 10.4161/cc.8.19.9658; Tang C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00788; Thientosapol ES, 2017, NUCLEIC ACIDS RES, V45, P3146, DOI 10.1093/nar/gkw1300; Vergani S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01157; Wang Q, 2017, J EXP MED, V214, P49, DOI 10.1084/jem.20161649; Wei LR, 2015, P NATL ACAD SCI USA, V112, pE728, DOI 10.1073/pnas.1500788112; Wiehe K, 2018, CELL HOST MICROBE, V23, P759, DOI 10.1016/j.chom.2018.04.018; Yaari G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00358; Yeap LS, 2015, CELL, V163, P1124, DOI 10.1016/j.cell.2015.10.042; Zivojnovic M, 2014, MOL CELL BIOL, V34, P2176, DOI 10.1128/MCB.01452-13	41	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								618409	10.3389/fimmu.2020.618409	http://dx.doi.org/10.3389/fimmu.2020.618409			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH4EN	33603748	gold, Green Published			2022-12-18	WOS:000618228800001
J	Seo, J; Park, YS; Kweon, TH; Kang, J; Son, S; Kim, HB; Seo, YR; Kang, MJ; Yi, EC; Lee, YH; Kim, JH; Park, B; Yang, WH; Cho, JW				Seo, Junghwa; Park, Yun Soo; Kweon, Tae Hyun; Kang, Jingu; Son, Seongjin; Kim, Han Byeol; Seo, Yu Ri; Kang, Min Jueng; Yi, Eugene C.; Lee, Yong-ho; Kim, Jin-Hong; Park, Boyoun; Yang, Won Ho; Cho, Jin Won			O-Linked N-Acetylglucosamine Modification of Mitochondrial Antiviral Signaling Protein Regulates Antiviral Signaling by Modulating Its Activity	FRONTIERS IN IMMUNOLOGY			English	Article						host defense mechanism; innate immunity; mitochondrial antiviral signaling protein; O-linked N-Acetylglucosamine (O-GlcNAc); RIG-I-like receptors signaling		Post-translational modifications, including O-GlcNAcylation, play fundamental roles in modulating cellular events, including transcription, signal transduction, and immune signaling. Several molecular targets of O-GlcNAcylation associated with pathogen-induced innate immune responses have been identified; however, the direct regulatory mechanisms linking O-GlcNAcylation with antiviral RIG-I-like receptor signaling are not fully understood. In this study, we found that cellular levels of O-GlcNAcylation decline in response to infection with Sendai virus. We identified a heavily O-GlcNAcylated serine-rich region between amino acids 249-257 of the mitochondrial antiviral signaling protein (MAVS); modification at this site disrupts MAVS aggregation and prevents MAVS-mediated activation and signaling. O-GlcNAcylation of the serine-rich region of MAVS also suppresses its interaction with TRAF3; this prevents IRF3 activation and production of interferon-beta. Taken together, these results suggest that O-GlcNAcylation of MAVS may be a master regulatory event that promotes host defense against RNA viruses.	[Seo, Junghwa; Park, Yun Soo; Kweon, Tae Hyun; Kang, Jingu; Son, Seongjin; Yi, Eugene C.; Lee, Yong-ho; Kim, Jin-Hong; Park, Boyoun; Yang, Won Ho; Cho, Jin Won] Yonsei Univ, Glycosylat Network Res Ctr, Seoul, South Korea; [Seo, Junghwa; Park, Yun Soo; Kweon, Tae Hyun; Kang, Jingu; Son, Seongjin] Yonsei Univ, Interdisciplinary Program Integrated OMICS Biomed, Grad Sch, Seoul, South Korea; [Kim, Han Byeol; Seo, Yu Ri; Kang, Min Jueng; Yi, Eugene C.] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Sch Convergence Sci & Technol, Coll Pharm, Seoul, South Korea; [Kim, Han Byeol; Seo, Yu Ri; Kang, Min Jueng; Yi, Eugene C.] Seoul Natl Univ, Coll Med, Coll Pharm, Seoul, South Korea; [Lee, Yong-ho] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Kim, Jin-Hong] Seoul Natl Univ, Coll Nat Sci, Dept Biol Sci, Seoul, South Korea; [Park, Boyoun; Yang, Won Ho; Cho, Jin Won] Yonsei Univ, Dept Syst Biol, Coll Life Sci & Biotechnol, Seoul, South Korea	Yonsei University; Yonsei University; Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University Health System; Seoul National University (SNU); Yonsei University	Cho, JW (corresponding author), Yonsei Univ, Glycosylat Network Res Ctr, Seoul, South Korea.; Cho, JW (corresponding author), Yonsei Univ, Dept Syst Biol, Coll Life Sci & Biotechnol, Seoul, South Korea.	chojw311@yonsei.ac.kr	Lee, Yong-ho/AAT-4106-2020	Lee, Yong-ho/0000-0002-6219-4942; Kim, Jin-Hong/0000-0002-6480-1929	National Research Foundation of Korea (NRF); Korean Government [NRF-2016R1A5A1010764, NRF-2015M3A9B6073840]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean Government(Korean Government)	This research was supported by the National Research Foundation of Korea (NRF). Grants were given to JC from the Korean Government (NRF-2016R1A5A1010764 and NRF-2015M3A9B6073840).	Angelova M, 2015, J VIROL, V89, P8474, DOI 10.1128/JVI.01002-15; Banerjee PS, 2013, CHEM SOC REV, V42, P4345, DOI 10.1039/c2cs35412h; Capotosti F, 2011, CELL, V144, P376, DOI 10.1016/j.cell.2010.12.030; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Gack MU, 2014, J VIROL, V88, P5213, DOI 10.1128/JVI.03370-13; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Gawlowski T, 2012, J BIOL CHEM, V287, P30024, DOI 10.1074/jbc.M112.390682; Golks A, 2007, EMBO J, V26, P4368, DOI 10.1038/sj.emboj.7601845; Herzog K, 2020, GUT, V69, P380, DOI 10.1136/gutjnl-2018-317423; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Jia YX, 2009, J IMMUNOL, V183, P4241, DOI 10.4049/jimmunol.0901646; Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5; Jochmann R, 2009, J VIROL, V83, P3704, DOI 10.1128/JVI.01384-08; Kapogiannis D, 2011, LANCET NEUROL, V10, P187, DOI 10.1016/S1474-4422(10)70277-5; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Li TL, 2018, CELL HOST MICROBE, V24, P791, DOI 10.1016/j.chom.2018.11.001; Liu BY, 2018, CURR OPIN IMMUNOL, V50, P75, DOI 10.1016/j.coi.2017.12.002; Liu BY, 2017, NAT IMMUNOL, V18, P214, DOI 10.1038/ni.3641; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Marotta NP, 2015, NAT CHEM, V7, P913, DOI [10.1038/NCHEM.2361, 10.1038/nchem.2361]; Okamoto M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01942; Ong QX, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00599; Ozcan S, 2010, BBA-GENE REGUL MECH, V1799, P353, DOI 10.1016/j.bbagrm.2010.02.005; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Paz S, 2011, CELL RES, V21, P895, DOI 10.1038/cr.2011.2; Pekkurnaz G, 2014, CELL, V158, P54, DOI 10.1016/j.cell.2014.06.007; Ryan P, 2019, ACS CHEM NEUROSCI, V10, P2209, DOI 10.1021/acschemneuro.9b00143; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shi YH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15138; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; Song N, 2019, CELL REP, V28, P2386, DOI 10.1016/j.celrep.2019.07.085; Vazquez C, 2015, J VIROL, V89, P6974, DOI 10.1128/JVI.01918-14; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yoo YS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8910; Yuzwa SA, 2012, NAT CHEM BIOL, V8, P393, DOI [10.1038/NCHEMBIO.797, 10.1038/nchembio.797]; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zeng QH, 2016, P NATL ACAD SCI USA, V113, P9333, DOI 10.1073/pnas.1606801113; Zhang WN, 2019, CELL, V178, P176, DOI 10.1016/j.cell.2019.05.003; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zhu YP, 2015, NAT CHEM BIOL, V11, P319, DOI [10.1038/nchembio.1774, 10.1038/NCHEMBIO.1774]	45	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								589259	10.3389/fimmu.2020.589259	http://dx.doi.org/10.3389/fimmu.2020.589259			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH1XW	33603735	Green Published, gold			2022-12-18	WOS:000618072200001
J	Sun, Q; Li, N; Jia, L; Guo, WF; Jiang, HX; Liu, BJ; Bao, CT; Liu, MM; Huang, J; Lei, LC				Sun, Qiang; Li, Na; Jia, Li; Guo, Wenfei; Jiang, Hexiang; Liu, Baijun; Bao, Chuntong; Liu, Mengmeng; Huang, Jing; Lei, Liancheng			Ribosomal Protein SA-Positive Neutrophil Elicits Stronger Phagocytosis and Neutrophil Extracellular Trap Formation and Subdues Pro-Inflammatory Cytokine Secretion Against Streptococcus suis Serotype 2 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						polymorphonuclear neutrophil; ribosomal protein SA; Streptococcus suis serotype 2; blood-brain barrier; infection		Streptococcus suis serotype 2 (SS2), an important zoonotic pathogen that causes septicemia, arthritis, and irreversible meningitis in pigs and humans, can be transmitted to humans from pigs. S. suis causes huge economic losses to the swine industry and poses a serious threat to public health. Previously, we found that the brain tissues of mice with SS2-induced meningitis showed disrupted structural integrity and significantly enhanced polymorphonuclear neutrophil (PMN) infiltration. We showed that the brain tissues of SS2-infected mice had increased ribosomal protein SA (RPSA)-positive PMN counts. However, the inflammatory responses of RPSA(+) PMNs to SS2 and their effects on the blood-brain barrier (BBB) remain unclear. Therefore, in studying the pathogenesis of SS2-induced meningitis, it is essential that we explore the functions of RPSA(+) PMNs and their effects on the BBB. Herein, using flow cytometry and immunofluorescence microscopy analyses, we found that RPSA expression enhances PMN-induced phagocytosis and PMN-induced formation of neutrophil extracellular traps (NETs), which facilitate further elimination of bacteria. PMN surface expression of RPSA also alleviates local inflammation and tissue injuries by inhibiting secretion of the pro-inflammatory cytokines, TNF-alpha and IL-6. Moreover, the single-cell BBB model showed that RPSA disrupts BBB integrity by downregulating expression of tight junction-associated membrane proteins on PMNs. Taken together, our data suggest that PMN-surface expression of RPSA is a double-edged sword. RPSA+ PMN owns a stronger ability of bacterial cleaning and weakens inflammatory cytokines release which are useful to anti-infection, but does hurt BBB. Partly, RPSA+ PMN may be extremely useful to control the infection as a therapeutic cellular population, following novel insights into the special PMN population.	[Sun, Qiang; Guo, Wenfei; Liu, Mengmeng; Huang, Jing] Jilin Univ, Lab Dept Hosp 1, Changchun, Peoples R China; [Li, Na; Jia, Li; Jiang, Hexiang; Liu, Baijun; Bao, Chuntong; Lei, Liancheng] Jilin Univ, Coll Vet Med, Changchun, Peoples R China; [Lei, Liancheng] Yangtze Univ, Coll Anim Sci, Jingzhou, Peoples R China	Jilin University; Jilin University; Yangtze University	Huang, J (corresponding author), Jilin Univ, Lab Dept Hosp 1, Changchun, Peoples R China.; Lei, LC (corresponding author), Jilin Univ, Coll Vet Med, Changchun, Peoples R China.; Lei, LC (corresponding author), Yangtze Univ, Coll Anim Sci, Jingzhou, Peoples R China.	jluhuangjing1@126.com; leilc@jlu.edu.cn	sun, qiang/GXF-0662-2022; Bao, Chuntong/AHC-1519-2022; Li, Na/AAO-8117-2020	Bao, Chuntong/0000-0003-3292-2272; Li, Na/0000-0001-5380-8554; lei, liancheng/0000-0002-5872-1842	National Key R&D Program of China [2017YFD0500204]	National Key R&D Program of China	This study was supported by the National Key R&D Program of China (2017YFD0500204).	Abouseada NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046233; Ajikumar A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205227; Auger JP, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5030048; Baloui H, 2009, J NEUROTRAUM, V26, P195, DOI 10.1089/neu.2008.0677; Barichello T, 2011, NEUROCHEM RES, V36, P1922, DOI 10.1007/s11064-011-0514-2; Bi YH, 2014, VET MICROBIOL, V173, P299, DOI 10.1016/j.vetmic.2014.08.010; Bolze A, 2013, SCIENCE, V340, P976, DOI 10.1126/science.1234864; Chabot-Roy G, 2006, MICROB PATHOGENESIS, V41, P21, DOI 10.1016/j.micpath.2006.04.001; Chen SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00559; Chung JW, 2003, J BIOL CHEM, V278, P16857, DOI 10.1074/jbc.M301028200; Cordeiro OD, 2012, MAR BIOTECHNOL, V14, P714, DOI 10.1007/s10126-012-9437-4; DiGiacomo V, 2016, BIOL REV, V91, P288, DOI 10.1111/brv.12170; Fuchs T, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00307; Gomes SFM, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01181; Gottschalk M, 2000, VET MICROBIOL, V76, P259, DOI 10.1016/S0378-1135(00)00250-9; Gough P, 2017, J IMMUNOL, V198, P4373, DOI 10.4049/jimmunol.1700253; Hlebowicz M, 2019, VECTOR-BORNE ZOONOT, V19, P557, DOI 10.1089/vbz.2018.2399; Iovino F, 2017, J EXP MED, V214, P1619, DOI 10.1084/jem.20161668; Iovino F, 2014, INFECT IMMUN, V82, P3555, DOI 10.1128/IAI.00046-14; Iovino F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068408; Kamoshida G, 2015, J INFECT CHEMOTHER, V21, P43, DOI 10.1016/j.jiac.2014.08.032; Kane BA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37907-7; Kayal S, 2002, MOL MICROBIOL, V44, P1407, DOI 10.1046/j.1365-2958.2002.02973.x; Kayal S, 2006, FEMS MICROBIOL REV, V30, P514, DOI 10.1111/j.1574-6976.2006.00021.x; Khan NA, 2012, MICROB PATHOGENESIS, V53, P269, DOI 10.1016/j.micpath.2012.07.001; Kim KJ, 2005, J BIOL CHEM, V280, P1360, DOI 10.1074/jbc.M410176200; Kim KM, 2018, J NEUROSCI, V38, P10672, DOI 10.1523/JNEUROSCI.0825-17.2018; Kral-Pointner JB, 2019, THROMB HAEMOSTASIS, V119, P1642, DOI 10.1055/s-0039-1693693; Lakschevitz FS, 2016, EXP CELL RES, V342, P200, DOI 10.1016/j.yexcr.2016.03.007; Lappann M, 2013, MOL MICROBIOL, V89, P433, DOI 10.1111/mmi.12288; LeBel G, 2019, ARCH MICROBIOL, V201, P833, DOI 10.1007/s00203-019-01655-7; Li Y, 2016, INT J BIOL MACROMOL, V93, P520, DOI 10.1016/j.ijbiomac.2016.08.069; Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603; Malipiero U, 2007, NEURODEGENER DIS, V4, P43, DOI 10.1159/000100358; Malygin AA, 2011, BIOCHIMIE, V93, P612, DOI 10.1016/j.biochi.2010.12.005; Masuda S, 2017, CYTOM PART A, V91A, P822, DOI 10.1002/cyto.a.23169; Meloni BP, 2006, J NEUROSCI RES, V83, P584, DOI 10.1002/jnr.20755; Mittal SK, 2018, INVEST OPHTH VIS SCI, V59, P1191, DOI 10.1167/iovs.17-23067; Morita C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103125; Naidoo K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141618; Orihuela CJ, 2009, J CLIN INVEST, V119, P1638, DOI 10.1172/JCI36759; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Prinz M, 2017, NAT NEUROSCI, V20, P136, DOI 10.1038/nn.4475; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; Salem I, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7315274; Schubert-Unkmeir A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000874; Selleri C, 2006, BLOOD, V108, P2476, DOI 10.1182/blood-2005-11-012625; Shaw CA, 2018, ADV EXP MED BIOL, V1091, P53, DOI 10.1007/978-981-13-1370-7_4; Silvestre F, 2010, SCI TOTAL ENVIRON, V408, P3176, DOI 10.1016/j.scitotenv.2010.04.005; Sogawa Y, 2011, J PHARMACOL SCI, V115, P63, DOI 10.1254/jphs.10194FP; Sollberger G, 2018, DEV CELL, V44, P542, DOI 10.1016/j.devcel.2018.01.019; Song DG, 2013, APPL BIOCHEM BIOTECH, V171, P1630, DOI 10.1007/s12010-013-0443-4; Stone NL, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00230; Stork M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003733; Sun DL, 2016, EUR J IMMUNOL, V46, P1704, DOI 10.1002/eji.201546239; Suzuki K, 2019, AM J PATHOL, V189, P1526, DOI 10.1016/j.ajpath.2019.05.002; Tregay N, 2019, THORAX, V74, P659, DOI 10.1136/thoraxjnl-2018-212509; Wang JP, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01001; Wu HY, 2015, J APPL GENET, V56, P481, DOI 10.1007/s13353-015-0275-8; Yadav A, 2009, MAGN RESON IMAGING, V27, P214, DOI 10.1016/j.mri.2008.06.010; Yu XW, 2017, HUM PATHOL, V61, P121, DOI 10.1016/j.humpath.2016.12.005; Zheng JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074674; Zhu ZX, 2020, J VIROL, V94, DOI 10.1128/JVI.01350-19; Zidane N, 2013, BIOSCIENCE REP, V33, P113, DOI 10.1042/BSR20120103	65	1	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								585399	10.3389/fimmu.2020.585399	http://dx.doi.org/10.3389/fimmu.2020.585399			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH4AL	33603733	gold, Green Published			2022-12-18	WOS:000618217900001
J	Tomaszewska, A; Jagasia, M; Beohou, E; van der Werf, S; Blaise, D; Kanfer, E; Milpied, N; Remenyi, P; Ciceri, F; Bourhis, JH; Chevallier, P; Solano, C; Socie, G; Bruno, B; Rambaldi, A; Castagna, L; Kroger, N; Corradini, P; Afanasyev, B; Ladetto, M; Niederwieser, D; Scheid, C; Sengeloev, H; Kroschinsky, F; Yakoub-Agha, I; Schoemans, H; Koenecke, C; Penack, O; Peric, Z; Greinix, H; Duarte, RF; Basak, GW				Tomaszewska, Agnieszka; Jagasia, Madan; Beohou, Eric; van der Werf, Steffie; Blaise, Didier; Kanfer, Edward; Milpied, Noel; Remenyi, Peter; Ciceri, Fabio; Bourhis, Jean H.; Chevallier, Patrice; Solano, Carlos; Socie, Gerard; Bruno, Benedetto; Rambaldi, Alessandro; Castagna, Luca; Kroger, Nicolaus; Corradini, Paolo; Afanasyev, Boris; Ladetto, Marco; Niederwieser, Dietger; Scheid, Christof; Sengeloev, Henrik; Kroschinsky, Frank; Yakoub-Agha, Ibrahim; Schoemans, Helene; Koenecke, Christian; Penack, Olaf; Peric, Zinaida; Greinix, Hildegard; Duarte, Rafael F.; Basak, Grzegorz W.			Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies	FRONTIERS IN IMMUNOLOGY			English	Article						transplantation; B-cell malignancy; conditioning; rituximab; non-relapse mortality after hematopoietic cell transplantation; graft-versus-host disease	VERSUS-HOST-DISEASE	Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001-2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1-77.3) and 43.2 months (range 0.3-179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4 degrees (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.	[Tomaszewska, Agnieszka; Chevallier, Patrice; Basak, Grzegorz W.] Med Univ Warsaw, Dept Hematol Transplantol & Internal Med, Warsaw, Poland; [Jagasia, Madan] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA; [Beohou, Eric] EBMT Paris Stat Unit, Paris, France; [van der Werf, Steffie] EBMT Data Off, Leiden, Netherlands; [Blaise, Didier] Inst Paoli Calmettes, Marseille, France; [Kanfer, Edward] Imperial Coll Healthcare, Hammersmith Hosp, London, England; [Milpied, Noel] Hop Haut Leveque, Bordeaux, France; [Remenyi, Peter] Del Pesyt Ctr Korhaz, Budapest, Hungary; [Ciceri, Fabio] Osped San Raffaele Srl, Milan, Italy; [Bourhis, Jean H.] Gustave Roussy, Inst Cancerol, Val De Marne, France; [Chevallier, Patrice] CHU Nantes, Nantes, France; [Solano, Carlos] Hosp Clin Univ, Valencia, Spain; [Solano, Carlos] Hop St Louis, Paris, France; [Socie, Gerard] Univ Torino, Citta Salute & Sci Torino, Turin, Italy; [Bruno, Benedetto; Rambaldi, Alessandro] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy; [Castagna, Luca] Ist Clin Humanitas, Milan, Italy; [Kroger, Nicolaus] Univ Hosp Eppendorf, Hamburg, Germany; [Corradini, Paolo] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Afanasyev, Boris] First State Pavlov Med Univ St Petersburg, St Petersburg, Russia; [Ladetto, Marco] H SS Antonio & Biagio, Alessandria, Italy; [Niederwieser, Dietger] Univ Hosp Leipzig, Leipzig, Germany; [Scheid, Christof] Univ Cologne, Cologne, Germany; [Sengeloev, Henrik] Rigshosp, Copenhagen, Denmark; [Kroschinsky, Frank] Univ Klinikum Dresden, Dresden, Germany; [Yakoub-Agha, Ibrahim] Hosp Huriez, CHU Lille, Lille, France; [Schoemans, Helene] Univ Hosp Leuven, Leuven, Belgium; [Schoemans, Helene] Katholieke Univ Leuven, Leuven, Belgium; [Koenecke, Christian] Hannover Med Sch, Hannover, Germany; [Penack, Olaf] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; [Peric, Zinaida] Univ Hosp Ctr Rebro, Zagreb, Croatia; [Greinix, Hildegard] Med Univ Graz, Dept Hematol & Oncol, Graz, Austria; [Duarte, Rafael F.] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain	Medical University of Warsaw; Vanderbilt University; UNICANCER; Institut Paoli-Calmette (IPC); Imperial College London; CHU Bordeaux; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; UNICANCER; Gustave Roussy; Nantes Universite; CHU de Nantes; Hospital Clinic Universitari de Valencia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin; ASST Papa Giovanni XXIII; IRCCS Humanitas Research Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; Pavlov First Saint Petersburg State Medical University; Leipzig University; University of Cologne; Rigshospitalet; University of Copenhagen; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Universite de Lille - ISITE; CHU Lille; KU Leuven; University Hospital Leuven; KU Leuven; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Graz; Hospital Puerta de Hierro-Majadahonda	Tomaszewska, A (corresponding author), Med Univ Warsaw, Dept Hematol Transplantol & Internal Med, Warsaw, Poland.	agnieszka_tomaszewska@onet.eu	DUARTE, Rafael F./Q-5884-2018; Blaise, Didier/R-2483-2016; ladetto, marco/AAA-5546-2022; Penack, Olaf/L-1068-2016	DUARTE, Rafael F./0000-0002-5240-9815; Blaise, Didier/0000-0002-5684-9447; ladetto, marco/0000-0002-8283-2681; Basak, Grzegorz/0000-0003-3858-8180; Schoemans, Helene/0000-0002-7568-8239; Kroger, Nicolaus/0000-0001-5103-9966; Penack, Olaf/0000-0003-4876-802X; Castagna, Luca/0000-0002-6239-7387				Arai S, 2012, BLOOD, V119, P6145, DOI 10.1182/blood-2011-12-395970; B AS, 2013, BIOL BLOOD MARROW TR, V19, pS140; Cutler C, 2006, BLOOD, V108, P756, DOI 10.1182/blood-2006-01-0233; Cutler C, 2013, BLOOD, V122, P1510, DOI 10.1182/blood-2013-04-495895; Epperla N, 2018, BIOL BLOOD MARROW TR, V24, P78, DOI 10.1016/j.bbmt.2017.10.011; Epperla N, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0487-y; Kapur R, 2008, HAEMATOL-HEMATOL J, V93, P1702, DOI 10.3324/haematol.13311; Kennedy VE, 2016, BIOL BLOOD MARROW TR, V22, P1801, DOI 10.1016/j.bbmt.2016.06.029; Kharfan-Dabaja MA, 2009, BIOL BLOOD MARROW TR, V15, P1005, DOI 10.1016/j.bbmt.2009.04.003; KHOURI I, 2001, BLOOD, V98; Khouri IF, 2008, BLOOD, V111, P5530, DOI 10.1182/blood-2008-01-136242; McSweeney PA, 2001, BLOOD, V97, P3390, DOI 10.1182/blood.V97.11.3390; Miklos DB, 2005, BLOOD, V105, P2973, DOI 10.1182/blood-2004-09-3660; Miklos DB, 2004, BLOOD, V103, P353, DOI 10.1182/blood-2003-03-0984; Mohty M, 2008, BONE MARROW TRANSPL, V41, P909, DOI 10.1038/bmt.2008.12; Ratanatharathorn V, 2003, BIOL BLOOD MARROW TR, V9, P505, DOI 10.1016/S1083-8791(03)00216-7; Sarantopoulos S, 2015, BIOL BLOOD MARROW TR, V21, P16, DOI 10.1016/j.bbmt.2014.10.029; Sauter CS, 2014, BIOL BLOOD MARROW TR, V20, P354, DOI 10.1016/j.bbmt.2013.11.029; Scrucca L, 2007, BONE MARROW TRANSPL, V40, P381, DOI 10.1038/sj.bmt.1705727; Shimabukuro-Vornhagen A, 2009, BLOOD, V114, P4919, DOI 10.1182/blood-2008-10-161638; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; van Dorp S, 2009, BIOL BLOOD MARROW TR, V15, P671, DOI 10.1016/j.bbmt.2009.02.005	22	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								613954	10.3389/fimmu.2020.613954	http://dx.doi.org/10.3389/fimmu.2020.613954			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH4CD	33603743	gold, Green Published			2022-12-18	WOS:000618222400001
J	Wang, X; Liu, DD; Qin, WT; Liu, YS; Yuan, X; Zhang, XX; Dai, CH; Zhang, DY				Wang, Xu; Liu, Dadong; Qin, Weiting; Liu, Yishu; Yuan, Xiao; Zhang, Xiaoxin; Dai, Chunhua; Zhang, Danyi			P2RX1-Involved Glycolytic Metabolism Supports Neutrophil Activation in Acute Pancreatitis	FRONTIERS IN IMMUNOLOGY			English	Article						acute pancreatitis; inflammation; neutrophil; purinergic signaling; purinergic receptor		Acute pancreatitis (AP) is characterized by disordered inflammation of the pancreas, and the underlying mechanisms remain unclear. Purinergic signaling plays crucial roles in initiating and amplifying inflammatory signals. Recent evidence reveals that targeting dysregulated purinergic signaling is promising for treating inflammation-associated diseases. To explore the potential involvement of purinergic signaling in AP, we investigated the expression profiles of purinergic signaling molecules in human and mouse pancreas tissues. Results showed that purinergic receptor P2RX1 was among the most highly expressed genes in both human and mouse pancreas tissues. Genetic ablation or specific antagonism of P2RX1 markedly alleviated inflammatory responses in caerulein-induced AP mice. Bone marrow chimeras and adoptive transfer studies revealed that neutrophil-derived P2RX1 contributed to the inflammatory responses in AP. Further studies demonstrated that P2RX1 promoted neutrophil activation by facilitating glycolytic metabolism. Therefore, our study indicates that purinergic receptor P2RX1 may be a potential therapeutic target to treat disordered inflammation in AP.	[Wang, Xu; Yuan, Xiao; Dai, Chunhua] Jiangsu Univ, Affiliated Hosp, Inst Oncol, Dept Radiat Oncol, Zhenjiang, Jiangsu, Peoples R China; [Liu, Dadong] Jiangsu Univ, Affiliated Hosp, Dept Intens Care Units, Zhenjiang, Jiangsu, Peoples R China; [Qin, Weiting] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiat Oncol, Shanghai, Peoples R China; [Liu, Yishu] Jiangsu Univ, Affiliated Hosp, Dept Gen Surg, Zhenjiang, Jiangsu, Peoples R China; [Zhang, Xiaoxin] Jiangsu Univ, Sch Med, Jiangsu Key Lab Med Sci & Lab Med, Zhenjiang, Jiangsu, Peoples R China; [Zhang, Danyi] Jiangsu Univ, Affiliated Peoples Hosp, Dept Lab Med, Zhenjiang, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University; Shanghai Jiao Tong University; Jiangsu University; Jiangsu University; Jiangsu University	Wang, X; Dai, CH (corresponding author), Jiangsu Univ, Affiliated Hosp, Inst Oncol, Dept Radiat Oncol, Zhenjiang, Jiangsu, Peoples R China.; Zhang, XX (corresponding author), Jiangsu Univ, Sch Med, Jiangsu Key Lab Med Sci & Lab Med, Zhenjiang, Jiangsu, Peoples R China.; Zhang, DY (corresponding author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Lab Med, Zhenjiang, Jiangsu, Peoples R China.	jsdxwx@126.com; zhangxiaoxin2014@163.com; daichunhua8@163.com; 407874677@qq.com		Wang, Xu/0000-0002-3768-777X	National Natural Science Foundation of China [81701945]; China Postdoctoral Science Foundation [2018M640403]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by the National Natural Science Foundation of China (ID: 81701945 to XW); China Postdoctoral Science Foundation (ID 2018M640403 to XW).	Antonioli L, 2019, PHARMACOL REV, V71, P345, DOI 10.1124/pr.117.014878; Awla D, 2012, GASTROENTEROLOGY, V143, P1352, DOI 10.1053/j.gastro.2012.07.098; Bakker OJ, 2014, NAT REV GASTRO HEPAT, V11, P462, DOI 10.1038/nrgastro.2014.39; Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Chen Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1051, DOI 10.1152/ajpcell.00216.2005; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Chen Y, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000549; Darbousset R, 2014, BLOOD, V124, P2575, DOI 10.1182/blood-2014-04-571679; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Gaisano HY, 2009, GASTROENTEROLOGY, V136, P2040, DOI 10.1053/j.gastro.2009.04.023; Hao L, 2019, GASTROENTEROLOGY, V156, P287, DOI 10.1053/j.gastro.2018.06.095; Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665; Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8; Lee PJ, 2019, NAT REV GASTRO HEPAT, V16, P479, DOI 10.1038/s41575-019-0158-2; Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev-immunol-051116-052406; Lommen J, 2017, CELL TISSUE RES, V369, P579, DOI 10.1007/s00441-017-2634-8; Merza M, 2015, GASTROENTEROLOGY, V149, P1920, DOI 10.1053/j.gastro.2015.08.026; Murthy P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00028; Nemeth T, 2020, NAT REV DRUG DISCOV, V19, P253, DOI 10.1038/s41573-019-0054-z; Novak I, 2008, PURINERG SIGNAL, V4, P237, DOI 10.1007/s11302-007-9087-6; Petrov MS, 2019, NAT REV GASTRO HEPAT, V16, P175, DOI 10.1038/s41575-018-0087-5; Sendler M, 2013, GUT, V62, P430, DOI 10.1136/gutjnl-2011-300771; Sil P, 2017, J IMMUNOL, V198, P428, DOI 10.4049/jimmunol.1600766; Steer M, 2002, GASTROENTEROLOGY, V122, P1168, DOI 10.1053/gast.2002.32761; Swamydas M, 2013, JOVE-J VIS EXP, DOI 10.3791/50586; Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6; Tu JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01146; Wang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00399; Wang X, 2017, P NATL ACAD SCI USA, V114, P4483, DOI 10.1073/pnas.1616752114; Yazdani HO, 2018, J HEPATOL, V68, P130, DOI 10.1016/j.jhep.2017.09.010	32	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								549179	10.3389/fimmu.2020.549179	http://dx.doi.org/10.3389/fimmu.2020.549179			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH4BN	33603729	Green Published, gold			2022-12-18	WOS:000618220800001
J	Echarri, AA; Beresford, M; Campbell, JP; Jones, RH; Butler, R; Gollob, KJ; Brum, PC; Thompson, D; Turner, JE				Arana Echarri, Ainhoa; Beresford, Mark; Campbell, John P.; Jones, Robert H.; Butler, Rachel; Gollob, Kenneth J.; Brum, Patricia C.; Thompson, Dylan; Turner, James E.			A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling	FRONTIERS IN IMMUNOLOGY			English	Review						breast cancer; tumors; clinical response; biomarkers; immunosenescence; lifestyle; exercise; physical activity	PROSTATE-SPECIFIC ANTIGEN; TUMOR-INFILTRATING LYMPHOCYTES; INDEPENDENT PROGNOSTIC-FACTORS; PHYSICAL-ACTIVITY; GENE-EXPRESSION; GROWTH-FACTOR; CATHEPSIN-D; NEOADJUVANT TREATMENT; MAMMOGRAPHIC DENSITY; CYTOKINE PRODUCTION	Breast cancer is the most common malignancy among women worldwide. Over the last four decades, diagnostic and therapeutic procedures have improved substantially, giving patients with localized disease a better chance of cure, and those with more advanced cancer, longer periods of disease control and survival. However, understanding and managing heterogeneity in the clinical response exhibited by patients remains a challenge. For some treatments, biomarkers are available to inform therapeutic options, assess pathological response and predict clinical outcomes. Nevertheless, some measurements are not employed universally and lack sensitivity and specificity, which might be influenced by tissue-specific alterations associated with aging and lifestyle. The first part of this article summarizes available and emerging biomarkers for clinical use, such as measurements that can be made in tumor biopsies or blood samples, including so-called liquid biopsies. The second part of this article outlines underappreciated factors that could influence the interpretation of these clinical measurements and affect treatment outcomes. For example, it has been shown that both adiposity and physical activity can modify the characteristics of tumors and surrounding tissues. In addition, evidence shows that inflammaging and immunosenescence interact with treatment and clinical outcomes and could be considered prognostic and predictive factors independently. In summary, changes to blood and tissues that reflect aging and patient characteristics, including lifestyle, are not commonly considered clinically or in research, either for practical reasons or because the supporting evidence base is developing. Thus, an aim of this article is to encourage an integrative phenomic approach in oncology research and clinical management.	[Arana Echarri, Ainhoa; Campbell, John P.; Thompson, Dylan; Turner, James E.] Univ Bath, Dept Hlth, Bath, Avon, England; [Beresford, Mark] Royal United Hosp Bath NHS Trust, Dept Haematol & Oncol, Bath, Avon, England; [Jones, Robert H.] Velindre Canc Ctr, Dept Med Oncol, Cardiff, Wales; [Jones, Robert H.] Cardiff Univ, Dept Canc & Genet, Cardiff, Wales; [Butler, Rachel] North Bristol NHS Trust, South West Genom Lab Hub, Bristol, Avon, England; [Gollob, Kenneth J.] AC Camargo Canc Ctr, Int Ctr Res, Sao Paulo, Brazil; [Brum, Patricia C.] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil	University of Bath; Velindre Cancer Centre; Cardiff University; North Bristol NHS Trust; A.C.Camargo Cancer Center; Universidade de Sao Paulo	Turner, JE (corresponding author), Univ Bath, Dept Hlth, Bath, Avon, England.	j.e.turner@bath.ac.uk	Brum, Patricia C/E-6605-2011; Gollob, Kenneth J/C-1341-2008; Gollob, Kenneth J/GPX-8434-2022	Brum, Patricia C/0000-0002-4750-6506; Gollob, Kenneth J/0000-0003-4184-3867; Campbell, John P./0000-0001-9989-6158; Turner, James/0000-0003-2427-1430; Arana Echarri, Ainhoa/0000-0001-7121-8232	GW4 BIOMED DTP [MR/N0137941/1]; Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI; MRC [2103689] Funding Source: UKRI	GW4 BIOMED DTP; Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Al-Azawi D, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-220; Al-Mahayri ZN, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00445; Alarfi Hiba, 2017, BMC Res Notes, V10, P550, DOI 10.1186/s13104-017-2876-2; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Allemani C, 2004, BRIT J CANCER, V91, P1263, DOI 10.1038/sj.bjc.6602153; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Alokail MS, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0038-0; Alvarez-Rodriguez L, 2012, CELL IMMUNOL, V273, P124, DOI 10.1016/j.cellimm.2012.01.001; Andersson J, 2005, ANN ONCOL, V16, P743, DOI 10.1093/annonc/mdi150; Andre F, 2011, NAT REV CLIN ONCOL, V8, P171, DOI 10.1038/nrclinonc.2011.4; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Angus L, 2017, CANCER TREAT REV, V52, P33, DOI 10.1016/j.ctrv.2016.11.001; Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Ashcraft KA, 2019, SEMIN RADIAT ONCOL, V29, P16, DOI 10.1016/j.semradonc.2018.10.001; Assersohn L, 2003, BREAST CANCER RES TR, V82, P113, DOI 10.1023/B:BREA.0000003968.45511.3f; Aveseh M, 2015, J PHYSIOL-LONDON, V593, P2635, DOI 10.1113/JP270463; Azam S, 2018, CANCER CAUSE CONTROL, V29, P1015, DOI 10.1007/s10552-018-1075-3; Bacalbasa N., 2015, GINECOEU, V11, P35, DOI [10.18643/gieu.2015.35, DOI 10.18643/GIEU.2015.35]; Bailur JK, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0541-z; Bajou K, 2004, ONCOGENE, V23, P6986, DOI 10.1038/sj.onc.1207859; Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207; BARRETT AJ, 1992, ANN NY ACAD SCI, V674, P1; Bekisz J, 2010, PHARMACEUTICALS, V3, P994, DOI 10.3390/ph3040994; Berben L, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1184; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bernstein ED, 1998, AGE, V21, P137, DOI 10.1007/s11357-998-0024-6; Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertholee D, 2017, CLIN PHARMACOKINET, V56, P317, DOI 10.1007/s40262-016-0450-z; Betof AS, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv040; Billgren AM, 2000, EUR J CANCER, V36, P1374, DOI 10.1016/S0959-8049(00)00114-3; Black MH, 2000, BREAST CANCER RES TR, V59, P1, DOI 10.1023/A:1006380306781; Blank TO, 2008, CANCER-AM CANCER SOC, V112, P2569, DOI 10.1002/cncr.23444; Bloomer RJ, 2013, J STRENGTH COND RES, V27, P2874, DOI 10.1519/JSC.0b013e318282d416; Boyd NF, 2007, NEW ENGL J MED, V356, P227, DOI 10.1056/NEJMoa062790; Boyd NF, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2942; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brown JK, 2003, CA-CANCER J CLIN, V53, P268, DOI 10.3322/canjclin.53.5.268; Brown JC, 2020, EXERC SPORT SCI REV, V48, P67, DOI 10.1249/JES.0000000000000214; Bueno-de-Mesquita JM, 2009, BREAST CANCER RES TR, V117, P483, DOI 10.1007/s10549-008-0191-2; Buss LA, 2018, J APPL PHYSIOL, V124, P938, DOI 10.1152/japplphysiol.00738.2017; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Cagney DN, 2018, NEURO-ONCOLOGY, V20, P1162, DOI 10.1093/neuonc/nox242; Califf RM, 2018, EXP BIOL MED, V243, P213, DOI 10.1177/1535370217750088; Campbell JP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00648; Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116; Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173; Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Castle J, 2014, BREAST, V23, P552, DOI 10.1016/j.breast.2014.07.002; CellSearch, GOLD STANDARD 1 ONLY; Cepeda-Lopez AC, 2019, INT J OBESITY, V43, P999, DOI 10.1038/s41366-018-0127-9; Chae BJ, 2009, JPN J CLIN ONCOL, V39, P217, DOI 10.1093/jjco/hyp007; Chan DSM, 2014, ANN ONCOL, V25, P1901, DOI 10.1093/annonc/mdu042; Chang YF, 2011, ANAL CHEM, V83, P5324, DOI 10.1021/ac200754x; Chlebowski RT, 2002, J CLIN ONCOL, V20, P1128, DOI 10.1200/JCO.20.4.1128; Chollet-Hinton L, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0736-y; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Chulpanova DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00402; Clark GM, 2008, MOL ONCOL, V1, P406, DOI 10.1016/j.molonc.2007.12.001; Colbert LH, 2004, J AM GERIATR SOC, V52, P1098, DOI 10.1111/j.1532-5415.2004.52307.x; Conlon KC, 2019, J INTERF CYTOK RES, V39, P6, DOI 10.1089/jir.2018.0019; Conze D, 2001, CANCER RES, V61, P8851; Courneya KS, 2007, J CLIN ONCOL, V25, P4396, DOI 10.1200/JCO.2006.08.2024; Courneya KS, 2014, MED SCI SPORT EXER, V46, P1744, DOI 10.1249/MSS.0000000000000297; Courneya KS, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-525; Courneya KS, 2003, MED SCI SPORT EXER, V35, P1846, DOI 10.1249/01.MSS.0000093622.41587.B6; Courneya KS, 2003, J CLIN ONCOL, V21, P1660, DOI 10.1200/JCO.2003.04.093; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crescioli C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031010; Crimmins E, 2008, ADV CLIN CHEM, V46, P161, DOI 10.1016/S0065-2423(08)00405-8; Criscitiello C, 2014, BREAST, V23, P69, DOI 10.1016/j.breast.2013.11.007; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Danilin S, 2012, ONCOIMMUNOLOGY, V1, P1484, DOI 10.4161/onci.21990; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Darlix A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2448-1; Das S, 2011, ASIAN PAC J CANCER P, V12, P2051; Dash P, 2015, INDIAN J CLIN BIOCHE, V30, P124, DOI 10.1007/s12291-014-0451-3; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756; de la Cruz-Lopez KG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01143; DE LA FUENTE DE.F, 2012, CURR IMMUNOL REV, V8, P63, DOI DOI 10.2174/157339512798991290; De Placido S, 2003, CLIN CANCER RES, V9, P1039; Delpech Y, 2012, BREAST CANCER RES TR, V135, P619, DOI 10.1007/s10549-012-2194-2; Demark-Wahnefried W, 2020, INT J CANCER, V146, P2784, DOI 10.1002/ijc.32637; Derhovanessian E, 2010, J IMMUNOL, V185, P4618, DOI 10.4049/jimmunol.1001629; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dethlefsen C, 2017, CANCER RES, V77, P4894, DOI 10.1158/0008-5472.CAN-16-3125; Dethlefsen C, 2016, BREAST CANCER RES TR, V159, P469, DOI 10.1007/s10549-016-3970-1; Di Benedetto S, 2015, BIOGERONTOLOGY, V16, P631, DOI 10.1007/s10522-015-9563-2; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Dowsett M, 2001, ENDOCR-RELAT CANCER, V8, P191, DOI 10.1677/erc.0.0080191; Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Dubsky P, 2013, ANN ONCOL, V24, P640, DOI 10.1093/annonc/mds334; Duffy MJ, 2017, EUR J CANCER, V75, P284, DOI 10.1016/j.ejca.2017.01.017; Duffy MJ, 2015, CLIN CHEM, V61, P809, DOI 10.1373/clinchem.2015.239863; Duffy MJ, 2004, CLIN CHEM, V50, P559, DOI 10.1373/clinchem.2003.025288; Duggal NA, 2019, NAT REV IMMUNOL, V19, P563, DOI 10.1038/s41577-019-0177-9; Duggal NA, 2018, AGING CELL, V17, DOI 10.1111/acel.12750; Ebeling FG, 2002, BRIT J CANCER, V86, P1217, DOI 10.1038/sj.bjc.6600248; Ellingsgaard H, 2019, CURR OPIN PHYSIOL, V10, P49, DOI 10.1016/j.cophys.2019.03.009; Enroth S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5684; Eppenberger-Castori S, 2002, INT J BIOCHEM CELL B, V34, P1318, DOI 10.1016/S1357-2725(02)00052-3; Esfahbodi A, 2018, BASIC CLIN CANC RES, V9, P4; Fairey AS, 2005, J APPL PHYSIOL, V98, P1534, DOI 10.1152/japplphysiol.00566.2004; Faist B, 2010, CLIN VACCINE IMMUNOL, V17, P986, DOI 10.1128/CVI.00455-09; Fasoulakis Z, 2018, CUREUS, V10, DOI 10.7759/cureus.3549; FDA, 2019, THERASCREEN PIK3CA R; FELDSCHUH J, 1977, CIRCULATION, V56, P605, DOI 10.1161/01.CIR.56.4.605; Ferioli Martina, 2018, Oncotarget, V9, P14005, DOI 10.18632/oncotarget.24456; FERNO M, 1994, EUR J CANCER, V30A, P2042, DOI 10.1016/0959-8049(94)00307-Q; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; Foekens JA, 1999, BRIT J CANCER, V79, P888, DOI 10.1038/sj.bjc.6690142; Foekens JA, 2006, J CLIN ONCOL, V24, P1665, DOI 10.1200/JCO.2005.03.9115; Fontanella C, 2015, BREAST CANCER RES TR, V150, P127, DOI 10.1007/s10549-015-3287-5; Fornvik D, 2019, BREAST CANCER RES TR, V177, P447, DOI 10.1007/s10549-019-05326-5; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Fuchs-Young R, 2011, BREAST CANCER RES TR, V130, P399, DOI 10.1007/s10549-010-1308-y; Fulop T, 2010, ANN NY ACAD SCI, V1197, P158, DOI 10.1111/j.1749-6632.2009.05370.x; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Gershuni V, 2017, BREAST CANCER RES TR, V163, P375, DOI 10.1007/s10549-017-4192-x; GIAI M, 1995, BRIT J CANCER, V72, P728, DOI 10.1038/bjc.1995.401; Gibson JT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590794; Gion M, 2001, EUR J CANCER, V37, P355, DOI 10.1016/S0959-8049(00)00396-8; Giuliano M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2907; Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041; Global-Cancer-Observatory, 2018, ESTIMATED NUMBER NEW; Gnant M, 2014, ANN ONCOL, V25, P339, DOI 10.1093/annonc/mdt494; Goldstein LJ, 2008, J CLIN ONCOL, V26, P4063, DOI 10.1200/JCO.2007.14.4501; Gonzalez-Neira A, 2012, PHARMACOGENOMICS, V13, P677, DOI [10.2217/pgs.12.44, 10.2217/PGS.12.44]; Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04; GRAHAM JD, 1995, CANCER RES, V55, P5063; Griggs JJ, 2012, J CLIN ONCOL, V30, P1553, DOI 10.1200/JCO.2011.39.9436; Griggs JJ, 2005, ARCH INTERN MED, V165, P1267, DOI 10.1001/archinte.165.11.1267; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Group F-NBW, 2016, BEST BIOMARKERS ENDP; Gucalp A, 2019, BREAST CANCER RES TR, V173, P37, DOI 10.1007/s10549-018-4921-9; Gupta N., 2014, ASIAN J MED SCI, V5, P25, DOI [10.3126/ajms.v5i4.7800, DOI 10.3126/AJMS.V5I4.7800]; Gupta SK., 2018, INT SURG J, V5, P580, DOI DOI 10.18203/2349-2902.ISJ20180356; Gwozdzinski K, 2013, SCI WORLD J, DOI 10.1155/2013/168376; Habel LA, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1412; HAHNEL R, 1979, CANCER, V44, P671, DOI 10.1002/1097-0142(197908)44:2<671::AID-CNCR2820440238>3.0.CO;2-V; Hajjaji N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00454; Hamilton Jamie A G, 2020, Aging Cancer, V1, P30, DOI 10.1002/aac2.12014; Harbeck N, 2013, EUR J CANCER, V49, P1825, DOI 10.1016/j.ejca.2013.01.007; Harbeck N, 2002, J CLIN ONCOL, V20, P1000, DOI 10.1200/JCO.2002.20.4.1000; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; Heppner BI, 2016, CLIN CANCER RES, V22, P5747, DOI 10.1158/1078-0432.CCR-15-2338; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hojman P, 2018, CELL METAB, V27, P10, DOI 10.1016/j.cmet.2017.09.015; Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479; Hong F, 2019, CANCERS, V11, DOI 10.3390/cancers11050706; Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968; Hopp TA, 2004, CLIN CANCER RES, V10, P2751, DOI 10.1158/1078-0432.CCR-03-0141; Huang HJ, 2005, BREAST CANCER RES TR, V91, P81, DOI 10.1007/s10549-004-8235-8; Huang Y, 2015, ONCOTARGET, V6, P17462, DOI 10.18632/oncotarget.3958; Hudson S, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1078-8; Huff WX, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112810; Imoto S, 2007, INT J CANCER, V120, P357, DOI 10.1002/ijc.22166; Jacobsen BM, 2012, MOL CELL ENDOCRINOL, V357, P18, DOI 10.1016/j.mce.2011.09.016; Jagodic M, 2005, NEOPLASMA, V52, P1; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; Jensen MB, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-0148-0; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5; Jin YW, 2020, CANCERS, V12, DOI 10.3390/cancers12051076; Johansson H, 2004, BREAST CANCER RES TR, V88, P63, DOI 10.1007/s10549-004-0746-9; Jones EL, 2012, ONCOLOGY-NY, V26, P793; Jones LW, 2013, CANCER PREV RES, V6, P925, DOI 10.1158/1940-6207.CAPR-12-0416; Jones LW, 2010, J APPL PHYSIOL, V108, P343, DOI 10.1152/japplphysiol.00424.2009; Kabel AM., 2017, J ONCOL SCI, V3, P5, DOI [10.1016/j.jons.2017.01.001, DOI 10.1016/J.JONS.2017.01.001]; Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50; Keller Karsten, 2013, Muscles Ligaments Tendons J, V3, P346; Kim HS, 2010, BREAST CANCER RES TR, V121, P777, DOI 10.1007/s10549-009-0560-5; Kim J, 2013, CANCER INVEST, V31, P550, DOI 10.3109/07357907.2013.830737; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; Kluttig A, 2009, BREAST CARE, V4, P82, DOI 10.1159/000211368; Ko IG, 2014, TOHOKU J EXP MED, V233, P17, DOI 10.1620/tjem.233.17; Kocaoz S, 2019, MENOPAUSE REV, V18, P68, DOI 10.5114/pm.2019.85786; Krop I, 2017, J CLIN ONCOL, V35, P2838, DOI 10.1200/JCO.2017.74.0472; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lafrenie RM, 2019, CLIN BREAST CANCER, V19, P433, DOI 10.1016/j.clbc.2019.05.002; Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041; Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675; Le Saux O, 2016, ANN ONCOL, V27, P1799, DOI 10.1093/annonc/mdw259; Lehrer S, 1996, BRIT J CANCER, V74, P871, DOI 10.1038/bjc.1996.450; Lennon H, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0539-4; Li JX, 2020, BREAST CANCER-TOKYO, V27, P621, DOI [10.1093/bib/bbaa159, 10.1007/s12282-020-01058-3]; Lin KR, 2018, CANCER IMMUNOL IMMUN, V67, P1743, DOI 10.1007/s00262-018-2213-1; Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Longo M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092358; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; LOVEN D, 1981, ISRAEL J MED SCI, V17, P960; Luen SJ, 2017, LANCET ONCOL, V18, P52, DOI [10.1016/S1470-2045(16)30631-3, 10.1016/s1470-2045(16)30631-3]; Lumachi F, 2013, CURR MED CHEM, V20, P596, DOI 10.2174/092986713804999303; Lyman GH, 2012, J ONCOL PRACT, V8, pE62, DOI 10.1200/JOP.2012.000606; Ma F, 2016, ONCOTARGET, V7, P66020, DOI 10.18632/oncotarget.11791; Maehle BO, 2009, APMIS, V117, P644, DOI 10.1111/j.1600-0463.2009.02510.x; Mahmoud S, 2012, ONCOIMMUNOLOGY, V1, P363, DOI 10.4161/onci.18614; Margaryan NV, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12534; Maric P, 2011, COLLEGIUM ANTROPOL, V35, P241; Martin M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3642; Martin M, 2013, ONCOLOGIST, V18, P917, DOI 10.1634/theoncologist.2012-0479; Mazzarella L, 2013, EUR J CANCER, V49, P3588, DOI 10.1016/j.ejca.2013.07.016; MCCANN AH, 1991, CANCER RES, V51, P3296; McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965.EPI-06-0034; McCormick R, 2018, BIOGERONTOLOGY, V19, P519, DOI 10.1007/s10522-018-9775-3; McNerlan S.E., 2009, HDB IMMUNOSENESCENCE, P771; Melzer D, 2020, NAT REV GENET, V21, P88, DOI 10.1038/s41576-019-0183-6; Memon AA, 2015, J DIABETES, V7, P369, DOI 10.1111/1753-0407.12184; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Merker JD, 2018, ARCH PATHOL LAB MED, V142, P1242, DOI 10.5858/arpa.2018-0901-SA; Miller MK, 2001, BREAST CANCER RES TR, V68, P111, DOI 10.1023/A:1011959127928; Minciullo PL, 2016, ARCH IMMUNOL THER EX, V64, P111, DOI 10.1007/s00005-015-0377-3; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mohsin SK, 2004, MODERN PATHOL, V17, P1545, DOI 10.1038/modpathol.3800229; Molina R, 1998, BREAST CANCER RES TR, V51, P109, DOI 10.1023/A:1005734429304; Molina R, 1996, ANTICANCER RES, V16, P2295; Molina R., 1993, International Journal of Biological Markers, V8, P113; Molina R, 2005, TUMOR BIOL, V26, P281, DOI 10.1159/000089260; Molina R, 2010, CLIN CHEM, V56, P1148, DOI 10.1373/clinchem.2009.135566; Mook S, 2009, BREAST CANCER RES TR, V116, P295, DOI 10.1007/s10549-008-0130-2; Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548; Moreira A, 2019, INT J CANCER, V144, P1147, DOI 10.1002/ijc.31763; Morrison DH, 2012, BRIT J CANCER, V107, P382, DOI 10.1038/bjc.2012.219; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Narita D, 2006, NEOPLASMA, V53, P161; Nelson HD, 2008, LANCET, V371, P760, DOI 10.1016/S0140-6736(08)60346-3; Nicolini A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-269; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nimmo MA, 2013, DIABETES OBES METAB, V15, P51, DOI 10.1111/dom.12156; Nishimura R, 2014, MOL CLIN ONCOL, V2, P1062, DOI 10.3892/mco.2014.400; Niskanen E, 1997, BRIT J CANCER, V76, P917, DOI 10.1038/bjc.1997.484; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Pakdel F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092591; Pal S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600584; Panni RZ, 2013, IMMUNOTHERAPY-UK, V5, P1075, DOI 10.2217/imt.13.102; Pararasa C, 2015, BIOGERONTOLOGY, V16, P235, DOI 10.1007/s10522-014-9536-x; Park M, 2015, J OBSTET GYNAECOL RE, V41, P784, DOI 10.1111/jog.12621; Pawelec G, 2017, BIOGERONTOLOGY, V18, P717, DOI 10.1007/s10522-017-9682-z; Pawelec G, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-15; PEARSON TC, 1995, BRIT J HAEMATOL, V89, P748; Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011; Penault-Llorca F, 2017, PATHOLOGY, V49, P166, DOI 10.1016/j.pathol.2016.11.006; Penault-Llorca F, 2009, J CLIN ONCOL, V27, P2809, DOI 10.1200/JCO.2008.18.2808; Petrelli F, 2015, BREAST CANCER RES TR, V153, P477, DOI 10.1007/s10549-015-3559-0; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Picon-Ruiz M, 2016, CANCER RES, V76, P491, DOI 10.1158/0008-5472.CAN-15-0927; Pierga JY, 2008, CLIN CANCER RES, V14, P7004, DOI 10.1158/1078-0432.CCR-08-0030; Pierobon M, 2013, BREAST CANCER RES TR, V137, P307, DOI 10.1007/s10549-012-2339-3; Planes-Laine G, 2019, CANCERS, V11, DOI 10.3390/cancers11071033; Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001; Purnell JQ., 2000, ENDOTEXT INTERNET; Qiu SQ, 2018, CANCER TREAT REV, V70, P178, DOI 10.1016/j.ctrv.2018.08.010; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Riley LB, 2000, BREAST CANCER RES TR, V60, P173, DOI 10.1023/A:1006394401199; Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X; Silva LCR, 2016, AGE, V38, DOI 10.1007/s11357-016-9879-0; Rodriguez J, 2005, INT J BIOL MARKER, V20, P103, DOI 10.1177/172460080502000204; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Rosner GL, 1996, J CLIN ONCOL, V14, P3000, DOI 10.1200/JCO.1996.14.11.3000; Ruffell B, 2012, P NATL ACAD SCI USA, V109, P2796, DOI 10.1073/pnas.1104303108; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Salgado R, 2015, JAMA ONCOL, V1, P448, DOI 10.1001/jamaoncol.2015.0830; Sauter ER, 2008, CANCER DETECT PREV, V32, P149, DOI 10.1016/j.cdp.2008.06.002; Schadler KL, 2016, ONCOTARGET, V7, P65429, DOI 10.18632/oncotarget.11748; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Schmidt ME, 2013, INT J CANCER, V133, P1431, DOI 10.1002/ijc.28130; Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHWARTZ RS, 1990, J GERONTOL, V45, pM181, DOI 10.1093/geronj/45.6.M181; Segal R, 2017, CURR ONCOL, V24, P40, DOI 10.3747/co.24.3376; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Sestak I, 2019, BREAST CANCER RES TR, V176, P377, DOI 10.1007/s10549-019-05226-8; Sestak I, 2016, BREAST CANCER RES TR, V159, P71, DOI 10.1007/s10549-016-3868-y; Sestak I, 2010, J CLIN ONCOL, V28, P3411, DOI 10.1200/JCO.2009.27.2021; Setrerrahmane S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0721-9; Shalamzari SA, 2014, IRAN J BASIC MED SCI, V17, P231; Shapiro CL, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0120-z; Smith KC, 2004, EUR J IMMUNOGENET, V31, P167, DOI 10.1111/j.1365-2370.2004.00462.x; Song GH, 2013, CANCER IMMUNOL IMMUN, V62, P1123, DOI 10.1007/s00262-013-1424-8; Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764; Spielmann G, 2011, BRAIN BEHAV IMMUN, V25, P1521, DOI 10.1016/j.bbi.2011.07.226; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Stanton SE, 2016, JAMA ONCOL, V2, P1354, DOI 10.1001/jamaoncol.2016.1061; Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177; Stuart-Harris R, 2008, BREAST, V17, P323, DOI 10.1016/j.breast.2008.02.002; Sturgeon CM, 2008, CLIN CHEM, V54, pE11, DOI 10.1373/clinchem.2008.105601; Swift Amelia, 2020, Evid Based Nurs, V23, P2, DOI 10.1136/ebnurs-2019-103225; Tesarova P, 2013, REP PRACT ONCOL RADI, V18, P26, DOI 10.1016/j.rpor.2012.05.005; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORPE SM, 1989, CANCER RES, V49, P6008; Timmons BW, 2008, EXERC IMMUNOL REV, V14, P8; Trim W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00169; Turkoz FP, 2013, J BUON, V18, P335; Turner JE, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4234765; Turner JE., 2016, ENCY BEHAV MED, P1; Turner JR., 2017, ENCY BEHAV MED, P1, DOI 10.1007/978-1-4614-6439-6_101903-1; Tzanikou E, 2020, CRIT REV CL LAB SCI, V57, P54, DOI 10.1080/10408363.2019.1670615; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; Van Mieghem T, 2007, BREAST CANCER RES TR, V106, P127, DOI 10.1007/s10549-006-9474-7; Van Poznak C, 2015, J CLIN ONCOL, V33, P2695, DOI 10.1200/JCO.2015.61.1459; van Waart H, 2015, J CLIN ONCOL, V33, P1918, DOI 10.1200/JCO.2014.59.1081; Vasto S, 2009, MECH AGEING DEV, V130, P40, DOI 10.1016/j.mad.2008.06.003; Viale G, 2008, JNCI-J NATL CANCER I, V100, P207, DOI 10.1093/jnci/djm289; Vina J, 2016, J PHYSIOL-LONDON, V594, P1989, DOI 10.1113/JP270536; Vogel CL, 2001, ONCOLOGY-BASEL, V61, P37, DOI 10.1159/000055400; Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0129-6; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wertheimer AM, 2014, J IMMUNOL, V192, P2143, DOI 10.4049/jimmunol.1301721; Whitham M, 2016, NAT REV DRUG DISCOV, V15, P719, DOI 10.1038/nrd.2016.153; Winters-Stone KM, 2018, CANCER EPIDEM BIOMAR, V27, P146, DOI 10.1158/1055-9965.EPI-17-0766; Witzel I, 2012, BRIT J CANCER, V107, P956, DOI 10.1038/bjc.2012.353; Witzel I, 2010, BREAST CANCER RES TR, V123, P437, DOI 10.1007/s10549-010-1030-9; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wolin KY, 2010, ONCOLOGIST, V15, P556, DOI 10.1634/theoncologist.2009-0285; World-Health-Organization, 2018, PHYS ACTIVITY RECOMM; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamamoto S, 2013, BREAST CANCER-TOKYO, V20, P262, DOI 10.1007/s12282-012-0332-7; Yang Y, 2017, ONCOL LETT, V14, P7549, DOI 10.3892/ol.2017.7164; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yeo B, 2015, BRIT J CANCER, V113, P390, DOI 10.1038/bjc.2015.222; YU H, 1995, CANCER RES, V55, P2104; Yu H, 1998, CLIN CANCER RES, V4, P1489; Zavagno G, 2000, BREAST, V9, P320, DOI 10.1054/brst.1999.0147; Zhang CY, 2020, CELL METAB, V31, P148, DOI 10.1016/j.cmet.2019.10.013; Zhao XX, 2017, ONCOTARGET, V8, P30576, DOI 10.18632/oncotarget.15736; Zhu ZJ, 2008, CANCER EPIDEM BIOMAR, V17, P1920, DOI 10.1158/1055-9965.EPI-08-0175; Zinger A, 2017, AGING DIS, V8, P611, DOI 10.14336/AD.2016.1230	347	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2021	11								616188	10.3389/fimmu.2020.616188	http://dx.doi.org/10.3389/fimmu.2020.616188			33	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	QG9IL	33597950	Green Accepted, gold, Green Published			2022-12-18	WOS:000617892900001
J	Hou, W; Wu, XL				Hou, Wen; Wu, Xiaoli			Diverse Functions of gamma delta T Cells in the Progression of Hepatitis B Virus and Hepatitis C Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Review						&#947; &#948; T cells; hepatitis B virus; hepatitis C virus; progression; cytokines		Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are primary risk factors for a wide spectrum of liver diseases that severely affect human health. The liver is an immunological organ that has an abundance of immune cells. Thus, various innate or adaptive immune cells are involved in the progression of HBV or HCV infection. Among those cells, a unique kind of immune cell, the gamma delta T cell, contributes to promoting or inhibiting the progression of liver diseases. To reveal the diverse roles of gamma delta T cells in HBV or HCV infection, the properties and functions of these cells in human and mouse models are analyzed. Here, we briefly describe the characteristics and functions of gamma delta T cells subsets in liver diseases. Then, we fully discuss the diverse roles of gamma delta T cells in the progression of HBV or HCV infection, including stages of acute infection, chronic infection, liver cirrhosis, and hepatocellular carcinoma. Finally, the functions and existing problems of gamma delta T cells in HBV or HCV infection are summarized. A better understanding of the function of gamma delta T cells during the progression of HBV and HCV infection will be helpful for the treatment of virus infection.	[Hou, Wen] Tianjin First Cent Hosp, Minist Hlth, Key Lab Crit Care Med, Tianjin, Peoples R China; [Hou, Wen] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Wu, Xiaoli] Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China	Tianjin Medical University; Nankai University; Tianjin University	Wu, XL (corresponding author), Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China.	wuxiaoli@tju.edu.cn			Natural Science Foundation of Tianjin City [18JCZDJC34500]; State Key Laboratory of Medicinal Chemical Biology, Nankai University [2019003]; Tianjin First Central Hospital Spring Funding [CM201813]	Natural Science Foundation of Tianjin City(Natural Science Foundation of Tianjin); State Key Laboratory of Medicinal Chemical Biology, Nankai University; Tianjin First Central Hospital Spring Funding	This work was supported by the Natural Science Foundation of Tianjin City (18JCZDJC34500), the State Key Laboratory of Medicinal Chemical Biology, Nankai University (2019003), and Tianjin First Central Hospital Spring Funding (CM201813).	Agrati C, 2006, INT IMMUNOL, V18, P11, DOI 10.1093/intimm/dxh337; Agrati C, 2001, MOL MED, V7, P11, DOI 10.1007/BF03401834; Alonzi T, 2004, J GEN VIROL, V85, P1509, DOI 10.1099/vir.0.19724-0; Benova K, 2020, ACTA VIROL, V64, P131, DOI 10.4149/av_2020_203; Cai XY, 2014, ASIAN PAC J CANCER P, V15, P775, DOI 10.7314/APJCP.2014.15.2.775; Cairo C, 2010, HUM IMMUNOL, V71, P968, DOI 10.1016/j.humimm.2010.06.014; Cannizzo ES, 2018, J VIRAL HEPATITIS, V25, P381, DOI 10.1111/jvh.12820; Chang KM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007715; Chang L, 2020, EXP THER MED, V19, P67, DOI 10.3892/etm.2019.8197; Chen M, 2008, J INFECT DIS, V198, P1643, DOI 10.1086/593065; Chen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120086; Chen M, 2012, J CLIN IMMUNOL, V32, P877, DOI 10.1007/s10875-012-9678-z; Conroy MJ, 2015, VIRAL IMMUNOL, V28, P201, DOI 10.1089/vim.2014.0133; Dewidar B, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111419; Di Blasi D, 2020, CELL MOL GASTROENTER, V9, P195, DOI 10.1016/j.jcmgh.2019.08.004; Ferrari C, 2015, LIVER INT, V35, P121, DOI 10.1111/liv.12749; Ghosh A, 2019, J VIRAL HEPATITIS, V26, P1105, DOI 10.1111/jvh.13121; Hammerich L, 2014, HEPATOLOGY, V59, P630, DOI 10.1002/hep.26697; Hoh A, 2013, LIVER INT, V33, P127, DOI 10.1111/liv.12011; Hunter S, 2018, J HEPATOL, V69, P654, DOI 10.1016/j.jhep.2018.05.007; Jia ZH, 2019, CLIN IMMUNOL, V202, P40, DOI 10.1016/j.clim.2019.03.005; Jiang H, 2019, INT IMMUNOPHARMACOL, V70, P167, DOI 10.1016/j.intimp.2019.02.019; Kohlgruber AC, 2018, NAT IMMUNOL, V19, P464, DOI 10.1038/s41590-018-0094-2; Kong XH, 2014, J IMMUNOL, V193, P1645, DOI 10.4049/jimmunol.1303432; Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001; Lai QT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088475; Lee Hannah M, 2019, Curr Treat Options Gastroenterol, V17, P271, DOI 10.1007/s11938-019-00236-3; Lee JW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179094; Li TY, 2019, WORLD J GASTROENTERO, V25, P3527, DOI 10.3748/wjg.v25.i27.3527; Liu MF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00477; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Papadopoulou M, 2020, IMMUNOL REV, V298, P99, DOI 10.1111/imr.12926; Par G, 2002, J HEPATOL, V37, P514, DOI 10.1016/S0168-8278(02)00218-0; Pellicci DG, 2020, NAT REV IMMUNOL, V20, P756, DOI 10.1038/s41577-020-0345-y; Qian L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6837241; Qian P, 2018, IMMUNOPHARM IMMUNOT, V40, P107, DOI 10.1080/08923973.2017.1386212; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Rajoriya N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00400; Ravens S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00510; Saeidi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02569; Seo W, 2016, HEPATOLOGY, V64, P616, DOI 10.1002/hep.28644; Shin EC, 2016, NAT REV IMMUNOL, V16, P509, DOI 10.1038/nri.2016.69; Sugai S, 2016, INT J ONCOL, V48, P1794, DOI 10.3892/ijo.2016.3403; Tanaka Y, 2007, MED CHEM, V3, P85, DOI 10.2174/157340607779317544; Tian W, 2018, ONCOL LETT, V15, P5433, DOI 10.3892/ol.2018.8026; Toutirais O, 2009, EUR J IMMUNOL, V39, P1361, DOI 10.1002/eji.200838409; Tseng CTK, 2001, HEPATOLOGY, V33, P1312, DOI 10.1053/jhep.2001.24269; Wang XF, 2018, FRONT MED-PRC, V12, P262, DOI 10.1007/s11684-017-0584-x; Wu D, 2018, CURR MED SCI, V38, P648, DOI 10.1007/s11596-018-1926-x; Wu XL, 2013, J INFECT DIS, V208, P1294, DOI 10.1093/infdis/jit312; Yi Y, 2013, J HEPATOL, V58, P977, DOI 10.1016/j.jhep.2012.12.015; Yin WW, 2016, SCI REP-UK, V6, DOI 10.1038/srep26296; Zhang JY, 2010, HEPATOLOGY, V51, P81, DOI 10.1002/hep.23273; Zhao N, 2021, HEPATOLOGY, V73, P1045, DOI 10.1002/hep.31412; Zhou BY, 2019, HEPATOL INT, V13, P631, DOI 10.1007/s12072-019-09969-w	55	1	1	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2021	11								619872	10.3389/fimmu.2020.619872	http://dx.doi.org/10.3389/fimmu.2020.619872			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QG7NV	33597951	Green Published, gold			2022-12-18	WOS:000617771300001
J	Kim, HR; Park, JS; Fatima, Y; Kausar, M; Park, JH; Jun, CD				Kim, Hye-Ran; Park, Jeong-Su; Fatima, Yasmin; Kausar, Maiza; Park, Jin-Hwa; Jun, Chang-Duk			Potentiating the Antitumor Activity of Cytotoxic T Cells via the Transmembrane Domain of IGSF4 That Increases TCR Avidity	FRONTIERS IN IMMUNOLOGY			English	Article						immunoglobulin superfamily member 4; transmembrane; TCR complex; TCR avidity; immunotherapy		A robust T-cell response is an important component of sustained antitumor immunity. In this respect, the avidity of TCR in the antigen-targeting of tumors is crucial for the quality of the T-cell response. This study reports that the transmembrane (TM) domain of immunoglobulin superfamily member 4 (IGSF4) binds to the TM of the CD3 zeta-chain through an interaction between His177 and Asp36, which results in IGSF4-CD3 zeta dimers. IGSF4 also forms homo-dimers through the GxxVA motif in the TM domain, thereby constituting large TCR clusters. Overexpression of IGSF4 lacking the extracellular (IG4 Delta EXT) domain potentiates the OTI CD8(+) T cells to release IFN-gamma and TNF-alpha and to kill OVA(+)-B16F10 melanoma cells. In animal models, IG4 Delta EXT significantly reduces B16F10 tumor metastasis as well as tumor growth. Collectively, the results indicate that the TM domain of IGSF4 can regulate TCR avidity, and they further demonstrate that TCR avidity regulation is critical for improving the antitumor activity of cytotoxic T cells.	[Kim, Hye-Ran; Park, Jeong-Su; Fatima, Yasmin; Kausar, Maiza; Park, Jin-Hwa; Jun, Chang-Duk] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju, South Korea; [Kim, Hye-Ran; Park, Jeong-Su; Fatima, Yasmin; Kausar, Maiza; Park, Jin-Hwa; Jun, Chang-Duk] Gwangju Inst Sci & Technol, Immune Synapse & Cell Therapy Res Ctr, Gwangju, South Korea	Gwangju Institute of Science & Technology (GIST); Gwangju Institute of Science & Technology (GIST)	Jun, CD (corresponding author), Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju, South Korea.; Jun, CD (corresponding author), Gwangju Inst Sci & Technol, Immune Synapse & Cell Therapy Res Ctr, Gwangju, South Korea.	cdjun@gist.ac.kr			Creative Research Initiative Program through National Research Foundation (NRF) grants - Ministry of Science and ICT (MSIT) [2015R1A3A2066253]; Basic Science Program through National Research Foundation (NRF) grants - Ministry of Education (MOE) [2019R1C1C1009570]; National R&D Program for Cancer Control, Ministry for Health and Welfare [1911264]; GIST Research Institute (GRI) IBBR - GIST, Korea	Creative Research Initiative Program through National Research Foundation (NRF) grants - Ministry of Science and ICT (MSIT); Basic Science Program through National Research Foundation (NRF) grants - Ministry of Education (MOE); National R&D Program for Cancer Control, Ministry for Health and Welfare; GIST Research Institute (GRI) IBBR - GIST, Korea	This work was supported by the Creative Research Initiative Program (2015R1A3A2066253) through National Research Foundation (NRF) grants funded by the Ministry of Science and ICT (MSIT), the Basic Science Program (2019R1C1C1009570) through National Research Foundation (NRF) grants funded by the Ministry of Education (MOE), the National R&D Program for Cancer Control, Ministry for Health and Welfare (1911264), and supported by GIST Research Institute (GRI) IBBR grant funded by the GIST in 2020, Korea.	AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Almasbak H, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5474602; Beck-Garcia K, 2015, BBA-MOL CELL RES, V1853, P802, DOI 10.1016/j.bbamcr.2014.12.017; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Bolliger L, 1999, J IMMUNOL, V163, P3867; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; Castro M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00132; Chinnasamy N, 2011, J IMMUNOL, V186, P685, DOI 10.4049/jimmunol.1001775; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Dinic J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10082; Donermeyer DL, 2006, J IMMUNOL, V177, P6911, DOI 10.4049/jimmunol.177.10.6911; Dustin ML, 2008, IMMUNOL REV, V221, P77, DOI 10.1111/j.1600-065X.2008.00589.x; Dustin ML, 2014, CANCER IMMUNOL RES, V2, P1023, DOI 10.1158/2326-6066.CIR-14-0161; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Hamano R, 2015, CELL MOL IMMUNOL, V12, P780, DOI 10.1038/cmi.2014.123; Hartmann J, 2017, EMBO MOL MED, V9, P1183, DOI 10.15252/emmm.201607485; He HT, 2005, SEMIN IMMUNOL, V17, P23, DOI 10.1016/j.smim.2004.09.001; Hur EM, 2003, J EXP MED, V198, P1463, DOI 10.1084/jem.20030232; Hurwitz AA, 2014, CANCER MICROENVIRON, V7, P1, DOI 10.1007/s12307-013-0143-1; June CH, 2014, CANCER IMMUNOL IMMUN, V63, P969, DOI 10.1007/s00262-014-1568-1; Jung YM, 2016, P NATL ACAD SCI USA, V113, pE5916, DOI 10.1073/pnas.1605399113; Kim HR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06090-8; Kim HR, 2011, J EXP MED, V208, P2545, DOI 10.1084/jem.20110853; Kirchgessner H, 2001, J EXP MED, V193, P1269, DOI 10.1084/jem.193.11.1269; Kumar R, 2011, IMMUNITY, V35, P375, DOI 10.1016/j.immuni.2011.08.010; Lee HJ, 2017, ONCOTARGET, V8, P113345, DOI 10.18632/oncotarget.23007; Lin J, 2001, J CELL SCI, V114, P243; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; Martelli MP, 2000, BLOOD, V96, P2181; Matthew E., 2004, MOL IMMUNOL, V40, P1295, DOI [10.1016/j.physbeh.2017.03.040, DOI 10.1016/J.PHYSBEH.2017.03.040]; Miller AM, 2019, CANCER IMMUNOL RES, V7, P40, DOI 10.1158/2326-6066.CIR-18-0371; Moran AE, 2016, J IMMUNOL, V197, P2509, DOI 10.4049/jimmunol.1502659; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Morris EC, 2016, BLOOD, V127, P3305, DOI 10.1182/blood-2015-11-629071; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Nakahata S, 2012, LEUKEMIA, V26, P1238, DOI 10.1038/leu.2011.379; Paradela A, 2005, J PROTEOME RES, V4, P2435, DOI 10.1021/pr050308v; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Pettmann J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02152; Riviere I, 2017, MOL THER, V25, P1117, DOI 10.1016/j.ymthe.2017.03.034; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Rocha-Perugini V, 2013, MOL CELL BIOL, V33, P3644, DOI 10.1128/MCB.00302-13; Rocha-Perugini V, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00653; Rohrs S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-86; Schamel WWA, 2013, IMMUNOL REV, V251, P13, DOI 10.1111/imr.12019; Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173; Schmitt TM, 2013, BLOOD, V122, P348, DOI 10.1182/blood-2013-01-478164; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Thaxton JE, 2014, HUM VACC IMMUNOTHER, V10, P3313, DOI 10.4161/21645515.2014.973314; Vardhana Santosha, 2008, J Vis Exp, DOI 10.3791/947; Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999; Yi JC, 2016, P NATL ACAD SCI USA, V113, P11061, DOI 10.1073/pnas.1613832113; Zhang JX, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819831068; Zhong S, 2013, P NATL ACAD SCI USA, V110, P6973, DOI 10.1073/pnas.1221609110	59	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2021	11								591054	10.3389/fimmu.2020.591054	http://dx.doi.org/10.3389/fimmu.2020.591054			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QG9KF	33597944	gold, Green Published			2022-12-18	WOS:000617897500001
J	Buchele, V; Konein, P; Vogler, T; Kunert, T; Enderle, K; Khan, H; Buttner-Herold, M; Lehmann, CHK; Amon, L; Wirtz, S; Dudziak, D; Neurath, MF; Neufert, C; Hildner, K				Buchele, Vera; Konein, Patrick; Vogler, Tina; Kunert, Timo; Enderle, Karin; Khan, Hanif; Buettner-Herold, Maike; Lehmann, Christian H. K.; Amon, Lukas; Wirtz, Stefan; Dudziak, Diana; Neurath, Markus F.; Neufert, Clemens; Hildner, Kai			Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Extrinsic Manner	FRONTIERS IN IMMUNOLOGY			English	Article						interferon regulatory factor 4 (IRF4); myeloid cells; Th17; intestinal inflammation; inflammatory bowel disease (IBD)	DENDRITIC CELLS	Inflammatory bowel diseases (IBDs) are characterized by chronic, inflammatory gastrointestinal lesions and often require life-long treatment with immunosuppressants and repetitive surgical interventions. Despite progress in respect to the characterization of molecular mechanisms e.g. exerted by TNF-alpha, currently clinically approved therapeutics fail to provide long-term disease control for most patients. The transcription factor interferon regulatory factor 4 (IRF4) has been shown to play important developmental as well as functional roles within multiple immune cells. In the context of colitis, a T cell-intrinsic role of IRF4 in driving immune-mediated gut pathology is established. Here, we conversely addressed the impact of IRF4 inactivation in non-T cells on T cell driven colitis in vivo. Employing the CD4(+)CD25(-) naive T cell transfer model, we found that T cells fail to elicit colitis in IRF4-deficient compared to IRF4-proficient Rag1 (-/-) mice. Reduced colitis activity in the absence of IRF4 was accompanied by hampered T cell expansion both within the mesenteric lymph node (MLN) and colonic lamina propria (cLP). Furthermore, the influx of various myeloids, presumably inflammation-promoting cells was abrogated overall leading to a less disrupted intestinal barrier. Mechanistically, gene profiling experiments revealed a Th17 response dominated molecular expression signature in colon tissues of IRF4-proficient, colitic Rag1 (-/-) but not in colitis-protected Rag1 (-/-) Irf4 (-/-) mice. Colitis mitigation in Rag1 (-/-) Irf4 (-/-) T cell recipients resulted in reduced frequencies and absolute numbers of IL-17a-producing T cell subsets in MLN and cLP possibly due to a regulation of conventional dendritic cell subset 2 (cDC2) known to impact Th17 differentiation. Together, extending the T cell-intrinsic role for IRF4 in the context of Th17 cell driven colitis, the provided data demonstrate a Th17-inducing and thereby colitis-promoting role of IRF4 through a T cell-extrinsic mechanism highlighting IRF4 as a putative molecular master switch among transcriptional regulators driving immune-mediated intestinal inflammation through both T cell-intrinsic and T cell-extrinsic mechanisms. Future studies need to further dissect IRF4 controlled pathways within distinct IRF4-expressing myeloid cell types, especially cDC2s, to elucidate the precise mechanisms accounting for hampered Th17 formation and, according to our data, the predominant mechanism of colitis protection in Rag1 (-/-) Irf4 (-/-) T cell receiving mice.	[Buchele, Vera; Konein, Patrick; Vogler, Tina; Kunert, Timo; Enderle, Karin; Khan, Hanif; Wirtz, Stefan; Neurath, Markus F.; Neufert, Clemens; Hildner, Kai] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany; [Buchele, Vera; Konein, Patrick; Vogler, Tina; Kunert, Timo; Enderle, Karin; Khan, Hanif; Lehmann, Christian H. K.; Amon, Lukas; Wirtz, Stefan; Dudziak, Diana; Neurath, Markus F.; Neufert, Clemens; Hildner, Kai] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Buettner-Herold, Maike] Univ Hosp Erlangen, Inst Pathol, Dept Nephropathol, Erlangen, Germany; [Lehmann, Christian H. K.; Amon, Lukas; Dudziak, Diana] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Dept Dermatol, Lab Dendrit Cell Biol, Erlangen, Germany; [Buchele, Vera] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Transfus Med & Hemostaseol, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Hildner, K (corresponding author), Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany.; Hildner, K (corresponding author), Univ Erlangen Nurnberg, Univ Hosp Erlangen, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.	Kai.Hildner@uk-erlangen.de		Amon, Lukas/0000-0003-3834-6114	Collaborative Research Center 1181 (DFG-CRC1181); Collaborative Research Center TRR241 (DFG-CRC/TR241 A08); Collaborative Research Center TRR221;  [DFG/DU548/5-1];  [DFG/HI 849/4-1];  [SPP1656/HI 849/5-1]	Collaborative Research Center 1181 (DFG-CRC1181); Collaborative Research Center TRR241 (DFG-CRC/TR241 A08); Collaborative Research Center TRR221; ; ; 	This study was supported by the Collaborative Research Centers 1181 (DFG-CRC1181, project B05, to KH and project A07, to DD), TRR241 (DFG-CRC/TR241 A08 to both CN & KH), TRR221 project B03 to KH, DFG/DU548/5-1 to DD, DFG/HI 849/4-1 and SPP1656/HI 849/5-1 (both to KH).	Adegbola SO, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082244; Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; Arnold IC, 2016, MUCOSAL IMMUNOL, V9, P352, DOI 10.1038/mi.2015.65; Atreya R, 2015, WORLD J GASTROENTERO, V21, P12963, DOI 10.3748/wjg.v21.i45.12963; Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89; Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192; Bajana S, 2012, J IMMUNOL, V189, P3368, DOI 10.4049/jimmunol.1102613; Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446; Betz BC, 2010, J EXP MED, V207, P933, DOI 10.1084/jem.20091548; Brasseit J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00023; Briseno CG, 2016, CELL REP, V15, P2462, DOI 10.1016/j.celrep.2016.05.025; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Castro F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061398; Cerovic V, 2014, TRENDS IMMUNOL, V35, P270, DOI 10.1016/j.it.2014.04.003; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; D'Haens G, 1999, GASTROENTEROLOGY, V116, P1029, DOI 10.1016/S0016-5085(99)70005-3; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Greulich T, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0751-x; Griseri T, 2015, IMMUNITY, V43, P187, DOI 10.1016/j.immuni.2015.07.008; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Hacker C, 2003, NAT IMMUNOL, V4, P380, DOI 10.1038/ni903; Hanzel J, 2020, EXPERT OPIN BIOL TH, V20, P399, DOI 10.1080/14712598.2020.1697227; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hildner K, 2016, DIGEST DIS, V34, P40, DOI 10.1159/000447281; Holtta V, 2008, INFLAMM BOWEL DIS, V14, P1175, DOI 10.1002/ibd.20475; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Izcue A, 2008, IMMUNITY, V28, P559, DOI 10.1016/j.immuni.2008.02.019; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Loschko J, 2016, J EXP MED, V213, P517, DOI 10.1084/jem.20160062; Mashayekhi M, 2011, IMMUNITY, V35, P249, DOI 10.1016/j.immuni.2011.08.008; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Mudter J, 2008, J CLIN INVEST, V118, P2415, DOI 10.1172/JCI33227; Murphy TL, 2013, NAT REV IMMUNOL, V13, P499, DOI 10.1038/nri3470; Muzaki ARBM, 2016, MUCOSAL IMMUNOL, V9, P336, DOI 10.1038/mi.2015.64; Nam S, 2016, J LEUKOCYTE BIOL, V100, P1273, DOI 10.1189/jlb.1A0215-068RR; Nam S, 2016, ARCH PHARM RES, V39, P1548, DOI 10.1007/s12272-016-0854-1; Negishi H, 2005, P NATL ACAD SCI USA, V102, P15989, DOI 10.1073/pnas.0508327102; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Ostanin DV, 2009, AM J PHYSIOL-GASTR L, V296, pG135, DOI 10.1152/ajpgi.90462.2008; Persson EK, 2013, IMMUNITY, V38, P958, DOI 10.1016/j.immuni.2013.03.009; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Punkenburg E, 2016, GUT, V65, P1139, DOI 10.1136/gutjnl-2014-308227; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; Sartor RB, 2010, GASTROENTEROLOGY, V139, P1816, DOI 10.1053/j.gastro.2010.10.036; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Schlitzer A, 2015, SEMIN CELL DEV BIOL, V41, P9, DOI 10.1016/j.semcdb.2015.03.011; Schlitzer A, 2014, CURR OPIN IMMUNOL, V26, P90, DOI 10.1016/j.coi.2013.11.002; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Schmitt H, 2019, GUT, V68, P814, DOI 10.1136/gutjnl-2017-315671; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Shale M, 2013, IMMUNOL REV, V252, P164, DOI 10.1111/imr.12039; Smids C, 2018, J CROHNS COLITIS, V12, P465, DOI 10.1093/ecco-jcc/jjx160; Suzuki S, 2004, P NATL ACAD SCI USA, V101, P8981, DOI 10.1073/pnas.0402139101; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szeto MCH, 2016, CASE REP IMMUNOL, V2016, DOI 10.1155/2016/7562123; Tamoutounour S, 2012, EUR J IMMUNOL, V42, P3150, DOI 10.1002/eji.201242847; Tamura T, 2005, J IMMUNOL, V174, P2573, DOI 10.4049/jimmunol.174.5.2573; Targan SR, 2012, GASTROENTEROLOGY, V143, pE26, DOI 10.1053/j.gastro.2012.07.084; Tindemans I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010110; Ullrich E, 2018, J CLIN INVEST, V128, P916, DOI 10.1172/JCI89242; Weber B, 2011, EUR J IMMUNOL, V41, P773, DOI 10.1002/eji.201040965; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; Yamamoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025812; Zigmond E, 2012, IMMUNITY, V37, P1076, DOI 10.1016/j.immuni.2012.08.026	77	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 29	2021	11								590893	10.3389/fimmu.2020.590893	http://dx.doi.org/10.3389/fimmu.2020.590893			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QG0NW	33584655	Green Submitted, Green Published, gold			2022-12-18	WOS:000617284200001
J	Steel, HC; Venter, WDF; Theron, AJ; Anderson, R; Feldman, C; Arulappan, N; Rossouw, TM				Steel, Helen C.; Venter, W. D. Francois; Theron, Annette J.; Anderson, Ronald; Feldman, Charles; Arulappan, Natasha; Rossouw, Theresa M.			Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						antiretroviral therapy; biomarkers; non-AIDS-defining disorders; human immunodeficiency virus; platelets; platelet-derived growth factor BB; soluble CD40 ligand; soluble CD62P		Systemic biomarkers of inflammation, including cytokines and chemokines, are potentially useful in the management of both HIV infection and non-AIDS-defining disorders. However, relatively little is known about the utility of measurement of circulating biomarkers of platelet activation as a strategy to monitor the efficacy of combination antiretroviral therapy (cART), as well as the persistence of systemic inflammation following virally-suppressive therapy in HIV-infected persons. These issues have been addressed in the current study to which a cohort consisting of 199 HIV-infected participants was recruited, 100 of whom were cART-naive and the remainder cART-treated and virally-suppressed. Fifteen healthy control participants were included for comparison. The study focused on the effects of cART on the responsiveness of three biomarkers of platelet activation, specifically soluble CD40 ligand (sCD40L), sCD62P (P-selectin), and platelet-derived growth factor-BB (PDGF-BB), measured using multiplex suspension bead array technology. Most prominently sCD40L in particular, as well as sCD62P, were significantly elevated in the cART-naive group relative to both the cART-treated and healthy control groups. However, levels of PDGF-BB were of comparable magnitude in both the cART-naive and -treated groups, and significantly higher than those of the control group. Although remaining somewhat higher in the virally-suppressed group relative to healthy control participants, these findings identify sCD40L, in particular, as a potential biomarker of successful cART, while PDGF-BB may be indicative of persistent low-level antigenemia.	[Steel, Helen C.; Theron, Annette J.; Anderson, Ronald; Rossouw, Theresa M.] Univ Pretoria, Dept Immunol, Pretoria, South Africa; [Venter, W. D. Francois] Univ Witwatersrand, Fac Hlth Sci, Ezintsha, Johannesburg, South Africa; [Feldman, Charles] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa; [Arulappan, Natasha] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa	University of Pretoria; University of Witwatersrand; University of Witwatersrand; University of Witwatersrand	Steel, HC (corresponding author), Univ Pretoria, Dept Immunol, Pretoria, South Africa.	helen.steel@up.ac.za	Steel, Helen C./AAM-3129-2021	Steel, Helen/0000-0001-5899-4472	National Health Laboratory Service Development Grant [004 94706]; Bill and Melinda Gates Foundation; South African Department of Health and South African Medical Research Council; National Research Foundation of South Africa	National Health Laboratory Service Development Grant; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); South African Department of Health and South African Medical Research Council; National Research Foundation of South Africa(National Research Foundation - South Africa)	The research in this article was funded by a National Health Laboratory Service Development Grant (004 94706). The Bill and Melinda Gates Foundation, as well as the South African Department of Health and South African Medical Research Council, supported the clinical trial that contributed specimens to this study. Charles Feldman is supported by the National Research Foundation of South Africa. We would like to thank the patients and staff of the Charlotte Maxeke Johannesburg Academic Hospital.	Anand AR, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00185; Antoniades C, 2009, J AM COLL CARDIOL, V54, P669, DOI 10.1016/j.jacc.2009.03.076; Benowitz NL, 2020, NICOTINE TOB RES, V22, P1086, DOI 10.1093/ntr/ntz132; Caso JAA, 1999, NEW ENGL J MED, V341, P1239, DOI 10.1056/NEJM199910143411617; Clayton Kiera L, 2017, Pathog Immun, V2, P179, DOI 10.20411/pai.v2i2.204; Damien P, 2013, J INFECT DIS, V208, P868, DOI 10.1093/infdis/jit260; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; Etulain J, 2015, BLOOD, V126, P242, DOI 10.1182/blood-2015-01-624023; Falasca K, 2019, HIV MED, V20, P681, DOI 10.1111/hiv.12789; Goehringer F, 2017, AIDS RES HUM RETROV, V33, P187, DOI [10.1089/aid.2016.0222, 10.1089/AID.2016.0222]; Gresele P, 2012, THROMB RES, V129, P301, DOI 10.1016/j.thromres.2011.11.022; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Inwald DP, 2003, CIRC RES, V92, P1041, DOI 10.1161/01.RES.0000070111.98158.6C; Jansen AJG, 2020, BLOOD ADV, V4, P2967, DOI 10.1182/bloodadvances.2020001640; Karvinen H, 2009, EUR J CLIN INVEST, V39, P320, DOI 10.1111/j.1365-2362.2009.02095.x; Kayrak M, 2011, HEART VESSELS, V26, P131, DOI 10.1007/s00380-010-0036-x; Koupenova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09607-x; Koupenova M, 2018, CIRC RES, V122, P337, DOI 10.1161/CIRCRESAHA.117.310795; Koupenova M, 2017, EUR HEART J, V38, P785, DOI 10.1093/eurheartj/ehw550; Koupenova M, 2014, BLOOD, V124, P791, DOI 10.1182/blood-2013-11-536003; Lau PP, 2006, ARTERIOSCL THROM VAS, V26, P143, DOI 10.1161/01.ATV.0000193510.19000.10; Loelius SG, 2017, J IMMUNOL, V198; Maggi P, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0226-2; Mause SF, 2005, ARTERIOSCL THROM VAS, V25, P1512, DOI 10.1161/01.ATV.0000170133.43608.37; Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355; Mesquita EC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33403-0; Michelson AD, 2010, NAT REV DRUG DISCOV, V9, P154, DOI 10.1038/nrd2957; Nijm J, 2005, AM J CARDIOL, V95, P452, DOI 10.1016/j.amjcard.2004.10.009; Nocella C, 2018, AM J CARDIOL, V122, P1477, DOI 10.1016/j.amjcard.2018.07.029; Nwosu FC, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/803185; O'Halloran JA, 2015, HIV MED, V16, P608, DOI 10.1111/hiv.12270; Pamukcu B, 2011, ANN MED, V43, P331, DOI 10.3109/07853890.2010.546362; Panicker SR, 2017, BLOOD, V130, P181, DOI 10.1182/blood-2017-02-770479; Perazzio SF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1443-5; Petoumenos K, 2011, HIV MED, V12, P412, DOI 10.1111/j.1468-1293.2010.00901.x; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Real F, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aat6263; Rogalska-Plonska M, 2017, KARDIOL POL, V75, P1324, DOI 10.5603/KP.a2017.0148; Simpson S, 2020, J IMMUNOL, V204; Sipsas NV, 2002, CLIN DIAGN LAB IMMUN, V9, P558, DOI 10.1128/CDLI.9.3.558-561.2002; Song YM, 2014, MOL MED REP, V10, P1555, DOI 10.3892/mmr.2014.2336; Sperk M, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009759; Steel HC, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/8357109; Sut C, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00042; Tong LJ, 2018, MOL MED REP, V17, P7595, DOI 10.3892/mmr.2018.8854; Trevillyan J, 2019, J INT AIDS SOC, V22, P5; Varo N, 2003, CIRCULATION, V108, P1049, DOI 10.1161/01.CIR.0000088521.04017.13; Yuan M, 2015, CARDIOLOGY, V131, P1, DOI 10.1159/000374105; Zhang ML, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3272098; Zhang S, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00954-7; Zirlik A, 2007, CIRCULATION, V115, P1571, DOI 10.1161/CIRCULATIONAHA.106.683201; 2014, NATL CONSOLIDATED GU	53	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 29	2021	11								594110	10.3389/fimmu.2020.594110	http://dx.doi.org/10.3389/fimmu.2020.594110			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF7CX	33584658	Green Published, gold			2022-12-18	WOS:000617051400001
J	Xing, YF; Cai, JR; Qin, JJ; Zhou, WY; Li, CM; Li, X				Xing, Yan-Fang; Cai, Jia-Rong; Qin, Jun-Jian; Zhou, Wen-Ying; Li, Can-Ming; Li, Xing			Expansion of Monocytic Myeloid-Derived Suppressor Cells in Patients Under Hemodialysis Might Lead to Cardiovascular and Cerebrovascular Events	FRONTIERS IN IMMUNOLOGY			English	Article						monocytic myeloid-derived suppressor cell; hemodialysis; end stage renal disease; cardiovascular diseases; arginase		Background The specific mechanism of cardiovascular and cerebrovascular vasculopathy in the context of end-stage renal disease has not been elucidated. In the present study, we investigated the clinical impact of myeloid-derived suppressor cells (MDSCs) on hemodialysis patients and their mechanism of action. Methods MDSCs were tested among 104 patients undergoing hemodialysis and their association with overall survival (OS) and cardiovascular and cerebrovascular events was determined. Results Hemodialysis patients presented a significantly higher level of monocytic MDSCs (M-MDSCs) compared to healthy controls. M-MDSC were tested 3 months after first testing among 103 hemodialysis patients, with one patient not retested due to early death. The repeated results of M-MDSC levels were consistent with the initial results. Patients with persistent high level of M-MDSCs presented decreased OS, as well as increased stroke and acute heart failure events. As illustrated by multivariate Cox regression, M-MDSC was an independent predictor for OS and stroke events of hemodialysis patients. T cell proliferations were significantly abrogated by hemodialysis-related M-MDSCs in a dose-dependent manner. Besides, M-MDSCs presented higher levels of CXCR4 and VLA-4 compared to monocytes, which indicated their enhanced capability to be recruited to atherosclerotic lesions. The expression of arginase I and activity of arginase was also significantly raised in hemodialysis-related M-MDSCs. Human coronary arterial endothelial cells (HCAECs) presented increased capability to migration by coculture with M-MDSCs, compared with monocyte group. Arginase inhibitor and L-arginine abrogated the immune suppressive function and induction of HCAECs migration of hemodialysis related M-MDSC. Plasma IFN-gamma, TNF-alpha and IL-6 were elevated in hemodialysis patients compared with healthy control. M-MDSC level was positively related to IL-6 level among hemodialysis patients. The plasma of hemodialysis patients induced M-MDSCs significantly compared with plasma from health donors. Besides, IL-6 neutralizing antibody significantly abrogated the induction. Neutralizing antibody of IFN-gamma and TNF-alpha partially decreased the generation of arginase of the induced M-MDSC. Conclusions M-MDSCs were elevated in ESRD patients under hemodialysis, and they exhibited a strong association with the risk of cardiovascular and cerebrovascular diseases. Hemodialysis related M-MDSC presented enhanced recruitment to atherosclerotic lesions, promoted the migration of endothelial cells through exhaustion of local L-arginine.	[Xing, Yan-Fang; Qin, Jun-Jian] Guangzhou Med Univ, Affiliated Hosp 3, Dept Nephrol, Guangzhou, Peoples R China; [Cai, Jia-Rong] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou, Peoples R China; [Zhou, Wen-Ying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cent Lab, Guangzhou, Peoples R China; [Li, Can-Ming] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Nephrol, Guangzhou, Peoples R China; [Li, Xing] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, Guangzhou, Peoples R China; [Li, Xing] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, Guangzhou, Peoples R China	Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xing, YF (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Dept Nephrol, Guangzhou, Peoples R China.; Li, X (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, Guangzhou, Peoples R China.; Li, X (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, Guangzhou, Peoples R China.	2574410512@qq.com; lixing9@mail.sysu.edu.cn			National Natural Science Foundation of China [81972677, 81700645]; Natural Science Foundation of Guangdong [2019A1515012198, 2019A1515011187]; Guangzhou Science and Technology Project [201904010461]; Fundamental Research Funds for the Central Universities [19ykpy17]; Tip-Top Scientific and Technology Innovative Youth Talents of Guangdong Special Support Program [2019TQ05Y266]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Project; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Tip-Top Scientific and Technology Innovative Youth Talents of Guangdong Special Support Program	This study was supported by the National Natural Science Foundation of China (81972677 and 81700645), Natural Science Foundation of Guangdong (No. 2019A1515012198 and 2019A1515011187), Guangzhou Science and Technology Project (201904010461), the Fundamental Research Funds for the Central Universities (19ykpy17), and Tip-Top Scientific and Technology Innovative Youth Talents of Guangdong Special Support Program (2019TQ05Y266).	Ahmadmehrabi S, 2018, SEMIN DIALYSIS, V31, P258, DOI 10.1111/sdi.12694; Ashma N, 2003, NEPHROL DIAL TRANSPL, V18, P2088, DOI 10.1093/ndt/gfg348; Barreto DV, 2010, KIDNEY INT, V77, P550, DOI 10.1038/ki.2009.503; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; CHATENOUD L, 1986, P NATL ACAD SCI USA, V83, P7457, DOI 10.1073/pnas.83.19.7457; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Evrard SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11853; Feng PH, 2012, AM J RESP CRIT CARE, V186, P1025, DOI 10.1164/rccm.201204-0636OC; Fu JZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140887; Gabrilovich D, 2015, CANCER CELL, V28, P147, DOI 10.1016/j.ccell.2015.07.007; He YM, 2018, NAT MED, V24, P224, DOI 10.1038/nm.4467; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; Kanbay M, 2014, INT UROL NEPHROL, V46, P1619, DOI 10.1007/s11255-014-0730-1; Libetta C, 2001, AM J KIDNEY DIS, V38, P286, DOI 10.1053/ajkd.2001.26092; Libetta C, 2010, INT REV IMMUNOL, V29, P608, DOI 10.3109/08830185.2010.522282; Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036; Liu X, 2014, CANCER-AM CANCER SOC, V120, P68, DOI 10.1002/cncr.28377; Memoli B, 1996, ASAIO J, V42, P60, DOI 10.1097/00002480-199601000-00014; Mestas J, 2008, TRENDS CARDIOVAS MED, V18, P228, DOI 10.1016/j.tcm.2008.11.004; Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005; Nan J, 2018, IMMUNOLOGY, V154, P144, DOI 10.1111/imm.12876; Rogacev KS, 2014, ARTERIOSCL THROM VAS, V34, P2120, DOI 10.1161/ATVBAHA.114.304172; Syed-Ahmed M, 2019, ADV CHRONIC KIDNEY D, V26, P8, DOI 10.1053/j.ackd.2019.01.004; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Xing YF, 2017, KIDNEY INT, V91, P1236, DOI 10.1016/j.kint.2016.12.015; Xing YF, 2016, ANN RHEUM DIS, V75, pE49, DOI 10.1136/annrheumdis-2016-209786; Xing YF, 2013, KIDNEY INT, V83, P970, DOI 10.1038/ki.2013.30; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Yang ZH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00149; Zawada AM, 2015, CYTOM PART A, V87A, P750, DOI 10.1002/cyto.a.22703; Zhang HN, 2018, P NATL ACAD SCI USA, V115, pE6927, DOI 10.1073/pnas.1721521115	32	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 29	2021	11								577253	10.3389/fimmu.2020.577253	http://dx.doi.org/10.3389/fimmu.2020.577253			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF7DG	33584644	Green Published, gold			2022-12-18	WOS:000617052300001
J	Yang, QY; Zhang, YT; Xiao, JN; Liang, YS; Ji, P; Wang, SJ; Wang, Y; Chen, YY				Yang, Qing-yuan; Zhang, Yu-tong; Xiao, Jia-ni; Liang, Yu-shuo; Ji, Ping; Wang, Shu-jun; Wang, Ying; Chen, Yingying			Age-Related Immunoreactivity Profiles to Diverse Mycobacterial Antigens in BCG-Vaccinated Chinese Population	FRONTIERS IN IMMUNOLOGY			English	Article						BCG vaccination; mycobacterial proteins; immunoreactive profiles; healthy population; aging		Long-term immunoreactivity to mycobacterial antigens in Bovis Calmette-Guerin (BCG)-vaccinated population is not well investigated. Herein, 361 volunteer healthy donors (HDs) with neonatal BCG vaccination from Shanghai region (China) were enrolled. They were subdivided into ESAT-6/CFP10(-) (E6C10(-)) and ESAT-6/CFP10(+) (E6C10(+)) groups based on gamma-interferon release assays (IGRAs). Three mycobacterial antigens, including Rv0934, Rv3006, and Rv3841, were subjected to the determination of immunoreactivity by ELISPOT assay. The immunoreactivities to three mycobacterial antigens were firstly compared among TB patients (N=39), E6C10(+) HDs (N=78, 21.61% of HDs) and E6C10(-) HDs (N=283, 78.39% of HDs). It was revealed that Rv3006 was dominant upon M.tb infection, while Rv3841 was likely to be more responsive upon latent TB infection. In E6C10(-) population, the immunoreactivity to Rv3841 maintained along with aging, whereas those to Rv3006 and Rv0934 attenuated in E6C10(-) HDs older than 45 years old. Our study implies the shift of dominant antigens at different infection statuses, providing the clues for the selection of mycobacterial antigens in vaccine development and precision revaccination in the future.	[Yang, Qing-yuan; Zhang, Yu-tong; Xiao, Jia-ni; Liang, Yu-shuo; Ji, Ping; Wang, Shu-jun; Wang, Ying; Chen, Yingying] Shanghai Jiao Tong Unviers, Sch Med, Dept Microbiol & Immunol, Shanghai Inst Immunol, Shanghai, Peoples R China; [Wang, Ying] Shanghai Jiao Tong Univ, Sch Med, Chinese Ctr Trop Dis Res, Minist Hlth,Sch Global Hlth,Key Lab Parasite & Ve, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Wang, Y; Chen, YY (corresponding author), Shanghai Jiao Tong Unviers, Sch Med, Dept Microbiol & Immunol, Shanghai Inst Immunol, Shanghai, Peoples R China.; Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Chinese Ctr Trop Dis Res, Minist Hlth,Sch Global Hlth,Key Lab Parasite & Ve, Shanghai, Peoples R China.	ywangssmu@shsmu.edu.cn; yingying.chen@shsmu.edu.cn			Chinese National Mega Science and Technology Program on Infectious Diseases [2018ZX10731301-001-004, 2018ZX10302301-002-002, 2013ZX10003007-003-003]; Shanghai Academic Research Leader Project [18XD1403300]; National Natural Science Foundation of China [81873868, 81501361]; Science and Technology Commission of Shanghai Municipality [19ZR1445800]	Chinese National Mega Science and Technology Program on Infectious Diseases; Shanghai Academic Research Leader Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by grants from Chinese National Mega Science and Technology Program on Infectious Diseases (2018ZX10731301-001-004, 2018ZX10302301-002-002, and 2013ZX10003007-003-003), Shanghai Academic Research Leader Project (18XD1403300), National Natural Science Foundation of China (81873868, 81501361), and Science and Technology Commission of Shanghai Municipality (19ZR1445800).	Aagaard C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005930; Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370; [Anonymous], 2018, GLOB TUB REP; Bettencourt P, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0148-y; Chen YY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03190; Donald PR, 2010, LANCET, V375, P1852, DOI 10.1016/S0140-6736(10)60580-6; ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P378; Freyne B, 2018, J INFECT DIS, V217, P1798, DOI 10.1093/infdis/jiy069; Haldar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044630; Hollm-Delgado MG, 2014, PEDIATRICS, V133, pE73, DOI 10.1542/peds.2013-2218; Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002; Kowalewicz-Kulbat M, 2017, EXPERT REV VACCINES, V16, P699, DOI 10.1080/14760584.2017.1333906; Landowski CP, 2001, J CLIN MICROBIOL, V39, P2418, DOI 10.1128/JCM.39.7.2418-2424.2001; Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332; Lefevre P, 1997, J BACTERIOL, V179, P2900, DOI 10.1128/jb.179.9.2900-2906.1997; Liu YY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03131; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; National BCG Vaccination Team, 1957, CHIN J ANTITUBERC, V05, P24; Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4; Ottenhoff THM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002607; Pang Y, 2015, VACCINE, V33, P209, DOI 10.1016/j.vaccine.2014.10.030; Pukazhvanthen P, 2014, TUBERCULOSIS, V94, P622, DOI 10.1016/j.tube.2014.09.006; Reddy PV, 2012, J BACTERIOL, V194, P567, DOI 10.1128/JB.05553-11; Sartain MJ, 2006, MOL CELL PROTEOMICS, V5, P2102, DOI 10.1074/mcp.M600089-MCP200; Sharma S, 2017, J MICROBIOL METH, V132, P134, DOI 10.1016/j.mimet.2016.12.006; Soares AP, 2013, J INFECT DIS, V207, P1084, DOI 10.1093/infdis/jis941; Tan JJ, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0243-2; Whittaker E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33499-4; Xiao JN, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00495; Yang XY, 2017, TUBERCULOSIS, V107, P119, DOI 10.1016/j.tube.2017.08.005	30	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 29	2021	11								608220	10.3389/fimmu.2020.608220	http://dx.doi.org/10.3389/fimmu.2020.608220			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF7CE	33584683	Green Published, gold			2022-12-18	WOS:000617049500001
J	Zamyatina, A; Heine, H				Zamyatina, Alla; Heine, Holger			Lipopolysaccharide Recognition in the Crossroads of TLR4 and Caspase-4/11 Mediated Inflammatory Pathways (vol 11, 585146, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						lipid A; inflammation; chemical structure; innate immunity; molecular recognition; TLR4/MD-2; inflammasome; aminoarabinose			[Zamyatina, Alla] Univ Nat Resources & Life Sci, Inst Organ Chem, Dept Chem, Vienna, Austria; [Heine, Holger] German Ctr Lung Dis DZL, Res Grp Innate Immun, Res Ctr Borstel, Leibniz Lung Ctr,Airway Res Ctr North ARCN, Borstel, Germany	University of Natural Resources & Life Sciences, Vienna; Forschungszentrum Borstel	Zamyatina, A (corresponding author), Univ Nat Resources & Life Sci, Inst Organ Chem, Dept Chem, Vienna, Austria.	alla.zamyatina@boku.ac.at	Zamyatina, Alla/N-8411-2014	Zamyatina, Alla/0000-0002-4001-3522	Austrian Science Fund FWF [P 32397] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Zamyatina A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585146	1	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	12								649442	10.3389/fimmu.2021.649442	http://dx.doi.org/10.3389/fimmu.2021.649442			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF5QI	33584736	Green Published, gold			2022-12-18	WOS:000616948100001
J	Zhang, MD; Xie, Y; Su, X; Liu, K; Zhang, YJ; Pang, WY; Wang, JP				Zhang, Mengdi; Xie, Yu; Su, Xing; Liu, Kun; Zhang, Yijie; Pang, Wuyan; Wang, Junpeng			Inonotus sanghuang Polyphenols Attenuate Inflammatory Response Via Modulating the Crosstalk Between Macrophages and Adipocytes (vol 10, 286, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Inonotus sanghuang; polyphenols; inflammation; obesity; NF-kappa B signaling; MAPK signaling			[Zhang, Mengdi; Xie, Yu; Su, Xing; Zhang, Yijie; Pang, Wuyan; Wang, Junpeng] Henan Univ, Inst Infect & Immun, Huaihe Hosp, Kaifeng, Peoples R China; [Xie, Yu] Henan Univ, Sch Phys Educ, Kaifeng, Peoples R China; [Liu, Kun] Hebei Univ Econ & Business, Coll Biol Sci & Engn, Shijiazhuang, Hebei, Peoples R China	Henan University; Henan University; Hebei University of Economics & Business	Wang, JP (corresponding author), Henan Univ, Inst Infect & Immun, Huaihe Hosp, Kaifeng, Peoples R China.	jpwangchina@henu.edu.cn						Zhang MD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00286	1	1	1	5	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	12								633354	10.3389/fimmu.2021.633354	http://dx.doi.org/10.3389/fimmu.2021.633354			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF6FH	33584735	Green Published, gold			2022-12-18	WOS:000616987600001
J	Masum, MA; Ichii, O; Elewa, YHA; Kon, Y				Masum, Md Abdul; Ichii, Osamu; Elewa, Yaser Hosny Ali; Kon, Yasuhiro			Podocyte Injury Through Interaction Between Tlr8 and Its Endogenous Ligand miR-21 in Obstructed and Its Collateral Kidney	FRONTIERS IN IMMUNOLOGY			English	Article						chronic kidney disease; obstructive nephropathy; podocyte; TLR8; obstructed and collateral kidney		While chronic kidney disease is prevalent in adults, obstructive nephropathy (ON) has been reported in both young and old patients. In ON, tubulointerstitial lesions (TILs) have been widely investigated, but glomerular lesions (GLs) have been largely neglected. Here, we show a novel mechanism underlying GL development in ON in young and old mice. TILs develop earlier than GLs owing to infiltration of inflammatory cells in the tubulointerstitium, but GLs develop following the activation of Toll-like receptor 8 (Tlr8) even though the absence of inflammatory cells infiltrating the glomerulus. TLR8 and interleukin 1 beta (IL1 beta) proteins colocalize with reducing podocyte function markers (PFMs), indicating the activation of TLR8 signaling in injured podocytes. Furthermore, glomerular and serum levels of miR-21, an endogenous ligand for Tlr8, were higher in the ON mouse model than in the sham control. The glomerular expression of Tlr8 positively correlates with miR-21 and the downstream cytokines Il1b and Il6 and negatively correlated with PFMs (Nphs1 and Synpo). We also show the colocalization of TLR8 and IL1 beta proteins with reducing PFMs in both obstructed and collateral kidney of young and old mice. Furthermore, in vitro study results revealed higher expression of Tlr8 and its downstream cytokines in glomeruli from obstructed kidneys following treatment with miR-21 mimic than in the control. In conclusion, the overexpression of Tlr8 may serve as a plausible mechanism underlying GL development in ON through podocyte injury.	[Masum, Md Abdul; Ichii, Osamu; Elewa, Yaser Hosny Ali; Kon, Yasuhiro] Hokkaido Univ, Fac Vet Med, Dept Basic Vet Sci, Lab Anat, Sapporo, Hokkaido, Japan; [Masum, Md Abdul] Sher E Bangla Agr Univ, Fac Anim Sci & Vet Med, Dept Anat Histol & Physiol, Dhaka, Bangladesh; [Ichii, Osamu] Hokkaido Univ, Fac Agr, Lab Agrobiomed Sci, Sapporo, Hokkaido, Japan; [Elewa, Yaser Hosny Ali] Zagazig Univ, Fac Vet Med, Dept Histol, Zagazig, Egypt	Hokkaido University; Sher-e-Bangla Agricultural University (SAU); Hokkaido University; Egyptian Knowledge Bank (EKB); Zagazig University	Masum, MA (corresponding author), Hokkaido Univ, Fac Vet Med, Dept Basic Vet Sci, Lab Anat, Sapporo, Hokkaido, Japan.; Masum, MA (corresponding author), Sher E Bangla Agr Univ, Fac Anim Sci & Vet Med, Dept Anat Histol & Physiol, Dhaka, Bangladesh.	Masum@vetmed.hokudai.ac.jp			Japan Society for the Promotion of Science [19F19092]; JSPS kakenhi [18H02331]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); JSPS kakenhi(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid for JSPS Research Fellow from the Japan Society for the Promotion of Science (ID No. 19F19092) and JSPS kakenhi (ID No. 18H02331).	Andersen-Nissen E, 2007, J IMMUNOL, V178, P4717, DOI 10.4049/jimmunol.178.8.4717; [Anonymous], A.D.A.M. medical encyclopedia [Internet] . Chronic unilateral obstructive uropathy; Azam S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01000; Baccala R, 2009, NAT REV RHEUMATOL, V5, P448, DOI 10.1038/nrrheum.2009.136; Banas MC, 2008, J AM SOC NEPHROL, V19, P704, DOI 10.1681/ASN.2007040395; Chassin C, 2008, J AM SOC NEPHROL, V19, P2364, DOI 10.1681/ASN.2007121273; Chevalier RL, 2010, PEDIATR NEPHROL, V25, P687, DOI 10.1007/s00467-009-1316-5; Delanaye P, 2017, CLIN KIDNEY J, V10, P370, DOI 10.1093/ckj/sfw154; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Eleftheriadis Theodoros, 2012, Inflammation & Allergy Drug Targets, V11, P464; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Garraud Olivier, 2010, Inflammation & Allergy Drug Targets, V9, P322; Gurkan S, 2013, J PATHOL, V231, P248, DOI 10.1002/path.4235; Ishidoya S, 1996, KIDNEY INT, V49, P1110, DOI 10.1038/ki.1996.161; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kimura J, 2014, SCI REP-UK, V4, DOI 10.1038/srep07290; Klahr S, 2000, INTERNAL MED, V39, P355, DOI 10.2169/internalmedicine.39.355; Machida H, 2010, NEPHROL DIAL TRANSPL, V25, P2530, DOI 10.1093/ndt/gfq058; Martinez-Klimova E, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040141; Masum MA, 2019, LUPUS, V28, P324, DOI 10.1177/0961203319828518; Masum MA, 2018, AUTOIMMUNITY, V51, P386, DOI 10.1080/08916934.2018.1549234; Masum MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28617-1; Masum MA, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0694-3; Mercer ES, 2004, J UROLOGY, V171, P1250, DOI 10.1097/01.ju.0000112915.69436.91; Mersmann J, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/174168; Ohashi R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018408.51388.57; Panda Shasanka S, 2013, J Indian Assoc Pediatr Surg, V18, P58, DOI 10.4103/0971-9261.109353; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Shigeoka AA, 2007, J IMMUNOL, V178, P6252, DOI 10.4049/jimmunol.178.10.6252; Takano Y, 2007, FEBS LETT, V581, P421, DOI 10.1016/j.febslet.2006.12.051; Timoshanko JR, 2004, AM J PATHOL, V164, P1967, DOI 10.1016/S0002-9440(10)63757-1; Tseng FF, 2004, ARCH PHYS MED REHAB, V85, P1509, DOI 10.1016/j.apmr.2003.09.033; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang JG, 2018, J MAGN RESON IMAGING, V47, P1572, DOI 10.1002/jmri.25915	36	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 22	2021	11								606488	10.3389/fimmu.2020.606488	http://dx.doi.org/10.3389/fimmu.2020.606488			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QC3OT	33552064	Green Published, gold			2022-12-18	WOS:000614743800001
J	Kong, QL; Lv, Z; Kang, Y; An, YQ; Liu, ZL; Zhang, JM				Kong, Qingli; Lv, Zhe; Kang, Yun; An, Yunqing; Liu, Zhenlong; Zhang, Jianmin			Bactericidal Permeability Increasing Protein Deficiency Aggravates Acute Colitis in Mice by Increasing the Serum Levels of Lipopolysaccharide	FRONTIERS IN IMMUNOLOGY			English	Article						bactericidal permeability-increasing protein; antibacterial peptide; ulcerative colitis; gram negative bacteria; gene knockout		Objective The objective of this study was to understand the role of bactericidal permeability increasing protein (BPI) in the pathogenesis of experimental murine colitis. Methods We used the Cre-LoxP system to generate BPI knockout (BPI KO) mice. Acute colitis was induced in BPI KO mice and wild-type (WT) mice by subjecting the mice to 5% dextran sulfate sodium (DSS). Mice were observed for symptoms of experimental colitis. The survival of BPI KO mice to infection with Acinetobacter baumannii, a gram-negative bacterium, was also assessed. Results Southern blot, RT-PCR, and western blot results showed that the 2(nd) and 3(rd) exons of the murine Bpi gene were knocked out systemically, confirming successful construction of the BPI KO mouse. BPI KO mice subjected to DSS showed increased symptoms of experimental colitis, increased colonic mucosal damage, increased epithelial permeability, elevated levels of serum LPS, and a disrupted fecal microbiome as compared with WT mice. Furthermore, BPI KO mice challenged intraperitoneally with A. baumannii died sooner than WT mice, and the total number of bacteria in the abdominal cavity, spleen, and liver was increased in BPI KO mice as compared to WT mice. Conclusions We successfully generated BPI KO mice. The BPI KO mice developed worse colitis than WT mice by increased colitis symptoms and colonic mucosal damage, elevated levels of serum LPS, and a disrupted microbiome. BPI could be a potential target for treatment of ulcerative colitis in humans.	[Kong, Qingli; Lv, Zhe; An, Yunqing; Liu, Zhenlong] Capital Med Univ, Sch Basic Med Sci, Dept Immunol, Beijing, Peoples R China; [Kang, Yun] NVSI Natl Vaccine & Serum Inst, Dept Res & Dev, Beijing, Peoples R China; [Zhang, Jianmin] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, CAMS Key Lab T Cell & Immunotherapy, Beijing, Peoples R China; [Zhang, Jianmin] Peking Union Med Coll, Sch Basic Med, State Key Lab Med Mol Biol, Beijing, Peoples R China	Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Kong, QL (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Immunol, Beijing, Peoples R China.; Zhang, JM (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, CAMS Key Lab T Cell & Immunotherapy, Beijing, Peoples R China.; Zhang, JM (corresponding author), Peking Union Med Coll, Sch Basic Med, State Key Lab Med Mol Biol, Beijing, Peoples R China.	kongql@ccmu.edu.cn; jzhang42@163.com			Beijing Municipality Natural Science Foundation [7172017]	Beijing Municipality Natural Science Foundation	This work was supported by the Beijing Municipality Natural Science Foundation (#7172017).	APPELMELK BJ, 1994, INFECT IMMUN, V62, P3564, DOI 10.1128/IAI.62.8.3564-3567.1994; Balakrishnan A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01567; BORREGAARD N, 1984, SCAND J HAEMATOL, V32, P225; Can G, 2015, SAUDI J GASTROENTERO, V21, P239, DOI 10.4103/1319-3767.161642; Canny G, 2002, P NATL ACAD SCI USA, V99, P3902, DOI 10.1073/pnas.052533799; Conrad K, 2014, AUTOIMMUN REV, V13, P463, DOI 10.1016/j.autrev.2014.01.028; Eckert M, 2006, J IMMUNOL, V176, P522, DOI 10.4049/jimmunol.176.1.522; Giroir BP, 2001, CRIT CARE MED, V29, pS130, DOI 10.1097/00003246-200107001-00039; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678; Kong QL, 2012, J MED MICROBIOL, V61, P1262, DOI 10.1099/jmm.0.040907-0; Lennartsson A, 2005, J LEUKOCYTE BIOL, V77, P369, DOI 10.1189/jlb.0304159; Levy O, 2000, INFECT IMMUN, V68, P5120, DOI 10.1128/IAI.68.9.5120-5125.2000; Li L., 2008, CHIN J IMMUNOL, V24, P8; Luo Y, 2001, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0320s22; Magnusson MK, 2017, INFLAMM BOWEL DIS, V23, P956, DOI 10.1097/MIB.0000000000001130; Mukherjee S, 2015, IMMUNITY, V42, P28, DOI 10.1016/j.immuni.2014.12.028; Nupponen I, 2002, PEDIATR RES, V51, P670, DOI 10.1203/01.PDR.0000017477.64723.9D; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Schinke S, 2004, INFLAMM BOWEL DIS, V10, P763, DOI 10.1097/00054725-200411000-00011; Schultz H, 2007, J IMMUNOL, V179, P2477, DOI 10.4049/jimmunol.179.4.2477; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Skopelja S, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88912; Turpin W, 2018, INFLAMM BOWEL DIS, V24, P1133, DOI 10.1093/ibd/izy085; Walmsley RS, 1997, GUT, V40, P105, DOI 10.1136/gut.40.1.105; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; Weitz A, 2013, INT J ANTIMICROB AG, V42, P571, DOI 10.1016/j.ijantimicag.2013.07.019; Woting A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060685; Yun K., 2010, LAB ANIM SCI, V27, P15, DOI [10.3969/j.issn.1006-6179.2010.04.004, DOI 10.3969/J.ISSN.1006-6179.2010.04.004]	29	1	1	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2021	11								614169	10.3389/fimmu.2020.614169	http://dx.doi.org/10.3389/fimmu.2020.614169			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB8NX	33552078	gold, Green Published			2022-12-18	WOS:000614395100001
J	Bottino, C; Walzer, T; Santoni, A; Castriconi, R				Bottino, Cristina; Walzer, Thierry; Santoni, Angela; Castriconi, Roberta			Editorial: TGF-beta as a Key Regulator of NK and ILCs Development and Functions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK cells; ILC; NKG2D activating receptor; epigenetic mechanisms; chemokine receptors; NK cell metabolism; transforming growth factor-beta			[Bottino, Cristina] Ist Giannina Gaslini, IRCCS, Lab Clin & Expt Immunol, Genoa, Italy; [Bottino, Cristina; Castriconi, Roberta] Univ Genoa, Dept Expt Med, Genoa, Italy; [Walzer, Thierry] Univ Lyon, Ctr Int Rech Infectiol, ENS Lyon, CNRS,UMR5308,INSERM,U1111, Lyon, France; [Santoni, Angela] Sapienza Univ Rome, Ist Pasteur Italia, Dept Mol Med, Rome, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Sapienza University Rome	Castriconi, R (corresponding author), Univ Genoa, Dept Expt Med, Genoa, Italy.	Roberta.Castriconi@unige.it	Walzer, Thierry/L-9418-2014	Walzer, Thierry/0000-0002-0857-8179				Casu B, 2019, CANCERS, V11, DOI 10.3390/cancers11010075; Clayton A, 2008, J IMMUNOL, V180, P7249, DOI 10.4049/jimmunol.180.11.7249; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Fionda C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010143; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Kovacs RJ, 2015, CARDIOVASC TOXICOL, V15, P309, DOI 10.1007/s12012-014-9297-4; Lan Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5488; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Regis S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00868; Selvarajah B, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav3048; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Ullrich E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26097; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461; Zingoni A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00447	15	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2021	11								631712	10.3389/fimmu.2020.631712	http://dx.doi.org/10.3389/fimmu.2020.631712			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA5UN	33542726	gold, Green Published			2022-12-18	WOS:000613511000001
J	Michaelis, L; Tress, M; Low, HC; Klees, J; Klameth, C; Lange, A; Griesshammer, A; Schafer, A; Menz, S; Steimle, A; Schulze-Osthoff, K; Frick, JS				Michaelis, Lena; Tress, Marcel; Loew, Hanna-Christine; Klees, Johanna; Klameth, Christian; Lange, Anna; Griesshammer, Anne; Schaefer, Andrea; Menz, Sarah; Steimle, Alex; Schulze-Osthoff, Klaus; Frick, Julia-Stefanie			Gut Commensal-Induced I kappa B zeta Expression in Dendritic Cells Influences the Th17 Response	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cells; Th17; intestinal commensals; inflammatory bowel disease; immunogenicity; Escherichia coli; Bacteroides vulgatus; I kappa B zeta	COLITIS; PLASTICITY; INDUCTION; PROTEIN; DISRUPTION; DYSBIOSIS; IMMUNITY	Intestinal commensal bacteria can have a large impact on the state of health and disease of the host. Regulation of Th17 cell development by gut commensals is known to contribute to their dichotomous role in promoting gut homeostasis and host defense, or development of autoimmune diseases. Yet, the underlying mechanisms remain to be fully elucidated. One candidate factor contributing to Th17 differentiation, and the expression of which could be influenced by commensals is the atypical nuclear I kappa B protein I kappa B zeta. I kappa B zeta acts as a transcriptional regulator of the expression of Th17-related secondary response genes in many cell types including dendritic cells (DCs). Insights into the regulation of I kappa B zeta in DCs could shed light on how these immune sentinel cells at the interface between commensals, innate and adaptive immune system drive an immune-tolerogenic or inflammatory Th17 cell response. In this study, the influence of two gut commensals of low (Bacteroides vulgatus) or high (Escherichia coli) immunogenicity on I kappa B zeta expression in DCs and its downstream effects was analyzed. We observed that the amount of I kappa B zeta expression and secretion of Th17-inducing cytokines correlated with the immunogenicity of these commensals. However, under immune-balanced conditions, E. coli also strongly induced an I kappa B zeta-dependent secretion of anti-inflammatory IL-10, facilitating a counter-regulative Treg response as assessed in in vitro CD4(+) T cell polarization assays. Yet, in an in vivo mouse model of T cell-induced colitis, prone to inflammatory and autoimmune conditions, administration of E. coli promoted an expansion of rather pro-inflammatory T helper cell subsets whereas administration of B. vulgatus resulted in the induction of protective T helper cell subsets. These findings might contribute to the development of new therapeutic strategies for the treatment of autoimmune diseases using commensals or commensal-derived components.	[Michaelis, Lena; Tress, Marcel; Loew, Hanna-Christine; Klees, Johanna; Klameth, Christian; Lange, Anna; Griesshammer, Anne; Schaefer, Andrea; Menz, Sarah; Steimle, Alex; Frick, Julia-Stefanie] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Dept Med Microbiol & Hyg, Tubingen, Germany; [Steimle, Alex] Luxembourg Inst Hlth, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Schulze-Osthoff, Klaus] Univ Tubingen, Interfac Inst Biochem, Tubingen, Germany	Eberhard Karls University of Tubingen; Luxembourg Institute of Health; Eberhard Karls University of Tubingen	Frick, JS (corresponding author), Univ Tubingen, Interfac Inst Microbiol & Infect Med, Dept Med Microbiol & Hyg, Tubingen, Germany.	julia-stefanie.frick@med.uni-tuebingen.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Frick, Julia-Stefanie/0000-0002-7662-7956; Steimle, Alexander/0000-0003-0961-8694	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy [EXC-2124]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Collaborative Research Centres 685 (CRC685); DFG research training group 1708; Bundesministerium fur Bildung und Forschung (BMBF); German Center for Infection Research (DZIF)	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Collaborative Research Centres 685 (CRC685)(German Research Foundation (DFG)); DFG research training group 1708(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); German Center for Infection Research (DZIF)	This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy-EXC-2124 and Collaborative Research Centres 685 (CRC685), the DFG research training group 1708, the Bundesministerium fur Bildung und Forschung (BMBF), and the German Center for Infection Research (DZIF).	Agalioti T, 2018, J AUTOIMMUN, V87, P50, DOI 10.1016/j.jaut.2017.12.003; Amatya N, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat4617; Antoni L, 2014, WORLD J GASTROENTERO, V20, P1165, DOI 10.3748/wjg.v20.i5.1165; Belikan P, 2018, J IMMUNOL, V200, P2554, DOI 10.4049/jimmunol.1701419; Brucklacher-Waldert V, 2016, J IMMUNOL, V196, P4893, DOI 10.4049/jimmunol.1600137; Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200; Chen YL, 2016, SCI REP-UK, V6, DOI 10.1038/srep35635; Chewning JH, 2014, J IMMUNOL, V193, P4769, DOI 10.4049/jimmunol.1401835; De Calisto J, 2011, METHODS MOL BIOL, V757, P411, DOI 10.1007/978-1-61779-166-6_24; DeGruttola AK, 2016, INFLAMM BOWEL DIS, V22, P1137, DOI 10.1097/MIB.0000000000000750; Di Lorenzo F, 2020, ACS CENTRAL SCI, V6, P1602, DOI 10.1021/acscentsci.0c00791; Frick JS, 2006, EUR J IMMUNOL, V36, P1537, DOI 10.1002/eji.200635840; Frick JS, 2010, INT J MED MICROBIOL, V300, P19, DOI 10.1016/j.ijmm.2009.08.010; Fu SH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093379; Gartlan KH, 2017, BLOOD ADV, V1, P341, DOI 10.1182/bloodadvances.2016002980; Granucci F, 2003, CURR OPIN MICROBIOL, V6, P72, DOI 10.1016/S1369-5274(03)00007-9; Gronbach K, 2014, GASTROENTEROLOGY, V146, P765, DOI 10.1053/j.gastro.2013.11.033; Hermann-Bank ML, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-788; Hildebrand DG, 2013, J IMMUNOL, V190, P4812, DOI 10.4049/jimmunol.1300089; Hirahara K, 2016, INT IMMUNOL, V28, P163, DOI 10.1093/intimm/dxw006; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Horber S, 2016, J BIOL CHEM, V291, P12851, DOI 10.1074/jbc.M116.718825; Hovhannisyan Z, 2011, GASTROENTEROLOGY, V140, P957, DOI 10.1053/j.gastro.2010.12.002; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Johnson EL, 2017, J MOL MED, V95, P1, DOI 10.1007/s00109-016-1492-2; Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kempski J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01373; Kiesler P, 2015, CELL MOL GASTROENTER, V1, P154, DOI 10.1016/j.jcmgh.2015.01.006; Kim J, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154983; Krajina T, 2004, EUR J IMMUNOL, V34, P705, DOI 10.1002/eji.200324463; Lange A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02114; Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Li BF, 2018, J IMMUNOL, V201, P2934, DOI 10.4049/jimmunol.1800016; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Lorscheid S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130835; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Maerz JK, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03093; Martinez-Sanchez ME, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00877; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McFarland BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078728; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Moudgil KD, 2011, J INTERF CYTOK RES, V31, P695, DOI 10.1089/jir.2011.0065; Muller A, 2018, P NATL ACAD SCI USA, V115, P10088, DOI 10.1073/pnas.1801377115; Muller M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002376; Nanki K, 2020, NATURE, V577, P254, DOI 10.1038/s41586-019-1844-5; Okamoto K, 2010, NATURE, V464, P1381, DOI 10.1038/nature08922; Okuma A, 2013, IMMUNITY, V38, P450, DOI 10.1016/j.immuni.2012.11.016; Rutella S, 2011, WORLD J GASTROENTERO, V17, P3761, DOI 10.3748/wjg.v17.i33.3761; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sato Kenya, 2010, Journal of Medical and Dental Sciences, V57, P55; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Schulke S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00455; Shiina T, 2004, J BIOL CHEM, V279, P55493, DOI 10.1074/jbc.M409770200; Sohail MU, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/9631435; Steimle A, 2019, MOL THER, V27, P1974, DOI 10.1016/j.ymthe.2019.07.007; Steimle A, 2016, J AUTOIMMUN, V75, P82, DOI 10.1016/j.jaut.2016.07.009; Steimle A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1958650; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Sundaram K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161931; Waidmann M, 2003, GASTROENTEROLOGY, V125, P162, DOI 10.1016/S0016-5085(03)00672-3; Webb CR, 2018, INFLAMM BOWEL DIS, V24, P361, DOI 10.1093/ibd/izx014; Willems M, 2016, ONCOTARGET, V7, P66310, DOI 10.18632/oncotarget.11624; Wu XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01112; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Zenobia C, 2015, PERIODONTOL 2000, V69, P142, DOI 10.1111/prd.12083; Zhao Q, 2018, IMMUNOLOGY, V154, P28, DOI 10.1111/imm.12896	70	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 19	2021	11								612336	10.3389/fimmu.2020.612336	http://dx.doi.org/10.3389/fimmu.2020.612336			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA5WK	33542719	gold, Green Published			2022-12-18	WOS:000613515900001
J	Song, JY; Griffin, JD; Larson, NR; Christopher, MA; Middaugh, CR; Berkland, CJ				Song, Jimmy Y.; Griffin, J. Daniel; Larson, Nicholas R.; Christopher, Matthew A.; Middaugh, C. Russell; Berkland, Cory J.			Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						EAE; poly-lysine; multiple sclerosis; Copaxone (R); glatiramer acetate; SC injection simulation	MYELIN BASIC-PROTEIN; CELL-PENETRATING PEPTIDES; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; T-CELLS; MECHANISM; SPECIFICITY; SUPPRESSION; DELIVERY; DISEASE	A synthetic peptide, K-PLP, consisting of 11-unit poly-lysine (K11) linked via polyethylene glycol (PEG) to proteolipid protein epitope (PLP) was synthesized, characterized, and evaluated for efficacy in ameliorating experimental autoimmune encephalomyelitis (EAE) induced by PLP. K-PLP was designed to mimic the cationic nature of the relapsing-remitting multiple sclerosis treatment, glatiramer acetate (GA). With a pI of similar to 10, GA is able to form visible aggregates at the site of injection via electrostatic interactions with the anionic extracellular matrix. Aggregation further facilitates the retention of GA at the site of injection and draining lymph nodes, which may contribute to its mechanism of action. K-PLP with a pI of similar to 11, was found to form visible aggregates in the presence of glycosaminoglycans and persist at the injection site and draining lymph nodes in vivo, similar to GA. Additionally, EAE mice treated with K-PLP showed significant inhibition of clinical symptoms compared to free poly-lysine and to PLP, which are the components of K-PLP. The ability of the poly-lysine motif to retain PLP at the injection site, which increased the local exposure of PLP to immune cells may be an important factor affecting drug efficacy.	[Song, Jimmy Y.; Griffin, J. Daniel; Larson, Nicholas R.; Christopher, Matthew A.; Middaugh, C. Russell; Berkland, Cory J.] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA; [Griffin, J. Daniel; Berkland, Cory J.] Univ Kansas, Dept Bioengn, Lawrence, KS 66045 USA; [Berkland, Cory J.] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66045 USA	University of Kansas; University of Kansas; University of Kansas	Berkland, CJ (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.; Berkland, CJ (corresponding author), Univ Kansas, Dept Bioengn, Lawrence, KS 66045 USA.; Berkland, CJ (corresponding author), Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66045 USA.	berkland@ku.edu			National Institutes of Health Biotechnology Training Grant [NIH0073415, 5T32GM008359-26]; National Institutes of Health COBRE Chemical Biology of Infectious Diseases grant [P20-GM113117]; PhRMA Foundation Postdoctoral Fellowship in Pharmaceutics; Madison and Lila Self Graduate Fellowship; Stella Fellowship from the University of Kansas	National Institutes of Health Biotechnology Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health COBRE Chemical Biology of Infectious Diseases grant; PhRMA Foundation Postdoctoral Fellowship in Pharmaceutics; Madison and Lila Self Graduate Fellowship; Stella Fellowship from the University of Kansas	This work was funded by the National Institutes of Health Biotechnology Training Grant (NIH0073415, 5T32GM008359-26), National Institutes of Health COBRE Chemical Biology of Infectious Diseases grant (P20-GM113117), PhRMA Foundation Postdoctoral Fellowship in Pharmaceutics, and the Madison and Lila Self Graduate Fellowship and Stella Fellowship from the University of Kansas.	Aharoni R, 1997, IMMUNOL LETT, V58, P79, DOI 10.1016/S0165-2478(97)00032-1; Aharoni R, 2003, P NATL ACAD SCI USA, V100, P14157, DOI 10.1073/pnas.2336171100; Aharoni R, 2000, P NATL ACAD SCI USA, V97, P11472, DOI 10.1073/pnas.97.21.11472; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; Aharoni R, 2014, J AUTOIMMUN, V54, P81, DOI 10.1016/j.jaut.2014.05.005; Aharoni R, 2011, J AUTOIMMUN, V37, P228, DOI 10.1016/j.jaut.2011.06.003; Alhakamy NA, 2013, THER DELIV, V4, P741, DOI [10.4155/TDE.13.44, 10.4155/tde.13.44]; Chen M, 2001, MULT SCLER, V7, P209, DOI 10.1191/135245801680209303; Falk K, 2000, J EXP MED, V191, P717, DOI 10.1084/jem.191.4.717; FRIDKISHARELI M, 1994, P NATL ACAD SCI USA, V91, P4872, DOI 10.1073/pnas.91.11.4872; Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202; Griffin JD, 2020, ADV DRUG DELIVER REV, V165-166, P105, DOI 10.1016/j.addr.2020.04.005; Griffin JD, 2019, BIOMATERIALS, V222, DOI 10.1016/j.biomaterials.2019.119440; Griffin JD, 2019, MOL PHARMACEUT, V16, P607, DOI 10.1021/acs.molpharmaceut.8b00887; Hartwell BL, 2018, J AUTOIMMUN, V93, P76, DOI 10.1016/j.jaut.2018.06.006; Kala M, 2011, J NEUROIMMUNOL, V235, P9, DOI 10.1016/j.jneuroim.2011.01.009; Kantengwa S, 2007, J NEUROIMMUNOL, V185, P123, DOI 10.1016/j.jneuroim.2006.12.014; Lalive PH, 2011, CNS DRUGS, V25, P401, DOI 10.2165/11588120-000000000-00000; Mangas A, 2009, CURR MED CHEM, V16, P3203, DOI 10.2174/092986709788803259; Munishkina LA, 2007, BBA-BIOMEMBRANES, V1768, P1862, DOI 10.1016/j.bbamem.2007.03.015; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Northrup L, 2017, J CONTROL RELEASE, V266, P156, DOI 10.1016/j.jconrel.2017.09.034; Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7; Song JY, 2019, J CONTROL RELEASE, V293, P36, DOI 10.1016/j.jconrel.2018.11.007; Teitelbaum D, 1996, J NEUROIMMUNOL, V64, P209, DOI 10.1016/0165-5728(95)00180-8; TEITELBAUM D, 1971, European Journal of Immunology, V1, P242, DOI 10.1002/eji.1830010406; Varkony H, 2009, EXPERT OPIN PHARMACO, V10, P657, DOI [10.1517/14656560902802877 , 10.1517/14656560902802877]; WEBB C, 1976, IMMUNOCHEMISTRY, V13, P333, DOI 10.1016/0019-2791(76)90344-X; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; Wegmann KW, 2008, J IMMUNOL, V181, P3301, DOI 10.4049/jimmunol.181.5.3301; Wegmann KW, 2014, J NEUROIMMUNOL, V274, P46, DOI 10.1016/j.jneuroim.2014.06.011; Wei YJ, 2018, SLAS TECHNOL, V23, P516, DOI 10.1177/2472630318780620; Wingerchuk DM, 2014, MAYO CLIN PROC, V89, P225, DOI 10.1016/j.mayocp.2013.11.002; Wu F, 2012, PHARM RES-DORDR, V29, P1843, DOI 10.1007/s11095-012-0708-6; Zhang CJ, 2014, IMMUNOL CELL BIOL, V92, P164, DOI 10.1038/icb.2013.81	35	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2021	11								603029	10.3389/fimmu.2020.603029	http://dx.doi.org/10.3389/fimmu.2020.603029			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA2QD	33537031	Green Published, gold			2022-12-18	WOS:000613292000001
J	Venhoff, N; Thiel, J; Schramm, MA; Jandova, I; Voll, RE; Glaser, C				Venhoff, Nils; Thiel, Jens; Schramm, Markus A.; Jandova, Ilona; Voll, Reinhard E.; Glaser, Cornelia			Case Report: Effective and Safe Treatment With Certolizumab Pegol in Pregnant Patients With Cogan's Syndrome: A Report of Three Pregnancies in Two Patients	FRONTIERS IN IMMUNOLOGY			English	Article						Cogan's syndrome; pregnancy; vasculitis; TNF-alpha inhibitor; Certolizumab pegol	WOMAN	Cogan's syndrome is a rare autoimmune disease characterized by ocular inflammation and audiovestibular manifestations. Treatment consists of systemic glucocorticoids and other immunosuppressive agents including methotrexate, cyclophosphamide and TNF-alpha-inhibitors. Due to potential ovarian or fetal toxicity immunosuppressive treatment options are limited during pregnancies. Thus far there is a paucity of reports on pregnancies in Cogan's syndrome. With minimal transplacental transfer, Certolizumab pegol is considered to be safe for the use in pregnant patients with underlying inflammatory diseases. However, there is no literature on the use of this TNF-alpha-inhibitor in Cogan's syndrome in general and especially during gestation. Here we report three pregnancies in two Cogan's Syndrome-patients treated with Certolizumab pegol. Treatment with Certolizumab pegol was effective and well tolerated in patients with Cogan's syndrome and seems to be a safe treatment option during pregnancy.	[Venhoff, Nils; Thiel, Jens; Schramm, Markus A.; Jandova, Ilona; Voll, Reinhard E.; Glaser, Cornelia] Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany	University of Freiburg	Venhoff, N (corresponding author), Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany.	nils.venhoff@uniklinik-freiburg.de						Bakalianou K, 2008, CLIN EXP OBSTET GYN, V35, P301; Clowse MEB, 2017, ANN RHEUM DIS, V76, P1890, DOI 10.1136/annrheumdis-2017-211384; COGAN DG, 1945, ARCH OPHTHALMOL-CHIC, V33, P144; Currie C, 2009, J MATERN-FETAL NEO M, V22, P928, DOI 10.1080/14767050902974236; Deliveliotou A, 2007, CLIN RHEUMATOL, V26, P2181, DOI 10.1007/s10067-007-0664-4; Durtette C, 2017, AUTOIMMUN REV, V16, P1219, DOI 10.1016/j.autrev.2017.10.005; Hazes JMW, 2011, RHEUMATOLOGY, V50, P1955, DOI 10.1093/rheumatology/ker302; Mariette X, 2018, ANN RHEUM DIS, V77, P228, DOI 10.1136/annrheumdis-2017-212196; Mora P, 2017, AUTOIMMUN REV, V16, P385, DOI 10.1016/j.autrev.2017.02.009; Riboni F, 2016, ISR MED ASSOC J, V18, P495; Scherg F, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2018-227917; Shamriz O, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1498640; Skorpen CG, 2016, ANN RHEUM DIS, V75, P795, DOI 10.1136/annrheumdis-2015-208840; Tarney CM, 2014, OBSTET GYNECOL, V124, P428, DOI 10.1097/AOG.0000000000000390	14	1	1	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2021	11								616992	10.3389/fimmu.2020.616992	http://dx.doi.org/10.3389/fimmu.2020.616992			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QA0LE	33537034	Green Published, gold			2022-12-18	WOS:000613141900001
J	Rueschenbaum, S; Cai, CC; Schmidt, M; Schwarzkopf, K; Dittmer, U; Zeuzem, S; Welsch, C; Lange, CM				Rueschenbaum, Sabrina; Cai, Chengcong; Schmidt, Matthias; Schwarzkopf, Katharina; Dittmer, Ulf; Zeuzem, Stefan; Welsch, Christoph; Lange, Christian M.			Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						liver immunology; macrophages; cytokines; interferons; inflammation; liver cirrhosis; acute-on-chronic liver failure	VITAMIN-D-RECEPTOR; STIMULATED GENES; INVOLVEMENT; LAMBDA	Interleukin-7 (IL-7) is an important cytokine with pivotal pro-survival functions in the adaptive immune system. However, the role of IL-7 in innate immunity is not fully understood. In the present study, the impact of hepatic IL-7 on innate immune cells was assessed by functional experiments as well as in patients with different stages of liver cirrhosis or acute-on-chronic liver failure (ACLF). Human hepatocytes and liver sinusoidal endothelial cells secreted IL-7 in response to stimulation with interferons (IFNs) of type I and II, yet not type III. De novo translation of interferon-response factor-1 (IRF-1) restricted IL-7 production to stimulation with type I and II IFNs. LPS-primed human macrophages were identified as innate immune target cells responding to IL-7 signaling by inactivation of Glycogen synthase kinase-3 (GSK3). IL-7-mediated GSK3 inactivation augmented LPS-induced secretion of pro-inflammatory cytokines and blunted LPS tolerance of macrophages. The IFN-IRF-1-IL-7 axis was present in liver cirrhosis patients. However, liver cirrhosis patients with or without ACLF had significantly lower concentrations of IL-7 in serum compared to healthy controls, which might contribute to LPS-tolerance in these patients. In conclusion, we propose the presence of an inflammatory cascade where IFNs of type I/II induce hepatocellular IL-7 in an IRF-1-restriced way. Beyond its role in adaptive immune responses, IL-7 appears to augment the response of macrophages to LPS and to ameliorate LPS tolerance, which may improve innate immune responses against invading pathogens.	[Rueschenbaum, Sabrina; Lange, Christian M.] Univ Duisburg Essen, Univ Hosp Essen, Dept Gastroenterol & Hepatol, Essen, Germany; [Rueschenbaum, Sabrina; Cai, Chengcong; Schmidt, Matthias; Schwarzkopf, Katharina; Zeuzem, Stefan; Welsch, Christoph; Lange, Christian M.] JW Goethe Univ Hosp, Dept Med 1, Frankfurt, Germany; [Dittmer, Ulf] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany	University of Duisburg Essen; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Duisburg Essen	Lange, CM (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Gastroenterol & Hepatol, Essen, Germany.; Lange, CM (corresponding author), JW Goethe Univ Hosp, Dept Med 1, Frankfurt, Germany.	Christian.Lange@uk-essen.de			Deutsche Forschungsgemeinschaft [LA 2806/2-1, LA 2806/5-1]; IFORES Forderprogramm of the University Duisburg-Essen	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); IFORES Forderprogramm of the University Duisburg-Essen	CML is supported by the Deutsche Forschungsgemeinschaft (LA 2806/2-1 and LA 2806/5-1 to CML) and by the IFORES Forderprogramm of the University Duisburg-Essen.	Albillos A, 2014, J HEPATOL, V61, P1385, DOI 10.1016/j.jhep.2014.08.010; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Cai C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00723; Chan HLY, 2016, J HEPATOL, V64, P1011, DOI 10.1016/j.jhep.2015.12.018; Coant N, 2011, J HEPATOL, V55, P784, DOI 10.1016/j.jhep.2010.12.039; Dill MT, 2012, GASTROENTEROLOGY, V143, P777, DOI 10.1053/j.gastro.2012.05.044; Heim MH, 2013, NAT REV IMMUNOL, V13, P535, DOI 10.1038/nri3463; Jenne CN, 2013, NAT IMMUNOL, V14, P996, DOI 10.1038/ni.2691; Knolle PA, 2014, GASTROENTEROLOGY, V146, P1193, DOI 10.1053/j.gastro.2013.12.036; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Lange CM, 2018, VISC MED, V34, P276, DOI 10.1159/000488690; Lange CM, 2014, J IMMUNOL, V192, P6037, DOI 10.4049/jimmunol.1302296; Mackall CL, 2011, NAT REV IMMUNOL, V11, P330, DOI 10.1038/nri2970; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042; Oshima S, 2004, MOL CELL BIOL, V24, P6298, DOI 10.1128/MCB.24.14.6298-6310.2004; Park SH, 2011, NAT IMMUNOL, V12, P607, DOI 10.1038/ni.2043; Pellegrini M, 2011, CELL, V144, P601, DOI 10.1016/j.cell.2011.01.011; Pickens SR, 2011, ARTHRITIS RHEUM-US, V63, P2884, DOI 10.1002/art.30493; Sawa Y, 2009, IMMUNITY, V30, P447, DOI 10.1016/j.immuni.2009.01.007; Schindler C, 2008, SEMIN CELL DEV BIOL, V19, P311, DOI 10.1016/j.semcdb.2008.08.010; Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006; Schwarzkopf K, 2019, HEPATOL COMMUN, V3, P392, DOI 10.1002/hep4.1303; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Unsinger J, 2010, J IMMUNOL, V184, P3768, DOI 10.4049/jimmunol.0903151; Wang J, 2016, NAT GENET, V48, P1396, DOI 10.1038/ng.3695; Wohlleber D, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.74	28	1	1	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2021	11								581352	10.3389/fimmu.2020.581352	http://dx.doi.org/10.3389/fimmu.2020.581352			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PY8XY	33584648	Green Published, gold			2022-12-18	WOS:000612325800001
J	Xavier, LL; Neves, PFR; Paz, LV; Neves, LT; Bagatini, PB; Timmers, LFSM; Rasia, AA; Mestriner, RG; Wieck, A				Xavier, Leder Leal; Ribas Neves, Paula Fernanda; Paz, Lisie Valeria; Neves, Laura Tartari; Bagatini, Pamela Brambilla; Saraiva Macedo Timmers, Luis Fernando; Rasia-Filho, Alberto Antonio; Mestriner, Regis Gemerasca; Wieck, Andrea			Does Angiotensin II Peak in Response to SARS-CoV-2?	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; Angiotensin-converting enzyme 2; angiotensin-II; immune activation; immune response	NECROSIS-FACTOR-ALPHA; CONVERTING ENZYME 2; T-CELLS; ALDOSTERONE SYSTEM; CIRCADIAN-RHYTHMS; ENDOTHELIAL-CELLS; TYPE-1 RECEPTOR; DOWN-REGULATION; SARS-COV; ACE2	Human infection by the SARS-CoV-2 is causing the current COVID-19 pandemic. With the growing numbers of cases and deaths, there is an urgent need to explore pathophysiological hypotheses in an attempt to better understand the factors determining the course of the disease. Here, we hypothesize that COVID-19 severity and its symptoms could be related to transmembrane and soluble Angiotensin-converting enzyme 2 (tACE2 and sACE2); Angiotensin II (ANG II); Angiotensin 1-7 (ANG 1-7) and angiotensin receptor 1 (AT1R) activation levels. Additionally, we hypothesize that an early peak in ANG II and ADAM-17 might represent a physiological attempt to reduce viral infection via tACE2. This viewpoint presents: (1) a brief introduction regarding the renin-angiotensin-aldosterone system (RAAS), detailing its receptors, molecular synthesis, and degradation routes; (2) a description of the proposed early changes in the RAAS in response to SARS-CoV-2 infection, including biological scenarios for the best and worst prognoses; and (3) the physiological pathways and reasoning for changes in the RAAS following SARS-CoV-2 infection.	[Xavier, Leder Leal; Ribas Neves, Paula Fernanda; Paz, Lisie Valeria; Neves, Laura Tartari; Bagatini, Pamela Brambilla; Mestriner, Regis Gemerasca; Wieck, Andrea] Pontificia Univ Catolica Rio Grande do Sul, Lab Biol Celular & Tecidual, Escola Ciencias Saude & Vida, PUCRS,Programa Posgrad Biol Celular & Mol, Porto Alegre, RS, Brazil; [Saraiva Macedo Timmers, Luis Fernando] Univ Vale Taquari UNIVATES, Programa Posgrad Ciencias Med PPGCM, Programa Posgrad Biotecnol PPGBiotec, Lajeado, Brazil; [Rasia-Filho, Alberto Antonio] Univ Fed Ciencias Saude Porto Alegre UFCSPA, Dept Ciencias Basicas Saude Fisiol, Porto Alegre, RS, Brazil	Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidade Federal de Ciencias da Saude de Porto Alegre	Xavier, LL (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Lab Biol Celular & Tecidual, Escola Ciencias Saude & Vida, PUCRS,Programa Posgrad Biol Celular & Mol, Porto Alegre, RS, Brazil.	lixavier@pums.br	Rasia-Filho, Alberto/AAC-1166-2022; Mestriner, Régis/A-5911-2015	Rasia-Filho, Alberto/0000-0003-4623-5916; Mestriner, Régis/0000-0001-9837-1691; Paz, Lisie/0000-0001-7259-9137	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [001]; Conselho Nacional de Pesquisa e Desenvolvimento (CNPq) [306644/2016-9, 423884/2018-2]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)(Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS))	This studywas financed in part by Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior-Brasil (CAPES)-Finance Code 001; Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)-Grant Numbers 306644/2016-9 and 423884/2018-2; Fundacao de Amparo aPesquisadoEstadodoRioGrandedoSul (FAPERGS). LXandARF are CNPq researchers.	[Anonymous], 2020, CANCER DISCOV, DOI [DOI 10.1038/S41379-019-0362-1, DOI 10.1038/S41421-020-0168-9]; Atlas SA, 2007, J MANAGE CARE PHARM, V13, pS9, DOI 10.18553/jmcp.2007.13.s8-b.9; Bestle D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000786; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Catanzaro M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0191-1; Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363; Coppo M, 2008, REGUL PEPTIDES, V151, P1, DOI 10.1016/j.regpep.2008.07.010; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; CUGINI P, 1982, CHRONOBIOLOGIA, V9, P229; CUGINI P, 1985, MATURITAS, V7, P175, DOI 10.1016/0378-5122(85)90024-6; Demogines A, 2012, J VIROL, V86, P6350, DOI 10.1128/JVI.00311-12; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Ferrao Fernanda M, 2014, World J Nephrol, V3, P64, DOI 10.5527/wjn.v3.i3.64; Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017; Fuchs S, 2008, HYPERTENSION, V51, P267, DOI 10.1161/HYPERTENSIONAHA.107.097865; Gallagher PE, 2008, AM J PHYSIOL-CELL PH, V295, pC1169, DOI 10.1152/ajpcell.00145.2008; Gallagher PE, 2006, AM J PHYSIOL-CELL PH, V290, pC420, DOI 10.1152/ajpcell.00409.2004; Ghazi Lama, 2017, F1000Res, V6, DOI 10.12688/f1000research.9692.1; Ghosal S, 2020, EFFECT ANGIOTENSIN C, DOI [04.23.20076661, 10.1101/2020.04.23.20076661]; Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09; Grivennikov SI, 2005, IMMUNITY, V22, P93, DOI 10.1016/j.immuni.2004.11.016; Guo J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10942; Hao LY, 2010, P NATL ACAD SCI USA, V107, P9747, DOI 10.1073/pnas.0911175107; Herichova I, 2014, Endocr Regul, V48, P144; Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13; Hoch NE, 2009, AM J PHYSIOL-REG I, V296, pR208, DOI 10.1152/ajpregu.90521.2008; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Ichiki T, 1998, HYPERTENSION, V31, P342, DOI 10.1161/01.HYP.31.1.342; Ihara M, 1999, HYPERTENSION, V33, P1399, DOI 10.1161/01.HYP.33.6.1399; Imayama I, 2006, CARDIOVASC RES, V72, P184, DOI 10.1016/j.cardiores.2006.07.014; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009; Jurewicz M, 2007, J AM SOC NEPHROL, V18, P1093, DOI 10.1681/ASN.2006070707; Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8; Kashuba E, 2013, BIOMARKERS, V18, P279, DOI 10.3109/1354750X.2013.787544; Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012; Kramkowski K, 2006, J PHYSIOL PHARMACOL, V57, P529; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kuoppala A, 2000, AM J PHYSIOL-HEART C, V278, pH1069, DOI 10.1152/ajpheart.2000.278.4.H1069; Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235; Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200; Leow MKS, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03097-w; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006; Liu MY, 2020, J TRANSL INTERN MED, V8, P9, DOI 10.2478/jtim-2020-0003; Liu X, 2014, VIRUS RES, V185, P64, DOI 10.1016/j.virusres.2014.03.010; Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8; Mackey K, 2020, ANN INTERN MED, V173, P195, DOI 10.7326/M20-1515; Magalhaes GS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00058; Mazzoccoli G, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020083; Cruz MME, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01023-2020; Mochel JP, 2013, CHRONOBIOL INT, V30, P1144, DOI 10.3109/07420528.2013.807275; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pastore L, 1999, CIRCULATION, V100, P1646, DOI 10.1161/01.CIR.100.15.1646; Patel BM, 2012, EUR J PHARMACOL, V697, P1, DOI 10.1016/j.ejphar.2012.09.034; Platten M, 2009, P NATL ACAD SCI USA, V106, P14948, DOI 10.1073/pnas.0903958106; Ramchand J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198144; Ruiz-Ortega M, 2001, CURR OPIN NEPHROL HY, V10, P321, DOI 10.1097/00041552-200105000-00005; Saleem TSM, 2010, OPEN ACCESS EMERG M, V2, P51; Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07; Singh A, 2007, J LEUKOCYTE BIOL, V82, P1201, DOI 10.1189/jlb.0407240; Sodhi CP, 2019, J IMMUNOL, V203, P3000, DOI 10.4049/jimmunol.1900579; Soro-Paavonen A, 2012, J HYPERTENS, V30, P375, DOI 10.1097/HJH.0b013e32834f04b6; Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5; Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Tanaka Y, 2005, FEBS LETT, V579, P1579, DOI 10.1016/j.febslet.2005.01.068; Tayeh MA, 1998, P ASSOC AM PHYSICIAN, V110, P412; Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001; Urra JM, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108486; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Wang KM, 2020, CIRCULATION, V142, P426, DOI 10.1161/CIRCULATIONAHA.120.047049; Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987; Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-x, 10.1038/s41368-020-0074-X]; Yang CW, 2017, RENAL FAILURE, V39, P719, DOI 10.1080/0886022X.2017.1398665; Zemlin AE, 2020, ANN CLIN BIOCHEM, V57, P339, DOI 10.1177/0004563220928361; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zipeto D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576745; Zisman LS, 2005, EUR HEART J, V26, P322, DOI 10.1093/eurheartj/ehi043; Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594; Zoufaly A, 2020, LANCET RESP MED, V8, P1154, DOI 10.1016/S2213-2600(20)30418-5	90	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2021	11								577875	10.3389/fimmu.2020.577875	http://dx.doi.org/10.3389/fimmu.2020.577875			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PZ1DE	33519802	Green Published, gold			2022-12-18	WOS:000612478600001
J	Huang, YF; Wu, XY; Gui, L; Jiang, YT; Tu, LD; Li, XM; Jiang, BX; Wang, YN; Zheng, XQ; Wei, QJ; Li, QX; Ou, JY; Chen, ZN; Xie, Y; Lin, ZM; Liao, ZT; Fang, LK; Qiu, ML; Cao, SY; Gu, JR				Huang, Yefei; Wu, Xinyu; Gui, Lian; Jiang, Yutong; Tu, Liudan; Li, Xiaomin; Jiang, Boxiong; Wang, Yina; Zheng, Xuqi; Wei, Qiujing; Li, Qiuxia; Ou, Jiayong; Chen, Zena; Xie, Ya; Lin, Zhiming; Liao, Zetao; Fang, Linkai; Qiu, Minli; Cao, Shuangyan; Gu, Jieruo			Age-Specific Imbalance of Circulating Tfh Cell Subsets and Its Association With Gout-Targeted Kidney Impairment	FRONTIERS IN IMMUNOLOGY			English	Article						gout; Tfh1; 2 cells; aging; B cells; kidney impairment	URIC-ACID; MONOSODIUM URATE; T-CELLS; IMMUNITY; DEATH	Objective Gout is a chronic disease characterized by the deposition of monosodium urate (MSU) crystals in tissue. Study with a focus on adaptive immune response remains to be understood although innate immune response has been reported extensively in gout etiology. Our study attempted to investigate the association of gout-related immune cell imbalance with clinical features and comorbidity with renal impairment and the implicated pathogenesis via the assessment of T and B cell subsets in different activity phases or with immune effects combined with the analyses of clinical parameters. Methods Fifty-eight gout patients and 56 age- and sex-matched healthy individuals were enrolled. To learn the roles of circulating T cells, a lymphocyte profile incorporating 32 T cell subsets was tested from isolated freshly peripheral blood monocyte cells (PBMCs) with multiple-color flow cytometry. Furthermore, the collected clinical features of participants were used to analyze the characteristics of these differential cell subsets. Stratified on the basis of the level of creatinine (Cr, enzymatic method), all patients were categorized into Cr-low (Cr <= 116 mu mol/L) and Cr-hi (Cr > 116 mu mol/L) groups to exploit whether these gout-associated T cell subsets were functional in gout-targeted kidney dysfunction. The differentiation of B cells was investigated in gout patients. Results Our results show that CD 4(+) T cells, Th2 cells, and Tc2 cells were upregulated, whereas Tc17 cells were downregulated. Tfh cells skewed toward the polarization of Tfh2 cells. Specifically, Tfh2 cells increased, but Tfh1 cells decreased, accompanied with aging for gout patients, suggesting that age might trigger the skewing of Tfh1/Tfh2 cell subsets to influence gout development. Moreover, Tfh2 cells were connected to renal dysfunction as well. No alterations of B cell subsets were observed in patients when compared to controls. Conclusions Our data demonstrate age-specific dysfunctions of Tfh1/2 cells in gout occurrence, and Tfh2 cell upregulation is associated with gout-targeted renal dysfunction. However, Tfh2 cells may function in auto-inflammatory gout independent of helping B differentiation, and an in-depth study remains to be conducted.	[Huang, Yefei; Wu, Xinyu; Gui, Lian; Jiang, Yutong; Tu, Liudan; Li, Xiaomin; Zheng, Xuqi; Wei, Qiujing; Li, Qiuxia; Ou, Jiayong; Chen, Zena; Xie, Ya; Lin, Zhiming; Liao, Zetao; Fang, Linkai; Qiu, Minli; Cao, Shuangyan; Gu, Jieruo] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou, Peoples R China; [Jiang, Boxiong] Sun Yat Sen Univ, Affiliated Hosp 3, Med Examinat Ctr, Guangzhou, Peoples R China; [Wang, Yina] Sun Yat Sen Univ, Affiliated Hosp 3, VIP Med Ctr, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Gu, JR (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol, Guangzhou, Peoples R China.	gujieruo@163.com	gui, lian/HHC-5056-2022; chen, zena/HGU-4571-2022		National Key R&D Program of China [2016YFC0903500]; Guangdong Science and Technology Plan Project [2016A020216013]; "Five and five" Project of the Third Affiliated Hospital of Sun Yat-Sen University [k00004]	National Key R&D Program of China; Guangdong Science and Technology Plan Project; "Five and five" Project of the Third Affiliated Hospital of Sun Yat-Sen University	Special thanks to the support from the National Key R&D Program of China (2016YFC0903500); Guangdong Science and Technology Plan Project (2016A020216013); and the "Five and five" Project of the Third Affiliated Hospital of Sun Yat-Sen University (k00004). The authors appreciate Prof. Zhinan Yin (The First Affiliated Hospital, Biomedical Translational Research Institute, Jinan University, Guangzhou 510632, China) for guiding this study design.	ABB J, 1984, BLUT, V48, P285; Conforti-Andreoni C, 2011, J IMMUNOL, V187, P5842, DOI 10.4049/jimmunol.1101408; Dalbeth N, 2016, LANCET, V388, P2039, DOI 10.1016/S0140-6736(16)00346-9; Fulop T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00271; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; GIBSON T, 1980, ANN RHEUM DIS, V39, P417, DOI 10.1136/ard.39.5.417; Gibson T, 2012, CURR OPIN RHEUMATOL, V24, P127, DOI 10.1097/BOR.0b013e32834f049f; Gupta Sudhir, 2007, P44; Haynes L, 2009, CURR OPIN IMMUNOL, V21, P414, DOI 10.1016/j.coi.2009.05.009; Karnekura R, 2015, CLIN IMMUNOL, V158, P204, DOI 10.1016/j.clim.2015.02.016; Kim CJ, 2018, IMMUNITY, V49, P1034, DOI 10.1016/j.immuni.2018.10.012; Kono H, 2010, J CLIN INVEST, V120, P1939, DOI 10.1172/JCI40124; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Lee SJ, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3483; Liu-Bryan R, 2005, J IMMUNOL, V174, P5016, DOI 10.4049/jimmunol.174.8.5016; Martin WJ, 2009, ARTHRITIS RHEUM-US, V60, P281, DOI 10.1002/art.24185; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mikuls TR, 2005, ANN RHEUM DIS, V64, P267, DOI 10.1136/ard.2004.024091; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Pawelec G, 1997, IMMUNOL TODAY, V18, P514, DOI 10.1016/S0167-5699(97)01145-6; Pene J, 2004, J IMMUNOL, V172, P5154, DOI 10.4049/jimmunol.172.9.5154; Richette P, 2010, LANCET, V375, P318, DOI 10.1016/S0140-6736(09)60883-7; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590, DOI 10.1073/pnas.260497597; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Zhang RH, 2019, J AUTOIMMUN, V96, P113, DOI 10.1016/j.jaut.2018.09.001	27	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2021	11								625458	10.3389/fimmu.2020.625458	http://dx.doi.org/10.3389/fimmu.2020.625458			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PW7CX	33505406	gold, Green Published			2022-12-18	WOS:000610829500001
J	Tracy, AM; Weil, E; Burge, CA				Tracy, Allison M.; Weil, Ernesto; Burge, Colleen A.			Ecological Factors Mediate Immunity and Parasitic Co-Infection in Sea Fan Octocorals	FRONTIERS IN IMMUNOLOGY			English	Article						ecological immunity; Gorgonia ventalina; co-infection; host demography; octocoral	CLIMATE-CHANGE; INFECTIOUS-DISEASES; GORGONIA-VENTALINA; AFRICAN BUFFALO; CORAL DISEASE; STRESS; TRANSCRIPTOME; PREVALENCE; SEVERITY; DYNAMICS	The interplay among environment, demography, and host-parasite interactions is a challenging frontier. In the ocean, fundamental changes are occurring due to anthropogenic pressures, including increased disease outbreaks on coral reefs. These outbreaks include multiple parasites, calling into question how host immunity functions in this complex milieu. Our work investigates the interplay of factors influencing co-infection in the Caribbean sea fan octocoral, Gorgonia ventalina, using metrics of the innate immune response: cellular immunity and expression of candidate immune genes. We used existing copepod infections and live pathogen inoculation with the Aspergillus sydowii fungus, detecting increased expression of the immune recognition gene Tachylectin 5A (T5A) in response to both parasites. Cellular immunity increased by 8.16% in copepod infections compared to controls and single Aspergillus infections. We also detected activation of cellular immunity in reef populations, with a 13.6% increase during copepod infections. Cellular immunity was similar in the field and in the lab, increasing with copepod infections and not the fungus. Amoebocyte density and the expression of T5A and a matrix metalloproteinase (MMP) gene were also positively correlated across all treatments and colonies, irrespective of parasitic infection. We then assessed the scaling of immune metrics to population-level disease patterns and found random co-occurrence of copepods and fungus across 15 reefs in Puerto Rico. The results suggest immune activation by parasites may not alter parasite co-occurrence if factors other than immunity prevail in structuring parasite infection. We assessed non-immune factors in the field and found that sea fan colony size predicted infection by the copepod parasite. Moreover, the effect of infection on immunity was small relative to that of site differences and live coral cover, and similar to the effect of reproductive status. While additional immune data would shed light on the extent of this pattern, ecological factors may play a larger role than immunity in controlling parasite patterns in the wild. Parsing the effects of immunity and ecological factors in octocoral co-infection shows how disease depends on more than one host and one parasite and explores the application of co-infection research to a colonial marine organism.	[Tracy, Allison M.] Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14850 USA; [Weil, Ernesto] Univ Puerto Rico, Dept Marine Sci, Mayaguez, PR 00709 USA; [Burge, Colleen A.] Univ Maryland Baltimore Cty, Inst Marine & Environm Technol, Baltimore, MD 21228 USA; [Tracy, Allison M.] Smithsonian Environm Res Ctr, POB 28, Edgewater, MD 21037 USA	Cornell University; University of Puerto Rico; University of Puerto Rico Mayaguez; University System of Maryland; University of Maryland Baltimore; University of Maryland Center for Environmental Science; Institute of Marine & Environmental Technology; University of Maryland Baltimore County; Smithsonian Institution; Smithsonian Environmental Research Center	Tracy, AM (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14850 USA.; Tracy, AM (corresponding author), Smithsonian Environm Res Ctr, POB 28, Edgewater, MD 21037 USA.	amtracy8@gmail.com			National Science Foundation [DGE-1650441]; Sigma Xi, Cornell Chapter; National Geographic Young Explorers Young Explorers Grant; Cornell Graduate School Research Travel Grant; NSF (IOS) [1017510]; Department of Marine Sciences, University of Puerto Rico at Mayaguez; University of Maryland Baltimore County; University of Maryland Baltimore; Betty Miller Francis `47 Fund; Cornell Department of Ecology and Evolutionary Biology Paul P. Feeny Fund	National Science Foundation(National Science Foundation (NSF)); Sigma Xi, Cornell Chapter; National Geographic Young Explorers Young Explorers Grant(National Geographic Society); Cornell Graduate School Research Travel Grant; NSF (IOS)(National Science Foundation (NSF)); Department of Marine Sciences, University of Puerto Rico at Mayaguez; University of Maryland Baltimore County; University of Maryland Baltimore; Betty Miller Francis `47 Fund; Cornell Department of Ecology and Evolutionary Biology Paul P. Feeny Fund	AT was supported by the National Science Foundation Graduate Research Fellowship Program (DGE-1650441); Sigma Xi, Cornell Chapter; a National Geographic Young Explorers Young Explorers Grant; a Cornell Graduate School Research Travel Grant; the Betty Miller Francis `47 Fund for field research; and the Cornell Department of Ecology and Evolutionary Biology Paul P. Feeny Fund. EW was partially funded by NSF (IOS#1017510) and the Department of Marine Sciences, University of Puerto Rico at Mayaguez. Logistical Support, lab and office space, was provided by EW and the Department of Marine Sciences, University of Puerto Rico at Mayaguez. Support was provided by start-up funds to CB to the Institute of Marine and Environmental Technology from the University of Maryland Baltimore County and the University of Maryland Baltimore.	Abolins S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003538; Adamo SA, 2012, HORM BEHAV, V62, P324, DOI 10.1016/j.yhbeh.2012.02.012; Altizer S, 2013, SCIENCE, V341, P514, DOI 10.1126/science.1239401; Anderson DA, 2016, PEERJ, V4, DOI 10.7717/peerj.1616; Andras JP, 2013, MOL ECOL, V22, P56, DOI 10.1111/mec.12104; Angilletta M Jr, 2003, HERPETOL REV, V34, P31; [Anonymous], **DATA OBJECT**; [Anonymous], **DATA OBJECT**, DOI DOI 10.5061/DRYAD.Q573N5TG0; [Anonymous], **DATA OBJECT**; [Anonymous], **DATA OBJECT**; Barton K., 2019, MUMIN MULTIMODEL INF; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Beechler BR, 2012, PHYSIOL BIOCHEM ZOOL, V85, P255, DOI 10.1086/665276; Bosch TCG, 2007, DEV BIOL, V303, P421, DOI 10.1016/j.ydbio.2006.12.012; Brock PM, 2014, INTEGR COMP BIOL, V54, P353, DOI 10.1093/icb/icu046; Bruno JF, 2007, PLOS BIOL, V5, P1220, DOI 10.1371/journal.pbio.0050124; Burge C, 2013, GORGONIA VENTALINA T, DOI [10.6084/M9.FIGSHARE.94326.V3, DOI 10.6084/M9.FIGSHARE.94326.V3]; Burge CA, 2020, MARINE DISEASE ECOLOGY, P83, DOI 10.1093/oso/9780198821632.003.0005; Burge CA, 2014, ANNU REV MAR SCI, V6, P249, DOI 10.1146/annurev-marine-010213-135029; Burge CA, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00180; Burge CA, 2012, DIS AQUAT ORGAN, V101, P1, DOI 10.3354/dao02487; Caldwell JM, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2017.2265; Cattadori IM, 2006, MICROMAMMALS AND MACROPARASITES: FROM EVOLUTIONARY ECOLOGY TO MANAGEMENT, P349, DOI 10.1007/978-4-431-36025-4_18; Cattadori IM, 2019, ECOL EVOL, V9, P13495, DOI 10.1002/ece3.5805; Chambers MC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224440; Clay PA, 2019, AM NAT, V193, P187, DOI 10.1086/701126; Closek CJ, 2014, ISME J, V8, P2411, DOI 10.1038/ismej.2014.85; Couch CS, 2013, MAR BIOL, V160, P2449, DOI 10.1007/s00227-013-2240-6; Cross PC, 2009, J APPL ECOL, V46, P467, DOI 10.1111/j.1365-2664.2008.01589.x; Dang VT, 2012, FISH SHELLFISH IMMUN, V32, P732, DOI 10.1016/j.fsi.2012.01.022; Ezenwa VO, 2015, SCIENCE, V347, P175, DOI 10.1126/science.1261714; Fenton A, 2014, INT J PARASITOL, V44, P437, DOI 10.1016/j.ijpara.2014.03.001; Freitak D, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-56; Fuess LE, 2017, P ROY SOC B-BIOL SCI, V284, DOI 10.1098/rspb.2017.0771; Graham AL, 2008, P NATL ACAD SCI USA, V105, P566, DOI 10.1073/pnas.0707221105; Groner ML, 2014, DIS AQUAT ORGAN, V108, P165, DOI 10.3354/dao02709; Hajek AE, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.0154; Harrison XA, 2018, PEERJ, V6, DOI 10.7717/peerj.4794; Harvell D, 2004, FRONT ECOL ENVIRON, V2, P375, DOI 10.1890/1540-9295(2004)002[0375:TRTOOD]2.0.CO;2; Hawley DM, 2011, FUNCT ECOL, V25, P48, DOI 10.1111/j.1365-2435.2010.01753.x; Hellard E, 2015, TRENDS PARASITOL, V31, P640, DOI 10.1016/j.pt.2015.07.005; Honkavaara J, 2009, ENTOMOL EXP APPL, V132, P165, DOI 10.1111/j.1570-7458.2009.00877.x; Ivanenko VN, 2017, MAR BIODIVERS, V47, P79, DOI 10.1007/s12526-015-0428-3; Johnson PTJ, 2011, ECOLOGY, V92, P535, DOI 10.1890/10-0570.1; Jolles AE, 2008, ECOLOGY, V89, P2239, DOI 10.1890/07-0995.1; Kenkel CD, 2018, GLOBAL CHANGE BIOL, V24, P158, DOI [10.1111/gcb.13833, 10.1111/gcb.]; Kernbach M, 2019, ENCY ECOLOGY, V3, P65, DOI [10.1016/B978-0-12-409548-9.10890-5, DOI 10.1016/B978-0-12-409548-9.10890-5]; Kim K, 2004, AM NAT, V164, pS52, DOI 10.1086/424609; Kvennefors ECE, 2010, DEV COMP IMMUNOL, V34, P1219, DOI 10.1016/j.dci.2010.06.016; Lamb JB, 2018, SCIENCE, V359, P460, DOI 10.1126/science.aar3320; Lazzaro BP, 2009, PHILOS T R SOC B, V364, P15, DOI 10.1098/rstb.2008.0141; Lefcheck JS, 2016, METHODS ECOL EVOL, V7, P573, DOI 10.1111/2041-210X.12512; Libro S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081821; Lin ZY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42100; Mann WT, 2014, MAR BIOL, V161, P2213, DOI 10.1007/s00227-014-2499-2; Miller DJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r59; Morgan M, 2015, PEERJ, V3, DOI 10.7717/peerj.1371; Muller EM, 2018, ELIFE, V7, DOI 10.7554/eLife.35066; Mydlarz LD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001811; Mydlarz LD, 2007, COMP BIOCHEM PHYS A, V146, P54, DOI 10.1016/j.cbpa.2006.09.005; Mydlarz LD, 2016, CNIDARIA PRESENT FUT, P441, DOI [10.1007/978-3-319-31305-4, DOI 10.1007/978-3-319-31305-4_28]; Naumann M, 2000, BIOCHEM PHARMACOL, V60, P1109, DOI 10.1016/S0006-2952(00)00390-7; Ocampo ID, 2015, IMMUNOGENETICS, V67, P515, DOI 10.1007/s00251-015-0854-1; Pait AS, 2007, 52 NOAA NOS NCCOS, V52; Pedersen AB, 2011, MOL ECOL, V20, P872, DOI 10.1111/j.1365-294X.2010.04938.x; Petes LE, 2003, MAR ECOL PROG SER, V264, P167, DOI 10.3354/meps264167; Pinzon JH, 2015, ROY SOC OPEN SCI, V2, DOI 10.1098/rsos.140214; Pinzon CJH, 2014, PEERJ, V2, DOI 10.7717/peerj.628; Pollock FJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002183; R Development Core Team, 2018, R LANG ENV STAT COMP; Robertson S, 2016, MOL ECOL RESOUR, V16, P701, DOI 10.1111/1755-0998.12497; Rollins-Smith LA, 2017, DEV COMP IMMUNOL, V66, P111, DOI 10.1016/j.dci.2016.07.002; Seneca FO, 2015, MOL ECOL, V24, P1467, DOI 10.1111/mec.13125; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; Thurber RLV, 2014, GLOBAL CHANGE BIOL, V20, P544, DOI 10.1111/gcb.12450; Toledo-Hernandez C, 2008, CORAL REEFS, V27, P707, DOI 10.1007/s00338-008-0387-2; Tracy AM, 2020, ECOL APPL, V30, DOI 10.1002/eap.2024; Tracy AM, 2019, P ROY SOC B-BIOL SCI, V286, DOI 10.1098/rspb.2019.1718; Tracy AM, 2018, OECOLOGIA, V186, P743, DOI 10.1007/s00442-017-4051-9; Traylor-Knowles N, 2017, CURR CLIM CHANGE REP, V3, P252, DOI 10.1007/s40641-017-0077-7; Tsounis G, 2017, ECOSPHERE, V8, DOI 10.1002/ecs2.1646; Weil E., 2008, UNDERWATER CARDS ASS; Weil E., 2016, MARINE ANIMAL FOREST, P1; Weil E, 2008, ASSESSMENT MONITORIN; Weil E, 2011, CORAL REEFS: AN ECOSYSTEM IN TRANSITION, P465, DOI 10.1007/978-94-007-0114-4_27; Weiss Y, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-400; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	87	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2021	11								608066	10.3389/fimmu.2020.608066	http://dx.doi.org/10.3389/fimmu.2020.608066			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PW7DR	33505396	Green Published, gold			2022-12-18	WOS:000610831500001
J	Bakthavatsalam, D; Craft, JW; Kazansky, A; Nguyen, N; Bae, G; Caivano, AR; Gundlach, CW; Aslam, A; Ali, S; Gupta, S; Lin, SY; Parthiban, HD; Vanderslice, P; Stephan, CC; Woodside, DG				Bakthavatsalam, Deenadayalan; Craft, John W., Jr.; Kazansky, Anna; Nguyen, Nghi; Bae, Goeun; Caivano, Amy R.; Gundlach, C. William; Aslam, Asra; Ali, Safa; Gupta, Shashikant; Lin, Sophie Y.; Parthiban, Hema D.; Vanderslice, Peter; Stephan, Clifford C.; Woodside, Darren G.			Identification of Inhibitors of Integrin Cytoplasmic Domain Interactions With Syk	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; cell adhesion; integrin; signaling; tyrosine kinase; immune response receptor; high-throughput screening; beta-lactam antibiotics	PROTEIN-TYROSINE KINASE; PLATELET GLYCOPROTEIN IIB/IIIA; MAINTENANCE THERAPY; SIGNAL-TRANSDUCTION; SH2 DOMAINS; ACTIVATION; IMMUNORECEPTOR; RECEPTOR; BINDING; P72(SYK)	Leukocyte inflammatory responses require integrin cell-adhesion molecule signaling through spleen tyrosine kinase (Syk), a non-receptor kinase that binds directly to integrin beta-chain cytoplasmic domains. Here, we developed a high-throughput screen to identify small molecule inhibitors of the Syk-integrin cytoplasmic domain interactions. Screening small molecule compound libraries identified the beta-lactam antibiotics cefsulodin and ceftazidime, which inhibited integrin beta-subunit cytoplasmic domain binding to the tandem SH2 domains of Syk (IC50 range, 1.02-4.9 mu M). Modeling suggested antagonist binding to Syk outside the pITAM binding site. Ceftazidime inhibited integrin signaling via Syk, including inhibition of adhesion-dependent upregulation of interleukin-1 beta and monocyte chemoattractant protein-1, but did not inhibit ITAM-dependent phosphorylation of Syk mediated by Fc gamma RI signaling. Our results demonstrate a novel means to target Syk independent of its kinase and pITAM binding sites such that integrin signaling via this kinase is abrogated but ITAM-dependent signaling remains intact. As integrin signaling through Syk is essential for leukocyte activation, this may represent a novel approach to target inflammation.	[Bakthavatsalam, Deenadayalan; Craft, John W., Jr.; Kazansky, Anna; Caivano, Amy R.; Gundlach, C. William; Gupta, Shashikant; Lin, Sophie Y.; Parthiban, Hema D.; Vanderslice, Peter; Woodside, Darren G.] Texas Heart Inst, Mol Cardiol Res Labs, Houston, TX 77025 USA; [Craft, John W., Jr.; Aslam, Asra; Ali, Safa] Univ Houston, Dept Biol & Chem, Houston, TX USA; [Nguyen, Nghi; Bae, Goeun; Stephan, Clifford C.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX USA	Texas Heart Institute; University of Houston System; University of Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Woodside, DG (corresponding author), Texas Heart Inst, Mol Cardiol Res Labs, Houston, TX 77025 USA.	dwoodside@texasheart.org		Craft, John/0000-0002-5679-5629	 [R01AI095575];  [CACDS SeFAC:63445-B5006]	; 	Grant support: R01AI095575 (DW). Microsoft CRM:0740135 and CACDS SeFAC:63445-B5006 provided support for computational resources (JC).	Abram CL, 2007, IMMUNOL REV, V218, P29, DOI 10.1111/j.1600-065X.2007.00531.x; Abram CL, 2009, ANNU REV IMMUNOL, V27, P339, DOI 10.1146/annurev.immunol.021908.132554; Abtahian F, 2006, MOL CELL BIOL, V26, P6936, DOI 10.1128/MCB.01040-06; Ambroise Y, 2002, CHEM BIOL, V9, P1219, DOI 10.1016/S1074-5521(02)00246-6; [Anonymous], 2005, NAT METHODS, V2, P319, DOI 10.1038/nmeth0405-319; Antenucci L, 2018, J BIOL CHEM, V293, P4591, DOI 10.1074/jbc.RA117.000660; Bakthavatsalam D, 2014, FEBS LETT, V588, P2133, DOI 10.1016/j.febslet.2014.04.049; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Cimmperman P, 2008, BIOPHYS J, V95, P3222, DOI 10.1529/biophysj.108.134973; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Craft JW, 2015, J PHYS CHEM B, V119, P1048, DOI 10.1021/jp506509c; Craft JW, 2005, J BIOMOL NMR, V33, P15, DOI 10.1007/s10858-005-1199-0; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734; Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Glickman JF, 2002, J BIOMOL SCREEN, V7, P3, DOI 10.1177/108705710200700102; Gong HX, 2010, SCIENCE, V327, P340, DOI 10.1126/science.1174779; Gradler U, 2013, J MOL BIOL, V425, P309, DOI 10.1016/j.jmb.2012.11.007; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Herter J, 2013, J IMMUNOL, V190, P4451, DOI 10.4049/jimmunol.1203179; Hughes CE, 2015, BLOOD, V125, P144, DOI 10.1182/blood-2014-05-579375; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jakus Z, 2007, TRENDS CELL BIOL, V17, P493, DOI 10.1016/j.tcb.2007.09.001; Kadkhodayan S, 2007, ASSAY DRUG DEV TECHN, V5, P501, DOI 10.1089/adt.2007.070; Kimura T, 1996, MOL CELL BIOL, V16, P1471; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Mocsai A, 2006, NAT IMMUNOL, V7, P1326, DOI 10.1038/ni1407; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Molloy ES, 2009, NAT REV RHEUMATOL, V5, P418, DOI 10.1038/nrrheum.2009.142; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Rolf MG, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.175; Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Serrao E, 2013, BIOORGAN MED CHEM, V21, P5963, DOI 10.1016/j.bmc.2013.07.047; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Sheppard JD, 2014, OPHTHALMOLOGY, V121, P475, DOI 10.1016/j.ophtha.2013.09.015; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; Steinman L, 2009, NAT REV IMMUNOL, V9, P440, DOI 10.1038/nri2548; Takakuma K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071646; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; ULLMAN EF, 1994, P NATL ACAD SCI USA, V91, P5426, DOI 10.1073/pnas.91.12.5426; Ungermannova D, 2013, J BIOMOL SCREEN, V18, P910, DOI 10.1177/1087057113485789; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Yan SR, 1998, J LEUKOCYTE BIOL, V64, P401, DOI 10.1002/jlb.64.3.401	64	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								575085	10.3389/fimmu.2020.575085	http://dx.doi.org/10.3389/fimmu.2020.575085			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU4DM	33488575	gold, Green Published			2022-12-18	WOS:000609257100001
J	Banerjee, S; Pal, A; Pal, A; Mandal, SC; Chatterjee, PN; Chatterjee, JK				Banerjee, Samiddha; Pal, Aruna; Pal, Abantika; Mandal, Subhas Chandra; Chatterjee, Paresh Nath; Chatterjee, Jayanta Kumar			RIG-I Has a Role in Immunity Against Haemonchus contortus, a Gastrointestinal Parasite in Ovis aries: A Novel Report	FRONTIERS IN IMMUNOLOGY			English	Article						RIG-I; innate immunity; parasite; Haemonchus contortus; sheep	RECOGNITION; EXPRESSION; RESISTANCE; RECEPTORS; CD14; WEB	Retinoic acid inducible gene I (RIG-I) is associated to the DExD/H box RNA helicases. It is a pattern recognition receptor (PRR), playing a crucial role in the system and is a germ line encoded host sensor to perceive pathogen-associated molecular patterns (PAMPs). So far, reports are available for the role of RIG-I in antiviral immunity. This is the first report in which we have documented the role of RIG-I in parasitic immunity. Haemonchus contortus is a deadly parasite affecting the sheep industry, which has a tremendous economic importance, and the parasite is reported to be prevalent in the hot and humid agroclimatic region. We characterize the RIG-I gene in sheep (Ovis aries) and identify the important domains or binding sites with Haemonchus contortus through in silico studies. Differential mRNA expression analysis reveals upregulation of the RIG-I gene in the abomasum of infected sheep compared with that of healthy sheep, further confirming the findings. Thus, it is evident that, in infected sheep, expression of RIG-I is triggered for binding to more pathogens (Haemonchus contortus). Genetically similar studies with humans and other livestock species were conducted to reveal that sheep may be efficiently using a model organism for studying the role of RIG-I in antiparasitic immunity in humans.	[Banerjee, Samiddha; Chatterjee, Jayanta Kumar] Visva Bharati Univ, Dept Anim Sci, Bolpur, India; [Pal, Aruna; Mandal, Subhas Chandra; Chatterjee, Paresh Nath] West Bengal Univ Anim & Fishery Sci, Dept LFC, Kolkata, India; [Pal, Abantika] Indian Inst Technol, Dept Comp Sci, Kharagpur, W Bengal, India	Visva Bharati University; West Bengal University of Animal & Fishery Sciences; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur	Pal, A (corresponding author), West Bengal Univ Anim & Fishery Sci, Dept LFC, Kolkata, India.	arunachatterjee@gmail.com			Department of Biotechnology, Ministry of Science and Technology, Govt. of India [BT/Bio-CARe/04/10100/2013-14]	Department of Biotechnology, Ministry of Science and Technology, Govt. of India(Department of Biotechnology (DBT) India)	The authors are thankful to the Department of Biotechnology, Ministry of Science and Technology, Govt. of India for providing the financial grant vide number No. BT/Bio-CARe/04/10100/2013-14. The authors are thankful to Vice-Chancellor, West Bengal University of Animal and Fishery Sciences and Visva Bharati University for providing lab space and support for carrying out the research work.	Awad A.H., 2016, TIKRIT J PURE SCI, V21, P11; Baum A, 2010, P NATL ACAD SCI USA, V107, P16303, DOI 10.1073/pnas.1005077107; de Matos AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081864; Ebina T, 2011, BIOINFORMATICS, V27, P487, DOI 10.1093/bioinformatics/btq700; Farooq U, 2018, INT J LIVEST RES, V8, P89, DOI [10.5455/ijlr.20170427114448, DOI 10.5455/IJLR.20170427114448]; Gadahi JA, 2016, ONCOTARGET, V7, P35670, DOI 10.18632/oncotarget.9589; Gibbons LM, 2014, RVC FAO GUID VET DIA; Glendinning SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022390; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Kitamura H, 2007, J DERMATOL SCI, V45, P127, DOI 10.1016/j.jdermsci.2006.11.003; Kolakofsky D, 2012, RNA, V18, P2118, DOI 10.1261/rna.035949.112; Kong L, 2009, CELL HOST MICROBE, V6, P150, DOI 10.1016/j.chom.2009.06.008; Lee C Y, 2011, J Parasitol Res, V2011, P101848, DOI 10.1155/2011/101848; LUBEGA GW, 1994, BIOCHEM PHARMACOL, V47, P1705, DOI 10.1016/0006-2952(94)90551-7; Majumdar T, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004779; Maqbool I, 2017, J Parasit Dis, V41, P1, DOI 10.1007/s12639-016-0765-6; Marnis H, 2019, FISH SHELLFISH IMMUN, V93, P965, DOI 10.1016/j.fsi.2019.08.034; Ohnishi T, 2007, FEMS IMMUNOL MED MIC, V51, P84, DOI 10.1111/j.1574-695X.2007.00281.x; Pal A, 2019, MITOCHONDRION, V46, P393, DOI 10.1016/j.mito.2018.10.003; Pal Aruna, 2011, Mol Biol Int, V2011, P507346, DOI 10.4061/2011/507346; Pal A, 2013, BUFFALO BULL, V32, P138; Pal A, 2009, SMALL RUMINANT RES, V82, P84, DOI 10.1016/j.smallrumres.2008.11.016; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Schmidt A, 2009, P NATL ACAD SCI USA, V106, P12067, DOI 10.1073/pnas.0900971106; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Toscan G, 2017, SEMIN-CIENC AGRAR, V38, P809, DOI 10.5433/1679-0359.2017v38n2p809; Verma AK, 2013, IOSR J PHARM BIOL SC, V8, P2319, DOI [10.9790/3008-0858293, DOI 10.9790/3008-0858293]; Vijay Pandey, 2010, Indian Journal of Small Ruminants, V16, P134; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Yatsuda AP, 2006, INFECT IMMUN, V74, P1989, DOI 10.1128/IAI.74.3.1989-1993.2006; Ye WJ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007298; Zhang Y, 2005, MOL BIOL REP, V32, P185, DOI 10.1007/s11033-005-3141-7	38	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								534705	10.3389/fimmu.2020.534705	http://dx.doi.org/10.3389/fimmu.2020.534705			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU9DQ	33488570	Green Submitted, Green Published, gold			2022-12-18	WOS:000609598100001
J	Pessoa-e-Silva, R; Trajano-Silva, LAM; Vaitkevicius-Antao, V; dos Santos, WJT; Magalhaes, FB; Moura, DMN; Nakasone, EKN; de Lorena, VMB; de Paiva-Cavalcanti, M				Pessoa-e-Silva, Romulo; Trajano-Silva, Lays Adrianne Mendonca; Vaitkevicius-Antao, Victor; Santos, Wagner Jose Tenorio dos; Magalhaes, Franklin Barbalho; Moura, Danielle Maria Nascimento; Nakasone, Eiji Kevin Nakasone; de Lorena, Virginia Maria Barros; de Paiva-Cavalcanti, Milena			Immunoprophylactic Potential of a New Recombinant Leishmania infantum Antigen for Canine Visceral Leishmaniasis: An In Vitro Finding	FRONTIERS IN IMMUNOLOGY			English	Article						recombinant antigens; immunoprophylaxis; vaccinology; dog; visceral leishmaniasis	IMMUNE-RESPONSE; VACCINE; DOGS; PROTEIN; STILL	The development and application of safe and effective immunoprophylactic/immunotherapeutic agents against canine visceral leishmaniasis (CanL) have been pointed out as the only means for the real control of the disease. Thus, this study aimed to evaluate the in vitro cellular immune response of dogs, elicited by the new recombinant proteins of Leishmania infantum, Lci10 and Lci13, in order to investigate their potential for vaccinology. Twenty-four dogs were submitted to clinical, parasitological, serological and molecular tests, and then separated into two study groups: 12 infected (InD) and 12 non-infected dogs (NInD), and six of each group were directed for Lci10 and Lci13 evaluation. Peripheral blood mononuclear cells (PBMC) were cultured and stimulated with Lci10 (10 mu g/ml) or Lci13 (5 mu g/ml), and with L. infantum soluble antigen (LSA) (25 mu g/ml) or no stimulus (NS) as controls. Afterwards, the mRNA levels of different cytokines were quantified through qPCR, and Nitric Oxide (NO) production was assessed in the culture supernatants. Significant differences were considered when p <= 0.05. The comparative analysis revealed that, in the NInD group, Lci13 promoted a significant increase in the expression of IFN-gamma in relation to LSA (p = 0.0362), and the expression of this cytokine in NInD was significantly higher than that presented in the InD (p = 0.0028). A negative expression for TGF-beta was obtained in both groups. Lci13 also induced a greater production of NO in relation to the NS sample in the NInD group. No significant differences were observed after stimulation with Lci10. In conclusion, the results suggest a protective role of Lci13 for uninfected animals, thus with a potential for immunoprophylaxis. The results will help to direct the antigen Lci13 for further studies (pre-clinical trials), in order to determine its immunogenicity and reactogenicity effects, as a way to consolidate its real applicability for vaccinology against CanL.	[Pessoa-e-Silva, Romulo; Trajano-Silva, Lays Adrianne Mendonca; Vaitkevicius-Antao, Victor; Santos, Wagner Jose Tenorio dos; Moura, Danielle Maria Nascimento; de Lorena, Virginia Maria Barros; de Paiva-Cavalcanti, Milena] Aggeu Magalhaes Inst, Dept Microbiol, Recife, PE, Brazil; [Magalhaes, Franklin Barbalho] Tabosa de Almeida Univ Ctr, Caruaru, Brazil; [Nakasone, Eiji Kevin Nakasone] Univ Fed Rural Pernambuco, Dept Vet Med, Recife, PE, Brazil	Universidade Federal Rural de Pernambuco (UFRPE)	de Paiva-Cavalcanti, M (corresponding author), Aggeu Magalhaes Inst, Dept Microbiol, Recife, PE, Brazil.	milena.cavalcanti@fiocruz.br	dos Santos, Wagner José Tenório/AAQ-6888-2021; dos Santos, Wagner José Tenório/AAE-3702-2022	dos Santos, Wagner José Tenório/0000-0001-7605-4687; Mendonca Trajano Silva, Lays Adrianne/0000-0002-0873-6683	Research Excellence Program (PROEP/FIOCRUZ), the Foundation for Science and Technology Support of the State of Pernambuco (FACEPE); National Council for Scientific and Technological Development (CNPq) [PQ 301223/2018-1]	Research Excellence Program (PROEP/FIOCRUZ), the Foundation for Science and Technology Support of the State of Pernambuco (FACEPE); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The authors appreciate Osvaldo Pompilio de Melo Neto for all experimental and intellectual support in the execution of this study. The authors also thank Thiago Andre Santos de Andrade assistance in the supply of dog samples. This work was supported by the Research Excellence Program (PROEP/FIOCRUZ), the Foundation for Science and Technology Support of the State of Pernambuco (FACEPE) and by the National Council for Scientific and Technological Development (CNPq Processo PQ 301223/2018-1).	Alexander J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00080; Ashford DA, 1998, AM J TROP MED HYG, V59, P53, DOI 10.4269/ajtmh.1998.59.53; Baneth G, 2002, VET PARASITOL, V106, P315, DOI 10.1016/S0304-4017(02)00115-2; Baneth G, 2008, TRENDS PARASITOL, V24, P324, DOI 10.1016/j.pt.2008.04.001; Baneth G, 2008, VET J, V175, P14, DOI 10.1016/j.tvjl.2006.11.011; Bhowmick S, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-8; Bianciardi P, 2009, TOXICOL PATHOL, V37, P770, DOI 10.1177/0192623309344088; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campos RM, 2008, MOL BIOCHEM PARASIT, V160, P157, DOI 10.1016/j.molbiopara.2008.04.013; Cavalcanti MD, 2009, VET J, V182, P356, DOI 10.1016/j.tvjl.2008.05.018; Costa-Pereira C, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0397-6; Fernandes CB, 2014, VACCINE, V32, P1287, DOI 10.1016/j.vaccine.2013.12.046; Foroughi-Parvar Faeze, 2014, Adv Prev Med, V2014, P569193, DOI 10.1155/2014/569193; de Albuquerque SDG, 2019, CYTOKINE, V123, DOI 10.1016/j.cyto.2019.154784; Gradoni L, 2015, VET PARASITOL, V208, P94, DOI 10.1016/j.vetpar.2015.01.003; Guedes R. F. de M., 2016, Ciencia Animal, V26, P37; Jain K, 2015, J IMMUNOL METHODS, V422, P1, DOI 10.1016/j.jim.2015.03.017; Lorena VMB, 2008, J CLIN LAB ANAL, V22, P91, DOI 10.1002/jcla.20209; Magalhaes FB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184867; Maia C, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/541571; Manna L, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0896-0; Martins VT, 2016, ACTA TROP, V154, P73, DOI 10.1016/j.actatropica.2015.11.006; Massone F, 2008, ANESTESIOLOGIA VET F, V5; Matralis D, 2016, PARASITE IMMUNOL, V38, P510, DOI 10.1111/pim.12335; Melo SN, 2018, PREV VET MED, V161, P19, DOI 10.1016/j.prevetmed.2018.10.010; Moreno J, 2002, TRENDS PARASITOL, V18, P399, DOI 10.1016/S1471-4922(02)02347-4; Moreno J, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00168; Moreno J, 2014, VET IMMUNOL IMMUNOP, V158, P199, DOI 10.1016/j.vetimm.2014.01.011; Costa CHN, 2011, REV SOC BRAS MED TRO, V44, P232, DOI 10.1590/S0037-86822011005000014; Oliveira GGS, 2011, AM J TROP MED HYG, V85, P1025, DOI 10.4269/ajtmh.2011.11-0102; Pessoa-e-Silva R, 2019, EXP PARASITOL, V199, P9, DOI 10.1016/j.exppara.2019.02.012; Proverbio D, 2014, BIOMED RES INT, V2014, P1, DOI DOI 10.1155/2014/640151; Regina-Silva S, 2016, VACCINE, V34, P2233, DOI 10.1016/j.vaccine.2016.03.019; Reguera RM, 2016, VET PARASITOL, V227, P98, DOI 10.1016/j.vetpar.2016.07.011; Reis AB, 2010, TRENDS PARASITOL, V26, P341, DOI 10.1016/j.pt.2010.04.005; Reis J.C., 2003, ESTATISTICA APLICADA, V1; Resende LA, 2013, VET PARASITOL, V198, P371, DOI 10.1016/j.vetpar.2013.09.011; Roatt BM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049780; Rodriguez-Cortes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155224; Romero GAS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000584; Saldarriaga OA, 2006, VACCINE, V24, P1928, DOI 10.1016/j.vaccine.2005.10.052; Santos FN, 2007, VACCINE, V25, P6176, DOI 10.1016/j.vaccine.2007.06.005; Schaut RG, 2016, VACCINE, V34, P5225, DOI 10.1016/j.vaccine.2016.09.016; Seva AP, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0160058, 10.1371/journal.pone.0162854]; Solano-Gallego L, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1598-y; Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y; Vaughan S, 2008, PROTIST, V159, P127, DOI 10.1016/j.protis.2007.08.005; Werneck GL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003172	48	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								605044	10.3389/fimmu.2020.605044	http://dx.doi.org/10.3389/fimmu.2020.605044			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU6KE	33488607	gold, Green Published			2022-12-18	WOS:000609409900001
J	Harp, KO; Botchway, F; Dei-Adomakoh, Y; Wilson, MD; Hood, JL; Adjei, AA; Stiles, JK; Driss, A				Harp, Keri Oxendine; Botchway, Felix; Dei-Adomakoh, Yvonne; Wilson, Michael D.; Hood, Joshua L.; Adjei, Andrew A.; Stiles, Jonathan K.; Driss, Adel			Hemoglobin Genotypes Modulate Inflammatory Response to Plasmodium Infection	FRONTIERS IN IMMUNOLOGY			English	Article						sickle cell disease; cytokines; chemokines; biomarkers; sickle cell trait; malaria severity; Hemoglobin C; cerebral malaria	SICKLE-CELL-DISEASE; MALARIA PATIENTS; BLOOD-CELLS; CHEMOKINES; EXPRESSION; CYTOKINES; CHILDREN	In 2018, 228 million cases and 405,000 malaria-associated deaths were reported worldwide with a majority being in Africa. A wide range of factors, including parasitemia, host immunity, inflammatory responses to infection, and host hemoglobin genotype, mediate the severity of malaria. Among the hemoglobinopathies, hemoglobin S (HbS) is caused by a single amino acid substitution of Glutamic Acid replaced by Valine at the sixth position of the beta-globin chain (E6V). Hemoglobin C (HbC) on the other hand, involves a single amino acid substitution of Glutamic Acid by a Lysine (E6K), which has received the most attention. These substitutions alter the stability of Hb leading to wide-ranging hematological disorders. The homozygous state of hemoglobin S (HbSS) results in sickle cell anemia (SCA) whereas the heterozygous state (HbAS) results in sickle cell trait (SCT). Both mutations are reported to mediate the reduction in the severity and fatality of Plasmodium falciparum malaria. The mechanism underlying this protection is poorly understood. Since both malaria and sickle cell disease (SCD) are associated with the destruction of erythrocytes and widespread systemic inflammation, identifying which inflammatory factor(s) mediate susceptibility of individuals with different hemoglobin genotypes to Plasmodium infection could result in the discovery of new predictive markers and interventions against malaria or SCD severity. We hypothesized that hemoglobin genotypes modulate the inflammatory response to Plasmodium infection. We conducted a cross-sectional study in Ghana, West Africa, between 2014 and 2019 to ascertain the relationships between blood inflammatory cytokines, Plasmodium infection, and hemoglobin genotype. A total of 923 volunteers were enrolled in the study. A total of 74, age and sex-matched subjects were identified with various genotypes including HbAS, HbAC, HbSS, HbSC, HbCC, or HbAA. Complete blood counts and serum inflammatory cytokine expression levels were assessed. The results indicate that differential expression of CXCL10, TNF-alpha, CCL2, IL-8, and IL-6 were tightly linked to hemoglobin genotype and severity of Plasmodium infection and that these cytokine levels may be predictive for susceptibility to severe malaria or SCD severity.	[Harp, Keri Oxendine; Driss, Adel] Morehouse Sch Med, Dept Physiol, 720 Westview Dr Sw, Atlanta, GA 30310 USA; [Botchway, Felix; Adjei, Andrew A.] Univ Ghana, Med Sch, Korle Bu Teaching Hosp, Dept Pathol, Accra, Ghana; [Dei-Adomakoh, Yvonne] Univ Ghana, Med Sch, Dept Haematol, Accra, Ghana; [Wilson, Michael D.] Univ Ghana, Noguchi Mem Inst Med Res, Dept Parasitol, Accra, Ghana; [Hood, Joshua L.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; [Hood, Joshua L.] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; [Hood, Joshua L.] Univ Louisville, Sch Med, Hepatobiol & Toxicol COBRE, Louisville, KY 40292 USA; [Stiles, Jonathan K.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA	Morehouse School of Medicine; University of Ghana; University of Ghana; University of Ghana; University of Louisville; University of Louisville; University of Louisville; Morehouse School of Medicine	Driss, A (corresponding author), Morehouse Sch Med, Dept Physiol, 720 Westview Dr Sw, Atlanta, GA 30310 USA.	adel.driss@gmail.com	Stiles, Jonathan K./AFM-1940-2022	, Adel/0000-0002-3344-2644	National Institutes of Health [NIH/FIC 1K01TW010282]; NIH/FIC UJMT Fogarty Global Health Fellows Program [5R25TW009340]; NIH/NIMHD Research Centers in Minority Institutions (RCMI) [5U54MD007602]; National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR002382]; NIH/NINDS [1R01NS091616]; National Institute on Minority Health and Health Disparities [G12MD007602]; NIH [2U54MD007602]; Elsa U. Pardee Foundation; University of Louisville Department of Pharmacology and Toxicology Faculty Start-up funds; UofL COBRE NIGMS NIH [P20GM113226]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/FIC UJMT Fogarty Global Health Fellows Program; NIH/NIMHD Research Centers in Minority Institutions (RCMI); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Elsa U. Pardee Foundation; University of Louisville Department of Pharmacology and Toxicology Faculty Start-up funds; UofL COBRE NIGMS NIH	The study was supported by National Institutes of Health, grant numbers NIH/FIC 1K01TW010282 (Driss, PI), NIH/FIC UJMT Fogarty Global Health Fellows Program #5R25TW009340 (Chi, PI), NIH/NIMHD Research Centers in Minority Institutions (RCMI) 5U54MD007602 (Bond, PI; Driss pilot PI), National Center for Advancing Translational Sciences of the National Institutes of Health TL1TR002382 (Harp, TL1 Trainee), NIH/NINDS 1R01NS091616 (Stiles, PI) and National Institute on Minority Health and Health Disparities G12MD007602 (Bond, PI), and NIH 2U54MD007602. The Elsa U. Pardee Foundation (Hood, PI), University of Louisville Department of Pharmacology and Toxicology Faculty Start-up funds (Hood, PI) and UofL COBRE NIGMS NIH P20GM113226 (McClain PI, Hood pilot PI) are also recognized for supporting J. L. Hood.	Abrams ET, 2003, J IMMUNOL, V170, P2759, DOI 10.4049/jimmunol.170.5.2759; Armah HB, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-147; Baptista LC, 2016, ANN HEMATOL, V95, P1859, DOI 10.1007/s00277-016-2780-1; Belisario AR, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154800; Biemba G, 2000, TROP MED INT HEALTH, V5, P256, DOI 10.1046/j.1365-3156.2000.00545.x; Cavalcante Janio Emanuel Andrade, 2016, Hematol Oncol Stem Cell Ther, V9, P14, DOI 10.1016/j.hemonc.2015.11.002; Chiang EY, 2005, HEMATOL ONCOL CLIN N, V19, P771, DOI 10.1016/j.hoc.2005.08.002; Clark Ian A, 2008, Travel Med Infect Dis, V6, P67, DOI 10.1016/j.tmaid.2007.07.002; Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Driss A, 2009, GENOM INSIGHTS, V2, P23; Driss A, 2012, DIS MARKERS, V32, P295, DOI [10.3233/DMA-2011-0888, 10.1155/2012/479275]; Driss A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-271; Du YT, 2017, INT IMMUNOPHARMACOL, V48, P219, DOI 10.1016/j.intimp.2017.05.008; Dunst J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00324; Edwin A. K., 2011, Pan African Medical Journal, V10, P14, DOI 10.4314/pamj.v10i0.72223; Ghansah A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034565; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Hannemann A, 2011, ANEMIA, V2011, DOI 10.1155/2011/248527; Ioannidis LJ, 2014, PARASITOLOGY, V141, P602, DOI 10.1017/S0031182013001984; Iqbal SA, 2016, J TROP PEDIATRICS, V62, P477, DOI 10.1093/tropej/fmw038; John Nitin, 2010, Oman Med J, V25, P3, DOI 10.5001/omj.2010.2; LEOPARDI R, 1992, J IMMUNOL, V149, P2397; Li XJ, 2017, J BIOMECH, V50, P34, DOI 10.1016/j.jbiomech.2016.11.022; Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journal.pmed.0020340; Ohene-Frempong K, 2008, PEDIATRICS, V121, pS120, DOI 10.1542/peds.2007-2022UUU; Okpala H, 2004, BLOOD REV, V18, P65, DOI 10.1016/S0268-960X(03)00037-7; Oyegue-Liabagui SL, 2017, AM J CLIN EXP IMMUNO, V6, P9; Perera MK, 2013, PATHOG GLOB HEALTH, V107, P21, DOI 10.1179/2047773212Y.0000000069; Qari MH, 2012, CLIN APPL THROMB-HEM, V18, P195, DOI 10.1177/1076029611420992; Quinn CT, 2013, PEDIATR CLIN N AM, V60, P1363, DOI 10.1016/j.pcl.2013.09.006; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Taylor SC, 1995, J INTERF CYTOK RES, V15, P1061, DOI 10.1089/jir.1995.15.1061; Thein SL, 2017, ADV EXP MED BIOL, V1013, P27, DOI 10.1007/978-1-4939-7299-9_2; Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841; WHO, 2019, WORLD MALARIA REPORT; Wilson N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081329; Wilson NO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060898; Wilson NO, 2011, DIS MARKERS, V30, P39, DOI [10.1155/2011/828256, 10.3233/DMA-2011-0763]; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e; Zhu YH, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8030080	41	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2020	11								593546	10.3389/fimmu.2020.593546	http://dx.doi.org/10.3389/fimmu.2020.593546			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PO1VB	33424841	gold, Green Published			2022-12-18	WOS:000604957200001
J	Wang, K; Zhao, Y; Wang, X; Wang, B; Qin, MQ; Zhu, GH; Wu, HT; Liu, ZF; Zheng, XL; Zheng, HY; Chen, ZG				Wang, Kai; Zhao, Yu; Wang, Xuan; Wang, Bin; Qin, Maoquan; Zhu, Guanghua; Wu, Huantong; Liu, Zhongfeng; Zheng, Xueling; Zheng, Huyong; Chen, Zhiguo			Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						CD19hsCAR-T; B-ALL; humanized scFv; selective domain; primary resistance; GVHD	T-CELLS	Background CD19 chimeric antigen receptor T cell (CD19CAR-T) has shown great potential to treat acute B cell lymphoblastic leukemia (B-ALL) and B cell lymphoma, and most of anti-CD19 scFv are derived from murine antibody sequences. However, about 10-20% of B-ALL patients exhibit primary resistance to murine-based CD19CAR-T (CD19mCAR-T). Herein, we report that a humanized selective CD19CAR-T (CD19hsCAR-T) may offer a solution to this problem. Case Description A 10-year old boy was diagnosed with high-risk B-ALL in Mar., 2013, and relapsed in Oct., 2018, after he underwent haplo-identical hematopoietic stem cell transplantation (HSCT) in 2017. The patient then received haplo-identical CD19mCAR-T infusions twice following induction chemotherapy with Vincristine, Dexamethasone and Asparaginase (VDL), but no response was observed. We further treated this patient with CD19hsCAR-T following chemotherapy with Vindesine, Idarubicin, Dexamethasone, and Pegylated Asparaginase (VDLD) plus bortezomib. The patient achieved minimal residual disease-negative (MRDneg) complete remission with incomplete hematopoietic recovery (CRi), and remained in CRi for more than 8 months with manageable side effect. The patient, unfortunately, died of unidentified pulmonary infection on Jan. 25 2020. Conclusion CD19hsCAR-T may have the potential to induce remission in patients who are primarily refractory to CD19mCAR-T.	[Wang, Kai; Wang, Bin; Qin, Maoquan; Zhu, Guanghua; Zheng, Xueling; Zheng, Huyong] Capital Med Univ, Beijing Key Lab Pediat Hematol Oncol, Beijing Childrens Hosp,Minist Educ,Hematol Oncol, Natl Key Discipline Pediat,Key Lab Major Dis Chil, Beijing, Peoples R China; [Zhao, Yu; Wang, Xuan; Wu, Huantong; Liu, Zhongfeng; Chen, Zhiguo] Capital Med Univ, Natl Clin Res Ctr Geriatr Dis, Beijing Inst Geriatr, Cell Therapy Ctr,Xuanwu Hosp, Beijing, Peoples R China; [Zhao, Yu; Wang, Xuan; Wu, Huantong; Liu, Zhongfeng; Chen, Zhiguo] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China; [Zhao, Yu; Wang, Xuan; Wu, Huantong; Liu, Zhongfeng; Chen, Zhiguo] Beijing Inst Brain Disorders, Ctr Neural Injury & Repair, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Zheng, HY (corresponding author), Capital Med Univ, Beijing Key Lab Pediat Hematol Oncol, Beijing Childrens Hosp,Minist Educ,Hematol Oncol, Natl Key Discipline Pediat,Key Lab Major Dis Chil, Beijing, Peoples R China.; Chen, ZG (corresponding author), Capital Med Univ, Natl Clin Res Ctr Geriatr Dis, Beijing Inst Geriatr, Cell Therapy Ctr,Xuanwu Hosp, Beijing, Peoples R China.; Chen, ZG (corresponding author), Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China.; Chen, ZG (corresponding author), Beijing Inst Brain Disorders, Ctr Neural Injury & Repair, Beijing, Peoples R China.	zhenghuyong@bch.com.cn; chenzhiguo@gmail.com		Zhao, Yu/0000-0002-4919-1341	Beijing Municipal Administration of Hospitals DengFeng Program [DFL20151101]; Capital Health and Development of Special Grant [2016-1-2091]; National Science and Technology Key Projects [2017ZX09304029004]; Stem Cell and Translation National Key Project [2016YFA0101403]; National Natural Science Foundation of China [81973351, 81661130160, 81422014, 81561138004]; Beijing Municipal Natural Science Foundation [5142005]; Beijing Talents Foundation [2017000021223TD03]; Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-Year Plan [CIT TCD20180333]; Beijing Medical System High Level Talent Award [2015-3-063]; Beijing Municipal Health Commission Fund [PXM 2018_026283_000002]; Beijing One Hundred, Thousand, and Ten Thousand Talents Fund [2018A03]; Royal Society-Newton Advanced Fellowship [NA150482]	Beijing Municipal Administration of Hospitals DengFeng Program; Capital Health and Development of Special Grant; National Science and Technology Key Projects; Stem Cell and Translation National Key Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation); Beijing Talents Foundation; Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-Year Plan; Beijing Medical System High Level Talent Award; Beijing Municipal Health Commission Fund; Beijing One Hundred, Thousand, and Ten Thousand Talents Fund; Royal Society-Newton Advanced Fellowship	This work was supported by the Beijing Municipal Administration of Hospitals DengFeng Program (Grant #DFL20151101), Capital Health and Development of Special Grant (Grant #2016-1-2091), and National Science and Technology Key Projects (Grant #2017ZX09304029004) to HZ, and grants from Stem Cell and Translation National Key Project (2016YFA0101403), National Natural Science Foundation of China (81973351, 81661130160, 81422014, 81561138004), Beijing Municipal Natural Science Foundation (5142005), Beijing Talents Foundation (2017000021223TD03), Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-Year Plan (CIT & TCD20180333), Beijing Medical System High Level Talent Award (2015-3-063), Beijing Municipal Health Commission Fund (PXM 2018_026283_000002), Beijing One Hundred, Thousand, and Ten Thousand Talents Fund (2018A03), and the Royal Society-Newton Advanced Fellowship (NA150482). This Study was also supported by the Beijing Municipal Administration of Hospitals DengFeng Program (No. DFL20151101), Capital Health and Development of Special Grant (No. 2016-1-2091), and National Science and Technology Key Projects (No. 2017ZX09304029004) to ZC.	[Anonymous], 2018, JAMA J AM MED ASSOC, DOI [DOI 10.1001/JAMA.2018.17585, DOI 10.1001/jama.2018.17585]; August KJ, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28062; Castagna L, 2016, TRANSFUS APHER SCI, V54, P345, DOI 10.1016/j.transci.2016.05.011; Cheng JL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01237; Cui L, 2018, AM J HEMATOL, V93, P913, DOI 10.1002/ajh.25124; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Ghosh A, 2017, NAT MED, V23, P242, DOI 10.1038/nm.4258; Jensen MC, 2010, BIOL BLOOD MARROW TR, V16, P1245, DOI 10.1016/j.bbmt.2010.03.014; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Lamers CHJ, 2011, BLOOD, V117, P72, DOI 10.1182/blood-2010-07-294520; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Majzner RG, 2018, CANCER DISCOV, V8, P1219, DOI 10.1158/2159-8290.CD-18-0442; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maus MV, 2013, CANCER IMMUNOL RES, V1, P26, DOI 10.1158/2326-6066.CIR-13-0006; McLellan AD, 2019, IMMUNOL CELL BIOL, V97, P664, DOI 10.1111/imcb.12254; Messinger YH, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28115; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Mueller KT, 2017, BLOOD, V130, P2317, DOI 10.1182/blood-2017-06-786129; Nie YR, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00197-1; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Porter D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0571-y; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; van der Windt GJW, 2013, P NATL ACAD SCI USA, V110, P14336, DOI 10.1073/pnas.1221740110; Wang XL, 2016, BLOOD, V127, P2980, DOI 10.1182/blood-2015-12-686725; Xu XJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02664; Yang YM, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2806.2806; Zhao Y, 2019, CLIN CANCER RES, V25, P5595, DOI 10.1158/1078-0432.CCR-19-0916	30	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2020	11								581116	10.3389/fimmu.2020.581116	http://dx.doi.org/10.3389/fimmu.2020.581116			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PO5OX	33424835	Green Published, gold			2022-12-18	WOS:000605219600001
J	Attaf, M; Roider, J; Malik, A; Rafael, CR; Dolton, G; Prendergast, AJ; Leslie, A; Ndung'u, T; Kloverpris, HN; Sewell, AK; Goulder, PJ				Attaf, Meriem; Roider, Julia; Malik, Amna; Rafael, Cristina Rius; Dolton, Garry; Prendergast, Andrew J.; Leslie, Alasdair; Ndung'u, Thumbi; Kloverpris, Henrik N.; Sewell, Andrew K.; Goulder, Philip J.			Cytomegalovirus-Mediated T Cell Receptor Repertoire Perturbation Is Present in Early Life (vol 11, 1587, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						cytomegalovirus; T cell receptor; T cell receptor repertoire; superdominance; paediatric repertoire; repertoire dynamics; memory inflation; HLA-B*44:03			[Attaf, Meriem; Rafael, Cristina Rius; Dolton, Garry; Sewell, Andrew K.] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, Wales; [Attaf, Meriem; Rafael, Cristina Rius; Dolton, Garry; Sewell, Andrew K.] Cardiff Univ, Syst Immun Res Inst, Cardiff, Wales; [Roider, Julia; Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Doris Duke Med Res Inst, Human Immunodeficiency Virus Pathogenesis Program, Durban, South Africa; [Roider, Julia; Leslie, Alasdair; Ndung'u, Thumbi; Kloverpris, Henrik N.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Africa Hlth Res Inst, Durban, South Africa; [Roider, Julia] German Ctr Infect Res, Munich, Germany; [Roider, Julia] Ludwig Maximilians Univ Munchen, Dept Infect Dis, Munich, Germany; [Malik, Amna; Goulder, Philip J.] Univ Oxford, Dept Paediat, Oxford, England; [Prendergast, Andrew J.] Zvitambo Inst Maternal & Child Hlth Res, Harare, Zimbabwe; [Prendergast, Andrew J.] Queen Mary Univ London, Blizard Inst, Ctr Genom & Child Hlth, London, England; [Prendergast, Andrew J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Leslie, Alasdair; Ndung'u, Thumbi; Kloverpris, Henrik N.] UCL, Infect & Immun, London, England; [Ndung'u, Thumbi; Goulder, Philip J.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA 02115 USA; [Ndung'u, Thumbi] Max Planck Inst Infect Biol, Virol & Immunol, Berlin, Germany	Cardiff University; Cardiff University; University of Kwazulu Natal; Africa Health Research Institute; University of Kwazulu Natal; German Center for Infection Research; University of Munich; University of Oxford; University of London; Queen Mary University London; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of London; University College London; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Max Planck Society	Goulder, PJ (corresponding author), Univ Oxford, Dept Paediat, Oxford, England.; Goulder, PJ (corresponding author), Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA 02115 USA.	philip.goulder@paediatrics.ox.ac.uk	Sewell, Andrew/GPT-4220-2022; Roider, Julia/ADV-9989-2022	Sewell, Andrew/0000-0003-3194-3135; Roider, Julia/0000-0002-1347-2838	MRC [G0500384] Funding Source: UKRI; Medical Research Council [G0500384] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Attaf M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01587	1	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2020	11								633633	10.3389/fimmu.2020.633633	http://dx.doi.org/10.3389/fimmu.2020.633633			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PN6OV	33408722	gold, Green Published			2022-12-18	WOS:000604597200001
J	Niu, XF; Li, S; Li, PC; Pan, WJ; Wang, Q; Feng, Y; Mo, XN; Yan, QH; Ye, XM; Luo, J; Qu, LB; Weber, D; Byrne-Steele, ML; Wang, Z; Yu, FJ; Li, F; Myers, RM; Lotze, MT; Zhong, NS; Han, J; Chen, L				Niu, Xuefeng; Li, Song; Li, Pingchao; Pan, Wenjing; Wang, Qian; Feng, Ying; Mo, Xiaoneng; Yan, Qihong; Ye, Xianmiao; Luo, Jia; Qu, Linbing; Weber, Daniel; Byrne-Steele, Miranda L.; Wang, Zhe; Yu, Fengjia; Li, Fang; Myers, Richard M.; Lotze, Michael T.; Zhong, Nanshan; Han, Jian; Chen, Ling			Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients (vol 11, 582010, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						COVID-19; SARS-CoV-2; T cell receptor; B cell receptor; immune repertoire; biomarker			[Niu, Xuefeng; Feng, Ying; Zhong, Nanshan; Chen, Ling] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China; [Li, Song; Wang, Zhe; Yu, Fengjia; Han, Jian] Jiangsu Ind Technol Res Inst JITRI, Appl Adaptome Immunol Inst, Nanjing, Peoples R China; [Li, Song; Pan, Wenjing; Weber, Daniel; Byrne-Steele, Miranda L.; Han, Jian] iRepertoire Inc, Huntsville, AL 35806 USA; [Li, Pingchao; Wang, Qian; Yan, Qihong; Ye, Xianmiao; Luo, Jia; Qu, Linbing; Chen, Ling] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Lab Computat Biomed, Guangzhou Regenerat Med & Hlth Guangdong Lab GRMH, Guangzhou, Peoples R China; [Pan, Wenjing; Myers, Richard M.; Han, Jian] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA; [Mo, Xiaoneng; Li, Fang; Chen, Ling] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China; [Lotze, Michael T.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); HudsonAlpha Institute for Biotechnology; Guangzhou Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chen, L (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China.; Han, J (corresponding author), Jiangsu Ind Technol Res Inst JITRI, Appl Adaptome Immunol Inst, Nanjing, Peoples R China.; Han, J (corresponding author), iRepertoire Inc, Huntsville, AL 35806 USA.; Chen, L (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Lab Computat Biomed, Guangzhou Regenerat Med & Hlth Guangdong Lab GRMH, Guangzhou, Peoples R China.; Han, J (corresponding author), HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.; Chen, L (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.	jhan@hudsonalpha.org; chen_ling@gibh.ac.cn						Niu XF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582010	1	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2020	11								633815	10.3389/fimmu.2020.633815	http://dx.doi.org/10.3389/fimmu.2020.633815			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PN6LN	33408723	Green Published, gold			2022-12-18	WOS:000604588600001
J	Herr, C; Chanson, M; Guillot, L				Herr, Christian; Chanson, Marc; Guillot, Loic			Editorial: Immune Responses of the Mucosal Epithelium in Chronic Lung Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lung; epithelium; chronic lung disease; innate immunity; host defense			[Herr, Christian] Saarland Univ, Dept Internal Med Pulmonol Allergol & Crit Care M, Homburg, Germany; [Chanson, Marc] Univ Geneva, Fac Med, Dept Cell Physiol & Metab, Geneva, Switzerland; [Guillot, Loic] Sorbonne Univ, INSERM UMR S 938, Ctr Rech St Antoine CRSA, Paris, France	Universitatsklinikum des Saarlandes; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Guillot, L (corresponding author), Sorbonne Univ, INSERM UMR S 938, Ctr Rech St Antoine CRSA, Paris, France.	loic.guillot@inserm.fr	Herr, Christian/AAH-5291-2021; Guillot, Loic/D-8893-2011	Guillot, Loic/0000-0001-6853-7945; Herr, Christian/0000-0001-9422-6569				Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4	1	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 18	2020	11								626437	10.3389/fimmu.2020.626437	http://dx.doi.org/10.3389/fimmu.2020.626437			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM7QI	33391291	Green Published, gold			2022-12-18	WOS:000603988300001
J	Hossny, E; Condino-Neto, A; Hammarstrom, L; Walter, JE				Hossny, Elham; Condino-Neto, Antonio; Hammarstrom, Lennart; Walter, Jolan Eszter			Editorial: Screening for Primary Immunodeficiency Disorders (PIDDs) in Neonates	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						primary immunodeficiency; screening; newborn; neonates; severe combined immunodeficiency			[Hossny, Elham] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Condino-Neto, Antonio] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil; [Hammarstrom, Lennart] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; [Walter, Jolan Eszter] Univ S Florida, Div Pediat Allergy & Immunol, Tampa, FL 33620 USA; [Walter, Jolan Eszter] Johns Hopkins All Childrens Hosp, Div Allergy & Immunol, St Petersburg, FL USA; [Walter, Jolan Eszter] Massachusetts Gen Hosp Children, Div Allergy & Immunol, Boston, MA USA	Egyptian Knowledge Bank (EKB); Ain Shams University; Universidade de Sao Paulo; Karolinska Institutet; Karolinska University Hospital; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine	Hossny, E (corresponding author), Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt.	elham.hossny@gmail.com	Condino-Neto, Antonio/D-4762-2012	Condino-Neto, Antonio/0000-0002-1069-3117; Hossny, Elham/0000-0001-6876-6318					0	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 18	2020	11								633266	10.3389/fimmu.2020.633266	http://dx.doi.org/10.3389/fimmu.2020.633266			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM7QH	33424872	Green Published, gold			2022-12-18	WOS:000603988200001
J	Wiebe, MC; Yanow, SK				Wiebe, Madeleine C.; Yanow, Stephanie K.			Do Antibodies to Malaria Surface Antigens Play a Role in Protecting Mothers From Maternal Anemia?	FRONTIERS IN IMMUNOLOGY			English	Review						pregnancy-associated malaria; anemia; inflammation; placenta; VAR2CSA antibodies; VSA(PAM) antibodies	FALCIPARUM-INFECTED ERYTHROCYTES; CHONDROITIN SULFATE-A; PLASMODIUM-FALCIPARUM; PLACENTAL MALARIA; IMMUNOGLOBULIN-G; PREGNANT-WOMEN; IMMUNITY; ADHESION; GAMMA; PRIMIGRAVIDAE	Pregnancy-associated malaria (PAM) caused by Plasmodium falciparum can result in detrimental outcomes for both mother and infant, including low infant birth weight, preterm birth, maternal anemia, spontaneous abortion, and maternal and/or infant mortality. Maternal anemia is a particularly complex outcome, as the body must both maintain erythropoiesis and tolerance of the growing fetus, while directing a Th1 response against the parasite. Underlying the pathogenesis of PAM is the expression of variant surface antigens (VSA(PAM)) on the surface of infected red blood cells (iRBC) that mediate sequestration of the iRBC in the placenta. Naturally acquired antibodies to VSA(PAM) can block sequestration and activate opsonic phagocytosis, both associated with improved pregnancy outcomes. In this review, we ask whether VSA(PAM) antibodies can also protect mothers against malarial anemia. Studies were identified where VSA(PAM) antibody titres and/or function were associated with higher maternal hemoglobin levels, thus supporting additional protective mechanisms for these antibodies against PAM. Yet these associations were not widely observed, and many studies reported no association between protection from maternal anemia and VSA(PAM) antibodies. We discuss the epidemiological, biological and technical factors that may explain some of the variability among these studies. We appraise the current evidence of these complex interactions between PAM-specific immunity and maternal anemia, propose potential mechanisms, and discuss knowledge gaps.	[Wiebe, Madeleine C.; Yanow, Stephanie K.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; [Yanow, Stephanie K.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada	University of Alberta; University of Alberta	Yanow, SK (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.; Yanow, SK (corresponding author), Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.	yanow@ualberta.ca			CIHR Frederick Banting and Charles Best Canada Graduate Scholarship	CIHR Frederick Banting and Charles Best Canada Graduate Scholarship(Canadian Institutes of Health Research (CIHR))	MCW holds a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship.	Achidi EA, 2007, INT J GYNECOL OBSTET, V97, P15, DOI 10.1016/j.ijgo.2006.12.015; Aitken EH, 2010, J INFECT DIS, V201, P1316, DOI 10.1086/651578; Arora G, 2018, ELIFE, V7, DOI 10.7554/eLife.36806; Ataide R, 2014, TRENDS PARASITOL, V30, P85, DOI 10.1016/j.pt.2013.12.007; Ataide R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022491; Ataide R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010807; Brabin B., 2001, Malaria in pregnancy: deadly parasite, susceptible host, P27, DOI 10.4324/9780203302255_chapter_2; Cao C, 2013, NUTR REV, V71, P35, DOI 10.1111/j.1753-4887.2012.00550.x; Chandrasiri UP, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1597-7; Chandrasiri UP, 2014, J INFECT DIS, V209, P1408, DOI 10.1093/infdis/jit646; Chapman AB, 1998, KIDNEY INT, V54, P2056, DOI 10.1046/j.1523-1755.1998.00217.x; Cutts JC, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1467-6; Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221; deMoraesPinto MI, 1997, IMMUNOLOGY, V90, P87, DOI 10.1046/j.1365-2567.1997.00139.x; Dobano C, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2317-2; Dondorp AM, 1999, AM J TROP MED HYG, V60, P733, DOI 10.4269/ajtmh.1999.60.733; Duffy PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003; Elliott SR, 2005, INFECT IMMUN, V73, P5903, DOI 10.1128/IAI.73.9.5903-5907.2005; Feng GQ, 2009, J INFECT DIS, V200, P299, DOI 10.1086/599841; Fowkes FJI, 2012, J INFECT DIS, V206, P1612, DOI 10.1093/infdis/jis566; Fried M, 1998, J IMMUNOL, V160, P2523; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Fried M, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2258-9; Gavina K, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00797-17; Ghosh K, 2007, PARASITOL RES, V101, P1463, DOI 10.1007/s00436-007-0742-1; Hountohotegbe T, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00042-20; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Jakeman GN, 1999, PARASITOLOGY, V119, P127, DOI 10.1017/S0031182099004564; Jaworowski A, 2009, CLIN VACCINE IMMUNOL, V16, P312, DOI 10.1128/CVI.00356-08; Kabyemela ER, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-26; Laelago T, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-0772-1; Lloyd YM, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00166-18; LOOAREESUWAN S, 1991, ACTA TROP, V48, P263, DOI 10.1016/0001-706X(91)90014-B; Mayor A, 2013, J INFECT DIS, V207, P1664, DOI 10.1093/infdis/jit083; MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517, DOI 10.4269/ajtmh.1984.33.517; Moore JM, 1999, J INFECT DIS, V179, P1218, DOI 10.1086/314737; Moore Kerryn A, 2017, Lancet Glob Health, V5, pe1101, DOI 10.1016/S2214-109X(17)30340-6; Mordmuller B, 2019, CLIN INFECT DIS, V69, P1509, DOI 10.1093/cid/ciy1140; Ndam NGT, 2006, J INFECT DIS, V193, P713, DOI 10.1086/500146; Ndam NT, 2015, EMERG INFECT DIS, V21, P813, DOI 10.3201/eid2105.141626; O'Neil-Dunne I, 2001, INFECT IMMUN, V69, P7487, DOI 10.1128/IAI.69.12.7487-7492.2001; Perkins DJ, 2011, INT J BIOL SCI, V7, P1427, DOI 10.7150/ijbs.7.1427; Reiling L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08528-z; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; Rogerson SJ, 2007, AM J TROP MED HYG, V77, P14; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Sander AF, 2011, J INFECT DIS, V203, P1679, DOI 10.1093/infdis/jir168; Sanghavi M, 2014, CIRCULATION, V130, P1003, DOI 10.1161/CIRCULATIONAHA.114.009029; Serra-Casas E, 2010, J INFECT DIS, V201, P123, DOI 10.1086/648595; Sirima SB, 2020, LANCET INFECT DIS, V20, P585, DOI 10.1016/S1473-3099(19)30739-X; Staalsoe T, 2004, INFECT IMMUN, V72, P5027, DOI 10.1128/IAI.72.9.5027-5030.2004; Staalsoe T, 2004, LANCET, V363, P283, DOI 10.1016/S0140-6736(03)15386-X; Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809; Stephens JK, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1857-1; Suguitan AL, 2003, AM J TROP MED HYG, V69, P574, DOI 10.4269/ajtmh.2003.69.574; Suguitan AL, 2003, J INFECT DIS, V188, P1074, DOI 10.1086/378500; Tebo AE, 2002, CLIN EXP IMMUNOL, V130, P300, DOI 10.1046/j.1365-2249.2002.01972.x; Thaxton JE, 2010, AM J REPROD IMMUNOL, V63, P482, DOI 10.1111/j.1600-0897.2010.00810.x; Vricella LK, 2017, AM J CLIN NUTR, V106, p1620S, DOI 10.3945/ajcn.117.155903; WALTER PR, 1982, AM J PATHOL, V109, P330; White NJ, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2509-9; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; WHO, 2011, WHO TECH REP SER, V959, P1; World Health Organization, 2004, AFRMAL0401 WHO REG O; Zhou JL, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-343	67	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 18	2020	11								609957	10.3389/fimmu.2020.609957	http://dx.doi.org/10.3389/fimmu.2020.609957			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM7MU	33391279	Green Published, gold			2022-12-18	WOS:000603979100001
J	Barreto-Duarte, B; Sterling, TR; Fiske, CT; Almeida, A; Nochowicz, CH; Smith, RM; Barnett, L; Warren, C; Blackman, A; Silva, JRLE; Andrade, BB; Kalams, SA				Barreto-Duarte, Beatriz; Sterling, Timothy R.; Fiske, Christina T.; Almeida, Alexandre; Nochowicz, Cynthia H.; Smith, Rita M.; Barnett, Louise; Warren, Christian; Blackman, Amondrea; e Silva, Jose Roberto; Andrade, Bruno B.; Kalams, Spyros A.			Increased Frequency of Memory CD4+T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; extrapulmonary tuberculosis; memory T-cell responses; cytokine; CD4+T cell	REGULATORY T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; ACTIVE TUBERCULOSIS; IMMUNE-RESPONSES; INFECTION; IMMUNOLOGY; DISEASE	Extrapulmonary TB (EPTB) occurs with increased frequency in persons with underlying immunodeficiency. Even after recovery from acute illness, differences in immune phenotype and activation persist. Studies defining characteristics of immune responses after recovery from extrapulmonary TB may provide insights into factors that increase TB risk. We performed two case-control studies (in the United States and Brazil) among HIV-seronegative adults with previous EPTB (n = 9; 25), previous pulmonary TB (n = 7; 25), latent M. tuberculosis (Mtb) infection (n = 11; 25), and uninfected TB contacts (n = 10; 25). We assessed the frequency of dual CD4+ interferon-gamma and tumor necrosis factor-alpha responses after stimulation with overlapping Mtb peptides from ESAT-6 or CFP-10, or gamma-irradiated Mtb H37Rv, proliferative responses to Mtb antigens, T-regulatory cell (Treg) frequency and phenotype. In both study populations, individuals with prior EPTB had the highest frequency of intracellular cytokine-producing cells in response to Mtb antigens (p < 0.05; p <.0001). Persons with prior EPTB in Brazil had the highest levels of CD4 proliferation to Mtb antigens (p < 0.0001), and the highest expression of CD39 on Tregs (p < 0.0001). Individuals with treated EPTB maintained high frequencies of Mtb-specific memory responses and active Treg cells, suggesting that susceptibility to EPTB occurs despite the ability to develop and maintain enhanced adaptive immune responses.	[Barreto-Duarte, Beatriz; Andrade, Bruno B.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil; [Barreto-Duarte, Beatriz; Andrade, Bruno B.] Multinat Org Network Sponsoring Translat & Epidem, Salvador, BA, Brazil; [Barreto-Duarte, Beatriz; Andrade, Bruno B.] Univ Salvador UNIFACS, Laureate Univ, Salvador, BA, Brazil; [Barreto-Duarte, Beatriz; Almeida, Alexandre; e Silva, Jose Roberto; Andrade, Bruno B.] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil; [Sterling, Timothy R.; Fiske, Christina T.; Nochowicz, Cynthia H.; Smith, Rita M.; Barnett, Louise; Warren, Christian; Blackman, Amondrea; Kalams, Spyros A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA; [Sterling, Timothy R.; Fiske, Christina T.; Nochowicz, Cynthia H.; Smith, Rita M.; Barnett, Louise; Warren, Christian; Blackman, Amondrea; Kalams, Spyros A.] Vanderbilt Univ, Med Ctr, Vanderbilt TB Ctr, Nashville, TN USA; [Andrade, Bruno B.] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil; [Andrade, Bruno B.] Ctr Univ Fac Tecnol & Ciencias UniFTC, Curso Med, Salvador, BA, Brazil; [Andrade, Bruno B.] Escola Bahiana Med & Saude Publ, Curso Med, Salvador, BA, Brazil	Fundacao Oswaldo Cruz; Universidade Salvador (UNIFACS); Universidade Federal do Rio de Janeiro; Vanderbilt University; Vanderbilt University; Universidade Federal da Bahia; Escola Bahiana de Medicina e Saude Publica	Andrade, BB (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Multinat Org Network Sponsoring Translat & Epidem, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Univ Salvador UNIFACS, Laureate Univ, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil.; Andrade, BB (corresponding author), Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Ctr Univ Fac Tecnol & Ciencias UniFTC, Curso Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Escola Bahiana Med & Saude Publ, Curso Med, Salvador, BA, Brazil.	bruno.andrade@fiocruz.br	Lapa e Silva, Jose R./AAS-4793-2020; de Almeida, Alexandre/C-6023-2012	Lapa e Silva, Jose R./0000-0003-3116-0253; de Almeida, Alexandre/0000-0002-4062-2504	National Institutes of Health, NIAID [1R21AI127129-01]; NIH [U01 AI069923]; NIAID [1 P30AI110527-03]; Brazilian Research Council/CNPq [469607/2014-9, K23AI091692]; Intramural Research Program of Fundacao Oswaldo Cruz; National Institutes of Health [U01 AI069923]; Coordenacao de Aperfeicoamento de Pessoal de Ni'vel Superior (CAPES)	National Institutes of Health, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Brazilian Research Council/CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Intramural Research Program of Fundacao Oswaldo Cruz; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Coordenacao de Aperfeicoamento de Pessoal de Ni'vel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	The study was supported by grants from the National Institutes of Health, NIAID 1R21AI127129-01 (SK); NIH U01 AI069923 (CCASAnet and RePORT-Brazil: LB, AB, JL, BA, TS), NIAID 1 P30AI110527-03 Tennessee Center for AIDS Research (TNCFAR) (CN, CW, SK, TS); Brazilian Research Council/CNPq 469607/2014-9 (AA, JL), K23AI091692 (CF). The work from BA was supported by the Intramural Research Program of Fundacao Oswaldo Cruz. BA and JL are senior scientists from CNPq. The work from LB was supported by the National Institutes of Health (U01 AI069923). BB-D received a research fellowship from the Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior (CAPES).	Adekambi T, 2015, J CLIN INVEST, V125, P1827, DOI 10.1172/JCI77990; Antas PRZ, 2006, J ALLERGY CLIN IMMUN, V117, P916, DOI 10.1016/j.jaci.2006.01.042; Araujo NCN, 2020, INT J INFECT DIS, V93, P277, DOI 10.1016/j.ijid.2020.02.015; Arlehamn CL, 2014, J IMMUNOL, V193, P2931, DOI 10.4049/jimmunol.1401151; Barcelo Helene, 2018, Curr Protoc Cytom, V84, pe35, DOI 10.1002/cpcy.35; BARNES PF, 1993, INFECT IMMUN, V61, P3482, DOI 10.1128/IAI.61.8.3482-3489.1993; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; BRASIL, 2019, MANUAL RECOMENDACOES, V2a, P366; Centers for Disease Control and Prevention (CDC), 2005, NAT TUB CONTR CTR DI; Chiacchio T, 2009, CLIN EXP IMMUNOL, V156, P463, DOI 10.1111/j.1365-2249.2009.03908.x; de Almeida AS, 2012, CLIN VACCINE IMMUNOL, V19, P45, DOI 10.1128/CVI.05263-11; Fiske CT, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3958-7; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001; Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30; Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002152, 10.1371/journal.pmed.1002119]; Jasenosky LD, 2015, IMMUNOL REV, V264, P74, DOI 10.1111/imr.12274; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Kim K, 2014, TUBERCULOSIS, V94, P494, DOI 10.1016/j.tube.2014.07.002; Kritski AL, 1996, AM J RESP CRIT CARE, V153, P331, DOI 10.1164/ajrccm.153.1.8542139; Lewinsohn DA, 2004, INT J TUBERC LUNG D, V8, P658; Marin ND, 2010, TUBERCULOSIS, V90, P252, DOI 10.1016/j.tube.2010.05.003; Murray LW, 2018, J INFECT DIS, V217, P1782, DOI 10.1093/infdis/jiy052; Pang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065496; Rahman S, 2009, AM J PATHOL, V174, P2211, DOI 10.2353/ajpath.2009.080941; Reichler MR, 2018, J INFECT DIS, V218, P1000, DOI 10.1093/infdis/jiy265; Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x; Rozot V, 2013, EUR J IMMUNOL, V43, P1568, DOI 10.1002/eji.201243262; Sahmoudi K, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0266-8; Scriba TJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006687; Scriba TJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TBTB2-0016-2016; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; Shea KM, 2014, AM J EPIDEMIOL, V179, P216, DOI 10.1093/aje/kwt246; Shivakoti R, 2017, INFECTION, V45, P11, DOI 10.1007/s15010-016-0960-5; Silveira-Mattos PS, 2020, CLIN INFECT DIS, V71, P1905, DOI 10.1093/cid/ciz1070; Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769; Sutherland I, 1976, Adv Tuberc Res, V19, P1; World Health Organization, 2019, SPECIAL INITIATIVE M	39	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2020	11								605338	10.3389/fimmu.2020.605338	http://dx.doi.org/10.3389/fimmu.2020.605338			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PM3MX	33391271	Green Published, gold			2022-12-18	WOS:000603708900001
J	van Zelm, MC; Ziegler-Heitbrock, L; Collins, AM; Chan, SK; Engel, P				van Zelm, Menno C.; Ziegler-Heitbrock, Loems; Collins, Andrew M.; Chan, Sanny K.; Engel, Pablo			Editorial: Nomenclature-Avoiding Babylonian Speech Confusion in Present Day Immunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						B cell; clusters of differentiation marker; allergen; cytokine; complement; C-type lectin receptor; immunoglobulin gene; monocytes and dendritic cells	COMPLEMENT; CELLS		[van Zelm, Menno C.] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Melbourne, Vic, Australia; [van Zelm, Menno C.] Monash Univ, Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [van Zelm, Menno C.] Alfred Hlth, Allergy Asthma & Clin Immunol, Melbourne, Vic, Australia; [Ziegler-Heitbrock, Loems] Monocyt Res, Munich, Germany; [Collins, Andrew M.] Univ New South Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia; [Chan, Sanny K.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO 80206 USA; [Chan, Sanny K.] Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA; [Engel, Pablo] Univ Barcelona, Dept Biomed Sci, Immunol Unit, Sch Med, Barcelona, Spain	Monash University; Monash University; University of New South Wales Sydney; National Jewish Health; National Jewish Health; University of Barcelona	van Zelm, MC (corresponding author), Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Melbourne, Vic, Australia.; van Zelm, MC (corresponding author), Monash Univ, Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia.; van Zelm, MC (corresponding author), Alfred Hlth, Allergy Asthma & Clin Immunol, Melbourne, Vic, Australia.; Ziegler-Heitbrock, L (corresponding author), Monocyt Res, Munich, Germany.; Collins, AM (corresponding author), Univ New South Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.; Chan, SK (corresponding author), Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO 80206 USA.; Chan, SK (corresponding author), Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA.; Engel, P (corresponding author), Univ Barcelona, Dept Biomed Sci, Immunol Unit, Sch Med, Barcelona, Spain.	menno.vanzelm@monash.edu; LZH@monocyte.eu; a.collins@unsw.edu.au; sannychan.ai@gmail.com; pengel@ub.edu		Engel, Pablo/0000-0001-8410-252X	Australian National Health and Medical Research Council (NHMRC) [1117687]; Jeffrey Modell Foundation	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Jeffrey Modell Foundation	MZ is supported by the Australian National Health and Medical Research Council (NHMRC; Senior Research Fellowship 1117687) and the Jeffrey Modell Foundation.	[Anonymous], 1981, J IMMUNOL, V127, P1261; [Anonymous], 2003, CLIN EXP RHEUMAT S29, V21, pS49, DOI DOI 10.1016/S1043-4666(02)00493-3; Boyd SD, 2010, J IMMUNOL, V184, P6986, DOI 10.4049/jimmunol.1000445; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Collins AM, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0236; Engel P, 2015, J IMMUNOL, V195, P4555, DOI 10.4049/jimmunol.1502033; Gadala-Maria D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00129; Goodman RE, 2019, ALLERGY, V74, P429, DOI 10.1111/all.13693; Hamann J, 2015, PHARMACOL REV, V67, P338, DOI 10.1124/pr.114.009647; Kemper C, 2014, MOL IMMUNOL, V61, P56, DOI 10.1016/j.molimm.2014.07.004; Lefranc MP, 2019, ANTIBODIES, V8, DOI 10.3390/antib8020029; Mantovani A, 2016, NAT IMMUNOL, V17, P215, DOI 10.1038/ni.3354; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; RAPP HJ, 1963, SCIENCE, V141, P738, DOI 10.1126/science.141.3582.738; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Watson CT, 2019, IMMUNOL CELL BIOL, V97, P888, DOI 10.1111/imcb.12288; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	17	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2020	11								621100	10.3389/fimmu.2020.621100	http://dx.doi.org/10.3389/fimmu.2020.621100			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PK7TU	33381126	Green Published, gold			2022-12-18	WOS:000602643100001
J	Hoffmann, D; Dvorakova, T; Schramme, F; Stroobant, V; Van den Eynde, BJ				Hoffmann, Delia; Dvorakova, Tereza; Schramme, Florence; Stroobant, Vincent; Van den Eynde, Benoit J.			Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance	FRONTIERS IN IMMUNOLOGY			English	Article						placenta; decidual stromal cell; immunohistochemistry; feto-maternal tolerance; TDO - tryptophan 2,3-dioxygenase; IDO1-indoleamine 2,3-dioxygenase 1	TUMORAL IMMUNE RESISTANCE; INDOLEAMINE 2,3-DIOXYGENASE; KYNURENINE PATHWAY; HUMAN PLACENTA; INHIBITION; INDUCTION; GROWTH; CANCER; DEGRADATION; SUPPRESSION	Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) catalyze the rate-limiting step of tryptophan catabolism along the kynurenine pathway, which has important immuno suppressive properties, particularly in tumor cells and dendritic cells. The prominent expression of IDO1 in the placenta also suggested a role in preventing immune rejection of fetal tissues, and pharmacological inhibition of IDO1 induced abortion of allogeneic fetuses in mice. However, this was later challenged by the lack of rejection of allogeneic fetuses in IDO1-KO mice, suggesting that other mechanisms may compensate for IDO1 deficiency. Here we investigated whether TDO could contribute to feto-maternal tolerance and compensate for IDO1 deficiency in IDO1-KO mice. Expression of TDO mRNA was previously detected in placental tissues. We developed a new chimeric rabbit anti-TDO antibody to confirm TDO expression at the protein level and identify the positive cell type by immunohistochemistry in murine placenta. We observed massive TDO expression in decidual stromal cells, starting at day E3.5, peaking at day E6.5 then declining rapidly while remaining detectable until gestation end. IDO1 was also induced in decidual stromal cells, but only at a later stage of gestation when TDO expression declined. To determine whether TDO contributed to feto-maternal tolerance, we mated TDO-KO and double IDO1-TDO-KO females with allogeneic males. However, we did not observe reduced fertility. These results suggest that, despite its expression in decidual stromal cells, TDO is not a dominant mechanism of feto-maternal tolerance able to compensate for the absence of IDO1. Redundant additional mechanisms of immunosuppression likely take over in these KO mice. The massive expression of TDO during decidualization might suggest a role of TDO in angiogenesis or vessel tonicity, as previously described for IDO1.	[Hoffmann, Delia; Dvorakova, Tereza; Schramme, Florence; Stroobant, Vincent; Van den Eynde, Benoit J.] Ludwig Inst Canc Res, Brussels, Belgium; [Hoffmann, Delia; Dvorakova, Tereza; Schramme, Florence; Stroobant, Vincent; Van den Eynde, Benoit J.] UCLouvain, de Duve Inst, Brussels, Belgium; [Van den Eynde, Benoit J.] Walloon Excellence Life Sci & Biotechnol, Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; WELBIO	Van den Eynde, BJ (corresponding author), Ludwig Inst Canc Res, Brussels, Belgium.; Van den Eynde, BJ (corresponding author), UCLouvain, de Duve Inst, Brussels, Belgium.; Van den Eynde, BJ (corresponding author), Walloon Excellence Life Sci & Biotechnol, Brussels, Belgium.	benoit.vandeneynde@bru.licr.org		Hoffmann, Delia/0000-0001-5574-6123	Ludwig Institute for Cancer Research; Fonds Scientifique pour la Recherche-FNRS, de Duve Institute; UCLouvain (Belgium); FNRS-FRIA [E082.14]; FNRS-Televie [7.4597.18]; UCLouvain	Ludwig Institute for Cancer Research; Fonds Scientifique pour la Recherche-FNRS, de Duve Institute; UCLouvain (Belgium); FNRS-FRIA(Fonds de la Recherche Scientifique - FNRS); FNRS-Televie(Fonds de la Recherche Scientifique - FNRS); UCLouvain	This work was supported by the Ludwig Institute for Cancer Research, the Fonds Scientifique pour la Recherche-FNRS, de Duve Institute and UCLouvain (Belgium). Financial support for authors: DH, FNRS-FRIA (Grant number: 1.E082.14); TD, FNRS-Televie (Grant number: 7.4597.18) F. Schramme: UCLouvain; VS: Ludwig Institute for Cancer Research; BV: Ludwig Institute for Cancer Research.	Baban B, 2004, J REPROD IMMUNOL, V61, P67, DOI 10.1016/j.jri.2003.11.003; Blaschitz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021774; Brochez L, 2017, EUR J CANCER, V76, P167, DOI 10.1016/j.ejca.2017.01.011; Broekhuizen M, 2020, HYPERTENSION, V76, P184, DOI 10.1161/HYPERTENSIONAHA.120.14970; Chang MY, 2011, CANCER BIOL THER, V12, P1050, DOI 10.4161/cbt.12.12.18142; CHON SY, 1995, J INTERF CYTOK RES, V15, P517, DOI 10.1089/jir.1995.15.517; Crosignani S, 2017, J MED CHEM, V60, P9617, DOI 10.1021/acs.jmedchem.7b00974; Croy BA, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.102830; DAI W, 1990, J BIOL CHEM, V265, P19871; Das SK, 2009, REPRODUCTION, V137, P889, DOI 10.1530/REP-08-0539; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Guleria I, 2007, J IMMUNOL, V178, P3345, DOI 10.4049/jimmunol.178.6.3345; Hennequart M, 2017, CANCER IMMUNOL RES, V5, P695, DOI 10.1158/2326-6066.CIR-16-0400; Hoffmann D, 2020, CANCER IMMUNOL RES, V8, P19, DOI 10.1158/2326-6066.CIR-19-0040; Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066; Iwahashi N, 2017, J REPROD IMMUNOL, V119, P54, DOI 10.1016/j.jri.2017.01.003; Kanai M, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-8; Keaton SA, 2019, INT J TRYPTOPHAN RES, V12, DOI 10.1177/1178646919840321; Koblish HK, 2010, MOL CANCER THER, V9, P489, DOI 10.1158/1535-7163.MCT-09-0628; Kudo Y, 2004, J REPROD IMMUNOL, V61, P87, DOI 10.1016/j.jri.2003.11.004; Lebovic DI, 2000, MOL HUM REPROD, V6, P269, DOI 10.1093/molehr/6.3.269; Li DD, 2014, J ENDOCRINOL, V220, P73, DOI 10.1530/JOE-13-0429; Ligam P, 2005, PLACENTA, V26, P498, DOI 10.1016/j.placenta.2004.08.009; Manuelpillai U, 2005, AM J OBSTET GYNECOL, V192, P280, DOI 10.1016/j.ajog.2004.06.090; Matty MA, 2015, IMMUNOL REV, V264, P276, DOI 10.1111/imr.12273; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Mondal A, 2016, EBIOMEDICINE, V14, P74, DOI 10.1016/j.ebiom.2016.11.013; Morelli SS, 2015, RES REP BIOL, V6, P171, DOI 10.2147/RRB.S80652; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Murthi P, 2017, PLACENTA, V52, P62, DOI 10.1016/j.placenta.2017.02.013; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Pilotte L, 2012, P NATL ACAD SCI USA, V109, P2497, DOI 10.1073/pnas.1113873109; Platten M, 2019, NAT REV DRUG DISCOV, V18, P379, DOI 10.1038/s41573-019-0016-5; SALTER M, 1995, BIOCHEM PHARMACOL, V49, P1435, DOI 10.1016/0006-2952(95)00006-L; Santillan MK, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12257; Schramme F, 2020, CANCER IMMUNOL RES, V8, P32, DOI 10.1158/2326-6066.CIR-19-0041; Schrocksnadel H, 1996, OBSTET GYNECOL, V88, P47, DOI 10.1016/0029-7844(96)00084-1; Schrocksnadel K, 2003, LIFE SCI, V72, P785, DOI 10.1016/S0024-3205(02)02304-4; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Shayda Hemmati, 2009, J Reprod Infertil, V10, P177; Smith C, 2012, CANCER DISCOV, V2, P722, DOI 10.1158/2159-8290.CD-12-0014; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Stanley CP, 2019, NATURE, V566, P548, DOI 10.1038/s41586-019-0947-3; Suzuki S, 2001, BIOCHEM J, V355, P425, DOI 10.1042/0264-6021:3550425; Tatsumi K, 2000, BIOCHEM BIOPH RES CO, V274, P166, DOI 10.1006/bbrc.2000.3115; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Theate I, 2015, CANCER IMMUNOL RES, V3, P161, DOI 10.1158/2326-6066.CIR-14-0137; Urata Y, 2014, AM J REPROD IMMUNOL, V72, P496, DOI 10.1111/aji.12282; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; van Baren N, 2015, CANCER IMMUNOL RES, V3, P978, DOI 10.1158/2326-6066.CIR-15-0095; Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092; Wei HX, 2020, REPROD SCI, V27, P1656, DOI 10.1007/s43032-020-00196-5; Yu CP, 2016, METAB BRAIN DIS, V31, P737, DOI 10.1007/s11011-016-9824-z; Zardoya-Laguardia P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23896-0	56	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2020	11								601759	10.3389/fimmu.2020.601759	http://dx.doi.org/10.3389/fimmu.2020.601759			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PH8HR	33363543	Green Published, gold			2022-12-18	WOS:000600647000001
J	Kraus, AU; Penna-Martinez, M; Shoghi, F; Meyer, G; Badenhoop, K				Kraus, Anna U.; Penna-Martinez, Marissa; Shoghi, Firouzeh; Meyer, Gesine; Badenhoop, Klaus			Monocytic Cytokines in Autoimmune Polyglandular Syndrome Type 2 Are Modulated by Vitamin D and HLA-DQ	FRONTIERS IN IMMUNOLOGY			English	Article						Addison&#8217; s disease; type 1 diabetes; autoimmune thyroiditis; autoimmune polyglandular syndrome type 2; cytokine gene expression; HLA DQ haplotypes	1,25-DIHYDROXYVITAMIN D-3; CELL-DIFFERENTIATION; POLYMORPHISMS; EXPRESSION; DISEASE; RISK; SUSCEPTIBILITY; INSUFFICIENCY; MATURATION; RECEPTOR	Context Autoimmune polyglandular syndrome (APS-2: autoimmune Addison's disease or type 1 diabetes) is conferred by predisposing HLA molecules, vitamin D deficiency, and heritable susceptibility. Organ destruction is accompanied by cytokine alterations. We addressed the monocytic cytokines of two distinct APS-2 cohorts, effects of vitamin D and HLA DQ risk. Methods APS-2 patients (n = 30) and healthy controls (n = 30) were genotyped for HLA DQA1/DQB1 and their CD14+ monocytes stimulated with IL1 beta and/or 1,25(OH)(2)D-3 for 24 h. Immune regulatory molecules (IL-6, IL-10, IL-23A, IL-15, CCL-2, PD-L1), vitamin D pathway gene transcripts (CYP24A1, CYP27B1, VDR), and CD14 were analyzed by enzyme-linked immunosorbent assay and RTqPCR. Results Pro-inflammatory CCL-2 was higher in APS-2 patients than in controls (p = 0.001), whereas IL-6 showed a trend - (p = 0.1). In vitro treatment with 1,25(OH)(2)D-3 reduced proinflammatory cytokines (IL-6, CCL-2, IL-23A, IL-15) whereas anti-inflammatory cytokines (IL-10 and PD-L1) rose both in APS-type 1 diabetes and APS-Addison ' s disease. Patients with adrenal autoimmunity showed a stronger response to vitamin D. Expression of IL-23A and vitamin D pathway genes VDR and CYP27B1 varied by HLA genotype and was lower in healthy individuals with high-risk HLA (p = 0.0025; p = 0.04), while healthy controls with low-risk HLA showed a stronger IL-10 and CD14 expression (p = 0.01; p = 0.03). Conclusion 1,25(OH)(2)D-3 regulates the monocytic response in APS-2 disorders type 1 diabetes or Addison ' s disease. The monocytic cytokine profile of individuals carrying HLA high-risk alleles is proinflammatory, enhances polyglandular autoimmunity and can be targeted by vitamin D.	[Kraus, Anna U.; Penna-Martinez, Marissa; Shoghi, Firouzeh; Meyer, Gesine; Badenhoop, Klaus] Univ Hosp Frankfurt, Div Endocrinol Diabet & Metab, Dept Internal Med 1, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Kraus, AU (corresponding author), Univ Hosp Frankfurt, Div Endocrinol Diabet & Metab, Dept Internal Med 1, Frankfurt, Germany.	Anna.Kraus@kgu.de	Meyer, Gesine/ABD-7219-2021		Else Kroner-Fresenius Foundation (EKFS); German Diabetes Society (Deutsche Diabetes Gesellschaft-DDG); Research Training Group Translational Research Innovation-Pharma (TRIP)	Else Kroner-Fresenius Foundation (EKFS); German Diabetes Society (Deutsche Diabetes Gesellschaft-DDG); Research Training Group Translational Research Innovation-Pharma (TRIP)	This work was supported by the Else Kroner-Fresenius Foundation (EKFS), Research Training Group Translational Research Innovation-Pharma (TRIP) and project funds from the German Diabetes Society (Deutsche Diabetes Gesellschaft-DDG).	BADENHOOP K, 1995, J CLIN ENDOCR METAB, V80, P2112, DOI 10.1210/jc.80.7.2112; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; Caprio M, 2017, EAT WEIGHT DISORD-ST, V22, P27, DOI 10.1007/s40519-016-0312-6; Cavalli G, 2016, P NATL ACAD SCI USA, V113, P1363, DOI 10.1073/pnas.1523482113; Cocco E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041678; Concannon P, 2005, DIABETES, V54, P2995, DOI 10.2337/diabetes.54.10.2995; Cooper JD, 2011, DIABETES, V60, P1624, DOI 10.2337/db10-1656; de Kerkhof PCMV, 2005, DERMATOLOGY, V210, P294; Eisenbarth GS, 2004, NEW ENGL J MED, V350, P2068, DOI 10.1056/NEJMra030158; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Feng M, 2013, ENDOCRINE, V43, P318, DOI 10.1007/s12020-012-9812-y; Goncalves-Mendes N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00065; Grant WB, 2020, NUTRIENTS, V12, P4, DOI DOI 10.3390/nu12040988; Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490; Hayes CE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00100; Husebye ES, 2010, IMMUNITY, V32, P479, DOI 10.1016/j.immuni.2010.03.016; Hypponen E, 2010, DIABETES OBES METAB, V12, P737, DOI 10.1111/j.1463-1326.2010.01211.x; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Infante M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092185; Johannsson G, 2012, J CLIN ENDOCR METAB, V97, P473, DOI 10.1210/jc.2011-1926; Kongsbak M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00148; Korf H, 2012, IMMUNOBIOLOGY, V217, P1292, DOI 10.1016/j.imbio.2012.07.018; Kraus AU, 2018, J STEROID BIOCHEM, V177, P53, DOI 10.1016/j.jsbmb.2017.07.026; Kraus AU, 2019, J CLIN ENDOCR METAB, V104, P1907, DOI 10.1210/jc.2018-01621; Luger TA, 2008, DERMATOLOGY, V217, P321, DOI 10.1159/000155642; Luopajarvi K, 2007, IMMUNOLOGY, V121, P189, DOI 10.1111/j.1365-2567.2007.02557.x; MANOLAGAS SC, 1986, J CLIN ENDOCR METAB, V63, P394, DOI 10.1210/jcem-63-2-394; Mauf S, 2015, J STEROID BIOCHEM, V147, P17, DOI 10.1016/j.jsbmb.2014.11.001; Miettinen ME, 2017, EUR J CLIN NUTR, V71, P128, DOI 10.1038/ejcn.2016.160; Moran-Auth Y, 2015, J STEROID BIOCHEM, V148, P184, DOI 10.1016/j.jsbmb.2015.01.003; Nilsson AG, 2014, EUR J ENDOCRINOL, V171, P369, DOI 10.1530/EJE-14-0327; Ongagna JC, 2001, CLIN BIOCHEM, V34, P59, DOI 10.1016/S0009-9120(00)00197-1; Pedersen AW, 2009, CLIN EXP IMMUNOL, V157, P48, DOI 10.1111/j.1365-2249.2009.03961.x; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Ramos-Lopez E, 2007, J STEROID BIOCHEM, V103, P807, DOI 10.1016/j.jsbmb.2006.12.056; RIGBY WFC, 1990, BLOOD, V76, P189, DOI 10.1182/blood.V76.1.189.bloodjournal761189; Rose K, 2013, CLIN EXP IMMUNOL, V171, P171, DOI 10.1111/cei.12013; Scherberich JE, 2005, EUR J MED RES, V10, P179; Skinningsrud B, 2011, J CLIN ENDOCR METAB, V96, pE1703, DOI 10.1210/jc.2011-0645; TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Wolden-Kirk H, 2014, ENDOCRINOLOGY, V155, P736, DOI 10.1210/en.2013-1409; Zella JB, 2003, ARCH BIOCHEM BIOPHYS, V417, P77, DOI 10.1016/S0003-9861(03)00338-2; Zhang Y, 2013, J BIOL CHEM, V288, P14544, DOI 10.1074/jbc.M112.427054; Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006	45	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2020	11								583709	10.3389/fimmu.2020.583709	http://dx.doi.org/10.3389/fimmu.2020.583709			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PH4SO	33365026	gold, Green Published			2022-12-18	WOS:000600404700001
J	Liu, YF; Xie, PF; Jiang, DS; Liu, J; Zhang, JG; Bian, TT; Shi, JH				Liu, Yifei; Xie, Pengfei; Jiang, Daishang; Liu, Jian; Zhang, Jianguo; Bian, Tingting; Shi, Jiahai			Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression	FRONTIERS IN IMMUNOLOGY			English	Article						ERLIN2; lung adenocarcinoma; prognosis; survival; tumor-infiltrating immune cells	CANCER; PROGNOSIS; AMPLICON; 8P11-12	Background Endoplasmic reticulum lipid raft-associated protein 2 (ERLIN2) is protein contained in the membrane of the endoplasmic reticulum. In lung adenocarcinoma (LUAD), the molecular function of ERLIN2 and the correlation between ERLIN2 and tumor-infiltrating immune cells have been unclear. The aim of our study was to determine the role of ERLIN2 in LUAD development to provide a better understanding of the molecular pathogenesis of this disease and identify new therapeutic targets for its treatment. Methods Immunohistochemistry, Western blotting, and real-time quantitative polymerase chain reaction were used to detect protein and mRNA levels of ERLIN2 in LUAD and adjacent normal tissues. Using the A549, H1299 cell line, ERLIN2-short hairpin RNA was applied to silence ERLIN2 to determine its role in LUAD cell proliferation and invasion. Based on mRNA expression of ERLIN2 from the Cancer Genome Atlas (TCGA) database, we identified ERLIN2-related protein-coding genes and analyzed the Kyoto Encyclopedia of Genes and Genomes pathway to explore its potential biological functions and determined the correlation between ERLIN2 and tumor-infiltrating immune cells. Results ERLIN2 was abnormally expressed in a variety of tumor tissues and is highly expressed in LUAD. This overexpression was associated with histological grade (P = 0.044), TNM stage (P = 0.01), and lymph node metastasis (P = 0.038). Patient overall survival was poorer with ERLIN2 overexpression. Downregulation of ERLIN2 inhibited LUAD cell proliferation and invasion in vitro. Based on mRNA expression of ERLIN2 from the TCGA database, 13 ERLIN2-related genes and 10 pathways were identified and showed a correlation between ERLIN2 and naive B cells and neutrophils. Conclusion ERLIN2 could serve as a potential diagnostic and prognostic biomarker for LUAD and has demonstrated to be correlated with immune infiltrates, which suggests that it may represent a new therapeutic target for LUAD.	[Liu, Yifei; Zhang, Jianguo; Bian, Tingting] Nantong Univ, Affiliated Hosp, Dept Pathol, Nantong, Peoples R China; [Liu, Yifei] Nantong Univ, Med Sch, Nantong, Peoples R China; [Xie, Pengfei] Nantong Univ, Affiliated Tumor Hosp, Dept Thorac Surg, Nantong, Peoples R China; [Jiang, Daishang] Nantong Univ, Affiliated Hosp, Dept Emergency Med, Nantong, Peoples R China; [Liu, Jian] Nantong Univ, Affiliated Hosp, Dept Chemotherapy, Nantong, Peoples R China; [Shi, Jiahai] Nantong Univ, Affiliated Hosp, Dept Cardiothorac Surg, Nantong, Peoples R China	Nantong University; Nantong University; Nantong University; Nantong University; Nantong University; Nantong University	Bian, TT (corresponding author), Nantong Univ, Affiliated Hosp, Dept Pathol, Nantong, Peoples R China.; Shi, JH (corresponding author), Nantong Univ, Affiliated Hosp, Dept Cardiothorac Surg, Nantong, Peoples R China.	ntdxbiantingting@sina.com; ntshijiahai0513@163.com		, liu/0000-0002-4571-2226; Bian, Tingting/0000-0001-5577-9216	Key Scientific and Technological Projects in Nantong City, Jiangsu, China [MS22019015]; Nantong Municipal Science and Technology Project [MSZ19164]; Jiangsu Post-doctoral Foundation Research Project, China [2019Z142]; Key Talents of Medical Science in J iangsu Province, China [QNRC2016682]; Nantong University Clinical Medicine Special Clinical Basic Research Youth Project [2019JQ001]	Key Scientific and Technological Projects in Nantong City, Jiangsu, China; Nantong Municipal Science and Technology Project; Jiangsu Post-doctoral Foundation Research Project, China; Key Talents of Medical Science in J iangsu Province, China; Nantong University Clinical Medicine Special Clinical Basic Research Youth Project	This study was funded by grants from the Key Scientific and Technological Projects in Nantong City, Jiangsu, China (MS22019015), Nantong Municipal Science and Technology Project (No. MSZ19164), Jiangsu Post-doctoral Foundation Research Project, China (No. 2019Z142), Key Talents of Medical Science in J iangsu Province, China (No. QNRC2016682), and Nantong University Clinical Medicine Special Clinical Basic Research Youth Project (No. 2019JQ001).	Barta JA, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2419; Bian TT, 2019, EXP THER MED, V17, P3317, DOI 10.3892/etm.2019.7370; Bian TT, 2017, BIOCHEM BIOPH RES CO, V492, P461, DOI 10.1016/j.bbrc.2017.08.074; Camidge DR, 2019, NAT REV CLIN ONCOL, V16, P341, DOI 10.1038/s41571-019-0173-9; Cao MM, 2019, THORAC CANCER, V10, P3, DOI 10.1111/1759-7714.12916; Carbone DP, 2015, J THORAC ONCOL, V10, P974, DOI 10.1097/JTO.0000000000000551; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Itoh H, 2015, J LEUKOCYTE BIOL, V98, P107, DOI 10.1189/jlb.4A0813-422RRR; Jung CY, 2018, TUBERC RESPIR DIS, V81, P29, DOI 10.4046/trd.2017.0120; Kargl J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14381; Li JH, 2019, J CANCER, V10, P4208, DOI 10.7150/jca.33457; Li W, 2020, ONCOTARGETS THER, V13, P323, DOI 10.2147/OTT.S226770; Liu J, 2018, CANCER SCI, V109, P289, DOI 10.1111/cas.13452; Muppa P, 2019, J THORAC ONCOL, V14, P1286, DOI 10.1016/j.jtho.2019.03.028; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pearce MMP, 2009, J BIOL CHEM, V284, P10433, DOI 10.1074/jbc.M809801200; Rinchai D, 2015, AUTOPHAGY, V11, P748, DOI 10.1080/15548627.2015.1040969; Ru BB, 2019, BIOINFORMATICS, V35, P4200, DOI 10.1093/bioinformatics/btz210; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teixido C, 2017, J THORAC DIS, V9, pE468, DOI 10.21037/jtd.2017.04.55; Wang GH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-225; Wang GH, 2012, BIOCHEM J, V446, P415, DOI 10.1042/BJ20112050; Wang S, 2019, CURR DRUG TARGETS, V20, P1180, DOI 10.2174/1389450120666190402145325; Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yildirim Y, 2011, HUM MOL GENET, V20, P1886, DOI 10.1093/hmg/ddr070; Zhang J, 2019, J THORAC ONCOL, V14, pE102, DOI 10.1016/j.jtho.2018.12.037; Zhang XB, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.24	30	1	1	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2020	11								568440	10.3389/fimmu.2020.568440	http://dx.doi.org/10.3389/fimmu.2020.568440			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PH4OS	33424830	gold, Green Published			2022-12-18	WOS:000600394700001
J	Yadav, RM; Gupta, M; Dalvi, A; Bargir, UA; Hule, G; Shabrish, S; Aluri, J; Kulkarni, M; Kambli, P; Uppuluri, R; Seshadri, S; Jagadeesh, S; Suresh, B; Raja, J; Taur, P; Malaischamy, S; Ghosh, P; Mahalingam, S; Kadam, P; Lashkari, HP; Tamhankar, P; Tamhankar, V; Mithbawkar, S; Bhattad, S; Jhawar, P; Makam, A; Bansal, V; Prasad, M; Govindaraj, G; Guhan, B; Tallapaka, KB; Desai, M; Raj, R; Madkaikar, MR				Yadav, Reetika Malik; Gupta, Maya; Dalvi, Aparna; Bargir, Umair Ahmed; Hule, Gouri; Shabrish, Snehal; Aluri, Jahnavi; Kulkarni, Manasi; Kambli, Priyanka; Uppuluri, Ramya; Seshadri, Suresh; Jagadeesh, Sujatha; Suresh, Beena; Raja, Jayarekha; Taur, Prasad; Malaischamy, Sivasankar; Ghosh, Priyanka; Mahalingam, Shweta; Kadam, Priya; Lashkari, Harsha Prasada; Tamhankar, Parag; Tamhankar, Vasundhara; Mithbawkar, Shilpa; Bhattad, Sagar; Jhawar, Prerna; Makam, Adinarayan; Bansal, Vandana; Prasad, Malathi; Govindaraj, Geeta; Guhan, Beena; Bharadwaj Tallapaka, Karthik; Desai, Mukesh; Raj, Revathi; Madkaikar, Manisha Rajan			Prenatal Diagnosis for Primary Immunodeficiency Disorders-An Overview of the Indian Scenario	FRONTIERS IN IMMUNOLOGY			English	Article						prenatal diagnosis; chorionic villus sampling; maternal contamination; cordocentesis; flow cytometry; variants of unknown significance		Prenatal Diagnosis (PND) forms an important part of primary preventive management for families having a child affected with primary immunodeficiency. Although individually sparse, collectively this group of genetic disorders represents a significant burden of disease. This paper discusses the prenatal services available for affected families at various centers across the country and the challenges and ethical considerations associated with genetic counseling. Mutation detection in the index case and analysis of chorionic villous sampling or amniocentesis remain the preferred procedures for PND and phenotypic analysis of cordocentesis sample is reserved for families with well-characterized index case seeking PND in the latter part of the second trimester of pregnancy. A total of 112 families were provided PND services in the last decade and the presence of an affected fetus was confirmed in 32 families. Post-test genetic counseling enabled the affected families to make an informed decision about the current pregnancy.	[Yadav, Reetika Malik; Gupta, Maya; Dalvi, Aparna; Bargir, Umair Ahmed; Hule, Gouri; Shabrish, Snehal; Aluri, Jahnavi; Kulkarni, Manasi; Kambli, Priyanka; Madkaikar, Manisha Rajan] Natl Inst Immunohaematol, ICMR, Dept Pediat Immunol & Leucocyte Biol, Ctr Excellence PIDs, Mumbai, Maharashtra, India; [Uppuluri, Ramya; Raj, Revathi] Apollo Hosp, Blood Marrow Transplantat, Dept Pediat Hematol Oncol, Chennai, Tamil Nadu, India; [Seshadri, Suresh; Jagadeesh, Sujatha; Suresh, Beena; Raja, Jayarekha] Mediscan Syst, Dept Clin Genet & Genet Counseling, Chennai, Tamil Nadu, India; [Taur, Prasad; Desai, Mukesh] Bai Jerbai Wadia Hosp Children, Dept Immunol, Mumbai, Maharashtra, India; [Taur, Prasad; Desai, Mukesh] Bai Jerbai Wadia Hosp Children, Dept Pediat Hematooncol, Mumbai, Maharashtra, India; [Malaischamy, Sivasankar; Ghosh, Priyanka; Mahalingam, Shweta; Kadam, Priya] MedGenome Labs Private Ltd, Bangalore, Karnataka, India; [Lashkari, Harsha Prasada] Kasturba Med Coll Hosp, Manipal Acad Higher Educ, Dept Pediat, Mangalore, India; [Tamhankar, Parag; Tamhankar, Vasundhara; Mithbawkar, Shilpa] Ctr Med Genet, Mumbai, Maharashtra, India; [Bhattad, Sagar] Aster CMI Hosp, Dept Pediat, Div Pediat Immunol & Rheumatol, Bangalore, Karnataka, India; [Jhawar, Prerna] Motherhood Hosp, Dept Fetal Med, Bangalore, Karnataka, India; [Makam, Adinarayan] Adi Adv Ctr Fetal Care, Dept Fetal Med, Bangalore, Karnataka, India; [Bansal, Vandana] Surya Hosp, Fetal Med Dept, Mumbai, Maharashtra, India; [Prasad, Malathi] Fetal Med Ctr, Trichy, India; [Govindaraj, Geeta; Guhan, Beena] Govt Med Coll, Dept Pediat, Calicut, Kerala, India; [Bharadwaj Tallapaka, Karthik] CCMB, CSIR, Ctr Cellular & Mol Biol, Hyderabad, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Immunohaemotology (NIIH); Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Mangalore; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Madkaikar, MR (corresponding author), Natl Inst Immunohaematol, ICMR, Dept Pediat Immunol & Leucocyte Biol, Ctr Excellence PIDs, Mumbai, Maharashtra, India.	madkaikarmanisha@gmail.com	Bargir, Umair Ahmed/AAR-4202-2020; Aluri, Jahnavi/AAB-3570-2022	Bargir, Umair Ahmed/0000-0001-6785-8042; shabrish, snehal/0000-0002-6407-5082; Yadav`, Reetika/0000-0002-5030-0437; Mahalingam, Shweta/0000-0001-8373-3848; Lashkari, Harsha prasada/0000-0002-6398-6546	Indian Council of Medical Research (ICMR), New Delhi, India [61/02/2012/IMM/BMS]	Indian Council of Medical Research (ICMR), New Delhi, India(Indian Council of Medical Research (ICMR))	We thankfully acknowledge Foundation for Primary Immunodeficiencies, USA for providing a platform to collate and present the data regarding prenatal services for PID in India. We acknowledge Indian Council of Medical Research (ICMR), New Delhi, India for funding the Centre of Excellence in PID (vide Grant No.61/02/2012/IMM/BMS). However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amendola LM, 2015, PERS MED, V12, P283, DOI 10.2217/PME.14.89; Chiu RWK, 2013, CLIN CHEM LAB MED, V51, P197, DOI 10.1515/cclm-2012-0601; Colah R B, 2011, Indian J Med Res, V134, P552; Delmonte OM, 2018, J CLIN IMMUNOL, V38, P646, DOI 10.1007/s10875-018-0537-4; GATES EA, 1993, WESTERN J MED, V159, P391; Ghi T, 2016, ULTRASOUND OBST GYN, V48, P26, DOI [10.1002/uog.15945, 10.1002/uog.15969]; Government of India International Institute for Population Sciences (IIPS) and ICF, 2022, NATL FAMILY HLTH SUR; Harris S, 2018, PRENATAL DIAG, V38, P897, DOI 10.1002/pd.5353; Madkaikar MR, 2012, INDIAN J PEDIATR, V79, P1605, DOI 10.1007/s12098-012-0737-5; Massa JD, 2020, J FETAL MED, V7, P9, DOI 10.1007/s40556-019-00228-4; Mellis R, 2018, EXPERT REV MOL DIAGN, V18, P689, DOI 10.1080/14737159.2018.1493924; Milunsky A, 1998, ETHICS PRENATAL DIAG, P999; Mishra A, 2014, J CLIN IMMUNOL, V34, P316, DOI 10.1007/s10875-014-9993-7; Parchure DS, 2016, GJTM, V1, P21; Rao T S Sathyanarayana, 2009, Indian J Psychiatry, V51, P3, DOI 10.4103/0019-5545.44897; Salomon LJ, 2019, ULTRASOUND OBST GYN, V54, P442, DOI 10.1002/uog.20353; Sigmon Justin R, 2008, Clin Mol Allergy, V6, P5, DOI 10.1186/1476-7961-6-5; Soheilirad Z, 2020, EGYPTIAN J MED HUMAN, V21, DOI 10.1186/s43042-020-0049-7; Stapleton G, 2017, MED HEALTH CARE PHIL, V20, P195, DOI 10.1007/s11019-016-9725-2; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Uppuluri R, 2019, J CLIN IMMUNOL, V39, P182, DOI 10.1007/s10875-019-00600-z; Verma IC, 2014, J FETAL MED, V1, P113, DOI 10.1007/s40556-014-0025-8; Vora NL, 2018, GENET MED, V20, P791, DOI 10.1038/s41436-018-0087-4; YANG WC, 2015, GENET MOL RES, V14, DOI DOI 10.4238/2015; Yenilmez ED, 2016, SICKLE CELL DISEASE - PAIN AND COMMON CHRONIC COMPLICATIONS, P39, DOI 10.5772/64646	25	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2020	11								612316	10.3389/fimmu.2020.612316	http://dx.doi.org/10.3389/fimmu.2020.612316			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PH4PH	33365035	gold, Green Published			2022-12-18	WOS:000600396200001
J	Ko, MK; Shao, H; Kaplan, HJ; Sun, DM				Ko, MinHee K.; Shao, Hui; Kaplan, Henry J.; Sun, Deming			CD73(+) Dendritic Cells in Cascading Th17 Responses of Experimental Autoimmune Uveitis-Induced Mice	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; adenosine receptors; bone marrow dendritic cells; bone marrow culture dendritic cells; CD73; experimental autoimmune uveitis; &#947; &#948; T cells; uveitis	A(2A) ADENOSINE RECEPTORS; T-CELLS; EXTRACELLULAR ATP; IMMUNOSUPPRESSIVE ACTIVITY; INTERNATIONAL UNION; VASCULAR LEAKAGE; EXPRESSION; ACTIVATION; GENERATION; PROMOTES	Previous studies have shown that CD73 is pivotal in the conversion of pro-inflammatory adenosine triphosphate into anti-inflammatory adenosine and that immune cells of the same type that express different levels of CD73 are functionally distinct. In this study we show that adenosine enhances the Th17 promoting effect of dendritic cells (DCs), and DCs expressing CD73 critically augment Th17 responses. Bone marrow dendritic cells (BMDCs) do not constantly express CD73; however, a significant portion of the BMDCs expressed CD73 after exposure to Toll-like receptor ligand, leading to stronger Th17 responses by converting adenosine monophosphate to adenosine. We show that the CD73(+) BMDCs play a critical role in cascading Th17 responses, and CD73(+) BMDCs are functionally augmented after treatment with Toll-like receptor ligand. Splenic antigen presenting cells (DCs) of CD73(-/-) mouse have a poor Th17-stimulating effect, even after exposure to lipopolysaccharide (LPS) or gamma delta T cells, indicating that induction of CD73(+) DCs is critically involved in augmented Th17 responses. We conclude that CD73(+) DCs critically trigger cascading Th17 responses, and the activated Th17 cells that express CD73 further augment Th17 responses, leading to cascading exacerbation. Hence, disabling the CD73 function of DCs should block this cascading response and mitigate Th17 responses.	[Ko, MinHee K.; Sun, Deming] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA; [Ko, MinHee K.; Sun, Deming] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA; [Shao, Hui] Univ Louisville, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40292 USA; [Kaplan, Henry J.] St Louis Univ SLU, SLU Sch Med, Dept Ophthalmol, Eye Inst, St Louis, MO USA	Doheny Eye Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Louisville	Sun, DM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.; Sun, DM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.	dsun@doheny.org			NIH [EY0022403, EY018827]; Research to Prevent Blindness, NYC	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness, NYC(Research to Prevent Blindness (RPB))	This work was supported by NIH grants EY0022403 and EY018827 and grant from for Research to Prevent Blindness, NYC.	Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Beavis PA, 2012, TRENDS IMMUNOL, V33, P231, DOI 10.1016/j.it.2012.02.009; Beigi RD, 2003, BRIT J PHARMACOL, V140, P507, DOI 10.1038/sj.bjp.0705470; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Bouguermouh S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005087; Canaday DH, 2002, INFECT IMMUN, V70, P6456, DOI 10.1128/IAI.70.11.6456-6459.2002; Chalmin F, 2012, IMMUNITY, V36, P362, DOI 10.1016/j.immuni.2011.12.019; Conter LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092009; Csoka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Desrosiers MD, 2007, J IMMUNOL, V179, P1884, DOI 10.4049/jimmunol.179.3.1884; Doherty GA, 2012, EUR J IMMUNOL, V42, P3062, DOI 10.1002/eji.201242623; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Ehrentraut H, 2013, FASEB J, V27, P2207, DOI 10.1096/fj.12-225201; Ehrentraut H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032416; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Fedele G, 2005, INFECT IMMUN, V73, P1590, DOI 10.1128/IAI.73.3.1590-1597.2005; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Hoskin DW, 2008, INT J ONCOL, V32, P527; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Jin DC, 2010, CANCER RES, V70, P2245, DOI 10.1158/0008-5472.CAN-09-3109; Kiss J, 2007, EUR J IMMUNOL, V37, P3334, DOI 10.1002/eji.200737793; Lappas CM, 2005, EXPERT OPIN INV DRUG, V14, P797, DOI 10.1517/13543784.14.7.797; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Liang DC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150078; Liang DC, 2015, IMMUN INFLAMM DIS, V3, P360, DOI 10.1002/iid3.74; Liang DC, 2014, J IMMUNOL, V193, P5498, DOI 10.4049/jimmunol.1401959; Liang DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108932; Liang DC, 2013, J IMMUNOL, V191, P1118, DOI 10.4049/jimmunol.1300626; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mahamed DA, 2015, INFECT IMMUN, V83, P721, DOI 10.1128/IAI.02536-14; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mills JH, 2008, P NATL ACAD SCI USA, V105, P9325, DOI 10.1073/pnas.0711175105; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Nian H, 2011, INVEST OPHTH VIS SCI, V52, P5920, DOI 10.1167/iovs.10-6758; Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood-2008-02-136325; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Peng Y, 2007, INVEST OPHTH VIS SCI, V48, P4153, DOI 10.1167/iovs.07-0251; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Ryzhov S, 2011, J IMMUNOL, V187, P6120, DOI 10.4049/jimmunol.1101225; Sauer AV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00265; Sciaraffia E, 2014, J LEUKOCYTE BIOL, V96, P113, DOI 10.1189/jlb.3A0513-302RR; Silva-Vilches C, 2019, J INVEST DERMATOL, V139, P541, DOI 10.1016/j.jid.2018.10.016; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Smyth LA, 2013, EUR J IMMUNOL, V43, P2430, DOI 10.1002/eji.201242909; Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; Wilkin F, 2001, J IMMUNOL, V166, P7172, DOI 10.4049/jimmunol.166.12.7172; Yegutkin GG, 2015, EUR J IMMUNOL, V45, P562, DOI 10.1002/eji.201444856; Yegutkin GG, 2011, EUR J IMMUNOL, V41, P1231, DOI 10.1002/eji.201041292; Zanin RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031205; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646	71	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 2	2020	11								601272	10.3389/fimmu.2020.601272	http://dx.doi.org/10.3389/fimmu.2020.601272			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PF1SC	33343573	gold, Green Published			2022-12-18	WOS:000598841500001
J	Ikuta, K; Scheiermann, C				Ikuta, Koichi; Scheiermann, Christoph			Editorial: Circadian Control of Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						circadian immunity; innate immunity; adaptive immunity; leukocyte migration; control of circadian immunity	CLOCK		[Ikuta, Koichi] Kyoto Univ, Inst Frontier Life & Med Sci, Lab Immune Regulat, Kyoto, Japan; [Scheiermann, Christoph] Univ Geneva, Fac Med, Dept Pathol & Immunol, Geneva, Switzerland; [Scheiermann, Christoph] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Physiol & Pathophysiol, Fac Med, Biomed Ctr, Planegg Martinsried, Germany; [Scheiermann, Christoph] Ludwig Maximilians Univ Munchen, Univ Hosp, Walter Brendel Ctr Expt Med, Munich, Germany	Kyoto University; University of Geneva; University of Munich; University of Munich	Ikuta, K (corresponding author), Kyoto Univ, Inst Frontier Life & Med Sci, Lab Immune Regulat, Kyoto, Japan.; Scheiermann, C (corresponding author), Univ Geneva, Fac Med, Dept Pathol & Immunol, Geneva, Switzerland.; Scheiermann, C (corresponding author), Ludwig Maximilians Univ Munchen, Inst Cardiovasc Physiol & Pathophysiol, Fac Med, Biomed Ctr, Planegg Martinsried, Germany.; Scheiermann, C (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Walter Brendel Ctr Expt Med, Munich, Germany.	ikuta.koichi.6c@kyoto-u.ac.jp; christoph.scheiermann@unige.ch	Scheiermann, Christoph/B-8261-2014	Scheiermann, Christoph/0000-0002-9212-0995	Japan Society for the Promotion of Science (JSPS) KAKENHI [20K21525, 18K15184]; Swiss National Science Foundation (SNF) [310030_182417]	Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF))	Work in KI's lab is supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers 20K21525 and 18K15184. Work in CS's lab is supported by the Swiss National Science Foundation (SNF, 310030_182417).	Adrover JM, 2019, IMMUNITY, V50, P390, DOI 10.1016/j.immuni.2019.01.002; FERNANDES G, 1976, J IMMUNOL, V117, P962; Gibbs J, 2014, NAT MED, V20, P919, DOI 10.1038/nm.3599; Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109; HALBERG F, 1960, P SOC EXP BIOL MED, V103, P142; Keller M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI 10.1073/pnas.0906361106; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Pourcet B, 2018, GASTROENTEROLOGY, V154, P1449, DOI 10.1053/j.gastro.2017.12.019; Scheiermann C, 2012, IMMUNITY, V37, P290, DOI 10.1016/j.immuni.2012.05.021; Shimba A, 2018, IMMUNITY, V48, P286, DOI 10.1016/j.immuni.2018.01.004; Spoelstra K, 2016, P NATL ACAD SCI USA, V113, P686, DOI 10.1073/pnas.1516442113; Suzuki K, 2016, J EXP MED, V213, P2567, DOI 10.1084/jem.20160723; Thaiss CA, 2014, CELL, V159, P514, DOI 10.1016/j.cell.2014.09.048; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660	14	1	1	14	27	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								618843	10.3389/fimmu.2020.618843	http://dx.doi.org/10.3389/fimmu.2020.618843			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE1KR	33329614	Green Published, gold			2022-12-18	WOS:000598130600001
J	Kuo, CJ; Hsu, YC; Wang, ST; Liou, BY; Lim, SBY; Chen, YW; Chen, CS				Kuo, Cheng-Ju; Hsu, Ya-Chu; Wang, Sin-Tian; Liou, Bang-Yu; Lim, Serene Boon-Yuean; Chen, Yi-Wei; Chen, Chang-Shi			IGLR-2, a Leucine-Rich Repeat Domain Containing Protein, Is Required for the Host Defense in Caenorhabditis elegans	FRONTIERS IN IMMUNOLOGY			English	Article						Caenorhabditis elegans; iglr-2; innate immunity; p38 MAPK pathway; enterohemorrhagic Escherichia coli	C. ELEGANS; INNATE IMMUNITY; ACTIVATION; INFECTION; SUSCEPTIBILITY; RECOGNITION; EVOLUTION; REVEALS; TOXIN	Enterohemorrhagic Escherichia coli (EHEC), a human pathogen, also infects Caenorhabditis elegans. We demonstrated previously that C. elegans activates the p38 MAPK innate immune pathway to defend against EHEC infection. However, whether a C. elegans pattern recognition receptor (PRR) exists to regulate the immune pathway remains unknown. PRRs identified in other metazoans contain several conserved domains, including the leucine-rich repeat (LRR). By screening a focused RNAi library, we identified the IGLR-2, a transmembrane protein containing the LRR domain, as a potential immune regulator in C. elegans. Our data showed that iglr-2 regulates the host susceptibility to EHEC infection. Moreover, iglr-2 is required for pathogen avoidance to EHEC. The iglr-2 overexpressed strain, which was more resistant to EHEC originally, showed hypersusceptibility to EHEC upon knockdown of the p38 MAPK pathway. Together, our data suggested that iglr-2 plays an important role in C. elegans to defend EHEC by regulating pathogen-avoidance behavior and the p38 MAPK pathway.	[Kuo, Cheng-Ju; Hsu, Ya-Chu; Liou, Bang-Yu; Lim, Serene Boon-Yuean; Chen, Chang-Shi] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan; [Kuo, Cheng-Ju; Wang, Sin-Tian; Chen, Yi-Wei; Chen, Chang-Shi] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University	Kuo, CJ; Chen, CS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan.; Kuo, CJ; Chen, CS (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.	chengjukuo@gmail.com; cschen@mail.ncku.edu.tw	Chen, Chang-Shi/B-9251-2009	Chen, Chang-Shi/0000-0002-8201-3635; Kuo, Cheng-Ju/0000-0002-2774-5948	Ministry of Science and Technology (MOST) [106-2321-B-006-005-and 107-2628-B-006-003-]	Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China)	This work is supported by the Ministry of Science and Technology (MOST) grants (106-2321-B-006-005-and 107-2628-B-006-003-) to C-SC. The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Aballay A, 2003, CURR BIOL, V13, P47, DOI 10.1016/S0960-9822(02)01396-9; Alper S, 2007, MOL CELL BIOL, V27, P5544, DOI 10.1128/MCB.02070-06; Altincicek B, 2010, DEV COMP IMMUNOL, V34, P1160, DOI 10.1016/j.dci.2010.06.010; Bodhicharla R, 2018, GENETICS, V210, P189, DOI 10.1534/genetics.118.301272; Boller T, 2009, ANNU REV PLANT BIOL, V60, P379, DOI 10.1146/annurev.arplant.57.032905.105346; Boulin Thomas, 2006, WormBook, P1, DOI 10.1895/wormbook.1.106.1; Brandt JP, 2015, CURR BIOL, V25, P2228, DOI 10.1016/j.cub.2015.07.037; BRENNER S, 1974, GENETICS, V77, P71; Ceron J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-30; Chang HC, 2011, NATURE, V480, P525, DOI 10.1038/nature10643; Cheesman HK, 2016, G3-GENES GENOM GENET, V6, P541, DOI 10.1534/g3.115.025650; Chen HD, 2017, AUTOPHAGY, V13, P371, DOI 10.1080/15548627.2016.1256933; Chou TC, 2013, CELL MICROBIOL, V15, P82, DOI 10.1111/cmi.12030; Clark LC, 2014, CELL MICROBIOL, V16, P27, DOI 10.1111/cmi.12234; Couillault C, 2004, NAT IMMUNOL, V5, P488, DOI 10.1038/ni1060; Dasgupta M, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00130-20; Dickinson DJ, 2013, NAT METHODS, V10, P1028, DOI 10.1038/NMETH.2641; Dixon SJ, 2006, DEVELOPMENT, V133, P1263, DOI 10.1242/dev.02300; Engelmann I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019055; Ewbank JJ, 2016, CURR OPIN IMMUNOL, V38, P1, DOI 10.1016/j.coi.2015.09.005; Friedland AE, 2013, NAT METHODS, V10, P741, DOI 10.1038/nmeth.2532; Gotenstein JR, 2010, DEVELOPMENT, V137, P3603, DOI 10.1242/dev.049189; He YX, 2018, J CELL SCI, V131, DOI 10.1242/jcs.209353; Irazoqui JE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000982; Irazoqui JE, 2010, NAT REV IMMUNOL, V10, P47, DOI 10.1038/nri2689; Kadandale Pavan, 2009, V518, P123, DOI 10.1007/978-1-59745-202-1_10; Kaji H, 2007, MOL CELL PROTEOMICS, V6, P2100, DOI 10.1074/mcp.M600392-MCP200; Kim YK, 2016, YONSEI MED J, V57, P5, DOI 10.3349/ymj.2016.57.1.5; Kuo CJ, 2018, AUTOPHAGY, V14, P233, DOI 10.1080/15548627.2017.1389824; Kuo CJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0423-2; Kuo CJ, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00082; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Ohto U, 2014, MICROBES INFECT, V16, P273, DOI 10.1016/j.micinf.2014.01.007; Peel N, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006543; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Pukkila-Worley R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002733; Pukkila-Worley R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002074; Reddy KC, 2009, SCIENCE, V323, P382, DOI 10.1126/science.1166527; Schulenburg H, 2004, IMMUNOL REV, V198, P36, DOI 10.1111/j.0105-2896.2004.0125.x; Schulenburg H, 2008, IMMUNOBIOLOGY, V213, P237, DOI 10.1016/j.imbio.2007.12.004; Selfors LM, 1998, P NATL ACAD SCI USA, V95, P6903, DOI 10.1073/pnas.95.12.6903; Sim S, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0624-8; Sowa JN, 2020, J VIROL, V94, DOI 10.1128/JVI.01173-19; Stuart LM, 2013, NAT REV IMMUNOL, V13, P199, DOI 10.1038/nri3398; Svensk E., 2016, WORM, V5, DOI DOI 10.1080/21624054.2016.1206171; Svensk E, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005982; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Twumasi-Boateng K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035400; Valanne S, 2011, J IMMUNOL, V186, P649, DOI 10.4049/jimmunol.1002302; Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316; Wang XD, 2019, FISH SHELLFISH IMMUN, V88, P318, DOI 10.1016/j.fsi.2019.03.003; Williams AB, 2019, GENETICS, V212, P1259, DOI 10.1534/genetics.119.302422; Wong D, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r194; Zanetti S, 2011, DEV BIOL, V354, P232, DOI 10.1016/j.ydbio.2011.04.001; Zhong Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00333	56	1	1	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								561337	10.3389/fimmu.2020.561337	http://dx.doi.org/10.3389/fimmu.2020.561337			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE1XL	33329523	gold, Green Published			2022-12-18	WOS:000598163900001
J	Lumbroso, D; Soboh, S; Maimon, A; Schif-Zuck, S; Ariel, A; Burstyn-Cohen, T				Lumbroso, Delphine; Soboh, Soaad; Maimon, Avi; Schif-Zuck, Sagie; Ariel, Amiram; Burstyn-Cohen, Tal			Macrophage-Derived Protein S Facilitates Apoptotic Polymorphonuclear Cell Clearance by Resolution Phase Macrophages and Supports Their Reprogramming (vol 9, 358, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						inflammation; macrophages; protein S; PROS1; apoptosis; efferocytosis			[Lumbroso, Delphine; Soboh, Soaad; Schif-Zuck, Sagie; Ariel, Amiram] Univ Haifa, Dept Biol, Fac Nat Sci, Haifa, Israel; [Lumbroso, Delphine; Maimon, Avi; Burstyn-Cohen, Tal] Hebrew Univ Jerusalem, Inst Dent Sci, Hadassah Med Sch, Fac Med Dent, Jerusalem, Israel	University of Haifa; Hebrew University of Jerusalem	Ariel, A (corresponding author), Univ Haifa, Dept Biol, Fac Nat Sci, Haifa, Israel.; Burstyn-Cohen, T (corresponding author), Hebrew Univ Jerusalem, Inst Dent Sci, Hadassah Med Sch, Fac Med Dent, Jerusalem, Israel.	amiram@research.haifa.ac.il; talbu@mail.huji.ac.il		Schif-Zuck, Sagie/0000-0001-5415-9488				Lumbroso D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00358	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								412281	10.3389/fimmu.2020.412281	http://dx.doi.org/10.3389/fimmu.2020.412281			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE2VC	33329508	Green Published, gold			2022-12-18	WOS:000598225600001
J	Sindher, S; Long, AJ; Purington, N; Chollet, M; Slatkin, S; Andorf, S; Tupa, D; Kumar, D; Woch, MA; O'Laughlin, KL; Assaad, A; Pongracic, J; Spergel, JM; Tam, J; Tilles, S; Wang, JL; Galli, SJ; Nadeau, KC; Chinthrajah, RS				Sindher, Sayantani; Long, Andrew J.; Purington, Natasha; Chollet, Madeleine; Slatkin, Sara; Andorf, Sandra; Tupa, Dana; Kumar, Divya; Woch, Margaret A.; O'Laughlin, Katherine L.; Assaad, Amal; Pongracic, Jacqueline; Spergel, Jonathan M.; Tam, Jonathan; Tilles, Stephen; Wang, Julie; Galli, Stephen J.; Nadeau, Kari C.; Chinthrajah, R. Sharon			Analysis of a Large Standardized Food Challenge Data Set to Determine Predictors of Positive Outcome Across Multiple Allergens (vol 9, 2689, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						food challenge; cumulative tolerated dose; AUC; biomarker evaluation; time-dependent ROC			[Sindher, Sayantani; Long, Andrew J.; Purington, Natasha; Andorf, Sandra; Tupa, Dana; Kumar, Divya; Woch, Margaret A.; O'Laughlin, Katherine L.; Galli, Stephen J.; Nadeau, Kari C.; Chinthrajah, R. Sharon] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Long, Andrew J.] Lucile Packard Childrens Hosp Stanford, Dept Pharm, Stanford, CA USA; [Chollet, Madeleine; Slatkin, Sara] Sch Med, Dept Med, Stanford, CA USA; [Assaad, Amal] Cincinnati Childrens Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Pongracic, Jacqueline] Ann & Robert H Lurie Childrens Hosp Chicago, Div Allergy & Immunol, Chicago, IL 60611 USA; [Spergel, Jonathan M.] Univ Penn, Childrens Hosp Philadelphia, Div Allergy & Immunol, Dept Pediat,Perelman Sch Med, Philadelphia, PA 19104 USA; [Tam, Jonathan] Childrens Hosp Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA 90027 USA; [Tilles, Stephen] Univ Washington, ASTHMA Inc, Clin Res Ctr, Northwest Asthma & Allergy Ctr, Seattle, WA 98195 USA; [Wang, Julie] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Galli, Stephen J.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Stanford University; Lucile Packard Children's Hospital (LPCH); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Children's Hospital Los Angeles; University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; Stanford University; Stanford University	Chinthrajah, RS (corresponding author), Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA.	schinths@stanford.edu						Sindher S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02689	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								625796	10.3389/fimmu.2020.625796	http://dx.doi.org/10.3389/fimmu.2020.625796			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE2VD	33329616	Green Published, gold			2022-12-18	WOS:000598225700001
J	Kinloch, AJ; Asano, Y; Mohsin, A; Henry, C; Abraham, R; Chang, A; Labno, C; Wilson, PC; Clark, MR				Kinloch, Andrew J.; Asano, Yuta; Mohsin, Azam; Henry, Carole; Abraham, Rebecca; Chang, Anthony; Labno, Christine; Wilson, Patrick C.; Clark, Marcus R.			Machine Learning to Quantify In Situ Humoral Selection in Human Lupus Tubulointerstitial Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						lupus nephritis; anti-vimentin antibodies; polyreactivity; antibody specificity; machine learning; image analysis; tubulointerstitial inflammation; antibody screening	DOUBLE-STRANDED DNA; VIMENTIN; AUTOANTIBODIES; ANTIBODIES; EXPRESSION	In human lupus nephritis, tubulointerstitial inflammation (TII) is associated with in situ expansion of B cells expressing anti-vimentin antibodies (AVAs). The mechanism by which AVAs are selected is unclear. Herein, we demonstrate that AVA somatic hypermutation (SHM) and selection increase affinity for vimentin. Indeed, germline reversion of several antibodies demonstrated that higher affinity AVAs can be selected from both low affinity B cell germline clones and even those that are strongly reactive with other autoantigens. While we demonstrated affinity maturation, enzyme-linked immunosorbent assays (ELISAs) suggested that affinity maturation might be a consequence of increasing polyreactivity or even non-specific binding. Therefore, it was unclear if there was also selection for increased specificity. Subsequent multi-color confocal microscopy studies indicated that while TII AVAs often appeared polyreactive by ELISA, they bound selectively to vimentin fibrils in whole cells or inflamed renal tissue. Using a novel machine learning pipeline (CytoSkaler) to quantify the cellular distribution of antibody staining, we demonstrated that TII AVAs were selected for both enhanced binding and specificity in situ. Furthermore, reversion of single predicted amino acids in antibody variable regions indicated that we could use CytoSkaler to capture both negative and positive selection events. More broadly, our data suggest a new approach to assess and define antibody polyreactivity based on quantifying the distribution of binding to native and contextually relevant antigens.	[Kinloch, Andrew J.; Asano, Yuta; Mohsin, Azam; Henry, Carole; Abraham, Rebecca; Wilson, Patrick C.; Clark, Marcus R.] Univ Chicago, Sect Rheumatol, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; [Kinloch, Andrew J.; Asano, Yuta; Mohsin, Azam; Henry, Carole; Abraham, Rebecca; Wilson, Patrick C.; Clark, Marcus R.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Chang, Anthony] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Labno, Christine] Univ Chicago, Light Microscopy Core, Chicago, IL 60637 USA; [Kinloch, Andrew J.] Eutrop Pharmaceut, New Platform Dev, Cambridge, MA USA; [Henry, Carole] Moderna, Infect Dis, Cambridge, MA USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Clark, MR (corresponding author), Univ Chicago, Sect Rheumatol, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA.; Clark, MR (corresponding author), Univ Chicago, Dept Med, Chicago, IL 60637 USA.	mclark@uchicago.edu	Wilson, Patrick/HGC-3157-2022	Mohsin, Azam/0000-0003-0021-3244; Asano, Yuta/0000-0002-4720-2238	NIH Autoimmunity Centers of Excellence [AI082724, AR55646]; DOD [LRI180083]	NIH Autoimmunity Centers of Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense)	NIH Autoimmunity Centers of Excellence (AI082724) and AR55646. DOD grant LRI180083.	AARDEN LA, 1975, ANN NY ACAD SCI, V254, P505, DOI 10.1111/j.1749-6632.1975.tb29197.x; Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522; Bilalic S, 2012, TRANSPL IMMUNOL, V27, P101, DOI 10.1016/j.trim.2012.06.006; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Chang A, 2011, J IMMUNOL, V186, P1849, DOI 10.4049/jimmunol.1001983; Clark MR, 2015, SEMIN NEPHROL, V35, P455, DOI 10.1016/j.semnephrol.2015.08.007; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Guo WZ, 2010, J EXP MED, V207, P2225, DOI 10.1084/jem.20092712; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Hsieh C, 2011, ARTHRIT CARE RES, V63, P865, DOI 10.1002/acr.20441; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Kaur K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125618; Kaur K, 2011, TRENDS IMMUNOL, V32, P524, DOI 10.1016/j.it.2011.08.007; Kavanaugh A, 2000, ARCH PATHOL LAB MED, V124, P71; Kinloch AJ, 2020, BIORXIV, DOI [10.1101/2020.06.29.178145v1, DOI 10.1101/2020.06.29.178145V1]; Kinloch AJ, 2020, LUPUS, V29, P569, DOI 10.1177/0961203320913606; Kinloch AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01516; Kinloch AJ, 2014, ARTHRITIS RHEUMATOL, V66, P3359, DOI 10.1002/art.38888; Liarski VM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008146; Makowski GS, 2003, ANN CLIN LAB SCI, V33, P142; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Pamfil C, 2018, ANN RHEUM DIS, V77, P1782, DOI 10.1136/annrheumdis-2018-213485; Shen Y, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/967584; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wellmann U, 2005, P NATL ACAD SCI USA, V102, P9258, DOI 10.1073/pnas.0500132102; Yurasov S, 2005, J EXP MED, V201, P703, DOI 10.1084/jem.20042251; Yurasov S, 2006, J EXP MED, V203, P2255, DOI 10.1084/jem.20061446	30	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2020	11								593177	10.3389/fimmu.2020.593177	http://dx.doi.org/10.3389/fimmu.2020.593177			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PD4EJ	33329582	Green Published, gold			2022-12-18	WOS:000597639600001
J	Lucas, CL; Tangye, SG				Lucas, Carrie L.; Tangye, Stuart G.			Editorial: Human Disorders of PI3K Biology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						PI3K; primary immunodeficiencies; Activated PI3K delta Syndrome; immunology; human genetics			[Lucas, Carrie L.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Tangye, Stuart G.] Garvan Inst Med Res, Immun & Inflammat Theme, Darlinghurst, NSW, Australia	Yale University; Garvan Institute of Medical Research	Lucas, CL (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.; Tangye, SG (corresponding author), Garvan Inst Med Res, Immun & Inflammat Theme, Darlinghurst, NSW, Australia.	carrie.lucas@yale.edu; s.tangye@garvan.org.au			Yale University; NIAID/NIH [R01AI138141, R21AI144315]; National Health and Medical Research Council of Australia	Yale University; NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	CLL was funded by Yale University and NIAID/NIH grants R01AI138141 and R21AI144315. SGT is supported by grants awarded by the National Health and Medical Research Council of Australia.		0	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2020	11								617464	10.3389/fimmu.2020.617464	http://dx.doi.org/10.3389/fimmu.2020.617464			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC2QU	33329612	gold, Green Published			2022-12-18	WOS:000596852500001
J	Cai, LL; Duan, JC; Qian, L; Wang, ZJ; Wang, SH; Li, SN; Wang, C; Zhao, J; Zhang, X; Bai, H; Wang, J				Cai, Liangliang; Duan, Jianchun; Qian, Li; Wang, Zhijie; Wang, Shuhang; Li, Sini; Wang, Chao; Zhao, Jie; Zhang, Xue; Bai, Hua; Wang, Jie			ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						PD-L1; ROS1 fusion; ROS1-G2032R mutation; non-small cell lung cancer; molecular targeted therapy; immunology checkpoint inhibitor therapy	B7-H1 EXPRESSION; OPEN-LABEL; DOCETAXEL; NIVOLUMAB; NSCLC; PEMBROLIZUMAB; ONCOGENES; ANTIBODY	The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable. Whether the administration of immune checkpoint inhibitor (ICI) therapy is suitable for ROS 1 fusion NSCLCs or after the development of crizotinib resistance is still unknown. In this study, five different crizotinib resistant concentration cell lines (HCC78CR1-5) from primary sensitive HCC78 cells were cultured. Ba/F3 cells expressing crizotinib sensitive ROS1 fusion and crizotinib resistant ROS1-G2032R mutation were used to explore the relationship between ROS1 fusion, ROS1-G2032R mutation and programmed death-ligand 1 (PD-L1) expression and the clinical potential of anti-PD-L1 ICI therapy. The signaling pathway net was compared between HCC78 and HCC78CR1-5 cells using RNA sequencing. Anti- PD-L1 ICI therapy was performed on mouse xenograft models with Ba/F3 ROS1 fusion or ROS1-G2032R mutation. HCC78CR1-5 showed more immunogenicity than HCC78 in immune-related pathways. The PD-L1 expression level was remarkably higher in HCC78CR1-5 with ROS1 fusion upregulation than HCC78 primary cell. Furthermore, the expression of PD-L1 was down-regulated by RNA interference with ROS1 siRNAs and up-regulated lower in Ba/F3 ROS1-G2032R resistant mutation than ROS1 fusion. Western blotting analysis showed the ROS1-SHP2 signaling pathway activation in HCC78CR1-5 cells, Ba/F3 ROS1 fusion and ROS1-G2032R resistant mutation. Mouse xenograft models with Ba/F3 ROS1 fusion showed more CD3+PD-1+ T cells both in blood and tissue, and more sensitivity than the cells with Ba/F3 ROS1-G2032R resistant mutation after anti-PD-L1 therapy. Our findings indicate that PD-L1 upregulation depends on ROS1 fusion more than ROS1-G2032R mutation. We share our insights of NSCLCs treatment management into the use of anti-PD-L1 ICI therapy in ROS1 fusion and not in ROS1-G2032R resistant mutation.	[Cai, Liangliang; Qian, Li] Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou, Jiangsu, Peoples R China; [Cai, Liangliang; Qian, Li] Jiangsu Key Lab Expt Translat Noncoding RNA Res, Yangzhou, Jiangsu, Peoples R China; [Cai, Liangliang; Duan, Jianchun; Wang, Zhijie; Wang, Shuhang; Li, Sini; Wang, Chao; Zhao, Jie; Zhang, Xue; Bai, Hua; Wang, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China	Yangzhou University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Cai, LL (corresponding author), Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou, Jiangsu, Peoples R China.; Cai, LL (corresponding author), Jiangsu Key Lab Expt Translat Noncoding RNA Res, Yangzhou, Jiangsu, Peoples R China.; Cai, LL; Bai, H; Wang, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China.	cailiangliang@yzu.edu.cn; baihuahb@sina.com; zlhuxi@163.com			National Key Research and Development Project [2019YFC1315700]; National Natural Sciences Foundation Key Program [81630071]; National Natural Science Foundation of China [81771689, 81900194]; Ministry of Education Innovation Team Development Project [IRT-17R10]; CAMS Key Lab of Translational Research on Lung Cancer [2018PT31035]; CAMS Innovation Fund for Medical Sciences [CIFMS 2016I2M-3-008]; Aiyou Foundation [KY201701]; Wujieping Foundation [320675018477]	National Key Research and Development Project; National Natural Sciences Foundation Key Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education Innovation Team Development Project; CAMS Key Lab of Translational Research on Lung Cancer; CAMS Innovation Fund for Medical Sciences; Aiyou Foundation; Wujieping Foundation	This work was supported by the National Key Research and Development Project (2019YFC1315700), the National Natural Sciences Foundation Key Program (81630071), the National Natural Science Foundation of China (81771689 and 81900194), the Ministry of Education Innovation Team Development Project (IRT-17R10), the CAMS Key Lab of Translational Research on Lung Cancer (2018PT31035), the CAMS Innovation Fund for Medical Sciences (CIFMS 2016I2M-3-008), the Aiyou Foundation(KY201701), and the Wujieping Foundation(320675018477).	Abdel-Rahman O, 2016, CRIT REV ONCOL HEMAT, V101, P75, DOI 10.1016/j.critrevonc.2016.03.007; Akbay EA, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-B290; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2017, J THORAC ONCOL, V12, pS1793, DOI 10.1016/j.jtho.2017.09.431; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Chen LD, 2018, INT J RADIAT ONCOL, V100, P916, DOI 10.1016/j.ijrobp.2017.11.041; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hong SD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1094598; Kaneda Hiroyasu, 2013, Cancer Manag Res, V5, P91, DOI 10.2147/CMAR.S32973; Koh J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1108514; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Lin JJ, 2017, J THORAC ONCOL, V12, P1611, DOI 10.1016/j.jtho.2017.08.002; Liu Z, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1758003; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Oxnard GR, 2013, J CLIN ONCOL, V31, P1097, DOI 10.1200/JCO.2012.42.9829; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Qian YG, 2008, CANCER INVEST, V26, P816, DOI 10.1080/07357900801941852; Rech AJ, 2013, CANCER DISCOV, V3, P1330, DOI 10.1158/2159-8290.CD-13-0775; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Song A, 2015, CLIN CANCER RES, V21, P2379, DOI 10.1158/1078-0432.CCR-14-1350; Sumimoto H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166626; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Zerdes I, 2018, ONCOGENE, V37, P4639, DOI 10.1038/s41388-018-0303-3; Zhang N, 2016, INT J ONCOL, V49, P1360, DOI 10.3892/ijo.2016.3632	34	1	2	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2020	11								527750	10.3389/fimmu.2020.527750	http://dx.doi.org/10.3389/fimmu.2020.527750			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB8IC	33324391	gold, Green Published			2022-12-18	WOS:000596557200001
J	Esgalhado, AJ; Reste-Ferreira, D; Albino, SE; Sousa, A; Amaral, AP; Martinho, A; Oliveira, IT; Verde, I; Lourenco, O; Fonseca, AM; Cardoso, EM; Arosa, FA				Esgalhado, Andre J.; Reste-Ferreira, Debora; Albino, Stephanie E.; Sousa, Adriana; Amaral, Ana Paula; Martinho, Antonio; Oliveira, Isabel T.; Verde, Ignacio; Lourenco, Olga; Fonseca, Ana M.; Cardoso, Elsa M.; Arosa, Fernando A.			CD45RA, CD8 beta, and IFN gamma Are Potential Immune Biomarkers of Human Cognitive Function	FRONTIERS IN IMMUNOLOGY			English	Article						effector-memory CD8+T cells; elderly; brain cognition; HLA class I; healthy aging; CD4+IFN&#947; +	CD8(+) T-CELLS; MHC CLASS-I; DISTINCT POPULATIONS; EXPRESSION; DISEASE; SYSTEM; NEUROGENESIS; GENERATION; IMPAIRMENT; BEHAVIOR	There is increasing evidence that in humans the adaptive immunological system can influence cognitive functions of the brain. We have undertaken a comprehensive immunological analysis of lymphocyte and monocyte populations as well as of HLA molecules expression in a cohort of elderly volunteers (age range, 64-101) differing in their cognitive status. Hereby, we report on the identification of a novel signature in cognitively impaired elderly characterized by: (1) elevated percentages of CD8+ T effector-memory cells expressing high levels of the CD45RA phosphate receptor (Temra (hi)); (2) high percentages of CD8+ T cells expressing high levels of the CD8 beta chain (CD8 beta(hi)); (3) augmented production of IFN gamma by in vitro activated CD4+ T cells. Noteworthy, CD3+CD8+ Temra (hi) and CD3+CD8 beta(hi) cells were associated with impaired cognition. Cytomegalovirus seroprevalence showed that all volunteers studied but one were CMV positive. Finally, we show that some of these phenotypic and functional features are associated with an increased frequency of the HLA-B8 serotype, which belongs to the ancestral haplotype HLA-A1, Cw7, B8, DR3, DQ2, among cognitively impaired volunteers. To our knowledge, this is the first proof in humans linking the amount of cell surface CD45RA and CD8 beta chain expressed by CD8+ Temra cells, and the amount of IFN gamma produced by in vitro activated CD4+ T cells, with impaired cognitive function in the elderly.	[Esgalhado, Andre J.; Reste-Ferreira, Debora; Albino, Stephanie E.; Sousa, Adriana; Amaral, Ana Paula; Verde, Ignacio; Lourenco, Olga; Fonseca, Ana M.; Cardoso, Elsa M.; Arosa, Fernando A.] Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Covilha, Portugal; [Martinho, Antonio] Coimbra Blood & Transplantat Ctr, Mol Genet Lab, Coimbra, Portugal; [Oliveira, Isabel T.] Univ Beira Interior, Cloud Comp Competence Ctr, C4 UBI, Covilha, Portugal; [Verde, Ignacio; Lourenco, Olga; Fonseca, Ana M.; Cardoso, Elsa M.; Arosa, Fernando A.] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal; [Cardoso, Elsa M.] Guarda Polytech Inst, IPG, Guarda, Portugal	Universidade da Beira Interior; Universidade da Beira Interior; Universidade da Beira Interior; Instituto Politecnico da Guarda	Arosa, FA (corresponding author), Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Covilha, Portugal.; Arosa, FA (corresponding author), Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal.	arosa@fcsaude.ubi.pt	Lourenço, Olga/S-6233-2016; Verde, Ignacio/M-3991-2013; Cardoso, Elsa M./AAL-5774-2020; Arosa, Fernando A./E-5640-2010; Fonseca, Ana Mafalda/H-3836-2012	Lourenço, Olga/0000-0002-8401-5976; Verde, Ignacio/0000-0003-3492-5725; Cardoso, Elsa M./0000-0002-6937-6474; Arosa, Fernando A./0000-0002-7209-4507; Reste-Ferreira, Debora/0000-0002-8769-1355; Fonseca, Ana Mafalda/0000-0003-1118-5525; Esgalhado, Andre/0000-0002-6552-4337; Amaral, Ana/0000-0003-1887-5027	FEDER [007491]; National Funds by FCT-Foundation for Science and Technology [UID/Multi/00709/2020]	FEDER(European Commission); National Funds by FCT-Foundation for Science and Technology	This study was funded by FEDER funds through the POCI-COMPETE 2020-Program Competitiveness and Internationalization in Axis I-strengthening research, technological development, and innovation (Project No. 007491) and from National Funds by FCT-Foundation for Science and Technology (Project UID/Multi/00709/2020). ITO is a grantee of C4-UBI, Cloud Computing Competence Centre, University of Beira Interior. AJE, DR-F, SEA, AS, and APA were supported by fellowships from Project No. 007491.	Amaral-Carvalho V, 2012, COGN BEHAV NEUROL, V25, P72, DOI 10.1097/WNN.0b013e318259594b; Arosa FA, 2007, TRENDS IMMUNOL, V28, P115, DOI 10.1016/j.it.2007.01.002; Arosa FA, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00665; Beers DR, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89530; Bieber AJ, 2003, ANN NEUROL, V53, P680, DOI 10.1002/ana.10578; BROD SA, 1989, J EXP MED, V170, P2147, DOI 10.1084/jem.170.6.2147; Brynskikh A, 2008, BRAIN BEHAV IMMUN, V22, P861, DOI 10.1016/j.bbi.2007.12.008; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Chou JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099432; Christensen K, 2008, P NATL ACAD SCI USA, V105, P13274, DOI 10.1073/pnas.0804931105; Coder B, 2017, ONCOTARGET, V8, P7116, DOI 10.18632/oncotarget.12572; Dansokho C, 2016, BRAIN, V139, P1237, DOI 10.1093/brain/awv408; de Miranda AS, 2017, J NEUROL SCI, V372, P482, DOI 10.1016/j.jns.2016.10.052; Dixon-Salazar TJ, 2014, J NEUROSCI, V34, P11844, DOI 10.1523/JNEUROSCI.4642-12.2014; Dursun E, 2015, J NEUROIMMUNOL, V283, P50, DOI 10.1016/j.jneuroim.2015.04.014; Evans FL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02171; Fonseca R, 2020, NAT IMMUNOL, V21, P412, DOI 10.1038/s41590-020-0607-7; Garay Paula A, 2010, Front Synaptic Neurosci, V2, P136, DOI 10.3389/fnsyn.2010.00136; Gate D, 2020, NATURE, V577, P399, DOI 10.1038/s41586-019-1895-7; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; Graff RM, 2018, BRAIN BEHAV IMMUN, V74, P143, DOI 10.1016/j.bbi.2018.08.017; Griffiths SJ, 2013, J IMMUNOL, V190, P5363, DOI 10.4049/jimmunol.1203267; Hauck F, 2012, J ALLERGY CLIN IMMUN, V130, P1144, DOI 10.1016/j.jaci.2012.07.029; Hedrich CM, 2014, J BIOL CHEM, V289, P2361, DOI 10.1074/jbc.M113.523605; Henson SM, 2012, CURR OPIN IMMUNOL, V24, P476, DOI 10.1016/j.coi.2012.04.001; Hu SX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105219; Kambayashi T, 2001, EUR J IMMUNOL, V31, P3248, DOI 10.1002/1521-4141(200111)31:11<3248::AID-IMMU3248>3.0.CO;2-3; Karpenko MN, 2018, CELL IMMUNOL, V327, P77, DOI 10.1016/j.cellimm.2018.02.011; Kim SJ, 2007, NEUROCHEM RES, V32, P1399, DOI 10.1007/s11064-007-9323-z; Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P8180, DOI 10.1073/pnas.0402268101; Kipnis J, 2012, NAT REV IMMUNOL, V12, P662, DOI 10.1038/nri3280; Konno A, 2002, BLOOD, V100, P4090, DOI 10.1182/blood-2002-04-1136; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; LAI R, 1994, BRIT J HAEMATOL, V87, P251, DOI 10.1111/j.1365-2141.1994.tb04906.x; Le Page A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00783; Lugli E, 2010, BLOOD, V116, P3238, DOI 10.1182/blood-2010-03-275438; Pita-Lopez ML, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00616; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; McManus RM, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0241-2; Michel JJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00530; Monteiro S, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.194; Morimoto K, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00916; O'Donnell LA, 2015, J NEUROCHEM, V135, P309, DOI 10.1111/jnc.13250; Ottum PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00539; Pereira BI, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00445; Price P, 1999, IMMUNOL REV, V167, P257, DOI 10.1111/j.1600-065X.1999.tb01398.x; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Reisberg B, 2007, INT PSYCHOGERIATR, V19, P421, DOI 10.1017/S1041610207005261; Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010; Romero P, 2007, J IMMUNOL, V178, P4112, DOI 10.4049/jimmunol.178.7.4112; Rook GAW, 2011, BRAIN BEHAV IMMUN, V25, P591, DOI 10.1016/j.bbi.2010.12.005; Saavedra D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00146; Sansoni P, 2008, EXP GERONTOL, V43, P61, DOI 10.1016/j.exger.2007.06.008; Saresella M, 2010, J ALZHEIMERS DIS, V21, P927, DOI 10.3233/JAD-2010-091696; Schwartz M, 2013, J NEUROSCI, V33, P17587, DOI 10.1523/JNEUROSCI.3241-13.2013; Serre-Miranda C, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000054; Simpson JM, 2002, CLIN REHABIL, V16, P843, DOI 10.1191/0269215502cr569oa; Smolders J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07053-9; Strazielle N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150945; Strominger I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01066; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Tabayoyong WB, 2007, LEUKEMIA RES, V31, P121, DOI 10.1016/j.leukres.2006.06.008; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; Vallejo AN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026558; Vallejo AN, 2011, AGEING RES REV, V10, P354, DOI 10.1016/j.arr.2010.09.006; Walker LJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00223; Washburn LR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018439; Werwitzke S, 2003, CLIN EXP IMMUNOL, V133, P334, DOI 10.1046/j.1365-2249.2003.02226.x; Younes SA, 2016, J CLIN INVEST, V126, P2745, DOI 10.1172/JCI85996; Zarif H, 2018, BRAIN BEHAV IMMUN, V69, P235, DOI 10.1016/j.bbi.2017.11.016	72	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2020	11								592656	10.3389/fimmu.2020.592656	http://dx.doi.org/10.3389/fimmu.2020.592656			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB8LO	33324408	Green Published, gold			2022-12-18	WOS:000596566200001
J	Qian, LR; Liu, M; Shen, JL; Cen, J; Zhao, DF				Qian, Liren; Liu, Miao; Shen, Jianliang; Cen, Jian; Zhao, Defeng			Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial	FRONTIERS IN IMMUNOLOGY			English	Article						corticosteroid; hydrogen; graft-versus-host-disease; refractory; chronic graft-versus-host-disease	FAILURE; CHILDREN; MARROW	Chronic graft-versus-host-disease (cGVHD) is the leading cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation(HSCT). There is no standard therapy for patients refractory or dependent to corticosteroid treatment. We hypothesized that hydrogen may exert therapeutic effects on cGVHD patients with few side effects. A prospective open-label phase 2 study of hydrogen was conducted. Patients received hydrogen-rich water 4ml/kg orally three times a day. Responses were graded in the skin, mouth, Gastrointestinal(GI), liver, eyes, lungs and joints and fascia every 3 months. A total of 24 patients (median age 27) were enrolled. Of the 24 patients, 18 (75%; 95% CI, 55.1% to 88%) had an objective response. No significant toxicity was observed. The estimated 4-year overall survival rate was 74.7%(95% CI, 54.9%-94.5%). The survival time was significantly prolonged in the response group. The survival rate at 4 years in the response group is significantly higher than the nonresponse group (86.6% vs 0%; p= 0.000132). Hydrogen showed great efficacy on cGVHD patients and long-term administration of hydrogen was not associated with significant toxic effects. The trial was registered at www.ClinicalTrials.Gov, NCT02918188.	[Qian, Liren; Shen, Jianliang; Cen, Jian] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Hematol, Beijing, Peoples R China; [Liu, Miao] Chinese Peoples Liberat Army Gen Hosp, Sch Med, Grad Sch, Dept Stat & Epidemiol, Beijing, Peoples R China; [Zhao, Defeng] Boren Hosp, Dept Hematol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Qian, LR (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Hematol, Beijing, Peoples R China.	qlr2007@126.com		Qian, Liren/0000-0002-7750-9177; Liu, Miao/0000-0002-7975-6702	National Natural Science Foundation of China [81800180]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant from the National Natural Science Foundation of China (Grant No. 81800180).	ABRAINI JH, 1994, J APPL PHYSIOL, V76, P1113, DOI 10.1152/jappl.1994.76.3.1113; Anasetti C, 2012, NEW ENGL J MED, V367, P1487, DOI 10.1056/NEJMoa1203517; Boberg E, 2020, STEM CELL TRANSL MED, V9, P1190, DOI 10.1002/sctm.20-0099; Flowers MED, 2015, BLOOD, V125, P606, DOI 10.1182/blood-2014-08-551994; Flowers MED, 2003, LEUKEMIA LYMPHOMA, V44, P1141, DOI 10.1080/1042819031000079096; Gilman AL, 2012, BIOL BLOOD MARROW TR, V18, P84, DOI 10.1016/j.bbmt.2011.05.016; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO;2-F; Inamoto Y, 2014, BLOOD, V124, P1363, DOI 10.1182/blood-2014-03-563544; Jacobsohn DA, 2009, BLOOD, V114, P4354, DOI 10.1182/blood-2009-05-224840; Lee SJ, 2015, BIOL BLOOD MARROW TR, V21, P984, DOI 10.1016/j.bbmt.2015.02.025; Li GM, 2013, J SURG RES, V181, P279, DOI 10.1016/j.jss.2012.06.058; Martin Paul J, 2011, Korean J Hematol, V46, P153, DOI 10.5045/kjh.2011.46.3.153; Martin PJ, 2010, J CLIN ONCOL, V28, P1011, DOI 10.1200/JCO.2009.25.6693; Martin PJ, 2009, BLOOD, V113, P5074, DOI 10.1182/blood-2009-02-202937; Miklos D, 2017, BLOOD, V130, P2243, DOI 10.1182/blood-2017-07-793786; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Pidala J, 2020, BIOL BLOOD MARROW TR, V26, P1612, DOI 10.1016/j.bbmt.2020.05.015; Pidala J, 2020, BIOL BLOOD MARROW TR, V26, P278, DOI 10.1016/j.bbmt.2019.09.002; Qian LR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3917393; Qian LR, 2017, J CELL MOL MED, V21, P2627, DOI 10.1111/jcmm.13155; Qiu P, 2019, INT J BIOL SCI, V15, P1261, DOI 10.7150/ijbs.30741; Sarantopoulos S, 2019, BLOOD, V133, P1191, DOI 10.1182/blood-2018-04-785899; Schoettler M, 2019, BONE MARROW TRANSPL, V54, P1158, DOI 10.1038/s41409-019-0450-3; Shapiro RM, 2020, EXPERT REV HEMATOL, V13, P519, DOI 10.1080/17474086.2020.1752175; SULLIVAN KM, 1988, BLOOD, V72, P546; Terasaki Y, 2011, AM J PHYSIOL-LUNG C, V301, pL415, DOI 10.1152/ajplung.00008.2011; Waller EK, 2019, BIOL BLOOD MARROW TR, V25, P2002, DOI 10.1016/j.bbmt.2019.06.023; Xu K L, 2018, Zhonghua Xue Ye Xue Za Zhi, V39, P89, DOI 10.3760/cma.j.issn.0253-2727.2018.02.001; Yao WF, 2019, AGING-US, V11, P12097, DOI 10.18632/aging.102542; Zecca M, 2002, BLOOD, V100, P1192, DOI 10.1182/blood-2001-11-0059; Zhang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23742	31	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2020	11								598359	10.3389/fimmu.2020.598359	http://dx.doi.org/10.3389/fimmu.2020.598359			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB8FK	33324415	Green Published, gold			2022-12-18	WOS:000596550200001
J	Facciuolo, A; Lee, AH; Trimble, MJ; Rawlyk, N; Townsend, HGG; Bains, M; Arsic, N; Mutharia, LM; Potter, A; Gerdts, V; Napper, S; Hancock, REW; Griebel, PJ				Facciuolo, Antonio; Lee, Amy H.; Trimble, Michael J.; Rawlyk, Neil; Townsend, Hugh G. G.; Bains, Manjeet; Arsic, Natasa; Mutharia, Lucy M.; Potter, Andrew; Gerdts, Volker; Napper, Scott; Hancock, Robert E. W.; Griebel, Philip J.			A Bovine Enteric Mycobacterium Infection Model to Analyze Parenteral Vaccine-Induced Mucosal Immunity and Accelerate Vaccine Discovery	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium; paratuberculosis; Peyer&#8217; s patches; innate lymphoid cell; vaccine; mucosal immunity; interleukin-21; interleukin-27	AVIUM SUBSPECIES PARATUBERCULOSIS; DELTA T-CELLS; TUBERCULOSIS INFECTION; PROTECTIVE EFFICACY; ANTIBODY-RESPONSE; SUBUNIT VACCINE; JOHNES-DISEASE; IMMUNIZATION; MECHANISMS; ANTIGENS	Mycobacterial diseases of cattle are responsible for considerable production losses worldwide. In addition to their importance in animals, these infections offer a nuanced approach to understanding persistent mycobacterial infection in native host species. Mycobacterium avium ssp. paratuberculosis (MAP) is an enteric pathogen that establishes a persistent, asymptomatic infection in the small intestine. Difficulty in reproducing infection in surrogate animal models and limited understanding of mucosal immune responses that control enteric infection in the natural host have been major barriers to MAP vaccine development. We previously developed a reproducible challenge model to establish a consistent MAP infection using surgically isolated intestinal segments prepared in neonatal calves. In the current study, we evaluated whether intestinal segments could be used to screen parenteral vaccines that alter mucosal immune responses to MAP infection. Using Silirum(R) - a commercial MAP bacterin - we demonstrate that intestinal segments provide a platform for assessing vaccine efficacy within a relatively rapid period of 28 days post-infection. Significant differences between vaccinates and non-vaccinates could be detected using quantitative metrics including bacterial burden in intestinal tissue, MAP shedding into the intestinal lumen, and vaccine-induced mucosal immune responses. Comparing vaccine-induced responses in mucosal leukocytes isolated from the site of enteric infection versus blood leukocytes revealed substantial inconsistences between these immune compartments. Moreover, parenteral vaccination with Silirum did not induce equal levels of protection throughout the small intestine. Significant control of MAP infection was observed in the continuous but not the discrete Peyer's patches. Analysis of these regional mucosal immune responses revealed novel correlates of immune protection associated with reduced infection that included an increased frequency of CD335(+) innate lymphoid cells, and increased expression of IL21 and IL27. Thus, intestinal segments provide a novel model to accelerate vaccine screening and discovery by testing vaccines directly in the natural host and provides a unique opportunity to interrogate mucosal immune responses to mycobacterial infections.	[Facciuolo, Antonio; Rawlyk, Neil; Townsend, Hugh G. G.; Arsic, Natasa; Potter, Andrew; Gerdts, Volker; Napper, Scott; Griebel, Philip J.] Univ Saskatchewan, Vaccine & Infect Dis Org, Int Vaccine Ctr VIDO InterVac, Saskatoon, SK, Canada; [Lee, Amy H.] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC, Canada; [Lee, Amy H.; Trimble, Michael J.; Bains, Manjeet; Hancock, Robert E. W.] Univ British Columbia, Ctr Microbial Dis & Immun Res, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Mutharia, Lucy M.] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON, Canada; [Napper, Scott] Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK, Canada; [Griebel, Philip J.] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, Canada	University of Saskatchewan; Simon Fraser University; University of British Columbia; University of Guelph; University of Saskatchewan; University of Saskatchewan	Griebel, PJ (corresponding author), Univ Saskatchewan, Vaccine & Infect Dis Org, Int Vaccine Ctr VIDO InterVac, Saskatoon, SK, Canada.; Griebel, PJ (corresponding author), Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, Canada.	philip.griebel@usask.ca		Trimble, Michael/0000-0002-0927-314X; Lee, Amy/0000-0003-3250-3246; Gerdts, Volker/0000-0001-8229-1611; Facciuolo, Antonio/0000-0003-4551-9386	Genome Canada (LSARP) [8309]; Genome British Columbia [225RVA]; University of Saskatchewan; Government of Saskatchewan (Saskatchewan Ministry of Agriculture-Agriculture Development Fund); Tier I Canada Research Chair in Neonatal Mucosal Immunology by Canada Institutes for Health Research (CIHR); Simon Fraser University's New Faculty Start-Up Grant	Genome Canada (LSARP)(Genome Canada); Genome British Columbia; University of Saskatchewan; Government of Saskatchewan (Saskatchewan Ministry of Agriculture-Agriculture Development Fund); Tier I Canada Research Chair in Neonatal Mucosal Immunology by Canada Institutes for Health Research (CIHR); Simon Fraser University's New Faculty Start-Up Grant	This work was supported by Genome Canada (LSARP #8309), Genome British Columbia (225RVA), University of Saskatchewan and Government of Saskatchewan (Saskatchewan Ministry of Agriculture-Agriculture Development Fund). PG is funded by a Tier I Canada Research Chair in Neonatal Mucosal Immunology provided by Canada Institutes for Health Research (CIHR). RH holds a Canada Research Chair in Health and Genomics and a UBC Killam Professorship. AL is supported by Simon Fraser University's New Faculty Start-Up Grant.	Allen AJ, 2009, CLIN VACCINE IMMUNOL, V16, P453, DOI 10.1128/CVI.00347-08; Allen M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00508; Ayele WY, 2004, VET MICROBIOL, V103, P209, DOI 10.1016/j.vetmic.2004.07.011; Baquero MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00534; Baquero MM, 2017, CELL IMMUNOL, V315, P34, DOI 10.1016/j.cellimm.2017.01.009; Baquero MM, 2016, VET IMMUNOL IMMUNOP, V170, P65, DOI 10.1016/j.vetimm.2015.12.002; Barkema HW, 2018, TRANSBOUND EMERG DIS, V65, P125, DOI 10.1111/tbed.12723; Bastida Felix, 2011, J Immune Based Ther Vaccines, V9, P8, DOI 10.1186/1476-8518-9-8; Booty MG, 2016, SCI REP-UK, V6, DOI 10.1038/srep36720; Bull TJ, 2014, VET RES, V45, DOI 10.1186/s13567-014-0112-9; Charavaryamath C, 2013, CLIN VACCINE IMMUNOL, V20, P156, DOI 10.1128/CVI.00496-12; Charavaryamath C, 2011, GUT MICROBES, V2, P134, DOI 10.4161/gmic.2.3.16483; Cheekatla SS, 2017, J IMMUNOL, V199, P2815, DOI 10.4049/jimmunol.1601231; Choi YH, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0652-7; Crossley BM, 2005, VET MICROBIOL, V107, P257, DOI 10.1016/j.vetmic.2005.01.017; Da Silva C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01254; de Silva K, 2015, VACCINE, V33, P149, DOI 10.1016/j.vaccine.2014.10.082; Dhand NK, 2016, VACCINE, V34, P5107, DOI 10.1016/j.vaccine.2016.08.064; Domingo-Gonzalez R, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0018-2016; Esin S, 2015, J INNATE IMMUN, V7, P11, DOI 10.1159/000363321; Facciuolo A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01020; Facciuolo A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158747; Facciuolo A, 2013, CLIN VACCINE IMMUNOL, V20, P1783, DOI 10.1128/CVI.00380-13; Faisal SM, 2013, CLIN VACCINE IMMUNOL, V20, P572, DOI 10.1128/CVI.00653-12; Fernandez M, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-5; Fries P, 2011, DEV COMP IMMUNOL, V35, P1038, DOI 10.1016/j.dci.2011.04.003; Fries PN, 2011, CELL IMMUNOL, V271, P428, DOI 10.1016/j.cellimm.2011.08.012; Fu XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151721; Garg A, 2006, J IMMUNOL, V177, P6192, DOI 10.4049/jimmunol.177.9.6192; Gonzalez J, 2005, J COMP PATHOL, V133, P184, DOI 10.1016/j.jcpa.2005.04.007; Griebel PJ, 1996, IMMUNOL TODAY, V17, P30, DOI 10.1016/0167-5699(96)80566-4; Guerra C, 2012, CLIN EXP IMMUNOL, V168, P142, DOI 10.1111/j.1365-2249.2011.04552.x; Gupta N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00709; Hines ME, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00026; Ioannou XP, 2002, J VIROL, V76, P9002, DOI 10.1128/JVI.76.18.9002-9010.2002; Kathaperumal K, 2009, VACCINE, V27, P123, DOI 10.1016/j.vaccine.2008.10.019; Kathaperumal K, 2008, VACCINE, V26, P1652, DOI 10.1016/j.vaccine.2008.01.015; Khare S, 2009, VET PATHOL, V46, P717, DOI 10.1354/vp.08-VP-0187-G-FL; Khare S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161946; Khare S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042127; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; Koets A, 2006, VACCINE, V24, P2550, DOI 10.1016/j.vaccine.2005.12.019; Koo HC, 2004, INFECT IMMUN, V72, P6870, DOI 10.1128/IAI.72.12.6870-6883.2004; Kruger C, 2015, VET PATHOL, V52, P276, DOI 10.1177/0300985814533804; Kudahl AB, 2009, J DAIRY SCI, V92, P4340, DOI 10.3168/jds.2009-2039; Liang GX, 2016, SCI REP-UK, V6, DOI 10.1038/srep24964; Ludwig L, 2019, VET IMMUNOL IMMUNOP, V216, DOI 10.1016/j.vetimm.2019.109919; McAloon CG, 2016, J DAIRY SCI, V99, P1449, DOI 10.3168/jds.2015-10156; Mortier RAR, 2014, VET RES, V45, DOI 10.1186/s13567-014-0071-1; Mortier RAR, 2014, J DAIRY SCI, V97, P5558, DOI 10.3168/jds.2014-8139; Muskens J, 2002, VET MICROBIOL, V86, P269, DOI 10.1016/S0378-1135(02)00006-8; Paidipally P, 2018, J INFECT DIS, V217, P1323, DOI 10.1093/infdis/jiy034; Park KT, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00064; Park KT, 2011, VACCINE, V29, P4709, DOI 10.1016/j.vaccine.2011.04.090; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Puech C, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0382-0; Reddacliff L, 2006, VET MICROBIOL, V115, P77, DOI 10.1016/j.vetmic.2005.12.021; Shippy DC, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/cvi.00478-16, 10.1128/CVI.00478-16]; Smith RL, 2009, J DAIRY SCI, V92, P2653, DOI 10.3168/jds.2008-1832; Stabel JR, 2014, J DAIRY SCI, V97, P6296, DOI 10.3168/jds.2014-8204; Stabel JR, 2011, CLIN VACCINE IMMUNOL, V18, P2079, DOI 10.1128/CVI.05421-11; Stabel JR, 2009, VET MICROBIOL, V136, P306, DOI 10.1016/j.vetmic.2008.11.025; Stabel JR, 2020, VET IMMUNOL IMMUNOP, V225, DOI 10.1016/j.vetimm.2020.110060; Stinson KJ, 2018, VET RES, V49, DOI 10.1186/s13567-018-0553-7; Stringer LA, 2013, VET REC, V173, P551, DOI 10.1136/vr.101799; Subharat S, 2012, VET IMMUNOL IMMUNOP, V149, P225, DOI 10.1016/j.vetimm.2012.07.005; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; Tewari D, 2014, CLIN VACCINE IMMUNOL, V21, P698, DOI 10.1128/CVI.00032-14; Vankayalapati R, 2004, J IMMUNOL, V172, P130, DOI 10.4049/jimmunol.172.1.130; Vankayalapati R, 2005, J IMMUNOL, V175, P4611, DOI 10.4049/jimmunol.175.7.4611; Venkatasubramanian S, 2017, MUCOSAL IMMUNOL, V10, P1031, DOI 10.1038/mi.2016.105; Waddell LA, 2015, EPIDEMIOL INFECT, V143, P3135, DOI 10.1017/S095026881500076X; Waters WR, 2003, INFECT IMMUN, V71, P5130, DOI 10.1128/IAI.71.9.5130-5138.2003; Whitlock RH, 1996, VET CLIN N AM-FOOD A, V12, P345, DOI 10.1016/S0749-0720(15)30410-2; Whittington R, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1943-4; Whittington RJ, 2012, VET IMMUNOL IMMUNOP, V148, P29, DOI 10.1016/j.vetimm.2011.03.003; Zhang RJ, 2006, J IMMUNOL, V176, P2610, DOI 10.4049/jimmunol.176.4.2610	77	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2020	11								586659	10.3389/fimmu.2020.586659	http://dx.doi.org/10.3389/fimmu.2020.586659			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB7GH	33329565	Green Published, gold			2022-12-18	WOS:000596484700001
J	Grand, M; Waqasi, M; Demarta-Gatsi, C; Wei, Y; Peronet, R; Commere, PH; Puig, A; Axelrod, J; Caldelari, R; Heussler, V; Amino, R; Mecheri, S				Grand, Morgane; Waqasi, Mishelle; Demarta-Gatsi, Claudia; Wei, Yu; Peronet, Roger; Commere, Pierre-Henri; Puig, Amandine; Axelrod, Jonathan; Caldelari, Reto; Heussler, Volker; Amino, Rogerio; Mecheri, Salaheddine			Hepatic Inflammation Confers Protective Immunity Against Liver Stages of Malaria Parasite	FRONTIERS IN IMMUNOLOGY			English	Article						CD8-CD4 T cells; inflammation; liver; malaria; vaccine	T-CELL-ACTIVATION; PLASMODIUM-BERGHEI; BONE-MARROW; ANTIGEN; IL-6; NEUTROPHILS; INDUCTION; RESPONSES; CD4(+); MEMORY	Deciphering the mechanisms by which Plasmodium parasites develop inside hepatocytes is an important step toward the understanding of malaria pathogenesis. We propose that the nature and the magnitude of the inflammatory response in the liver are key for the establishment of the infection. Here, we used mice deficient in the multidrug resistance-2 gene (Mdr2(-/-))-encoded phospholipid flippase leading to the development of liver inflammation. Infection of Mdr2(-/-) mice with Plasmodium berghei ANKA (PbANKA) sporozoites (SPZ) resulted in the blockade of hepatic exo-erythrocytic forms (EEFs) with no further development into blood stage parasites. Interestingly, cultured primary hepatocytes from mutant and wild-type mice are equally effective in supporting EEF development. The abortive infection resulted in a long-lasting immunity in Mdr2(-/-) mice against infectious SPZ where neutrophils and IL-6 appear as key effector components along with CD8(+) and CD4(+) effector and central memory T cells. Inflammation-induced breakdown of liver tolerance promotes anti-parasite immunity and provides new approaches for the design of effective vaccines against malaria disease.	[Grand, Morgane; Waqasi, Mishelle; Demarta-Gatsi, Claudia; Peronet, Roger; Puig, Amandine; Mecheri, Salaheddine] Inst Pasteur, Unite Biol Interact Hote Parasites, Paris, France; [Grand, Morgane; Waqasi, Mishelle; Demarta-Gatsi, Claudia; Peronet, Roger; Puig, Amandine; Mecheri, Salaheddine] CNRS, ERL9195, Paris, France; [Grand, Morgane; Waqasi, Mishelle; Demarta-Gatsi, Claudia; Peronet, Roger; Puig, Amandine; Mecheri, Salaheddine] INSERM, U1201, Paris, France; [Grand, Morgane] Sorbonne Univ, Coll Doctoral, Paris, France; [Wei, Yu] Chinese Acad Sci, Univ Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai, Peoples R China; [Wei, Yu] Inst Pasteur, Unit Virol Mol Culaire & Vaccinol, Paris, France; [Commere, Pierre-Henri] Inst Pasteur, Imagopole, Paris, France; [Axelrod, Jonathan] Hadassah Med Org, Goldyne Savad Inst Gene Therapy, Jerusalem, Israel; [Caldelari, Reto; Heussler, Volker] Univ Bern, Inst Cell Biol, Bern, Switzerland; [Amino, Rogerio] Inst Pasteur, Malaria Infect & Immun Unit, Paris, France; [Demarta-Gatsi, Claudia] Med Malaria Venture MMV, Geneva, Switzerland	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Bern; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mecheri, S (corresponding author), Inst Pasteur, Unite Biol Interact Hote Parasites, Paris, France.; Mecheri, S (corresponding author), CNRS, ERL9195, Paris, France.; Mecheri, S (corresponding author), INSERM, U1201, Paris, France.	smecheri@pasteur.fr			French Parasitology consortium ParaFrap [ANR-11-LABX0024]; Institut Pasteur; Helmut Horten Foundation, Agno, Switzerland	French Parasitology consortium ParaFrap; Institut Pasteur(European Commission); Helmut Horten Foundation, Agno, Switzerland	This work has been supported by the French Parasitology consortium ParaFrap (ANR-11-LABX0024), and by a grant from Institut Pasteur to MG, and SM. CD-G was supported by a postdoctoral fellowship from the Helmut Horten Foundation, Agno, Switzerland.	Andrade BB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019841; Asensi V, 2004, INFECT IMMUN, V72, P3823, DOI 10.1128/IAI.72.7.3823-3828.2004; Barash H, 2010, P NATL ACAD SCI USA, V107, P2207, DOI 10.1073/pnas.0908867107; Barcus MJ, 2002, AM J TROP MED HYG, V66, P140, DOI 10.4269/ajtmh.2002.66.140; Bertolino P, 2001, J IMMUNOL, V166, P5430, DOI 10.4049/jimmunol.166.9.5430; CALLERY MP, 1989, TRANSPLANTATION, V47, P1092; CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0; Castellino F, 2007, J IMMUNOL, V178, P778, DOI 10.4049/jimmunol.178.2.778; Crispe IN, 2014, HEPATOLOGY, V60, P2109, DOI 10.1002/hep.27254; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; Dabo N. T., 2015, Bayero Journal of Pure and Applied Sciences, V8, P89, DOI 10.4314/bajopas.v8i1.16; Demarta-Gatsi C, 2016, J EXP MED, V213, P1419, DOI 10.1084/jem.20151976; Diehl L, 2008, HEPATOLOGY, V47, P296, DOI 10.1002/hep.21965; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Diehl SA, 2012, IMMUNOL CELL BIOL, V90, P802, DOI 10.1038/icb.2012.17; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; Fielding CA, 2008, J IMMUNOL, V181, P2189, DOI 10.4049/jimmunol.181.3.2189; FREUDENBERG MA, 1982, BRIT J EXP PATHOL, V63, P56; Frevert U, 2005, PLOS BIOL, V3, P1034, DOI 10.1371/journal.pbio.0030192; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gola A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9128; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Holz LE, 2012, J HEPATOL, V57, P830, DOI 10.1016/j.jhep.2012.05.015; Horst AK, 2016, CELL MOL IMMUNOL, V13, P277, DOI 10.1038/cmi.2015.112; Ichikawa S, 2011, J IMMUNOL, V186, P5549, DOI 10.4049/jimmunol.1003917; Ishizuka AS, 2016, NAT MED, V22, P614, DOI 10.1038/nm.4110; Katzenellenbogen M, 2007, MOL CANCER RES, V5, P1159, DOI 10.1158/1541-7786.MCR-07-0172; Klotz C, 2008, INT J PARASITOL, V38, P1639, DOI 10.1016/j.ijpara.2008.05.018; KNOLLE P, 1995, J HEPATOL, V22, P226, DOI 10.1016/0168-8278(95)80433-1; KOCH AE, 1994, J CLIN INVEST, V94, P1012, DOI 10.1172/JCI117414; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Krzych U, 2018, ENCY MALARIA, P1, DOI [10.1007/978-1-4614-8757-9_137-1, DOI 10.1007/978-1-4614-8757-9_137-1]; Lanton T, 2017, HEPATOLOGY, V65, P1600, DOI 10.1002/hep.29004; LU L, 1994, J EXP MED, V179, P1823, DOI 10.1084/jem.179.6.1823; Lukacs-Kornek V, 2013, J HEPATOL, V59, P1124, DOI 10.1016/j.jhep.2013.05.033; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; Maletto BA, 2006, BLOOD, V108, P3094, DOI 10.1182/blood-2006-04-016659; Mathieu C, 2015, CELL MICROBIOL, V17, P542, DOI 10.1111/cmi.12382; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Mizutani N, 2014, J IMMUNOL, V192, P1372, DOI 10.4049/jimmunol.1301538; Mowat AM, 2002, T LYMPHOCYTES LIVER, P101; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nganou-Makamdop K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036508; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; Opata MM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006960; Portugal S, 2011, EMBO REP, V12, P1233, DOI 10.1038/embor.2011.213; Potikha T, 2013, HEPATOLOGY, V58, P192, DOI 10.1002/hep.26335; Raich-Regue D, 2014, IMMUNOL LETT, V161, P216, DOI 10.1016/j.imlet.2013.11.016; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Schildberg FA, 2008, EUR J IMMUNOL, V38, P957, DOI 10.1002/eji.200738060; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Steers N, 2005, EUR J IMMUNOL, V35, P2335, DOI 10.1002/eji.200425680; Suwa T, 2000, AM J PHYSIOL-HEART C, V279, pH2954, DOI 10.1152/ajpheart.2000.279.6.H2954; TEREBUH PD, 1992, AM J PATHOL, V140, P649; THURSZ MR, 1995, NAT MED, V1, P374, DOI 10.1038/nm0495-374; Tvinnereim AR, 2004, J IMMUNOL, V173, P1994, DOI 10.4049/jimmunol.173.3.1994; Usynin I, 2007, CELL MICROBIOL, V9, P2610, DOI 10.1111/j.1462-5822.2007.00982.x; Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC; VREDEN SGS, 1992, EUR J IMMUNOL, V22, P2271, DOI 10.1002/eji.1830220914; WAKI S, 1982, EXP PARASITOL, V53, P335, DOI 10.1016/0014-4894(82)90076-5; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; Yanez DM, 1996, J IMMUNOL, V157, P1620	66	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2020	11								585502	10.3389/fimmu.2020.585502	http://dx.doi.org/10.3389/fimmu.2020.585502			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7QG	33329563	Green Published, gold			2022-12-18	WOS:000595115400001
J	Casagrande, FB; Ferreira, SD; de Sousa, ESA; Guimaraes, JPT; Romera, LMD; Tessaro, FHG; de Almeida, SR; Rodrigues, SFD; Martins, JO				Casagrande, Felipe Beccaria; Ferreira, Sabrina de Souza; Alho de Sousa, Emanuella Sarmento; Torres Guimaraes, Joao Pedro; Dal'Mas Romera, Lavinia Maria; Galvao Tessaro, Fernando Henrique; de Almeida, Sandro Rogerio; de Paula Rodrigues, Stephen Fernandes; Martins, Joilson O.			Insulin Modulates Inflammatory Cytokine Release in Acute Stages and Augments Expression of Adhesion Molecules and Leukocytes in Lungs on Chronic Stages of Paracoccidioidomycosis	FRONTIERS IN IMMUNOLOGY			English	Article						macrophages; type 1 diabetes; inflammation; Paracoccidioidomycosis; systemic mycosis; fungal infection; vascular cell adhesion molecule-1 expression	MONONUCLEAR-CELLS; IMMUNE-RESPONSE; DIABETIC MICE; IFN-GAMMA; T-CELLS; SUSCEPTIBILITY; INFECTION; TYPE-1; GLYCOPROTEIN; MACROPHAGES	Type 1 diabetes mellitus (T1D) is caused by partial destruction of the insulin-producing beta cells in the pancreas and is a major issue for public health care worldwide. Reduced or impaired immunological responses, which render patients more susceptible to infections, have been observed in T1D, and this dysfunction is often related to a lack of insulin in the blood. Paracoccidioidomycosis is an important systemic mycosis endemic in Latin America. To evaluate the effects of T1D on this fungal infection and the modulatory effects of insulin, we induced diabetes in C57Bl/6 male mice (alloxan, 60 mg/kg), infected the mice (Pb18, 1 x 10(6) cells), and treated the mice with neutral protamine Hagedorn (NPH) insulin (2 IU/600 mg/dL blood glucose). Twenty-four hours after infection, infected diabetic mice showed reduced secretion of interferon (IFN)-gamma and interleukine (IL)-12 p70 compared to infected nondiabetic controls. On the 45th day of infection, infected diabetic mice presented higher IFN-gamma levels, a higher tumor necrosis factor (TNF)-alpha:IL-10 ratio, and lower adhesion molecule expression levels than nondiabetic mice. In the in vitro experiments, alveolar macrophages from diabetic animals showed reduced phagocytic activity compared to those from control animals at 4, 12, and 24 h. In infected diabetic mice, treatment with insulin restored IL-12 p70 levels at 24 h of infection, reduced IFN-gamma levels and the TNF-alpha:IL-10 ratio at 45 days, and restored vascular cell adhesion molecule (VCAM)-1 expression in pulmonary blood vessels, and this treatment reduced the diminished phosphorylation of extracellular signal-regulated kinases (ERK) and increased nuclear factor-kappa-B(i kappa b)-alpha and jun amino-terminal kinases (JNK) p46 levels in infected nondiabetic mice. In addition, insulin promoted increased phagocytic activity in the alveolar macrophages of diabetic mice. These data suggest that T1D mice are more susceptible to Pb18 infection and that insulin modulates this inflammation in diabetic mice by augmenting the expression of adhesion molecules and leukocytes in the lungs and by reducing chronic inflammation.	[Casagrande, Felipe Beccaria; Ferreira, Sabrina de Souza; Alho de Sousa, Emanuella Sarmento; Torres Guimaraes, Joao Pedro; Galvao Tessaro, Fernando Henrique; Martins, Joilson O.] Univ Sao Paulo FCF USP, Dept Clin & Toxicol Ana, Lab Immunoendocrinol, Sch Pharmaceut Sci, Sao Paulo, Brazil; [Dal'Mas Romera, Lavinia Maria; de Almeida, Sandro Rogerio] Univ Sao Paulo FCF USP, Dept Clin & Toxicol Ana, Lab Mycol, Sch Pharmaceut Sci, Sao Paulo, Brazil; [de Paula Rodrigues, Stephen Fernandes] Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Pharmacol, Lab Vasc Nanopharmacol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Martins, JO (corresponding author), Univ Sao Paulo FCF USP, Dept Clin & Toxicol Ana, Lab Immunoendocrinol, Sch Pharmaceut Sci, Sao Paulo, Brazil.	martinsj@usp.br	Sarmento, Emanuella/ABH-8180-2022; Dal Mas Romera, Lavínia Maria/S-1501-2017; Martins, Joilson O./G-4367-2011; Rodrigues, Stephen Fernandes/F-7073-2012; Torres Guimaraes, Joao Pedro/D-7974-2019	Sarmento, Emanuella/0000-0001-8861-635X; Dal Mas Romera, Lavínia Maria/0000-0002-9625-0615; Martins, Joilson O./0000-0003-2630-7038; Rodrigues, Stephen Fernandes/0000-0002-6818-0365; tessaro, fernando/0000-0002-0389-5976; Ferreira, Sabrina/0000-0002-1779-8528; Torres Guimaraes, Joao Pedro/0000-0003-3818-6990; Casagrande, Felipe/0000-0003-1117-4754	Sao Paulo Research Foundation (FAPESP) [2014/05214-1, 2017/11540-7, 2020/13215-9]; National Counsel of Technological and Scientific Development (CNPq) [470523/2013-1, 301617/2016-3]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Counsel of Technological and Scientific Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	The authors are supported by grant 2014/05214-1, 2017/11540-7 and 2020/13215-9 from Sao Paulo Research Foundation (FAPESP), grant 470523/2013-1 and 301617/2016-3 from National Counsel of Technological and Scientific Development (CNPq, Projeto Universal 2013, PQ-1D) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES).	Alba-Loureiro TC, 2006, J ENDOCRINOL, V188, P295, DOI 10.1677/joe.1.06438; Aljada A, 2002, J CLIN ENDOCR METAB, V87, P1419, DOI 10.1210/jc.87.3.1419; Anjos-Valotta EA, 2006, INFLAMM RES, V55, P16, DOI 10.1007/s00011-005-0003-7; [Anonymous], 2012, CELL BIOCH FUNCT, DOI DOI 10.1002/cbf.2840; Arruda C, 2007, MICROBES INFECT, V9, P308, DOI 10.1016/j.micinf.2006.12.005; Ayala TS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47836-8; Benard G, 2001, CYTOKINE, V13, P248, DOI 10.1006/cyto.2000.0824; Benard G, 2008, MYCOPATHOLOGIA, V165, P209, DOI 10.1007/s11046-007-9065-0; Calich VLG, 2008, FEMS IMMUNOL MED MIC, V53, P1, DOI 10.1111/j.1574-695X.2008.00378.x; Calich VLG, 1998, BRAZ J MED BIOL RES, V31, P615, DOI 10.1590/S0100-879X1998000500003; CALICH VLG, 1985, BRIT J EXP PATHOL, V66, P585; Carey IM, 2018, DIABETES CARE, V41, P513, DOI 10.2337/dc17-2131; Casagrande FB, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/6209694; Cavassani KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021423; Chiarella AP, 2007, MICROBES INFECT, V9, P1078, DOI 10.1016/j.micinf.2007.04.016; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Dandona P, 2001, J CLIN ENDOCR METAB, V86, P3257, DOI 10.1210/jc.86.7.3257; de Castro LF, 2013, J INFECTION, V67, P470, DOI 10.1016/j.jinf.2013.07.019; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; dos Santos SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019690; Ferracini M, 2010, MOL IMMUNOL, V47, P1974, DOI 10.1016/j.molimm.2010.04.018; Tessaro FHG, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.11.014; Huo CY, 2017, MICROB PATHOGENESIS, V113, P233, DOI 10.1016/j.micpath.2017.10.026; International Diabetes Federation, 2019, DIABETES ATLAS, V9th; Kashino SS, 2000, J INTERF CYTOK RES, V20, P89, DOI 10.1089/107999000312766; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Koley H, 2017, JPN J INFECT DIS, V70, P111, DOI 10.7883/yoken.JJID.2015.418; Lachmandas E, 2018, EUR J CLIN MICROBIOL, V37, P371, DOI 10.1007/s10096-017-3145-y; Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0; Magalhaes A, 2012, CLIN VACCINE IMMUNOL, V19, P23, DOI 10.1128/CVI.05414-11; Martins JO, 2010, SHOCK, V33, P76, DOI 10.1097/SHK.0b013e3181a85ec4; Moreira APV., 2008, BOL EPIDEMIOL PAUL, V5, P11; Olaru F, 2010, J INVEST DERMATOL, V130, P1866, DOI 10.1038/jid.2010.37; Oliveira SJ, 2002, MICROBES INFECT, V4, P139, DOI 10.1016/S1286-4579(01)01521-0; Pang WW, 2013, P NATL ACAD SCI USA, V110, P3011, DOI 10.1073/pnas.1222861110; Rio DC, 2010, COLD SPRING HARB PRO, V2010, P1, DOI DOI 10.1101/PDB.PROT5439; Rodrigues V, 2012, J IMMUNOL, V188; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Rosa LFBPC, 1996, CELL BIOCHEM FUNCT, V14, P33, DOI 10.1002/cbf.637; Sharma S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/279393; Shikanai-Yasuda MA, 2018, EPIDEMIOL SERV SAUDE, V27, DOI 10.5123/S1679-49742018000500001; Spiller F, 2012, DIABETES, V61, P1584, DOI 10.2337/db11-0825; Sun CM, 2012, J CELL PHYSIOL, V227, P1670, DOI 10.1002/jcp.22891; Sunahara KKS, 2014, CELL PHYSIOL BIOCHEM, V34, P2017, DOI 10.1159/000366397; Trinanes J, 2012, DIABETES CARE, V35, P427, DOI 10.2337/dc11-1665; Tristao FSM, 2013, MYCOPATHOLOGIA, V176, P1, DOI 10.1007/s11046-013-9671-y; Viardot A, 2007, ENDOCRINOLOGY, V148, P346, DOI 10.1210/en.2006-0686; Wang J, 2017, J RECEPT SIG TRANSD, V37, P409, DOI 10.1080/10799893.2017.1298131; World health organization, 2016, DIABETES 2016 GLOBAL; Yano H, 2012, INFECT IMMUN, V80, P4409, DOI 10.1128/IAI.00787-12; Yu T, 2016, MED SCI MONITOR, V22, P3062, DOI 10.12659/MSM.897270	51	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2020	11								583385	10.3389/fimmu.2020.583385	http://dx.doi.org/10.3389/fimmu.2020.583385			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ2FG	33312173	gold, Green Published			2022-12-18	WOS:000594747800001
J	Gomez-Mora, E; Carrillo, J; Urrea, V; Rigau, J; Alegre, J; Cabrera, C; Oltra, E; Castro-Marrero, J; Blanco, J				Gomez-Mora, Elisabet; Carrillo, Jorge; Urrea, Victor; Rigau, Josepa; Alegre, Jose; Cabrera, Cecilia; Oltra, Elisa; Castro-Marrero, Jesus; Blanco, Julia			Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery	FRONTIERS IN IMMUNOLOGY			English	Article						cryopreservation; immunophenotyping; immune biomarkers; myalgic encephalomyelitis; chronic fatigue syndrome; freeze-thaw process	REGULATORY T-CELLS; ADENOSINE METABOLISM; FLOW-CYTOMETRY; PHENOTYPE	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex neuroimmune disorder characterized by numerous symptoms of unknown etiology. The ME/CFS immune markers reported so far have failed to generate a clinical consensus, perhaps partly due to the limitations of biospecimen biobanking. To address this issue, we performed a comparative analysis of the impact of long-term biobanking on previously identified immune markers and also explored additional potential immune markers linked to infection in ME/CFS. A correlation analysis of marker cryostability across immune cell subsets based on flow cytometry immunophenotyping of fresh blood and frozen PBMC samples collected from individuals with ME/CFS (n = 18) and matched healthy controls (n = 18) was performed. The functionality of biobanked samples was assessed on the basis of cytokine production assay after stimulation of frozen PBMCs. T cell markers defining Treg subsets and the expression of surface glycoprotein CD56 in T cells and the frequency of the effector CD8 T cells, together with CD57 expression in NK cells, appeared unaltered by biobanking. By contrast, NK cell markers CD25 and CD69 were notably increased, and NKp46 expression markedly reduced, by long-term cryopreservation and thawing. Further exploration of Treg and NK cell subsets failed to identify significant differences between ME/CFS patients and healthy controls in terms of biobanked PBMCs. Our findings show that some of the previously identified immune markers in T and NK cell subsets become unstable after cell biobanking, thus limiting their use in further immunophenotyping studies for ME/CFS. These data are potentially relevant for future multisite intervention studies and cooperative projects for biomarker discovery using ME/CFS biobanked samples. Further studies are needed to develop novel tools for the assessment of biomarker stability in cryopreserved immune cells from people with ME/CFS.	[Gomez-Mora, Elisabet; Carrillo, Jorge; Urrea, Victor; Cabrera, Cecilia; Blanco, Julia] Inst Invest Ciancies Salut Germans Trios & Pujol, IrsiCaixa AIDS Res Inst, Badalona, Spain; [Rigau, Josepa] Rigau Private Clin, Tarragona, Spain; [Alegre, Jose] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Div Rheumatol, ME CFS Clin Unit, Barcelona, Spain; [Oltra, Elisa] Univ Catolica Valencia San Vicente Martir, Sch Med, Valencia, Spain; [Castro-Marrero, Jesus] Univ Autonoma Barcelona, Vall dHebron Hosp Res Inst, Div Rheumatol, ME CFS Res Unit, Barcelona, Spain; [Blanco, Julia] Univ Vic, Cent Univ Catalonia UVio UCC, Chair Infect Dis & Immun, Ctr Hlth & Social Care Res CESS,Fac Med, Vic, Spain	Institut de Recerca de la Sida - IrsiCaixa; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Universidad Catolica de Valencia San Vicente Martir; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Blanco, J (corresponding author), Inst Invest Ciancies Salut Germans Trios & Pujol, IrsiCaixa AIDS Res Inst, Badalona, Spain.; Castro-Marrero, J (corresponding author), Univ Autonoma Barcelona, Vall dHebron Hosp Res Inst, Div Rheumatol, ME CFS Res Unit, Barcelona, Spain.; Blanco, J (corresponding author), Univ Vic, Cent Univ Catalonia UVio UCC, Chair Infect Dis & Immun, Ctr Hlth & Social Care Res CESS,Fac Med, Vic, Spain.	jesus.castro@vhir.org; jblanco@irsicaixa.es	Blanco, Julià/A-5347-2008; Carrillo, Jorge/AAL-9481-2021; Cabrera, Cecilia/S-1113-2019; Urrea, Victor/ABF-9634-2021; Oltra, Elisa/I-3642-2015	Blanco, Julià/0000-0002-2225-0217; Carrillo, Jorge/0000-0003-0221-5948; Cabrera, Cecilia/0000-0002-9941-6828; Castro-Marrero, Jesus/0000-0002-2481-3052; Oltra, Elisa/0000-0003-0598-2907	Association of Healthcare Workers for ME/CFS Research (ASSSEM) in Catalonia, Spain	Association of Healthcare Workers for ME/CFS Research (ASSSEM) in Catalonia, Spain	This study was partially supported by the Association of Healthcare Workers for ME/CFS Research (ASSSEM) in Catalonia, Spain. Funders had no role in the study design, data collection and analysis, interpretation, decision of publish, or writing of the manuscript.	Bansal AS, 2012, BRAIN BEHAV IMMUN, V26, P24, DOI 10.1016/j.bbi.2011.06.016; Bjorkstrom NK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027664; BLANCO J, 1993, J CELL PHYSIOL, V157, P77, DOI 10.1002/jcp.1041570110; Brenu EW, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-88; Brenu EW, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-81; Brenu EW, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-1; Brenu EW, 2014, INT IMMUNOL, V26, P233, DOI 10.1093/intimm/dxt068; Broderick G, 2010, BRAIN BEHAV IMMUN, V24, P1209, DOI 10.1016/j.bbi.2010.04.012; Carruthers BM, 2011, J INTERN MED, V270, P327, DOI 10.1111/j.1365-2796.2011.02428.x; Castro-Marrero J, 2017, BRIT J PHARMACOL, V174, P345, DOI 10.1111/bph.13702; Chege D, 2011, AIDS, V25, P741, DOI 10.1097/QAD.0b013e328344cefb; Cliff JM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00796; Cuadrado E, 2018, IMMUNITY, V48, P1046, DOI 10.1016/j.immuni.2018.04.008; Curriu M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-68; Diks AM, 2019, J IMMUNOL METHODS, V475, DOI 10.1016/j.jim.2019.06.007; Esfandyarpour R, 2019, P NATL ACAD SCI USA, V116, P10250, DOI 10.1073/pnas.1901274116; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Hornig M, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1400121; Inst Med, 2015, BEYOND MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME: REDEFINING AN ILLNESS, P1; Irlbeck David M, 2014, BMC Res Notes, V7, P461, DOI 10.1186/1756-0500-7-461; Karhan E, BIORXIV, DOI [10.1101/2019.12.23.887505, DOI 10.1101/2019.12.23.887505]; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; Lacerda EM, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01026; Lauer Fredine T, 2017, Curr Protoc Toxicol, V74, DOI 10.1002/cptx.31; Lemieux J, 2016, J IMMUNOL METHODS, V434, P73, DOI 10.1016/j.jim.2016.04.010; Li YH, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6587296; Rivas JL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01028; Massanella M, 2012, AIDS, V26, P2285, DOI 10.1097/QAD.0b013e328359f20f; Metzger K, 2008, BIOCHEM BIOPH RES CO, V376, P231, DOI 10.1016/j.bbrc.2008.08.135; Missailidis D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031142; Moneghetti KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20941-w; Montoya JG, 2017, P NATL ACAD SCI USA, V114, pE7150, DOI 10.1073/pnas.1710519114; Moreno-Fernandez ME, 2011, BLOOD, V117, P5372, DOI 10.1182/blood-2010-12-323162; Naviaux RK, 2016, P NATL ACAD SCI USA, V113, pE5472, DOI 10.1073/pnas.1607571113; Ohta A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00304; Parsons MS, 2014, J IMMUNOL, V192, P308, DOI 10.4049/jimmunol.1301247; Patel DD, 2015, IMMUNITY, V43, P1040, DOI 10.1016/j.immuni.2015.12.003; Sattui S, 2012, CYTOM PART B-CLIN CY, V82B, P54, DOI 10.1002/cyto.b.20621; Sotzny F, 2018, AUTOIMMUN REV, V17, P601, DOI 10.1016/j.autrev.2018.01.009; Strawbridge R, 2019, NEUROSCI BIOBEHAV R, V107, P69, DOI 10.1016/j.neubiorev.2019.08.011; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Umansky V, 2014, CANCER IMMUNOL IMMUN, V63, P1073, DOI 10.1007/s00262-014-1553-8; Veluchamy JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep43873; Zhang HY, 2011, J FORMOS MED ASSOC, V110, P701, DOI 10.1016/j.jfma.2011.09.006	45	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 17	2020	11								582330	10.3389/fimmu.2020.582330	http://dx.doi.org/10.3389/fimmu.2020.582330			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC8XC	33329554	gold, Green Published			2022-12-18	WOS:000597281200001
J	Benedictus, L; Steinbach, S; Holder, T; Bakker, D; Vrettou, C; Morrison, WI; Vordermeier, M; Connelley, T				Benedictus, Lindert; Steinbach, Sabine; Holder, Thomas; Bakker, Douwe; Vrettou, Christina; Morrison, W. Ivan; Vordermeier, Martin; Connelley, Timothy			Hydrophobic Mycobacterial Antigens Elicit Polyfunctional T Cells in Mycobacterium bovis Immunized Cattle: Association With Protection Against Challenge?	FRONTIERS IN IMMUNOLOGY			English	Article						bovine tuberculosis; lipopeptides; Mycobacterium bovis; vaccine; hydrophobic antigens	BCG VACCINATION; LIPID ANTIGENS; TUBERCULOSIS; INFECTION; LIPOPEPTIDES; RESPONSES; VACCINES; RECOGNITION; VIRULENCE; EPITOPES	Bovine tuberculosis (bTB), caused by Mycobacterium bovis, is a chronic disease of cattle with a detrimental impact on food quality and production. Research on bTB vaccines has predominantly been focused on proteinaceous antigens. However, mycobacteria have a thick and intricate lipid outer layer and lipids as well as lipopeptides are important for immune-evasion and virulence. In humans, lipid extracts of M. tuberculosis have been shown to elicit immune responses effective against M. tuberculosis in vitro. Chloroform-methanol extraction (CME) was applied to M. bovis BCG to obtain a hydrophobic antigen extract (CMEbcg) containing lipids and lipopeptides. CMEbcg stimulated IFN-gamma+IL-2(+) and IL-17A(+)IL-22(+) polyfunctional T cells and elicited T cell responses with a Th1 and Th17 cytokine release profile in both M. bovis BCG vaccinated and M. bovis challenged calves. Lipopeptides were shown to be the immunodominant antigens in CMEbcg, stimulating CD4 T cells via MHC class II. CMEbcg expanded T cells killed CMEbcg loaded monocytes and the CMEbcg-specific CD3 T cell proliferative response following M. bovis BCG vaccination was the best predictor for reduced pathology following challenge with M. bovis. Although the high predictive value of CMEbcg-specific immune responses does not confirm a causal relationship with protection against M. bovis challenge, when taking into account the in vitro antimycobacterial phenotype of CMEbcg-specific T cells (e.g. Th1/Th17 cytokine profile), it is indicative that CMEbcg-specific immune responses could play a functional role in immunity against M. bovis. Based on these findings we conclude that lipopeptides of M. bovis are potential novel subunit vaccine candidates and that further studies into the functional characterization of lipopeptide-specific immune responses together with their role in protection against bovine tuberculosis are warranted.	[Benedictus, Lindert; Vrettou, Christina; Morrison, W. Ivan; Connelley, Timothy] Univ Edinburgh, Roslin Inst, Div Infect & Immun, Easter Bush, England; [Steinbach, Sabine; Holder, Thomas; Vordermeier, Martin] Anim & Plant Hlth Agcy, Dept Bacteriol, Weybridge, Surrey, England; [Vordermeier, Martin] Aberystwyth Univ, Inst Biol Environm & Rural Sci, Ctr Bovine TB, Aberystwyth, Dyfed, Wales	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; Animal & Plant Health Agency UK; Aberystwyth University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Institute of Biological, Environmental, Rural & Sciences (IBERS)	Benedictus, L; Connelley, T (corresponding author), Univ Edinburgh, Roslin Inst, Div Infect & Immun, Easter Bush, England.	L.Benedictus1@uu.nl; timothy.connelley@roslin.ed.ac.uk		Benedictus, Lindert/0000-0001-7605-2710	UK Biotechnology and Biological Sciences Research Council (BBSRC) [BBN004647/1]; UK Department for Environment, Food and Rural affairs on behalf of England, Scotland and Wales [SE3299]; BBSRC; BBSRC [BB/N004647/1] Funding Source: UKRI	UK Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK Department for Environment, Food and Rural affairs on behalf of England, Scotland and Wales; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was funded by the UK Biotechnology and Biological Sciences Research Council (BBSRC, Grant number BBN004647/1) and the bovine tuberculosis research budget held and administered centrally by the UK Department for Environment, Food and Rural affairs on behalf of England, Scotland and Wales (Project Code SE3299). Work at the Roslin Institute is supported by Strategic Program Grants from the BBSRC.	[Anonymous], 2019, IMMUNE EPITOPE DATAB; Infantes-Lorenzo JA, 2017, CLIN PROTEOM, V14, DOI 10.1186/s12014-017-9171-z; Ashhurst AS, 2019, J MED CHEM, V62, P8080, DOI 10.1021/acs.jmedchem.9b00832; BALDWIN CL, 1987, PARASITE IMMUNOL, V9, P499, DOI 10.1111/j.1365-3024.1987.tb00526.x; Bastian M, 2008, J IMMUNOL, V180, P3436, DOI 10.4049/jimmunol.180.5.3436; Becker K, 2016, FEBS LETT, V590, P3800, DOI 10.1002/1873-3468.12273; BEHAR SM, 1995, J EXP MED, V182, P2007, DOI 10.1084/jem.182.6.2007; Bhuju S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003077; Blunt L, 2015, VACCINE, V33, P7276, DOI 10.1016/j.vaccine.2015.10.113; Borsuk S, 2009, TUBERCULOSIS, V89, P423, DOI 10.1016/j.tube.2009.07.003; Brulle JK, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-223; BUDDLE BM, 1995, VACCINE, V13, P1123, DOI 10.1016/0264-410X(94)00055-R; Buddle BM, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00259; Coad M, 2019, VET MICROBIOL, V230, P1, DOI 10.1016/j.vetmic.2019.01.007; Coad M, 2010, VET RES, V41, DOI 10.1051/vetres/2009062; Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590; Cousins DV, 2001, REV SCI TECH OIE, V20, P71, DOI 10.20506/rst.20.1.1263; De Libero G, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00219, 10.3389/fimmu.2014.00679]; DEFRA, 2014, STRAT ACH OFF BOV TU; Dobson G., 1985, CHEM METHODS BACTERI, P237; Egbe NF, 2016, SCI REP-UK, V6, DOI 10.1038/srep24320; Endsley JJ, 2007, VACCINE, V25, P8384, DOI 10.1016/j.vaccine.2007.10.011; Endsley JJ, 2004, J IMMUNOL, V173, P2607, DOI 10.4049/jimmunol.173.4.2607; Farrell D, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000071; Fitzgerald SD, 2013, VET PATHOL, V50, P488, DOI 10.1177/0300985812467472; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ghazaei C, 2018, J RES MED SCI, V23, DOI 10.4103/jrms.JRMS_904_17; Gupta N, 2016, VACCINE, V34, P5677, DOI 10.1016/j.vaccine.2016.08.075; Hart J, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-119; Hoek A, 2010, VACCINE, V28, P5910, DOI 10.1016/j.vaccine.2010.06.042; Hu D, 2014, VACCINE, V32, P2308, DOI 10.1016/j.vaccine.2014.02.069; Jasenosky LD, 2015, IMMUNOL REV, V264, P74, DOI 10.1111/imr.12274; Jones GJ, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00551-16, 10.1128/cvi.00551-16]; Kaufmann E, 2016, J IMMUNOL, V196, P2723, DOI 10.4049/jimmunol.1502307; Khoshnood S, 2018, INT J BIOL MACROMOL, V120, P180, DOI 10.1016/j.ijbiomac.2018.08.037; Layre E, 2011, J LIPID RES, V52, P1098, DOI 10.1194/jlr.M013482; Layre E, 2009, CHEM BIOL, V16, P82, DOI 10.1016/j.chembiol.2008.11.008; Livingstone PG, 2015, NEW ZEAL VET J, V63, P98, DOI 10.1080/00480169.2015.1013581; Loing E, 2000, J IMMUNOL, V164, P900, DOI 10.4049/jimmunol.164.2.900; Vazquez CL, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00720-16; Maggioli MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122571; Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; More SJ, 2015, VET REC, V177, P224, DOI 10.1136/vr.103163; Morita D, 2016, IMMUNOLOGY, V149, P139, DOI 10.1111/imm.12646; Motoi Y, 2014, INT IMMUNOL, V26, P563, DOI 10.1093/intimm/dxu054; Neyrolles O, 2001, J IMMUNOL, V166, P447, DOI 10.4049/jimmunol.166.1.447; Nugent G, 2017, VET MICROBIOL, V208, P181, DOI 10.1016/j.vetmic.2017.07.029; Olea-Popelka F, 2017, LANCET INFECT DIS, V17, pE21, DOI 10.1016/S1473-3099(16)30139-6; Pirson C, 2015, CLIN VACCINE IMMUNOL, V22, P178, DOI 10.1128/CVI.00638-14; Pirson C, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-54; POLLOCK JM, 1994, IMMUNOLOGY, V82, P9; Prados-Rosales R, 2014, MBIO, V5, DOI 10.1128/mBio.01921-14; RayWaters W, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/768542; Rhodes SG, 2014, CLIN VACCINE IMMUNOL, V21, P39, DOI 10.1128/CVI.00522-13; Rizzi C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051396; ROBINSON JH, 1992, IMMUNOLOGY, V76, P593; Rodriguez-Campos S, 2014, RES VET SCI, V97, pS5, DOI 10.1016/j.rvsc.2014.02.009; Sakthi S, 2016, VACCINE, V34, P735, DOI 10.1016/j.vaccine.2015.12.059; Sander P, 2004, MOL MICROBIOL, V52, P1543, DOI 10.1111/j.1365-2958.2004.04041.x; Scherer CFC, 2009, TRANSBOUND EMERG DIS, V56, P228, DOI 10.1111/j.1865-1682.2008.01058.x; Seshadri C, 2013, J IMMUNOL, V190, P278, DOI 10.4049/jimmunol.1201667; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Skinner MA, 2003, IMMUNOLOGY, V110, P234, DOI 10.1046/j.1365-2567.2003.01731.x; Smith NH, 2009, NAT REV MICROBIOL, V7, P537, DOI 10.1038/nrmicro2165; Srinivasan S, 2018, TRANSBOUND EMERG DIS, V65, P1627, DOI 10.1111/tbed.12915; Steinbach S, 2019, VET IMMUNOL IMMUNOP, V217, DOI 10.1016/j.vetimm.2019.109930; Steinbach S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29990; Stone DM, 2000, CLIN IMMUNOL, V96, P280, DOI 10.1006/clim.2000.4900; Sulzenbacher G, 2006, EMBO J, V25, P1436, DOI 10.1038/sj.emboj.7601048; Nguyen TKA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121923; Tyne AS, 2013, VACCINE, V31, P4322, DOI 10.1016/j.vaccine.2013.07.022; Van Rhijn I, 2009, EUR J IMMUNOL, V39, P3031, DOI 10.1002/eji.200939619; Bianco MV, 2011, VIRULENCE, V2, P233, DOI 10.4161/viru.2.3.15888; Vordermeier HM, 2016, ANNU REV ANIM BIOSCI, V4, P87, DOI 10.1146/annurev-animal-021815-111311; Vordermeier HM, 2009, INFECT IMMUN, V77, P3364, DOI 10.1128/IAI.00287-09; Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002; Vordermeier HM, 1999, CLIN DIAGN LAB IMMUN, V6, P675, DOI 10.1128/CDLI.6.5.675-682.1999; Vordermeier M, 2012, METHODS MOL BIOL, V792, P219, DOI 10.1007/978-1-61779-325-7_17; Waters WR, 2012, VACCINE, V30, P2611, DOI 10.1016/j.vaccine.2012.02.018; Waters WR, 2009, VACCINE, V27, P1201, DOI 10.1016/j.vaccine.2008.12.018; Wedlock DN, 2007, VET IMMUNOL IMMUNOP, V118, P50, DOI 10.1016/j.vetimm.2007.04.005; Wedlock DN, 2003, TUBERCULOSIS, V83, P339, DOI 10.1016/S1472-9792(03)00055-6; Whelan AO, 2011, VACCINE, V29, P5453, DOI 10.1016/j.vaccine.2011.05.057; World Health Organization, 2015, WHO EST GLOB BURD FO; Yang HL, 2012, FEMS IMMUNOL MED MIC, V66, P273, DOI 10.1111/j.1574-695X.2012.01002.x; Zeman M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00318	88	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2020	11								588180	10.3389/fimmu.2020.588180	http://dx.doi.org/10.3389/fimmu.2020.588180			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV4VT	33281817	Green Published, gold			2022-12-18	WOS:000592210300001
J	Keshtkar-Jahromi, M; Reisler, RB; Haller, JM; Clizbe, DP; Rivard, RG; Cardile, AP; Pierson, BC; Norris, S; Saunders, D; Pittman, PR				Keshtkar-Jahromi, Maryam; Reisler, Ronald B.; Haller, Jeannine M.; Clizbe, Denise P.; Rivard, Robert G.; Cardile, Anthony P.; Pierson, Benjamin C.; Norris, Sarah; Saunders, David; Pittman, Phillip R.			The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; Western Equine Encephalitis; immunogenicity; clinical trial; inactivated	ENCEPHALOMYELITIS; VIRUS	Background Western Equine Encephalitis (WEE) is a naturally acquired infection and potentially devastating bioweapon, with no specific human countermeasures. An experimental inactivated Western Equine Encephalitis Vaccine (WEEV; WEE TSI-GSD 210) has been used under an IND (investigational New Drug) protocol at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) since 1976. Methods Over 24 years from 1987 to 2011, 876 subjects received 3 primary vaccine doses under 3 studies with 1,537 booster doses administered (FY87-8, phase 2, laboratory workers, vaccine lots 1-81-1, 1-81-2, and 2-1-91; FY99-12, phase 2 laboratory workers, lot 2-1-91; and FY09-02, phase 1 healthy volunteer, lot 3-1-92). Post-vaccination safety and immunogenicity [plaque reduction neutralization test 80% (PRNT80) > 1:40] were analyzed. Results Overall PRNT80 response to the primary series in FY87-8 was 42% (326/770) but dropped to 16% (14/87) in FY99-12, prompting study FY09-02, which achieved 89% (17/19). The first booster response rate was 68% (814/1194) in FY87-8, 53% (171/324) in FY99-12, and 100% (10/10) in FY09-02. The majority of definitely related adverse reactions (AEs) were mild and local with no definitely related serious AEs. No laboratory acquired WEE infection was documented during this period despite 4 reported exposures in vaccinated subjects. Conclusion The TSI-GSD 210 WEE vaccine was immunogenic, safe and well tolerated. Use of this vaccine could be considered in an emergency setting. Despite decades of safe and effective use under IND, full licensure is not planned due to manufacturing constraints, and a strategic decision to develop alternatives.	[Keshtkar-Jahromi, Maryam] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA; [Reisler, Ronald B.; Haller, Jeannine M.; Clizbe, Denise P.; Rivard, Robert G.; Cardile, Anthony P.; Pierson, Benjamin C.; Norris, Sarah; Saunders, David; Pittman, Phillip R.] US Army, Med Res Inst Infect Dis, Div Med, Ft Detrick, MD 21702 USA	Johns Hopkins University	Keshtkar-Jahromi, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.	maryam.keshtkar@jhmi.edu; sarah.l.norris2.civ@mail.mil	Pittman, Phillip/ADI-6097-2022		US Army Medical Research and Development Command (USAMRDC); Defense Threat Reduction Agency (DTRA); USAMRIID; Joint Product Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)	US Army Medical Research and Development Command (USAMRDC); Defense Threat Reduction Agency (DTRA)(United States Department of DefenseDefense Threat Reduction Agency); USAMRIID; Joint Product Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)	This work was supported by the US Army Medical Research and Development Command (USAMRDC); Defense Threat Reduction Agency (DTRA); multiple extramural partners with at-risk laboratory personnel; and USAMRIID. Funding for safety, potency testing, and product storage was provided to USAMRIID by the Joint Product Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).	Arechiga-Ceballos N, 2015, REV SCI TECH OIE, V34, P491, DOI 10.20506/rst.34.2.2374; BARTELLONI PJ, 1971, AM J TROP MED HYG, V20, P146, DOI 10.4269/ajtmh.1971.20.146; Bergren NA, 2014, J VIROL, V88, P9260, DOI 10.1128/JVI.01463-14; BURKE DS, 1977, J INFECT DIS, V136, P354, DOI 10.1093/infdis/136.3.354; Burke DS, 2011, PROTECTING FRONTLINE; Delfraro A, 2011, EMERG INFECT DIS, V17, P952, DOI 10.3201/eid1705.101068; Fothergill LD, 1939, J AMER MED ASSOC, V113, P206, DOI 10.1001/jama.1939.02800280018005; Gold H, 1942, ANN INTERN MED, V16, P556, DOI 10.7326/0003-4819-16-3-556; GRIFFIN DE, 2007, FIELDS VIROLOGY; HELWIG FC, 1940, JAMA-J AM MED ASSOC, V115, P291, DOI DOI 10.1001/JAMA.1940.72810300005007C; Honnold SP, 2018, TXB MILITARY MED MED, P479; Hu WG, 2018, VACCINE, V36, P5194, DOI 10.1016/j.vaccine.2018.06.064; Ko SY, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3113; MANGIAFICO JA, 1988, AM J TROP MED HYG, V39, P593, DOI 10.4269/ajtmh.1988.39.593; Meyer KF, 1931, SCIENCE, V74, P227, DOI 10.1126/science.74.1913.227; Pittman P.R., 2013, VACCINES, P1008; Pittman PR, 2009, VACCINE, V27, P4879, DOI 10.1016/j.vaccine.2009.02.090; RANDALL R, 1949, J IMMUNOL, V63, P313; Reed DS, 2014, J VIROL, V88, P12077, DOI 10.1128/JVI.01406-14; Robb LL, 2019, J MED ENTOMOL, V56, P584, DOI 10.1093/jme/tjy214; Rusnak JM, 2004, J OCCUP ENVIRON MED, V46, P801, DOI 10.1097/01.jom.0000135539.99691.4e; Weaver SC, 2009, VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES, P339, DOI 10.1016/B978-0-12-369408-9.00021-4; World Health organization Information Sheet, OBS RAT VACC REACT I	23	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 9	2020	11								555464	10.3389/fimmu.2020.555464	http://dx.doi.org/10.3389/fimmu.2020.555464			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OU1VA	33240257	Green Published, gold			2022-12-18	WOS:000591321700001
J	Cao, JT; Zhang, YS; Chen, Y; Liang, SY; Liu, DP; Fan, WL; Xu, YX; Liu, HH; Zhou, ZK; Liu, XL; Hou, SS				Cao, Junting; Zhang, Yunsheng; Chen, Ying; Liang, Suyun; Liu, Dapeng; Fan, Wenlei; Xu, Yaxi; Liu, Hehe; Zhou, Zhengkui; Liu, Xiaolin; Hou, Shuisheng			Dynamic Transcriptome Reveals the Mechanism of Liver Injury Caused by DHAV-3 Infection in Pekin Duck	FRONTIERS IN IMMUNOLOGY			English	Article						duck hepatitis A virus 3; RNA-seq; duck; liver; apoptosis	HEPATITIS-VIRUS; MOLECULAR EPIDEMIOLOGY; IMMUNE-RESPONSES; APOPTOSIS; CHICKEN; PROTEIN; TYPE-1; RECOGNITION; EXPRESSION; RESISTANCE	Duck hepatitis A virus 3 (DHAV-3) is a wild endemic virus, which seriously endangers the duck industry in China. The present study aims to elucidate the mechanism of duck resistance to DHAV-3 infection. Both resistant and susceptible ducks were challenged with DHAV-3 in this experiment. The histopathological features and serum biochemical indices (ALT and AST) were analyzed to estimate liver injury status at 6, 12, 15, and 24 h post-infection (hpi). The dynamic transcriptomes of liver were analyzed to explain the molecular regulation mechanism in ducks against DHAV-3. The result showed that the liver injury in susceptible ducks was more serious than that in the resistant ducks throughout the four time points. A total of 2,127 differentially expressed genes (DEGs) were identified by comparing the transcriptome of the two populations. The expression levels of genes involved in innate immune response increased rapidly in susceptible ducks from 12 hpi. Similarly, the expression of genes involved in cytokine regulation also increased at the same time points, while the expression levels of these genes in resistant ducks remained similar between the various time points. KEGG enrichment analysis of the DEGs revealed that the genes involved in cytokine regulation and apoptosis were highly expressed in susceptible ducks than that in resistant ducks, suggesting that excessive cytokine storm and apoptosis may partially explain the mechanism of liver injury caused by DHAV-3 infection. Besides, we found that the FUT9 gene may contribute to resistance towards DHAV-3 in resistant ducklings. These findings will provide insight into duck resistance and susceptibility to DHAV-3 infection in the early phases, facilitate the development of a strategy for DHAV-3 prevention and treatment, and enhance genetic resistance via genetic selection in animal breeding.	[Cao, Junting; Liu, Xiaolin] Northwest A&F Univ, Coll Anim Sci & Technol, Shaanxi Key Lab Mol Biol Agr, Yangling, Shaanxi, Peoples R China; [Cao, Junting; Zhang, Yunsheng; Chen, Ying; Liang, Suyun; Liu, Dapeng; Fan, Wenlei; Xu, Yaxi; Liu, Hehe; Zhou, Zhengkui; Hou, Shuisheng] Chinese Acad Agr Sci, Inst Anim Sci, Minist Agr, Key Lab Anim Genet Breeding & Reprod Poultry, Beijing, Peoples R China; [Fan, Wenlei] Qingdao Agr Univ, Coll Food Sci & Engn, Qingdao, Peoples R China	Northwest A&F University - China; Chinese Academy of Agricultural Sciences; Institute of Animal Science, CAAS; Ministry of Agriculture & Rural Affairs; Qingdao Agricultural University	Liu, XL (corresponding author), Northwest A&F Univ, Coll Anim Sci & Technol, Shaanxi Key Lab Mol Biol Agr, Yangling, Shaanxi, Peoples R China.; Hou, SS (corresponding author), Chinese Acad Agr Sci, Inst Anim Sci, Minist Agr, Key Lab Anim Genet Breeding & Reprod Poultry, Beijing, Peoples R China.	liuxiaolin@nwsuaf.edu.cn; houss@263.net	zhang, yunsheng/AAP-8347-2021		National Natural Science Foundation of China [31772592]; Chinese Agriculture Research System of Waterfowl [CARS-42]; Central Publicinterest Scientific Institution Basal Research Fund [2019-YWFYB-08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Agriculture Research System of Waterfowl; Central Publicinterest Scientific Institution Basal Research Fund	This work was supported by grants from the National Natural Science Foundation of China (31772592), Chinese Agriculture Research System of Waterfowl (CARS-42) and Central Publicinterest Scientific Institution Basal Research Fund (2019-YWFYB-08).	Chakraborty P, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020074; Cheng L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.450; Chou AH, 2005, J IMMUNOL, V174, P2160, DOI 10.4049/jimmunol.174.4.2160; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Dalio RJD, 2017, ANN BOT-LONDON, V119, P749, DOI [10.1093/aob/mcx076, 10.1093/aob/mcw238]; Deist MS, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00027-17, 10.1128/cvi.00027-17]; Kakizaki M, 2016, JPN J INFECT DIS, V69, P405, DOI 10.7883/yoken.JJID.2015.499; Kashiwazaki H, 2014, PATHOL INT, V64, P199, DOI 10.1111/pin.12159; Kim MC, 2006, J GEN VIROL, V87, P3307, DOI 10.1099/vir.0.81804-0; Kim WR, 2008, HEPATOLOGY, V47, P1363, DOI 10.1002/hep.22109; Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976; Lai YL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53285-0; Liu C, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6120-4; Morris R, 2018, PROTEIN SCI, V27, P1984, DOI 10.1002/pro.3519; Niu GJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02392; Nystrom K, 2009, GLYCOBIOLOGY, V19, P847, DOI 10.1093/glycob/cwp057; Orzalli MH, 2017, TRENDS CELL BIOL, V27, P810, DOI 10.1016/j.tcb.2017.05.007; Rohaim MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02025; Sahraeian SME, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00050-4; Sarson AJ, 2008, ANIM GENET, V39, P232, DOI 10.1111/j.1365-2052.2008.01710.x; Sheng XD, 2014, POULTRY SCI, V93, P527, DOI 10.3382/ps.2013-03510; Sikora M, 2009, HUM MOL GENET, V18, P3136, DOI 10.1093/hmg/ddp240; Soliman M, 2015, ARCH VIROL, V160, P493, DOI 10.1007/s00705-014-2264-3; Swaggerty CL, 2004, IMMUNOLOGY, V113, P139, DOI 10.1111/j.1365-2567.2004.01939.x; Taghavi M, 2017, EUR J PHARMACOL, V808, P8, DOI 10.1016/j.ejphar.2016.11.013; Takeuchi O, 2008, CURR OPIN IMMUNOL, V20, P17, DOI 10.1016/j.coi.2008.01.002; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464; Tseng CH, 2007, VIRUS RES, V123, P190, DOI 10.1016/j.virusres.2006.09.007; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Wang LY, 2008, VIRUS GENES, V37, P52, DOI 10.1007/s11262-008-0233-1; Wang XY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01128; Wen X, 2018, TRANSBOUND EMERG DIS, V65, P10, DOI 10.1111/tbed.12741; Wilk E, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1867-8; WILLIAMS ALB, 1988, GASTROENTEROLOGY, V95, P734, DOI 10.1016/S0016-5085(88)80022-2; Wilson JAC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006155; Xie JY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01845; Yan YY, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2080-5; Yeganeh B, 2015, WORLD J GASTROENTERO, V21, P13225, DOI 10.3748/wjg.v21.i47.13225; Yugo DM, 2016, AVIAN DIS, V60, P576, DOI 10.1637/11229-070515-Review.1; Zahoor I, 2018, MOL BIOL REP, V45, P31, DOI 10.1007/s11033-017-4138-8; Zavala G, 2006, AVIAN DIS, V50, P209, DOI 10.1637/7444-092405R.1; Zeeshan M, 2019, J SURG RES, V242, P151, DOI 10.1016/j.jss.2019.04.021; Zekarias B, 2002, VET RES, V33, P109, DOI 10.1051/vetres:2002001; Zhang HR, 2012, AVIAN PATHOL, V41, P613, DOI 10.1080/03079457.2012.745641; Zhang QZ, 2015, VET MICROBIOL, V177, P229, DOI 10.1016/j.vetmic.2015.04.002; Zhang R, 2017, ACTA VIROL, V61, P463, DOI 10.4149/av_2017_409; Zou Z, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01613	48	1	1	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 6	2020	11								568565	10.3389/fimmu.2020.568565	http://dx.doi.org/10.3389/fimmu.2020.568565			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OT0FL	33240261	Green Published, gold			2022-12-18	WOS:000590530400001
J	Cinicola, B; Uva, A; Leonardi, L; Moratto, D; Giliani, S; Carsetti, R; Ferrari, S; Zicari, AM; Duse, M				Cinicola, Bianca; Uva, Andrea; Leonardi, Lucia; Moratto, Daniele; Giliani, Silvia; Carsetti, Rita; Ferrari, Simona; Zicari, Anna Maria; Duse, Marzia			Case Report: A Case of X-Linked Agammaglobulinemia With High Serum IgE Levels and Allergic Rhinitis	FRONTIERS IN IMMUNOLOGY			English	Article						X-linked Agammaglobulinemia; BTK gene; protein expression; mild phenotype; IgE production; allergy	GENOTYPE-PHENOTYPE CORRELATION; MUTATIONS; DIAGNOSIS; PATIENT; GENE	X-linked Agammaglobulinemia (XLA) is a rare genetic disorder of B-lymphocyte differentiation, characterized by the absence or paucity of circulating B cells, markedly reduced levels of all serum immunoglobulin isotypes and lack of specific antibody production. Bruton Tyrosine Kinase (BTK) gene encodes a cytoplasmic tyrosine kinase involved in the B cell maturation and its mutation, blocking B cell differentiation at the pre-B cell stage, and is responsible for XLA. All domains may be affected by the mutation, and the many genotypes are associated with a wide range of clinical presentations. Little is known about genotype-phenotype correlation in this disorder, and factors influencing the phenotype of XLA are not clearly understood. In this report we present a unique case of a young patient affected by XLA. The disease was genetically diagnosed at birth due to a family history of XLA, but during follow up, it was characterized by a CD19+ B cell percentage consistently greater than 2%. He never suffered severe infections, but at two years of age, he developed persistent rhinitis. Thus, total serum IgE levels were measured and detected over the normal range, and specific allergic investigations showed sensitization to dust mites. Further immunological tests (BTK expression, functional "in vitro" B cell proliferation upon CpG stimulation, B cell subset analysis) explained these findings as possible manifestations of a mild XLA phenotype. XLA patients rarely present with allergic manifestations, which could warrant further investigation. High serum IgE levels could be a sign of a mild phenotype, but their role and the mechanisms underlying their production in XLA need to be clarified.	[Cinicola, Bianca; Uva, Andrea; Leonardi, Lucia; Zicari, Anna Maria; Duse, Marzia] Sapienza Univ Rome, Dept Pediat, Policlin Umberto 1, Rome, Italy; [Moratto, Daniele; Giliani, Silvia] Spedali Civili Hosp, A Nocivelli Inst Mol Med, Cytogenet & Med Genet Unit, Brescia, Italy; [Moratto, Daniele] Spedali Civili Hosp, Flow Cytometry Unit, Clin Chem Lab, Brescia, Italy; [Giliani, Silvia] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Carsetti, Rita] Bambino Gesu Children Hosp, B Cell Physiopathol Unit, Immunol Res Area, Rome, Italy; [Ferrari, Simona] S Orsola Malpighi Univ Hosp, Med Genet Unit, Bologna, Italy	Sapienza University Rome; University Hospital Sapienza Rome; Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; University of Brescia; IRCCS Bambino Gesu; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Cinicola, B (corresponding author), Sapienza Univ Rome, Dept Pediat, Policlin Umberto 1, Rome, Italy.	biancacinicola@gmail.com	leonardi, lucia/CAI-9838-2022	leonardi, lucia/0000-0002-2554-1263; Cinicola, Bianca Laura/0000-0003-1268-5038				Aadam Z, 2016, J CLIN IMMUNOL, V36, P187, DOI 10.1007/s10875-016-0251-z; Broides A, 2006, CLIN IMMUNOL, V118, P195, DOI 10.1016/j.clim.2005.10.007; Carrillo-Tapia E, 2018, EXPERT REV CLIN IMMU, V14, P83, DOI 10.1080/1744666X.2018.1413349; Chen XF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004544; Chun JK, 2008, YONSEI MED J, V49, P28, DOI 10.3349/ymj.2008.49.1.28; Conley ME, 2002, CURR OPIN ALLERGY CL, V2, P517, DOI 10.1097/00130832-200212000-00007; Conley ME, 2002, J PEDIATR-US, V141, P566, DOI 10.1067/mpd.2002.127711; Fujioka T, 2011, PEDIATR INT, V53, P611, DOI 10.1111/j.1442-200X.2011.03409.x; GAJLPECZALSKA KJ, 1973, LANCET, V1, P1254; GANIER M, 1977, JAMA-J AM MED ASSOC, V237, P1852; Gaspar HB, 2000, CLIN EXP IMMUNOL, V120, P346, DOI 10.1046/j.1365-2249.2000.01230.x; Holinski-Feder E, 1998, PEDIATRICS, V101, P276, DOI 10.1542/peds.101.2.276; Kaneko H, 2005, CLIN EXP IMMUNOL, V140, P520, DOI 10.1111/j.1365-2249.2005.02784.x; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Lee PPW, 2010, J CLIN IMMUNOL, V30, P121, DOI 10.1007/s10875-009-9341-5; Lopez-Granados E, 2005, J ALLERGY CLIN IMMUN, V116, P690, DOI 10.1016/j.jaci.2005.04.043; Lougaris V, 2020, J ALLERGY CLIN IMMUN, V146, P429, DOI 10.1016/j.jaci.2020.03.001; Melo KM, 2013, ISRN PEDIAT, V2013, DOI [10.1155/2013/470286, DOI 10.1155/2013/470286]; Nonoyama S, 1998, J IMMUNOL, V161, P3925; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Shabestari MS, 2008, J INVEST ALLERG CLIN, V18, P300; Shillitoe BMJ, 2019, CURR OPIN ALLERGY CL, V19, P571, DOI 10.1097/ACI.0000000000000584; Sigmon Justin R, 2008, Clin Mol Allergy, V6, P5, DOI 10.1186/1476-7961-6-5; Stewart D M, 2001, Curr Allergy Asthma Rep, V1, P558, DOI 10.1007/s11882-001-0065-8; Takada H, 2004, BLOOD, V103, P185, DOI 10.1182/blood-2003-06-1964; Teimourian S, 2008, J PEDIAT HEMATOL ONC, V30, P679, DOI 10.1097/MPH.0b013e318180bb45; Valiaho J, 2006, HUM MUTAT, V27, P1209, DOI 10.1002/humu.20410; Vetrie D, 2012, J IMMUNOL, V188, P2948; Wada T, 2008, CURR OPIN ALLERGY CL, V8, P510, DOI 10.1097/ACI.0b013e328314b651; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad	31	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2020	11								582376	10.3389/fimmu.2020.582376	http://dx.doi.org/10.3389/fimmu.2020.582376			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OX3GA	33224144	Green Published, gold			2022-12-18	WOS:000593456200001
J	Roldan, NG; Duda, KA				Gonzalez Roldan, Nestor; Duda, Katarzyna Anna			Editorial: Role of Lipids in the Dynamics of Allergic Airway Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lipid adjuvants; natural killer T cell; asthma; structure-activity relationship; allergic inflammation; allergen-specific immunotherapy			[Gonzalez Roldan, Nestor] Leibniz Lung Ctr, Res Ctr Borstel, Grp Allergobiochem Prior Res Area Asthma & Allerg, Borstel, Germany; German Ctr Lung Res DZL, Airway Res Ctr North ARCN, Borstel, Germany	Forschungszentrum Borstel	Roldan, NG (corresponding author), Leibniz Lung Ctr, Res Ctr Borstel, Grp Allergobiochem Prior Res Area Asthma & Allerg, Borstel, Germany.	ngonzalez@fz-borstel.de						Albacker LA, 2013, NAT MED, V19, P1297, DOI 10.1038/nm.3321; Birkholz AM, 2015, BIOMED J, V38, P470, DOI 10.1016/j.bj.2016.01.003; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Fahy E, 2011, BBA-MOL CELL BIOL L, V1811, P637, DOI 10.1016/j.bbalip.2011.06.009; Woodfolk JA, 2015, ALLERGOL INT, V64, P295, DOI 10.1016/j.alit.2015.06.001; Yoshimoto T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00716	6	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 4	2020	11								612297	10.3389/fimmu.2020.612297	http://dx.doi.org/10.3389/fimmu.2020.612297			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OS1WK	33250902	Green Published, gold			2022-12-18	WOS:000589955900001
J	Davis, RP; Almishri, W; Jenne, CN; Swain, MG				Davis, Rachelle Paige; Almishri, Wagdi; Jenne, Craig Neal; Swain, Mark Gordon			The Antidepressant Mirtazapine Activates Hepatic Macrophages, Facilitating Pathogen Clearance While Limiting Tissue Damage in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						mirtazapine; imaging; macrophage; inflammation; infection; liver	KUPFFER CELLS; INTRAVASCULAR COAGULATION; LIVER; SEROTONIN; POLARIZATION; PHAGOCYTOSIS; INFLAMMATION; NEUTROPHILS; DEPRESSION; MODULATION	Background and Aims Mirtazapine is an atypical antidepressant with antagonist activity for serotonin and histamine receptors. Clinical and experimental evidence suggests that, in addition to treating depression, mirtazapine also alters liver innate immunity and suppresses immune-driven hepatic macrophage activation. Liver macrophages, Kupffer cells, represent the largest collection of fixed macrophages in the body and are critical in regulating hepatic immunity. In addition to their capacity to regulate inflammation, Kupffer cells are key sentinels for clearing blood-borne pathogens, preventing their dissemination within the body. This process involves pathogen capture, phagocytosis, and activation-induced killing via reactive oxygen species (ROS) production. Therefore, we speculated that mirtazapine might adversely alter Kupffer cell pathogen-associated activation and killing. Methods Mice were treated with mirtazapine and time-dependent changes in Kupffer cells were characterized using intravital microscopy. Macrophage and neutrophil responses, bacterial dissemination, and liver damage were assessed following i.v. infection with a pathogenic strain of S. aureus. Results Mirtazapine rapidly (within 1.5 h) activates Kupffer cells, indicated by a loss of elongated shape with cellular rounding. However, this shape change did not result in impaired pathogen capture function, and, in fact, generated enhanced ROS production in response to S. aureus-induced sepsis. Neutrophil dynamics were altered with reduced cellular recruitment to the liver following infection. Bacterial dissemination post-intravenous administration was not altered by mirtazapine treatment; however, hepatic abscess formation was significantly reduced. Conclusions Mirtazapine rapidly activates Kupffer cells, associated with preserved bacterial capture functions and enhanced ROS generation capacity. Moreover, these changes in Kupffer cells were linked to a beneficial reduction in hepatic abscess size. In contrast to our initial speculation, mirtazapine may have beneficial effects in sepsis and warrants further exploration.	[Davis, Rachelle Paige; Almishri, Wagdi; Jenne, Craig Neal; Swain, Mark Gordon] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Davis, Rachelle Paige; Almishri, Wagdi; Jenne, Craig Neal; Swain, Mark Gordon] Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada	University of Calgary; University of Calgary	Swain, MG (corresponding author), Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.; Swain, MG (corresponding author), Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada.	swain@ucalgary.ca			Canadian Foundation for Innovation; Alberta Innovates and Advanced Education; Cal Wenzel Family Foundation Chair in Hepatology; Canadian Institutes in health Research Team Inflammation grant; University of Calgary Faculty of Graduate Studies Indigenous Graduate Award; Canada Research Chairs program; Canadian Liver Foundation	Canadian Foundation for Innovation(Canada Foundation for Innovation); Alberta Innovates and Advanced Education; Cal Wenzel Family Foundation Chair in Hepatology; Canadian Institutes in health Research Team Inflammation grant(Canadian Institutes of Health Research (CIHR)); University of Calgary Faculty of Graduate Studies Indigenous Graduate Award; Canada Research Chairs program(Canada Research Chairs); Canadian Liver Foundation	This study was supported by grants from the Canadian Foundation for Innovation, Alberta Innovates and Advanced Education, the Cal Wenzel Family Foundation Chair in Hepatology (MS), and the Canadian Institutes in health Research Team Inflammation grant. RD is funded by the Canadian Liver Foundation and the University of Calgary Faculty of Graduate Studies Indigenous Graduate Award. CJ is supported by the Canada Research Chairs program.	Alcocer-Gomez E, 2017, PHARMACOL RES, V121, P114, DOI 10.1016/j.phrs.2017.04.028; Almishri W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00803; Anttila SAK, 2001, CNS DRUG REV, V7, P249; Benjamin S, 2011, EXPERT OPIN PHARMACO, V12, P1623, DOI 10.1517/14656566.2011.585459; Carestia A, 2020, BLOOD, V135, P1281, DOI 10.1182/blood.2019002783; Chapman Daniel P, 2005, Prev Chronic Dis, V2, pA14; Chosay John G., 1997, American Journal of Physiology, V272, pG1195; de las Casas-Engel M, 2013, J IMMUNOL, V190, P2301, DOI 10.4049/jimmunol.1201133; El-Tanbouly DM, 2017, TOXICOL APPL PHARM, V329, P224, DOI 10.1016/j.taap.2017.06.012; Fang CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038886; Flannagan RS, 2015, PATHOGENS, V4, P826, DOI 10.3390/pathogens4040826; Frokjaer VG, 2015, BIOL PSYCHIAT, V78, P534, DOI 10.1016/j.biopsych.2015.04.015; Frolkis AD, 2019, GUT, V68, P1606, DOI 10.1136/gutjnl-2018-317182; Gaschler GJ, 2009, AM J RESP CRIT CARE, V179, P666, DOI 10.1164/rccm.200808-1306OC; Gill JM, 2010, J AM BOARD FAM MED, V23, P499, DOI 10.3122/jabfm.2010.04.090299; Gregory SH, 1996, J IMMUNOL, V157, P2514; Harter M, 2007, PSYCHOTHER PSYCHOSOM, V76, P354, DOI 10.1159/000107563; He JQ, 2013, J LEUKOCYTE BIOL, V93, P301, DOI 10.1189/jlb.0612311; Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039; Heymann F, 2015, JOVE-J VIS EXP, DOI 10.3791/52607; Holub M, 2009, J IMMUNOL, V183, P3309, DOI 10.4049/jimmunol.0803041; Horiguchi N, 2010, HEPATOLOGY, V51, P1724, DOI 10.1002/hep.23532; Jain N, 2018, NAT MATER, V17, P1134, DOI 10.1038/s41563-018-0190-6; Jenne CN, 2013, CELL HOST MICROBE, V13, P169, DOI 10.1016/j.chom.2013.01.005; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Kim SJ, 2016, SEMIN IMMUNOL, V28, P546, DOI 10.1016/j.smim.2016.10.013; Knudsen AR, 2016, INT J EXP PATHOL, V97, P133, DOI 10.1111/iep.12188; Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673; Kubera M, 2006, PHARMACOL BIOCHEM BE, V85, P813, DOI 10.1016/j.pbb.2006.11.017; Lee YS, 2001, J KOREAN MED SCI, V16, P585, DOI 10.3346/jkms.2001.16.5.585; Lesurtel M, 2014, LIVER TRANSPLANT, V20, P147, DOI 10.1002/lt.23759; Liu ZT, 2014, INT J MED SCI, V11, P925, DOI 10.7150/ijms.8951; Mauler M, 2019, CIRCULATION, V139, P918, DOI 10.1161/CIRCULATIONAHA.118.033942; McDonald B, 2017, BLOOD, V129, P1357, DOI 10.1182/blood-2016-09-741298; McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110; Mendoza-Coronel E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00303; Mikulski Z, 2010, AM J PHYSIOL-LUNG C, V299, pL272, DOI 10.1152/ajplung.00032.2010; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Mullish BH, 2014, ALIMENT PHARM THER, V40, P880, DOI 10.1111/apt.12925; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Pollitt EJG, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007112; PRATTEN MK, 1986, BIOCHIM BIOPHYS ACTA, V881, P307, DOI 10.1016/0304-4165(86)90020-6; Proto JD, 2018, IMMUNITY, V49, P666, DOI 10.1016/j.immuni.2018.07.015; Ruddell RG, 2008, J HEPATOL, V48, P666, DOI 10.1016/j.jhep.2008.01.006; Shaheen AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194839; Simon GE, 2001, WESTERN J MED, V175, P292, DOI 10.1136/ewjm.175.5.292; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Smolag KI, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1731135; Surewaard BGJ, 2018, CELL HOST MICROBE, V24, P271, DOI 10.1016/j.chom.2018.06.017; Surewaard BGJ, 2017, METHODS, V128, P12, DOI 10.1016/j.ymeth.2017.05.004; Surewaard BGJ, 2016, J EXP MED, V213, P1141, DOI 10.1084/jem.20160334; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Tacke F, 2014, J HEPATOL, V60, P1090, DOI 10.1016/j.jhep.2013.12.025; Ustun TB, 2004, BRIT J PSYCHIAT, V184, P386, DOI 10.1192/bjp.184.5.386; Vallerand IA, 2018, RMD OPEN, V4; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vasicek O, 2020, J PHYSIOL BIOCHEM, V76, P49, DOI 10.1007/s13105-019-00714-3; Wong CHY, 2013, NAT IMMUNOL, V14, P785, DOI 10.1038/ni.2631; Xu RN, 2014, CELL MOL IMMUNOL, V11, P224, DOI 10.1038/cmi.2014.2	59	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 3	2020	11								578654	10.3389/fimmu.2020.578654	http://dx.doi.org/10.3389/fimmu.2020.578654			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OR7ZL	33250892	Green Published, gold			2022-12-18	WOS:000589686700001
J	Posch, W; Bermejo-Jambrina, M; Lass-Florl, C; Wilflingseder, D				Posch, Wilfried; Bermejo-Jambrina, Marta; Lass-Floerl, Cornelia; Wilflingseder, Doris			Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity	FRONTIERS IN IMMUNOLOGY			English	Review						complement receptors; dendritic cells; HIV-1; antiviral immunity; immune activation; SAMHD1; antigen presentation; type I IFN	IMMUNODEFICIENCY-VIRUS TYPE-1; IMMATURE DENDRITIC CELLS; INTRACELLULAR COMPLEMENT; HIV-1 INFECTION; ENVELOPE GLYCOPROTEIN; ENHANCES INFECTION; SAMHD1 RESTRICTS; T-CELLS; INNATE; OPSONIZATION	Upon entry of human immunodeficiency virus 1 (HIV-1) into the host, innate immune mechanisms are acting as a first line of defense, that considerably also modify adaptive immunity by the provision of specific signals. Innate and adaptive immune responses are intimately linked and dendritic cells (DCs) together with complement (C) play an important role in regulation of adaptive immunity. Initially, the role of complement was considered to primarily support - or COMPLEMENT - cytolytic actions of antibodies or antibody-complexed antigens (immune complexes, ICs) or directly kill the pathogens by complement-mediated lysis. Recently, the role of complement was revised and found to significantly augmenting and modulating adaptive immunity, in particular against viruses. Complement and DCs are therefore predestined to open novel avenues for antiviral research and potential therapeutic interventions. Recent studies on interactions of complement-opsonized HIV-1 with DCs demonstrated a high potential of such primed DCs to initiate efficient antiviral and cytotoxic anti-HIV-1 immunity and complement-coated viral particles shift DCs functions via CR3 and CR4 in an antithetic manner. This review will focus on our current knowledge of CR3 and CR4 actions on DCs during HIV-1 binding and the outcome of infection influenced by entry and signaling pathways.	[Posch, Wilfried; Bermejo-Jambrina, Marta; Lass-Floerl, Cornelia; Wilflingseder, Doris] Med Univ Innsbruck, Inst Hyg & Med Microbiol, Innsbruck, Austria; [Bermejo-Jambrina, Marta] Univ Amsterdam, Acad Med Ctr, Amsterdam Infect & Immun Inst, Dept Expt Immunol, Amsterdam, Netherlands	Medical University of Innsbruck; University of Amsterdam; Academic Medical Center Amsterdam	Wilflingseder, D (corresponding author), Med Univ Innsbruck, Inst Hyg & Med Microbiol, Innsbruck, Austria.	doris.wilflingseder@i-med.ac.at	Bermejo Jambrina, Marta/GLT-8468-2022; Posch, Wilfried/AAH-6845-2019	Posch, Wilfried/0000-0001-8955-7654; Lass-Florl, Cornelia/0000-0002-2946-7785; Bermejo Jambrina, Marta/0000-0003-1931-6913; Wilflingseder, Doris/0000-0002-5888-5118	Austrian National Bank (OeNB Jubilaumsfonds) [17614]; Austrian Science Fund FWF [P33510-B]	Austrian National Bank (OeNB Jubilaumsfonds); Austrian Science Fund FWF(Austrian Science Fund (FWF))	We thank the Austrian National Bank (OeNB Jubilaumsfonds, number 17614 to WP) and the Austrian Science Fund FWF, project #: P33510-B (to DW).	Ahmed Z, 2015, J INVEST DERMATOL, V135, P1225, DOI 10.1038/jid.2014.490; Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012; Bajtay Z, 2004, J IMMUNOL, V173, P4775, DOI 10.4049/jimmunol.173.8.4775; Balandya E, 2010, J IMMUNOL, V185, P7596, DOI 10.4049/jimmunol.1002846; Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banki Z, 2005, AIDS, V19, P481, DOI 10.1097/01.aids.0000162336.20439.8d; Banki Z, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000891; Berlier W, 2006, HUM REPROD, V21, P1135, DOI 10.1093/humrep/dei496; Berlier W, 2006, J CLIN VIROL, V36, P204, DOI 10.1016/j.jcv.2006.04.004; Bermejo-Jambrina M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02010; Bermejo-Jambrina M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00590; Biermann MHC, 2014, EXPERT REV CLIN IMMU, V10, P1151, DOI 10.1586/1744666X.2014.944162; Bouhlal H, 2002, J IMMUNOL, V169, P3301, DOI 10.4049/jimmunol.169.6.3301; Bouhlal H, 2007, J IMMUNOL, V178, P1086, DOI 10.4049/jimmunol.178.2.1086; Carroll MC, 2012, IMMUNITY, V37, P199, DOI 10.1016/j.immuni.2012.08.002; Ceccaldi PE, 2006, J VIROL, V80, P4771, DOI 10.1128/JVI.80.10.4771-4780.2006; Cribier A, 2013, CELL REP, V3, P1036, DOI 10.1016/j.celrep.2013.03.017; Cunningham AL, 2010, CURR OPIN MICROBIOL, V13, P524, DOI 10.1016/j.mib.2010.06.002; Ellegard R, 2014, J IMMUNOL, V193, P4590, DOI 10.4049/jimmunol.1401781; Fernandez S, 2011, J INFECT DIS, V204, P1927, DOI 10.1093/infdis/jir659; Fraietta JA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003658; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; Geijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Granelli-Piperno A, 2004, P NATL ACAD SCI USA, V101, P7669, DOI 10.1073/pnas.0402431101; Gringhuis SI, 2017, NAT IMMUNOL, V18, P474, DOI 10.1038/ni0417-474c; Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Jauregui P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22432-4; Jauregui P, 2015, J VIROL, V89, P5701, DOI 10.1128/JVI.03575-14; Keller CW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00570; Kim KA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-55; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lahouassa H, 2012, NAT IMMUNOL, V13, P223, DOI 10.1038/ni.2236; Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040; Liszewski MK, 2013, MOL IMMUNOL, V56, P257, DOI 10.1016/j.molimm.2013.05.055; Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018; Manel N, 2011, CELL, V147, P271, DOI 10.1016/j.cell.2011.09.010; Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337; Mercier SK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003700; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Mlcochova P, 2017, EMBO J, V36, P604, DOI 10.15252/embj.201696025; Moris A, 2006, BLOOD, V108, P1643, DOI 10.1182/blood-2006-02-006361; Norton TD, 2015, GENE THER, V22, P227, DOI 10.1038/gt.2014.117; Nyamweya S, 2013, REV MED VIROL, V23, P221, DOI 10.1002/rmv.1739; Pauls E, 2014, J IMMUNOL, V193, P1988, DOI 10.4049/jimmunol.1400873; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; Posch W, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005005; Posch W, 2012, J ALLERGY CLIN IMMUN, V130, P1368, DOI 10.1016/j.jaci.2012.08.025; Pruenster M, 2005, EUR J IMMUNOL, V35, P2691, DOI 10.1002/eji.200425940; Rinaldo CR, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/164203; Rosetti F, 2016, IMMUNOL REV, V269, P175, DOI 10.1111/imr.12373; Saidi H, 2012, AIDS RES HUM RETROV, V28, P1485, DOI [10.1089/aid.2012.0049, 10.1089/AID.2012.0049]; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554; Schifferli JA, 1996, RES IMMUNOL, V147, P109, DOI 10.1016/0923-2494(96)87183-5; Schumann K, 2010, IMMUNITY, V32, P703, DOI 10.1016/j.immuni.2010.04.017; Stax MJ, 2009, VIROLOGY, V391, P203, DOI 10.1016/j.virol.2009.06.011; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; Steinman RM, 2010, EUR J IMMUNOL, V40, P2085, DOI 10.1002/eji.201040733; STOIBER H, 1994, EUR J IMMUNOL, V24, P294, DOI 10.1002/eji.1830240203; STOIBER H, 1995, AIDS, V9, P19, DOI 10.1097/00002030-199501000-00003; STOIBER H, 1995, MOL IMMUNOL, V32, P371, DOI 10.1016/0161-5890(94)00156-U; STOIBER H, 1995, IMMUNOBIOLOGY, V193, P98, DOI 10.1016/S0171-2985(11)80158-0; Stoiber H, 2008, VACCINE, V26, pI79, DOI 10.1016/j.vaccine.2008.11.050; Su B, 2014, J VIROL, V88, P5109, DOI 10.1128/JVI.03057-13; Sugawara S, 2019, AIDS RES HUM RETROV, V35, P25, DOI [10.1089/aid.2018.0161, 10.1089/AID.2018.0161]; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; THIEBLEMONT N, 1995, J IMMUNOL, V155, P4861; THIELENS NM, 1993, J IMMUNOL, V151, P6583; Thomas R, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6374379; Tjomsland V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023542; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Vaahtomeri K, 2017, CELL REP, V19, P902, DOI 10.1016/j.celrep.2017.04.027; Vorup-Jensen T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02716; West EE, 2020, IMMUNOL REV, V295, P68, DOI 10.1111/imr.12852; West EE, 2018, MOL IMMUNOL, V102, P228, DOI 10.1016/j.molimm.2018.06.246; West EE, 2018, ADV IMMUNOL, V138, P35, DOI 10.1016/bs.ai.2018.02.001; White TE, 2013, CELL HOST MICROBE, V13, P441, DOI 10.1016/j.chom.2013.03.005; White TE, 2013, VIROLOGY, V436, P81, DOI 10.1016/j.virol.2012.10.029; Wilflingseder D, 2005, MOL IMMUNOL, V42, P229, DOI 10.1016/j.molimm.2004.06.019; Wilflingseder D, 2007, J IMMUNOL, V178, P7840, DOI 10.4049/jimmunol.178.12.7840; Wilflingseder D, 2015, J INFECT DIS, V212, P44, DOI 10.1093/infdis/jiv014	87	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 3	2020	11								572114	10.3389/fimmu.2020.572114	http://dx.doi.org/10.3389/fimmu.2020.572114			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OR8AF	33224139	Green Published, gold			2022-12-18	WOS:000589688800001
J	Susal, C; Mueller, TF; Legendre, C; Schemmer, P				Suesal, Caner; Mueller, Thomas Friedrich; Legendre, Christophe; Schemmer, Peter			Editorial: Transplantation of Marginal Organs-Immunological Aspects and Therapeutic Perspectives	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						organ transplantation; marginal donors; expanded criteria donors; machine perfusion; organ allocation; graft survival; delayed graft function; antigen silencing			[Suesal, Caner] Heidelberg Univ Hosp, Inst Immunol, Heidelberg, Germany; [Mueller, Thomas Friedrich] Univ Hosp Zurich, Clin Nephrol, Zurich, Switzerland; [Legendre, Christophe] Paris Descartes Univ, Serv Transplantat Renale & Unite Soins Intensifs, Hop Necker Enfants Malad, AP HP, Paris, France; [Schemmer, Peter] Med Univ Graz, Dept Surg, Gen Visceral & Transplant Surg, Graz, Austria	Ruprecht Karls University Heidelberg; University of Zurich; University Zurich Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical University of Graz	Susal, C (corresponding author), Heidelberg Univ Hosp, Inst Immunol, Heidelberg, Germany.	caner.suesal@med.uni-heidelberg.de						Figueiredo C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/796046; Statistics Report Library, 2019, REP 2072P ALL ET KID; Susal C, 2020, TRANSPL INT, V33, P849, DOI 10.1111/tri.13628; Wiegmann B, 2014, BIOMATERIALS, V35, P8123, DOI 10.1016/j.biomaterials.2014.06.007	4	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2020	11								612576	10.3389/fimmu.2020.612576	http://dx.doi.org/10.3389/fimmu.2020.612576			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OP8UT	33193459	gold, Green Accepted, Green Published			2022-12-18	WOS:000588366900001
J	Wieckowski, S; Avenal, C; Orjalo, AV; Gygax, D; Cymer, F				Wieckowski, Sebastien; Avenal, Cecile; Orjalo, Arturo V., Jr.; Gygax, Daniel; Cymer, Florian			Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells	FRONTIERS IN IMMUNOLOGY			English	Article						breast cancer; Fc&#947; RIIIA; flow cytometry; natural killer cells; glycosylation; trastuzumab; antibody-dependent cell-mediated cytotoxicity	NATURAL-KILLER-CELLS; FC-GAMMA-RIIIA; NK CELLS; MONOCLONAL-ANTIBODIES; FLOW-CYTOMETRY; QUALITY ATTRIBUTES; EFFECTOR-CELLS; T-CELLS; TRASTUZUMAB; ADCC	Pharmaceutical manufacturing relies on rigorous methods of quality control of drugs and in particular of the physico-chemical and functional characterizations of monoclonal antibodies. To that end, robust bioassays are very often limited to reporter gene assays and the use of immortalized cell lines that are supposed to mimic immune cells such as natural killer (NK) cells to the detriment of primary materials, which are appreciated for their biological validity but are also difficult to exploit due to the great diversity between individuals. Here, we characterized the phenotype of the peripheral blood circulating cytotoxic cells of 30 healthy donors, in particular the repertoire of cytotoxic markers, using flow cytometry. In parallel, we characterized the antibody-dependent cellular cytotoxicity (ADCC) effector functions of these primary cells by measuring their cytolytic activity against a cancer cell-line expressing HER2 in the presence of trastuzumab and with regards to FCGR3A genotype. We could not establish a correlation or grouping of individuals using the data generated from whole peripheral blood mononuclear cells, however the isolation of the CD56-positive population, which is composed not only of NK cells but also of natural killer T (NKT) and gamma delta-T cells, as well as subsets of activated cytotoxic T cells, monocytes and dendritic cells, made it possible to standardize the parameters of the ADCC and enhance the overall functional avidity without however eliminating the inter-individual diversity. Finally, the use of primary CD56(+) cells in ADCC experiments comparing glycoengineered variants of trastuzumab was conclusive to test the limits of this type of ex vivo system. Although the effector functions of CD56(+) cells reflected to some extent the in vitro receptor binding properties and cytolytic activity data using NK92 cells, as previously published, reaching a functional avidity plateau could limit their use in a quality control framework.	[Wieckowski, Sebastien; Gygax, Daniel] Univ Appl Life Sci & Arts Northwestern Switzerlan, Inst Chem & Bioanalyt, Sch Life Sci, Muttenz, Switzerland; [Avenal, Cecile; Cymer, Florian] F Hoffmann La Roche Ltd, Dept PTDE A, Basel, Switzerland; [Orjalo, Arturo V., Jr.] Genentech Inc, Biol Technol, San Francisco, CA 94080 USA	FHNW University of Applied Sciences & Arts Northwestern Switzerland; Roche Holding; Roche Holding; Genentech	Cymer, F (corresponding author), F Hoffmann La Roche Ltd, Dept PTDE A, Basel, Switzerland.	Florian.Cymer@roche.com	Wieckowski, Sébastien/AAF-4147-2020	Wieckowski, Sébastien/0000-0001-8121-4446; Cymer, Florian/0000-0002-6548-8743	Roche	Roche(Roche Holding)	This work was supported by Roche. The funder had the following involvement in the study: participation in study design, participated in collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication.	Alt N, 2016, BIOLOGICALS, V44, P291, DOI 10.1016/j.biologicals.2016.06.005; Angelo LS, 2015, IMMUNOL RES, V62, P341, DOI 10.1007/s12026-015-8664-y; Barrow AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00909; Benonisson H, 2018, J IMMUNOL, V201, P3741, DOI 10.4049/jimmunol.1800700; Bjorkstrom NK, 2010, TRENDS IMMUNOL, V31, P401, DOI 10.1016/j.it.2010.08.003; Boero S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0680-0; Botticelli Andrea, 2015, World J Oncol, V6, P437, DOI 10.14740/wjon934w; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Capietto AH, 2011, J IMMUNOL, V187, P1031, DOI 10.4049/jimmunol.1100681; Carrega P, 2014, J IMMUNOL, V192, P3805, DOI 10.4049/jimmunol.1301889; Clemenceau B, 2008, J IMMUNOL, V180, P5327, DOI 10.4049/jimmunol.180.8.5327; Closa L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02991; Collins PL, 2019, CELL, V176, P348, DOI 10.1016/j.cell.2018.11.045; Cymer F, 2018, BIOLOGICALS, V52, P1, DOI 10.1016/j.biologicals.2017.11.001; Erokhina SA, 2018, IMMUNOL CELL BIOL, V96, P212, DOI 10.1111/imcb.1032; European Medicines Agency (EMA), 2016, EMACHMPBWP5325172008; Filipovic I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02692; Fregni G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076928; Ganesan S, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03173; Geraghty DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00970; Geuijen KPM, 2017, FEBS OPEN BIO, V7, P1557, DOI 10.1002/2211-5463.12283; Griffith P, 2017, GENE TECHNOL, V06, P143, DOI [10.4172/2329-6682.1000143, DOI 10.4172/2329-6682.1000143]; Hargreaves CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142379; Hayes JM, 2017, MOL CELL PROTEOMICS, V16, P1770, DOI 10.1074/mcp.M117.066944; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hsieh YT, 2017, J IMMUNOL METHODS, V441, P56, DOI 10.1016/j.jim.2016.12.002; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Hussain K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00390; Kleeberger CA, 1999, CLIN DIAGN LAB IMMUN, V6, P14, DOI 10.1128/CDLI.6.1.14-19.1999; Krijgsman D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00367; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Larsen Stine K., 2014, Critical Reviews in Oncogenesis, V19, P91; Lee HH, 2019, CANCER CELL, V36, P168, DOI 10.1016/j.ccell.2019.06.008; Li TZ, 2017, P NATL ACAD SCI USA, V114, P3485, DOI 10.1073/pnas.1702173114; Mahapatra S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181134; Mamessier E, 2011, J CLIN INVEST, V121, P3609, DOI 10.1172/JCI45816; Mata MM, 2014, J IMMUNOL METHODS, V406, P1, DOI 10.1016/j.jim.2014.01.017; McKinney W., 2010, P 9 PYTH SCI C, P56, DOI [10.25080/Majora-92bf1922-012, 10.25080/Majora-92bf1922-00a, DOI 10.25080/MAJORA-92BF1922-00A]; Mellor JD, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-1; Melsen JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00262; Messaoudene M, 2014, CANCER RES, V74, P81, DOI 10.1158/0008-5472.CAN-13-1303; Michel T, 2016, J IMMUNOL, V196, P2923, DOI 10.4049/jimmunol.1502570; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Moriya H, 2014, BIOMED REP, V2, P265, DOI 10.3892/br.2013.210; Muntasell A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01544; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nakajima T, 2018, ONCOL LETT, V15, P2604, DOI 10.3892/ol.2017.7556; Nelson MH, 2015, IMMUNOL REV, V263, P90, DOI 10.1111/imr.12245; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Paul S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1235106; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Pfefferle A, 2019, CELL REP, V29, P2284, DOI 10.1016/j.celrep.2019.10.058; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Pores-Fernando AT, 2009, CELL IMMUNOL, V254, P105, DOI 10.1016/j.cellimm.2008.07.004; ROBERTSON MJ, 1990, BLOOD, V76, P2421; Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005; Schmitz M, 2002, BLOOD, V100, P1502, DOI 10.1182/blood.V100.4.1502.h81602001502_1502_1504; Schnueriger A, 2011, MOL IMMUNOL, V48, P1512, DOI 10.1016/j.molimm.2011.04.010; Seidel UJE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00618; Shi Y, 2015, J IMMUNOL, V194, P4379, DOI 10.4049/jimmunol.1402891; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Staser KW, 2018, CYTOM PART A, V93A, P186, DOI 10.1002/cyto.a.23303; Sun HY, 2019, CELL MOL IMMUNOL, V16, P205, DOI 10.1038/s41423-018-0192-y; Tamura K, 2011, ANN ONCOL, V22, P1302, DOI 10.1093/annonc/mdq585; Thom MD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126755; Thomann M, 2019, BIOANALYSIS, V11, P1437, DOI 10.4155/bio-2019-0124; TOLLERUD DJ, 1991, J CLIN LAB ANAL, V5, P255; Vallat R., 2018, J OPEN SOURCE SOFTW, V3, P1026, DOI [10.21105/joss.01026, DOI 10.21105/JOSS.01026]; Van Acker HH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00892; Varchetta S, 2007, CANCER RES, V67, P11991, DOI 10.1158/0008-5472.CAN-07-2068; Veluchamy JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep43873; Verschoor CP, 2018, CYTOM PART A, V93A, P548, DOI 10.1002/cyto.a.23372; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Vivier E, CURRENT TOPICS MICRO, V395; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Wang W, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00368; Wang X, 2018, PROTEIN CELL, V9, P74, DOI 10.1007/s13238-017-0447-x; Xie Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01647; Yamashita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19772; Yeap WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep34310; Zhou YG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01095; 1997, DIABETES CARE, V20, DOI DOI 10.1097/00002371-199705000-00007	84	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2020	11								552596	10.3389/fimmu.2020.552596	http://dx.doi.org/10.3389/fimmu.2020.552596			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ0KG	33193318	Green Published, gold			2022-12-18	WOS:000588480900001
J	Ryffel, B; Huang, F; Robinet, P; Panek, C; Couillin, I; Erard, F; Piotet, J; Le Bert, M; Mackowiak, C; Arias, MT; Dimier-Poisson, I; Zheng, SG				Ryffel, Bernhard; Huang, Feng; Robinet, Pauline; Panek, Corine; Couillin, Isabelle; Erard, Francois; Piotet, Julie; Le Bert, Marc; Mackowiak, Claire; Torres Arias, Marbel; Dimier-Poisson, Isabelle; Zheng, Song Guo			Blockade of IL-33R/ST2 Signaling Attenuates Toxoplasma gondii Ileitis Depending on IL-22 Expression (vol 10, 702, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Toxoplasma gondii; IL-33/ST2 receptor; neutralizing antibody; IL-22; parasite-induced ileitis; innate immunity			[Ryffel, Bernhard; Huang, Feng] Sun Yat Sen Univ, Dept Clin Immunol, Affiliated Hosp 3, Guangzhou, Peoples R China; [Ryffel, Bernhard; Robinet, Pauline; Panek, Corine; Couillin, Isabelle; Erard, Francois; Piotet, Julie; Le Bert, Marc; Mackowiak, Claire] INEM UMR 7355 CNRS, Orleans, France; [Ryffel, Bernhard; Robinet, Pauline; Panek, Corine; Couillin, Isabelle; Erard, Francois; Piotet, Julie; Le Bert, Marc; Mackowiak, Claire] Univ Orleans, Orleans, France; [Torres Arias, Marbel] Univ Fuerzas Armadas, ESPE, Immunol & Virol Lab, Nanosci & Nanotechnol Ctr, Sangolqui, Ecuador; [Dimier-Poisson, Isabelle] Univ Tours, UMR 1282 Infectiol Anim & Sante Publ, INRA, Tours, France; [Zheng, Song Guo] Ohio State Coll Med, Dept Internal Med, Columbus, OH 43210 USA	Sun Yat Sen University; Universite de Orleans; Escuela Politecnica Superior del Ejercito; INRAE; Universite de Tours; University System of Ohio; Ohio State University	Ryffel, B (corresponding author), Sun Yat Sen Univ, Dept Clin Immunol, Affiliated Hosp 3, Guangzhou, Peoples R China.; Ryffel, B (corresponding author), INEM UMR 7355 CNRS, Orleans, France.; Ryffel, B (corresponding author), Univ Orleans, Orleans, France.; Zheng, SG (corresponding author), Ohio State Coll Med, Dept Internal Med, Columbus, OH 43210 USA.	bernhard.ryffel@cnrs-orleans.fr; SongGuo.Zheng@osumc.edu	Le Bert, Marc/AAR-4577-2021; Torres, Marbel/AIE-3077-2022	Le Bert, Marc/0000-0002-5945-3800; Torres, Marbel/0000-0002-3902-5083				Ryffel B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00702	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2020	11								592865	10.3389/fimmu.2020.592865	http://dx.doi.org/10.3389/fimmu.2020.592865			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OP5OK	33193440	gold, Green Published			2022-12-18	WOS:000588135800001
J	Toh, ZQ; He, L; Chen, C; Huang, A; Russell, FM; Garland, SM; Reyburn, R; Ratu, T; Tuivaga, E; Frazer, IH; Mulholland, EK; Licciardi, PV				Toh, Zheng Quan; He, Laura; Chen, Catherine; Huang, Angela; Russell, Fiona M.; Garland, Suzanne M.; Reyburn, Rita; Ratu, Tupou; Tuivaga, Evelyn; Frazer, Ian H.; Mulholland, E. Kim; Licciardi, Paul V.			Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method	FRONTIERS IN IMMUNOLOGY			English	Article						human papillomavirus (HPV); ELISA&#8212; enzyme-linked immunosorbent assay; antibody; pseudovirion; subtypes		Human papillomavirus (HPV) vaccines are safe and effective in preventing HPV infection and cervical precancers. Neutralizing antibodies are thought to be the primary mechanism of protection for HPV vaccines, although the exact level required for protection has not been identified. Three common serological assays used in clinical trials to measure HPV antibodies are HPV pseudovirion-based neutralization assay (PBNA), competitive or total Luminex immunoassays (cLIA or LIA) and VLP-based enzyme linked immunosorbent assays (ELISA). While PBNA is the gold-standard for measuring neutralizing antibodies (NAb), it is labor intensive. Luminex immunoassay and VLP-ELISA are rapid and high throughput, but their reagents and equipment can be difficult to source. Nevertheless, data generated from these assays generally correlate well with PBNA. Here, we described a simplified high-throughput PsV-based ELISA for HPV antibody measurement, to circumvent some of the limitations of existing assays. Using this assay, we were able to differentiate HPV-specific IgG and IgM, and found a strong correlation between HPV-specific IgG and NAb levels, as previously determined by PBNA. This assay platform is simpler and less time-consuming than PBNA. In addition, the materials can be readily produced and obtained commercially. This assay can be used as an alternative method to measure HPV antibodies.	[Toh, Zheng Quan; He, Laura; Chen, Catherine; Huang, Angela; Russell, Fiona M.; Garland, Suzanne M.; Reyburn, Rita; Mulholland, E. Kim; Licciardi, Paul V.] Murdoch Childrens Res Inst, New Vaccines, Infect & Immun, Parkville, Vic, Australia; [Toh, Zheng Quan; Huang, Angela; Russell, Fiona M.; Mulholland, E. Kim; Licciardi, Paul V.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Garland, Suzanne M.] Univ Melbourne, Dept Obstet & Gynecol, Parkville, Vic, Australia; [Garland, Suzanne M.] Royal Womens Hosp, Ctr Womens Infect Dis Res, Reg WHO HPV Reference Lab, Parkville, Vic, Australia; [Ratu, Tupou; Tuivaga, Evelyn] Minist Hlth & Med Serv, Publ Hlth Serv, Suva, Fiji; [Frazer, Ian H.] Univ Queensland, Diamantina Inst, Fac Med, Brisbane, Qld, Australia; [Mulholland, E. Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Queensland; University of London; London School of Hygiene & Tropical Medicine	Licciardi, PV (corresponding author), Murdoch Childrens Res Inst, New Vaccines, Infect & Immun, Parkville, Vic, Australia.; Licciardi, PV (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.	paul.licciardi@mcri.edu.au		Chen, Catherine/0000-0001-9659-1877	Department of Foreign Affairs and Trade of the Australian government; Fiji Health Sector Support Program (FHSSP); Australian National Health and Medical Research Council (NHMRC); NHMRC; Victorian government's Operational Infrastructure Support Program	Department of Foreign Affairs and Trade of the Australian government(Australian Government); Fiji Health Sector Support Program (FHSSP); Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian government's Operational Infrastructure Support Program	This work was supported by the Department of Foreign Affairs and Trade of the Australian government and the Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by ABT Associates on behalf of the Australian government. PL is supported by an Australian National Health and Medical Research Council (NHMRC) Career Development Fellowship. FR, SG and IF are supported by NHMRC Leadership Fellowships. This work was also supported in part by the Victorian government's Operational Infrastructure Support Program. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	[Anonymous], 2014, Wkly Epidemiol Rec, V89, P465; Brown DR, 2011, HUM VACCINES, V7, P230, DOI 10.4161/hv.7.2.13948; Buck CB, 2005, METH MOLEC MED, V119, P445; Dessy FJ, 2008, HUM VACCINES, V4, P425, DOI 10.4161/hv.4.6.6912; Ferguson M, 2011, VACCINE, V29, P6520, DOI 10.1016/j.vaccine.2011.07.007; Kreimer AR, 2018, VACCINE, V36, P4774, DOI 10.1016/j.vaccine.2017.12.078; Pinto LA, 2018, VACCINE, V36, P4792, DOI 10.1016/j.vaccine.2017.11.089; Robbins HA, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00328; Roberts C, 2014, HUM VACC IMMUNOTHER, V10, P2168, DOI 10.4161/hv.29205; Sankaranarayanan R, 2018, VACCINE, V36, P4783, DOI 10.1016/j.vaccine.2018.02.087; Toh ZQ, 2019, INFECT DRUG RESIST, V12, P1951, DOI 10.2147/IDR.S178381; Toh ZQ, 2017, CLIN INFECT DIS, V64, P852, DOI 10.1093/cid/ciw865	12	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2020	11								585768	10.3389/fimmu.2020.585768	http://dx.doi.org/10.3389/fimmu.2020.585768			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OP3XC	33193410	Green Published, gold			2022-12-18	WOS:000588013800001
J	Koudriavtseva, T; Stefanile, A; Fiorelli, M; Lapucci, C; Lorenzano, S; Zannino, S; Conti, L; D'Agosto, G; Pimpinelli, F; Di Domenico, EG; Mandoj, C; Giannarelli, D; Donzelli, S; Blandino, G; Salvetti, M; Inglese, M				Koudriavtseva, Tatiana; Stefanile, Annunziata; Fiorelli, Marco; Lapucci, Caterina; Lorenzano, Svetlana; Zannino, Silvana; Conti, Laura; D'Agosto, Giovanna; Pimpinelli, Fulvia; Di Domenico, Enea Gino; Mandoj, Chiara; Giannarelli, Diana; Donzelli, Sara; Blandino, Giovanni; Salvetti, Marco; Inglese, Matilde			Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; coagulation; complement; platelets; relapse; infection; cerebral hypoperfusion	BRAIN-BARRIER ABNORMALITIES; APPEARING WHITE-MATTER; INNATE IMMUNE-SYSTEM; PROTEIN-C; ANTIPHOSPHOLIPID ANTIBODIES; PERFORMANCE-CHARACTERISTICS; INFLAMMATORY RESPONSE; DIAGNOSTIC-CRITERIA; DISEASE-ACTIVITY; PERFUSION MRI	Introduction Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with an underlying immune-mediated and inflammatory pathogenesis. Innate immunity, in addition to the adaptive immune system, plays a relevant role in MS pathogenesis. It represents the immediate non-specific defense against infections through the intrinsic effector mechanism "immunothrombosis" linking inflammation and coagulation. Moreover, decreased cerebral blood volume (CBV), cerebral blood flow (CBF), and prolonged mean transit time (MTT) have been widely demonstrated by MRI in MS patients. We hypothesized that coagulation/complement and platelet activation during MS relapse, likely during viral infections, could be related to CBF decrease. Our specific aims are to evaluate whether there are differences in serum/plasma levels of coagulation/complement factors between relapsing-remitting (RR) MS patients (RRMS) in relapse and those in remission and healthy controls as well as to assess whether brain hemodynamic changes detected by MRI occur in relapse compared with remission. This will allow us to correlate coagulation status with perfusion and demographic/clinical features in MS patients. Materials and Methods This is a multi-center, prospective, controlled study. RRMS patients (1 degrees group: 30 patients in relapse; 2 degrees group: 30 patients in remission) and age/sex-matched controls (3 degrees group: 30 subjects) will be enrolled in the study. Patients and controls will be tested for either coagulation/complement (C3, C4, C4a, C9, PT, aPTT, fibrinogen, factor II, VIII, and X, D-dimer, antithrombin, protein C, protein S, von-Willebrand factor), soluble markers of endothelial damage (thrombomodulin, Endothelial Protein C Receptor), antiphospholipid antibodies, lupus anticoagulant, complete blood count, viral serological assays, or microRNA microarray. Patients will undergo dynamic susceptibility contrast-enhanced MRI using a 3.0-T scanner to evaluate CBF, CBV, MTT, lesion number, and volume. Statistical Analysis ANOVA and unpaired t-tests will be used. The level of significance was set at p <= 0.05. Discussion Identifying a link between activation of coagulation/complement system and cerebral hypoperfusion could improve the identification of novel molecular and/or imaging biomarkers and targets, leading to the development of new effective therapeutic strategies in MS.	[Koudriavtseva, Tatiana; Stefanile, Annunziata; Zannino, Silvana; Conti, Laura; Mandoj, Chiara] IRCCS Regina Elena Natl Canc Inst, Dept Clin Expt Oncol, Rome, Italy; [Fiorelli, Marco; Lorenzano, Svetlana] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy; [Lapucci, Caterina; Inglese, Matilde] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy; [D'Agosto, Giovanna; Pimpinelli, Fulvia; Di Domenico, Enea Gino] IRCC San Gallicano Inst, Clin Pathol & Microbiol Unit, Rome, Italy; [Giannarelli, Diana] IRCCS Regina Elena Natl Canc Inst, Sci Direct, Biostat, Rome, Italy; [Donzelli, Sara; Blandino, Giovanni] IRCCS Regina Elena Natl Canc Inst, Oncogen & Epigenet Unit, Rome, Italy; [Salvetti, Marco] Sapienza Univ, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs NEMOS, Rome, Italy; [Inglese, Matilde] Icahn Sch Med Mt Sinai, Dept Neurol Radiol & Neurosci, New York, NY USA	Sapienza University Rome; University of Genoa; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Icahn School of Medicine at Mount Sinai	Koudriavtseva, T (corresponding author), IRCCS Regina Elena Natl Canc Inst, Dept Clin Expt Oncol, Rome, Italy.	tatiana.koudriavtseva@ifo.gov.it	Mandoj, Chiara/AAA-8130-2021; Salvetti, Marco/K-3836-2016; Inglese, Matilde/AAH-3189-2020; Lapucci, Caterina/ABA-9667-2021; Lapucci, Caterina/AAA-6723-2021; D'AGOSTO, GIOVANNA/K-3029-2016; Donzelli, Sara/AAA-2557-2021; Mandoj, Chiara/J-2645-2017; Di Domenico, Enea Gino/I-2542-2019	Mandoj, Chiara/0000-0001-6131-7843; Inglese, Matilde/0000-0002-9610-0297; Lapucci, Caterina/0000-0002-3527-6520; D'AGOSTO, GIOVANNA/0000-0002-5737-8798; Donzelli, Sara/0000-0002-8529-2895; Mandoj, Chiara/0000-0001-6131-7843; Di Domenico, Enea Gino/0000-0001-6295-6006; stefanile, Annunziata/0000-0001-9730-5836	Italian Ministry of Health [PE-2013-02357745]	Italian Ministry of Health(Ministry of Health, Italy)	This study is funded by the Italian Ministry of Health (Project code: PE-2013-02357745).	Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Adhya S, 2006, NEUROIMAGE, V33, P1029, DOI 10.1016/j.neuroimage.2006.08.008; Alizadeh A, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00035; Alonso R, 2018, NEUROBIOL DIS, V117, P42, DOI 10.1016/j.nbd.2018.05.022; Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Antoniak S, 2018, RES PRACT THROMB HAE, V2, P549, DOI 10.1002/rth2.12109; Antoniak S, 2014, BLOOD, V123, P2605, DOI 10.1182/blood-2013-09-526277; Appert-Flory A, 2007, THROMB RES, V120, P733, DOI 10.1016/j.thromres.2006.12.002; Baker HN, 2012, JOVE-J VIS EXP, DOI 10.3791/4084; Barnes P W, 2010, Lab Hematol, V16, P23, DOI 10.1532/LH96.09015; Barnes PW, 2004, CLIN CHEM, V50, pA184; Bidot CJ, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-36; Boesen MS, 2019, MULT SCLER J, V25, P783, DOI 10.1177/1352458518771871; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; Calamante F, 2013, PROG NUCL MAG RES SP, V74, P1, DOI 10.1016/j.pnmrs.2013.04.002; Capozzi A, 2012, J IMMUNOL METHODS, V379, P48, DOI 10.1016/j.jim.2012.02.020; CLAUDIO L, 1995, ACTA NEUROPATHOL, V90, P228; Correale J, 2006, NEUROLOGY, V67, P652, DOI 10.1212/01.wnl.0000233834.09743.3b; Cutter GR, 1999, BRAIN, V122, P871, DOI 10.1093/brain/122.5.871; Dahiya N, 2015, TRANSFUS MED REV, V29, P215, DOI 10.1016/j.tmrv.2015.08.002; Danckwardt S, 2013, J MOL MED, V91, P1257, DOI 10.1007/s00109-013-1074-5; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; Davalos D, 2012, SEMIN IMMUNOPATHOL, V34, P43, DOI 10.1007/s00281-011-0290-8; De Craemer AS, 2016, J THROMB HAEMOST, V14, P1779, DOI 10.1111/jth.13389; Devreese KM, 2017, J THROMB HAEMOST, V15, P91, DOI 10.1111/jth.13560; Disanto G, 2012, NEUROLOGY, V78, P823, DOI 10.1212/WNL.0b013e318249f6f0; Ebrahimkhani S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14301-3; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Esmon CT, 2011, J THROMB HAEMOST, V9, P182, DOI 10.1111/j.1538-7836.2011.04323.x; Esmon CT, 2006, SEMIN THROMB HEMOST, V32, P49, DOI 10.1055/s-2006-939554; Esmon CT, 2012, SEMIN IMMUNOPATHOL, V34, P127, DOI 10.1007/s00281-011-0284-6; Esmon CT, 2004, TRENDS IMMUNOL, V25, P536, DOI 10.1016/j.it.2004.08.003; Espinosa-Parrilla Y, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00151; FAN ST, 1993, J IMMUNOL, V150, P2972; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; Festoff BW, 2012, J NEUROL SCI, V323, P61, DOI 10.1016/j.jns.2012.08.008; Fiorini A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065184; Flick MJ, 2004, J CLIN INVEST, V113, P1596, DOI 10.1172/JCI200420741; Gandhi R, 2010, J NEUROIMMUNOL, V221, P7, DOI 10.1016/j.jneuroim.2009.10.015; Gardiner Chris, 2006, Lab Hematol, V12, P32, DOI 10.1532/LH96.05031; Garg N, 2007, J NEUROIMMUNOL, V187, P159, DOI 10.1016/j.jneuroim.2007.04.008; Geens T, 2015, INT J LAB HEMATOL, V37, P372, DOI 10.1111/ijlh.12295; Genc K, 2007, MED HYPOTHESES, V68, P710, DOI 10.1016/j.mehy.2006.09.004; Genc S, 2017, INT J LAB HEMATOL, V39, P633, DOI 10.1111/ijlh.12717; Gobel K, 2016, ANN NEUROL, V80, P946, DOI 10.1002/ana.24807; Griffin JH, 2007, J THROMB HAEMOST, V5, P73, DOI 10.1111/j.1538-7836.2007.02491.x; Griffin JH, 2006, BLOOD CELL MOL DIS, V36, P211, DOI 10.1016/j.bcmd.2005.12.023; Gveric D, 2001, BRAIN, V124, P1978, DOI 10.1093/brain/124.10.1978; Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559; Hedley BD, 2011, INT J LAB HEMATOL, V33, P45, DOI 10.1111/j.1751-553X.2010.01239.x; Horstman LL, 2011, FRONT BIOSCI-LANDMRK, V16, P2921, DOI 10.2741/3890; Horstman LL, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-10; Huber AR, 2013, HAMOSTASEOLOGIE, V33, P295, DOI 10.5482/HAMO-12-05-0002; Inglese M, 2008, J CEREBR BLOOD F MET, V28, P164, DOI 10.1038/sj.jcbfm.9600504; Ingram G, 2012, MULT SCLER J, V18, P1401, DOI 10.1177/1352458512438238; Ingram G, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-53; Iwaniec T, 2015, THROMB RES, V136, P1033, DOI 10.1016/j.thromres.2015.08.021; Jagot F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00129; James PD, 2012, AM J HEMATOL, V87, pS4, DOI 10.1002/ajh.23142; Kadam Rashmi Ashish, 2017, Perspect Clin Res, V8, P107, DOI 10.4103/picr.PICR_147_16; Kirichuk VF, 2003, ZH NEVROPATOL PSIKH, P34; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Kirk J, 1996, Mult Scler, V1, P242; Koudriavtseva T, 2016, NEURAL REGEN RES, V11, P1727, DOI 10.4103/1673-5374.194804; Koudriavtseva T, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00063; Koudriavtseva T, 2014, NEUROL SCI, V35, P1737, DOI 10.1007/s10072-014-1823-4; Koudriavtseva T, 2014, J NEUROL, V261, P2028, DOI 10.1007/s00415-014-7506-5; Koudriavtseva T, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00119; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; KWON EE, 1994, J NEUROPATH EXP NEUR, V53, P625, DOI 10.1097/00005072-199411000-00010; Kwoun WJ, 2018, ANN LAB MED, V38, P484, DOI 10.3343/alm.2018.38.5.484; Lakos G, 2012, ARTHRITIS RHEUM-US, V64, P1, DOI 10.1002/art.33349; Langer HF, 2012, CIRC RES, V110, P1202, DOI 10.1161/CIRCRESAHA.111.256370; Lapointe E, 2018, AM J NEURORADIOL, V39, P994, DOI 10.3174/ajnr.A5504; Li HJ, 2015, CLIN RHEUMATOL, V34, P471, DOI 10.1007/s10067-014-2843-4; Ling M, 2019, CLIN LAB MED, V39, P579, DOI 10.1016/j.cll.2019.07.006; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Mandoj C, 2015, NEUROSCI LETT, V606, P156, DOI 10.1016/j.neulet.2015.08.054; Martin M, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1470-2; Martins TB, 2018, CLIN CHIM ACTA, V485, P7, DOI 10.1016/j.cca.2018.06.008; Mayo L, 2012, IMMUNOL REV, V248, P170, DOI 10.1111/j.1600-065X.2012.01135.x; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Acuna JM, 2017, MULT SCLER RELAT DIS, V18, P157, DOI 10.1016/j.msard.2017.09.033; Moll NM, 2011, ANN NEUROL, V70, P764, DOI 10.1002/ana.22521; Morrell CN, 2014, BLOOD, V123, P2759, DOI 10.1182/blood-2013-11-462432; Murta V, 2013, MOL CELL NEUROSCI, V53, P6, DOI 10.1016/j.mcn.2012.06.004; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Oikonen M, 2011, MULT SCLER J, V17, P672, DOI 10.1177/1352458510394397; Parsons ME, 2017, MULT SCLER J EXP TRA, V3, P1; PHILLIPS DR, 1988, BLOOD, V71, P831; Plantone D, 2019, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01175; Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y; Plumb J, 2002, BRAIN PATHOL, V12, P154; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Prohaszka Z, 2016, IMMUNOBIOLOGY, V221, P1247, DOI 10.1016/j.imbio.2016.06.008; Putnam TJ, 1937, J AMER MED ASSOC, V108, P1477, DOI 10.1001/jama.1937.02780180001001; Qu CH, 2019, EXP THER MED, V17, P1390, DOI 10.3892/etm.2018.7072; Rainger GE, 2015, PLATELETS, V26, P507, DOI 10.3109/09537104.2015.1064881; Ryu JK, 2018, NAT IMMUNOL, V19, P1212, DOI 10.1038/s41590-018-0232-x; Saberi A, 2018, ACTA NEUROL BELG, V118, P361, DOI 10.1007/s13760-018-0976-y; Saluk-Bijak J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020110; Salvagno GL, 2012, CLIN BIOCHEM, V45, P372, DOI 10.1016/j.clinbiochem.2011.12.005; Sheremata William A, 2008, J Neuroinflammation, V5, P27, DOI 10.1186/1742-2094-5-27; SIBLEY WA, 1965, ANN NY ACAD SCI, V122, P457; Simpson S, 2012, MULT SCLER J, V18, P799, DOI 10.1177/1352458511428081; Solano C, 2011, INT J LAB HEMATOL, V33, P67, DOI 10.1111/j.1751-553X.2010.01248.x; Soon D, 2007, MULT SCLER J, V13, P884, DOI 10.1177/1352458507076970; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Spadaro M, 1999, MULT SCLER, V5, P121, DOI 10.1191/135245899678847211; Stavrou EX, 2014, CELLULAR MOL PATHOBI, P277, DOI [10.1016/B978-0-12-405206-2.00015-6, DOI 10.1016/B978-0-12-405206-2.00015-6]; Steelman AJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00520; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tatomir A, 2017, IMMUNOL RES, V65, P1103, DOI 10.1007/s12026-017-8961-8; Tebo AE, 2019, CLIN LAB MED, V39, P553, DOI 10.1016/j.cll.2019.07.004; Thrower BW, 2009, NEUROLOGIST, V15, P1, DOI 10.1097/NRL.0b013e31817acf1a; Tokunaga N, 2016, BLOOD COAGUL FIBRIN, V27, P474, DOI 10.1097/MBC.0000000000000436; Uzawa A, 2018, CLIN EXP IMMUNOL, V193, P47, DOI 10.1111/cei.13123; van der Poll T, 2012, CURR VASC PHARMACOL, V10, P632, DOI 10.2174/157016112801784549; Varga AW, 2009, J NEUROL SCI, V282, P28, DOI 10.1016/j.jns.2008.12.036; Wachowicz B, 2016, ACTA NEUROBIOL EXP, V76, P269, DOI 10.21307/ane-2017-026; Wan LY, 2020, INT J LAB HEMATOL, V42, P206, DOI 10.1111/ijlh.13156; Weiner HL, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-1002-8; Weisel JW, 2005, ADV PROTEIN CHEM, V70, P247, DOI 10.1016/S0065-3233(04)70008-X; Xue ML, 2012, J BIOL CHEM, V287, P16356, DOI 10.1074/jbc.M111.325951; Yamaji K, 2005, THROMB RES, V115, P319, DOI 10.1016/j.thromres.2004.09.011; Yuksel M, 2002, THROMB HAEMOSTASIS, V88, P267; Zhang Yingze, 2020, Methods Mol Biol, V2102, P129, DOI 10.1007/978-1-0716-0223-2_6; Zivadinov R, 2012, NEUROL RES, V34, P761, DOI 10.1179/1743132812Y.0000000076	128	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2020	11								548604	10.3389/fimmu.2020.548604	http://dx.doi.org/10.3389/fimmu.2020.548604			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OO9JM	33193314	Green Published, gold			2022-12-18	WOS:000587689600001
J	Shao, QQ; Liu, X; Huang, YF; Chen, X; Wang, HY				Shao, Qianqian; Liu, Xin; Huang, Yufei; Chen, Xi; Wang, Huayang			Human Decidual Stromal Cells in Early Pregnancy Induce Functional Re-Programming of Monocyte-Derived Dendritic Cells via Crosstalk Between G-CSF and IL-1 beta	FRONTIERS IN IMMUNOLOGY			English	Article						decidual stromal cells; dendritic cells; G-CSF; IL-1 beta; spontaneous abortions	COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; HUMAN ENDOMETRIUM; EMBRYONIC IMPLANTATION; MENSTRUAL-CYCLE; IN-VITRO; EXPRESSION; RECEPTOR; INTERFACE; CYTOKINES	Accumulation of dendritic cells (DCs) is a special characteristic of the decidual microenvironment. Decidua-infiltrated DCs show unique phenotypes and functions that promote the establishment of fetal-maternal tolerance. However, the regulatory mechanisms yet to be fully investigated. Decidual stromal cells (DSCs) are the major cellular component of decidua tissue. The interactions between DSCs and decidua-infiltrated immunocytes dictate immune tolerance in early pregnancy. Therefore, in the present study, we explore the effect of early pregnancy DSCs on monocyte-derived DCs and the relevant mechanisms. DSC-conditioned DCs showed altered phenotypes, secretion profiles and Th2 priming potential. G-CSF concentration was significantly up-regulated in the co-culture supernatant between DSCs and DCs. Supplementation of G-CSF neutralizing antibody partly reversed the reprogramming of DCs mediated by DSCs. Furthermore, G-CSF production was promoted by IL-1 beta, which was mainly produced by DCs and significantly up-regulated after their cultivation with DSCs. Interestingly, the effects of DSC on IL-1 beta production of DCs occurred in their immature stage but not their mature stage. Lastly, no significant difference of G-CSF was found in DSCs from healthy early pregnancy women and spontaneous abortions (SA) patients. However, DSCs from SA patients secreted less G-CSF in response to exogenous rhIL-1 beta or DC cultivation. In conclusion, our study bolster the understanding of the decidual immunomodulatory microenvironment during early pregnancy, and brings new insight into the potential clinical value of G-CSF in pregnancy disorders.	[Shao, Qianqian] Shandong Univ, Lab Basic Med Sci, Qilu Hosp, Jinan, Peoples R China; [Liu, Xin] Shandong Univ, Dept Ultrasound, Qilu Hosp, Jinan, Peoples R China; [Huang, Yufei] Shandong Univ, Dept Obstet & Gynecol, Qilu Hosp, Jinan, Peoples R China; [Chen, Xi] Shandong Univ, Dept Clin Lab, Hosp 2, Jinan, Peoples R China; [Wang, Huayang] Shandong Univ, Dept Clin Lab, Qilu Hosp, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Wang, HY (corresponding author), Shandong Univ, Dept Clin Lab, Qilu Hosp, Jinan, Peoples R China.	huayang_w8908@163.com			National Natural Science Foundation of China [81702815, 81300510]; Key Technology Research and Development Program of Shandong, China [2019GSF108247]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Technology Research and Development Program of Shandong, China	This study was supported by National Natural Science Foundation of China (grant nos. 81702815 and 81300510) and Key Technology Research and Development Program of Shandong, China (grant nos. 2019GSF108247).	Baston-Bust DM, 2013, CYTOKINE, V64, P79, DOI 10.1016/j.cyto.2013.07.023; Blois S, 2004, AM J REPROD IMMUNOL, V51, P40, DOI 10.1046/j.8755-8920.2003.00120.x; Gardner L, 2003, BIOL REPROD, V69, P1438, DOI 10.1095/biolreprod.103.017574; Gellersen B, 2007, SEMIN REPROD MED, V25, P445, DOI 10.1055/s-2007-991042; Gleicher N, 2013, HUM REPROD, V28, P172, DOI 10.1093/humrep/des370; Gnainsky Y, 2010, FERTIL STERIL, V94, P2030, DOI 10.1016/j.fertnstert.2010.02.022; Houser BL, 2011, J IMMUNOL, V186, P2633, DOI 10.4049/jimmunol.1003153; Kammerer U, 2003, AM J PATHOL, V162, P887, DOI 10.1016/S0002-9440(10)63884-9; Kreines FM, 2018, J ASSIST REPROD GEN, V35, P2031, DOI 10.1007/s10815-018-1296-0; Ledee N, 2008, HUM REPROD, V23, P2001, DOI 10.1093/humrep/den192; Makinoda S, 2008, CURR MED CHEM, V15, P604, DOI 10.2174/092986708783769740; Plaks V, 2008, J CLIN INVEST, V118, P3954, DOI 10.1172/JCI36682; Presicce P, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98306; Rieger L, 2004, J SOC GYNECOL INVEST, V11, P488, DOI 10.1016/j.jsgi.2004.05.007; Riemann D, 2019, CLIN EXP IMMUNOL, V195, P179, DOI 10.1111/cei.13219; Rutella S, 2005, J IMMUNOL, V175, P7085, DOI 10.4049/jimmunol.175.11.7085; Rutella S, 2007, TRANSPLANTATION, V84, pS26, DOI 10.1097/01.tp.0000269611.66517.bf; SAITO S, 1994, GROWTH FACTORS, V10, P135, DOI 10.3109/08977199409010987; Salmassi A, 2005, HUM REPROD, V20, P2434, DOI 10.1093/humrep/dei071; Santjohanser C, 2013, ARCH IMMUNOL THER EX, V61, P159, DOI 10.1007/s00005-012-0212-z; Scarpellini F, 2009, HUM REPROD, V24, P2703, DOI 10.1093/humrep/dep240; Shao QQ, 2012, BLOOD, V119, P4636, DOI 10.1182/blood-2011-08-376418; Shih KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042389; SHORTER SC, 1992, IMMUNOLOGY, V75, P468; SIMON C, 1994, ENDOCRINOLOGY, V134, P521, DOI 10.1210/en.134.2.521; Simon C, 1998, FERTIL STERIL, V70, P896, DOI 10.1016/S0015-0282(98)00275-1; Sugita K, 2003, AM J REPROD IMMUNOL, V50, P83, DOI 10.1034/j.1600-0897.2003.00024.x; Tirado-Gonzalez I, 2010, PLACENTA, V31, P1019, DOI 10.1016/j.placenta.2010.09.008; Toth B, 2011, J REPROD IMMUNOL, V90, P117, DOI 10.1016/j.jri.2011.05.002; Vacca P, 2015, IMMUNOL LETT, V168, P170, DOI 10.1016/j.imlet.2015.05.006; von Wolff M, 2000, MOL HUM REPROD, V6, P627; Wurfel W, 2015, J REPROD IMMUNOL, V108, P123, DOI 10.1016/j.jri.2015.01.010; Wurfel W, 2010, HUM REPROD, V25, P2151, DOI 10.1093/humrep/deq106; Ziebe S, 2013, FERTIL STERIL, V99, P1600, DOI 10.1016/j.fertnstert.2012.12.043	34	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2020	11								574270	10.3389/fimmu.2020.574270	http://dx.doi.org/10.3389/fimmu.2020.574270			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OO9ND	33193360	Green Published, gold			2022-12-18	WOS:000587699300001
J	De Clercq, E; Van Gils, M; Schautteet, K; Devriendt, B; Kiekens, C; Chiers, K; Van Den Broeck, W; Cox, E; Dean, D; Vanrompay, D				De Clercq, Evelien; Van Gils, Matthias; Schautteet, Katelijn; Devriendt, Bert; Kiekens, Celien; Chiers, Koen; van den Broeck, Wim; Cox, Eric; Dean, Deborah; Vanrompay, Daisy			Chlamydia trachomatis L2c Infection in a Porcine Model Produced Urogenital Pathology and Failed to Induce Protective Immune Responses Against Re-Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Chlamydia trachomatis; genital infection; immunology; large animal model; lymphogranuloma venereum; re-infection	PELVIC-INFLAMMATORY-DISEASE; GENITAL-TRACT INFECTION; LYMPHOGRANULOMA-VENEREUM; ACQUIRED-IMMUNITY; WOMEN; MURINE; CELLS; PIGS; SEX; SUSCEPTIBILITY	The current study was designed to evaluate the pathogenesis, pathology and immune response of female genital tract infection with Chlamydia trachomatis L2c, the most recently discovered lymphogranuloma venereum strain, using a porcine model of sexually transmitted infections. Pigs were mock infected, infected once or infected and re-infected intravaginally, and samples were obtained for chlamydial culture, gross and microscopic pathology, and humoral and cell-mediated immunity. Intravaginal inoculation of pigs with this bacterium resulted in an infection that was confined to the urogenital tract, where inflammation and pathology were caused that resembled what is seen in human infection. Re-infection resulted in more severe gross pathology than primary infection, and chlamydial colonization of the urogenital tract was similar for primary infected and re-infected pigs. This indicates that primary infection failed to induce protective immune responses against re-infection. Indeed, the proliferative responses of mononuclear cells from blood and lymphoid tissues to C. trachomatis strain L2c were never statistically different among groups, suggesting that C. trachomatis-specific lymphocytes were not generated following infection or re-infection. Nevertheless, anti-chlamydial antibodies were elicited in sera and vaginal secretions after primary infection and re-infection, clearly resulting in a secondary systemic and mucosal antibody response. While primary infection did not protect against reinfection, the porcine model is relevant for evaluating immune and pathogenic responses for emerging and known C. trachomatis strains to advance drug and/or vaccine development in humans.	[De Clercq, Evelien; Van Gils, Matthias; Schautteet, Katelijn; Kiekens, Celien; Vanrompay, Daisy] Univ Ghent, Fac Biosci Engn, Lab Immunol & Anim Biotechnol, Dept Anim Prod, Ghent, Belgium; [Devriendt, Bert; Cox, Eric] Univ Ghent, Lab Immunol, Fac Vet Med, Merelbeke, Belgium; [Chiers, Koen] Univ Ghent, Dept Pathol Bacteriol & Poultry Dis, Fac Vet Med, Merelbeke, Belgium; [van den Broeck, Wim] Univ Ghent, Dept Morphol, Fac Vet Med, Merelbeke, Belgium; [Dean, Deborah] Childrens Hosp Oakland, Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA USA; [Dean, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Dean, Deborah] Univ Calif Berkeley, Joint Grad Program Bioengn, Berkeley, CA 94720 USA	Ghent University; Ghent University; Ghent University; Ghent University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Vanrompay, D (corresponding author), Univ Ghent, Fac Biosci Engn, Lab Immunol & Anim Biotechnol, Dept Anim Prod, Ghent, Belgium.	Daisy.Vanrompay@UGent.be	Devriendt, Bert/AAM-6666-2021; Van den Broeck, Wim/B-5526-2009	Devriendt, Bert/0000-0002-3222-8769; Cox, Eric/0000-0003-4281-2990; Van den Broeck, Wim/0000-0001-6683-5658	Special Research Fund of Ghent University (BOF)	Special Research Fund of Ghent University (BOF)(Ghent University)	The research was supported by the Special Research Fund of Ghent University (BOF).	Aggarwal K, 2002, SEX TRANSM INFECT, V78, P458, DOI 10.1136/sti.78.6.458; Ahdoot A, 2006, J CLIN GASTROENTEROL, V40, P385, DOI 10.1097/00004836-200605000-00005; [Anonymous], 1984, BACTERIOL; Bakken IJ, 2007, SEX TRANSM DIS, V34, P739, DOI 10.1097/01.olq.0000261326.65503.f6; Barnes R, P 6 INT S HUM CHLAM, P503; BARRON AL, 1984, INFECT IMMUN, V44, P82, DOI 10.1128/IAI.44.1.82-85.1984; Batteiger BE, 1996, INFECT IMMUN, V64, P542, DOI 10.1128/IAI.64.2.542-547.1996; Batteiger BE, 2010, J INFECT DIS, V201, pS178, DOI 10.1086/652400; Behets FMT, 1999, J INFECT DIS, V180, P1382, DOI 10.1086/315005; Benyeogor I, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5495-6; Berglund T, 2005, EURO SURVEILL, V10, pE0503033, DOI [10.2807/esw.10.09.02655-en, DOI 10.2807/ESW.10.09.02655-EN]; Brunham RC, 1996, J INFECT DIS, V173, P950, DOI 10.1093/infdis/173.4.950; BRUNHAM RC, 1983, INFECT IMMUN, V39, P1491, DOI 10.1128/IAI.39.3.1491-1494.1983; Cotter TW, 1997, INFECT IMMUN, V65, P2145, DOI 10.1128/IAI.65.6.2145-2152.1997; DAN M, 1980, BRIT J VENER DIS, V56, P344; De Clercq E, 2014, THESIS; De Clercq E, 2014, VET RES, V45, DOI 10.1186/s13567-014-0095-6; De Munain JL, 2008, SEX TRANSM DIS, V35, P918, DOI 10.1097/OLQ.0b013e31817e9228; de Vries HJC, 2015, J EUR ACAD DERMATOL, V29, P1, DOI 10.1111/jdv.12461; Golden MR, 2000, SEX TRANSM DIS, V27, P329, DOI 10.1097/00007435-200007000-00006; Gomes JP, 2009, SEX TRANSM DIS, V36, P88, DOI 10.1097/OLQ.0b013e31818b1e27; Gomes JP, 2006, MICROBES INFECT, V8, P16, DOI 10.1016/j.micinf.2005.05.014; Gotz H, 2004, EURO SURVEILL, V8, DOI [10.2807/esw.08.04.02367-en, DOI 10.2807/ESW.08.04.02367-EN]; Gupta R, 2016, ONCOTARGET, V7, P64726, DOI 10.18632/oncotarget.11461; Gupta R, 2015, AM J REPROD IMMUNOL, V73, P126, DOI 10.1111/aji.12281; Gupta S, 2006, INT J STD AIDS, V17, P157, DOI 10.1258/095646206775809150; Hillis SD, 1997, AM J OBSTET GYNECOL, V176, P103, DOI 10.1016/S0002-9378(97)80020-8; Hook CE, 2004, CLIN EXP IMMUNOL, V138, P54, DOI 10.1111/j.1365-2249.2004.02596.x; Igietseme JU, 2013, J INFECT DIS, V207, P1095, DOI 10.1093/infdis/jit009; Igietseme Joseph U., 1993, Regional Immunology, V5, P317; Joyner JL, 2002, SEX TRANSM DIS, V29, P196, DOI 10.1097/00007435-200204000-00002; KATZ BP, 1987, SEX TRANSM DIS, V14, P160, DOI 10.1097/00007435-198707000-00008; Kimani J, 1996, J INFECT DIS, V173, P1437, DOI 10.1093/infdis/173.6.1437; Kropp RY, 2005, CAN MED ASSOC J, V172, P1674, DOI 10.1503/cmaj.050621; Liassine N, 2005, EURO SURVEILL, V10, pE0507144, DOI [10.2807/esw.10.28.02748-en, DOI 10.2807/ESW.10.28.02748-EN]; Mabey D, 2002, SEX TRANSM INFECT, V78, P90, DOI 10.1136/sti.78.2.90; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Mayr A, 1974, VIROLOGISCHE ARBEITS, P35; McClarty G, 2007, CURR OPIN MICROBIOL, V10, P47, DOI 10.1016/j.mib.2006.12.003; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536; Morton Anna N, 2006, Sex Health, V3, P189, DOI 10.1071/SH06029; Ness RB, 2008, SEX TRANSM DIS, V35, P129, DOI 10.1097/OLQ.0b013e3181557c25; Nieuwenhuis RF, 2004, CLIN INFECT DIS, V39, P996, DOI 10.1086/423966; NOVAK M, 1993, VACCINE, V11, P55, DOI 10.1016/0264-410X(93)90339-Y; Parks KS, 1997, SEX TRANSM DIS, V24, P229, DOI 10.1097/00007435-199704000-00008; Perine PL, 1998, LYMPHOGRANULOMA VENE, P423; Perry LL, 1997, J IMMUNOL, V158, P3344; PETERSON EM, 1990, INFECT IMMUN, V58, P938, DOI 10.1128/IAI.58.4.938-943.1990; Peuchant O, 2011, CLIN MICROBIOL INFEC, V17, pE21, DOI 10.1111/j.1469-0691.2011.03661.x; Pickering H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09193-2; Plettenberg A, 2004, EURO SURVEILL, V8, DOI [10.2807/esw.08.30.02509-en, DOI 10.2807/ESW.08.30.02509-EN]; PUNNONEN R, 1979, FERTIL STERIL, V31, P656; RAMSEY KH, 1991, INFECT IMMUN, V59, P925, DOI 10.1128/IAI.59.3.925-931.1991; Ramsey KH, 2000, INFECT IMMUN, V68, P7186, DOI 10.1128/IAI.68.12.7186-7189.2000; RANK RG, 1983, INFECT IMMUN, V39, P463, DOI 10.1128/IAI.39.1.463-465.1983; RANK RG, 1988, INFECT IMMUN, V56, P2243, DOI 10.1128/IAI.56.9.2243-2249.1988; RANK RG, 1979, INFECT IMMUN, V26, P573, DOI 10.1128/IAI.26.2.573-579.1979; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Rietmeijer CA, 2002, SEX TRANSM DIS, V29, P65, DOI 10.1097/00007435-200202000-00001; Riley MM, 2012, INFECT IMMUN, V80, P2194, DOI 10.1128/IAI.00169-12; Ronn MM, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-70; Schachter J, 1999, CHLAMYDIA, P139; Schautteet K, 2012, VACCINE, V30, P2869, DOI 10.1016/j.vaccine.2012.02.044; Somboonna N, 2011, MBIO, V2, DOI 10.1128/mBio.00045-11; Spaargaren J, 2005, EMERG INFECT DIS, V11, P1090; Su H, 1997, INFECT IMMUN, V65, P1993, DOI 10.1128/IAI.65.6.1993-1999.1997; SU H, 1995, INFECT IMMUN, V63, P3302, DOI 10.1128/IAI.63.9.3302-3308.1995; Tseng CTK, 1998, INFECT IMMUN, V66, P5867, DOI 10.1128/IAI.66.12.5867-5875.1998; Vall Mayans M, 2005, EURO SURVEILL, V10, DOI [10.2807/esw.10.05.02634-en, DOI 10.2807/ESW.10.05.02634-EN]; Vanrompay D, 2005, INFECT IMMUN, V73, P8317, DOI 10.1128/IAI.73.12.8317-8321.2005; VANROMPAY D, 1992, J VET MED B, V39, P105, DOI 10.1111/j.1439-0450.1992.tb01144.x; VANZAANE D, 1987, VET IMMUNOL IMMUNOP, V16, P23, DOI 10.1016/0165-2427(87)90171-1; Verweij SP, 2012, SEX TRANSM INFECT, V88, P346, DOI 10.1136/sextrans-2011-050298; Viravan C, 1996, CLIN INFECT DIS, V22, P233, DOI 10.1093/clinids/22.2.233; Von Holstein I, 2004, EURO SURVEILL, V8, DOI [10.2807/esw.08.25.02490-en, DOI 10.2807/ESW.08.25.02490-EN]; WANG SP, 1973, INFECT IMMUN, V7, P356, DOI 10.1128/IAI.7.3.356-360.1973; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; WHO, 2012, GLOB INC PREV SEL CU; WOLNERHANSSEN P, 1991, SEX TRANSM DIS, V18, P21, DOI 10.1097/00007435-199101000-00005; World Health Organization, 2008, M POST SURV BLIND TR; Yeruva L, 2014, MBIO, V5, DOI 10.1128/mBio.01241-14	82	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2020	11								555305	10.3389/fimmu.2020.555305	http://dx.doi.org/10.3389/fimmu.2020.555305			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OO5HJ	33193323	Green Published, gold			2022-12-18	WOS:000587409100001
J	Weinfurter, JT; Graham, ME; Ericsen, AJ; Matschke, LM; Llewellyn-Lacey, S; Price, DA; Wiseman, RW; Reynolds, MR				Weinfurter, Jason T.; Graham, Michael E.; Ericsen, Adam J.; Matschke, Lea M.; Llewellyn-Lacey, Sian; Price, David A.; Wiseman, Roger W.; Reynolds, Matthew R.			Identifying a Minor Histocompatibility Antigen in Mauritian Cynomolgus Macaques Encoded by APOBEC3C	FRONTIERS IN IMMUNOLOGY			English	Article						minor histocompatibility antigen (mHAg); APOBEC; cynomolgus macaque; non-human primate (NHP); CD8 T cell; epitope; HIV; cellular immunotherapy	GRAFT-VERSUS-LEUKEMIA; STEM-CELL TRANSPLANTATION; T-CELLS; LYMPHOCYTE IMMUNOTHERAPY; MACACA-FASCICULARIS; LATENT RESERVOIR; HIV; VIRUS; COMPLEX; INFECTION	Allogeneic hematopoietic stem cell transplants can lead to dramatic reductions in human immunodeficiency virus (HIV) reservoirs. This effect is partially mediated by donor T cells recognizing lymphocyte-expressed minor histocompatibility antigens (mHAgs). The potential to mark malignant and latently infected cells for destruction makes mHAgs attractive targets for cellular immunotherapies. However, testing such HIV reservoir reduction strategies will likely require preclinical studies in non-human primates (NHPs). In this study, we used a combination of alloimmunization, whole exome sequencing, and bioinformatics to identify an mHAg in Mauritian cynomolgus macaques (MCMs). We mapped the minimal optimal epitope to a 10-mer peptide (SW10) in apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3C (APOBEC3C) and determined the major histocompatibility complex class I restriction element as Mafa-A1*063, which is expressed in almost 90% of MCMs. APOBEC3C SW10-specific CD8(+) T cells recognized immortalized B cells but not fibroblasts from an mHAg-positive MCM. These results provide a framework for identifying mHAgs in a non-transplant setting and suggest that APOBEC3C SW10 could be used as a model antigen to test mHAg-targeted therapies in NHPs.	[Weinfurter, Jason T.; Matschke, Lea M.; Reynolds, Matthew R.] Univ Wisconsin Madison, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; [Graham, Michael E.; Ericsen, Adam J.; Wiseman, Roger W.; Reynolds, Matthew R.] Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA; [Llewellyn-Lacey, Sian; Price, David A.] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, Wales; [Price, David A.] Cardiff Univ, Sch Med, Syst Immun Res Inst, Cardiff, Wales	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cardiff University; Cardiff University	Reynolds, MR (corresponding author), Univ Wisconsin Madison, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.; Reynolds, MR (corresponding author), Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.	matt.reynolds@wisc.edu	Price, David A/C-7876-2013	Price, David A/0000-0001-9416-2737; Weinfurter, Jason/0000-0001-8076-2598	National Institutes of Health (NIH) [R01 AI118495, R24 OD021322]; Office of Research Infrastructure Programs/OD [P51OD011106]; Research Facilities Improvement Program [RR15459-01, RR020141-01]; Wellcome Trust Senior Investigator Award [100326/Z/12/Z]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Research Infrastructure Programs/OD; Research Facilities Improvement Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Wellcome Trust Senior Investigator Award(Wellcome Trust)	This study was funded by the National Institutes of Health (NIH) via grants R01 AI118495 and R24 OD021322 awarded to MR. Additional support was provided by the Office of Research Infrastructure Programs/OD via grant P51OD011106 awarded to the WNPRC at the University of Wisconsin-Madison. This research was conducted in part at a facility constructed with support from the Research Facilities Improvement Program via grants RR15459-01 and RR020141-01. DP was supported by a Wellcome Trust Senior Investigator Award (100326/Z/12/Z). The funders had no role in study design, collection, analysis, interpretation of the data, or manuscript preparation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591; Bleakley M, 2011, IMMUNOL CELL BIOL, V89, P396, DOI 10.1038/icb.2010.124; Bonhomme M, 2008, MOL ECOL, V17, P1009, DOI 10.1111/j.1365-294X.2007.03645.x; Budde ML, 2010, IMMUNOGENETICS, V62, P773, DOI 10.1007/s00251-010-0481-9; Burwitz BJ, 2009, J VIROL, V83, P6011, DOI 10.1128/JVI.00199-09; Caskey JR, 2019, IMMUNOGENETICS, V71, P531, DOI 10.1007/s00251-019-01125-w; Cavalcante MB, 2017, ARCH GYNECOL OBSTET, V295, P511, DOI 10.1007/s00404-016-4270-z; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Crooks AM, 2015, J INFECT DIS, V212, P1361, DOI 10.1093/infdis/jiv218; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Deeks SG, 2012, NAT REV IMMUNOL, V12, P607, DOI 10.1038/nri3262; denHaan JMM, 1996, EUR J IMMUNOL, V26, P2680, DOI 10.1002/eji.1830261120; Dickinson AM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00496; Falkenburg JHF, 2011, BIOL BLOOD MARROW TR, V17, pS33, DOI 10.1016/j.bbmt.2010.11.009; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Fuchs KJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00659; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; Granados DP, 2016, LEUKEMIA, V30, P1344, DOI 10.1038/leu.2016.22; Griffioen M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00100; Griffioen M, 2012, HAEMATOL-HEMATOL J, V97, P1196, DOI 10.3324/haematol.2011.049478; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Gupta RK, 2020, LANCET HIV, V7, pE340, DOI 10.1016/S2352-3018(20)30069-2; Henrich TJ, 2013, J INFECT DIS, V207, P1694, DOI 10.1093/infdis/jit086; Holman N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179039; Hutter G, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0114-y; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Hultquist JF, 2011, J VIROL, V85, P11220, DOI 10.1128/JVI.05238-11; Janelle V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00276; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; Kling C, 2006, HUM REPROD, V21, P429, DOI 10.1093/humrep/dei316; Koelsch KK, 2017, JAIDS-J ACQ IMM DEF, V75, P328, DOI 10.1097/QAI.0000000000001381; Koning FA, 2009, J VIROL, V83, P9474, DOI 10.1128/JVI.01089-09; Laumont CM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau5516; LAWLER SH, 1995, AM J PHYS ANTHROPOL, V96, P133, DOI 10.1002/ajpa.1330960203; Leith JG, 2003, AIDS RES HUM RETROV, V19, P957, DOI 10.1089/088922203322588305; Li N, 2011, BLOOD, V118, P5965, DOI 10.1182/blood-2011-07-367011; Lupski JR, 2013, GENOME MED, V5, DOI 10.1186/gm461; Margolis DM, 2020, CELL, V181, P189, DOI 10.1016/j.cell.2020.03.005; Mitsuyasu R, 2013, CURR OPIN HIV AIDS, V8, P224, DOI 10.1097/COH.0b013e32835ef0a1; MOWBRAY JF, 1987, LANCET, V2, P679; O'Connor SL, 2007, IMMUNOGENETICS, V59, P449, DOI 10.1007/s00251-007-0209-7; Olson ME, 2018, CELL CHEM BIOL, V25, P36, DOI 10.1016/j.chembiol.2017.10.007; Oostvogels R, 2014, HAEMATOLOGICA, V99, P1854, DOI 10.3324/haematol.2014.109801; Osada N, 2015, GENOME BIOL EVOL, V7, P821, DOI 10.1093/gbe/evv033; Pitman MC, 2018, LANCET HIV, V5, pE317, DOI 10.1016/S2352-3018(18)30039-0; Prall TM, 2017, IMMUNOGENETICS, V69, P325, DOI 10.1007/s00251-017-0977-7; Refsland EW, 2010, NUCLEIC ACIDS RES, V38, P4274, DOI 10.1093/nar/gkq174; Reynolds MR, 2012, VACCINE, V30, P4465, DOI 10.1016/j.vaccine.2012.04.082; Salgado M, 2018, ANN INTERN MED, V169, P674, DOI 10.7326/M18-0759; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; Spierings E, 2013, BIOL BLOOD MARROW TR, V19, P1244, DOI 10.1016/j.bbmt.2013.06.001; Van Bergen CAM, 2010, CANCER RES, V70, P9073, DOI 10.1158/0008-5472.CAN-10-1832; VANDERHARST D, 1994, BLOOD, V83, P1060; Vincent K, 2014, BIOL BLOOD MARROW TR, V20, P37, DOI 10.1016/j.bbmt.2013.10.020; Vincent K, 2011, BLOOD, V118, P2951, DOI 10.1182/blood-2011-04-350868; Warren EH, 2013, TISSUE ANTIGENS, V81, P183, DOI 10.1111/tan.12090; Warren EH, 2010, BLOOD, V115, P3869, DOI 10.1182/blood-2009-10-248997; Warren EH, 1998, BLOOD, V91, P2197, DOI 10.1182/blood.V91.6.2197; Weinfurter JT, 2020, BIORXIV, DOI [10.1101/2020.06.10.145250, DOI 10.1101/2020.06.10.145250]; Wiseman RW, 2007, J VIROL, V81, P349, DOI 10.1128/JVI.01841-06; Wiseman RW, 2013, ILAR J, V54, P196, DOI 10.1093/ilar/ilt036; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	65	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2020	11								586251	10.3389/fimmu.2020.586251	http://dx.doi.org/10.3389/fimmu.2020.586251			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OO4WK	33193411	gold, Green Published, Green Accepted			2022-12-18	WOS:000587380600001
J	Ayadi, I; Balam, S; Audran, R; Bikorimana, JP; Nebie, I; Diakite, M; Felger, I; Tanner, M; Spertini, F; Corradin, G; Arevalo, M; Herrera, S; Agnolon, V				Ayadi, Imen; Balam, Saidou; Audran, Regine; Bikorimana, Jean-Pierre; Nebie, Issa; Diakite, Mahamadou; Felger, Ingrid; Tanner, Marcel; Spertini, Francois; Corradin, Giampietro; Arevalo, Myriam; Herrera, Socrates; Agnolon, Valentina			P. falciparum and P. vivax Orthologous Coiled-Coil Candidates for a Potential Cross-Protective Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; plasmodium falciparum; plasmodium vivax; vaccine; coiled-coil peptides; immune response	CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; MALARIA; ANTIBODIES; STABILITY; RESPONSES; PEPTIDES	Over the last four decades, significant efforts have been invested to develop vaccines against malaria. Although most efforts are focused on the development of P. falciparum vaccines, the current availability of the parasite genomes, bioinformatics tools, and high throughput systems for both recombinant and synthetic antigen production have helped to accelerate vaccine development against the P. vivax parasite. We have previously in silico identified several P. falciparum and P. vivax proteins containing alpha-helical coiled-coil motifs that represent novel putative antigens for vaccine development since they are highly immunogenic and have been associated with protection in many in vitro functional assays. Here, we selected five pairs of P. falciparum and P. vivax orthologous peptides to assess their sero-reactivity using plasma samples collected in P. falciparum- endemic African countries. Pf-Pv cross-reactivity was also investigated. The pairs Pf27/Pv27, Pf43/Pv43, and Pf45/Pv45 resulted to be the most promising candidates for a cross-protective vaccine because they showed a high degree of recognition in direct and competition ELISA assays and cross-reactivity with their respective ortholog. The recognition of P. vivax peptides by plasma of P. falciparum infected individuals indicates the existence of a high degree of cross-reactivity between these two Plasmodium species. The design of longer polypeptides combining these epitopes will allow the assessment of their immunogenicity and protective efficacy in animal models.	[Ayadi, Imen; Corradin, Giampietro] Univ Lausanne, Biochem Dept, Epalinges, Switzerland; [Balam, Saidou; Diakite, Mahamadou] Univ Sci Tech & Technol Bamako USTTB, Univ Clin Res Ctr UCRC, Bamako, Mali; [Balam, Saidou] Univ Hosp Regensburg, Dept Internal Med Nephrol 2, Regensburg, Germany; [Audran, Regine; Bikorimana, Jean-Pierre; Spertini, Francois; Agnolon, Valentina] Ctr Hosp Univ Vaudois CHUV, Div Immunol & Allergy, Lausanne, Switzerland; [Nebie, Issa] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso; [Felger, Ingrid; Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, Basel, Switzerland; [Arevalo, Myriam] Malaria Vaccine & Drug Dev Ctr, Cali, Colombia; [Arevalo, Myriam; Herrera, Socrates] Caucaseco Sci Res Ctr, Cali, Colombia; [Ayadi, Imen] Univ Geneva, Dept Cell Physiol & Metab, Geneva, Switzerland; [Bikorimana, Jean-Pierre] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada	University of Lausanne; University of Science & Technology of Bamako; University of Regensburg; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Basel; Swiss Tropical & Public Health Institute; University of Geneva; Universite de Montreal	Agnolon, V (corresponding author), Ctr Hosp Univ Vaudois CHUV, Div Immunol & Allergy, Lausanne, Switzerland.	valentina.agnolon@chuv.ch		BALAM, Dr Saidou/0000-0002-7178-7758; Nebie, Issa/0000-0003-3051-3600	NIAID-NIH [R01AI148843]	NIAID-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Studies were supported by the NIAID-NIH Grant No. R01AI148843.	Agak GW, 2008, VACCINE, V26, P1963, DOI 10.1016/j.vaccine.2008.02.020; Arevalo-Herrera M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119335; Cespedes N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179863; Cespedes N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100440; Cohen J, 2010, HUM VACCINES, V6, P90, DOI 10.4161/hv.6.1.9677; Commons RJ, 2018, LANCET INFECT DIS, V18, P1025, DOI 10.1016/S1473-3099(18)30348-7; Corradin Giarnpietro, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P259, DOI 10.2174/187153007782794371; Dhiman S, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0527-7; Gunalan K, 2018, TRENDS PARASITOL, V34, P420, DOI 10.1016/j.pt.2018.02.006; Guven E, 2014, J IMMUNOL METHODS, V403, P26, DOI 10.1016/j.jim.2013.11.014; Haberland A, 2018, ANAL BIOANAL CHEM, V410, P5101, DOI 10.1007/s00216-018-1172-x; Herrera S, 2005, AM J TROP MED HYG, V73, P3, DOI 10.4269/ajtmh.2005.73.3; Herrera S, 2004, INT J PARASITOL, V34, P1535, DOI 10.1016/j.ijpara.2004.10.009; Hviid L, 1998, Expert Rev Mol Med, V1998, P1, DOI 10.1017/S1462399498000179; Ikeda M, 2018, EMERG INFECT DIS, V24, P718, DOI 10.3201/eid2404.170141; Jiang ZQ, 2016, BIOPOLYMERS, V106, P144, DOI 10.1002/bip.22808; Karch CP, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0295-0; Kathrine PMA, 2017, YELLOW FEVER MALARIA; Kulangara C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005419; Ladeia-Andrade S, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.01965-18, 10.1128/aac.01965-18]; Liguori A, 2018, MBIO, V9, DOI 10.1128/mBio.01914-18; Moncunill G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01008; Mordmuller B, 2017, NATURE, V542, P445, DOI 10.1038/nature21060; Moritz CP, 2019, J IMMUNOL METHODS, V466, P52, DOI 10.1016/j.jim.2019.01.004; Mueller I, 2015, VACCINE, V33, P7489, DOI 10.1016/j.vaccine.2015.09.060; Niangaly A, 2017, AM J TROP MED HYG, V97, P744, DOI 10.4269/ajtmh.17-0254; Oboh MA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2305062; Olugbile S, 2009, INFECT IMMUN, V77, P5701, DOI 10.1128/IAI.00652-09; Olugbile S, 2011, VACCINE, V29, P7090, DOI 10.1016/j.vaccine.2011.06.122; RIECKMANN KH, 1989, LANCET, V2, P1183, DOI 10.1016/S0140-6736(89)91792-3; Rutledge GG, 2017, NATURE, V542, P101, DOI 10.1038/nature21038; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Silva SR, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2411-5; Terato K, 2014, J IMMUNOL METHODS, V407, P15, DOI 10.1016/j.jim.2014.03.013; Tong P, 2013, J ANTIMICROB CHEMOTH, V68, P2533, DOI 10.1093/jac/dkt230; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Villard V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000645; WHO, 2017, WORLD MAL REP 2017, P196; World Health Organization, 2018, WORLD MALARIA REPORT, DOI [10.30875/f309483f-en, DOI 10.30875/F309483F-EN]; World Health Organization, 2019, WORLD MALARIA REPORT, DOI [10.30875/7e6f8c91-en, DOI 10.30875/7E6F8C91-EN]; World Health Organization, 2018, STAT REP ART RES ACT; Yadava A, 2007, INFECT IMMUN, V75, P1177, DOI 10.1128/IAI.01667-06	42	1	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2020	11								574330	10.3389/fimmu.2020.574330	http://dx.doi.org/10.3389/fimmu.2020.574330			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL9PH	33193361	Green Published, gold			2022-12-18	WOS:000585661600001
J	Kolomansky, A; Kaye, I; Ben-Califa, N; Gorodov, A; Awida, Z; Sadovnic, O; Ibrahim, M; Liron, T; Hiram-Bab, S; Oster, HS; Sarid, N; Perry, C; Gabet, Y; Mittelman, M; Neumann, D				Kolomansky, Albert; Kaye, Irit; Ben-Califa, Nathalie; Gorodov, Anton; Awida, Zamzam; Sadovnic, Ofer; Ibrahim, Maria; Liron, Tamar; Hiram-Bab, Sahar; Oster, Howard S.; Sarid, Nadav; Perry, Chava; Gabet, Yankel; Mittelman, Moshe; Neumann, Drorit			Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						rituximab; follicular lymphoma; anti-CD20 antibodies; RANKL (receptor activator for nuclear factor k B ligand); B cell depletion; bone density; CD115	RECEPTOR ACTIVATOR; OSTEOCLAST PRECURSORS; ESTROGEN DEFICIENCY; MINERAL DENSITY; RANKL; DIFFERENTIATION; LIGAND; INTERLEUKIN-7; OSTEOPOROSIS; EXPRESSION	Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet been described. Here, we used cross-sectional X-ray imaging (CT/PET-CT) to serially assess bone density in patients with follicular lymphoma receiving rituximab maintenance therapy. Remarkably, this treatment prevented the decline in bone mass observed in the control group of patients who did not receive active maintenance therapy. In accordance with these data, anti-CD20-mediated B cell depletion in normal C57BL/6J female mice led to a significant increase in bone mass, as reflected by a 7.7% increase in bone mineral density (whole femur), and a similar to 5% increase in cortical as well as trabecular tissue mineral density. Administration of anti-CD20 antibodies resulted in a significant decrease in osteoclastogenic signals, including RANKL, which correlated with a reduction in osteoclastogenic potential of bone marrow cells derived from B-cell-depleted animals. Taken together, our data suggest that in addition to its anti-tumor activity, anti-CD20 treatment has a favorable effect on bone mass. Our murine studies indicate that B cell depletion has a direct effect on bone remodeling.	[Kolomansky, Albert; Ben-Califa, Nathalie; Gorodov, Anton; Awida, Zamzam; Ibrahim, Maria; Neumann, Drorit] Tel Aviv Univ, Dept Cell & Dev Biol, Tel Aviv, Israel; [Kolomansky, Albert; Kaye, Irit; Oster, Howard S.; Mittelman, Moshe] Tel Aviv Sourasky Med Ctr, Dept Med A, Tel Aviv, Israel; [Kolomansky, Albert; Kaye, Irit; Ben-Califa, Nathalie; Gorodov, Anton; Awida, Zamzam; Sadovnic, Ofer; Ibrahim, Maria; Liron, Tamar; Hiram-Bab, Sahar; Oster, Howard S.; Sarid, Nadav; Perry, Chava; Gabet, Yankel; Mittelman, Moshe; Neumann, Drorit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Gorodov, Anton] Open Univ Israel, Raanana, Israel; [Sadovnic, Ofer] Tel Aviv Sourasky Med Ctr, Dept Radiol, Tel Aviv, Israel; [Liron, Tamar; Hiram-Bab, Sahar; Gabet, Yankel] Tel Aviv Univ, Dept Anat & Anthropol, Tel Aviv, Israel; [Sarid, Nadav; Perry, Chava] Tel Aviv Sourasky Med Ctr, Inst Hematol, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Open University Israel; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Neumann, D (corresponding author), Tel Aviv Univ, Dept Cell & Dev Biol, Tel Aviv, Israel.; Neumann, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	histo6@tauex.tau.ac.il		Gabet, Yankel/0000-0002-7494-0631; Neumann, Drorit/0000-0002-4805-7511	Sackler Faculty of Medicine, Tel Aviv University; Israel Science Foundation (ISF) [1822/12, 343/17]; Cancer Biology Research Center, Tel Aviv University	Sackler Faculty of Medicine, Tel Aviv University; Israel Science Foundation (ISF)(Israel Science Foundation); Cancer Biology Research Center, Tel Aviv University	This work was supported by the Schauder Memorial Endowment Fund, Sackler Faculty of Medicine, Tel Aviv University, by the Israel Science Foundation (ISF) Grant No. 1822/12 to YG, Grant No. 343/17 to DN and by a grant from the Dotan Hemato-oncology Fund, the Cancer Biology Research Center, Tel Aviv University to DN, MM, and YG.	Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604; Avivi I, 2019, AGING CELL, V18, DOI 10.1111/acel.12959; BENAYAHU D, 1993, BIOCHEM BIOPH RES CO, V194, P391, DOI 10.1006/bbrc.1993.1832; Blin-Wakkach C, 2004, J BONE MINER RES, V19, P1137, DOI 10.1359/JBMR.040318; Choi Y, 2003, EXP MOL MED, V35, P385, DOI 10.1038/emm.2003.51; Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X; Deshet-Unger N, 2020, THERANOSTICS, V10, P8744, DOI 10.7150/thno.45845; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Dubrovsky AM, 2018, CALCIFIED TISSUE INT, V102, P607, DOI 10.1007/s00223-018-0401-9; Florencio-Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746; Freedman A, 2012, AM J HEMATOL, V87, P988, DOI 10.1002/ajh.23313; Fujiwara Y, 2016, J BIOL CHEM, V291, P24838, DOI 10.1074/jbc.M116.742452; Gabet Y, 2010, BLOOD, V116, P3964, DOI 10.1182/blood-2010-01-263830; Hein G, 2011, RHEUMATOL INT, V31, P269, DOI 10.1007/s00296-010-1560-9; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; Hiram-Bab S, 2015, FASEB J, V29, P1890, DOI 10.1096/fj.14-259085; Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011; Hu FL, 2017, J AUTOIMMUN, V76, P53, DOI 10.1016/j.jaut.2016.09.002; Keren Z, 2011, BLOOD, V117, P3104, DOI 10.1182/blood-2010-09-307983; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood-2006-07-037994; Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625; Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179; Martin CE, 2017, IMMUNITY, V47, P171, DOI 10.1016/j.immuni.2017.07.005; MASUZAWA T, 1994, J CLIN INVEST, V94, P1090, DOI 10.1172/JCI117424; Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489; Pinto CM, 2013, LUPUS, V22, P1128, DOI 10.1177/0961203313502861; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Noh T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005438; Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945; Pierpont TM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00163; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; Sato T, 2001, J BONE MINER RES, V16, P2215, DOI 10.1359/jbmr.2001.16.12.2215; Schwaiger BJ, 2017, BONE, V101, P62, DOI 10.1016/j.bone.2017.04.008; Scott David L, 2010, Lancet, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Shahaf G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00077; Svendsen P, 2017, LEUKEMIA LYMPHOMA, V58, P1105, DOI 10.1080/10428194.2016.1233543; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100; Toubi E, 2007, ANN RHEUM DIS, V66, P818, DOI 10.1136/ard.2006.062505; Weber NK, 2014, AM J GASTROENTEROL, V109, P401, DOI 10.1038/ajg.2013.478; Wheater G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201527; Xu S, 2016, J BONE MINER RES, V31, P1320, DOI 10.1002/jbmr.2800; Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816; Yun TJ, 2001, J IMMUNOL, V166, P1482, DOI 10.4049/jimmunol.166.3.1482; Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood-2006-08-041384	46	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2020	11								561294	10.3389/fimmu.2020.561294	http://dx.doi.org/10.3389/fimmu.2020.561294			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI4NC	33193330	Green Published, gold			2022-12-18	WOS:000583256400001
J	Banda, NK; Tomlinson, S; Scheinman, RI; Ho, N; Ramirez, JR; Mehta, G; Wang, GK; Vu, VP; Simberg, D; Kulik, L; Holers, VM				Banda, Nirmal K.; Tomlinson, Stephen; Scheinman, Robert, I; Nhu Ho; Ramirez, Joseline Ramos; Mehta, Gaurav; Wang, Guankui; Vu, Vivian Pham; Simberg, Dmitri; Kulik, Liudmila; Holers, V. Michael			C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						natural antibodies; single chain; C2-Crry; complement; complement inhibitor; arthritis	COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; ALTERNATIVE PATHWAY; PASSIVE TRANSFER; LECTIN PATHWAY; POLYREACTIVE ANTIBODIES; DEPENDENT APOPTOSIS; SYNOVIAL-FLUID; ACTIVATION; PROTEIN	Natural IgM antibodies (NAbs) have been shown to recognize injury-associated neoepitopes and to initiate pathogenic complement activation. The NAb termed C2 binds to a subset of phospholipids displayed on injured cells, and its role(s) in arthritis, as well as the potential therapeutic benefit of a C2 NAb-derived ScFv-containing protein fused to a complement inhibitor, complement receptor-related y (Crry), on joint inflammation are unknown. Our first objective was to functionally test mAb C2 binding to apoptotic cells from the joint and also evaluate its inflammation enhancing capacity in collagen antibody-induced arthritis (CAIA). The second objective was to generate and test the complement inhibitory capacity of C2-Crry fusion protein in the collagen-induced arthritis (CIA) model. The third objective was to demonstrate in vivo targeting of C2-Crry to damaged joints in mice with arthritis. The effect of C2-NAb on CAIA in C57BL/6 mice was examined by inducing a suboptimal disease. The inhibitory effect of C2-Crry in DBA/1J mice with CIA was determined by injecting 2x per week with a single dose of 0.250 mg/mouse. Clinical disease activity (CDA) was examined, and knee joints were fixed for analysis of histopathology, C3 deposition, and macrophage infiltration. In mice with suboptimal CAIA, at day 10 there was a significant (p < 0.017) 74% increase in the CDA in mice treated with C2 NAb, compared to mice treated with F632 control NAb. In mice with CIA, at day 35 there was a significant 39% (p < 0.042) decrease in the CDA in mice treated with C2-Crry. Total scores for histopathology were also 50% decreased (p < 0.0005) in CIA mice treated with C2-Crry. C3 deposition was significantly decreased in the synovium (44%; p < 0.026) and on the surface of cartilage (42%; p < 0.008) in mice treated with C2-Crry compared with PBS treated CIA mice. Furthermore, C2-Crry specifically bound to apoptotic fibroblast-like synoviocytes in vitro, and also localized in the knee joints of arthritic mice as analyzed by in vivo imaging. In summary, NAb C2 enhanced arthritis-related injury, and targeted delivery of C2-Crry to inflamed joints demonstrated disease modifying activity in a mouse model of human inflammatory arthritis.	[Banda, Nirmal K.; Nhu Ho; Ramirez, Joseline Ramos; Mehta, Gaurav; Kulik, Liudmila; Holers, V. Michael] Univ Colorado, Div Rheumatol, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA; [Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Scheinman, Robert, I; Nhu Ho; Wang, Guankui; Vu, Vivian Pham; Simberg, Dmitri] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Medical University of South Carolina; University of Colorado System; University of Colorado Anschutz Medical Campus	Banda, NK (corresponding author), Univ Colorado, Div Rheumatol, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA.	Nirmal.Banda@cuanschutz.edu			National Institutes of Health [2R56R01AR51749-15, R01 AI154959-05, U01AI132894]; Department of Veteran's Affairs grant [RX001141]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veteran's Affairs grant(US Department of Veterans Affairs)	Supported by National Institutes of Health grant 2R56R01AR51749-15 to VH (PI) and NB (Co-I), R01 AI154959-05 to DS and U01AI132894 to ST, and by Department of Veteran's Affairs grant RX001141 to ST.	Al-Zoobi L, 2014, INT IMMUNOL, V26, P451, DOI 10.1093/intimm/dxu046; Alexander JJ, 2007, EUR J IMMUNOL, V37, P1691, DOI 10.1002/eji.200636638; Alexander JJ, 2005, J IMMUNOL, V175, P8312, DOI 10.4049/jimmunol.175.12.8312; Ammitzboll CG, 2012, RHEUMATOL INT, V32, P1457, DOI 10.1007/s00296-011-1879-x; [Anonymous], 1999, SCIENCE; Arend WP, 2013, J IMMUNOL, V190, P6423, DOI 10.4049/jimmunol.1300580; Arend WP, 2012, NAT REV RHEUMATOL, V8, P573, DOI 10.1038/nrrheum.2012.134; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Arnold JN, 2005, J BIOL CHEM, V280, P29080, DOI 10.1074/jbc.M504528200; Atkinson C, 2015, CIRCULATION, V131, P1171, DOI 10.1161/CIRCULATIONAHA.114.010482; AVRAMEAS S, 1995, RES IMMUNOL, V146, P235, DOI 10.1016/0923-2494(96)80259-8; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; Avrameas S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01320; Banda NK, 2007, J IMMUNOL, V179, P4101, DOI 10.4049/jimmunol.179.6.4101; Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904; Banda Nirmal K, 2018, Immunohorizons, V2, P274, DOI 10.4049/immunohorizons.1800053; Banda NK, 2017, J IMMUNOL, V199, P1835, DOI 10.4049/jimmunol.1700119; Banda NK, 2014, J IMMUNOL, V193, P2455, DOI 10.4049/jimmunol.1400752; Banda NK, 2012, J IMMUNOL, V188, P1469, DOI 10.4049/jimmunol.1102310; Banda NK, 2010, J IMMUNOL, V185, P5598, DOI 10.4049/jimmunol.1001564; Banda NK, 2009, J IMMUNOL, V183, P5928, DOI 10.4049/jimmunol.0901826; Banda NK, 2003, J IMMUNOL, V171, P2109, DOI 10.4049/jimmunol.171.4.2109; Banda NK, 2002, ARTHRITIS RHEUM-US, V46, P3065, DOI 10.1002/art.10591; Barilla-LaBarca ML, 2002, J IMMUNOL, V168, P6298, DOI 10.4049/jimmunol.168.12.6298; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Bemis EA, 2019, MOL IMMUNOL, V112, P256, DOI 10.1016/j.molimm.2019.05.012; BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531; Bryant Adam, 2006, Ther Clin Risk Manag, V2, P207, DOI 10.2147/tcrm.2006.2.2.207; Burastero S E, 1989, Contrib Microbiol Immunol, V11, P231; BURASTERO SE, 1988, J EXP MED, V168, P1979, DOI 10.1084/jem.168.6.1979; Campisi L, 2014, AM J TRANSPLANT, V14, P1488, DOI 10.1111/ajt.12736; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.immunol.7.1.513; CASALI P, 1989, IMMUNOL TODAY, V10, P364, DOI 10.1016/0167-5699(89)90268-5; Catrina AI, 2005, ARTHRITIS RHEUM-US, V52, P61, DOI 10.1002/art.20764; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Doering J, 2004, GUT, V53, P1632, DOI 10.1136/gut.2003.037911; DURANDY A, 1990, J IMMUNOL, V144, P60; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Elvington A, 2012, J IMMUNOL, V188, P1460, DOI 10.4049/jimmunol.1102132; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fleming SD, 2006, AUTOIMMUNITY, V39, P379, DOI 10.1080/08916930600739381; FOLEY S, 1993, EUR J IMMUNOL, V23, P1381, DOI 10.1002/eji.1830230630; Fridkis-Hareli M, 2019, MOL IMMUNOL, V105, P150, DOI 10.1016/j.molimm.2018.09.013; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2009, PEDIATR BLOOD CANCER, V53, P533, DOI 10.1002/pbc.21922; GADOL N, 1986, IMMUNOL REV, V93, P23, DOI 10.1111/j.1600-065X.1986.tb01500.x; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gifford G, 2019, J CONTROL RELEASE, V302, P181, DOI 10.1016/j.jconrel.2019.04.009; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Haas MS, 2010, CARDIOVASC RES, V87, P618, DOI 10.1093/cvr/cvq141; Helmick CG, 2008, ARTHRITIS RHEUM-US, V58, P15, DOI 10.1002/art.23177; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; Hietala MA, 2004, EUR J IMMUNOL, V34, P1208, DOI 10.1002/eji.200424895; Holers VM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01057; Hootman JM, 2006, ARTHRITIS RHEUM-US, V54, P226, DOI 10.1002/art.21562; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Liu FM, 2014, ATHEROSCLEROSIS, V234, P237, DOI 10.1016/j.atherosclerosis.2014.03.004; Lofchy LA, 2019, MOL PHARMACEUT, V16, P2445, DOI 10.1021/acs.molpharmaceut.9b00059; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; Mehta G, 2015, J IMMUNOL, V194, P5446, DOI 10.4049/jimmunol.1403012; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002; Nagata S, 2010, CELL, V140, P619, DOI 10.1016/j.cell.2010.02.014; Nakazawa F, 2001, J RHEUMATOL, V28, P1800; Nandakumar KS, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2089; Narang A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0894-6; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Ochsenbein AF, 2000, IMMUNOL TODAY, V21, P624, DOI 10.1016/S0167-5699(00)01754-0; Ogden CA, 2005, AUTOIMMUNITY, V38, P259, DOI 10.1080/08916930500124452; Posnett DN, 1997, J EXP MED, V185, P1721, DOI 10.1084/jem.185.10.1721; Quartier P, 2005, EUR J IMMUNOL, V35, P252, DOI 10.1002/eji.200425497; Smith MD, 2010, RHEUMATOLOGY, V49, P862, DOI 10.1093/rheumatology/kep467; Song H, 2007, J IMMUNOL, V179, P7860, DOI 10.4049/jimmunol.179.11.7860; Swierkot J, 2004, ANN RHEUM DIS, V63, P599, DOI 10.1136/ard.2003.015370; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wang Y, 2000, J IMMUNOL, V164, P4340, DOI 10.4049/jimmunol.164.8.4340; WATSON WC, 1987, ARTHRITIS RHEUM, V30, P460, DOI 10.1002/art.1780300418; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; Wener M., 1999, LUPUS MOL CELLULAR P, P574, DOI [10.1007/978-1-59259-703-1_35, DOI 10.1007/978-1-59259-703-1_35]; Werneburg S, 2020, IMMUNITY, V52, P167, DOI 10.1016/j.immuni.2019.12.004; Wu XB, 2008, J IMMUNOL, V181, P2732, DOI 10.4049/jimmunol.181.4.2732; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498; Zhang M, 2006, J EXP MED, V203, P141, DOI 10.1084/jem.20050390; Zhang M, 2004, P NATL ACAD SCI USA, V101, P3886, DOI 10.1073/pnas.0400347101; Zhang M, 2006, J MOL CELL CARDIOL, V41, P62, DOI 10.1016/j.yjmcc.2006.02.006	89	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 16	2020	11								575154	10.3389/fimmu.2020.575154	http://dx.doi.org/10.3389/fimmu.2020.575154			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK6BR	33178202	gold, Green Published			2022-12-18	WOS:000584734100001
J	Wu, J; Zhang, HL; Zheng, Y; Jin, XY; Liu, MY; Li, S; Zhao, Q; Liu, XL; Wang, YS; Shi, M; Zhang, SN; Tian, JW; Sun, Y; Zhang, MM; Yu, B				Wu, Jian; Zhang, Hanlu; Zheng, Yang; Jin, Xiangyuan; Liu, Mingyang; Li, Shuang; Zhao, Qi; Liu, Xianglan; Wang, Yongshun; Shi, Ming; Zhang, Shengnan; Tian, Jinwei; Sun, Yong; Zhang, Maomao; Yu, Bo			The Long Noncoding RNA MALAT1 Induces Tolerogenic Dendritic Cells and Regulatory T Cells via miR155/Dendritic Cell-Specific Intercellular Adhesion Molecule-3 Grabbing Nonintegrin/IL10 Axis (vol 9, 1847, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						MALAT1 long noncoding RNA; tolerogenic dendritic cell; immune tolerance; dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin; miR155; IL10			[Wu, Jian; Zhang, Hanlu; Zheng, Yang; Liu, Mingyang; Li, Shuang; Zhao, Qi; Liu, Xianglan; Zhang, Shengnan; Tian, Jinwei; Sun, Yong; Zhang, Maomao; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China; [Wu, Jian; Zhang, Hanlu; Zheng, Yang; Liu, Mingyang; Li, Shuang; Zhao, Qi; Liu, Xianglan; Zhang, Shengnan; Tian, Jinwei; Sun, Yong; Zhang, Maomao; Yu, Bo] Harbin Med Univ, Minist Educ, Key Lab Myocardial Ischemia, Harbin, Peoples R China; [Jin, Xiangyuan] Harbin Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Harbin, Peoples R China; [Wang, Yongshun] Univ Hong Kong, Sch Biomed Sci, Pokfulam, Hong Kong, Peoples R China; [Shi, Ming] Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; University of Hong Kong; Harbin Institute of Technology	Zhang, MM; Yu, B (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China.; Zhang, MM; Yu, B (corresponding author), Harbin Med Univ, Minist Educ, Key Lab Myocardial Ischemia, Harbin, Peoples R China.	maomaolp1983@163.com; yubodr@163.com						Wu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01847	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 16	2020	11								582491	10.3389/fimmu.2020.582491	http://dx.doi.org/10.3389/fimmu.2020.582491			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL9NQ	33178211	Green Published, gold			2022-12-18	WOS:000585657300001
J	Bosisio, D; Bazzoni, F				Bosisio, Daniela; Bazzoni, Flavia			Editorial: Regulation of Soluble Immune Mediators by Non-Coding RNAs	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						microRNAs; Y-RNAs; lncRNAs; toll-like receptors (TLRs); extracellular vesicles (EVs); ribonucleoproteins; autoimmunity; endotoxin tolerance	SYSTEM		[Bosisio, Daniela] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Bazzoni, Flavia] Univ Verona, Div Gen Pathol, Dept Med, Verona, Italy	University of Brescia; University of Verona	Bosisio, D (corresponding author), Univ Brescia, Dept Mol & Translat Med, Brescia, Italy.; Bazzoni, F (corresponding author), Univ Verona, Div Gen Pathol, Dept Med, Verona, Italy.	daniela.bosisio@unibs.it; flavia.bazzoni@univr.it			Ministero dell'Universita e della Ricerca (PRIN 2017); University of Brescia (Fondi Locali 2019); University of Verona-Joint Project [JPVR17WCBR]; Fondo Unico per la ricerca (FUR)	Ministero dell'Universita e della Ricerca (PRIN 2017); University of Brescia (Fondi Locali 2019); University of Verona-Joint Project; Fondo Unico per la ricerca (FUR)	DB and FB are supported by Ministero dell'Universita e della Ricerca (PRIN 2017), University of Brescia (Fondi Locali 2019), University of Verona-Joint Project (project JPVR17WCBR) and Fondo Unico per la ricerca (FUR).	Bosisio D, 2019, CANCER LETT, V452, P59, DOI 10.1016/j.canlet.2019.03.021; Chen YG, 2017, NAT IMMUNOL, V18, P962, DOI 10.1038/ni.3771; Christopher Ajay Francis, 2016, Perspect Clin Res, V7, P68, DOI 10.4103/2229-3485.179431; Mehta A, 2016, NAT REV IMMUNOL, V16, P279, DOI 10.1038/nri.2016.40; Murillo OD, 2019, CELL, V177, P463, DOI 10.1016/j.cell.2019.02.018; Shah MY, 2016, EBIOMEDICINE, V12, P34, DOI 10.1016/j.ebiom.2016.09.017; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Zhang PJ, 2019, J INTEGR BIOINFORMAT, V16, DOI 10.1515/jib-2019-0027	8	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2020	11								607222	10.3389/fimmu.2020.607222	http://dx.doi.org/10.3389/fimmu.2020.607222			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK6LO	33178230	gold, Green Published			2022-12-18	WOS:000584759800001
J	Mortier, E; Ma, A; Malynn, BA; Neurath, MF				Mortier, Erwan; Ma, Averil; Malynn, Barbara A.; Neurath, Markus F.			Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cytokine; oncology; inflammation; inhibitor; therapy			[Mortier, Erwan] Univ Nantes, CNRS, INSERM, CRCINA, Nantes, France; [Ma, Averil; Malynn, Barbara A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Neurath, Markus F.] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Erlangen, Germany; [Neurath, Markus F.] Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; University of California System; University of California San Francisco; University of Erlangen Nuremberg	Mortier, E (corresponding author), Univ Nantes, CNRS, INSERM, CRCINA, Nantes, France.	erwan.mortier@univ-nantes.fr	Mortier, Erwan/AAH-7925-2021; Mortier, Erwan/ABG-6465-2021	Mortier, Erwan/0000-0002-6321-6488					0	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2020	11								608636	10.3389/fimmu.2020.608636	http://dx.doi.org/10.3389/fimmu.2020.608636			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK6SQ	33178231	Green Published, gold			2022-12-18	WOS:000584778200001
J	Reijmers, RM; Troeberg, L; Lord, MS; Petrey, AC				Reijmers, Rogier M.; Troeberg, Linda; Lord, Megan S.; Petrey, Aaron C.			Editorial: Proteoglycans and Glycosaminoglycan Modification in Immune Regulation and Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						glycosaminoglycan (GAG); proteoglycans (PG); immune response; inflammation; heparan sulfate (HS); chondroitin sulfate (CS); dermatan sulfate (DS); hyaluronan			[Reijmers, Rogier M.] LUMICKS BV, Amsterdam, Netherlands; [Troeberg, Linda] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England; [Lord, Megan S.] Univ New South Wales Sydney, Grad Sch Biomed Engn, Sydney, NSW, Australia; [Petrey, Aaron C.] Univ Utah, Mol Med Program, Salt Lake City, UT 84112 USA; [Petrey, Aaron C.] Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA	University of East Anglia; University of New South Wales Sydney; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Reijmers, RM (corresponding author), LUMICKS BV, Amsterdam, Netherlands.; Troeberg, L (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England.; Lord, MS (corresponding author), Univ New South Wales Sydney, Grad Sch Biomed Engn, Sydney, NSW, Australia.; Petrey, AC (corresponding author), Univ Utah, Mol Med Program, Salt Lake City, UT 84112 USA.; Petrey, AC (corresponding author), Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA.	r.reijmers@lumicks.com; l.troeberg@uea.ac.uk; m.lord@unsw.edu.au; aaron.petrey@u2m2.utah.edu	Reijmers, Rogier/M-2620-2019; Petrey, Aaron C./AAD-8623-2020	Reijmers, Rogier/0000-0001-7471-7715; Petrey, Aaron C./0000-0002-2696-599X; /0000-0003-0939-4651	Versus Arthritis [21245]; National Institutes of Health [HL135265]	Versus Arthritis(Versus Arthritis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank all authors for their contribution to our Research Topic. This work was supported by Versus Arthritis (grant 21245, LT) and National Institutes of Health (HL135265, AP).	Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Kjellen L, 2018, CURR OPIN STRUC BIOL, V50, P101, DOI 10.1016/j.sbi.2017.12.011; Weiss RJ, 2020, P NATL ACAD SCI USA, V117, P9311, DOI 10.1073/pnas.1920880117	3	1	1	6	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2020	11								595867	10.3389/fimmu.2020.595867	http://dx.doi.org/10.3389/fimmu.2020.595867			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OM0UW	33178227	Green Accepted, Green Published, gold			2022-12-18	WOS:000585746600001
J	Zhang, TT; Zhang, XY; Sun, ZH; Liu, G; Hou, XL; Wei, LM				Zhang, Tingting; Zhang, Xinyue; Sun, Zhenhong; Liu, Gen; Hou, Xiaolan; Wei, Liangmeng			Duck HMGB2 Mediates Signaling Pathways in the Innate Immunity of Hosts Against Viral Infections	FRONTIERS IN IMMUNOLOGY			English	Article						duck high-mobility group box 2; characterization; subcellular localization; innate immunity; signaling pathway; antiviral activity	CHROMATIN PROTEIN; EXPRESSION; CLONING; GENE; ANTIBACTERIAL; PATHOGENICITY; RESPONSES; FAMILY; PLAGUE	High-mobility group box 2 (HMGB2) belongs to the HMG-box family that participates in a variety of biologic processes. Recent studies have suggested that HMGB2 plays an important role in the innate immunity of fish. Cherry Valley duck is the main duck bred for meat consumption in China, but there is limited research available on the impact of duck HMGB2 (duHMGB2) in antiviral innate immunity. Here, duHMGB2 genes were first cloned and analyzed from the spleen of Cherry Valley ducks. We show that duHMGB2 is widely distributed in most tissues of healthy ducks, and duHMGB2 was differentially expressed in three organs (the spleen, brain, and lung) of ducks during different viral infections. duHMGB2 is mainly expressed in the nucleus of duck embryo fibroblast (DEF) cells. However, duHMGB2 is released into the cytoplasm after viral infection. DuHMGB2 induced expression of several genes that regulate the immune response. Moreover, duHMGB2 activated and upregulatede transcription factor NF-kappa B promoter activity. We also used single gene manipulations (knockout or overexpression) to confirm that duHMGB2 can inhibit the replication of duck plague virus, duck Tembusu virus, and the novel duck reovirus in DEF cells. These data show that duHMGB2 can activate the antiviral innate immunity of the host. Thus, duHMGB2 may be considered an immune adjuvant against infectious diseases in duck.	[Zhang, Tingting; Sun, Zhenhong; Hou, Xiaolan; Wei, Liangmeng] Shandong First Med Univ, Coll Basic Med Sci, Collaborat Innovat Ctr Origin & Control Emerging, Tai An, Shandong, Peoples R China; [Zhang, Xinyue; Hou, Xiaolan; Wei, Liangmeng] Shandong Agr Univ, Sino German Cooperat Res Ctr Zoonosis Anim Origin, Shandong Prov Key Lab Anim Biotechnol & Dis Contr, Tai An, Shandong, Peoples R China; [Zhang, Xinyue; Hou, Xiaolan; Wei, Liangmeng] Shandong Agr Univ, Coll Anim Sci & Vet Med, Shandong Prov Engn Technol Res Ctr Anim Dis Contr, Tai An, Shandong, Peoples R China; [Liu, Gen] Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Key Laboratory of Animal Biotechnology & Disease Control & Prevention of Shandong Province; Shandong Agricultural University; Shandong Agricultural University; Jining Medical University	Hou, XL; Wei, LM (corresponding author), Shandong First Med Univ, Coll Basic Med Sci, Collaborat Innovat Ctr Origin & Control Emerging, Tai An, Shandong, Peoples R China.; Hou, XL; Wei, LM (corresponding author), Shandong Agr Univ, Sino German Cooperat Res Ctr Zoonosis Anim Origin, Shandong Prov Key Lab Anim Biotechnol & Dis Contr, Tai An, Shandong, Peoples R China.; Hou, XL; Wei, LM (corresponding author), Shandong Agr Univ, Coll Anim Sci & Vet Med, Shandong Prov Engn Technol Res Ctr Anim Dis Contr, Tai An, Shandong, Peoples R China.	18754808293@163.com; lmwei@sdau.edu.cn			National Natural Science Foundation of China [31972664]; Natural Science Foundation of Shandong Province [ZR2017JL018]; China Postdoctoral Science Foundation [2018M632268, 2019T120404]; Shandong Double Tops Program [SYL2017YSTD11]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shandong Double Tops Program	This work was supported by the National Natural Science Foundation of China (31972664), the Project of Natural Science Foundation of Shandong Province (ZR2017JL018), the China Postdoctoral Science Foundation (2018M632268 and 2019T120404), and the Shandong Double Tops Program (SYL2017YSTD11).	Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chen H, 2019, VET IMMUNOL IMMUNOP, V218, DOI 10.1016/j.vetimm.2019.109953; Hou XL, 2020, VET RES, V51, DOI 10.1186/s13567-020-00742-8; Jiao PR, 2015, POULTRY SCI, V94, P1170, DOI 10.3382/ps/pev082; Li N, 2016, SCI REP-UK, V6, DOI 10.1038/srep32183; Li N, 2016, VET MICROBIOL, V192, P181, DOI 10.1016/j.vetmic.2016.07.015; Li N, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00425; Long H, 2014, FISH SHELLFISH IMMUN, V37, P66, DOI 10.1016/j.fsi.2014.01.013; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Pan LF, 2018, AM J TRANSL RES, V10, P402; Qu YR, 2018, VIROLOGY, V525, P19, DOI 10.1016/j.virol.2018.09.001; Rao YL, 2013, DEV COMP IMMUNOL, V41, P164, DOI 10.1016/j.dci.2013.06.002; Ronfani L, 2001, DEVELOPMENT, V128, P1265; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Ueda T, 2010, BBA-GENE REGUL MECH, V1799, P114, DOI 10.1016/j.bbagrm.2009.11.005; Wang GH, 2019, FISH SHELLFISH IMMUN, V84, P719, DOI 10.1016/j.fsi.2018.10.066; Wang GW, 2013, POULTRY SCI, V92, P2892, DOI 10.3382/ps.2013-03356; Wang HC, 2009, SHOCK, V32, P348, DOI 10.1097/SHK.0b013e3181a551bd; Wei L, 2016, POULTRY SCI, V95, P2290, DOI 10.3382/ps/pew162; Wei LM, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-66; Yanai H, 2011, J INTERN MED, V270, P301, DOI 10.1111/j.1365-2796.2011.02433.x; Yanai H, 2012, TRENDS IMMUNOL, V33, P633, DOI 10.1016/j.it.2012.10.005; Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512; Zhang QC, 2010, BBA-GENE REGUL MECH, V1799, P28, DOI 10.1016/j.bbagrm.2009.11.009; Zou J, 2010, CURR PHARM DESIGN, V16, P4185, DOI 10.2174/138161210794519093	27	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2020	11								572289	10.3389/fimmu.2020.572289	http://dx.doi.org/10.3389/fimmu.2020.572289			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK7BX	33178199	Green Published, gold			2022-12-18	WOS:000584802300001
J	Camacho, F; Moreno, E; Garcia-Alles, LF; Santiago, GC; Gilleron, M; Vasquez, A; Choong, YS; Reyes, F; Norazmi, MN; Sarmiento, ME; Acosta, A				Camacho, Frank; Moreno, Ernesto; Garcia-Alles, Luis F.; Chinea Santiago, Glay; Gilleron, Martine; Vasquez, Aleikar; Choong, Yee Siew; Reyes, Fatima; Norazmi, Mohd Nor; Sarmiento, Maria E.; Acosta, Armando			A Direct Role for the CD1b Endogenous Spacer in the Recognition of a Mycobacterium tuberculosis Antigen by T-Cell Receptors	FRONTIERS IN IMMUNOLOGY			English	Article						CD1b; Mycobacterium tuberculosis; sulfoglycolipids; Ac(2)SGL; scTCR; endogenous spacer	CRYSTAL-STRUCTURE; DOMAIN ANTIBODY; BINDING GROOVE; PROTEIN	Lipids, glycolipids and lipopeptides derived from Mycobacterium tuberculosis (Mtb) are presented to T cells by monomorphic molecules known as CD1. This is the case of the Mtb-specific sulfoglycolipid Ac(2)SGL, which is presented by CD1b molecules and is recognized by T cells found in tuberculosis (TB) patients and in individuals with latent infections. Our group, using filamentous phage display technology, obtained two specific ligands against the CD1b-Ac(2)SGL complex: (i) a single chain T cell receptor (scTCR) from a human T cell clone recognizing the CD1b-AcSGL complex; and (ii) a light chain domain antibody (dAb kappa 11). Both ligands showed lower reactivity to a synthetic analog of Ac(2)SGL (SGL12), having a shorter acyl chain as compared to the natural antigen. Here we put forward the hypothesis that the CD1b endogenous spacer lipid (EnSpacer) plays an important role in the recognition of the CD1b-Ac(2)SGL complex by specific T cells. To support this hypothesis we combined: (a) molecular binding assays for both the scTCR and the dAb kappa 11 antibody domain against a small panel of synthetic Ac(2)SGL analogs having different acyl chains, (b) molecular modeling of the CD1b-Ac(2)SGL/EnSpacer complex, and (c) modeling of the interactions of this complex with the scTCR. Our results contribute to understand the mechanisms of lipid presentation by CD1b molecules and their interactions with T-cell receptors and other specific ligands, which may help to develop specific tools targeting Mtb infected cells for therapeutic and diagnostic applications.	[Camacho, Frank; Vasquez, Aleikar; Reyes, Fatima] Univ Concepcion, Biol Sci Sch, Concepcion, Chile; [Moreno, Ernesto] Univ Medellin, Fac Basic Sci, Medellin, Colombia; [Garcia-Alles, Luis F.] Univ Toulouse, TBI, CNRS, INRA,INSA, Toulouse, France; [Chinea Santiago, Glay] Ctr Genet Engn & Biotechnol, Havana, Cuba; [Gilleron, Martine] Univ Toulouse, Inst Pharmacol & Biol Struct, Toulouse, France; [Choong, Yee Siew] Univ Sains Malaysia, Inst Res Mol Med INFORMM, Minden, Malaysia; [Norazmi, Mohd Nor; Sarmiento, Maria E.; Acosta, Armando] Univ Sains Malaysia, Sch Hlth Sci, Hlth Campus, Kubang Kerian, Malaysia	Universidad de Concepcion; Universidad de Medellin; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse; Centro de Ingenieria Genetica y Biotecnologia; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universiti Sains Malaysia; Universiti Sains Malaysia	Moreno, E (corresponding author), Univ Medellin, Fac Basic Sci, Medellin, Colombia.; Norazmi, MN; Sarmiento, ME; Acosta, A (corresponding author), Univ Sains Malaysia, Sch Hlth Sci, Hlth Campus, Kubang Kerian, Malaysia.	emoreno@udem.edu.co; norazmimn@usm.my; mari@usm.my; armando@usm.my	Camacho, Frank/AAX-1345-2020; Choong, Yee Siew/A-6907-2011	Camacho, Frank/0000-0003-2247-7160; Choong, Yee Siew/0000-0001-5067-2073; Moreno, Ernesto/0000-0002-2309-4826	LRGS Grant (Ministry of Higher Education, Malaysia) [203.PPSK.67212001, 203.PPSK.67212002]	LRGS Grant (Ministry of Higher Education, Malaysia)(Ministry of Education, Malaysia)	This work was supported by LRGS Grant 203.PPSK.67212001 and 203.PPSK.67212002 (Ministry of Higher Education, Malaysia).	Acharya B, 2020, MOL BIOL REP, V47, P4065, DOI 10.1007/s11033-020-05413-7; Batuwangala T, 2004, J IMMUNOL, V172, P2382, DOI 10.4049/jimmunol.172.4.2382; Bettencourt P, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0148-y; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; CAMACHO F, 2013, BMC IMMUNOL S1, V0014; Camacho F, 2016, INT J MYCOBACT, V5, P120, DOI 10.1016/j.ijmyco.2015.12.002; Chancellor A, 2018, IMMUNOLOGY, V154, P196, DOI 10.1111/imm.12912; Dass SA, 2020, INT J BIOL MACROMOL, V155, P305, DOI 10.1016/j.ijbiomac.2020.03.229; Dass SA, 2018, MOL IMMUNOL, V101, P189, DOI 10.1016/j.molimm.2018.07.001; Floyd K, 2018, LANCET RESP MED, V6, P299, DOI 10.1016/S2213-2600(18)30057-2; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Garcia-Alles LF, 2006, EMBO J, V25, P3684, DOI 10.1038/sj.emboj.7601244; Garcia-Alles LF, 2011, P NATL ACAD SCI USA, V108, P17755, DOI 10.1073/pnas.1110118108; Garcia-Alles LF, 2011, P NATL ACAD SCI USA, V108, P13230, DOI 10.1073/pnas.1105627108; Gau B, 2013, CHEMBIOCHEM, V14, P2413, DOI 10.1002/cbic.201300482; Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097; Gras S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13257; Guiard J, 2009, J IMMUNOL, V182, P7030, DOI 10.4049/jimmunol.0804044; Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hurley CK, 2021, HUM IMMUNOL, V82, P457, DOI 10.1016/j.humimm.2020.03.005; Lensink MF, 2017, PROTEINS, V85, P359, DOI 10.1002/prot.25215; Lepore M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01365; Mori L, 2008, IMMUNOL LETT, V117, P1, DOI 10.1016/j.imlet.2007.11.027; Robinson J, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006862; Scriba TJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TBTB2-0016-2016; SHAHINE A, 2019, NAT COMMUN, P00001, DOI DOI 10.1109/tmag.2013.2278570; Shahine A, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aao1384; Sia JK, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0022-2018; Van Rhijn I, 2015, IMMUNOL REV, V264, P138, DOI 10.1111/imr.12253; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; World Health Organization, 2019, GLOB TUB REP GEN 201	32	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2020	11								566710	10.3389/fimmu.2020.566710	http://dx.doi.org/10.3389/fimmu.2020.566710			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OH5FJ	33162982	Green Published, gold			2022-12-18	WOS:000582605700001
J	Kappler, K; Restin, T; Lasanajak, Y; Smith, DF; Bassler, D; Hennet, T				Kappler, Katharina; Restin, Tanja; Lasanajak, Yi; Smith, David F.; Bassler, Dirk; Hennet, Thierry			Limited Neonatal Carbohydrate-Specific Antibody Repertoire Consecutive to Partial Prenatal Transfer of Maternal Antibodies	FRONTIERS IN IMMUNOLOGY			English	Article						immunoglobulin; glycosylation; glycan; microarray; microbiota; bacteroides	CORD BLOOD; ANTICARBOHYDRATE ANTIBODIES; PLACENTAL-TRANSFER; SERUM ANTIBODIES; IMMUNOGLOBULIN-G; FC-RECEPTOR; IGG; VACCINATION; TRANSPORT; RESPONSES	Despite the prominence of carbohydrate-specific antibodies in human sera, data on their emergence and antigen specificities are limited. Whereas maternal IgG are transferred prenatally to the fetal circulation, IgM present in cord blood originate from fetal B lymphocytes. Considering the limited exposure of the fetus to foreign antigens, we assessed the repertoire of carbohydrate-specific antibodies in human cord blood and matched maternal blood samples using glycan arrays. Carbohydrate-specific IgM was absent in cord blood, whereas low cord blood IgG reactivity to glycans was detectable. Comparing IgG reactivities of matched pairs, we observed a general lack of correlation in the antigen specificity of IgG from cord blood and maternal blood due to a selective exclusion of most carbohydrate-specific IgG from maternofetal transfer. Given the importance of intestinal bacteria in inducing carbohydrate-specific antibodies, we analyzed global antibody specificities toward commensal bacteria. Similar IgG reactivities to specific Bacteroides species were detected in matched cord and maternal blood samples, thus pointing to an efficient maternal transfer of anti-microbial IgG. Due to the observed selectivity in maternofetal IgG transfer, the lack of fetal antibodies to carbohydrate epitopes is only partially compensated by maternal IgG, thus resulting in a weak response to carbohydrate antigens in neonates.	[Kappler, Katharina; Restin, Tanja; Hennet, Thierry] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Restin, Tanja; Bassler, Dirk] Univ Zurich, Univ Hosp Zurich, Dept Neonatol, Zurich, Switzerland; [Lasanajak, Yi; Smith, David F.] Emory Univ, Sch Med, Dept Biochem, Emory Comprehens Glyc Core, Atlanta, GA 30322 USA	University of Zurich; University of Zurich; University Zurich Hospital; Emory University	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Zurich, Switzerland.	thierry.hennet@uzh.ch	Smith, David/GQQ-8257-2022; Restin, Tanja/AAR-9091-2021	Restin, Tanja/0000-0002-8816-6069; Kappler, Katharina/0000-0001-8225-8280	Swiss National Foundation [314730_172880]; Novartis FreeNovation; Emory Comprehensive Glycomics Core (ECGC) - Emory Integrated Core Facility - Emory University School of Medicine	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Novartis FreeNovation(Novartis); Emory Comprehensive Glycomics Core (ECGC) - Emory Integrated Core Facility - Emory University School of Medicine	This work was supported by the Swiss National Foundation grant 314730_172880 and by Novartis FreeNovation to TH and partially supported by the Emory Comprehensive Glycomics Core (ECGC), which is an Emory Integrated Core Facility subsidized by the Emory University School of Medicine. The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	ARAKAWA K, 1982, PEDIATR RES, V16, P247, DOI 10.1203/00006450-198203000-00017; Ardissone AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090784; Baril L, 2004, CLIN EXP IMMUNOL, V135, P474, DOI 10.1111/j.1365-2249.2003.02357.x; BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127; BAUMAN WA, 1981, P NATL ACAD SCI-BIOL, V78, P4588, DOI 10.1073/pnas.78.7.4588; BOERSMA ER, 1981, ARCH DIS CHILD, V56, P31, DOI 10.1136/adc.56.1.31; Branch DR, 2015, TRANSFUSION, V55, pS74, DOI 10.1111/trf.13087; Calvert A, 2017, CURR OPIN INFECT DIS, V30, P268, DOI 10.1097/QCO.0000000000000372; Collado MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23129; CEDERQVIST LL, 1978, AM J OBSTET GYNECOL, V131, P520, DOI 10.1016/0002-9378(78)90113-8; COHEN IR, 1968, J CLIN INVEST, V47, P1053, DOI 10.1172/JCI105795; Comstock LE, 2006, CELL, V126, P847, DOI 10.1016/j.cell.2006.08.021; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Dotan N, 2006, LUPUS, V15, P442, DOI 10.1191/0961203306lu2331oa; ENGLUND JA, 1995, J INFECT DIS, V171, P99, DOI 10.1093/infdis/171.1.99; Erlich KS, 2012, HUM VACC IMMUNOTHER, V8, P1029, DOI 10.4161/hv.20473; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; Hamanova M, 2015, IMMUNOL LETT, V164, P40, DOI 10.1016/j.imlet.2015.02.001; HAMMARSTROM L, 1983, CLIN EXP IMMUNOL, V51, P600; Harrison LM, 2004, FEMS IMMUNOL MED MIC, V42, P94, DOI 10.1016/j.femsim.2004.06.010; HENRY S, 1995, VOX SANG, V69, P166, DOI 10.1111/j.1423-0410.1995.tb02591.x; Huflejt ME, 2009, MOL IMMUNOL, V46, P3037, DOI 10.1016/j.molimm.2009.06.010; Israel EJ, 1997, IMMUNOLOGY, V92, P69, DOI 10.1046/j.1365-2567.1997.00326.x; Jennewein MF, 2019, CELL, V178, P202, DOI 10.1016/j.cell.2019.05.044; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Kaul A, 2012, INFLAMM BOWEL DIS, V18, P1872, DOI 10.1002/ibd.22862; Khasbiullina NR, 2019, BIOCHEMISTRY-MOSCOW+, V84, P608, DOI 10.1134/S0006297919060038; Kilic A, 2003, J TROP PEDIATRICS, V49, P302, DOI 10.1093/tropej/49.5.302; KOHLER PF, 1966, NATURE, V210, P1070, DOI 10.1038/2101070a0; Leuridan E, 2011, VACCINE, V29, P2222, DOI 10.1016/j.vaccine.2010.06.004; Lim ES, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0475-7; Liu Y, 2017, GLYCOBIOLOGY, V27, P280, DOI 10.1093/glycob/cww118; Lood R, 2015, FUTURE MICROBIOL, V10, P1659, DOI 10.2217/fmb.15.89; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100; Marionneau S, 2001, BIOCHIMIE, V83, P565, DOI 10.1016/S0300-9084(01)01321-9; Martinez DR, 2019, CELL, V178, P190, DOI 10.1016/j.cell.2019.05.046; Martinez David R, 2018, PLoS Pathog, V14, pe1007161, DOI 10.1371/journal.ppat.1007161; Michaelsson J, 2006, J IMMUNOL, V176, P5741, DOI 10.4049/jimmunol.176.10.5741; Muthana SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119298; Nagao AT, 1998, SCAND J IMMUNOL, V47, P609; New JS, 2016, IMMUNOL REV, V270, P32, DOI 10.1111/imr.12397; Oyelaran O, 2009, J PROTEOME RES, V8, P4301, DOI 10.1021/pr900515y; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; Perez-Munoz ME, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0268-4; Pochechueva T, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-017-0305-8; Proenca JT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04081-1; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Rollenske T, 2018, NAT IMMUNOL, V19, P617, DOI 10.1038/s41590-018-0106-2; Rowlands S, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.02.051; SEDMAN PC, 1994, GASTROENTEROLOGY, V107, P643, DOI 10.1016/0016-5085(94)90110-4; Shah U, 2003, PEDIATR RES, V53, P295, DOI 10.1203/01.PDR.0000047663.81816.E3; Shen CJ, 2014, VACCINE, V32, P5337, DOI 10.1016/j.vaccine.2014.07.036; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Stout MJ, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.018; TAYLOR R, 1990, J DIAGN MED SONOG, V6, P35, DOI 10.1177/875647939000600106; van den Elsen LWJ, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00047; von Gunten S, 2009, J ALLERGY CLIN IMMUN, V123, P1268, DOI 10.1016/j.jaci.2009.03.013; Westerman LE, 2005, P NATL ACAD SCI USA, V102, P7268, DOI 10.1073/pnas.0502437102; Wexler AG, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.26; Wilcox CR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01294; Wopereis H, 2014, PEDIAT ALLERG IMM-UK, V25, P428, DOI 10.1111/pai.12232; Xia L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218575; Yeh P, 2010, XENOTRANSPLANTATION, V17, P197, DOI 10.1111/j.1399-3089.2010.00579.x; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053; Yu Y, 2014, MOL CELL PROTEOMICS, V13, P2944, DOI 10.1074/mcp.M114.039875; Zhao YY, 2011, J HISTOCHEM CYTOCHEM, V59, P474, DOI 10.1369/0022155411400871; Zola H, 1997, IMMUNOL CELL BIOL, V75, P587, DOI 10.1038/icb.1997.92	69	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2020	11								573629	10.3389/fimmu.2020.573629	http://dx.doi.org/10.3389/fimmu.2020.573629			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK2LY	33162988	Green Published, Green Accepted, gold			2022-12-18	WOS:000584483400001
J	Pfeil, J; Simonetti, M; Lauer, U; Volkmer, R; von Thulen, B; Durek, P; Krahmer, R; Leenders, F; Hamann, A; Hoffmann, U				Pfeil, Jennifer; Simonetti, Mario; Lauer, Uta; Volkmer, Rudolf; von Thulen, Bianca; Durek, Pawel; Krahmer, Ralf; Leenders, Frank; Hamann, Alf; Hoffmann, Ute			Tolerogenic Immunomodulation by PEGylated Antigenic Peptides	FRONTIERS IN IMMUNOLOGY			English	Article						immune tolerance; autoimmunity; peptide vaccination; nanoparticles; regulatory T cells	REGULATORY T-CELLS; SINUSOIDAL ENDOTHELIAL-CELLS; PERIPHERAL TOLERANCE; MULTIPLE-SCLEROSIS; IN-VIVO; INDUCTION; LIVER; THERAPY; PHARMACOKINETICS; VISUALIZATION	Current treatments for autoimmune disorders rely on non-specific immunomodulatory and global immunosuppressive drugs, which show a variable degree of efficiency and are often accompanied by side effects. In contrast, strategies aiming at inducing antigen-specific tolerance promise an exclusive specificity of the immunomodulation. However, although successful in experimental models, peptide-based tolerogenic "inverse" vaccines have largely failed to show efficacy in clinical trials. Recent studies showed that repetitive T cell epitopes, coupling of peptides to autologous cells, or peptides coupled to nanoparticles can improve the tolerogenic efficacy of peptides, suggesting that size and biophysical properties of antigen constructs affect the induction of tolerance. As these materials bear hurdles with respect to preparation or regulatory aspects, we wondered whether conjugation of peptides to the well-established and clinically proven synthetic material polyethylene glycol (PEG) might also work. We here coupled the T cell epitope OVA(323-339) to polyethylene glycols of different size and structure and tested the impact of these nano-sized constructs on regulatory (Treg) and effector T cells in the DO11.10 adoptive transfer mouse model. Systemic vaccination with PEGylated peptides resulted in highly increased frequencies of Foxp3(+) Tregs and reduced frequencies of antigen-specific T cells producing pro-inflammatory TNF compared to vaccination with the native peptide. PEGylation was found to extend the bioavailability of the model peptide. Both tolerogenicity and bioavailability were dependent on PEG size and structure. In conclusion, PEGylation of antigenic peptides is an effective and feasible strategy to improve Treg-inducing, peptide-based vaccines with potential use for the treatment of autoimmune diseases, allergies, and transplant rejection.	[Pfeil, Jennifer; Lauer, Uta; Durek, Pawel; Hamann, Alf; Hoffmann, Ute] Deutsch Rheuma Forschungszentrum, Expt Rheumatol, Leibniz Inst DRFZ, Berlin, Germany; [Pfeil, Jennifer; Simonetti, Mario; Lauer, Uta; Hamann, Alf; Hoffmann, Ute] Charite, Dept Rheumatol & Clin Immunol, Berlin, Germany; [Volkmer, Rudolf] Charite, Inst Med Immunol, Berlin, Germany; [von Thulen, Bianca; Krahmer, Ralf; Leenders, Frank] Celares GmbH, Berlin, Germany; [Simonetti, Mario] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Mol & Cellular Immunol Immune Regulat, Dresden, Germany; [von Thulen, Bianca] Noack Laboratorien GmbH, Sarstedt, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technische Universitat Dresden	Hamann, A (corresponding author), Deutsch Rheuma Forschungszentrum, Expt Rheumatol, Leibniz Inst DRFZ, Berlin, Germany.; Hamann, A (corresponding author), Charite, Dept Rheumatol & Clin Immunol, Berlin, Germany.	hamann@drfz.de			German Research Foundation [CRC 650 TP1]; Federal Ministry of Education and Research [01GU0722]; Federal Ministry for Economic Affairs and Energy [ZIM -KF 2441003SK1]	German Research Foundation(German Research Foundation (DFG)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Federal Ministry for Economic Affairs and Energy	This work was supported by the German Research Foundation (CRC 650 TP1), by the Federal Ministry of Education and Research (Innovative Therapies -01GU0722-) and the Federal Ministry for Economic Affairs and Energy (ZIM -KF 2441003SK1-).	Adler Adam J, 2005, Curr Immunol Rev, V1, P21, DOI 10.2174/1573395052952879; Arnold B, 2002, TRANSPL IMMUNOL, V10, P109, DOI 10.1016/S0966-3274(02)00056-4; Bailon P, 2009, EXPERT OPIN DRUG DEL, V6, P1, DOI [10.1517/17425240802650568, 10.1517/17425240802650568 ]; Belkaid Y, 2008, IMMUNITY, V29, P362, DOI 10.1016/j.immuni.2008.08.005; Ben-Akiva E, 2019, BIOMATER SCI-UK, V7, P14, DOI 10.1039/c8bm01285g; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Campbell N, 1999, IMMUNOL REV, V172, P315, DOI 10.1111/j.1600-065X.1999.tb01375.x; Carambia A, 2015, J HEPATOL, V62, P1349, DOI 10.1016/j.jhep.2015.01.006; Carambia A, 2014, J HEPATOL, V61, P594, DOI 10.1016/j.jhep.2014.04.027; Caretto D, 2010, J IMMUNOL, V184, P30, DOI 10.4049/jimmunol.0903412; Crispe IN, 2000, IMMUNOL REV, V174, P47, DOI 10.1034/j.1600-0528.2002.017412.x; Diao L, 2013, CLIN PHARMACOKINET, V52, P855, DOI 10.1007/s40262-013-0079-0; Dolgin E, 2010, NAT MED, V16, P740, DOI 10.1038/nm0710-740; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feng XX, 2019, ADV SCI, V6, DOI 10.1002/advs.201802040; Fishburn CS, 2008, J PHARM SCI-US, V97, P4167, DOI 10.1002/jps.21278; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1; Gupta S, 2015, BIOCONJUGATE CHEM, V26, P669, DOI 10.1021/bc500608f; Hultkrantz S, 2005, IMMUNOLOGY, V116, P362, DOI 10.1111/j.1365-2567.2005.02236.x; Hunter Z, 2014, ACS NANO, V8, P2148, DOI 10.1021/nn405033r; Hussain Z, 2019, DRUG DELIV TRANSL RE, V9, P721, DOI 10.1007/s13346-019-00631-4; Janssen O, 2000, CELL TISSUE RES, V301, P85, DOI 10.1007/s004419900155; JORGENSEN KE, 1979, AM J PHYSIOL, V236, pF103, DOI 10.1152/ajprenal.1979.236.2.F103; Kang JS, 2009, EXPERT OPIN EMERG DR, V14, P363, DOI 10.1517/14728210902907847; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Keijzer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026684; Kishimoto TK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00230; Klugewitz K, 2002, J IMMUNOL, V169, P2407, DOI 10.4049/jimmunol.169.5.2407; Knolle PA, 2006, Z GASTROENTEROL, V44, P51, DOI 10.1055/s-2005-858988; Knolle PA, 1999, GASTROENTEROLOGY, V116, P1428, DOI 10.1016/S0016-5085(99)70508-1; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Kruse N, 2009, HEPATOLOGY, V50, P1904, DOI 10.1002/hep.23191; Kunkel D, 2003, EUR J IMMUNOL, V33, P1292, DOI 10.1002/eji.200323383; Kuo R, 2017, MOL THER, V25, P1676, DOI 10.1016/j.ymthe.2017.03.032; LaMothe RA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00281; Maldonado RA, 2015, P NATL ACAD SCI USA, V112, pE156, DOI 10.1073/pnas.1408686111; Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934; Miller SD, 2007, NAT REV IMMUNOL, V7, P665, DOI 10.1038/nri2153; Mu QM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068559; Pearson RM, 2019, NANOMED-NANOTECHNOL, V18, P282, DOI 10.1016/j.nano.2018.10.001; Pearson RM, 2017, ADV DRUG DELIVER REV, V114, P240, DOI 10.1016/j.addr.2017.04.005; Pfeil J, 2020, BIORXIV, DOI [10.1101/2020.09.08.280875, DOI 10.1101/2020.09.08.280875]; Poppenborg SM, 2016, EUR J PHARM SCI, V91, P122, DOI 10.1016/j.ejps.2016.06.007; Puentes F, 2016, J NEUROIMMUNE PHARM, V11, P749, DOI 10.1007/s11481-016-9701-x; Puentes F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064888; Robertson JM, 2000, J IMMUNOL, V164, P4706, DOI 10.4049/jimmunol.164.9.4706; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakane T, 1997, PHARMACEUT RES, V14, P1085, DOI 10.1023/A:1012117815460; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Siewert C, 2008, J IMMUNOL, V180, P146, DOI 10.4049/jimmunol.180.1.146; Smith CE, 2006, J AUTOIMMUN, V27, P218, DOI 10.1016/j.jaut.2006.12.002; Smith CE, 2005, P NATL ACAD SCI USA, V102, P9595, DOI 10.1073/pnas.0504131102; Steinman L, 2010, J INTERN MED, V267, P441, DOI 10.1111/j.1365-2796.2010.02224.x; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Thomson AW, 2010, NAT REV IMMUNOL, V10, P753, DOI 10.1038/nri2858; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; Unger WWJ, 2003, J IMMUNOL, V171, P4592, DOI 10.4049/jimmunol.171.9.4592; van Eden W, 2020, HUM VACC IMMUNOTHER, V16, P228, DOI 10.1080/21645515.2019.1593085; Veronese FM, 1997, J BIOACT COMPAT POL, V12, P196, DOI 10.1177/088391159701200303; Westendorf AM, 2006, ANN NY ACAD SCI, V1072, P401, DOI 10.1196/annals.1326.035; You S, 2018, CURR OPIN ORGAN TRAN, V23, P83, DOI 10.1097/MOT.0000000000000494; Zhang P, 2016, J CONTROL RELEASE, V244, P184, DOI 10.1016/j.jconrel.2016.06.040; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; Zheng JC, 2012, IMMUNOPHARM IMMUNOT, V34, P866, DOI 10.3109/08923973.2012.666979; Zubizarreta I, 2019, P NATL ACAD SCI USA, V116, P8463, DOI 10.1073/pnas.1820039116	67	1	1	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 9	2020	11								529035	10.3389/fimmu.2020.529035	http://dx.doi.org/10.3389/fimmu.2020.529035			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OG5XD	33162973	Green Published, gold			2022-12-18	WOS:000581955600001
J	Li, YL; Puebla-Clark, L; Hernandez, J; Diaz, I; Mateu, E				Li, Yanli; Puebla-Clark, Lucinda; Hernandez, Jesus; Diaz, Ivan; Mateu, Enric			Development of Pig Conventional Dendritic Cells From Bone Marrow Hematopoietic Cellsin vitro	FRONTIERS IN IMMUNOLOGY			English	Article						Flt3L; cDC1; cDC2; CD14(+)DC; pig	IN-VITRO; T-CELLS; COMMITTED PROGENITORS; STEADY-STATE; FLT3 LIGAND; MOUSE; INFECTION; SUBSETS; BLOOD; IDENTIFICATION	In recent years, porcine dendritic cells (DCs) have been identified from pig tissues. However, studying the interaction of porcine DCs with pathogens is still difficult due to the scarcity of DCs in tissues. In the present work, the Flt3-ligand (Flt3L)-basedin vitroderivation system was further characterized and compared with other cytokine derivation models using a combination of factors: stem cell factor (SCF), GM-CSF, and IL-4. The method using Flt3L alone or combined with SCF supported the development of pig bone marrow hematopoietic cells intoin vivoequivalent conventional DCs (cDCs). The equivalent cDC1 (the minor population in the cultures) were characterized as CADM1(+)CD14(-)MHC-II(+)CD172a(-/lo)CD1(-)CD163(-)DEC205(+)CD11R3(lo)CD11R1(+)CD33(+)CD80/86(+). They expressed high levels of FLT3, ZBTB46, XCR1, and IRF8 mRNA, were efficient in endocytosing dextran and in proliferating allogenic CD4(+)CD8(+)T cells, but were deficient in phagocyting inactivatedStaphylococcus aureus(S. aureus). Also, after poly I:C stimulation, they predominantly produced IL-12p40a and matured as indicated by the increase of MHC-I, MHC-II, and CD80/86. The equivalent cDC2 (the main population) were CADM1(+)CD14(-)MHC-II+C D172a(+)CD1(+)CD163(-/lo)DEC205(lo)CD11R3(+)CD11R1(+)CD33(+)CD80/86(+); meanwhile, they overexpressed Fc epsilon R1 alpha and IRF4 mRNA. They showed high efficiency in the endocytosis of dextran, but weak in phagocytosing bacteria. They supported allogenic CD4(+)CD8(-)/CD4(+)CD8(+)T cell proliferation and were high producers of IL-12p40 (upon TLR7 stimulation) and IL-10 (upon TLR7 stimulation). TLR ligand stimulation also induced their maturation. In addition, a CD14(+)population was identified with the phenotype CADM1(+)CD14(+)MHC-II(+)CD172a(+)CD1(+)CD163(+)DEC205(-)CD11R3(+)CD11R1(+)CD33(-/lo)CD80/86(+). They shared some functional similarities with cDC2 and were distinguishable from macrophages. This CD14(+)population was efficient in phagocytingS. aureusbut showed less maturation upon TLR ligand stimulation than cDC1 or cDC2. The alternative methods of DC derivation including GM-CSF and/or IL-4 produced mostly CADM1(-)cells that did not fulfill the canonical phenotype ofbona fideporcine DCs. Our study provides an exhaustive characterization of Flt3L-derived DCs with different methods that can help thein vitrostudy of the interaction of DCs with porcine-relevant pathogens.	[Li, Yanli; Mateu, Enric] Univ Autonoma Barcelona, Fac Vet, Dept Sanitat & Anat Anim, Barcelona, Spain; [Puebla-Clark, Lucinda; Hernandez, Jesus] Ctr Invest Alimentac & Desarrollo, Lab Inmunol, Hermosillo, Sonora, Mexico; [Diaz, Ivan; Mateu, Enric] IRTA UAB, Ctr Recerca Sanitat Anim, Bellaterra, Spain	Autonomous University of Barcelona; CIAD - Centro de Investigacion en Alimentacion y Desarrollo; IRTA	Li, YL (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Sanitat & Anat Anim, Barcelona, Spain.	yanli.li@uab.cat	luque, ivan diaz/I-2654-2015; diaz, ivan/C-7043-2008; Mateu, Enric/AAZ-8429-2021	luque, ivan diaz/0000-0002-8090-1073; diaz, ivan/0000-0002-8090-1073; Mateu, Enric/0000-0003-2715-6032; Li, Yanli/0000-0001-6190-9849; Puebla-Clark, Lucinda/0000-0002-5363-3026	Veterinary Infectious Diseases Diagnostic Laboratory of the UAB; CONACYT	Veterinary Infectious Diseases Diagnostic Laboratory of the UAB; CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was funded by the Veterinary Infectious Diseases Diagnostic Laboratory of the UAB. LP-C was supported by CONACYT to perform a research stay at UAB.	Auray G, 2016, J IMMUNOL, V197, P4791, DOI 10.4049/jimmunol.1600672; Bordet E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02299; Bourdely P, 2020, IMMUNITY, V53, P335, DOI 10.1016/j.immuni.2020.06.002; Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035; Carrasco CP, 2001, IMMUNOLOGY, V104, P175, DOI 10.1046/j.1365-2567.2001.01299.x; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Crozat K, 2010, J EXP MED, V207, P1283, DOI 10.1084/jem.20100223; Cytlak U., 2019, IMMUNITY, DOI [10.2139/ssrn.3365028, DOI 10.2139/SSRN.3365028]; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Dominguez J, 2001, VET IMMUNOL IMMUNOP, V80, P111, DOI 10.1016/S0165-2427(01)00286-0; Edwards JC, 2017, SCI REP-UK, V7, DOI 10.1038/srep40942; Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Guzylack-Piriou L, 2010, DEV COMP IMMUNOL, V34, P455, DOI 10.1016/j.dci.2009.12.006; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Harman AN, 2013, J IMMUNOL, V190, P66, DOI 10.4049/jimmunol.1200779; Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632; Ho CCM, 2017, CELL, V168, P1041, DOI 10.1016/j.cell.2017.02.011; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Hurst J, 2020, J CELL MOL MED, V24, P4312, DOI 10.1111/jcmm.15091; Ibrahim Z, 2006, XENOTRANSPLANTATION, V13, P488, DOI 10.1111/j.1399-3089.2006.00346.x; Idoyaga J, 2009, P NATL ACAD SCI USA, V106, P1524, DOI 10.1073/pnas.0812247106; Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140; Karsunky H, 2003, J EXP MED, V198, P305, DOI 10.1084/jem.20030323; Kronin V, 1996, J IMMUNOL, V157, P3819; Lee J, 2015, J EXP MED, V212, P385, DOI 10.1084/jem.20141442; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Maisonnasse P, 2016, MUCOSAL IMMUNOL, V9, P835, DOI 10.1038/mi.2015.105; Marquet F, 2014, J IMMUNOL, V193, P5883, DOI 10.4049/jimmunol.1303150; MATTSSON JG, 1995, J CLIN MICROBIOL, V33, P893, DOI 10.1128/JCM.33.4.893-897.1995; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002; Mildner A, 2013, ADV IMMUNOL, V120, P69, DOI 10.1016/B978-0-12-417028-5.00003-X; Naik SH, 2007, NAT IMMUNOL, V8, P1217, DOI 10.1038/ni1522; Nizzoli G, 2016, EUR J IMMUNOL, V46, P1622, DOI 10.1002/eji.201546136; Nizzoli G, 2013, BLOOD, V122, P932, DOI 10.1182/blood-2013-04-495424; Olivier A, 2006, BLOOD, V107, P2694, DOI 10.1182/blood-2005-03-0970; Parra-Sanchez H, 2018, MOL IMMUNOL, V96, P1, DOI 10.1016/j.molimm.2018.02.003; Pirtskhalaishvili G, 2000, BRIT J CANCER, V83, P506, DOI 10.1054/bjoc.2000.1289; PLOEMACHER RE, 1993, LEUKEMIA, V7, P1381; Quintana J, 2002, VET RES, V33, P229, DOI 10.1051/vetres:2002011; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Schlitzer A, 2014, CURR OPIN IMMUNOL, V26, P90, DOI 10.1016/j.coi.2013.11.002; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Segales J, 2009, VET MICROBIOL, V134, P199, DOI 10.1016/j.vetmic.2008.08.002; Segura E, 2012, J EXP MED, V209, P653, DOI 10.1084/jem.20111457; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Soldevila F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01800; Statista, 2020, NUMB PIGS WORLDW 201; Tamoutounour S, 2013, IMMUNITY, V39, P925, DOI 10.1016/j.immuni.2013.10.004; Varol C, 2009, IMMUNITY, V31, P502, DOI 10.1016/j.immuni.2009.06.025; Vremec D, 1997, EUR J IMMUNOL, V27, P40, DOI 10.1002/eji.1830270107; Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615; Worah K, 2016, CELL REP, V16, P2953, DOI 10.1016/j.celrep.2016.08.023	56	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2020	11								553859	10.3389/fimmu.2020.553859	http://dx.doi.org/10.3389/fimmu.2020.553859			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OE6LM	33162975	Green Published, gold			2022-12-18	WOS:000580640100001
J	Sun, LG; Jin, CH; Tan, SL; Liu, WT; Yang, YG				Sun, Liguang; Jin, Chun-Hui; Tan, Shulian; Liu, Wentao; Yang, Yong-Guang			Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies	FRONTIERS IN IMMUNOLOGY			English	Review						humanized mouse; cancer; immunotherapy; CAR T cell; human immune system mouse; allogeneic hematopoietic cell transplantation	T-CELL RESPONSES; SCID-HU MOUSE; XENOGRAFT REJECTION; HUMAN B; THERAPY; TRANSPLANTATION; INFECTION; INNATE; BLOOD; RECONSTITUTION	Mouse models are the most commonly used in vivo system for biomedical research, in which immune-related diseases and therapies can be investigated in syngeneic and immunologically intact hosts. However, because there are significant differences between rodent and human, most findings from conventional mouse models cannot be applied to humans. The humanized mouse with a functional human immune system, also referred to as human immune system (HIS) mouse, is the only model available to date for in vivo studies in real-time of human immune function under physiological and pathological conditions. HIS mice with human tumor xenografts are considered an emerging and promising in vivo model for modeling human cancer immunotherapy. In this review, we briefly discuss the protocols to construct HIS mice and elaborate their pros and cons. Particular attention is given to HIS mouse models with human tumor that is autologous or genetically identical to the human immune system, which are discussed with examples of their usefulness in modeling human cancer immunotherapies.	[Sun, Liguang; Jin, Chun-Hui; Tan, Shulian; Liu, Wentao; Yang, Yong-Guang] First Hosp Jilin Univ, Minist Educ, Key Lab Organ Regenerat & Transplantat, Changchun, Peoples R China; [Sun, Liguang; Tan, Shulian; Liu, Wentao; Yang, Yong-Guang] Jilin Univ, Natl Local Joint Engn Lab Anim Models Human Dis, Changchun, Peoples R China; [Jin, Chun-Hui] First Hosp Jilin Univ, Dept Pathol, Changchun, Peoples R China; [Yang, Yong-Guang] Jilin Univ, Int Ctr Future Sci, Changchun, Peoples R China	Jilin University; Jilin University; Jilin University; Jilin University	Liu, WT; Yang, YG (corresponding author), First Hosp Jilin Univ, Minist Educ, Key Lab Organ Regenerat & Transplantat, Changchun, Peoples R China.; Liu, WT; Yang, YG (corresponding author), Jilin Univ, Natl Local Joint Engn Lab Anim Models Human Dis, Changchun, Peoples R China.; Yang, YG (corresponding author), Jilin Univ, Int Ctr Future Sci, Changchun, Peoples R China.	liuwtt70@163.com; yongg@jlu.edu.cn		Liu, Wentao/0000-0001-5534-7173; Yang, Yong-Guang/0000-0003-4985-1247				Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Barth H, 2008, J HEPATOL, V49, P134, DOI 10.1016/j.jhep.2008.03.012; Borsotti C, 2017, BLOOD ADV, V1, P2007, DOI 10.1182/bloodadvances.2017006932; Brainard DM, 2009, J VIROL, V83, P7305, DOI 10.1128/JVI.02207-08; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Cheng L, 2015, ANTIVIR RES, V121, P1, DOI 10.1016/j.antiviral.2015.06.012; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Dey BR, 2005, BRIT J HAEMATOL, V128, P351, DOI 10.1111/j.1365-2141.2004.05328.x; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Habiro K, 2009, AM J TRANSPLANT, V9, P1324, DOI 10.1111/j.1600-6143.2009.02646.x; Heining C, 2007, BONE MARROW TRANSPL, V39, P613, DOI 10.1038/sj.bmt.1705648; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hu Z, 2012, CELL MOL IMMUNOL, V9, P232, DOI 10.1038/cmi.2011.63; Ide K, 2007, P NATL ACAD SCI USA, V104, P5062, DOI 10.1073/pnas.0609661104; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Jackson HJ, 2015, CANCER DISCOV, V5, P1238, DOI 10.1158/2159-8290.CD-15-1275; Jin CH, 2019, EBIOMEDICINE, V39, P173, DOI 10.1016/j.ebiom.2018.12.013; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kalscheuer H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003481; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; Lan P, 2004, BLOOD, V103, P3964, DOI 10.1182/blood-2003-10-3697; Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388; Li Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00063; Liu C., 2012, J IMMUNOL, DOI [10.4049/jimmunol.1103065, DOI 10.4049/JIMMUNOL.1103065, DOI 10.4049/jimmunol.120004]; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Miller JS, 2007, BLOOD, V110, P2761, DOI 10.1182/blood-2007-05-090340; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Proto JD, 2018, J CLIN INVEST, V128, P2370, DOI 10.1172/JCI97785; PURTILO DT, 1991, INT J CANCER, V47, P510, DOI 10.1002/ijc.2910470407; Qin HY, 2015, BLOOD, V126, P629, DOI 10.1182/blood-2014-11-612903; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Rong ZL, 2014, CELL STEM CELL, V14, P121, DOI 10.1016/j.stem.2013.11.014; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Rubio MT, 2003, BLOOD, V102, P2300, DOI 10.1182/blood-2002-12-3949; Saito TI, 2006, EXP HEMATOL, V34, P1271, DOI 10.1016/j.exphem.2006.04.022; Sato M, 2020, RESPIR INVESTIG, V58, P344, DOI 10.1016/j.resinv.2020.04.005; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107; Small TN, 1999, BLOOD, V93, P467, DOI 10.1182/blood.V93.2.467.402k22_467_480; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Strowig T, 2009, J EXP MED, V206, P1423, DOI 10.1084/jem.20081720; Takenaka K, 2007, NAT IMMUNOL, V8, P1313, DOI 10.1038/ni1527; Tan SL, 2017, P NATL ACAD SCI USA, V114, P10954, DOI 10.1073/pnas.1710415114; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Tonomura N, 2008, XENOTRANSPLANTATION, V15, P129, DOI 10.1111/j.1399-3089.2008.00450.x; Tonomura N, 2008, BLOOD, V111, P4293, DOI 10.1182/blood-2007-11-121319; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Wahl A, 2019, NAT BIOTECHNOL, V37, P1163, DOI 10.1038/s41587-019-0225-9; Wang H, 2007, P NATL ACAD SCI USA, V104, P13744, DOI 10.1073/pnas.0702881104; Watanabe Y, 2009, INT IMMUNOL, V21, P843, DOI 10.1093/intimm/dxp050; Wunderlich M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88181; Xia JX, 2016, EBIOMEDICINE, V10, P101, DOI 10.1016/j.ebiom.2016.06.028; Yang YG, 2000, TRANSPLANTATION, V69, P163, DOI 10.1097/00007890-200001150-00027; Yoshihara S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00186; Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021	64	1	1	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2020	11								591669	10.3389/fimmu.2020.591669	http://dx.doi.org/10.3389/fimmu.2020.591669			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OG5SG	33133105	Green Published, gold			2022-12-18	WOS:000581942900001
J	Boscardin, SB; Dudziak, D; Munz, C; Rosa, DS				Boscardin, Silvia Beatriz; Dudziak, Diana; Muenz, Christian; Rosa, Daniela Santoro			Editorial: Harnessing the Participation of Dendritic Cells in Immunity and Tolerance	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						dendritic cell; DC subtypes; antigen presentation; dendritic cell vaccine therapy; dendritic cell activation	ANTIGEN		[Boscardin, Silvia Beatriz] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil; [Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Dept Dermatol, Lab Dendrit Cell Biol, Erlangen, Germany; [Dudziak, Diana] Med Immunol Campus Erlangen, Erlangen, Germany; [Dudziak, Diana] Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Dudziak, Diana] Comprehens Canc Ctr Erlangen European Metropolita, Erlangen, Germany; [Muenz, Christian] Univ Zurich, Inst Expt Immunol, Viral Immunobiol, Zurich, Switzerland; [Rosa, Daniela Santoro] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil	Universidade de Sao Paulo; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Zurich; Universidade Federal de Sao Paulo (UNIFESP)	Boscardin, SB (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.	sbboscardin@usp.br	Boscardin, Silvia Beatriz/C-3397-2012	Boscardin, Silvia Beatriz/0000-0002-7845-7110	Sao Paulo Research Foundation (FAPESP) [2018/07142-9, 2017/17471-7]; Brazilian National Research Council (CNPq) [472509/2011-0]; Coordination for the Improvement of Higher Level Personnel (CAPES) [001]; Cancer Research Switzerland [KFS-4091-02-2017, KFS-4962-02-2020]; KFSP-PrecisionMS of the University of Zurich; HMZ ImmunoTargET of the University of Zurich; Coronavirusfonds UZH; Cancer Research Center Zurich; Vontobel Foundation; Baugarten Foundation; Sobek Foundation; Swiss Vaccine Research Institute; Roche; Novartis; Swiss National Science Foundation [310030B_182827, CRSII5_180323]; German Research Foundation (DFG) [CRC1181TPA7, DU548/5-1]; Agence Nationale de la Recherche (ANR); DFG [DU548/6-1]; Interdisziplinares Zentrum fur Klinische Forschung (IZKF) [IZKF-A80]; Bavarian State of Ministry of Science and Art, Bayresq.Net (IRIS); CNPq	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Level Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Cancer Research Switzerland; KFSP-PrecisionMS of the University of Zurich; HMZ ImmunoTargET of the University of Zurich; Coronavirusfonds UZH; Cancer Research Center Zurich; Vontobel Foundation; Baugarten Foundation; Sobek Foundation; Swiss Vaccine Research Institute; Roche(Roche Holding); Novartis(Novartis); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); DFG(German Research Foundation (DFG)); Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Bavarian State of Ministry of Science and Art, Bayresq.Net (IRIS); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Sao Paulo Research Foundation (FAPESP, grant numbers 2018/07142-9 and 2017/17471-7), the Brazilian National Research Council (CNPq, grant number 472509/2011-0), and the Coordination for the Improvement of Higher Level Personnel (CAPES, Finance Code 001) to SB and DR, by Cancer Research Switzerland (KFS-4091-02-2017 and KFS-4962-02-2020), KFSP-PrecisionMS and HMZ ImmunoTargET of the University of Zurich, the Coronavirusfonds UZH, the Cancer Research Center Zurich, the Vontobel Foundation, the Baugarten Foundation, the Sobek Foundation, the Swiss Vaccine Research Institute, Roche, Novartis and the Swiss National Science Foundation (310030B_182827 and CRSII5_180323) to CM, and by the German Research Foundation (DFG) (CRC1181TPA7, DU548/5-1), Agence Nationale de la Recherche (ANR) and the DFG (DU548/6-1), the Interdisziplinares Zentrum fur Klinische Forschung (IZKF) (IZKF-A80) and the Bavarian State of Ministry of Science and Art, Bayresq.Net (IRIS) to DD. SB and DR received fellowships from CNPq.	Amon L, 2019, INT REV CEL MOL BIO, V349, P55, DOI 10.1016/bs.ircmb.2019.10.001; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Heidkamp GF, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai7677; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; MacLennan ICM, 2002, IMMUNITY, V17, P235, DOI 10.1016/S1074-7613(02)00398-9; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Steinman RM, 2007, EUR J IMMUNOL, V37, pS53, DOI 10.1002/eji.200737400	10	1	1	6	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2020	11								595841	10.3389/fimmu.2020.595841	http://dx.doi.org/10.3389/fimmu.2020.595841			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI5SB	33117409	Green Published, Green Accepted, gold			2022-12-18	WOS:000583336900001
J	Karlsson, EA; Beck, MA; MacIver, NJ				Karlsson, Erik A.; Beck, Melinda A.; MacIver, Nancie J.			Editorial: Nutritional Aspects of Immunity and Immunometabolism in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						nutrition; immunology and infectious diseases; obesity; undernutrition; micronutrient deficiency; immune metabolism; micobiome; influenza			[Karlsson, Erik A.] Inst Pasteur Cambodge, Virol Unit, Phnom Penh, Cambodia; [Beck, Melinda A.] Univ N Carolina, Dept Nutr, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA; [MacIver, Nancie J.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [MacIver, Nancie J.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA; [MacIver, Nancie J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University	Karlsson, EA (corresponding author), Inst Pasteur Cambodge, Virol Unit, Phnom Penh, Cambodia.	ekarlsson@pasteur-kh.org	Karlsson, Erik Albert/M-3577-2017	MacIver, Nancie/0000-0003-3676-9391	DHHS [1 IDSEP190051-01-00]; NIH [RO1-AI078090, R01-DK106090]	DHHS; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by DHHS 1 IDSEP190051-01-00 (EK), NIH R01-DK106090 (NM), and NIH RO1-AI078090 (MB).		0	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2020	11								595115	10.3389/fimmu.2020.595115	http://dx.doi.org/10.3389/fimmu.2020.595115			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OD4MK	33133106	Green Published, gold			2022-12-18	WOS:000579826400001
J	Meng, QQ; Wu, YH; Sui, XH; Meng, JJ; Wang, TT; Lin, Y; Wang, ZW; Zhou, XM; Qi, YM; Du, JF; Gao, YF				Meng, Qingqing; Wu, Yahong; Sui, Xinghua; Meng, Jingjie; Wang, Tingting; Lin, Yan; Wang, Zhiwei; Zhou, Xiuman; Qi, Yuanming; Du, Jiangfeng; Gao, Yanfeng			POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction	FRONTIERS IN IMMUNOLOGY			English	Article						neoantigen prediction; peptides; immunogenicity; prediction model; cancer immunotherapy	CYTOLYTIC T-LYMPHOCYTES; CELL EPITOPE; IDENTIFICATION; CANCER; SEQUENCE; DATABASE; SURFACE; SITES; ACID; NEOANTIGENS	Whole genome/exome sequencing data for tumors are now abundant, and many tumor antigens, especially mutant antigens (neoantigens), have been identified for cancer immunotherapy. However, only a small fraction of the peptides from these antigens induce cytotoxic T cell responses. Therefore, efficient methods to identify these antigenic peptides are crucial. The current models of major histocompatibility complex (MHC) binding and antigenic prediction are still inaccurate. In this study, 360 9-mer peptides with verified immunological activity were selected to construct a prediction of tumor neoantigen (POTN) model, an immunogenic prediction model specifically for the human leukocyte antigen-A2 allele. Based on the physicochemical properties of amino acids, such as the residue propensity, hydrophobicity, and organic solvent/water, we found that the predictive capability of POTN is superior to that of the prediction programs SYPEITHI, IEDB, and NetMHCpan 4.0. We used POTN to screen peptides for the cancer-testis antigen located on the X chromosome, and we identified several peptides that may trigger immunogenicity. We synthesized and measured the binding affinity and immunogenicity of these peptides and found that the accuracy of POTN is higher than that of NetMHCpan 4.0. Identifying the properties related to the T cell response or immunogenicity paves the way to understanding the MHC/peptide/T cell receptor complex. In conclusion, POTN is an efficient prediction model for screening high-affinity immunogenic peptides from tumor antigens, and thus provides useful information for developing cancer immunotherapy.	[Meng, Qingqing; Wu, Yahong; Meng, Jingjie; Wang, Tingting; Lin, Yan; Wang, Zhiwei; Zhou, Xiuman; Qi, Yuanming; Du, Jiangfeng; Gao, Yanfeng] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Peoples R China; [Sui, Xinghua; Gao, Yanfeng] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen, Peoples R China	Zhengzhou University; Sun Yat Sen University	Du, JF; Gao, YF (corresponding author), Zhengzhou Univ, Sch Life Sci, Zhengzhou, Peoples R China.; Gao, YF (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen, Peoples R China.	jiangfengdu@zzu.edu.cn; gaoyf29@mail.sysu.edu.cn		yahong, Wu/0000-0001-6381-611X	National Natural Science Foundation of China [31500620, U1604286, 81601448]; Henan Province; Key Scientific Research Projects of Henan Higher Education Institutions [19A180007, 19A180009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Henan Province; Key Scientific Research Projects of Henan Higher Education Institutions	This work was supported by National Natural Science Foundation of China (Project No. 31500620, U1604286, 81601448), the Henan Province and the Key Scientific Research Projects of Henan Higher Education Institutions (No. 19A180007, 19A180009).	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906; [Anonymous], 2017, NAT BIOTECHNOL, V35, P97, DOI 10.1038/nbt.3800; Aspord C, 2011, AM J TRANSPLANT, V11, P2613, DOI 10.1111/j.1600-6143.2011.03722.x; Benz C, 2002, GASTROENTEROLOGY, V122, P1201, DOI 10.1053/gast.2002.33021; Calis JJA, 2015, IMMUNOGENETICS, V67, P85, DOI 10.1007/s00251-014-0815-0; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Capietto AH, 2017, CURR OPIN IMMUNOL, V46, P58, DOI 10.1016/j.coi.2017.04.007; Chen KY, 2012, IMMUNOL RES, V53, P182, DOI 10.1007/s12026-012-8295-5; Chowell D, 2015, P NATL ACAD SCI USA, V112, pE1754, DOI 10.1073/pnas.1500973112; COLLANTES ER, 1995, J MED CHEM, V38, P2705, DOI 10.1021/jm00014a022; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Donnes P, 2006, NUCLEIC ACIDS RES, V34, pW194, DOI 10.1093/nar/gkl284; Doran SL, 2019, J CLIN ONCOL, V37, P2759, DOI 10.1200/JCO.18.02424; DUNN WJ, 1987, J MED CHEM, V30, P1121, DOI 10.1021/jm00390a002; Fleri W, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5974574; Freudenmann LK, 2018, IMMUNOLOGY, V154, P331, DOI 10.1111/imm.12936; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Jones S, 1997, J MOL BIOL, V272, P121, DOI 10.1006/jmbi.1997.1234; Jones S, 1997, J MOL BIOL, V272, P133, DOI 10.1006/jmbi.1997.1233; Jorgensen KW, 2014, IMMUNOLOGY, V141, P18, DOI 10.1111/imm.12160; Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8; Kaspari A, 1996, INT J PEPT PROT RES, V48, P486; Kawashima S, 2008, NUCLEIC ACIDS RES, V36, pD202, DOI 10.1093/nar/gkm998; Kesmir C, 2002, PROTEIN ENG, V15, P287, DOI 10.1093/protein/15.4.287; Khatun S, 2019, FEBS LETT, V593, P3029, DOI 10.1002/1873-3468.13536; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Kusov Y, 2007, VIRUS RES, V130, P296, DOI 10.1016/j.virusres.2007.06.002; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; Li L, 2017, ANN ONCOL, V28, P11, DOI 10.1093/annonc/mdx681; Liu MKP, 2013, J CLIN INVEST, V123, P380, DOI 10.1172/JCI65330; Liu W, 2012, AMINO ACIDS, V42, P2257, DOI 10.1007/s00726-011-0966-3; Lv H, 2010, IMMUNOL LETT, V133, P94, DOI 10.1016/j.imlet.2010.07.007; Ma WB, 2004, INT J CANCER, V109, P698, DOI 10.1002/ijc.20038; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; Maoz A, 2017, NEW ENGL J MED, V376, DOI 10.1056/NEJMc1616637; Martin SD, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1371895; Matsuda T, 2018, CLIN CANCER RES, V24, P5357, DOI 10.1158/1078-0432.CCR-18-0142; Mehta GU, 2018, J IMMUNOTHER, V41, P241, DOI 10.1097/CJI.0000000000000223; Minenkova O, 2003, INT J CANCER, V106, P534, DOI 10.1002/ijc.11269; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Panchenko AR, 2004, PROTEIN SCI, V13, P884, DOI 10.1110/ps.03465504; Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Piancatelli D, 2004, TISSUE ANTIGENS, V63, P158, DOI 10.1111/j.1399-0039.2004.00161.x; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Robinson J, 2016, HUM IMMUNOL, V77, P233, DOI 10.1016/j.humimm.2016.01.020; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schirle M, 2000, EUR J IMMUNOL, V30, P2216, DOI 10.1002/1521-4141(2000)30:18<2216::AID-IMMU2216>3.3.CO;2-F; Sidney J, 1996, IMMUNOL TODAY, V17, P261, DOI 10.1016/0167-5699(96)80542-1; Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4; Tenzer S, 2004, J IMMUNOL, V172, P1083, DOI 10.4049/jimmunol.172.2.1083; Tung CW, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-446; van der Burg SH, 2016, NAT REV CANCER, V16, P219, DOI 10.1038/nrc.2016.16; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Varela-Calvino R, 2004, J VIROL, V78, P13399, DOI 10.1128/JVI.78.24.13399-13408.2004; Vigneron Nathalie, 2013, Cancer Immun, V13, P15; Vitiello A, 2017, NAT BIOTECHNOL, V35, P815, DOI 10.1038/nbt.3932; Weinzierl AO, 2008, J GEN VIROL, V89, P2090, DOI 10.1099/vir.0.2008/000711-0; Wu JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02559; Wu YH, 2012, SCAND J IMMUNOL, V76, P278, DOI 10.1111/j.1365-3083.2012.02738.x; Wu YH, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2942679; Zeng J, 2001, J COMPUT AID MOL DES, V15, P573, DOI 10.1023/A:1011145123635	70	1	1	1	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2020	11								02193	10.3389/fimmu.2020.02193	http://dx.doi.org/10.3389/fimmu.2020.02193			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OD4TV	33133063	Green Published, gold			2022-12-18	WOS:000579845900001
J	Grimholt, U; Fosse, JH; Sundaram, AYM				Grimholt, Unni; Fosse, Johanna H.; Sundaram, Arvind Y. M.			Selective Stimulation of Duplicated Atlantic Salmon MHC Pathway Genes by Interferon-Gamma	FRONTIERS IN IMMUNOLOGY			English	Article						MHC pathways; whole genome duplications; interferon gamma; teleost; antigen presentation; homeologs; Atlantic salmon	HLA CLASS-I; IFN-GAMMA; ANEMIA-VIRUS; EXPRESSION; COMPLEX; IDENTIFICATION; FAMILY; COEVOLUTION; CHEMOKINES; HAPLOTYPES	Induction of cellular immune responses rely on Major histocompatibility complex (MHC) molecules presenting pathogenic peptides to T cells. Peptide processing, transport, loading and editing is a constitutive process in most cell types, but is accelerated upon infection. Recently, an unexpected complexity in the number of functional genes involved in MHC class I peptide cleavage, peptide transport, peptide loading and editing was found in teleosts, originating from the second and third whole genome duplication events. Salmonids have expanded upon this with functional duplicates also from a fourth unique salmonid whole genome duplication. However, little is known about how individual gene duplicates respond in the context of stimulation. Here we set out to investigate how interferon gamma (IFNg) regulates the transcription of immune genes in Atlantic salmon with particular focus on gene duplicates and MHC pathways. We identified a range of response patterns in Atlantic salmon gene duplicates, with upregulation of all duplicates for some genes, like interferon regulatory factor 1 (IRF1) and interferon induced protein 44-like (IFI44.L), but only induction of one or a few duplicates of other genes, such as TAPBP and ERAP2. A master regulator turned out to be the IRF1 and not the enhanceosome as seen in mammals. If IRF1 also collaborates with CIITA and possibly NLRC5 in regulating IFNg induction of MHCI and MHCII expression in Atlantic salmon, as in zebrafish, remains to be established. Altogether, our results show the importance of deciphering between gene duplicates, as they often respond very differently to stimulation and may have different biological functions.	[Grimholt, Unni; Fosse, Johanna H.] Norwegian Vet Inst, Oslo, Norway; [Sundaram, Arvind Y. M.] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway	Norwegian Veterinary Institute; University of Oslo	Grimholt, U (corresponding author), Norwegian Vet Inst, Oslo, Norway.	unni.grimholt@vetinst.no		Hol, Johanna/0000-0001-5837-5006; Grimholt, Unni/0000-0002-0202-8061	Norwegian Research Council [274635, 254876]	Norwegian Research Council(Research Council of NorwayEuropean Commission)	This research was funded by the Norwegian Research Council projects #274635 and #254876.	Aamelfot M, 2013, J ANAT, V222, P547, DOI 10.1111/joa.12033; Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429; Basler M, 2013, CURR OPIN IMMUNOL, V25, P74, DOI 10.1016/j.coi.2012.11.004; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boyle LH, 2013, P NATL ACAD SCI USA, V110, P3465, DOI 10.1073/pnas.1222342110; Briolat V, 2014, J IMMUNOL, V192, P4328, DOI 10.4049/jimmunol.1302611; Bushnell B., 2014, BBMAP FAST ACCURATE; Cascio P, 2014, BIOMOLECULES, V4, P566, DOI 10.3390/biom4020566; Castro R, 2008, MOL IMMUNOL, V45, P3454, DOI 10.1016/j.molimm.2008.03.015; Chang SC, 2005, P NATL ACAD SCI USA, V102, P17107, DOI 10.1073/pnas.0500721102; Chen F, 2018, FISH SHELLFISH IMMUN, V72, P301, DOI 10.1016/j.fsi.2017.11.012; Chen HN, 2016, SCI REP-UK, V6, DOI 10.1038/srep28902; Chen J, 2013, DEV COMP IMMUNOL, V41, P137, DOI 10.1016/j.dci.2013.05.006; Chen ZL, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav0547; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DANNEVIG BH, 1995, VET RES, V26, P438; Dannevig BH, 1997, FISH SHELLFISH IMMUN, V7, P213, DOI 10.1006/fsim.1996.0076; DeDiego ML, 2019, MBIO, V10, DOI 10.1128/mBio.01839-19; Dehler CE, 2019, J IMMUNOL, V203, P465, DOI 10.4049/jimmunol.1801376; Dijkstra JM, 2003, FISH SHELLFISH IMMUN, V14, P177, DOI 10.1006/fsim.2002.0431; Ellertsdottir E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042131; Evnouchidou I, 2014, J IMMUNOL, V193, P901, DOI 10.4049/jimmunol.1302855; Gobin SJP, 1999, J IMMUNOL, V163, P1428; Grimholt U, 2018, BMC EVOL BIOL, V18, DOI 10.1186/s12862-018-1138-9; Grimholt Unni, 2016, Biology-Basel, V5, DOI 10.3390/biology5010006; Grimholt U, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862-015-0309-1; Guillaume B, 2010, P NATL ACAD SCI USA, V107, P18599, DOI 10.1073/pnas.1009778107; Hermann C, 2015, ELIFE, V4, DOI 10.7554/eLife.09617; Hetland DL, 2010, FISH SHELLFISH IMMUN, V28, P30, DOI 10.1016/j.fsi.2009.09.011; Hou J, 2020, J IMMUNOL, V204, P2401, DOI 10.4049/jimmunol.1801480; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Indraccolo S, 2007, J IMMUNOL, V178, P1122, DOI 10.4049/jimmunol.178.2.1122; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; Jongsma MLM, 2019, MOL IMMUNOL, V113, P16, DOI 10.1016/j.molimm.2017.12.005; Jorgensen SM, 2006, FISH SHELLFISH IMMUN, V21, P548, DOI 10.1016/j.fsi.2006.03.004; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; KITAMURA A, 1994, EUR J BIOCHEM, V224, P877, DOI 10.1111/j.1432-1033.1994.00877.x; Klein J., 1986, NATURAL HIST MAJOR H; Kohda K, 1998, J IMMUNOL, V160, P4923; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; Lacy P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00190; Laing KJ, 2004, MOL IMMUNOL, V41, P793, DOI 10.1016/j.molimm.2004.03.038; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liau NPD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04013-1; Lien S, 2016, NATURE, V533, P200, DOI 10.1038/nature17164; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ludigs K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005088; Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585; Maccari G, 2017, NUCLEIC ACIDS RES, V45, pD860, DOI 10.1093/nar/gkw1050; Martin SAM, 2007, PROTEOMICS, V7, P2275, DOI 10.1002/pmic.200700020; Masternak K, 2000, GENE DEV, V14, P1156; McConnell SC, 2016, P NATL ACAD SCI USA, V113, pE5014, DOI 10.1073/pnas.1607602113; McConnell SC, 2014, IMMUNOGENETICS, V66, P199, DOI 10.1007/s00251-013-0749-y; Meissner TB, 2012, J IMMUNOL, V188, P4951, DOI 10.4049/jimmunol.1103160; Meissner TB, 2010, P NATL ACAD SCI USA, V107, P13794, DOI 10.1073/pnas.1008684107; Min W, 1996, J IMMUNOL, V156, P3174; Murata S, 2018, NAT IMMUNOL, V19, P923, DOI 10.1038/s41590-018-0186-z; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Nie L, 2014, DEV COMP IMMUNOL, V43, P23, DOI 10.1016/j.dci.2013.10.007; Pober JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01907; Power D, 2015, VIROLOGY, V481, P142, DOI 10.1016/j.virol.2015.02.046; Rene C, 2016, HLA, V87, P338, DOI 10.1111/tan.12787; Robertsen B, 2019, DEV COMP IMMUNOL, V90, P80, DOI 10.1016/j.dci.2018.09.004; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; Sachini N, 2017, BBA-GENE REGUL MECH, V1860, P537, DOI 10.1016/j.bbagrm.2016.10.013; Santambrogio L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01033; Sobhkhez M, 2014, FEBS OPEN BIO, V4, P858, DOI 10.1016/j.fob.2014.09.007; Sumanas S, 2006, PLOS BIOL, V4, P60, DOI 10.1371/journal.pbio.0040010; Sumanas S, 2005, BLOOD, V106, P534, DOI 10.1182/blood-2004-12-4653; Sun BJ, 2011, J VIROL, V85, P9188, DOI 10.1128/JVI.00319-11; Torraca V, 2015, DIS MODEL MECH, V8, P253, DOI 10.1242/dmm.017756; van den Elsen PJ, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00048; van Hateren A, 2013, J BIOL CHEM, V288, P32797, DOI 10.1074/jbc.M113.474031; van's Gravesande KS, 2002, J IMMUNOL, V168, P4488, DOI 10.4049/jimmunol.168.9.4488; Walker BA, 2011, P NATL ACAD SCI USA, V108, P8396, DOI 10.1073/pnas.1019496108; Wang TY, 2019, FISH SHELLFISH IMMUN, V90, P413, DOI 10.1016/j.fsi.2019.04.303; Zhao H, 2008, FISH SHELLFISH IMMUN, V24, P459, DOI 10.1016/j.fsi.2008.01.003; Zou J, 2005, J IMMUNOL, V175, P2484, DOI 10.4049/jimmunol.175.4.2484	80	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2020	11								571650	10.3389/fimmu.2020.571650	http://dx.doi.org/10.3389/fimmu.2020.571650			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OC9SH	33123146	Green Published, gold			2022-12-18	WOS:000579494800001
J	Wang, XW; Yang, Y; Cai, WQ; Lu, YY				Wang, Xianwang; Yang, Yue; Cai, Wen-Qi; Lu, Yingying			The Relationship of Sphingosine Kinase 1 With Pyroptosis Provides a New Strategy for Tumor Therapy	FRONTIERS IN IMMUNOLOGY			English	Review						spingosine kinase 1; pyroptosis; calcium and integrin-binding protein 1; cancer; sphingosine-1-phosphate	INFLAMMATORY CASPASES; NLRP3 INFLAMMASOME; NUCLEAR EXPORT; CANCER; IDENTIFICATION; ACTIVATION; RELEASE; PROTEIN; PATHOGENESIS; DIVERSITY	Sphingosine kinase 1 (SPHK1) is a crucial molecule that catalyzes sphingosine to synthesize sphingosine-1-phosphate (S1P), facilitating cell survival signaling. Pyroptosis is a perplexing inflammatory mode of cell death primarily triggered by caspase-1, evoked by the NLRP3 inflammasome. Sphingosine is identified as a danger-associated molecular pattern (DAMP), which activates the NLRP3 inflammasome assembly and induces the pyroptosis. It has been demonstrated that macrophages play a pro-tumorigenic role and are closely associated with tumor progression. Attenuation of SPHK1 activity contributes significantly to macrophage pyroptosis and tumor inhibition. Calcium and integrin-binding protein 1 (CIB1) plays an important role in the translocation of SPHK1 from the cytoplasm to the plasma membrane, whereas CIB2 blocks the subcellular trafficking of SPHK1. Therefore, knockout of CIB1 or over-expression of CIB2 will result in sphingosine accumulation and contribute significantly to cancer treatment by several approaches. First, it directly provokes cancer cell apoptosis or triggers robust anti-tumor immunity by pyroptosis-induced inflammation. Second, it could restrain SPHK1 translocation from the cytoplasm to the plasma membrane and further pyroptosis, which not only drive M2 macrophages death but also facilitate tumor microenvironment inflammation as well as the further release of sphingosine from damaged macrophages. The perspective might provide novel insight into the association between SPHK1 and pyroptosis and suggest the potential target for cancer therapy.	[Wang, Xianwang; Yang, Yue; Cai, Wen-Qi] Yangtze Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Jingzhou, Peoples R China; [Lu, Yingying] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen, Peoples R China	Yangtze University; Sun Yat Sen University	Wang, XW (corresponding author), Yangtze Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Jingzhou, Peoples R China.; Lu, YY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen, Peoples R China.	275379987@qq.com; luyy39@mail.sysu.edu.cn		Lu, Yingying/0000-0002-5423-9522	National Natural Science Foundation of China [31700736, 31501116]; China Scholarship Council [201908420102]; Hubei Medical Youth Tip-Top Talent; Leading Talent Program of Yangtze Talent Project; College Students Innovative Entrepreneurial Training Program in Yangtze University [2018184, 2019372]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Scholarship Council(China Scholarship Council); Hubei Medical Youth Tip-Top Talent; Leading Talent Program of Yangtze Talent Project; College Students Innovative Entrepreneurial Training Program in Yangtze University	This work was supported by grants from the National Natural Science Foundation of China (31700736, 31501116), China Scholarship Council (201908420102), Hubei Medical Youth Tip-Top Talent (to XW), Leading Talent Program of Yangtze Talent Project (to XW), and the College Students Innovative Entrepreneurial Training Program in Yangtze University (2018184, 2019372).	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Andl CD, 2016, CELL MOL GASTROENTER, V2, P400, DOI 10.1016/j.jcmgh.2016.04.004; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Chen KW, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6676; Chen LS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0538-5; Chu Q, 2016, ONCOTARGET, V7, P84658, DOI 10.18632/oncotarget.12384; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; de Carvalho RNVH, 2019, J LEUKOCYTE BIOL, V106, P631, DOI 10.1002/JLB.MA1118-471R; Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200; Dominguez G, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0527-z; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Gordon S, 2014, IMMUNOL REV, V262, P36, DOI 10.1111/imr.12223; Gordon S, 2011, EUR J IMMUNOL, V41, P2470, DOI 10.1002/eji.201141988; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Inagaki Y, 2003, BIOCHEM BIOPH RES CO, V311, P168, DOI 10.1016/j.bbrc.2003.09.194; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005; Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287; Komohara Y, 2016, ADV DRUG DELIVER REV, V99, P180, DOI 10.1016/j.addr.2015.11.009; Krzesniak M, 2020, CELL SIGNAL, V69, DOI 10.1016/j.cellsig.2020.109552; Lee JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03674-2; Luheshi NM, 2012, EUR J IMMUNOL, V42, P716, DOI 10.1002/eji.201142079; Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Man SM, 2017, SCI REP-UK, V7, DOI 10.1038/srep45126; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Pizato N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20422-0; Shen HY, 2014, NAT CELL BIOL, V16, P652, DOI 10.1038/ncb2987; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Siegel RM, 2006, NAT REV IMMUNOL, V6, P308, DOI 10.1038/nri1809; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Taha TA, 2006, FEBS LETT, V580, P6047, DOI 10.1016/j.febslet.2006.09.070; Teng JF, 2020, CANCERS, V12, DOI 10.3390/cancers12010193; Wang XW, 2017, CELL PHYSIOL BIOCHEM, V43, P1413, DOI 10.1159/000481873; Wang Z, 2013, STRUCTURE, V21, P798, DOI 10.1016/j.str.2013.02.025; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Weigert A, 2010, BLOOD, V115, P3531, DOI 10.1182/blood-2009-10-243444; Xia XJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1883-8; Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8; Zhu W, 2017, ONCOGENE, V36, P2619, DOI 10.1038/onc.2016.428; Zhu WY, 2017, CANCER RES, V77, P4823, DOI 10.1158/0008-5472.CAN-17-0025; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	48	1	1	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2020	11								574990	10.3389/fimmu.2020.574990	http://dx.doi.org/10.3389/fimmu.2020.574990			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA4HZ	33123153	gold, Green Published			2022-12-18	WOS:000577749800001
J	Hunegnaw, R; Hait, SH; Enyindah-Asonye, G; Rahman, MA; Ko, EJ; Hogge, CJ; Hoang, T; Robert-Guroff, M				Hunegnaw, Ruth; Hait, Sabrina Helmold; Enyindah-Asonye, Gospel; Rahman, Mohammad Arif; Ko, Eun-Ju; Hogge, Christopher J.; Hoang, Tanya; Robert-Guroff, Marjorie			A Mucosal Adenovirus Prime/Systemic Envelope Boost Vaccine Regimen Elicits Responses in Cervicovaginal and Alveolar Macrophages of Rhesus Macaques Associated With Delayed SIV Acquisition and B Cell Help	FRONTIERS IN IMMUNOLOGY			English	Article						cervicovaginal macrophage; alveolar macrophage; simian immunodeficiency virus; B cell help; rhesus macaques; Fc gamma RIII; replicating adenovirus recombinant vaccine	IMMUNODEFICIENCY VIRUS ENV; IMMUNE-RESPONSES; DENDRITIC CELLS; RECEPTOR EXPRESSION; SUBCAPSULAR SINUS; APRIL; BAFF; TRANSMISSION; STRATEGIES; TRANSPORT	Vaccine strategies targeting the mucosal portal of entry may prevent HIV acquisition and systemic infection. Macrophages in cervicovaginal compartments are one of the first cell types to encounter virus upon vaginal exposure. Their activation can lead to recruitment of additional macrophages and CD4(+) T-cells susceptible to viral infection. However, they are also critical in providing early protection against invading pathogens. Therefore, understanding their response to immunization is important for vaccine design. We immunized rhesus macaques twice mucosally with replicating adenovirus (Ad) SIV recombinants, followed by two intramuscular boosts with SIV gp120 protein. Macaques were subsequently challenged intravaginally with repeated low doses of SIVmac251. Using flow cytometry, we evaluated responses of cervicovaginal macrophages (CVM) and alveolar macrophages (AM) in bronchoalveolar lavage as initial immunization was to the upper respiratory tract. The frequency of CVM increased over the course of immunization; however, CCR5 expression significantly decreased. Significantly increased expression of the chemokines CCL3 (p < 0.01), CCL4, CCL5, and CXCL8 (p < 0.0001 for all) on CVM was seen post-1(st)Ad but their expression significantly decreased post-2(nd)boost. CD4(+) T-cell frequency in the cervical mucosa remained unchanged. CVM Fc gamma RIII expression was significantly increased at all time points post-immunization compared to naive animals. Fc gamma RIII expression post-2(nd)Ad positively correlated with the number of challenges needed for infection (r = 0.68; p = 0.0051). Vaccination increased AM Fc gamma RIII expression which post-2(nd)boost correlated with antibody-dependent phagocytosis. Activation of AMs was evident by increased expression of CD40 and CD80 post-2(nd)Ad compared to naive macaques. APRIL expression also significantly increased post-2(nd)Ad and correlated with B cell frequency in bronchoalveolar lavage (BAL) (r = 0.73; p = 0.0019) and total IgG in BAL-fluid (r = 0.53; p = 0.047). B cells cultured with SIV gp120-stimulated AM supernatant from vaccinated macaques exhibited significant increases in B cell activation markers CD38 and CD69 compared to B cells cultured alone or with AM supernatant from unvaccinated macaques. Overall, the vaccine regimen did not induce recruitment of susceptible cells to the vaginal mucosa but increased CVM Fc gamma RIII expression which correlated with delayed SIV acquisition. Further, immunization induced expression of AM cytokines, including those associated with providing B cell help.	[Hunegnaw, Ruth; Hait, Sabrina Helmold; Enyindah-Asonye, Gospel; Rahman, Mohammad Arif; Ko, Eun-Ju; Hogge, Christopher J.; Hoang, Tanya; Robert-Guroff, Marjorie] NCI, Immune Biol Retroviral Infect Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA; [Ko, Eun-Ju] Jeju Natl Univ, Coll Vet Med, Jeju, South Korea; [Ko, Eun-Ju] Jeju Natl Univ, Vet Med Res Inst, Jeju, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jeju National University; Jeju National University	Robert-Guroff, M (corresponding author), NCI, Immune Biol Retroviral Infect Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA.	guroffm@mail.nih.gov		Rahman, Mohammad Arif/0000-0002-6120-8943	Intramural Research Program of the National Institutes of Health, National Cancer Institute	Intramural Research Program of the National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Allard B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01777; Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886; Barouch DH, 2010, CURR OPIN HIV AIDS, V5, P386, DOI 10.1097/COH.0b013e32833cfe4c; Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bessa J, 2009, J IMMUNOL, V183, P3788, DOI 10.4049/jimmunol.0804004; Buge SL, 1997, J VIROL, V71, P8531, DOI 10.1128/JVI.71.11.8531-8541.1997; Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007; CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796; CHENG SM, 1992, J VIROL, V66, P6721, DOI 10.1128/JVI.66.11.6721-6727.1992; Chu VT, 2007, J IMMUNOL, V179, P5947, DOI 10.4049/jimmunol.179.9.5947; Chu VT, 2014, IMMUNITY, V40, P582, DOI 10.1016/j.immuni.2014.02.014; Covens K, 2013, BLOOD, V121, P5176, DOI 10.1182/blood-2012-12-471953; Enyindah-Asonye G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00511; Gonzalez SF, 2010, NAT IMMUNOL, V11, P427, DOI 10.1038/ni.1856; Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959; Hait SH, 2020, J IMMUNOL, V204, P3315, DOI 10.4049/jimmunol.2000165; Huard B, 2010, J CLIN INVEST, V120, P1362, DOI 10.1172/JCI33760C1; Hughes CE, 2018, FEBS J, V285, P2944, DOI 10.1111/febs.14466; Hunegnaw R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01537; Jenkins LMM, 2010, NAT CHEM BIOL, V6, P887, DOI 10.1038/NCHEMBIO.456; Jiang Y, 1999, J HUMAN VIROL, V2, P123; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, UNAIDS REP GLOB AIDS; JUNGI TW, 1986, IMMUNOLOGY, V58, P131; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; KASTELLO MD, 1979, AM J VET RES, V40, P271; Kawakami T, 2019, NEPHROL DIAL TRANSPL, V34, P960, DOI 10.1093/ndt/gfy296; Kirby AC, 2009, J IMMUNOL, V183, P1983, DOI 10.4049/jimmunol.0901089; KLESSIG DF, 1979, CELL, V17, P957, DOI 10.1016/0092-8674(79)90335-0; Ko EJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00779; Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Matchett WE, 2019, J VIROL, V93, DOI 10.1128/JVI.02016-18; Musich T, 2018, J IMMUNOL, V201, P2287, DOI 10.4049/jimmunol.1800677; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Patterson LJ, 2008, EXPERT OPIN BIOL TH, V8, P1347, DOI [10.1517/14712598.8.9.1347, 10.1517/14712598.8.9.1347 ]; Patterson LJ, 2012, CLIN VACCINE IMMUNOL, V19, P629, DOI 10.1128/CVI.00010-12; Patterson LJ, 2003, J VIROL, V77, P8607, DOI 10.1128/JVI.77.16.8607-8620.2003; Perno CF, 2006, ANTIVIR RES, V71, P293, DOI 10.1016/j.antiviral.2006.05.015; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; Polverino F, 2016, MULTIDISCIP RESP MED, V11, DOI 10.1186/s40248-016-0051-6; Rahman MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66964-0; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Shang L, 2017, MUCOSAL IMMUNOL, V10, P508, DOI 10.1038/mi.2016.62; Stephenson KE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205139; Stieh DJ, 2016, CELL HOST MICROBE, V19, P529, DOI 10.1016/j.chom.2016.03.005; Wira CR, 2005, IMMUNOL REV, V206, P306, DOI 10.1111/j.0105-2896.2005.00287.x; Yeap WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep34310	52	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								571804	10.3389/fimmu.2020.571804	http://dx.doi.org/10.3389/fimmu.2020.571804			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OC1CW	33117363	gold, Green Published			2022-12-18	WOS:000578901600001
J	Niu, LL; Xuan, XT; Wang, JZ; Li, LL; Yang, D; Jing, YK; Westerberg, LS; Liu, CH				Niu, LinLin; Xuan, Xingtian; Wang, Jinzhi; Li, Liling; Yang, Di; Jing, Yukai; Westerberg, Lisa S.; Liu, Chaohong			Akt2 Regulates the Differentiation and Function of NKT17 Cells via FoxO-1-ICOS Axis (vol 9, 1940, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						Akt2; iNKT; ICOS; NKT17; FoxO-1			[Niu, LinLin; Xuan, Xingtian; Wang, Jinzhi; Li, Liling; Yang, Di] Chongqing Key Lab Child Infect & Immun, Chongqing, Peoples R China; [Niu, LinLin; Xuan, Xingtian; Wang, Jinzhi; Li, Liling; Yang, Di] Chongqing Med Univ, Dept Pediat Res Inst, Childrens Hosp, Chongqing, Peoples R China; [Niu, LinLin; Xuan, Xingtian; Wang, Jinzhi; Li, Liling; Yang, Di] Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China; [Jing, Yukai; Liu, Chaohong] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China; [Westerberg, Lisa S.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	Chongqing Medical University; Huazhong University of Science & Technology; Karolinska Institutet	Liu, CH (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.	chaohongliu80@126.com						Niu LL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01940	1	1	1	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								589346	10.3389/fimmu.2020.589346	http://dx.doi.org/10.3389/fimmu.2020.589346			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB2LJ	33101321	Green Published, gold			2022-12-18	WOS:000578304700001
J	Peters, SO; Hussain, T; Adenaike, AS; Hazzard, J; Morenikeji, OB; De Donato, M; Paul, S; Babar, M; Yakubu, A; Imumorin, IG				Peters, Sunday O.; Hussain, Tanveer; Adenaike, Adeyemi S.; Hazzard, Jordan; Morenikeji, Olanrewaju B.; De Donato, Marcos; Paul, Sujay; Babar, Masroor; Yakubu, Abdulmojeed; Imumorin, Ikhide G.			Evolutionary Pattern of Interferon Alpha Genes in Bovidae and Genetic Diversity of IFNAA in the Bovine Genome	FRONTIERS IN IMMUNOLOGY			English	Article						interferons; type I; haplotypes; IFNAA; gene diversity	SINGLE NUCLEOTIDE POLYMORPHISMS; EXPRESSION; PREDICTION; RECEPTOR	Interferons are secretory proteins induced in response to specific extracellular stimuli which stimulate intra- and intercellular networks for regulating innate and acquired immunity, resistance to viral infections, and normal and tumor cell survival and death. Type 1 interferons plays a major role in the CD8 T-cell response to viral infection. The genomic analysis carried out here for type I interferons within Bovidae family shows that cattle, bison, water buffalo, goat, and sheep (all Bovidae), have different number of genes of the different subtypes, with a large increase in the numbers, compared to human and mouse genomes. A phylogenetic analysis of the interferon alpha (IFNA) proteins in this group shows that the genes do not follow the evolutionary pattern of the species, but rather a cycle of duplications and deletions in the different species. In this study we also studied the genetic diversity of the bovine interferon alpha A (IFNAA), as an example of the IFNA genes in cattle, sequencing a fragment of the coding sequence in 18 breeds of cattle from Pakistan, Nigeria and USA. Similarity analysis allowed the allocation of sequences into 22 haplotypes. Bhagnari, Brangus, Sokoto Gudali, and White Fulani, had the highest number of haplotypes, while Angus, Hereford and Nari Master had the least. However, when analyzed by the average haplotype count, Angus, Bhagnari, Hereford, Holstein, Muturu showed the highest values, while Cholistani, Lohani, and Nari Master showed the lowest values. Haplotype 4 was found in the highest number of individuals (74), and in 15 breeds. Sequences for yak, bison, and water buffalo, were included within the bovine haplotypes. Medium Joining network showed that the sequences could be divided into 4 groups: one with highly similar haplotypes containing mostly Asian and African breeds, one with almost all of theBos taurusAmerican breeds, one mid-diverse group with mostly Asian and African sequences, and one group with highly divergent haplotypes with five N'Dama sequences and one from each of White Fulani, Dhanni, Tharparkar, and Bhagnari. The large genetic diversity found in IFNAA could be a very good indication of the genetic variation among the different genes of IFNA and could be an adaptation for these species in response to viral challenges they face.	[Peters, Sunday O.; Hazzard, Jordan] Berry Coll, Dept Anim Sci, Mt Berry, GA 30149 USA; [Peters, Sunday O.] Univ Georgia, Dept Anim & Dairy Sci, Athens, GA 30602 USA; [Hussain, Tanveer; Babar, Masroor] Virtual Univ Pakistan, Dept Mol Biol, Lahore, Pakistan; [Adenaike, Adeyemi S.] Fed Univ Agr, Dept Anim Breeding & Genet, Abeokuta, Nigeria; [Morenikeji, Olanrewaju B.] Rochester Inst Technol, Dept Biomed Sci, Rochester, NY 14623 USA; [Morenikeji, Olanrewaju B.] Hamilton Coll, Dept Biol, Clinton, NY 13323 USA; [De Donato, Marcos; Paul, Sujay] Tecnol Monterrey Escuela Ingn & Ciencias, Queretaro, Mexico; [Yakubu, Abdulmojeed] Nasarawa State Univ, Dept Anim Sci, Lafia, Nigeria; [Imumorin, Ikhide G.] Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA; [Imumorin, Ikhide G.] First Tech Univ, Dept Biol Sci, Ibadan, Nigeria	University System of Georgia; University of Georgia; Virtual University of Pakistan; University of Agriculture, Abeokuta; Rochester Institute of Technology; Hamilton College; Tecnologico de Monterrey; University System of Georgia; Georgia Institute of Technology	Peters, SO (corresponding author), Berry Coll, Dept Anim Sci, Mt Berry, GA 30149 USA.; Peters, SO (corresponding author), Univ Georgia, Dept Anim & Dairy Sci, Athens, GA 30602 USA.	speters@berry.edu	Babar, Masroor Ellahi/AAC-8150-2021; De Donato, Marcos/I-5307-2012; Paul, Sujay/R-7572-2019; Hussain, Tanveer/GWQ-5172-2022; Peters, Sunday/AAE-9683-2021; Hussain, Tanveer/E-4749-2016	De Donato, Marcos/0000-0001-8860-6020; Hussain, Tanveer/0000-0002-2522-2406; Paul, Sujay/0000-0001-5024-7261; Peters, Sunday/0000-0002-0216-926X; Yakubu, Abdulmojeed/0000-0002-0700-9361	Higher Education Commission of Pakistan [20-1703]	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan)	This Higher Education Commission of Pakistan was acknowledged for funding (Project No. 20-1703).	Babar ME, 2009, PAK J ZOOL, V9, P361; Babenko VN, 2018, BMC NEUROSCI, V19, DOI 10.1186/s12868-018-0413-4; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Barendse W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029601; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; Chen JB, 2004, J INTERF CYTOK RES, V24, P687, DOI 10.1089/jir.2004.24.687; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; Cook LE, 2020, J VIROL, V94, DOI 10.1128/JVI.00841-19; de Alencar SA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/715139; De Andrea Marco, 2002, Eur J Paediatr Neurol, V6 Suppl A, pA41, DOI 10.1053/ejpn.2002.0573; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Ganyo Ebenezer Yaw, 2018, F1000Res, V7, P314, DOI 10.12688/f1000research.14032.2; GROMIHA MM, 1995, INT J PEPT PROT RES, V45, P225; Haiman CA, 2003, HUM MOL GENET, V12, P2679, DOI 10.1093/hmg/ddg294; Hussain T, 2016, PAK J ZOOL, V48, P1633; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Kumar A, 2012, FEBS OPEN BIO, V2, P285, DOI 10.1016/j.fob.2012.09.003; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; MacEachern S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-177; Majekodunmi AO, 2014, PASTORALISM, V4, DOI 10.1186/s13570-014-0020-7; Mbole-Kariuki MN, 2014, HEREDITY, V113, P297, DOI 10.1038/hdy.2014.31; Michels AW, 2011, J IMMUNOL, V187, P5921, DOI 10.4049/jimmunol.1100746; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nei M., 2000, MOL EVOLUTION PHYLOG; Ng CT, 2015, CELL HOST MICROBE, V17, P653, DOI 10.1016/j.chom.2015.04.005; Ozato K, 2002, BIOTECHNIQUES, P66; Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7; Paul F, 2015, GENE, V567, P132, DOI 10.1016/j.gene.2015.04.087; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Peters Sunday O, 2018, J Genomics, V6, P88, DOI 10.7150/jgen.26491; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; R Development Core Team, 2018, R LANG ENV STAT COMP; Redmond AK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01558; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; Rosen BD, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa021; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Sang YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112378; Shabbir MZ, 2012, J VIROL, V86, P13828, DOI 10.1128/JVI.02626-12; Shao JW, 2015, J INTERF CYTOK RES, V35, P168, DOI 10.1089/jir.2013.0139; Sommer Simone, 2005, Frontiers in Zoology, V2, P1, DOI 10.1186/1742-9994-2-16; Suprovych TM, 2018, REGUL MECH BIOSYST, V9, P568, DOI 10.15421/021885; TAJIMA F, 1989, GENETICS, V123, P585; Takeshima S, 2018, BMC GENET, V19, DOI 10.1186/s12863-018-0618-7; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; Walker AM, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-187; Woelk CH, 2007, GENE, V397, P38, DOI 10.1016/j.gene.2007.03.018; Xu L, 2013, PROTEIN CELL, V4, P383, DOI 10.1007/s13238-013-3021-1; Yakubu A, 2017, S AFR J ANIM SCI, V47, P146, DOI 10.4314/sajas.v47i2.6; Yamauchi S, 2016, SCI REP-UK, V6, DOI 10.1038/srep38336; Yates CM, 2013, J MOL BIOL, V425, P3949, DOI 10.1016/j.jmb.2013.07.012; Yu DW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094444	54	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								580412	10.3389/fimmu.2020.580412	http://dx.doi.org/10.3389/fimmu.2020.580412			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OC4HA	33117386	Green Published, gold			2022-12-18	WOS:000579117600001
J	Feng, X; Ma, BF; Liu, B; Ding, P; Wei, JH; Cheng, P; Li, SY; Chen, DX; Sun, ZJ; Li, Z				Feng, Xiao; Ma, Bin-Fang; Liu, Bo; Ding, Peng; Wei, Jin-Hua; Cheng, Pang; Li, Sheng-Yu; Chen, Dong-Xu; Sun, Zhi-Jian; Li, Zhen			The Involvement of the Chemokine RANTES in Regulating Luminal Acidification in Rat Epididymis	FRONTIERS IN IMMUNOLOGY			English	Article						RANTES; epididymis; epididymal epithelium; luminal acidification; macrophages; iNOS	MALE REPRODUCTIVE-TRACT; MONONUCLEAR PHAGOCYTES; CONVERTING-ENZYME; T-CELL; MACROPHAGES; EXPRESSION; PROTEIN; METASTASIS; ACTIVATION; INHIBITOR	Background A complex interplay between different cell types in the epithelium leads to activation of the luminal acidifying capacity of the epididymis, a process that is crucial for sperm maturation and storage. Basal cells sense the luminal angiotensin II (ANG II) and stimulate proton secretion in clear cells through nitric oxide (NO). Our previous study has shown the chemokine regulated upon activation normal T-cell expressed and secreted (RANTES) was expressed in the F4/80 positive macrophages of human epididymis. The objective of this study was to explore the involvement of RANTES in regulating the luminal acidification in the rat epididymis. Methods The role of RANTES was investigated byin vivoperfusion with recombinant RANTES, Met-RANTES, and PBS of different pH values. Furthermore, rats vasectomy was performed to alter the epididymal luminal pH. RIA was used to measure the tissue homogenate ANG II concentration. Real time-PCR and western blot were employed to examine the expression levels of AGTR2, RANTES, CCR1, CCR5, and iNOS in epididymis. Results RANTES was restricted to the basal macrophages of epididymal ducts and co-localized with its receptors CCR1 and CCR5. Both V-ATPase and iNOS were up-regulated in the cauda epididymis after perfused with recombinant RANTES, while the antagonist Met-RANTES perfusion led to a complete abrogation of the increased expression of V-ATPase in the apical membrane of clear cells and iNOS in macrophages. Upon alkaline perfusion, RANTES expression was significantly increased and the apical accumulation of V-ATPase in the clear cells was induced in the cauda epididymis. The luminal pH in the cauda epididymis increased after vasectomy. The concentration of the ANG II and the expression levels of AGTR2, RANTES, CCR1, CCR5, and iNOS dropped in the cauda epididymis following vasectomy. Conclusion Upon the activation of basal cells, RANTES might induce the NO release from macrophages by interacting with its receptors, which increases proton secretion by adjacent clear cells. Thus, RANTES is possible to participate in the crosstalk among basal cells, macrophages and clear cells for the fine control of an optimum acidic luminal environment that is critical for male fertility.	[Feng, Xiao; Ma, Bin-Fang; Liu, Bo; Ding, Peng; Wei, Jin-Hua; Cheng, Pang; Li, Sheng-Yu; Chen, Dong-Xu; Li, Zhen] Fourth Mil Med Univ, Dept Human Anat Histol & Embryol, Xian, Peoples R China; [Sun, Zhi-Jian] Gen Hosp Northern Theater Command, Shenyang, Peoples R China	Air Force Military Medical University	Li, Z (corresponding author), Fourth Mil Med Univ, Dept Human Anat Histol & Embryol, Xian, Peoples R China.	lizhenhe@fmmu.edu.cn			National Natural Science Foundation of China [81170614, 31871515]; Natural Science Foundation of Liaoning Province, China [20170540905]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Liaoning Province, China(Natural Science Foundation of Liaoning Province)	This work was supported by the National Natural Science Foundation of China (Nos. 81170614 and 31871515) and the Natural Science Foundation of Liaoning Province, China (No. 20170540905).	Aldinucci D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051477; Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Azenshtein E, 2002, CANCER RES, V62, P1093; Battistone MA, 2020, MOL HUM REPROD, V26, P14, DOI 10.1093/molehr/gaz059; Battistone MA, 2019, J PHYSIOL-LONDON, V597, P1957, DOI 10.1113/JP277565; Beaulieu V, 2005, J BIOL CHEM, V280, P8452, DOI 10.1074/jbc.M412750200; Breton S, 2019, ANDROLOGY-US, V7, P631, DOI 10.1111/andr.12632; Bruserud O, 2007, HAEMATOLOGICA, V92, P332, DOI 10.3324/haematol.10148; CAFLISCH CR, 1990, CONTRACEPTION, V42, P589, DOI 10.1016/0010-7824(90)90085-A; Cheng P, 2017, TISSUE CELL, V49, P582, DOI 10.1016/j.tice.2017.07.006; Da Silva N, 2016, CELL TISSUE RES, V363, P97, DOI 10.1007/s00441-015-2270-0; Da Silva N, 2011, REPRODUCTION, V141, P653, DOI 10.1530/REP-10-0493; Erkelens MN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00551; Fang HH, 2018, CANCER SCI, V109, P1949, DOI 10.1111/cas.13593; Fink Marc Y, 2019, Immunohorizons, V3, P412, DOI 10.4049/immunohorizons.1900041; Gatti JL, 1999, BIOL REPROD, V60, P937, DOI 10.1095/biolreprod60.4.937; Guazzone VA, 2018, ANDROLOGIA, V50, DOI 10.1111/and.13120; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; Homma T, 2010, INT ARCH ALLERGY IMM, V152, P9, DOI 10.1159/000312120; Ignatov A, 2006, BRIT J PHARMACOL, V149, P490, DOI 10.1038/sj.bjp.0706909; Kashiwagi M, 2002, NEPHRON, V92, P165, DOI 10.1159/000064454; Kato T, 2013, CYTOKINE, V64, P251, DOI 10.1016/j.cyto.2013.06.313; Kondoh G, 2005, NAT MED, V11, P160, DOI 10.1038/nm1179; Lee HH, 2017, MOL MED REP, V16, P4421, DOI 10.3892/mmr.2017.7208; Li Z, 2010, FERTIL STERIL, V93, P2661, DOI 10.1016/j.fertnstert.2010.01.053; Liu P, 2019, NEURAL REGEN RES, V14, P1335, DOI 10.4103/1673-5374.253510; Mazzini E, 2014, IMMUNITY, V40, P248, DOI 10.1016/j.immuni.2013.12.012; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; Pasquier J, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0787-z; Pastor-Soler N, 2005, PHYSIOLOGY, V20, P417, DOI 10.1152/physiol.00036.2005; Pholpramool C, 2011, CLIN EXP PHARMACOL P, V38, P353, DOI 10.1111/j.1440-1681.2011.05525.x; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Reikvam H, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070970; Saez F, 2004, J ANDROL, V25, P784; Shum WW, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.116681; Shum WWC, 2008, CELL, V135, P1108, DOI 10.1016/j.cell.2008.10.020; Smith TB, 2014, ANDROLOGY-US, V2, P755, DOI 10.1111/j.2047-2927.2014.00251.x; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; Villalta F, 1998, INFECT IMMUN, V66, P4690, DOI 10.1128/IAI.66.10.4690-4695.1998; Wijayarathna R, 2019, ANDROLOGY-US, V7, P703, DOI 10.1111/andr.12682; Wilmes V, 2020, INT J LEGAL MED, V134, P575, DOI 10.1007/s00414-019-02051-y; Yeung CH, 2004, MOL REPROD DEV, V68, P159, DOI 10.1002/mrd.20067; Zhao WH, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101192	43	1	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								583274	10.3389/fimmu.2020.583274	http://dx.doi.org/10.3389/fimmu.2020.583274			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA7PM	33072131	Green Published, gold			2022-12-18	WOS:000577973200001
J	Hou, J; Ye, WJ; Loo, HL; Wong, LH; Chen, JZ				Hou, Jue; Ye, Weijian; Loo, Hooi Linn; Wong, Lan Hiong; Chen, Jianzhu			Successive Immunization With Epitope-Decreasing Dengue Antigens Induced Conservative Anti-Dengue Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						dengue virus; vaccine development; sequential immunization; immunoglobulin diversification; epitope-decreasing	IN-DEPTH ANALYSIS; ANTIBODIES; VACCINE; INFECTION; SEROTYPES; EFFICACY; TOOLKIT	Repeated homologous antigen immunization has been hypothesized to hinder antibody diversification, whereas sequential immunization with heterologous immunogens can educate B cell differentiations towards conserved residues thereby facilitating the generation of cross-reactive immunity. In this study, we developed a sequential vaccination strategy that utilized epitope-decreasing antigens to reinforce the cross-reactivity of T and B cell immune responses against all four serotypes dengue virus. The epitope-decreasing immunization was implemented by sequentially inoculating mice with antigens of decreasing domain complexity that first immunized with DENV1 live-attenuated virus, following by the Envelope protein (Env), and then Env domain III (EDIII) subunit protein. When compared to mice immunized with DENV1 live-attenuated virus three times, epitope-decreasing immunization induced higher TNF-alpha CD8(+)T cell immune response against consensus epitopes. Epitope-decreasing immunization also significantly improved neutralizing antibody response to heterologous serotypes. Moreover, this sequential approach promoted somatic hypermutations in the immunoglobulin gene of antigen-specific memory B cells in comparison to repeated immunization. This proof-of-concept work on epitope-decreasing sequential vaccination sheds light on how successively exposing the immune system to decreasing-epitope antigens can better induce cross-reactive antibodies.	[Hou, Jue; Ye, Weijian; Loo, Hooi Linn; Wong, Lan Hiong; Chen, Jianzhu] Singapore MIT Alliance Res & Technol SMART, Interdisciplinary Res Grp Infect Dis, Singapore, Singapore; [Chen, Jianzhu] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Chen, Jianzhu] MIT, Dept Biol, Cambridge, MA 02139 USA	Singapore-MIT Alliance for Research & Technology Centre (SMART); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hou, J; Chen, JZ (corresponding author), Singapore MIT Alliance Res & Technol SMART, Interdisciplinary Res Grp Infect Dis, Singapore, Singapore.; Chen, JZ (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Chen, JZ (corresponding author), MIT, Dept Biol, Cambridge, MA 02139 USA.	joseph.houjue@gmail.com; jchen@mit.edu		ye, weijian/0000-0002-3247-0686	National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology's (SMART) Interdisciplinary Research Group in Infectious Disease Research Program	National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology's (SMART) Interdisciplinary Research Group in Infectious Disease Research Program(National Research Foundation, SingaporeSingapore-MIT Alliance for Research & Technology Centre (SMART))	This work was supported by the National Research Foundation of Singapore through the Singapore-MIT Alliance for Research and Technology's (SMART) Interdisciplinary Research Group in Infectious Disease Research Program.	BLOK J, 1985, J GEN VIROL, V66, P1323, DOI 10.1099/0022-1317-66-6-1323; BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6; Dayan GH, 2014, HUM VACC IMMUNOTHER, V10, P2853, DOI 10.4161/21645515.2014.972131; Durbin AP, 2011, J INFECT DIS, V203, P327, DOI 10.1093/infdis/jiq059; Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030; Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094; Guy B, 2009, AM J TROP MED HYG, V80, P302, DOI 10.4269/ajtmh.2009.80.302; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; Halstead SB, 2009, ANN NY ACAD SCI, V1171, pE48, DOI 10.1111/j.1749-6632.2009.05052.x; HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352; Hou J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00216-0; Hou J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01429; Hou J, 2016, HUM VACC IMMUNOTHER, V12, P545, DOI 10.1080/21645515.2015.1082692; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Midgley CM, 2011, J VIROL, V85, P410, DOI 10.1128/JVI.01826-10; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Tsai WY, 2015, J VIROL, V89, P7348, DOI 10.1128/JVI.00273-15; Vander Heiden JA, 2014, BIOINFORMATICS, V30, P1930, DOI 10.1093/bioinformatics/btu138; Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037; Wang S, 2015, CELL, V160, P785, DOI 10.1016/j.cell.2015.01.027; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974	27	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								585133	10.3389/fimmu.2020.585133	http://dx.doi.org/10.3389/fimmu.2020.585133			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY2NI	33101316	Green Published, gold			2022-12-18	WOS:000576232400001
J	Radermacher, P; Billiar, TR; Ghezzi, P; Martin, L; Thiemermann, C				Radermacher, Peter; Billiar, Timothy R.; Ghezzi, Pietro; Martin, Lukas; Thiemermann, Christoph			Editorial: Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis and Trauma	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sepsis; trauma; multiple organ failure; SIRS; animal models; translational studies; clinical trials			[Radermacher, Peter] Ulm Univ Hosp, Inst Anesthesiol Pathophysiol & Proc Engn, Ulm, Germany; [Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Billiar, Timothy R.] UPMC Int & Commercial Serv Div, Pittsburgh, PA USA; [Ghezzi, Pietro] Brighton & Sussex Med Sch, Dept Clin Med, Brighton, E Sussex, England; [Martin, Lukas] Univ Hosp RWTH, Fac Med, Dept Intens & Intermediate Care, Aachen, Germany; [Thiemermann, Christoph] Queen Mary Univ London, William Harvey Res Inst, Ctr Translat Med & Therapeut, London, England	Ulm University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Brighton; University of Sussex; RWTH Aachen University; RWTH Aachen University Hospital; University of London; Queen Mary University London	Radermacher, P (corresponding author), Ulm Univ Hosp, Inst Anesthesiol Pathophysiol & Proc Engn, Ulm, Germany.	peter.radermacher@uni-ulm.de		Thiemermann, Christoph/0000-0003-4228-9722; Ghezzi, Pietro/0000-0003-0911-8358	Deutsche Forschungsgemeinschaft (DFG) [CRC 1149, MA 7082/3-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft (DFG): CRC 1149, MA 7082/3-1.	de Porto AP, 2019, MOL MED, V25, DOI 10.1186/s10020-018-0069-7; Goncalves-de-Albuquerque CF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00901; O'Brien S, 2016, LANCET ONCOL, V17, P1409, DOI 10.1016/S1470-2045(16)30212-1; Talisa VB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01502	4	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								1987	10.3389/fimmu.2020.01987	http://dx.doi.org/10.3389/fimmu.2020.01987			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA5XY	33101267	Green Accepted, gold, Green Published			2022-12-18	WOS:000577858900001
J	Huang, Y; Chen, XT; Yang, SC; Yang, HF; Hou, XT; Chen, WF; Li, J; Deng, RH; Luo, JQ; Wang, JY; Shen, X; Chen, LZ; Wang, CX; Qiu, J; Huang, G				Huang, Yang; Chen, Xu-Tao; Yang, Shi-Cong; Yang, Hui-Fei; Hou, Xiao-Tao; Chen, Wen-Fang; Li, Jun; Deng, Rong-Hai; Luo, Jin-Quan; Wang, Jin-Yuan; Shen, Xue; Chen, Li-Zhong; Wang, Chang-Xi; Qiu, Jiang; Huang, Gang			Detection of Proximal Tubule Involvement by BK Polyomavirus in Kidney Transplant Recipients With Urinary Sediment Double-Immunostaining	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; BK polyomavirus; BKPyVAN; urinary sediment; double-immunostaining; proximal tubule	RENAL-ALLOGRAFT RECIPIENTS; HISTOLOGICAL EVOLUTION; ACCURATELY PREDICTS; VIRUS NEPHROPATHY; REPLICATION; CYTOLOGY; DISEASE	Background The extent and depth of BK polyomavirus (BKPyV) infection in renal allograft correlate with prognosis. This study was designed to evaluate the value of urinary sediment double-immunostaining for predicting BKPyV infection in proximal tubular epithelium. Materials and methods A total of 76 urine sediment cell blocks, as well as the corresponding transplanted kidney tissues with BK polyomavirus associated-nephropathy (BKPyVAN), were evaluated by automatic double-immunostaining with anti-58-kDa Golgi protein (58K, a proximal renal tubular marker) + anti-SV40-T and anti-homogentisate 1, 2-dioxygenase (HGD, a renal tubular marker) + anti-SV40-T. Results Immunohistochemical staining demonstrated that 58K was expressed in proximal tubular epithelium but not in distal tubular epithelium or transitional epithelium. Of the 76 patients, 28 (36.8%) had urinary 58K(+)/SV40-T(+) cells and HGD(+)/SV40-T(+) cells, 41 (53.9%) had only HGD(+)/SV40-T(+) cells, one (1.3%) had only 58K(+)/SV40-T(+) cells, and six (7.9%) had only 58K(-)/HGD(-)/SV40-T(+) cells. The presence of urinary 58K(+)/SV40-T(+) cells was correlated with BKPyV infection in proximal tubular epithelium (P< 0.001,r= 0.806). The mean extent of SV40-T staining was significantly more extensive in patients with urinary 58K(+)/SV40-T(+) cells than those without urinary 58K(+)/SV40-T(+) cells (21.4 vs. 12.0%,P< 0.001). The positive predictive value, negative predictive value, sensitivity, and specificity of urinary 58K(+)/SV40-T(+) cells for predicting BKPyV infection in proximal tubular epithelium were 89.7% (95% CI: 71.5-97.3%), 91.5% (95% CI: 78.7-97.2%), 86.7% (95% CI: 68.4-95.6%), and 93.5% (95% CI: 81.1-98.3%), respectively. Conclusion Urinary sediment double-immunostaining with anti-58K and anti-SV40-T is valuable for predicting the extent and depth of BKPyV infection in renal allograft.	[Huang, Yang; Chen, Xu-Tao; Li, Jun; Deng, Rong-Hai; Luo, Jin-Quan; Chen, Li-Zhong; Wang, Chang-Xi; Qiu, Jiang; Huang, Gang] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou, Peoples R China; [Yang, Shi-Cong; Chen, Wen-Fang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China; [Yang, Hui-Fei] Jinan Univ, Fuda Canc Hosp, Guangzhou, Peoples R China; [Hou, Xiao-Tao] Guangzhou KingMed Ctr Clin Lab Co Ltd, Guangzhou, Peoples R China; [Wang, Jin-Yuan; Shen, Xue] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China; [Huang, Gang] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Organ Donat & Transplant I, Guangzhou, Peoples R China; [Huang, Gang] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Int Cooperat Base Sci & Technol Or, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Jinan University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Qiu, J; Huang, G (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou, Peoples R China.; Huang, G (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Organ Donat & Transplant I, Guangzhou, Peoples R China.; Huang, G (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Int Cooperat Base Sci & Technol Or, Guangzhou, Peoples R China.	gnandqj@126.com; huangg8@mail.sysu.edu.cn			National Natural Science Foundation of China [81770749]; Medical Scientific Research Foundation of Guangdong Province of China [A2017164]; China Organ Transplantation Development Foundation [2019JYJH07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Scientific Research Foundation of Guangdong Province of China; China Organ Transplantation Development Foundation	This work was supported by grants from National Natural Science Foundation of China (81770749), Medical Scientific Research Foundation of Guangdong Province of China (No. A2017164), and China Organ Transplantation Development Foundation (2019JYJH07).	Ambalathingal GR, 2017, CLIN MICROBIOL REV, V30, P503, DOI 10.1128/CMR.00074-16; Becker GJ, 2016, AM J KIDNEY DIS, V67, P954, DOI 10.1053/j.ajkd.2015.11.011; Boan P, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1652-6; Celik B, 2004, HUM PATHOL, V35, P367, DOI 10.1016/j.humpath.2003.09.009; CHEN XT, 2020, ANN TRANSL MED, V0008; Chen XT, 2019, J INFECT DIS, V219, P1879, DOI 10.1093/infdis/jiz022; Drachenberg CB, 2017, AM J TRANSPLANT, V17, P2078, DOI 10.1111/ajt.14314; Drachenberg CB, 2004, AM J TRANSPLANT, V4, P2082, DOI 10.1046/j.1600-6143.2004.00603.x; Drachenberg CB, 2007, TRANSPLANTATION, V84, P323, DOI 10.1097/01.tp.0000269706.59977.a5; Drachenberg RC, 2001, AM J TRANSPLANT, V1, P373, DOI 10.1034/j.1600-6143.2001.10414.x; Gill M, 2019, HYPERTENSION, V73, P1112, DOI 10.1161/HYPERTENSIONAHA.119.12707; Goerlich N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57524-7; Haas M, 2018, AM J TRANSPLANT, V18, P293, DOI 10.1111/ajt.14625; Herawi M, 2006, AM J SURG PATHOL, V30, P345; Hirsch HH, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13528; Hirsch HH, 2005, TRANSPLANTATION, V79, P1277, DOI 10.1097/01.TP.0000156165.83160.09; Hirsch HH, 2002, NEW ENGL J MED, V347, P488, DOI 10.1056/NEJMoa020439; Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9; Huang G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142460; Huang G, 2015, DIAGN MICR INFEC DIS, V81, P21, DOI 10.1016/j.diagmicrobio.2014.09.024; Kanarek N, 2018, NATURE, V559, P632, DOI 10.1038/s41586-018-0316-7; Lamarche C, 2016, TRANSPLANTATION, V100, P2276, DOI 10.1097/TP.0000000000001333; Ma MKM, 2015, AM J NEPHROL, V42, P410, DOI 10.1159/000443514; Menter T, 2013, AM J TRANSPLANT, V13, P1474, DOI 10.1111/ajt.12218; Nankivell BJ, 2017, AM J TRANSPLANT, V17, P2065, DOI 10.1111/ajt.14292; Nankivell BJ, 2020, CLIN J AM SOC NEPHRO, V15, P1015, DOI 10.2215/CJN.13611119; Nickeleit V, 2000, NEW ENGL J MED, V342, P1309, DOI 10.1056/NEJM200005043421802; Nickeleit V, 1999, J AM SOC NEPHROL, V10, P1080; Nickeleit V, 2018, J AM SOC NEPHROL, V29, P680, DOI 10.1681/ASN.2017050477; Nickeleit V, 2015, CURR OPIN ORGAN TRAN, V20, P348, DOI 10.1097/MOT.0000000000000192; Perland E, 2017, J MOL NEUROSCI, V61, P199, DOI 10.1007/s12031-016-0867-8; Ranzi AD, 2012, ACTA CYTOL, V56, P543, DOI 10.1159/000341425; Ravindran A, 2018, KIDNEY INT, V94, P433, DOI 10.1016/j.kint.2018.01.007; Sawinski D, 2015, NEPHROL DIAL TRANSPL, V30, P209, DOI 10.1093/ndt/gfu023; Singh HK, 2015, TRANSPLANTATION, V99, P609, DOI 10.1097/TP.0000000000000367; Singh HK, 2009, J AM SOC NEPHROL, V20, P416, DOI 10.1681/ASN.2008010117; Yamanaka K, 2012, CLIN TRANSPLANT, V26, P20, DOI 10.1111/j.1399-0012.2012.01636.x; Yi SG, 2017, CURR OPIN ORGAN TRAN, V22, P320, DOI 10.1097/MOT.0000000000000429	38	1	3	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2020	11								582678	10.3389/fimmu.2020.582678	http://dx.doi.org/10.3389/fimmu.2020.582678			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX3LB	33072129	Green Published, gold			2022-12-18	WOS:000575612700001
J	Bruzzaniti, S; Cirillo, E; Prencipe, R; Giardino, G; Lepore, MT; Garziano, F; Perna, F; Procaccini, C; Mascolo, L; Pagano, C; Fattorusso, V; Mozzillo, E; Bifulco, M; Matarese, G; Franzese, A; Pignata, C; Galgani, M				Bruzzaniti, Sara; Cirillo, Emilia; Prencipe, Rosaria; Giardino, Giuliana; Lepore, Maria Teresa; Garziano, Federica; Perna, Francesco; Procaccini, Claudio; Mascolo, Luigi; Pagano, Cristina; Fattorusso, Valentina; Mozzillo, Enza; Bifulco, Maurizio; Matarese, Giuseppe; Franzese, Adriana; Pignata, Claudio; Galgani, Mario			CD4(+)T Cell Defects in a Mulibrey Patient With SpecificTRIM37Mutations	FRONTIERS IN IMMUNOLOGY			English	Article						immune response; CD4(+)T cells; immunological defects; TRIM37; Mulibrey syndrome	TRIM FAMILY; T-CELLS; UBIQUITIN; NANISM; FEATURES; IMMUNITY; RECEPTOR	Mulibrey (muscle-liver-brain-eye) syndrome (MUL) is an autosomal recessive disorder caused by mutations in theTRIpartite motif(TRIM)37gene, encoding for TRIM37 a member of the TRIM E3 ubiquitin ligase protein family. MUL patients are characterized by growth retardation, dysmorphic features, and a wide range of abnormalities affecting different organs. However, T-cell abnormalities have not been observed in MUL subjects, to date. Here we described the immunological features of a MUL child carrying recently identifiedTRIM37mutations, a 17q22 deletion of maternal origin combined with aTRIM37variant of paternal origin. Here we found quantitative and functional defects in CD4(+)T cells from this MUL case. Low levels of TRIM37 protein were specifically detected in CD4(+)T cells of MUL patient and associated with their altered proliferation and cytokine production. Of note, both CD4(+)and CD8(+)T lymphocytes of MUL child displayed an effector memory phenotype compared with healthy children. This clinical case research highlighted the possible role of TRIM37 in the control of immune cell number and function, especially in CD4(+)T cells. Finally, this study may contribute to the novel mechanistic studies aim of identifying, in depth, the role of the TRIM37 protein in the immune system.	[Bruzzaniti, Sara; Lepore, Maria Teresa; Procaccini, Claudio; Matarese, Giuseppe; Galgani, Mario] CNR, Lab Immunol, Ist Endocrinol & Oncol Sperimentale G Salvatore, Naples, Italy; [Bruzzaniti, Sara] Univ Napoli Federico II, Dipartimento Biol, Naples, Italy; [Cirillo, Emilia; Prencipe, Rosaria; Giardino, Giuliana; Fattorusso, Valentina; Mozzillo, Enza; Franzese, Adriana; Pignata, Claudio] Univ Napoli Federico II, Dipartimento Sci Med Traslaz, Naples, Italy; [Garziano, Federica; Procaccini, Claudio] Fdn Santa Lucia, Unita Neuroimmunol, Rome, Italy; [Perna, Francesco] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Naples, Italy; [Mascolo, Luigi] Univ Napoli Federico II, Div Farmacol, Dipartimento Neurosci & Sci Riprodutt Odontostoma, Naples, Italy; [Pagano, Cristina; Bifulco, Maurizio; Matarese, Giuseppe; Galgani, Mario] Univ Napoli Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; IRCCS Santa Lucia; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II	Galgani, M (corresponding author), CNR, Lab Immunol, Ist Endocrinol & Oncol Sperimentale G Salvatore, Naples, Italy.; Franzese, A; Pignata, C (corresponding author), Univ Napoli Federico II, Dipartimento Sci Med Traslaz, Naples, Italy.; Galgani, M (corresponding author), Univ Napoli Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy.	franzese@unina.it; pignata@unina.it; mario.galgani@unina.it	Giardino, Giuliana/AAF-9841-2021; Galgani, Mario/AAC-3298-2022; Bruzzaniti, Sara/AHD-0747-2022; Matarese, Giuseppe/AAO-4077-2021	Matarese, Giuseppe/0000-0001-9429-0616; Bifulco, Maurizio/0000-0002-1771-4531; Pagano, Cristina/0000-0002-9181-6595	Juvenile Diabetes Research Foundation (JDRF) [2-SRA-2018-479-S-B]; National Multiple Sclerosis Society (NMSS) [PP-1804-30725]; Fondazione Italiana Sclerosi Multipla (FISM) [2016/R/18, 2018/S/5]; Progetti di Rilevante Interesse Nazionale (PRIN) [2017 K55HLC 001]; Italian Ministry of Health [GR-2016-02363749, GR-2018-12366154]	Juvenile Diabetes Research Foundation (JDRF)(Juvenile Diabetes Research Foundation); National Multiple Sclerosis Society (NMSS)(National Multiple Sclerosis Society); Fondazione Italiana Sclerosi Multipla (FISM)(Fondazione Italiana Sclerosi Multipla (FISM)); Progetti di Rilevante Interesse Nazionale (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Italian Ministry of Health(Ministry of Health, Italy)	This paper was supported by grants from the Juvenile Diabetes Research Foundation (JDRF n. 2-SRA-2018-479-S-B) and the National Multiple Sclerosis Society (NMSS n. PP-1804-30725) to MG; Fondazione Italiana Sclerosi Multipla (FISM n. 2016/R/18 and FISM n. 2018/S/5), and Progetti di Rilevante Interesse Nazionale (PRIN, 2017 K55HLC 001) to GM; the Italian Ministry of Health grants (n. GR-2016-02363749 and n. GR-2018-12366154) to CPr.	Moro-Garcia MA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00107; Brigant B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010067; Bruzzaniti S, 2019, P NATL ACAD SCI USA, V116, P15625, DOI 10.1073/pnas.1906303116; Chikuma S, 2012, NAT IMMUNOL, V13, P596, DOI 10.1038/ni.2293; De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011; DIANZANI U, 1989, EUR J IMMUNOL, V19, P1037, DOI 10.1002/eji.1830190613; Ebner P, 2017, CRIT REV BIOCHEM MOL, V52, P425, DOI 10.1080/10409238.2017.1325829; Friend SF, 2014, AM J CLIN EXP IMMUNO, V3, P107; Garcia-Prat M, 2019, CYTOM PART B-CLIN CY, V96, P223, DOI 10.1002/cyto.b.21728; Gilani SR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008959; Gorentla Balachandra K, 2012, J Clin Cell Immunol, V2012, P5; Hamalainen RH, 2006, GENE, V366, P180, DOI 10.1016/j.gene.2005.08.008; HARALDSSON A, 1993, EUR J PEDIATR, V152, P509, DOI 10.1007/BF01955061; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; Jobic F, 2017, AM J MED GENET A, V173, P2782, DOI 10.1002/ajmg.a.38381; Karlberg N, 2004, J MED GENET, V41, P92, DOI 10.1136/jmg.2003.014118; Kettunen KM, 2016, BIOL OPEN, V5, P584, DOI 10.1242/bio.016246; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; McKinstry KK, 2012, J CLIN INVEST, V122, P2847, DOI 10.1172/JCI63689; Mozzillo E, 2016, AM J MED GENET A, V170, P2196, DOI 10.1002/ajmg.a.37770; Notarangelo LD, 1995, BAMBINO IMMUNODEPRES; O'Leary CE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00618; Park Y, 2014, ADV IMMUNOL, V124, P17, DOI 10.1016/B978-0-12-800147-9.00002-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Tanaka S, 2018, J EXP MED, V215, P1853, DOI 10.1084/jem.20170779; Terrazzano G, 2020, NAT METAB, V2, P142, DOI 10.1038/s42255-020-0173-1; Versteeg GA, 2013, IMMUNITY, V38, P384, DOI 10.1016/j.immuni.2012.11.013; Zhou XF, 2012, P NATL ACAD SCI USA, V109, P20083, DOI 10.1073/pnas.1214704109	31	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 18	2020	11								1742	10.3389/fimmu.2020.01742	http://dx.doi.org/10.3389/fimmu.2020.01742			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY5WZ	33042106	gold, Green Published			2022-12-18	WOS:000576460700001
J	Vallet, H; Bayard, C; Lepetitcorps, H; O'Hana, J; Fastenackels, S; Fali, T; Cohen-Bittan, J; Khiami, F; Boddaert, J; Sauce, D				Vallet, Helene; Bayard, Charles; Lepetitcorps, Helene; O'Hana, Jessica; Fastenackels, Solene; Fali, Tinhinane; Cohen-Bittan, Judith; Khiami, Frederic; Boddaert, Jacques; Sauce, Delphine			Hip Fracture Leads to Transitory Immune Imprint in Older Patients	FRONTIERS IN IMMUNOLOGY			English	Article						acute stress; immune response; aging; inflammation; regulation loop	T-CELL; MONOCYTES; FRACTALKINE; EXPRESSION; DEATH	Background:Hip fracture (HF) is common in the geriatric population and is associated with a poor vital and functional prognosis which could be impacted by immunological changes. The objective here is to decipher immune changes occurring in the 1st days following HF and determine how phenotype, function, and regulation of innate and adaptive compartments adapt during acute stress event. Methods:We included HF patients, aged over 75 years. For each patient, blood samples were taken at five different timepoints: four in the perioperative period (day 0 to hospital discharge) and one at long term (6-12 months). Phenotypical and functional analysis were performed longitudinally on fresh blood or cryopreserved PBMCs. Clinical data were prospectively collected. Results:One-hundred HF patients and 60 age-matched controls were included. Innate compartment exhibits pro-inflammatory phenotypes (hyperleukocytosis, increase of CD14+ CD16+ proportion and CCR2 expression), maintaining its ability to produce pro-inflammatory cytokines. Adaptive compartment extends toward a transitory immunosuppressive profile (leucopenia) associated with an active T-cell proliferation. Furthermore, increases of LAG-3 and PD-1 and a decrease of 2-B4 expression are observed on T-cells, reinforcing their transitory suppressive status. Of note, these immune changes are transitory and sequential but may participate to a regulation loop necessary for homeostatic immune control at long term. Conclusion:HF is associated with several transitory immunological changes including pro-inflammatory phenotype in innate compartment and immunosuppressive profile in adaptive compartment. A comprehensive assessment of immune mechanisms implicated in the patient's prognosis after HF could pave the way to develop new immune therapeutics strategies.	[Vallet, Helene; Bayard, Charles; Lepetitcorps, Helene; O'Hana, Jessica; Fastenackels, Solene; Fali, Tinhinane; Khiami, Frederic; Boddaert, Jacques; Sauce, Delphine] Sorbonne Univ, Ctr Immunol & Malad Infect Cimi Paris, INSERM, Paris, France; [Vallet, Helene] Assistance Pubi Hop Paris APHP, Hop St Antoine, Dept Geriatr, Paris, France; [Cohen-Bittan, Judith; Boddaert, Jacques] Assistance Publ Hop Paris APHP, Dept Geriatr, Hop Pitie Salpetriere, Paris, France; [Khiami, Frederic] APHP, Hop Pitie Salpetriere, Dept Orthoped Surg, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Vallet, H; Sauce, D (corresponding author), Sorbonne Univ, Ctr Immunol & Malad Infect Cimi Paris, INSERM, Paris, France.; Vallet, H (corresponding author), Assistance Pubi Hop Paris APHP, Hop St Antoine, Dept Geriatr, Paris, France.	helene.vallet@aphp.fr; delphine.sauce@sorbonne-universite.fr	SAUCE, Delphine/ABE-5975-2020; FALI, Tinhinane/ABD-8594-2020; Bayard, Charles/H-8148-2017	SAUCE, Delphine/0000-0003-4596-7373; Bayard, Charles/0000-0001-5444-9493; FALI, Tinhinane/0000-0002-6995-2187	Sorbonne University [M18JR31262]; Prix Lucienne Chaffoteaux/Fondation de France; Prix Paul Benettot/Fondation de l'Avenir	Sorbonne University; Prix Lucienne Chaffoteaux/Fondation de France; Prix Paul Benettot/Fondation de l'Avenir	This work was supported by Sorbonne University (Emergence grant number M18JR31262). HV is a recipient of Prix Lucienne Chaffoteaux/Fondation de France and of Prix Paul Benettot/Fondation de l'Avenir.	Baehl S, 2016, GERONTOLOGY, V62, P477, DOI 10.1159/000443142; Baehl S, 2015, EXP GERONTOL, V65, P58, DOI 10.1016/j.exger.2015.03.009; Bandyopadhyay G, 2007, CRIT CARE MED, V35, P794, DOI 10.1097/01.CCM.0000256847.61085.A5; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; Boddaert J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083795; Britanova OV, 2014, J IMMUNOL, V192, P2689, DOI 10.4049/jimmunol.1302064; Diamantopoulos AP, 2013, CLIN INTERV AGING, V8, P817, DOI 10.2147/CIA.S45468; da Mota NVF, 2018, SHOCK, V50, P293, DOI 10.1097/SHK.0000000000001078; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Gainaru G, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1977-1; Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003-4819-152-6-201003160-00008; KATZ S, 1976, MED CARE, V14, P116, DOI 10.1097/00005650-197605001-00018; Larsen M, 2017, EBIOMEDICINE, V26, P157, DOI 10.1016/j.ebiom.2017.11.003; Laudanski K, 2006, P NATL ACAD SCI USA, V103, P15564, DOI 10.1073/pnas.0607028103; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Liu Q, 2015, INT J CLIN EXP PATHO, V8, P1374; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; McBride MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01043; Pachot A, 2008, J IMMUNOL, V180, P6421, DOI 10.4049/jimmunol.180.9.6421; Patil NK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112413; Rimmele T, 2016, SHOCK, V45, P282, DOI 10.1097/SHK.0000000000000495; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Rosencher N, 2005, J THROMB HAEMOST, V3, P2006, DOI 10.1111/j.1538-7836.2005.01545.x; Sauce D, 2016, SCI REP-UK, V6, DOI 10.1038/srep28129; Sauce D, 2009, J CLIN INVEST, V119, P3070, DOI 10.1172/JCI39269; Sun TS, 2011, INJURY, V42, P707, DOI 10.1016/j.injury.2011.01.010; Tajeu GS, 2014, J GERONTOL A-BIOL, V69, P346, DOI 10.1093/gerona/glt105; Vallet H, 2017, J GERONTOL A-BIOL, V72, P438, DOI 10.1093/gerona/glw097; Venet F, 2010, SHOCK, V34, P358, DOI 10.1097/SHK.0b013e3181dc0977; White GE, 2012, ARTERIOSCL THROM VAS, V32, P589, DOI 10.1161/ATVBAHA.111.237412; Zhang H, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8492090; Zhang Y, 2011, CRIT CARE, V15, DOI 10.1186/cc10059	32	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 18	2020	11								571759	10.3389/fimmu.2020.571759	http://dx.doi.org/10.3389/fimmu.2020.571759			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	NY5XR	33072114	Green Published, gold			2022-12-18	WOS:000576462500001
J	Marchbank, KJ; Frazer-Abel, A; Dragon-Durey, MA; Dixon, BP				Marchbank, Kevin J.; Frazer-Abel, Ashley; Dragon-Durey, Marie-Agnes; Dixon, Bradley P.			Editorial: Autoantibodies in Kidney Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoantibody (aAb); complement; aHUS; C3G; lupus; immune complex; IgAN pathogenesis; nephrology			[Marchbank, Kevin J.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Marchbank, Kevin J.] Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Frazer-Abel, Ashley] Univ Colorado Denver, Med Rheumatol, Denver, CO USA; [Dragon-Durey, Marie-Agnes] Univ Paris, Georges Pompidou European Hosp, APHP, Lab Immunol,INSERM UMRS1138,Cordeliers Res Ctr, Paris, France; [Dixon, Bradley P.] Univ Colorado Denver, Dept Pediat Nephrol, Denver, CO USA; [Dixon, Bradley P.] Childrens Hosp Colorado, Dept Pediat Nephrol, Aurora, CO USA	Newcastle University - UK; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	Marchbank, KJ (corresponding author), Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.; Marchbank, KJ (corresponding author), Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England.	kevin.marchbank@newcastle.ac.uk	, Dragon-Durey/AGM-3653-2022	Dixon, Bradley/0000-0003-3704-0922; marchbank, kevin james/0000-0003-1312-5411	Kidney Research UK; Northern Counties Kidney Research Fund	Kidney Research UK(Kidney Research UK (KRUK)); Northern Counties Kidney Research Fund	KM thanks UKRI, Kidney Research UK and the Northern Counties Kidney Research Fund for supporting his research in this area.		0	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2020	11								591338	10.3389/fimmu.2020.591338	http://dx.doi.org/10.3389/fimmu.2020.591338			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY3CN	33042166	Green Published, gold			2022-12-18	WOS:000576272200001
J	Drabe, CH; Marvig, RL; Borgwardt, L; Lundgren, JD; Maquart, HVH; Katzenstein, TL; Helleberg, M				Drabe, Camilla Heldbjerg; Marvig, Rasmus L.; Borgwardt, Line; Lundgren, Jens D.; Maquart, Hanne Vibeke Hansen; Katzenstein, Terese Lea; Helleberg, Marie			Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis	FRONTIERS IN IMMUNOLOGY			English	Article						immunodeficiency; leishmaniasis; hyper IgM syndrome; genetics; diagnostic; whole genome sequencing	COMMON VARIABLE IMMUNODEFICIENCY; CD40-CD40 LIGAND INTERACTIONS; CD40 LIGAND; VISCERAL LEISHMANIASIS; PATIENT; MUTATION; GENE	A previously healthy 19-year-old Syrian man presented with atypical and severe mucosal leishmaniasis caused byLeishmania tropica. During a 2-year period, he had three severe relapses despite various treatment strategies, including liposomal amphotericin B and Miltefosine. Because of the unusual clinical presentation, potential underlying immunodeficiency was investigated. Normal T and NK cell counts were found. The B cell count was slightly elevated at 0.7 x 10(9)cells/L (0.09 x 10(9)to 0.57 x 10(9)cells/L), but the proportions of memory and isotype switched memory B cells were severely diminished IgG levels were low, at 309 mg/dL (610-1490 mg/dL). The initial IgM and IgA levels were within normal range, but the IgA levels decreased to 57 mg/dL (70-430 mg/dL) during follow up. Common variable immunodeficiency (CVID) was initially suspected, because the immunological results of low IgG and IgA, low switched memory B cells, no profound T cell deficiency found and absence of secondary cause of hypogammaglobulinemia were compatible with this diagnosis (ESID 2019). However, the highly unusual and severe clinical presentation ofL. tropicais not suggestive of B-cell deficiency or CVID. Eventually a pathogenic nonsense variant in the CD40 ligand gene [p.(Arg11*)] was identified by whole genome sequencing, thus enabling the diagnosis of X-linked hyper IgM syndrome. This case illustrates and supports the potential for the use of whole genome sequencing in accurate diagnosis of primary immunodeficiencies.	[Drabe, Camilla Heldbjerg; Lundgren, Jens D.; Katzenstein, Terese Lea; Helleberg, Marie] Copenhagen Univ Hosp, Rigshosp, Dept Infect Dis, Copenhagen, Denmark; [Marvig, Rasmus L.; Borgwardt, Line] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Copenhagen, Denmark; [Lundgren, Jens D.; Helleberg, Marie] Copenhagen Univ Hosp, Rigshosp, Ctr Excellence Personalised Med Infect Complicat, Dept Infect Dis,PERSIMUNE, Copenhagen, Denmark; [Maquart, Hanne Vibeke Hansen] Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Drabe, CH (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Infect Dis, Copenhagen, Denmark.	Camilla.h.drabe@gmail.com	Lundgren, Jens/AAE-6876-2019; Helleberg, Marie/ABC-8199-2020	Helleberg, Marie/0000-0002-2370-1657; Drabe, Camilla Heldbjerg/0000-0002-9053-9047; Marvig, Rasmus L./0000-0002-5267-3173	Danish National Research Foundation [DNRF126]	Danish National Research Foundation(Danmarks Grundforskningsfond)	PERSIMUNE was supported by the Danish National Research Foundation (Grant Number DNRF126).	Akuffo H, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006375; Ameratunga R, 2013, CLIN EXP IMMUNOL, V174, P203, DOI 10.1111/cei.12178; Ameratunga R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02678; Aversa G, 1994, Semin Immunol, V6, P295, DOI 10.1006/smim.1994.1038; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2; Conceicao-Silva F, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00330; Conceicao-Silva F, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01308; Danielian S, 2007, J CLIN IMMUNOL, V27, P455, DOI 10.1007/s10875-007-9089-8; Davies EG, 2010, BRIT J HAEMATOL, V149, P167, DOI 10.1111/j.1365-2141.2010.08077.x; Franca TT, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00130; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; HAN SH, 1995, J IMMUNOL, V155, P556; Gonzalez-Granado LI, 2016, J CLIN IMMUNOL, V36, P363, DOI 10.1007/s10875-016-0270-9; Kiani-Alikhan S, 2012, J CLIN IMMUNOL, V32, P70, DOI 10.1007/s10875-011-9607-6; Kuo CY, 2018, CELL REP, V23, P2606, DOI 10.1016/j.celrep.2018.04.103; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Lipsky PE, 1997, ANN NY ACAD SCI, V815, P372, DOI 10.1111/j.1749-6632.1997.tb52088.x; Maio P, 2009, NEW MICROBIOL, V32, P223; Martin JC, 1996, CLIN INFECT DIS, V23, P1188, DOI 10.1093/clinids/23.5.1188; Meng XX, 2018, INNATE IMMUN-LONDON, V24, P4, DOI 10.1177/1753425917739681; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; Okwor I, 2016, CELL IMMUNOL, V309, P32, DOI 10.1016/j.cellimm.2016.06.004; Pedersen MS, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2862-y; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Seyama K, 1998, J INFECT DIS, V178, P318, DOI 10.1086/515633; Subauste CS, 2009, SEMIN IMMUNOL, V21, P273, DOI 10.1016/j.smim.2009.06.003; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Uronen H, 2000, CLIN EXP IMMUNOL, V121, P346, DOI 10.1046/j.1365-2249.2000.01307.x; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; World Health Organization (WHO), 2019, LEISHMANIASIS; Yong PFK, 2008, J CLIN PATHOL, V61, P1220, DOI 10.1136/jcp.2008.058362	35	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								567856	10.3389/fimmu.2020.567856	http://dx.doi.org/10.3389/fimmu.2020.567856			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX9CU	33013931	Green Published, gold			2022-12-18	WOS:000576000600001
J	Govender, L; Mikulic, J; Wyss, JC; Gaide, O; Thome, M; Golshayan, D				Govender, Lerisa; Mikulic, Josip; Wyss, Jean-Christophe; Gaide, Olivier; Thome, Margot; Golshayan, Dela			Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts	FRONTIERS IN IMMUNOLOGY			English	Article						transplantation; paracaspase; NF-kB; calcineurin inhibitors; regulatory T cells; Th17 cells	NF-KAPPA-B; REGULATORY T-CELLS; PARACASPASE MALT1; ACTIVATION; INHIBITION; CLEAVAGE; INTERLEUKIN-2; PROTEASE; CYCLOSPORINE; DEFICIENCY	Strategies targeting T cells are the cornerstone of immunosuppression after solid organ transplantation. The transcription factor NF-kappa B is a key regulator of downstream T-cell activation and induction of inflammatory mediators; its full activation via antigen receptor engagement requires both the scaffold and the protease activity of the paracaspase Malt1. Experimental studies have highlighted that Malt1-deficient mice were resistant to experimental autoimmune encephalomyelitis, although they lacked peripheral regulatory T cells (Treg). Here, we compared targeting Malt1 versus using calcineurin inhibitors as immunosuppression in a stringent experimental transplantation model. We found that Malt1-deficiency impaired Th1-mediated alloresponsesin vitroandin vivoand significantly prolonged MHC-mismatched skin allograft survival, compared to cyclosporine. However, it paradoxically enhanced Th17 differentiation in the transplantation setting. Interestingly, more selective inhibition of Malt1 protease activity in wild-type mouse and human peripheral T cellsin vitroled to attenuation of alloreactive Th1 cells, while preserving preexisting Treg in the peripheral T-cell pool, and without promoting Th17 differentiation. Thus, there is a place for further investigation of the role of Malt1 signaling in the setting of transplantation.	[Govender, Lerisa; Mikulic, Josip; Wyss, Jean-Christophe; Golshayan, Dela] Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland; [Govender, Lerisa; Mikulic, Josip; Wyss, Jean-Christophe; Golshayan, Dela] Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Dept Med & Serv Immunol, Lausanne, Switzerland; [Govender, Lerisa; Mikulic, Josip; Wyss, Jean-Christophe; Gaide, Olivier; Golshayan, Dela] Univ Lausanne UNIL, Lausanne, Switzerland; [Gaide, Olivier] Lausanne Univ Hosp CHUV, Dept Med & Serv Dermatol, Lausanne, Switzerland; [Thome, Margot] Univ Lausanne UNIL, Dept Biochem, Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Golshayan, D (corresponding author), Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland.; Golshayan, D (corresponding author), Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Dept Med & Serv Immunol, Lausanne, Switzerland.; Golshayan, D (corresponding author), Univ Lausanne UNIL, Lausanne, Switzerland.	Dela.Golshayan@chuv.ch	Thome, Margot/F-8167-2011	Thome, Margot/0000-0002-5656-2139; Golshayan, Dela/0000-0001-5631-6096; Golshayan, Dela/0000-0001-9274-0732	Swiss National Science Foundation; Fondation Pierre Mercier pour La Science; Fondation Medi-CAL Futur; Fondation Lausannoise pour la Transplantation d'Organes; Leenaards Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Fondation Pierre Mercier pour La Science; Fondation Medi-CAL Futur; Fondation Lausannoise pour la Transplantation d'Organes; Leenaards Foundation	This work was supported by the Swiss National Science Foundation, Fondation Pierre Mercier pour La Science, Fondation Medi-CAL Futur, and Fondation Lausannoise pour la Transplantation d'Organes. MT and OG acknowledge support from the Leenaards Foundation.	Bardet M, 2018, IMMUNOL CELL BIOL, V96, P81, DOI 10.1111/imcb.1018; Benghiat Fleur Samantha, 2009, Transplant Rev (Orlando), V23, P11, DOI 10.1016/j.trre.2008.08.007; Bertossi A, 2014, EMBO J, V33, P2740, DOI 10.15252/embj.201490217; Bornancin F, 2015, J IMMUNOL, V194, P3723, DOI 10.4049/jimmunol.1402254; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brustle A, 2012, J CLIN INVEST, V122, P4698, DOI 10.1172/JCI63528; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Csizmadia V, 2001, TRANSPLANTATION, V71, P835, DOI 10.1097/00007890-200104150-00003; Delles AM, 2002, IMMUNOL INVEST, V31, P233, DOI 10.1081/IMM-120016243; DEMEYER A, 2019, FRONT IMMUNOL, V10; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Fontan L, 2018, J CLIN INVEST, V128, P4397, DOI 10.1172/JCI99436; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Gewies A, 2014, CELL REP, V9, P1292, DOI 10.1016/j.celrep.2014.10.044; Golshayan D, 2007, BLOOD, V109, P827, DOI 10.1182/blood-2006-05-025460; Golshayan D, 2008, TRANSPL IMMUNOL, V20, P21, DOI 10.1016/j.trim.2008.08.006; Govender L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00421; Govender L, 2014, EXPERT REV CLIN IMMU, V10, P1197, DOI 10.1586/1744666X.2014.943191; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hatcher JM, 2019, BIOORG MED CHEM LETT, V29, P1336, DOI 10.1016/j.bmcl.2019.03.046; Huber M, 2013, J CLIN INVEST, V123, P247, DOI 10.1172/JCI63681; Jaworski M, 2014, EMBO J, V33, P2765, DOI 10.15252/embj.201488987; Jeltsch KM, 2014, NAT IMMUNOL, V15, P1079, DOI 10.1038/ni.3008; Kang HG, 2007, AM J TRANSPLANT, V7, P1907, DOI 10.1111/j.1600-6143.2007.01881.x; Konczalla L, 2020, INT J CANCER, V146, P1618, DOI 10.1002/ijc.32567; Lemaitre PH, 2013, AM J TRANSPLANT, V13, P611, DOI 10.1111/ajt.12067; Liu HP, 2013, EUR J IMMUNOL, V43, P1716, DOI 10.1002/eji.201242889; Ma LL, 2008, TRANSPLANTATION, V85, P903, DOI 10.1097/TP.0b013e318166cde1; Martin K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00745; Mc Guire C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-124; Mc Guire C, 2013, J IMMUNOL, V190, P2896, DOI 10.4049/jimmunol.1201351; Meloni L, 2018, MOLECULES, V23, DOI 10.3390/molecules23123144; Moreau A, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015461; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Naito T, 2011, INT IMMUNOL, V23, P661, DOI 10.1093/intimm/dxr078; Porras DL, 2012, TRANSPLANTATION, V93, P976, DOI 10.1097/TP.0b013e31824d11d7; Quancard J, 2019, NAT CHEM BIOL, V15, P304, DOI 10.1038/s41589-018-0222-1; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rosebeck S, 2011, CELL CYCLE, V10, P2485, DOI 10.4161/cc.10.15.16923; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Vokaer B, 2010, J IMMUNOL, V185, P3417, DOI 10.4049/jimmunol.0903961; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yu JY, 2014, J IMMUNOL, V193, P422, DOI 10.4049/jimmunol.1303237; Yu JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127083; Yuan XL, 2008, J EXP MED, V205, P3133, DOI 10.1084/jem.20081937; Zeiser R, 2008, CELL CYCLE, V7, P458, DOI 10.4161/cc.7.4.5454; Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329; Zhou P, 2003, AM J TRANSPLANT, V3, P139, DOI 10.1034/j.1600-6143.2003.00033.x	52	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								576651	10.3389/fimmu.2020.576651	http://dx.doi.org/10.3389/fimmu.2020.576651			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX9JA	33042160	gold, Green Published			2022-12-18	WOS:000576016800001
J	Liang, J; Liang, JW; Hao, HR; Lin, H; Wang, P; Wu, YF; Jiang, XL; Fu, CD; Li, Q; Ding, P; Liu, HZ; Xiong, QP; Lai, XP; Zhou, L; Chan, SYE; Hou, SZ				Liang, Jian; Liang, Jiwang; Hao, Hairong; Lin, Huan; Wang, Peng; Wu, Yanfang; Jiang, Xiaoli; Fu, Chaodi; Li, Qian; Ding, Ping; Liu, Huazhen; Xiong, Qingping; Lai, Xiaoping; Zhou, Lian; Chan, Shamyuen; Hou, Shaozhen			The Extracts of Morinda officinalis and Its Hairy Roots Attenuate Dextran Sodium Sulfate-Induced Chronic Ulcerative Colitis in Mice by Regulating Inflammation and Lymphocyte Apoptosis (vol 8, 905, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						Morinda officinalis; hairy roots culture; ulcerative colitis; anti-inflammatory; immunoregulatory; apoptosis			[Liang, Jian; Lin, Huan; Wu, Yanfang; Li, Qian; Ding, Ping; Xiong, Qingping; Lai, Xiaoping; Zhou, Lian; Hou, Shaozhen] Guangzhou Univ Chinese Med, Guangdong Prov Key Lab New Chinese Med Dev & Res, Guangzhou, Peoples R China; [Liang, Jiwang; Wang, Peng; Jiang, Xiaoli; Fu, Chaodi; Chan, Shamyuen] Shenzhen Fan Mao Pharmaceut Co Ltd, Shenzhen, Peoples R China; [Hao, Hairong] Xuzhou Med Univ, Affiliated Huaian Hosp, Huaian, Peoples R China; [Liu, Huazhen] Guangdong Prov Hosp Chinese Med, Guangdong Prov Acad Chinese Med Sci, Sect Immunol, Guangzhou, Peoples R China	Guangzhou University of Chinese Medicine; Xuzhou Medical University; Guangzhou University of Chinese Medicine	Hou, SZ (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Key Lab New Chinese Med Dev & Res, Guangzhou, Peoples R China.; Chan, SYE (corresponding author), Shenzhen Fan Mao Pharmaceut Co Ltd, Shenzhen, Peoples R China.	zl@gzucm.edu.cn; samchan@phytogaa.com; hsz0214@gzucm.edu.cn						Liang J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00905	1	1	2	5	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								2092	10.3389/fimmu.2020.02092	http://dx.doi.org/10.3389/fimmu.2020.02092			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX8AP	33042122	Green Published, gold			2022-12-18	WOS:000575927200001
J	Zhang, LL; Li, JL; Ji, MX; Tian, D; Wang, LY; Chen, C; Tian, M				Zhang, Lei-lei; Li, Jin-Long; Ji, Ming-Xin; Tian, Dan; Wang, Li-Yan; Chen, Chen; Tian, Miao			AttenuatedP. falciparumParasite Shows Cytokine Variations in Humanized Mice	FRONTIERS IN IMMUNOLOGY			English	Article						humanized mice; clodronate-loaded liposomes; NOD; SCID; IL-2rg(-); (NSG) growth mutants; TK; NOG; cytokine; C9 parasite mutants (C9-M); complemented parasites (C9-C)	NATURAL-KILLER-CELLS; RED-BLOOD-CELLS; IN-VIVO MODEL; PLASMODIUM-FALCIPARUM; CHIMERIC MICE; HUMAN MALARIA; MOUSE MODELS; NOG MICE; IMMUNOCOMPROMISED MICE; HEMATOPOIETIC STEM	A recently developed humanized mouse has been used to assess the immune response evoked against the isolated attenuated C9 parasite clone (C9-M; carrying a single insertion disrupting the open reading frame (ORF) of PF3D7_1305500) ofPlasmodium falciparum. Significant human RBC engraftment was achieved by ameliorating the residual non-adaptive immune response using clodronate-loaded liposome treatment. Controlled reactive professional phagocytic leukocytes in immunodeficient mice allowed for sizeable human blood chimerism and injected huRBCs acted asbona fidehost cells forP. falciparum. huRBC-reconstituted immunodeficient mice received infectious challenge with attenuatedP. falciparumC9 parasite mutants (C9-M), complemented (C9-C), and wild type (NF54) progenitors to study the role of immune effectors in the clearance of the parasite from mouse circulation. C9-M and NF54 parasites grew and developed in the huRBC-reconstituted humanized NSG mice. Further, the presence of mutant parasites in deep-seated tissues suggests the escape of parasites from the host's immune responses and thus extended the survival of the parasite. Our results suggest an evasion mechanism that may have been employed by the parasite to survive the mouse's residual non-adaptive immune responses. Collectively, our data suggest that huRBCs reconstituted NSG mice infected with attenuatedP.falciparumis a valuable tool to explore the role of C9 mutation in the growth and survival of parasite mutants and their response to the host's immune responses. This mouse might help in identifying novel chemotherapeutic targets to develop new anti-malarial drugs.	[Zhang, Lei-lei; Ji, Ming-Xin; Tian, Dan] Second Hosp Jilin Univ, Dept Anesthesiol, Changchun, Peoples R China; [Li, Jin-Long] Second Hosp Jilin Univ, Dept Gastrointestinal Surg, Changchun, Peoples R China; [Wang, Li-Yan; Chen, Chen] Second Hosp Jilin Univ, Dept Operating Room, Changchun, Peoples R China; [Tian, Miao] Second Hosp Jilin Univ, Dept Gynecol & Obstet, Changchun, Peoples R China	Jilin University; Jilin University; Jilin University; Jilin University	Tian, M (corresponding author), Second Hosp Jilin Univ, Dept Gynecol & Obstet, Changchun, Peoples R China.	tmiaolook@zoho.com.cn	Zhang, Lei/GYQ-7446-2022		Second Hospital of Jilin University, Changchun, China	Second Hospital of Jilin University, Changchun, China	Authors express their gratitude toward The Second Hospital of Jilin University, Changchun, China for funding the proposed study.	Amolegbe SA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21351-8; Angulo-Barturen I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002252; Arie S, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5127; Arnold L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018045; Arnold L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-197; Audige A, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0209-9; Thu AM, 2017, FEBS J, V284, P2569, DOI 10.1111/febs.14127; Badell E, 2000, J EXP MED, V192, P1653, DOI 10.1084/jem.192.11.1653; Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; Balu B, 2013, EUKARYOT CELL, V12, P1171, DOI 10.1128/EC.00028-13; Balu B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013282; Balu B, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-83; Brehm M, 2016, TRANSL IMMUNOL MECH, V2016, P285, DOI [DOI 10.1016/B978-0-12-801577-3.00012-5, 10.1016/B978-0-12-801577-3.00012-5]; Cassado AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00225; Cu LW, 2015, AM J TROP MED HYG, V93, P57, DOI 10.4269/ajtmh.15-0007; de Back DZ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00009; Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331; Druilhe P, 2005, PLOS MED, V2, P1135, DOI 10.1371/journal.pmed.0020344; Druilhe P, 2002, TRENDS MICROBIOL, V10, pS38, DOI 10.1016/S0966-842X(02)02437-X; Druilhe P, 2007, CURR OPIN MICROBIOL, V10, P371, DOI 10.1016/j.mib.2007.07.009; Fomin ME, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170108; Fox A, 1998, TRANSPLANTATION, V66, P1407, DOI 10.1097/00007890-199812150-00002; Haldar K, 2018, NAT REV MICROBIOL, V16, P156, DOI 10.1038/nrmicro.2017.161; Hasegawa M, 2011, BIOCHEM BIOPH RES CO, V405, P405, DOI 10.1016/j.bbrc.2011.01.042; Herndler-Brandstetter D, 2017, P NATL ACAD SCI USA, V114, pE9626, DOI 10.1073/pnas.1705301114; Higuchi Y, 2014, XENOBIOTICA, V44, P146, DOI 10.3109/00498254.2013.836257; Hyde JE, 2005, TRENDS PARASITOL, V21, P494, DOI 10.1016/j.pt.2005.08.020; Itescu S, 1998, HUM IMMUNOL, V59, P275, DOI 10.1016/S0198-8859(98)00026-3; Ito M, 2008, CURR TOP MICROBIOL, V324, P53; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Kai Y, 2015, J GASTROENTEROL, V50, P1145, DOI 10.1007/s00535-015-1108-6; Kamimura H, 2015, DRUG METAB DISPOS, V43, P309, DOI 10.1124/dmd.114.061689; Kenney LL, 2016, AM J TRANSPLANT, V16, P389, DOI 10.1111/ajt.13520; Kim M, 2014, TRANSPL P, V46, P1186, DOI 10.1016/j.transproceed.2013.11.098; King M, 2007, ANN NY ACAD SCI, V1103, P90, DOI 10.1196/annals.1394.011; Kosaka K, 2013, BIOCHEM BIOPH RES CO, V441, P230, DOI 10.1016/j.bbrc.2013.10.040; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lavazec C, 2006, NUCLEIC ACIDS RES, V34, P6696, DOI 10.1093/nar/gkl942; Li QG, 2007, CYTOM PART A, V71A, P297, DOI 10.1002/cyto.a.20380; Lin Y, 1997, J IMMUNOL, V158, P5658; McCarthy JS, 2016, ANTIMICROB AGENTS CH, V60, P3669, DOI 10.1128/AAC.02883-15; Menard D, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a025619; Moreno A, 2001, ANTIMICROB AGENTS CH, V45, P1847, DOI 10.1128/AAC.45.6.1847-1853.2001; Moreno-Sabater A, 2018, EXPERT OPIN DRUG DIS, V13, P131, DOI 10.1080/17460441.2018.1410136; Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8; Persson KEM, 2006, J CLIN MICROBIOL, V44, P1665, DOI 10.1128/JCM.44.5.1665-1673.2006; ROWE AW, 1968, CRYOBIOLOGY, V5, P119, DOI 10.1016/S0011-2240(68)80154-3; Shanks GD, 2006, J POSTGRAD MED, V52, P277; Shimizu M, 2017, XENOBIOTICA, V47, P844, DOI 10.1080/00498254.2016.1247218; Silva MT, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00174; Siu E, 2015, ANN NY ACAD SCI, V1342, P29, DOI 10.1111/nyas.12618; Soulard V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8690; Suzuki E, 2017, EUR J DRUG METAB PH, V42, P965, DOI 10.1007/s13318-017-0413-2; Tsukada A, 2013, REGUL TOXICOL PHARM, V65, P316, DOI 10.1016/j.yrtph.2013.01.008; Uchida T, 2015, J VIROL, V89, P10087, DOI 10.1128/JVI.01126-15; Vaughan AM, 2012, FUTURE MICROBIOL, V7, P657, DOI [10.2217/FMB.12.27, 10.2217/fmb.12.27]; Watanabe S, 2007, BLOOD, V109, P212, DOI 10.1182/blood-2006-04-017681; White NJ, 2010, TRENDS PARASITOL, V26, P11, DOI 10.1016/j.pt.2009.10.007; WHO, 2017, GLOB HEP REP 2017; Wu GS, 2000, TRANSPLANT P, V32, P1069, DOI 10.1016/S0041-1345(00)01127-1; Xu D, 2015, J PHARMACOL EXP THER, V354, P73, DOI [10.1124/jpet,115.223393, 10.1124/jpet.115.224493]; Xu D, 2015, J PHARMACOL EXP THER, V352, P274, DOI 10.1124/jpet.114.220798; Xu D, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001628; Xu DY, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00274; Yamazaki H, 2013, CHEM RES TOXICOL, V26, P486, DOI 10.1021/tx400008g	65	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								1801	10.3389/fimmu.2020.01801	http://dx.doi.org/10.3389/fimmu.2020.01801			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX9HH	33013831	gold, Green Published			2022-12-18	WOS:000576012300001
J	Hoober, JK; van Vliet, SJ; Dudziak, D; Eggink, LL				Hoober, J. Kenneth; van Vliet, Sandra J.; Dudziak, Diana; Eggink, Laura L.			Editorial: Sentinel CLECs at Immunological Decision Nodes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sentinel receptors; CLEC receptors; immunomodulation; dendritic cells; ligand diversity			[Hoober, J. Kenneth; Eggink, Laura L.] Susav Biosci Inc, Tempe, AZ 85281 USA; [van Vliet, Sandra J.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands; [van Vliet, Sandra J.] Amsterdam Infect & Immun Inst, Dept Mol Cell Biol & Immunol, Canc Ctr Amsterdam, Amsterdam, Netherlands; [Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Lab Dendrit Cell Biol, Dept Dermatol, Erlangen, Germany; [Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen European Metropolita, Erlangen, Germany; [Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Med Immunol Campus Erlangen, Erlangen, Germany	Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Hoober, JK (corresponding author), Susav Biosci Inc, Tempe, AZ 85281 USA.	jkhoober@susavion.com		van Vliet, Sandra/0000-0003-1811-2687					0	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2020	11								2066	10.3389/fimmu.2020.02066	http://dx.doi.org/10.3389/fimmu.2020.02066			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV9CW	33013874	gold, Green Published			2022-12-18	WOS:000574611000001
J	Quan, H; Kim, J; Na, YR; Kim, JH; Kim, BJ; Kim, BJ; Hong, JJ; Hwang, ES; Seok, SH				Quan, Hailian; Kim, Jiyeon; Na, Yi Rang; Kim, Jung Heon; Kim, Byoung-Jun; Kim, Bum-Joon; Hong, Jung Joo; Hwang, Eung Soo; Seok, Seung Hyeok			Human Cytomegalovirus-Induced Interleukin-10 Production Promotes the Proliferation ofMycobacterium massiliensein Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						human cytomegalovirus; macrophage; Mycobacterium massiliense; interleukin-10; non-tuberculous mycobacteria	IL-10; INFECTION; CELLS; M1	Human cytomegalovirus (HCMV) exploits the interleukin-10 (IL-10) pathway as a part of its infection cycle through the manipulation of the host IL-10 signaling cascade. Based on its immunomodulatory nature, HCMV attenuates the host immune response and facilitates the progression of co-infection with other pathogens in an immune-competent host. To investigate the impact of HCMV infection on the burden of non-tuberculous mycobacteria (NTM), whose prevalence is growing rapidly worldwide, macrophages were infected with HCMV and further challenged withMycobacterium massiliense in vitro. The results showed that HCMV infection significantly increased host IL-10 synthesis and promoted the proliferation ofM. massiliensein an IL-10-dependent manner. Transcriptomic analysis revealed that HCMV infection dampened the regulatory pathways of interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), and interleukin-1 (IL-1), consequently abrogating the immune responses toM. massiliensecoinfection in macrophages. These findings provide a mechanistic basis of how HCMV infection may facilitate the development of pathogenic NTM co-infection by upregulating IL-10 expression.	[Quan, Hailian; Kim, Jiyeon; Na, Yi Rang; Kim, Byoung-Jun; Kim, Bum-Joon; Hwang, Eung Soo; Seok, Seung Hyeok] Seoul Natl Univ, Coll Med, Dept Microbiol & Immunol, Seoul, South Korea; [Quan, Hailian; Kim, Jiyeon; Na, Yi Rang; Kim, Jung Heon; Kim, Byoung-Jun; Hwang, Eung Soo; Seok, Seung Hyeok] Seoul Natl Univ, Med Res Ctr, Inst Endem Dis, Seoul, South Korea; [Kim, Jiyeon; Kim, Jung Heon; Hwang, Eung Soo; Seok, Seung Hyeok] Seoul Natl Univ, Coll Med, Global Ctr Infect Dis, Seoul, South Korea; [Na, Yi Rang] Seoul Natl Univ Hosp, Transdisciplinary Dept Med & Adv Technol, Seoul, South Korea; [Hong, Jung Joo] Korea Res Inst Biosci & Biotechnol, Natl Primate Res Ctr, Cheongju, South Korea; [Seok, Seung Hyeok] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Seoul National University (SNU)	Hwang, ES; Seok, SH (corresponding author), Seoul Natl Univ, Coll Med, Dept Microbiol & Immunol, Seoul, South Korea.; Hwang, ES; Seok, SH (corresponding author), Seoul Natl Univ, Med Res Ctr, Inst Endem Dis, Seoul, South Korea.; Hwang, ES; Seok, SH (corresponding author), Seoul Natl Univ, Coll Med, Global Ctr Infect Dis, Seoul, South Korea.; Seok, SH (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.	hesss@snu.ac.kr; lamseok@snu.ac.kr			SNUH Research Fund [03-2018-0180, 43-20200020]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF2020R1A4A2002903, 2020R1A2C2010202]; Korea Research Institute of Bioscience and Biotechnology Research Initiative Program [KGM4571922]	SNUH Research Fund; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Korea Research Institute of Bioscience and Biotechnology Research Initiative Program	This work was supported by grants from the SNUH Research Fund (Grant Nos. 03-2018-0180 and 43-20200020), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF2020R1A4A2002903 and 2020R1A2C2010202), and the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program (KGM4571922).	Avdic S, 2016, J VIROL, V90, P3819, DOI 10.1128/JVI.03066-15; Bayer C, 2013, J VIROL, V87, P67, DOI 10.1128/JVI.01585-12; Boonstra A, 2006, J IMMUNOL, V177, P7551, DOI 10.4049/jimmunol.177.11.7551; Chan G, 2008, J IMMUNOL, V181, P698, DOI 10.4049/jimmunol.181.1.698; Chang WLW, 2010, P NATL ACAD SCI USA, V107, P22647, DOI 10.1073/pnas.1013794108; Cobelens Frank, 2018, F1000Res, V7, P280, DOI 10.12688/f1000research.14184.2; Freudenberg MA, 2002, J IMMUNOL, V169, P1665, DOI 10.4049/jimmunol.169.4.1665; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guo GQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0122-4; Hwang ES, 2009, J VIROL, V83, P12388, DOI 10.1128/JVI.00304-09; Kaufmann SHE, 2016, IMMUNITY, V44, P476, DOI 10.1016/j.immuni.2016.02.014; Kim JH, 2018, MICROBIOL IMMUNOL, V62, P229, DOI 10.1111/1348-0421.12575; Lachmann R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200267; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murray PJ, 2006, CURR OPIN PHARMACOL, V6, P379, DOI 10.1016/j.coph.2006.01.010; Nagamatsu K, 2009, J EXP MED, V206, P3073, DOI 10.1084/jem.20090494; O'Leary S, 2011, AM J RESP CELL MOL, V45, P172, DOI 10.1165/rcmb.2010-0319OC; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; R Development Core Team, 2021, LANG ENV STAT COMP; Redford PS, 2014, J INFECT DIS, V209, P270, DOI 10.1093/infdis/jit424; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; Ruger K, 2014, J CLIN MICROBIOL, V52, P244, DOI 10.1128/JCM.01249-13; Sanchez V, 2012, VIROLOGY, V433, P64, DOI 10.1016/j.virol.2012.07.015; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sinzger C, 1999, J GEN VIROL, V80, P2867, DOI 10.1099/0022-1317-80-11-2867; Stockdale L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192086; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Varani Stefania, 2011, Herpesviridae, V2, P6, DOI 10.1186/2042-4280-2-6	30	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2020	11								518605	10.3389/fimmu.2020.518605	http://dx.doi.org/10.3389/fimmu.2020.518605			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV9CO	33013921	Green Published, gold			2022-12-18	WOS:000574610200001
J	Wong, CHY; Jenne, CN; Kolaczkowska, E				Wong, Connie H. Y.; Jenne, Craig N.; Kolaczkowska, Elzbieta			Editorial: Intravital Microscopy Imaging of Leukocytes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						intravital microscopy (IVM); intravital imaging; leukocytes; inflammation; eye; heart; liver; lymph nodes			[Wong, Connie H. Y.] Monash Univ, Sch Clin Sci, Monash Hlth, Ctr Inflammatory Dis,Dept Med, Clayton, Vic, Australia; [Jenne, Craig N.] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Kolaczkowska, Elzbieta] Jagiellonian Univ, Inst Zool & Biomed Res, Dept Expt Hematol, Krakow, Poland	Monash University; University of Calgary; Jagiellonian University	Kolaczkowska, E (corresponding author), Jagiellonian Univ, Inst Zool & Biomed Res, Dept Expt Hematol, Krakow, Poland.	ela.kolaczkowska@uj.edu.pl	Kolaczkowska, Elzbieta/AAC-1988-2021	Kolaczkowska, Elzbieta/0000-0002-3573-3584; Wong, Connie/0000-0002-9020-1847	CSL Centenary Fellowship; Canada Research Chairs Program; National Science Center, Poland (NCN) [2018/29/B/NZ6/00713]	CSL Centenary Fellowship; Canada Research Chairs Program(Canada Research Chairs); National Science Center, Poland (NCN)	CW was supported by the CSL Centenary Fellowship. CJ was supported by the Canada Research Chairs Program. EK was supported by a grant [No. 2018/29/B/NZ6/00713] from the National Science Center, Poland (NCN).	Alieva Maria, 2014, Intravital, V3, pe29917, DOI 10.4161/intv.29917; Croce AC, 2010, LASER SURG MED, V42, P371, DOI 10.1002/lsm.20923; Hwa C, 2007, AM J PHYSIOL-HEART C, V293, pH2667, DOI 10.1152/ajpheart.00704.2007; Secklehner J, 2017, IMMUNOL CELL BIOL, V95, P506, DOI 10.1038/icb.2017.25; Vono M, 2017, BLOOD, V129, P1991, DOI 10.1182/blood-2016-10-744441	5	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2020	11								2137	10.3389/fimmu.2020.02137	http://dx.doi.org/10.3389/fimmu.2020.02137			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NW6ZW	33013902	gold, Green Published			2022-12-18	WOS:000575167000001
J	Jamal, F; Singh, MK; Hansa, J; Pushpanjali; Ahmad, G; Dikhit, MR; Umar, MS; Bimal, S; Das, P; Mujeeb, AA; Singh, SK; Zubair, S; Owais, M				Jamal, Fauzia; Singh, Manish K.; Hansa, Jagadish; Pushpanjali; Ahmad, Ghufran; Dikhit, Manas Ranjan; Umar, Mohd Saad; Bimal, Sanjiva; Das, Pradeep; Mujeeb, Anzar Abdul; Singh, Shubhankar K.; Zubair, Swaleha; Owais, Mohammad			Leishmania-Specific Promiscuous Membrane Protein Tubulin Folding Cofactor D Divulges Th-1/Th-2 Polarization in the Host via ERK-1/2 and p38 MAPK Signaling Cascade (vol 11, 817, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						tubulin folding cofactor D; Leishmania donovani; immunoprophylaxis; Th(1)response; T-cell proliferation; MAPK signaling; peptide cocktail; humoral response			[Jamal, Fauzia; Umar, Mohd Saad; Mujeeb, Anzar Abdul; Owais, Mohammad] Aligarh Muslim Univ, Interdesciplinary Biotechnol Unit, Aligarh, Uttar Pradesh, India; [Singh, Manish K.; Hansa, Jagadish; Pushpanjali; Ahmad, Ghufran; Singh, Shubhankar K.] Rajendra Mem Res Inst Med Sci, Dept Microbiol, Patna, Bihar, India; [Dikhit, Manas Ranjan] Rajendra Mem Res Inst Med Sci, Dept Bioinformat, Patna, Bihar, India; [Bimal, Sanjiva] Rajendra Mem Res Inst Med Sci, Dept Immunol, Patna, Bihar, India; [Das, Pradeep] Rajendra Mem Res Inst Med Sci, Dept Mol Biol, Patna, Bihar, India; [Zubair, Swaleha] Aligarh Muslim Univ, Dept Comp Sci, Aligarh, Uttar Pradesh, India	Aligarh Muslim University; Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI); Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI); Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI); Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI); Aligarh Muslim University	Owais, M (corresponding author), Aligarh Muslim Univ, Interdesciplinary Biotechnol Unit, Aligarh, Uttar Pradesh, India.; Singh, SK (corresponding author), Rajendra Mem Res Inst Med Sci, Dept Microbiol, Patna, Bihar, India.; Zubair, S (corresponding author), Aligarh Muslim Univ, Dept Comp Sci, Aligarh, Uttar Pradesh, India.	shubhankar30@gmail.com; swalehazubair@yahoo.com; mdowais2012@gmail.com	HANSA, JAGADISH/G-3699-2018	HANSA, JAGADISH/0000-0002-4153-3095; Mohammad, Owais/0000-0001-7377-7388				Jamal F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00817	1	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2020	11								2019	10.3389/fimmu.2020.02019	http://dx.doi.org/10.3389/fimmu.2020.02019			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3XK	33013858	gold, Green Published			2022-12-18	WOS:000574258700001
J	Son, M; Diamond, B; Shin, JS				Son, Myoungsun; Diamond, Betty; Shin, Jeon-Soo			Editorial: The Role of HMGB1 in Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HMGB1; secretion; inflammation; sepsis; cancer; immune function; potential therapeutics	HMG-1		[Son, Myoungsun; Diamond, Betty] Feinstein Inst Med Res, Inst Mol Med, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Manhasset, NY USA; [Son, Myoungsun; Diamond, Betty] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY USA; [Shin, Jeon-Soo] Yonsei Univ, Dept Microbiol, Coll Med, Seoul, South Korea; [Shin, Jeon-Soo] Yonsei Univ, Inst Immunol & Immunol Dis, Coll Med, Seoul, South Korea; [Shin, Jeon-Soo] Yonsei Univ, Inst Basic Sci, Ctr Nanomed, Seoul, South Korea	Northwell Health; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Institute for Basic Science - Korea (IBS); Yonsei University	Shin, JS (corresponding author), Yonsei Univ, Dept Microbiol, Coll Med, Seoul, South Korea.; Shin, JS (corresponding author), Yonsei Univ, Inst Immunol & Immunol Dis, Coll Med, Seoul, South Korea.; Shin, JS (corresponding author), Yonsei Univ, Inst Basic Sci, Ctr Nanomed, Seoul, South Korea.	jsshin6203@yuhs.ac		Shin, Jeon-Soo/0000-0002-8294-3234	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI135063, P01AI02852]; National Research Foundation (NRF) of Korea [2017R1A2B3006704, 2019R1A6A1A03032869]; Research Center Program of Institute for Basic Science (IBS) in Korea [IBS-R026-D1]; Brain Korea 21 PLUS Project for Medical Science	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Research Center Program of Institute for Basic Science (IBS) in Korea; Brain Korea 21 PLUS Project for Medical Science	This work was supported by grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI135063 (MS) and P01AI02852 (BD)], the National Research Foundation (NRF) of Korea (2017R1A2B3006704, 2019R1A6A1A03032869), the Research Center Program of Institute for Basic Science (IBS) in Korea (IBS-R026-D1), and the Brain Korea 21 PLUS Project for Medical Science (J-SS).	Andersson U, 2011, J INTERN MED, V269, P2, DOI 10.1111/j.1365-2796.2010.02320.x; Andersson U, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00172-4; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Bianchi ME, 2017, IMMUNOL REV, V280, P74, DOI 10.1111/imr.12601; Fleming V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00398; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Magna M, 2014, MOL MED, V20, P138, DOI 10.2119/molmed.2013.00164; Venereau E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00422; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248	9	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2020	11								594253	10.3389/fimmu.2020.594253	http://dx.doi.org/10.3389/fimmu.2020.594253			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3WK	33013940	gold, Green Published			2022-12-18	WOS:000574256100001
J	Szegezdi, E; Legembre, P				Szegezdi, Eva; Legembre, Patrick			Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						TNF; apoptosis; inflammation; death receptor; nuclear factor kappa B	CANCER; HOMOLOG		[Szegezdi, Eva] Natl Univ Ireland, Discipline Biochem, Galway, Ireland; [Legembre, Patrick] Univ Limoges, INSERM, U1262, CRIBL, Limoges, France	Ollscoil na Gaillimhe-University of Galway; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Limoges	Legembre, P (corresponding author), Univ Limoges, INSERM, U1262, CRIBL, Limoges, France.	patrick.legembre@inserm.fr	Legembre, Patrick/U-1882-2019; Szegezdi, Eva/B-7142-2008	Legembre, Patrick/0000-0001-6649-8049; Szegezdi, Eva/0000-0002-5708-3535	INCa [PLBIO18-059]; ANR PRCE; Ligue Contre le Cancer; Fondation de France	INCa(Institut National du Cancer (INCA) France); ANR PRCE(French National Research Agency (ANR)); Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation de France(Fondation de France)	This work was funded by INCa (PLBIO18-059), ANR PRCE, Ligue Contre le Cancer and Fondation de France (Price Jean Valade) for PL.	Dondelinger Y, 2016, CELL MOL LIFE SCI, V73, P2165, DOI 10.1007/s00018-016-2191-4; Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017; Edmond V, 2015, ONCOGENE, V34, P996, DOI 10.1038/onc.2014.55; Fischer R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00401; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Malireddi RKS, 2020, J EXP MED, V217, DOI 10.1084/jem.20191644; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Poissonnier A, 2016, IMMUNITY, V45, P209, DOI 10.1016/j.immuni.2016.06.028; Qadir AS, 2017, CELL REP, V18, P2373, DOI 10.1016/j.celrep.2017.02.037; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343	12	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2020	11								2162	10.3389/fimmu.2020.02162	http://dx.doi.org/10.3389/fimmu.2020.02162			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3VV	33013910	Green Published, gold			2022-12-18	WOS:000574254600001
J	Attaf, N; Cervera-Marzal, I; Dong, C; Gil, L; Renand, A; Spinelli, L; Milpied, P				Attaf, Noudjoud; Cervera-Marzal, Inaki; Dong, Chuang; Gil, Laurine; Renand, Amedee; Spinelli, Lionel; Milpied, Pierre			FB5P-seq: FACS-Based 5-Prime End Single-Cell RNA-seq for Integrative Analysis of Transcriptome and Antigen Receptor Repertoire in B and T Cells (vol 11, 216, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						single-cell RNA sequencing; transcriptome; antigen receptor; B cells; T cells			[Attaf, Noudjoud; Cervera-Marzal, Inaki; Dong, Chuang; Gil, Laurine; Spinelli, Lionel; Milpied, Pierre] Aix Marseille Univ, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France; [Renand, Amedee] Univ Nantes, Ctr Rech Transplantat & Immunol UMR1064, INSERM, Nantes, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Milpied, P (corresponding author), Aix Marseille Univ, CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France.	milpied@ciml.univ-mrs.fr	Milpied, Pierre J/Q-1380-2015	Milpied, Pierre J/0000-0003-1873-5358; ATTAF, Noudjoud/0000-0001-7254-7679				Attaf N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00216	1	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2020	11								2047	10.3389/fimmu.2020.02047	http://dx.doi.org/10.3389/fimmu.2020.02047			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0HJ	33013865	Green Published, gold			2022-12-18	WOS:000570549700001
J	Boggiatto, PM; Schaut, RG; Olsen, SC				Boggiatto, Paola M.; Schaut, Robert G.; Olsen, Steven C.			Enhancing the Detection of Brucella-Specific CD4(+) T Cell Responses in Cattle via in vitro Antigenic Expansion and Restimulation	FRONTIERS IN IMMUNOLOGY			English	Article						Brucella; proliferation; IFN-gamma; antigenic expansion; T cell responses	TH1 CELLS; MEMORY; RB51; PROLIFERATION; INFECTION; SUBSETS	Bovine brucellosis, cause by infection withBrucella abortus, causes reproductive failure in cattle, has a major economic impact to producers, and as a zoonoses, it is a disease of public health concern. Characterization of the protective immune response againstBrucellainfection is important to our understanding of disease pathogenesis and for the development of diagnostic assays and vaccines. Most of the knowledge regarding protection againstBrucellacomes from studies in the murine model, but less is known about the immune responses in cattle. Assessment of antigen-specific T cell frequency and functional phenotype are critical to understand the immune status of the host, characterize mechanisms of protective immunity and immunopathology, and to predict immune protection. The frequency of circulating T cells specific for a particular pathogen is often very low, making analysis of such responses difficult. Our goal was to develop a flow-cytometry based approach to better trackBrucella-specific T cell responses. Using peripheral blood mononuclear cells (PMBC) fromBrucella abortusstrain RB51-vaccinated cattle, we optimized anin vitrostimulation protocol based on a combination of antigen and pan-T cell stimulation. We then assessed RB51-specific T cell responses by concurrently measuring proliferation and cytokine production using flow-cytometry. This methodology enhances the detection of peripheral,Brucella-specific responses in cattle following RB51 vaccination. This protocol is versatile in that it can be modified to fit otherin vitrostimulation systems and additional functional or phenotypic parameters can be added for flow cytometric detection and characterization of antigen-specific T cells.	[Boggiatto, Paola M.; Olsen, Steven C.] ARS, Infect Bacterial Dis Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50010 USA; [Schaut, Robert G.] ARS, Food Safety & Enter Pathogens Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA USA; [Schaut, Robert G.] Oak Ridge Inst Sci & Educ ORISE, ARS Participat Program, Oak Ridge, TN USA; [Schaut, Robert G.] Elanco Anim Hlth, Farm Anim Res Therapeut, Greenfield, IN USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA); Oak Ridge Associated Universities; United States Department of Energy (DOE); Oak Ridge Institute for Science & Education	Boggiatto, PM (corresponding author), ARS, Infect Bacterial Dis Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50010 USA.	paola.boggiatto@usda.gov			United States Department of Agriculture [50 30-32000-224-00D]	United States Department of Agriculture(United States Department of Agriculture (USDA))	This work was supported by intramural funds from the United States Department of Agriculture (Project No. 50 30-32000-224-00D).	Anthony Donald D, 2012, Cells, V1, P127, DOI 10.3390/cells1020127; Divekar AA, 2006, J IMMUNOL, V176, P1465, DOI 10.4049/jimmunol.176.3.1465; Dorneles EMS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136696; Dorneles EMS, 2014, VACCINE, V32, P6034, DOI 10.1016/j.vaccine.2014.08.060; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Guy CS, 2013, NAT IMMUNOL, V14, P262, DOI 10.1038/ni.2538; Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007; Kallas EG, 1999, J INFECT DIS, V179, P1124, DOI 10.1086/314702; Munier CML, 2009, J IMMUNOL METHODS, V345, P1, DOI 10.1016/j.jim.2009.03.013; Olsen S C, 2000, Vet Ther, V1, P183; Palmer MV, 1997, AM J VET RES, V58, P472; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; STEVENS MG, 1995, VET IMMUNOL IMMUNOP, V44, P223, DOI 10.1016/0165-2427(94)05311-F; STEVENS MG, 1994, INFECT IMMUN, V62, P4646, DOI 10.1128/IAI.62.10.4646-4649.1994; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Vitry MA, 2014, J IMMUNOL, V192, P3740, DOI 10.4049/jimmunol.1302561; Vitry MA, 2012, INFECT IMMUN, V80, P4271, DOI 10.1128/IAI.00761-12; ZHAN YF, 1993, INFECT IMMUN, V61, P4899, DOI 10.1128/IAI.61.11.4899-4901.1993	18	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								1944	10.3389/fimmu.2020.01944	http://dx.doi.org/10.3389/fimmu.2020.01944			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP9HT	32983124	gold, Green Published			2022-12-18	WOS:000570482000001
J	Healy, ZR; Weinhold, KJ; Murdoch, DM				Healy, Zachary R.; Weinhold, Kent J.; Murdoch, David M.			Transcriptional Profiling of CD8+CMV-Specific T Cell Functional Subsets Obtained Using a Modified Method for Isolating High-Quality RNA From Fixed and Permeabilized Cells	FRONTIERS IN IMMUNOLOGY			English	Article						polyfunctional T cells; CMV; RNAseq; fixation; permeabilization; RNA quality	CYTOMEGALOVIRUS-SPECIFIC CD4(+); FLOW-CYTOMETRIC ANALYSIS; TRANSPLANT RECIPIENTS; MESSENGER-RNA; SIGNAL TRANSDUCER; STAT5 ACTIVATION; CMV DNAEMIA; ATAC-SEQ; EXPRESSION; EXPANSION	Previous studies suggest that the presence of antigen-specific polyfunctional T cells is correlated with improved pathogen clearance, disease control, and clinical outcomes; however, the molecular mechanisms responsible for the generation, function, and survival of polyfunctional T cells remain unknown. The study of polyfunctional T cells has been, in part, limited by the need for intracellular cytokine staining (ICS), necessitating fixation and cell membrane permeabilization that leads to unacceptable degradation of RNA. Adopting elements from prior research efforts, we developed and optimized a modified protocol for the isolation of high-quality RNA (i.e., RIN > 7) from primary human T cells following aldehyde-fixation, detergent-based permeabilization, intracellular cytokines staining, and sorting. Additionally, this method also demonstrated utility preserving RNA when staining for transcription factors. This modified protocol utilizes an optimized combination of an RNase inhibitor and high-salt buffer that is cost-effective while maintaining the ability to identify and resolve cell populations for sorting. Overall, this protocol resulted in minimal loss of RNA integrity, quality, and quantity during cytoplasmic staining of cytokines and subsequent flourescence-activated cell sorting. Using this technique, we obtained the transcriptional profiles of functional subsets (i.e., non-functional, monofunctional, bifunctional, polyfunctional) of CMV-specific CD8+T cells. Our analyses demonstrated that these functional subsets are molecularly distinct, and that polyfunctional T cells are uniquely enriched for transcripts involved in viral response, inflammation, cell survival, proliferation, and metabolism when compared to monofunctional cells. Polyfunctional T cells demonstrate reduced activation-induced cell death and increased proliferation after antigen re-challenge. Furtherin silicoanalysis of transcriptional data suggested a critical role forSTAT5transcriptional activity in polyfunctional cell activation. Pharmacologic inhibition ofSTAT5was associated with a significant reduction in polyfunctional cell cytokine expression and proliferation, demonstrating the requirement of STAT5 activity not only for proliferation and cell survival, but also cytokine expression. Finally, we confirmed this association between CMV-specific CD8+ polyfunctionality withSTAT5signaling also exists in immunosuppressed transplant recipients using single cell transcriptomics, indicating that results from this study may translate to this vulnerable patient population. Collectively, these results shed light on the mechanisms governing polyfunctional T cell function and survival and may ultimately inform multiple areas of immunology, including but not limited to the development of new vaccines, CAR-T cell therapies, and adoptive T cell transfer.	[Healy, Zachary R.; Murdoch, David M.] Duke Univ Hosp, Dept Med, Div Pulm & Crit Care Med, Durham, NC 27710 USA; [Weinhold, Kent J.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA	Duke University; Duke University	Healy, ZR (corresponding author), Duke Univ Hosp, Dept Med, Div Pulm & Crit Care Med, Durham, NC 27710 USA.	zachary.healy@duke.edu			NIH [R21 AI099784-01A1, K99 1K99AI143927-01A1, T32 HL007538]; NHLBI Loan Repayment Grant through NHLBI [L30 HL007538]; Duke University Center for AIDS Research (CFAR) [P30 AI 64518]; National Center for Advancing Translational Sciences (NIH) [UL1TR001117]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI Loan Repayment Grant through NHLBI; Duke University Center for AIDS Research (CFAR); National Center for Advancing Translational Sciences (NIH)	This publication was supported by the following: NIH R21 AI099784-01A1, K99 1K99AI143927-01A1, T32 HL007538, an NHLBI Loan Repayment Grant through NHLBI L30 HL007538, the Duke University Center for AIDS Research (CFAR) (P30 AI 64518) as well as by the National Center for Advancing Translational Sciences (NIH) (UL1TR001117). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ackermann AM, 2016, MOL METAB, V5, P233, DOI 10.1016/j.molmet.2016.01.002; Alles J, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0383-5; Allison KA, 2016, ELIFE, V5, DOI 10.7554/eLife.10134; Clari MA, 2012, CLIN VACCINE IMMUNOL, V19, P791, DOI 10.1128/CVI.05633-11; Arlehamn CL, 2014, J IMMUNOL, V193, P2931, DOI 10.4049/jimmunol.1401151; Baan CC, 2016, TRANSPLANTATION, V100, P1833, DOI 10.1097/TP.0000000000001226; Bacher P, 2013, CYTOM PART A, V83A, P692, DOI [10.1002/cyto.a.22317, 10.1002/cyto.22317]; Bak S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02953; Beliakova-Bethell N, 2014, CYTOM PART A, V85A, P94, DOI 10.1002/cyto.a.22352; Bitar M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00722; Brown AL, 2009, RNA, V15, P2364, DOI 10.1261/rna.1733509; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Burel JG, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87499; Burel JG, 2015, EUR CYTOKINE NETW, V26, P67, DOI 10.1684/ecn.2015.0369; Camargo JF, 2019, BLOOD, V133, P867, DOI 10.1182/blood-2018-10-878918; Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246; Chiu YL, 2014, J CLIN INVEST, V124, P198, DOI 10.1172/JCI70510; Christensen Rikke, 2011, Curr Protoc Cytom, VChapter 7, DOI 10.1002/0471142956.cy0740s57; Conley JM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00076; Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; DING ZC, 2017, SCI REP UK, V0007; Ding ZC, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1171445; ESSER C, 1995, CYTOMETRY, V21, P382, DOI 10.1002/cyto.990210411; Feau S, 2011, NAT IMMUNOL, V12, P908, DOI 10.1038/ni.2079; Fox A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01141; Gabanti E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106044; Gasser O, 2009, AM J TRANSPLANT, V9, P794, DOI 10.1111/j.1600-6143.2008.02539.x; Gerlach JP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37977-7; Gerna G, 2006, AM J TRANSPLANT, V6, P2356, DOI 10.1111/j.1600-6143.2006.01488.x; Gerna G, 2011, AM J TRANSPLANT, V11, P2463, DOI 10.1111/j.1600-6143.2011.03636.x; Gimenez E, 2015, TRANSPL INFECT DIS, V17, P361, DOI 10.1111/tid.12391; Gimenez E, 2015, J GEN VIROL, V96, P2822, DOI 10.1099/vir.0.000203; Gordon CL, 2018, CELL REP, V23, P768, DOI 10.1016/j.celrep.2018.03.074; Grange M, 2013, J IMMUNOL, V191, P3712, DOI 10.4049/jimmunol.1300319; Grange M, 2012, CANCER RES, V72, P76, DOI 10.1158/0008-5472.CAN-11-2187; Grifoni A, 2020, IMMUNOLOGY, V160, P3, DOI 10.1111/imm.13161; Grifoni A, 2018, J IMMUNOL, V201, P3487, DOI 10.4049/jimmunol.1801090; Guler A, 2020, EUR J IMMUNOL, V50, P234, DOI 10.1002/eji.201948302; Han Q, 2012, P NATL ACAD SCI USA, V109, P1607, DOI 10.1073/pnas.1117194109; Han YW, 2007, J MICROBIOL BIOTECHN, V17, P1955; Hand TW, 2010, P NATL ACAD SCI USA, V107, P16601, DOI 10.1073/pnas.1003457107; Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x; Hendrickson DG, 2018, METHODS MOL BIOL, V1819, P317, DOI 10.1007/978-1-4939-8618-7_15; Hertoghs KML, 2010, J CLIN INVEST, V120, P4077, DOI 10.1172/JCI42758; Hrvatin S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089459; Hudson WH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07956-7; Iglesias-Ussel M, 2013, J IMMUNOL METHODS, V391, P22, DOI 10.1016/j.jim.2013.02.003; Illumina, 2014, EV RNA QUAL FFPE SAM; Jensen UB, 2010, CYTOM PART A, V77A, P798, DOI 10.1002/cyto.a.20914; Jia GS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07307-6; Jones W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43282-8; Kagoya Y, 2018, NAT MED, V24, P352, DOI 10.1038/nm.4478; Kalia V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02987; Klenerman P, 2018, IMMUNOL REV, V283, P99, DOI 10.1111/imr.12653; Krol L, 2011, BONE MARROW TRANSPL, V46, P1089, DOI 10.1038/bmt.2010.261; Kunnath-Velayudhan S, 2018, J IMMUNOL METHODS, V456, P77, DOI 10.1016/j.jim.2018.02.008; Lilleri D, 2008, HAEMATOLOGICA, V93, P248, DOI 10.3324/haematol.11912; Lilleri D, 2006, BLOOD, V108, P1406, DOI 10.1182/blood-2005-11-012864; Lilleri D, 2018, J MED VIROL, V90, P1620, DOI 10.1002/jmv.25225; Lilleri D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041648; Lin JX, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028449; Litjens NHR, 2013, CLIN EXP IMMUNOL, V174, P179, DOI 10.1111/cei.12152; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ludwig LS, 2019, CELL REP, V27, P3228, DOI 10.1016/j.celrep.2019.05.046; Lykidis D, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm433; Man K, 2013, NAT IMMUNOL, V14, P1155, DOI 10.1038/ni.2710; Markley JC, 2010, BLOOD, V115, P3508, DOI 10.1182/blood-2009-09-241398; Moretto MM, 2016, J IMMUNOL, V196, P375, DOI 10.4049/jimmunol.1501258; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Morris SC, 2009, J IMMUNOL, V182, P1429, DOI 10.4049/jimmunol.182.3.1429; Mousset CM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1488565; Munoz-Cobo B, 2012, J MED VIROL, V84, P259, DOI 10.1002/jmv.22254; Nebbia G, 2008, AM J TRANSPLANT, V8, P2590, DOI 10.1111/j.1600-6143.2008.02425.x; Nilsson H, 2014, J BIOTECHNOL, V192, P62, DOI 10.1016/j.jbiotec.2014.09.016; Nishimoto KP, 2007, J MICROBIOL METH, V70, P205, DOI 10.1016/j.mimet.2007.03.022; Pachnio A, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005832; Pechhold S, 2009, NAT BIOTECHNOL, V27, P1038, DOI 10.1038/nbt.1579; Perez-Bercoff L, 2014, BIOL BLOOD MARROW TR, V20, P128, DOI 10.1016/j.bbmt.2013.10.006; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; Pollizzi KN, 2015, J CLIN INVEST, V125, P2090, DOI 10.1172/JCI77746; Pourgheysari B, 2007, J VIROL, V81, P7759, DOI 10.1128/JVI.01262-06; Powell JD, 2010, IMMUNITY, V33, P301, DOI 10.1016/j.immuni.2010.09.002; Razonable RR, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13512; Renkema KR, 2016, J EXP MED, V213, P1319, DOI 10.1084/jem.20151359; Romero IG, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-42; Sandstedt M, 2015, CYTOM PART A, V87A, P1079, DOI 10.1002/cyto.a.22783; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Snyder LD, 2011, AM J TRANSPLANT, V11, P553, DOI 10.1111/j.1600-6143.2010.03405.x; Snyder LD, 2016, AM J RESP CRIT CARE, V193, P78, DOI 10.1164/rccm.201504-0733OC; Stamou P, 2010, CURR DIR AUTOIMMUN, V11, P61, DOI 10.1159/000289197; Stern A, 2019, CURR INFECT DIS REP, V21, DOI 10.1007/s11908-019-0699-0; Terrazzini N, 2018, J INFECT DIS, V217, P1997, DOI 10.1093/infdis/jiy096; Tian Y, 2019, J CLIN INVEST, V129, P1727, DOI 10.1172/JCI123726; URAK R, 2017, J IMMUNOTHER CANCER, V0005; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Verdeil G, 2006, EUR J IMMUNOL, V36, P3090, DOI 10.1002/eji.200636347; WANG JY, 2019, SCI REP UK, V9; Wimmer I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24781-6; Xiang CC, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh185; Xiao ZG, 2007, J EXP MED, V204, P2667, DOI 10.1084/jem.20062376; Xu BL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1043-3; Yong MK, 2018, CURR INFECT DIS REP, V20, DOI 10.1007/s11908-018-0610-4; Yong MK, 2017, J INFECT DIS, V215, P1684, DOI 10.1093/infdis/jix192; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057; Zhang Q, 2019, AM J CANCER RES, V9, P2379; Zimmerman MG, 2019, J VIROL, V93, DOI 10.1128/JVI.00665-19; Zoon CK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020270; Zoon CK, 2015, INT J MOL SCI, V16, P8744, DOI 10.3390/ijms16048744	108	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								1859	10.3389/fimmu.2020.01859	http://dx.doi.org/10.3389/fimmu.2020.01859			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP8WZ	32983102	Green Published, gold			2022-12-18	WOS:000570453300001
J	Laabei, M; Colineau, L; Bettoni, S; Maziarz, K; Ermert, D; Riesbeck, K; Ram, S; Blom, AM				Laabei, Maisem; Colineau, Lucie; Bettoni, Serena; Maziarz, Karolina; Ermert, David; Riesbeck, Kristian; Ram, Sanjay; Blom, Anna M.			Antibacterial Fusion Proteins EnhanceMoraxella catarrhalisKilling	FRONTIERS IN IMMUNOLOGY			English	Article						pathogen; Moraxella catarrhalis; fusion proteins; complement; antibacterial	MORAXELLA-CATARRHALIS; FACTOR-H; C4B-BINDING PROTEIN; COMPLEMENT INHIBITOR; C4B BINDING; USPA2 PROTEIN; OTITIS-MEDIA; ALPHA-CHAIN; EVASION; VITRONECTIN	Moraxella catarrhalisis a human-specific commensal of the respiratory tract and an opportunistic pathogen. It is one of the leading cause of otitis media in children and of acute exacerbations in patients with chronic obstructive pulmonary disease, resulting in significant morbidity and economic burden. Vaccines and new immunotherapeutic strategies to treat this emerging pathogen are needed. Complement is a key component of innate immunity that mediates the detection, response, and subsequent elimination of invading pathogens. Many pathogens includingM. catarrhalishave evolved complement evasion mechanisms, which include the binding of human complement inhibitors such as C4b-binding protein (C4BP) and Factor H (FH). Inhibiting C4BP and FH acquisition byM. catarrhalismay provide a novel therapeutic avenue to treat infections. To achieve this, we created two chimeric proteins that combined the Moraxella-binding domains of C4BP and FH fused to human immunoglobulin Fcs: C4BP domains 1 and 2 and FH domains 6 and 7 fused to IgM and IgG Fc, respectively. As expected, FH6-7/IgG displaced FH from the bacterial surface while simultaneously activating complement via Fc-C1q interactions, together increasing pathogen elimination. C4BP1-2/IgM also increased serum killing of the bacteria through enhanced complement deposition, but did not displace C4BP from the surface ofM. catarrhalis. These Fc fusion proteins could act as anti-infective immunotherapies. Many microbes bind the complement inhibitors C4BP and FH through the same domains asM. catarrhalis, therefore these Fc fusion proteins may be promising candidates as adjunctive therapy against many different drug-resistant pathogens.	[Laabei, Maisem; Colineau, Lucie; Bettoni, Serena; Maziarz, Karolina; Ermert, David; Blom, Anna M.] Lund Univ, Div Med Prot Chem, Dept Translat Med, Fac Med, Malmo, Sweden; [Laabei, Maisem] Univ Bath, Dept Biol & Biochem, Bath, Avon, England; [Riesbeck, Kristian] Lund Univ, Dept Translat Med, Clin Microbiol, Fac Med, Malmo, Sweden; [Ram, Sanjay] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA USA	Lund University; University of Bath; Lund University; University of Massachusetts System; University of Massachusetts Worcester	Blom, AM (corresponding author), Lund Univ, Div Med Prot Chem, Dept Translat Med, Fac Med, Malmo, Sweden.	anna.blom@med.lu.se	Blom, Anna/AFS-7369-2022; Laabei, Maisem/AAH-6383-2021; Blom, Anna/AFS-7343-2022; Blom, Anna/B-9607-2009	Laabei, Maisem/0000-0002-8425-3704; Blom, Anna/0000-0002-1348-1734; Colineau, Lucie/0000-0001-6221-0765; Riesbeck, Kristian/0000-0001-6274-6965; Bettoni, Serena/0000-0002-7840-4596	Swedish Research Council [2018-02392, 2019-01053]; Soderberg Foundation; Osterlund Foundation; Lars Hierta's Memorial Foundation [FO2018-0063]; Tore Nilson's Foundation [2019-00750, 2017-00519, 2018-00616]; Royal Physiographic Society of Lund; Royal Society, United Kingdom; Berth von Kantzows Foundation; Sten K. Johnsons Foundation; O. E. och Edla Johanssons Foundation; Langmanska kulturfonden [BA20-1272]; Thelma Zoegas fondation [TZ2019-0039]; National Institutes of Health/National Institutes of Allergy and Infectious Diseases grants [AI132296, AI136007, AI114790, AI147930]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Soderberg Foundation; Osterlund Foundation; Lars Hierta's Memorial Foundation; Tore Nilson's Foundation; Royal Physiographic Society of Lund; Royal Society, United Kingdom(Royal Society of London); Berth von Kantzows Foundation; Sten K. Johnsons Foundation; O. E. och Edla Johanssons Foundation; Langmanska kulturfonden; Thelma Zoegas fondation; National Institutes of Health/National Institutes of Allergy and Infectious Diseases grants	AB and KR were supported by the Swedish Research Council (2018-02392 and 2019-01053, respectively), The Soderberg Foundation, The Osterlund Foundation. ML was supported by the Lars Hierta's Memorial Foundation (FO2018-0063), the Tore Nilson's Foundation (2017-00519; 2018-00616), the Royal Physiographic Society of Lund and Royal Society, United Kingdom. LC was supported by the Royal Physiographic Society of Lund and the Berth von Kantzows Foundation. SB was supported by Sten K. Johnsons Foundation, the Tore Nilson's Foundation (2019-00750), the Royal Physiographic Society of Lund and the O. E. och Edla Johanssons Foundation. Langmanska kulturfonden (BA20-1272), Thelma Zoegas fondation (TZ2019-0039). SR was supported by National Institutes of Health/National Institutes of Allergy and Infectious Diseases grants AI132296, AI136007, AI114790, and AI147930.	Aebi C, 2011, ADV EXP MED BIOL, V697, P107, DOI 10.1007/978-1-4419-7185-2_9; Attia AS, 2006, INFECT IMMUN, V74, P1597, DOI 10.1128/IAI.74.3.1597-1611.2006; Attia AS, 2005, INFECT IMMUN, V73, P2400, DOI 10.1128/IAI.73.4.2400-2410.2005; Bell JS, 2019, NEUROPATH APPL NEURO, V45, P195, DOI 10.1111/nan.12520; Berends ETM, 2014, FEMS MICROBIOL REV, V38, P1146, DOI 10.1111/1574-6976.12080; Bernhard S, 2014, J INFECT DIS, V210, P1306, DOI 10.1093/infdis/jiu241; BERNSTEIN JM, 1978, CLIN EXP IMMUNOL, V33, P340; Bettoni S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131886; Blom AM, 2004, ARCH IMMUNOL THER EX, V52, P83; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 2017, J IMMUNOL, V199, P3828, DOI 10.4049/jimmunol.1700426; Blom AM, 2009, MOL IMMUNOL, V46, P2808, DOI 10.1016/j.molimm.2009.04.025; Cope LD, 1999, J BACTERIOL, V181, P4026, DOI 10.1128/JB.181.13.4026-4034.1999; de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005; Ermert D, 2019, MOL IMMUNOL, V114, P49, DOI 10.1016/j.molimm.2019.07.018; Ermert D, 2016, IMMUNOL LETT, V169, P82, DOI 10.1016/j.imlet.2015.11.014; Figueira MA, 2007, INFECT IMMUN, V75, P325, DOI 10.1128/IAI.01054-06; Forsgren A, 2001, J IMMUNOL, V167, P2112, DOI 10.4049/jimmunol.167.4.2112; Funaki T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1408-3; Hardig Y, 1997, BIOCHEM J, V323, P469; Heesterbeek DAC, 2018, J INNATE IMMUN, V10, P455, DOI 10.1159/000491439; Hoiczyk E, 2000, EMBO J, V19, P5989, DOI 10.1093/emboj/19.22.5989; HOL C, 1995, FEMS IMMUNOL MED MIC, V11, P207; Hovingh ES, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02004; Kennedy AT, 2016, J IMMUNOL, V196, P1239, DOI 10.4049/jimmunol.1501581; Khan R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01203; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kumpitsch C, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0703-z; Laabei M, 2019, J INNATE IMMUN, V11, P3, DOI 10.1159/000492944; Laabei M, 2018, J IMMUNOL, V201, P2721, DOI 10.4049/jimmunol.1800734; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; LOOS M, 1979, INFECT IMMUN, V25, P583, DOI 10.1128/IAI.25.2.583-585.1979; Meier PS, 2002, VACCINE, V20, P1754, DOI 10.1016/S0264-410X(02)00030-0; Meri T, 2004, INFECT IMMUN, V72, P6633, DOI 10.1128/IAI.72.11.6633-6641.2004; Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002; MERLE NS, 2015, FRONT IMMUNOL, V6; Murphy TF, 2005, AM J RESP CRIT CARE, V172, P195, DOI 10.1164/rccm.200412-1747OC; Murphy TF, 2005, INFECT IMMUN, V73, P3471, DOI 10.1128/IAI.73.6.3471-3478.2005; Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375; Narkio-Makela M, 2001, CLIN EXP IMMUNOL, V124, P369, DOI 10.1046/j.1365-2249.2001.01523.x; Nordstrom T, 2004, J IMMUNOL, V173, P4598, DOI 10.4049/jimmunol.173.7.4598; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; Nunn MA, 2005, J IMMUNOL, V174, P2084, DOI 10.4049/jimmunol.174.4.2084; Shaughnessy J, 2018, J IMMUNOL, V201, P2700, DOI 10.4049/jimmunol.1701666; Shaughnessy J, 2016, J IMMUNOL, V196, P1732, DOI 10.4049/jimmunol.1500292; Shaughnessy J, 2014, CLIN VACCINE IMMUNOL, V21, P1452, DOI 10.1128/CVI.00444-14; Shlaes DM, 2013, ANTIMICROB AGENTS CH, V57, P4605, DOI 10.1128/AAC.01277-13; Siddiq S, 2015, ARCH DIS CHILDHOOD-E, V100, P193, DOI 10.1136/archdischild-2013-305550; Singh B, 2015, INFECT IMMUN, V83, P3458, DOI 10.1128/IAI.00310-15; Singh B, 2010, MOL MICROBIOL, V75, P1426, DOI 10.1111/j.1365-2958.2010.07066.x; Spaniol V, 2009, J INFECT DIS, V200, P1593, DOI 10.1086/644640; STENFORS LE, 1992, ACTA OTO-LARYNGOL, V112, P96, DOI 10.3109/00016489209100789; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; Su YC, 2013, MICROBES INFECT, V15, P375, DOI 10.1016/j.micinf.2013.02.004; Su YC, 2012, FUTURE MICROBIOL, V7, P1073, DOI [10.2217/fmb.12.80, 10.2217/FMB.12.80]; Varsano S, 2000, THORAX, V55, P364, DOI 10.1136/thorax.55.5.364; Vogl G, 2008, MOL IMMUNOL, V45, P1485, DOI 10.1016/j.molimm.2007.08.011; Wong SM, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00040; World Medical Association, 2013, DECL HELS ETH PRINC, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]	59	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								2122	10.3389/fimmu.2020.02122	http://dx.doi.org/10.3389/fimmu.2020.02122			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP9BS	32983170	Green Published, gold			2022-12-18	WOS:000570465800001
J	Lagos, L; Bekkelund, AK; Skugor, A; Anestad, R; Akesson, CP; Press, CM; Overland, M				Lagos, Leidy; Bekkelund, Alexander Kashulin; Skugor, Adrijana; Anestad, Ragnhild; Akesson, Caroline P.; Press, Charles McL.; Overland, Margareth			Cyberlindnera jadiniiYeast as a Protein Source for Weaned Piglets-Impact on Immune Response and Gut Microbiota	FRONTIERS IN IMMUNOLOGY			English	Article						post-weaning pig; novel protein; yeast; health; microbiota	NK CELLS; PLASMA-CELLS; YEAST; GROWTH; PIGS; GENES; PERFORMANCE; RESISTANCE; BACTERIA; HEALTH	Supplying novel feed ingredients for pig production is crucial to enhance food security and decrease the environmental impact of meat production. Several studies have focused on evaluating the beneficial health effects of yeast in pigs. However, its use as a protein source has been partially addressed. Previously, we have shown that yeast at high inclusion levels maintains growth performance and digestibility, while nutrient digestibility, intestinal villi height and fecal consistency were improved. The present study combined microbiome, short-chain fatty acid, and immune parameter analysis to investigate the effect of high inclusion of yeast in diets for post-weaning piglets. Our results showed that yeast did not have a significant impact on the hematological or biochemical parameters in blood. The different immune cell subpopulations isolated from blood and distal jejunal lymph nodes (DJLN) were analyzed by flow cytometry and showed that yeast diet induced an increased number of the subtype of leukocytes CD45+/CD3-/CD8+, a special type of Natural Killer (NK) cells. Also, a very mild to moderate infiltration of neutrophilic granulocytes and lower IgA level were observed in the colon of yeast fed piglets. The microbiome profiling in different compartments of the gastrointestinal tract of piglets was performed using 16S rRNA metabarcoding. The results showed that 40% replacement of dietary protein had a statistically significant effect on the microbial communities in cecum and colon, while the microbial population in ileum and jejunum were not affected. Analysis of predicted microbial metabolic pathways analysis revealed significant upregulation of short-chain fatty acids, ether lipid metabolisms, secondary bile acids, and several other important biosynthesis pathways in cecum and colon of pigs fed yeast. In conclusion, the results showed that diet containing 40% of yeast protein positively shaped microbial community in the large intestine and increased the number of a specific subpopulation of NK cells in the DJLN. These results showed that yeast modulates the microbiome and decreases the secretion of IgA in the colon of post-weaning pigs.	[Lagos, Leidy; Skugor, Adrijana; Anestad, Ragnhild; Overland, Margareth] Norwegian Univ Life Sci, Fac Biosci, Dept Anim & Aquacultural Sci, As, Norway; [Bekkelund, Alexander Kashulin] Norwegian Univ Life Sci, Dept Food Safety & Infect Biol, Oslo, Norway; [Akesson, Caroline P.; Press, Charles McL.] Norwegian Univ Life Sci, Fac Vet Med, Dept Preclin Sci & Pathol, Oslo, Norway	Norwegian University of Life Sciences; Norwegian University of Life Sciences; Norwegian University of Life Sciences	Lagos, L; Overland, M (corresponding author), Norwegian Univ Life Sci, Fac Biosci, Dept Anim & Aquacultural Sci, As, Norway.	leidy.lagos@nmbu.no; margareth.overland@nmbu.no			Research Council of Norway, Foods of Norway, a Center for Research-based Innovation [237841/030]	Research Council of Norway, Foods of Norway, a Center for Research-based Innovation(Research Council of Norway)	We are grateful for the support from The Research Council of Norway, Foods of Norway, a Center for Research-based Innovation, 237841/030.	Abe T, 2016, EXP ANIM TOKYO, V65, P345, DOI 10.1538/expanim.16-0022; Alizadeh M, 2016, POULTRY SCI, V95, P2266, DOI 10.3382/ps/pew154; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bolyen E, 2019, NAT BIOTECHNOL, V37, P1091, DOI 10.1038/s41587-019-0252-6; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Campbell JM, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049-1891-4-19; Cruz A, 2019, LIVEST SCI, V226, P31, DOI 10.1016/j.livsci.2019.06.003; De Pelsmaeker S, 2018, J LEUKOCYTE BIOL, V103, P129, DOI 10.1002/JLB.4A0417-163RR; Elghandour MMY, 2020, J APPL MICROBIOL, V128, P658, DOI 10.1111/jam.14416; Fang H, 2018, J HAZARD MATER, V357, P53, DOI 10.1016/j.jhazmat.2018.05.066; Fernandes J, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.23; Fouhse JM, 2019, ANIMAL, V13, P1591, DOI 10.1017/S1751731118003361; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gaskins HR, 2002, ANIM BIOTECHNOL, V13, P29, DOI 10.1081/ABIO-120005768; Green JMH, 2019, P NATL ACAD SCI USA, V116, P23202, DOI 10.1073/pnas.1905618116; Greenland S, 2016, EUR J EPIDEMIOL, V31, P337, DOI 10.1007/s10654-016-0149-3; Hakze-van der Honing RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022673; Heo JM, 2013, J ANIM PHYSIOL AN N, V97, P207, DOI 10.1111/j.1439-0396.2012.01284.x; Ipharraguerre IR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32107-9; Johansson S, 2015, ALIMENT PHARM THER, V42, P1111, DOI 10.1111/apt.13389; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kiros TG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23373-8; Koepke JR, 2017, J ANIM SCI, V95, P5030, DOI 10.2527/jas2017.1679; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Lalles JP, 2007, P NUTR SOC, V66, P260, DOI 10.1017/S0029665107005484; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lassen MG, 2010, J IMMUNOL, V184, P2693, DOI 10.4049/jimmunol.0901362; Lemke A, 2016, MUCOSAL IMMUNOL, V9, P83, DOI 10.1038/mi.2015.38; Lin J, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00033; Liu KY, 2013, PEDIATR RES, V74, P402, DOI 10.1038/pr.2013.125; Marques FZ, 2017, CIRCULATION, V135, P964, DOI [10.1161/CIRCULATIONAHA.116.024545, 10.1161/circulationaha.116.024545]; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; McLamb BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059838; Mei HE, 2009, BLOOD, V113, P2461, DOI 10.1182/blood-2008-04-153544; Morton JT, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00162-16; Olsen L, 2015, VET RES, V46, DOI 10.1186/s13567-014-0136-1; Overland M, 2017, J SCI FOOD AGR, V97, P733, DOI 10.1002/jsfa.8007; Quan JP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22692-0; Reichardt N, 2014, ISME J, V8, P1323, DOI 10.1038/ismej.2014.14; Scott KP, 2006, J BACTERIOL, V188, P4340, DOI 10.1128/JB.00137-06; Sedgwick P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4483; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Smith MG, 2010, VET MICROBIOL, V145, P299, DOI 10.1016/j.vetmic.2010.04.004; Stanley D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00187; Upadhaya SD, 2019, J SCI FOOD AGR, V99, P6076, DOI 10.1002/jsfa.9885; Vernocchi P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01144; Weedman SM, 2011, J ANIM SCI, V89, P1908, DOI 10.2527/jas.2009-2539; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1310-0; Yitbarek A, 2012, POULTRY SCI, V91, P1105, DOI 10.3382/ps.2011-02109; Zhaxi YP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61279-6	51	1	1	4	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								1924	10.3389/fimmu.2020.01924	http://dx.doi.org/10.3389/fimmu.2020.01924			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0AN	33013844	gold, Green Published			2022-12-18	WOS:000570531500001
J	Kramer, J; Kromer-Olbrisch, T; Lakomek, HJ; Schellinger, PD; Foell, D; Meuth, SG; Straeten, V				Kraemer, Julia; Kroemer-Olbrisch, Tanja; Lakomek, Heinz-Juergen; Schellinger, Peter D.; Foell, Dirk; Meuth, Sven G.; Straeten, Vera			Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; Adult onset still disease; secondary autoimmunity; alemtuzumab; rituximab; anakinra; case report	CLASSIFICATION; CRITERIA	Background Autoimmune adverse events are the most relevant risks of alemtuzumab therapy. We present a patient with relapsing-remitting multiple sclerosis, who developed adult-onset Still's disease (AOSD) following alemtuzumab treatment. Case Presentation The patient suffered from sore throat, swallowing difficulties, high spiking quotidian fever, generalized skin rash, arthritis, and myalgia 2 months after the second course of alemtuzumab. Laboratory tests revealed elevated acute-phase reactants, anemia, neutrophilic leukocytosis, and thrombocytosis. Serum calprotectin, interleukin-2, and interleukin-6 levels were strongly increased. Autoimmune, rheumatic, neoplastic, infectious, and granulomatous disorders were excluded. The NLRP1 and NLRP3 gene test, which was performed under the presumption of a cryopyrin-associated autoinflammatory syndrome, was negative. Based on the Yamaguchi and Fautrel criteria, and supported by the histological findings from a skin biopsy of the rash, the diagnosis of AOSD was established. Therapy with the anti-IL-1 agent (anakinra) led to a significant improvement of symptoms and blood parameters. However, anakinra had to be converted to rituximab due to generalized drug eruption. Following therapy with rituximab, the patient has fully recovered. Conclusion The current case highlights AOSD as another rare and potentially life-threatening secondary autoinflammatory/autoimmune event following alemtuzumab treatment.	[Kraemer, Julia; Meuth, Sven G.] Univ Hosp Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany; [Kroemer-Olbrisch, Tanja] Ruhr Univ Bochum, Dept Dermatol Venerol Allergol & Phlebol, Johannes Wesling Hosp Minden, Univ Hosp, Minden, Germany; [Lakomek, Heinz-Juergen] Ruhr Univ Bochum, Dept Rheumatol & Phys Med, Johannes Wesling Hosp Minden, Univ Hosp, Minden, Germany; [Schellinger, Peter D.; Straeten, Vera] Ruhr Univ Bochum, Dept Neurol & Neurogeriatr, Johannes Wesling Hosp Minden, Univ Hosp, Minden, Germany; [Foell, Dirk] Univ Hosp Munster, Dept Pediat Rheumatol & Immunol, Munster, Germany	University of Munster; Ruhr University Bochum; Ruhr University Bochum; Ruhr University Bochum; University of Munster	Kramer, J (corresponding author), Univ Hosp Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany.	julia.kraemer@ukmuenster.de	Meuth, Sven G/HHM-8941-2022	Meuth, Sven G/0000-0003-2571-3501				[Anonymous], 2020, Neurol Neuroimmunol Neuroinflamm, V7, DOI 10.1212/NXI.0000000000000657; Barclay K, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00253; Behera Sapan Kumar, 2018, Hosp Pract (1995), V46, P152, DOI 10.1080/21548331.2018.1451205; Cho YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061243; Coles AJ, 2017, NEUROLOGY, V89, P1117, DOI 10.1212/WNL.0000000000004354; EMA, 2019, MEAS MIN RISK SER SI; Giacomelli R, 2018, J AUTOIMMUN, V93, P24, DOI 10.1016/j.jaut.2018.07.018; Guo Q, 2016, CLIN RHEUMATOL, V35, P73, DOI 10.1007/s10067-015-3108-6; Jung JY, 2019, EXPERT REV MOL DIAGN, V19, P459, DOI 10.1080/14737159.2019.1615449; Kaegi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01990; Kearsley-Fleet L, 2019, RHEUMATOLOGY, V58, P331, DOI 10.1093/rheumatology/key306; Killestein J, 2019, MULT SCLER J, V25, P1206, DOI 10.1177/1352458519851219; Li S, 2020, CLIN REV ALLERG IMMU, V58, P71, DOI 10.1007/s12016-019-08747-8; Mori Francesca, 2019, Acta Biomed, V90, P66, DOI 10.23750/abm.v90i3-S.8167; Pfeuffer S, 2018, MULT SCLER J, V24, P1783, DOI 10.1177/1352458518804124; Pichler WJ, 2011, FORUM MED SUISSE, V11, P879; Saarela M, 2018, NEUROLOGY, V90, P849, DOI 10.1212/WNL.0000000000005420; Shiohara T, 2019, ALLERGOL INT, V68, P301, DOI 10.1016/j.alit.2019.03.006; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424	19	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								2099	10.3389/fimmu.2020.02099	http://dx.doi.org/10.3389/fimmu.2020.02099			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0AM	33013884	Green Published, gold			2022-12-18	WOS:000570531400001
J	Punga, AR; Kusner, L; Berrih-Aknin, S; Le Panse, R				Punga, Anna Rostedt; Kusner, Linda; Berrih-Aknin, Sonia; Le Panse, Rozen			Editorial: Advances in Autoimmune Myasthenia Gravis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoantibodies; CD4 T cells; thymus; therapy; miRNA	THYMUS; CELLS; ROLES		[Punga, Anna Rostedt] Uppsala Univ, Dept Neurosci, Clin Neurophysiol, Uppsala, Sweden; [Kusner, Linda] George Washington Univ, Dept Physiol & Pharmacol, Washington, DC USA; [Berrih-Aknin, Sonia; Le Panse, Rozen] Sorbonne Univ, Ctr Res Myol, Assoc Inst Myol, INSERM, Paris, France	Uppsala University; George Washington University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Le Panse, R (corresponding author), Sorbonne Univ, Ctr Res Myol, Assoc Inst Myol, INSERM, Paris, France.	rozen.lepanse@upmc.fr						Cron MA, 2018, ANN NY ACAD SCI, V1412, P137, DOI 10.1111/nyas.13519; Dragin N, 2016, J CLIN INVEST, V126, P1525, DOI 10.1172/JCI81894; Giraud M, 2008, ANN NY ACAD SCI, V1132, P180, DOI 10.1196/annals.1405.027; Gradolatto A, 2014, J AUTOIMMUN, V52, P53, DOI 10.1016/j.jaut.2013.12.015; Li YK, 2020, J NEUROIMMUNOL, V345, DOI 10.1016/j.jneuroim.2020.577279; Mantegazza R, 2018, CURR OPIN NEUROL, V31, P517, DOI 10.1097/WCO.0000000000000596; Marx A, 2013, AUTOIMMUN REV, V12, P875, DOI 10.1016/j.autrev.2013.03.007; Sengupta M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205464; Wang SH, 2018, EXPERT REV NEUROTHER, V18, P573, DOI 10.1080/14737175.2018.1491310; Weiner HL, 1999, J CLIN INVEST, V104, P1667, DOI 10.1172/JCI8775; Wolfe GI, 2019, LANCET NEUROL, V18, P259, DOI 10.1016/S1474-4422(18)30392-2; Yilmaz V, 2018, ANN CLIN TRANSL NEUR, V5, P1408, DOI 10.1002/acn3.645	12	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								1688	10.3389/fimmu.2020.01688	http://dx.doi.org/10.3389/fimmu.2020.01688			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP9XG	32983085	gold, Green Published			2022-12-18	WOS:000570522800001
J	Mondino, A; Manzo, T				Mondino, Anna; Manzo, Teresa			To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors	FRONTIERS IN IMMUNOLOGY			English	Review						T cell; memory; adoptive T cell immunotherapy of cancer; competition; tumor immunity	CHIMERIC ANTIGEN RECEPTORS; HEMATOPOIETIC STEM-CELLS; RESIDENT MEMORY; INFILTRATING LYMPHOCYTES; VIRAL PERSISTENCE; DENDRITIC CELLS; NAIVE CD4(+); B-CELL; CD8(+); TISSUE	The generation of immunological memory is a hallmark of adaptive immunity by which the immune system "remembers" a previous encounter with an antigen expressed by pathogens, tumors, or normal tissues; and, upon secondary encounters, mounts faster and more effective recall responses. The establishment of T cell memory is influenced by both cell-intrinsic and cell-extrinsic factors, including genetic, epigenetic and environmental triggers. Our current knowledge of the mechanisms involved in memory T cell differentiation has instructed new opportunities to engineer T cells with enhanced anti-tumor activity. The development of adoptive T cell therapy has emerged as a powerful approach to cure a subset of patients with advanced cancers. Efficacy of this approach often requires long-term persistence of transferred T cell products, which can vary according to their origin and manufacturing conditions. Host preconditioning and post-transfer supporting strategies have shown to promote their engraftment and survival by limiting the competition with a hostile tumor microenvironment and between pre-existing immune cell subsets. Although in the general view pre-existing memory can confer a selective advantage to adoptive T cell therapy, here we propose that also "bad memories"-in the form of antigen-experienced T cell subsets-co-evolve with consequences on newly transferred lymphocytes. In this review, we will first provide an overview of selected features of memory T cell subsets and, then, discuss their putative implications for adoptive T cell therapy.	[Mondino, Anna] IRCCS San Raffaele Sci Inst, Div Immunol Transplantat & Infect Dis, Milan, Italy; [Manzo, Teresa] IRCCS European Inst Oncol, Dept Expt Oncol, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS European Institute of Oncology (IEO)	Mondino, A (corresponding author), IRCCS San Raffaele Sci Inst, Div Immunol Transplantat & Infect Dis, Milan, Italy.	mondino.anna@hsr.it	mondino, anna/K-9434-2016	mondino, anna/0000-0003-0833-6927; Manzo, Teresa/0000-0001-8552-3625	Associazione Italiana per la Ricerca sul Cancroo (AIRC) [IG 2014-15883, IG 2018-21763, 2018-21474]; TRANSCAN [TRS-2016-00000373]	Associazione Italiana per la Ricerca sul Cancroo (AIRC)(Fondazione AIRC per la ricerca sul cancro); TRANSCAN	AM acknowledges the support of Associazione Italiana per la Ricerca sul Cancro (AIRC: IG 2014-15883 and IG 2018-21763) and of TRANSCAN (TRS-2016-00000373). TM is the recipient of a Start Up Grant from Associazione Italiana per la Ricerca sul Cancro (AIRC StartUp 2018-21474).	Ajina A, 2018, MOL CANCER THER, V17, P1795, DOI 10.1158/1535-7163.MCT-17-1097; Amsen D, 2018, NAT IMMUNOL, V19, P538, DOI 10.1038/s41590-018-0114-2; Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Badovinac VP, 2007, IMMUNITY, V26, P827, DOI 10.1016/j.immuni.2007.04.013; Bar JJ, 2008, IMMUNITY, V28, P859, DOI 10.1016/j.immuni.2008.04.010; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bauer CA, 2014, J CLIN INVEST, V124, P2425, DOI 10.1172/JCI66375; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Berger C, 2009, BLOOD, V114, P2417, DOI 10.1182/blood-2008-12-189266; Bergsbaken T, 2015, NAT IMMUNOL, V16, P406, DOI 10.1038/ni.3108; Blair DA, 2007, P NATL ACAD SCI USA, V104, P15045, DOI 10.1073/pnas.0703767104; Blanc C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01722; Boddupalli CS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88955; Boutet M, 2016, CANCER RES, V76, P1757, DOI 10.1158/0008-5472.CAN-15-1545; Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; Bridgeman JS, 2014, CLIN EXP IMMUNOL, V175, P258, DOI 10.1111/cei.12216; Bromley SK, 2013, J IMMUNOL, V190, P970, DOI 10.4049/jimmunol.1202805; Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001; Carrio R, 2007, EUR J IMMUNOL, V37, P3078, DOI 10.1002/eji.200737585; Casey KA, 2012, J IMMUNOL, V188, P4866, DOI 10.4049/jimmunol.1200402; Chacon JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060031; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chang JT, 2014, NAT IMMUNOL, V15, P1104, DOI 10.1038/ni.3031; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chmielewski M, 2011, CANCER RES, V71, P5697, DOI 10.1158/0008-5472.CAN-11-0103; Choi YS, 2013, J IMMUNOL, V190, P4014, DOI 10.4049/jimmunol.1202963; Chou J, 2012, J IMMUNOTHER, V35, P131, DOI 10.1097/CJI.0b013e31824300c7; Cieri N, 2013, BLOOD, V121, P573, DOI 10.1182/blood-2012-05-431718; Crittenden MR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25482-w; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; Crompton JG, 2014, IMMUNOL REV, V257, P264, DOI 10.1111/imr.12135; Cui WG, 2010, IMMUNOL REV, V236, P151, DOI 10.1111/j.1600-065X.2010.00926.x; Curtsinger JM, 1999, J IMMUNOL, V162, P3256; Czechowicz A, 2011, HEMATOL ONCOL CLIN N, V25, P75, DOI 10.1016/j.hoc.2010.11.006; d'Onofrio A, 2005, PHYSICA D, V208, P220, DOI 10.1016/j.physd.2005.06.032; D'Souza A, 2017, BIOL BLOOD MARROW TR, V23, P1417, DOI 10.1016/j.bbmt.2017.05.035; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Demirer T, 2008, NAT CLIN PRACT ONCOL, V5, P256, DOI 10.1038/ncponc1104; Dickinson AM, 2002, NAT MED, V8, P410, DOI 10.1038/nm0402-410; Ding ZC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12488-z; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dwyer CJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00263; Edwards J, 2018, CLIN CANCER RES, V24, P3036, DOI 10.1158/1078-0432.CCR-17-2257; Elia AR, 2018, CLIN CANCER RES, V24, P2171, DOI 10.1158/1078-0432.CCR-17-2210; Erkes DA, 2017, J IMMUNOL, V198, P2979, DOI 10.4049/jimmunol.1601064; Friedman KM, 2012, J IMMUNOTHER, V35, P400, DOI 10.1097/CJI.0b013e31825898c5; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018; Haluszczak C, 2009, J EXP MED, V206, P435, DOI 10.1084/jem.20081829; Hammerl D, 2018, TRENDS IMMUNOL, V39, P921, DOI 10.1016/j.it.2018.09.004; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Harty JT, 2008, NAT REV IMMUNOL, V8, P107, DOI 10.1038/nri2251; Hataye J, 2006, SCIENCE, V312, P114, DOI 10.1126/science.1124228; Henrickson SE, 2013, IMMUNITY, V39, P496, DOI 10.1016/j.immuni.2013.08.034; Hinrichs CS, 2008, BLOOD, V111, P5326, DOI 10.1182/blood-2007-09-113050; Hirayama AV, 2019, BLOOD, V133, P1876, DOI 10.1182/blood-2018-11-887067; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hope JL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01595; Hosios AM, 2016, DEV CELL, V36, P540, DOI 10.1016/j.devcel.2016.02.012; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Jameson SC, 2015, ADV IMMUNOL, V126, P173, DOI 10.1016/bs.ai.2014.12.001; Jenq RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035222; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Karrer U, 2003, J IMMUNOL, V170, P2022, DOI 10.4049/jimmunol.170.4.2022; Kavazovic I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02831; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Kedl RM, 2000, J EXP MED, V192, P1105, DOI 10.1084/jem.192.8.1105; Khazen R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48711-2; Kim C, 2013, IMMUNITY, V39, P508, DOI 10.1016/j.immuni.2013.08.033; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; Kishton RJ, 2017, CELL METAB, V26, P94, DOI 10.1016/j.cmet.2017.06.016; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Klebanoff CA, 2012, J IMMUNOTHER, V35, P651, DOI 10.1097/CJI.0b013e31827806e6; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Kuhn NF, 2019, CANCER CELL, V35, P473, DOI 10.1016/j.ccell.2019.02.006; Kunert A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1378842; Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Leitao C, 2009, J IMMUNOL, V182, P5232, DOI 10.4049/jimmunol.0804071; Li YQ, 2005, J IMMUNOL, V175, P2261, DOI 10.4049/jimmunol.175.4.2261; Liu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02689-5; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Lugli E, 2013, NAT PROTOC, V8, P33, DOI 10.1038/nprot.2012.143; Ma L, 2019, SCIENCE, V365, P162, DOI 10.1126/science.aav8692; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Malandro N, 2016, IMMUNITY, V44, P179, DOI 10.1016/j.immuni.2015.12.018; Malherbe L, 2004, IMMUNITY, V21, P669, DOI 10.1016/j.immuni.2004.09.008; Mami-Chouaib F, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0399-6; Manzo T, 2020, J EXP MED, V217, DOI 10.1084/jem.20191920; Manzo T, 2017, CANCER RES, V77, P658, DOI 10.1158/0008-5472.CAN-16-0725; Martin MD, 2019, J CLIN INVEST, V129, P3894, DOI 10.1172/JCI124443; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Marusina AI, 2017, J AUTOIMMUN, V77, P76, DOI 10.1016/j.jaut.2016.11.001; Marzo AL, 2005, NAT IMMUNOL, V6, P793, DOI 10.1038/ni1227; Masopust D, 2014, J IMMUNOL, V192, P2413, DOI 10.1126/science.1058867; Masopust D, 2010, J EXP MED, V207, P553, DOI 10.1084/jem.20090858; Maurice NJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12980-2; McKinney EF, 2015, NATURE, V523, P612, DOI 10.1038/nature14468; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Mehlhop-Williams ER, 2014, J EXP MED, V211, P345, DOI 10.1084/jem.20131271; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Menares E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12319-x; Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x; Michelini RH, 2013, CANCER RES, V73, P4641, DOI 10.1158/0008-5472.CAN-12-3464; Michelini RH, 2010, CANCER RES, V70, P3505, DOI 10.1158/0008-5472.CAN-09-4253; Miller CH, 2020, NAT IMMUNOL, V21, P567, DOI 10.1038/s41590-020-0653-1; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Morabito KM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01861; Nelson CE, 2019, CELL REP, V28, P3092, DOI 10.1016/j.celrep.2019.08.038; Nguyen QP, 2019, IMMUNOLOGY, V157, P3, DOI 10.1111/imm.13059; O'Sullivan D, 2014, IMMUNITY, V41, P75, DOI 10.1016/j.immuni.2014.06.005; Obst R, 2005, J EXP MED, V201, P1555, DOI 10.1084/jem.20042521; Ohue Y, 2019, CANCER SCI, V110, P2080, DOI 10.1111/cas.14069; Oja AE, 2018, MUCOSAL IMMUNOL, V11, P654, DOI 10.1038/mi.2017.94; Oja AE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02654; Omilusik KD, 2019, CURR OPIN IMMUNOL, V58, P89, DOI 10.1016/j.coi.2019.04.009; Osborne LC, 2010, CYTOKINE, V50, P105, DOI 10.1016/j.cyto.2009.09.008; Pan YD, 2017, NATURE, V543, P252, DOI 10.1038/nature21379; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pepper M, 2011, IMMUNITY, V35, P583, DOI 10.1016/j.immuni.2011.09.009; Pepper M, 2011, NAT IMMUNOL, V12, P467, DOI 10.1038/ni.2038; Pepper M, 2010, NAT IMMUNOL, V11, P83, DOI 10.1038/ni.1826; Pilipow K, 2015, CANCER RES, V75, P5187, DOI 10.1158/0008-5472.CAN-15-1498; Poschke IC, 2020, CLIN CANCER RES, V26, P4289, DOI 10.1158/1078-0432.CCR-19-3845; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Quiel J, 2011, P NATL ACAD SCI USA, V108, P3312, DOI 10.1073/pnas.1018525108; Reading JL, 2018, IMMUNOL REV, V283, P194, DOI 10.1111/imr.12657; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Richer MJ, 2013, IMMUNITY, V38, P140, DOI 10.1016/j.immuni.2012.09.017; Rizzuto GA, 2009, J EXP MED, V206, P849, DOI 10.1084/jem.20081382; Rosato PC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08534-1; Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Schietinger A, 2014, TRENDS IMMUNOL, V35, P51, DOI 10.1016/j.it.2013.10.001; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Schober K, 2020, NAT IMMUNOL, V21, P434, DOI 10.1038/s41590-020-0628-2; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Sierro S, 2005, EUR J IMMUNOL, V35, P1113, DOI 10.1002/eji.200425534; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Singh NJ, 2012, IMMUNITY, V37, P735, DOI 10.1016/j.immuni.2012.08.008; Smazynski J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01741; Smith C, 2019, J CLIN INVEST, V129, P5020, DOI 10.1172/JCI128323; Smith LK, 2018, IMMUNITY, V48, P299, DOI 10.1016/j.immuni.2018.01.006; Snyder CM, 2008, IMMUNITY, V29, P650, DOI 10.1016/j.immuni.2008.07.017; Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Taube JM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.963413; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Terakura S, 2012, BLOOD, V119, P72, DOI 10.1182/blood-2011-07-366419; Topham DJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00515; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Turula H, 2013, EUR J IMMUNOL, V43, P1252, DOI 10.1002/eji.201242940; Urak R, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0227-4; van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568-019-0235-4; van der Windt GJW, 2013, P NATL ACAD SCI USA, V110, P14336, DOI 10.1073/pnas.1221740110; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; van Leeuwen EMM, 2009, CURR OPIN IMMUNOL, V21, P167, DOI 10.1016/j.coi.2009.02.005; Walsh SR, 2019, J CLIN INVEST, V129, P5400, DOI 10.1172/JCI126199; Wang XL, 2012, J IMMUNOTHER, V35, P689, DOI 10.1097/CJI.0b013e318270dec7; Webb JR, 2015, CANCER IMMUNOL RES, V3, P926, DOI 10.1158/2326-6066.CIR-14-0239; Webb JR, 2014, CLIN CANCER RES, V20, P434, DOI 10.1158/1078-0432.CCR-13-1877; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; White JT, 2017, NAT REV IMMUNOL, V17, P391, DOI 10.1038/nri.2017.34; White JT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11291; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Witherden D, 2000, J EXP MED, V191, P355, DOI 10.1084/jem.191.2.355; Wrzesinski C, 2005, CURR OPIN IMMUNOL, V17, P195, DOI 10.1016/j.coi.2005.02.002; Wrzesinski C, 2007, J CLIN INVEST, V117, P492, DOI 10.1172/JCI30414; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Xu AZ, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0098-2; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; Yang JP, 2006, P NATL ACAD SCI USA, V103, P147, DOI 10.1073/pnas.0509054103; Ye B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.42; Ye J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.994398; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhou JX, 2019, PROTEIN CELL, V10, P764, DOI 10.1007/s13238-019-0643-y; Zimmermann VS, 2007, J IMMUNOL, V179, P2899, DOI 10.4049/jimmunol.179.5.2899	194	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2020	11								1915	10.3389/fimmu.2020.01915	http://dx.doi.org/10.3389/fimmu.2020.01915			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP8DA	32973794	gold, Green Published			2022-12-18	WOS:000570400300001
J	Oyoshi, M; Chinthrajah, RS				Oyoshi, Michiko; Chinthrajah, R. Sharon			Editorial: Insights Into the Etiology, Prevention, and Treatment of Food Allergy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						food allergy; immunology; allergic diseases; immunotherapy; food hypersensitivity			[Oyoshi, Michiko] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA; [Chinthrajah, R. Sharon] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Stanford University	Chinthrajah, RS (corresponding author), Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA.	schinths@stanford.edu			NIAID NIH HHS [R01 AI142872] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))			0	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2020	11								1937	10.3389/fimmu.2020.01937	http://dx.doi.org/10.3389/fimmu.2020.01937			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM5VB	32973797	gold, Green Published			2022-12-18	WOS:000568163500001
J	Lehmann, N; Paret, C; El Malki, K; Russo, A; Neu, MA; Wingerter, A; Seidmann, L; Foersch, S; Ziegler, N; Roth, L; Backes, N; Sandhoff, R; Faber, J				Lehmann, Nadine; Paret, Claudia; El Malki, Khalifa; Russo, Alexandra; Neu, Marie Astrid; Wingerter, Arthur; Seidmann, Larissa; Foersch, Sebastian; Ziegler, Nicole; Roth, Lea; Backes, Nora; Sandhoff, Roger; Faber, Joerg			Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						pediatric papillary renal cell carcinoma; TILs; unconventional T cells; CD1d; lipid antigens	NKT CELLS; CD1D; RECOGNITION; LYMPHOCYTES; MICROENVIRONMENT; IDENTIFICATION; IMMUNOTHERAPY; INVOLVEMENT; ANTITUMOR; CHILDREN	Papillary renal cell carcinoma (PRCC) is a rare entity in children with no established therapy protocols for advanced diseases. Immunotherapy is emerging as an important therapeutic tool for childhood cancer. Tumor cells can be recognized and killed by conventional and unconventional T cells. Unconventional T cells are able to recognize lipid antigens presented via CD1 molecules independently from major histocompatibility complex, which offers new alternatives for cancer immunotherapies. The nature of those lipids is largely unknown and alpha-galactosylceramide is currently used as a synthetic model antigen. In this work, we analyzed infiltrating lymphocytes of two pediatric PRCCs using flow cytometry, immunohistochemistry and qRT-PCR. Moreover, we analyzed the CD1d expression within both tumors. Tumor lipids of PRCC samples and three normal kidney samples were fractionated and the recognition of tumor own lipid fractions by unconventional T cells was analyzed in anin vitroassay. We identified infiltrating lymphocytes including gamma delta T cells and iNKT cells, as well as CD1d expression in both samples. One lipid fraction, containing ceramides and monoacylglycerides amongst others, was able to induce the proliferation of iNKT cells isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors and of one matched PRCC patient. Furthermore, CD1d tetramer stainings revealed that a subset of iNKT cells is able to bind lipids being present in fraction 2 via CD1d. We conclude that PRCCs are infiltrated by conventional and unconventional T cells and express CD1d. Moreover, certain lipids, present in pediatric PRCC, are able to stimulate unconventional T cells. Manipulating these lipids and T cells may open new strategies for therapy of pediatric PRCCs.	[Lehmann, Nadine; Paret, Claudia; El Malki, Khalifa; Russo, Alexandra; Neu, Marie Astrid; Wingerter, Arthur; Ziegler, Nicole; Roth, Lea; Backes, Nora; Faber, Joerg] Johannes Gutenberg Univ Mainz, Dept Pediat Hematol Oncol, Ctr Pediat & Adolescent Med, Univ Med Ctr, Mainz, Germany; [Lehmann, Nadine; Paret, Claudia; El Malki, Khalifa; Russo, Alexandra; Neu, Marie Astrid; Wingerter, Arthur; Ziegler, Nicole; Roth, Lea; Backes, Nora; Faber, Joerg] Johannes Gutenberg Univ Mainz, Univ Canc Ctr UCT, Univ Med Ctr, Mainz, Germany; [Seidmann, Larissa; Foersch, Sebastian] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Pathol, Mainz, Germany; [Sandhoff, Roger] German Canc Res Ctr, Lipid Pathobiochem, Heidelberg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ)	Faber, J (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pediat Hematol Oncol, Ctr Pediat & Adolescent Med, Univ Med Ctr, Mainz, Germany.; Faber, J (corresponding author), Johannes Gutenberg Univ Mainz, Univ Canc Ctr UCT, Univ Med Ctr, Mainz, Germany.	faber@uni-mainz.de	Paret, Claudia/T-2913-2019	Paret, Claudia/0000-0002-9094-1634; Neu, Marie A./0000-0002-8564-7115				Adams EJ, 2015, CELL IMMUNOL, V296, P31, DOI 10.1016/j.cellimm.2015.04.008; Annbalavanan M, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27766; Badalamenti G, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2018.01.013; Bae EA, 2019, ARCH PHARM RES, V42, P543, DOI 10.1007/s12272-019-01139-8; Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; Bayerle A, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158741; Brown LCW, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001610; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chang DH, 2005, J EXP MED, V201, P1503, DOI 10.1084/jem.20042592; Chong TW, 2015, J CLIN PATHOL, V68, P200, DOI 10.1136/jclinpath-2014-202735; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; De Libero G, 2005, NAT REV IMMUNOL, V5, P485, DOI 10.1038/nri1631; De Libero G, 2006, FEBS LETT, V580, P5580, DOI 10.1016/j.febslet.2006.08.029; De Libero G, 2009, EUR J IMMUNOL, V39, P2648, DOI 10.1002/eji.200939425; Fritzsching B, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.990800; Garcia-Garijo A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01392; Geissler K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985082; Geller JI, 2004, CANCER-AM CANCER SOC, V101, P1575, DOI 10.1002/cncr.20548; Giraldo NA, 2015, CLIN CANCER RES, V21, P3031, DOI 10.1158/1078-0432.CCR-14-2926; Girardi E, 2012, IMMUNOL REV, V250, P167, DOI 10.1111/j.1600-065X.2012.01166.x; Girardi E, 2012, NAT IMMUNOL, V13, P851, DOI 10.1038/ni.2371; Godfrey DI, 2018, IMMUNITY, V48, P453, DOI 10.1016/j.immuni.2018.03.009; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Hishiki T, 2018, PEDIATR SURG INT, V34, P195, DOI 10.1007/s00383-017-4189-x; Hix LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020702; Indolfi P, 2003, J CLIN ONCOL, V21, P530, DOI 10.1200/JCO.2003.02.072; Jennemann R, 2007, J BIOL CHEM, V282, P3083, DOI 10.1074/jbc.M610304200; Kain L, 2014, IMMUNITY, V41, P543, DOI 10.1016/j.immuni.2014.08.017; Kosub DA, 2008, J VIROL, V82, P1155, DOI 10.1128/JVI.01275-07; Kowalczyk D, 1996, IMMUNOL LETT, V53, P15, DOI 10.1016/0165-2478(96)02605-3; Lanitis E, 2017, ANN ONCOL, V28, P18, DOI 10.1093/annonc/mdx238; Legrand F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005926; Lepore M, 2014, J EXP MED, V211, P1360, DOI 10.1084/jem.20140410; Liu DF, 2013, CLIN IMMUNOL, V149, P55, DOI 10.1016/j.clim.2013.06.005; Lo Presti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01395; Machado I, 2018, VIRCHOWS ARCH, V472, P815, DOI 10.1007/s00428-018-2316-2; Mangan BA, 2013, J IMMUNOL, V191, P30, DOI 10.4049/jimmunol.1300121; Maturu P, 2014, TRANSL ONCOL, V7, P484, DOI 10.1016/j.tranon.2014.05.008; McCarthy C, 2007, J EXP MED, V204, P1131, DOI 10.1084/jem.20062342; Metelitsa LS, 2004, J EXP MED, V199, P1213, DOI 10.1084/jem.20031462; Mina M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1019981; Mochizuki K, 2019, PEDIATR HEMAT ONCOL, V36, P17, DOI 10.1080/08880018.2019.1578843; Nair S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01178; Nakano O, 2001, CANCER RES, V61, P5132; NATORI T, 1994, TETRAHEDRON, V50, P2771, DOI 10.1016/S0040-4020(01)86991-X; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Paget C, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000169; Parekh VV, 2004, J IMMUNOL, V173, P3693, DOI 10.4049/jimmunol.173.6.3693; Patel O, 2012, NAT IMMUNOL, V13, P857, DOI 10.1038/ni.2372; Perlman Elizabeth J, 2010, Surg Pathol Clin, V3, P641; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; Rao Q, 2011, INT J SURG PATHOL, V19, P170, DOI 10.1177/1066896909354337; Remark R, 2013, CLIN CANCER RES, V19, P4079, DOI 10.1158/1078-0432.CCR-12-3847; Saroha A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01386; Selle B, 2006, CANCER-AM CANCER SOC, V107, P2906, DOI 10.1002/cncr.22346; Uldrich AP, 2013, NAT IMMUNOL, V14, P1137, DOI 10.1038/ni.2713; Vermeulen JF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1398877; von Gerichten J, 2019, J LIPID RES, V60, P1892, DOI 10.1194/jlr.RA119000236; Wu D, 2017, CELL MOL IMMUNOL, V14, P245, DOI 10.1038/cmi.2016.55; Yamashita K, 2018, ANTICANCER RES, V38, P4233, DOI 10.21873/anticanres.12719; Zhao YJ, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-017-1378-2	62	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2020	11								1819	10.3389/fimmu.2020.01819	http://dx.doi.org/10.3389/fimmu.2020.01819			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM1WT	32973759	Green Published, gold			2022-12-18	WOS:000567895200001
J	Majdoubi, A; Lee, JS; Kishta, OA; Balood, M; Moulefera, MA; Ishido, S; Talbot, S; Cheong, C; Alquier, T; Thibodeau, J				Majdoubi, Abdelilah; Lee, Jun Seong; Kishta, Osama A.; Balood, Mohammad; Moulefera, Mohamed Abdelwafi; Ishido, Satoshi; Talbot, Sebastien; Cheong, Cheolho; Alquier, Thierry; Thibodeau, Jacques			Lack of the E3 Ubiquitin Ligase March1 Affects CD8 T Cell Fate and Exacerbates Insulin Resistance in Obese Mice	FRONTIERS IN IMMUNOLOGY			English	Article						March1; obesity; T cell metabolism; memory CD8 T cell	ADIPOSE-TISSUE INFLAMMATION; MHC II UBIQUITINATION; TYROSINE PHOSPHORYLATION; MEMORY; MACROPHAGES; ACTIVATION; RECEPTOR; DIFFERENTIATION; MAINTENANCE; METABOLISM	Obesity is a major risk factor for the development of insulin resistance and type 2 diabetes. However, the mechanisms that trigger the underlying adipose tissues inflammation are not completely understood. Here, we show that the E3 ubiquitin ligase March1 controls the phenotypic and functional properties of CD8(+)T cells in mice white adipose tissue. In a diet-induced obesity model, mice lacking March1 [March1 knockout (KO)] show increased insulin resistance compared to their WT counterparts. Also, in obese March1 KO mice, the proportions of effector/memory (Tem) and resident/memory (Trm) CD8(+)T cells were higher in the visceral adipose tissue, but not in the spleen. The effect of March1 on insulin resistance and on the phenotype of adipose tissue CD8(+)T cells was independent of major histocompatibility complex class II ubiquitination. Interestingly, we adoptively transferred either WT or March1 KO splenic CD8(+)T cells into obese WT chimeras that had been reconstituted with Rag1-deficient bone marrow. We observed an enrichment of Tem and Trm cells and exacerbated insulin resistance in mice that received March1 KO CD8 T cells. Mechanistically, we found that March1 deficiency alters the metabolic activity of CD8(+)T cells. Our results provide additional evidence of the involvement of CD8(+)T cells in adipose tissue inflammation and suggest that March1 controls the metabolic reprogramming of these cells.	[Majdoubi, Abdelilah; Lee, Jun Seong; Kishta, Osama A.; Moulefera, Mohamed Abdelwafi; Thibodeau, Jacques] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Balood, Mohammad; Talbot, Sebastien] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada; [Ishido, Satoshi] Hyogo Coll Med, Dept Microbiol, Nishinomiya, Hyogo, Japan; [Cheong, Cheolho] Inst Rech Clin Montreal IRCM, Montreal, PQ, Canada; [Alquier, Thierry] Univ Montreal, Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Montreal Diabet Res Ctr, Montreal, PQ, Canada; [Alquier, Thierry] Univ Montreal, Dept Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Hyogo College of Medicine; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Thibodeau, J (corresponding author), Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada.	Jacques.thibodeau@umontreal.ca	Kishta, Osama/HGA-8810-2022	balood, mohammad/0000-0001-5647-7826; Majdoubi, Abdelilah/0000-0002-2053-4793	Canadian Foundation for innovation (John R. Evans Leaders Fund); Canadian Institute for Health Research (CIHR) [MOP1368802]; Fonds de la recherche en sante du Quebec (FRQS); Saputo research Chair	Canadian Foundation for innovation (John R. Evans Leaders Fund); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de la recherche en sante du Quebec (FRQS)(Fonds de la Recherche en Sante du Quebec); Saputo research Chair	This work was supported by grants from the Canadian Foundation for innovation (John R. Evans Leaders Fund to JT) and the Canadian Institute for Health Research (CIHR; MOP1368802 to JT). TA was supported by a salary award from the Fonds de la recherche en sante du Quebec (FRQS). JT holds the Saputo research Chair.	Ablack JNG, 2015, J CELL SCI, V128, P4273, DOI 10.1242/jcs.178129; Bantug GR, 2018, NAT REV IMMUNOL, V18, P19, DOI 10.1038/nri.2017.99; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Bhagwandin C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204898; Buchholz VR, 2016, ANNU REV IMMUNOL, V34, P65, DOI 10.1146/annurev-immunol-032414-112014; Cham CM, 2008, EUR J IMMUNOL, V38, P2438, DOI 10.1002/eji.200838289; Cham CM, 2005, J IMMUNOL, V174, P4670, DOI 10.4049/jimmunol.174.8.4670; Chen XL, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100977; Cho KW, 2014, CELL REP, V9, P605, DOI 10.1016/j.celrep.2014.09.004; Cho KJ, 2015, P NATL ACAD SCI USA, V112, P10449, DOI 10.1073/pnas.1507981112; Deng T, 2013, CELL METAB, V17, P411, DOI 10.1016/j.cmet.2013.02.009; Engin AB, 2017, ADV EXP MED BIOL, V960, pV, DOI 10.1007/978-3-319-48382-5_1; Eyster CA, 2011, MOL BIOL CELL, V22, P3218, DOI 10.1091/mbc.E10-11-0874; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Fujita H, 2013, J CELL SCI, V126, P2798, DOI 10.1242/jcs.119909; Gubser PM, 2013, NAT IMMUNOL, V14, P1064, DOI 10.1038/ni.2687; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Han SJ, 2017, IMMUNITY, V47, P1154, DOI 10.1016/j.immuni.2017.11.009; Ikeda K, 2017, CELL REP, V21, P1824, DOI 10.1016/j.celrep.2017.10.082; Ishikawa R, 2014, INT IMMUNOL, V26, P283, DOI 10.1093/intimm/dxt066; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kucharska AM, 2015, ADV EXP MED BIOL, V866, P35, DOI 10.1007/5584_2015_147; Lee BC, 2014, BBA-MOL BASIS DIS, V1842, P446, DOI 10.1016/j.bbadis.2013.05.017; Lee JS, 2018, J IMMUNOL, V201, P1784, DOI 10.4049/jimmunol.1800322; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Matsuki Y, 2007, EMBO J, V26, P846, DOI 10.1038/sj.emboj.7601556; Misumi I, 2019, CELL REP, V27, P514, DOI 10.1016/j.celrep.2019.03.030; Mittal SK, 2015, J BIOL CHEM, V290, P27158, DOI 10.1074/jbc.M115.682708; Nagarajan A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12639; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; O'Sullivan D, 2019, IMMUNOL CELL BIOL, V97, P636, DOI 10.1111/imcb.12274; O'Sullivan D, 2018, IMMUNITY, V49, P375, DOI 10.1016/j.immuni.2018.07.018; Oh J, 2018, J CELL BIOL, V217, P1395, DOI 10.1083/jcb.201611141; Oh J, 2013, J EXP MED, V210, P1069, DOI 10.1084/jem.20122695; Ohmura-Hoshino M, 2009, J IMMUNOL, V183, P6893, DOI 10.4049/jimmunol.0902178; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Philip M, 2019, CURR OPIN IMMUNOL, V58, P98, DOI 10.1016/j.coi.2019.04.014; Popov Y, 2010, J HEPATOL, V52, P130, DOI 10.1016/j.jhep.2009.10.019; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shaul ME, 2010, DIABETES, V59, P1171, DOI 10.2337/db09-1402; Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589; Tsai S, 2018, CELL METAB, V28, P922, DOI 10.1016/j.cmet.2018.08.003; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; WANG Q, 2018, FRONT IMMUNOL, V0009; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Wu D, 2020, J EXP MED, V217, DOI 10.1084/jem.20191542; Yang HW, 2010, J IMMUNOL, V185, P1836, DOI 10.4049/jimmunol.1000021; Zhang LJ, 2018, TRENDS MOL MED, V24, P30, DOI 10.1016/j.molmed.2017.11.005	52	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 17	2020	11								1953	10.3389/fimmu.2020.01953	http://dx.doi.org/10.3389/fimmu.2020.01953			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM0XC	32973799	Green Published, gold			2022-12-18	WOS:000567827100001
J	Zayed, H				Zayed, Hatem			Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks, Usingin vitroEvolution and Reverse Genetics	FRONTIERS IN IMMUNOLOGY			English	Article						VLP vaccines; COVID-19; pandemic outbreak; SARS-CoV2; integrating vectors; coronaviruses	VIRUS-LIKE PARTICLES		[Zayed, Hatem] Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, Doha, Qatar	Qatar University	Zayed, H (corresponding author), Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, Doha, Qatar.	hatem.zayed@qu.edu.qa		Zayed, Hatem/0000-0001-8838-6638				Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254; Baranyi L, 2013, HUM GENE THER METHOD, V24, P214, DOI 10.1089/hgtb.2013.002; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; de Wispelaere M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004081; Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210; Fontana D, 2016, METHODS MOL BIOL, V1403, P155, DOI 10.1007/978-1-4939-3387-7_7; Ivics Z, 2004, CURR ISSUES MOL BIOL, V6, P43; Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496; Kikuchi Miho, 2002, Methods Mol Biol, V182, P243; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; McBurney SP, 2007, VIROLOGY, V358, P334, DOI 10.1016/j.virol.2006.08.032; Moingeon P, 2003, CURR OPIN MICROBIOL, V6, P462, DOI 10.1016/j.mib.2003.08.002; Muratori C, 2010, METHODS MOL BIOL, V614, P111, DOI 10.1007/978-1-60761-533-0_7; Rigouin C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10758-4; Stobart CC, 2014, VIRUSES-BASEL, V6, P2531, DOI 10.3390/v6072531; Thompson CM, 2016, METHODS MOL BIOL, V1350, P299, DOI 10.1007/978-1-4939-3043-2_14; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xu LL, 2016, VACCINE, V34, P2627, DOI 10.1016/j.vaccine.2016.03.031; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	20	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 14	2020	11								2051	10.3389/fimmu.2020.02051	http://dx.doi.org/10.3389/fimmu.2020.02051			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NJ5MW	32922408	Green Published, gold			2022-12-18	WOS:000566088000001
J	Iannetta, M; Isnard, S; Manuzak, J; Guillerme, JB; Notin, M; Bailly, K; Andrieu, M; Amraoui, S; Vimeux, L; Figueiredo, S; Charmeteau-de Muylder, B; Vaton, L; Hatton, EX; Samri, A; Autran, B; Thiebaut, R; Chaghil, N; Glohi, D; Charpentier, C; Descamps, D; Brun-Vezinet, F; Matheron, S; Cheynier, R; Hosmalin, A				Iannetta, Marco; Isnard, Stephane; Manuzak, Jennifer; Guillerme, Jean-Baptiste; Notin, Mathilde; Bailly, Karine; Andrieu, Muriel; Amraoui, Sonia; Vimeux, Lene; Figueiredo, Suzanne; Charmeteau-de Muylder, Benedicte; Vaton, Laura; Hatton, Etienne X.; Samri, Assia; Autran, Brigitte; Thiebaut, Rodolphe; Chaghil, Nathalie; Glohi, David; Charpentier, Charlotte; Descamps, Diane; Brun-Vezinet, Francoise; Matheron, Sophie; Cheynier, Remi; Hosmalin, Anne		IMMUNOVIR-2 Study Grp ANRS CO5 HIV	Conventional Dendritic Cells and Slan(+)Monocytes During HIV-2 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-2; monocytes; slan(+)monocytes; dendritic cells; cDC1; cDC2; controls	MICROBIAL TRANSLOCATION; SOLUBLE CD14; MACROPHAGE ACTIVATION; IMMUNE ACTIVATION; MONOCYTE SUBSET; 6-SULFO LACNAC; VIRUS TYPE-2; MARKER; PLASMA; NOMENCLATURE	HIV-2 infection is characterized by low viremia and slow disease progression as compared to HIV-1 infection. Circulating CD14(++)CD16(+)monocytes were found to accumulate and CD11c(+)conventional dendritic cells (cDC) to be depleted in a Portuguese cohort of people living with HIV-2 (PLWHIV-2), compared to blood bank healthy donors (HD). We studied more precisely classical monocytes; CD16(+)inflammatory (intermediate, non-classical and slan(+)monocytes, known to accumulate during viremic HIV-1 infection); cDC1, important for cross-presentation, and cDC2, both depleted during HIV-1 infection. We analyzed by flow cytometry these PBMC subsets from Paris area residents: 29 asymptomatic, untreated PLWHIV-2 from the IMMUNOVIR-2 study, part of the ANRS-CO5 HIV-2 cohort: 19 long-term non-progressors (LTNP; infection >= 8 years, undetectable viral load, stable CD4 counts >= 500/mu L; 17 of West-African origin -WA), and 10 non-LTNP (P; progressive infection; 9 WA); and 30 age-and sex-matched controls: 16 blood bank HD with unknown geographical origin, and 10 HD of WA origin (GeoHD). We measured plasma bacterial translocation markers by ELISA. Non-classical monocyte counts were higher in GeoHD than in HD (54 vs. 32 cells/mu L,p= 0.0002). Slan(+)monocyte counts were twice as high in GeoHD than in HD (WA: 28 vs. 13 cells/mu L,p= 0.0002). Thus cell counts were compared only between participants of WA origin. They were similar in LTNP, P and GeoHD, indicating that there were no HIV-2 related differences. cDC counts did not show major differences between the groups. Interestingly, inflammatory monocyte counts correlated with plasma sCD14 and LBP only in PLWHIV-2, especially LTNP, and not in GeoHD. In conclusion, in LTNP PLWHIV-2, inflammatory monocyte counts correlated with LBP or sCD14 plasma levels, indicating a potential innate immune response to subclinical bacterial translocation. As GeoHD had higher inflammatory monocyte counts than HD, our data also show that specific controls are important to refine innate immunity studies.	[Iannetta, Marco; Isnard, Stephane; Manuzak, Jennifer; Guillerme, Jean-Baptiste; Notin, Mathilde; Bailly, Karine; Andrieu, Muriel; Amraoui, Sonia; Vimeux, Lene; Figueiredo, Suzanne; Charmeteau-de Muylder, Benedicte; Vaton, Laura; Hatton, Etienne X.; Cheynier, Remi; Hosmalin, Anne] Univ Paris, Inst Cochin, INSERM, CNRS, Paris, France; [Samri, Assia; Autran, Brigitte] Sorbonne Univ, Ctr Immunol & Malad Infect, Inserm 1135, Cimi Paris, France; [Thiebaut, Rodolphe; Chaghil, Nathalie] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, CHU Bordeaux, INSERM,CIC,UMR 1219 1401, Bordeaux, France; [Glohi, David; Charpentier, Charlotte; Descamps, Diane; Brun-Vezinet, Francoise; Matheron, Sophie] Hop Bichat Claude Bernard, Serv Malad Infect, AP HP, Paris, France; [Matheron, Sophie] Univ Paris, INSERM, UMR 1137, IAME Infect Antimicrobials Modelling Evolut, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Hosmalin, A (corresponding author), Univ Paris, Inst Cochin, INSERM, CNRS, Paris, France.	anne.hosmalin@inserm.fr	Iannetta, Marco/B-5596-2017; Pedroza-Martins, Livia/C-4258-2008; Cheynier, Remi/E-9921-2010	Iannetta, Marco/0000-0002-6938-8627; Cheynier, Remi/0000-0003-1146-660X; Hatton, Etienne/0000-0003-2493-8354; Pedroza-Martins, Livia/0000-0002-5243-9563; Manuzak, Jennifer/0000-0002-0079-2306	ANRS; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale; Universite Paris Diderot, France; French Government's Investissement d'Avenir program, Laboratoires d'Excellence Integrative Biology of Emerging Infectious Diseases [ANR-10-LABX-62-IBEID]	ANRS(ANRSFrench National Research Agency (ANR)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Paris Diderot, France; French Government's Investissement d'Avenir program, Laboratoires d'Excellence Integrative Biology of Emerging Infectious Diseases(French National Research Agency (ANR))	This work was supported by the ANRS, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale, the Universite Paris Diderot, France and the French Government's Investissement d'Avenir program, Laboratoires d'Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX-62-IBEID).	Ancuta P, 2000, EUR J IMMUNOL, V30, P1872, DOI 10.1002/1521-4141(200007)30:7<1872::AID-IMMU1872>3.0.CO;2-2; Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516; Andersen MN, 2018, J INFECT DIS, V218, P1291, DOI 10.1093/infdis/jiy318; Appleby LJ, 2013, IMMUNOL LETT, V152, P32, DOI 10.1016/j.imlet.2013.03.004; Bachem A, 2010, J EXP MED, V207, P1273, DOI 10.1084/jem.20100348; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; BRUNVEZINET F, 1987, LANCET, V1, P128; Burdo TH, 2013, AIDS, V27, P1387, DOI 10.1097/QAD.0b013e32836010bd; Burdo TH, 2011, J INFECT DIS, V204, P1227, DOI 10.1093/infdis/jir520; Burdo TH, 2011, J INFECT DIS, V204, P154, DOI 10.1093/infdis/jir214; Cavaleiro R, 2013, J INFECT DIS, V207, P1730, DOI 10.1093/infdis/jit085; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Crozat K, 2010, J EXP MED, V207, P1283, DOI 10.1084/jem.20100223; de Baey A, 2003, J IMMUNOL, V170, P5089, DOI 10.4049/jimmunol.170.10.5089; Dutertre CA, 2012, BLOOD, V120, P2259, DOI 10.1182/blood-2012-03-418681; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; Esbjornsson J, 2019, LANCET HIV, V6, pE25, DOI 10.1016/S2352-3018(18)30254-6; Fernandes SM, 2018, MUCOSAL IMMUNOL, V11, P236, DOI 10.1038/mi.2017.44; Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618; Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; He TY, 2019, J CLIN INVEST, V129, P5474, DOI 10.1172/JCI121208; HOBER D, 1993, MICROBIOL IMMUNOL, V37, P785, DOI 10.1111/j.1348-0421.1993.tb01706.x; Hofer TP, 2015, BLOOD, V126, P2601, DOI 10.1182/blood-2015-06-651331; Honge BL, 2016, JAIDS-J ACQ IMM DEF, V72, P254, DOI 10.1097/QAI.0000000000000939; Iannetta M, 2019, IMMUNOBIOLOGY, V224, P231, DOI 10.1016/j.imbio.2018.11.011; Jones GJ, 2001, AIDS, V15, P1657, DOI 10.1097/00002030-200109070-00008; Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Lester RT, 2009, P NATL ACAD SCI USA, V106, pE89, DOI 10.1073/pnas.0906913106; Lichtner M, 2016, CURR HIV RES, V14, P331, DOI 10.2174/1570162X14666160120152100; Manion M, 2017, J VIRUS ERAD, V3, P24; Monnig MA, 2016, AIDS CARE, V28, P1434, DOI 10.1080/09540121.2016.1189497; Mudd JC, 2016, J INFECT DIS, V214, pS58, DOI 10.1093/infdis/jiw258; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429; Nabatanzi R, 2019, J INFECT DIS, V220, P1414, DOI 10.1093/infdis/jiz320; Negi N, 2017, MICROB PATHOGENESIS, V111, P331, DOI 10.1016/j.micpath.2017.08.004; Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006; Nyamweya S, 2013, REV MED VIROL, V23, P221, DOI 10.1002/rmv.1739; Pacanowski J, 2001, BLOOD, V98, P3016, DOI 10.1182/blood.V98.10.3016; Pacanowski M, 2004, J INFECT DIS, V190, P1889, DOI 10.1086/425020; Piguet V, 2014, CURR OPIN HIV AIDS, V9, P478, DOI 10.1097/COH.0000000000000096; Redd AD, 2009, P NATL ACAD SCI USA, V106, P6718, DOI 10.1073/pnas.0901983106; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X; Soares RS, 2011, J VIROL, V85, P2429, DOI 10.1128/JVI.01921-10; Steele AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097171; Tchounga B, 2016, CURR OPIN HIV AIDS, V11, P537, DOI 10.1097/COH.0000000000000299; Thiebaut R, 2012, CLIN INFECT DIS, V55, P1417, DOI 10.1093/cid/cis708; Thiebaut R, 2011, AIDS, V25, P865, DOI 10.1097/QAD.0b013e328344892e; Thieblemont N, 1995, EUR J IMMUNOL, V25, P3418, DOI 10.1002/eji.1830251232; Vermi W, 2018, CANCER RES, V78, P3544, DOI 10.1158/0008-5472.CAN-17-2344; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	55	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2020	11								1658	10.3389/fimmu.2020.01658	http://dx.doi.org/10.3389/fimmu.2020.01658			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NJ3YM	32903610	Green Published, gold			2022-12-18	WOS:000565983000001
J	Wang, Y; Wang, K; Fu, J				Wang, Yan; Wang, Ke; Fu, Jian			HDAC6 Mediates Poly (I:C)-Induced TBK1 and Akt Phosphorylation in Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						innate immunity; infection; cytokine; acetylation; microtubule	HISTONE DEACETYLASE 6; POLARIZATION; ACTIVATION; GSK3-BETA; REGULATOR; PATHWAY; HEALTH; IL-10	Macrophages are derived from monocytes in the bone marrow and play an important role in anti-viral innate immune responses. Macrophages produce cytokines such as interferons and IL-10 upon viral infection to modulate anti-viral immune responses. Type I interferons (IFNs) promote anti-viral defense. IL-10 is a suppressor cytokine that down-regulates anti-viral immune responses. HDAC6 is a tubulin deacetylase that can modulate microtubule dynamics and microtubule-mediated cell signaling pathways. In the present study, we investigated the potential role of HDAC6 in macrophage anti-viral responses by examining poly (I:C)-induced IFN-beta and IL-10 production in mouse bone marrow-derived macrophages (BMDMs). We also investigated the role of HDAC6 in poly (I:C)-induced anti-viral signaling such as TBK1, GSK-3 beta, and Akt activation in mouse BMDMs. Our data showed that HDAC6 deletion enhanced poly (I:C)-induced INF-beta expression in macrophages by up-regulating TBK1 activity and eliminating the inhibitory regulation of GSK-3 beta. Furthermore, HDAC6 deletion inhibited poly (I:C)-induced suppressor cytokine IL-10 production in the BMDMs, which was associated with the inhibition of Akt activation. Our results suggest that HDAC6 modulates IFN-beta and IL-10 production in macrophages through its regulation of TBK1, GSK-3 beta, and Akt signaling. HDAC6 could act as a suppressor of anti-viral innate immune responses in macrophages.	[Wang, Yan; Wang, Ke] Second Hosp Jilin Univ, Dept Resp & Crit Care Med, Changchun, Peoples R China; [Wang, Yan; Fu, Jian] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, Lexington, KY USA	Jilin University; University of Kentucky	Wang, K (corresponding author), Second Hosp Jilin Univ, Dept Resp & Crit Care Med, Changchun, Peoples R China.	wke@jlu.edu.cn						Alfano M, 2013, ARTERIOSCL THROM VAS, V33, P1145, DOI 10.1161/ATVBAHA.112.300171; Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673; Choi SJ, 2016, EMBO J, V35, P429, DOI 10.15252/embj.201592586; Ciani L, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-27; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ellermann-Eriksen S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-59; Eng CH, 2006, MOL BIOL CELL, V17, P5004, DOI 10.1091/mbc.E05-10-0914; Gao R, 2015, AM J PHYSIOL-LUNG C, V308, pL847, DOI 10.1152/ajplung.00274.2014; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Giustiniani J, 2009, CELL SIGNAL, V21, P529, DOI 10.1016/j.cellsig.2008.12.004; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; Ha SD, 2007, J BIOL CHEM, V282, P36230, DOI 10.1074/jbc.M707622200; Hwang I, 2015, BIOCHEM BIOPH RES CO, V467, P973, DOI 10.1016/j.bbrc.2015.10.033; Ko R, 2016, BMB REP, V49, P305, DOI 10.5483/BMBRep.2016.49.6.059; Kruize Z, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02828; Kumar P, 2009, J CELL BIOL, V184, P895, DOI 10.1083/jcb.200901042; Lei CQ, 2010, IMMUNITY, V33, P878, DOI 10.1016/j.immuni.2010.11.021; Li L, 2015, CELL MOL LIFE SCI, V72, P4237, DOI 10.1007/s00018-015-2000-5; Li Y, 2013, FEBS J, V280, P775, DOI 10.1111/febs.12079; Liu L, 2019, TOXICOL APPL PHARM, V370, P178, DOI 10.1016/j.taap.2019.03.017; Louis C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00434; Lunemann A, 2015, CURR TOP MICROBIOL, V391, P265, DOI 10.1007/978-3-319-22834-1_9; Martin M, 2003, J IMMUNOL, V171, P717, DOI 10.4049/jimmunol.171.2.717; Matsumoto M, 2008, ADV DRUG DELIVER REV, V60, P805, DOI 10.1016/j.addr.2007.11.005; Matsumoto M, 2011, REV MED VIROL, V21, P67, DOI 10.1002/rmv.680; Matthias P, 2008, CELL CYCLE, V7, P7, DOI 10.4161/cc.7.1.5186; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Moreno-Gonzalo O, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006799; Namekata K, 2012, J NEUROSCI, V32, P264, DOI 10.1523/JNEUROSCI.4884-11.2012; Nyman TA, 2018, J PROTEOMICS, V180, P99, DOI 10.1016/j.jprot.2017.06.018; Saha B, 2014, J LEUKOCYTE BIOL, V96, P757, DOI 10.1189/jlb.4MR0314-141R; Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/EPI.14.69, 10.2217/epi.14.69]; Shah N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04121-y; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Silvin A, 2015, CURR OPIN IMMUNOL, V32, P54, DOI 10.1016/j.coi.2014.12.003; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009; Zdrenghea MT, 2015, REV MED VIROL, V25, P33, DOI 10.1002/rmv.1817; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83; Zhao W, 2013, FEBS LETT, V587, P542, DOI 10.1016/j.febslet.2013.01.052; Zhou FQ, 2005, SCIENCE, V308, P211, DOI 10.1126/science.1110301	42	1	1	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2020	11								1776	10.3389/fimmu.2020.01776	http://dx.doi.org/10.3389/fimmu.2020.01776			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI4LC	32849638	Green Published, gold			2022-12-18	WOS:000565324400001
J	Di Rosa, F				Di Rosa, Francesca			Editorial: Serafino Zappacosta and the Ceppellini School: A Pioneer Model for Nurturing Education in Immunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						education; innate immunity; adaptive immunity; MHC; vaccination			[Di Rosa, Francesca] Consiglio Nazl Ric IBPM CNR, Inst Mol Biol & Pathol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Di Rosa, F (corresponding author), Consiglio Nazl Ric IBPM CNR, Inst Mol Biol & Pathol, Rome, Italy.	francesca.dirosa@cnr.it	Di Rosa, Francesca/AAW-8612-2020	Di Rosa, Francesca/0000-0003-0252-9138				Carbone E, 2018, EUR J IMMUNOL, V48, P559, DOI 10.1002/eji.201870065; Colucci F, 2016, EMBO REP, V17, P1241, DOI 10.15252/embr.201643019; Di Giacomo A, 2017, EUR J IMMUNOL, V47, P10, DOI 10.1002/eji.201770016; Di Giacomo A, 2014, EUR J IMMUNOL, V44, P1573, DOI 10.1002/eji.201470055; La Cava A, 2006, TISSUE ANTIGENS, V68, P279, DOI 10.1111/j.1399-0039.2006.00686.x; Natalini A, 2019, EUR J IMMUNOL, V49, P361, DOI 10.1002/eji.201970035	6	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2020	11								1524	10.3389/fimmu.2020.01524	http://dx.doi.org/10.3389/fimmu.2020.01524			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI3WF	32903651	gold, Green Published			2022-12-18	WOS:000565285700001
J	Kiss, M; Burns, H; Donnelly, S; Hawthorne, WJ				Kiss, Michelle; Burns, Heather; Donnelly, Sheila; Hawthorne, Wayne J.			Effectiveness of Helminth Therapy in the Prevention of Allograft Rejection: A Systematic Review of Allogeneic Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						transplantation; allograft survival; helminths; helminth therapy; immune regulation	NEUTRAL THIOL PROTEASE; TRICHINELLA-SPIRALIS; IMMUNE-RESPONSE; SURVIVAL; CELLS; HEART; MICE; SKIN; IMMUNOSUPPRESSION; PROLONGATION	Background:The unique immunomodulatory capacity of helminth parasites has been investigated as a novel strategy in the prevention of allograft rejection after transplantation. This review was conducted to fully evaluate the specific effects of helminth therapy on allograft survival reported in published studies of animal models of allogeneic transplantation. Method:Following PRISMA protocol guidelines, a literature search was conducted using PubMed, MEDLINE via OvidSP, along with additional manual searches of selected reference lists. Publications describing helminth intervention within allograft transplantation models were screened for relevance to eligibility criteria. Primary and secondary outcomes were extracted using standardized data collection tables. The SYRCLE risk of bias assessment tool was used for quality assessment. Due to heterogeneity of study designs, meta-analysis could not be performed; rather outcomes are presented as a narrative synthesis with concept mapping. This review was registered in PROSPERO with ID: CRD42018097175. Results:The literature search generated 1,443 publications, which after screening for relevance to the eligibility criteria yielded 15 publications for qualitative analysis. All 15 publications reported improvement to allograft survival as a result of helminth therapy. This prolonged allograft survival was not significantly different when helminth-derived products were used compared to live infection. However, the extent of positive impact on allograft survival was noted to be dependent on study design factors, such as the chronicity of the live helminth infection, allograft type and the species/genus of helminth selected. Conclusion:Both live and product-based helminth therapy have potential applications as novel immune regulators or adjuncts for the prevention of allograft rejection. However, there were differences in efficacy between different worms and preparations of worm-derived products. Therefore, further studies are required to determine the most appropriate worm for a specific allograft, to elucidate the optimal dose and route of administration, and to better understand the modulation of immune responses that can mediate tolerance.	[Kiss, Michelle; Burns, Heather; Hawthorne, Wayne J.] Westmead Hosp, Ctr Transplant & Renal Res, Westmead Inst Med Res, Sydney, NSW, Australia; [Kiss, Michelle; Hawthorne, Wayne J.] Univ Sydney, Sydney, NSW, Australia; [Donnelly, Sheila] Univ Technol Sydney, Sch Life Sci, Sydney, NSW, Australia; [Hawthorne, Wayne J.] Univ Sydney, Western Clin Sch, Dept Surg, Sydney, NSW, Australia	University of Sydney; Westmead Institute for Medical Research; University of Sydney; University of Technology Sydney; University of Sydney	Hawthorne, WJ (corresponding author), Westmead Hosp, Ctr Transplant & Renal Res, Westmead Inst Med Res, Sydney, NSW, Australia.; Hawthorne, WJ (corresponding author), Univ Sydney, Sydney, NSW, Australia.; Hawthorne, WJ (corresponding author), Univ Sydney, Western Clin Sch, Dept Surg, Sydney, NSW, Australia.	wayne.hawthorne@sydney.edu.au		Donnelly, Sheila/0000-0003-2005-3698	NHMRC project [APP1087341]	NHMRC project(National Health and Medical Research Council (NHMRC) of Australia)	This project was supported by an NH&MRC project grant APP1087341.	ALKARMI T, 1995, COMP IMMUNOL MICROB, V18, P171, DOI 10.1016/0147-9571(95)00005-S; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; ARAUJO FG, 1977, CLIN EXP IMMUNOL, V28, P289; Ashour DS, 2013, EXPERT REV CLIN IMMU, V9, P669, DOI 10.1586/1744666X.2013.811187; Baron S, 1996, MED MICROBIOLOGY; BARRIGA OO, 1978, IMMUNOLOGY, V34, P167; CHERNYAKHOVSKAYA IY, 1972, REV EUR ETUD CL BIOL, V17, P395; CHIMYSHKYAN KL, 1976, BIOMED EXPRESS, V25, P176; Motran CC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00664; Dantal J, 1998, LANCET, V351, P623, DOI 10.1016/S0140-6736(97)08496-1; de Ruiter K, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12404; Deng GG, 2016, PARASITOL RES, V115, P407, DOI 10.1007/s00436-015-4762-y; Diaz A, 2007, EUR J IMMUNOL, V37, P3319, DOI 10.1002/eji.200737765; Dutta P, 2010, TRANSPLANTATION, V90, P1071, DOI 10.1097/TP.0b013e3181f8f296; Erken MHA, 2012, CHINESE MED J-PEKING, V125, P4412, DOI 10.3760/cma.j.issn.0366-6999.2012.24.016; FAUBERT GM, 1975, IMMUNOLOGY, V28, P1041; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Fuller BJ, 2000, TRANSPLANTATION, V69, P327, DOI 10.1097/00007890-200002150-00002; Gause WC, 2003, TRENDS IMMUNOL, V24, P269, DOI 10.1016/S1471-4906(03)00101-7; Gondorf F, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004616; HAMAJIMA F, 1994, PARASITE IMMUNOL, V16, P261, DOI 10.1111/j.1365-3024.1994.tb00348.x; Harnett MM, 2017, TRENDS PARASITOL, V33, P694, DOI 10.1016/j.pt.2017.05.007; He CS, 2004, J IMMUNOL, V172, P240, DOI 10.4049/jimmunol.172.1.240; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Ingulli E, 2010, PEDIATR NEPHROL, V25, P61, DOI 10.1007/s00467-008-1020-x; Johnston CJ, 2014, TRANSPLANTATION, V97, P127, DOI 10.1097/TP.0b013e3182a53f59; Jones ND, 2001, J IMMUNOL, V166, P2824, DOI 10.4049/jimmunol.166.4.2824; Kang SA, 2012, VET PARASITOL, V186, P319, DOI 10.1016/j.vetpar.2011.12.002; Ledingham DL, 1996, TRANSPLANTATION, V61, P184, DOI 10.1097/00007890-199601270-00003; Li T, 2011, CHINESE MED J-PEKING, V124, P2818, DOI 10.3760/cma.j.issn.0366-6999.2011.18.004; Liwski R, 2000, TRANSPLANTATION, V69, P1912, DOI 10.1097/00007890-200005150-00029; Lund ME, 2016, SCI REP-UK, V6, DOI 10.1038/srep37789; Maizels RM, 2018, IMMUNITY, V49, P801, DOI 10.1016/j.immuni.2018.10.016; Maizels RM, 2016, J ALLERGY CLIN IMMUN, V138, P666, DOI 10.1016/j.jaci.2016.07.007; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Mariotti J, 2008, BLOOD, V112, P4765, DOI 10.1182/blood-2008-05-154278; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Pearce EJ, 2005, PARASITE IMMUNOL, V27, P265, DOI 10.1111/j.1365-3024.2005.00765.x; Robinson MW, 2013, INT J PARASITOL, V43, P283, DOI 10.1016/j.ijpara.2012.11.004; Rook GAW, 2005, GUT, V54, P317, DOI 10.1136/gut.2004.053785; SARTONO E, 1995, J INFECT DIS, V171, P1683, DOI 10.1093/infdis/171.6.1683; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Smallwood TB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00453; Steptoe RJ, 1997, J IMMUNOL, V159, P5483; SVETMOLD.GJ, 1969, LANCET, V2, P320; Szkudlinski J, 1996, COMP BIOCHEM PHYS A, V113, P383, DOI 10.1016/0300-9629(95)02079-9; Taylor MD, 2012, TRENDS IMMUNOL, V33, P181, DOI 10.1016/j.it.2012.01.001; YAMAKAMI K, 1990, COMP BIOCHEM PHYS B, V95, P755, DOI 10.1016/0305-0491(90)90312-H	50	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2020	11								1604	10.3389/fimmu.2020.01604	http://dx.doi.org/10.3389/fimmu.2020.01604			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI3VU	32849543	Green Published, gold			2022-12-18	WOS:000565284600001
J	Lavergne, M; Belville, C; Choltus, H; Gross, C; Minet-Quinard, R; Gallot, D; Sapin, V; Blanchon, L				Lavergne, Marilyne; Belville, Corinne; Choltus, Helena; Gross, Christelle; Minet-Quinard, Regine; Gallot, Denis; Sapin, Vincent; Blanchon, Loic			Human Amnion Epithelial Cells (AECs) Respond to the FSL-1 Lipopeptide by Engaging the NLRP7 Inflammasome	FRONTIERS IN IMMUNOLOGY			English	Article						fetal membranes; amnion epithelial cells; inflammation; NLRP7; inflammasomes; FSL-1; mycoplasmas	HUMAN FETAL MEMBRANES; RECURRENT HYDATIDIFORM MOLES; PRETERM PREMATURE RUPTURE; POLYMERASE-CHAIN-REACTION; STRUCTURAL CHARACTERISTICS; MYCOPLASMA-FERMENTANS; STERILE INFLAMMATION; CASPASE-1 ACTIVATION; OXIDATIVE STRESS; LABOR	Context and Objectives:Inflammation is the leading mechanism involved in both physiological and pathological rupture of fetal membranes. Our aim was to obtain a better characterization of the inflammasome-dependent inflammation processes in these tissues, with a particular focus on the nucleotide-binding oligomerization domain (NOD)-like receptor, pyrin domain containing protein 7 (NLRP7) inflammasome. Methods:The presence of NLRP7 inflammasome actors [NLRP7, apoptosis-associated speck-like protein containing a CARD domain (ASC), and caspase-1] was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) in human amnion and choriodecidua at the three trimesters and at term. The protein concentrations were then determined by enzyme-linked immunosorbent assay in term tissues, with or without labor. The presence ofMycoplasma salivariumandMycoplasma fermentansin human fetal membranes was investigated using a PCR approach. Human amnion epithelial cells (AECs) were treated for 4 or 20 h with fibroblast-stimulating lipopeptide-1 (FSL-1), aM. salivarium-derived ligand. Transcripts and proteins quantity was then measured by RT-quantitative PCR and Western blotting, respectively. NLRP7 and ASC colocalization was confirmed by immunofluorescence. Western blots allowed analysis of pro-caspase-1 and gasdermin D cleavage. Results:NLRP7, ASC, and caspase-1 transcripts were expressed in both sheets of human fetal membranes during all pregnancy stages, but only ASC protein expression was increased with labor. In addition,M. salivariumandM. fermentanswere detected for the first time in human fetal membranes. NLRP7 and caspase-1 transcripts, as well as NLRP7, ASC, and pro-caspase-1 protein levels, were increased in FSL-1-treated AECs. The NLRP7 inflammasome assembled around the nucleus, and pro-caspase-1 and gasdermin D were cleaved into their mature forms after FSL-1 stimulation. Conclusion:Two new mycoplasmas,M. salivariumandM. fermentans, were identified in human fetal membranes, and a lipopeptide derived fromM. salivariumwas found to induce NLRP7 inflammasome formation in AECs.	[Lavergne, Marilyne; Belville, Corinne; Choltus, Helena; Gross, Christelle; Minet-Quinard, Regine; Gallot, Denis; Sapin, Vincent; Blanchon, Loic] Clermont Auvergne Univ, Translat Approach Epithelial Injury & Repair Team, INSERM, Genet Reprod & Dev GReD Lab,UMR 6293,U1103,CNRS, Clermont Ferrand, France; [Minet-Quinard, Regine; Sapin, Vincent] CHU Clermont Ferrand, Med Biochem & Mol Biol Dept, Clermont Ferrand, France; [Gallot, Denis] CHU Clermont Ferrand, Obstet & Gynecol Dept, Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; CHU Clermont Ferrand	Blanchon, L (corresponding author), Clermont Auvergne Univ, Translat Approach Epithelial Injury & Repair Team, INSERM, Genet Reprod & Dev GReD Lab,UMR 6293,U1103,CNRS, Clermont Ferrand, France.	loic.blanchon@uca.fr		LAVERGNE, Marilyne/0000-0002-4101-8675; Choltus, Helena/0000-0002-7557-7029	CLARA (Canceropole Lyon Auvergne Rhone-Alpes); Region Auvergne Rhone-Alpes; French ministerial grant	CLARA (Canceropole Lyon Auvergne Rhone-Alpes); Region Auvergne Rhone-Alpes(Region Auvergne-Rhone-Alpes); French ministerial grant	ML was supported by the CLARA (Canceropole Lyon Auvergne Rhone-Alpes) and the Region Auvergne Rhone-Alpes. HC was supported by a French ministerial grant.	Abdelaziz DH, 2011, J BIOL CHEM, V286, P3203, DOI 10.1074/jbc.M110.197681; Abi Nahed R, 2019, J MOL MED, V97, P355, DOI 10.1007/s00109-018-01737-x; Agbakoba N R, 2007, West Afr J Med, V26, P28; Behnia F, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.05.041; BLANCHARD A, 1993, CLIN INFECT DIS, V17, pS272, DOI 10.1093/clinids/17.Supplement_1.S272; Boucher D, 2018, J EXP MED, V215, P827, DOI 10.1084/jem.20172222; BOURNE GL, 1960, AM J OBSTET GYNECOL, V79, P1070, DOI 10.1016/0002-9378(60)90512-3; Bouvier D, 2015, J CLIN ENDOCR METAB, V100, pE1270, DOI 10.1210/jc.2015-2057; Brickle A, 2015, PLACENTA, V36, P1393, DOI 10.1016/j.placenta.2015.10.015; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chai M, 2012, PLACENTA, V33, P604, DOI 10.1016/j.placenta.2012.04.014; Chai M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/316146; Cox C, 2016, J MATERN-FETAL NEO M, V29, P3646, DOI 10.3109/14767058.2016.1140734; El Khwad M, 2005, BIOL REPROD, V72, P720, DOI 10.1095/biolreprod.104.033647; Eren E, 2015, CLIN CHIM ACTA, V439, P18, DOI 10.1016/j.cca.2014.09.024; Faro J, 2019, BIOL REPROD, V100, P1290, DOI 10.1093/biolre/ioy261; Gomez-Lopez N, 2017, REPROD SCI, V24, P934, DOI 10.1177/1933719116675058; Gomez-Lopez N, 2019, AM J REPROD IMMUNOL, V82, DOI 10.1111/aji.13184; Gomez-Lopez N, 2021, J MATERN-FETAL NEO M, V34, P569, DOI 10.1080/14767058.2019.1610740; Gomez-Lopez N, 2019, BIOL REPROD, V100, P1306, DOI 10.1093/biolre/ioy264; Gomez-Lopez N, 2019, J PERINAT MED, V47, P276, DOI 10.1515/jpm-2018-0271; Gomez-Lopez N, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13049; Gomez-Lopez N, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12648; Goradia P, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8237087; Gotsch F, 2008, J MATERN-FETAL NEO M, V21, P605, DOI 10.1080/14767050802212109; Groslambert M, 2018, J INFLAMM RES, V11, P359, DOI 10.2147/JIR.S141220; Gunn L, 1996, REPROD FERT DEVELOP, V8, P1069, DOI 10.1071/RD9961069; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; Hoss F, 2017, CELL MOL LIFE SCI, V74, P1211, DOI 10.1007/s00018-016-2396-6; Huang JY, 2017, REPROD BIOL ENDOCRIN, V15, DOI 10.1186/s12958-017-0286-x; Janzen C, 2017, J CLIN ENDOCR METAB, V102, P1261, DOI 10.1210/jc.2016-3150; Jayaprakash TP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166794; Jin J, 2018, PLACENTA, V67, P15, DOI 10.1016/j.placenta.2018.05.008; Kacerovsky M, 2008, Ceska Gynekol, V73, P154; Kacerovsky Marian, 2009, Acta Medica (Hradec Kralove), V52, P117; Keelan JA, 1999, AM J OBSTET GYNECOL, V181, P1530, DOI 10.1016/S0002-9378(99)70400-X; Khare S, 2012, IMMUNITY, V36, P464, DOI 10.1016/j.immuni.2012.02.001; Kim YK, 2016, YONSEI MED J, V57, P5, DOI 10.3349/ymj.2016.57.1.5; Kohli S, 2016, BLOOD, V128, P2153, DOI 10.1182/blood-2016-03-705434; Kwak DW, 2014, J MATERN-FETAL NEO M, V27, P333, DOI 10.3109/14767058.2013.818124; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lappas M, 2014, AM J REPROD IMMUNOL, V71, P189, DOI 10.1111/aji.12174; Latino MA, 2018, J PERINAT MED, V46, P503, DOI 10.1515/jpm-2016-0305; Lim R, 2018, J REPROD IMMUNOL, V127, P24, DOI 10.1016/j.jri.2018.04.003; Lim R, 2018, REPRODUCTION, V155, P207, DOI 10.1530/REP-17-0604; Mahadevan S, 2014, HUM MOL GENET, V23, P706, DOI 10.1093/hmg/ddt457; MALAK TM, 1994, BRIT J OBSTET GYNAEC, V101, P375, DOI 10.1111/j.1471-0528.1994.tb11908.x; Marcellin L, 2017, J IMMUNOL, V198, P1345, DOI 10.4049/jimmunol.1601482; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matias ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129095; McLaren J, 2000, AM J OBSTET GYNECOL, V182, P409, DOI 10.1016/S0002-9378(00)70232-8; McLaren J, 1999, HUM REPROD, V14, P237, DOI 10.1093/humrep/14.1.237; McLaren J, 1999, HUM REPROD, V14, P2895, DOI 10.1093/humrep/14.11.2895; Menon R, 2011, PLACENTA, V32, P317, DOI 10.1016/j.placenta.2011.01.015; Menon Ramkumar, 2019, Obstet Gynecol Sci, V62, P199, DOI [10.5468/ogs.2019.62.3.149, 10.5468/ogs.2019.62.4.199]; Menon R, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00196; Menon R, 2016, HUM REPROD UPDATE, V22, P535, DOI 10.1093/humupd/dmw022; Menon R, 2016, PLACENTA, V44, P1, DOI 10.1016/j.placenta.2016.05.013; Menon R, 2016, AGING-US, V8, P216, DOI 10.18632/aging.100891; Menon R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031136; Messaed C, 2011, J BIOL CHEM, V286, P43313, DOI 10.1074/jbc.M111.306191; Modi BP, 2017, MOL GENET GENOM MED, V5, P720, DOI 10.1002/mgg3.330; Moein-Vaziri N, 2018, TAIWAN J OBSTET GYNE, V57, P1, DOI 10.1016/j.tjog.2017.12.001; Morwood CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108390; Murdoch S, 2006, NAT GENET, V38, P300, DOI 10.1038/ng1740; Nambayan RJT, 2019, J BIOL CHEM, V294, P439, DOI 10.1074/jbc.RA118.004407; Nguyen NMP, 2018, MODERN PATHOL, V31, P1116, DOI 10.1038/s41379-018-0031-9; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; Palazon-Riquelme P, 2018, IMMUNOLOGY, V155, P320, DOI 10.1111/imm.12989; Panaitescu B, 2019, J MATERN-FETAL NEO M, V32, P1978, DOI 10.1080/14767058.2017.1422714; Platnich JM, 2019, ARCH BIOCHEM BIOPHYS, V670, P4, DOI 10.1016/j.abb.2019.02.008; Plazyo O, 2016, BIOL REPROD, V95, DOI 10.1095/biolreprod.116.144139; Radian AD, 2015, MOL IMMUNOL, V67, P294, DOI 10.1016/j.molimm.2015.06.013; Rathkey JK, 2017, J BIOL CHEM, V292, P14649, DOI 10.1074/jbc.M117.797217; Rider P, 2017, J IMMUNOL, V198, P1395, DOI 10.4049/jimmunol.1601342; Riley SC, 1999, J ENDOCRINOL, V162, P351, DOI 10.1677/joe.0.1620351; Rock KL, 2013, NAT REV RHEUMATOL, V9, P13, DOI 10.1038/nrrheum.2012.143; Romero R, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12440; Runic R, 1998, J CLIN ENDOCR METAB, V83, P660, DOI 10.1210/jc.83.2.660; Saeki A, 2018, MOL ORAL MICROBIOL, V33, P300, DOI 10.1111/omi.12225; Sansonetti PJ, 2000, IMMUNITY, V12, P581, DOI 10.1016/S1074-7613(00)80209-5; Sborgi L, 2016, EMBO J, V35, P1766, DOI 10.15252/embj.201694696; Singer H, 2014, MOL HUM REPROD, V20, P990, DOI 10.1093/molehr/gau060; Slim R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00242; Stodle GS, 2018, CLIN EXP IMMUNOL, V193, P84, DOI 10.1111/cei.13130; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Timenetsky J, 2006, BRAZ J MED BIOL RES, V39, P907, DOI 10.1590/S0100-879X2006000700009; van Golen RF, 2013, J GASTROEN HEPATOL, V28, P394, DOI 10.1111/jgh.12072; WANG RYH, 1992, J CLIN MICROBIOL, V30, P245, DOI 10.1128/JCM.30.1.245-248.1992; Weel IC, 2017, J REPROD IMMUNOL, V123, P40, DOI 10.1016/j.jri.2017.09.002; Xie F, 2010, BJOG-INT J OBSTET GY, V117, P99, DOI 10.1111/j.1471-0528.2009.02428.x; Xu LQ, 2019, J MATERN-FETAL NEO M, V32, P1792, DOI 10.1080/14767058.2017.1418313; Yang D, 2017, IMMUNOL REV, V280, P41, DOI 10.1111/imr.12577; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou Y, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0161918, 10.1371/journal.pone.0152853]	96	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2020	11								1645	10.3389/fimmu.2020.01645	http://dx.doi.org/10.3389/fimmu.2020.01645			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF6AX	32849565	gold, Green Published			2022-12-18	WOS:000563378900001
J	Ludwig, K; Husain, RA; Rubio, I				Ludwig, Kristin; Husain, Ralf A.; Rubio, Ignacio			mTORC1 Is Not Principally Involved in the Induction of Human Endotoxin Tolerance	FRONTIERS IN IMMUNOLOGY			English	Article						mTORC1; endotoxin tolerance; monocytes; macrophage; sepsis; immune suppression	IRAK-M EXPRESSION; PATTERN-RECOGNITION; TRAINED IMMUNITY; HUMAN MONOCYTES; IN-VITRO; INNATE; MACROPHAGES; HSP90; TSC1	Endotoxin tolerance represents a safeguard mechanism for preventing detrimental prolonged inflammation and exaggerated immune/inflammatory responses from innate immune cells to recurrent harmless pathogens. On the other hand, excessive immune tolerance can contribute to pathological immunosuppression, e.g., as present in sepsis. Monocyte activation is accompanied by intracellular metabolic rearrangements that are reportedly orchestrated by the metabolic signaling node mTORC1. mTORC1-dependent metabolic re-wiring plays a major role in monocyte/macrophage polarization, but whether mTORC1 participates in the induction of endotoxin tolerance and other immune adaptive programs, such as immune training, is not clear. This connection has been difficult to test in the past due to the lack of appropriate models of human endotoxin tolerance allowing for the genetic manipulation of mTORC1. We have addressed this shortcoming by investigating monocytes from tuberous sclerosis (TSC) patients that feature a functional loss of the tumor suppressor TSC1/2 and a concomitant hyperactivation of mTORC1. Subjecting these cells to various protocols of immune priming and adaptation showed that the TSC monocytes are not compromised in the induction of tolerance. Analogously, we find that pharmacological mTORC1 inhibition does not prevent endotoxin tolerance induction in human monocytes. Interestingly, neither manipulation affected the capacity of activated monocytes to switch to increased lactic fermentation. In sum, our findings document that mTORC1 is unlikely to be involved in the induction of endotoxin tolerance in human monocytes and argue against a causal link between an mTORC1-dependent metabolic switch and the induction of immune tolerance.	[Ludwig, Kristin; Rubio, Ignacio] Univ Hosp Jena, Inst Mol Cell Biol, Ctr Mol BioMed, Jena, Germany; [Husain, Ralf A.] Univ Hosp Jena, Dept Neuropediat, Jena, Germany; [Rubio, Ignacio] Univ Hosp Jena, Clin Anaesthesiol & Intens Care, Jena, Germany; [Rubio, Ignacio] Univ Hosp Jena, Ctr Sepsis Control & Care CSCC, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Rubio, I (corresponding author), Univ Hosp Jena, Inst Mol Cell Biol, Ctr Mol BioMed, Jena, Germany.; Rubio, I (corresponding author), Univ Hosp Jena, Clin Anaesthesiol & Intens Care, Jena, Germany.; Rubio, I (corresponding author), Univ Hosp Jena, Ctr Sepsis Control & Care CSCC, Jena, Germany.	ignacio.rubio@med.uni-jena.de	Husain, Ralf A./AAO-7658-2020	Husain, Ralf A./0000-0003-0798-6346	Deutsche Forschungsgemeinschaft [DFG-RTG1715]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by Grant No. DFG-RTG1715 from the Deutsche Forschungsgemeinschaft to KL and IR.	Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Arts RJW, 2016, SEMIN IMMUNOL, V28, P425, DOI 10.1016/j.smim.2016.09.002; Baillie JK, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006641; Bekkering S, 2016, CLIN VACCINE IMMUNOL, V23, P926, DOI 10.1128/CVI.00349-16; Bermejo-Martin JF, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110400; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Byles V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3834; Bzowska M, 2017, J LEUKOCYTE BIOL, V102, P763, DOI 10.1189/jlb.2MA0117-019R; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Dolch A, 2019, EUR J IMMUNOL, V49, P302, DOI 10.1002/eji.201847883; Escoll P, 2003, BIOCHEM BIOPH RES CO, V311, P465, DOI 10.1016/j.bbrc.2003.10.019; Freise N, 2019, BLOOD, V134, P134, DOI 10.1182/blood.2019000320; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garcia-Valtanen P, 2017, IMMUNOL CELL BIOL, V95, P601, DOI 10.1038/icb.2017.13; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Ifrim DC, 2014, CLIN VACCINE IMMUNOL, V21, P534, DOI 10.1128/CVI.00688-13; Ifrim DC, 2013, J IMMUNOL, V190, P4129, DOI 10.4049/jimmunol.1202611; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Leonhardt J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02818; Liu D, 2019, J CELL BIOCHEM, V120, P56, DOI 10.1002/jcb.27547; Lyroni K, 2017, J IMMUNOL, V198, P1297, DOI 10.4049/jimmunol.1600009; Meyer CU, 2015, NEUROPEDIATRICS, V46, P335, DOI 10.1055/s-0035-1562925; Mulder WJM, 2019, NAT REV DRUG DISCOV, V18, P553, DOI 10.1038/s41573-019-0025-4; OREN R, 1963, J CELL BIOL, V17, P487, DOI 10.1083/jcb.17.3.487; Pai GM, 2016, ONCOTARGET, V7, P85365, DOI 10.18632/oncotarget.13378; Rodriguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698; Rubio I, 2019, LANCET INFECT DIS, V19, pE422, DOI 10.1016/S1473-3099(19)30567-5; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sager RA, 2018, TRENDS BIOCHEM SCI, V43, P935, DOI 10.1016/j.tibs.2018.09.018; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Seeley JJ, 2018, NATURE, V559, P114, DOI 10.1038/s41586-018-0253-5; Seeley JJ, 2017, J LEUKOCYTE BIOL, V101, P107, DOI 10.1189/jlb.3MR0316-118RR; SHORT MP, 1995, BRAIN PATHOL, V5, P173, DOI 10.1111/j.1750-3639.1995.tb00591.x; van Eeghen AM, 2012, EUR J HUM GENET, V20, P510, DOI 10.1038/ejhg.2011.241; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Woodford MR, 2017, EMBO J, V36, P3650, DOI 10.15252/embj.201796700; Zeng H, 2013, CURR OPIN IMMUNOL, V25, P347, DOI 10.1016/j.coi.2013.05.002	38	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2020	11								1515	10.3389/fimmu.2020.01515	http://dx.doi.org/10.3389/fimmu.2020.01515			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI3WC	32849516	gold, Green Published			2022-12-18	WOS:000565285400001
J	Kahn, J; Pregartner, G; Avian, A; Kniepeiss, D; Muller, H; Schemmer, P				Kahn, Judith; Pregartner, Gudrun; Avian, Alexander; Kniepeiss, Daniela; Mueller, Helmut; Schemmer, Peter			The Graz Liver Allocation Strategy-Impact of Extended Criteria Grafts on Outcome Considering Immunological Aspects	FRONTIERS IN IMMUNOLOGY			English	Article						extended donor criteria; immunological aspects; liver transplantation; liver allocation; outcome	DONOR CRITERIA; RISK-FACTORS; ISCHEMIC CHOLANGIOPATHY; PRIMARY NONFUNCTION; BILIARY STRICTURES; TRANSPLANTATION; DONATION; DEATH; EUROTRANSPLANT; GUIDELINES	Background:Transplant centers are forced to use livers of extended criteria donors for transplantation due to a dramatic organ shortage. The outcome effect of extended donor criteria (EDCs) remains unclear. Thus, this study was designed to assess the impact of EDCs on outcome including immunological aspects after liver transplantation (LT). Patients and Methods:Between November 2016 and March 2018, 49 patients (85.7% male) with a mean age of 57 +/- 11 years underwent LT. The impact of EDCs on outcome after LT was assessed retrospectively using both MedOcs and ENIS (Eurotransplant Network Information System). Results:About 80% of grafts derived from extended criteria donors. Alanine aminotransferase/aspartate aminotransferase (AST/ALT) levels elevated more than three times above normal values in organ donors was the only significant risk factor for primary dysfunction (PDF) and primary non-function (PNF)/Re-LT and early non-anastomotic biliary strictures (NAS). Balance of risk (BAR) score did not differ between EDC and non-EDC recipients. PDF (14.3% of all patients) and PNF (6.1% of all patients) occurred in 23.1% of EDC-graft recipients and in 10.0% of non-EDC-graft recipients (RR 2.31,p= 0.663). The 90-day mortality was 3.6%. There was no difference of early non-anastomotic biliary tract complications and biopsy proven rejections (BPR). There was no correlation of PDF/PNF with BPR and NAS, respectively; however, 66.7% of the patients with BPR also developed early NAS (p< 0.001). Conclusion:With the Graz liver allocation strategy, excellent survival can be achieved selecting livers with no more than 2 not outcome-relevant EDCs for patients with MELD >20. Further, BPR is associated with biliary complications.	[Kahn, Judith; Kniepeiss, Daniela; Mueller, Helmut; Schemmer, Peter] Med Univ Graz, Dept Surg, Gen Visceral & Transplant Surg, Graz, Austria; [Kahn, Judith; Kniepeiss, Daniela; Mueller, Helmut; Schemmer, Peter] Med Univ Graz, Transplant Ctr Graz, Graz, Austria; [Pregartner, Gudrun; Avian, Alexander] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz	Schemmer, P (corresponding author), Med Univ Graz, Dept Surg, Gen Visceral & Transplant Surg, Graz, Austria.; Schemmer, P (corresponding author), Med Univ Graz, Transplant Ctr Graz, Graz, Austria.	judith.kahn@medunigraz.at; peter.schemmer@medunigraz.at		Avian, Alexander/0000-0003-1084-5763				Adam R, 2012, J HEPATOL, V57, P675, DOI 10.1016/j.jhep.2012.04.015; Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912; Agrawal A, 2010, AGING-US, V2, P93, DOI 10.18632/aging.100121; Attia M, 2008, TRANSPL INT, V21, P713, DOI 10.1111/j.1432-2277.2008.00696.x; Aubert O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3557; Blok JJ, 2016, LIVER TRANSPLANT, V22, P1107, DOI 10.1002/lt.24449; Briceno J, 2000, TRANSPL INT, V13, pS249, DOI 10.1111/j.1432-2277.2000.tb02029.x; Broomhead RH, 2012, LIVER TRANSPLANT, V18, P771, DOI 10.1002/lt.23406; Bundesarztekammer D., 2004, BEKANNTMACHUNGEN BUN, V3, P1; Burra P, 2016, J HEPATOL, V64, P433, DOI 10.1016/j.jhep.2015.10.006; Busuttil RW, 2005, ANN SURG, V241, P905, DOI 10.1097/01.sla.0000164077.77912.98; Busuttil RW, 2003, LIVER TRANSPLANT, V9, P651, DOI 10.1053/jlts.2003.50105; Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602; Cursio R, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/164329; Das S, 2016, PROG TRANSPLANT, V26, P340, DOI 10.1177/1526924816663516; Durand F, 2008, LIVER TRANSPLANT, V14, P1694, DOI 10.1002/lt.21668; Dutkowski P, 2011, ANN SURG, V254, P745, DOI 10.1097/SLA.0b013e3182365081; Feng S, 2006, AM J TRANSPLANT, V6, P783, DOI 10.1111/j.1600-6143.2006.01242.x; Figueras J, 1996, TRANSPLANTATION, V61, P410, DOI 10.1097/00007890-199602150-00016; Foley DP, 2011, ANN SURG, V253, P817, DOI 10.1097/SLA.0b013e3182104784; Fruhauf NR, 2011, TRANSPLANTATION, V92, P1378, DOI 10.1097/TP.0b013e318236cd2f; Gao QM, 2019, ANN SURG, V270, P333, DOI 10.1097/SLA.0000000000002876; GOES N, 1995, TRANSPLANTATION, V59, P565; Goldaracena N, 2012, TRANSPL P, V44, P2219, DOI 10.1016/j.transproceed.2012.07.113; Guichelaar MMJ, 2003, AM J TRANSPLANT, V3, P885, DOI 10.1034/j.1600-6143.2003.00165.x; Hoyer DP, 2015, LIVER INT, V35, P1756, DOI 10.1111/liv.12766; Jay CL, 2011, ANN SURG, V253, P259, DOI 10.1097/SLA.0b013e318204e658; Jurewicz M, 2011, AM J TRANSPLANT, V11, P348, DOI 10.1111/j.1600-6143.2010.03360.x; Kahn J, 2018, TRANSPL INT, V31, P11; Kniepeiss D, 2003, TRANSPLANT INT, V16, P730, DOI 10.1007/s00147-003-0621-3; Kollmann D, 2018, LIVER TRANSPLANT, V24, P779, DOI 10.1002/lt.25068; Linecker M, 2018, J HEPATOL, V68, P798, DOI 10.1016/j.jhep.2017.11.008; Lozanovski VJ, 2018, LANGENBECK ARCH SURG, V403, P719, DOI 10.1007/s00423-018-1704-z; Mocchegiani F, 2015, ANN TRANSPL, V20, P218, DOI 10.12659/AOT.892393; Mourad MM, 2014, WORLD J GASTROENTERO, V20, P6159, DOI 10.3748/wjg.v20.i20.6159; Nemes B, 2016, EXPERT REV GASTROENT, V10, P827, DOI 10.1586/17474124.2016.1149061; Nemes B, 2016, EXPERT REV GASTROENT, V10, P841, DOI 10.1586/17474124.2016.1149062; Nickkholgh A, 2007, NEPHROL DIAL TRANSPL, V22, P29, DOI 10.1093/ndt/gfm654; Nunez K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061750; Oberhuber R, 2012, AM J TRANSPLANT, V12, P38, DOI 10.1111/j.1600-6143.2011.03798.x; Opelz G, 2009, HUM IMMUNOL, V70, P627, DOI 10.1016/j.humimm.2009.04.009; Pascher A, 2014, CURR OPIN GASTROEN, V30, P320, DOI 10.1097/MOG.0000000000000061; Petrowsky H, 2014, ANN SURG, V259, P1186, DOI 10.1097/SLA.0000000000000265; Radunz S, 2011, LIVER INT, V31, P1021, DOI 10.1111/j.1478-3231.2011.02525.x; Rippe C, 2012, EXP GERONTOL, V47, P45, DOI 10.1016/j.exger.2011.10.004; Saidi RF, 2014, INT J TRANSPLANT MED, V5, P87; Scalea JR, 2016, LIVER TRANSPLANT, V22, P1197, DOI 10.1002/lt.24494; Schemmer P, 2007, TRANSPL P, V39, P529, DOI 10.1016/j.transproceed.2006.12.002; Schemmer P, 2009, CLIN TRANSPLANT, V23, P42, DOI 10.1111/j.1399-0012.2009.01109.x; Schrem H, 2012, CHIRURG, V83, P980, DOI 10.1007/s00104-012-2325-7; Schrem H, 2014, LANGENBECK ARCH SURG, V399, P1011, DOI 10.1007/s00423-014-1247-x; Schulte K, 2017, J LIVER DIS TRANSPLA, V6, P1, DOI [10.4172/2325-9612.1000147, DOI 10.4172/2325-9612.1000147]; Segev DL, 2007, HEPATOLOGY, V46, P1907, DOI 10.1002/hep.21888; Silberhumer GR, 2013, TRANSPL INT, V26, P990, DOI 10.1111/tri.12156; Slegtenhorst BR, 2014, TRANSPLANTATION, V97, P1091, DOI 10.1097/TP.0000000000000072; Tait BD, 2013, TRANSPLANTATION, V95, P19, DOI 10.1097/TP.0b013e31827a19cc; Tector AJ, 2006, ANN SURG, V244, P439, DOI 10.1097/01.sla.0000234896.18207.fa; Tullius SG, 2011, NEW ENGL J MED, V364, P1369, DOI 10.1056/NEJMc1103007; Uehara M, 2019, ACS NANO, V13, P12393, DOI 10.1021/acsnano.9b05115; Uemura T, 2012, TRANSPL INT, V25, P671, DOI 10.1111/j.1432-2277.2012.01474.x; Uemura T, 2007, LIVER TRANSPLANT, V13, P227, DOI 10.1002/lt.20992	61	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1584	10.3389/fimmu.2020.01584	http://dx.doi.org/10.3389/fimmu.2020.01584			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF6WK	32849538	gold, Green Published			2022-12-18	WOS:000563436300001
J	Kruger, R; Martin, E; Dmytrus, J; Feiterna-Sperling, C; Meisel, C; Unterwalder, N; Kolsch, U; Wahn, V; Hofmann, J; Korn, P; Latour, S; Boztug, K; von Bernuth, H				Krueger, Renate; Martin, Emmanuel; Dmytrus, Jasmin; Feiterna-Sperling, Cornelia; Meisel, Christian; Unterwalder, Nadine; Koelsch, Uwe; Wahn, Volker; Hofmann, Joerg; Korn, Paula; Latour, Sylvain; Boztug, Kaan; von Bernuth, Horst			CD70 Deficiency Associated With Chronic Epstein-Barr Virus Infection, Recurrent Airway Infections and Severe Gingivitis in a 24-Year-Old Woman	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; CVID; CD70-deficiency; EBV; gingivitis	IMMUNODEFICIENCY; IMMUNITY; REVEALS; HUMANS	Most of the few patients with homozygous CD70 deficiency described to date suffered from EBV-related malignancies in early childhood. We present a woman with CD70 deficiency diagnosed in adulthood. She presented in childhood with recurrent airway infections due to encapsulated bacteria, herpes zoster and a fulminant EBV infection followed by chronic EBV infection with mild lymphoproliferation and severe gingivitis/periodontal disease with high EBV viral load in saliva and gingival plaques as an adult. Up to the age of 24 years she developed no malignancy despite constant EBV viremia since primary EBV infection 15 years previously. Immunologic evaluation in childhood showed hypogammaglobulinemia with impaired polysaccharide responsiveness. She has been stable on immunoglobulin substitution with no further severe viral infections and no bacterial airway infections in adulthood. Targeted panel sequencing at the age of 20 years revealed a homozygousCD70missense mutation (ENST00000245903.3:c.2T>C). CD70 deficiency was confirmed by absent CD70 expression of B cells and activated T cell blasts. The patient finished high school, persues an academic career and has rarely sick days at college. The clinical course of our patient may help to counsel parents of CD70-deficient patients with regard to prognosis and therapeutic options including haematopoetic stem cell transplantation.	[Krueger, Renate; Feiterna-Sperling, Cornelia; Wahn, Volker; von Bernuth, Horst] Charite Univ Med Berlin, Dept Pediat Pneumonol Immunol & Intens Care Med, Berlin, Germany; [Martin, Emmanuel; Latour, Sylvain] Inst Natl Sante & Rech Med UMR 1163, Lab Lymphocyte Activat & Susceptibil EBV Infect, Paris, France; [Dmytrus, Jasmin; Boztug, Kaan] St Anna Childrens Canc Res Inst, Vienna, Austria; [Dmytrus, Jasmin; Boztug, Kaan] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Dmytrus, Jasmin; Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Meisel, Christian; Unterwalder, Nadine; Koelsch, Uwe; von Bernuth, Horst] Lab Berlin GmbH, Dept Immunol, Berlin, Germany; [Meisel, Christian; Unterwalder, Nadine] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Hofmann, Joerg] Charite Univ Med Berlin, Inst Virol, Berlin, Germany; [Korn, Paula] Charite Univ Med Berlin, Dept Oral & Maxillofacial Surg, Berlin, Germany; [Latour, Sylvain] Univ Paris, Imagine Inst, Paris, France; [Boztug, Kaan] Med Univ Vienna, Dept Pediat & Adolescent Med, St Anna Childrens Hosp, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria; [von Bernuth, Horst] Charite Univ Med Berlin, Berlin, Germany; [von Bernuth, Horst] Berlin Inst Hlth BIH, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Saint Anna Children's Hospital; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UDICE-French Research Universities; Universite Paris Cite; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kruger, R (corresponding author), Charite Univ Med Berlin, Dept Pediat Pneumonol Immunol & Intens Care Med, Berlin, Germany.	r.krueger@charite.de	Boztug, Kaan/AAM-4161-2021; Martin, Emmanuel/F-9743-2016; von Bernuth, Horst/AAQ-9797-2021; von Bernuth, Horst/ABD-7779-2020	Boztug, Kaan/0000-0001-8387-9185; Martin, Emmanuel/0000-0003-4211-7373; von Bernuth, Horst/0000-0002-5812-7675; Hofmann, Joerg/0000-0003-3966-515X; Feiterna-Sperling, Cornelia/0000-0003-4171-1098; Meisel, Christian/0000-0003-0222-991X	German Research Foundation (DFG); Open Access Publication Fund of Charite -Universitatsmedizin Berlin; Ligue Contre le Cancer-Equipe Labellisee (France); Agence Nationale de la Recherche (France) [ANR-10-IAHU-01, ANR-18-CE15-0025-01]; Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent (France); ESID	German Research Foundation (DFG)(German Research Foundation (DFG)); Open Access Publication Fund of Charite -Universitatsmedizin Berlin; Ligue Contre le Cancer-Equipe Labellisee (France); Agence Nationale de la Recherche (France)(French National Research Agency (ANR)); Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent (France); ESID	We acknowledge support from the ESID registry, the German Research Foundation (DFG) and the Open Access Publication Fund of Charite -Universitatsmedizin Berlin (RK). This work was also supported by grants from the Ligue Contre le Cancer-Equipe Labellisee (France) (SL), Agence Nationale de la Recherche-ANR-18-CE15-0025-01 (France) (SL) and ANR-10-IAHU-01 (France) (Institute Imagine), the Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent (France) (SL).	Abolhassani H, 2017, J EXP MED, V214, P91, DOI 10.1084/jem.20160849; Alosaimi MF, 2019, J ALLERGY CLIN IMMUN, V144, P574, DOI 10.1016/j.jaci.2019.03.002; Caorsi R, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02015; Contreras A, 1999, ORAL MICROBIOL IMMUN, V14, P206, DOI 10.1034/j.1399-302X.1999.140402.x; Gao ZL, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000005980, 10.1097/md.0000000000005980]; Ghosh S, 2020, BLOOD, V136, P2638, DOI 10.1182/blood.2020006738; Giess RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175279; Guerreiro M, 2010, EUR J IMMUNOL, V40, P1566, DOI 10.1002/eji.200940000; Izawa K, 2017, J EXP MED, V214, P73, DOI 10.1084/jem.20160784; Kern F, 1998, NAT MED, V4, P975, DOI 10.1038/nm0898-975; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kredel LI, 2019, INT J COLORECTAL DIS, V34, P229, DOI 10.1007/s00384-018-3170-z; Latour S, 2019, IMMUNOL REV, V291, P174, DOI 10.1111/imr.12791; Latour S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01103; Muller H, 2017, NUCLEIC ACIDS RES, V45, pW567, DOI 10.1093/nar/gkx425; Ozen A, 2017, NEW ENGL J MED, V377, P52, DOI 10.1056/NEJMoa1615887; Rodriguez R, 2019, J EXP MED, V216, P2800, DOI 10.1084/jem.20190678; Salzer E, 2016, NAT IMMUNOL, V17, P1352, DOI 10.1038/ni.3575; Shabani M, 2016, CRIT REV ONCOL HEMAT, V108, P109, DOI 10.1016/j.critrevonc.2016.10.014; Slots J, 2019, PERIODONTOL 2000, V79, P210, DOI 10.1111/prd.12241; Somekh I, 2019, BLOOD, V134, P1510, DOI 10.1182/blood.2019000644; Streitz M, 2013, TRANSPLANT RES, V2, DOI 10.1186/2047-1440-2-17	22	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1593	10.3389/fimmu.2020.01593	http://dx.doi.org/10.3389/fimmu.2020.01593			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF7RB	32849540	Green Published, gold			2022-12-18	WOS:000563490600001
J	Lavaert, M; Valcke, B; Vandekerckhove, B; Leclercq, G; Liang, KL; Taghon, T				Lavaert, Marieke; Valcke, Brecht; Vandekerckhove, Bart; Leclercq, Georges; Liang, Kai Ling; Taghon, Tom			Conventional and Computational Flow Cytometry Analyses Reveal Sustained Human Intrathymic T Cell Development From Birth Until Puberty	FRONTIERS IN IMMUNOLOGY			English	Article						human thymopoiesis; aging; computational flow cytometry; puberty; thymic involution	HEMATOPOIETIC STEM; BONE-MARROW; IN-VITRO; THYMUS; DIFFERENTIATION; REGENERATION; VISUALIZATION; PROGENITORS; EXPRESSION; DYNAMICS	The thymus is the organ where subsets of mature T cells are generated which subsequently egress to function as central mediators in the immune system. While continuously generating T cells even into adulthood, the thymus does undergo involution during life. This is characterized by an initial rapid decrease in thymic cellularity during early life and by a second age-dependent decline in adulthood. The thymic cellularity of neonates remains low during the first month after birth and the tissue reaches a maximum in cellularity at 6 months of age. In order to study the effect that this first phase of thymic involution has on thymic immune subset frequencies, we performed multi-color flow cytometry on thymic samples collected from birth to 14 years of age. In consideration of the inherent limitations posed by conventional flow cytometry analysis, we established a novel computational analysis pipeline that is adapted from single-cell transcriptome sequencing data analysis. This allowed us to overcome technical effects by batch correction, analyze multiple samples simultaneously, limit computational cost by subsampling, and to rely on KNN-graphs for graph-based clustering. As a result, we successfully identified rare, distinct and gradually developing immune subsets within the human thymus tissues. Although the thymus undergoes early involution from infanthood onwards, our data suggests that this does not affect human T-cell development as we did not observe significant alterations in the proportions of T-lineage developmental intermediates from birth to puberty. Thus, in addition to providing an interesting novel strategy to analyze conventional flow cytometry data for the thymus, our work shows that the early phase of human thymic involution mainly limits the overall T cell output since no obvious changes in thymocyte subsets could be observed.	[Lavaert, Marieke; Valcke, Brecht; Vandekerckhove, Bart; Leclercq, Georges; Liang, Kai Ling; Taghon, Tom] Univ Ghent, Fac Med & Hlth Sci, Dept Diagnost Sci, Ghent, Belgium	Ghent University	Liang, KL; Taghon, T (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Diagnost Sci, Ghent, Belgium.	kailing.liang@UGent.be; tom.taghon@UGent.be	Liang, Kai Ling/K-2125-2019; Leclercq, Georges/H-9659-2017	Liang, Kai Ling/0000-0002-8534-2362; Taghon, Tom/0000-0002-5781-0288; Leclercq, Georges/0000-0002-1691-5294	Fund for Scientific Research Flanders; Foundation against Cancer; Ghent University	Fund for Scientific Research Flanders(FWO); Foundation against Cancer; Ghent University(Ghent University)	This work was supported by the Fund for Scientific Research Flanders, the Foundation against Cancer and the Ghent University.	Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Aw D, 2012, BIOGERONTOLOGY, V13, P77, DOI 10.1007/s10522-011-9349-0; Bredenkamp N, 2014, DEVELOPMENT, V141, P1627, DOI 10.1242/dev.103614; Cante-Barrett K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00032; Chen LZ, 2009, BLOOD, V113, P567, DOI 10.1182/blood-2008-05-156265; De Smedt M, 2011, HAEMATOL-HEMATOL J, V96, P646, DOI 10.3324/haematol.2010.036343; Draxler DF, 2017, CYTOM PART A, V91A, P336, DOI 10.1002/cyto.a.23080; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; Haddad R, 2006, IMMUNITY, V24, P217, DOI 10.1016/j.immuni.2006.01.008; Hao QL, 2008, BLOOD, V111, P1318, DOI 10.1182/blood-2007-08-106294; Hie B, 2019, CELL SYST, V8, P483, DOI 10.1016/j.cels.2019.05.003; Hince M, 2008, CELL IMMUNOL, V252, P122, DOI 10.1016/j.cellimm.2007.10.007; Lavaert M, 2020, IMMUNITY, V52, P1088, DOI 10.1016/j.immuni.2020.03.019; Lepletier A, 2019, CELL REP, V27, P3887, DOI 10.1016/j.celrep.2019.05.045; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Martin-Gayo E, 2017, J EXP MED, V214, P3361, DOI 10.1084/jem.20161564; McInnes L., 2018, ARXIV180203426; Min H, 2004, J IMMUNOL, V173, P245, DOI 10.4049/jimmunol.173.1.245; Nunez S, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah4447; Offner F, 1999, BRIT J HAEMATOL, V104, P801, DOI 10.1046/j.1365-2141.1999.01265.x; Ortman CL, 2002, INT IMMUNOL, V14, P813, DOI 10.1093/intimm/dxf042; Park JE, 2020, SCIENCE, V367, P868, DOI 10.1126/science.aay3224; PENIT C, 1989, J IMMUNOL, V142, P3369; Prabhu SB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162242; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Seet CS, 2017, NAT METHODS, V14, P521, DOI [10.1038/NMETH.4237, 10.1038/nmeth.4237]; Semposski GD, 2002, MOL IMMUNOL, V38, P841, DOI 10.1016/S0161-5890(01)00122-5; Shanley DP, 2009, TRENDS IMMUNOL, V30, P374, DOI 10.1016/j.it.2009.05.001; Six EM, 2007, J EXP MED, V204, P3085, DOI 10.1084/jem.20071003; STEINMANN GG, 1985, SCAND J IMMUNOL, V22, P563, DOI 10.1111/j.1365-3083.1985.tb01916.x; Sutherland JS, 2008, CLIN CANCER RES, V14, P1138, DOI 10.1158/1078-0432.CCR-07-1784; Sutherland JS, 2005, J IMMUNOL, V175, P2741, DOI 10.4049/jimmunol.175.4.2741; Traag VA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41695-z; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vanhecke D, 1997, J IMMUNOL, V158, P3730; Varas A, 2000, J IMMUNOL, V164, P6260, DOI 10.4049/jimmunol.164.12.6260; Weerkamp F, 2005, J ALLERGY CLIN IMMUN, V115, P834, DOI 10.1016/j.jaci.2004.10.031; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0	38	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1659	10.3389/fimmu.2020.01659	http://dx.doi.org/10.3389/fimmu.2020.01659			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ND8RX	32849574	Green Published, gold			2022-12-18	WOS:000562171000001
J	da Silva, TP; Bittencourt, TL; de Oliveira, AL; Prata, RBD; Menezes, V; Ferreira, H; Nery, JAD; de Oliveira, EB; da Silva, GMS; Sarno, EN; Pinheiro, RO				da Silva, Tatiana Pereira; Bittencourt, Tamiris Lameira; de Oliveira, Ariane Leite; da Silva Prata, Rhana Berto; Menezes, Vinicius; Ferreira, Helen; da Costa Nery, Jose Augusto; de Oliveira, Eliane Barbosa; Sperandio da Silva, Gilberto Marcelo; Sarno, Euzenir Nunes; Pinheiro, Roberta Olmo			Macrophage Polarization in Leprosy-HIV Co-infected Patients	FRONTIERS IN IMMUNOLOGY			English	Article						leprosy; HIV-1; monocyte subsets; macrophage phenotype; co-infection	RECONSTITUTION INFLAMMATORY SYNDROME; PREFERENTIALLY HARBORS HIV-1; CD16(+) MONOCYTE SUBSET; MYCOBACTERIUM-LEPRAE; REVERSAL REACTION; DENDRITIC CELLS; TYPE-1 REACTION; REPLICATION; ACTIVATION; EXPRESSION	In HIV-infected individuals, a paradoxical clinical deterioration may occur in preexisting leprosy when highly active antiretroviral therapy (HAART)-associated reversal reaction (RR) develops. Leprosy-HIV co-infected patients during HAART may present a more severe form of the disease (RR/HIV), but the immune mechanisms related to the pathogenesis of leprosy-HIV co-infection remain unknown. Although the adaptive immune responses have been extensively studied in leprosy-HIV co-infected individuals, recent studies have described that innate immune cells may drive the overall immune responses to mycobacterial antigens. Monocytes are critical to the innate immune system and play an important role in several inflammatory conditions associated with chronic infections. In leprosy, different tissue macrophage phenotypes have been associated with the different clinical forms of the disease, but it is not clear how HIV infection modulates the phenotype of innate immune cells (monocytes or macrophages) during leprosy. In the present study, we investigated the phenotype of monocytes and macrophages in leprosy-HIV co-infected individuals, with or without RR. We did not observe differences between the monocyte profiles in the studied groups; however, analysis of gene expression within the skin lesion cells revealed that the RR/HIV group presents a higher expression of macrophage scavenger receptor 1 (MRS1), CD209 molecule (CD209), vascular endothelial growth factor (VEGF), arginase 2 (ARG2), and peroxisome proliferator-activated receptor gamma (PPARG) when compared with the RR group. Our data suggest that different phenotypes of tissue macrophages found in the skin from RR and RR/HIV patients could differentially contribute to the progression of leprosy.	[da Silva, Tatiana Pereira; Bittencourt, Tamiris Lameira; de Oliveira, Ariane Leite; da Silva Prata, Rhana Berto; Menezes, Vinicius; Ferreira, Helen; da Costa Nery, Jose Augusto; de Oliveira, Eliane Barbosa; Sarno, Euzenir Nunes; Pinheiro, Roberta Olmo] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Leprosy Lab, Rio De Janeiro, Brazil; [Sperandio da Silva, Gilberto Marcelo] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Chagas Dis Clin Res Lab, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Pinheiro, RO (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Leprosy Lab, Rio De Janeiro, Brazil.	robertaolmo@gmail.com	; Pinheiro, Roberta/A-2525-2013	Prata, Rhana/0000-0002-1294-790X; SILVA, TATIANA/0000-0002-4016-3002; Pinheiro, Roberta/0000-0001-8471-4227	Coordination for the Improvement of Higher Education Personnel (CAPES)	Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	We would like to especially thank all patients who agreed to participate in this study. We are also grateful to the Souza Araujo Out-Patient Unit team for support with the patients. We are grateful for the support from the Coordination for the Improvement of Higher Education Personnel (CAPES).	Andrade PR, 2015, EXPERT REV CLIN IMMU, V11, P391, DOI 10.1586/1744666X.2015.1012501; Pires CAA, 2015, AN BRAS DERMATOL, V90, P27, DOI 10.1590/abd1806-4841.20153048; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; Brown JN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003664; Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673; Cassol E, 2009, J IMMUNOL, V182, P6237, DOI 10.4049/jimmunol.0803447; CONVIT J, 1972, B WORLD HEALTH ORGAN, V46, P821; Silva BJD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006103; Fonseca ABD, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-016-0229-3; Barbosa MGD, 2017, MICROBES INFECT, V19, P505, DOI 10.1016/j.micinf.2017.06.006; de Oliveira AL, 2013, IMMUNOLOGY, V140, P47, DOI 10.1111/imm.12108; de Sousa JR, 2016, ACTA TROP, V157, P108, DOI 10.1016/j.actatropica.2016.01.008; Acosta CCD, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007151; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; Epskamp S, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i04; Fulco TD, 2014, INFECT IMMUN, V82, P3968, DOI 10.1128/IAI.02194-14; Ganor Y, 2019, NAT MICROBIOL, V4, P633, DOI 10.1038/s41564-018-0335-z; Geluk A, 2014, J CLIN IMMUNOL, V34, P245, DOI 10.1007/s10875-013-9979-x; Graff JW, 2012, J BIOL CHEM, V287, P21816, DOI 10.1074/jbc.M111.327031; Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33; Jaworowski A, 2007, J INFECT DIS, V196, P38, DOI 10.1086/518443; Khadge S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1128-0; Lagier JC, 2014, EXPERT OPIN DRUG SAF, V13, P341, DOI 10.1517/14740338.2014.887677; LIENHARDT C, 1994, LEPROSY REV, V65, P9; Lockwood DNJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001327; Machado PRL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003865; Madureira BP, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.11.001; Mane Deepa Rajesh, 2017, J Oral Maxillofac Pathol, V21, P211, DOI 10.4103/jomfp.JOMFP_234_16; Martinez-Nunez RT, 2009, J BIOL CHEM, V284, P16334, DOI 10.1074/jbc.M109.011601; Menezes VM, 2014, T ROY SOC TROP MED H, V108, P63, DOI 10.1093/trstmh/trt113; Menezes VM, 2009, AIDS, V23, P641, DOI 10.1097/QAD.0b013e3283291405; Montoya D, 2010, ADV IMMUNOL, V105, P1, DOI 10.1016/S0065-2776(10)05001-7; Montoya D, 2009, CELL HOST MICROBE, V6, P343, DOI 10.1016/j.chom.2009.09.002; Moura DF, 2012, EUR J IMMUNOL, V42, P2925, DOI 10.1002/eji.201142198; Narayan N P, 2001, Indian J Lepr, V73, P329; Orenstein JM, 2007, ULTRASTRUCT PATHOL, V31, P151, DOI 10.1080/01913120701344343; Ottenhoff THM, 2005, INT J LEPROSY, V73, P208; Pinheiro RO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00518; Porcheray F, 2006, VIROLOGY, V349, P112, DOI 10.1016/j.virol.2006.02.031; Nogueira MRS, 2016, MEM I OSWALDO CRUZ, V111, P635, DOI 10.1590/0074-02760160122; SAMPAIO EP, 1995, INFECT IMMUN, V63, P1848, DOI 10.1128/IAI.63.5.1848-1854.1995; Secchin-De-Andrade PJ, 2016, LEPROSY REV, V87, P516; Swaminathan G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002937; Tarique M, 2017, CYTOKINE, V91, P82, DOI 10.1016/j.cyto.2016.12.011; Teles RMB, 2010, INFECT IMMUN, V78, P1012, DOI 10.1128/IAI.00896-09; Ustianowski AP, 2006, LANCET INFECT DIS, V6, P350, DOI 10.1016/S1473-3099(06)70493-5; Wahl SM, 2006, J LEUKOCYTE BIOL, V80, P973, DOI 10.1189/jlb.0306130; Wang JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01174-9; Wong ME, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02517; Xavier MB, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006633; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	51	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2020	11								1493	10.3389/fimmu.2020.01493	http://dx.doi.org/10.3389/fimmu.2020.01493			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC8GC	32849508	Green Published, gold			2022-12-18	WOS:000561450300001
J	Frankiewicz, A; Peczynski, C; Giebel, S; Harrington, A; Socie, G; Niederwieser, D; Scheid, C; Bornhauser, M; Kroger, N; Elmaagacli, A; Afanasyev, B; Dreger, P; Rossig, C; Blaise, D; Kratz, C; Yakoub-Agha, I; Kremens, B; Niemeyer, CM; Wulf, G; Blau, I; Penack, O; Greinix, H; Basak, GW				Frankiewicz, Andrzej; Peczynski, Christophe; Giebel, Sebastian; Harrington, Alenca; Socie, Gerard; Niederwieser, Dietger; Scheid, Christoph; Bornhaeuser, Martin; Kroeger, Nicolaus; Elmaagacli, Ahmet; Afanasyev, Boris; Dreger, Peter; Roessig, Claudia; Blaise, Didier; Kratz, Christian; Yakoub-Agha, Ibrahim; Kremens, Bernhard; Niemeyer, Charlotte Marie; Wulf, Gerald; Blau, Igor; Penack, Olaf; Greinix, Hildegard; Basak, Grzegorz W.			Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT	FRONTIERS IN IMMUNOLOGY			English	Article						health care expenditure; human development index; hematopoietic cell transplantation; acute graft-vs; -host disease; transplant-related mortality	ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; ACUTE GVHD; MORTALITY; SOCIETY; ADULTS	Acute graft-vs.-host disease (aGvHD) is one of the most frequent causes of transplant-related mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). Its treatment is complex and costly. The aim of this study was to retrospectively analyze the impact of country-specific socioeconomic factors on outcome of patients who experience severe aGvHD. Adults with hematological malignancies receiving alloHCT from either HLA-matched siblings (n= 1,328) or unrelated donors (n= 2,824) developing grade 3 or 4 aGvHD were included. In univariate analysis, the probability of TRM at 2 years was increased for countries with lower current Health Care Expenditure (HCE,p= 0.04), lower HCE as % of Gross Domestic Product per capita (p= 0.003) and lower values of the Human Development Index (p= 0.02). In a multivariate model, the risk of TRM was most strongly predicted by current HCE (HR = 0.76,p= 0.006). HCE >median was also associated with reduced risk of the overall mortality (HR 0.73,p= 0.0006) and reduced risk of treatment failure (either relapse or TRM; HR 0.77,p= 0.004). We conclude that country-specific socioeconomic factors, in particular current HCE, are strongly associated with survival of patients who experience severe aGvHD.	[Frankiewicz, Andrzej; Giebel, Sebastian] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Bone Marrow Transplantat & Oncohematol, Gliwice, Poland; [Peczynski, Christophe; Harrington, Alenca] CEREST TC Hop St Antoine, EBMT Paris Study Off, Paris, France; [Socie, Gerard] Hop St Louis, Dept Hematol BMT 1, Paris, France; [Niederwieser, Dietger] Univ Hosp Leipzig, Div Hematol Oncol & Hemostasiol, Leipzig, Germany; [Scheid, Christoph] Univ Cologne, Dept Med 1, Cologne, Germany; [Bornhaeuser, Martin] Univ Klinikum Dresden, Med Klin & Poliklin, Dresden, Germany; [Kroeger, Nicolaus] Univ Hosp Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany; [Elmaagacli, Ahmet] Asklepios Klin St Georg, Dept Haematol, Hamburg, Germany; [Afanasyev, Boris] First State Pavlov Med Univ St Petersburg, Raisa Gorbacheva Mem Res Inst Paediat Oncol Hemat, St Petersburg, Russia; [Dreger, Peter] Heidelberg Univ, Med Klin & Poliklin, Heidelberg, Germany; [Roessig, Claudia] Univ Klinikum Muenster, Klin Kinder & Jugendmed Padiat Hamatol & Onkol &, Munster, Germany; [Blaise, Didier] Ctr Rech Cancerol Marseille, Programme Transplantat & Therapie Cellulaire, Inst Paoli Calmettes, Marseille, France; [Kratz, Christian] Hannover Med Sch, Dept Pediat Haematol Oncol, Hannover, Germany; [Yakoub-Agha, Ibrahim] Hop HURIEZ UAM Allo CSH CHRU, Lille, France; [Kremens, Bernhard] Univ Hosp, Dept Pediat Hematol Oncol, Essen, Germany; [Niemeyer, Charlotte Marie] Univ Med Ctr, Dept Pediat & Adolescent Med, Pediat Hematol & Oncol, Freiburg, Germany; [Wulf, Gerald] Univ Klinikum Goettingen, Abt Hamatol & Onkol, Gottingen, Germany; [Blau, Igor; Penack, Olaf] Charite Univ Med Berlin, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany; [Greinix, Hildegard] Univ Klin Innere Med, Klin Abt Hamatol, Graz, Austria; [Basak, Grzegorz W.] Med Uniwers Warsaw, Dept Haematol Oncol & Internal Med, Warsaw, Poland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Leipzig University; University of Cologne; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Asklepios Klinik St. Georg; Pavlov First Saint Petersburg State Medical University; Ruprecht Karls University Heidelberg; University of Munster; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Hannover Medical School; University of Duisburg Essen; University of Freiburg; University of Gottingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Frankiewicz, A; Giebel, S (corresponding author), Maria Sklodowska Curie Natl Res Inst Oncol, Dept Bone Marrow Transplantat & Oncohematol, Gliwice, Poland.	andrzej.frankiewicz@io.gliwice.pl; sgiebel@io.gliwice.pl	Blaise, Didier/R-2483-2016; Penack, Olaf/L-1068-2016	Blaise, Didier/0000-0002-5684-9447; Frankiewicz, Andrzej/0000-0001-8826-7030; Peczynski, Christophe/0000-0002-3829-0088; Penack, Olaf/0000-0003-4876-802X; Kroger, Nicolaus/0000-0001-5103-9966; Basak, Grzegorz/0000-0003-3858-8180; Giebel, Sebastian/0000-0002-4827-4401				Andersen PK, 1999, STAT MED, V18, P1489, DOI 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#; Cavazzana-Calvo M, 2009, CURR OPIN IMMUNOL, V21, P544, DOI 10.1016/j.coi.2009.08.001; D'Souza A, 2017, CURRENT USES OUTCOME; Flowers MED, 2011, BLOOD, V117, P3214, DOI 10.1182/blood-2010-08-302109; Frassoni F, 2000, LANCET, V355, P1393, DOI 10.1016/S0140-6736(00)02137-1; Giebel S, 2013, BONE MARROW TRANSPL, V48, P238, DOI 10.1038/bmt.2012.131; Giebel S, 2017, HAEMATOLOGICA, V102, P139, DOI 10.3324/haematol.2016.145631; Giebel S, 2016, ONCOLOGIST, V21, P377, DOI 10.1634/theoncologist.2015-0314; Giebel S, 2010, BLOOD, V116, P122, DOI 10.1182/blood-2010-01-266478; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO;2-F; Gratwohl A, 2010, JAMA-J AM MED ASSOC, V303, P1617, DOI 10.1001/jama.2010.491; Hamilton BK, 2018, BIOL BLOOD MARROW TR, V24, P393, DOI 10.1016/j.bbmt.2017.10.009; Hoogard P, 1995, LIFETIME DATA ANAL, V1, P255, DOI DOI 10.1007/BF00985760; HOROWITZ MM, 1992, BLOOD, V79, P2771; Jagasia M, 2012, BLOOD, V119, P296, DOI 10.1182/blood-2011-06-364265; Karanth M, 2006, BONE MARROW TRANSPL, V37, P419, DOI 10.1038/sj.bmt.1705260; Matsuo K, 2000, BONE MARROW TRANSPL, V26, P1061, DOI 10.1038/sj.bmt.1702681; Pasquini MC, 2015, CURRENT USE OUTCOME; Van Lint MT, 1998, BLOOD, V92, P2288; Xhaard A, 2012, BIOL BLOOD MARROW TR, V18, P406, DOI 10.1016/j.bbmt.2011.06.012; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337	22	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2020	11								1537	10.3389/fimmu.2020.01537	http://dx.doi.org/10.3389/fimmu.2020.01537			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NA8JA	32793210	Green Published, gold			2022-12-18	WOS:000560062700001
J	Soulillou, JP; Padler-Karavani, V				Soulillou, Jean-Paul; Padler-Karavani, Vered			Editorial: Human Antibodies Against the Dietary Non-human Neu5Gc-Carrying Glycans in Normal and Pathologic States	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer; xenotranplantation; sialic acid; N-glycolylneuraminic acid; inflammation; biotherapeutic; diet; carbohydrate			[Soulillou, Jean-Paul] Univ Nantes, INSERM, CRTI, Nantes, France; [Soulillou, Jean-Paul] CHU Nantes, ITUN, Nantes, France; [Padler-Karavani, Vered] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, Tel Aviv, Israel	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Tel Aviv University	Soulillou, JP (corresponding author), Univ Nantes, INSERM, CRTI, Nantes, France.; Soulillou, JP (corresponding author), CHU Nantes, ITUN, Nantes, France.; Padler-Karavani, V (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, Tel Aviv, Israel.	Jean-paul.Soulillou@univ-nantes.fr; vkaravani@tauex.tau.ac.il	PADLER-KARAVANI, VERED/AAC-6055-2022	PADLER-KARAVANI, VERED/0000-0002-4761-3571	European Union H2020 Program grants (ERC-2016-STG) [716220]	European Union H2020 Program grants (ERC-2016-STG)	This work was supported by the European Union H2020 Program grants (ERC-2016-STG-716220) (to VP-K).	Labrada M, 2018, SEMIN ONCOL, V45, P41, DOI 10.1053/j.seminoncol.2018.04.003	1	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2020	11								1589	10.3389/fimmu.2020.01589	http://dx.doi.org/10.3389/fimmu.2020.01589			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NA8JO	32793227	gold, Green Published			2022-12-18	WOS:000560064100001
J	Agazio, A; Cimons, J; Shotts, KM; Guo, KJ; Santiago, ML; Pelanda, R; Torres, RM				Agazio, Amanda; Cimons, Jennifer; Shotts, Kristin M.; Guo, Kejun; Santiago, Mario L.; Pelanda, Roberta; Torres, Raul M.			Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; peripheral tolerance; autoreactive; polyreactive; HIV-1; bnAbs; H2A	NEUTRALIZING ANTIBODIES; MARGINAL ZONE; GENETIC DISSECTION; IMMUNE-RESPONSE; TOLERANCE; AUTOANTIBODIES; INDUCTION; AUTOREACTIVITY; IDENTIFICATION; SELECTION	Peripheral tolerance is essential for silencing weakly autoreactive B cells that have escaped central tolerance, but it is unclear why these potentially pathogenic B cells are retained rather than being eliminated entirely. Release from peripheral tolerance restraint can occur under certain circumstances (i.e., strong TLR stimulus), that are present during infection. In this regard, we hypothesized that autoreactive B cells could function as a reserve population that can be activated to contribute to the humoral immune response, particularly with pathogens, such as HIV-1, that exploit immune tolerance to avoid host defense. In this study, we identify a population of autoreactive B cells with the potential to neutralize HIV-1 and experimentally release them from the functional restrictions of peripheral tolerance. We have previously identified murine monoclonal antibodies that displayed autoreactivity against histone H2A and neutralized HIV-1in vitro. Here, we identify additional H2A-reactive IgM monoclonal antibodies and demonstrate that they are both autoreactive and polyreactive with self and foreign antigens and are able to neutralize multiple clades of tier 2 HIV-1. Flow cytometric analysis of H2A-reactive B cells in naive wildtype mice revealed that these B cells are present in peripheral B cell populations and we further document that murine H2A-reactive B cells are restrained by peripheral tolerance mechanisms. Specifically, we show endogenous H2A-reactive B cells display increased expression of the inhibitory mediators CD5 and phosphatase and tensin homolog (PTEN) phosphatase and fail to mobilize calcium upon immunoreceptor stimulation; all characterized markers of anergy. Moreover, we show that toll-like receptor stimulation or provision of CD4 T cell help induces thein vitroproduction of H2A-reactive antibodies, breaking tolerance. Thus, we have identified a novel poly/autoreactive B cell population that has the potential to neutralize HIV-1 but is silenced by immune tolerance.	[Agazio, Amanda; Cimons, Jennifer; Shotts, Kristin M.; Pelanda, Roberta; Torres, Raul M.] Univ Colorado, Dept Immunol & Microbiol, Aurora, CO 80045 USA; [Guo, Kejun; Santiago, Mario L.] Univ Colorado, Sch Med, Div Infect Dis, Dept Med, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Torres, RM (corresponding author), Univ Colorado, Dept Immunol & Microbiol, Aurora, CO 80045 USA.	raul.torres@cuanschutz.edu		Agazio, Amanda/0000-0003-3344-7901	National Institutes of Health [AI052157, AI136534, T32 AR007534, AI116603, AI052310, AI131639]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funding by the following National Institutes of Health grants AI052157, AI136534 (RT), T32 AR007534 (AA), AI116603 (MS), AI052310, and AI131639 (RP).	ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; Bonsignori M, 2014, J CLIN INVEST, V124, P1835, DOI 10.1172/JCI73441; Browne CD, 2009, IMMUNITY, V31, P749, DOI 10.1016/j.immuni.2009.08.026; Burnett DL, 2019, IMMUNOL REV, V292, P61, DOI 10.1111/imr.12808; Burnett DL, 2018, SCIENCE, V360, P223, DOI 10.1126/science.aao3859; Cashman KS, 2019, IMMUNOL REV, V292, P76, DOI 10.1111/imr.12820; Chakrabarti BK, 2013, J VIROL, V87, P13239, DOI 10.1128/JVI.01247-13; Chen YF, 2005, J IMMUNOL, V174, P7692, DOI 10.4049/jimmunol.174.12.7692; Cusick MF, 2012, CLIN REV ALLERG IMMU, V42, P102, DOI [10.1007/s12016-011-8294-7, 10.1007/s12016-011-8293-8]; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; deCamp A, 2014, J VIROL, V88, P2489, DOI 10.1128/JVI.02853-13; Dimitrov JD, 2013, J IMMUNOL, V191, P993, DOI 10.4049/jimmunol.1300880; Dosenovic P, 2012, J IMMUNOL, V188, P6018, DOI 10.4049/jimmunol.1200466; Doyle-Cooper C, 2013, J IMMUNOL, V191, P3186, DOI 10.4049/jimmunol.1301285; Eisen HN, 2010, P NATL ACAD SCI USA, V107, P22373, DOI 10.1073/pnas.1012051108; Ekland EH, 2004, J IMMUNOL, V172, P4700, DOI 10.4049/jimmunol.172.8.4700; Fournier EM, 2012, J EXP MED, V209, P1797, DOI 10.1084/jem.20120332; Francis Lisa, 2010, Int J Clin Rheumtol, V5, P59, DOI 10.2217/ijr.09.72; Getahun A, 2016, J EXP MED, V213, P751, DOI 10.1084/jem.20150537; Getts DR, 2013, IMMUNOL REV, V255, P197, DOI 10.1111/imr.12091; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GRANDIEN A, 1994, EUR J IMMUNOL, V24, P1345, DOI 10.1002/eji.1830240616; Gupta S, 2015, J VIROL, V89, P4158, DOI 10.1128/JVI.02904-14; Halverson R, 2004, NAT IMMUNOL, V5, P645, DOI 10.1038/ni1076; Hamilton JA, 2015, J IMMUNOL, V194, P5022, DOI 10.4049/jimmunol.1402335; HASPEL MV, 1983, NATURE, V304, P73, DOI 10.1038/304073a0; Haynes Barton F., 2005, Human Antibodies, V14, P59; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hippen KL, 2000, J EXP MED, V191, P883, DOI 10.1084/jem.191.5.883; Huang HC, 2006, P NATL ACAD SCI USA, V103, P3734, DOI 10.1073/pnas.0600214103; Ismail N, 2005, IMMUNOLOGY, V115, P34, DOI 10.1111/j.1365-2567.2005.02128.x; Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X; Landais E, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0443-0; Li YJ, 2002, J EXP MED, V195, P181, DOI 10.1084/jem.20011453; Liu MF, 2015, J VIROL, V89, P784, DOI 10.1128/JVI.02378-14; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; McGuire AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10618; Meffre E, 2008, CURR OPIN IMMUNOL, V20, P632, DOI 10.1016/j.coi.2008.09.001; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Mohan C, 1998, J CLIN INVEST, V101, P1362; Moody MA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag0851; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Noorchashm H, 1999, INT IMMUNOL, V11, P765, DOI 10.1093/intimm/11.5.765; Ogden CA, 2005, AUTOIMMUNITY, V38, P259, DOI 10.1080/08916930500124452; PRABHAKAR BS, 1984, J IMMUNOL, V133, P2815; Pujanauski LM, 2013, P NATL ACAD SCI USA, V110, P1422, DOI 10.1073/pnas.1213713110; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAJEWSKY K, 1971, PROC R SOC SER B-BIO, V176, P385, DOI 10.1098/rspb.1971.0002; Reed JH, 2016, J EXP MED, V213, P1255, DOI 10.1084/jem.20151978; Roskin KM, 2020, NAT IMMUNOL, V21, P199, DOI 10.1038/s41590-019-0581-0; Rubtsov AV, 2008, J IMMUNOL, V180, P3882, DOI 10.4049/jimmunol.180.6.3882; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; SATOH M, 1994, J EXP MED, V180, P2341, DOI 10.1084/jem.180.6.2341; Satoh M, 2000, CLIN EXP IMMUNOL, V121, P399, DOI 10.1046/j.1365-2249.2000.01276.x; Schroeder KMS, 2017, J EXP MED, V214, P2283, DOI 10.1084/jem.20161190; Schroeder KMS, 2017, CURR OPIN IMMUNOL, V47, P26, DOI 10.1016/j.coi.2017.06.004; Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09; Sfriso P, 2010, J LEUKOCYTE BIOL, V87, P385, DOI 10.1189/jlb.0709517; Shlomchik MJ, 2009, CURR OPIN IMMUNOL, V21, P626, DOI 10.1016/j.coi.2009.08.005; Simonich CA, 2016, CELL, V166, P77, DOI 10.1016/j.cell.2016.05.055; Smith MJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123384; Smith MJ, 2017, JOVE-J VIS EXP, DOI 10.3791/55382; Smith MJ, 2015, DIABETES, V64, P1703, DOI 10.2337/db13-1798; Sobel ES, 2002, J IMMUNOL, V169, P2694, DOI 10.4049/jimmunol.169.5.2694; Srivastava B, 2005, J EXP MED, V202, P1225, DOI 10.1084/jem.20051038; Taylor JJ, 2012, J EXP MED, V209, P2065, DOI 10.1084/jem.20112272; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; TSAO BP, 1993, EUR J IMMUNOL, V23, P2332, DOI 10.1002/eji.1830230942; Verkoczy L, 2014, CURR OPIN HIV AIDS, V9, P224, DOI 10.1097/COH.0000000000000049; Verkoczy L, 2011, J IMMUNOL, V187, P3785, DOI 10.4049/jimmunol.1101633; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; Wakui M, 2004, J IMMUNOL, V173, P7368, DOI 10.4049/jimmunol.173.12.7368; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yang G, 2013, J EXP MED, V210, P241, DOI 10.1084/jem.20121977; Zhang L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12973-1; Zhang RJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf0618; Zhou ZH, 2007, CELL HOST MICROBE, V1, P51, DOI 10.1016/j.chom.2007.01.002; Zhou ZH, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-7; Zhuang HY, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00291	80	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2020	11								1565	10.3389/fimmu.2020.01565	http://dx.doi.org/10.3389/fimmu.2020.01565			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MZ7ZT	32849530	gold, Green Published			2022-12-18	WOS:000559346000001
J	Kowalewski, C; Hashimoto, T; Joly, P				Kowalewski, Cezary; Hashimoto, Takashi; Joly, Pascal			Editorial: Autoimmune Blistering Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						pemphigus; pemphigoid; dermatitis herpetiformis; pathgenesis of autoimmune blistering diseases; treatment of autoimmune blistering diseases			[Kowalewski, Cezary] Med Univ Warsaw, Dept Immunodermatol, Warsaw, Poland; [Hashimoto, Takashi] Osaka City Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan; [Joly, Pascal] Normandie Univ, Ctr Reference Malad Bulleuses Autoimmunes, Rouen Univ Hosp, Deparment Dermatol, Rouen, France	Medical University of Warsaw; Osaka Metropolitan University; CHU de Rouen	Kowalewski, C (corresponding author), Med Univ Warsaw, Dept Immunodermatol, Warsaw, Poland.	ckowalewski@wum.edu.pl							0	1	1	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2020	11								1614	10.3389/fimmu.2020.01614	http://dx.doi.org/10.3389/fimmu.2020.01614			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MZ8AW	32793239	gold, Green Published			2022-12-18	WOS:000559348900001
J	Hocine, HR; Quach, HT; Adusumilli, PS				Hocine, Hocine Rachid; Quach, Hue T.; Adusumilli, Prasad S.			Commentary: Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						solid tumors; blood-brain barrier; CAR T cells; regional administration; CNS lymphoma	CHECKPOINT BLOCKADE; IMMUNOTHERAPY		[Hocine, Hocine Rachid; Quach, Hue T.; Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA; [Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Adusumilli, PS (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA.; Adusumilli, PS (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA.	adusumip@mskcc.org		HOCINE, Hocine R/0000-0003-1144-9818	National Institutes of Health [P30 CA008748, R01 CA236615-01, R01 CA235667]; U.S. Department of Defense [BC132124, LC160212, CA170630, CA180889]; Comedy vs. Cancer Award; Druckenmiller Center for Lung Cancer Research Fellowship; Emerson Collective Cancer Research Fund; Esophageal Cancer Education Fund; Memorial Sloan Kettering Technology Development Fund; Miner Fund for Mesothelioma Research; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center; Batishwa Fellowship	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense(United States Department of Defense); Comedy vs. Cancer Award; Druckenmiller Center for Lung Cancer Research Fellowship; Emerson Collective Cancer Research Fund; Esophageal Cancer Education Fund; Memorial Sloan Kettering Technology Development Fund; Miner Fund for Mesothelioma Research; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center; Batishwa Fellowship	PA's laboratory work was supported by grants from the National Institutes of Health (P30 CA008748, R01 CA236615-01, and R01 CA235667), the U.S. Department of Defense (BC132124, LC160212, CA170630, and CA180889), the Batishwa Fellowship, the Comedy vs. Cancer Award, the Druckenmiller Center for Lung Cancer Research Fellowship, the Emerson Collective Cancer Research Fund, the Esophageal Cancer Education Fund, the Memorial Sloan Kettering Technology Development Fund, the Miner Fund for Mesothelioma Research, the Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center.	Adusumilli PS, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010162; Akhavan D, 2019, IMMUNOL REV, V290, P60, DOI 10.1111/imr.12773; Bachanova V, 2020, BLOOD REV, V40, DOI 10.1016/j.blre.2019.100640; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Grosser R, 2019, CANCER CELL, V36, P471, DOI 10.1016/j.ccell.2019.09.006; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Mulazzani M, 2019, P NATL ACAD SCI USA, V116, P24275, DOI 10.1073/pnas.1903854116; Sehn LH, 2015, BLOOD, V125, P22, DOI 10.1182/blood-2014-05-577189; Tahmasebi S, 2019, STEM CELL REV REP, V15, P619, DOI 10.1007/s12015-019-09901-7	10	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2020	11								1503	10.3389/fimmu.2020.01503	http://dx.doi.org/10.3389/fimmu.2020.01503			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MY6FO	32793205	Green Published, gold			2022-12-18	WOS:000558510900001
J	Suzuki, AS; Yagi, R; Kimura, MY; Iwamura, C; Shinoda, K; Onodera, A; Hirahara, K; Tumes, DJ; Koyama-Nasu, R; Iismaa, SE; Graham, RM; Motohashi, S; Nakayama, T				Suzuki, Akane S.; Yagi, Ryoji; Kimura, Motoko Y.; Iwamura, Chiaki; Shinoda, Kenta; Onodera, Atsushi; Hirahara, Kiyoshi; Tumes, Damon J.; Koyama-Nasu, Ryo; Iismaa, Siiri E.; Graham, Robert M.; Motohashi, Shinichiro; Nakayama, Toshinori			Essential Role for CD30-Transglutaminase 2 Axis in Memory Th1 and Th17 Cell Generation	FRONTIERS IN IMMUNOLOGY			English	Article						TG2; CD30; memory Th cell generation; Th17; Th1; memory precursor; airway inflammation	CD4(+) T-CELLS; CROSS-LINKING; EFFECTOR; TRANSGLUTAMINASE; DIFFERENTIATION; MAINTENANCE; RESPONSES; PLASTICITY; CD30; INFLAMMATION	Memory helper T (Th) cells are crucial for secondary immune responses against infectious microorganisms but also drive the pathogenesis of chronic inflammatory diseases. Therefore, it is of fundamental importance to understand how memory T cells are generated. However, the molecular mechanisms governing memory Th cell generation remain incompletely understood. Here, we identified CD30 as a molecule heterogeneously expressed on effector Th1 and Th17 cells, and CD30(hi)effector Th1 and Th17 cells preferentially generated memory Th1 and Th17 cells. We found that CD30 mediated signal induced Transglutaminase-2 (TG2) expression, and that the TG2 expression in effector Th cells is essential for memory Th cell generation. In fact,Cd30-deficiency resulted in the impaired generation of memory Th1 and Th17 cells, which can be rescued by overexpression of TG2. Furthermore,transglutaminase-2(Tgm2)-deficient CD4 T cells failed to become memory Th cells. As a result, T cells fromTgm2-deficient mice displayed impaired antigen-specific antibody production and attenuated Th17-mediated allergic responses. Our data indicate that CD30-induced TG2 expression in effector Th cells is essential for the generation of memory Th1 and Th17 cells, and that CD30 can be a marker for precursors of memory Th1 and Th17 cells.	[Suzuki, Akane S.; Motohashi, Shinichiro] Chiba Univ, Grad Sch Med, Dept Med Immunol, Chiba, Japan; [Yagi, Ryoji; Kimura, Motoko Y.; Iwamura, Chiaki; Shinoda, Kenta; Onodera, Atsushi; Hirahara, Kiyoshi; Tumes, Damon J.; Koyama-Nasu, Ryo; Nakayama, Toshinori] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan; [Onodera, Atsushi] Chiba Univ, Inst Global Prominent Res, Chiba, Japan; [Tumes, Damon J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Tumes, Damon J.] Univ South Australia, Adelaide, SA, Australia; [Iismaa, Siiri E.; Graham, Robert M.] Victor Chang Cardiac Res Inst, Mol Cardiol & Biophys Div, Sydney, NSW, Australia	Chiba University; Chiba University; Chiba University; Centre for Cancer Biology; SA Pathology; University of South Australia; Victor Chang Cardiac Research Institute	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan.	tnakayama@faculty.chiba-u.jp	Tumes, Damon J/B-9917-2009; Hirahara, Kiyoshi/E-2460-2017; Iismaa, Siiri/C-9300-2013	Tumes, Damon J/0000-0001-5709-857X; Hirahara, Kiyoshi/0000-0002-9128-9449; Iismaa, Siiri/0000-0003-2409-7356	Ministry of Education, Culture, Sports, Science and Technology (MEXT Japan) [26221305, JP19H05650, 15K08523, 15K08524, 17K08876]; Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from AMED [JP19ek0410060, JP19ek0410045]; Takeda Science Foundation; Naito Foundation; Japanese Society for the Promotion of Science postdoctoral fellowship [24790460, 26860315]; AMED-CREST, AMED [JP19gm1210003]	Ministry of Education, Culture, Sports, Science and Technology (MEXT Japan)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from AMED; Takeda Science Foundation(Takeda Science Foundation (TSF)); Naito Foundation(Naito Memorial Foundation); Japanese Society for the Promotion of Science postdoctoral fellowship(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); AMED-CREST, AMED	This work was supported by the following grants: Ministry of Education, Culture, Sports, Science and Technology (MEXT Japan) Grants-in-Aid for Scientific Research (S) 26221305, JP19H05650 (C) 15K08523, 15K08524, and 17K08876; Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from AMED (JP19ek0410060 and JP19ek0410045); AMED-CREST, AMED (JP19gm1210003), Takeda Science Foundation; and the Naito Foundation. A. S. Suzuki was supported by a Japanese Society for the Promotion of Science postdoctoral fellowship (#24790460 and 26860315).	Ahlers JD, 2010, TRENDS MOL MED, V16, P478, DOI 10.1016/j.molmed.2010.07.007; Ahmed R, 2009, NAT REV IMMUNOL, V9, P662, DOI 10.1038/nri2619; Arens R, 2010, IMMUNOL REV, V235, P190, DOI 10.1111/j.0105-2896.2010.00899.x; Croft M, 2014, SEMIN IMMUNOL, V26, P183, DOI 10.1016/j.smim.2014.02.005; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Dooms H, 2007, J EXP MED, V204, P547, DOI 10.1084/jem.20062381; Eckert RL, 2014, PHYSIOL REV, V94, P383, DOI 10.1152/physrev.00019.2013; Endo Y, 2019, NAT METAB, V1, P261, DOI 10.1038/s42255-018-0025-4; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Gaspal F, 2008, J IMMUNOL, V180, P2824, DOI 10.4049/jimmunol.180.5.2824; Gaspal FMC, 2005, J IMMUNOL, V174, P3891, DOI 10.4049/jimmunol.174.7.3891; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; Gundemir S, 2012, BBA-MOL CELL RES, V1823, P406, DOI 10.1016/j.bbamcr.2011.09.012; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Huang L, 2015, AM J CANCER RES, V5, P2756; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Iwamura C, 2007, INT IMMUNOL, V19, P755, DOI 10.1093/intimm/dxm042; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Kaech SM, 2007, IMMUNITY, V27, P393, DOI 10.1016/j.immuni.2007.08.007; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; Kim JH, 2014, IMMUNOLOGY, V142, P506, DOI 10.1111/imm.12282; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Lee CS, 2017, APOPTOSIS, V22, P1057, DOI 10.1007/s10495-017-1396-9; Lees JR, 2010, IMMUNOLOGY, V130, P463, DOI 10.1111/j.1365-2567.2010.03288.x; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; MacLeod MKL, 2010, IMMUNOLOGY, V130, P10, DOI 10.1111/j.1365-2567.2010.03260.x; Maekawa Y, 2015, NAT MED, V21, P55, DOI 10.1038/nm.3758; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; McKinstry KK, 2010, IMMUNOL REV, V236, P110, DOI 10.1111/j.1600-065X.2010.00921.x; McNamee EN, 2013, IMMUNOL RES, V55, P58, DOI 10.1007/s12026-012-8349-8; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Moulton VR, 2006, J IMMUNOL, V177, P869, DOI 10.4049/jimmunol.177.2.869; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nakayama T, 2002, J IMMUNOL, V168, P87, DOI 10.4049/jimmunol.168.1.87; Nakayama T, 2008, CURR OPIN IMMUNOL, V20, P265, DOI 10.1016/j.coi.2008.03.011; Nakayama T, 2017, ANNU REV IMMUNOL, V35, P53, DOI 10.1146/annurev-immunol-051116-052350; Nakayama T, 2009, SEMIN IMMUNOL, V21, P78, DOI 10.1016/j.smim.2009.02.001; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Ndejembi MP, 2006, J IMMUNOL, V177, P7698, DOI 10.4049/jimmunol.177.11.7698; Nishimura H, 2005, J IMMUNOL, V175, P4627, DOI 10.4049/jimmunol.175.7.4627; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Reiner SL, 2014, NAT REV IMMUNOL, V14, P699, DOI 10.1038/nri3734; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029421; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Sansonetti PJ, 2007, IMMUNITY, V26, P149, DOI 10.1016/j.immuni.2007.02.004; Sarkar S, 2008, J EXP MED, V205, P625, DOI 10.1084/jem.20071641; Shinoda K, 2012, P NATL ACAD SCI USA, V109, P7409, DOI 10.1073/pnas.1118539109; Strutt TM, 2013, IMMUNOL REV, V255, P149, DOI 10.1111/imr.12088; Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105; Tatsukawa H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.150; Tatsukawa H, 2009, GASTROENTEROLOGY, V136, P1783, DOI 10.1053/j.gastro.2009.01.007; Teijaro JR, 2009, J IMMUNOL, V182, P6834, DOI 10.4049/jimmunol.0803860; Umeda K, 2011, MICROBIOL IMMUNOL, V55, P645, DOI 10.1111/j.1348-0421.2011.00362.x; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Watanabe Y, 2014, P NATL ACAD SCI USA, V111, P12829, DOI 10.1073/pnas.1321245111; Willers J, 2003, CLIN CANCER RES, V9, P2744; Williams MA, 2008, IMMUNITY, V28, P533, DOI 10.1016/j.immuni.2008.02.014; Yagi R, 2010, IMMUNITY, V32, P507, DOI 10.1016/j.immuni.2010.04.004; Yamashita M, 2004, J BIOL CHEM, V279, P39454, DOI 10.1074/jbc.M405989200; Youngblood B, 2013, IMMUNOLOGY, V139, P277, DOI 10.1111/imm.12074; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zonca S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.30	68	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2020	11								1536	10.3389/fimmu.2020.01536	http://dx.doi.org/10.3389/fimmu.2020.01536			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MY6CV	32793209	Green Accepted, Green Published			2022-12-18	WOS:000558503800001
J	Shim, D; Kim, H; Shin, SJ				Shim, Dahee; Kim, Hagyu; Shin, Sung Jae			Mycobacterium tuberculosis Infection-Driven Foamy Macrophages and Their Implications in Tuberculosis Control as Targets for Host-Directed Therapy (vol 11, 910, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Mycobacterium tuberculosis; foamy macrophage; tuberculosis; immune responses; lipid metabolism; lung inflammation; host-directed therapy			[Shim, Dahee; Kim, Hagyu; Shin, Sung Jae] Yonsei Univ, Coll Med, Dept Microbiol, Inst Immunol & Immunol Dis,Brain Korea 21 Program, Seoul, South Korea; [Shim, Dahee] Hanyang Univ, Coll Nat Sci, Res Inst Nat Sci, Dept Life Sci, Seoul, South Korea	Yonsei University; Yonsei University Health System; Hanyang University	Shin, SJ (corresponding author), Yonsei Univ, Coll Med, Dept Microbiol, Inst Immunol & Immunol Dis,Brain Korea 21 Program, Seoul, South Korea.	sjshin@yuhs.ac						Barisch C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006095; Shim D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00910	2	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2020	11								1601	10.3389/fimmu.2020.01601	http://dx.doi.org/10.3389/fimmu.2020.01601			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MU6TS	32765536	Green Published, gold			2022-12-18	WOS:000555804100001
J	Qiu, FF; Liu, HZ; Liang, CL; Nie, GD; Dai, ZH				Qiu, Feifei; Liu, Huazhen; Liang, Chun-Ling; Nie, Golay D.; Dai, Zhenhua			A New Immunosuppressive Molecule Emodin Induces both CD4(+)FoxP3(+) and CD8(+)CD122(+) Regulatory T Cells and Suppresses Murine Allograft Rejection (vol 8, 1519, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						transplant immunology; regulatory T cell; T cell; immunosuppression; allograft rejection			[Qiu, Feifei; Liu, Huazhen; Liang, Chun-Ling; Dai, Zhenhua] Guangdong Prov Hosp Chinese Med, Guangdong Prov Acad Chinese Med Sci, Sect Immunol, Guangzhou, Peoples R China; [Nie, Golay D.] Univ Texas Med Branch, Sch Med, Galveston, TX 77555 USA	Guangzhou University of Chinese Medicine; University of Texas System; University of Texas Medical Branch Galveston	Dai, ZH (corresponding author), Guangdong Prov Hosp Chinese Med, Guangdong Prov Acad Chinese Med Sci, Sect Immunol, Guangzhou, Peoples R China.	zdai2009@hotmail.com						Qiu FF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01519	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2020	11								1381	10.3389/fimmu.2020.01381	http://dx.doi.org/10.3389/fimmu.2020.01381			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MW2VI	32765495	gold, Green Published			2022-12-18	WOS:000556900800001
J	Wang, J; Dong, RR; Zou, P; Chen, YJ; Li, N; Wang, Y; Zhang, T; Pan, XZ				Wang, Jing; Dong, Ruirui; Zou, Ping; Chen, Yuejuan; Li, Na; Wang, Yao; Zhang, Ting; Pan, Xiuzhen			Identification of a Novel Linear B Cell Epitope on the Sao Protein ofStreptococcus suisSerotype 2	FRONTIERS IN IMMUNOLOGY			English	Article						Streptococcus suis; surface antigen one; B-cell epitope; ELISA; synthetic peptide; homology analysis	STREPTOCOCCUS-SUIS; SURFACE PROTEIN; PEPTIDES	Surface antigen one (Sao) protein is a bacterial surface protein identified in the important zoonotic pathogenStreptococcus suisserotype 2 (S.suis 2) during an extensive search for functional proteins. The Sao protein is anchored to the bacterial cell wall by the LPVTG motif and is widely distributed in manyS.suisserotypes. In this paper, we present the immunodominant epitope peptide of the Sao protein that is recognized by BALB/c antibodies against the Sao protein:(355)SEKQMPSVVNENAVTPEKQMTNKENDNIET(384)(location Sao(355-384)). To determine the core epitope recognized by antibodies, we prepared truncation peptide libraries. Analyses of the immunoreactivity of truncation peptides with anti-Sao(355-384)serum revealed that the most immunoreactive sequence was(355)SEKQMPSVVNENAVTPEK(372)(location Sao(355-372)). Moreover, we observed that this core epitope also showed good specificity based on the ratio of reactivity with serum fromS.suis-positive patients compared to serum fromS.suis-negative patients. Our results point to the potential of using the Sao(355-372)peptide in diagnostic assays to determineS.suisinfection in humans.	[Wang, Jing; Dong, Ruirui; Zou, Ping; Chen, Yuejuan; Li, Na; Wang, Yao; Zhang, Ting] Nanjing Med Univ, Affiliated Wuxi Matern & Child Hlth Care Hosp, Wuxi, Jiangsu, Peoples R China; [Pan, Xiuzhen] Hua Dong Res Inst Med & Biotech, Dept Microbiol, Nanjing, Peoples R China	Nanjing Medical University	Zhang, T (corresponding author), Nanjing Med Univ, Affiliated Wuxi Matern & Child Hlth Care Hosp, Wuxi, Jiangsu, Peoples R China.; Pan, XZ (corresponding author), Hua Dong Res Inst Med & Biotech, Dept Microbiol, Nanjing, Peoples R China.	zhangting040715@163.com; panxiuzhen_2004@163.com			National Natural Science Foundation of China [81701635]; National Natural Science Foundation	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This research was supported by a grant from the National Natural Science Foundation of China [Grant No. 81701635]. JW was the recipient from National Natural Science Foundation.	Abdelgawad A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138370; Carvalho GBF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182299; Chandrashekar R, 2017, VET J, V226, P6, DOI 10.1016/j.tvjl.2017.06.005; Dutkiewicz J, 2018, ANN AGR ENV MED, V25, P186, DOI 10.26444/aaem/85651; Estrada AA, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00377-19; Feliciano ND, 2016, IMMUNOL LETT, V172, P89, DOI 10.1016/j.imlet.2016.03.002; Feng YJ, 2007, FEMS MICROBIOL LETT, V275, P80, DOI 10.1111/j.1574-6968.2007.00859.x; Goyette-Desjardins G, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.45; Kerdsin A, 2012, J MED MICROBIOL, V61, P1669, DOI 10.1099/jmm.0.048587-0; Lee AJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178199; Li YY, 2006, INFECT IMMUN, V74, P305, DOI 10.1128/IAI.74.1.305-312.2006; Lu YD, 2015, SCI REP-UK, V5, DOI 10.1038/srep13364; Okura M, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5030045; Segura M, 2017, TRENDS MICROBIOL, V25, P586, DOI 10.1016/j.tim.2017.02.005; Srinivasan V, 2016, DIAGN MICR INFEC DIS, V85, P131, DOI 10.1016/j.diagmicrobio.2016.02.013; van der Wal FJ, 2016, J VIROL METHODS, V235, P15, DOI 10.1016/j.jviromet.2016.04.022; Wang L, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw091; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698; Yu HJ, 2006, EMERG INFECT DIS, V12, P914, DOI 10.3201/eid1206.051194; Zhang JH, 2013, J CLIN MICROBIOL, V51, P3250, DOI 10.1128/JCM.01183-13	20	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2020	11								1492	10.3389/fimmu.2020.01492	http://dx.doi.org/10.3389/fimmu.2020.01492			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NA3VC	32765516	gold, Green Published			2022-12-18	WOS:000559741400001
J	Sorensen, M; Kantorek, J; Byrnes, L; Boutin, S; Mall, MA; Lasitschka, F; Zabeck, H; Nguyen, D; Dalpke, AH				Soerensen, Michael; Kantorek, Julia; Byrnes, Lauren; Boutin, Sebastien; Mall, Marcus A.; Lasitschka, Felix; Zabeck, Heike; Nguyen, Dao; Dalpke, Alexander H.			Pseudomonas aeruginosa Modulates the Antiviral Response of Bronchial Epithelial Cells (vol 11, 96, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Pseudomonas aeruginosa; cystic fibrosis; virus; antiviral response; interferon; protease; LasR			[Soerensen, Michael; Kantorek, Julia; Byrnes, Lauren; Boutin, Sebastien; Dalpke, Alexander H.] Univ Hosp Heidelberg, Dept Infect Dis Med Microbiol & Hyg, Heidelberg, Germany; [Soerensen, Michael] Lab Enders & Partners, Stuttgart, Germany; [Boutin, Sebastien; Dalpke, Alexander H.] Univ Hosp Heidelberg, Translat Lung Res Ctr Heidelberg TLRC, German Ctr Lung Res DZL, Heidelberg, Germany; [Mall, Marcus A.] Charite Univ Med Berlin, Dept Pediat Pulmonol Immunol & Intens Care Med, Berlin, Germany; [Mall, Marcus A.] BIH, Berlin, Germany; [Lasitschka, Felix] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Lasitschka, Felix] German Ctr Infect Res DZIF, TI Biobanking, Heidelberg, Germany; [Zabeck, Heike] Univ Hosp Heidelberg, Thoraxklin, Heidelberg, Germany; [Nguyen, Dao] McGill Univ, Res Inst, Meakins Christie Labs, Hlth Ctr, Montreal, PQ, Canada; [Nguyen, Dao] McGill Univ, Dept Med, Montreal, PQ, Canada; [Dalpke, Alexander H.] Tech Univ Dresden, Inst Med Microbiol & Hyg, Fac Med, Dresden, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Ruprecht Karls University Heidelberg; German Center for Infection Research; Ruprecht Karls University Heidelberg; McGill University; McGill University; Technische Universitat Dresden	Dalpke, AH (corresponding author), Univ Hosp Heidelberg, Dept Infect Dis Med Microbiol & Hyg, Heidelberg, Germany.; Dalpke, AH (corresponding author), Univ Hosp Heidelberg, Translat Lung Res Ctr Heidelberg TLRC, German Ctr Lung Res DZL, Heidelberg, Germany.; Dalpke, AH (corresponding author), Tech Univ Dresden, Inst Med Microbiol & Hyg, Fac Med, Dresden, Germany.	alexander.dalpke@ukdd.de	Mall, Marcus A./AAA-1498-2022	Mall, Marcus A./0000-0002-4057-2199				Sorensen M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00096	1	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 10	2020	11								1453	10.3389/fimmu.2020.01453	http://dx.doi.org/10.3389/fimmu.2020.01453			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MU6KL	32754158	Green Published, gold			2022-12-18	WOS:000555780000001
J	Kloss, S; Dehmel, S; Braun, A; Parnham, MJ; Kohl, U; Schiffmann, S				Kloess, Stephan; Dehmel, Susann; Braun, Armin; Parnham, Michael J.; Koehl, Ulrike; Schiffmann, Susanne			From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment	FRONTIERS IN IMMUNOLOGY			English	Review						immunotherapy; immune tolerance; checkpoint inhibitors; chimeric antigen receptors (CARs); autoimmune disease	SYSTEMIC-LUPUS-ERYTHEMATOSUS; STEM-CELL TRANSPLANTATION; NK CELLS; T-CELLS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ENCEPHALOMYELITIS; CARCINOEMBRYONIC ANTIGEN; PROTEASOME INHIBITORS; MULTIPLE-SCLEROSIS; POTENTIAL ROLE	Success in cancer treatment over the last four decades has ranged from improvements in classical drug therapy to immune oncology. Anti-cancer drugs have also often proven beneficial for the treatment of inflammatory and autoimmune diseases. In this review, we report on challenging examples that bridge between treatment of cancer and immune-mediated diseases, addressing mechanisms and experimental models as well as clinical investigations. Patient-derived tumor xenograft (PDX) (humanized) mouse models represent useful tools for preclinical evaluation of new therapies and biomarker identification. However, new developments using humanex vivoapproaches modeling cancer, for example in microfluidic human organs-on-chips, promise to identify key molecular, cellular and immunological features of human cancer progression in a fully human setting. Classical drugs which bridge the gap, for instance, include cytotoxic drugs, proteasome inhibitors, PI3K/mTOR inhibitors and metabolic inhibitors. Biologicals developed for cancer therapy have also shown efficacy in the treatment of autoimmune diseases. In immune oncology, redirected chimeric antigen receptor (CAR) T cells have achieved spectacular remissions in refractory B cell leukemia and lymphoma and are currently under development for tolerance induction using cell-based therapies such as CAR Tregs or NK cells. Finally, a brief outline will be given of the lessons learned from bridging cancer and autoimmune diseases as well as tolerance induction.	[Kloess, Stephan; Koehl, Ulrike] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany; [Kloess, Stephan; Koehl, Ulrike] Hannover Med Sch MHH, Inst Cellular Therapeut, Hannover, Germany; [Dehmel, Susann; Braun, Armin] Fraunhofer Inst Toxicol & Expt Med ITEM, Hannover, Germany; [Parnham, Michael J.] Fraunhofer Inst Mol Biol & Appl Ecol IME, Frankfurt, Germany; [Parnham, Michael J.; Koehl, Ulrike] Fraunhofer Cluster Excellence Immune Mediated Dis, Frankfurt, Germany; [Koehl, Ulrike] Univ Leipzig, Inst Clin Immunol, Leipzig, Germany; [Schiffmann, Susanne] Univ Hosp Frankfurt, Inst Clin Pharmacol, Frankfurt, Germany; [Schiffmann, Susanne] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol TMP, Frankfurt, Germany	Fraunhofer Gesellschaft; Hannover Medical School; Fraunhofer Gesellschaft; Fraunhofer Gesellschaft; Leipzig University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Fraunhofer Gesellschaft	Kloss, S (corresponding author), Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany.; Kloss, S (corresponding author), Hannover Med Sch MHH, Inst Cellular Therapeut, Hannover, Germany.	stephan.kbess@izi.fraunhofer.de	Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463	Landesoffensive zur Entwicklung wissenschaftlich-okonomischer Exzellenz (LOEWE), Center Translationale Medizin und Pharmakologie (TMP); LOEWE Center Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases (DRUID); LOEWE Center Translational Biodiversity Genomics (TBG)	Landesoffensive zur Entwicklung wissenschaftlich-okonomischer Exzellenz (LOEWE), Center Translationale Medizin und Pharmakologie (TMP); LOEWE Center Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases (DRUID); LOEWE Center Translational Biodiversity Genomics (TBG)	This work was supported by the Landesoffensive zur Entwicklung wissenschaftlich-okonomischer Exzellenz (LOEWE), Center Translationale Medizin und Pharmakologie (TMP), the LOEWE Center Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases (DRUID) and the LOEWE Center Translational Biodiversity Genomics (TBG).	Albornoz N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143379; Aleksandrova K, 2019, TRANSFUS MED HEMOTH, V46, P47, DOI 10.1159/000495772; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Atkins MB, 2009, NAT REV DRUG DISCOV, V8, P535, DOI 10.1038/nrd2924; Baay-Guzman GJ, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-60; Baharlooi H, 2020, INT J STEM CELLS, V13, P13, DOI 10.15283/ijsc19108; Barbado J, 2018, LUPUS, V27, P2161, DOI 10.1177/0961203318804922; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Berinstein NL, 1998, ANN ONCOL, V9, P995, DOI 10.1023/A:1008416911099; Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006; Bishop MR, 2019, BLOOD ADV, V3, P2230, DOI 10.1182/bloodadvances.2019000151; Blat D, 2014, MOL THER, V22, P1018, DOI 10.1038/mt.2014.41; Blunt MD, 2020, INT J IMMUNOGENET, V47, P1, DOI 10.1111/iji.12461; Boardman DA, 2019, NAT BIOMED ENG, V3, P259, DOI 10.1038/s41551-019-0359-6; Bork U, 2015, BRIT J CANCER, V112, P1306, DOI 10.1038/bjc.2015.88; Boross P, 2012, AM J CANCER RES, V2, P676; Bruno S, 2015, IMMUNOL LETT, V168, P154, DOI 10.1016/j.imlet.2015.06.007; Bruyn GAW, 2008, ANN RHEUM DIS, V67, P1090, DOI 10.1136/ard.2007.078808; Cane G, 2010, CELL MICROBIOL, V12, P640, DOI 10.1111/j.1462-5822.2009.01422.x; Capasso A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0518-z; Chamberlain PP, 2019, NAT CHEM BIOL, V15, P937, DOI 10.1038/s41589-019-0362-y; Cheng RJ, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00285; Chmielewski M, 2015, EXPERT OPIN BIOL TH, V15, P1145, DOI 10.1517/14712598.2015.1046430; Ciccocioppo R, 2015, MAYO CLIN PROC, V90, P747, DOI 10.1016/j.mayocp.2015.03.023; Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841; Claes N, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00642; Curran MP, 2009, DRUGS, V69, P859, DOI 10.2165/00003495-200969070-00006; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Dawson NAJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123672; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Duijvestein M, 2010, GUT, V59, P1662, DOI 10.1136/gut.2010.215152; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Ferreira LMR, 2019, NAT REV DRUG DISCOV, V18, P749, DOI 10.1038/s41573-019-0041-4; Fong ELS, 2016, BIOMATERIALS, V108, P197, DOI 10.1016/j.biomaterials.2016.08.052; Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9; Fraser AG, 2003, EUR J GASTROEN HEPAT, V15, P225, DOI 10.1097/00042737-200303000-00003; Gerdtsson Anna S, 2019, Oncotarget, V10, P7016, DOI 10.18632/oncotarget.27271; Gremese E, 2019, J LEUKOCYTE BIOL, V106, P1063, DOI 10.1002/JLB.5RU0519-145R; Guedan S, 2019, ANNU REV IMMUNOL, V37, P145, DOI 10.1146/annurev-immunol-042718-041407; Hagner Nicole, 2010, Cancer Manag Res, V2, P293, DOI 10.2147/CMR.S10043; Harrell CR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121605; Hartmann J, 2017, EMBO MOL MED, V9, P1183, DOI 10.15252/emmm.201607485; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hess A, 2016, TOXICOL IN VITRO, V32, P347, DOI 10.1016/j.tiv.2016.01.006; Hideshima T, 2011, MOL CANCER THER, V10, P2034, DOI 10.1158/1535-7163.MCT-11-0433; Holdaas H, 2016, J TRANSPLANT, V2016, DOI 10.1155/2016/4369574; Hollyman D, 2009, J IMMUNOTHER, V32, P169, DOI 10.1097/CJI.0b013e318194a6e8; Holzapfel BM, 2015, STEM CELLS, V33, P1696, DOI 10.1002/stem.1978; Holzinger Astrid, 2020, Recent Results Cancer Res, V214, P93, DOI 10.1007/978-3-030-23765-3_3; Holzinger A, 2016, CANCER IMMUNOL IMMUN, V65, P1433, DOI 10.1007/s00262-016-1895-5; Hwang HJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1225-9; Ikebe C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/951512; Inoue A, 2019, CANCERS, V11, DOI 10.3390/cancers11091321; Jha AK, 2015, IMMUNITY, V42, P419, DOI 10.1016/j.immuni.2015.02.005; Jiang W, 2017, P NATL ACAD SCI USA, V114, pE6202, DOI 10.1073/pnas.1705491114; Johansson S, 2006, CURR TOP MICROBIOL, V298, P259; Johansson S, 2005, TRENDS IMMUNOL, V26, P613, DOI 10.1016/j.it.2005.08.008; Kang BJ, 2020, TUBERC RESPIR DIS, V83, P61, DOI 10.4046/trd.2019.0048; Kelly CM, 2016, J GASTROINTEST ONCOL, V7, P750, DOI 10.21037/jgo.2016.06.10; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kochall S, 2017, JOVE-J VIS EXP, V125, P55357, DOI [10.3791/5535728745637, DOI 10.3791/5535728745637]; Koehl U, 2005, KLIN PADIATR, V217, P345, DOI 10.1055/s-2005-872520; Kohl U, 2018, HUM GENE THER, V29, P559, DOI 10.1089/hum.2017.254; Koga Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050418; Kohler S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024523; Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559; Lalu MM, 2012, CRIT CARE MED, V40, P1373, DOI 10.1097/CCM.0b013e31824317f7; Lang PA, 2012, P NATL ACAD SCI USA, V109, P1210, DOI 10.1073/pnas.1118834109; Lazo JS, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.527; Le CT, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0789-4; Lee JC, 2011, CANCER RES, V71, P2871, DOI 10.1158/0008-5472.CAN-10-0552; Lee JY, 2015, ONCOTARGET, V6, P25619, DOI 10.18632/oncotarget.4627; Levine TD, 1999, NEUROLOGY, V52, P1701, DOI 10.1212/WNL.52.8.1701; Li X, 2013, BONE MARROW TRANSPL, V48, P544, DOI 10.1038/bmt.2012.184; Liang J, 2010, ANN RHEUM DIS, V69, P1423, DOI 10.1136/ard.2009.123463; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Loza MJ, 2002, EUR J IMMUNOL, V32, P3453, DOI 10.1002/1521-4141(200212)32:12<3453::AID-IMMU3453>3.0.CO;2-D; Lu JH, 2019, JOVE-J VIS EXP, V149, DOI 10.3791/5987131380849; Lunemann A, 2009, MOL MED, V15, P352, DOI 10.2119/molmed.2009.00035; MacDonald KG, 2016, J CLIN INVEST, V126, P1413, DOI 10.1172/JCI82771; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Mathur L, 2020, SMALL, V16, DOI 10.1002/smll.201904321; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; McLaughlin KA, 2008, ADV IMMUNOL, V98, P121, DOI 10.1016/S0065-2776(08)00404-5; Meijer TG, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2017-0003; Mekala DJ, 2005, BLOOD, V105, P2090, DOI 10.1182/blood-2004-09-3579; Miflin G, 1997, BONE MARROW TRANSPL, V19, P9, DOI 10.1038/sj.bmt.1700603; Mitra A, 2013, TRENDS BIOTECHNOL, V31, P347, DOI 10.1016/j.tibtech.2013.03.006; Musette P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00622; Nagaraj AS, 2018, JOVE-J VIS EXP, DOI 10.3791/58569; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Oki T, 2004, J NEUROL SCI, V222, P7, DOI 10.1016/j.jns.2004.03.026; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Passweg JR, 2000, BONE MARROW TRANSPL, V26, P1033, DOI 10.1038/sj.bmt.1702669; Plaks V, 2013, SCIENCE, V341, P1186, DOI 10.1126/science.1235226; Plosker GL, 2003, DRUGS, V63, P803, DOI 10.2165/00003495-200363080-00005; Ponticelli C, 2018, AUTOIMMUN REV, V17, P1022, DOI 10.1016/j.autrev.2018.04.007; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Qin WT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02298; Rajitha P, 2017, CURR PHARM DESIGN, V23, P3550, DOI 10.2174/1381612823666170601105439; Royce ME, 2015, BREAST CANCER-BASIC, V9, DOI 10.4137/BCBCR.S29268; Saeedi Pardis, 2019, Stem Cell Investig, V6, P34, DOI 10.21037/sci.2019.08.11; Saito R, 2020, INT J CLIN ONCOL, V25, P831, DOI 10.1007/s10147-019-01520-z; Schilsky RL, 2010, NAT REV DRUG DISCOV, V9, P363, DOI 10.1038/nrd3181; Schioppo T, 2017, DRUG DES DEV THER, V11, P2891, DOI 10.2147/DDDT.S139248; Schuster IS, 2014, IMMUNITY, V41, P646, DOI 10.1016/j.immuni.2014.09.013; Schuster SJ, 2017, NEW ENGL J MED, V377, P2545, DOI 10.1056/NEJMoa1708566; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Siegler EL, 2018, HUM GENE THER, V29, P534, DOI 10.1089/hum.2017.243; Sivori S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101702; Skuljec J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01125; Smithson JE, 1996, J PATHOL, V180, P146, DOI 10.1002/(SICI)1096-9896(199610)180:2<146::AID-PATH643>3.0.CO;2-E; Sorensen PS, 2016, THER ADV NEUROL DISO, V9, P44, DOI 10.1177/1756285615601933; Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Stohl W, 2014, EXPERT OPIN THER TAR, V18, P473, DOI 10.1517/14728222.2014.888415; Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68; Swords RT, 2018, BLOOD, V131, P1415, DOI 10.1182/blood-2017-09-805895; Takahashi K, 2004, BRAIN, V127, P1917, DOI 10.1093/brain/awh219; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; ter Heine R, 2018, BRIT J CLIN PHARMACO, V84, P1575, DOI 10.1111/bcp.13591; Trusheim MR, 2011, NAT REV DRUG DISCOV, V10, P817, DOI 10.1038/nrd3557; Uchida Junji, 2018, World J Transplant, V8, P150, DOI 10.5500/wjt.v8.i5.150; Velardi A, 2002, TRENDS IMMUNOL, V23, P438, DOI 10.1016/S1471-4906(02)02284-6; Verbrugge SE, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0529-1; von Knethen A, 2019, THERANOSTICS, V9, P2003, DOI 10.7150/thno.28057; Waggoner SN, 2010, J CLIN INVEST, V120, P1925, DOI 10.1172/JCI41264; Walsh AJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep18889; Wang DD, 2017, CLIN EXP MED, V17, P333, DOI 10.1007/s10238-016-0427-0; Wang DD, 2017, CELL MOL IMMUNOL, V14, P423, DOI 10.1038/cmi.2015.89; Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769, 10.3727/096368911X582769c]; Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-19; Wang WX, 2020, CANCER LETT, V472, P175, DOI 10.1016/j.canlet.2019.11.033; Wang XY, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.15; Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weinblatt Michael E, 2013, Trans Am Clin Climatol Assoc, V124, P16; Wolf S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194975; Xi JJ, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111646; Yakoub-Agha I, 2020, HAEMATOLOGICA, V105, P297, DOI 10.3324/haematol.2019.229781; Yang CL, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1687-x; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yip H, 2019, AM J CLIN EXP UROL, V7, P313; Yoshida GJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0829-z; Ytting H, 2015, SCAND J GASTROENTERO, V50, P1025, DOI 10.3109/00365521.2014.998271; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677; Zhang C, 2017, J AUTOIMMUN, V83, P22, DOI 10.1016/j.jaut.2017.02.005	151	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2020	11								1423	10.3389/fimmu.2020.01423	http://dx.doi.org/10.3389/fimmu.2020.01423			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MS1FF	32733473	Green Published, gold			2022-12-18	WOS:000554029800001
J	Dutta, NK; Schneider, BE				Dutta, Noton K.; Schneider, Bianca E.			Are There Sex-Specific Differences in Response to Adjunctive Host-Directed Therapies for Tuberculosis?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Mycobacterium tuberculosis; tuberculosis; host directed therapy; statins; treatment outcome; sex-specific differences; male-bias; mouse models	STATIN USE; RISK; SUSCEPTIBILITY; TESTOSTERONE; SIMVASTATIN; MACROPHAGES; MICE		[Dutta, Noton K.] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA; [Schneider, Bianca E.] Leibniz Lung Ctr, Res Ctr Borstel, Prior Res Area Infect, Jr Res Grp Coinfect, Borstel, Germany	Johns Hopkins University; Forschungszentrum Borstel	Dutta, NK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21205 USA.	ndutta1@jhmi.edu		Dutta, Noton/0000-0002-5066-3342				Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bruiners N, 2020, BIORXIV, DOI [10.2139/ssrn.3552811, DOI 10.2139/SSRN.3552811]; Chamekh M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01806; D'Agostino P, 1999, ANN NY ACAD SCI, V876, P426, DOI 10.1111/j.1749-6632.1999.tb07667.x; Dibbern J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11438-z; Duan HZ, 2020, INT J INFECT DIS, V93, P168, DOI 10.1016/j.ijid.2020.01.036; Dutta NK, 2019, J INFECT DIS, V221, P1079, DOI [10.1093/infdis/jiz51731605489, DOI 10.1093/INFDIS/JIZ51731605489]; Dutta NK, 2020, J INFECT DIS, V222, P336, DOI 10.1093/infdis/jiz676; Dutta NK, 2016, J ANTIMICROB CHEMOTH, V71, P1570, DOI 10.1093/jac/dkw014; Frank DJ, 2019, J INFECT DIS, V219, P1518, DOI 10.1093/infdis/jiy712; Gourdy P, 2005, BLOOD, V105, P2415, DOI 10.1182/blood-2004-07-2819; Hargreaves JR, 2011, AM J PUBLIC HEALTH, V101, P654, DOI 10.2105/AJPH.2010.199505; Hennessy E, 2016, ANTIMICROB AGENTS CH, V60, P5111, DOI 10.1128/AAC.00192-16; Hertz D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61503-3; Hertz D, 2019, SEMIN IMMUNOPATHOL, V41, P225, DOI 10.1007/s00281-018-0725-6; Bini EI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093831; Janele D, 2006, ANN NY ACAD SCI, V1069, P168, DOI 10.1196/annals.1351.015; Kak Gunjan, 2018, BioMolecular Concepts, V9, P64, DOI 10.1515/bmc-2018-0007; Karp I, 2007, CAN MED ASSOC J, V176, P333, DOI 10.1503/cmaj.060627; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Lai CC, 2016, THORAX, V71, P646, DOI 10.1136/thoraxjnl-2015-207052; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Nakajima K, 1999, CLIN THER, V21, P2047, DOI 10.1016/S0149-2918(00)87236-7; Neyrolles O, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000199; Nhamoyebonde S, 2014, J INFECT DIS, V209, pS100, DOI 10.1093/infdis/jiu147; OHTAWA M, 1992, EUR J DRUG METAB PH, V17, P175, DOI 10.1007/BF03190142; Pace S, 2017, J CLIN INVEST, V127, P3167, DOI 10.1172/JCI92885; Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550; Pineros AR, 2017, SCI REP-UK, V7, DOI 10.1038/srep41240; Refai A, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00327; Rettew JA, 2008, BIOL REPROD, V78, P432, DOI 10.1095/biolreprod.107.063545; Sada-Ovalle I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000239; Su VYF, 2017, CHEST, V152, P598, DOI 10.1016/j.chest.2017.04.170; Vilaplana C, 2013, J INFECT DIS, V208, P199, DOI 10.1093/infdis/jit152; Vree Tom B, 2003, ScientificWorldJournal, V3, P1332; World Health Organization, 2019, GLOB TUB REP 2019; YAMAMOTO Y, 1990, AM REV RESPIR DIS, V142, P430, DOI 10.1164/ajrccm/142.2.430; Yang Z, 2014, ELIFE, V3, DOI 10.7554/eLife.03711; Zissimopoulos JM, 2017, JAMA NEUROL, V74, P225, DOI [10.1001/jamaneurol.2016.3783, 10.1001/ja]	39	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1465	10.3389/fimmu.2020.01465	http://dx.doi.org/10.3389/fimmu.2020.01465			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR1UR	32733484	Green Published, gold			2022-12-18	WOS:000553377300001
J	Laplagne, C; Meddour, S; Figarol, S; Michelas, M; Calvayrac, O; Favre, G; Laurent, C; Fournie, JJ; Cabantous, S; Poupot, M				Laplagne, Chloe; Meddour, Sarah; Figarol, Sarah; Michelas, Marie; Calvayrac, Olivier; Favre, Gilles; Laurent, Camille; Fournie, Jean-Jacques; Cabantous, Stephanie; Poupot, Mary			V gamma 9V delta 2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						RHOB; V gamma 9V delta 2 T cells; phosphoantigen; endosomes; split-GFP; TCR activation	IN-VIVO; EXPRESSION; RECOGNITION; INHIBITORS	V gamma 9V delta 2 T cells are known to be efficient anti-tumor effectors activated through phosphoantigens (PAg) that are naturally expressed by tumor cells or induced by amino bisphosphonates treatment. This PAg-activation which is TCR and butyrophilin BTN3A dependent can be modulated by NKG2D ligands, immune checkpoint ligands, adhesion molecules, and costimulatory molecules. This could explain the immune-resistance observed in certain clinical trials based on V gamma 9V delta 2 T cells therapies. In NSCLC, encouraging responses were obtained with zoledronate administrations for 50% of patients. According to thein vivoresults, we showed that thein vitroV gamma 9V delta 2 T cell reactivity depends on the NSCLC cell line considered. If the PAg-pretreated KRAS mutated A549 is highly recognized and killed by V gamma 9V delta 2 T cells, the EGFR mutated PC9 remains resistant to these killers despite a pre-treatment either with zoledronate or with exogenous BrHPP. The immune resistance of PC9 was shown not to be due to immune checkpoint ligands able to counterbalance NKG2D ligands or adhesion molecules such as ICAM-1 highly expressed by PC9. RHOB has been shown to be involved in the V gamma 9V delta 2 TCR signaling against these NSCLC cell lines, in this study we therefore focused on its intracellular behavior. In comparison to a uniform distribution of RHOB in endosomes and at the plasma membrane in A549, the presence of large endosomal clusters of RHOB was visualized by a split-GFP system, suggesting that RHOB rerouting in the PC9 tumor cell could impair the reactivity of the immune response.	[Laplagne, Chloe; Meddour, Sarah; Figarol, Sarah; Michelas, Marie; Calvayrac, Olivier; Favre, Gilles; Laurent, Camille; Fournie, Jean-Jacques; Cabantous, Stephanie; Poupot, Mary] Inserm UMR1037, Ctr Rech Cancerol Toulouse, Toulouse, France; [Laplagne, Chloe; Meddour, Sarah; Figarol, Sarah; Michelas, Marie; Calvayrac, Olivier; Favre, Gilles; Laurent, Camille; Fournie, Jean-Jacques; Cabantous, Stephanie; Poupot, Mary] Univ Toulouse III Paul Sabatier, Toulouse, France; [Laplagne, Chloe; Meddour, Sarah; Figarol, Sarah; Michelas, Marie; Calvayrac, Olivier; Favre, Gilles; Laurent, Camille; Fournie, Jean-Jacques; Cabantous, Stephanie; Poupot, Mary] ERL 5294 CNRS, Toulouse, France; [Favre, Gilles; Laurent, Camille] IUCT O, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Poupot, M (corresponding author), Inserm UMR1037, Ctr Rech Cancerol Toulouse, Toulouse, France.; Poupot, M (corresponding author), Univ Toulouse III Paul Sabatier, Toulouse, France.; Poupot, M (corresponding author), ERL 5294 CNRS, Toulouse, France.	mary.poupot@inserm.fr	Cabantous, Stephanie/AAB-5113-2020; FAVRE, Gilles/K-9189-2014; Cabantous, Stephanie/M-3282-2014	Cabantous, Stephanie/0000-0002-8406-9421; FAVRE, Gilles/0000-0002-2344-1883; Cabantous, Stephanie/0000-0002-8406-9421; SARAH, FIGAROL/0000-0002-3863-563X	INSERM, CNRS; University Hospital of Bordeaux; Toulouse III University	INSERM, CNRS; University Hospital of Bordeaux; Toulouse III University	This work was funded by INSERM, CNRS, the University Hospital of Bordeaux and Toulouse III University.	Cabantous S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02854; Calvayrac O, 2017, EMBO MOL MED, V9, P238, DOI 10.15252/emmm.201606646; Calvayrac O, 2014, CLIN CANCER RES, V20, P6541, DOI 10.1158/1078-0432.CCR-14-0506; Casetti R, 2005, J IMMUNOL, V175, P1593, DOI 10.4049/jimmunol.175.3.1593; Corvaisier M, 2005, J IMMUNOL, V175, P5481, DOI 10.4049/jimmunol.175.8.5481; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Fournie JJ, 2013, CELL MOL IMMUNOL, V10, P35, DOI 10.1038/cmi.2012.39; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Girard P, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1601483; Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; Hebbeler AM, 2007, CANCER IMMUNOL IMMUN, V56, P819, DOI 10.1007/s00262-006-0235-6; Izumi H, 2018, LUNG CANCER, V122, P200, DOI 10.1016/j.lungcan.2018.06.022; Kabelitz D, 2004, J IMMUNOL, V173, P6767, DOI 10.4049/jimmunol.173.11.6767; Kakimi K, 2014, TRANSL LUNG CANCER R, V3, P23, DOI 10.3978/j.issn.2218-6751.2013.11.01; Kamon H, 2006, EMBO J, V25, P4108, DOI 10.1038/sj.emboj.7601286; Karunakaran MM, 2020, IMMUNITY, V52, P487, DOI 10.1016/j.immuni.2020.02.014; Koraichi F, 2018, J CELL SCI, V131, DOI 10.1242/jcs.210419; Liu SY, 2017, MOL IMMUNOL, V87, P200, DOI 10.1016/j.molimm.2017.04.015; Liu ZY, 2009, J GASTROEN HEPATOL, V24, P900, DOI 10.1111/j.1440-1746.2008.05668.x; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Ocana-Morgner C, 2009, BLOOD, V113, P1474, DOI 10.1182/blood-2008-04-152587; Perez-Sala D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008117; Poupot M, 2004, IMMUNOL LETT, V95, P129, DOI 10.1016/j.imlet.2004.06.013; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365-2141.2008.07435.x; Rossi C, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1554175; Rothbauer U, 2008, MOL CELL PROTEOMICS, V7, P282, DOI 10.1074/mcp.M700342-MCP200; Sebestyen Z, 2016, CELL REP, V15, P1973, DOI 10.1016/j.celrep.2016.04.081; Sharma A, 2018, J IMMUNOL, V201, P2452, DOI 10.4049/jimmunol.1800537; Sicard H, 2005, J IMMUNOL, V175, P5471, DOI 10.4049/jimmunol.175.8.5471; Wherlock M, 2004, J CELL SCI, V117, P3221, DOI 10.1242/jcs.01193	33	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1396	10.3389/fimmu.2020.01396	http://dx.doi.org/10.3389/fimmu.2020.01396			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR2GH	32733462	Green Published, gold			2022-12-18	WOS:000553407600001
J	Singh, S; Yanow, SK; Agrawal, B				Singh, Shakti; Yanow, Stephanie K.; Agrawal, Babita			Editorial: Heterologous Immunity: Implications and Applications in Vaccines and Immunotherapies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						heterologous immunity; trained immunity; vaccines; immunotherapies; autoimmunity			[Singh, Shakti] Harbor UCLA Med Ctr, Lundquist Inst Biomed Innovat, Torrance, CA 90509 USA; [Yanow, Stephanie K.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Agrawal, Babita] Univ Alberta, Fac Med & Dent, Dept Surg, Edmonton, AB, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Alberta; University of Alberta	Agrawal, B (corresponding author), Univ Alberta, Fac Med & Dent, Dept Surg, Edmonton, AB, Canada.	bagrawal@ualberta.ca	singh, shakti/D-4070-2014	singh, shakti/0000-0001-6521-0998					0	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1408	10.3389/fimmu.2020.01408	http://dx.doi.org/10.3389/fimmu.2020.01408			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR2CO	32774334	Green Published, gold			2022-12-18	WOS:000553397900001
J	Fisher, KL; Mabuka, JM; Sivro, A; Ngcapu, S; Passmore, JAS; Osman, F; Ndlovu, B; Karim, QA; Karim, SSA; Chung, AW; Baxter, C; Archary, D				Fisher, Kimone Leigh; Mabuka, Jennifer M.; Sivro, Aida; Ngcapu, Sinaye; Passmore, Jo-Ann Shelley; Osman, Farzana; Ndlovu, Bongiwe; Karim, Quarraisha Abdool; Karim, Salim S. Abdool; Chung, Amy W.; Baxter, Cheryl; Archary, Derseree			Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women	FRONTIERS IN IMMUNOLOGY			English	Article						Fc-mediated activity; tenofovir; HIV; women; ADCC-antibody dependent cellular cytotoxicity; ADNP; genital tract	PROTECTIVE EFFICACY; SHIV CHALLENGE; GENITAL-TRACT; VACCINE; INFECTION; CYTOTOXICITY; IGG; RESPONSES; VIRUS; INDIVIDUALS	The RV144 HIV-vaccine trial highlighted the importance of envelope-specific non-neutralizing antibody (nNAb) Fc-mediated functions as immune correlates of reduced risk of infection. Since pre-exposure prophylaxis (PrEP) and HIV-vaccines are being used as a combination prevention strategy in at risk populations, the effects of PrEP on nNAb functions both mucosally and systemically remain undefined. Previous animal and human studies demonstrated reduced HIV-specific antibody binding avidity post-HIV seroconversion with PrEP, which in turn may affect antibody functionality. In seroconverters from the CAPRISA 004 tenofovir gel trial, we previously reported significantly higher detection and titres of HIV-specific binding antibodies in the plasma and genital tract (GT) that distinguished the tenofovir from the placebo arm. We hypothesized that higher HIV-specific antibody titres and detection reflected corresponding increased antibody-dependent neutrophil-mediated phagocytosis (ADNP) and NK-cell-activated antibody-dependent cellular cytotoxic (ADCC) activities. HIV-specific V1V2-gp70, gp120, gp41, p66, and p24 antibodies in GT and plasma samples of 48 seroconverters from the CAPRISA 004 tenofovir gel trial were tested for ADCP and ADCC at 3, 6- and 12-months post-HIV-infection. GT gp41- and p24-specific ADNP were significantly higher in the tenofovir than the placebo arm at 6 and 12 months respectively (p< 0.05). Plasma gp120-, gp41-, and p66-specific ADNP, and GT gp41-specific ADCC increased significantly over time (p< 0.05) in the tenofovir arm. In the tenofovir arm only, significant inverse correlations were observed between gp120-specific ADCC and gp120-antibody titres (r= -0.54;p= 0.009), and gp41-specific ADNP and gp41-specific antibody titres at 6 months post-infection (r= -0.50;p= 0.015). In addition, in the tenofovir arm, gp41-specific ADCC showed significant direct correlations between the compartments (r= 0.53;p= 0.045). Certain HIV-specific nNAb activities not only dominate specific immunological compartments but can also exhibit diverse functions within the same compartment. Our previous findings of increased HIV specific antibody detection and titres in women who used tenofovir gel, and the limited differences in nNAb activities between the arms, suggest that prior PrEP did not modulate these nNAb functions post-HIV seroconversion. Together these data provide insight into envelope-specific-nNAb Fc-mediated functions at the site of exposure which may inform on ensuing immunity during combination HIV prevention strategies including PrEP and HIV vaccines.	[Fisher, Kimone Leigh; Sivro, Aida; Ngcapu, Sinaye; Passmore, Jo-Ann Shelley; Osman, Farzana; Karim, Quarraisha Abdool; Karim, Salim S. Abdool; Baxter, Cheryl; Archary, Derseree] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa; [Mabuka, Jennifer M.] Univ KwaZulu Natal, Africa Hlth Res Inst, Durban, South Africa; [Mabuka, Jennifer M.; Ndlovu, Bongiwe] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa; [Sivro, Aida; Ngcapu, Sinaye; Archary, Derseree] Univ KwaZulu Natal, Dept Med Microbiol, Durban, South Africa; [Passmore, Jo-Ann Shelley] Univ Cape Town, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa; [Passmore, Jo-Ann Shelley] Natl Hlth Lab Serv, Cape Town, South Africa; [Karim, Quarraisha Abdool; Karim, Salim S. Abdool] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Chung, Amy W.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Baxter, Cheryl] Univ KwaZulu Natal, Dept Publ Hlth, Durban, South Africa	University of Kwazulu Natal; Africa Health Research Institute; University of Kwazulu Natal; University of Kwazulu Natal; University of Kwazulu Natal; University of Cape Town; Columbia University; University of Melbourne; University of Kwazulu Natal	Archary, D (corresponding author), Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.; Archary, D (corresponding author), Univ KwaZulu Natal, Dept Med Microbiol, Durban, South Africa.	desh.archary@caprisa.org	Abdool Karim, Quarraisha/GVS-1160-2022; Abdool Karim, Salim/N-5947-2013	Abdool Karim, Quarraisha/0000-0002-0985-477X; Fisher, Kimone/0000-0002-0708-4775; Sivro, Aida/0000-0001-9215-5285; Abdool Karim, Salim/0000-0002-4986-2133; Chung, Amy/0000-0003-0020-9704	National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) [AI51794, AI104387, AI115981, AI116086]; CONRAD (USAID) [GP00-08-00005-00, PPA-09-046]; National Research Foundation [67385]; Medical Research Council of South Africa; Technology Innovation Agency; Columbia University-Southern African Fogarty AIDS International Training and Research Programme (AITRP) - Fogarty International Centre, NIH [D43TW00231]; Medical Research Council of South Africa SelfInitiated Grant (MRC SIR); NRF Research Career Advancement Fellowship [RCA13101656388]; Poliomyelitis Research Foundation [18/95, PRF17/02]; European and Developing Countries Clinical Trials Partnership (EDCTP) [TMA2017SF-1960]; South African Department of Science and Technology; National Research Foundation's DST-NRF Centre of Excellence in HIV prevention [UID:96354]; University of KwaZulu-Natal College of Health Sciences; Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [DEL-15-006]; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust [107752/Z/15/Z]; UK government; National Research Foundation (NRF) of South Africa Thuthuka [TTK160517165310]	National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CONRAD (USAID)(United States Agency for International Development (USAID)); National Research Foundation; Medical Research Council of South Africa(South African Medical Research Council); Technology Innovation Agency; Columbia University-Southern African Fogarty AIDS International Training and Research Programme (AITRP) - Fogarty International Centre, NIH; Medical Research Council of South Africa SelfInitiated Grant (MRC SIR); NRF Research Career Advancement Fellowship; Poliomyelitis Research Foundation; European and Developing Countries Clinical Trials Partnership (EDCTP); South African Department of Science and Technology; National Research Foundation's DST-NRF Centre of Excellence in HIV prevention; University of KwaZulu-Natal College of Health Sciences; Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust(Wellcome Trust); UK government; National Research Foundation (NRF) of South Africa Thuthuka	We would like to acknowledge Dr. Galit Alter, from the Ragon Institute, and Dr. Georgia Tomaras, from The Duke Human Vaccine Institute, who shared their ADCC and ADNP protocols respectively for this study. We would like to thank the CAPRISA 004 and CAPRISA 002 teams as well as the study participants for their participation in these studies. Gilead Sciences supplied the tenofovir gel that was manufactured by CONRAD for the CAPRISA 004 trial. The CAPRISA 002 study team has received support from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) (grants #AI51794, #AI104387, #AI115981, and #AI116086), from CONRAD (USAID co-operative grant #GP00-08-00005-00, subproject agreement #PPA-09-046), from the National Research Foundation (grant #67385), the Medical Research Council of South Africa, the Technology Innovation Agency, and the Columbia University-Southern African Fogarty AIDS International Training and Research Programme (AITRP) funded by the Fogarty International Centre, NIH (grant #D43TW00231). DA was supported through the Medical Research Council of South Africa SelfInitiated Grant (MRC SIR), the National Research Foundation (NRF) of South Africa Thuthuka (grant #TTK160517165310), the NRF Research Career Advancement Fellowship (grant #RCA13101656388), the Poliomyelitis Research Foundation (PRF17/02), and a senior fellowship through the European and Developing Countries Clinical Trials Partnership (EDCTP) (grant #TMA2017SF-1960) funds. KF was funded through the South African Department of Science and Technology and the National Research Foundation's DST-NRF Centre of Excellence in HIV prevention (grant #UID:96354), the University of KwaZulu-Natal College of Health Sciences, the Poliomyelitis Research Foundation (grant #18/95) and supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant #DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant #107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust, or the UK government.	Ackerman ME, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005315; Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Archary D, 2016, MUCOSAL IMMUNOL, V9, P821, DOI 10.1038/mi.2015.145; Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Banerjee K, 2010, AIDS RES HUM RETROV, V26, P445, DOI 10.1089/aid.2009.0223; Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Battle-Miller K, 2002, J INFECT DIS, V185, P439, DOI 10.1086/338828; Baum LL, 1996, J IMMUNOL, V157, P2168; Baxter C, 2016, AJAR-AFR J AIDS RES, V15, P109, DOI 10.2989/16085906.2016.1196224; BELEC L, 1995, J INFECT DIS, V172, P691, DOI 10.1093/infdis/172.3.691; Choi I, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004185; Chung AW, 2018, AIDS, V32, P1207, DOI 10.1097/QAD.0000000000001812; Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Chung AW, 2011, P NATL ACAD SCI USA, V108, P7505, DOI 10.1073/pnas.1016048108; Chung AW, 2009, J IMMUNOL, V182, P1202, DOI 10.4049/jimmunol.182.2.1202; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Florese RH, 2009, J IMMUNOL, V182, P3718, DOI 10.4049/jimmunol.0803115; French MA, 2013, AIDS, V27, P519, DOI 10.1097/QAD.0b013e32835cb720; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974; Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433; Isitman G, 2011, VIROLOGY, V412, P110, DOI 10.1016/j.virol.2010.12.044; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7; Kersh EN, 2012, J INFECT DIS, V206, P770, DOI 10.1093/infdis/jis422; Laeyendecker O, 2015, J INFECT DIS, V212, P754, DOI 10.1093/infdis/jiv110; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Li ZL, 2011, P NATL ACAD SCI USA, V108, P4388, DOI 10.1073/pnas.1012861108; Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011; Liu JY, 2016, SCIENCE, V353, P1045, DOI 10.1126/science.aag0491; Liu PH, 2014, J VIROL, V88, P5165, DOI 10.1128/JVI.03765-13; Mabuka J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002739; Madhavi V, 2017, J VIROL, V91, DOI 10.1128/JVI.00700-17; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Milligan C, 2015, CELL HOST MICROBE, V17, P500, DOI 10.1016/j.chom.2015.03.002; Moja P, 1997, IMMUNOL LETT, V1, P133, DOI 10.1016/S0165-2478(97)85532-0; Moog C, 2014, MUCOSAL IMMUNOL, V7, P46, DOI 10.1038/mi.2013.23; Mureithi MW, 2012, JAIDS-J ACQ IMM DEF, V60, P124, DOI 10.1097/QAI.0b013e31824f53a9; Nag P, 2004, J INFECT DIS, V190, P1970, DOI 10.1086/425582; Overbaugh J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007039; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Seaton KE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101863; Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817; Tjiam MC, 2017, JAIDS-J ACQ IMM DEF, V76, pE90, DOI 10.1097/QAI.0000000000001477; Tjiam MC, 2015, J IMMUNOL, V194, P5320, DOI 10.4049/jimmunol.1402918; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tudor D, 2009, MUCOSAL IMMUNOL, V2, P412, DOI 10.1038/mi.2009.89; Tuero I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005101; UNAIDS, 2018, UNAIDS GLOB HIV AIDS; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Wills S, 2018, J VIROL, V92, DOI 10.1128/JVI.01552-17; Worley MJ, 2018, J IMMUNOL METHODS, V457, P41, DOI 10.1016/j.jim.2018.03.007; Xiao P, 2010, J VIROL, V84, P7161, DOI 10.1128/JVI.00410-10; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Zolla-Pazner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053629	59	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 6	2020	11								1274	10.3389/fimmu.2020.01274	http://dx.doi.org/10.3389/fimmu.2020.01274			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR2TE	32733445	Green Published, gold			2022-12-18	WOS:000553442300001
J	Antonoglou, MB; Alberti, AS; Redolfi, DM; Bivona, AE; Lynch, MJF; Truant, SN; Sarratea, MB; Lopez, LVI; Malchiodi, EL; Fernandez, MM				Belen Antonoglou, Maria; Sanchez Alberti, Andres; Maria Redolfi, Daniela; Ernesto Bivona, Augusto; Fernandez Lynch, Maria Julieta; Noli Truant, Sofia; Belen Sarratea, Maria; Iannantuono Lopez, Laura Valeria; Luis Malchiodi, Emilio; Mariel Fernandez, Marisa			Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection	FRONTIERS IN IMMUNOLOGY			English	Article						cruzipain; chimeric immunogen; immune modulators; Trypanosoma cruzi; mutant superantigen	T-CELL RESPONSES; PRIME-BOOST IMMUNIZATION; TOXIC-SHOCK-SYNDROME; CHAGAS-DISEASE; CLASS-II; SALMONELLA-ENTERICA; OVERLAP EXTENSION; IMMUNE-RESPONSE; CPG DNA; VACCINES	Chagas disease is an endemic chronic parasitosis in Latin America affecting more than 7 million people. Around 100 million people are currently at risk of acquiring the infection; however, no effective vaccine has been developed yet. Trypanosoma cruzi is the etiological agent of this parasitosis and as an intracellular protozoan it can reside within different tissues, mainly muscle cells, evading host immunity and allowing progression towards the chronic stage of the disease. Considering this intracellular parasitism triggers strong cellular immunity that, besides being necessary to limit infection, is not sufficient to eradicate the parasite from tissues, a differential immune response is required and new strategies for vaccines against Chagas disease need to be explored. In this work, we designed, cloned and expressed a chimeric molecule, named NCz-SEGN24A, comprising a parasite antigen, the N-terminal domain of the major cysteine protease of T cruzi, cruzipain (Nt-Cz), and a non-toxic form of the staphylococcal superantigen (SAg) G, SEG, with the residue Asn24 mutated to Ala (N24A). The mutant SAg SEGN24A, retains its ability to trigger classical activation of macrophages without inducing T cell apoptosis. To evaluate, as a proof of concept, the immunogenicity and efficacy of the chimeric immunogen vs. its individual antigens, C3H mice were immunized intramuscularly with NCz-SEGN24A co-adjuvanted with CpG-ODN, or the recombinant proteins Nt-Cz plus SEGN24A with the same adjuvant. Vaccinated mice significantly produced Nt-Cz-specific IgG titers after immunization and developed higher IgG2a than IgG1 titers. Specific cell-mediated immunity was assessed by in-vivo DTH and significant responses were obtained. To assess protection, mice were challenged with trypomastigotes of T. cruzi. Both schemes reduced the parasite load throughout the acute phase, but only mice immunized with NCz-SEGN24A showed significant differences against control; moreover, these mice maintained 100% survival. These results encourage testing mutated superantigens fused to specific antigens as immune modulators against pathogens.	[Belen Antonoglou, Maria; Sanchez Alberti, Andres; Maria Redolfi, Daniela; Ernesto Bivona, Augusto; Fernandez Lynch, Maria Julieta; Noli Truant, Sofia; Belen Sarratea, Maria; Luis Malchiodi, Emilio; Mariel Fernandez, Marisa] Univ Buenos Aires, Fac Farm & Bioquim, Dept Microbiol Inmunol Biotecnol & Genet, Catedra Inmunol, Buenos Aires, DF, Argentina; [Belen Antonoglou, Maria; Sanchez Alberti, Andres; Maria Redolfi, Daniela; Ernesto Bivona, Augusto; Fernandez Lynch, Maria Julieta; Noli Truant, Sofia; Belen Sarratea, Maria; Iannantuono Lopez, Laura Valeria; Luis Malchiodi, Emilio; Mariel Fernandez, Marisa] Univ Buenos Aires, UBA CONICET, Inst Estudios Inmunidad Humoral Prof Ricardo A Ma, Buenos Aires, DF, Argentina; [Sanchez Alberti, Andres; Ernesto Bivona, Augusto; Luis Malchiodi, Emilio] Univ Buenos Aires, UBA CONICET, Fac Med, Dept Microbiol Parasitol & Inmunol, Buenos Aires, DF, Argentina; [Sanchez Alberti, Andres; Ernesto Bivona, Augusto; Luis Malchiodi, Emilio] Univ Buenos Aires, UBA CONICET, Inst Microbiol & Parasitol Med IMPaM, Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Fernandez, MM (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Dept Microbiol Inmunol Biotecnol & Genet, Catedra Inmunol, Buenos Aires, DF, Argentina.; Fernandez, MM (corresponding author), Univ Buenos Aires, UBA CONICET, Inst Estudios Inmunidad Humoral Prof Ricardo A Ma, Buenos Aires, DF, Argentina.	mmfernan@ffyb.uba.ar		Sanchez Alberti, Andres/0000-0001-5369-2889; Bivona, Augusto/0000-0002-0520-0226; Noli Truant, Sofia/0000-0002-5490-9186; Fernandez, Marisa/0000-0002-7480-5907	Universidad de Buenos Aires [20020170100323BA]; Fundacion Bunge Born	Universidad de Buenos Aires(University of Buenos Aires); Fundacion Bunge Born	This work was supported by the Grants from the Universidad de Buenos Aires (2018-2021 #20020170100323BA) and Fundacion Bunge & Born (2015-2017) destined to support neglected diseases studies.	Alberti AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00128; Andreano E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01722; Bachmann MF, 2007, EUR J IMMUNOL, V37, P1502, DOI 10.1002/eji.200637023; Badovinac VP, 2004, NAT IMMUNOL, V5, P809, DOI 10.1038/ni1098; Beaumier CM, 2013, TRANSL RES, V162, P144, DOI 10.1016/j.trsl.2013.03.006; Bilate AMB, 2008, REV INST MED TROP SP, V50, P67, DOI 10.1590/S0036-46652008000200001; Bivona AE, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165658; Bivona AE, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006384; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Cazorla SI, 2008, VACCINE, V26, P1999, DOI 10.1016/j.vaccine.2008.02.011; Cazorla SI, 2008, INFECT IMMUN, V76, P324, DOI 10.1128/IAI.01163-07; Cazorla SI, 2010, J INFECT DIS, V202, P136, DOI 10.1086/652872; Cazorla SI, 2009, EXPERT REV VACCINES, V8, P921, DOI [10.1586/erv.09.45, 10.1586/ERV.09.45]; Coria LM, 2016, J IMMUNOL, V196, P4014, DOI 10.4049/jimmunol.1501188; Corral RS, 2000, VACCINE, V19, P234, DOI 10.1016/S0264-410X(00)00172-9; Dickgreber N, 2009, J IMMUNOL, V182, P1260, DOI 10.4049/jimmunol.182.3.1260; Ibanez AE, 2015, J CONTROL RELEASE, V220, P18, DOI 10.1016/j.jconrel.2015.10.011; Fernandez MM, 2007, PROTEINS, V68, P389, DOI 10.1002/prot.21388; Fernandez MM, 2011, J BIOL CHEM, V286, P1189, DOI 10.1074/jbc.M110.142471; Fernandez MM, 2006, MOL IMMUNOL, V43, P927, DOI 10.1016/j.molimm.2005.06.029; Frank FM, 2003, VACCINE, V22, P77, DOI 10.1016/S0264-410X(03)00541-3; Ganem MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066244; Gascon J, 2010, ACTA TROP, V115, P22, DOI 10.1016/j.actatropica.2009.07.019; Golob-Urbanc A, 2019, J BIOL CHEM, V294, P6294, DOI 10.1074/jbc.RA118.006742; Guinazu N, 2007, INT J PARASITOL, V37, P1243, DOI 10.1016/j.ijpara.2007.03.010; Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8; Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063; Hotez P, 2011, HEALTH AFFAIR, V30, P1080, DOI 10.1377/hlthaff.2011.0317; Hu DL, 2003, J INFECT DIS, V188, P743, DOI 10.1086/377308; Jarraud S, 1999, J CLIN MICROBIOL, V37, P2446, DOI 10.1128/JCM.37.8.2446-2449.1999; Jarraud S, 2001, J IMMUNOL, V166, P669, DOI 10.4049/jimmunol.166.1.669; Laderach D, 1996, INT J PARASITOL, V26, P1249, DOI 10.1016/S0020-7519(96)00099-9; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Liu XT, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818762910; Ma WX, 2004, J CLIN IMMUNOL, V24, P294, DOI 10.1023/B:JOCI.0000025451.41948.94; Matos MN, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005300; Matos MN, 2016, VACCINE, V34, P3243, DOI 10.1016/j.vaccine.2016.05.011; Matos MN, 2014, INFECT IMMUN, V82, P4265, DOI 10.1128/IAI.02190-14; McIntosh JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093598; Miyaji EN, 2011, BRAZ J MED BIOL RES, V44, P500, DOI 10.1590/S0100-879X2011007500064; Nardy AF, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/178947; Pack AD, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007410; Padilla AM, 2009, J IMMUNOL, V183, P1245, DOI 10.4049/jimmunol.0901178; Radcliff FJ, 2012, CLIN VACCINE IMMUNOL, V19, P574, DOI 10.1128/CVI.05446-11; Ribeiro AL, 2012, NAT REV CARDIOL, V9, P576, DOI 10.1038/nrcardio.2012.109; Rueckert C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003001; Rynkiewicz D, 2011, VACCINE, V29, P6313, DOI 10.1016/j.vaccine.2011.05.047; Sales PA, 2017, AM J TROP MED HYG, V97, P1289, DOI 10.4269/ajtmh.16-0761; Alberti AS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0010-z; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Schnapp AR, 2002, MICROBES INFECT, V4, P805, DOI 10.1016/S1286-4579(02)01600-3; Schnapp AR, 2002, INFECT IMMUN, V70, P5065, DOI 10.1128/IAI.70.9.5065-5074.2002; Svensson A, 2017, IMMUNOL RES, V65, P1164, DOI 10.1007/s12026-017-8972-5; Truant SN, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03008; Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9; Wurch T, 1998, BIOTECHNOL TECH, V12, P653, DOI 10.1023/A:1008848517221; Zuniga E, 1999, CLIN IMMUNOL, V93, P81, DOI 10.1006/clim.1999.4744	57	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2020	11								1279	10.3389/fimmu.2020.01279	http://dx.doi.org/10.3389/fimmu.2020.01279			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD5EO	32695105	gold, Green Published			2022-12-18	WOS:000615541400001
J	Guler, AA; Rossi, FW; Bellando-Randone, S; Prevete, N; Tufan, A; Manetti, M; de Paulis, A; Matucci-Cerinic, M				Guler, Aslihan Avanoglu; Rossi, Francesca Wanda; Bellando-Randone, Silvia; Prevete, Nella; Tufan, Abdurrahman; Manetti, Mirko; de Paulis, Amato; Matucci-Cerinic, Marco			The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Review						resolvins; resolution of inflammation; systemic sclerosis; innate immunity; adaptive immunity; fibrosis	DENDRITIC CELLS; MACROPHAGE POLARIZATION; LIPID MEDIATORS; D-SERIES; INFLAMMATION; RESOLUTION; D1; E1; RECEPTOR; PATHOGENESIS	Resolvins, the member of specialized pro-resolving mediators, are produced from omega-3 polyunsaturated fatty acids as a response to an acute inflammatory process in that termination and resolution of inflammation. In the acute inflammation, these lipid mediators limit polymorphonuclear cells infiltration, proinflammatory cytokine production; promote efferocytosis, and regulate several cell types being important roles in innate and adaptive immunity. Any dysregulation or defect of the resolution phase result in prolonged, persistent inflammation and eventually fibrosis. Resolvins are implicated in the development of various chronic autoimmune diseases. Systemic sclerosis (SSc) is a very complicated, chronic autoimmune disorder proceeding with vasculopathy, inflammation, and fibrosis. Dysregulation of innate and adaptive immunity is another important contributing factor in the pathogenesis of SSc. In this review, we will focus on the different roles of this new family of lipid mediators, characterized by the ability to prevent the spread of inflammation and its chronicity in various ways and how they can control the development of fibrotic diseases like SSc.	[Guler, Aslihan Avanoglu; Bellando-Randone, Silvia; Manetti, Mirko; Matucci-Cerinic, Marco] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Guler, Aslihan Avanoglu; Bellando-Randone, Silvia; Manetti, Mirko; Matucci-Cerinic, Marco] AOUC, Div Rheumatol, Dept Geriatr Med, Florence, Italy; [Guler, Aslihan Avanoglu; Tufan, Abdurrahman] Gazi Univ, Div Rheumatol, Dept Internal Med, Fac Med, Ankara, Turkey; [Rossi, Francesca Wanda; Prevete, Nella; de Paulis, Amato] Univ Naples Federico II, Dept Internal Med Clin Immunol & Rheumatol, Naples, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; Gazi University; University of Naples Federico II	Bellando-Randone, S (corresponding author), Univ Florence, Dept Expt & Clin Med, Florence, Italy.; Bellando-Randone, S (corresponding author), AOUC, Div Rheumatol, Dept Geriatr Med, Florence, Italy.	s.bellandorandone@gmail.com	Manetti, Mirko/AEH-9944-2022; CERINIC, marco MATUCCI/AAO-2769-2020; de Paulis, Amato/AHE-5275-2022; TUFAN, Abdurrahman/A-7613-2016	Manetti, Mirko/0000-0003-3956-8480; de Paulis, Amato/0000-0003-0347-2540; TUFAN, Abdurrahman/0000-0001-6244-9362				Abdolmaleki F, 2020, CLIN REV ALLERG IMMU, V58, P82, DOI 10.1007/s12016-019-08754-9; Akagi D, 2015, FASEB J, V29, P2504, DOI 10.1096/fj.14-265363; Antoniou KM, 2008, CURR OPIN RHEUMATOL, V20, P686, DOI 10.1097/BOR.0b013e3283126985; Ariel A, 2013, J PATHOL, V229, P250, DOI 10.1002/path.4108; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; Arnardottir HH, 2016, J IMMUNOL, V197, P2362, DOI 10.4049/jimmunol.1502268; Ballerie A, 2019, IMMUNOL CELL BIOL, V97, P340, DOI 10.1111/imcb.12217; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Barnes TC, 2012, RHEUMATOLOGY, V51, P1166, DOI 10.1093/rheumatology/ker520; Brown M, 2019, CLIN EXP IMMUNOL, V195, P310, DOI 10.1111/cei.13238; Bruni C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02045; Cakmak G, 2016, SARCOIDOSIS VASC DIF, V33, P349; Carvalheiro T, 2020, CLIN EXP IMMUNOL, V201, P25, DOI 10.1111/cei.13417; Chiang N, 2015, J EXP MED, V212, P1203, DOI 10.1084/jem.20150225; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Chiurchiu V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7483; Chizzolini C, 2018, IMMUNOL LETT, V195, P61, DOI 10.1016/j.imlet.2017.09.007; Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030; Cutolo M, 2019, EXPERT REV CLIN IMMU, V15, P753, DOI 10.1080/1744666X.2019.1614915; Cutolo M, 2017, RHEUMATOLOGY, V56, pV45, DOI 10.1093/rheumatology/kex199; Dalli J, 2013, CHEM BIOL, V20, P188, DOI 10.1016/j.chembiol.2012.11.010; Dean S, 2019, RHEUMATOLOGY, V58, P1285, DOI 10.1093/rheumatology/kez072; Dona M, 2008, BLOOD, V112, P848, DOI 10.1182/blood-2007-11-122598; Dowson C, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0630-3; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; El Kebir D, 2012, P NATL ACAD SCI USA, V109, P14983, DOI 10.1073/pnas.1206641109; Fetterman JW, 2009, AM J HEALTH-SYST PH, V66, P1169, DOI 10.2146/ajhp080411; Flavahan NA, 2015, NAT REV RHEUMATOL, V11, P146, DOI 10.1038/nrrheum.2014.195; Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39; Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910; Fuschiotti P, 2013, ARTHRITIS RHEUM-US, V65, P236, DOI 10.1002/art.37706; Gasparini G, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154799; Gourh P, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2821; Hamaguchi Y, 2018, J SCLERODERMA RELAT, V3, P201, DOI 10.1177/2397198318783930; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Higashi-Kuwata N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3066; Hong S, 2008, J IMMUNOL, V180, P3512, DOI 10.4049/jimmunol.180.5.3512; Hsiao HM, 2015, AM J PATHOL, V185, P3189, DOI 10.1016/j.ajpath.2015.08.008; Hsiao HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058258; Huang XL, 2015, INFLAMM RES, V64, P151, DOI 10.1007/s00011-015-0806-0; Isobe Y, 2012, J BIOL CHEM, V287, P10525, DOI 10.1074/jbc.M112.340612; Janko C, 2008, AUTOIMMUN REV, V8, P9, DOI 10.1016/j.autrev.2008.07.015; Kafaja S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98380; Kain V, 2015, J MOL CELL CARDIOL, V84, P24, DOI 10.1016/j.yjmcc.2015.04.003; Kang JW, 2018, BRIT J PHARMACOL, V175, P2441, DOI 10.1111/bph.14212; Khanna D, 2016, J SCLERODERMA RELAT, V1, P186, DOI 10.5301/jsrd.5000207; Kim N, 2016, EUR J IMMUNOL, V46, P81, DOI 10.1002/eji.201545673; Kim TH, 2012, INT IMMUNOPHARMACOL, V14, P384, DOI 10.1016/j.intimp.2012.08.005; Kioon MDA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam8458; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kowal-Bielecka O, 2010, SEMIN ARTHRITIS RHEU, V40, P73, DOI 10.1016/j.semarthrit.2008.10.009; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Kurasawa K, 2000, ARTHRITIS RHEUM-US, V43, P2455, DOI 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K; Lafyatis R, 2007, ARTHRITIS RHEUM, V56, P3167, DOI 10.1002/art.22847; Lech M, 2013, BBA-MOL BASIS DIS, V1832, P989, DOI 10.1016/j.bbadis.2012.12.001; Manetti M, 2008, ARTHRITIS RHEUM-US, V58, P2866, DOI 10.1002/art.23806; Manoussakis MN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112100; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Maugeri N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3089; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Mizraji G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00785; Norling LV, 2012, ARTERIOSCL THROM VAS, V32, P1970, DOI 10.1161/ATVBAHA.112.249508; Norris PC, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax4895; Norris PC, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan1471; Norris PC, 2018, PROSTAG LEUKOTR ESS, V138, P81, DOI 10.1016/j.plefa.2016.01.001; Oh SF, 2012, J IMMUNOL, V188, P4527, DOI 10.4049/jimmunol.1103652; Oh SF, 2011, J CLIN INVEST, V121, P569, DOI 10.1172/JCI42545; Olewicz-Gawlik A, 2014, INT J RHEUM DIS, V17, P664, DOI 10.1111/1756-185X.12290; Pope NH, 2016, FASEB J, V30, P4192, DOI 10.1096/fj.201600144RR; Postlethwaite AE, 2004, CURR OPIN RHEUMATOL, V16, P733, DOI 10.1097/01.bor.0000139310.77347.9c; Prevete N, 2018, PHARMACOL RES, V128, P80, DOI 10.1016/j.phrs.2017.09.024; Qiu WH, 2014, EXP THER MED, V7, P1481, DOI 10.3892/etm.2014.1641; Qu XL, 2012, J PATHOL, V228, P506, DOI 10.1002/path.4050; Ramon S, 2012, J IMMUNOL, V189, P1036, DOI 10.4049/jimmunol.1103483; Rolla G, 2016, J BREATH RES, V10, DOI 10.1088/1752-7155/10/4/046013; Rout-Pitt N, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0834-8; SalmonEhr V, 1996, ARCH DERMATOL, V132, P802, DOI 10.1001/archderm.132.7.802; Sanges S, 2017, REV MED INTERNE, V38, P113, DOI 10.1016/j.revmed.2016.02.016; Sato M, 2019, FASEB J, V33, P12750, DOI 10.1096/fj.201900283R; Sato S, 2000, J RHEUMATOL, V27, P2838; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Schwanke RC, 2016, EUR J PHARMACOL, V785, P156, DOI 10.1016/j.ejphar.2015.08.050; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2018, J CLIN INVEST, V128, P2657, DOI 10.1172/JCI97943; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2004, HISTOCHEM CELL BIOL, V122, P305, DOI 10.1007/s00418-004-0695-8; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Settimio R, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/318621; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Soldano S, 2018, ANN RHEUM DIS, V77, P1842, DOI 10.1136/annrheumdis-2018-213648; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Trombetta AC, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0891-z; Tyndall AJ, 2010, ANN RHEUM DIS, V69, P1809, DOI 10.1136/ard.2009.114264; van der Vorst EPC, 2019, ARTERIOSCL THROM VAS, V39, P685, DOI 10.1161/ATVBAHA.119.312386; Varga J, 2017, J SCLERODERMA RELAT, V2, P137, DOI 10.5301/jsrd.5000249; Vassiliou EK, 2008, J IMMUNOL, V181, P4534, DOI 10.4049/jimmunol.181.7.4534; Vermi W, 2005, J EXP MED, V201, P509, DOI 10.1084/jem.20041310; Volkmann ER, 2019, NAT REV RHEUMATOL, V15, P208, DOI 10.1038/s41584-019-0184-z; Wigley FM, 2016, NEW ENGL J MED, V375, P556, DOI 10.1056/NEJMra1507638; Winkler JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep18972; Wu MY, 2018, CELL PHYSIOL BIOCHEM, V46, P1650, DOI 10.1159/000489241; Xia J, 2019, Zhonghua Yi Xue Za Zhi, V99, P1111, DOI 10.3760/cma.j.issn.0376-2491.2019.14.015; Yang XQ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4430; Yang YY, 2019, AM J PHYSIOL-LUNG C, V316, pL1013, DOI 10.1152/ajplung.00415.2018; Yatomi M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12628; Zabel BA, 2005, J IMMUNOL, V174, P244, DOI 10.4049/jimmunol.174.1.244; Zhang HW, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105877	111	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 19	2020	11								1249	10.3389/fimmu.2020.01249	http://dx.doi.org/10.3389/fimmu.2020.01249			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MK2SL	32636845	Green Published, gold			2022-12-18	WOS:000548635400001
J	Dezfouli, SA; Nikdad, M; Ghamarnejad, O; Khajeh, E; Arefidoust, A; Mohammadi, S; Majlesara, A; Sabagh, M; Gharabaghi, N; Kentar, M; Younsi, A; Eckert, C; Poth, T; Golriz, M; Mehrabi, A; Nickkholgh, A				Dezfouli, Sepehr Abbasi; Nikdad, Mohammadsadegh; Ghamarnejad, Omid; Khajeh, Elias; Arefidoust, Alireza; Mohammadi, Sara; Majlesara, Ali; Sabagh, Mohammadsadegh; Gharabaghi, Negin; Kentar, Modar; Younsi, Alexander; Eckert, Christoph; Poth, Tanja; Golriz, Mohammad; Mehrabi, Arianeb; Nickkholgh, Arash			Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						oral preconditioning; brain death donor; kidney transplantation; pig; calcineurin inhibitors; inhibitors of mammalian target for rapamycin; TNF-alpha	ISCHEMIA-REPERFUSION INJURY; N-OCTANOYL DOPAMINE; RAT-KIDNEY; ISCHEMIA/REPERFUSION INJURY; CYCLOSPORINE; ORGANS; LIVER; ACTIVATION; PROTECTS; FTY720	Background: The systemic inflammatory cascade triggered in donors after brain death enhances the ischemia-reperfusion injury after organ transplantation. Intravenous steroids are routinely used in the intensive care units for the donor preconditioning. Immunosuppressive medications could be potentially used for this purpose as well. Data regarding donor preconditioning with calcineurin inhibitors or inhibitors of mammalian target for Rapamycin is limited. The aim of this project is to investigate the effects of (oral) donor preconditioning with a calcineurin inhibitor (Cyclosporine) vs. an inhibitor of mammalian target for Rapamycin (Everolimus) compared to the conventional administration of steroid in the setting of donation after brain death in porcine renal transplantation. Methods: Six hours after the induction of brain death, German landrace donor pigs (33.2 +/- 3.9 kg) were randomly preconditioned with either Cyclosporine (n = 9) or Everolimus (n = 9) administered via nasogastric tube with a repeated dose just before organ procurement. Control donors received intravenous Methylprednisolone (n = 8). Kidneys were procured, cold-stored in Histidine-Tryptophane-Ketoglutarate solution at 4 C and transplanted in nephrectomized recipients after a mean cold ischemia time of 18 h. No post-transplant immunosuppression was given to avoid confounding bias. Blood samples were obtained at 4 h post reperfusion and daily until postoperative day 5 for complete blood count, blood urea nitrogen, creatinine, and electrolytes. Graft protocol biopsies were performed 4 h after reperfusion to assess early histological and immunohistochemical changes. Results: There was no difference in the hemodynamic parameters, hemoglobin/ hematocrit and electrolytes between the groups. Serum blood urea nitrogen and creatinine peaked on postoperative day 1 in all groups and went back to the preoperative levels at the conclusion of the study on postoperative day 5. Histological assessment of the kidney grafts revealed no significant differences between the groups. TNF-alpha expression was significantly lower in the study groups compared with Methylprednisolone group (p = 0.01) Immunohistochemistry staining for cytochrome c showed no difference between the groups. Conclusion: Oral preconditioning with Cyclosporine or Everolimus is feasible in donation after brain death pig kidney transplantation and reduces the expression of TNF-alpha. Future studies are needed to further delineate the role of oral donor preconditioning against ischemia-reperfusion injury.	[Dezfouli, Sepehr Abbasi; Nikdad, Mohammadsadegh; Ghamarnejad, Omid; Khajeh, Elias; Arefidoust, Alireza; Mohammadi, Sara; Majlesara, Ali; Sabagh, Mohammadsadegh; Gharabaghi, Negin; Golriz, Mohammad; Mehrabi, Arianeb; Nickkholgh, Arash] Ruprecht Karls Univ Heidelberg, Dept Gen Abdominal & Transplant Surg, Heidelberg, Germany; [Kentar, Modar; Younsi, Alexander] Ruprecht Karls Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany; [Eckert, Christoph; Poth, Tanja] Ruprecht Karls Univ Heidelberg, Inst Pathol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Nickkholgh, A (corresponding author), Ruprecht Karls Univ Heidelberg, Dept Gen Abdominal & Transplant Surg, Heidelberg, Germany.	arash.nickkholgh@med.uni-heidelberg.de	Younsi, Alexander/AAW-7869-2020; Nikdad, Mohammadsadegh/AAW-7418-2021; Abbasi Dezfouli, Sepehr Abbasi/AAW-6535-2021	Younsi, Alexander/0000-0002-8218-9243; Nikdad, Mohammadsadegh/0000-0001-5789-8171; 	Novartis Pharma GmbH, Nurnberg, Germany	Novartis Pharma GmbH, Nurnberg, Germany	This study was partly funded through a research grant from Novartis Pharma GmbH, Nurnberg, Germany. Parts of this work have been presented at American Transplant Congress (ATC) during 1st-5th June, 2019 (Boston, MA, USA), and 19th Congress of European Society forOrgan Transplantation (ESOT) during 15st-18th September (Copenhagen, Denmark).	Allred DC, 1998, MODERN PATHOL, V11, P155; AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1; Cicora F, 2013, TRANSPL IMMUNOL, V28, P203, DOI 10.1016/j.trim.2013.04.002; de Vries DK, 2011, AM J TRANSPLANT, V11, P1064, DOI 10.1111/j.1600-6143.2011.03466.x; Delbridge MS, 2007, TRANSPL P, V39, P2992, DOI 10.1016/j.transproceed.2007.04.027; Delbridge MS, 2007, TRANSPLANTATION, V84, P187, DOI 10.1097/01.tp.0000269794.74990.da; Golling M, 2003, TRANSPLANTATION, V75, P1154, DOI 10.1097/01.TP.0000062868.34247.8F; Golling M, 2007, LIVER TRANSPLANT, V13, P607, DOI 10.1002/lt.21069; Golriz M, 2012, EUR SURG RES, V49, P121, DOI 10.1159/000343132; Goncalves GM, 2007, TRANSPL P, V39, P417, DOI 10.1016/j.transproceed.2007.01.027; Goncalves GM, 2006, KIDNEY INT, V70, P1742, DOI 10.1038/sj.ki.5001893; Guan X, 2008, J SURG RES, V146, P127, DOI 10.1016/j.jss.2007.06.014; Inman SR, 2003, UROLOGY, V62, P750, DOI 10.1016/S0090-4295(03)00475-8; Kotsch K, 2008, ANN SURG, V248, P1042, DOI 10.1097/SLA.0b013e318190e70c; Kusaka M, 2007, TRANSPLANTATION, V83, P62, DOI 10.1097/01.tp.0000250485.53865.b8; Li S, 2017, AM J TRANSPLANT, V17, P1802, DOI 10.1111/ajt.14207; Martinez-Palli G, 2011, NEPHROL DIAL TRANSPL, V26, P1813, DOI 10.1093/ndt/gfq646; Nickkholgh Arash, 2012, HPB Surg, V2012, P783479, DOI 10.1155/2012/783479; Pratschke J, 2001, ANN SURG, V234, P732, DOI 10.1097/00000658-200112000-00004; Pratschke J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001; Ryan JB, 2003, TRANSPLANTATION, V76, P766, DOI 10.1097/01.TP.0000079254.81264.6D; Shihab FS, 2009, TRANSPLANTATION, V87, P326, DOI 10.1097/TP.0b013e3181945332; Singh D, 2005, TOXICOLOGY, V207, P339, DOI 10.1016/j.tox.2004.09.018; Smith M, 2004, J HEART LUNG TRANSPL, V23, pS217, DOI 10.1016/j.healun.2004.06.017; Spindler RS, 2015, TRANSPLANTATION, V99, P935, DOI 10.1097/TP.0000000000000577; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; van der Woude FJ, 2004, J INVEST MED, V52, P323, DOI 10.1136/jim-52-05-32; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Weiss S, 2007, AM J TRANSPLANT, V7, P1584, DOI 10.1111/j.1600-6143.2007.01799.x; Wilhelm MJ, 2000, CIRCULATION, V102, P2426, DOI 10.1161/01.CIR.102.19.2426; Yang CW, 2001, TRANSPLANTATION, V72, P1753; Yoneyama Hiroyuki, 2005, Medical Molecular Morphology, V38, P136, DOI 10.1007/s00795-005-0289-0	32	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2020	11								1222	10.3389/fimmu.2020.01222	http://dx.doi.org/10.3389/fimmu.2020.01222			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MJ8YI	32625210	Green Published, gold			2022-12-18	WOS:000548373100001
J	Phillips, N; Ke, E; Nham, A; Seidl, M; Freeman, B; Abadejos, JR; Xiao, CC; Nemazee, D; Ku, MC; Kirak, O				Phillips, Nathaniel; Ke, Eugene; Nham, Amy; Seidl, Maximilian; Freeman, Brent; Abadejos, Justin R.; Xiao, Changchun; Nemazee, David; Ku, Manching; Kirak, Oktay			Prediabetes Induced by a Single Autoimmune B Cell Clone	FRONTIERS IN IMMUNOLOGY			English	Article						diabetes; autoimmunity; B cell; animal model; pancreas; cloning; somatic cell nuclear transfer (SCNT); nucleic acid sensing	TYPE-1 DIABETES-MELLITUS; NOD MICE; BETA; LYMPHOCYTES; INFECTION; PROTEINS; ETIOLOGY; SUBSETS; ANERGY; IFIH1	While B cells play a significant role in the onset of type-1 diabetes (T1D), little is know about their role in those early stages. Thus, to gain new insights into the role of B cells in T1D, we converted a physiological early pancreas-infiltrating B cell into a novel BCR mouse model using Somatic Cell Nuclear Transfer (SCNT). Strikingly, SCNT-derived B1411 model displayed neither developmental block nor anergy. Instead, B1411 underwent spontaneous germinal center reactions. Without T cell help, B1411-Rag1(-/-)was capable of forming peri-/intra-pancreatic lymph nodes, and undergoing class-switching. RNA-Seq analysis identified 93 differentially expressed genes in B1411 compared to WT B cells, includingIrf7, Usp18, andMda5that had been linked to a potential viral etiology of T1D. We also found various members of the oligoadenylate synthase (OAS) family to be enriched in B1411, such asOas1, which had recently also been linked to T1D. Strikingly, when challenged with glucose B1411-Rag1(-/-)mice displayed impaired glucose tolerance.	[Phillips, Nathaniel; Nham, Amy; Freeman, Brent; Abadejos, Justin R.; Xiao, Changchun; Nemazee, David; Kirak, Oktay] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Ke, Eugene] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Seidl, Maximilian] Heinrich Heine Univ, Inst Pathol, Dusseldorf, Germany; [Seidl, Maximilian] Univ Hosp Dusseldorf, Dusseldorf, Germany; [Ku, Manching; Kirak, Oktay] Univ Freiburg, Fac Med, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol,Med Ctr, Freiburg, Germany	Scripps Research Institute; Salk Institute; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Freiburg	Kirak, O (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.; Ku, MC; Kirak, O (corresponding author), Univ Freiburg, Fac Med, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol,Med Ctr, Freiburg, Germany.	manching.ku@uniklinik-freiburg.de; oktay.kirak@uniklinik-freiburg.de	Seidl, Maxmilian/ABF-3322-2021; Kirak, Oktay/H-6347-2013	Seidl, Maxmilian/0000-0002-5559-4980; Kirak, Oktay/0000-0002-6524-4685	Scripps Research Institute start up fund; National Cancer Institute of the National Institutes of Health [T32CA009370]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [SFB1160/2-Z02]; NIH [R37 AI059714]; Deutsche Forschungsgemeinschaft (DFG, German Foundation) [413517907]	Scripps Research Institute start up fund; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft (DFG, German Foundation)(German Research Foundation (DFG))	Research reported in this publication was supported by The Scripps Research Institute start up fund (OK), the National Cancer Institute of the National Institutes of Health under Award Number T32CA009370 (EK), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) SFB1160/2-Z02 (MK), and NIH grant R37 AI059714 (DN). OK is a fellow in the IMM-PACT Clinician Scientist Program, Faculty of Medicine, Medical Center-University of Freiburg, funded by the Deutsche Forschungsgemeinschaft (DFG, German Foundation)-413517907.	Atkinson MA, 2014, LANCET, V383, P69, DOI 10.1016/S0140-6736(13)60591-7; BODANSKY HJ, 1992, BRIT MED J, V304, P1020, DOI 10.1136/bmj.304.6833.1020; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Cambier JC, 2007, NAT REV IMMUNOL, V7, P633, DOI 10.1038/nri2133; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; Chatenoud L, 2010, NAT REV ENDOCRINOL, V6, P149, DOI 10.1038/nrendo.2009.275; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; de Beeck AO, 2016, NAT REV ENDOCRINOL, V12, P263, DOI 10.1038/nrendo.2016.30; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Domsgen E, 2016, SCI REP-UK, V6, DOI 10.1038/srep39378; Dotta F, 2007, P NATL ACAD SCI USA, V104, P5115, DOI 10.1073/pnas.0700442104; Drescher KM, 2015, REV MED VIROL, V25, P19, DOI 10.1002/rmv.1815; Ghazarian L, 2013, CELL MOL LIFE SCI, V70, P239, DOI 10.1007/s00018-012-1042-1; Gorman JA, 2017, NAT IMMUNOL, V18, P744, DOI 10.1038/ni.3766; Hartmann S, 2013, MODERN PATHOL, V26, P648, DOI 10.1038/modpathol.2012.217; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hober D, 2010, NAT REV ENDOCRINOL, V6, P279, DOI 10.1038/nrendo.2010.27; Hornung V, 2014, NAT REV IMMUNOL, V14, P521, DOI 10.1038/nri3719; Hu CY, 2007, J CLIN INVEST, V117, P3857, DOI 10.1172/JCI32405; HUTCHINGS PR, 1990, J AUTOIMMUN, V3, P175, DOI 10.1016/0896-8411(90)90139-J; Kirak Oktay, 2010, J Vis Exp, DOI 10.3791/2168; Kirak O, 2010, SCIENCE, V328, P243, DOI 10.1126/science.1178590; Kopska T, 2008, TRANSPL P, V40, P3611, DOI 10.1016/j.transproceed.2008.04.020; Ku M, 2018, J ALLERGY CLIN IMMUN, V142, P997, DOI 10.1016/j.jaci.2018.04.038; Ku MC, 2016, P NATL ACAD SCI USA, V113, pE2316, DOI 10.1073/pnas.1523664113; Ku MC, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r85, 10.1186/gb-2012-13-10-R85]; Leeth CM, 2016, DIABETES, V65, P1977, DOI 10.2337/db15-1606; Lehuen A, 2010, NAT REV IMMUNOL, V10, P501, DOI 10.1038/nri2787; MATSUMOTO M, 1993, CELL IMMUNOL, V148, P189, DOI 10.1006/cimm.1993.1101; MILLER BJ, 1988, J IMMUNOL, V140, P52; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728; Nemazee D, 2006, NAT REV IMMUNOL, V6, P728, DOI 10.1038/nri1939; Patterson CC, 2009, LANCET, V373, P2027, DOI 10.1016/S0140-6736(09)60568-7; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Phillips Jenny M, 2009, Rev Diabet Stud, V6, P97, DOI 10.1900/RDS.2009.6.97; Redondo MJ, 2008, NEW ENGL J MED, V359, P2849, DOI 10.1056/NEJMc0805398; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rojas M, 2001, J IMMUNOL, V166, P3194, DOI 10.4049/jimmunol.166.5.3194; Santin I, 2013, DIABETES OBES METAB, V15, P71, DOI 10.1111/dom.12162; Serreze DV, 1998, J IMMUNOL, V161, P3912; Silveira PA, 2004, J IMMUNOL, V172, P5086, DOI 10.4049/jimmunol.172.8.5086; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Stolp J, 2013, J IMMUNOL, V191, P97, DOI 10.4049/jimmunol.1203252; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tedford K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02482-4; Tessier MC, 2006, J MED GENET, V43, P129, DOI 10.1136/jmg.2005.035212; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Todd JA, 2010, IMMUNITY, V32, P457, DOI 10.1016/j.immuni.2010.04.001; Zikherman J, 2012, NATURE, V489, P160, DOI 10.1038/nature11311	51	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2020	11								1073	10.3389/fimmu.2020.01073	http://dx.doi.org/10.3389/fimmu.2020.01073			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MH7YN	32625203	gold, Green Published			2022-12-18	WOS:000546939700001
J	Bonorino, C; Mognol, G				Bonorino, Cristina; Mognol, Giuliana			Editorial: T Cell Exhaustion	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						exhaustion; T cells; cancer; viral infection; PD-1; PDL-1 axis			[Bonorino, Cristina] Univ Fed Ciencias Saude Porto Alegre, Dept Ciencias Basicas Saude, Porto Alegre, RS, Brazil; [Bonorino, Cristina] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Mognol, Giuliana] Bluestar Genom, San Diego, CA USA	Universidade Federal de Ciencias da Saude de Porto Alegre; University of California System; University of California San Diego	Bonorino, C (corresponding author), Univ Fed Ciencias Saude Porto Alegre, Dept Ciencias Basicas Saude, Porto Alegre, RS, Brazil.; Bonorino, C (corresponding author), Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.	cristinabonorino@gmail.com			CNPq [306572/2018-9]	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	CB is the recipient of a 1B fellowship from CNPq - nr. 306572/2018-9.	Mognol GP, 2017, P NATL ACAD SCI USA, V114, pE2776, DOI 10.1073/pnas.1620498114; Schietinger A, 2014, TRENDS IMMUNOL, V35, P51, DOI 10.1016/j.it.2013.10.001; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862	3	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2020	11								920	10.3389/fimmu.2020.00920	http://dx.doi.org/10.3389/fimmu.2020.00920			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MH7CA	32612599	gold, Green Published			2022-12-18	WOS:000546881200001
J	Cifaldi, L; Di Santo, J; Olive, D				Cifaldi, Loredana; Di Santo, James; Olive, Daniel			Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK cells; NK cell-based immunotherapy; cancer immunotherapy; immune checkpoint inhibitors; adoptive transfer of NK and CAR-NK cells; ligands for NK cell-activating receptors			[Cifaldi, Loredana] Osped Pediat Bambino Gesu, Acad Dept Pediat DPUO, IRCCS, Rome, Italy; [Di Santo, James] Inst Pasteur, Innate Immun Unit, Paris, France; [Di Santo, James] INSERM, U1223, Paris, France; [Olive, Daniel] Aix Marseille Univ, CNRS, Canc Res Ctr Marseille, Inst Paoli Calmettes,INSERM,U1068,U7258, Marseille, France	IRCCS Bambino Gesu; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Cifaldi, L (corresponding author), Osped Pediat Bambino Gesu, Acad Dept Pediat DPUO, IRCCS, Rome, Italy.	loredana.cifaldi@opbg.net	Di Santo, James P/M-4298-2014	Di Santo, James P/0000-0002-7146-1862; Cifaldi, Loredana/0000-0001-5014-430X	Italian Ministry of Health (Rome, Italy) [GR-2011-02352151]	Italian Ministry of Health (Rome, Italy)(Ministry of Health, Italy)	This work was supported by grant from the Italian Ministry of Health (Rome, Italy) Grant GR-2011-02352151 to LC.		0	1	1	8	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2020	11								1132	10.3389/fimmu.2020.01132	http://dx.doi.org/10.3389/fimmu.2020.01132			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MO6QM	32612604	Green Published, gold			2022-12-18	WOS:000551647900001
J	Yin, GN; Zeng, WX; Hu, KJ; Gao, J; Liu, JP; Chen, Y; Chen, FL				Yin, Guangnian; Zeng, Wenxin; Hu, Kaijiao; Gao, Jie; Liu, Jianping; Chen, Yan; Chen, Feilan			Parental Uveitis Influences Offspring With an Increased Susceptibility to the Experimental Autoimmune Uveitis	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmune uveitis (EAU); parental uveitis; offspring; differentially expressed gene (DEG); immune system; susceptibility	INFLAMMATORY-BOWEL-DISEASE; GENE-EXPRESSION; MUSCLES; SEX	Purpose:Previous studies have shown that parental abnormal physiological conditions such as inflammation, stress, and obesity can be transferred to offspring. The purpose of this study was to investigate the impact of parental uveitis on the development and susceptibility to experimental autoimmune uveitis (EAU) in offspring. Methods:Parental male and female B10RIII mice were immunized with interphotoreceptor retinoid binding protein (IRBP) 161-180 in complete Freund's adjuvant and were immediately allowed to mate. Gross examination of the offspring gestated with EAU was performed to determine the influence of parental uveitis on offspring development after birth. Gene expression profiles were analyzed in the affected eyes of offspring under EAU to identify differentially expressed genes (DEGs). Adult offspring were given 5, 25, and 50 mu g IRBP(161-180)to compare their susceptibility to EAU. Immunized mice were clinically and pathologically evaluated for the development of EAU. Ag-specific T-cell proliferation and IL-17 production from spleens and lymph nodes were evaluated on day 14 or 35 after immunization. Results:Hair loss, delay of eye opening, and swollen spleens in the offspring from parents with uveitis were observed from day 14 to 39 after birth. DEGs were involved in the immune system process, muscle system process, and cell development. The altered antigen processing and presentation, cell adhesion molecules, and phagosome in the eyes of the offspring from uveitis-affected parents were enriched. Offspring gestated with EAU showed a susceptibility to EAU and an earlier onset and higher severity of EAU compared to the control group mice. IRBP-specific lymphocyte proliferation and IL-17 production were observed in the EAU offspring with exposure to parental uveitis. Conclusions:The results suggest that mouse parents with uveitis can increase their offspring's susceptibility to EAU, probably through altering cell adhesion molecules and antigen processing and presentation related to the T-cell proliferation and Th17 response.	[Yin, Guangnian; Zeng, Wenxin; Hu, Kaijiao; Gao, Jie; Chen, Feilan] Chongqing Med Univ, Lab Anim Ctr, Chongqing, Peoples R China; [Yin, Guangnian; Zeng, Wenxin; Hu, Kaijiao; Gao, Jie; Chen, Feilan] Chongqing Med Univ, Chongqing Engn Res Ctr Rodent Lab Anim, Chongqing, Peoples R China; [Liu, Jianping] Chongqing Med Univ, Pathol Dept, Chongqing, Peoples R China; [Chen, Yan] Chongqing Med & Pharmaceut Coll, Coll Pharm, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Chen, FL (corresponding author), Chongqing Med Univ, Lab Anim Ctr, Chongqing, Peoples R China.; Chen, FL (corresponding author), Chongqing Med Univ, Chongqing Engn Res Ctr Rodent Lab Anim, Chongqing, Peoples R China.	cfl761219@163.com	Chen, Feilan/AAE-8397-2022	Chen, Feilan/0000-0001-8645-3382	National Natural Science Foundation Project [81670843]; Chongqing Science and Technology Commission (CSTC) from the Project of the Nature Science Foundation of Chongqing [2016jcyjA0265]; Project of Yuzhong District Science and Technology Commission	National Natural Science Foundation Project(National Natural Science Foundation of China (NSFC)); Chongqing Science and Technology Commission (CSTC) from the Project of the Nature Science Foundation of Chongqing; Project of Yuzhong District Science and Technology Commission	The authors are grateful for the support from the National Natural Science Foundation Project (Grant no. 81670843) and the Chongqing Science and Technology Commission (CSTC, Grant no. 2016jcyjA0265) from the Project of the Nature Science Foundation of Chongqing and the Project of Yuzhong District Science and Technology Commission.	Adams RCM, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/9160941; Agarwal AB, 2016, INVEST OPHTH VIS SCI, V57, P5576, DOI 10.1167/iovs.16-20294; BENNETT RA, 1991, GASTROENTEROLOGY, V100, P1638, DOI 10.1016/0016-5085(91)90663-6; Brophy S, 2003, J RHEUMATOL, V30, P2054; Caspi Rachel R, 2003, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1506s53; De Jesus DF, 2020, J CLIN INVEST, V130, P2391, DOI 10.1172/JCI127502; Dudele A, 2017, INT J OBESITY, V41, P1420, DOI 10.1038/ijo.2017.136; Dusek J, 2008, PEDIATR NEPHROL, V23, P2091, DOI 10.1007/s00467-008-0879-x; Haensgen H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01257; Hicks-Nelson A, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070089; Hsu YR, 2019, EYE, V33, P66, DOI 10.1038/s41433-018-0223-z; Julian K, 2010, OCUL IMMUNOL INFLAMM, V18, P172, DOI 10.3109/09273941003678837; Kayserili H, 2009, HUM MOL GENET, V18, P4357, DOI 10.1093/hmg/ddp391; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Liao LB, 2019, NEUROSCI RES, V147, P9, DOI 10.1016/j.neures.2018.11.006; Liu N, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008368; MARTINEZ AJ, 1980, ARCH OPHTHALMOL-CHIC, V98, P533; McQuaid GA, 2019, BEHAV BRAIN RES, V375, DOI 10.1016/j.bbr.2019.112145; Muhammad SA, 2019, J BIOL RES-THESSALON, V26, DOI 10.1186/s40709-019-0094-x; Rajabi F, 2019, IMMUNOL INVEST, V48, P555, DOI 10.1080/08820139.2019.1597109; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Stager David Jr, 2013, Trans Am Ophthalmol Soc, V111, P119; SuttorpSchulten MSA, 1996, BRIT J OPHTHALMOL, V80, P844, DOI 10.1136/bjo.80.9.844; TRIZIO D, 1974, J IMMUNOL, V113, P1093; WHO, 2018, NON DIS; World Health Organization, 2017, NONC DIS PROGR MON; Xu HP, 2008, EXP EYE RES, V87, P319, DOI 10.1016/j.exer.2008.06.012	27	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2020	11								1053	10.3389/fimmu.2020.01053	http://dx.doi.org/10.3389/fimmu.2020.01053			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MH7BT	32612602	Green Published, gold			2022-12-18	WOS:000546880500001
J	Karim, AF; Soltis, AR; Sukumar, G; Konigs, C; Ewing, NP; Dalgard, CL; Wilkerson, MD; Pratt, KP				Karim, Ahmad Faisal; Soltis, Anthony R.; Sukumar, Gauthaman; Koenigs, Christoph; Ewing, Nadia P.; Dalgard, Clifton L.; Wilkerson, Matthew D.; Pratt, Kathleen P.			Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators	FRONTIERS IN IMMUNOLOGY			English	Article						hemophilia A; RNAseq analysis; innate and adaptive immune response; factor VIII (FVIII); PBMC (peripheral blood mononuclear cells)	COAGULATION-FACTOR-VIII; THERAPEUTIC FACTOR-VIII; RECOMBINANT FACTOR-VIII; VON-WILLEBRAND-FACTOR; TOLERANCE INDUCTION; EMICIZUMAB PROPHYLAXIS; HUMAN INTERLEUKIN-32; T-CELLS; KAPPA-B; MECHANISM	Formation of pathological anti-FVIII antibodies, or "inhibitors," is the most serious complication of therapeutic FVIII infusions, affecting up to 1/3 of severe Hemophilia A (HA) patients. Inhibitor formation is a classical T-cell dependent adaptive immune response. As such, it requires help from the innate immune system. However, the roles of innate immune cells and mechanisms of inhibitor development vs. immune tolerance, achieved with or without Immune Tolerance Induction (ITI) therapy, are not well-understood. To address these questions, temporal transcriptomics profiling of FVIII-stimulated peripheral blood mononuclear cells (PBMCs) was carried out for HA subjects with and without a current or historic inhibitor using RNA-Seq. PBMCs were isolated from 40 subjects in the following groups: HA with an inhibitor that resolved either following ITI or spontaneously; HA with a current inhibitor; HA with no inhibitor history and non-HA controls. PBMCs were stimulated with 5 nM FVIII and RNA was isolated 4, 16, 24, and 48 h following stimulation. Time-series differential expression analysis was performed and distinct transcriptional signatures were identified for each group, providing clues as to cellular mechanisms leading to or accompanying their disparate anti-FVIII antibody responses. Subjects with a current inhibitor showed differential expression of 56 genes and a clustering analysis identified three major temporal profiles. Interestingly, gene ontology enrichments featured innate immune modulators, includingNLRP3, TLR8, IL32, CLEC10A, andCOLEC12. NLRP3andTLR8are associated with enhanced secretion of the pro-inflammatory cytokines IL-1 beta and TNF alpha, while IL32, which has several isoforms, has been associated with both inflammatory and regulatory immune processes. RNA-Seq results were validated by RT-qPCR, ELISAs, multiplex cytokine analysis, and flow cytometry. The inflammatory status of HA patients suffering from an ongoing inhibitor includes up-regulated innate immune modulators, which may act as ongoing danger signals that influence the responses to, and eventual outcomes of, ITI therapy.	[Karim, Ahmad Faisal; Pratt, Kathleen P.] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA; [Karim, Ahmad Faisal; Soltis, Anthony R.; Wilkerson, Matthew D.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Soltis, Anthony R.; Sukumar, Gauthaman; Dalgard, Clifton L.; Wilkerson, Matthew D.] Uniformed Serv Univ Hlth Sci, Collaborat Hlth Initiat Res Program, Henry Jackson Fdn Adv Mil Med, Bethesda, MD 20814 USA; [Soltis, Anthony R.; Sukumar, Gauthaman; Dalgard, Clifton L.; Wilkerson, Matthew D.] Uniformed Serv Univ Hlth Sci, Amer Genome Ctr, Bethesda, MD 20814 USA; [Sukumar, Gauthaman; Dalgard, Clifton L.; Wilkerson, Matthew D.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Koenigs, Christoph] Goethe Univ, Dept Pediat, Frankfurt, Germany; [Ewing, Nadia P.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA	Uniformed Services University of the Health Sciences - USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; Goethe University Frankfurt; City of Hope	Pratt, KP (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA.	Kathleen.pratt@usuhs.edu	Sukumar, Gauthaman/A-1697-2018	Dalgard, Clifton/0000-0003-2025-8239; Sukumar, Gauthaman/0000-0003-3129-4171	Grifols, Inc.; NHLBI [R01 HL130448, 1RC2 HL101851, IAAA-A-HL-007.001]	Grifols, Inc.; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by an unrestricted, investigator-initiated grant from Grifols, Inc. and by NHLBI grants R01 HL130448, 1RC2 HL101851, and IAAA-A-HL-007.001 to the Collaborative Health Sciences Research Program of the Uniformed Services University of the Health Sciences. Grifols did not play any role in experimental design, or in conduct of experiments, or in writing the manuscript. KP is an inventor on FVIII-related patents.	Al-Shobaili HA, 2018, INT J HEALTH SCI-IJH, V12, P29; Al-Shobaili Hani A, 2018, Diseases, V6, DOI 10.3390/diseases6010021; Aledort LM, 2019, HAEMOPHILIA, V25, P183, DOI 10.1111/hae.13670; Bae S, 2012, CYTOKINE, V58, P79, DOI 10.1016/j.cyto.2011.12.024; Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216; Brackmann HH, 2018, HAEMOPHILIA, V24, P3, DOI 10.1111/hae.13445; BRAY GL, 1993, AM J HEMATOL, V42, P375, DOI 10.1002/ajh.2830420408; Delignat S, 2012, HAEMOPHILIA, V18, P248, DOI 10.1111/j.1365-2516.2011.02679.x; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Frey BJ, 2007, SCIENCE, V315, P972, DOI 10.1126/science.1136800; Gouw SC, 2013, BLOOD, V121, P4046, DOI 10.1182/blood-2012-09-457036; Gouw SC, 2012, BLOOD, V119, P2922, DOI 10.1182/blood-2011-09-379453; Gouw SC, 2009, SEMIN THROMB HEMOST, V35, P723, DOI 10.1055/s-0029-1245105; Hay CRM, 2011, BLOOD, V117, P6367, DOI 10.1182/blood-2010-09-308668; Herczenik E, 2012, J ALLERGY CLIN IMMUN, V129, P501, DOI 10.1016/j.jaci.2011.08.029; Hong JT, 2017, PHARMACOL THERAPEUT, V174, P127, DOI 10.1016/j.pharmthera.2017.02.025; Hu GL, 2007, THROMB HAEMOSTASIS, V97, P788, DOI 10.1160/TH06-09-0519; Hu GL, 2003, J THROMB HAEMOST, V1, P2159, DOI 10.1046/j.1538-7836.2003.00366.x; Jacquemin M, 2003, BLOOD, V101, P1351, DOI 10.1182/blood-2002-05-1369; James EA, 2007, J THROMB HAEMOST, V5, P2399, DOI 10.1111/j.1538-7836.2007.02762.x; Jing WQ, 2019, BLOOD ADV, V3, P3099, DOI 10.1182/bloodadvances.2019000650; Kang JW, 2014, BIOCHIMIE, V101, P248, DOI 10.1016/j.biochi.2014.01.013; Kang JW, 2013, FEBS LETT, V587, P3776, DOI 10.1016/j.febslet.2013.10.019; Kang JW, 2013, J BIOL CHEM, V288, P23650, DOI 10.1074/jbc.M113.465575; KATSIKIS PD, 1994, J EXP MED, V179, P1517, DOI 10.1084/jem.179.5.1517; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kis-Toth K, 2018, BLOOD ADV, V2, P2904, DOI 10.1182/bloodadvances.2018024497; Lacroix-Desmazes S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02991; Lai JD, 2018, J THROMB HAEMOST, V16, P533, DOI 10.1111/jth.13936; Mahlangu J, 2018, NEW ENGL J MED, V379, P811, DOI 10.1056/NEJMoa1803550; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Meunier Sylvain, 2017, Blood Adv, V1, P1842, DOI 10.1182/bloodadvances.2017008706; Oldenburg J, 2017, NEW ENGL J MED, V377, P809, DOI 10.1056/NEJMoa1703068; Ovlisen K, 2009, HAEMOPHILIA, V15, P802, DOI 10.1111/j.1365-2516.2008.01973.x; Peyron I, 2018, HAEMATOLOGICA, V103, P172, DOI 10.3324/haematol.2017.175083; Peyvandi F, 2018, J THROMB HAEMOST, V16, P39, DOI 10.1111/jth.13888; Peyvandi F, 2016, NEW ENGL J MED, V374, P2054, DOI 10.1056/NEJMoa1516437; Pfistershammer K, 2006, THROMB HAEMOSTASIS, V96, P309, DOI 10.1160/TH05-11-0729; Pipe SW, 2016, BLOOD, V128, P2007, DOI 10.1182/blood-2016-04-713289; RAGNI MV, 1989, TRANSFUSION, V29, P447, DOI 10.1046/j.1537-2995.1989.29589284147.x; Reding MT, 1999, THROMB HAEMOSTASIS, V82, P509, DOI 10.1055/s-0037-1615873; Reipert BM, 2010, HAEMOPHILIA, V16, P25, DOI 10.1111/j.1365-2516.2008.01962.x; Ribeiro-Dias F, 2017, J LEUKOCYTE BIOL, V101, P39, DOI [10.1189/jlb.4RU0416-175RR, 10.1189/jlb.4ru0416-175rr]; Schep SJ, 2018, BLOOD REV, V32, P326, DOI 10.1016/j.blre.2018.02.003; Shapiro AD, 2018, J THROMB HAEMOST, V16, P2362, DOI 10.1111/jth.14296; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Teyssandier M, 2013, HAEMOPHILIA, V19, P399, DOI 10.1111/hae.12081; van den Berg HM, 2019, BLOOD, V134, P317, DOI 10.1182/blood.2019000658; van Haren SD, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002246; van Vulpen LFD, 2015, BLOOD, V126, P2239, DOI 10.1182/blood-2015-03-635524; Volkers P, 2019, HAEMOPHILIA, V25, P398, DOI 10.1111/hae.13747; Watanabe Y, 2010, MOL CELL, V37, P123, DOI 10.1016/j.molcel.2009.10.028; Weyand AC, 2019, BLOOD, V133, P389, DOI 10.1182/blood-2018-08-872291; Wu HY, 2001, THROMB HAEMOSTASIS, V85, P125, DOI 10.1055/s-0037-1612915; Xin T, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0832-x; Yan HM, 2018, ONCOL LETT, V16, P41, DOI 10.3892/ol.2018.8649; Yao QM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00613; Zhang AH, 2011, BLOOD, V117, P2223, DOI 10.1182/blood-2010-06-293324; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	60	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 12	2020	11								1219	10.3389/fimmu.2020.01219	http://dx.doi.org/10.3389/fimmu.2020.01219			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3AZ	32595650	Green Published, gold			2022-12-18	WOS:000543845400001
J	Morris, MC; Chapman, TJ; Pichichero, ME; Broderick, G				Morris, Matthew C.; Chapman, Timothy J.; Pichichero, Michael E.; Broderick, Gordon			Immune Network Modeling Predicts Specific Nasopharyngeal and Peripheral Immune Dysregulation in Otitis-Prone Children	FRONTIERS IN IMMUNOLOGY			English	Article						pediatric population; systems biology; otitis; immune signaling; numerical models; regulatory logic; immune homeostasis	NONTYPABLE HAEMOPHILUS-INFLUENZAE; REGULATORY T-CELLS; MEMORY TH17 CELLS; STREPTOCOCCUS-PNEUMONIAE; YOUNG-CHILDREN; IFN-GAMMA; PNEUMOCOCCAL CARRIAGE; ANTIBODY-RESPONSE; MEDIA; DIFFERENTIATION	Acute otitis media (AOM) pathogenesis involves nasopharyngeal colonization by potential otopathogens and a viral co-infection. Stringently-defined otitis prone (sOP) children show characteristic patterns of immune dysfunction. We hypothesized that otitis proneness is largely a result of altered signaling between immune components that are otherwise competent, resulting in increased susceptibility to infection by bacterial otopathogens. To test this, we constructed a regulatory immune network model linking immune cells and signaling elements known to be involved in AOM and/or dysregulated in sOP children. The alignment of immune response mechanisms with data fromin vivoandin vitroexperimental observations produced 82 putative immune network models, each describing variants of immune regulatory networks consistent with available observations. Analysis of these models suggested that new measurements of serum levels of IL-4 and CXCL8 could refine competing models and resulted in the elimination of 38 of the models. Further analysis of the remaining 44 models suggested specific deviations in the predicted regulation of nasopharyngeal and peripheral immunity during response to AOM. Specifically, immune responses active in sOP children during AOM were characterized by early and constitutive activation of pro-inflammatory signaling in the nasopharynx and a Th2- and Treg-dominated profile in the periphery. We conclude that sOP children have altered regulation of key immune mediators during both health and pathogenesis. This altered regulation may be amenable to therapeutic intervention.	[Morris, Matthew C.; Broderick, Gordon] Rochester Gen Hosp, Res Inst, Ctr Clin Syst Biol, Rochester, NY 14621 USA; [Chapman, Timothy J.; Pichichero, Michael E.] Rochester Gen Hosp, Res Inst, Ctr Infect Dis & Immunol, Rochester, NY 14621 USA; [Broderick, Gordon] Rochester Inst Technol, Dept Biomed Engn, Rochester, NY 14623 USA	Rochester General Hospital; Rochester General Hospital; Rochester Institute of Technology	Broderick, G (corresponding author), Rochester Gen Hosp, Res Inst, Ctr Clin Syst Biol, Rochester, NY 14621 USA.; Pichichero, ME (corresponding author), Rochester Gen Hosp, Res Inst, Ctr Infect Dis & Immunol, Rochester, NY 14621 USA.; Broderick, G (corresponding author), Rochester Inst Technol, Dept Biomed Engn, Rochester, NY 14623 USA.	michael.pichichero@rochesterregional.org; gordon.broderick@rochesterregional.org	Pichichero, Michael E/AID-7886-2022	Chapman, Timothy/0000-0002-2337-2136	NIH NIDCD [R01 DC008671]; Department of Defense Congressionally Directed Medical Research Program [GW140142]; Elsevier BV (Amsterdam)	NIH NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Department of Defense Congressionally Directed Medical Research Program(United States Department of Defense); Elsevier BV (Amsterdam)	This work was supported by NIH NIDCD R01 DC008671 to MP, the Department of Defense Congressionally Directed Medical Research Program GW140142 to GB, and Elsevier BV (Amsterdam) through a Collaborative Research Award to GB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Elsevier BV reserved the right to review the manuscript for confidential information content.	Allen EK, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0411-7; Basha S, 2015, CLIN EXP IMMUNOL, V182, P314, DOI 10.1111/cei.12660; Basha S, 2017, J INFECT DIS, V215, P1321, DOI 10.1093/infdis/jix090; Boudewyns A, 2011, OTOL NEUROTOL, V32, P799, DOI 10.1097/MAO.0b013e31821b0d07; Brown JR, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00254-19; Chen X, 2014, J LEUKOCYTE BIOL, V95, P723, DOI 10.1189/jlb.1213633; Chonmaitree T, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3555; De Wals P, 2009, CLIN THER, V31, P2152, DOI 10.1016/j.clinthera.2009.10.014; Ede LC, 2013, PEDIATR RES, V73, P349, DOI 10.1038/pr.2012.179; Gray C, 2014, MUCOSAL IMMUNOL, V7, P705, DOI 10.1038/mi.2013.89; Guimera R, 2009, P NATL ACAD SCI USA, V106, P22073, DOI 10.1073/pnas.0908366106; Ilia S, 2014, PEDIATR INFECT DIS J, V33, P518, DOI 10.1097/INF.0000000000000229; Isla A, 2011, ENFERM INFEC MICR CL, V29, P167, DOI 10.1016/j.eimc.2010.05.008; Jiang XL, 2015, RESPIRATION, V90, P25, DOI 10.1159/000381724; Kaur R, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0181; Kaur R, 2011, PEDIATR INFECT DIS J, V30, P645, DOI 10.1097/INF.0b013e31821c2d8b; Kaur R, 2011, VACCINE, V29, P1023, DOI 10.1016/j.vaccine.2010.11.055; Khan MN, 2012, FEMS IMMUNOL MED MIC, V65, P439, DOI 10.1111/j.1574-695X.2012.00967.x; Lewnard JA, 2016, J INFECT DIS, V213, P1596, DOI 10.1093/infdis/jiv761; Li WC, 2018, P NATL ACAD SCI USA, V115, pE7149, DOI 10.1073/pnas.1802261115; LINDBERG K, 1994, CLIN EXP IMMUNOL, V97, P396; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Liu KY, 2013, LARYNGOSCOPE, V123, P1500, DOI 10.1002/lary.23973; Liu KY, 2013, INT IMMUNOL, V25, P353, DOI 10.1093/intimm/dxs154; Long D, 2019, J AUTOIMMUN, V99, P1, DOI 10.1016/j.jaut.2019.01.013; McGuire HM, 2015, J IMMUNOL, V195, P5123, DOI 10.4049/jimmunol.1501463; Monasta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036226; Morris MC, 2017, INNATE IMMUN-LONDON, V23, P667, DOI 10.1177/1753425917737825; Naradikian MS, 2016, J IMMUNOL, V197, P1023, DOI 10.4049/jimmunol.1600522; Neill DR, 2014, AM J RESP CRIT CARE, V189, P1250, DOI 10.1164/rccm.201401-0128OC; Nokso-Koivisto J, 2015, CURR OPIN PEDIATR, V27, P110, DOI 10.1097/MOP.0000000000000184; Novichkova S, 2003, BIOINFORMATICS, V19, P1699, DOI 10.1093/bioinformatics/btg207; Pacifici R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00057; Patel JA, 2009, PEDIATR INFECT DIS J, V28, P1002, DOI 10.1097/INF.0b013e3181aa5b13; Pichichero ME, 2018, BIOMARKERS APPL, V118, P1, DOI [10.29011/BMAP-118, DOI 10.29011/BMAP-118]; Pichichero ME, 2008, PEDIATR INFECT DIS J, V27, P958, DOI 10.1097/INF.0b013e318179a2ac; Pichichero ME, 2016, J INFECT DIS, V213, P2014, DOI 10.1093/infdis/jiw053; Pichichero ME, 2013, PEDIATR INFECT DIS J, V32, P1163, DOI 10.1097/INF.0b013e31829e887e; R Core Team, 2017, R LANG ENV STAT COMP; Rye MS, 2011, GENES IMMUN, V12, P352, DOI 10.1038/gene.2011.2; Schilder AGM, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.63; Schmitt N, 2015, CURR OPIN IMMUNOL, V34, P130, DOI 10.1016/j.coi.2015.03.007; Schmitt N, 2013, BLOOD, V121, P3375, DOI 10.1182/blood-2012-08-448902; Sedghamiz H, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00048; Sedghamiz H, 2018, BMC SYST BIOL, V12, DOI 10.1186/s12918-018-0599-1; Sedghamiz H, 2017, IEEE INT C BIOINF BI, P200, DOI 10.1109/BIBE.2017.00040; Sharma SK, 2013, CURR ALLERGY ASTHM R, V13, P495, DOI 10.1007/s11882-013-0370-z; Sharma SK, 2012, J INFECT DIS, V205, P1225, DOI 10.1093/infdis/jis179; Sharma SK, 2011, J INFECT DIS, V204, P645, DOI 10.1093/infdis/jir340; Spiro DM, 2011, EXPERT REV ANTI-INFE, V9, P177, DOI [10.1586/eri.10.175, 10.1586/ERI.10.175]; THOMAS R, 1995, B MATH BIOL, V57, P247, DOI 10.1016/0092-8240(94)00036-C; Thomas R, 2001, CHAOS, V11, P180, DOI 10.1063/1.1349893; Thomas R, 2001, CHAOS, V11, P170, DOI 10.1063/1.1350439; Tonello E, 2019, BOOLEAN ANAL LATERAL, P1; Varela PL, 2018, ELECTRON NOTES THEOR, V335, P113, DOI 10.1016/j.entcs.2018.03.011; Verhoeven D, 2013, MED MICROBIOL IMMUN, V202, P295, DOI 10.1007/s00430-013-0293-2; Verschoor CP, 2014, INFECT IMMUN, V82, P4824, DOI 10.1128/IAI.02251-14; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Wang Y, 2017, MUCOSAL IMMUNOL, V10, P250, DOI 10.1038/mi.2016.41; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yu SF, 2015, CELL CYCLE, V14, P3362, DOI 10.1080/15384101.2015.1093703; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	63	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2020	11								1168	10.3389/fimmu.2020.01168	http://dx.doi.org/10.3389/fimmu.2020.01168			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD2SL	32595639	Green Published, gold			2022-12-18	WOS:000543823200001
J	Zhao, RQ; Zhang, HH; Zhang, Y; Li, D; Huang, CX; Li, FB				Zhao, Rongqing; Zhang, Huihui; Zhang, Yan; Li, Dan; Huang, Chuanxin; Li, Fubin			In vivo Screen Identifies Zdhhc2 as a Critical Regulator of Germinal Center B Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						germinal center B cell; in vivoscreen; shRNA; GC selection; Zdhhc2	PALMITOYL ACYLTRANSFERASE DHHC2; TERM ANTIGEN RETENTION; WIDE CRISPR SCREEN; PROTEIN PALMITOYLATION; NEURONAL DEVELOPMENT; INTERFERENCE SCREEN; TUMOR-SUPPRESSOR; C-MYC; EXPRESSION; DEFICIENCY	Germinal center (GC) B cell differentiation is critical for the production of affinity-matured pathogen-specific antibodies, the dysregulation of which may lead to humoral immunodeficiency or autoimmunity. The development of anin vivoscreening system for factors regulating GC B cell differentiation has been a challenge. Here we describe a small-scalein vivoscreening system with NP-specific B1-8(hi)cells and a retroviral shRNA library targeting 78 candidate genes to search for B cell-intrinsic factors that specifically regulate GC B cell differentiation.Zdhhc2, a gene encoding palmitoyltransferase ZDHHC2 and highly expressed in GC B cells, is identified as a strong positive regulator of GC B cell differentiation. B1-8(hi)cells transduced withZdhhc2-shRNA are severely compromised in differentiating into GC B cells. A further analysis ofin vitrodifferentiated B cells transduced withZdhhc2-shRNA shows thatZdhhc2is critical for the proliferation and the survival of B cells stimulated by CD40L, BAFF, and IL-21 and consequently impacts on their differentiation into GC B cells and post-GC B cells. These studies not only identifyZdhhc2as a novel regulator of GC B cell differentiation but also represent a proof of concept ofin vivoscreen for regulators of GC B cell differentiation.	[Zhao, Rongqing; Zhang, Huihui; Zhang, Yan; Huang, Chuanxin; Li, Fubin] Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Fac Basic Med, Shanghai Inst Immunol,Sch Med, Shanghai, Peoples R China; [Li, Dan] Boston Consulting Grp Inc, Shenzhen, Peoples R China; [Huang, Chuanxin; Li, Fubin] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ, Sch Med, Shanghai, Peoples R China; [Li, Fubin] Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Syst Biomed, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Boston Consulting Group (BCG); Shanghai Jiao Tong University; Shanghai Jiao Tong University	Li, FB (corresponding author), Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Fac Basic Med, Shanghai Inst Immunol,Sch Med, Shanghai, Peoples R China.; Li, FB (corresponding author), Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ, Sch Med, Shanghai, Peoples R China.; Li, FB (corresponding author), Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Syst Biomed, Shanghai, Peoples R China.	fubin.li@sjtu.edu.cn			Chinese Mega Project on InfectiousDiseases Grant [2018ZX10302301]; NationalNatural Science Foundation of China (NNSFC) [31422020]; 973 Program [2014CB943600]; NNSFC [31600704, 31800778]; "Shu Guang" project from Shanghai Municipal Education Commission; Shanghai Education Development Foundation; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions ofHigher Learning; innovative research teamof high-level local universities in Shanghai [SSMU-2DCX20180100]	Chinese Mega Project on InfectiousDiseases Grant; NationalNatural Science Foundation of China (NNSFC)(National Natural Science Foundation of China (NSFC)); 973 Program(National Basic Research Program of China); NNSFC(National Natural Science Foundation of China (NSFC)); "Shu Guang" project from Shanghai Municipal Education Commission; Shanghai Education Development Foundation; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions ofHigher Learning; innovative research teamof high-level local universities in Shanghai	This work was supported by the Chinese Mega Project on InfectiousDiseases Grant 2018ZX10302301, theNationalNatural Science Foundation of China (NNSFC) Project 31422020, 973 Program 2014CB943600, and NNSFC Projects 31600704 and 31800778. FL was supported by the "Shu Guang" project from Shanghai Municipal Education Commission and Shanghai Education Development Foundation. HZ was supported by the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions ofHigher Learning. HZ, YZ, and FL were also supported by the innovative research teamof high-level local universities in Shanghai (SSMU-2DCX20180100).	Adams BD, 2012, CELL REP, V2, P1048, DOI 10.1016/j.celrep.2012.09.014; Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736; Ashenden M, 2017, MOL CANCER THER, V16, P1967, DOI 10.1158/1535-7163.MCT-16-0731; Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015; Brichta L, 2015, NAT NEUROSCI, V18, P1325, DOI 10.1038/nn.4070; Brink R, 2018, ANNU REV IMMUNOL, V36, P339, DOI 10.1146/annurev-immunol-051116-052510; Burnett DL, 2018, SCIENCE, V360, P223, DOI 10.1126/science.aao3859; Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418; Caron G, 2009, J IMMUNOL, V182, P7595, DOI 10.4049/jimmunol.0804272; Cato MH, 2011, NAT PROTOC, V6, P953, DOI 10.1038/nprot.2011.344; Chen RQ, 2014, IMMUNITY, V41, P325, DOI 10.1016/j.immuni.2014.08.002; Chen SD, 2015, CELL, V160, P1246, DOI 10.1016/j.cell.2015.02.038; Cherukuri A, 2004, J BIOL CHEM, V279, P31973, DOI 10.1074/jbc.M404410200; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; CUTRONA G, 1995, J EXP MED, V181, P699, DOI 10.1084/jem.181.2.699; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; De Silva NS, 2012, IMMUNOL REV, V247, P73, DOI 10.1111/j.1600-065X.2012.01113.x; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fukata Y, 2010, NAT REV NEUROSCI, V11, P161, DOI 10.1038/nrn2788; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gonzalez-Martin A, 2016, NAT IMMUNOL, V17, P433, DOI 10.1038/ni.3385; Grammer AC, 2003, J CLIN INVEST, V112, P1506, DOI 10.1172/JCI200319301; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; Guan XM, 2011, SCI CHINA CHEM, V54, P1888, DOI 10.1007/s11426-011-4428-2; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Huang CX, 2014, BLOOD, V123, P1012, DOI 10.1182/blood-2013-07-518605; Ivaldi C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037187; Katigbak A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38968; Ko PJ, 2018, EMBO REP, V19, DOI 10.15252/embr.201846666; Li M, 2019, CELL MOL IMMUNOL, V16, P757, DOI 10.1038/s41423-018-0185-x; Li SX, 2014, CANCER-AM CANCER SOC, V120, P1520, DOI 10.1002/cncr.28593; Li X, 2018, IMMUNITY, V48, P530, DOI 10.1016/j.immuni.2018.03.006; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Lougaris V, 2005, IMMUNOL REV, V203, P48, DOI 10.1111/j.0105-2896.2005.00229.x; Lu PW, 2017, SCIENCE, V356, DOI 10.1126/science.aai9264; Lu Y, 2019, SCIENCE, V366, P460, DOI 10.1126/science.aau6391; Malina A, 2013, GENE DEV, V27, P2602, DOI 10.1101/gad.227132.113; MANDEL TE, 1981, IMMUNOLOGY, V43, P353; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Meyer-Hermann ME, 2006, MATH MED BIOL, V23, P255, DOI 10.1093/imammb/dql012; Misaki R, 2010, J CELL BIOL, V191, P23, DOI 10.1083/jcb.200911143; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Murugaesu N, 2014, CANCER DISCOV, V4, P304, DOI 10.1158/2159-8290.CD-13-0287; Nojima T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1475; Noritake J, 2009, J CELL BIOL, V186, P147, DOI 10.1083/jcb.200903101; Pavri R, 2011, ADV IMMUNOL, V110, P1, DOI 10.1016/B978-0-12-387663-8.00005-3; Planey SL, 2009, MOL BIOL CELL, V20, P1454, DOI 10.1091/mbc.E08-08-0849; Rolf J, 2010, J IMMUNOL, V185, P4042, DOI 10.4049/jimmunol.1001730; Sanders SS, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00115; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Sharma C, 2008, MOL BIOL CELL, V19, P3415, DOI 10.1091/mbc.E07-11-1164; Shi W, 2015, NAT IMMUNOL, V16, P663, DOI 10.1038/ni.3154; Song CQ, 2017, GASTROENTEROLOGY, V152, P1161, DOI 10.1053/j.gastro.2016.12.002; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Vikstrom I, 2010, SCIENCE, V330, P1095, DOI 10.1126/science.1191793; Warnatz K, 2006, BLOOD, V107, P3045, DOI 10.1182/blood-2005-07-2955; Weber J, 2015, P NATL ACAD SCI USA, V112, P13982, DOI 10.1073/pnas.1512392112; Weisel FJ, 2016, IMMUNITY, V44, P116, DOI 10.1016/j.immuni.2015.12.004; Willis SN, 2014, J IMMUNOL, V192, P3200, DOI 10.4049/jimmunol.1303216; Woolfrey KM, 2015, J NEUROSCI, V35, P442, DOI 10.1523/JNEUROSCI.2243-14.2015; Xu CL, 2017, P NATL ACAD SCI USA, V114, P722, DOI 10.1073/pnas.1615735114; Zeidman R, 2011, MOL MEMBR BIOL, V28, P473, DOI 10.3109/09687688.2011.630682; Zhang J, 2008, MOL CELL PROTEOMICS, V7, P1378, DOI 10.1074/mcp.M800069-MCP200; Zhang WQ, 2019, P NATL ACAD SCI USA, V116, P18550, DOI 10.1073/pnas.1901340116; Zingler P, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0405-8	75	1	1	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 10	2020	11								1025	10.3389/fimmu.2020.01025	http://dx.doi.org/10.3389/fimmu.2020.01025			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3RH	32587588	Green Published, gold			2022-12-18	WOS:000543887800001
J	Choi, A; Ibanez, LI; Strohmeier, S; Krammer, F; Garcia-Sastre, A; Schotsaert, M				Choi, Angela; Ibanez, Lorena I.; Strohmeier, Shirin; Krammer, Florian; Garcia-Sastre, Adolfo; Schotsaert, Michael			Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; pre-existing immunity; TIV; alveolar macrophage; tissue-resident memory T cell; germinal center B cell; heterosubtypic immunity	TISSUE-RESIDENT; NONNEUTRALIZING ANTIBODIES; CELLS; MACROPHAGES; INTERFERON; MAGNITUDE; INDUCTION; MICE	Conventional influenza vaccines aim at the induction of virus-neutralizing antibodies that provide with sterilizing immunity. However, influenza vaccination often confers protection from disease but not from infection. The impact of infection-permissive vaccination on the immune response elicited by subsequent influenza virus infection is not well-understood. Here, we investigated to what extent infection-permissive immunity, in contrast to virus-neutralizing immunity, provided by a trivalent inactivated virus vaccine (TIV) modulates disease and virus-induced host immune responses after sublethal vaccine-matching H1N1 infection in a mouse model. More than one TIV vaccination was needed to induce a serum HI titer and provide sterilizing immunity upon homologous virus infection. However, single TIV administration provided infection-permissive immunity, characterized by lower viral lung titers and faster recovery. Despite the presence of replicating virus, single TIV vaccination prevented induction of pro-inflammatory cyto- and chemokines, alveolar macrophage depletion as well as the establishment of lung-resident B and T cells after infection. To investigate virus infection-induced cross-protective heterosubtypic immune responses in vaccinated and unvaccinated animals, mice were re-infected with a lethal dose of H3N2 virus 4 weeks after H1N1 infection. Single TIV vaccination did not prevent H1N1 virus infection-induced heterosubtypic cross-protection, but shifted the mechanism of cross-protection from the cellular to the humoral branch of the immune system. These results suggest that suboptimal vaccination with conventional influenza vaccines may still positively modulate disease outcome after influenza virus infection, while promoting humoral heterosubtypic immunity after virus infection.	[Choi, Angela; Strohmeier, Shirin; Krammer, Florian; Garcia-Sastre, Adolfo; Schotsaert, Michael] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Choi, Angela] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA; [Ibanez, Lorena I.] Consejo Nacl Invest Cient & Tecn, Inst Ciencia & Tecnol Dr Cesar Milstein, Buenos Aires, DF, Argentina; [Garcia-Sastre, Adolfo; Schotsaert, Michael] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Garcia-Sastre, A; Schotsaert, M (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Garcia-Sastre, A; Schotsaert, M (corresponding author), Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.	adolfo.garcia-sastre@mssm.edu; michael.schotsaert@mssm.edu	Krammer, Florian/H-3237-2019	Krammer, Florian/0000-0003-4121-776X	NIAID [P01AI097092]; CRIP (Center for Research on Influenza Pathogenesis), an NIAID [HHSN272201400008C]; SEM CIVIC, an NIAID [75N93019C00051]	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CRIP (Center for Research on Influenza Pathogenesis), an NIAID; SEM CIVIC, an NIAID	These studies were partially funded by NIAID grant P01AI097092 to AG-S, by CRIP (Center for Research on Influenza Pathogenesis), an NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract #HHSN272201400008C) and by SEM CIVIC, an NIAID funded Sinai Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center (contract #75N93019C00051) to AG-S and FK.	Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Bodewes R, 2013, J VIROL, V87, P4293, DOI 10.1128/JVI.02536-12; Bodewes R, 2011, J VIROL, V85, P11995, DOI 10.1128/JVI.05213-11; Califano D, 2018, J IMMUNOL, V201, P134, DOI 10.4049/jimmunol.1701406; Cao RG, 2014, J INFECT DIS, V210, P224, DOI 10.1093/infdis/jiu079; Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168; CDC, 2018, INFL FLU INCL SEAS A; Choi A, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030113; Coughlan L, 2018, CELL HOST MICROBE, V24, P18, DOI 10.1016/j.chom.2018.06.016; Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908; Dunbar PR, 2020, MUCOSAL IMMUNOL, V13, P161, DOI 10.1038/s41385-019-0224-7; Epstein SL, 2006, J INFECT DIS, V193, P49, DOI 10.1086/498980; Epstein SL, 1997, J IMMUNOL, V158, P1222; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Ghoneim HE, 2013, J IMMUNOL, V191, P1250, DOI 10.4049/jimmunol.1300014; Grant EJ, 2016, CURR OPIN VIROL, V16, P132, DOI 10.1016/j.coviro.2016.01.016; Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Helft J, 2012, J CLIN INVEST, V122, P4037, DOI 10.1172/JCI60659; Hillaire MLB, 2011, J GEN VIROL, V92, P2339, DOI 10.1099/vir.0.033076-0; Jain A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05489-7; Kim JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep37341; Koutsakos M, 2019, NAT IMMUNOL, V20, P613, DOI 10.1038/s41590-019-0320-6; Krammer F, 2019, J INFECT DIS, V219, pS62, DOI 10.1093/infdis/jiy711; Kreijtz JHCM, 2009, VACCINE, V27, P4983, DOI 10.1016/j.vaccine.2009.05.079; Laidlaw BJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003207; LaMere MW, 2011, J VIROL, V85, P5027, DOI 10.1128/JVI.00150-11; LaMere MW, 2011, J IMMUNOL, V186, P4331, DOI 10.4049/jimmunol.1003057; Lapuente D, 2018, MUCOSAL IMMUNOL, V11, P1265, DOI 10.1038/s41385-018-0017-4; Lee YN, 2016, J IMMUNOL, V196, P2637, DOI 10.4049/jimmunol.1501637; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091; Neyt K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00312; Pineros YSS, 2019, ALLERGY, V74, P1898, DOI 10.1111/all.13802; Samarasinghe AE, 2017, J IMMUNOL, V198, P3214, DOI 10.4049/jimmunol.1600787; Schenkel JM, 2016, J IMMUNOL, V196, P3920, DOI 10.4049/jimmunol.1502337; Schepens B, 2018, CURR OPIN IMMUNOL, V53, P22, DOI 10.1016/j.coi.2018.03.024; Schotsaert M, 2013, MUCOSAL IMMUNOL, V6, P276, DOI 10.1038/mi.2012.69; Seo SH, 2001, J VIROL, V75, P2516, DOI 10.1128/JVI.75.6.2516-2525.2001; Skountzou I, 2014, CLIN VACCINE IMMUNOL, V21, P1481, DOI 10.1128/CVI.00374-14; Starbeck-Miller GR, 2015, ADV EXP MED BIOL, V850, P31, DOI 10.1007/978-3-319-15774-0_3; Thomson CA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00087; Van Braeckel-Budimir N, 2018, CELL REP, V24, P3374, DOI 10.1016/j.celrep.2018.08.073; Weinfurter JT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002381; Wu T, 2014, J LEUKOCYTE BIOL, V95, P215, DOI 10.1189/jlb.0313180; Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832; Zhang A, 2019, J IMMUNOL, V202, P335, DOI 10.4049/jimmunol.1801149	49	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2020	11								1166	10.3389/fimmu.2020.01166	http://dx.doi.org/10.3389/fimmu.2020.01166			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC6CB	32582220	gold, Green Published			2022-12-18	WOS:000543371400001
J	Alfituri, OA; Bradford, BM; Paxton, E; Morrison, LJ; Mabbott, NA				Alfituri, Omar A.; Bradford, Barry M.; Paxton, Edith; Morrison, Liam J.; Mabbott, Neil A.			Influence of the Draining Lymph Nodes and Organized Lymphoid Tissue Microarchitecture on Susceptibility to IntradermalTrypanosoma bruceiInfection	FRONTIERS IN IMMUNOLOGY			English	Article						Trypanosoma brucei; trypanosomes; spleen; lymph nodes; B cells; lymphotoxin	TUMOR-NECROSIS-FACTOR; TRYPANOSOMA-CONGOLENSE; LYMPHOTOXIN-ALPHA; MEDIATED PHAGOCYTOSIS; AFRICAN TRYPANOSOMES; ABNORMAL-DEVELOPMENT; AFFINITY MATURATION; DEFICIENT; MICE; INFECTION	Infection of the mammalian host with African trypanosomes begins when the tsetse fly vector injects the parasites into the skin dermis during blood feeding. After injection into the skin, trypanosomes first accumulate in the draining lymph node before disseminating systemically. Whether this early accumulation within the draining lymph node is important for the trypanosomes to establish infection was not known. Lymphotoxin-beta-deficient mice (LT beta(-/-)mice) lack most secondary lymphoid tissues, but retain the spleen and mesenteric lymph nodes. These mice were used to test the hypothesis that the establishment of infection after intradermal (ID)T. bruceiinfection would be impeded in the absence of the skin draining lymph nodes. However, LT beta(-/-)mice revealed greater susceptibility to IDT. bruceiinfection than wild-type mice, indicating that the early accumulation of the trypanosomes in the draining lymph nodes was not essential to establish systemic infection. Although LT beta(-/-)mice were able to control the first parasitemia wave as effectively as wild-type mice, they were unable to control subsequent parasitemia waves. LT beta(-/-)mice also lack organized B cell follicles and germinal centers within their remaining secondary lymphoid tissues. As a consequence, LT beta(-/-)mice have impaired immunoglobulin (Ig) isotype class-switching responses. When the disturbed microarchitecture of the B cell follicles in the spleens of LT beta(-/-)mice was restored by reconstitution with wild-type bone marrow, their susceptibility to IDT. bruceiinfection was similar to that of wild-type control mice. This effect coincided with the ability to produce significant serum levels of Ig isotype class-switched parasite-specific antibodies. Thus, our data suggest that organized splenic microarchitecture and the production of parasite-specific Ig isotype class-switched antibodies are essential for the control of ID African trypanosome infections.	[Alfituri, Omar A.; Bradford, Barry M.; Paxton, Edith; Morrison, Liam J.; Mabbott, Neil A.] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Alfituri, Omar A.; Bradford, Barry M.; Paxton, Edith; Morrison, Liam J.; Mabbott, Neil A.] Univ Edinburgh, Royal Dick Sch Vet Sci, Edinburgh, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh	Mabbott, NA (corresponding author), Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.	neil.mabbott@roslin.ed.ac.uk		Morrison, Liam/0000-0002-8304-9066; Alfituri, Omar/0000-0002-6367-5588	Biotechnology and Biological Sciences Research Council [BB/J01446X/1];  [BBS/E/D/20231762];  [BBS/E/D/20002174]; BBSRC [BBS/E/D/20002174, BBS/E/D/20231762] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); ; ; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This study was supported by project Institute Strategic Programme Grant funding (BBS/E/D/20231762 and BBS/E/D/20002174) and a Strategic Skills Award and EASTBIO doctoral training partnership studentship (BB/J01446X/1) from the Biotechnology and Biological Sciences Research Council.	Adams A. R. D., 1936, Annals of Tropical Medicine and Parasitology, V30, P521; Alfituri OA, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12609; Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; BANKS TA, 1995, J IMMUNOL, V155, P1685; Baral TN, 2007, J INFECT DIS, V195, P1513, DOI 10.1086/515577; BLACK SJ, 1986, PARASITE IMMUNOL, V8, P425, DOI 10.1111/j.1365-3024.1986.tb00859.x; Caljon G, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005744; CAMPBELL GH, 1977, INFECT IMMUN, V18, P434, DOI 10.1128/IAI.18.2.434-438.1977; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; DEMPSEY WL, 1983, J IMMUNOL, V130, P405; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; EMERY DL, 1980, ACTA TROP, V37, P375; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Fu YX, 1997, J EXP MED, V185, P2111, DOI 10.1084/jem.185.12.2111; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Glaysher BR, 2007, J IMMUNOL, V178, P3757, DOI 10.4049/jimmunol.178.6.3757; Patrick G, 2007, INT J PARASITOL, V37, P1391, DOI 10.1016/j.ijpara.2007.04.019; Heesters BA, 2014, NAT REV IMMUNOL, V14, P495, DOI 10.1038/nri3689; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; JENNI L, 1977, Acta Tropica, V34, P35; Koni PA, 1998, J EXP MED, V187, P1977, DOI 10.1084/jem.187.12.1977; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Krautler NJ, 2012, CELL, V150, P194, DOI 10.1016/j.cell.2012.05.032; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Magez S, 2006, J INFECT DIS, V193, P1575, DOI 10.1086/503808; Magez S, 2002, INFECT IMMUN, V70, P1342, DOI 10.1128/IAI.70.3.1342-1351.2002; Magez S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000122; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; MORRISON WI, 1985, PARASITE IMMUNOL, V7, P63, DOI 10.1111/j.1365-3024.1985.tb00479.x; MORRISON WI, 1981, LAB INVEST, V45, P547; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Okwor I, 2009, J INFECT DIS, V200, P361, DOI 10.1086/599792; Onyilagha C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003716; Pan WL, 2006, MICROBES INFECT, V8, P1209, DOI 10.1016/j.micinf.2005.11.009; Radwanska M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000078; REINITZ DM, 1990, INFECT IMMUN, V58, P2337, DOI 10.1128/IAI.58.7.2337-2342.1990; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Shapiro DA, 1998, J IMMUNOL, V161, P3393; Shi MQ, 2004, J LEUKOCYTE BIOL, V76, P399, DOI 10.1189/jlb.1003500; Stijlemans B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00582; Tabel H, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002090; Taylor KA, 1996, EXP PARASITOL, V83, P106, DOI 10.1006/expr.1996.0054; Tumanov AV, 2002, IMMUNITY, V17, P239, DOI 10.1016/S1074-7613(02)00397-7; Victoratos P, 2006, IMMUNITY, V24, P65, DOI 10.1016/j.immuni.2005.11.013; Vincendeau P, 2006, AN ACAD BRAS CIENC, V78, P645, DOI 10.1590/S0001-37652006000400004; Wei GJ, 2011, J INFECT DIS, V203, P418, DOI 10.1093/infdis/jiq051	47	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 3	2020	11								1118	10.3389/fimmu.2020.01118	http://dx.doi.org/10.3389/fimmu.2020.01118			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC3AY	32582198	Green Published, gold			2022-12-18	WOS:000543165400001
J	Rodriguez, H; Prados-Rosales, R; Lavin, JL; Mazzone, M; Anguita, J				Rodriguez, Hector; Prados-Rosales, Rafael; Lavin, Jose Luis; Mazzone, Massimiliano; Anguita, Juan			Editorial: Macrophage Metabolism and Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						macrophage; metabolism; infection; disease; immune response			[Rodriguez, Hector; Anguita, Juan] CIC bioGUNE BRTA, Basque Res & Technol Alliance, Inflammat & Macrophage Plast Lab, Derio, Spain; [Prados-Rosales, Rafael] Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth & Microbiol, Madrid, Spain; [Lavin, Jose Luis] CIC bioGUNE BRTA, Basque Res & Technol Alliance, Bioinformat Unit, Derio, Spain; [Mazzone, Massimiliano] VIB, Ctr Canc Biol, Lab Tumor Inflammat & Angiogenesis, Leuven, Belgium; [Mazzone, Massimiliano] Katholieke Univ Leuven, Ctr Canc Biol, Dept Oncol, Lab Tumor Inflammat & Angiogenesis, Leuven, Belgium; [Anguita, Juan] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Lavin, Jose Luis] Neiker BRTA, Dept Appl Math, Basque Res & Technol Alliance, Bioinformat Unit, Derio, Spain	Autonomous University of Madrid; Flanders Institute for Biotechnology (VIB); KU Leuven; Basque Foundation for Science	Rodriguez, H; Anguita, J (corresponding author), CIC bioGUNE BRTA, Basque Res & Technol Alliance, Inflammat & Macrophage Plast Lab, Derio, Spain.; Prados-Rosales, R (corresponding author), Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth & Microbiol, Madrid, Spain.; Lavin, JL (corresponding author), CIC bioGUNE BRTA, Basque Res & Technol Alliance, Bioinformat Unit, Derio, Spain.; Mazzone, M (corresponding author), VIB, Ctr Canc Biol, Lab Tumor Inflammat & Angiogenesis, Leuven, Belgium.; Mazzone, M (corresponding author), Katholieke Univ Leuven, Ctr Canc Biol, Dept Oncol, Lab Tumor Inflammat & Angiogenesis, Leuven, Belgium.; Anguita, J (corresponding author), Basque Fdn Sci, Ikerbasque, Bilbao, Spain.	hrodriguez@cicbiogune.es; rafael.prados@uam.es; joluito@gmail.com; massimiliano.mazzone@kuleuven.vib.be; janguita@cicbiogune.es	Rodríguez, Héctor/E-6887-2013; JL, Lavín/J-7892-2013; Anguita, Juan/D-5432-2011; Prados-Rosales, Rafael/D-5840-2019	Rodríguez, Héctor/0000-0002-9948-2497; JL, Lavín/0000-0003-0914-3211; Anguita, Juan/0000-0003-2061-7182; Prados-Rosales, Rafael/0000-0001-5964-0166	FEDER funds [RTI2018-096494-B-100, SAF2016-77433-R]; ERC [773208]; MCI [SEV-2016-0644]; Ministry of Science and Innovation (MCI)	FEDER funds(European Commission); ERC(European Research Council (ERC)European Commission); MCI; Ministry of Science and Innovation (MCI)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	Funded by grants from the Ministry of Science and Innovation (MCI) co-financed with FEDER funds (RTI2018-096494-B-100 to JA and SAF2016-77433-R to RP-R). MM is supported by an ERC Consolidator grant (acronym: ImmunoFit; #773208). RP-R is a Ramon y Cajal Fellow from the MCI. We thank the MCI for the Severo Ochoa Excellence accreditation (SEV-2016-0644).		0	1	1	4	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 29	2020	11								1078	10.3389/fimmu.2020.01078	http://dx.doi.org/10.3389/fimmu.2020.01078			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MB1HQ	32547561	Green Published, gold			2022-12-18	WOS:000542358300001
J	Oliveira, EH; Assis, AF; Speck-Hernandez, CA; Duarte, MJ; Passos, GA				Oliveira, Ernna H.; Assis, Amanda F.; Speck-Hernandez, Cesar A.; Duarte, Max Jordan; Passos, Geraldo A.			Aire Gene Influences the Length of the 3 ' UTR of mRNAs in Medullary Thymic Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Aire; mTECs; miRNA-mRNA interaction; 3'UTR length; peripheral tissue antigens	AUTOIMMUNE REGULATOR AIRE; SELF-ANTIGEN EXPRESSION; ALTERNATIVE POLYADENYLATION; P-TEFB; HEALTH; TRANSCRIPTOME; DISRUPTION; ELONGATION; POLYMERASE; MECHANISMS	Aire is a transcriptional controller in medullary thymic epithelial cells (mTECs) modulating a set of peripheral tissue antigens (PTAs) and non-PTA mRNAs as well as miRNAs. Even miRNAs exerting posttranscriptional control of mRNAs in mTECs, the composition of miRNA-mRNA networks may differ. Under reduction in Aire expression, networks exhibited greater miRNA diversity controlling mRNAs. Variations in the number of 3'UTR binding sites of Aire-dependent mRNAs may represent a crucial factor that influence the miRNA interaction. To test this hypothesis, we analyzed through bioinformatics the length of 3'UTRs of a large set of Aire-dependent mRNAs. The data were obtained from existing RNA-seq of mTECs of wild type or Aire-knockout (KO) mice. We used computational algorithms as FASTQC, STAR and HTSEQ for sequence alignment and counting reads, DESEQ2 for the differential expression, 3USS for the alternative 3'UTRs and TAPAS for the alternative polyadenylation sites. We identified 152 differentially expressed mRNAs between these samples comprising those that encode PTAs as well as transcription regulators. In Aire KO mTECs, most of these mRNAs featured an increase in the length of their 3'UTRs originating additional miRNA binding sites and new miRNA controllers. Results from thein silicoanalysis were statistically significant and the predicted miRNA-mRNA interactions were thermodynamically stable. Even with noin vivoorin vitroexperiments, they were adequate to show that lack of Aire in mTECs might favor the downregulation of PTA mRNAs and transcription regulators via miRNA control. This could unbalance the overall transcriptional activity in mTECs and thus the self-representation.	[Oliveira, Ernna H.; Speck-Hernandez, Cesar A.; Duarte, Max Jordan; Passos, Geraldo A.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Mol Immunogenet Grp, Ribeirao Preto, Brazil; [Assis, Amanda F.] Univ Estado Minas Gerais, Passos, Brazil; [Passos, Geraldo A.] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Basic & Oral Biol, Lab Genet & Mol Biol, Ribeirao Preto, Brazil	Universidade de Sao Paulo; Universidade do Estado de Minas Gerais; Universidade de Sao Paulo	Passos, GA (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Mol Immunogenet Grp, Ribeirao Preto, Brazil.; Passos, GA (corresponding author), Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Basic & Oral Biol, Lab Genet & Mol Biol, Ribeirao Preto, Brazil.	passos@usp.br	Duarte, Max Jordan/AAR-4612-2020; Passos, Geraldo Aleixo/ABE-3251-2020	Duarte, Max Jordan/0000-0001-6211-3690; Passos, Geraldo Aleixo/0000-0002-4408-140X	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo, Brazil) [13/17481-1, 17/10780-4]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brasilia, Brazil) [305787/2017-9]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brasilia, Brazil) [8882317599/2019-01]; CAPES [001]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brasilia, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brasilia, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was funded by the following agencies, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo, Brazil, Grants 13/17481-1 and 17/10780-4), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brasilia, Brazil, Grant No 305787/2017-9). EHO was a PNPD post-doctoral fellow from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brasilia, Brazil, Fellowship No. 8882317599/2019-01). This study was financed in part by the CAPES-Financial code 001.	Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Abramson J, 2016, IMMUNOL REV, V271, P127, DOI 10.1111/imr.12419; Abramson J, 2016, EUR J IMMUNOL, V46, P22, DOI 10.1002/eji.201545792; Abramson J, 2010, CELL, V140, P123, DOI 10.1016/j.cell.2009.12.030; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson MS, 2016, NAT REV IMMUNOL, V16, P247, DOI 10.1038/nri.2016.9; Arefeen A, 2018, BIOINFORMATICS, V34, P2521, DOI 10.1093/bioinformatics/bty110; Bansal K, 2017, NAT IMMUNOL, V18, P263, DOI 10.1038/ni.3675; Blechschmidt K, 1999, GENOME RES, V9, P158; Bruserud O, 2016, CURR OPIN IMMUNOL, V43, P8, DOI 10.1016/j.coi.2016.07.003; Chuprin A, 2015, NAT IMMUNOL, V16, P737, DOI 10.1038/ni.3194; Cipolla GA, 2016, BBA-GENE REGUL MECH, V1859, P1306, DOI 10.1016/j.bbagrm.2016.07.006; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Curinha A, 2014, NUCLEUS-PHILA, V5, P508, DOI 10.4161/nucl.36360; Cutolo M, 2014, AUTOIMMUN REV, V13, P85, DOI 10.1016/j.autrev.2013.07.006; Danan-Gotthold M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1079-9; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eldershaw SA, 2011, CLIN EXP IMMUNOL, V163, P296, DOI 10.1111/j.1365-2249.2010.04316.x; Elkon R, 2013, NAT REV GENET, V14, P496, DOI 10.1038/nrg3482; Giraud M., 2019, THYMUS TRANSCRIPTOME, P169, DOI [10.1007/978-3-030-12040-5_7, DOI 10.1007/978-3-030-12040-5_7]; Giraud M, 2012, P NATL ACAD SCI USA, V109, P535, DOI 10.1073/pnas.1119351109; Girauda M, 2014, P NATL ACAD SCI USA, V111, P1491, DOI 10.1073/pnas.1323535111; Gruber AJ, 2019, NAT REV GENET, V20, P599, DOI 10.1038/s41576-019-0145-z; Husebye ES, 2018, NEW ENGL J MED, V378, P1132, DOI 10.1056/NEJMra1713301; Idda ML, 2018, NUCLEIC ACIDS RES, V46, P12040, DOI 10.1093/nar/gky866; Incani F, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0085-z; Irla M., 2019, THYMUS TRANSCRIPTOME, P149, DOI DOI 10.1007/978-3-030-12040-5_6; Keane P, 2015, BIOINFORMATICS, V31, P986, DOI 10.1093/bioinformatics/btu785; Klein L, 2015, CELL, V163, P794, DOI 10.1016/j.cell.2015.10.057; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Kumar PG, 2001, J BIOL CHEM, V276, P41357, DOI 10.1074/jbc.M104898200; Le Pera L, 2015, BIOINFORMATICS, V31, P1845, DOI 10.1093/bioinformatics/btv035; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Macedo C, 2015, IMMUNOBIOLOGY, V220, P93, DOI 10.1016/j.imbio.2014.08.015; Macedo C, 2013, IMMUNOBIOLOGY, V218, P554, DOI 10.1016/j.imbio.2012.06.013; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Ogorodnikov A, 2016, PFLUG ARCH EUR J PHY, V468, P993, DOI 10.1007/s00424-016-1828-3; Oliveira EH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00526; Oven I, 2007, MOL CELL BIOL, V27, P8815, DOI 10.1128/MCB.01085-07; Passos GA, 2019, THYMUS TRANSCRIPTOME, P318, DOI [10.1007/978-3-030-12040-5_9, DOI 10.1007/978-3-030-12040-5_9]; Passos GA, 2018, IMMUNOLOGY, V153, P10, DOI 10.1111/imm.12831; Passos GA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00352; Perniola R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00098; Perniola R, 2014, BBA-MOL BASIS DIS, V1842, P326, DOI 10.1016/j.bbadis.2013.11.020; Perniola R, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/207403; Peterson P, 2015, NAT IMMUNOL, V16, P680, DOI 10.1038/ni.3195; Pezzi N, 2016, MOL IMMUNOL, V77, P157, DOI 10.1016/j.molimm.2016.08.003; Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111; Purohit S, 2005, BIOCHEM BIOPH RES CO, V327, P939, DOI 10.1016/j.bbrc.2004.12.093; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ribeiro C, 2019, IMMUNOL LETT, V215, P24, DOI 10.1016/j.imlet.2019.01.012; Saare M, 2012, EXP CELL RES, V318, P1767, DOI 10.1016/j.yexcr.2012.04.013; Sansom SN, 2014, GENOME RES, V24, P1918, DOI 10.1101/gr.171645.113; Speck-Hernandez CA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00964; St-Pierre C, 2015, J IMMUNOL, V195, P498, DOI 10.4049/jimmunol.1500558; Takaba H, 2017, TRENDS IMMUNOL, V38, P805, DOI 10.1016/j.it.2017.07.010; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Tian B, 2013, TRENDS BIOCHEM SCI, V38, P312, DOI 10.1016/j.tibs.2013.03.005; Turner RE, 2018, SEMIN CELL DEV BIOL, V75, P61, DOI 10.1016/j.semcdb.2017.08.056; Ucar O, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00093; Wolff AS, 2019, THYMUS TRANSCRIPTOME, P318, DOI [10.1007/978-3-030-12040-5_8, DOI 10.1007/978-3-030-12040-5_8]; Yamano T, 2019, J EXP MED, V216, P1027, DOI 10.1084/jem.20181430; Yoshida H, 2015, P NATL ACAD SCI USA, V112, pE4448, DOI 10.1073/pnas.1512081112	65	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2020	11								1039	10.3389/fimmu.2020.01039	http://dx.doi.org/10.3389/fimmu.2020.01039			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LZ8CD	32547551	Green Published, gold			2022-12-18	WOS:000541447700001
J	Trindade, AJ; Thaniyavarn, T; Townsend, K; Klasek, R; Tsveybel, KP; Kennedy, JC; Goldberg, HJ; El-Chemaly, S				Trindade, Anil J.; Thaniyavarn, Tany; Townsend, Keri; Klasek, Robin; Tsveybel, Karen P.; Kennedy, John C.; Goldberg, Hilary J.; El-Chemaly, Souheil			Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres	FRONTIERS IN IMMUNOLOGY			English	Article						alemtuzumab; chronic lung allograft dysfunction; lung transplantation; short telomeres; chronic rejection; telomere length; augmented immunosuppression	BRONCHIOLITIS OBLITERANS SYNDROME; RANDOMIZED CONTROLLED-TRIAL; SURVIVAL BENEFIT; ACUTE REJECTION; LENGTH; AZITHROMYCIN; DIAGNOSIS; DISEASE; ERA; BOS	Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1-3). Side effects of alemtuzumab include bone marrow suppression, infection, and malignancy. Whether alemtuzumab can be safely used in allograft recipients that have an increased propensity for bone marrow suppression due to telomeropathies is unknown. In a retrospective case series, we report outcomes associated with alemtuzumab in three lung allograft recipients with short telomere lengths, comparing endpoints such as leukopenia, transfusion needs, infection, hospitalization and survival to those of 17 patients without known telomeropathies that received alemtuzumab. We show that the use of alemtuzumab in lung transplant recipients with short telomeres is safe, though is associated with an increased incidence of neutropenia, thrombocytopenia and anemia requiring packed red blood cell transfusions. Alemtuzumab appears to be an acceptable advanced immunosuppressive therapy in patients with telomeropathies, though given the design and scope of this study, the actual clinical effect needs further evaluation in larger trials.	[Trindade, Anil J.; Thaniyavarn, Tany; Townsend, Keri; Klasek, Robin; Tsveybel, Karen P.; Kennedy, John C.; Goldberg, Hilary J.; El-Chemaly, Souheil] Brigham & Womens Hosp, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Trindade, Anil J.; Thaniyavarn, Tany; Kennedy, John C.; Goldberg, Hilary J.; El-Chemaly, Souheil] Harvard Med Sch, Boston, MA 02115 USA; [Trindade, Anil J.] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Vanderbilt University	Trindade, AJ (corresponding author), Brigham & Womens Hosp, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.; Trindade, AJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Trindade, AJ (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA.	anil.trindade@vumc.org	Kennedy, John/ABB-8227-2020		NIH [R01-HL130275]; John M. Kent Memorial Fund	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); John M. Kent Memorial Fund	Research in the SE-C Lab is supported by NIH R01-HL130275 and by the John M. Kent Memorial Fund.	Benden C, 2017, J HEART LUNG TRANSPL, V36, P921, DOI 10.1016/j.healun.2017.05.030; Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; Calado RT, 2009, P NATL ACAD SCI USA, V106, P1187, DOI 10.1073/pnas.0807057106; Corris PA, 2015, THORAX, V70, P442, DOI 10.1136/thoraxjnl-2014-205998; Courtwright A, 2017, J HEART LUNG TRANSPL, V36, P833, DOI 10.1016/j.healun.2017.02.020; Courtwright AM, 2019, ANN AM THORAC SOC, V16, P175, DOI 10.1513/AnnalsATS.201808-508CME; Davis WA, 2012, AM J TRANSPLANT, V12, P745, DOI 10.1111/j.1600-6143.2011.03849.x; El-Chemaly S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00076; Ensor CR, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.12899; Faust HE, 2017, THORAX, V72, P1052, DOI 10.1136/thoraxjnl-2016-209897; George G, 2015, CHEST, V147, P1549, DOI 10.1378/chest.14-0631; Meyer KC, 2014, EUR RESPIR J, V44, P1479, DOI 10.1183/09031936.00107514; Moniodis A, 2018, J HEART LUNG TRANSPL, V37, P340, DOI 10.1016/j.healun.2017.03.017; Newton CA, 2017, J HEART LUNG TRANSPL, V36, P845, DOI 10.1016/j.healun.2017.02.005; Parizi AS, 2018, AM J TRANSPLANT, V18, P684, DOI 10.1111/ajt.14492; Rana A, 2015, JAMA SURG, V150, P252, DOI 10.1001/jamasurg.2014.2038; Reams BD, 2007, AM J TRANSPLANT, V7, P2802, DOI 10.1111/j.1600-6143.2007.02000.x; Ruttens D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193564; Shay JW, 2019, NAT REV GENET, V20, P299, DOI 10.1038/s41576-019-0099-1; Singer JP, 2017, AM J TRANSPLANT, V17, P1334, DOI 10.1111/ajt.14081; Stewart S, 2007, J HEART LUNG TRANSPL, V26, P1229, DOI 10.1016/j.healun.2007.10.017; van der Zwan M, 2018, CLIN PHARMACOKINET, V57, P191, DOI 10.1007/s40262-017-0573-x; Verleden GM, 2019, J HEART LUNG TRANSPL, V38, P493, DOI 10.1016/j.healun.2019.03.009; Verleden GM, 2011, TRANSPL INT, V24, P651, DOI 10.1111/j.1432-2277.2011.01248.x; Verleden SE, 2016, CHEST, V150, P219, DOI 10.1016/j.chest.2016.04.014; Vock DM, 2017, ANN AM THORAC SOC, V14, P172, DOI 10.1513/AnnalsATS.201606-507OC; Vos R, 2011, EUR RESPIR J, V37, P164, DOI 10.1183/09031936.00068310; Vos R, 2019, J HEART LUNG TRANSPL, V38, P516, DOI 10.1016/j.healun.2018.11.014; Wagner CL, 2018, J CLIN INVEST, V128, P5222, DOI 10.1172/JCI120216; Weng NP, 2001, J LEUKOCYTE BIOL, V70, P861	30	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2020	11								1063	10.3389/fimmu.2020.01063	http://dx.doi.org/10.3389/fimmu.2020.01063			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MB7IN	32547557	Green Published, gold			2022-12-18	WOS:000542773300001
J	Hao, L; Marshall, AJ; Liu, LX				Hao, Li; Marshall, Aaron J.; Liu, Lixin			Bam32/DAPP1-Dependent Neutrophil Reactive Oxygen Species in WKYMVm-Induced Microvascular Hyperpermeability	FRONTIERS IN IMMUNOLOGY			English	Article						WKYMVm; microvascular permeability; neutrophils; reactive oxygen species; Bam32; DAPP1	VAL-D-MET; FORMYL PEPTIDE RECEPTORS; ADAPTER PROTEIN; LEUKOCYTE RECRUITMENT; STAPHYLOCOCCUS-AUREUS; OXIDATIVE STRESS; CELL ADHESION; ACTIVATION; BAM32; LUNG	B cell adaptor molecule of 32 kDa (Bam32), known as dual adapter for phosphotyrosine and 3-phosphoinositides 1 (DAPP1), has been implicated in regulating lymphocyte proliferation and recruitment during inflammation. However, its role in neutrophils during inflammation remains unknown. Using intravital microscopy, we examined the role of Bam32 in formyl peptide receptor agonist WKYMVm-induced permeability changes in post-capillary venules and assessed simultaneously neutrophil adhesion and emigration in cremaster muscles of Bam32-deficient (Bam32(-/-)) and wild-type (WT) control mice. We observed significantly reduced WKYMVm-induced microvascular hyperpermeability accompanied by markedly decreased neutrophil emigration in Bam32(-/-) mice. The Bam32-specific decrease in WKYMVm-induced hyperpermeability was neutrophil-dependent as this was verified in bone marrow transplanted chimeric mice. We discovered that Bam32 was critically required for WKYMVm-induced intracellular and extracellular production of reactive oxygen species (ROS) in neutrophils. Pharmacological scavenging of ROS eliminated the differences in WKYMVm-induced hyperpermeability between Bam32(-/-) and WT mice. Deficiency of Bam32 decreased WKYMVm-induced ERK1/2 but not p38 or JNK phosphorylation in neutrophils. Inhibition of ERK1/2 signaling cascade suppressed WKYMVm-induced ROS generation in WT neutrophils and microvascular hyperpermeability in WT mice. In conclusion, our study reveals that Bam32-dependent, ERK1/2-involving ROS generation in neutrophils is critical in WKYMVm-induced microvascular hyperpermeability during neutrophil recruitment.	[Hao, Li; Liu, Lixin] Univ Saskatchewan, Dept Anat Physiol & Pharmacol, Coll Med, Saskatoon, SK, Canada; [Marshall, Aaron J.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada	University of Saskatchewan; University of Manitoba	Liu, LX (corresponding author), Univ Saskatchewan, Dept Anat Physiol & Pharmacol, Coll Med, Saskatoon, SK, Canada.	lixin.liu@usask.ca			Natural Sciences and Engineering Research Council of Canada [RGPIN 06611-2018]; China Scholarship Council	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); China Scholarship Council(China Scholarship Council)	This work was supported by a research grant to LL from the Natural Sciences and Engineering Research Council of Canada (RGPIN 06611-2018). LH was supported by a Ph.D. scholarship from China Scholarship Council.	Abernathy VJ, 1996, AM J PHYSIOL-HEART C, V271, pH507, DOI 10.1152/ajpheart.1996.271.2.H507; Al-Alwan M, 2010, J IMMUNOL, V184, P6961, DOI 10.4049/jimmunol.0904176; Bae YS, 1999, J LEUKOCYTE BIOL, V66, P915, DOI 10.1002/jlb.66.6.915; Bae YS, 1999, J LEUKOCYTE BIOL, V65, P241, DOI 10.1002/jlb.65.2.241; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Farivar AS, 2004, J HEART LUNG TRANSPL, V23, P585, DOI 10.1016/S1053-2498(03)00300-0; Fournier E, 2003, CURR BIOL, V13, P1858, DOI 10.1016/j.cub.2003.09.034; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Han A, 2003, IMMUNITY, V19, P621, DOI 10.1016/S1074-7613(03)00275-9; Hao L, 2019, J LEUKOCYTE BIOL, V106, P1117, DOI 10.1002/JLB.3A0518-184RR; Hara K, 2008, J EXP MICROBIOL IMMU, V12, P62; Hattori H, 2010, P NATL ACAD SCI USA, V107, P3546, DOI 10.1073/pnas.0914351107; He HQ, 2013, MOL PHARMACOL, V83, P389, DOI 10.1124/mol.112.081315; He R, 2000, J IMMUNOL, V165, P4598, DOI 10.4049/jimmunol.165.8.4598; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; Horewicz VV, 2015, EUR J PHARMACOL, V746, P267, DOI 10.1016/j.ejphar.2014.11.026; Hossain M, 2013, AM J PHYSIOL-CELL PH, V304, pC895, DOI 10.1152/ajpcell.00297.2012; Hou S, 2010, MOL IMMUNOL, V48, P89, DOI 10.1016/j.molimm.2010.09.007; Krahn AK, 2004, J IMMUNOL, V172, P331, DOI 10.4049/jimmunol.172.1.331; Lei X, 2012, BIOCHEM BIOPH RES CO, V423, P484, DOI 10.1016/j.bbrc.2012.05.146; Li LF, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0275-6; Liu LX, 2005, J EXP MED, V201, P409, DOI 10.1084/jem.20040830; Marshall AJ, 2007, BIOCHEM SOC T, V35, P181, DOI 10.1042/BST0350181; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894; Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373; Niiro H, 2003, IMMUNITY, V19, P637, DOI 10.1016/S1074-7613(03)00303-0; Ortner D, 2011, J IMMUNOL, V187, P3972, DOI 10.4049/jimmunol.1003072; Pestonjamasp KN, 2006, BLOOD, V108, P2814, DOI 10.1182/blood-2006-01-010363; Peters AM, 1998, CLIN SCI, V94, P7, DOI 10.1042/cs0940007; Phillipson M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001649; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Rane MJ, 1997, J IMMUNOL, V159, P5070; Rao R, 2008, FRONT BIOSCI-LANDMRK, V13, P7210, DOI 10.2741/3223; Rao RM, 2007, CIRC RES, V101, P234, DOI 10.1161/CIRCRESAHA.107.151860b; Sommers CL, 2008, INT IMMUNOL, V20, P811, DOI 10.1093/intimm/dxn039; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Su Y, 2012, IMMUNOLOGY, V137, P65, DOI 10.1111/j.1365-2567.2012.03608.x; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Sun CX, 2004, BLOOD, V104, P3758, DOI 10.1182/blood-2004-03-0781; Kuwabara WMT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116410; Winther M, 2018, BASIC CLIN PHARMACOL, V122, P191, DOI 10.1111/bcpt.12903; Wrzaczek M, 2013, CURR OPIN PLANT BIOL, V16, P575, DOI 10.1016/j.pbi.2013.07.002; Xu N., 2011, J VIS EXP, V55, P3296; Zarbock A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502; Zhang TT, 2010, J IMMUNOL, V184, P164, DOI 10.4049/jimmunol.0902505	52	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2020	11								1028	10.3389/fimmu.2020.01028	http://dx.doi.org/10.3389/fimmu.2020.01028			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LZ0QP	32536926	Green Published, gold			2022-12-18	WOS:000540936600001
J	Bangash, MN; Abbott, TEF; Patel, NSA; Hinds, CJ; Thiemermann, C; Pearse, RM				Bangash, Mansoor Nawaz; Abbott, Tom E. F.; Patel, Nimesh S. A.; Hinds, Charles Johnston; Thiemermann, Christoph; Pearse, Rupert Mark			The Effect of beta(2)-Adrenoceptor Agonists on Leucocyte-Endothelial Adhesion in a Rodent Model of Laparotomy and Endotoxemia	FRONTIERS IN IMMUNOLOGY			English	Article						adrenergic beta(2) receptor agonists; dopexamine; inflammation; microcirculation; surgery	PERIOPERATIVE MYOCARDIAL INJURY; GUIDED HEMODYNAMIC THERAPY; MAJOR SURGERY; OXYGEN DELIVERY; BLOOD-FLOW; DOPEXAMINE; INFLAMMATION; TERBUTALINE; INHIBITION; MORTALITY	Background: The beta(2)-adrenoceptor agonist dopexamine may possess anti-inflammatory actions which could reduce organ injury during endotoxemia and laparotomy. Related effects on leucocyte-endothelial adhesion remain unclear. Methods: Thirty anesthetized Wistar rats underwent laparotomy followed by induction of endotoxemia with lipopolysaccharide and peptidoglycan (n = 24) or sham (n = 6). Animals received dopexamine at 0.5 or 1 mu g kg(-1) min(-1) (D0.5 and D1), salbutamol at 0.1 mu g kg(-1) min(-1), or saline vehicle (Sham and Control) for 5 h. Intravital microscopy was performed in the ileum of the small intestine to assess leucocyteendothelial adhesion, arteriolar diameter, and functional capillary density. Global hemodynamics and biochemical indices of renal and hepatic function were also measured. Results: Endotoxemia was associated with an increase in adherent leucocytes in post-capillary venules, intestinal arteriolar vasoconstriction as well-reduced arterial pressure and relative cardiac index, but functional capillary density in the muscularis was not significantly altered. Dopexamine and salbutamol administration were associated with reduced leucocyte-endothelial adhesion in post-capillary venules compared to control animals. Arteriolar diameter, arterial pressure and relative cardiac index all remained similar between treated animals and controls. Functional capillary density was similar for all groups. Control group creatinine was significantly increased compared to sham and higher dose dopexamine. Conclusions: In a rodent model of laparotomy and endotoxemia, beta(2)-agonists were associated with reduced leucocyte-endothelial adhesion in post-capillary venules. This effect may explain some of the anti-inflammatory actions of these agents.	[Bangash, Mansoor Nawaz] Univ Hosp Birmingham NHS Trust, Dept Crit Care & Anaesthesia, Birmingham, W Midlands, England; [Abbott, Tom E. F.; Patel, Nimesh S. A.; Hinds, Charles Johnston; Thiemermann, Christoph; Pearse, Rupert Mark] Queen Mary Univ London, Ctr Translat Med & Therapeut, William Harvey Res Inst, London, England	University of London; Queen Mary University London	Bangash, MN (corresponding author), Univ Hosp Birmingham NHS Trust, Dept Crit Care & Anaesthesia, Birmingham, W Midlands, England.	mansoor.bangash@uhb.nhs.uk	Abbott, Tom E F/J-7214-2015; Bangash, Mansoor/AAR-6546-2020; Pearse, Rupert/H-5426-2011	Abbott, Tom E F/0000-0002-8664-3001; Bangash, Mansoor/0000-0001-5039-5184; Pearse, Rupert/0000-0002-4373-5934; Thiemermann, Christoph/0000-0003-4228-9722	British Journal of Anaesthesia/Royal College of Anaesthetists Project Grant; Intensive Care Society Young Investigator Award; Kidney Research UK Post-Doctoral Fellowship [PDF4/2009]; Medical Research Council; British Journal of Anaesthesia Clinical Research Training Fellowship; National Institute of Health Research	British Journal of Anaesthesia/Royal College of Anaesthetists Project Grant; Intensive Care Society Young Investigator Award; Kidney Research UK Post-Doctoral Fellowship(Kidney Research UK (KRUK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Journal of Anaesthesia Clinical Research Training Fellowship; National Institute of Health Research(National Institute for Health Research (NIHR))	This work was supported by research grants from a British Journal of Anaesthesia/Royal College of Anaesthetists Project Grant and an Intensive Care Society Young Investigator Award. NP was supported by a Kidney Research UK Post-Doctoral Fellowship (PDF4/2009). TA was supported by a jointly funded Medical Research Council and British Journal of Anaesthesia Clinical Research Training Fellowship. This work forms part of the research themes contributing to the translational portfolio of Barts and The London Cardiovascular Biomedical Research Unit, which was supported and funded by the National Institute of Health Research. RP is a National Institute for Health Research (UK) Research Professor.	Ackland GL, 2019, BRIT J ANAESTH, V122, P180, DOI 10.1016/j.bja.2018.09.002; Arif E, 2019, NEPHROLOGY, V24, P497, DOI 10.1111/nep.13584; Bangash MN, 2013, CRIT CARE, V17, DOI 10.1186/cc12585; Bangash MN, 2012, BRIT J PHARMACOL, V165, P2015, DOI 10.1111/j.1476-5381.2011.01588.x; Birnbaum J, 2006, CRIT CARE, V10, DOI 10.1186/cc5011; Bloemen PGM, 1997, AM J PHYSIOL-LUNG C, V272, pL580, DOI 10.1152/ajplung.1997.272.4.L580; BOWDEN JJ, 1994, J APPL PHYSIOL, V77, P397, DOI 10.1152/jappl.1994.77.1.397; BROWN RA, 1985, BRIT J PHARMACOL, V85, P599, DOI 10.1111/j.1476-5381.1985.tb10554.x; Chen RC, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav5562; Chilcoat CD, 2008, J LEUKOCYTE BIOL, V83, P964, DOI 10.1189/jlb.0405192; DERIAN CK, 1995, J IMMUNOL, V154, P308; Edwards MR, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023455; Futier E, 2017, JAMA-J AM MED ASSOC, V318, P1346, DOI 10.1001/jama.2017.14172; Gillies MA, 2015, BRIT J ANAESTH, V115, P227, DOI 10.1093/bja/aev137; Grocott MPW, 2013, BRIT J ANAESTH, V111, P535, DOI 10.1093/bja/aet155; Horstick G, 2000, J SURG RES, V94, P28, DOI 10.1006/jsre.2000.5990; Hummel IB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064556; JACINTO SM, 1994, N-S ARCH PHARMACOL, V350, P277; Jhanji S, 2010, CRIT CARE, V14, DOI 10.1186/cc9220; Jhanji S, 2009, CRIT CARE MED, V37, P1961, DOI 10.1097/CCM.0b013e3181a00a1c; Khuri SF, 2005, ANN SURG, V242, P326, DOI 10.1097/01.sla.0000179621.33268.83; Liaw WJ, 2003, SHOCK, V19, P281, DOI 10.1097/00024382-200303000-00014; Link A, 2008, CRIT CARE, V12, DOI 10.1186/cc7158; Luan HH, 2019, CELL, V178, P1231, DOI 10.1016/j.cell.2019.07.033; LUND N, 1995, J TRAUMA, V38, P767, DOI 10.1097/00005373-199505000-00016; Nakamura A, 2004, J AM SOC NEPHROL, V15, P316, DOI 10.1097/01.ASN.0000111247.76908.59; Nakamura A, 2000, NEPHROL DIAL TRANSPL, V15, P1928, DOI 10.1093/ndt/15.12.1928; Nakamura A, 2010, J NEPHROL, V23, P341; Oberbeck R, 2004, IMMUNOBIOLOGY, V208, P429, DOI 10.1078/0171-2985-00290; Pearse RM, 2008, CRIT CARE MED, V36, P1323, DOI 10.1097/CCM.0b013e31816a091b; Pearse RM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5759; Pearse RM, 2014, JAMA-J AM MED ASSOC, V311, P2181, DOI 10.1001/jama.2014.5305; Pearse RM, 2012, LANCET, V380, P1059, DOI 10.1016/S0140-6736(12)61148-9; Ryan EG, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024256; Schmidt H, 2000, CRIT CARE MED, V28, P1979, DOI 10.1097/00003246-200006000-00049; Schmidt H, 1996, CRIT CARE MED, V24, P1233, DOI 10.1097/00003246-199607000-00028; Schmidt H, 1996, J SURG RES, V61, P521, DOI 10.1006/jsre.1996.0157; Schmidt W, 1998, CRIT CARE MED, V26, P1639, DOI 10.1097/00003246-199810000-00012; Secchi A, 2001, CRIT CARE MED, V29, P597, DOI 10.1097/00003246-200103000-00023; SHOEMAKER WC, 1987, INTENS CARE MED, V13, P230, DOI 10.1007/BF00265111; Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1; Taqueti VR, 2013, JACC-CARDIOVASC IMAG, V6, P668, DOI 10.1016/j.jcmg.2013.02.005; Toung T, 2000, SHOCK, V13, P267, DOI 10.1097/00024382-200004000-00003; Tsao CM, 2010, INTENS CARE MED, V36, P1571, DOI 10.1007/s00134-010-1839-z; Uusaro A, 2000, INTENS CARE MED, V26, P299, DOI 10.1007/s001340051153; van Till JWO, 2010, J SURG RES, V164, P321, DOI 10.1016/j.jss.2009.09.020; Wu CC, 2000, SHOCK, V14, P60, DOI 10.1097/00024382-200014010-00011; Wu JY, 2002, CHINESE J PHYSIOL, V45, P155	48	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 21	2020	11								1001	10.3389/fimmu.2020.01001	http://dx.doi.org/10.3389/fimmu.2020.01001			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW8QF	32670267	Green Published, Green Submitted, gold			2022-12-18	WOS:000539407800001
J	Lamikanra, AA; Tsang, HP; Elsiddig, S; Spencer, M; Curnow, E; Danby, R; Roberts, DJ				Lamikanra, Abigail A.; Tsang, Hoi Pat; Elsiddig, Shaza; Spencer, Michael; Curnow, Elinor; Danby, Robert; Roberts, David J.			The Migratory Properties and Numbers of T Regulatory Cell Subsets in Circulation Are Differentially Influenced by Season and Are Associated With Vitamin D Status	FRONTIERS IN IMMUNOLOGY			English	Article						Tregs; regulatory T cells; vitamin D3; seasons; tolerance; migration	VERSUS-HOST-DISEASE; HUMAN IMMUNE-SYSTEM; CD4(+)CD25(+); EXPRESSION; METABOLITES; RECEPTOR; CORTISOL; CD45RA; GRAFTS; SINGLE	The control of peripheral immune responses by FOXP3(+) T regulatory (Treg) cells is essential for immune tolerance. However, at any given time, Treg frequencies in whole blood can vary more than fivefold between individuals. An understanding of factors that influence Treg numbers and migration within and between individuals would be a powerful tool for cellular therapies that utilize the immunomodulatory properties of Tregs to control pathology associated with inflammation. We sought to understand how season could influence Treg numbers and phenotype by monitoring the proportion of natural thymus-derived Tregs (nTregs) defined as (CD3(+)CD4(+)CD25(+)FOXP3(+)CD127(-/low)) cells as a proportion of CD4(+) T cells and compared these to all FOXP3(+) Tregs (allTregs, CD3(+)CD25(+)FOXP3(+)CD127(-/low)). We were able to determine changes within individuals during 1 year suggesting an influence of season on nTreg frequencies. We found that, between individuals at any given time, nTreg/CD4(+) T cells ranged from 1.8% in February to 8.8% in the summer where median nTreg/CD4 in January and February was 2.4% (range 3.75-1.76) and in July and August was 4.5% (range 8.81-3.17) p = 0.025. Importantly we were able to monitor individual nTreg frequencies throughout the year in donors that started the year with high or low nTregs. Some nTreg variation could be attributed to vitamin D status where normal linear regression estimated that an absolute increase in nTreg/CD4(+) by 0.11% could be expected with 10 nmol increase in serum 25 (OH) vitamin D3 (p = 0.005, 95% CI: 0.03-0.19). We assessed migration markers on Tregs for the skin and/or gut. Here cutaneous lymphocyte associated antigen (CLA(+)) expression on CD25(+)FOXP3(+)CD4(+)/CD4(+) was compared with the same population expressing the gut associated integrin, beta 7. Gut tropic CD25(+)FOXP3(+)beta 7(+)Tregs/CD4(+) had similar dynamics to nTreg/CD4(+). Conversely, CD25(+)FOXP3(+)CLA(+)Tregs/CD4(+) showed no association with vitamin D status. Important for cellular therapies requiring isolation of Tregs, the absolute number of beta 7(+)CD4(+)CD25(+)FOXP3(+)Tregs was positively associated with 25(OH)vitamin D3 (R-2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA(+)CD4(+)CD25(+)FOXP3(+)Tregs in the periphery were not influenced by vitamin D status. These baseline observations provide new opportunities to utilize seasonal variables that influence Treg numbers and their migratory potential in patients or donors.	[Lamikanra, Abigail A.; Tsang, Hoi Pat; Elsiddig, Shaza; Spencer, Michael; Roberts, David J.] Natl Hlth Serv Blood & Transplant, Oxford, England; [Lamikanra, Abigail A.; Tsang, Hoi Pat; Elsiddig, Shaza; Spencer, Michael; Roberts, David J.] Univ Oxford, Radcliffe Dept Med, Nuffield Div Clin Lab Sci, Oxford, England; [Curnow, Elinor] NHS Blood & Transplant Stat & Clin Studies, Bristol, Avon, England; [Danby, Robert] Churchill Hosp, Dept Haematol, Oxford, England; [Danby, Robert] Anthony Nolan Res Inst, London, England	NHS Blood & Transplant (NHSBT); University of Oxford; University of Oxford	Lamikanra, AA; Roberts, DJ (corresponding author), Natl Hlth Serv Blood & Transplant, Oxford, England.; Lamikanra, AA; Roberts, DJ (corresponding author), Univ Oxford, Radcliffe Dept Med, Nuffield Div Clin Lab Sci, Oxford, England.	abigeil.lamikanra@ndcls.ox.ac.uk; david.roberts@ndcls.ox.ac.uk	Danby, Robert/AAE-7955-2021	Danby, Robert/0000-0002-2985-7222	NHS Blood and Transplant intramural RD funding	NHS Blood and Transplant intramural RD funding	This work was supported by the NHS Blood and Transplant intramural R&D funding.	Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Al-Dujaili EAS, 2016, THER ADV ENDOCRINOL, V7, P153, DOI 10.1177/2042018816653357; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arruvito L, 2007, J IMMUNOL, V178, P2572, DOI 10.4049/jimmunol.178.4.2572; Belden Z, 2017, AM J NEPHROL, V46, P298, DOI 10.1159/000480652; Blache C, 2010, BIOL BLOOD MARROW TR, V16, P430, DOI 10.1016/j.bbmt.2009.10.027; Booth NJ, 2010, J IMMUNOL, V184, P4317, DOI 10.4049/jimmunol.0903781; Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Canavan JB, 2016, GUT, V65, P584, DOI 10.1136/gutjnl-2014-306919; Carr EJ, 2016, NAT IMMUNOL, V17, P461, DOI 10.1038/ni.3371; Chaidos A, 2012, BLOOD, V119, P5030, DOI 10.1182/blood-2011-11-389304; Danby RD, 2016, BONE MARROW TRANSPL, V51, P110, DOI 10.1038/bmt.2015.215; Di Ianni M, 2011, BLOOD, V117, P3921, DOI 10.1182/blood-2010-10-311894; Dopico XC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8000; Druzd D, 2017, IMMUNITY, V46, P120, DOI 10.1016/j.immuni.2016.12.011; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Engelhardt BG, 2011, BONE MARROW TRANSPL, V46, P436, DOI 10.1038/bmt.2010.127; Farez MF, 2015, CELL, V162, P1338, DOI 10.1016/j.cell.2015.08.025; Fisher SA, 2017, BRIT J HAEMATOL, V176, P448, DOI 10.1111/bjh.14433; Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x; Hadlow NC, 2014, CHRONOBIOL INT, V31, P243, DOI 10.3109/07420528.2013.844162; Hesterberg RS, 2018, J IMMUNOL, V201, P3269, DOI 10.4049/jimmunol.1800940; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409; Hornero RA, 2017, TRANSPLANTATION, V101, P302, DOI 10.1097/TP.0000000000001278; Hsu PS, 2018, J IMMUNOL, V200, P3970, DOI 10.4049/jimmunol.1701533; Issa F, 2013, TRENDS IMMUNOL, V34, P107, DOI 10.1016/j.it.2012.11.003; Kang SW, 2012, J IMMUNOL, V188, P5276, DOI 10.4049/jimmunol.1101211; Kearns MD, 2015, EUR J CLIN NUTR, V69, P193, DOI 10.1038/ejcn.2014.209; Khoo AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029250; Kongsbak M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096695; Kordasti S, 2016, BLOOD, V128, P1193, DOI 10.1182/blood-2016-03-703702; Kunicki MA, 2018, J IMMUNOL, V200, P336, DOI 10.4049/jimmunol.1701025; Lee MK, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0635-z; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Moriyama M, 2019, P NATL ACAD SCI USA, V116, P3118, DOI 10.1073/pnas.1815029116; Omland SH, 2016, ACTA DERM-VENEREOL, V96, P917, DOI 10.2340/00015555-2440; Pastore D, 2012, BIOL BLOOD MARROW TR, V18, P887, DOI 10.1016/j.bbmt.2011.10.039; Perry C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074722; Persson R, 2008, CHRONOBIOL INT, V25, P923, DOI 10.1080/07420520802553648; Pfeffer PE, 2018, IMMUNOLOGY, V153, P502, DOI 10.1111/imm.12852; Rolf L, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00263; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Sarkar S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219122; Seddiki N, 2006, BLOOD, V107, P2830, DOI 10.1182/blood-2005-06-2403; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Smolders J, 2013, J NEUROPATH EXP NEUR, V72, P91, DOI 10.1097/NEN.0b013e31827f4fcc; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Tocheva AS, 2017, J IMMUNOL, V198, P1452, DOI 10.4049/jimmunol.1600255; Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031; Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103; Wacker M, 2013, DERM-ENDOCRINOL, V5, DOI [10.4161/derm.24494, 10.4161/derm.24476]; Walker BR, 1997, J CLIN ENDOCR METAB, V82, P4015, DOI 10.1210/jc.82.12.4015; Watad A, 2016, EUR J EPIDEMIOL, V31, P1081, DOI 10.1007/s10654-016-0165-3; Zhang W, 2015, CYTOTHERAPY, V17, P1268, DOI 10.1016/j.jcyt.2015.05.015	58	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2020	11								685	10.3389/fimmu.2020.00685	http://dx.doi.org/10.3389/fimmu.2020.00685			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW1DC	32508805	Green Published, gold			2022-12-18	WOS:000538885200001
J	Pierzynowska, K; Wolinski, J; Westrom, B; Pierzynowski, SG				Pierzynowska, Kateryna; Wolinski, Jaroslaw; Westrom, Bjorn; Pierzynowski, Stefan G.			Maternal Immunoglobulins in Infants-Are They More Than Just a Form of Passive Immunity?	FRONTIERS IN IMMUNOLOGY			English	Review						immunoglobulins; extra-immunological effects; neonatal; brain development; gut development	COLOSTRUM; GLOBULIN; IMPAIRMENT; PROTECTS; CHILDREN; PRETERM; NEURONS; STROKE; BRAIN; BLOOD	In the present review, we highlight the possible "extra-immunological" effects of maternal immunoglobulins (Ig) transferred to the blood circulation of offspring, either via the placenta before birth or via the colostrum/milk across the gut after birth in different mammalian species. Using the newborn pig as a model, since they are naturally born agammaglobulinemic, intravenously (i.v.) infused purified serum Ig rapidly improved the vitality, suckling behavior, and ensured the survival of both preterm and term piglets. In further studies, we found that proper brain development requires i.v. Ig supplementation. Studies have reported on the positive effects of i.v. Ig treatment in children with epilepsy. Moreover, feeding newborn pigs an elementary diet supplemented with Ig improved the gut structure, and recently a positive impact of enteral or parenteral Ig supplementation on the absorption of polyunsaturated fatty acids (PUFAs) was observed in the newborn pig. Summarized, our own results and those found in the literature, indicate the existence of important extra-immune effects of maternal Ig, in addition to the classical protective effects of transferred maternal passive immunity, including effects on the development of the brain, gut, and possibly other organ systems in the neonate. These additional properties of circulating Ig could have an impact on care guidelines for human neonates, especially those born prematurely with low plasma Ig levels.	[Pierzynowska, Kateryna; Wolinski, Jaroslaw] Polish Acad Sci, Kielanowski Inst Anim Physiol & Nutr, Dept Anim Physiol, Jablonna, Poland; [Pierzynowska, Kateryna; Westrom, Bjorn; Pierzynowski, Stefan G.] Lund Univ, Dept Biol, Lund, Sweden; [Pierzynowska, Kateryna; Pierzynowski, Stefan G.] SGP Grp, Trelleborg, Sweden; [Pierzynowski, Stefan G.] Inst Rural Hlth, Dept Med Biol, Lublin, Poland	Polish Academy of Sciences; Kielanowski Institute of Animal Physiology & Nutrition of the Polish Academy of Sciences; Lund University; Institute of Rural Health in Lublin, Poland	Pierzynowska, K (corresponding author), Polish Acad Sci, Kielanowski Inst Anim Physiol & Nutr, Dept Anim Physiol, Jablonna, Poland.; Pierzynowska, K (corresponding author), Lund Univ, Dept Biol, Lund, Sweden.; Pierzynowska, K (corresponding author), SGP Grp, Trelleborg, Sweden.	Katerina.Goncharova@biol.lu.se	Pierzynowski, Stefan Grzegorz/AAU-6107-2021; Woliński, Jarosław/AAH-3109-2021; Westrom, Bjorn Ragnar/N-2232-2016	Pierzynowski, Stefan Grzegorz/0000-0002-0308-3214; Woliński, Jarosław/0000-0001-8645-1045; Westrom, Bjorn Ragnar/0000-0001-9296-2845				Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; AUMAITRE A, 1978, ANN RECH VET, V9, P181; Burrin DG, 1997, J NUTR, V127, P1284, DOI 10.1093/jn/127.7.1284; Chavoshzadeh Z, 2018, IRAN J CHILD NEUROL, V12, P7; Congdon EE, 2013, J BIOL CHEM, V288, P35452, DOI 10.1074/jbc.M113.491001; Duse M, 1996, CLIN EXP IMMUNOL, V104, P71, DOI 10.1111/cei.1996.104.s1.71; Fernandez-Vizarra P, 2012, BRAIN, V135, P2826, DOI 10.1093/brain/aws195; Goncharova K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180002; Gopalakrishna KP, 2019, NAT MED, V25, P1110, DOI 10.1038/s41591-019-0480-9; Harada E, 2002, J VET MED A, V49, P358, DOI 10.1046/j.1439-0442.2002.00457.x; Harris NL, 2006, J IMMUNOL, V177, P6256, DOI 10.4049/jimmunol.177.9.6256; Hernandez-Castellano LE, 2015, J DAIRY SCI, V98, P204, DOI 10.3168/jds.2014-8350; HIRAYAMA H, 1986, INT J CLIN PHARM TH, V24, P109; Hirvorien M, 2017, EPILEPSY RES, V138, P32, DOI 10.1016/j.eplepsyres.2017.10.005; Hurley WL, 2011, NUTRIENTS, V3, P442, DOI 10.3390/nu3040442; Kam TI, 2013, J CLIN INVEST, V123, P2791, DOI 10.1172/JCI66827; Kowal C, 2015, IMMUNOL RES, V63, P18, DOI 10.1007/s12026-015-8714-5; Lok KZ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0294-8; Ma N, 2020, MED RES REV, V40, P606, DOI 10.1002/med.21628; Ma N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00005; Machiavelli A, 2019, GUT MICROBES, V10, P599, DOI 10.1080/19490976.2018.1560768; Nakamura K, 2007, MOL CELL BIOL, V27, P5128, DOI 10.1128/MCB.01072-06; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; PECHADRE JC, 1977, REV EEG NEUROPHYSIOL, V7, P443, DOI 10.1016/S0370-4475(77)80049-X; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Pierzynowska K, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/3813250; Pierzynowski S, 2014, INT J DEV NEUROSCI, V35, P64, DOI 10.1016/j.ijdevneu.2014.03.003; Qu LT, 2011, BRAIN BEHAV IMMUN, V25, P1399, DOI 10.1016/j.bbi.2011.04.008; Samarghitean C, 2009, J IMMUNOL, V183, P7569, DOI 10.4049/jimmunol.0901837; Savman K, 2019, LAKARTIDNINGEN, V116; Socha-Banasiak A, 2017, J BIOL REG HOMEOS AG, V31, P87; Stamou Marianna, 2019, J Neurol Neuromedicine, V4, P26, DOI 10.29245/2572.942X/2019/1.1243; Stamou M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-017-1050-z; Synnes A, 2018, CLIN PERINATOL, V45, P393, DOI 10.1016/j.clp.2018.05.002; Thom V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00875; Valcheva R, 2019, GUT MICROBES, V10, P334, DOI 10.1080/19490976.2018.1526583; van der Kleij H, 2010, J ALLERGY CLIN IMMUN, V125, P757, DOI 10.1016/j.jaci.2009.10.054; VANENGELEN BGM, 1994, EUR J PEDIATR, V153, P762, DOI 10.1007/BF01954498; Villani F, 2002, NEUROL SCI, V23, pS33, DOI 10.1007/s100720200013; Widiapradja A, 2012, J NEUROCHEM, V122, P321, DOI 10.1111/j.1471-4159.2012.07754.x; Wolinski J, 2012, J ANIM SCI, V90, P327, DOI [10.2527/jas53926, 10.2527/jas.53926]	41	1	1	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2020	11								855	10.3389/fimmu.2020.00855	http://dx.doi.org/10.3389/fimmu.2020.00855			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW1EC	32508816	Green Published, gold			2022-12-18	WOS:000538887800001
J	Chouaib, S; Lorens, J				Chouaib, Salem; Lorens, James			Editorial: Targeting the Tumor Microenvironment for a More Effective and Efficient Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						EMT; epithelial to mesenchymal transition; hypoxia; tumor microenvironment; anti-PD 1; T cells			[Chouaib, Salem] Gulf Med Univ, Thumbay Res Inst Precis Med, Dept Expt Oncol, Ajman, U Arab Emirates; [Chouaib, Salem] Univ Paris Saclay, Gustave Roussy, UMR 1186, INSERM, Villejuif, France; [Lorens, James] Univ Bergen, Dept Biomed, Ctr Canc Biomarkers CCBIO, Bergen, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Bergen	Chouaib, S (corresponding author), Gulf Med Univ, Thumbay Res Inst Precis Med, Dept Expt Oncol, Ajman, U Arab Emirates.; Chouaib, S (corresponding author), Univ Paris Saclay, Gustave Roussy, UMR 1186, INSERM, Villejuif, France.	Salem.CHOUAIB@gustaveroussy.fr	Lorens, James/B-9737-2017	Lorens, James/0000-0002-6782-3349					0	1	1	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 15	2020	11								933	10.3389/fimmu.2020.00933	http://dx.doi.org/10.3389/fimmu.2020.00933			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LV5WF	32670262	gold, Green Published			2022-12-18	WOS:000538504400001
J	Marx, S; Adam, C; Mihm, J; Weyrich, M; Sester, U; Sester, M				Marx, Stefanie; Adam, Claudia; Mihm, Janine; Weyrich, Michael; Sester, Urban; Sester, Martina			A Polyclonal Immune Function Assay Allows Dose-Dependent Characterization of Immunosuppressive Drug Effects but Has Limited Clinical Utility for Predicting Infection on an Individual Basis	FRONTIERS IN IMMUNOLOGY			English	Article						immunomonitoring; transplantation; immunosuppression; infection; pharmacodynamics; pharmacokinetics; T-cell	CMV INFECTION; KIDNEY; RISK; TRANSPLANTATION; INHIBITION; RECIPIENTS; THERAPY	Dosage of immunosuppressive drugs after transplantation critically determines rejection and infection episodes. In this study, a global immune function assay was characterized among controls, dialysis-patients, and transplant-recipients to evaluate its utility for pharmacodynamic monitoring of immunosuppressive drugs and for predicting infections. Whole-blood samples were stimulated with anti-CD3/toll-like-receptor (TLR7/8)-agonist in the presence or absence of drugs and IFN-gamma secretion was measured by ELISA. Additional stimulation-induced cytokines were characterized among T-, B-, and NK-cells using flow-cytometry. Cytokine-secretion was dominated by IFN-gamma, and mainly observed in CD4, CD8, and NK-cells. Intra-assay variability was low (CV = 10.4 +/- 6.2%), whereas variability over time was high, even in the absence of clinical events (CV = 65.0 +/- 35.7%). Cyclosporine A, tacrolimus and steroids dose-dependently inhibited IFN-gamma secretion, and reactivity was further reduced when calcineurin inhibitors were combined with steroids. Moreover, IFN-gamma levels significantly differed between controls, dialysis-patients, and transplant-recipients, with lowest IFN-gamma levels early after transplantation (p< 0.001). However, a single test had limited ability to predict infectious episodes. In conclusion, the assay may have potential for basic pharmacodynamic characterization of immunosuppressive drugs and their combinations, and for assessing loss of global immunocompetence after transplantation, but its application to guide drug-dosing and to predict infectious on an individual basis is limited.	[Marx, Stefanie; Sester, Martina] Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany; [Adam, Claudia; Mihm, Janine; Weyrich, Michael; Sester, Urban] Saarland Univ, Dept Internal Med 4, Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Sester, M (corresponding author), Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany.	martina.sester@uks.eu	Sester, Martina/AAA-3383-2022		Qiagen	Qiagen	The study was in part funded by an investigator-initiated grant from Qiagen, and from institutional funds.	de Jonge H, 2009, THER DRUG MONIT, V31, P416, DOI 10.1097/FTD.0b013e3181aa36cd; Dendle C, 2019, AM J TRANSPLANT, V19, P166, DOI 10.1111/ajt.14900; Egli A, 2009, TRANSPLANTATION, V88, P1161, DOI 10.1097/TP.0b013e3181bca422; Fernandez-Ruiz M, 2015, AM J TRANSPLANT, V15, P1323, DOI 10.1111/ajt.13107; Fernandez-Ruiza M, 2013, AM J TRANSPLANT, V13, P685, DOI 10.1111/ajt.12055; Gardiner BJ, 2018, CLIN INFECT DIS, V67, P1395, DOI 10.1093/cid/ciy295; Girndt M, 2001, KIDNEY INT, V59, pS206, DOI 10.1046/j.1523-1755.2001.59780206.x; Hanson KE, 2018, CLIN INFECT DIS, V66, P1398, DOI 10.1093/cid/cix1009; Humar A, 2006, AM J TRANSPLANT, V6, P262, DOI 10.1111/j.1600-6143.2005.01207.x; Kirsch S, 2012, J CLIN IMMUNOL, V32, P1381, DOI 10.1007/s10875-012-9730-z; Kotton CN, 2018, TRANSPLANTATION, V102, P900, DOI 10.1097/TP.0000000000002191; Leyking S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0420-5; Lindh M, 2018, OPEN FORUM INFECT DI, V5, DOI [10.1093/ofid/ofy050, DOI 10.1093/0FID/0]; Mian M, 2018, CLIN INFECT DIS, V66, P1392, DOI 10.1093/cid/cix1008; Morteau O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013294; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Ravaioli M, 2015, TRANSPLANTATION, V99, P1625, DOI 10.1097/TP.0000000000000650; Schub D, 2015, J INFECT DIS, V211, P600, DOI 10.1093/infdis/jiu500; Sester M, 2016, AM J TRANSPLANT, V16, P1697, DOI 10.1111/ajt.13684; Sester U, 2005, AM J TRANSPLANT, V5, P1483, DOI 10.1111/j.1600-6143.2005.00871.x; Sester U, 2009, EUR RESPIR J, V34, P702, DOI 10.1183/09031936.00013409; Sommerer C, 2016, THER DRUG MONIT S1, pS50, DOI [10.1097/FTD.00000000000 00234, DOI 10.1097/FTD.00000000000]; Sommerer C, 2009, NEPHROL DIAL TRANSPL, V24, P21, DOI 10.1093/ndt/gfn556; Sood S, 2017, LIVER TRANSPLANT, V23, P487, DOI 10.1002/lt.24730; Sood S, 2016, WORLD J HEPATOL, V8, P1569, DOI 10.4254/wjh.v8.i35.1569; Sood Siddharth, 2014, World J Transplant, V4, P30, DOI 10.5500/wjt.v4.i1.30; Sood S, 2014, TRANSPLANTATION, V97, pE50, DOI 10.1097/TP.0000000000000078; Strassl R, 2018, J INFECT DIS, V218, P1191, DOI 10.1093/infdis/jiy306; van Rossum HH, 2010, THER DRUG MONIT, V32, P3, DOI 10.1097/FTD.0b013e3181c0eecb	29	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 15	2020	11								916	10.3389/fimmu.2020.00916	http://dx.doi.org/10.3389/fimmu.2020.00916			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MW0JS	32499781	Green Published, gold			2022-12-18	WOS:000556734300001
J	Suo, X; Wu, ZG; Lillehoj, H; Tuo, WB				Suo, Xun; Wu, Zhiguang; Lillehoj, Hyun; Tuo, Wenbin			Editorial: Immunoparasitology: A Unique Interplay Between Host and Pathogen	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						parasite; helminth; protozoa; Apicomplexa; flagellate; co-infection; immunity; vaccines			[Suo, Xun] China Agr Univ, Natl Anim Protozoa Lab, Beijing, Peoples R China; [Suo, Xun] China Agr Univ, Coll Vet Med, Beijing, Peoples R China; [Suo, Xun] China Agr Univ, Minist Agr, Key Lab Anim Epidemiol, Beijing, Peoples R China; [Wu, Zhiguang] Univ Edinburgh, Roslin Inst, Easter Bush, Midlothian, Scotland; [Lillehoj, Hyun] ARS, USDA, Anim Biosci & Biotechnol Lab, Beltsville, MD USA; [Tuo, Wenbin] ARS, USDA, Anim Parasit Dis Lab, Beltsville, MD 20704 USA	China Agricultural University; China Agricultural University; China Agricultural University; Ministry of Agriculture & Rural Affairs; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Tuo, WB (corresponding author), ARS, USDA, Anim Parasit Dis Lab, Beltsville, MD 20704 USA.	wenbin.tuo@usda.gov			National Natural Science Foundation of China [31572507]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We wish to thank all authors who have participated in this Research Topic and the reviewers for their insightful comments and suggestions. XS was supported by the National Natural Science Foundation of China (31572507).		0	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2020	11								880	10.3389/fimmu.2020.00880	http://dx.doi.org/10.3389/fimmu.2020.00880			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LT2QO	32457761	gold, Green Published			2022-12-18	WOS:000536917000001
J	Nicolai, O; Potschke, C; Schmoeckel, K; Darisipudi, MN; van der Linde, J; Raafat, D; Broker, BM				Nicolai, Oliver; Poetschke, Christian; Schmoeckel, Katrin; Darisipudi, Murthy N.; van der Linde, Julia; Raafat, Dina; Broeker, Barbara M.			Antibody Production in Murine Polymicrobial Sepsis-Kinetics and Key Players	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; splenectomy; T cell; antibody-secreting cells; IgM; IgG	B-CELL SUBSETS; ASCENDENS STENT PERITONITIS; CD4(+) T-LYMPHOCYTES; MARGINAL-ZONE; PROFOUND DEPLETION; DENDRITIC CELLS; LYMPHOID-TISSUE; PLASMA-CELLS; B-1 CELLS; B1B CELLS	Although antigen-specific priming of antibody responses is impaired during sepsis, there is nevertheless a strong increase in IgM and IgG serum concentrations. Using colon ascendens stent peritonitis (CASP), a mouse model of polymicrobial abdominal sepsis, we observed substantial increases in IgM as well as IgG of all subclasses, starting at day 3 and peaking 2 weeks after sepsis induction. The dominant source of antibody-secreting cells was by far the spleen, with a minor contribution of the mesenteric lymph nodes. Remarkably, sepsis induction in splenectomized mice did not change the dynamics of the serum IgM/IgG reaction, indicating that the marginal zone B cells, which almost exclusively reside in the spleen, are dispensable in such a setting. Hence, in systemic bacterial infection, the function of the spleen as dominant niche of antibody-producing cells can be compensated by extra-splenic B cell populations as well as other lymphoid organs. Depletion of CD4+ T cells did not affect the IgM response, while it impaired IgG generation of all subclasses with the exception of IgG3. Taken together, our data demonstrate that the robust class-switched antibody response in sepsis encompasses both T cell-dependent and -independent components.	[Nicolai, Oliver; Poetschke, Christian; Schmoeckel, Katrin; Darisipudi, Murthy N.; Raafat, Dina; Broeker, Barbara M.] Univ Med Greifswald, Dept Immunol, Inst Immunol & Transfus Med, Greifswald, Germany; [van der Linde, Julia] Univ Med Greifswald, Dept Gen Surg Visceral Thorac & Vasc Surg, Greifswald, Germany; [Raafat, Dina] Alexandria Univ, Fac Pharm, Dept Microbiol & Immunol, Alexandria, Egypt; [Nicolai, Oliver] ZAS Zent Archiv Serv GmbH, Neubrandenburg, Germany; [Poetschke, Christian] Salutas Pharma GmbH, Barleben, Germany; [Schmoeckel, Katrin] CHEPLAPHARM Arzneimittel GmbH, Greifswald, Germany	Greifswald Medical School; Greifswald Medical School; Egyptian Knowledge Bank (EKB); Alexandria University	Broker, BM (corresponding author), Univ Med Greifswald, Dept Immunol, Inst Immunol & Transfus Med, Greifswald, Germany.	broeker@uni-greifswald.de	Raafat, Dina/ABD-2266-2021	Raafat, Dina/0000-0002-3610-9863	German Research Foundation (DFG) [RTG-840]	German Research Foundation (DFG)(German Research Foundation (DFG))	This research was funded by the German Research Foundation (DFG; RTG-840) to ON, CP, and KS.	Adib-Conquy M, 2009, THROMB HAEMOSTASIS, V101, P36, DOI 10.1160/TH08-07-0421; Allman D, 2008, CURR OPIN IMMUNOL, V20, P149, DOI 10.1016/j.coi.2008.03.014; Altamura M, 2001, IMMUNOPHARM IMMUNOT, V23, P153, DOI 10.1081/IPH-100103856; Alugupalli KR, 2003, BLOOD, V102, P2843, DOI 10.1182/blood-2003-02-0426; AMLOT PL, 1985, EUR J IMMUNOL, V15, P508, DOI 10.1002/eji.1830150516; AMLOT PL, 1985, LANCET, V1, P1008, DOI 10.1016/S0140-6736(85)91613-7; Barr TA, 2007, EUR J IMMUNOL, V37, P3040, DOI 10.1002/eji.200636483; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Berberich S, 2008, J IMMUNOL, V180, P2196, DOI 10.4049/jimmunol.180.4.2196; Berberich S, 2007, BLOOD, V109, P4627, DOI 10.1182/blood-2006-12-064345; Brunner M, 2004, INTENS CARE MED, V30, P1468, DOI 10.1007/s00134-004-2184-x; Busse M, 2008, GUT, V57, P188, DOI 10.1136/gut.2007.121616; Calis J, 2013, NEW ENGL J MED, V369, P2062, DOI [10.1056/NEJMc1312359, 10.1056/NEJMra1208623]; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Cavassani KA, 2010, BLOOD, V115, P4403, DOI 10.1182/blood-2009-09-241083; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Chu VT, 2011, SCAND J IMMUNOL, V73, P508, DOI 10.1111/j.1365-3083.2011.02544.x; Cinel I, 2009, CRIT CARE MED, V37, P291, DOI 10.1097/CCM.0b013e31819267fb; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; COUTINHO A, 1974, J EXP MED, V139, P74, DOI 10.1084/jem.139.1.74; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P1314; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P3712; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; Elzey BD, 2005, CELL IMMUNOL, V238, P1, DOI 10.1016/j.cellimm.2005.12.005; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Fairfax KA, 2007, J IMMUNOL, V178, P4104, DOI 10.4049/jimmunol.178.7.4104; Fernandes BF, 2010, TRANSPL IMMUNOL, V22, P195, DOI 10.1016/j.trim.2009.12.002; Flohe SB, 2006, J LEUKOCYTE BIOL, V79, P473, DOI 10.1189/jlb.0705413; Francois B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98960; Gao N, 2001, J IMMUNOL, V167, P2011, DOI 10.4049/jimmunol.167.4.2011; Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779; Grimminger F, 1997, INTERNIST, V38, P541, DOI 10.1007/PL00002644; Gurung P, 2011, J IMMUNOL, V187, P2148, DOI 10.4049/jimmunol.1101180; Gustave CA, 2018, J IMMUNOL, V200, P2418, DOI 10.4049/jimmunol.1700929; Ha SA, 2006, J EXP MED, V203, P2541, DOI 10.1084/jem.20061041; Hayakawa K, 2000, CURR OPIN IMMUNOL, V12, P346, DOI 10.1016/S0952-7915(00)00098-4; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hotchkiss RS, 2009, NAT MED, V15, P496, DOI 10.1038/nm0509-496; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jacobs S, 2000, ACTA ANAESTH SCAND, V44, P88, DOI 10.1034/j.1399-6576.2000.440116.x; JONES JM, 1976, J IMMUNOL, V116, P52; Kelly-Scumpia KM, 2011, J EXP MED, V208, P1673, DOI 10.1084/jem.20101715; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lanzavecchia A, 2006, IMMUNOL REV, V211, P303, DOI 10.1111/j.0105-2896.2006.00403.x; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; Madan R, 2009, J IMMUNOL, V183, P2312, DOI 10.4049/jimmunol.0900185; Maier S, 2004, SHOCK, V21, P505, DOI 10.1097/01.shk.0000126906.52367.dd; MANDLER R, 1993, J IMMUNOL, V150, P407; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1111/j.1600-065X.2000.imr017515.x; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Meyer-Bahlburg A, 2012, FRONT BIOSCI-LANDMRK, V17, P1499, DOI 10.2741/4000; Mohr A, 2012, EUR J IMMUNOL, V42, P341, DOI 10.1002/eji.201141692; Moon H, 2012, J KOREAN MED SCI, V27, P27, DOI 10.3346/jkms.2012.27.1.27; Muenzer JT, 2010, INFECT IMMUN, V78, P1582, DOI 10.1128/IAI.01213-09; Nguyen HH, 2012, J IMMUNOL, V189, P3112, DOI 10.4049/jimmunol.1200360; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Ochsenbein AF, 2000, J IMMUNOL, V164, P6296, DOI 10.4049/jimmunol.164.12.6296; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Osuchowski MF, 2006, J IMMUNOL, V177, P1967, DOI 10.4049/jimmunol.177.3.1967; Panda S, 2015, J IMMUNOL, V194, P13, DOI 10.4049/jimmunol.1400844; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Potschke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081752; Rangel-Moreno J, 2009, IMMUNITY, V30, P731, DOI 10.1016/j.immuni.2009.03.014; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Savage HP, 2015, ANN NY ACAD SCI, V1362, P132, DOI 10.1111/nyas.12799; Schmoeckel K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192197; Schmoeckel K, 2015, SHOCK, V43, P192, DOI 10.1097/SHK.0000000000000267; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shrum Bradly, 2014, BMC Res Notes, V7, P233, DOI 10.1186/1756-0500-7-233; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sjaastad FV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02532; Slade E, 2003, CRIT CARE, V7, P1, DOI 10.1186/cc1876; De La Rica AS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.59; Teixeira FM, 2008, CLIN EXP IMMUNOL, V154, P255, DOI 10.1111/j.1365-2249.2008.03728.x; Terasawa M, 2008, BIOCHEM BIOPH RES CO, V377, P589, DOI 10.1016/j.bbrc.2008.10.011; Tinsley KW, 2003, J IMMUNOL, V171, P909, DOI 10.4049/jimmunol.171.2.909; Traeger T, 2010, JOVE-J VIS EXP, V46, P2299; Wang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105636; Wang ZF, 2008, J IMMUNOL, V181, P8735, DOI 10.4049/jimmunol.181.12.8735; Wardemann H, 2002, J EXP MED, V195, P771, DOI 10.1084/jem.20011140; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; Weinstein JS, 2013, J IMMUNOL, V190, P3916, DOI 10.4049/jimmunol.1201880; Wesche DE, 2005, J LEUKOCYTE BIOL, V78, P325, DOI 10.1189/jlb.0105017; Yang Y, 2007, P NATL ACAD SCI USA, V104, P4542, DOI 10.1073/pnas.0700001104; Yende S, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8686; Zantl N, 1998, INFECT IMMUN, V66, P2300, DOI 10.1128/IAI.66.5.2300-2309.1998	96	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2020	11								828	10.3389/fimmu.2020.00828	http://dx.doi.org/10.3389/fimmu.2020.00828			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LS1XB	32425951	Green Published, gold			2022-12-18	WOS:000536183400001
J	Obar, JJ; Carvalho, A; Vitte, J; Ranque, S				Obar, Joshua J.; Carvalho, Agostinho; Vitte, Joana; Ranque, Stephane			Editorial: Host and Pathogen Determinants of Allergic and Invasive Fungal Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						fungal diseases; fungal infection; fungal allergy; allergic bronchopulmonary mycoses; aspergillosis; coccidioidomycosis; talaromycosis; cryptococcosis			[Obar, Joshua J.] Geisel Sch Med Dartmouth, Dept Microbiol Immunol, Lebanon, NH USA; [Carvalho, Agostinho] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; [Carvalho, Agostinho] ICVS 3Bs PT Govt Associate Lab, Guimaraes, Portugal; [Vitte, Joana] Aix Marseille Univ, Inst Rech Dev, Serv Sante Armees, MEPHI Microbes Evolut Phylogenie & Infect,AP HM, Marseille, France; [Vitte, Joana; Ranque, Stephane] IHU Mediterranee Infect, Marseille, France; [Ranque, Stephane] Aix Marseille Univ, Inst Rech Dev, Serv Sante Armees,AP HM, VITROME Vecteurs Infect Tropicales & Mediterranee, Marseille, France	Dartmouth College; Universidade do Minho; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Ranque, S (corresponding author), IHU Mediterranee Infect, Marseille, France.; Ranque, S (corresponding author), Aix Marseille Univ, Inst Rech Dev, Serv Sante Armees,AP HM, VITROME Vecteurs Infect Tropicales & Mediterranee, Marseille, France.	stephane.ranque@ap-hm.fr	Carvalho, Agostinho/D-2667-2009; Ranque, Stéphane/K-2317-2015; Vitte, Joana/G-2572-2013	Carvalho, Agostinho/0000-0001-8935-8030; Ranque, Stéphane/0000-0003-3293-5276; Obar, Joshua/0000-0003-4068-7911; Vitte, Joana/0000-0002-3344-9408					0	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2020	11								856	10.3389/fimmu.2020.00856	http://dx.doi.org/10.3389/fimmu.2020.00856			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LS1XR	32425953	Green Published, gold			2022-12-18	WOS:000536185000001
J	Galeev, A; Suwandi, A; Bakker, H; Oktiviyari, A; Routier, FH; Krone, L; Hensel, M; Grassl, GA				Galeev, Alibek; Suwandi, Abdulhadi; Bakker, Hans; Oktiviyari, Ade; Routier, Francoise H.; Krone, Lena; Hensel, Michael; Grassl, Guntram A.			Proteoglycan-Dependent Endo-Lysosomal Fusion Affects Intracellular Survival ofSalmonellaTyphimurium in Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Salmonella; proteoglycans; glycosaminoglycans; xylosyltransferase; PIKfyve; gentamicin	TYPHIMURIUM-CONTAINING VACUOLES; ENTERICA SEROVAR TYPHIMURIUM; SALMONELLA-TYPHIMURIUM; ENDOSOMAL SYSTEM; HEPARAN-SULFATE; REPLICATION; GENTAMICIN; INVASION; KINASE; GENE	Proteoglycans (PGs) are glycoconjugates which are predominately expressed on cell surfaces and consist of glycosaminoglycans (GAGs) linked to a core protein. An initial step of GAGs assembly is governed by the beta-D-xylosyltransferase enzymes encoded in mammals by theXylT1/XylT2genes. PGs are essential for the interaction of a cell with other cells as well as with the extracellular matrix. A number of studies highlighted a role of PGs in bacterial adhesion, invasion, and immune response. In this work, we investigated a role of PGs inSalmonella entericaserovar Typhimurium (S. Typhimurium) infection of epithelial cells. Gentamicin protection and chloroquine resistance assays were applied to assess invasion and replication ofS. Typhimurium in wild-type and xylosyltransferase-deficient (Delta XylT2) Chinese hamster ovary (CHO) cells lacking PGs. We found thatS. Typhimurium adheres to and invades CHO WT and CHO Delta XylT2cells at comparable levels. However, 24 h after infection, proteoglycan-deficient CHO Delta XylT2cells are significantly less colonized byS. Typhimurium compared to CHO WT cells. This proteoglycan-dependent phenotype could be rescued by addition of PGs to the cell culture medium, as well as by complementation of theXylT2gene. Chloroquine resistance assay and immunostaining revealed that in the absence of PGs, significantly less bacteria are associated withSalmonella-containing vacuoles (SCVs) due to a re-distribution of endocytosed gentamicin. Inhibition of endo-lysosomal fusion by a specific inhibitor of phosphatidylinositol phosphate kinase PIKfyve significantly increasedS. Typhimurium burden in CHO Delta XylT2cells demonstrating an important role of PGs for PIKfyve dependent vesicle fusion which is modulated bySalmonellato establish infection. Overall, our results demonstrate that PGs influence survival of intracellularSalmonellain epithelial cells via modulation of PIKfyve-dependent endo-lysosomal fusion.	[Galeev, Alibek; Suwandi, Abdulhadi; Oktiviyari, Ade; Grassl, Guntram A.] Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany; [Galeev, Alibek; Suwandi, Abdulhadi; Oktiviyari, Ade; Grassl, Guntram A.] German Ctr Infect Res DZIF, Hannover, Germany; [Bakker, Hans; Routier, Francoise H.] Hannover Med Sch, Inst Clin Biochem, Hannover, Germany; [Krone, Lena; Hensel, Michael] Univ Osnabruck, Div Microbiol, Osnabruck, Germany	Hannover Medical School; German Center for Infection Research; Hannover Medical School; University Osnabruck	Grassl, GA (corresponding author), Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany.; Grassl, GA (corresponding author), German Ctr Infect Res DZIF, Hannover, Germany.	grassl.guntram@mh-hannover.de	Oktiviyari, Ade/GPG-3649-2022; Bakker, Hans/A-1787-2017	Oktiviyari, Ade/0000-0002-1392-200X; Bakker, Hans/0000-0002-1364-9154; Galeev, Alibek/0000-0001-6489-9738	Deutsche Forschungsgemeinschaft (DFG) [SPP1656/2]; German Federal Ministry of Education and Research (BMBF) Infect-ERA consortium [031L0093B]; DFG collaborative research center [SFB 900 TP08, 158989968]; Hannover Biomedical Research School (HBRS); Center for Infection Biology (ZIB); DFG [SFB 944 P4]; Infect-ERA consortium [031L0093A]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF) Infect-ERA consortium(Federal Ministry of Education & Research (BMBF)); DFG collaborative research center(German Research Foundation (DFG)); Hannover Biomedical Research School (HBRS); Center for Infection Biology (ZIB); DFG(German Research Foundation (DFG)); Infect-ERA consortium	GG was supported by the Deutsche Forschungsgemeinschaft (DFG) priority program SPP1656/2, the German Federal Ministry of Education and Research (BMBF) Infect-ERA consortium grant 031L0093B and DFG collaborative research center SFB 900 TP08 (Project number 158989968). AG was supported by the Hannover Biomedical Research School (HBRS) and by the Center for Infection Biology (ZIB). MH was supported by the DFG SFB 944 P4 and Infect-ERA consortium grant 031L0093A.	Allam US, 2012, VIRULENCE, V3, P122, DOI 10.4161/viru.19029; Alonso A, 2004, INT MICROBIOL, V7, P181; Bakker H, 2009, J BIOL CHEM, V284, P2576, DOI 10.1074/jbc.M804394200; Becavin C, 2014, MBIO, V5, DOI 10.1128/mBio.00969-14; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Brumell JH, 2002, INFECT IMMUN, V70, P3264, DOI 10.1128/IAI.70.6.3264-3270.2002; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cuellar K, 2007, J BIOL CHEM, V282, P5195, DOI 10.1074/jbc.M611048200; Denamur S, 2011, FREE RADICAL BIO MED, V51, P1656, DOI 10.1016/j.freeradbiomed.2011.07.015; Drecktrah D, 2004, INFECT IMMUN, V72, P4331, DOI 10.1128/IAI.72.8.4331-4335.2004; Dukes JD, 2006, BIOCHEM J, V395, P239, DOI 10.1042/BJ20051451; Dukes JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028659; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; Friand V, 2015, BIOL CELL, V107, P331, DOI 10.1111/boc.201500010; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Henry-Stanley MJ, 2003, MED MICROBIOL IMMUN, V192, P107, DOI 10.1007/s00430-002-0165-7; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Iozzo RV, 2015, MATRIX BIOL, V42, P11, DOI 10.1016/j.matbio.2015.02.003; Karasawa T, 2008, J CELL SCI, V121, P2871, DOI 10.1242/jcs.023705; Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634; Kerr MC, 2010, EMBO J, V29, P1331, DOI 10.1038/emboj.2010.28; Knodler LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084681; Knuff K, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00335; Krishna S, 2016, DEV CELL, V38, P536, DOI 10.1016/j.devcel.2016.08.001; Kuhle V, 2006, TRAFFIC, V7, P716, DOI 10.1111/j.1600-0854.2006.00422.x; Lambert MA, 2009, FEMS MICROBIOL LETT, V297, P209, DOI 10.1111/j.1574-6968.2009.01666.x; Leong JM, 1998, INFECT IMMUN, V66, P994, DOI 10.1128/IAI.66.3.994-999.1998; Liss V, 2017, CELL HOST MICROBE, V21, P390, DOI 10.1016/j.chom.2017.02.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuura M, 2012, INNATE IMMUN-LONDON, V18, P764, DOI 10.1177/1753425912440599; Menashe O, 2008, ANTIMICROB AGENTS CH, V52, P920, DOI 10.1128/AAC.00382-07; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Mota LJ, 2009, CELL MICROBIOL, V11, P1236, DOI 10.1111/j.1462-5822.2009.01329.x; Myrdal SE, 2005, HEARING RES, V204, P170, DOI 10.1016/j.heares.2005.02.005; Nagai J, 2014, BIOCHEM PHARMACOL, V90, P331, DOI 10.1016/j.bcp.2014.05.018; Noster J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007741; Notenboom S, 2006, J PHARMACOL EXP THER, V318, P1194, DOI 10.1124/jpet.106.104547; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Perrett CA, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.31; Rajashekar R, 2008, TRAFFIC, V9, P2100, DOI 10.1111/j.1600-0854.2008.00821.x; Reuter T, 2020, MOL CELL PROTEOMICS, V19, P900, DOI 10.1074/mcp.RA119.001841; Rostand KS, 1997, INFECT IMMUN, V65, P1; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Seputiene V, 2003, J BACTERIOL, V185, P2475, DOI 10.1128/JB.185.8.2475-2484.2003; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; ten Dam GB, 2003, J HISTOCHEM CYTOCHEM, V51, P727; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; van Wijk XM, 2017, MBIO, V8, DOI 10.1128/mBio.02128-16; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x	58	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2020	11								731	10.3389/fimmu.2020.00731	http://dx.doi.org/10.3389/fimmu.2020.00731			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MV7ME	32411142	Green Published, gold			2022-12-18	WOS:000556536300001
J	Lio, WM; Cercek, B; Yano, J; Yang, W; Ghermezi, J; Zhao, XN; Zhou, JC; Zhou, B; Freeman, MR; Chyu, KY; Shah, PK; Dimayuga, PC				Lio, Wai Man; Cercek, Bojan; Yano, Juliana; Yang, Wei; Ghermezi, Jonathan; Zhao, Xiaoning; Zhou, Jianchang; Zhou, Bo; Freeman, Michael R.; Chyu, Kuang-Yuh; Shah, Prediman K.; Dimayuga, Paul C.			Sex as a Determinant of Responses to a Coronary Artery Disease Self-Antigen Identified by Immune-Peptidomics	FRONTIERS IN IMMUNOLOGY			English	Article						coronary artery disease; atherosclerosis; immune-peptidome; self-antigen; sexual dimorphism	CD4(+) T-CELLS; ATHEROSCLEROSIS; MICE; AUTOIMMUNITY; MECHANISMS; DIMORPHISM	A significant body of work implicates the adaptive immune response in atherosclerosis, the main underlying cause of coronary artery disease (CAD), yet specific antigens involved remain to be fully identified. The pathobiology of CAD is influenced by sex with many factors that may be involved in the underlying mechanisms. Given the reported sexual dimorphic nature of immune-inflammatory responses, we investigated the influence of sex on potential CAD self-antigens from acute coronary syndrome (ACS) patients using immune-precipitation of soluble HLA Class-I/peptide complexes and mass spectrometry. Relevance of identified self-antigens to atherosclerosis, the major underlying cause of CAD, was tested in the apoE-/- atherosclerotic mouse model. Soluble HLA Class-I complexes from ACS patients and self-reported controls were immune-precipitated and subjected to elution, denaturation and size-exclusion to obtain HLA-bound peptides. Peptides were then subjected to mass spectrometry and patient-unique self-peptides were grouped as common to both female and male, or unique to either sex. Three peptides common to both female and male patients (COL6A1, CDSN, and SAA2), and 2 peptides each unique to female (COL1A1 and COL5A2) or male (SAA1 and KRT 9) patients were selected and mouse homologs of the peptides were screened for self-reactive immune responses in apoE-/- mice. The screening step revealed potential sex-influenced immune responses which was associated with differential immune profiles. Based on the frequency in patient plasma, COL6A1, COL5A2, and KRT 9 peptides were then tested in immunization studies. Neither COL5A2 nor KRT 9 peptide immunization resulted in significant effects on atherosclerosis compared to controls. On the other hand, female mice immunized with COL6A1 peptide had significantly reduced atherosclerosis whereas male mice had significantly increased atherosclerosis, associated with differential immune profiles. Our study identified potential self-antigens involved in atherosclerosis using the immune peptidome of CAD patients. Altering self-reactive immune responses to COL6A1 in apoE-/- mice resulted in differential effects on atherosclerosis burden with sex as a determinant of outcome.	[Lio, Wai Man; Cercek, Bojan; Yano, Juliana; Ghermezi, Jonathan; Zhao, Xiaoning; Zhou, Jianchang; Chyu, Kuang-Yuh; Shah, Prediman K.; Dimayuga, Paul C.] Cedars Sinai Med Ctr, Dept Cardiol, Smidt Heart Inst, Oppenheimer Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA; [Yang, Wei; Zhou, Bo; Freeman, Michael R.] Cedars Sinai Med Ctr, Dept Surg, Div Canc Biol & Therapeut, Los Angeles, CA 90048 USA; [Yang, Wei; Zhou, Bo; Freeman, Michael R.] Cedars Sinai Med Ctr, Dept Biomed Sci, Div Canc Biol & Therapeut, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Dimayuga, PC (corresponding author), Cedars Sinai Med Ctr, Dept Cardiol, Smidt Heart Inst, Oppenheimer Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA.	paul.dimayuga@cshs.org	Yang, Wei/ABA-5268-2020; Yang, Wei/C-3047-2008	Yang, Wei/0000-0003-2575-3570	American Heart Association Innovative Research Grant [17IRG33410704]; Eleanor and Harold Foonberg Endowed Chair in Cardiac Intensive Care Fund; Heart Foundation; Petersen Foundation; Spielberg Fund; Joe Weider Foundation; Annenberg Foundation,; Steinberg Foundation	American Heart Association Innovative Research Grant(American Heart Association); Eleanor and Harold Foonberg Endowed Chair in Cardiac Intensive Care Fund; Heart Foundation; Petersen Foundation; Spielberg Fund; Joe Weider Foundation; Annenberg Foundation,; Steinberg Foundation	This study was supported by an American Heart Association Innovative Research Grant #17IRG33410704 (PD). Additional support was provided by The Joe Weider Foundation (PD); Eleanor and Harold Foonberg Endowed Chair in Cardiac Intensive Care Fund (BC); and The Heart Foundation, The Petersen Foundation, Spielberg Fund, Annenberg Foundation, Steinberg Foundation (PS).	Ahrends T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13438-1; Ammirati E, 2012, J AM HEART ASSOC, V1, P27, DOI 10.1161/JAHA.111.000125; Bjorkbacka H, 2010, J INTERN MED, V268, P50, DOI 10.1111/j.1365-2796.2009.02209.x; Boeer U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105964; Burrows SR, 2006, TRENDS IMMUNOL, V27, P11, DOI 10.1016/j.it.2005.11.001; Caligiuri G, 1999, ATHEROSCLEROSIS, V145, P301, DOI 10.1016/S0021-9150(99)00081-7; Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825; Cercek B, 2003, LANCET, V361, P809, DOI 10.1016/S0140-6736(03)12706-7; Cescon M, 2015, J CELL SCI, V128, P3525, DOI 10.1242/jcs.169748; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Davies RW, 2012, CIRC-CARDIOVASC GENE, V5, P217, DOI 10.1161/CIRCGENETICS.111.961243; de la Cuesta Fernando, 2011, Mol Cell Proteomics, V10, DOI 10.1074/mcp.M110.003517; den Hartigh LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108564; Dhanji S, 2006, J IMMUNOL, V177, P138, DOI 10.4049/jimmunol.177.1.138; Dimayuga PC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005318; Eickhoff S, 2015, CELL, V162, P1322, DOI 10.1016/j.cell.2015.08.004; Engelbertsen D, 2018, CARDIOVASC RES, V114, P180, DOI 10.1093/cvr/cvx196; Finn OJ, 2017, CANCER IMMUNOL RES, V5, P347, DOI 10.1158/2326-6066.CIR-17-0112; Fredrikson GN, 2003, ARTERIOSCL THROM VAS, V23, P879, DOI 10.1161/01.ATV.0000067937.93716.DB; Hansson GK, 2009, ARTERIOSCL THROM VAS, V29, P1714, DOI 10.1161/ATVBAHA.108.179713; Hassan C, 2015, J BIOL CHEM, V290, P2593, DOI 10.1074/jbc.M114.607028; Hor JL, 2015, IMMUNITY, V43, P554, DOI 10.1016/j.immuni.2015.07.020; Jain A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05489-7; KATSUDA S, 1992, ARTERIOSCLER THROMB, V12, P494, DOI 10.1161/01.ATV.12.4.494; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Kimura T, 2018, CIRCULATION, V138, P1130, DOI 10.1161/CIRCULATIONAHA.117.031420; Kirii H, 2003, ARTERIOSCL THROM VAS, V23, P656, DOI 10.1161/01.ATV.0000064374.15232.C3; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Kyaw T, 2013, CIRCULATION, V127, P1028, DOI 10.1161/CIRCULATIONAHA.112.001347; Lamason R, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-2; MacLeod MKL, 2011, P NATL ACAD SCI USA, V108, P7914, DOI 10.1073/pnas.1104588108; Malhotra D, 2016, NAT IMMUNOL, V17, P187, DOI 10.1038/ni.3327; Markiewicz M, 2007, J DERMATOL SCI, V47, P217, DOI 10.1016/j.jdermsci.2007.05.008; Merched AJ, 2016, FASEB J, V30, P2123, DOI 10.1096/fj.201500131; MERZ CNB, 2006, J AM COLL CARDIOL, V47, pS21, DOI [DOI 10.1016/J.JACC.2004.12.084, 10.1016/j.jacc.2004.12.084]; Mihailovic PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213025; Mihailovic PM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187432; Morley S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12136; Novais FO, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006196; Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Robinet P, 2018, ARTERIOSCL THROM VAS, V38, P292, DOI 10.1161/ATVBAHA.117.309524; Rubtsova K, 2015, J CLIN INVEST, V125, P2187, DOI 10.1172/JCI78082; Saupe F, 2015, FASEB J, V29, P3253, DOI 10.1096/fj.15-271502; Schneider-Hohendorf T, 2018, P NATL ACAD SCI USA, V115, P2168, DOI 10.1073/pnas.1716146115; Swee LK, 2014, EUR J IMMUNOL, V44, P1299, DOI 10.1002/eji.201343840; Targonska-Stepniak B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/793628; Teupser D, 2004, P NATL ACAD SCI USA, V101, P17795, DOI 10.1073/pnas.0408096101; van Dijk RA, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001403; van Duijn J, 2018, CURR OPIN LIPIDOL, V29, P411, DOI 10.1097/MOL.0000000000000541; Wierer M, 2018, MOL CELL PROTEOMICS, V17, P321, DOI 10.1074/mcp.RA117.000315; Wu MS, 2013, BIOCHEM BIOPH RES CO, V441, P618, DOI 10.1016/j.bbrc.2013.10.105; Yao YK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15402; Ying HY, 2010, J IMMUNOL, V185, P1375, DOI 10.4049/jimmunol.0903369; Zhou XH, 2000, CIRCULATION, V102, P2919; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	57	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2020	11								694	10.3389/fimmu.2020.00694	http://dx.doi.org/10.3389/fimmu.2020.00694			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LL7AS	32373127	Green Published, gold			2022-12-18	WOS:000531708600001
J	Yotsumoto, K; Sanui, T; Tanaka, U; Yamato, H; Alshargabi, R; Shinjo, T; Nakao, Y; Watanabe, Y; Hayashi, C; Taketomi, T; Fukuda, T; Nishimura, F				Yotsumoto, Karen; Sanui, Terukazu; Tanaka, Urara; Yamato, Hiroaki; Alshargabi, Rehab; Shinjo, Takanori; Nakao, Yuki; Watanabe, Yukari; Hayashi, Chikako; Taketomi, Takaharu; Fukuda, Takao; Nishimura, Fusanori			Amelogenin Downregulates Interferon Gamma-Induced Major Histocompatibility Complex Class II Expression Through Suppression of Euchromatin Formation in the Class II Transactivator Promoter IV Region in Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						amelogenin; periodontal tissue regeneration; macrophages; major histocompatibility complex class II; interferon gamma; class II transactivator; immunosuppression	PROTEIN-PROTEIN INTERACTIONS; TUMOR-ASSOCIATED MACROPHAGES; ENAMEL MATRIX; GENE-EXPRESSION; ACTIVATION; TUBERCULOSIS; INVOLVEMENT; RECEPTOR; DEFECTS; PEPTIDE	Enamel matrix derivatives (EMDs)-based periodontal tissue regenerative therapy is known to promote healing with minimal inflammatory response after periodontal surgery, i. e., it promotes wound healing with reduced pain and swelling. It has also been reported that macrophages stimulated with amelogenin, a major component of EMD, produce various anti-inflammatory cytokines and growth factors. We previously found that stimulation of monocytes with murine recombinant M180 (rM180) amelogenin suppresses major histocompatibility complex class II (MHC II) gene expression using microarray analysis. However, the detailed molecular mechanisms for this process remain unclear. In the present study, we demonstrated that rM180 amelogenin selectively downmodulates the interferon gamma (IFN gamma)-induced cell surface expression of MHC II molecules in macrophages and this mechanism mediated by rM180 appeared to be widely conserved across species. Furthermore, rM180 accumulated in the nucleus of macrophages at 15 min after stimulation and inhibited the protein expression of class II transactivator (CIITA) which controls the transcription of MHC II by IFN gamma. In addition, reduced MHC II expression on macrophages pretreated with rM180 impaired the expression of T cell activation markers CD25 and CD69, T cell proliferation ability, and IL-2 production by allogenic CD4(+) T lymphocytes in mixed lymphocyte reaction assay. The chromatin immunoprecipitation assay showed that IFN gamma stimulation increased the acetylation of histone H3 lysine 27, which is important for conversion to euchromatin, as well as the trimethylation of histone H3 lysine 4 levels in the CIITA promoter IV (p-IV) region, but both were suppressed in the group stimulated with IFN gamma after rM180 treatment. In conclusion, the present study shows that amelogenin suppresses MHC II expression by altering chromatin structure and inhibiting CIITA p-IV transcription activity, and attenuates subsequent T cell activation. Clinically observed acceleration of wound healing after periodontal surgery by amelogenin may be partially mediated by the mechanism elucidated in this study. In addition, the use of recombinant amelogenin is safe because it is biologically derived protein. Therefore, amelogenin may also be used in future as an immunosuppressant with minimal side effects for organ transplantation or MHC II-linked autoimmune diseases such as type I diabetes, multiple sclerosis, and rheumatoid arthritis, among others.	[Yotsumoto, Karen; Sanui, Terukazu; Tanaka, Urara; Yamato, Hiroaki; Alshargabi, Rehab; Shinjo, Takanori; Nakao, Yuki; Watanabe, Yukari; Hayashi, Chikako; Fukuda, Takao; Nishimura, Fusanori] Kyushu Univ, Fac Dent Sci, Div Oral Rehabil, Dept Periodontol, Fukuoka, Japan; [Taketomi, Takaharu] Kurume Univ, Sch Med, Dent & Oral Med Ctr, Kurume, Fukuoka, Japan	Kyushu University; Kurume University	Sanui, T; Fukuda, T (corresponding author), Kyushu Univ, Fac Dent Sci, Div Oral Rehabil, Dept Periodontol, Fukuoka, Japan.	sanuteru@dent.kyushu-u.ac.jp; tfukuda@dent.kyushu-u.ac.jp		Shinjo, Takanori/0000-0002-8269-2826	Japan Society for the Promotion of Science, Takeda Science Foundation [JP17K11986, JP20K09958]	Japan Society for the Promotion of Science, Takeda Science Foundation(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceTakeda Science Foundation (TSF))	This work was supported by Grants-in-Aid for Scientific Research C (JP17K11986 and JP20K09958) from the Japan Society for the Promotion of Science, Takeda Science Foundation. Technical support was provided from the Research Support Center, Graduate School of Medical Sciences, Kyushu University.	ACCOLLA RS, 1986, J EXP MED, V164, P369, DOI 10.1084/jem.164.1.369; Almqvist S, 2012, CYTOKINE, V58, P274, DOI 10.1016/j.cyto.2012.02.001; Bartlett JD, 2006, CURR TOP DEV BIOL, V74, P57, DOI 10.1016/S0070-2153(06)74003-0; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Boyd NH, 2015, MOL IMMUNOL, V67, P482, DOI 10.1016/j.molimm.2015.08.003; Brown L J, 1993, Periodontol 2000, V2, P57; Carleton MM, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119477; Chang YC, 2008, BLOOD, V111, P5054, DOI 10.1182/blood-2007-12-130609; Chavez-Galan L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00263; CHEN EH, 1994, DEV DYNAM, V199, P189, DOI 10.1002/aja.1001990304; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Du C, 2005, SCIENCE, V307, P1450, DOI 10.1126/science.1105675; Fleischer J, 1996, IMMUNOLOGY, V89, P592, DOI 10.1046/j.1365-2567.1996.d01-785.x; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Fukuda T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078129; Gestrelius S, 2000, Clin Oral Investig, V4, P120, DOI 10.1007/s007840050127; Glomsda BA, 2003, SPINAL CORD, V41, P610, DOI 10.1038/sj.sc.3101512; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600-051X.1997.tb00247.x; Hatakeyama J, 2006, J DENT RES, V85, P144, DOI 10.1177/154405910608500206; Hatakeyama J, 2003, J BIOL CHEM, V278, P35743, DOI 10.1074/jbc.M306284200; Hoang AM, 2002, J DENT RES, V81, P497, DOI 10.1177/154405910208100713; Iacob S, 2008, BONE, V42, P1072, DOI 10.1016/j.bone.2008.01.023; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jepsen S, 2004, J PERIODONTOL, V75, P1150, DOI 10.1902/jop.2004.75.8.1150; Kobayashi KS, 2012, NAT REV IMMUNOL, V12, P813, DOI 10.1038/nri3339; Kwiek B, 2008, J ALLERGY CLIN IMMUN, V122, P126, DOI 10.1016/j.jaci.2008.05.005; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Martins L, 2017, J CELL PHYSIOL, V232, P556, DOI 10.1002/jcp.25453; Masternak K, 2000, GENE DEV, V14, P1156; Matsuzawa M, 2009, J PERIODONTAL RES, V44, P289, DOI 10.1111/j.1600-0765.2008.01091.x; Montaner LJ, 1999, J IMMUNOL, V162, P4606; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Panjwani N, 1999, J IMMUNOL, V163, P1936; Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8; Ramseier CA, 2012, PERIODONTOL 2000, V59, P185, DOI 10.1111/j.1600-0757.2011.00432.x; Ravindranath RMH, 2007, ARCH ORAL BIOL, V52, P1161, DOI 10.1016/j.archoralbio.2007.06.008; Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708; Romanelli M, 2008, CLIN INTERV AGING, V3, P263, DOI 10.2147/CIA.S1846; Sanui T., 2017, AM J MOL BIOL, V7, P107, DOI [10.4236/ajmb.2017.72009, DOI 10.4236/ajmb.2017.72009, DOI 10.4236/AJMB.2017.72009]; SCHNEEBERGER EE, 1986, LAB INVEST, V55, P138; Sculean A, 2008, J CLIN PERIODONTOL, V35, P817, DOI 10.1111/j.1600-051X.2008.01295.x; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Spiller KL, 2014, BIOMATERIALS, V35, P4477, DOI 10.1016/j.biomaterials.2014.02.012; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Swanson EC, 2006, EUR J ORAL SCI, V114, P239, DOI 10.1111/j.1600-0722.2006.00321.x; Tompkins K, 2006, BONE, V38, P172, DOI 10.1016/j.bone.2005.08.013; Toyoda K, 2016, J CELL PHYSIOL, V231, P414, DOI 10.1002/jcp.25087; Wang HJ, 2005, J BONE MINER RES, V20, P1032, DOI 10.1359/JBMR.050111; Wang HJ, 2006, EUR J ORAL SCI, V114, P276, DOI 10.1111/j.1600-0722.2006.00289.x; Yamakoshi Y, 2011, J ORAL BIOSCI, V53, P275, DOI 10.2330/joralbiosci.53.275; Yamamichi K, 2017, ARCH ORAL BIOL, V83, P241, DOI 10.1016/j.archoralbio.2017.08.005; Yang MY, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00552; Zhang H, 2010, ARCH ORAL BIOL, V55, P417, DOI 10.1016/j.archoralbio.2010.03.009; Zou Y, 2007, BIOCHEM J, V408, P347, DOI 10.1042/BJ20070881	61	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2020	11								709	10.3389/fimmu.2020.00709	http://dx.doi.org/10.3389/fimmu.2020.00709			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LM5RD	32373130	gold, Green Published			2022-12-18	WOS:000532305400001
J	Sarapulov, AV; Petrov, P; Hernandez-Perez, S; Sustar, V; Kuokkanen, E; Cords, L; Samuel, RVM; Vainio, M; Fritzsche, M; Carrasco, YR; Mattila, PK				Sarapulov, Alexey V.; Petrov, Petar; Hernandez-Perez, Sara; Sustar, Vid; Kuokkanen, Elina; Cords, Lena; Samuel, Rufus V. M.; Vainio, Marika; Fritzsche, Marco; Carrasco, Yolanda R.; Mattila, Pieta K.			Missing-in-Metastasis/Metastasis Suppressor 1 Regulates B Cell Receptor Signaling, B Cell Metabolic Potential, and T Cell-Independent Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						MIM; MTSS1; I-BAR domain protein; BCR; B cell receptor signaling; actin cytoskeleton; TLR; metabolism	IMMUNOLOGICAL SYNAPSE; ANTIGEN RECEPTOR; CROSS-TALK; ACTIN; MIM; ACTIVATION; METASTASIS; PROTEIN; EXPRESSION; DYNAMICS	Efficient generation of antibodies by B cells is one of the prerequisites of protective immunity. B cell activation by cognate antigens via B cell receptors (BCRs), or pathogen-associated molecules through pattern-recognition receptors, such as Toll-like receptors (TLRs), leads to transcriptional and metabolic changes that ultimately transform B cells into antibody-producing plasma cells or memory cells. BCR signaling and a number of steps downstream of it rely on coordinated action of cellular membranes and the actin cytoskeleton, tightly controlled by concerted action of multiple regulatory proteins, some of them exclusive to B cells. Here, we dissect the role of Missing-In-Metastasis (MIM), or Metastasis suppressor 1 (MTSS1), a cancer-associated membrane and actin cytoskeleton regulating protein, in B cell-mediated immunity by taking advantage of MIM knockout mouse strain. We show undisturbed B cell development and largely normal composition of B cell compartments in the periphery. Interestingly, we found that MIM-/- B cells are defected in BCR signaling in response to surface-bound antigens but, on the other hand, show increased metabolic activity after stimulation with LPS or CpG. In vivo, MIM knockout animals exhibit impaired IgM antibody responses to immunization with T cell-independent antigen. This study provides the first comprehensive characterization of MIM in B cells, demonstrates its regulatory role for B cell-mediated immunity, as well as proposes new functions for MIM in tuning receptor signaling and cellular metabolism, processes, which may also contribute to the poorly understood functions of MIM in cancer.	[Sarapulov, Alexey V.; Petrov, Petar; Hernandez-Perez, Sara; Sustar, Vid; Kuokkanen, Elina; Samuel, Rufus V. M.; Vainio, Marika; Mattila, Pieta K.] Univ Turku, Inst Biomed, Turku, Finland; [Sarapulov, Alexey V.; Petrov, Petar; Hernandez-Perez, Sara; Sustar, Vid; Kuokkanen, Elina; Samuel, Rufus V. M.; Vainio, Marika; Mattila, Pieta K.] Univ Turku, MediCity Res Labs, Turku, Finland; [Sarapulov, Alexey V.; Petrov, Petar; Hernandez-Perez, Sara; Vainio, Marika; Mattila, Pieta K.] Univ Turku, Turku Biosci, Turku, Finland; [Sarapulov, Alexey V.; Petrov, Petar; Hernandez-Perez, Sara; Vainio, Marika; Mattila, Pieta K.] Abo Akad Univ, Turku, Finland; [Cords, Lena] Univ Oxford, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England; [Fritzsche, Marco] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Fritzsche, Marco] Rosalind Franklin Inst, Didcot, Oxon, England; [Carrasco, Yolanda R.] Ctr Nacl Biotecnol CNB CSIC, Dept Immunol & Oncol, Madrid, Spain	University of Turku; University of Turku; University of Turku; Abo Akademi University; University of Oxford; University of Oxford; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mattila, PK (corresponding author), Univ Turku, Inst Biomed, Turku, Finland.; Mattila, PK (corresponding author), Univ Turku, MediCity Res Labs, Turku, Finland.; Mattila, PK (corresponding author), Univ Turku, Turku Biosci, Turku, Finland.; Mattila, PK (corresponding author), Abo Akad Univ, Turku, Finland.	pieta.mattila@utu.fi	Mattila, Pieta K/G-6815-2013; Petrov, Petar/AAN-3817-2021; Hernández-Pérez, Sara/AAN-7281-2021; Petrov, Petar/D-8067-2019	Mattila, Pieta K/0000-0003-2805-0686; Hernández-Pérez, Sara/0000-0002-0227-1045; Petrov, Petar/0000-0001-5551-8032; Sarapulov, Alexey/0000-0001-6445-7438; Vinod, Rufus/0000-0003-4722-3300; Carrasco, Yolanda R./0000-0003-2148-1926; Fritzsche, Marco/0000-0002-8712-7471	Academy of Finland [25700, 296684, 307313, 327378, 286712]; Sigrid Juselius foundation; Jane and Aatos Erkko foundation; Turku doctoral program in molecular medicine (TuDMM); Magnus Ehrnrooth foundation; Finnish Cultural foundation; Wellcome Trust [212343/Z/18/Z]; EPSRC [EP/S004459/1]	Academy of Finland(Academy of Finland); Sigrid Juselius foundation(Sigrid Juselius Foundation); Jane and Aatos Erkko foundation; Turku doctoral program in molecular medicine (TuDMM); Magnus Ehrnrooth foundation; Finnish Cultural foundation(Finnish Cultural FoundationFinnish IT center for science); Wellcome Trust(Wellcome TrustEuropean Commission); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the Academy of Finland (grant ID: 25700, 296684, 307313, and 327378 to PM; 286712 to VS), Sigrid Juselius and Jane and Aatos Erkko foundations (to PM), Turku doctoral program in molecular medicine (TuDMM) (to SH-P and MV), and Magnus Ehrnrooth (to AS) and Finnish Cultural (to VS) foundations. MF and LC were supported by the Wellcome Trust (212343/Z/18/Z) and EPSRC (EP/S004459/1).	Akkaya M, 2018, NAT IMMUNOL, V19, P871, DOI 10.1038/s41590-018-0156-5; Bekeredjian-Ding I, 2009, IMMUNOLOGY, V128, P311, DOI 10.1111/j.1365-2567.2009.03173.x; Bolger-Munro M, 2019, ELIFE, V8, DOI 10.7554/eLife.44574; Boothby M, 2017, IMMUNITY, V46, P743, DOI 10.1016/j.immuni.2017.04.009; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Cao M, 2012, BIOCHEM J, V446, P469, DOI 10.1042/BJ20120329; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Caro-Maldonado A, 2014, J IMMUNOL, V192, P3626, DOI 10.4049/jimmunol.1302062; Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007; Carrasco YR, 2004, IMMUNITY, V20, P589, DOI 10.1016/S1074-7613(04)00105-0; Coughlin JJ, 2005, J IMMUNOL, V175, P7179, DOI 10.4049/jimmunol.175.11.7179; Depoil D, 2008, NAT IMMUNOL, V9, P63, DOI 10.1038/ni1547; Dillard P, 2014, BIOPHYS J, V107, P2629, DOI 10.1016/j.bpj.2014.10.044; Dye JR, 2007, J IMMUNOL, V179, P229, DOI 10.4049/jimmunol.179.1.229; Fahrenkamp D, 2017, LEUKEMIA, V31, P1017, DOI 10.1038/leu.2017.19; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Haas KM, 2011, J IMMUNOL, V187, P5183, DOI 10.4049/jimmunol.1101990; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; Hsu MC, 2006, P NATL ACAD SCI USA, V103, P5905, DOI 10.1073/pnas.0601502103; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Jellusova J, 2018, IMMUNOL LETT, V201, P1, DOI 10.1016/j.imlet.2018.11.003; Ketchum C, 2014, BIOPHYS J, V106, P26, DOI 10.1016/j.bpj.2013.10.043; Kuokkanen E, 2015, TRAFFIC, V16, P311, DOI 10.1111/tra.12257; Lee A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02852-4; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Li LS, 2017, J CELL SCI, V130, P1475, DOI 10.1242/jcs.198937; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Liu CH, 2012, J IMMUNOL, V188, P3237, DOI 10.4049/jimmunol.1103065; Londhe P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00104; Luxembourg AT, 1998, J IMMUNOL, V161, P5226; Machesky LM, 2007, J MOL MED-JMM, V85, P569, DOI 10.1007/s00109-007-0207-0; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Mattila PK, 2016, J CELL BIOL, V212, P267, DOI 10.1083/jcb.201504137; Mattila PK, 2013, IMMUNITY, V38, P461, DOI 10.1016/j.immuni.2012.11.019; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Merida I, 2010, PROTEIN KINASE C IN CANCER SIGNALING AND THERAPY, P55, DOI 10.1007/978-1-60761-543-9_4; Miettinen TP, 2017, TRENDS CELL BIOL, V27, P393, DOI 10.1016/j.tcb.2017.02.006; Minguet S, 2008, EUR J IMMUNOL, V38, P2475, DOI 10.1002/eji.200738094; Morbach H, 2016, J ALLERGY CLIN IMMUN, V137, P889, DOI 10.1016/j.jaci.2015.08.040; Otero DC, 2001, J BIOL CHEM, V276, P1474, DOI 10.1074/jbc.M003918200; Otipoby KL, 2015, P NATL ACAD SCI USA, V112, P12145, DOI 10.1073/pnas.1516428112; Papa S, 2019, ONCOGENE, V38, P2223, DOI 10.1038/s41388-018-0582-8; Petrove P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40697-1; Price MJ, 2018, CELL REP, V23, P3152, DOI 10.1016/j.celrep.2018.05.053; Ricci JE, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00556; Saarikangas J, 2015, DEV CELL, V33, P644, DOI 10.1016/j.devcel.2015.04.014; Saarikangas J, 2011, J CELL SCI, V124, P1245, DOI 10.1242/jcs.082610; Safari F, 2012, MEMBRANES, V2, DOI 10.3390/membranes2010091; Sarapulov AV, 2019, MISSING IN METASTASI, DOI [10.1101/782276v2, DOI 10.1101/782276V2]; Schnyder T, 2011, IMMUNITY, V34, P905, DOI 10.1016/j.immuni.2011.06.001; Schweighoffer E, 2017, J EXP MED, V214, P1269, DOI 10.1084/jem.20161117; Shaheen S, 2017, ELIFE, V6, DOI 10.7554/eLife.23060; Sindhava VJ, 2017, J CLIN INVEST, V127, P1651, DOI 10.1172/JCI89931; Snapper CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00598; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; Suthers AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00775; Treanor B, 2010, IMMUNITY, V32, P187, DOI 10.1016/j.immuni.2009.12.005; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Yu D, 2012, ONCOGENE, V31, P3561, DOI 10.1038/onc.2011.509; Yu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020845; Zhan T, 2016, LEUKEMIA, V30, P1327, DOI 10.1038/leu.2016.39; Zhao P, 2019, BBA-GEN SUBJECTS, V1863, P502, DOI 10.1016/j.bbagen.2018.12.002	65	1	1	3	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2020	11								599	10.3389/fimmu.2020.00599	http://dx.doi.org/10.3389/fimmu.2020.00599			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LK0GX	32373113	Green Published, gold			2022-12-18	WOS:000530537900001
J	del Amo, PC; Debebe, B; Razavi-Mohseni, M; Nakaoka, S; Worth, A; Wallace, D; Beverley, P; Macallan, D; Asquith, B				del Amo, Pedro Costa; Debebe, Bisrat; Razavi-Mohseni, Milad; Nakaoka, Shinji; Worth, Andrew; Wallace, Diana; Beverley, Peter; Macallan, Derek; Asquith, Becca			The Rules of Human T Cell Fate in vivo	FRONTIERS IN IMMUNOLOGY			English	Article						lymphocyte; fate; decision; proliferation; lifespan; mathematical model; labeling; half-life	LIFE-SPAN; RAPID TURNOVER; PROLIFERATION; DEATH; LYMPHOCYTES; APOPTOSIS; DYNAMICS; KINETICS; DIVISION; MODEL	The processes governing lymphocyte fate (division, differentiation, and death), are typically assumed to be independent of cell age. This assumption has been challenged by a series of elegant studies which clearly show that, for murine cells in vitro, lymphocyte fate is age-dependent and that younger cells (i.e., cells which have recently divided) are less likely to divide or die. Here we investigate whether the same rules determine human T cell fate in vivo. We combined data from in vivo stable isotope labeling in healthy humans with stochastic, agent-based mathematical modeling. We show firstly that the choice of model paradigm has a large impact on parameter estimates obtained using stable isotope labeling i.e., different models fitted to the same data can yield very different estimates of T cell lifespan. Secondly, we found no evidence in humans in vivo to support the model in which younger T cells are less likely to divide or die. This age-dependent model never provided the best description of isotope labeling; this was true for naive and memory, CD4(+) and CD8(+) T cells. Furthermore, this age-dependent model also failed to predict an independent data set in which the link between division and death was explored using Annexin V and deuterated glucose. In contrast, the age-independent model provided the best description of both naive and memory T cell dynamics and was also able to predict the independent dataset.	[del Amo, Pedro Costa; Debebe, Bisrat; Asquith, Becca] Imperial Coll London, Dept Infect Dis, London, England; [Razavi-Mohseni, Milad] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Nakaoka, Shinji] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi, Saitama, Japan; [Nakaoka, Shinji] Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido, Japan; [Worth, Andrew] Univ Oxford, Jenner Inst Labs, Oxford, England; [Wallace, Diana] UCL, Div Infect & Immun, London, England; [Beverley, Peter] Imperial Coll London, TB Res Ctr, Natl Heart & Lung Res Inst, London, England; [Macallan, Derek] Univ London, St Georges Hosp, Inst Infect & Immun, London, England	Imperial College London; Johns Hopkins University; Japan Science & Technology Agency (JST); Hokkaido University; University of Oxford; University of London; University College London; Imperial College London; St Georges University London; University of London	Asquith, B (corresponding author), Imperial Coll London, Dept Infect Dis, London, England.	b.asquith@imperial.ac.uk		Debebe, Bisrat Johnathan/0000-0002-6551-5641; Asquith, Becca/0000-0002-5911-3160	European Union Seventh Framework Programme (FP7/2007-2013) [317040]; Medical Research Council UK [103865, J007439, G1001052]; Leukemia and Lymphoma Research [15012]; JST PRESTO program [JPMJPR16E9]; Japan Society for the Promotion of Science (JSPS) [25871132, 16K052565]; MRC [G1001052, MR/J007439/1] Funding Source: UKRI	European Union Seventh Framework Programme (FP7/2007-2013); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Leukemia and Lymphoma Research; JST PRESTO program; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 317040 (QuanTI). BA was a Wellcome Trust Investigator (103865) and was funded by the Medical Research Council UK (J007439 and G1001052), the European Union Seventh Framework Programme (FP7/20072013) under grant agreement 317040 (QuanTI) and Leukemia and Lymphoma Research (15012). DM received funding from the Medical Research Council UK (G1001052). SN received funding from the JST PRESTO program (JPMJPR16E9) and the Japan Society for the Promotion of Science (JSPS) Grantsin-Aid 25871132 and 16K052565. The Imperial College High Performance Computing Service was used for this work.	Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2; Asquith B, 2007, P NATL ACAD SCI USA, V104, P8035, DOI 10.1073/pnas.0608832104; Asquith B, 2017, NAT IMMUNOL, V18, P12; Asquith B, 2011, MATHEMATICAL MODELS AND IMMUNE CELL BIOLOGY, P141, DOI 10.1007/978-1-4419-7725-0_7; Baker CTH, 2005, J COMPUT APPL MATH, V184, P50, DOI 10.1016/j.cam.2005.02.003; Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27; Barsov EV, 2011, IMMUNOTHERAPY-UK, V3, P407, DOI 10.2217/IMT.10.107; Boelen L, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao2892; Bonhoeffer S, 2000, J IMMUNOL, V164, P5049, DOI 10.4049/jimmunol.164.10.5049; Burnham K.P., 2002, MODEL SELECTION MULT, V2nd Edn, DOI 10.1007/b97636; Busch R, 2007, NAT PROTOC, V2, P3045, DOI 10.1038/nprot.2007.420; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; COTTER TG, 1995, TRENDS BIOTECHNOL, V13, P150, DOI 10.1016/S0167-7799(00)88926-X; De Boer RJ, 2003, J IMMUNOL, V170, P2479, DOI 10.4049/jimmunol.170.5.2479; De Boer RJ, 2013, J THEOR BIOL, V327, P45, DOI 10.1016/j.jtbi.2012.12.025; Deenick EK, 2003, J IMMUNOL, V170, P4963, DOI 10.4049/jimmunol.170.10.4963; del Amo PC, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005523; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; Dowling MR, 2009, IMMUNOL CELL BIOL, V87, P445, DOI 10.1038/icb.2009.11; Dowling MR, 2009, TRENDS IMMUNOL, V30, P295, DOI 10.1016/j.it.2009.04.006; Dowling MR, 2005, J R SOC INTERFACE, V2, P517, DOI 10.1098/rsif.2005.0069; Duffy KR, 2012, SCIENCE, V335, P338, DOI 10.1126/science.1213230; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Flossdorf M, 2015, NAT IMMUNOL, V16, P891, DOI 10.1038/ni.3235; Gett AV, 2000, NAT IMMUNOL, V1, P239, DOI 10.1038/79782; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Gossel G, 2017, ELIFE, V6, DOI 10.7554/eLife.23013; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hasper HJ, 2000, CYTOMETRY, V40, P167, DOI 10.1002/(SICI)1097-0320(20000601)40:2<167::AID-CYTO11>3.3.CO;2-T; Hawkins ED, 2007, P NATL ACAD SCI USA, V104, P5032, DOI 10.1073/pnas.0700026104; Heinzel S, 2017, NAT IMMUNOL, V18, P96, DOI 10.1038/ni.3598; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Lahoz-Beneytez J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00474; Lahoz-Beneytez J, 2016, BLOOD, V127, P3431, DOI 10.1182/blood-2016-03-700336; Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Macallan DC, 2009, NAT PROTOC, V4, P1313, DOI 10.1038/nprot.2009.117; Marchingo JM, 2014, SCIENCE, V346, P1123, DOI 10.1126/science.1260044; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; RAMALHO AT, 1995, MUTAT RES-FUND MOL M, V331, P47, DOI 10.1016/0027-5107(95)00049-O; Regoes RR, 2007, P NATL ACAD SCI USA, V104, P1599, DOI 10.1073/pnas.0508830104; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Segawa K, 2011, P NATL ACAD SCI USA, V108, P19246, DOI 10.1073/pnas.1114799108; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Soetaert K, R PACKAGE FME INVERS; Tanchot C, 1998, IMMUNOL TODAY, V19, P575, DOI 10.1016/S0167-5699(98)01344-9; van Gent R, 2008, CANCER RES, V68, P10137, DOI 10.1158/0008-5472.CAN-08-2325; Vibert J, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005417; Vrisekoop N, 2008, P NATL ACAD SCI USA, V105, P6115, DOI 10.1073/pnas.0709713105; Wellard C, 2011, MATHEMATICAL MODELS AND IMMUNE CELL BIOLOGY, P107, DOI 10.1007/978-1-4419-7725-0_5; Westera L, 2013, BLOOD, V122, P2205, DOI 10.1182/blood-2013-03-488411; Yates A, 2007, PLOS MED, V4, P948, DOI 10.1371/journal.pmed.0040177; Younes SA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001171; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01	56	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2020	11								573	10.3389/fimmu.2020.00573	http://dx.doi.org/10.3389/fimmu.2020.00573			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH8LJ	32322253	gold, Green Published, Green Accepted			2022-12-18	WOS:000529033900001
J	Negrini, R; Villanacci, V; Poiesi, C; Savio, A				Negrini, Riccardo; Villanacci, Vincenzo; Poiesi, Claudio; Savio, Antonella			Anti-Glycan Autoantibodies Induced by Helicobacter pylori as a Potential Risk Factor for Myocardial Infarction	FRONTIERS IN IMMUNOLOGY			English	Article						myocardial infarction; Helicobacter pylori; molecular mimicry; autoimmunity; histo-blood group antigens; thrombophilia	BLOOD-GROUP ANTIGENS; MOLECULAR MIMICRY; LEWIS-X; MONOCLONAL-ANTIBODIES; HUMAN PLASMA; O ANTIGEN; GROUP-B; GROUP-A; LIPOPOLYSACCHARIDE; INFECTION	A number of epidemiological studies have evaluated the potential association between H. pylori and cardiovascular disease, but with contrasting results. We have previously shown that Helicobacter pylori infection is able to induce in mice and humans autoantibodies cross-reacting with histo-blood group Lewis antigens, expressed in different organs and in plasma glycoproteins and glycolipids. The aim of this study was to assess whether immunization of animals with H. pylori might induce myocardial histopathological changes. We have retrospectively examined, in detail, the histology of archived organs from mice and rabbits immunized with H. pylori in our previous studies. Human sera and cross-reacting monoclonal antibodies were also tested against bacterial preparations and tissue sections. Areas of myocardial necrosis, associated with coronary thrombotic occlusion, were found in 5 of 20 mice and 2 of 5 rabbits previously immunized with suspensions of H. pylori. No similar lesions were found in control animals, suggesting a causal link with H. pylori immunization. The animals bearing myocardial lesions had not been infected but only immunized months earlier with parenteral injections of dead H. pylori cells. This strongly suggests that immunization, by itself, might play a causative role. We propose that the cross-reactive autoimmune response induced by H. pylori could promote thrombotic occlusion through direct endothelial damage or by perturbing the coagulation process.	[Negrini, Riccardo] Presidio Gardone VT ASST Spedali Civili, Dept Lab Med, Brescia, Italy; [Villanacci, Vincenzo] ASST Spedali Civili, Inst Pathol, Brescia, Italy; [Poiesi, Claudio] ASST Spedali Civili, Inst Microbiol & Virol, Brescia, Italy; [Savio, Antonella] Royal Marsden NHS Fdn Trust, Histopathol & Cytol Dept, London, England	Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; Royal Marsden NHS Foundation Trust	Negrini, R (corresponding author), Presidio Gardone VT ASST Spedali Civili, Dept Lab Med, Brescia, Italy.	riccardonegrini54@gmail.com			Foundation Le Rondini Citta' Di Lumezzane Onlus	Foundation Le Rondini Citta' Di Lumezzane Onlus	We would like to thank Dr. R. John Dobbs MD and Dr. Sylvia Dobbs MD (Institute of Pharmaceutical Science, King's College London) for their useful suggestions and critically reading the manuscript and Mrs. Giuliana Bresciani for technical support with the immunohistochemistry tests. We thank the Foundation Le Rondini Citta' Di Lumezzane Onlus for financial funding of the open access publication fee.	Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; Branch DR, 2015, TRANSFUSION, V55, pS74, DOI 10.1111/trf.13087; Campbell LA, 2004, NAT REV MICROBIOL, V2, P23, DOI 10.1038/nrmicro796; Canis K, 2010, J THROMB HAEMOST, V8, P137, DOI 10.1111/j.1538-7836.2009.03665.x; Chey WD, 2017, AM J GASTROENTEROL, V112, P212, DOI 10.1038/ajg.2016.563; Chmiela M, 2017, WORLD J GASTROENTERO, V23, P3964, DOI 10.3748/wjg.v23.i22.3964; Chmiela M, 2015, WORLD J CARDIOL, V7, P187, DOI 10.4330/wjc.v7.i4.187; Cho W, 2008, ANAL CHEM, V80, P5286, DOI 10.1021/ac8008675; Cho W, 2010, J PROTEOME RES, V9, P5960, DOI 10.1021/pr100747p; Croce MV, 2007, PATHOL ONCOL RES, V13, P130, DOI 10.1007/BF02893488; Daniels MC, 2013, SAVING THE SOUL OF GEORGIA: DONALD L. HOLLOWELL AND THE STRUGGLE FOR CIVIL RIGHTS, P11; de Groot PG, 2012, BLOOD, V120, P266, DOI 10.1182/blood-2012-03-378646; Durbin SV, 2018, ACS OMEGA, V3, P16882, DOI 10.1021/acsomega.8b02238; Groot HE, 2020, ARTERIOSCL THROM VAS, V40, P830, DOI 10.1161/ATVBAHA.119.313658; Heneghan MA, 2000, INFECT IMMUN, V68, P937, DOI 10.1128/IAI.68.2.937-941.2000; Heneghan MA, 2001, INFECT IMMUN, V69, P4774, DOI 10.1128/IAI.69.8.4774-4781.2001; Henry SM, 1999, IMMUNOHEMATOLOGY, V12, P51; HIRONAKA T, 1992, J BIOL CHEM, V267, P8012; Jia YJ, 2017, J MED VIROL, V89, P2196, DOI 10.1002/jmv.24858; Klaamas K, 2002, IMMUNOL INVEST, V31, P191, DOI 10.1081/IMM-120016240; Lee M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193646; Li H, 2018, TOXINS, V10, DOI 10.3390/toxins10090364; Lin WL, 2013, ARTERIOSCL THROM VAS, V33, P2366, DOI 10.1161/ATVBAHA.113.301221; Liu J, 2015, HELICOBACTER, V20, P176, DOI 10.1111/hel.12188; Magalhaes A, 2009, GLYCOBIOLOGY, V19, P1525, DOI 10.1093/glycob/cwp131; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MATSUI T, 1993, BLOOD, V82, P663; Matsuura E, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-47; MOLLICONE R, 1985, LAB INVEST, V53, P219; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Monteiro MA, 1998, J BIOL CHEM, V273, P11533, DOI 10.1074/jbc.273.19.11533; Monteiro MA, 2000, GLYCOBIOLOGY, V10, P701, DOI 10.1093/glycob/10.7.701; NEGRINI R, 1992, SCAND J GASTROENTERO, V27, P599, DOI 10.3109/00365529209000125; Negrini R, 1996, GASTROENTEROLOGY, V111, P655, DOI 10.1053/gast.1996.v111.pm8780570; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; NEGRINI R, 1989, GASTROENTEROLOGY, V96, P414, DOI 10.1016/0016-5085(89)91565-5; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; Nystrom K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002188; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Razuka-Ebela D, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12520; Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sarici SU, 2015, HELICOBACTER, V20, P418, DOI 10.1111/hel.12226; Schenkel-Brunner H, 2013, HUMAN BLOOD GROUPS C, P47; SimoonsSmit IM, 1996, J CLIN MICROBIOL, V34, P2196, DOI 10.1128/JCM.34.9.2196-2200.1996; SODETZ JM, 1979, J BIOL CHEM, V254, P754; Stanley P, 2017, ESSENTIALS GLYCOBIOL, P161, DOI DOI 10.1101/GLYCOBIOLOGY.3E.014; Wang G, 1999, MICROBIOL-SGM, V145, P3245, DOI 10.1099/00221287-145-11-3245; Wang JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.019021; Wolf D, 2019, CIRC RES, V124, P315, DOI 10.1161/CIRCRESAHA.118.313591; Yu XJ, 2017, EXP THER MED, V13, P787, DOI 10.3892/etm.2017.4028	53	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2020	11								597	10.3389/fimmu.2020.00597	http://dx.doi.org/10.3389/fimmu.2020.00597			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LI5EY	32322255	Green Published, gold			2022-12-18	WOS:000529510200001
J	Aniweh, Y; Nyarko, PB; Charles-Chess, E; Ansah, F; Osier, FHA; Quansah, E; Thiam, LG; Kamuyu, G; Marsh, K; Conway, DJ; Tetteh, KKA; Awandare, GA				Aniweh, Yaw; Nyarko, Prince B.; Charles-Chess, Essel; Ansah, Felix; Osier, Faith H. A.; Quansah, Evelyn; Thiam, Laty Gaye; Kamuyu, Gathoni; Marsh, Kevin; Conway, David J.; Tetteh, Kevin K. A.; Awandare, Gordon A.			Plasmodium falciparum Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria	FRONTIERS IN IMMUNOLOGY			English	Article						Malaria; armadillo; invasion; merozoites; antigen; antibodies; recombinant protein	BINDING-PROTEIN; ERYTHROCYTE INVASION; CLINICAL MALARIA; RECEPTOR; HOMOLOG; ANTIGENS; TRANSCRIPTOME; VIRULENCE; VIVAX	Understanding the functional role of proteins expressed by Plasmodium falciparum is an important step toward unlocking potential targets for the development of therapeutic or diagnostic interventions. The armadillo (ARM) repeat protein superfamily is associated with varied functions across the eukaryotes. Therefore, it is important to understand the role of members of this protein family in Plasmodium biology. The Plasmodium falciparum armadillo repeats only (PfARO; Pf3D7_0414900) and P. falciparum merozoite organizing proteins (PfMOP; Pf3D7_0917000) are armadillo-repeat containing proteins previously characterized in P. falciparum. Here, we describe the characterization of another ARM repeat-containing protein in P. falciparum, which we have named the P. falciparum Merozoites-Associated Armadillo repeats protein (PfMAAP). Antibodies raised to three different synthetic peptides of PfMAAP show apical staining of free merozoites and those within the mature infected schizont. We also demonstrate that the antibodies raised to the PfMAAP peptides inhibited invasion of erythrocytes by merozoites from different parasite isolates. In addition, naturally acquired human antibodies to the N- and C- termini of PfMAAP are associated with a reduced risk of malaria in a prospective cohort analysis.	[Aniweh, Yaw; Nyarko, Prince B.; Charles-Chess, Essel; Ansah, Felix; Quansah, Evelyn; Thiam, Laty Gaye; Awandare, Gordon A.] Univ Ghana, WACCBIP, Accra, Ghana; [Nyarko, Prince B.; Charles-Chess, Essel; Ansah, Felix; Quansah, Evelyn; Thiam, Laty Gaye; Awandare, Gordon A.] Univ Ghana, Dept Biochem Cell & Mol Biol, Coll Basic & Appl Sci, Accra, Ghana; [Osier, Faith H. A.; Marsh, Kevin] Ctr Geog Med Res Coast, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Osier, Faith H. A.] Heidelberg Univ Hosp, Ctr Infect Dis, Parasitol, Heidelberg, Germany; [Osier, Faith H. A.] Pwani Univ, Dept Biochem, Kilifi, Kenya; [Osier, Faith H. A.; Marsh, Kevin] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England; [Kamuyu, Gathoni] UCL, Div Med, Dept Resp Med, London, England; [Marsh, Kevin] Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden; [Conway, David J.; Tetteh, Kevin K. A.] London Sch Trop Med & Hyg, Dept Infect Biol, London, England	University of Ghana; University of Ghana; Ruprecht Karls University Heidelberg; Pwani University; University of Oxford; University of London; University College London; Karolinska Institutet; University of London; London School of Hygiene & Tropical Medicine	Aniweh, Y; Awandare, GA (corresponding author), Univ Ghana, WACCBIP, Accra, Ghana.; Awandare, GA (corresponding author), Univ Ghana, Dept Biochem Cell & Mol Biol, Coll Basic & Appl Sci, Accra, Ghana.; Tetteh, KKA (corresponding author), London Sch Trop Med & Hyg, Dept Infect Biol, London, England.	yaniweh@ug.edu.gh; Kevin.Tetteh@lshtm.ac.uk; gawandare@ug.edu.gh	Tetteh, Kevin/GYQ-9704-2022; Nyarko, Prince/L-5382-2018	Tetteh, Kevin/0000-0003-2733-0037; Awandare, Gordon/0000-0002-8793-3641; Nyarko, Prince/0000-0002-8236-1111; Conway, David/0000-0002-8711-3037; Thiam, Laty Gaye/0000-0001-7086-4726; Aniweh, Yaw/0000-0002-8415-2727	Wellcome/African Academy of Sciences of DELTAS Africa; World Bank African Centers of Excellence [ACE02-WACCBIP, DEL-15-007]; Q7 the National Institute for Health Research [16/136/33]; WACCBIP DELTAS Masters fellowship - WACCBIP DELTAS Postdoctoral fellowship; WACCBIP ACE; Tackling Infections to Benefit Africa (TIBA) partnership under a National Institute of Health Research Global Health Research Unit	Wellcome/African Academy of Sciences of DELTAS Africa; World Bank African Centers of Excellence; Q7 the National Institute for Health Research; WACCBIP DELTAS Masters fellowship - WACCBIP DELTAS Postdoctoral fellowship; WACCBIP ACE; Tackling Infections to Benefit Africa (TIBA) partnership under a National Institute of Health Research Global Health Research Unit	This work was supported with funds from a Wellcome/African Academy of Sciences of DELTAS Africa, World Bank African Centers of Excellence (ACE02-WACCBIP: Awandare) grant (DEL-15-007: Awandare) and a Q7 the National Institute for Health Research, using Official Development Assistance (ODA) funding (16/136/33: Woolhouse). The funders had no role in the conception, study design, data collection and analysis, decision to publish or preparation of the manuscript. YA was supported by a WACCBIP DELTAS Masters fellowship, while EQ was supported by WACCBIP DELTAS Postdoctoral fellowship to YA. PN, EC-C, and LT are supported by WACCBIP ACE PhD and Master's fellowships. FA was supported by the Tackling Infections to Benefit Africa (TIBA) partnership under a National Institute of Health Research Global Health Research Unit grant to University of Edinburgh.	Absalon S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11449; Amambua-Ngwa A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002992; Aniweh Y, 2016, MOL MICROBIOL, V102, P386, DOI 10.1111/mmi.13468; Awandare GA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24218-0; Baker J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022593; Baum J, 2009, INT J PARASITOL, V39, P371, DOI 10.1016/j.ijpara.2008.10.006; Beck JR, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003162; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Cabrera A, 2012, TRAFFIC, V13, P1335, DOI 10.1111/j.1600-0854.2012.01394.x; Cao J, 2009, PARASITOL INT, V58, P29, DOI 10.1016/j.parint.2008.09.005; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Collins CR, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000273; Cowman AF, 2017, CELL HOST MICROBE, V22, P232, DOI 10.1016/j.chom.2017.07.003; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Gruber M, 2005, NUCLEIC ACIDS RES, V33, pW239, DOI 10.1093/nar/gki405; Gunalan K, 2011, INFECT IMMUN, V79, P3421, DOI 10.1128/IAI.00201-11; Heiber A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003546; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Kana IH, 2019, J INFECT DIS, V220, P275, DOI 10.1093/infdis/jiz088; Kana IH, 2018, J INFECT DIS, V218, P956, DOI 10.1093/infdis/jiy258; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Llinas M, 2006, NUCLEIC ACIDS RES, V34, P1166, DOI 10.1093/nar/gkj517; Lobo CA, 2003, BLOOD, V101, P4628, DOI 10.1182/blood-2002-10-3076; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Mayer DCG, 2002, J EXP MED, V196, P1523, DOI 10.1084/jem.20020750; Mbengue B, 2019, CLIN EXP IMMUNOL, V196, P86, DOI 10.1111/cei.13254; Meerstein-Kessel L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18840-7; Miao J, 2011, NAT PROTOC, V6, P140, DOI 10.1038/nprot.2010.185; Michon P, 2002, MOL BIOL EVOL, V19, P1128, DOI 10.1093/oxfordjournals.molbev.a004171; Mitra P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148446; Mueller C, 2013, CELL HOST MICROBE, V13, P289, DOI 10.1016/j.chom.2013.02.001; Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006; Nakamura Y, 2017, GENESIS, V55, DOI 10.1002/dvg.22991; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Persson KEM, 2013, J IMMUNOL, V191, P785, DOI 10.4049/jimmunol.1300444; Peterson DS, 2000, MOL BIOCHEM PARASIT, V105, P105, DOI 10.1016/S0166-6851(99)00173-5; Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030; Proellocks NI, 2010, TRENDS PARASITOL, V26, P297, DOI 10.1016/j.pt.2010.02.012; Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571; Rayner JC, 2000, P NATL ACAD SCI USA, V97, P9648, DOI 10.1073/pnas.160469097; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Seck MC, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-3114-2; Singh S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005410; Tetteh KKA, 2013, INFECT IMMUN, V81, P3835, DOI 10.1128/IAI.00301-13; Tewari R, 2010, TRENDS CELL BIOL, V20, P470, DOI 10.1016/j.tcb.2010.05.003; Tham WH, 2009, INFECT IMMUN, V77, P2427, DOI 10.1128/IAI.00048-09; Wright GJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003943; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zhang M, 2018, SCIENCE, V360, P506, DOI 10.1126/science.aap7847; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zimmermann L, 2018, J MOL BIOL, V430, P2237, DOI 10.1016/j.jmb.2017.12.007	51	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2020	11								505	10.3389/fimmu.2020.00505	http://dx.doi.org/10.3389/fimmu.2020.00505			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH8LB	32318061	Green Published, Green Accepted, gold			2022-12-18	WOS:000529033100001
J	Duhaze, J; Hassler, S; Bachelet, D; Gleizes, A; Hacein-Bey-Abina, S; Allez, M; Deisenhammer, F; Fogdell-Hahn, A; Mariette, X; Pallardy, M; Broet, P				Duhaze, Julianne; Hassler, Signe; Bachelet, Delphine; Gleizes, Aude; Hacein-Bey-Abina, Salima; Allez, Matthieu; Deisenhammer, Florian; Fogdell-Hahn, Anna; Mariette, Xavier; Pallardy, Marc; Broet, Philippe		ABIRISK Consortium	A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort	FRONTIERS IN IMMUNOLOGY			English	Article						immunogenicity; biotherapy; machine learning; survival random forest; prediction		Predicting immunogenicity for biotherapies using patient and drug-related factors represents nowadays a challenging issue. With the growing ability to collect massive amount of data, machine learning algorithms can provide efficient predictive tools. From the bio-clinical data collected in the multi-cohort of autoimmune diseases treated with biotherapies from the ABIRISK consortium, we evaluated the predictive power of a custom-built random survival forest for predicting the occurrence of anti-drug antibodies. This procedure takes into account the existence of a population composed of immune-reactive and immune-tolerant subjects as well as the existence of a tiny expected proportion of relevant predictive variables. The practical application to the ABIRISK cohort shows that this approach provides a good predictive accuracy that outperforms the classical survival random forest procedure. Moreover, the individual predicted probabilities allow to separate high and low risk group of patients. To our best knowledge, this is the first study to evaluate the use of machine learning procedures to predict biotherapy immunogenicity based on bioclinical information. It seems that such approach may have potential to provide useful information for the clinical practice of stratifying patients before receiving a biotherapy.	[Duhaze, Julianne; Broet, Philippe] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Duhaze, Julianne; Hassler, Signe; Bachelet, Delphine; Broet, Philippe] Paris Saclay Univ, Paul Brousse Hosp, Fac Med, INSERM,CESP,UMR 1018, Villejuif, France; [Hassler, Signe] Sorbonne Univ, Immunol Immunopathol Immunotherapy i3, INSERM, UMR 959, Paris, France; [Hassler, Signe] Hop La Pitie Salpetriere, AP HP, Biotherapy CIC BTi, Paris, France; [Bachelet, Delphine] Hop Xavier Bichat, AP HP Nord, Dept Biostat Epidemiol & Clin Res, INSERM,CIC EC 1425, Paris, France; [Gleizes, Aude; Hacein-Bey-Abina, Salima] Paris Saclay Univ, Le Kremlin Bicetre Hosp, AP HP, Clin Immunol Lab, Le Kremlin Bicetre, France; [Gleizes, Aude; Pallardy, Marc] Paris Saclay Univ, Fac Pharm, INSERM, UMR 996, Chatenay Malabry, France; [Hacein-Bey-Abina, Salima] Paris Descartes Sorbonne Cite Univ, Fac Pharm, CNRS, UTCBS,UMR 8258, Paris, France; [Allez, Matthieu] Paris Diderot Univ, St Louis Hosp, AP HP, Dept Gastroenterol, Paris, France; [Deisenhammer, Florian] Innsbruck Med, Innsbruck, Austria; [Fogdell-Hahn, Anna] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Mariette, Xavier] Univ Paris Saclay, AP HP, Ctr Immunol Viral Infect & Autoimmune Dis, INSERM,UMR 1184, Paris, France	Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Duhaze, J; Broet, P (corresponding author), Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada.; Duhaze, J; Broet, P (corresponding author), Paris Saclay Univ, Paul Brousse Hosp, Fac Med, INSERM,CESP,UMR 1018, Villejuif, France.	julianne.duhaze@inserm.fr; marc.pallardy@inserm.fr; philippe.broet@inserm.fr	Bachelet, Delphine/AAD-8385-2022	Fogdell-Hahn, Anna/0000-0002-0311-9184; Allez, Matthieu/0000-0002-2012-7522	University Paris-Saclay (France)	University Paris-Saclay (France)	The research of the JD was supported by a grant from University Paris-Saclay (France). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], RECURSIVE PARTITIONI; [Anonymous], BIOTECHNOLOGY; [Anonymous], ANT IMM PRED AN CLIN; Bou-Hamad I, 2011, STAT SURV, V5, P44, DOI 10.1214/09-SS047; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Broet P, 2001, BIOMETRICS, V57, P844, DOI 10.1111/j.0006-341X.2001.00844.x; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Fleming T. R., 1991, COUNTING PROCESSES S; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Hastie T., 2017, ELEMENTS STAT LEARNI, P219; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Maller RA, 1995, BIOMETRICS, V51, P1197, DOI 10.2307/2533253; Panov P, 2007, LECT NOTES COMPUT SC, V4723, P118; Pineda C, 2016, BIODRUGS, V30, P195, DOI 10.1007/s40259-016-0174-5; Tsodikov AD, 2003, J AM STAT ASSOC, V98, P1063, DOI 10.1198/01622145030000001007; Yakovlev A. Yu., 1996, STOCHASTIC MODELS TU	16	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2020	11								608	10.3389/fimmu.2020.00608	http://dx.doi.org/10.3389/fimmu.2020.00608			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH5WC	32318076	Green Published, gold			2022-12-18	WOS:000528854300001
J	Ignatius, A; Sobacchi, C				Ignatius, Anita; Sobacchi, Cristina			Editorial: Innate Immunity in the Context of Osteoimmunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						osteoimmunology; innate immunity; fracture healing; bone regeneration; chemokines	BONE; CELLS; CD4(+)		[Ignatius, Anita] Ulm Univ, Inst Orthoped Res & Biomech, Med Ctr, Ulm, Germany; [Sobacchi, Cristina] CNR, Milan Unit, IRGB, Milan, Italy; [Sobacchi, Cristina] Humanitas Clin & Res Ctr IRCCS, Rozzano, Italy	Ulm University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR)	Sobacchi, C (corresponding author), CNR, Milan Unit, IRGB, Milan, Italy.; Sobacchi, C (corresponding author), Humanitas Clin & Res Ctr IRCCS, Rozzano, Italy.	cristina.sobacchi@humanitasresearch.it	Ignatius, Anita/M-6012-2013; SOBACCHI, CRISTINA/J-9345-2018	Ignatius, Anita/0000-0002-4782-1979; SOBACCHI, CRISTINA/0000-0002-2684-7184	Fondazione Beppe e Nuccy Angiolini	Fondazione Beppe e Nuccy Angiolini	The financial support of Fondazione Beppe e Nuccy Angiolini to this publication is gratefully acknowledged.	Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196; Ginaldi L, 2016, CURR MED CHEM, V23, P3754, DOI 10.2174/0929867323666160907162546; Ibanez L, 2016, J BONE MINER RES, V31, P1899, DOI 10.1002/jbmr.2868; Kroner J, 2017, J BONE MINER RES, V32, P2431, DOI 10.1002/jbmr.3234; Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood-2009-11-255026; Mercier FE, 2012, NAT REV IMMUNOL, V12, P49, DOI 10.1038/nri3132; Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016; Pettit AR, 2008, BONE, V43, P976, DOI 10.1016/j.bone.2008.08.128; Wakkach A, 2008, BLOOD, V112, P5074, DOI 10.1182/blood-2008-01-132787; Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213	10	1	1	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 7	2020	11								603	10.3389/fimmu.2020.00603	http://dx.doi.org/10.3389/fimmu.2020.00603			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH5WB	32318075	gold, Green Published			2022-12-18	WOS:000528854200001
J	Borras, C; Delaunay, K; Slaoui, Y; Abache, T; Jorieux, S; Naud, MC; El Sanharawi, M; Gelize, E; Lassiaz, P; An, N; Kowalczuk, L; Ayassami, C; Moulin, A; Behar-Cohen, F; Mascarelli, F; Dinet, V				Borras, Celine; Delaunay, Kimberley; Slaoui, Yousri; Abache, Toufik; Jorieux, Sylvie; Naud, Marie-Christine; El Sanharawi, Mohamed; Gelize, Emmanuelle; Lassiaz, Patricia; An, Na; Kowalczuk, Laura; Ayassami, Cedric; Moulin, Alexandre; Behar-Cohen, Francine; Mascarelli, Frederic; Dinet, Virginia			Mechanisms of FH Protection Against Neovascular AMD	FRONTIERS IN IMMUNOLOGY			English	Article						AMD; complement factor H; FH Y402H polymorphism; TSP-1; therapeutic target	COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; MEMBRANE ATTACK COMPLEX; MACULAR DEGENERATION; BRUCHS MEMBRANE; GEOGRAPHIC ATROPHY; HEPARAN-SULFATE; MOUSE MODEL; IDENTIFICATION; LOCALIZATION	A common allele (402H) of the complement factor H (FH) gene is the major risk factor for age-related macular degeneration (AMD), the leading cause of blindness in the elderly population. Development and progression of AMD involves vascular and inflammatory components partly by deregulation of the alternative pathway of the complement system (AP). The loss of central vision results from atrophy and/or from abnormal neovascularization arising from the choroid. The functional link between FH, the main inhibitor of AP, and choroidal neovascularization (CNV) in AMD remains unclear. In a murine model of CNV used as a model for neovascular AMD (nAMD), intraocular human recombinant FH (recFH) reduced CNV as efficiently as currently used anti-VEGF (vascular endothelial growth factor) antibody, decreasing deposition of C3 cleavage fragments, membrane attack complex (MAC), and microglia/macrophage recruitment markers in the CNV lesion site. In sharp contrast, recFH carrying the H402 risk variant had no effect on CNV indicating a causal link to disease etiology. Only the recFH NTal region (recFH1-7), containing the CCPs1-4 C3-convertase inhibition domains and the CCP7 binding domain, exerted all differential biological effects. The CTal region (recFH7-20) containing the CCP7 and CCPs19-20 binding domains was antiangiogenic but did not reduce the microglia/macrophage recruitment. The antiangiogenic effect of both recFH1-20 and recFH-CCP7-20 resulted from thrombospondin-1 (TSP-1) upregulation independently of the C3 cleavage fragments generation. This study provides insight on the mechanistic role of FH in nAMD and invites to reconsider its therapeutic potential.	[Borras, Celine; Delaunay, Kimberley; Naud, Marie-Christine; El Sanharawi, Mohamed; Gelize, Emmanuelle; Lassiaz, Patricia; An, Na; Ayassami, Cedric; Mascarelli, Frederic; Dinet, Virginia] Univ Paris, Sorbonne Univ, Inserm UMR1138, Ctr Rech Cordeliers, Paris, France; [Borras, Celine] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France; [Delaunay, Kimberley; Naud, Marie-Christine; El Sanharawi, Mohamed; Gelize, Emmanuelle; Lassiaz, Patricia; An, Na; Kowalczuk, Laura; Ayassami, Cedric; Moulin, Alexandre; Mascarelli, Frederic; Dinet, Virginia] INSERM, U1138, Paris, France; [Delaunay, Kimberley; Naud, Marie-Christine; El Sanharawi, Mohamed; Gelize, Emmanuelle; Lassiaz, Patricia; An, Na; Mascarelli, Frederic; Dinet, Virginia] Univ Pierre & Marie Curie Paris6, UMRS1138, Paris, France; [Slaoui, Yousri] CNRS, Lab Math & Applicat UMR 7348, Poitiers, France; [Abache, Toufik; Jorieux, Sylvie] Lab Francais Fractionnement & Biotechnol LFB, Lille, France; [Kowalczuk, Laura; Moulin, Alexandre] Lausanne Univ, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland; [Behar-Cohen, Francine] Hop Cochin, AP HP, Ophtalmopole, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; University of Lausanne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Behar-Cohen, F (corresponding author), Hop Cochin, AP HP, Ophtalmopole, Paris, France.	francine.behar@gmail.com		behar cohen, francine/0000-0001-8571-9513; Dinet, virginie/0000-0002-5458-0253	Agence Nationale de la Recherche Scientifique RPIB Innovision; Ministere de la Recherche	Agence Nationale de la Recherche Scientifique RPIB Innovision(French National Research Agency (ANR)); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France)	This work was supported by the Agence Nationale de la Recherche Scientifique RPIB Innovision and the Ministere de la Recherche (Celine Borras, PhD).	Bantseev V, 2018, J OCUL PHARMACOL TH, V34, P204, DOI 10.1089/jop.2017.0063; Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670; Bonyadi M, 2017, OPHTHALMIC GENET, V38, P365, DOI 10.1080/13816810.2016.1242019; Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783; Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130; Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491; Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392; Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006; Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015; Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613; Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342; Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104; Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357; GORDON DL, 1995, J IMMUNOL, V155, P348; Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126; Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418; Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307; Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266; Loeven MA, 2018, INVEST OPHTH VIS SCI, V59, P722, DOI 10.1167/iovs.IOVS-17-22893; Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168; Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015; Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]; Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297; Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702; Perkins SJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00126; Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050; Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212; Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106; Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554; Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206; Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001; van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x; Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1; Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2	39	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 3	2020	11								443	10.3389/fimmu.2020.00443	http://dx.doi.org/10.3389/fimmu.2020.00443			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH1EB	32318056	Green Published, gold			2022-12-18	WOS:000528531400001
J	Iizasa, H; Kim, H; Kartika, AV; Kanehiro, Y; Yoshiyama, H				Iizasa, Hisashi; Kim, Hyoji; Kartika, Andy Visi; Kanehiro, Yuichi; Yoshiyama, Hironori			Role of Viral and Host microRNAs in Immune Regulation of Epstein-Barr Virus-Associated Diseases (vol 11, 367, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						microRNAs; herpes virus; immune evasion; BART miRNA; BHRF miRNA			[Iizasa, Hisashi; Kim, Hyoji; Kartika, Andy Visi; Kanehiro, Yuichi; Yoshiyama, Hironori] Shimane Univ, Fac Med, Dept Microbiol, Matsue, Shimane, Japan	Shimane University	Yoshiyama, H (corresponding author), Shimane Univ, Fac Med, Dept Microbiol, Matsue, Shimane, Japan.	yosiyama@med.shimane-u.ac.jp	Yoshiyama, Hironori/H-5674-2019; Kartika, Andy Visi/GQY-4450-2022	Yoshiyama, Hironori/0000-0001-7588-278X; 				Iizasa H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00367	1	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 3	2020	11								498	10.3389/fimmu.2020.00498	http://dx.doi.org/10.3389/fimmu.2020.00498			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LH1EV	32318060	gold, Green Published			2022-12-18	WOS:000528533400001
J	Kolev, K; Medcalf, RL				Kolev, Krasimir; Medcalf, Robert L.			Editorial: Fibrinolysis in Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hemostasis; fibrin; contact system of coagulation; plasmin; staphylocoagulase; animal model			[Kolev, Krasimir] Semmelweis Univ, Dept Med Biochem, Budapest, Hungary; [Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia	Semmelweis University; Monash University	Kolev, K (corresponding author), Semmelweis Univ, Dept Med Biochem, Budapest, Hungary.	krasimir.kolev@eok.sote.hu	Kolev, Krasimir/J-7648-2019; Kolev, Krasimir/A-3517-2008	Kolev, Krasimir/0000-0002-5612-004X; Kolev, Krasimir/0000-0002-5612-004X				Draxler DF, 2019, BLOOD ADV, V3, P1598, DOI 10.1182/bloodadvances.2019000092; Liesenborghs L, 2018, J THROMB HAEMOST, V16, P441, DOI 10.1111/jth.13928; Maas C, 2018, BLOOD, V131, P1903, DOI 10.1182/blood-2017-04-569111; Macrae FL, 2018, J CLIN INVEST, V128, P3356, DOI 10.1172/JCI98734; Mantuano E, 2017, BLOOD, V130, P1364, DOI 10.1182/blood-2017-04-780205; Opneja A, 2019, THROMB RES, V179, P56, DOI 10.1016/j.thromres.2019.05.001; Varju I, 2019, THROMB RES, V182, P1, DOI 10.1016/j.thromres.2019.08.003	7	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2020	11								582	10.3389/fimmu.2020.00582	http://dx.doi.org/10.3389/fimmu.2020.00582			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LE5HX	32296445	Green Published, gold			2022-12-18	WOS:000526750900001
J	Bonaud, A; Clare, S; Bisio, V; Sowerby, JM; Yao, SG; Ostergaard, H; Balabanian, K; Smith, KGC; Espeli, M				Bonaud, Amelie; Clare, Simon; Bisio, Valeria; Sowerby, John M.; Yao, Shugang; Ostergaard, Hanne; Balabanian, Karl; Smith, Kenneth G. C.; Espeli, Marion			Leupaxin Expression Is Dispensable for B Cell Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						leupaxin; B cells; plasma cells; cell activation; humoral immune response	FOCAL ADHESION; TYROSINE PHOSPHORYLATION; PROSTATE-CANCER; GERMINAL CENTER; PAXILLIN; RECEPTOR; ACTIVATION; PROTEIN; ROLES; CD19	The generation of a potent humoral immune response by B cells relies on the integration of signals induced by the B cell receptor, toll-like receptors and both negative and positive co-receptors. Several reports also suggest that integrin signaling plays an important role in this process. How integrin signaling is regulated in B cells is however still partially understood. Integrin activity and function are controlled by several mechanisms including regulation by molecular adaptors of the paxillin family. In B cells, Leupaxin (Lpxn) is the most expressed member of the family and in vitro studies suggest that it could dampen BCR signaling. Here, we report that Lpxn expression is increased in germinal center B cells compared to naive B cells. Moreover, Lpxn deficiency leads to decreased B cell differentiation into plasma cells in vitro. However, Lpxn seems dispensable for the generation of a potent B cell immune response in vivo. Altogether our results suggest that Lpxn is dispensable for T-dependent and T-independent B cell immune responses.	[Bonaud, Amelie; Balabanian, Karl; Espeli, Marion] Univ Paris Saclay, Univ Paris Sud, Fac Med,Inflammat Chemokines & Immunopathol, Inst Natl Sante & Rech Med INSERM, Clamart, France; [Bonaud, Amelie; Bisio, Valeria; Balabanian, Karl; Espeli, Marion] Univ Paris, Inserm U1160, EMiLy, Inst Rech St Louis, Paris, France; [Clare, Simon] Wellcome Trust Sanger Inst, Wellcome Trust Genome, Hinxton, England; [Sowerby, John M.; Smith, Kenneth G. C.] Univ Cambridge, Dept Med, Cambridge Biomed, Sch Clin Med, Cambridge, England; [Sowerby, John M.; Smith, Kenneth G. C.] Univ Cambridge, Jeffrey Cheah Biomed Ctr Cambridge Biomed, Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge, England; [Yao, Shugang; Ostergaard, Hanne] Univ Alberta, Li Ka Shing Inst Virol, Dept Med Microbiol & Immunol, Edmonton, AB, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Wellcome Trust Sanger Institute; University of Cambridge; University of Cambridge; University of Alberta	Bonaud, A; Espeli, M (corresponding author), Univ Paris Saclay, Univ Paris Sud, Fac Med,Inflammat Chemokines & Immunopathol, Inst Natl Sante & Rech Med INSERM, Clamart, France.; Bonaud, A; Espeli, M (corresponding author), Univ Paris, Inserm U1160, EMiLy, Inst Rech St Louis, Paris, France.	amelie.bonaud@inserm.fr; marion.espeli@inserm.fr	Bisio, Valeria/AAL-5285-2020; Espeli, Marion/AAH-4483-2021	Bisio, Valeria/0000-0002-5459-2123; Espeli, Marion/0000-0001-5005-1664; Smith, Kenneth/0000-0003-3829-4326; Bonaud, Amelie/0000-0002-4153-9171	Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LabEx LERMIT) - ANR under the program Investissements d'Avenir [ANR-10-LABX-33, ANR-11-IDEX-0003-01]; ANR @RAction starting grant [ANR-14-ACHN-0008]; Wellcome-Trust [083650/Z/07/Z]; INCa grant (PRT-K 2017)	Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LabEx LERMIT) - ANR under the program Investissements d'Avenir(French National Research Agency (ANR)); ANR @RAction starting grant(French National Research Agency (ANR)); Wellcome-Trust(Wellcome Trust); INCa grant (PRT-K 2017)	This work was funded by a Junior Team Leader starting grant from the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LabEx LERMIT) supported by a grant from ANR (ANR-10-LABX-33 to ME) under the program Investissements d'Avenir (ANR-11-IDEX-0003-01) and by an ANR @RAction starting grant (ANR-14-ACHN-0008 to ME) and by the Wellcome-Trust (Programme Grant Number 083650/Z/07/Z to KS) and VB was supported by an INCa grant (PRT-K 2017).	Biajoux V, 2016, CELL REP, V17, P193, DOI 10.1016/j.celrep.2016.08.068; Bonaud A, 2015, BLOOD, V126, P757, DOI 10.1182/blood-2015-03-630277; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Carrasco YR, 2006, EMBO J, V25, P889, DOI 10.1038/sj.emboj.7600944; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Chen PW, 2010, CELL ADHES MIGR, V4, P527, DOI 10.4161/cam.4.4.12399; Chew V, 2007, J BIOL CHEM, V282, P27181, DOI 10.1074/jbc.M704625200; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; Corcoran LM, 2016, CURR OPIN IMMUNOL, V39, P59, DOI 10.1016/j.coi.2015.12.008; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; Deakin Nicholas O, 2012, Genes Cancer, V3, P362, DOI 10.1177/1947601912458582; Dierks S, 2015, ONCOTARGET, V6, P13591, DOI 10.18632/oncotarget.3792; Espeli M, 2012, J EXP MED, V209, P2307, DOI 10.1084/jem.20121752; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Jellusova J, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00096; Kaulfuss S, 2008, MOL ENDOCRINOL, V22, P1606, DOI 10.1210/me.2006-0546; Lechouane F, 2013, EUR J IMMUNOL, V43, P619, DOI 10.1002/eji.201242912; Li XL, 1998, J IMMUNOL, V161, P5901; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Lo CG, 2003, J EXP MED, V197, P353, DOI 10.1084/jem.20021569; Lu TT, 2002, SCIENCE, V297, P409, DOI 10.1126/science.1071632; McHeyzer-Williams MG, 1999, CURR OPIN IMMUNOL, V11, P172, DOI 10.1016/S0952-7915(99)80029-6; Muller J, 2013, P NATL ACAD SCI USA, V110, P12402, DOI 10.1073/pnas.1304888110; Natt J, 2015, METHODS MOL BIOL, V1291, P87, DOI 10.1007/978-1-4939-2498-1_8; Petropoulos C, 2016, J CELL BIOL, V213, P585, DOI 10.1083/jcb.201510036; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Romanova LY, 2011, CELL ADHES MIGR, V5, P457, DOI 10.4161/cam.5.6.18219; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC581, DOI 10.1152/ajpcell.00636.2005; Tanaka T, 2010, CANCER SCI, V101, P363, DOI 10.1111/j.1349-7006.2009.01398.x; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Watanabe N, 2005, MOL CELL BIOCHEM, V269, P13, DOI 10.1007/s11010-005-2149-6; White JK, 2013, CELL, V154, P452, DOI 10.1016/j.cell.2013.06.022; Xu HP, 2015, NAT IMMUNOL, V16, P1274, DOI 10.1038/ni.3287; Xu YK, 2014, AUTOIMMUNITY, V47, P430, DOI 10.3109/08916934.2014.921810; Zan H, 2013, AUTOIMMUNITY, V46, P83, DOI 10.3109/08916934.2012.749244	36	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2020	11								466	10.3389/fimmu.2020.00466	http://dx.doi.org/10.3389/fimmu.2020.00466			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC3UJ	32269569	Green Published, gold, Green Submitted			2022-12-18	WOS:000596930300001
J	Grodeland, G; Baranowska-Hustad, M; Abadejos, J; Blane, TR; Teijaro, J; Nemazee, D; Bogen, B				Grodeland, Gunnveig; Baranowska-Hustad, Marta; Abadejos, Justin; Blane, Tanya R.; Teijaro, John; Nemazee, David; Bogen, Bjarne			Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin	FRONTIERS IN IMMUNOLOGY			English	Article						DNA vaccine; hemagglutinin (HA); MHCII; APC-targeted antigen; stem domain	NEUTRALIZING EPITOPE; B-CELLS; IN-VIVO; ANTIGEN; IMMUNOGENICITY; VACCINES; MICE; RECOGNITION; EFFICACY	Novel and more broadly protective vaccines against influenza are needed to efficiently meet antigenic drift and shift. Relevant to this end, the stem domain of hemagglutinin (HA) is highly conserved, and antibodies specific for epitopes located to the stem have been demonstrated to be able to confer broad protection against various influenza subtypes. However, a remaining challenge is to induce antibodies against the poorly immunogenic stem by vaccination strategies that can be scaled up for prophylactic vaccination of the general population. Here, we have developed DNA vaccines where the conserved stem domain of HA from influenza A/PR/8/34 (H1N1) and A/Shanghai/2/2013 (H7N9) was targeted toward MHC class II molecules on antigen-presenting cells (APC) for increased immunogenicity. Each of these vaccines induced antibodies that cross-reacted with other subtypes in the corresponding phylogenetic influenza groups. Importantly, when mixing the MHCII-targeted stem domains from H1N1 and H7N9 influenza viruses into one vaccine bolus, we observed broad protection against candidate stains from both phylogenetic groups 1 and 2.	[Grodeland, Gunnveig; Baranowska-Hustad, Marta; Bogen, Bjarne] Univ Oslo, KG Jebsen Ctr Influenza Vaccine Res, Inst Clin Med, Oslo, Norway; [Grodeland, Gunnveig; Baranowska-Hustad, Marta; Bogen, Bjarne] Oslo Univ Hosp, Oslo, Norway; [Abadejos, Justin; Blane, Tanya R.; Teijaro, John; Nemazee, David] Scripps Res Inst, Dept Immunol & Microbiol, San Diego, CA USA	University of Oslo; University of Oslo; Scripps Research Institute	Grodeland, G (corresponding author), Univ Oslo, KG Jebsen Ctr Influenza Vaccine Res, Inst Clin Med, Oslo, Norway.; Grodeland, G (corresponding author), Oslo Univ Hosp, Oslo, Norway.	gunnveig.grodeland@medisin.uio.no		Grodeland, Gunnveig/0000-0001-6285-3162	NIH [R01AI132317, R37AI059714]; Stiftelsen K. G. Jebsen	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stiftelsen K. G. Jebsen	DN, JA, and TB were supported by grants R01AI132317 and R37AI059714 from the NIH. GG and BB were supported by a grant from Stiftelsen K. G. Jebsen.	Ahlen G, 2007, J IMMUNOL, V179, P4741, DOI 10.4049/jimmunol.179.7.4741; Anderson AM, 2018, J IMMUNOL, V200, P2057, DOI 10.4049/jimmunol.1701088; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Bommakanti G, 2010, P NATL ACAD SCI USA, V107, P13701, DOI 10.1073/pnas.1007465107; CARAYANNIOTIS G, 1987, NATURE, V327, P59, DOI 10.1038/327059a0; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Dreyfus C, 2013, J VIROL, V87, P7149, DOI 10.1128/JVI.02975-12; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Fossum E, 2015, EUR J IMMUNOL, V45, P624, DOI 10.1002/eji.201445080; Fredriksen AB, 2006, MOL THER, V13, P776, DOI 10.1016/j.ymthe.2005.10.019; Fredriksen AB, 2007, BLOOD, V110, P1797, DOI 10.1182/blood-2006-06-032938; Friesen RHE, 2014, P NATL ACAD SCI USA, V111, P445, DOI 10.1073/pnas.1319058110; GRAVES PN, 1983, VIROLOGY, V126, P106, DOI 10.1016/0042-6822(83)90465-8; Grodeland G, 2016, J IMMUNOL, V197, P3575, DOI 10.4049/jimmunol.1600893; Grodeland G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00367; Grodeland G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080008; Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; KAWAMURA H, 1986, J IMMUNOL, V136, P58; Lu Y, 2014, P NATL ACAD SCI USA, V111, P125, DOI 10.1073/pnas.1308701110; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Mullarkey CE, 2016, MBIO, V7, DOI 10.1128/mBio.01624-16; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Ota T, 2013, J IMMUNOL, V191, P3179, DOI 10.4049/jimmunol.1301283; Russell RJ, 2004, VIROLOGY, V325, P287, DOI 10.1016/j.virol.2004.04.040; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SNIDER DP, 1987, J IMMUNOL, V139, P1609; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Sutton TC, 2017, J VIROL, V91, DOI 10.1128/JVI.01603-17; Tan GS, 2014, J VIROL, V88, P13580, DOI 10.1128/JVI.02289-14; Terajima M, 2011, J VIROL, V85, P13463, DOI 10.1128/JVI.05193-11; THOMPSON K, 1990, IMMUNOLOGY, V71, P323; Valkenburg SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep22666; Wheatley AK, 2015, J IMMUNOL, V195, P602, DOI 10.4049/jimmunol.1402835; Wohlbold TJ, 2015, VACCINE, V33, P3314, DOI 10.1016/j.vaccine.2015.05.038; Wollacott AM, 2016, EBIOMEDICINE, V5, P147, DOI 10.1016/j.ebiom.2016.02.021; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927	44	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2020	11								431	10.3389/fimmu.2020.00431	http://dx.doi.org/10.3389/fimmu.2020.00431			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LE2IO	32269566	Green Published, gold			2022-12-18	WOS:000526547000001
J	Muthui, MK; Kamau, A; Bousema, T; Blagborough, AM; Bejon, P; Kapulu, MC				Muthui, Michelle K.; Kamau, Alice; Bousema, Teun; Blagborough, Andrew M.; Bejon, Philip; Kapulu, Melissa C.			Immune Responses to Gametocyte Antigens in a Malaria Endemic Population-The African falciparum Context: A Systematic Review and Meta-Analysis (vol 10, 2480, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						immunity; Plasmodium falciparum; gametocytes; Pfs230; Pfs48; 45			[Muthui, Michelle K.; Kamau, Alice; Bejon, Philip; Kapulu, Melissa C.] KEMRI Wellcome Trust Programme, Dept Biosci, Kilifi, Kenya; [Bousema, Teun] London Sch Hyg & Trop Med, Immunol & Infect Dept, London, England; [Bousema, Teun] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands; [Blagborough, Andrew M.] Imperial Coll London, Dept Life Sci, London, England; [Blagborough, Andrew M.] Univ Cambridge, Dept Pathol, Cambridge, England; [Bejon, Philip; Kapulu, Melissa C.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England	University of London; London School of Hygiene & Tropical Medicine; Radboud University Nijmegen; Imperial College London; University of Cambridge; University of Oxford	Muthui, MK (corresponding author), KEMRI Wellcome Trust Programme, Dept Biosci, Kilifi, Kenya.	mmuthui@kemri-wellcome.org	Bousema, Teun/N-3574-2014; Kapulu, Melissa/ABC-1311-2021	Bousema, Teun/0000-0003-2666-094X; Kapulu, Melissa/0000-0003-0321-7128				Amoah LE, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-017-2607-5; Muthui MK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02480	2	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2020	11								389	10.3389/fimmu.2020.00389	http://dx.doi.org/10.3389/fimmu.2020.00389			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LA1QL	32265905	Green Published, gold			2022-12-18	WOS:000523729400001
J	Serrano-Coll, H; Spina, JP; Salazar-Pelaez, L; Cardona-Castro, N				Serrano-Coll, Hector; Pablo Spina, Juan; Salazar-Pelaez, Lina; Cardona-Castro, Nora			Notch Signaling Pathway Expression in the Skin of Leprosy Patients: Association With Skin and Neural Damage	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium leprae; Hes-1 transcription factor; Runx-1 transcription factor; inflammation; epidermis; hair follicle; eccrine gland; nerve fiber	STEM-CELLS; DIFFERENTIATION; PROLIFERATION; COMMITMENT; RUNX1	Introduction: Leprosy is an infectious disease caused by Mycobacterium leprae, a debilitating disease that affects the skin and peripheral nerves. It is possible that tissue changes during infection with leprosy are related to alterations in the activity of the Notch signaling pathway, an innate signaling pathway in the physiology of the skin and peripheral nerves. Methods: This is a descriptive observational study. Thirty skin biopsies from leprosy patients and 15 from individuals with no history of this disease were evaluated. In these samples, gene expressions of cellular components associated with the Notch signaling pathway, Hes-1, Hey-1, Runx-1 Jagged-1, Notch-1, and Numb, were evaluated using q-PCR, and protein expression was evaluated using immunohistochemistry of Runx-1 and Hes-1. Results: Changes were observed in the transcription of Notch signaling pathway components; Hes-1 was downregulated and Runx-1 upregulated in the skin of infected patients. These results were confirmed by immunohistochemistry, where reduction of Hes-1 expression was found in the epidermis, eccrine glands, and hair follicles. Increased expression of Runx-1 was found in inflammatory cells in the dermis of infected patients; however, it is not related to tissue changes. With these results, a multivariate analysis was performed to determine the causes of transcription factor Hes-1 reduction. It was concluded that tissue inflammation was the main cause. Conclusions: The tissue changes found in the skin of infected patients could be associated with a reduction in the expression of Hes-1, a situation that would promote the survival and proliferation of M. leprae in this tissue.	[Serrano-Coll, Hector; Salazar-Pelaez, Lina; Cardona-Castro, Nora] Univ CES, Escuela Grad, Ciencias Salud, Grp Ciencias Basicas, Medellin, Colombia; [Serrano-Coll, Hector; Cardona-Castro, Nora] Univ CES, Linea Invest Lepra, Inst Colombiano Med Trop, Medellin, Colombia; [Pablo Spina, Juan] Univ Antioquia, Ctr Invest Dermatol CIDERM, Lab Dermatopatol, Fac Med, Medenn, Colombia	Universidad de Antioquia	Serrano-Coll, H; Cardona-Castro, N (corresponding author), Univ CES, Escuela Grad, Ciencias Salud, Grp Ciencias Basicas, Medellin, Colombia.; Serrano-Coll, H; Cardona-Castro, N (corresponding author), Univ CES, Linea Invest Lepra, Inst Colombiano Med Trop, Medellin, Colombia.	serrano.hector@uces.edu.co; ncardona@ces.edu.co	Salazar-Pelaéz, Lina/AAH-2360-2021; Cardona-Castro, Nora/L-6846-2015	Serrano-Coll, Hector/0000-0002-8872-872X; Salazar-Pelaez, Lina/0000-0001-6224-1078; Cardona-Castro, Nora/0000-0002-4716-6636	 [727-2015]		This work received financial support for HS-C (Colciencias doctoral scholarship 727-2015).	Aubin-Houzelstein G, 2012, ADV EXP MED BIOL, V727, P142, DOI 10.1007/978-1-4614-0899-4_11; Baltodano PA, 2016, J PLAST RECONSTR AES, V69, P966, DOI 10.1016/j.bjps.2016.03.013; Bland K., 2018, BREAST COMPREHENSIVE; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Blok DJ, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1143-4; Cardona-Castro N, 2018, CURR TROP MED REP, V5, P85, DOI 10.1007/s40475-018-0145-7; Cleaton M, 2009, BRIT SOC INV DERM AN, DOI [10.1111/j.1365-2133.2009.09092.x, DOI 10.1111/J.1365-2133.2009.09092.X]; College of American Pathologists, 2018, TEMPL REP RES BIOM T; Cui CY, 2015, EXP DERMATOL, V24, P644, DOI 10.1111/exd.12773; Davis GL, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002404; Flores AN, 2014, NAT REV UROL, V11, P499, DOI 10.1038/nrurol.2014.195; Gori JL, 2015, J CLIN INVEST, V125, P1243, DOI 10.1172/JCI79328; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Horzum U, 2014, METHODSX, V1, P56, DOI 10.1016/j.mex.2014.06.004; Hsu YC, 2014, NAT MED, V20, P847, DOI 10.1038/nm.3643; Ito G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079693; Joshi Rajiv, 2011, Indian J Dermatol, V56, P505, DOI 10.4103/0019-5154.87132; Kibbie J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005808; Lin HY, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015842, 10.1371/journal.pone.0019135]; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Lu C, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015222; Ma ZX, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0658-8; Massi D, 2012, ADV EXP MED BIOL, V727, P131, DOI 10.1007/978-1-4614-0899-4_10; Moriyama M, 2008, DEV CELL, V14, P594, DOI 10.1016/j.devcel.2008.01.017; Nowell C, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a017772; Panelos J, 2009, CANCER BIOL THER, V8, P1986, DOI 10.4161/cbt.8.21.9921; Pinheiro RO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00518; Qiagen, 2014, RT2 PROF PCR ARR HDB; Qiagen, 2012, RNEASYR MIN HDB; Riyaz Najeeba, 2017, Skinmed, V15, P45; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Serrano-Coll H, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty062; Serrano-Coll H, 2017, MED HYPOTHESES, V109, P162, DOI 10.1016/j.mehy.2017.10.009; Takeuchi H, 2010, SEMIN CELL DEV BIOL, V21, P638, DOI 10.1016/j.semcdb.2010.03.003; Tapinos N, 2006, NAT MED, V12, P961, DOI 10.1038/nm1433; Troletti CD, 2018, BRAIN BEHAV IMMUN, V69, P48, DOI 10.1016/j.bbi.2017.12.016; Tumbar T, 2012, STEM CELL REV REP, V8, P561, DOI 10.1007/s12015-012-9348-9; Wong WF, 2011, J BIOL CHEM, V286, P11110, DOI 10.1074/jbc.M110.166694; Woodhoo A, 2009, NAT NEUROSCI, V12, P839, DOI 10.1038/nn.2323; World Health Organization, 2016, GLOB LEPR STRAT 2016; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Yu F, 2017, J VET SCI, V18, P359, DOI 10.4142/jvs.2017.18.3.359; Zhou XZ, 2013, STEM CELLS, V31, P1511, DOI 10.1002/stem.1426	43	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2020	11								368	10.3389/fimmu.2020.00368	http://dx.doi.org/10.3389/fimmu.2020.00368			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC9UH	32265900	gold, Green Published			2022-12-18	WOS:000525678900001
J	Kishore, U; Ghebrehiwet, B				Kishore, Uday; Ghebrehiwet, Berhane			Editorial: C1q: A Molecular Bridge to Innate and Adaptive Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						complement; classical pathway; C1q; C1 complex; infection; cancer; non-complement functions	MODULAR ORGANIZATION; CRYSTAL-STRUCTURE; GLOBULAR HEAD; COMPLEMENT		[Kishore, Uday] Brunel Univ London, Coll Hlth & Life Sci, Biosci, Uxbridge, Middx, England; [Ghebrehiwet, Berhane] State Univ New York, Dept Med, New York, NY 10027 USA	Brunel University; State University of New York (SUNY) System; SUNY Delhi	Kishore, U (corresponding author), Brunel Univ London, Coll Hlth & Life Sci, Biosci, Uxbridge, Middx, England.; Ghebrehiwet, B (corresponding author), State Univ New York, Dept Med, New York, NY 10027 USA.	uday.kishore@brunel.ac.uk; berhane.ghebrehiwet@stonybrook.edu						Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007; Bulla R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10346; Cai YT, 2015, J BIOL CHEM, V290, P22570, DOI 10.1074/jbc.M115.670661; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Gaboriaud C, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00092; Ghai R, 2007, IMMUNOBIOLOGY, V212, P253, DOI 10.1016/j.imbio.2006.11.001; Kishore U, 1999, IMMUNOPHARMACOLOGY, V42, P15, DOI 10.1016/S0162-3109(99)00011-9; Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Kouser L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00317; Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047; Nayak A, 2012, INNATE IMMUN-LONDON, V18, P350, DOI 10.1177/1753425910396252; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1067, DOI 10.1016/j.jaci.2018.09.039; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2	14	1	1	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2020	11								417	10.3389/fimmu.2020.00417	http://dx.doi.org/10.3389/fimmu.2020.00417			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC7TK	32256491	gold, Green Published, Green Submitted			2022-12-18	WOS:000525535600001
J	Seiler, C; Bayless, NL; Vergara, R; Pintye, J; Kinuthia, J; Osborn, L; Matemo, D; Richardson, BA; John-Stewart, G; Holmes, S; Blish, CA				Seiler, Christof; Bayless, Nicholas L.; Vergara, Rosemary; Pintye, Jillian; Kinuthia, John; Osborn, Lusi; Matemo, Daniel; Richardson, Barbra A.; John-Stewart, Grace; Holmes, Susan; Blish, Catherine A.			Influenza-Induced Interferon Lambda Response Is Associated With Longer Time to Delivery Among Pregnant Kenyan Women	FRONTIERS IN IMMUNOLOGY			English	Article						pregnancy; preterm; time to delivery; interferon; immune; influenza virus	GENE-EXPRESSION; IMMUNE-SYSTEM; PRETERM BIRTH; A VIRUS; SPONTANEOUS LABOR; INFLAMMATION; TERM; CELL; INFECTIONS; NETWORK	Specific causes of preterm birth remain unclear. Several recent studies have suggested that immune changes during pregnancy are associated with the timing of delivery, yet few studies have been performed in low-income country settings where the rates of preterm birth are the highest. We conducted a retrospective nested case-control evaluation within a longitudinal study among HIV-uninfected pregnant Kenyan women. To characterize immune function in these women, we evaluated unstimulated and stimulated peripheral blood mononuclear cells in vitro with the A/California/2009 strain of influenza to understand the influenza-induced immune response. We then evaluated transcript expression profiles using the Affymetrix Human GeneChip Transcriptome Array 2.0. Transcriptional profiles of sufficient quality for analysis were obtained from 54 women; 19 of these women delivered 37 weeks. The median time to birth from sample collection was 13 weeks. No transcripts were significantly associated with preterm birth in a case-control study of matched term and preterm birth (n = 42 women). In the influenza-stimulated samples, expression of IFNL1 was associated with longer time to delivery-the amount of time between sample collection and delivery (n = 54 women). A qPCR analysis confirmed that influenza-induced IFNL expression was associated with longer time to delivery. These data indicate that during pregnancy, ex vivo influenza stimulation results in altered transcriptional response and is associated with time to delivery in cohort of women residing in an area with high preterm birth prevalence.	[Seiler, Christof; Holmes, Susan] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Seiler, Christof] Maastricht Univ, Dept Data Sci & Knowledge Engn, Maastricht, Netherlands; [Bayless, Nicholas L.; Blish, Catherine A.] Stanford Univ, Sch Med, Immunol Program, Stanford, CA 94305 USA; [Vergara, Rosemary; Blish, Catherine A.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Pintye, Jillian; Richardson, Barbra A.; John-Stewart, Grace] Univ Washington, Sch Med, Dept Global Hlth, Seattle, WA USA; [Kinuthia, John; Osborn, Lusi; Matemo, Daniel] Kenyatta Natl Hosp, Nairobi, Kenya; [Richardson, Barbra A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Blish, Catherine A.] Chan Zuckerberg Biohub, San Francisco, CA 94158 USA	Stanford University; Maastricht University; Stanford University; Stanford University; University of Washington; University of Washington Seattle; Kenyatta National Hospital; University of Washington; University of Washington Seattle	Blish, CA (corresponding author), Stanford Univ, Sch Med, Immunol Program, Stanford, CA 94305 USA.; Blish, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.; Blish, CA (corresponding author), Chan Zuckerberg Biohub, San Francisco, CA 94158 USA.	cblish@stanford.edu		Blish, Catherine/0000-0001-6946-7627; Holmes, Susan/0000-0002-2208-8168	National Institutes of Health [U01AI131302, F31HD089675, DP1DA046089, R01AI133698, P01HD064915]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health U01AI131302 to CB and SH, F31HD089675 to NB, DP1DA046089 to CB, and R01AI133698 and P01HD064915 to GJ-S. CB was the Tashia and John Morgridge Endowed Faculty Scholar in Pediatric Translational Medicine from the Maternal Child Health Research Institute, and a Chan Zuckerberg Investigator.	Aghaeepour N, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2946; Arenas-Hernandez M, 2019, J IMMUNOL, V202, P2585, DOI 10.4049/jimmunol.1801350; Beisser D, 2010, BIOINFORMATICS, V26, P1129, DOI 10.1093/bioinformatics/btq089; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Bollopragada S, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.032; Bukowski R, 2006, PLOS MED, V3, P918, DOI 10.1371/journal.pmed.0030169; Canty A, 2019, BOOT BOOTSTRAP R S P; Cappelletti M, 2016, J LEUKOCYTE BIOL, V99, P67, DOI 10.1189/jlb.3MR0615-272RR; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Charpigny G, 2003, BIOL REPROD, V68, P2289, DOI 10.1095/biolreprod.102.013763; Davison A., 1997, BOOTSTRAP METHODS TH, V94; Dittrich MT, 2008, BIOINFORMATICS, V24, pI223, DOI 10.1093/bioinformatics/btn161; Efron B., 1993, INTRO BOOTSTRAP, P436, DOI [10.1007/978-1-4899-4541-9, DOI 10.1007/978-1-4899-4541-9]; Eidem HR, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0099-8; Forbes RL, 2012, J INFECT DIS, V206, P646, DOI 10.1093/infdis/jis377; Fox J., 2018, R COMPANION APPL REG; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Gaudilliere B, 2015, CYTOM PART A, V87A, P817, DOI 10.1002/cyto.a.22720; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Haddad R, 2006, AM J OBSTET GYNECOL, V195, P394, DOI 10.1016/j.ajog.2005.08.057; Heng YJJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155191; Heng YJJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096901; Ho D.E., 2011, J STAT SOFTW, V42, P1, DOI [10.18637/jss.v042.i08, DOI 10.18637/JSS.V042.I08]; Howson CP., 2012, BORN TOO SOON GLOBAL; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kay AW, 2015, J INFECT DIS, V212, P861, DOI 10.1093/infdis/jiv138; Kay AW, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00289; Kay AW, 2014, P NATL ACAD SCI USA, V111, P14506, DOI 10.1073/pnas.1416569111; Kinuthia J, 2015, AIDS, V29, P2025, DOI 10.1097/QAD.0000000000000793; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; Kraus TA, 2012, J CLIN IMMUNOL, V32, P300, DOI 10.1007/s10875-011-9627-2; Kronstad LM, 2018, J IMMUNOL, V201, P2117, DOI 10.4049/jimmunol.1800161; Le Gars M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02469; Le Gars M, 2016, J INFECT DIS, V214, P1666, DOI 10.1093/infdis/jiw448; Lee ACC, 2019, LANCET GLOB HEALTH, V7, pE2, DOI 10.1016/S2214-109X(18)30484-4; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; Mor G, 2011, ANN NY ACAD SCI, V1221, P80, DOI 10.1111/j.1749-6632.2010.05938.x; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Muglia LJ, 2010, NEW ENGL J MED, V362, P529, DOI 10.1056/NEJMra0904308; Nacu S, 2007, BIOINFORMATICS, V23, P850, DOI 10.1093/bioinformatics/btm019; Nelson AC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11414; Ngo TTM, PREPRINT, DOI [10.1101/212910, DOI 10.1101/212910]; Norwitz ER, 1999, NEW ENGL J MED, V341, P660, DOI 10.1056/NEJM199908263410906; Norwitz ER, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023143; Pan WY, 2017, CLIN CHEM, V63, P1695, DOI 10.1373/clinchem.2017.273888; Pavlicev M, 2017, GENOME RES, V27, P349, DOI 10.1101/gr.207597.116; Pazos M, 2012, IMMUNOL RES, V54, P254, DOI 10.1007/s12026-012-8303-9; Pique-Regi R, 2019, ELIFE, V8, DOI 10.7554/eLife.52004; Racicot K, 2014, AM J REPROD IMMUNOL, V72, P107, DOI 10.1111/aji.12289; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; ROMERO R, 1992, AM J OBSTET GYNECOL, V166, P1576, DOI 10.1016/0002-9378(92)91636-O; Romero R, 2006, PLOS MED, V3, P739, DOI 10.1371/journal.pmed.0030276; Romero R, 2014, J MATERN-FETAL NEO M, V27, P1397, DOI 10.3109/14767058.2013.860963; Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816; Sandman CA, 2006, PEPTIDES, V27, P1457, DOI 10.1016/j.peptides.2005.10.002; Shen-Orr SS, 2016, CELL SYST, V3, P374, DOI 10.1016/j.cels.2016.09.009; Shynlova O, 2013, REPROD SCI, V20, P154, DOI 10.1177/1933719112446084; Tarca AL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36649-w; Tenenbaum D, 2018, KEGGREST CLIENT SIDE; Venables W.N., 2002, MODERN APPL STAT S, Vfourth, DOI [10.1007/978-0-387-21706-2, DOI 10.1007/978-0-387-21706-2]; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Wagura P, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1740-2; World Health Organization, 2017, PRET BIRTH FACT SHEE	64	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2020	11								452	10.3389/fimmu.2020.00452	http://dx.doi.org/10.3389/fimmu.2020.00452			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC7YT	32256497	gold, Green Published			2022-12-18	WOS:000525550200001
J	Smolock, E; Robert, J				Smolock, Elaine; Robert, Jacques			Broadening and Strengthening Underrepresented Group Inclusion in Immunological Research	FRONTIERS IN IMMUNOLOGY			English	Article						educational program; Diversity & Inclusion; graduate program; career developement; training & development	EXPERIENCES; STUDENTS	Promoting diversity across biomedical fields is crucial for building comprehensive and innovative research programs, as well as providing trainees from underrepresented groups (URGs) the ability to establish agency and develop skills in a culturally and structurally supportive environment. Despite this awareness, there is still a lack of students from URGs being trained for independent research careers. The Immunology, Microbiology, and Virology (IMV) graduate program at the University of Rochester School of Medicine and Dentistry (URSMD) has been working for the last 13 years to increase diversity through an NIH funded Post-baccalaureate Research Education Program (PREP). Historically, our program has trained URG scholars in Immunology, but as we have progressed we have embraced the understanding that both the scholars and the institution benefit from expanding the interdisciplinary nature of our program. Over the last 3 years, we have integrated a broader and highly collaborative faculty mentor pool, including representation from Immunology, Microbiology, Virology, Neuroscience, Genetics, Biochemistry, Biophysics, Toxicology, and Biomedical Engineering. This expansion, coupled with changes in our education program, including skill building workshops and cross campus integration with our student diversity groups and the Office of Diversity and Inclusion, has strengthened the competitiveness and success of our cohorts. These improvements are enhancing the diversity of our graduate school, creating a research environment that retains students from URGs in biomedical research. We attribute our success to the interdisciplinary and team-building nature of our pipeline program, as well as the URSMD's initiatives to be a more inclusive and equitable institution.	[Smolock, Elaine; Robert, Jacques] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA; [Smolock, Elaine] Univ Rochester, Sch Med & Dent, Ctr Profess Dev Grad Educ & Postdoctoral Affairs, Rochester, NY USA	University of Rochester; University of Rochester	Robert, J (corresponding author), Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA.	jacques_robert@urmc.rochester.edu			NIH [R25G GM064133]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	UR-PREP was supported by NIH R25G GM064133.	Estrada M, 2011, J EDUC PSYCHOL, V103, P206, DOI 10.1037/a0020743; Feldon DF, 2011, SCIENCE, V333, P1037, DOI 10.1126/science.1204109; Gazley JL, 2014, J RES SCI TEACH, V51, P1021, DOI 10.1002/tea.21164; Gibau GS, 2015, CBE-LIFE SCI EDUC, V14, DOI 10.1187/cbe.14-06-0103; Gibbs KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114736; Gibbs KD, 2013, CBE-LIFE SCI EDUC, V12, P711, DOI 10.1187/cbe.13-02-0021; Guerrero Lourdes R, 2017, BMC Proc, V11, P14, DOI 10.1186/s12919-017-0085-6; McGee R, 2016, AIDS BEHAV, V20, pS231, DOI 10.1007/s10461-016-1486-7; McGee R, 2012, MT SINAI J MED, V79, P397, DOI 10.1002/msj.21310; Meyers FJ, 2016, FASEB J, V30, P507, DOI 10.1096/fj.15-276139; Meyers LC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190606; Nikaj S, 2018, FASEB J, V32, P6410, DOI 10.1096/fj.201800639; Remich R, 2016, CBE-LIFE SCI EDUC, V15, DOI 10.1187/cbe.16-01-0035; Saetermoe Carrie L, 2017, BMC Proc, V11, P21, DOI 10.1186/s12919-017-0089-2; Schultz JS, 2012, IEEE PULSE, V3, P30, DOI 10.1109/MPUL.2012.2196833; Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613; Urizar Guido G Jr, 2017, BMC Proc, V11, P26, DOI 10.1186/s12919-017-0088-3; Williams SN, 2017, CBE-LIFE SCI EDUC, V16, DOI 10.1187/cbe.17-01-0021; Wood Christine V, 2016, J Women Minor Sci Eng, V22, P159, DOI 10.1615/JWomenMinorScienEng.2016014000; Wyatt GE, 2019, AM J ORTHOPSYCHIAT, V89, P321, DOI 10.1037/ort0000414	20	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2020	11								465	10.3389/fimmu.2020.00465	http://dx.doi.org/10.3389/fimmu.2020.00465			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	LC8AL	32256499	Green Published, gold			2022-12-18	WOS:000525554800001
J	Verma, NK; Tran, T; Kelleher, D				Verma, Navin Kumar; Tran, Thai; Kelleher, Dermot			Editorial: Adaptor Protein Regulation in Immune Signalling	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate and adaptive immunity; leukocyte motility; T cells; B cells; NK cells; mast cells; monocytes; CG-NAP			[Verma, Navin Kumar; Kelleher, Dermot] Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, Singapore, Singapore; [Tran, Thai] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Kelleher, Dermot] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Kelleher, Dermot] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; University of British Columbia; University of British Columbia	Verma, NK; Kelleher, D (corresponding author), Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, Singapore, Singapore.; Tran, T (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore.; Kelleher, D (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.; Kelleher, D (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada.	nkverma@ntu.edu.sg; phstt@nus.edu.sg; dermot.kelleher@ubc.ca	Verma, Navin Kumar/B-7641-2008	Verma, Navin Kumar/0000-0002-5940-6633; TRAN, Thai/0000-0002-8662-3676	Lee Kong Chian School of Medicine, Nanyang Technological University Singapore [L0412290]; Singapore Ministry of Education (MOE) [MOE2017-T2-2-004, MOE2019-T2-1059, NUHSRO/2019/048/T1/SEED-MAR/01]	Lee Kong Chian School of Medicine, Nanyang Technological University Singapore(Nanyang Technological University); Singapore Ministry of Education (MOE)(Ministry of Education, Singapore)	This work was supported, in part, by the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore Start-Up Grant (L0412290), and the Singapore Ministry of Education (MOE) under its Singapore MOE Academic Research Fund (AcRF) Tier 2 Grant (MOE2017-T2-2-004) to NV and the Singapore MOE AcRF Tier 2 grant (MOE2019-T2-1059) and Tier 1 grant (NUHSRO/2019/048/T1/SEED-MAR/01) to TT.	Catron DM, 2010, J IMMUNOL, V184, P3609, DOI 10.4049/jimmunol.1000077; de Marcken M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw1347; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Krovi SH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01393; Kruger A, 2015, EMBO REP, V16, P1656, DOI 10.15252/embr.201540861; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597	6	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 13	2020	11								441	10.3389/fimmu.2020.00441	http://dx.doi.org/10.3389/fimmu.2020.00441			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC7XP	32231669	gold, Green Published			2022-12-18	WOS:000525547000001
J	Geiger, KM; Guignard, D; Yang, C; Bikorimana, JP; Correia, BE; Houard, S; Mkindi, C; Daubenberger, CA; Spertini, F; Corradin, G; Audran, R				Geiger, Kristina M.; Guignard, Daniel; Yang, Che; Bikorimana, Jean-Pierre; Correia, Bruno E.; Houard, Sophie; Mkindi, Catherine; Daubenberger, Claudia A.; Spertini, Francois; Corradin, Giampietro; Audran, Regine			Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; Plasmodium falciparum; vaccine; P27A; clinical trial; immune response; adjuvant; populations	INTRINSICALLY UNSTRUCTURED PROTEINS; PLASMODIUM-FALCIPARUM	P27A is a novel synthetic malaria vaccine candidate derived from the blood stage Plasmodium falciparum protein Trophozoite Exported Protein 1 (TEX1/PFF0165c). In phase 1a/1b clinical trials in malaria unexposed adults in Switzerland and in malaria pre-exposed adults in Tanzania, P27A formulated with Alhydrogel and GLA-SE adjuvants induced antigen-specific antibodies and T-cell activity. The GLA-SE adjuvant induced significantly stronger humoral responses than the Alhydrogel adjuvant. Groups of pre-exposed and unexposed subjects received identical vaccine formulations, which supported the comparison of the cellular and humoral response to P27A in terms of fine specificity and affinity for populations and adjuvants. Globally, fine specificity of the T and B cell responses exhibited preferred recognized sequences and did not highlight major differences between adjuvants or populations. Affinity of anti-P27A antibodies was around 10(-8) M in all groups. Pre-exposed volunteers presented anti-P27A with higher affinity than unexposed volunteers. Increasing the dose of GLA-SE from 2.5 to 5 mu g in pre-exposed volunteers improved anti-P27A affinity and decreased the number of recognized epitopes. These results indicate a higher maturation of the humoral response in pre-exposed volunteers, particularly when immunized with P27A formulated with 5 mu g GLA-SE.	[Geiger, Kristina M.; Guignard, Daniel; Corradin, Giampietro] Univ Lausanne, Biochem Dept, Epalinges, Switzerland; [Geiger, Kristina M.] Univ Calif Berkeley, Dept Infect Dis & Immun, Berkeley, CA 94720 USA; [Yang, Che; Correia, Bruno E.] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland; [Yang, Che; Correia, Bruno E.] Swiss Inst Bioinformat, Lausanne, Switzerland; [Bikorimana, Jean-Pierre; Spertini, Francois; Audran, Regine] CHU Vaudois, Div Immunol & Allergy, Lausanne, Switzerland; [Houard, Sophie] European Vaccine Initiat, Heidelberg, Germany; [Mkindi, Catherine; Daubenberger, Claudia A.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Mkindi, Catherine; Daubenberger, Claudia A.] Univ Basel, Basel, Switzerland; [Mkindi, Catherine] Ifakara Hlth Inst, Dept Intervent & Clin Trials, Bagamoyo, Tanzania	University of Lausanne; University of California System; University of California Berkeley; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute of Bioinformatics; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Ifakara Health Institute	Audran, R (corresponding author), CHU Vaudois, Div Immunol & Allergy, Lausanne, Switzerland.	regine.audran@chuv.ch		Daubenberger, Claudia/0000-0001-7136-0642	European Vaccine Initiative (EVI) from an Irish Aid grant; European and Developing Countries Clinical Trials Partnership (EDCTP)	European Vaccine Initiative (EVI) from an Irish Aid grant; European and Developing Countries Clinical Trials Partnership (EDCTP)	The European Vaccine Initiative (EVI) provided funding from an Irish Aid grant for the phase 1a study in Switzerland, and also provided the P27A vaccine and the Alhydrogel. Infectious Disease Research Institute (IDRI) provided the GLASE adjuvant. The European and Developing Countries Clinical Trials Partnership (EDCTP) provided funding for the phase 1b study in Tanzania.	Balam S, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-510; Braitbard O, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-12; Coler RN, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0057-5; Corradin G, 2012, ADV IMMUNOL, V114, P107, DOI 10.1016/B978-0-12-396548-6.00005-6; Corradin G, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001387; Corradin Giarnpietro, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P259, DOI 10.2174/187153007782794371; Feng ZP, 2006, MOL BIOCHEM PARASIT, V150, P256, DOI 10.1016/j.molbiopara.2006.08.011; Frimpong A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02769; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hill DL, 2019, J EXP MED, V216, P1857, DOI 10.1084/jem.20190301; Kulangara C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046112; Laurens MB, 2018, ANNU REV MICROBIOL, V72, P273, DOI 10.1146/annurev-micro-090817-062427; Mahmoudi S, 2017, HUM VACC IMMUNOTHER, V13, P2098, DOI 10.1080/21645515.2017.1295906; Olugbile S, 2009, INFECT IMMUN, V77, P5701, DOI 10.1128/IAI.00652-09; Penn-Nicholson A, 2018, LANCET RESP MED, V6, P287, DOI [10.1016/S2213-2600(18)30077-8, 10.1016/s2213-2600(18)30077-8]; Remarque EJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038898; Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Slutzki M, 2012, J MOL RECOGNIT, V25, P616, DOI 10.1002/jmr.2178; Steiner-Monard V, 2019, CLIN INFECT DIS, V68, P466, DOI 10.1093/cid/ciy514; Villard V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000645; WHO, 2019, WORLD MALARIA REPORT; Woodberry T, 2008, J INFECT DIS, V198, P134, DOI 10.1086/588711; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	24	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 10	2020	11								412	10.3389/fimmu.2020.00412	http://dx.doi.org/10.3389/fimmu.2020.00412			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC0SY	32210975	Green Accepted, Green Published, gold			2022-12-18	WOS:000525041700001
J	Bogorodskiy, AO; Bolkhovitina, EL; Gensch, T; Troyanova, NI; Mishin, AV; Okhrimenko, IS; Braun, A; Spies, E; Gordeliy, VI; Sapozhnikov, AM; Borshchevskiy, VI; Shevchenko, MA				Bogorodskiy, Andrey O.; Bolkhovitina, Elena L.; Gensch, Thomas; Troyanova, Natalia, I; Mishin, Alexey, V; Okhrimenko, Ivan S.; Braun, Armin; Spies, Emma; Gordeliy, Valentin, I; Sapozhnikov, Alexander M.; Borshchevskiy, Valentin, I; Shevchenko, Marina A.			Murine Intraepithelial Dendritic Cells Interact With Phagocytic Cells During Aspergillus fumigatus-Induced Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						intraepithelial dendritic cells; Aspergillus fumigatus; mouse model; conducting airway mucosa; whole-mount specimens; fluorescent confocal laser-scanning microscopy	LUNG; RECOGNITION; RECRUITMENT; CD11B/CD18; COMPLEMENT; SUBSETS; ACQUIRE; TISSUES; DC	People are constantly exposed to airborne fungal spores, including Aspergillus fumigatus conidia that can cause life-threatening conditions in immunocompromised patients or acute exacerbations in allergics. However, immunocompetent hosts do not exhibit mycoses or systemic inflammation, due to the sufficient but not excessive antifungal immune response that prevent fungal invasion. Intraepithelial dendritic cells (IE-DCs) of the conducting airway mucosa are located in the primary site of the inhalant pathogen entry; these cells can sense A. fumigatus conidia and maintain homeostasis. The mechanisms by which IE-DCs contribute to regulating the antifungal immune response and controlling conidia dissemination are not understood. To clarify the role of IE-DCs in the balance between pathogen sensing and immune tolerance we investigated the A. fumigatus conidia distribution in optically cleared mouse lungs and estimated the kinetics of the local phagocytic response during the course of inflammation. MHCII+ antigen-presenting cells, including IE-DCs, and CD11b(+) phagocytes were identified by immunohistochemistry and three-dimensional fluorescence confocal laser-scanning microscopy of conducting airway whole-mounts. Application of A. fumigatus conidia increased the number of CD11b(+) phagocytes in the conducting airway mucosa and induced the trafficking of these cells through the conducting airway wall to the luminal side of the epithelium. Some CD11b(+) phagocytes internalized conidia in the conducting airway lumen. During the migration through the airway wall, CD11b(+) phagocytes formed clusters. Permanently located in the airway wall IE-DCs contacted both single CD11b(+) phagocytes and clusters. Based on the spatiotemporal characteristics of the interactions between IE-DCs and CD11b(+) phagocytes, we provide a novel anatomical rationale for the contribution of IE-DCs to controlling the excessive phagocyte-mediated immune response rather than participating in pathogen uptake.	[Bogorodskiy, Andrey O.; Mishin, Alexey, V; Okhrimenko, Ivan S.; Gordeliy, Valentin, I; Borshchevskiy, Valentin, I] Moscow Inst Phys & Technol, Res Ctr Mol Mech Aging & Age Related Dis, Dolgoprudnyi, Russia; [Bolkhovitina, Elena L.; Troyanova, Natalia, I; Sapozhnikov, Alexander M.; Shevchenko, Marina A.] Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Dept Immunol, Lab Cell Interact, Moscow, Russia; [Gensch, Thomas] Forschungszentrum Julich, Inst Biol Informat Proc IBI Mol & Cellular Physio, Julich, Germany; [Braun, Armin; Spies, Emma] Fraunhofer Inst Toxicol & Expt Med ITEM, Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany; [Braun, Armin; Spies, Emma] German Ctr Lung Res DZL, Hannover, Germany; [Braun, Armin; Spies, Emma] Fraunhofer Int Consortium Antiinfect Res iCAIR, Hannover, Germany; [Braun, Armin; Spies, Emma] Hannover Med Sch, Inst Immunol, Hannover, Germany; [Gordeliy, Valentin, I; Borshchevskiy, Valentin, I] Forschungszentrum Julich, Inst Biol Informat Proc IBI Struct Biochem 7, Julich, Germany; [Gordeliy, Valentin, I] Univ Grenoble Alpes, Inst Biol Struct, CEA, CNRS, Grenoble, France	Moscow Institute of Physics & Technology; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Helmholtz Association; Research Center Julich; Fraunhofer Gesellschaft; Hannover Medical School; Helmholtz Association; Research Center Julich; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Borshchevskiy, VI (corresponding author), Moscow Inst Phys & Technol, Res Ctr Mol Mech Aging & Age Related Dis, Dolgoprudnyi, Russia.; Shevchenko, MA (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Dept Immunol, Lab Cell Interact, Moscow, Russia.; Borshchevskiy, VI (corresponding author), Forschungszentrum Julich, Inst Biol Informat Proc IBI Struct Biochem 7, Julich, Germany.	borshchevskiy.vi@phystech.edu; mshevch@gmail.com	Gordeliy, Valentin I/J-3636-2013; Bogorodskiy, Andrey/R-7690-2016; Okhrimenko, Ivan/I-4293-2016; Braun, Armin/B-8750-2009; Borshchevskiy, Valentin I./F-2287-2014; Mishin, Alexey V/F-2960-2014; Sapozhnikov, Alexander M/J-8704-2018	Gordeliy, Valentin I/0000-0001-5782-5896; Bogorodskiy, Andrey/0000-0002-7589-7823; Braun, Armin/0000-0002-1142-1463; Borshchevskiy, Valentin I./0000-0003-4398-9712; Mishin, Alexey V/0000-0003-3759-380X; Shevchenko, Marina/0000-0001-5278-9937; Sapozhnikov, Alexander/0000-0002-4934-677X; Okhrimenko, Ivan/0000-0002-1053-2778	Russian Foundation for Basic Research [18-315-00166, 20-015-00526]; Ministry of Science and Higher Education of the Russian Federation; Russian Science Foundation [19-75-00082]	Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Ministry of Science and Higher Education of the Russian Federation; Russian Science Foundation(Russian Science Foundation (RSF))	This work was supported by the Russian Foundation for Basic Research, grants No. 18-315-00166 and No. 20-015-00526, and by the grant from the Ministry of Science and Higher Education of the Russian Federation Analysis of CD11b+ cell migration was supported by the Russian Science Foundation, grant No. 19-75-00082.	Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264; Akoumianaki T, 2016, CELL HOST MICROBE, V19, P79, DOI 10.1016/j.chom.2015.12.002; Bose O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118513; Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748; Conejero L, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90420; del Fresno C, 2018, SCIENCE, V362, P351, DOI 10.1126/science.aan8423; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; Espinosa V, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00272; Espinosa-Cueto P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182126; Fisher MC, 2018, SCIENCE, V360, P739, DOI 10.1126/science.aap7999; Grabowska J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02472; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hoffmann FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01046; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Jakubzick C, 2008, J IMMUNOL METHODS, V337, P121, DOI 10.1016/j.jim.2008.07.005; Kalleda N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01107; Lammermann T, 2016, J LEUKOCYTE BIOL, V100, P55, DOI 10.1189/jlb.1MR0915-403; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lambrecht BN, 2001, EUR RESPIR J, V18, P692; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; Lother J, 2014, INT J MED MICROBIOL, V304, P1160, DOI 10.1016/j.ijmm.2014.08.009; Lukacsi S, 2017, IMMUNOL LETT, V189, P64, DOI 10.1016/j.imlet.2017.05.014; Moalli F, 2010, BLOOD, V116, P5170, DOI 10.1182/blood-2009-12-258376; Oremland M, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0275-2; Osorio F, 2014, NAT IMMUNOL, V15, P248, DOI 10.1038/ni.2808; Park SJ, 2010, J IMMUNOL, V185, P6190, DOI 10.4049/jimmunol.1002064; Ramirez-Ortiz ZG, 2012, VIRULENCE, V3, P635, DOI 10.4161/viru.22295; Rao GVS, 2003, J TOXICOL ENV HEAL A, V66, P1441, DOI 10.1080/15287390306417; Renkawitz J, 2019, NATURE, V568, P546, DOI 10.1038/s41586-019-1087-5; Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Scott GD, 2014, AM J RESP CELL MOL, V51, P43, DOI 10.1165/rcmb.2013-0284OC; Shevchenko MA, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5379085; Shevchenko MA, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-78; Teschner D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00123; Uderhardt S, 2019, CELL, V177, P541, DOI 10.1016/j.cell.2019.02.028; van de Veerdonk FL, 2017, NAT REV MICROBIOL, V15, P661, DOI 10.1038/nrmicro.2017.90; Veres TZ, 2007, AM J RESP CELL MOL, V37, P553, DOI 10.1165/rcmb.2007-0087OC; Veres TZ, 2017, J IMMUNOL, V198, P895, DOI 10.4049/jimmunol.1601448; Veres TZ, 2013, J IMMUNOL, V190, P897, DOI 10.4049/jimmunol.1200220; Veres TZ, 2011, AM J PATHOL, V179, P603, DOI 10.1016/j.ajpath.2011.04.039; Vroman H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00941; Zelante T, 2015, CELL REP, V12, P1789, DOI 10.1016/j.celrep.2015.08.030; Ziegler S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06238-4	46	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2020	11								298	10.3389/fimmu.2020.00298	http://dx.doi.org/10.3389/fimmu.2020.00298			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LB7CH	32161590	Green Published, gold			2022-12-18	WOS:000524789000001
J	Sun, HW; Shi, KQ; Qi, K; Kong, HR; Zhang, J; Dai, SJ; Ye, W; Deng, T; He, QY; Zhou, MT				Sun, Hongwei; Shi, Keqing; Qi, Kai; Kong, Hongru; Zhang, Jie; Dai, Shengjie; Ye, Wen; Deng, Tuo; He, Qiye; Zhou, Mengtao			Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26 (vol 10, 2819, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						natural killer; pancreatic cancer; extracellular vesicles; miR-3607-3p; IL-26			[Sun, Hongwei; Kong, Hongru; Zhang, Jie; Dai, Shengjie; Ye, Wen; Deng, Tuo] Wenzhou Med Univ, Dept Hepatobiliary Surg, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Wenzhou, Peoples R China; [Shi, Keqing] Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Ctr Precis Med, Affiliated Hosp 1, Wenzhou, Peoples R China; [Qi, Kai] Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai, Peoples R China; [He, Qiye] Singlera Genom Inc, San Diego, CA USA; [He, Qiye] Singlera Genom Shanghai Ltd, Shanghai, Peoples R China; [Zhou, Mengtao] Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Precis Med Ctr Lab, Wenzhou, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; Wenzhou Medical University	Zhou, MT (corresponding author), Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Precis Med Ctr Lab, Wenzhou, Peoples R China.	qianazi@yeah.net	Shi, Keqing/GZK-5146-2022	Shi, Keqing/0000-0002-5070-3834				Sun HW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02819	1	1	1	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2020	11								277	10.3389/fimmu.2020.00277	http://dx.doi.org/10.3389/fimmu.2020.00277			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LA1WR	32153584	Green Published, gold			2022-12-18	WOS:000523745700001
J	Raynor, J; Lin, AD; Hummel, SA; Lampe, K; Jordan, M; Hoebe, K; Hildeman, DA				Raynor, Jana; Lin, Adora; Hummel, Sarah A.; Lampe, Kristin; Jordan, Michael; Hoebe, Kasper; Hildeman, David A.			The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+T Cell Responses During Viral Infection	FRONTIERS IN IMMUNOLOGY			English	Article						NK cells; NK DC cross talk; CD4 T cells; viral infection; innate; adaptive immune response	NATURAL-KILLER-CELLS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; ANTIVIRAL T-CELLS; COMPLEX CLASS-I; IMMUNE-RESPONSES; MICE; RECOGNITION; DEFICIENT; CD8(+); VACCINATION	Increasing evidence points to a key role for NK cells in controlling adaptive immune responses. In studies examining the role of CD1d on CD4+ T cell responses, we found that a line of CD1d-deficient mice on the C57BL/6J background had a homozygous 129 locus on chromosome 6 containing the entire NK cell gene cluster. Mice possessing this locus (C57BL/6.NKC129) displayed a >10-fold reduction in antigen-specific CD4+ T cell responses after intracranial infection with lymphocytic choriomeningitis virus (LCMV). Neither parental strain displayed defects in viral-specific CD4+ T cell responses. Interestingly, following infection, increased numbers of NK cells accumulated in the lymph nodes of C57BL/6.NKC129 mice and displayed enhanced in vivo functionality. Moreover, depletion of NK cells with anti-asialo-GM-1 antibody in C57BL/6.NKC129 mice resulted in a >20-fold increase in viral-specific CD4+ T cell responses. Mechanistically, we found that dendritic cell antigen presentation and early type I IFN production were significantly decreased in C57BL/6.NKC129 mice, but were restored in perforin-deficient C57BL/6.NKC129 mice or following NK depletion. Together, these data reveal that the variable genomic regions containing the activating/inhibitory NK cell receptors are key determinants of antigen-specific CD4+ T cell responses, controlling type I IFN production and the antigen-presenting capacity of dendritic cells.	[Raynor, Jana; Lin, Adora; Hummel, Sarah A.; Lampe, Kristin; Jordan, Michael; Hoebe, Kasper; Hildeman, David A.] Univ Cincinnati, Coll Med, Dept Pediat, Div Immunobiol,Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA; [Raynor, Jana; Lin, Adora] Univ Cincinnati, Dept Pediat, Grad Program Immunol, Cincinnati Childrens Hosp Med Ctr,Coll Med, Cincinnati, OH USA; [Lin, Adora] Childrens Natl Hlth Syst, Washington, DC USA; [Raynor, Jana] St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Hoebe, Kasper] Janssen R&D, Spring House, PA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Children's National Health System; St Jude Children's Research Hospital; Johnson & Johnson; Janssen Pharmaceuticals	Hildeman, DA (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Div Immunobiol,Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA.	david.hildeman@cchmc.org	Lin, Adora/AAO-5404-2021	Lin, Adora/0000-0002-1036-2983; Hummel, Sarah/0000-0003-4446-6198	Public Health Service [AI057753, AI074743]	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	This work was supported by Public Health Service Grant AI057753 (to DH) and AI074743 (KH).	Aichele P, 2006, J IMMUNOL, V176, P4525, DOI 10.4049/jimmunol.176.8.4525; Andrews DM, 2010, J EXP MED, V207, P1333, DOI 10.1084/jem.20091193; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; BILSLAND CAG, 1991, EUR J IMMUNOL, V21, P71, DOI 10.1002/eji.1830210112; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Brandstadter JD, 2011, J INNATE IMMUN, V3, P274, DOI 10.1159/000324176; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Brown MG, 2001, SCIENCE, V292, P934, DOI 10.1126/science.1060042; Carlyle JR, 2008, SEMIN IMMUNOL, V20, P321, DOI 10.1016/j.smim.2008.05.004; Carlyle JR, 2006, J IMMUNOL, V176, P7511, DOI 10.4049/jimmunol.176.12.7511; Cook KD, 2013, J IMMUNOL, V190, P641, DOI 10.4049/jimmunol.1202448; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Crouse J, 2015, TRENDS IMMUNOL, V36, P49, DOI 10.1016/j.it.2014.11.001; Crouse J, 2014, IMMUNITY, V40, P961, DOI 10.1016/j.immuni.2014.05.003; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Diana J, 2009, IMMUNITY, V30, P289, DOI 10.1016/j.immuni.2008.12.017; DOHERTY PC, 1993, J NEUROIMMUNOL, V46, P11, DOI 10.1016/0165-5728(93)90228-Q; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786; Hildeman D, 1997, J VIROL, V71, P9672, DOI 10.1128/JVI.71.12.9672-9678.1997; Hildeman D, 1996, VACCINE, V14, P1223, DOI 10.1016/S0264-410X(96)00028-X; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Krebs P, 2009, BLOOD, V113, P6593, DOI 10.1182/blood-2009-01-201467; Lampe K, 2015, EUR J IMMUNOL, V45, P2072, DOI 10.1002/eji.201445352; Lee SH, 2009, J EXP MED, V206, P2235, DOI 10.1084/jem.20082387; LEHMANNGRUBE F, 1993, J VIROL, V67, P332, DOI 10.1128/JVI.67.1.332-339.1993; Lin AA, 2010, J NEUROIMMUNOL, V226, P8, DOI 10.1016/j.jneuroim.2010.05.026; Lin AA, 2009, J VIROL, V83, P8604, DOI 10.1128/JVI.02477-08; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Mars LT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087717; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031; Orr MT, 2010, NAT IMMUNOL, V11, P321, DOI 10.1038/ni.1849; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.3.CO;2-F; Park SH, 1999, J EXP MED, V190, P885, DOI 10.1084/jem.190.6.885; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Patel R, 2010, J IMMUNOL, V185, P4783, DOI 10.4049/jimmunol.1001287; Peppa D, 2013, J EXP MED, V210, P99, DOI 10.1084/jem.20121172; QUINN DG, 1993, INT IMMUNOL, V5, P1193, DOI 10.1093/intimm/5.10.1193; Roberts TJ, 2004, J IMMUNOL, V172, P3454, DOI 10.4049/jimmunol.172.6.3454; Rydyznski C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7375; Rydyznski CE, 2018, CELL REP, V24, P3367, DOI 10.1016/j.celrep.2018.08.075; Salio M, 2014, ANNU REV IMMUNOL, V32, P323, DOI 10.1146/annurev-immunol-032713-120243; Sheridan R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021979; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Spence PM, 2001, IMMUNOLOGY, V104, P168, DOI 10.1046/j.1365-2567.2001.01302.x; Terrell CE, 2013, BLOOD, V121, P5184, DOI 10.1182/blood-2013-04-495309; Waggoner SN, 2012, NATURE, V481, P394, DOI 10.1038/nature10624; Waggoner SN, 2010, J CLIN INVEST, V120, P1925, DOI 10.1172/JCI41264; Wickstrom SL, 2014, J IMMUNOL, V192, P1577, DOI 10.4049/jimmunol.1300960; Wojciechowski S, 2006, EUR J IMMUNOL, V36, P1694, DOI 10.1002/eji.200635897; Xu HC, 2014, IMMUNITY, V40, P949, DOI 10.1016/j.immuni.2014.05.004; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	60	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 20	2020	11								197	10.3389/fimmu.2020.00197	http://dx.doi.org/10.3389/fimmu.2020.00197			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KT4HC	32153566	gold, Green Published			2022-12-18	WOS:000518974800001
J	Abudukelimu, A; Barberis, M; Redegeld, F; Sahin, N; Sharma, RP; Westerhoff, HV				Abudukelimu, Abulikemu; Barberis, Matteo; Redegeld, Frank; Sahin, Nilgun; Sharma, Raju P.; Westerhoff, Hans, V			Complex Stability and an Irrevertible Transition Reverted by Peptide and Fibroblasts in a Dynamic Model of Innate Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						innate immunity; inflammation; irreversible transitions; bi-stability; fibroblasts; systems biology	ACUTE INFLAMMATORY RESPONSE; IMMUNOGLOBULIN LIGHT-CHAIN; IN-SILICO; MATHEMATICAL-MODEL; SYSTEMS BIOLOGY; IRREVERSIBLE TRANSITIONS; SENSITIVITY-ANALYSIS; CLINICAL-TRIALS; TNF-ALPHA; T-CELLS	We here apply a control analysis and various types of stability analysis to an in silico model of innate immunity that addresses the management of inflammation by a therapeutic peptide. Motivation is the observation, both in silico and in experiments, that this therapy is not robust. Our modeling results demonstrate how (1) the biological phenomena of acute and chronic modes of inflammation may reflect an inherently complex bistability with an irrevertible flip between the two modes, (2) the chronic mode of the model has stable, sometimes unique, steady states, while its acute-mode steady states are stable but not unique, (3) as witnessed by TNF levels, acute inflammation is controlled by multiple processes, whereas its chronic-mode inflammation is only controlled by TNF synthesis and washout, (4) only when the antigen load is close to the acute mode's flipping point, many processes impact very strongly on cells and cytokines, (5) there is no antigen exposure level below which reduction of the antigen load alone initiates a flip back to the acute mode, and (6) adding healthy fibroblasts makes the transition from acute to chronic inflammation revertible, although (7) there is a window of antigen load where such a therapy cannot be effective. This suggests that triple therapies may be essential to overcome chronic inflammation. These may comprise (1) anti-immunoglobulin light chain peptides, (2) a temporarily reduced antigen load, and (3a) fibroblast repopulation or (3b) stem cell strategies.	[Abudukelimu, Abulikemu; Barberis, Matteo; Westerhoff, Hans, V] Univ Amsterdam, Swammerdam Inst Life Sci, Synthet Syst Biol & Nucl Org, Amsterdam, Netherlands; [Abudukelimu, Abulikemu; Sahin, Nilgun; Sharma, Raju P.; Westerhoff, Hans, V] Vrije Univ Amsterdam, Mol Cell Physiol, Amsterdam, Netherlands; [Barberis, Matteo] Univ Surrey, Syst Biol, Sch Biosci & Med, Fac Hlth & Med Sci, Guildford, Surrey, England; [Barberis, Matteo] Univ Surrey, Ctr Math & Computat Biol, Guildford, Surrey, England; [Redegeld, Frank] Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands; [Westerhoff, Hans, V] Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester, Lancs, England; [Westerhoff, Hans, V] Vrije Univ Amsterdam, Syst Biol Amsterdam, Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; University of Surrey; University of Surrey; Utrecht University; University of Manchester; Vrije Universiteit Amsterdam	Westerhoff, HV (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Synthet Syst Biol & Nucl Org, Amsterdam, Netherlands.; Westerhoff, HV (corresponding author), Vrije Univ Amsterdam, Mol Cell Physiol, Amsterdam, Netherlands.; Westerhoff, HV (corresponding author), Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester, Lancs, England.; Westerhoff, HV (corresponding author), Vrije Univ Amsterdam, Syst Biol Amsterdam, Amsterdam, Netherlands.	h.v.westerhoff@uva.nl	Sharma, Raju Prasad/F-4481-2017; Westerhoff, Hans/I-5762-2012	Sharma, Raju Prasad/0000-0001-9103-9127; Barberis, Matteo/0000-0001-5640-7422; Westerhoff, Hans/0000-0002-0443-6114	research Priority Area Systems Biology of the University of Amsterdam; Synpol: EU-FP7 [KBBE. 2012.3.402, 311815]; Corbel: EU-H2020 [NFRADEV-4-2014-2015, 654248]; EOSC-Life [824087]; Epipredict: EU-H2020 MSCAITN-2014-ETN: Marie Sklodowska-Curie Innovative Training Networks (ITN-ETN) [642691]; BBSRC China [BB/J020060/1]; Systems Biology Grant of the University of Surrey; Swammerdam Institute for Life Science Starting Grant of the University of Amsterdam; BBSRC [BB/J020060/1] Funding Source: UKRI	research Priority Area Systems Biology of the University of Amsterdam; Synpol: EU-FP7; Corbel: EU-H2020; EOSC-Life; Epipredict: EU-H2020 MSCAITN-2014-ETN: Marie Sklodowska-Curie Innovative Training Networks (ITN-ETN); BBSRC China(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Systems Biology Grant of the University of Surrey; Swammerdam Institute for Life Science Starting Grant of the University of Amsterdam; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This study was funded by the research Priority Area Systems Biology of the University of Amsterdam as well as by various other grants to HW, i.e., Synpol: EU-FP7 (KBBE. 2012.3.402 #311815), Corbel: EU-H2020 (NFRADEV-4-2014-2015 #654248), EOSC-Life: #824087, Epipredict: EU-H2020 MSCAITN-2014-ETN: Marie Sklodowska-Curie Innovative Training Networks (ITN-ETN) #642691, BBSRC China: BB/J020060/1, and grants to MB, i.e., the Systems Biology Grant of the University of Surrey and the Swammerdam Institute for Life Science Starting Grant of the University of Amsterdam.	Abudukelimu A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01596; Aderem A, 2011, MBIO, V2, DOI 10.1128/mBio.00325-10; Alam M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136139; An G, 2004, CRIT CARE MED, V32, P2050, DOI 10.1097/01.CCM.0000139707.13729.7D; Antia R, 2003, J THEOR BIOL, V221, P585, DOI 10.1006/jtbi.2003.3208; Arican O, 2005, MEDIAT INFLAMM, P273, DOI 10.1155/MI.2005.273; Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; Bayry J, 2008, P NATL ACAD SCI USA, V105, P10221, DOI 10.1073/pnas.0803453105; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-74; Bruggeman FJ, 2005, FEBS J, V272, P1965, DOI 10.1111/j.1742-4658.2005.04626.x; Carlos TM, 2001, J LEUKOCYTE BIOL, V70, P171; CELADA F, 1992, IMMUNOL TODAY, V13, P56, DOI 10.1016/0167-5699(92)90135-T; Chapman JD, 2011, COMPUT METH PROG BIO, V104, P37, DOI 10.1016/j.cmpb.2010.08.019; Chen KC, 2000, MOL BIOL CELL, V11, P369, DOI 10.1091/mbc.11.1.369; Chow CC, 2005, SHOCK, V24, P74, DOI 10.1097/01.shk.0000168526.97716.f3; Clermont G, 2004, CRIT CARE MED, V32, P2061, DOI 10.1097/01.CCM.0000142394.28791.C3; Cockrell RC, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005876; Delitala M, 2013, COMPUT MATH APPL, V66, P1010, DOI 10.1016/j.camwa.2013.06.026; Demeestere D, 2015, DRUG DISCOV TODAY, V20, P928, DOI 10.1016/j.drudis.2015.05.003; Dimitrova E, 2018, BMC SYST BIOL, V12, DOI 10.1186/s12918-018-0580-z; Eftimie R, 2017, J THEOR BIOL, V420, P82, DOI 10.1016/j.jtbi.2017.02.022; Figueiredo LM, 2008, PLOS BIOL, V6, P1539, DOI 10.1371/journal.pbio.0060161; Folcik VA, 2007, THEOR BIOL MED MODEL, V4, DOI 10.1186/1742-4682-4-39; Galli SJ, 2011, NAT IMMUNOL, V12, P1035, DOI 10.1038/ni.2109; Geenen S, 2012, EUR J PHARM SCI, V46, P233, DOI 10.1016/j.ejps.2011.08.017; George AJT, 2005, TRENDS IMMUNOL, V26, P653, DOI 10.1016/j.it.2005.09.011; Glansdorff P., 1978, THERMODYNAMIC THEORY; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Guidi GM, 1997, J PHYS CHEM A, V101, P9367, DOI 10.1021/jp972244k; Heinrich R., 1996, REGULATION CELLULAR, DOI [10.1007/978-1-4613-1161-4, DOI 10.1007/978-1-4613-1161-4]; HERVAGAULT JF, 1987, J THEOR BIOL, V127, P439, DOI 10.1016/S0022-5193(87)80141-8; Hoops S, 2006, BIOINFORMATICS, V22, P3067, DOI 10.1093/bioinformatics/btl485; Hu DW, 2006, J PHYS CHEM A, V110, P5361, DOI 10.1021/jp0561975; Jeon YH, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-182; Joo J, 2007, ANN NY ACAD SCI, V1115, P221, DOI 10.1196/annals.1407.014; Kormelink TG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025392; Kumar R, 2004, J THEOR BIOL, V230, P145, DOI 10.1016/j.jtbi.2004.04.044; Lee HY, 2009, J VIROL, V83, P7151, DOI 10.1128/JVI.00098-09; Ma JF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05468-w; Maeda K, 2019, NPJ SYST BIOL APPL, V5, DOI 10.1038/s41540-019-0091-6; Mata J, 2007, IMMUNOL REV, V216, P198; Maurya MR, 2007, ADV EXP MED BIOL, V598, P62; Mavroudis PD, 2018, COMPUTATION, V7, DOI 10.3390/computation7010003; MELNICOFF MJ, 1989, CELL IMMUNOL, V118, P178, DOI 10.1016/0008-8749(89)90367-5; Miller R, 2005, J PHARMACOKINET PHAR, V32, P185, DOI 10.1007/s10928-005-0074-7; Murase A, 2005, J MATH BIOL, V51, P247, DOI 10.1007/s00285-005-0321-y; Nakano T, 2011, CLIN CHIM ACTA, V412, P843, DOI 10.1016/j.cca.2011.03.007; Niarakis A, 2014, CURR TOP MICROBIOL, V382, P69, DOI 10.1007/978-3-319-07911-0_4; Olgart C, 2001, EUR RESPIR J, V18, P115, DOI 10.1183/09031936.01.00069901; Petersen BK, 2019, J COMPUT BIOL, V26, P597, DOI 10.1089/cmb.2018.0168; Pigozzo AB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S7; Pilling D, 2015, P NATL ACAD SCI USA, V112, P11929, DOI 10.1073/pnas.1507387112; Prince JM, 2006, MOL MED, V12, P88, DOI 10.2119/2006-00012.Prince; Qomlaqi M, 2017, MATH BIOSCI, V292, P1, DOI 10.1016/j.mbs.2017.07.006; Reddy NM, 2009, J IMMUNOL, V183, P4601, DOI 10.4049/jimmunol.0901754; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; Reijenga KA, 2005, J THEOR BIOL, V232, P385, DOI 10.1016/j.jtbi.2004.08.019; Remick DG, 2003, CURR PHARM DESIGN, V9, P75, DOI 10.2174/1381612033392567; Reynolds A, 2006, J THEOR BIOL, V242, P220, DOI 10.1016/j.jtbi.2006.02.016; Rijnierse A, 2010, J IMMUNOL, V185, P653, DOI 10.4049/jimmunol.0901129; Rullmann JAC, 2005, IEE P SYST BIOL, V152, P256, DOI 10.1049/ip-syb:20050053; Scherbakova A, 2013, CYTOM PART A, V83A, P585, DOI 10.1002/cyto.a.22283; Shahaf G, 2006, INT IMMUNOL, V18, P31, DOI 10.1093/intimm/dxh346; Smith AM, 2011, J THEOR BIOL, V276, P106, DOI 10.1016/j.jtbi.2011.01.052; Sontag ED, 2017, CELL SYST, V4, P231, DOI 10.1016/j.cels.2016.12.003; Subramanian N, 2015, WIRES SYST BIOL MED, V7, P13, DOI 10.1002/wsbm.1288; Tanaka RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019895; Teusink B, 2000, EUR J BIOCHEM, V267, P5313, DOI 10.1046/j.1432-1327.2000.01527.x; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Uthaisangsook S, 2002, ANN ALLERG ASTHMA IM, V88, P253, DOI 10.1016/S1081-1206(10)62005-4; van Schouwenburg PA, 2013, NAT REV RHEUMATOL, V9, P164, DOI 10.1038/nrrheum.2013.4; Verhaak PFM, 2005, SOC SCI MED, V60, P789, DOI 10.1016/j.socscimed.2004.06.012; Walker W.E., 2003, INTEGR ASSESS, V4, P5; Watzl C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00359; Westerhoff H., 1987, THERMODYNAMICS CONTR; Westerhoff HV, 2009, J MATH BIOL, V58, P7, DOI 10.1007/s00285-008-0160-8; WESTERHOFF HV, 1987, ARCH BIOCHEM BIOPHYS, V257, P154, DOI 10.1016/0003-9861(87)90554-6; Wodarz D, 2005, INT IMMUNOL, V17, P1269, DOI 10.1093/intimm/dxh303; Wu QL, 2004, CELL MOL IMMUNOL, V1, P57; Zak DE, 2009, IMMUNOL REV, V227, P264, DOI 10.1111/j.1600-065X.2008.00721.x	80	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2020	10								3091	10.3389/fimmu.2019.03091	http://dx.doi.org/10.3389/fimmu.2019.03091			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR2XU	32117197	Green Published, gold			2022-12-18	WOS:000517483800001
J	Carbone, E; De Felice, M; Di Rosa, F; D'Oro, U; Fontana, S; La Cava, A; Maio, M; Matarese, G; Racioppi, L; Ruggiero, G; Terrazzano, G				Carbone, Ennio; De Felice, Mario; Di Rosa, Francesca; D'Oro, Ugo; Fontana, Silvia; La Cava, Antonio; Maio, Michele; Matarese, Giuseppe; Racioppi, Luigi; Ruggiero, Giuseppina; Terrazzano, Giuseppe			Serafino Zappacosta: An Enlightened Mentor and Educator	FRONTIERS IN IMMUNOLOGY			English	Article						education; MHC; T cells; NK cells; immune response	T-CELL PROLIFERATION; CLASS-II MOLECULES; MONOCLONAL-ANTIBODIES; NATURAL-KILLER; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; PEPTIDE BINDING; DENDRITIC CELLS; HLA; ANTIGEN	With this article, the authors aim to honor the memory of Serafino Zappacosta, who had been their mentor during the early years of their career in science. The authors discuss how the combination of Serafino Zappacosta's extraordinary commitment to teaching and passion for science created a fostering educational environment that led to the creation of the "Ruggero Ceppellini Advanced School of Immunology." The review also illustrates how the research on the MHC and the inspirational scientific context in the Zappacosta's laboratory influenced the authors' early scientific interests, and subsequent professional work as immunologists.	[Carbone, Ennio] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Carbone, Ennio] Karolinska Inst, Dept Microbiol Cell & Tumor Biol, Stockholm, Sweden; [De Felice, Mario; Fontana, Silvia; Matarese, Giuseppe] CNR, IEOS, Naples, Italy; [Di Rosa, Francesca] CNR, Inst Mol Biol & Pathol, IBPM, Rome, Italy; [D'Oro, Ugo] GlaxoSmithKline, Siena, Italy; [La Cava, Antonio] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [Maio, Michele] Univ Hosp Siena, Ctr Immunooncol Med Oncol & Immunotherapy, Dept Oncol, Siena, Italy; [Matarese, Giuseppe; Racioppi, Luigi] Univ Napoli Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy; [Racioppi, Luigi] Duke Univ, Sch Med, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27706 USA; [Ruggiero, Giuseppina; Terrazzano, Giuseppe] Univ Napoli Federico II, Dipartimento Sci Med Traslaz, Naples, Italy; [Terrazzano, Giuseppe] Univ Basilicata, Dipartimento Sci, Potenza, Italy	Magna Graecia University of Catanzaro; Karolinska Institutet; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); GlaxoSmithKline; University of California System; University of California Los Angeles; Siena Biotech; University of Siena; University Hospital of Siena; University of Naples Federico II; Duke University; University of Naples Federico II; University of Basilicata	Di Rosa, F (corresponding author), CNR, Inst Mol Biol & Pathol, IBPM, Rome, Italy.; Ruggiero, G (corresponding author), Univ Napoli Federico II, Dipartimento Sci Med Traslaz, Naples, Italy.	francesca.dirosa@cnr.it; giruggie@unina.it	Matarese, Giuseppe/AAO-4077-2021; Di Rosa, Francesca/AAW-8612-2020; racioppi, luigi/AGB-8665-2022	Matarese, Giuseppe/0000-0001-9429-0616; Di Rosa, Francesca/0000-0003-0252-9138; La Cava, Antonio/0000-0002-8839-0933				Al-Daccak R, 2004, CURR OPIN IMMUNOL, V16, P108, DOI 10.1016/j.coi.2003.11.006; Ali TH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6639; [Anonymous], 1699, AVENTURES TELEMAQUES; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Bodmer W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01280; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; CARBONE E, 1991, SCAND J IMMUNOL, V33, P185, DOI 10.1111/j.1365-3083.1991.tb03748.x; Carbone E, 2000, J IMMUNOL, V164, P6130, DOI 10.4049/jimmunol.164.12.6130; Carbone E, 1999, EUR J IMMUNOL, V29, P4022, DOI 10.1002/(SICI)1521-4141(199912)29:12<4022::AID-IMMU4022>3.3.CO;2-F; Carbone E, 1996, EUR J IMMUNOL, V26, P683, DOI 10.1002/eji.1830260326; D'Oro U, 1992, HLA 1991, P632; De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011; Di Giacomo AM, 2019, CLIN CANCER RES, V25, P7351, DOI 10.1158/1078-0432.CCR-19-1335; Di Giacomo A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01494; Di Rosa F, 2016, NAT REV IMMUNOL, V16, P271, DOI 10.1038/nri.2016.31; DIROSA F, 1993, HUM IMMUNOL, V38, P251, DOI 10.1016/0198-8859(93)90552-C; FONTANA S, 1987, CANCER RES, V47, P4178; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GALLAGHER RB, 1990, IMMUNOL TODAY, V11, P187, DOI 10.1016/0167-5699(90)90078-N; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; Giovazzino A, 2019, BRIT J HAEMATOL, V185, P357, DOI 10.1111/bjh.15496; Harton Jonathan, 2016, F1000Res, V5, DOI 10.12688/f1000research.7610.1; Huard B, 1996, EUR J IMMUNOL, V26, P1180, DOI 10.1002/eji.1830260533; IAFFAIOLI RV, 1985, INT J CANCER, V35, P581, DOI 10.1002/ijc.2910350503; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Karre K, 2008, NAT IMMUNOL, V9, P477, DOI 10.1038/ni0508-477; Kaufmann SHE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01214; La Cava A, 2006, TISSUE ANTIGENS, V68, P279, DOI 10.1111/j.1399-0039.2006.00686.x; LACAVA A, 1994, INT J CANCER, V58, P123, DOI 10.1002/ijc.2910580120; Liu YY, 2014, J IMMUNOL, V192, P4069, DOI 10.4049/jimmunol.1302897; Long Long, 2018, Genes Cancer, V9, P176, DOI 10.18632/genesandcancer.180; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Lui Y, 2018, NAT IMMUNOL, V19, P1278, DOI 10.1038/s41590-018-0257-1; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MANZO C, 1990, CELL IMMUNOL, V125, P79, DOI 10.1016/0008-8749(90)90064-X; Matarese G, 2005, P NATL ACAD SCI USA, V102, P5150, DOI 10.1073/pnas.0408995102; Merkenschlager J, 2019, BLOOD, V133, P1108, DOI 10.1182/blood-2018-11-885467; Montanaro D, 2001, CLIN EXP IMMUNOL, V123, P288, DOI 10.1046/j.1365-2249.2001.01457.x; PANZA N, 1982, TISSUE ANTIGENS, V20, P155; PIAZZA A, 1980, HUM IMMUNOL, V1, P297, DOI 10.1016/0198-8859(80)90105-6; PINTO A, 1984, LANCET, V2, P867; Procaccini C, 2016, IMMUNITY, V44, P712, DOI 10.1016/j.immuni.2016.02.022; QUARANTA V, 1981, J IMMUNOL, V126, P548; RACIOPPI L, 1990, J IMMUNOL, V145, P3635; RACIOPPI L, 1988, CANCER RES, V48, P3816; Racioppi L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10424-5; Ruggiero G, 2004, IMMUNOLOGY, V111, P318, DOI 10.1111/j.1365-2567.2004.01811.x; RUGGIERO G, 1991, EUR J IMMUNOL, V21, P29, DOI 10.1002/eji.1830210106; RUGGIERO G, 1987, EUR J IMMUNOL, V17, P1585, DOI 10.1002/eji.1830171110; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; Sanna V, 2003, J CLIN INVEST, V111, P241, DOI 10.1172/JCI200316721; Shapiro M, 2017, HAEMATOLOGICA, V102, P874, DOI 10.3324/haematol.2016.148965; Silberschmidt D, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-9; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Simpson E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01246; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Terrazzano G, 2004, SCAND J IMMUNOL, V59, P356, DOI 10.1111/j.0300-9475.2003.01387.x; Terrazzano G, 2000, TISSUE ANTIGENS, V55, P326, DOI 10.1034/j.1399-0039.2000.550406.x; Terrazzano G, 2007, J IMMUNOL, V179, P372, DOI 10.4049/jimmunol.179.1.372; THAKER Y, 2018, J IMMUNOL S, V200, P101; Tulli L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00330; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; ZAPPACOSTA S, 1980, TISSUE ANTIGENS, V16, P286; ZAPPACOSTA S, 1985, ANN NY ACAD SCI, V458, P46, DOI 10.1111/j.1749-6632.1985.tb14589.x; Zhang QX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aah4569; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	68	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 13	2020	11								217	10.3389/fimmu.2020.00217	http://dx.doi.org/10.3389/fimmu.2020.00217			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR3XM	32117323	Green Published, gold			2022-12-18	WOS:000517551900001
J	Cocker, ATH; Shah, NHM; Raj, I; Dermont, S; Khan, W; Mandalia, S; Imami, N; Johnson, MR				Cocker, Alexander T. H.; Shah, Nishel M.; Raj, Inez; Dermont, Sarah; Khan, Waheed; Mandalia, Sundhiya; Imami, Nesrina; Johnson, Mark R.			Pregnancy Gestation Impacts on HIV-1-Specific Granzyme B Response and Central Memory CD4 T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; pregnancy; T-cell responses; Gag and Nef; immunity; reproduction	INFLUENZA-A VIRUS; ANTIRETROVIRAL THERAPY; VIRAL LOAD; HIV-1 INFECTION; PHARMACOKINETICS; ASSOCIATION; LYMPHOCYTES; EXPRESSION; VIREMIA; BLOOD	Pregnancy induces alterations in peripheral T-cell populations with both changes in subset frequencies and anti-viral responses found to alter with gestation. In HIV-1 positive women anti-HIV-1 responses are associated with transmission risk, however detailed investigation into both HIV-1-specific memory responses associated with HIV-1 control and T-cell subset changes during pregnancy have not been undertaken. In this study we aimed to define pregnancy and gestation related changes to HIV-1-specific responses and T-cell phenotype in ART treated HIV-1 positive pregnant women. Eleven non-pregnant and 24 pregnant HIV-1 positive women were recruited, peripheral blood samples taken, fresh cells isolated, and compared using ELISpot assays and flow cytometry analysis. Clinical data were collected as part of standard care, and non-parametric statistics used. Alterations in induced IFN gamma, IL-2, IL-10, and granzyme B secretion by peripheral blood mononuclear cells in response to HIV-1 Gag and Nef peptide pools and changes in T-cell subsets between pregnant and non-pregnant women were assessed, with data correlated with participant clinical parameters and longitudinal analysis performed. Cross-sectional comparison identified decreased IL-10 Nef response in HIV-1 positive pregnant women compared to non-pregnant, while correlations exhibited reversed Gag and Nef cytokine and protease response associations between groups. Longitudinal analysis of pregnant participants demonstrated transient increases in Gag granzyme B response and in the central memory CD4 T-cell subset frequency during their second trimester, with a decrease in CD4 effector memory T cells from their second to third trimester. Gag and Nef HIV-1-specific responses diverge with pregnancy time-point, coinciding with relevant T-cell phenotype, and gestation associated immunological adaptations. Decreased IL-10 Nef and both increased granzyme B Gag response and central memory CD4 T cells implies that amplified antigen production is occurring, which suggests a period of compromised HIV-1 control in pregnancy.	[Cocker, Alexander T. H.; Shah, Nishel M.; Mandalia, Sundhiya; Imami, Nesrina; Johnson, Mark R.] Imperial Coll London, London, England; [Raj, Inez; Dermont, Sarah; Khan, Waheed] Chelsea & Westminster Hosp, London, England	Imperial College London; Imperial College London	Cocker, ATH (corresponding author), Imperial Coll London, London, England.	a.cocker15@imperial.ac.uk	Cocker, Alex/Y-1017-2019; Shah, Nishel/AAV-7031-2020	Cocker, Alex/0000-0001-7162-0774; Shah, Nishel/0000-0002-5694-9915; Imami, Nesrina/0000-0001-9673-2895	Westminster Medical School Research Trust; CW+; Borne	Westminster Medical School Research Trust; CW+; Borne	Westminster Medical School Research Trust, CW+, and Borne.	Adland E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073117; Aghaeepour N, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2946; Alatrakchi N, 2005, AIDS, V19, P25, DOI 10.1097/00002030-200501030-00003; Bento CAM, 2009, AIDS, V23, P9, DOI 10.1097/QAD.0b013e328317461e; Buhelt S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060634; Calvert C, 2015, TROP MED INT HEALTH, V20, P122, DOI 10.1111/tmi.12412; Carvalho-Silva WHV, 2020, J LEUKOCYTE BIOL, V107, P85, DOI 10.1002/JLB.4A0919-235R; Casazza JP, 2001, J VIROL, V75, P6508, DOI 10.1128/JVI.75.14.6508-6516.2001; Coleman BL, 2018, INFLUENZA OTHER RESP, V12, P22, DOI 10.1111/irv.12504; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Curry AE, 2008, J REPROD IMMUNOL, V77, P152, DOI 10.1016/j.jri.2007.06.051; Dagenais-Lussier X, 2016, J VIROL, V90, P7967, DOI 10.1128/JVI.00994-16; Dembek CJ, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-20; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10; Frater J, 2014, AIDS, V28, P699, DOI 10.1097/QAD.0000000000000130; Ghiglione Y, 2019, JAIDS-J ACQ IMM DEF, V80, P1, DOI 10.1097/QAI.0000000000001887; Gilbert EM, 2015, PHARMACOTHERAPY, V35, P838, DOI 10.1002/phar.1626; Glowala-Kosinska M, 2016, BIOL BLOOD MARROW TR, V22, P834, DOI 10.1016/j.bbmt.2016.01.014; Gravett MG, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S2; Gray CM, 2009, J VIROL, V83, P470, DOI 10.1128/JVI.01678-08; Heffron R, 2014, JAIDS-J ACQ IMM DEF, V65, P231, DOI 10.1097/QAI.0000000000000013; Hygino J, 2012, CLIN IMMUNOL, V145, P177, DOI 10.1016/j.clim.2012.10.001; Janes H, 2013, J INFECT DIS, V208, P1231, DOI 10.1093/infdis/jit322; Jansen CA, 2005, AIDS, V19, P1145, DOI 10.1097/01.aids.0000176214.17990.94; Jin X, 1998, J INFECT DIS, V178, P1317, DOI 10.1086/314455; Kay AW, 2014, P NATL ACAD SCI USA, V111, P14506, DOI 10.1073/pnas.1416569111; Kraus TA, 2012, J CLIN IMMUNOL, V32, P300, DOI 10.1007/s10875-011-9627-2; Lamorde M, 2018, CLIN INFECT DIS, V67, P785, DOI 10.1093/cid/ciy161; Le Gars M, 2016, J INFECT DIS, V214, P1666, DOI 10.1093/infdis/jiw448; Lopez M, 2008, AIDS RES HUM RETROV, V24, P1197, DOI 10.1089/aid.2008.0088; Lugli E, 2013, NAT PROTOC, V8, P33, DOI 10.1038/nprot.2012.143; MACLEAN MA, 1992, EUR J OBSTET GYN R B, V43, P167, DOI 10.1016/0028-2243(92)90169-Y; Maharaj NR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170063; Mandala WL, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12678; Mlotshwa M, 2010, J VIROL, V84, P12018, DOI 10.1128/JVI.01472-10; Mulligan N, 2018, AIDS, V32, P729, DOI [10.1097/qad.0000000000001755, 10.1097/QAD.0000000000001755]; Ndhlovu ZM, 2015, J VIROL, V89, P10735, DOI 10.1128/JVI.01527-15; Nguyen TP, 2017, J LEUKOCYTE BIOL, V102, P499, DOI 10.1189/jlb.3A1216-520RR; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; Okoye AA, 2013, IMMUNOL REV, V254, P54, DOI 10.1111/imr.12066; Patel D, 2009, INT J INFECT DIS, V13, P266, DOI 10.1016/j.ijid.2008.07.004; Perdomo-Celis F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210540; Perfetto SP, 2006, NAT PROTOC, V1, P1522, DOI 10.1038/nprot.2006.250; Radebe M, 2015, AIDS, V29, P23, DOI 10.1097/QAD.0000000000000508; Revelle William, 2020, CRAN; RICH KC, 1995, J INFECT DIS, V172, P1221, DOI 10.1093/infdis/172.5.1221; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sappenfield Elisabeth, 2013, Infect Dis Obstet Gynecol, V2013, P752852, DOI 10.1155/2013/752852; Schieffer M, 2014, J VIROL, V88, P7357, DOI 10.1128/JVI.00728-14; Shah NM, 2019, CLIN IMMUNOL, V208, DOI 10.1016/j.clim.2019.108254; Shah NM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01138; Streiner DL, 2015, AM J CLIN NUTR, V102, P721, DOI 10.3945/ajcn.115.113548; Tanko RF, 2018, CLIN IMMUNOL, V195, P127, DOI 10.1016/j.clim.2018.06.001; Thomas AS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006629; Thomson KA, 2018, J INFECT DIS, V218, P16, DOI 10.1093/infdis/jiy113; Turk G, 2013, J VIROL, V87, P7445, DOI 10.1128/JVI.00865-13; van der Galien R, 2019, CLIN PHARMACOKINET, V58, P309, DOI 10.1007/s40262-018-0684-z; Warren JA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00291; Wei T., 2021, R PACKAGECORRPLOTVIS; Westrop SJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005474; Yue FY, 2017, J VIROL, V91, DOI 10.1128/JVI.02233-16; Zakhour R, 2016, AM J TROP MED HYG, V95, P970, DOI 10.4269/ajtmh.15-0773	63	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2020	11								153	10.3389/fimmu.2020.00153	http://dx.doi.org/10.3389/fimmu.2020.00153			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KS0UJ	32117291	Green Published, gold			2022-12-18	WOS:000518026700001
J	Li, LW; McCall, C; Hu, XY				Li, Liwu; McCall, Charles; Hu, Xiaoyu			Editorial: Innate Immunity Programming and Memory in Resolving and Non-Resolving Inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate immune memory; inflammation dynamics; resolving and non-resolving inflammation; acute disease; chronic disease			[Li, Liwu] Virginia Tech, Dept Biol Sci, Blacksburg, VA 24061 USA; [McCall, Charles] Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27101 USA; [Hu, Xiaoyu] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Hu, Xiaoyu] Tsinghua Univ, Sch Med, Beijing, Peoples R China	Virginia Polytechnic Institute & State University; Wake Forest University; Tsinghua University; Tsinghua University	Li, LW (corresponding author), Virginia Tech, Dept Biol Sci, Blacksburg, VA 24061 USA.; McCall, C (corresponding author), Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27101 USA.; Hu, XY (corresponding author), Tsinghua Univ, Inst Immunol, Beijing, Peoples R China.; Hu, XY (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.	lwli@vt.edu; chmccall@wakehealth.edu; xiaoyuhu@tsinghua.edu.cn	Hu, Xiaoyu/D-5403-2017	Hu, Xiaoyu/0000-0002-4289-6998; Li, Liwu/0000-0001-8870-5299				Baker B, 2015, J BIOL CHEM, V290, P6670, DOI 10.1074/jbc.M114.611442; Chen KQ, 2015, EBIOMEDICINE, V2, P324, DOI 10.1016/j.ebiom.2015.03.001; Geng S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav2309; Geng S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13436; Morris MC, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00680; Yuan RX, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00497	6	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2020	11								177	10.3389/fimmu.2020.00177	http://dx.doi.org/10.3389/fimmu.2020.00177			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KS0UP	32117304	Green Published, gold			2022-12-18	WOS:000518027500001
J	Liao, HY; Li, S; Yu, YS; Yue, YS; Su, KH; Zheng, Q; Jiang, NG; Zhang, ZX				Liao, Hongyan; Li, Song; Yu, Yangsheng; Yue, Yinshi; Su, Kaihong; Zheng, Qin; Jiang, Nenggang; Zhang, Zhixin			Characteristics of Plasmablast Repertoire in Chronically HIV-Infected Individuals for Immunoglobulin H and L Chain Profiled by Single-Cell Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						human immunodeficiency virus; plasmablast; repertoire; variable region; single-cell PCR	MONOCLONAL-ANTIBODIES; POTENT NEUTRALIZATION; STRUCTURAL BASIS; GENE SEGMENTS; IG; REPRESENTATION; GLYCOPROTEIN; EXPRESSION; GERMLINE; PRODUCTS	Characterization of the diversified immunoglobulin (Ig) repertoire may provide insight into pathways that shape an efficient antibody (Ab) repertoire for immune response against human immunodeficiency virus (HIV) infection. This study aimed to profile characteristics of the plasmablast repertoire during chronic HIV infection. Ig variable regions of plasmablasts from both chronically HIV-infected donors (HIVDs) previously treated with antiretroviral therapy (ART) and healthy donors (HDs) were amplified by single-cell PCR to establish the basis for further repertoire analysis. We compared the plasmablast repertoires expressed in multiple chronically HIVDs after ART treatment cessation and HDs. We also examined the non-productive repertoire to identify the indication of the immediate products of the rearrangement machinery without an impact of selection during HIV infection. We found multiple differences between the productive repertoires of HIVD and HD subjects, including biased usages of VH3-49, VH1-2, VH3-33, VH3-74, and VH5-51 in VH and D1-7, D1-14, D1-20, and D5-5/18 in D segments in the HIVD group, as well as shorter and preferential glycine usages in CDRH3 regions. Gene selections were also detected in light chains. Notably, differences between productive rearrangements of HIVDs and HDs outnumbered those between productive and non-productive rearrangements within HIVDs. HIV infection may exert a dominant impact on the development of the plasmablast repertoire. The impact of selection is of limited significance in shaping the plasmablast repertoire. Overall, the data indicate that the environment in which the plasmablasts live can affect the distribution of the VH and VL genes in the repertoire and the amino acid compositions of the expressed Abs.	[Liao, Hongyan; Zheng, Qin; Jiang, Nenggang] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China; [Liao, Hongyan; Yu, Yangsheng; Yue, Yinshi; Su, Kaihong] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Li, Song] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Ctr Canc, Jinan, Peoples R China; [Su, Kaihong] Univ Nebraska Med Ctr, Internal Med, Omaha, NE USA; [Su, Kaihong] Univ Nebraska Med Ctr, Eppley Res Inst, Omaha, NE USA; [Zhang, Zhixin] Sichuan Univ, West China Univ Hosp 2, State Key Lab Biotherapy, Minist Educ,Key Lab Birth Defects,Dept Pediat, Chengdu, Peoples R China	Sichuan University; University of Nebraska System; University of Nebraska Medical Center; Shandong University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Sichuan University	Zheng, Q; Jiang, NG (corresponding author), Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China.	zhengqinhx@scu.edu.cn; j790114@163.com		Zheng, Qin/0000-0002-5174-5593; Zhang, Zhixin/0000-0003-3924-1082	National Natural Science Foundation of China [81902129]; Sichuan University [2018SCUH0064]; Postdoc Research Project of West China Hospital [2018HXBH021]; China Postdoc Science Foundation [2018M633376]; Science & Technology Department of Sichuan Province [2019YFS0321]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan University(Sichuan University); Postdoc Research Project of West China Hospital; China Postdoc Science Foundation; Science & Technology Department of Sichuan Province	The authors are grateful to Drs. Uriel Sandkovsky and Susan Swindells for recruiting HIV-infected donors, and Shilpa Buch, Howard Gendelman, and Uriel Sandkovsky for the valuable discussions. This work was kindly supported by the National Natural Science Foundation of China (grant no. 81902129), Sichuan University (2018SCUH0064), Postdoc Research Project of West China Hospital (grant no. 2018HXBH021), China Postdoc Science Foundation (grant no. 2018M633376), and Science & Technology Department of Sichuan Province (grant no. 2019YFS0321).	BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916; FRIPPIAT JP, 1995, HUM MOL GENET, V4, P983; Gorny MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027780; Gorny MK, 2009, MOL IMMUNOL, V46, P917, DOI 10.1016/j.molimm.2008.09.005; Hioe CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010254; Howie B, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5624; Hoxie JA, 2010, ANNU REV MED, V61, P135, DOI 10.1146/annurev.med.60.042507.164323; Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398; Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100; Jordan N, 2016, ARTHRIT CARE RES, V68, P711, DOI 10.1002/acr.22723; KIPPS TJ, 1990, J EXP MED, V171, P189, DOI 10.1084/jem.171.1.189; KLEIN U, 1994, J EXP MED, V180, P1383, DOI 10.1084/jem.180.4.1383; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Li LZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039534; Liao HY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01691; Liao HY, 2013, CLIN IMMUNOL, V146, P46, DOI 10.1016/j.clim.2012.11.003; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Longo NS, 2017, J IMMUNOL, V198, P3963, DOI 10.4049/jimmunol.1700133; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385; Nakagawa F, 2013, CURR OPIN INFECT DIS, V26, P17, DOI 10.1097/QCO.0b013e32835ba6b1; Pejchal R, 2010, P NATL ACAD SCI USA, V107, P11483, DOI 10.1073/pnas.1004600107; Pinder CL, 2017, J IMMUNOL, V199, P4180, DOI 10.4049/jimmunol.1701253; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reddy ST, 2010, NAT BIOTECHNOL, V28, P965, DOI 10.1038/nbt.1673; Sasso EH, 1996, J CLIN INVEST, V97, P2074, DOI 10.1172/JCI118644; SCHROEDER HW, 1990, P NATL ACAD SCI USA, V87, P6146, DOI 10.1073/pnas.87.16.6146; SCHROEDER HW, 1987, SCIENCE, V238, P791, DOI 10.1126/science.3118465; Souto-Carneiro MM, 2008, J IMMUNOL, V180, P1040, DOI 10.4049/jimmunol.180.2.1040; STEWART AK, 1993, J EXP MED, V177, P409, DOI 10.1084/jem.177.2.409; SUZUKI I, 1995, J IMMUNOL, V154, P3902; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Watson CT, 2017, TRENDS IMMUNOL, V38, P459, DOI 10.1016/j.it.2017.04.003; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688; Zemlin M, 2003, J MOL BIOL, V334, P733, DOI 10.1016/j.jmb.2003.10.007; Zhou TQ, 2015, CELL, V161, P1280, DOI 10.1016/j.cell.2015.05.007; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	41	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2020	10								3163	10.3389/fimmu.2019.03163	http://dx.doi.org/10.3389/fimmu.2019.03163			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR2PZ	32117215	Green Published, gold			2022-12-18	WOS:000517463500001
J	Rolfe, BE; Pio, R; Woodruff, TM; Markiewski, MM; Manthey, HD				Rolfe, Barbara E.; Pio, Ruben; Woodruff, Trent M.; Markiewski, Maciej M.; Manthey, Helga D.			Editorial: The Role of Complement in Tumors	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						complement; cancer; metastasis; C5b-9; C1q; C3a; C5a; complement regulatory proteins	CANCER; MODULATION		[Rolfe, Barbara E.; Manthey, Helga D.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia; [Pio, Ruben] Univ Navarra, Ctr Appl Med Res CIMA, Pamplona, Spain; [Woodruff, Trent M.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Markiewski, Maciej M.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Immunotherapeut & Biotechnol, Abilene, TX USA	University of Queensland; University of Navarra; University of Queensland; Texas Tech University System; Texas Tech University	Rolfe, BE (corresponding author), Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia.	b.rolfe@uq.edu.au	Woodruff, Trent/AAS-4629-2020; Woodruff, Trent M/B-4861-2009; Pio, Ruben/F-5353-2017	Woodruff, Trent/0000-0003-1382-911X; Woodruff, Trent M/0000-0003-1382-911X; Pio, Ruben/0000-0002-6831-6111; Rolfe, Barbara/0000-0002-0468-1371	Australian National Health and Medical Research Council (NHMRC) [APP1103951, APP1164202]; Cancer Council Queensland (CCQ); AECC Scientific Foundation; Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional Una manera de hacer Europa [PI17/00411]; National Institute of Health [R01CA190209]	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland (CCQ)(Cancer Council Queensland); AECC Scientific Foundation; Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional Una manera de hacer Europa; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	BR, RP, TW, and HM acknowledge support from grants from the Australian National Health and Medical Research Council (NHMRC; APP1103951 and APP1164202) and Cancer Council Queensland (CCQ). RP was supported by the AECC Scientific Foundation, and Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional Una manera de hacer Europa (PI17/00411) and MM by the National Institute of Health (R01CA190209).	Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Clarke EV, 2014, J LEUKOCYTE BIOL, V96, P745, DOI 10.1189/jlb.3MR0214-109R; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535; Hawksworth OA, 2017, MOL IMMUNOL, V89, P36, DOI 10.1016/j.molimm.2017.05.015; Kolev M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00001; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Ostrand-Rosenberg S, 2008, NAT BIOTECHNOL, V26, P1348, DOI 10.1038/nbt1208-1348; Thielens NM, 2017, MOL IMMUNOL, V89, P73, DOI 10.1016/j.molimm.2017.05.025	11	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2020	11								139	10.3389/fimmu.2020.00139	http://dx.doi.org/10.3389/fimmu.2020.00139			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KS0UI	32117286	Green Published, gold			2022-12-18	WOS:000518026600001
J	Prado, JG; Frater, J				Prado, Julia G.; Frater, John			Editorial: Immune Surveillance of the HIV Reservoir: Mechanisms, Therapeutic Targeting and New Avenues for HIV Cure	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HIV; reservoir; immunity; cure; CD8; BNAB; NK; immunotherapy			[Prado, Julia G.] IrsiCaixa AIDS Res Inst, Barcelona, Spain; [Prado, Julia G.] Univ Autonoma Barcelona, Germans Trias & Pujol Res Inst, Barcelona, Spain; [Frater, John] Univ Oxford, Nuffield Dept Med, Oxford, England; [Frater, John] Univ Oxford, NIHR Biomed Res Ctr, Oxford, England	Institut de Recerca de la Sida - IrsiCaixa; Autonomous University of Barcelona; University of Oxford; University of Oxford	Prado, JG (corresponding author), IrsiCaixa AIDS Res Inst, Barcelona, Spain.; Prado, JG (corresponding author), Univ Autonoma Barcelona, Germans Trias & Pujol Res Inst, Barcelona, Spain.; Frater, J (corresponding author), Univ Oxford, Nuffield Dept Med, Oxford, England.; Frater, J (corresponding author), Univ Oxford, NIHR Biomed Res Ctr, Oxford, England.	jgarciaprado@irsicaixa.es; john.frater@ndm.ox.ac.uk		G Prado, Julia/0000-0002-5439-4645; Frater, John/0000-0001-7163-7277	Medical Research Council [MR/P011233/1, MR/L006588/1] Funding Source: Medline; MRC [MR/L006588/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Borducchi EN, 2018, NATURE, V564, pE8, DOI 10.1038/s41586-018-0721-y; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P250; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1600693, 10.1056/NEJMoa1105243]; Descours B, 2017, NATURE, V543, P564, DOI 10.1038/nature21710; Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Thornhill JP, 2019, MUCOSAL IMMUNOL, V12, P1212, DOI 10.1038/s41385-019-0180-2	12	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2020	11								70	10.3389/fimmu.2020.00070	http://dx.doi.org/10.3389/fimmu.2020.00070			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KK4UR	32082325	Green Published, gold			2022-12-18	WOS:000512739500001
J	Sung, MH; Regot, S				Sung, Myong-Hee; Regot, Sergi			Editorial: Understanding Immunobiology Through the Specificity of NF-kappa B	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NF-kappaB (NF-kappa B); microscopy; systems biology; quantitative methodologies; high throughput profiling; mathematical modeling			[Sung, Myong-Hee] NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA; [Regot, Sergi] Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Sung, MH (corresponding author), NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA.	sungm@mail.nih.gov		Sung, Myong-Hee/0000-0002-9739-8558					0	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 30	2020	11								59	10.3389/fimmu.2020.00059	http://dx.doi.org/10.3389/fimmu.2020.00059			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KM8FL	32117237	gold, Green Published			2022-12-18	WOS:000514375800001
J	Abolhassani, H; Lim, CK; Aghamohammadi, A; Hammarstrom, L				Abolhassani, Hassan; Lim, Che Kang; Aghamohammadi, Asghar; Hammarstrom, Lennart			Histocompatibility Complex Status and Mendelian Randomization Analysis in Unsolved Antibody Deficiency	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; antibody deficiency; common variable immunodeficiency (CVID); whole exome sequencing; full-resolution MHC typing; Mendelian randomization	COMMON VARIABLE IMMUNODEFICIENCY; IMMUNOGLOBULIN-A DEFICIENCY; IGA DEFICIENCY; SUSCEPTIBILITY; DIAGNOSIS; GENES; ASSOCIATION; MANAGEMENT; DISORDERS; GENOMICS	The pathogenesis in the majority of patients with common variable immunodeficiency (CVID), the most common symptomatic primary immunodeficiency, remains unknown. We aimed to compare the minor and major histocompatibility complex (MHC) markers as well as polygenic scores of common genetic variants between patients with monogenic CVID and without known genetic mutation detected. Monogenic patients were identified in a CVID cohort using whole exome sequencing. Computational full-resolution MHC typing and confirmatory PCR amplicon-based high-resolution typing were performed. Exome-wide polygenic scores were developed using significantly different variants and multi-variant Mendelian randomization (MR) analyses were used to test the causality of significant genetic variants on antibody levels and susceptibility to infectious diseases. Among 83 CVID patients (44.5% females), monogenic defects were found in 40 individuals. Evaluation of the remaining CVID patients without known genetic mutation detected showed 13 and 27 significantly associated MHC-class I and II alleles, respectively. The most significant partial haplotype linked with the unsolved CVID was W*01:01:01-DMA*01:01:01-DMB*01:03:01:02-TAP1*01:01:01 (P < 0.001), where carriers had a late onset of the disease, only infection clinical phenotype, a non-familial form of CVID, post-germinal center defects and a non-progressive form of their disease. Exclusion of monogenic diseases allowed MR analyses to identify significant genetic variants associated with bacterial infections and improved discrepancies observed in MR analyses of previous GWAS studies with low pleiotropy mainly for a lower respiratory infection, bacterial infection and Streptococcal infection. This is the first study on the full-resolution of minor and major MHC typing and polygenic scores on CVID patients and showed that exclusion of monogenic forms of the disease unraveled an independent role of MHC genes and common genetic variants in the pathogenesis of CVID.	[Abolhassani, Hassan; Lim, Che Kang; Hammarstrom, Lennart] Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; [Abolhassani, Hassan; Aghamohammadi, Asghar] Univ Tehran Med Sci, Childrens Med Ctr, Pediat Ctr Excellence, Res Ctr Immunodeficiencies, Tehran, Iran	Karolinska Institutet; Karolinska University Hospital; Tehran University of Medical Sciences	Hammarstrom, L (corresponding author), Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden.	lennart.hammarstrom@ki.se	Abolhassani, Hassan/B-3465-2014	Abolhassani, Hassan/0000-0002-4838-0407; LIM, CHE KANG/0000-0002-3361-0900	Swedish Research Council; Ruth and Richard Julin Foundation; Jonas Soderquist scholarship	Swedish Research Council(Swedish Research CouncilEuropean Commission); Ruth and Richard Julin Foundation; Jonas Soderquist scholarship	We thank the families who participated in the study and made this research possible. This study was supported by the Swedish Research Council, the Jonas Soderquist scholarship, and the Ruth and Richard Julin Foundation.	Abolhassani H, 2014, J INVEST ALLERG CLIN, V24, P6; Abolhassani H, 2018, J CLIN IMMUNOL, V38, P816, DOI 10.1007/s10875-018-0556-1; Abolhassani H, 2019, GENET MED, V21, P243, DOI 10.1038/s41436-018-0012-x; Abolhassani H, 2016, EXPERT REV CLIN IMMU, V12, P1321, DOI 10.1080/1744666X.2016.1198696; Aghamohammadi A, 2004, ACTA MED IRAN, V42, P272; Aghamohammadi A, 2008, INT ARCH ALLERGY IMM, V147, P87, DOI 10.1159/000135694; Aghamohammadi A, 2014, J CLIN IMMUNOL, V34, P478, DOI 10.1007/s10875-014-0001-z; Amanzadeh Amir, 2012, Avicenna Journal of Medical Biotechnology, V4, P103; Bai L, 2013, P NATL ACAD SCI USA, V110, P16097, DOI 10.1073/pnas.1303218110; Barton James C, 2003, BMC Med Genet, V4, P3, DOI 10.1186/1471-2350-4-3; Barton JC, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/542706; Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Cheraghi T, 2014, J INVEST ALLERG CLIN, V24, P198; Coussa Razek Georges, 2018, Am J Ophthalmol Case Rep, V10, P18, DOI 10.1016/j.ajoc.2018.01.024; de la Concha EG, 1999, CLIN EXP IMMUNOL, V116, P516; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219; Fang MY, 2016, J CLIN IMMUNOL, V36, pS68, DOI 10.1007/s10875-016-0260-y; Ferreira RC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002476; Giannobile JV, 2009, J ALLERGY CLIN IMMUN, V123, pS11, DOI 10.1016/j.jaci.2008.12.055; Ginori A, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-12; Johnston DT, 2006, CLIN IMMUNOL, V119, P346, DOI 10.1016/j.clim.2006.02.001; Jolles S, 2013, J ALLER CL IMM-PRACT, V1, P545, DOI 10.1016/j.jaip.2013.09.015; Kartal O, 2016, WIEN KLIN WOCHENSCHR, V128, P822, DOI 10.1007/s00508-015-0769-8; Kienzler AK, 2017, CLIN EXP IMMUNOL, V188, P326, DOI 10.1111/cei.12947; Kiyotani K, 2017, J HUM GENET, V62, P397, DOI 10.1038/jhg.2016.141; Lang ML, 2009, EXPERT REV VACCINES, V8, P1109, DOI [10.1586/erv.09.56, 10.1586/ERV.09.56]; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Mills DM, 2003, SEMIN IMMUNOL, V15, P325, DOI 10.1016/j.smim.2003.09.004; OLERUP O, 1992, P NATL ACAD SCI USA, V89, P10653, DOI 10.1073/pnas.89.22.10653; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Torkamani A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/s41576-018-0018-x; van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020; VANTHIEL DH, 1977, ANN INTERN MED, V86, P10, DOI 10.7326/0003-4819-86-1-10; Venhoff N, 2013, J CLIN IMMUNOL, V33, P909, DOI 10.1007/s10875-013-9892-3; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; Waldrep ML, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-100; Wang YG, 2016, J ALLERGY CLIN IMMUN, V138, P1495, DOI 10.1016/j.jaci.2016.07.011; Xie C, 2017, P NATL ACAD SCI USA, V114, P8059, DOI 10.1073/pnas.1707945114	46	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2020	11								14	10.3389/fimmu.2020.00014	http://dx.doi.org/10.3389/fimmu.2020.00014			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KJ2CD	32038658	Green Published, gold			2022-12-18	WOS:000511864800001
J	Tian, XY; Ma, J; Wang, T; Tian, J; Zhang, Y; Mao, LX; Xu, HX; Wang, SJ				Tian, Xinyu; Ma, Jie; Wang, Ting; Tian, Jie; Zhang, Yue; Mao, Lingxiang; Xu, Huaxi; Wang, Shengjun			Long Non-Coding RNA HOXA Transcript Antisense RNA Myeloid-Specific 1-HOXA1 Axis Downregulates the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in Lung Cancer (vol 9, 473, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						long non-coding RNA; HOXA transcript antisense RNA myeloid-specific 1; HOXA1; myeloid-derived suppressor cells; lung cancer			[Tian, Xinyu; Zhang, Yue; Mao, Lingxiang; Wang, Shengjun] Jiangsu Univ, Dept Lab Med, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China; [Tian, Xinyu; Ma, Jie; Tian, Jie; Xu, Huaxi; Wang, Shengjun] Jiangsu Univ, Sch Med, Jiangsu Key Lab Lab Med, Dept Immunol, Zhenjiang, Jiangsu, Peoples R China; [Wang, Ting] Jiangsu Canc Hosp, Dept Lab Med, Nanjing, Peoples R China	Jiangsu University; Jiangsu University; Nanjing Medical University	Mao, LX; Wang, SJ (corresponding author), Jiangsu Univ, Dept Lab Med, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China.; Wang, SJ (corresponding author), Jiangsu Univ, Sch Med, Jiangsu Key Lab Lab Med, Dept Immunol, Zhenjiang, Jiangsu, Peoples R China.	maolingxiang@aliyun.com; sjwjs@ujs.edu.cn						Tian XY, 2018, FRONT IMMUNOL, V9, DOI [10.3389/fimmu.2018.00473, 10.3389/fimmu.2018.01683]	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2020	10								2929	10.3389/fimmu.2019.02929	http://dx.doi.org/10.3389/fimmu.2019.02929			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KH8VA	32038606	Green Published, gold			2022-12-18	WOS:000510927300001
J	Malmegrim, KCR; Toubert, A; Farge, D; Oliveira, MC				Ribeiro Malmegrim, Kelen Cristina; Toubert, Antoine; Farge, Dominique; Oliveira, Maria Carolina			Editorial: Immune Profile After Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hematopoietic stem cell transplantation; autoimmune diseases; immune reconstitution; immune monitoring; cell therapy	PULSE CYCLOPHOSPHAMIDE; SYSTEMIC-SCLEROSIS		[Ribeiro Malmegrim, Kelen Cristina] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, Brazil; [Ribeiro Malmegrim, Kelen Cristina; Oliveira, Maria Carolina] Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Hemotherapy Ctr, Ctr Cell Based Therapy, Ribeirao Preto, Brazil; [Toubert, Antoine] Univ Paris, Inst Rech St Louis, EMiLy, Paris, France; [Toubert, Antoine] INSERM, UMRS Microenvironm Lymphocyte Dev & Homing 1160, Paris, France; [Toubert, Antoine] Hop St Louis, AP HP, Lab Immunol & Histocompatibilite, Paris, France; [Farge, Dominique] Hop St Louis, AP HP, Unite Med Interne Malad Autoimmunes & Pathol Vasc, Paris, France; [Farge, Dominique] Univ Paris, IRSL, Rech Clin Appl Hematol, Paris, France; [Farge, Dominique] McGill Univ, Dept Med, Montreal, PQ, Canada; [Oliveira, Maria Carolina] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Div Rheumatol Allergy Immunol & Immunotherapy, Ribeirao Preto, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; McGill University; Universidade de Sao Paulo	Oliveira, MC (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Hemotherapy Ctr, Ctr Cell Based Therapy, Ribeirao Preto, Brazil.; Oliveira, MC (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Div Rheumatol Allergy Immunol & Immunotherapy, Ribeirao Preto, Brazil.	mcarolor@usp.br	Rodrigues, Maria Carolina Oliveira/A-2302-2012; Malmegrim, Kelen/H-1016-2015	Rodrigues, Maria Carolina Oliveira/0000-0003-0691-2222; Malmegrim, Kelen/0000-0002-9303-0086				Alexander T, 2018, J AUTOIMMUN, V92, P35, DOI 10.1016/j.jaut.2018.06.002; Burt RK, 2019, JAMA-J AM MED ASSOC, V321, P165, DOI 10.1001/jama.2018.18743; Burt RK, 2011, LANCET, V378, P498, DOI 10.1016/S0140-6736(11)60982-3; Muraro PA, 2017, NAT REV NEUROL, V13, P391, DOI 10.1038/nrneurol.2017.81; Sullivan KM, 2018, NEW ENGL J MED, V378, P35, DOI 10.1056/NEJMoa1703327; van Laar JM, 2014, JAMA-J AM MED ASSOC, V311, P2490, DOI 10.1001/jama.2014.6368	6	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 9	2020	10								3044	10.3389/fimmu.2019.03044	http://dx.doi.org/10.3389/fimmu.2019.03044			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KE9UB	31993057	Green Published, gold			2022-12-18	WOS:000508894800001
J	Krishna, MT; Worm, M; Bilo, MB				Krishna, Mamidipudi Thirumala; Worm, Margitta; Bilo, Maria Beatrice			Editorial: Anaphylaxis - A Distinct Immunological Syndrome, but How Much Do We Really Understand?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						anaphylaxis; IgE; tryptase; food allergy; venom allergy; general anesthesia; mastocytosis	HYMENOPTERA VENOM ALLERGY; TRYPTASE		[Krishna, Mamidipudi Thirumala] Univ Hosp Birmingham NHS Fdn Trust, Dept Allergy & Immunol, Birmingham, W Midlands, England; [Krishna, Mamidipudi Thirumala] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Worm, Margitta] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergy, Div Allergy & Immunol, Berlin, Germany; [Bilo, Maria Beatrice] Univ Hosp Ancona, Dept Internal Med, Allergy Unit, Ancona, Italy; [Bilo, Maria Beatrice] Polytech Univ Marche, Dept Clin & Mol Sci, Ancona, Italy	University of Birmingham; University of Birmingham; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Marche Polytechnic University	Krishna, MT (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Dept Allergy & Immunol, Birmingham, W Midlands, England.; Krishna, MT (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.	mtkrishna@yahoo.com		Worm, Margitta/0000-0002-3449-1245				Baretto RL, 2017, ALLERGY, V72, P2031, DOI 10.1111/all.13226; Bonadonna P, 2018, J ALLER CL IMM-PRACT, V6, P1368, DOI 10.1016/j.jaip.2017.11.025; Bonadonna P, 2018, IMMUNOL ALLERGY CLIN, V38, P455, DOI 10.1016/j.iac.2018.04.010; Cohen SG, 2002, J ALLERGY CLIN IMMUN, V110, P331; Jarkvist J, 2020, ALLERGY, V75, P169, DOI 10.1111/all.13980; Krishna MT, 2014, CLIN EXP IMMUNOL, V178, P399, DOI 10.1111/cei.12424; Krishna MT, 2011, CLIN EXP ALLERGY, V41, P1201, DOI 10.1111/j.1365-2222.2011.03788.x; Krishna MT, 2011, CLIN EXP IMMUNOL, V163, P131, DOI 10.1111/j.1365-2249.2010.04296.x; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1097/WOX.0b013e318211496c; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262; Turner PJ, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100066; Zanotti R, 2015, J ALLERGY CLIN IMMUN, V136, P135, DOI 10.1016/j.jaci.2014.11.035	13	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 19	2019	10								2943	10.3389/fimmu.2019.02943	http://dx.doi.org/10.3389/fimmu.2019.02943			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JZ5XW	31921193	Green Published, gold			2022-12-18	WOS:000505177000001
J	Herbert, A				Herbert, Alan			Contextual Cell Death in Adaptive Immunity: Selecting a Winning Response	FRONTIERS IN IMMUNOLOGY			English	Article						intransitive logic; phenotypic plasticity; contextual cell death; trogocytosis; transendocytosis; chaos & non-linearity; CAR (chimeric antigen receptor) T cells; gene therapeutics	T-CELLS; MECHANISM; PATHWAY	Winning the game "Rock, Scissors, Paper" depends on what others do. There is no guarantee that one choice will always win. Does the adaptive immune system use the same intransitive logic to select winners? Here I propose that specialized receptor-ligand pairs, called clicks, initiate contextual cell death to select the best adaptive immune response to a particular challenge. The outcome depends heavily on the phenotypic plasticity of the immune system and upon cell assemblies built from different lineages. These assemblies are self-organizing and use clicks to determine the combination of cells best equipped to defeat a threat. The arrangement is highly adaptive and capable of rapid evolution. Opportunities exist to re-engineer click-based assemblies to produce novel therapeutics.	[Herbert, Alan] InsideOutBio Inc, Discovery, Charlestown, MA 02129 USA		Herbert, A (corresponding author), InsideOutBio Inc, Discovery, Charlestown, MA 02129 USA.	alan.herbert@insideoutbio.com	Herbert, Alan/AAY-4286-2020	Herbert, Alan/0000-0002-0093-1572				Barrat FJ, 1999, P NATL ACAD SCI USA, V96, P8645, DOI 10.1073/pnas.96.15.8645; Baxter AG, 2002, NAT REV IMMUNOL, V2, P439, DOI 10.1038/nri823; Boissonnas A, 2010, IMMUNITY, V32, P266, DOI 10.1016/j.immuni.2009.11.015; BRETSCHER PA, 1968, NATURE, V220, P444, DOI 10.1038/220444a0; Brink R, 2018, ANNU REV IMMUNOL, V36, P339, DOI 10.1146/annurev-immunol-051116-052510; Freitas AA, 2000, ANNU REV IMMUNOL, V18, P83, DOI 10.1146/annurev.immunol.18.1.83; GARDNER M, 1970, SCI AM, V223, P110; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; GROSSMAN Z, 1986, CANCER RES, V46, P2651; Hagglof T, 2016, NAT IMMUNOL, V17, P1407, DOI 10.1038/ni.3583; Hartmann J, 2017, EMBO MOL MED, V9, P1183, DOI 10.15252/emmm.201607485; Herbert A, 2019, OSF PREPRINTS, DOI [10.31219/osf.io/nhxf4, DOI 10.31219/OSF.IO/NHXF4]; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Jain A, 2017, J IMMUNOL, V198, P3791, DOI 10.4049/jimmunol.1602000; Jiang WZ, 2011, J IMMUNOL, V187, P781, DOI 10.4049/jimmunol.1100789; Keller AN, 2017, CURR OPIN IMMUNOL, V46, P66, DOI 10.1016/j.coi.2017.04.002; Keren L, 2018, CELL, V174, P1373, DOI 10.1016/j.cell.2018.08.039; Kurioka A, 2018, IMMUNOLOGY, V154, P547, DOI 10.1111/imm.12925; Liszewski MK, 2017, MOL IMMUNOL, V84, P2, DOI 10.1016/j.molimm.2017.01.004; Marin E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00274; Morandi B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039170; Nagorsen D, 2009, LEUKEMIA LYMPHOMA, V50, P886, DOI 10.1080/10428190902943077; Nakayama M, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00672; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Orgad R, 2017, SEMIN IMMUNOPATHOL, V39, P121, DOI 10.1007/s00281-016-0589-6; Ovcinnikovs V, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw0902; Paul WE, 2014, CANCER IMMUNOL RES, V2, P503, DOI 10.1158/2326-6066.CIR-14-0046; Poli A, 2018, TRENDS IMMUNOL, V39, P460, DOI 10.1016/j.it.2018.01.011; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Setty M, 2019, NAT BIOTECHNOL, V37, P451, DOI 10.1038/s41587-019-0068-4; Siddiqui S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00337; Vinay Kumar AA., 2020, ROBBINS COTRAN PATHO, P1328; Westera L, 2015, AGING CELL, V14, P219, DOI 10.1111/acel.12311; Yamada Akiko, 2017, Front Immunol, V8, P403, DOI 10.3389/fimmu.2017.00403; Zingoni A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00476	35	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2019	10								2898	10.3389/fimmu.2019.02898	http://dx.doi.org/10.3389/fimmu.2019.02898			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JZ3RR	31921159	Green Published, Green Submitted, gold			2022-12-18	WOS:000505019500001
J	Grobner, R; Kapferer-Seebacher, I; Amberger, A; Redolfi, R; Dalonneau, F; Bjorck, E; Milnes, D; Bally, I; Rossi, V; Thielens, N; Stoiber, H; Gaboriaud, C; Zschocke, J				Grobner, Rebekka; Kapferer-Seebacher, Ines; Amberger, Albert; Redolfi, Rita; Dalonneau, Fabien; Bjorck, Erik; Milnes, Di; Bally, Isabelle; Rossi, Veronique; Thielens, Nicole; Stoiber, Heribert; Gaboriaud, Christine; Zschocke, Johannes			C1R Mutations Trigger Constitutive Complement 1 Activation in Periodontal Ehlers-Danlos Syndrome (vol 10, 2537, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						complement system; connective tissue; periodontitis; C1r/s; Ehlers-Danlos syndrome			[Grobner, Rebekka; Amberger, Albert; Redolfi, Rita; Zschocke, Johannes] Med Univ Innsbruck, Inst Human Genet, Innsbruck, Austria; [Kapferer-Seebacher, Ines] Med Univ Innsbruck, Dept Operat & Restorat Dent, Innsbruck, Austria; [Dalonneau, Fabien; Bally, Isabelle; Rossi, Veronique; Thielens, Nicole; Gaboriaud, Christine] Univ Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France; [Bjorck, Erik] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Bjorck, Erik] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden; [Milnes, Di] Royal Brisbane & Womens Hosp, Genet Hlth Queensland, Herston, Qld, Australia; [Stoiber, Heribert] Med Univ Innsbruck, Inst Virol, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Royal Brisbane & Women's Hospital; Medical University of Innsbruck	Zschocke, J (corresponding author), Med Univ Innsbruck, Inst Human Genet, Innsbruck, Austria.	johannes.zschocke@i-med.ac.at	Zschocke, Johannes/C-5885-2013; Rossi, Véronique/AAF-3412-2021; Thielens, Nicole M/F-2512-2013; Bjorck, Erik/I-3261-2013	Zschocke, Johannes/0000-0002-0046-8274; Rossi, Véronique/0000-0002-6700-3578; Thielens, Nicole M/0000-0002-7354-0302; Bjorck, Erik/0000-0002-1210-2245				Grobner R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02537	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2019	10								2837	10.3389/fimmu.2019.02837	http://dx.doi.org/10.3389/fimmu.2019.02837			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW8BM	31879527	gold, Green Published			2022-12-18	WOS:000503272100001
J	Garcia-Carmona, Y; Ting, AT; Radigan, L; Divakar, SKA; Chavez, J; Meffre, E; Cerutti, A; Cunningham-Rundles, C				Garcia-Carmona, Yolanda; Ting, Adrian T.; Radigan, Lin; Divakar, Sai Krishna Athuluri; Chavez, Jose; Meffre, Eric; Cerutti, Andrea; Cunningham-Rundles, Charlotte			TACI Isoforms Regulate Ligand Binding and Receptor Function (vol 9, 2125, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						TACI; isoforms; B cell; activation; TLR9			[Garcia-Carmona, Yolanda; Ting, Adrian T.; Radigan, Lin; Chavez, Jose; Cerutti, Andrea; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Precis Immunol Inst, Dept Clin Immunol, New York, NY 10029 USA; [Divakar, Sai Krishna Athuluri] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Cerutti, Andrea] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain; [Cerutti, Andrea] Inst Hosp Mar Invest Med IMIM, Program Inflammatory & Cardiovasc Disorders, Barcelona, Spain; [Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med & Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Yale University; ICREA; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Icahn School of Medicine at Mount Sinai	Cunningham-Rundles, C (corresponding author), Icahn Sch Med Mt Sinai, Precis Immunol Inst, Dept Clin Immunol, New York, NY 10029 USA.; Cunningham-Rundles, C (corresponding author), Icahn Sch Med Mt Sinai, Dept Med & Pediat, New York, NY 10029 USA.	charlotte.cunningham-rundles@mssm.edu						Garcia-Carmona Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02125	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 3	2019	10								2772	10.3389/fimmu.2019.02772	http://dx.doi.org/10.3389/fimmu.2019.02772			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW4RK	31839795	gold, Green Published			2022-12-18	WOS:000503040300001
J	Chain, B; Greiff, V; Textor, J; Yaari, G				Chain, Benny; Greiff, Victor; Textor, Johannes; Yaari, Gur			Editorial: Methods and Applications of Computational Immunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						systems immunology; computational biology; bioinformatics; mathematical modeling; innate and adaptive immune response			[Chain, Benny] UCL, Div Infect & Immun, Dept Comp Sci, London, England; [Greiff, Victor] Univ Oslo, Dept Immunol, Oslo, Norway; [Textor, Johannes] Radboud Inst Mol Life Sci, Dept Tumor Immunol, Nijmegen, Netherlands; [Yaari, Gur] Bar Ilan Univ, Fac Engn, Ramat Gan, Israel	University of London; University College London; University of Oslo; Bar Ilan University	Greiff, V (corresponding author), Univ Oslo, Dept Immunol, Oslo, Norway.	victor.greiff@medisin.uio.no	Textor, Johannes/E-1792-2016; Yaari, Gur/ABD-5122-2021	Textor, Johannes/0000-0002-0459-9458; Yaari, Gur/0000-0001-9311-9884; Greiff, Victor/0000-0003-2622-5032					0	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2019	10								2818	10.3389/fimmu.2019.02818	http://dx.doi.org/10.3389/fimmu.2019.02818			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW0XD	31849986	Green Published, gold			2022-12-18	WOS:000502782100001
J	Lukin, K				Lukin, Kara			Leveraging Micro-Stories to Build Engagement, Inclusion, and Neural Networking in Immunology Education	FRONTIERS IN IMMUNOLOGY			English	Article						immunology education; storytelling; neural networking; retention; diversity; inclusion	IMMEDIACY; RETRIEVAL; MEMORY	Storytelling is a highly effective strategy for delivering course content. It can provide real-world contexts and the relevance students desire. Through personal connections to the narrative details, anecdotes facilitate the incorporation of content into pre-existing knowledge and neural networks that enhances retention. In addition, stories can honor students' diverse backgrounds, which builds a sense of belonging and community. In turn, these aspects can drive intrinsic motivation to learn and increase students' alertness in class and overall engagement in the course. Despite the educational power of stories, there often is not enough time to integrate them into curricula. To address this dilemma, faculty can condense stories into micro-stories that require relatively minimal class time. Many aspects of stories that enhance learning can be leveraged in just a few sentences by focusing on narrative details that engage a variety of cognitive and emotional processes. In particular, the inclusion of multiple sensory descriptions and small details, like locations and names, can provide sufficient context to maintain the value stories provide. Micro-stories can function independently or extend a single theme throughout a course. Presented in this Perspective are examples of micro-stories for concepts in immunology and strategies for developing them. Proposals are made for leveraging micro-stories to enhance student engagement and course community, content retention and retrieval, and satisfaction with immunology courses of all sizes and levels.	[Lukin, Kara] Western Governors Univ, Dept Gen Educ, Salt Lake City, UT 84107 USA; [Lukin, Kara] Univ Colorado, Dept Integrat Biol, Denver, CO 80202 USA	University of Colorado System; University of Colorado Denver	Lukin, K (corresponding author), Western Governors Univ, Dept Gen Educ, Salt Lake City, UT 84107 USA.; Lukin, K (corresponding author), Univ Colorado, Dept Integrat Biol, Denver, CO 80202 USA.	iamkaralukin@gmail.com						ANDERSON JR, 1983, SCIENCE, V220, P25, DOI 10.1126/science.6828877; Andrews C., 2018, CODEX, V4, P29; Avraamidou L, 2009, INT J SCI EDUC, V31, P1683, DOI 10.1080/09500690802380695; BOWER GH, 1970, J VERB LEARN VERB BE, V9, P529, DOI 10.1016/S0022-5371(70)80096-2; Brewer C, 2011, AM ASS ADV SCI VIS C; Bruner Jerome, 1986, ACTUAL MINDS POSSIBL, DOI DOI 10.4159/9780674029019; Cooper KM, 2017, CBE-LIFE SCI EDUC, V16, DOI 10.1187/cbe.16-08-0265; Cuevas J, 2018, THEORY RES EDUC, V16, P40, DOI 10.1177/1477878517731450; Fink L. D., 2003, WHAT IS SIGNIFICANT; Frisch JK, 2008, J BIOL EDUC, V42, P164, DOI 10.1080/00219266.2008.9656135; Gasiewski JA, 2012, RES HIGH EDUC, V53, P229, DOI 10.1007/s11162-011-9247-y; Geha R., 2016, CASE STUDIES IMMUNOL; Herreid C. F., 1997, J COLL SCI TEACH, V27, P163; Herreid Clyde Freeman, 2006, START STORY CASE STU, P405; International Diabetes Federation, 2017, DIABETES ATLAS, Veighth; Karpicke JD, 2011, SCIENCE, V331, P772, DOI 10.1126/science.1199327; KELLEY DH, 1988, COMMUN EDUC, V37, P198, DOI 10.1080/03634528809378719; Kim YK, 2016, RES HIGH EDUC, V57, P288, DOI 10.1007/s11162-015-9387-6; LeFebvre L., 2014, J SCHOLARSH TEACH LE, V14, P29, DOI [10.14434/josotl.v14i2.4002, DOI 10.14434/JOSOTL.V14I2.4002]; McGinley L, 2017, WASHINGTON POST; MEHRABIAN A, 1971, J EXP RES PERS, V5, P127; Museus SD, 2017, REV HIGH EDUC, V40, P187, DOI 10.1353/rhe.2017.0001; National Research Council (NRC), 2003, BIO 2010 TRANSF UND; Negrete A, 2003, FACT VIA FICTION PAN; O'Sullivan PB, 2004, J LANG SOC PSYCHOL, V23, P464, DOI 10.1177/0261927X04269588; Paivio A, 2013, IMAGERY VERBAL PROCE; Prins R, 2017, EDUC MEDIA INT, V54, P20, DOI 10.1080/09523987.2017.1324361; Rohrer D, 2014, PSYCHON B REV, V21, P1323, DOI 10.3758/s13423-014-0588-3; Schmader T, 2003, J PERS SOC PSYCHOL, V85, P440, DOI 10.1037/0022-3514.85.3.440; Solberg OD, 2008, HUM IMMUNOL, V69, P443, DOI 10.1016/j.humimm.2008.05.001; Szurmak J, 2013, ACRL 2013; THORNDYKE PW, 1977, COGNITIVE PSYCHOL, V9, P77, DOI 10.1016/0010-0285(77)90005-6; Tokuhama-Espinosa T., 2010, NEW SCI TEACHING LEA; Wadman Meredith, 2019, SCIENCE; Warren M., 2019, NATURE; Wheeler ME, 2000, P NATL ACAD SCI USA, V97, P11125, DOI 10.1073/pnas.97.20.11125; Wheeler RL, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01830; Williams J., 2000, STRATEGIC PROCESSING; Witt PL, 2004, COMMUN MONOGR, V71, P184, DOI 10.1080/036452042000228054	39	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 28	2019	10								2682	10.3389/fimmu.2019.02682	http://dx.doi.org/10.3389/fimmu.2019.02682			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	JV4PY	31849933	Green Published, gold			2022-12-18	WOS:000502348500001
J	Kavanagh, DPJ; Kalia, N				Kavanagh, Dean Philip John; Kalia, Neena			Live Intravital Imaging of Cellular Trafficking in the Cardiac Microvasculature-Beating the Odds	FRONTIERS IN IMMUNOLOGY			English	Review						cardiac imaging; motion artifact detection; motion artifact removal; intravital imaging; microcirculation; ischaemia and reperfusion injury; cardiac microcirculation	DISK CONFOCAL MICROSCOPY; CORONARY MICROCIRCULATION; EJECTION FRACTION; VIVO OBSERVATION; RAT-HEART; LANGENDORFF; DYSFUNCTION; REPERFUSION; ADHESION; BLOOD	Although mortality rates from cardiovascular disease in the developed world are falling, the prevalence of cardiovascular disease (CVD) is not. Each year, the number of people either being diagnosed as suffering with CVD or undergoing a surgical procedure related to it, such as percutaneous coronary intervention, continues to increase. In order to ensure that we can effectively manage these diseases in the future, it is critical that we fully understand their basic physiology and their underlying causative factors. Over recent years, the important role of the cardiac microcirculation in both acute and chronic disorders of the heart has become clear. The recruitment of inflammatory cells into the cardiac microcirculation and their subsequent activation may contribute significantly to tissue damage, adverse remodeling, and poor outcomes during recovery. However, our basic understanding of the cardiac microcirculation is hampered by an historic inability to image the microvessels of the beating heart-something we have been able to achieve in other organs for over 100 years. This stems from a couple of clear and obvious difficulties related to imaging the heart-firstly, it has significant inherent contractile motion and is affected considerably by the movement of lungs. Secondly, it is located in an anatomically challenging position for microscopy. However, recent microscopic and technological developments have allowed us to overcome some of these challenges and to begin to answer some of the basic outstanding questions in cardiac microvascular physiology, particularly in relation to inflammatory cell recruitment. In this review, we will discuss some of the historic work that took place in the latter part of last century toward cardiac intravital, before moving onto the advanced work that has been performed since. This work, which has utilized technology such as spinning-disk confocal and multiphoton microscopy, has-along with some significant advancements in algorithms and software-unlocked our ability to image the "business end" of the cardiac vascular tree. This review will provide an overview of these techniques, as well as some practical pointers toward software and other tools that may be useful for other researchers who are considering utilizing this technique themselves.	[Kavanagh, Dean Philip John; Kalia, Neena] Univ Birmingham, Coll Med & Dent Sci, Inst Cardiovasc Sci, Birmingham, W Midlands, England	University of Birmingham	Kavanagh, DPJ (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Cardiovasc Sci, Birmingham, W Midlands, England.	d.kavanagh@bham.ac.uk			British Heart Foundation [PG/14/92/31234] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Abicht JM, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12390; Aguirre AD, 2014, P NATL ACAD SCI USA, V111, P11257, DOI 10.1073/pnas.1401316111; Bajpai G, 2019, CIRC RES, V124, P263, DOI 10.1161/CIRCRESAHA.118.314028; Bayguinov Peter O, 2018, Curr Protoc Cytom, V85, pe39, DOI 10.1002/cpcy.39; Bell RM, 2011, J MOL CELL CARDIOL, V50, P940, DOI 10.1016/j.yjmcc.2011.02.018; Bhatnagar P, 2016, HEART, V102, P1945, DOI 10.1136/heartjnl-2016-309573; Botcherby EJ, 2013, CIRC RES, V113, P863, DOI 10.1161/CIRCRESAHA.113.301704; British Heart Foundation, 2019, STAT COMP; Bub G, 2010, AM J PHYSIOL-HEART C, V298, pH1616, DOI 10.1152/ajpheart.00481.2009; CHILIAN WM, 1991, BLOOD VESSELS, V28, P236; CHILIAN WM, 1991, CIRC RES, V69, P561, DOI 10.1161/01.RES.69.3.561; CHILIAN WM, 1986, AM J PHYSIOL, V251, pH779, DOI 10.1152/ajpheart.1986.251.4.H779; Cotter MJ, 2001, AM J PATHOL, V159, P473, DOI 10.1016/S0002-9440(10)61719-1; Crea F, 2014, EUR HEART J, V35, P1101, DOI 10.1093/eurheartj/eht513; DE Faria M, 2015, ENCY MEMBRANES, P1, DOI [10.1007/978-3-642-40872-4_1468-1, DOI 10.1007/978-3-642-40872-4_1468-1]; DENG QM, 1995, J THORAC CARDIOV SUR, V109, P466, DOI 10.1016/S0022-5223(95)70277-6; Dunn KW, 2014, IMART SOFTWARE CORRE, V3, DOI 10.4161/intv.2821026090271; Evans E, 2007, BJA EDUC, V7, P2, DOI 10.1093/bjaceaccp/mkl061; Frantz S, 2013, FASEB J, V27, P871, DOI 10.1096/fj.12-214049; Gomez-Conde I, 2015, COMPUT BIOL MED, V64, P246, DOI 10.1016/j.compbiomed.2015.07.001; Hama T, 1998, CELL SIGNAL, V10, P331, DOI 10.1016/S0898-6568(97)00136-8; JONES CJH, 1993, CIRCULATION, V87, P1264, DOI 10.1161/01.CIR.87.4.1264; JONES CJH, 1995, CIRCULATION, V91, P1807, DOI 10.1161/01.CIR.91.6.1807; Jones JS, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00969; Jung K, 2013, CIRC RES, V112, P891, DOI 10.1161/CIRCRESAHA.111.300484; Kaneko T, 2000, CIRC RES, V86, P1093, DOI 10.1161/01.RES.86.10.1093; KASSAB GS, 1993, AM J PHYSIOL, V265, pH350, DOI 10.1152/ajpheart.1993.265.1.H350; Kavanagh DPJ, 2019, CARDIOVASC RES, V115, P1918, DOI 10.1093/cvr/cvz118; Kavanagh DPJ, 2013, CELL TRANSPLANT, V22, P1485, DOI 10.3727/096368912X653192; Kavanagh DPJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059150; Kavanagh DPJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213162; Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; KUHNLE GEH, 1993, J APPL PHYSIOL, V74, P1462, DOI 10.1152/jappl.1993.74.3.1462; Kupatt C, 1997, CARDIOVASC RES, V36, P386, DOI 10.1016/S0008-6363(97)00191-0; Langendorff O., 1895, PFLUGERS ARCH, V61, P291, DOI [DOI 10.1007/BF01812150, 10.1007/BF01812150]; Lee S, 2008, 2008 IEEE/RSJ INTERNATIONAL CONFERENCE ON ROBOTS AND INTELLIGENT SYSTEMS, VOLS 1-3, CONFERENCE PROCEEDINGS, P1192, DOI 10.1109/IROS.2008.4651123; Lee S, 2008, IEEE T ROBOT, V24, P45, DOI 10.1109/TRO.2007.914847; Lee S, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.3.036005; Lee S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2060; Li W, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86660; Li WJ, 2019, J CLIN INVEST, V129, P2293, DOI 10.1172/JCI126428; Li WJ, 2012, J CLIN INVEST, V122, P2499, DOI 10.1172/JCI62970; Liao RL, 2012, AM J PHYSIOL-HEART C, V303, pH156, DOI 10.1152/ajpheart.00333.2012; LIKOFF W, 1967, NEW ENGL J MED, V276, P1063, DOI 10.1056/NEJM196705112761904; Looney MR, 2011, NAT METHODS, V8, P91, DOI 10.1038/NMETH.1543; MARTINI J, 1969, Microvascular Research, V1, P244, DOI 10.1016/0026-2862(69)90026-0; Marzi I., 1994, TRANSPLANTATIONSMEDI, V6, P91; Matsumoto T, 2005, FLUID DYN RES, V37, P60, DOI 10.1016/j.fluiddyn.2004.02.005; Matsumoto-Ida M, 2006, CIRCULATION, V114, P1497, DOI 10.1161/CIRCULATIONAHA.106.628834; Matsuura R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34295-w; Minamikawa T, 1997, AM J PHYSIOL-HEART C, V272, pH236, DOI 10.1152/ajpheart.1997.272.1.H236; NELLIS SH, 1981, CIRC RES, V49, P342, DOI 10.1161/01.RES.49.2.342; Nellis SH, 1982, MICROCIRCULATION HEA, P61; Okazaki Y, 2000, EUR J CARDIO-THORAC, V18, P90, DOI 10.1016/S1010-7940(00)00436-X; Oreopoulos J, 2014, METHOD CELL BIOL, V123, P153, DOI 10.1016/B978-0-12-420138-5.00009-4; Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092; Pittet MJ, 2011, CELL, V147, P983, DOI 10.1016/j.cell.2011.11.004; Podesser BK, 1999, J PHARMACOL TOXICOL, V41, P9, DOI 10.1016/S1056-8719(99)00018-0; Preibisch S, 2010, NAT METHODS, V7, P418, DOI 10.1038/nmeth0610-418; Presson RG, 2011, AM J PATHOL, V179, P75, DOI 10.1016/j.ajpath.2011.03.048; Pries AR, 2008, CARDIOVASC RES, V80, P165, DOI 10.1093/cvr/cvn136; Pries AR, 2017, EUR HEART J, V38, P478, DOI 10.1093/eurheartj/ehv760; RAGOSTA M, 1994, CIRCULATION, V89, P2562, DOI 10.1161/01.CIR.89.6.2562; Rubart M, 2003, AM J PHYSIOL-CELL PH, V284, pC1654, DOI 10.1152/ajpcell.00469.2002; Savvatis K, 2014, CIRC-HEART FAIL, V7, P161, DOI 10.1161/CIRCHEARTFAILURE.113.000604; Seta Y, 1996, J Card Fail, V2, P243, DOI 10.1016/S1071-9164(96)80047-9; Shamonin DP, 2014, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00050; Sherlock B, 2015, BIOMED OPT EXPRESS, V6, P1876, DOI 10.1364/BOE.6.001876; Shimozawa T, 2013, P NATL ACAD SCI USA, V110, P3399, DOI 10.1073/pnas.1216696110; Soulet D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053942; STEINHAUSEN M, 1978, PFLUG ARCH EUR J PHY, V378, P9, DOI 10.1007/BF00581952; Sumen C, 2004, IMMUNITY, V21, P315, DOI 10.1016/S1074-7613(04)00237-7; Sutherland FJ, 2000, PHARMACOL RES, V41, P613, DOI 10.1006/phrs.1999.0653; Takarabe Kyoumi, 2007, Asian Cardiovasc Thorac Ann, V15, P204; Teo GSL, 2015, STEM CELLS, V33, P265, DOI 10.1002/stem.1848; TILLMANNS H, 1974, CIRC RES, V34, P561, DOI 10.1161/01.RES.34.4.561; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; Toyota E, 2005, AM J PHYSIOL-HEART C, V288, pH1598, DOI 10.1152/ajpheart.01103.2003; Toyota E, 2002, CIRCULATION, V105, P621, DOI 10.1161/hc0502.102964; Ustione A, 2011, J MICROSC-OXFORD, V243, P221, DOI 10.1111/j.1365-2818.2011.03532.x; Van Linthout Sophie, 2017, Curr Heart Fail Rep, V14, P251, DOI 10.1007/s11897-017-0337-9; Vinegoni C, 2015, NAT PROTOC, V10, P1802, DOI 10.1038/nprot.2015.119; Vinegoni C, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00147; Vinegoni Claudio, 2012, Intravital, V1, P115; Vinegoni C, 2013, BIOMED OPT EXPRESS, V4, P2095, DOI 10.1364/BOE.4.002095; Wagner DD, 2008, BLOOD, V111, P5271, DOI 10.1182/blood-2008-01-078204; Westermann D, 2007, BASIC RES CARDIOL, V102, P500, DOI 10.1007/s00395-007-0673-0; White RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066489; Xie F, 2018, ULTRASOUND MED BIOL, V44, P1053, DOI 10.1016/j.ultrasmedbio.2018.01.004; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YADA T, 1993, CIRC RES, V72, P939, DOI 10.1161/01.RES.72.5.939; Yoder BA, 2000, AM J RESP CRIT CARE, V162, P1867, DOI 10.1164/ajrccm.162.5.9912145; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zhang YY, 2017, EUR J HEART FAIL, V19, P1379, DOI 10.1002/ejhf.942	95	1	1	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2019	10								2782	10.3389/fimmu.2019.02782	http://dx.doi.org/10.3389/fimmu.2019.02782			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JU6LT	31849965	Green Published, gold			2022-12-18	WOS:000501786700001
J	Mabbott, NA; Hase, K				Mabbott, Neil A.; Hase, Koji			Editorial: Immunological Consequences of Antigen Sampling at Mucosal Surfaces	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mucosal immunity; oral tolerance; M cells; macrophages; dendritic cells; intestinal epithelial cells; mucosal-associated lymphoid tissues; respiratory tract	M CELLS		[Mabbott, Neil A.] Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Hase, Koji] Keio Univ, Grad Sch Pharmaceut Sci, Fac Pharm, Div Biochem, Tokyo, Japan	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; Keio University	Mabbott, NA (corresponding author), Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.; Hase, K (corresponding author), Keio Univ, Grad Sch Pharmaceut Sci, Fac Pharm, Div Biochem, Tokyo, Japan.	neil.mabbott@roslin.ed.ac.uk; hase-kj@pha.keio.ac.jp			Medical Research Council [MR/S000763/1]; Biotechnological and Biological Sciences Research Council [BB/S00547/1, BBS/E/D/10002071, BBS/E/D/20002173]; Japan Society for the Promotion of Science [16K15294, 16H01369, 17KT0055, 17H04089, 18H04680]; BBSRC [BB/S005471/1, BB/R012377/1, BBS/E/D/20002173, BBS/E/D/20002174, BBS/E/D/10002071, BB/S019294/1] Funding Source: UKRI; MRC [MR/S000763/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnological and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	NMwas supported by project funding fromthe Medical Research Council (grant MR/S000763/1) and project and Institute Strategic Program grant funding from the Biotechnological and Biological Sciences Research Council (grant numbers: BB/S00547/1, BBS/E/D/10002071, and BBS/E/D/20002173). KH was supported by the Japan Society for the Promotion of Science (grant numbers: 16K15294, 16H01369, 17KT0055, 17H04089, and 18H04680).	Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Date Y, 2017, INT IMMUNOL, V29, P471, DOI 10.1093/intimm/dxx064; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Ivanov II, 2012, CELL HOST MICROBE, V12, P496, DOI 10.1016/j.chom.2012.09.009; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Rios D, 2016, MUCOSAL IMMUNOL, V9, P907, DOI 10.1038/mi.2015.121; Sehgal A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03638-6; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Wosen JE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02144	9	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2019	10								2773	10.3389/fimmu.2019.02773	http://dx.doi.org/10.3389/fimmu.2019.02773			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JU6MD	31849958	Green Published, gold			2022-12-18	WOS:000501787700001
J	Cantarelli, C; Guglielmo, C; Hartzell, S; Salem, FE; Andrighetto, S; Gazivoda, VP; Fiaccadori, E; La Manna, G; Zaza, G; Leventhal, J; Tassiulas, I; Cravedi, P				Cantarelli, Chiara; Guglielmo, Chiara; Hartzell, Susan; Salem, Fadi El; Andrighetto, Sofia; Gazivoda, Victor P.; Fiaccadori, Enrico; La Manna, Gaetano; Zaza, Gianluigi; Leventhal, Jeremy; Tassiulas, Ioannis; Cravedi, Paolo			Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus	FRONTIERS IN IMMUNOLOGY			English	Article						lupus; prevnar; vaccination; T-FH; T-FR	CONNECTIVE-TISSUE DISEASE; SERIOUS INFECTIONS; IMMUNE-RESPONSES; T-CELLS; ERYTHEMATOSUS; VACCINATIONS; INFLUENZA; COVERAGE	Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-lpr mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin severity score. We also compared immunophenotypes and function of T and B cells from treated and untreated animals. Prevnar-13 elicited the formation of anti-pneumococcal IgM and IgG. Prevnar-13 treated animals showed reduced albuminuria, renal histological lesions, and milder dermatitis compared to vehicle-treated controls. Mitigated disease severity was associated with reduced and increased T follicular helper cells (T-FH) and T follicular regulatory cells (T-FR), respectively, in Prevnar-treated animals. T cells from Prevnar-13 vaccinated mice showed differential cytokine production after aCD3/aCD28 stimulation, with significantly decreased IL-17 and IL-4, and increased IL-10 production compared to non-vaccinated mice. In conclusion, pneumococcal vaccination elicits anti-pneumococcal antibody response and ameliorates disease severity in MRL-lpr mice, which associates with fewer T-FH and increased T-FR. Together, the data support use of Prevnar vaccination in individuals with SLE.	[Cantarelli, Chiara; Guglielmo, Chiara; Hartzell, Susan; Leventhal, Jeremy; Cravedi, Paolo] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA; [Cantarelli, Chiara; Fiaccadori, Enrico] Univ Parma, Dipartimento Med & Chirurg, Azienda Osped Univ Parma, Unita Operat Complessa Nefrol, Parma, Italy; [Guglielmo, Chiara; La Manna, Gaetano] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Nephrol Dialysis & Renal Transplant Unit, St Orsola Hosp, Bologna, Italy; [Salem, Fadi El] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Andrighetto, Sofia; Zaza, Gianluigi] Univ Hosp Verona, Dept Med, Renal Unit, Verona, Italy; [Gazivoda, Victor P.] Maimonides Hosp, Dept Surg, New York, NY USA; [Tassiulas, Ioannis] Icahn Sch Med Mt Sinai, Dept Med, Div Rheumatol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; University of Parma; University Hospital of Parma; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; Icahn School of Medicine at Mount Sinai; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Maimonides Medical Center; Icahn School of Medicine at Mount Sinai	Cravedi, P (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA.	paolo.cravedi@mssm.edu	Zaza, Gianluigi/K-3827-2018	Gazivoda, Victor/0000-0002-2923-6573; Salem, Fadi/0000-0002-2603-2778; La Manna, Gaetano/0000-0001-5473-8551	NIAID NIH HHS [R01 AI132949] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abudulai LN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176641; Andrade Mariana M C, 2019, Oncotarget, V10, P3451, DOI 10.18632/oncotarget.26919; Aringer M, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2341; Avci FY, 2013, SEMIN IMMUNOL, V25, P146, DOI 10.1016/j.smim.2013.05.005; Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535; Bajema IM, 2018, KIDNEY INT, V93, P789, DOI 10.1016/j.kint.2017.11.023; Bertsias G, 2008, ANN RHEUM DIS, V67, P195, DOI 10.1136/ard.2007.070367; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Broker M, 2017, VACCINE, V35, P3286, DOI 10.1016/j.vaccine.2017.04.078; Chehab G, 2018, RHEUMATOLOGY, V57, P1439, DOI 10.1093/rheumatology/key120; Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001; Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032; Donadei C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127428; Elkayam O, 2005, AUTOIMMUNITY, V38, P493, DOI 10.1080/08916930500285725; Feldman CH, 2017, ARTHRITIS RHEUMATOL, V69, P387, DOI 10.1002/art.39849; Feldman CH, 2015, ARTHRITIS RHEUMATOL, V67, P1577, DOI 10.1002/art.39070; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Godsell J, 2016, SCI REP-UK, V6, DOI 10.1038/srep34604; GRAYZEL A, 1991, J CLIN INVEST, V87, P842, DOI 10.1172/JCI115088; Jha V, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010018; Jonnalagadda M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065519; Kar S, 2016, J IMMUNOL, V196, P4204, DOI 10.4049/jimmunol.1502550; Kashef Sara, 2008, Iran J Immunol, V5, P181, DOI IJIv5i3A7; Kowal C, 1999, EUR J IMMUNOL, V29, P1901, DOI 10.1002/(SICI)1521-4141(199906)29:06<1901::AID-IMMU1901>3.0.CO;2-L; Lawson EF, 2015, SEMIN ARTHRITIS RHEU, V44, P666, DOI 10.1016/j.semarthrit.2015.01.002; Luijten RKMAC, 2014, LUPUS, V23, P1512, DOI 10.1177/0961203314543918; Maillefert JF, 1999, RHEUMATOLOGY, V38, P978, DOI 10.1093/rheumatology/38.10.978; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; McCool TL, 1999, INFECT IMMUN, V67, P4862, DOI 10.1128/IAI.67.9.4862-4869.1999; Murdaca G, 2016, HUM VACC IMMUNOTHER, V12, P632, DOI 10.1080/21645515.2015.1107685; Murdaca G, 2014, AUTOIMMUN REV, V13, P75, DOI 10.1016/j.autrev.2013.07.007; Nickerson KM, 2010, J IMMUNOL, V184, P1840, DOI 10.4049/jimmunol.0902592; Ochoa-Reparaz J, 2010, MUCOSAL IMMUNOL, V3, P487, DOI 10.1038/mi.2010.29; Older SA, 1999, SEMIN ARTHRITIS RHEU, V29, P131, DOI 10.1016/S0049-0172(99)80024-9; Purroy C, 2017, J AM SOC NEPHROL, V28, P2377, DOI 10.1681/ASN.2016101100; Ripley BJM, 2005, ANN RHEUM DIS, V64, P849, DOI 10.1136/ard.2004.022681; Rua-Figueroa I, 2017, SEMIN ARTHRITIS RHEU, V47, P38, DOI 10.1016/j.semarthrit.2017.01.010; Ruiz-Perez B, 2005, P NATL ACAD SCI USA, V102, P16753, DOI 10.1073/pnas.0505688102; Sacre K, 2018, ANN RHEUM DIS, V77, P1540, DOI 10.1136/annrheumdis-2017-212789; Saito K, 2013, AUTOIMMUNITY, V46, P231, DOI 10.3109/08916934.2012.757307; Schurder J, 2018, JOINT BONE SPINE, V85, P333, DOI 10.1016/j.jbspin.2017.05.012; Sen G, 2005, J IMMUNOL, V175, P3084, DOI 10.4049/jimmunol.175.5.3084; Serre J, 2017, EUR J INTERN MED, V43, pE43, DOI 10.1016/j.ejim.2017.05.023; Shapiro E, 2000, SEMIN ARTHRITIS RHEU, V30, P215; Singh JA, 2016, BMC MED, V14, DOI [10.1186/s12916-016-0673-8, 10.1186/s12916-016-0557-y]; Stephen Tom Li, 2010, Int J Microbiol, V2010, P917075, DOI 10.1155/2010/917075; Stingele F, 2004, J IMMUNOL, V172, P1483, DOI 10.4049/jimmunol.172.3.1483; Thorburn AN, 2012, J IMMUNOL, V188, P4611, DOI 10.4049/jimmunol.1101299; Tsokos GC, 2016, NAT REV RHEUMATOL, V12, P716, DOI 10.1038/nrrheum.2016.186; Yazdany J, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3011; Zhou HY, 2018, CLIN RHEUMATOL, V37, P2405, DOI 10.1007/s10067-018-4124-0	51	1	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2019	10								2695	10.3389/fimmu.2019.02695	http://dx.doi.org/10.3389/fimmu.2019.02695			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JT9JG	31824490	Green Published, gold			2022-12-18	WOS:000501296900001
J	Thauland, TJ; Khan, HA; Butte, MJ				Thauland, Timothy J.; Khan, Humza A.; Butte, Manish J.			The Actin-Capping Protein Alpha-Adducin Is Required for T-Cell Costimulation	FRONTIERS IN IMMUNOLOGY			English	Article						T cell; cytoskeleton; costimulation; adducin; actin; immune synapse	MARCKS-RELATED DOMAIN; RHO-KINASE; SPECTRIN; CD28; PHOSPHORYLATION; FILAMENTS; COMPLEX; RLTPR	Alpha-adducin (Add1) is a critical component of the actin-spectrin network in erythrocytes, acting to cap the fast-growing, barbed ends of actin filaments, and recruiting spectrin to these junctions. Add1 is highly expressed in T cells, but its role in T-cell activation has not been examined. Using a conditional knockout model, we show that Add1 is necessary for complete activation of CD4+ T cells in response to low levels of antigen but is dispensable for CD8+ T cell activation and response to infection. Surprisingly, costimulatory signals through CD28 were completely abrogated in the absence of Add1. This study is the first to examine the role of actin-capping in T cells, and it reveals a previously unappreciated role for the actin cytoskeleton in regulating costimulation.	[Thauland, Timothy J.; Khan, Humza A.; Butte, Manish J.] Univ Calif Los Angeles, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Butte, MJ (corresponding author), Univ Calif Los Angeles, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90024 USA.	mbutte@ucla.edu	Butte, Manish/T-8860-2019; Butte, Manish/AAM-8604-2020	Butte, Manish/0000-0002-4490-5595; Butte, Manish/0000-0002-4490-5595; Khan, Humza/0000-0002-2384-2740	NIH [R01 GM110482]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful for funding from the NIH (R01 GM110482 to MB).	Badour K, 2007, P NATL ACAD SCI USA, V104, P1593, DOI 10.1073/pnas.0610543104; Boomer JS, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002436; Burkhardt JK, 2008, ANNU REV IMMUNOL, V26, P233, DOI 10.1146/annurev.immunol.26.021607.090347; Cullinan P, 2002, IMMUNOL REV, V189, P111, DOI 10.1034/j.1600-065X.2002.18910.x; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Isakov N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00273; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Liang YM, 2013, NAT IMMUNOL, V14, P858, DOI 10.1038/ni.2634; Lu QJ, 2004, MOL IMMUNOL, V41, P435, DOI 10.1016/j.molimm.2004.03.028; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Meissner JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189545; Robledo RF, 2008, BLOOD, V112, P4298, DOI 10.1182/blood-2008-05-156000; Roncagalli R, 2016, J EXP MED, V213, P2437, DOI 10.1084/jem.20160579; Roybal KT, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad4149; Thauland TJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah3737; Thauland TJ, 2019, ACTIN CAPPING PROTEI, DOI [10.1101/580191, DOI 10.1101/580191]; Tskvitaria-Fuller I, 2003, J IMMUNOL, V171, P2287, DOI 10.4049/jimmunol.171.5.2287; Wang B, 2000, J IMMUNOL, V164, P1216, DOI 10.4049/jimmunol.164.3.1216; Yokosuka T, 2008, IMMUNITY, V29, P589, DOI 10.1016/j.immuni.2008.08.011	23	1	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2019	10								2706	10.3389/fimmu.2019.02706	http://dx.doi.org/10.3389/fimmu.2019.02706			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JT9KU	31824498	Green Published, Green Submitted, gold			2022-12-18	WOS:000501301000001
J	Jawinski, K; Hartmann, M; Singh, C; Kinnear, E; Busse, DC; Ciabattini, A; Fiorino, F; Medaglini, D; Trombetta, CM; Montomoli, E; Contreras, V; Le Grand, R; Coiffier, C; Primard, C; Verrier, B; Tregoning, JS				Jawinski, Karina; Hartmann, Marcus; Singh, Charanjit; Kinnear, Ekaterina; Busse, David C.; Ciabattini, Annalisa; Fiorino, Fabio; Medaglini, Donata; Trombetta, Claudia Maria; Montomoli, Emanuele; Contreras, Vanessa; Le Grand, Roger; Coiffier, Celine; Primard, Charlotte; Verrier, Bernard; Tregoning, John S.			Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection	FRONTIERS IN IMMUNOLOGY			English	Article						influena virus; protozoa; adjuvant; nanoparticle; vaccine manufacture	POLY(LACTIC ACID); CUTTING EDGE; TRANSFORMATION; PROTEINS	Current influenza vaccines manufactured using eggs have considerable limitations, both in terms of scale up production and the potential impact passaging through eggs can have on the antigenicity of the vaccine virus strains. Alternative methods of manufacture are required, particularly in the context of an emerging pandemic strain. Here we explore the production of recombinant influenza haemagglutinin using the ciliated protozoan Tetrahymena thermophila. For the first time we were able to produce haemagglutinin from both seasonal influenza A and B strains. This ciliate derived material was immunogenic, inducing an antibody response in both mice and non-human primates. Mice immunized with ciliate derived haemagglutinin were protected against challenge with homologous influenza A or B viruses. The antigen could also be combined with submicron particles containing a Nod2 ligand, significantly boosting the immune response and reducing the dose of antigen required. Thus, we show that Tetrahymena can be used as a manufacturing platform for viral vaccine antigens.	[Jawinski, Karina; Hartmann, Marcus] Cilian AG, Munster, Germany; [Singh, Charanjit; Kinnear, Ekaterina; Busse, David C.; Tregoning, John S.] Imperial Coll London, Dept Infect Dis, St Marys Campus, London, England; [Ciabattini, Annalisa; Fiorino, Fabio; Medaglini, Donata] Univ Siena, Lab Mol Microbiol & Biotechnol, Dept Med Biotechnol, Siena, Italy; [Trombetta, Claudia Maria; Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, Siena, Italy; [Montomoli, Emanuele] VisMederi Srl, Siena, Italy; [Contreras, Vanessa; Le Grand, Roger] Univ Paris Sud 11, INSERM U1184, Immunol Viral Infect & Autoimmune Dis, CEA,IDMIT Dept,IBFJ, Le Kremlin Bicetre, France; [Coiffier, Celine] Univ Lyon 1, Lab Biol Tissulaire & Ingn Therapeut, UMR 5305, CNRS,IBCP, Lyon, France; [Primard, Charlotte; Verrier, Bernard] Adjuvatis, Lyon, France	Imperial College London; University of Siena; University of Siena; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tregoning, JS (corresponding author), Imperial Coll London, Dept Infect Dis, St Marys Campus, London, England.	john.tregoning@imperial.ac.uk	; MONTOMOLI, EMANUELE/Q-2122-2015; MEDAGLINI, DONATA/R-1149-2018; verrier, bernard/J-4094-2017	Busse, David/0000-0003-3872-3557; MONTOMOLI, EMANUELE/0000-0001-7595-4974; MEDAGLINI, DONATA/0000-0003-1729-7325; Tregoning, John/0000-0001-8093-8741; Trombetta, Claudia Maria/0000-0001-7229-9919; CIABATTINI, ANNALISA/0000-0002-4585-7783; Contreras, Vanessa/0000-0003-4072-9819; Fiorino, Fabio/0000-0002-1440-8061; Primard, Charlotte/0000-0002-3341-9161; verrier, bernard/0000-0002-8478-7095	European Community's European 7th Framework Program ADITEC [HEALTH-F4-2011-18 280873]; National Institute for Health Research (NIHR) Imperial Biomedical Research Center (BRC); ANR (French National Research Agency) under the frame of European Innovative Research & Technological Development Projects in Nanomedicine within the framework of the ERA-NET, EuroNanoMed-II concerning the FlunanoAir research program; Wellcome Trust	European Community's European 7th Framework Program ADITEC; National Institute for Health Research (NIHR) Imperial Biomedical Research Center (BRC)(National Institute for Health Research (NIHR)); ANR (French National Research Agency) under the frame of European Innovative Research & Technological Development Projects in Nanomedicine within the framework of the ERA-NET, EuroNanoMed-II concerning the FlunanoAir research program(French National Research Agency (ANR)); Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by the European Community's European 7th Framework Program ADITEC (HEALTH-F4-2011-18 280873). JT is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Center (BRC). Support from ANR (French National Research Agency) under the frame of European Innovative Research & Technological Development Projects in Nanomedicine within the framework of the ERA-NET, EuroNanoMed-II concerning the FlunanoAir research program. DB was supported by a Wellcome Trust studentship.	Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z; Calow J, 2016, MABS-AUSTIN, V8, P1498, DOI 10.1080/19420862.2016.1228504; CassidyHanley D, 1997, GENETICS, V146, P135; Chalmers JJ, 1996, CYTOTECHNOLOGY, V20, P163, DOI 10.1007/BF00350397; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Ciabattini A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00427; Collins K, 2005, CURR BIOL, V15, pR317, DOI 10.1016/j.cub.2005.04.039; Cowan GJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087198; Donis RO, 2014, VACCINE, V32, P6583, DOI 10.1016/j.vaccine.2014.06.045; Gaertig J, 2000, METHOD CELL BIOL, V62, P485; Groves HT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00126; Gutjahr A, 2017, J IMMUNOL, V198, P4205, DOI 10.4049/jimmunol.1602131; Gutjahr A, 2016, TRENDS IMMUNOL, V37, P716, DOI 10.1016/j.it.2016.08.005; Hartmann M., 2014, IND SCALE SUSPENSION, P294, DOI [10.1002/9783527683321.ch09, DOI 10.1002/9783527683321.CH09]; Hellenbroich D, 1999, APPL MICROBIOL BIOT, V51, P447, DOI 10.1007/s002530051415; Ikonomou L, 2003, APPL MICROBIOL BIOT, V62, P1, DOI 10.1007/s00253-003-1223-9; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert L, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00321; Legaz S, 2016, NANOTOXICOLOGY, V10, P1136, DOI 10.1080/17435390.2016.1181806; Meghrous J, 2009, VACCINE, V28, P309, DOI 10.1016/j.vaccine.2009.10.048; Moon CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053900; Pandey A, 2010, HUM VACCINES, V6, P178, DOI 10.4161/hv.6.2.9899; Parker L, 2016, J GEN VIROL, V97, P1333, DOI 10.1099/jgv.0.000457; Pavot V, 2016, BIOMATERIALS, V75, P327, DOI 10.1016/j.biomaterials.2015.10.034; Pavot V, 2014, NANOMEDICINE-UK, V9, P2703, DOI [10.2217/NNM.14.156, 10.2217/nnm.14.156]; Pavot V, 2014, J IMMUNOL, V193, P5781, DOI 10.4049/jimmunol.1402184; Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015; Santoro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01248; Shang YH, 2002, P NATL ACAD SCI USA, V99, P3734, DOI 10.1073/pnas.052016199; She YM, 2013, PROTEOMICS, V13, P3537, DOI 10.1002/pmic.201300096; Siggins MK, 2015, VACCINE, V33, P4954, DOI 10.1016/j.vaccine.2015.07.034; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063; Subbarao K, 2019, CELL HOST MICROBE, V25, P773, DOI 10.1016/j.chom.2019.05.012; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Tussey L, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw015; Weide T, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-12; Zhu CH, 2018, J VET MED SCI, V80, P1610, DOI 10.1292/jvms.18-0291	39	1	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2019	10								2661	10.3389/fimmu.2019.02661	http://dx.doi.org/10.3389/fimmu.2019.02661			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JR1IR	31798589	Green Published, gold			2022-12-18	WOS:000499388100001
J	Pejoski, D; Ballester, M; Auderset, F; Vono, M; Christensen, D; Andersen, P; Lambert, PH; Siegrist, CA				Pejoski, David; Ballester, Marie; Auderset, Floriane; Vono, Maria; Christensen, Dennis; Andersen, Peter; Lambert, Paul-Henri; Siegrist, Claire-Anne			Site-Specific DC Surface Signatures Influence CD4(+) T Cell Co-stimulation and Lung-Homing (vol 10, 1650, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						CD11b(+) dendritic cells; lung CD4(+) T cells; lung homing; tissue imprinting; costimulation; vaccination route			[Pejoski, David; Ballester, Marie; Auderset, Floriane; Vono, Maria; Lambert, Paul-Henri; Siegrist, Claire-Anne] Univ Geneva, Dept Pathol & Immunol, Fac Med, Geneva, Switzerland; [Pejoski, David; Ballester, Marie; Auderset, Floriane; Vono, Maria; Lambert, Paul-Henri; Siegrist, Claire-Anne] Univ Geneva, World Hlth Org Collaborating Ctr Vaccine Immunol, Fac Med, Geneva, Switzerland; [Christensen, Dennis; Andersen, Peter] Statens Serum Inst, Ctr Vaccine Res, Copenhagen, Denmark; [Andersen, Peter] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark	University of Geneva; University of Geneva; World Health Organization; Statens Serum Institut; University of Copenhagen	Pejoski, D (corresponding author), Univ Geneva, Dept Pathol & Immunol, Fac Med, Geneva, Switzerland.; Pejoski, D (corresponding author), Univ Geneva, World Hlth Org Collaborating Ctr Vaccine Immunol, Fac Med, Geneva, Switzerland.	david.pejoski@unige.ch	Christensen, Dennis/C-6378-2008; Pejoski, David/J-8243-2019	Christensen, Dennis/0000-0003-2382-8639; Pejoski, David/0000-0001-5010-0550				Pejoski D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01650	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 11	2019	10								2640	10.3389/fimmu.2019.02640	http://dx.doi.org/10.3389/fimmu.2019.02640			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ8EL	31777477	Green Published, gold			2022-12-18	WOS:000499171700001
J	Vajdy, M				Vajdy, Michael			Editorial: Induction and Maintenance of Long-Term Immunological Memory Following Infection or Vaccination	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunological memory; B cell memory; T cell memory; vaccination; adjuvant; infection	RESPONSES; ADJUVANT		[Vajdy, Michael] EpitoGenesis Inc, Sacramento, CA 95834 USA		Vajdy, M (corresponding author), EpitoGenesis Inc, Sacramento, CA 95834 USA.	vajdy@epitogenesis.com						Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; Patel S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050516; Patel S, 2016, IMMUNOLOGY, V148, P352, DOI 10.1111/imm.12614; Vajdy M, 2006, CURR MED CHEM, V13, P3023, DOI 10.2174/092986706778521760	4	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 8	2019	10								2658	10.3389/fimmu.2019.02658	http://dx.doi.org/10.3389/fimmu.2019.02658			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ4TU	31781127	Green Published, gold			2022-12-18	WOS:000498940900001
J	Gessani, S; Van Duijnhoven, FJ; Moreno-Aliaga, MJ				Gessani, Sandra; Van Duijnhoven, Franzel J.; Jesus Moreno-Aliaga, Maria			Editorial: Diet, Inflammation and Colorectal Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						diet; obesity; inflammation; colorectal cancer; dietary factors			[Gessani, Sandra] Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy; [Van Duijnhoven, Franzel J.] Wageningen Univ & Res, Div Human Nutr & Hlth, Wageningen, Netherlands; [Jesus Moreno-Aliaga, Maria] Univ Navarra, Dept Nutr Food Sci & Physiol, Ctr Nutr Res, Pamplona, Spain; [Jesus Moreno-Aliaga, Maria] Navarras Hlth Res Inst IdiSNA, Pamplona, Spain; [Jesus Moreno-Aliaga, Maria] Carlos III Hlth Inst, CIBERobn Physiopathol Obes & Nutr, Madrid, Spain	Istituto Superiore di Sanita (ISS); Wageningen University & Research; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN	Gessani, S (corresponding author), Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy.	sandra.gessani@iss.it	van Duijnhoven, Fränzel/GWC-0059-2022; Gessani, Sandra/K-5151-2016	Gessani, Sandra/0000-0002-8451-0758				Afshari K, 2019, J CELL PHYSIOL, V234, P21519, DOI 10.1002/jcp.28777; Bishayee A, 2016, SEMIN CANCER BIOL, V40-41, P1, DOI 10.1016/j.semcancer.2016.08.006; Durazzo A, 2019, PHYTOTHER RES, V33, P2221, DOI 10.1002/ptr.6419; Gucalp A, 2016, SEMIN ONCOL, V43, P154, DOI 10.1053/j.seminoncol.2015.09.012; Martinez-Fernandez L, 2015, PROSTAG OTH LIPID M, V121, P24, DOI 10.1016/j.prostaglandins.2015.07.003; Martinez-Useros J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0772-5; Saus E, 2019, MOL ASPECTS MED, V69, P93, DOI 10.1016/j.mam.2019.05.001; Volpato M, 2018, CANCER METAST REV, V37, P545, DOI 10.1007/s10555-018-9744-y	8	1	1	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 7	2019	10								2598	10.3389/fimmu.2019.02598	http://dx.doi.org/10.3389/fimmu.2019.02598			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ0CU	31787978	gold, Green Published			2022-12-18	WOS:000498623600001
J	Tamburini, BAJ; Padera, TP; Lund, AW				Tamburini, Beth Ann Jiron; Padera, Timothy P.; Lund, Amanda W.			Editorial: Regulation of Immune Function by the Lymphatic Vasculature	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lymphatic vasculature; lymphatic endothelial cell (LEC); leukocyte trafficking; lymphedema; immune regulation; cancer lymphatics; antigen presentation			[Tamburini, Beth Ann Jiron] Univ Colorado, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Anschutz Med Campus, Aurora, CO 80045 USA; [Tamburini, Beth Ann Jiron] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO 80045 USA; [Padera, Timothy P.] Harvard Med Sch, Massachusetts Gen Hosp, Edwin L Steele Labs, Dept Radiat Oncol,Res Inst, Boston, MA 02115 USA; [Lund, Amanda W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Harvard Medical School; Massachusetts General Hospital; Oregon Health & Science University	Tamburini, BAJ (corresponding author), Univ Colorado, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Anschutz Med Campus, Aurora, CO 80045 USA.; Tamburini, BAJ (corresponding author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO 80045 USA.; Padera, TP (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Edwin L Steele Labs, Dept Radiat Oncol,Res Inst, Boston, MA 02115 USA.; Lund, AW (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.	beth.tamburini@cuanschutz.edu; tpadera@steele.mgh.harvard.edu; lunda@ohsu.edu		Lund, Amanda/0000-0001-7389-9983	University of Colorado Department of Medicine Outstanding Early Career Scholar and RNA Biosciences Clinical Scholar Award; National Institutes of Health NIAID [R01 AI121209]; OHSU Knight Cancer Center support grant from the National Institutes of Health [NIH P30-CA069533]; Department of Defense Peer Reviewed Cancer Research Program [W81XH-15-1-0348]; V Foundation for Cancer Research [V2015-024]; American Cancer Society [RSG-18-169-01-LIB]; National Institutes of Health NCI [R01CA238163]; National Institutes of Health [R01CA214913, R01HL128168, R21AI135092]; Melanoma Research Alliance; Cancer Research Institute CLIP Program; NATIONAL CANCER INSTITUTE [R01CA214913, R01CA238163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI135092, R01AI121209] Funding Source: NIH RePORTER	University of Colorado Department of Medicine Outstanding Early Career Scholar and RNA Biosciences Clinical Scholar Award; National Institutes of Health NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OHSU Knight Cancer Center support grant from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Peer Reviewed Cancer Research Program(United States Department of Defense); V Foundation for Cancer Research; American Cancer Society(American Cancer Society); National Institutes of Health NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; Cancer Research Institute CLIP Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	BT was supported by the University of Colorado Department of Medicine Outstanding Early Career Scholar and RNA Biosciences Clinical Scholar Award and National Institutes of Health NIAID (R01 AI121209). AL was supported by the OHSU Knight Cancer Center support grant from the National Institutes of Health (NIH P30-CA069533), Department of Defense Peer Reviewed Cancer Research Program (W81XH-15-1-0348), Melanoma Research Alliance, V Foundation for Cancer Research (V2015-024), American Cancer Society (RSG-18-169-01-LIB), Cancer Research Institute CLIP Program, National Institutes of Health NCI (R01CA238163), and is a Cancer Research Institute Lloyd J. Old STAR. TP was supported by the National Institutes of Health (R01CA214913, R01HL128168, and R21AI135092).		0	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2019	10								2597	10.3389/fimmu.2019.02597	http://dx.doi.org/10.3389/fimmu.2019.02597			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JP9AN	31781105	Green Published, gold			2022-12-18	WOS:000498549900001
J	Costello, R; Cantillo, JF; Kenter, AL				Costello, Ryan; Cantillo, Jose F.; Kenter, Amy L.			Chicken MBD4 Regulates Immunoglobulin Diversification by Somatic Hypermutation	FRONTIERS IN IMMUNOLOGY			English	Article						Ig; somatic hypermutation; B cells; uracil DNA glycosylase; DT40; CRISPR	MISMATCH REPAIR; CLASS-SWITCH; GLYCOSYLASE DOMAIN; GENE CONVERSION; CUTTING EDGE; DNA; URACIL; MUTATIONS; DEAMINASE; MED1	Immunoglobulin (Ig) diversification occurs via somatic hypermutation (SHM) and class switch recombination (CSR), and is initiated by activation-induced deaminase (AID), which converts cytosine to uracil. Variable (V) region genes undergo SHM to create amino acid substitutions that produce antibodies with higher affinity for antigen. The conversion of cytosine to uracil in DNA promotes mutagenesis. Two distinct DNA repair mechanisms regulate uracil processing in Ig genes. The first involves base removal by the uracil DNA glycosylase (UNG), and the second detects uracil via the mismatch repair (MMR) complex. Methyl binding domain protein 4 (MBD4) is a uracil glycosylase and an intriguing candidate for involvement in somatic hypermutation because of its interaction with the MMR MutL homolog 1 (MLH1). We found that the DNA uracil glycosylase domain of MBD4 is highly conserved among mammals, birds, shark, and insects. Conservation of the human and chicken MBD4 uracil glycosylase domain structure is striking. Here we examined the function of MBD4 in chicken DT40 B cells which undergo constitutive SHM. We constructed structural variants of MBD4 DT40 cells using CRISPR/Cas9 genome editing. Disruption of the MBD4 uracil glycosylase catalytic region increased SHM frequency in IgM loss assays. We propose that MBD4 plays a role in SHM.	[Costello, Ryan; Cantillo, Jose F.; Kenter, Amy L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kenter, AL (corresponding author), Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA.	star1@uic.edu	Costello, Ryan/HCH-3123-2022; Cantillo, Jose Fernando/F-5570-2017	Cantillo, Jose Fernando/0000-0002-6736-1527; Costello, Ryan/0000-0001-7028-1627	National Institutes of Health [R21AI133050, RO1AI121286]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants to AK from the National Institutes of Health (R21AI133050, RO1AI121286).	Arakawa H, 2004, PLOS BIOL, V2, P967, DOI 10.1371/journal.pbio.0020179; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bardwell PD, 2003, J IMMUNOL, V170, P1620, DOI 10.4049/jimmunol.170.4.1620; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Chaudhuri Jayanta, 2007, Adv Immunol, V94, P157, DOI 10.1016/S0065-2776(06)94006-1; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Cortellino S, 2003, P NATL ACAD SCI USA, V100, P15071, DOI 10.1073/pnas.2334585100; Di Noia JM, 2006, EMBO J, V25, P585, DOI 10.1038/sj.emboj.7600939; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Dingler FA, 2014, EUR J IMMUNOL, V44, P1925, DOI 10.1002/eji.201444482; Durandy A, 2006, CURR OPIN RHEUMATOL, V18, P369, DOI 10.1097/01.bor.0000231905.12172.b5; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Grigera F, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00316-16; Grigera F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078370; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Kumar S, 2013, GENE DEV, V27, P2439, DOI 10.1101/gad.227165.113; Miyaki M, 2001, ONCOGENE, V20, P5215, DOI 10.1038/sj.onc.1204578; Morera S, 2012, NUCLEIC ACIDS RES, V40, P9917, DOI 10.1093/nar/gks714; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Pearson WR, 2013, CURR PROTOC BIOINFOR, V42, DOI 10.1002/0471250953.bi0301s42; Peled JU, 2008, ANNU REV IMMUNOL, V26, P481, DOI 10.1146/annurev.immunol.26.021607.090236; Phung QH, 1999, J IMMUNOL, V162, P3121; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Saribasak H, 2006, J IMMUNOL, V176, P365, DOI 10.4049/jimmunol.176.1.365; Saribasak H, 2009, PHILOS T R SOC B, V364, P605, DOI 10.1098/rstb.2008.0188; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Visnes T, 2009, PHILOS T R SOC B, V364, P563, DOI 10.1098/rstb.2008.0186; Wu PY, 2003, J BIOL CHEM, V278, P5285, DOI 10.1074/jbc.M210884200; Zanotti KJ, 2016, DNA REPAIR, V38, P110, DOI 10.1016/j.dnarep.2015.11.011; Zubani GG, 2017, J EXP MED, V214, P1169, DOI 10.1084/jem.20161576	38	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 1	2019	10								2540	10.3389/fimmu.2019.02540	http://dx.doi.org/10.3389/fimmu.2019.02540			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JR9KN	31736964	gold, Green Published			2022-12-18	WOS:000499935300001
J	Edelblum, K; Gustafsson, K; Pennington, DJ; Willcox, BE; Ribot, JC				Edelblum, Karen; Gustafsson, Kenth; Pennington, Daniel J.; Willcox, Benjamin E.; Ribot, Julie C.			Bordeaux 2018: Wine, Cheese, and gamma delta T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						gamma delta T cells; conference report; recent advances; ongoing research; futures perspectives	RECOGNITION; RECEPTOR; PROTEIN; STRESS		[Edelblum, Karen] Rutgers New Jersey Med Sch, Dept Pathol Immunol & Lab Med, Ctr Immun & Inflammat, Newark, NJ 07103 USA; [Gustafsson, Kenth] Infect Immun & Inflammat Program, London, England; [Gustafsson, Kenth] UCL Great Ormond St Inst Child Hlth, Mol & Cellular Immunol Sect, London, England; [Pennington, Daniel J.] Queen Mary Univ London, Barts & London Sch Med, Blizard Inst, London, England; [Willcox, Benjamin E.] Univ Birmingham, Canc Immunol & Immunotherapy Ctr, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Ribot, Julie C.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of London; University College London; University of London; Queen Mary University London; University of Birmingham; Universidade de Lisboa	Edelblum, K (corresponding author), Rutgers New Jersey Med Sch, Dept Pathol Immunol & Lab Med, Ctr Immun & Inflammat, Newark, NJ 07103 USA.; Ribot, JC (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.	karen.edelblum@rutgers.edu; jribot@medecina.ulisboa.pt	Ribot, Julie/D-5487-2014	Ribot, Julie/0000-0002-7852-343X; Pennington, Daniel/0000-0001-7889-9923	NIH; American association of Immunology; University of Bordeaux (Idex); Region Nouvelle-Aquitaine; Fondation ARC; SIRIC Brio; European Federation of Immunological Societies; Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado [UID/BIM/50005/2019]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American association of Immunology; University of Bordeaux (Idex); Region Nouvelle-Aquitaine(Region Nouvelle-Aquitaine); Fondation ARC; SIRIC Brio; European Federation of Immunological Societies; Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado	We thank all researchers cited in this report for their input and sincerely apologize to those who could not be covered due to length restrictions. We thank Maaya Wakasugi for the visuals of the congress. We thank Wendy Havran for her valuable contribution to fund raising. This conference was generously sponsored by an NIH grant, American association of Immunology, University of Bordeaux (Idex), Region Nouvelle-Aquitaine, Fondation ARC, SIRIC Brio, European Federation of Immunological Societies and various commercial sponsors. UID/BIM/50005/2019, project funded by Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado. We thank all the members of the ImmunoConcEpT laboratory who have been actively involved in this congress organization. The authors acknowledge Matthias Eberl, Julie Dechanet-Merville, and Maria Mamani Matsuda for critical comments on the manuscript.	Adams EJ, 2008, NAT IMMUNOL, V9, P777, DOI 10.1038/ni.1620; Bas A, 2011, P NATL ACAD SCI USA, V108, P4376, DOI 10.1073/pnas.1010647108; Benveniste PM, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aav4036; Boyden LM, 2008, NAT GENET, V40, P656, DOI 10.1038/ng.108; Cai YH, 2019, J INVEST DERMATOL, V139, P146, DOI 10.1016/j.jid.2018.07.025; Cai YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4986; Chen CY, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003501; Correia DV, 2011, BLOOD, V118, P992, DOI 10.1182/blood-2011-02-339135; Davey MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04076-0; Davey MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14760; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Hao JL, 2011, J IMMUNOL, V187, P4979, DOI 10.4049/jimmunol.1101389; Hassane M, 2017, MUCOSAL IMMUNOL, V10, P1056, DOI 10.1038/mi.2016.113; Huang YF, 2016, J IMMUNOL, V196, P217, DOI 10.4049/jimmunol.1501064; Huang YF, 2015, P NATL ACAD SCI USA, V112, pE39, DOI 10.1073/pnas.1415107111; Hunter S, 2018, J HEPATOL, V69, P654, DOI 10.1016/j.jhep.2018.05.007; Kohlgruber AC, 2018, NAT IMMUNOL, V19, P464, DOI 10.1038/s41590-018-0094-2; Li HS, 2011, CANCER IMMUNOL IMMUN, V60, P361, DOI 10.1007/s00262-010-0945-7; Luoma AM, 2013, IMMUNITY, V39, P1032, DOI 10.1016/j.immuni.2013.11.001; Mamedov MR, 2018, IMMUNITY, V48, P350, DOI 10.1016/j.immuni.2018.01.009; Marlin R, 2017, P NATL ACAD SCI USA, V114, P3163, DOI 10.1073/pnas.1621052114; Melandri D, 2018, NAT IMMUNOL, V19, P1352, DOI 10.1038/s41590-018-0253-5; Mensurado S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2004990; Ravens S, 2017, NAT IMMUNOL, V18, P393, DOI 10.1038/ni.3686; Ribeiro M, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay5199; Ribot JC, 2014, J IMMUNOL, V192, P2237, DOI 10.4049/jimmunol.1303119; Sandrock I, 2018, J EXP MED, V215, P3006, DOI 10.1084/jem.20181439; Schmolka N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao1392; Tosolini M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284723; Uldrich AP, 2013, NAT IMMUNOL, V14, P1137, DOI 10.1038/ni.2713; Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394; Zuberbuehler MK, 2019, NAT IMMUNOL, V20, P73, DOI 10.1038/s41590-018-0274-0	32	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2019	10								2544	10.3389/fimmu.2019.02544	http://dx.doi.org/10.3389/fimmu.2019.02544			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JJ9BT	31708934	Green Published, gold			2022-12-18	WOS:000494447300001
J	Demaria, M; Barry, A; Murphy, K				Demaria, Maria; Barry, Anita; Murphy, Kim			Using Inquiry-Based Learning to Enhance Immunology Laboratory Skills	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; undergraduate student; pedagogy; inquiry-based learning; active learning and teaching methodologies; laboratory skills	INSTRUCTION; PERFORMANCE; STRENGTHEN; SCIENCE	A challenge in teaching immunology in the undergraduate laboratory is to encompass the many varied skills that need to be applied when performing an investigative study of such a complex area. It requires background knowledge, data analysis skills, critical thinking, and design capacities to include relevant controls and applications of particular techniques to answer a research question. It also requires strong technical skills. One such approach is to use inquiry-based learning which allows students a more proactive and integrative role in their learning. In one of our final year immunology units we have incorporated an inquiry-based exercise that runs across four 5-hour sessions. Students are given two cornerstone immunology techniques (ELISA and a flow cytometry-based cytokine bead array), which they use to formulate a study investigating inflammation. Stage one is to design the experiment with some guidance from teaching staff, stage two is to perform the experiment, and then finally students are required to analyze the data, apply appropriate statistics, and write a report outlining their findings. This approach provides students ownership of the process and allows them the opportunity to investigate a real-world problem rather than just attempting to obtain the expected "correct answer." Feedback from both students and staff has been positive with strong engagement and high quality reports produced.	[Demaria, Maria; Barry, Anita; Murphy, Kim] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia	Monash University	Murphy, K (corresponding author), Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia.	kim.murphy@monash.edu						Aditomo A, 2013, STUD HIGH EDUC, V38, P1239, DOI 10.1080/03075079.2011.616584; Banchi H., 2008, SCI CHILDREN, V46, P26; Berkes C, 2015, BIOSCENE, V41, P3; Eckert GU, 2004, MED TEACH, V26, P521, DOI 10.1080/01421590412331285414; Edelson DC, 1999, J LEARN SCI, V8, P391, DOI 10.1207/s15327809jls0803&4_3; Freeman S, 2014, P NATL ACAD SCI USA, V111, P8410, DOI 10.1073/pnas.1319030111; Gormally C., 2009, INT J FORTHE SCHOLAR, DOI DOI 10.20429/ijsotl.2009.030216; Gunn KE, 2013, J MICROBIOL BIOL EDU, V14, P189, DOI 10.1128/jmbe.v14i2.542; Kirschner PA, 2006, EDUC PSYCHOL-US, V41, P75, DOI 10.1207/s15326985ep4102_1; Kvam PH, 2000, AM STAT, V54, P136, DOI 10.2307/2686032; Levy P, 2012, STUD HIGH EDUC, V37, P85, DOI 10.1080/03075079.2010.499166; Lord T, 2006, AM BIOL TEACH, V68, P342, DOI 10.1662/0002-7685(2006)68[342:DTIIIA]2.0.CO;2; Manzoni-de-Almeida D., 2016, INVESTIGACOES ENSINO, V21, DOI [10.22600/1518-8795.ienci2016v21n2p105, DOI 10.22600/1518-8795.IENCI2016V21N2P105]; Metz AM, 2008, CBE-LIFE SCI EDUC, V7, P317, DOI 10.1187/cbe.07-07-0046; Michel da Rosa Ana Cecilia, 2003, Med Educ Online, V8, P4335, DOI 10.3402/meo.v8i.4335; Moskovitz C, 2011, SCIENCE, V332, P919, DOI 10.1126/science.1200353; Spronken-Smith R, 2010, STUD HIGH EDUC, V35, P723, DOI 10.1080/03075070903315502; Summerlee A, 2010, CAN J HIGH EDUC, V40, P78; Weaver GC, 2008, NAT CHEM BIOL, V4, P577, DOI 10.1038/nchembio1008-577	19	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2019	10								2510	10.3389/fimmu.2019.02510	http://dx.doi.org/10.3389/fimmu.2019.02510			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology	JK2FJ	31695704	Green Published, gold			2022-12-18	WOS:000494662300001
J	Asad, M; Sabur, A; Shadab, M; Das, S; Kamran, M; Didwania, N; Ali, N				Asad, Mohammad; Sabur, Abdus; Shadab, Mohammad; Das, Sonali; Kamran, Mohd.; Didwania, Nicky; Ali, Nahid			EBI-3 Chain of IL-35 Along With TGF-beta Synergistically Regulate Anti-leishmanial Immunity (vol 10, 616, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						regulatory T cells; Leishmania; immune response; interleukin-35; transforming growth factor beta; immune suppression			[Asad, Mohammad; Sabur, Abdus; Shadab, Mohammad; Das, Sonali; Kamran, Mohd.; Didwania, Nicky; Ali, Nahid] IICB, CSIR, Infect Dis & Immunol Div, Kolkata, India; [Asad, Mohammad] Univ Alabama Birmingham, Sch Med, Dept Dermatol, Birmingham, AL USA; [Shadab, Mohammad] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); University of Alabama System; University of Alabama Birmingham; University of Rochester	Ali, N (corresponding author), IICB, CSIR, Infect Dis & Immunol Div, Kolkata, India.	nali@iicb.res.in	KAMRAN, MOHD/ABF-8235-2021; Asad, Mohammad/AAE-4367-2020	KAMRAN, MOHD/0000-0001-9007-6735; Asad, Mohammad/0000-0003-3078-200X				Asad M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00616	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2019	10								2409	10.3389/fimmu.2019.02409	http://dx.doi.org/10.3389/fimmu.2019.02409			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JJ7DA	31681298	Green Published, gold			2022-12-18	WOS:000494312500001
J	Ellis, K; Pennell, CA				Ellis, Kiara; Pennell, Christopher A.			Demystifying Cancer Immunotherapy for Lay Audiences	FRONTIERS IN IMMUNOLOGY			English	Article						cancer; community; engagement; immunotherapy; outreach	MONOCLONAL-ANTIBODY; IMMIGRANT WOMEN; T-CELLS; BARRIERS; CTLA-4; BREAST	Immunotherapy is now mainstream. Advertisements are ubiquitous in print and visual media for immune based-therapies for various conditions and diseases. Smaller companies that develop novel immunotherapies are often quickly acquired by larger companies. More and more clinical trials are open for immune-based therapies, particularly for immune checkpoint blockades. As such, immunologists need to engage the public in conversations about the strengths and limitations of immunotherapy, and the necessity of research in propelling the field further. In this article, we discuss approaches we have taken to convey key concepts in immunology and cancer immunotherapy to non-scientists and health care professionals without expertise in immunology. Although the devil is always in the details, basic concepts in immunology and immunotherapy can be readily conveyed using stories and analogies, some of which we present here.	[Ellis, Kiara; Pennell, Christopher A.] Univ Minnesota, Off Community Engagement & Educ, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Pennell, Christopher A.] Univ Minnesota, Dept Lab Med & Pathol, Ctr Immunol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Pennell, CA (corresponding author), Univ Minnesota, Off Community Engagement & Educ, Masonic Canc Ctr, Minneapolis, MN 55455 USA.; Pennell, CA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Ctr Immunol, Minneapolis, MN 55455 USA.	penne001@umn.edu			MCC's Cancer Center Support Grant from the NCI [P30-CA077598-21]	MCC's Cancer Center Support Grant from the NCI	We gratefully acknowledge the philanthropic support of the Minnesota Masonic Charities and MCC's Cancer Center Support Grant from the NCI (P30-CA077598-21).	Bianconi E, 2013, ANN HUM BIOL, V40, P463, DOI 10.3109/03014460.2013.807878; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ghebre RG, 2015, J IMMIGR MINOR HEALT, V17, P722, DOI 10.1007/s10903-014-0080-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HENDERSON DA, 1980, PUBLIC HEALTH REP, V95, P422; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee HY, 2017, J TRANSCULT NURS, V28, P353, DOI 10.1177/1043659616649670; Lor M, 2014, J CANCER EDUC, V29, P358, DOI 10.1007/s13187-014-0615-0; Maloney DG, 1997, BLOOD, V90, P2188; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mohammed S, 2016, ADV ANAT PATHOL, V23, P180, DOI 10.1097/PAP.0000000000000116; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Ottaviano M, 2019, VIRCHOWS ARCH, V474, P421, DOI 10.1007/s00428-019-02538-4; Sewali B, 2015, CANCER MED-US, V4, P620, DOI 10.1002/cam4.429; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stossel LM, 2012, J GEN INTERN MED, V27, P1165, DOI 10.1007/s11606-012-2046-0; Thomas L., 1959, CELLULAR HUMORAL ASP, P529; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	23	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2019	10								2488	10.3389/fimmu.2019.02488	http://dx.doi.org/10.3389/fimmu.2019.02488			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JJ7BI	31681338	Green Published, gold			2022-12-18	WOS:000494308100001
J	Mbiribindi, B; Mukherjee, S; Wellington, D; Das, J; Khakoo, SI				Mbiribindi, Berenice; Mukherjee, Sayak; Wellington, Dannielle; Das, Jayajit; Khakoo, Salim I.			Spatial Clustering of Receptors and Signaling Molecules Regulates NK Cell Response to Peptide Repertoire Changes (vol 10, 605, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						NK cells; peptide antagonism; KIR; HLA-C; signaling; modeling			[Mbiribindi, Berenice; Khakoo, Salim I.] Univ Southampton, Fac Med, Dept Clin & Expt Sci, Southampton, Hants, England; [Mukherjee, Sayak] Inst Bioinformat & Appl Biotechnol, Bangalore, Karnataka, India; [Wellington, Dannielle] Univ Southampton, Fac Med, Dept Canc Sci, Southampton, Hants, England; [Das, Jayajit] Nationwide Childrens Hosp, Res Inst, Battelle Ctr Math Med, Columbus, OH 43205 USA; [Das, Jayajit] Ohio State Univ, Wexner Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Das, Jayajit] Ohio State Univ, Biophys Program, Columbus, OH 43210 USA	University of Southampton; University of Southampton; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Khakoo, SI (corresponding author), Univ Southampton, Fac Med, Dept Clin & Expt Sci, Southampton, Hants, England.; Das, J (corresponding author), Nationwide Childrens Hosp, Res Inst, Battelle Ctr Math Med, Columbus, OH 43205 USA.; Das, J (corresponding author), Ohio State Univ, Wexner Coll Med, Dept Pediat, Columbus, OH 43210 USA.; Das, J (corresponding author), Ohio State Univ, Biophys Program, Columbus, OH 43210 USA.	jayajit.das@nationwidechildrens.org; s.i.khakoo@soton.ac.uk	Das, Jayajit/AAD-8502-2022	Das, Jayajit/0000-0001-9649-4698				Mbiribindi B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00605	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2019	10								2370	10.3389/fimmu.2019.02370	http://dx.doi.org/10.3389/fimmu.2019.02370			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1CG	31660057	Green Published, gold			2022-12-18	WOS:000497322400001
J	Kalogiro, DI; Russell, MJ; Bonneuil, WV; Frattolin, J; Watson, D; Moore, JE; Kypraios, T; Brook, BS				Kalogiro, Dimitris I.; Russell, Matthew J.; Bonneuil, Willy V.; Frattolin, Jennifer; Watson, Daniel; Moore, James E., Jr.; Kypraios, Theodore; Brook, Bindi S.			An Integrated Pipeline for Combining in vitro Data and Mathematical Models Using a Bayesian Parameter Inference Approach to Characterize Spatio-temporal Chemokine Gradient Formation	FRONTIERS IN IMMUNOLOGY			English	Article						chemokine transport dynamics; microfluidic device; model validation; Bayesian parameter inference; sequential Bayesian updating; MCMC methods; partial differential equations	MIGRATION; PLATFORM; CCL21	All protective and pathogenic immune and inflammatory responses rely heavily on leukocyte migration and localization. Chemokines are secreted chemoattractants that orchestrate the positioning and migration of leukocytes through concentration gradients. The mechanisms underlying chemokine gradient establishment and control include physical as well as biological phenomena. Mathematical models offer the potential to both understand this complexity and suggest interventions to modulate immune function. Constructing models that have powerful predictive capability relies on experimental data to estimate model parameters accurately, but even with a reductionist approach most experiments include multiple cell types, competing interdependent processes and considerable uncertainty. Therefore, we propose the use of reduced modeling and experimental frameworks in complement, to minimize the number of parameters to be estimated. We present a Bayesian optimization framework that accounts for advection and diffusion of a chemokine surrogate and the chemokine CCL19, transport processes that are known to contribute to the establishment of spatio-temporal chemokine gradients. Three examples are provided that demonstrate the estimation of the governing parameters as well as the underlying uncertainty. This study demonstrates how a synergistic approach between experimental and computational modeling benefits from the Bayesian approach to provide a robust analysis of chemokine transport. It provides a building block for a larger research effort to gain holistic insight and generate novel and testable hypotheses in chemokine biology and leukocyte trafficking.	[Kalogiro, Dimitris I.; Russell, Matthew J.; Kypraios, Theodore; Brook, Bindi S.] Univ Nottingham, Sch Math Sci, Ctr Math Med & Biol, Nottingham, England; [Bonneuil, Willy V.; Frattolin, Jennifer; Watson, Daniel; Moore, James E., Jr.] Imperial Coll London, Dept Bioengn, London, England	University of Nottingham; Imperial College London	Brook, BS (corresponding author), Univ Nottingham, Sch Math Sci, Ctr Math Med & Biol, Nottingham, England.	bindi.brook@nottingham.ac.uk	Kalogiros, Dimitris/AAT-2638-2021	Kalogiros, Dimitris/0000-0001-6401-8355; Frattolin, Jennifer/0000-0002-9820-0232; Watson, Daniel/0000-0001-7841-6637	Sir Leon Bagrit Trust; Wellcome Trust [206284/Z/17/Z]	Sir Leon Bagrit Trust; Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by the Sir Leon Bagrit Trust and Wellcome Trust Collaborative Award 206284/Z/17/Z.	Al-Baradi AM, 2012, J POLYM SCI POL PHYS, V50, P1286, DOI 10.1002/polb.23120; Bayes T., 1763, M F R S PHIL T R SOC, V53, P370, DOI [10.1098/rstl.1763.0053, DOI 10.1098/RSTL.1763.0053]; Bolker B.M., 2008, ECOLOGICAL MODELS DA; Brooks S., 2011, HDB MARKOV CHAIN MON, DOI [10. 1201/b10905, DOI 10.1201/B10905, 10.1201/b10905]; Davidian M, 1995, NONLINEAR MODELS REP; Farahat WA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037333; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Gamerman D, 2006, MARKOV CHAIN MONTE C; HASTINGS WK, 1970, BIOMETRIKA, V57, P97, DOI 10.2307/2334940; JAMBUNATHAN MV, 1954, ANN MATH STAT, V25, P401, DOI 10.1214/aoms/1177728800; KELLER EF, 1970, J THEOR BIOL, V26, P399, DOI 10.1016/0022-5193(70)90092-5; Luther SA, 2002, J IMMUNOL, V169, P424, DOI 10.4049/jimmunol.169.1.424; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Moore JE, 2018, CURR OPIN BIOMED ENG, V5, P90, DOI 10.1016/j.cobme.2018.03.001; Nibbs RJB, 2013, NAT REV IMMUNOL, V13, P815, DOI 10.1038/nri3544; Patil A, 2010, J STAT SOFTW, V35, P1; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schumann K, 2010, IMMUNITY, V32, P703, DOI 10.1016/j.immuni.2010.04.017; Schwarz J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36440; Smith R.C, 2013, UNCERTAINTY QUANTIFI, V12, DOI DOI 10.1111/J.2517-6161.1996.TB02080.X; Takanori K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.00; Ulvmar MH, 2014, NAT IMMUNOL, V15, P623, DOI 10.1038/ni.2889; Vickerman V, 2008, LAB CHIP, V8, P1468, DOI 10.1039/b802395f	23	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2019	10								1986	10.3389/fimmu.2019.01986	http://dx.doi.org/10.3389/fimmu.2019.01986			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN8IO	31681255	Green Published, gold			2022-12-18	WOS:000497135700001
J	Kivisi, CA; Muthui, M; Hunt, M; Fegan, G; Otto, TD; Githinji, G; Warimwe, GM; Rance, R; Marsh, K; Bull, PC; Abdi, AI				Kivisi, Cheryl A.; Muthui, Michelle; Hunt, Martin; Fegan, Greg; Otto, Thomas Dan; Githinji, George; Warimwe, George M.; Rance, Richard; Marsh, Kevin; Bull, Peter C.; Abdi, Abdirahman I.			Exploring Plasmodium falciparum Var Gene Expression to Assess Host Selection Pressure on Parasites During Infancy	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; maternal antibodies; var gene expression; age; infants	NATURALLY ACQUIRED-IMMUNITY; FETAL-HEMOGLOBIN; 1ST YEAR; MALARIA; ANTIBODIES; RISK; SEQUESTRATION; ERYTHROCYTES; INFECTION; ANTIGENS	In sub-Saharan Africa, children below 5 years bear the greatest burden of severe malaria because they lack naturally acquired immunity that develops following repeated exposure to infections by Plasmodium falciparum. Antibodies to the surface of P. falciparum infected erythrocytes (IE) play an important role in this immunity. In children under the age of 6 months, relative protection from severe malaria is observed and this is thought to be partly due to trans-placental acquired protective maternal antibodies. However, the protective effect of maternal antibodies has not been fully established, especially the role of antibodies to variant surface antigens (VSA) expressed on IE. Here, we assessed the immune pressure on parasites infecting infants using markers associated with the acquisition of naturally acquired immunity to surface antigens. We hypothesized that, if maternal antibodies to VSA imposed a selection pressure on parasites, then the expression of a relatively conserved subset of var genes called group A var genes in infants should change with waning maternal antibodies. To test this, we compared their expression in parasites from children between 0 and 12 months and above 12 months of age. The transcript quantity and the proportional expression of group A var subgroup, including those containing domain cassette 13, were positively associated with age during the first year of life, which contrasts with above 12 months. This was accompanied by a decline in infected erythrocyte surface antibodies and an increase in parasitemia during this period. The observed increase in group A var gene expression with age in the first year of life, when the maternal antibodies are waning and before acquisition of naturally acquired antibodies with repeated exposure, is consistent with the idea that maternally acquired antibodies impose a selection pressure on parasites that infect infants and may play a role in protecting these infants against severe malaria.	[Kivisi, Cheryl A.; Muthui, Michelle; Fegan, Greg; Githinji, George; Warimwe, George M.; Marsh, Kevin; Bull, Peter C.; Abdi, Abdirahman I.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Kivisi, Cheryl A.; Rance, Richard; Abdi, Abdirahman I.] Pwani Univ, Biosci Res Ctr, Kilifi, Kenya; [Kivisi, Cheryl A.] Pwani Univ, Dept Biol Sci, Kilifi, Kenya; [Hunt, Martin; Otto, Thomas Dan] Wellcome Sanger Inst, Cambridge, England; [Warimwe, George M.; Marsh, Kevin] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [Fegan, Greg] Swansea Univ, Sch Med, Swansea Trials Unit, Swansea, W Glam, Wales; [Otto, Thomas Dan] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland	Pwani University; Pwani University; Wellcome Trust Sanger Institute; University of Oxford; Swansea University; University of Glasgow	Kivisi, CA; Abdi, AI (corresponding author), KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.; Kivisi, CA; Abdi, AI (corresponding author), Pwani Univ, Biosci Res Ctr, Kilifi, Kenya.; Kivisi, CA (corresponding author), Pwani Univ, Dept Biol Sci, Kilifi, Kenya.	c.andisi@pu.ac.ke; aabdi@kemri-wellcome.org	Otto, Thomas/ABE-7632-2020; Fegan, Greg/AAW-5636-2021	Fegan, Greg/0000-0002-2663-2765; Abdi, Abdirahman/0000-0001-7989-2125; Kivisi, Cheryl Andisi/0000-0003-0545-9665; Otto, Thomas/0000-0002-1246-7404	Wellcome Trust [084535, 084538, 209289, 080883]	Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by Wellcome Trust grants; 084535 to PB, 084538 to KM, 209289 to AA, and 080883 to CK.	Abdi AI, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2686-0; Abdi AI, 2016, SCI REP-UK, V6, DOI 10.1038/srep19882; Abdi AI, 2015, SCI REP-UK, V5, DOI 10.1038/srep18034; Amaratunga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014798; Archer NM, 2019, BLOOD ADV, V3, P2149, DOI 10.1182/bloodadvances.2019000399; Avril M, 2012, P NATL ACAD SCI USA, V109, pE1782, DOI 10.1073/pnas.1120534109; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Bull PC, 2007, MOL BIOCHEM PARASIT, V154, P98, DOI 10.1016/j.molbiopara.2007.03.011; Bull PC, 2005, PLOS PATHOG, V1, P202, DOI 10.1371/journal.ppat.0010026; Bull PC, 2016, PARASITOLOGY, V143, P171, DOI 10.1017/S0031182015001274; Ceesay SJ, 2015, EMERG INFECT DIS, V21, P1114, DOI 10.3201/eid2107.142036; Chen QJ, 2004, VACCINE, V22, P2701, DOI 10.1016/j.vaccine.2004.02.015; Claessens A, 2012, P NATL ACAD SCI USA, V109, pE1772, DOI 10.1073/pnas.1120461109; COLOMBO B, 1976, BRIT J HAEMATOL, V32, P79, DOI 10.1111/j.1365-2141.1976.tb01877.x; Cyrklaff M, 2011, SCIENCE, V334, P1283, DOI 10.1126/science.1213775; Deloron P, 1997, CLIN EXP IMMUNOL, V110, P212; Dobbs KR, 2016, PARASITOLOGY, V143, P129, DOI 10.1017/S0031182015001626; Ghumra A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002665; HOGH B, 1995, INFECT IMMUN, V63, P4034; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274; Kinyanjui SM, 2004, J IMMUNOL METHODS, V288, P9, DOI 10.1016/j.jim.2004.01.022; LaMonte G, 2012, CELL HOST MICROBE, V12, P187, DOI 10.1016/j.chom.2012.06.007; Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27; Lavstsen T, 2012, P NATL ACAD SCI USA, V109, pE1791, DOI 10.1073/pnas.1120455109; Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915; Murungi LM, 2017, INT J PARASITOL, V47, P153, DOI 10.1016/j.ijpara.2016.09.005; Mwaniki MK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-313; Normark J, 2007, P NATL ACAD SCI USA, V104, P15835, DOI 10.1073/pnas.0610485104; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; Riley EM, 2000, INFECT IMMUN, V68, P5856, DOI 10.1128/IAI.68.10.5856-5863.2000; Rottmann M, 2006, INFECT IMMUN, V74, P3904, DOI 10.1128/IAI.02073-05; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897; Snow RW, 1998, B I PASTEUR, V96, P15, DOI 10.1016/S0020-2452(98)80025-0; Taylor HM, 2000, MOL BIOCHEM PARASIT, V105, P13, DOI 10.1016/S0166-6851(99)00159-0; Warimwe GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070467; Warimwe GM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003247; Warimwe GM, 2009, P NATL ACAD SCI USA, V106, P21801, DOI 10.1073/pnas.0907590106	41	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 9	2019	10								2328	10.3389/fimmu.2019.02328	http://dx.doi.org/10.3389/fimmu.2019.02328			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN6CB	31681266	Green Accepted, Green Published, gold			2022-12-18	WOS:000496982900001
J	Osorio, F; Everts, B				Osorio, Fabiola; Everts, Bart			Editorial: Looking Beyond Pattern Recognition: Perturbations in Cellular Homeostasis and Metabolism as Emerging Regulators of Dendritic Cell Function	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						dendritic cell; autophagy; epigenetics; metabolism; cellular stress; migration			[Osorio, Fabiola] Univ Chile, Fac Med, Immunol Program, Inst Biomed Sci, Santiago, Chile; [Everts, Bart] Leiden Univ, Med Ctr, Leiden, Netherlands	Universidad de Chile; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Osorio, F (corresponding author), Univ Chile, Fac Med, Immunol Program, Inst Biomed Sci, Santiago, Chile.; Everts, B (corresponding author), Leiden Univ, Med Ctr, Leiden, Netherlands.	fabiolaosorio@med.uchile.cl; B.Everts@lumc.nl	Everts, Bart/H-6986-2016	Everts, Bart/0000-0002-3764-5131					0	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2019	10								2335	10.3389/fimmu.2019.02335	http://dx.doi.org/10.3389/fimmu.2019.02335			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JA7VN	31611884	Green Published, gold			2022-12-18	WOS:000488055800001
J	Landskron, G; Lopez, MDLF; Dubois-Camacho, K; Diaz-Jimenez, D; Orellana-Serradell, O; Romero, D; Sepulveda, SA; Salazar, C; Parada-Venegas, D; Quera, R; Simian, D; Gonzalez, MJ; Lopez-Kostner, F; Kronberg, U; Abedrapo, M; Gallegos, I; Contreras, HR; Pena, C; Diaz-Araya, G; Roa, JC; Hermoso, MA				Landskron, Glauben; De la Fuente Lopez, Marjorie; Dubois-Camacho, Karen; Diaz-Jimenez, David; Orellana-Serradell, Octavio; Romero, Diego; Sepulveda, Santiago A.; Salazar, Christian; Parada-Venegas, Daniela; Quera, Rodrigo; Simian, Daniela; Gonzalez, Maria-Julieta; Lopez-Kostner, Francisco; Kronberg, Udo; Abedrapo, Mario; Gallegos, Ivan; Contreras, Hector R.; Pena, Cristina; Diaz-Araya, Guillermo; Carlos Roa, Juan; Hermoso, Marcela A.			Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer (vol 10, 1394, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						colorectal cancer; cancer associated fibroblasts; interleukin 33; desmoplasia; epithelial-mesenchymal transition			[Landskron, Glauben; De la Fuente Lopez, Marjorie; Dubois-Camacho, Karen; Diaz-Jimenez, David; Orellana-Serradell, Octavio; Salazar, Christian; Parada-Venegas, Daniela; Hermoso, Marcela A.] Univ Chile, Fac Med, Biomed Sci Inst, Innate Immun Lab,Immunol Program, Santiago, Chile; [De la Fuente Lopez, Marjorie; Simian, Daniela] Clin Las Condes, Acad Direct, Res Subdirect, Santiago, Chile; [Romero, Diego; Sepulveda, Santiago A.; Carlos Roa, Juan] Pontificia Univ Catolica Chile, Fac Med, Pathol Dept, Santiago, Chile; [Quera, Rodrigo] Clin Las Condes, Gastroenterol Dept, Inflammatory Bowel Dis Program, Santiago, Chile; [Gonzalez, Maria-Julieta] Univ Chile, Fac Med, Inst Biomed Sci, Cell & Mol Biol Program, Santiago, Chile; [Lopez-Kostner, Francisco; Kronberg, Udo; Abedrapo, Mario] Clin Las Condes, Coloproctol Dept, Santiago, Chile; [Abedrapo, Mario] Hosp Clin Univ Chile, Coloproctol Surg Dept, Santiago, Chile; [Gallegos, Ivan] Hosp Clin Univ Chile, Pathol Dept, Santiago, Chile; [Contreras, Hector R.] Univ Chile, Fac Med, Dept Basic & Clin Oncol, Santiago, Chile; [Pena, Cristina] Ramon y Cajal Univ Hosp, IRYCIS, CIBERONC, Med Oncol Dept, Madrid, Spain; [Diaz-Araya, Guillermo] Univ Chile, Fac Chem Pharmaceut Sci, Mol Pharmacol Lab, Santiago, Chile	Universidad de Chile; Clinica Las Condes; Pontificia Universidad Catolica de Chile; Clinica Las Condes; Universidad de Chile; Clinica Las Condes; Universidad de Chile; Universidad de Chile; Universidad de Chile; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitario Ramon y Cajal; Universidad de Chile	Hermoso, MA (corresponding author), Univ Chile, Fac Med, Biomed Sci Inst, Innate Immun Lab,Immunol Program, Santiago, Chile.	mhermoso@med.uchile.cl	Hermoso, Marcela A./AAF-6893-2021; Landskron, Glauben/AAT-3277-2021; Roa, Juan C./K-4749-2014; Contreras, Hector/CAE-9087-2022	Hermoso, Marcela A./0000-0002-7936-7571; Landskron, Glauben/0000-0002-7953-6769; Roa, Juan C./0000-0001-8313-8774; Contreras, Hector/0000-0003-4012-2662				Landskron G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01394	1	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2019	10								2149	10.3389/fimmu.2019.02149	http://dx.doi.org/10.3389/fimmu.2019.02149			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JA1MZ	31595174	Green Published, gold			2022-12-18	WOS:000487582400001
J	Kohler, H; Pashov, AD; Kieber-Emmons, T				Kohler, Heinz; Pashov, Anastas Dimitrov; Kieber-Emmons, Thomas			Commentary: Immunology's Coming of Age	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antibody; idiotype; selection; natural antibody; therapeutic antibody	ANTIBODY; PROTEINS; SERUM		[Kohler, Heinz] Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; [Pashov, Anastas Dimitrov] Bulgarian Acad Sci, Stephan Angelov Inst Microbiol, Sofia, Bulgaria; [Kieber-Emmons, Thomas] Univ Arkansas Med Sci, Pathol, Little Rock, AR 72205 USA	University of Kentucky; Bulgarian Academy of Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Kohler, H (corresponding author), Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA.	heinz.kohler@uky.edu	Pashov, Anastas/AAE-7997-2019					Breinl F, 1930, H-S Z PHYSIOL CHEM, V192, P45, DOI 10.1515/bchm2.1930.192.1-3.45; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; Eisen HN, 2015, ANNU REV IMMUNOL, V33, P1, DOI 10.1146/annurev-immunol-111214-122349; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Hood LE, 2008, J IMMUNOL, V180, P7055, DOI 10.4049/jimmunol.180.11.7055; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KABAT EA, 1970, ANN NY ACAD SCI, V169, P43; Kaufmann SHE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00684; Kaveri SV, 1998, IMMUNOLOGIST, V6, P227; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kieber-Emmons T, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00196; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lemke H, 2016, CRIT REV IMMUNOL, V36, P13, DOI 10.1615/CritRevImmunol.2016016606; Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; Mackie TJ, 1925, J HYG-CAMBRIDGE, V24, P176, DOI 10.1017/S0022172400008676; Maddur MS, 2020, CLIN REV ALLERG IMMU, V58, P213, DOI 10.1007/s12016-019-08746-9; Marrack J, 1934, NATURE, V133, P292, DOI 10.1038/133292b0; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; RUDIKOFF S, 1972, P NATL ACAD SCI USA, V69, P3689, DOI 10.1073/pnas.69.12.3689; Schwartz RH, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006908; Shepard HM, 2017, CLIN MED, V17, P220, DOI 10.7861/clinmedicine.17-3-220; Silverman GJ, 2015, ANN NY ACAD SCI, V1362, P164, DOI 10.1111/nyas.12788; Silverstein AM, 2001, ELS, DOI [10.1038/npg.els.0003078, DOI 10.1038/NPG.ELS.0003078]; Smith KA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00502; Steplewski Z, 2015, J INFECT DIS, V212, pS59, DOI 10.1093/infdis/jiu638; Vas J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00004; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	28	1	3	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 12	2019	10								2175	10.3389/fimmu.2019.02175	http://dx.doi.org/10.3389/fimmu.2019.02175			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IW8ZG	31572385	Green Published, gold			2022-12-18	WOS:000485282100002
J	Baliban, SM; Curtis, B; Amin, MN; Levine, MM; Pasetti, MF; Simon, R				Baliban, Scott M.; Curtis, Brittany; Amin, Mohammed N.; Levine, Myron Mike; Pasetti, Marcela F.; Simon, Raphael			Maternal Antibodies Elicited by Immunization With an O-Polysaccharide Glycoconjugate Vaccine Protect Infant Mice Against Lethal Salmonella Typhimurium Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Salmonella; polysaccharide; flagellin; glycoconjugate; vaccine; antibody; maternal transfer; infant	INVASIVE NONTYPHOIDAL SALMONELLA; ENTERICA SEROVAR TYPHIMURIUM; IMMUNE-RESPONSES; DISEASE; ENTERITIDIS; CHILDREN; STRAINS; BURDEN; IMPACT; CELLS	Non-typhoidal Salmonella (NTS) are a leading cause of pediatric invasive bacterial infections in sub-Saharan Africa with high associated case fatality rates in children under 5 years old. We have developed glycoconjugate vaccines consisting of the lipid A-removed surface polysaccharide of NTS, core and O-polysaccharide (COPS), and the flagellarmonomer protein (FliC) from the homologous serovar as the carrier. We previously established that COPS: FliC was immunogenic and protective in mice immunized as adults or infants; however, the brief period of murine infancy precluded the evaluation of protection against invasive NTS (iNTS) disease in early life. In the present study, we used a mouse model of maternal immunization to investigate transmission of S. Typhimurium COPS: FliC-induced maternal antibodies and protection against lethal iNTS challenge in infant mice. We found that vaccinated dams developed high levels of COPS-and FliC-specific IgG, which were transferred to their offspring. Sera from both vaccinated mothers and their litters mediated complement-dependent bactericidal activity in-vitro. Passively immunized 2-week old infant mice born to vaccinated mothers were fully protected from challenge with an S. Typhimurium blood isolate from sub-Saharan Africa. The pre-clinical findings reported herein demonstrate that anti-COPS: FliC antibodies induced by vaccination are sufficient for protection of murine infants against experimental S. Typhimurium infection. By underscoring the protective role of antibody, our results suggest thatmaintaining an adequate titer of protective anti-Salmonella antibodies during early life, either through pediatric or maternal COPS: FliC vaccination, may reduce iNTS disease in young children in sub-Saharan Africa.	[Baliban, Scott M.; Curtis, Brittany; Amin, Mohammed N.; Levine, Myron Mike; Pasetti, Marcela F.; Simon, Raphael] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA; [Baliban, Scott M.; Curtis, Brittany; Amin, Mohammed N.; Levine, Myron Mike; Pasetti, Marcela F.; Simon, Raphael] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Levine, Myron Mike; Pasetti, Marcela F.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Simon, R (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.; Simon, R (corresponding author), Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.	rsimon@som.umaryland.edu			NIH-NIAID [R01AI110627, T32AI007524]	NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH-NIAID R01AI110627 (RS PI); NIH-NIAID T32AI007524 (PIs = Kathleen Neuzil, Marcelo Sztein).	Ao TT, 2015, EMERG INFECT DIS, V21, P941, DOI 10.3201/eid2106.140999; APPLEBY P, 1983, J REPROD IMMUNOL, V5, P203, DOI 10.1016/0165-0378(83)90236-X; Baliban SM, 2018, MOLECULES, V23, DOI 10.3390/molecules23071749; Baliban SM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006522; Baliban SM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005493; Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; Edwards KM, 2015, VACCINE, V33, P6469, DOI 10.1016/j.vaccine.2015.07.085; Goh Y.S., 2016, J VACCINES VACCIN, V7, P322, DOI [10.4172/2157-7560.1000322, DOI 10.4172/2157-7560.1000322]; Goh YS, 2015, INFECT IMMUN, V83, P3722, DOI 10.1128/IAI.00547-15; Gondwe EN, 2010, P NATL ACAD SCI USA, V107, P3070, DOI 10.1073/pnas.0910497107; Hegerle N, 2018, J APPL MICROBIOL, V125, P575, DOI 10.1111/jam.13772; Jeon J, 2018, GASTROENTEROLOGY, V154, P2152, DOI 10.1053/j.gastro.2018.02.021; MacLennan CA, 2008, J CLIN INVEST, V118, P1553, DOI 10.1172/JCI33998; MacLennan CA, 2013, CLIN VACCINE IMMUNOL, V20, P1487, DOI 10.1128/CVI.00465-13; Marks F, 2017, LANCET GLOB HEALTH, V5, pE310, DOI 10.1016/S2214-109X(17)30022-0; Matiasovic J, 2013, VET J, V196, P114, DOI 10.1016/j.tvjl.2012.08.002; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Nyirenda TS, 2014, J INFECT DIS, V210, P56, DOI 10.1093/infdis/jiu045; Ramachandran G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151875; Rondini S, 2013, MICROB PATHOGENESIS, V63, P19, DOI 10.1016/j.micpath.2013.05.014; SHOPE SR, 1991, J MED MICROBIOL, V35, P53, DOI 10.1099/00222615-35-1-53; Si W, 2014, RES VET SCI, V97, P191, DOI 10.1016/j.rvsc.2014.08.001; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Simon R, 2014, PROTEIN EXPRES PURIF, V102, P1, DOI 10.1016/j.pep.2014.07.005; Simon R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064680; Simon R, 2011, INFECT IMMUN, V79, P4240, DOI 10.1128/IAI.05484-11; Sow SO, 2009, AM J TROP MED HYG, V80, P1033, DOI 10.4269/ajtmh.2009.80.1033; Tapia MD, 2015, CLIN INFECT DIS, V61, pS332, DOI 10.1093/cid/civ729; Tennant SM, 2011, INFECT IMMUN, V79, P4175, DOI 10.1128/IAI.05278-11; Trebicka E, 2013, CLIN VACCINE IMMUNOL, V20, P1491, DOI 10.1128/CVI.00289-13; Uche Ifeanyi Valentine, 2017, PLoS Negl Trop Dis, V11, pe0005118, DOI 10.1371/journal.pntd.0005118; Thiem VD, 2011, CLIN VACCINE IMMUNOL, V18, P730, DOI 10.1128/CVI.00532-10; Wilcox CR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01294	33	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2019	10								2124	10.3389/fimmu.2019.02124	http://dx.doi.org/10.3389/fimmu.2019.02124			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IV8UC	31555302	Green Published, gold			2022-12-18	WOS:000484539500001
J	Ioannidou, K; Randin, O; Semilietof, A; Maby-El Hajjami, H; Baumgaertner, P; Vanhecke, D; Speiser, DE				Ioannidou, Kalliopi; Randin, Olivier; Semilietof, Aikaterini; Maby-El Hajjami, Helene; Baumgaertner, Petra; Vanhecke, Dominique; Speiser, Daniel E.			Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						avidity; T cell response; melanoma; IFN-gamma Elispot assay; cytotoxicity assay; adoptive T cell transfer	TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; ADOPTIVE TRANSFER; TRANSFER THERAPY; CLONES; CTL; IMMUNOTHERAPY; REPERTOIRE; GENERATION; EFFICACY	The efficacy of T cells depends on their functional avidity, i.e., the strength of T cell interaction with cells presenting cognate antigen. The overall T cell response is composed of multiple T cell clonotypes, involving different T cell receptors and variable levels of functional avidity. Recently, it has been proposed that the presence of low avidity tumor antigen-specific CD8 T cells hinder their high avidity counterparts to protect from tumor growth. Here we analyzed human cytotoxic CD8 T cells specific for the melanoma antigen Melan-A/MART-1. We found that the presence of low avidity T cells did not result in reduced cytotoxicity of tumor cells, nor reduced cytokine production, by high avidity T cells. In vivo in NSG-HLA-A2 mice, the anti-tumor effect of high avidity T cells was similar in presence or absence of low avidity T cells. These data indicate that low avidity T cells are not hindering anti-tumor T cell responses, a finding that is reassuring because low avidity T cells are an integrated part of natural T cell responses.	[Ioannidou, Kalliopi; Randin, Olivier; Semilietof, Aikaterini; Maby-El Hajjami, Helene; Baumgaertner, Petra; Vanhecke, Dominique; Speiser, Daniel E.] Lausanne Univ Hosp Ctr CHUV, Dept Oncol, Lausanne, Switzerland; [Ioannidou, Kalliopi] CHU Vaudois, Inst Pathol, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Speiser, DE (corresponding author), Lausanne Univ Hosp Ctr CHUV, Dept Oncol, Lausanne, Switzerland.	doc@dspeiser.ch	Speiser, Daniel E./F-2173-2013		Swiss Cancer Research [KFS-3971-08-2016]; Swiss National Science Foundation [310030-179459, CRSII3-160708]; Alfred and Annemarie von Sick, Switzerland; University of Lausanne, Switzerland; Cancer Research Institute, USA	Swiss Cancer Research; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Alfred and Annemarie von Sick, Switzerland; University of Lausanne, Switzerland; Cancer Research Institute, USA	This project was supported by the Swiss Cancer Research (KFS-3971-08-2016), the Swiss National Science Foundation (310030-179459, CRSII3-160708), Alfred and Annemarie von Sick, Switzerland, the University of Lausanne, Switzerland, and the Cancer Research Institute, USA.	AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Appay V, 2006, J IMMUNOL, V177, P1670, DOI 10.4049/jimmunol.177.3.1670; Baumgaertner P, 2012, INT J CANCER, V130, P2607, DOI 10.1002/ijc.26297; Belz GT, 2000, J VIROL, V74, P3486, DOI 10.1128/JVI.74.8.3486-3493.2000; Besser MJ, 2013, CLIN CANCER RES, V19, P4792, DOI 10.1158/1078-0432.CCR-13-0380; Bobinet M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051716; Bullock TNJ, 2001, J IMMUNOL, V167, P5824, DOI 10.4049/jimmunol.167.10.5824; Chung B, 2014, CELL REP, V8, P871, DOI 10.1016/j.celrep.2014.06.052; Cornberg M, 2006, J CLIN INVEST, V116, P1443, DOI 10.1172/JCI27804; Cukalac T, 2014, P NATL ACAD SCI USA, V111, P1485, DOI 10.1073/pnas.1323736111; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dudley ME, 2003, J IMMUNOTHER, V26, P332, DOI 10.1097/00002371-200307000-00005; Dustin ML, 2016, ANNU REV CELL DEV BI, V32, P303, DOI 10.1146/annurev-cellbio-100814-125330; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Dutoit V, 2001, CANCER RES, V61, P5850; Hanson J, 2015, CELLS-BASEL, V4, P71, DOI 10.3390/cells4010071; Hesse MD, 2001, J IMMUNOL, V167, P1353, DOI 10.4049/jimmunol.167.3.1353; Hurwitz AA, 2014, CANCER MICROENVIRON, V7, P1, DOI 10.1007/s12307-013-0143-1; Ioannidou K, 2017, SCI REP-UK, V7, DOI 10.1038/srep44320; Janicki CN, 2008, CANCER RES, V68, P2993, DOI 10.1158/0008-5472.CAN-07-5008; Mallone R, 2005, BLOOD, V106, P2798, DOI 10.1182/blood-2004-12-4848; McMahan RH, 2007, SEMIN CANCER BIOL, V17, P317, DOI 10.1016/j.semcancer.2007.06.006; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Murphy A, 2005, IMMUNITY, V22, P403, DOI 10.1016/j.immuni.2005.03.007; Radvanyi LG, 2012, CLIN CANCER RES, V18, P6758, DOI 10.1158/1078-0432.CCR-12-1177; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Rubio V, 2003, NAT MED, V9, P1377, DOI 10.1038/nm942; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Saint-Jean M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3530148; Tomaru U, 2003, NAT MED, V9, P469, DOI 10.1038/nm845; Ullenhag GJ, 2012, CANCER IMMUNOL IMMUN, V61, P725, DOI 10.1007/s00262-011-1182-4; Vigano S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/153863; von Essen MR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/163453; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Wu R, 2012, CANCER J, V18, P160, DOI 10.1097/PPO.0b013e31824d4465; Yee C, 1999, J IMMUNOL, V162, P2227; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zeh HJ, 1999, J IMMUNOL, V162, P989; Zehn D, 2010, J IMMUNOL, V184, P6320, DOI 10.4049/jimmunol.1000149	42	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2019	10								2115	10.3389/fimmu.2019.02115	http://dx.doi.org/10.3389/fimmu.2019.02115			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IV8TX	31555299	gold, Green Published			2022-12-18	WOS:000484539000001
J	Paula-Neto, HA; Pereira, RM; Carneiro, LAM				Paula-Neto, Heitor A.; Pereira, Renata M.; Carneiro, Leticia A. M.			Editorial: Producing, Sensing and Responding to Cellular Stress in Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						stress response; homeostasis; immune response; host-pathogen; innate immunity; UPR; autphagy; integrated stress response			[Paula-Neto, Heitor A.] Univ Fed Rio de Janeiro, Fac Farm, Rio De Janeiro, Brazil; [Pereira, Renata M.; Carneiro, Leticia A. M.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Paula-Neto, HA (corresponding author), Univ Fed Rio de Janeiro, Fac Farm, Rio De Janeiro, Brazil.; Pereira, RM; Carneiro, LAM (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.	heitorapneto@gmail.com; renata.pereira@micro.ufrj.br; leticiac@micro.ufrj.br	Pereira, Renata/V-6194-2019; Carneiro, Leticia/T-8978-2019	Carneiro, Leticia/0000-0001-5870-8288; Pereira, Renata/0000-0002-7719-8356					0	1	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2019	10								2053	10.3389/fimmu.2019.02053	http://dx.doi.org/10.3389/fimmu.2019.02053			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IV8SH	31555279	Green Published, gold			2022-12-18	WOS:000484534800001
J	Akuthota, P; Neves, JS; Ueki, S				Akuthota, Praveen; Neves, Josiane S.; Ueki, Shigeharu			Editorial: Severe Eosinophilic Disorders: Mechanisms and Clinical Management	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						asthma; eosinophils; hypereosinophilia; IL-5; degranulation; rhinosinusitis			[Akuthota, Praveen] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA; [Neves, Josiane S.] Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil; [Ueki, Shigeharu] Akita Univ, Grad Sch Med, Dept Gen Internal Med & Clin Lab Med, Akita, Japan	University of California System; University of California San Diego; Universidade Federal do Rio de Janeiro; Akita University	Ueki, S (corresponding author), Akita Univ, Grad Sch Med, Dept Gen Internal Med & Clin Lab Med, Akita, Japan.	shigeharu.ueki@gmail.com	Ueki, Shigeharu/I-3566-2019; Neves, Josiane Sabbadini/X-9801-2019	Ueki, Shigeharu/0000-0002-3537-7735; Neves, Josiane Sabbadini/0000-0002-6645-1715				Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 4	2019	10								2118	10.3389/fimmu.2019.02118	http://dx.doi.org/10.3389/fimmu.2019.02118			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IU7NX	31552048	Green Published, gold			2022-12-18	WOS:000483771700002
J	Van Nuffel, AMT; Boudousquie, C; Tuyaerts, S				Van Nuffel, An M. T.; Boudousquie, Caroline; Tuyaerts, Sandra			Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer vaccines; personalized; adjuvant; antigen-presenting cell; in situ vaccination; immunosuppression; biomarkers			[Van Nuffel, An M. T.] Anticanc Fund, Brussels, Belgium; [Boudousquie, Caroline] CHU Vaudois, Dept Oncol, Lausanne, Switzerland; [Tuyaerts, Sandra] Katholieke Univ Leuven, Dept Oncol, Div Gynecol Oncol, Leuven, Belgium; [Tuyaerts, Sandra] Leuven Canc Inst LKI, Leuven, Belgium	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); KU Leuven	Tuyaerts, S (corresponding author), Katholieke Univ Leuven, Dept Oncol, Div Gynecol Oncol, Leuven, Belgium.; Tuyaerts, S (corresponding author), Leuven Canc Inst LKI, Leuven, Belgium.	sandra.tuyaerts@kuleuven.be	Tuyaerts, Sandra/J-6625-2019	Tuyaerts, Sandra/0000-0003-1255-8071; Van Nuffel, An/0000-0001-9354-0089	Anticancer Fund; Verelst Uterine Cancer Fund Leuven	Anticancer Fund; Verelst Uterine Cancer Fund Leuven	ST is financially supported by The Anticancer Fund (www.anticancerfund.org) and the associated Verelst Uterine Cancer Fund Leuven. AV is employee of The Anticancer Fund.	Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Gouttefangeas C, 2018, CANCER IMMUNOL IMMUN, V67, P1911, DOI 10.1007/s00262-018-2158-4; Hammerich L, 2016, IMMUNOTHERAPY-UK, V8, P315, DOI 10.2217/imt.15.120; Palucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049; Segura E, 2016, METHODS MOL BIOL, V1423, P3, DOI 10.1007/978-1-4939-3606-9_1; Subbiah V, 2018, TRENDS CANCER, V4, P101, DOI 10.1016/j.trecan.2017.12.004	6	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2019	10								2032	10.3389/fimmu.2019.02032	http://dx.doi.org/10.3389/fimmu.2019.02032			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IT4GU	31507617	Green Published, gold			2022-12-18	WOS:000482819600003
J	Li, XC; Zhou, J; Zhou, JF; Wang, Y; Mae, HY; Wang, Y; Zhao, S; Fang, WH				Li, Xin-Cang; Zhou, Jian; Zhou, Jun-Fang; Wang, Yue; Mae, Hongyu; Wang, Yuan; Zhao, Shu; Fang, Wen-Hong			SpBark Suppresses Bacterial Infection by Mediating Hemocyte Phagocytosis in an Invertebrate Model, Scylla paramamosain	FRONTIERS IN IMMUNOLOGY			English	Article						scavenger receptor-like protein; C-type lectin domain; LPS-binding activity; bacterial clearance; phagocytosis activity; Scylla paramamosain	INNATE IMMUNE-SYSTEM; RICH SRCR DOMAIN; SCAVENGER RECEPTOR; ANTIBACTERIAL IMMUNITY; ENHANCING PHAGOCYTOSIS; RECOGNITION; SHRIMP; SUPERFAMILY; PROLIFERATION; ANTIFUNGAL	Scavenger receptors are cell surface membrane-bound receptors that typically bind multiple ligands and promote the removal of endogenous proteins and pathogens. In this study, we characterized a novel scavenger receptor-like protein, namely, SpBark. SpBark was upregulated in hemocytes after challenges with bacteria, suggesting that it might be involved in antibacterial defense. SpBark is a type I transmembrane protein with four extracellular domains, including three scavenger receptor cysteine-rich domains (SRCRDs) and a C-type lectin domain (CTLD). Western blot assay showed that SpBark CTLD possessed a much stronger binding activity to tested microbes than the three SRCRDs. It also exhibited apparent binding activities to lipopolysaccharide (LPS) and acetylated low-density lipoprotein (ac-LDL), whereas the other SRCRDs showed much lower or no binding activities to these components. Agglutination activities were observed in the presence of Ca2+ by incubating microorganisms with SpBark CTLD instead of SRCRDs. These results suggested that SpBark CTLD was the major binding site for ac-LDL and LPS. Coating Vibrio parahemolyticus with SpBark CTLD promoted bacterial clearance in vivo. This finding indicated that SpBark might participate in the immune defenses against Gram-negative bacteria through a certain mechanism. The promotion of bacterial clearance by SpBark was further determined using SpBark-silenced crabs injected with V. parahemolyticus. SpBark knockdown by injection of SpBark dsRNA remarkably suppressed the clearance of bacteria in hemolymph. Meanwhile, it also severely restrained the phagocytosis of bacteria. This finding suggested that SpBark could modulate the phagocytosis of bacteria, and the promotion of bacterial clearance by SpBark was closely related to SpBark-mediated phagocytosis activity. The likely mechanism of bacterial clearance mediated by SpBark was as follows: SpBark acted as a pattern recognition receptor, which could sense and bind to LPS on the surface of invading bacteria with its CTLD in hemolymph. The binding to LPS made the bacteria adhere to the surface of hemocytes. This process would facilitate phagocytosis of the bacteria, resulting in their removal. This study provided new insights into the hemocyte phagocytosis mechanisms of invertebrates and the multiple biological functions of Bark proteins.	[Li, Xin-Cang; Zhou, Jian; Zhou, Jun-Fang; Wang, Yue; Wang, Yuan; Zhao, Shu; Fang, Wen-Hong] Chinese Acad Fishery Sci, East China Sea Fisheries Res Inst, Key Lab East China Sea Fishery Resources Exploita, Minist Agr, Shanghai, Peoples R China; [Wang, Yue; Mae, Hongyu] Shantou Univ, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Peoples R China	Chinese Academy of Fishery Sciences; East China Sea Fisheries Research Institute, CAFS; Ministry of Agriculture & Rural Affairs; Shantou University	Li, XC; Fang, WH (corresponding author), Chinese Acad Fishery Sci, East China Sea Fisheries Res Inst, Key Lab East China Sea Fishery Resources Exploita, Minist Agr, Shanghai, Peoples R China.	lixin8687@163.com; fwenhong@163.com			National Natural Science Foundation of China [31772886]; special research grant for the National Non-profit Institute (East China Sea Fisheries Research Institute) [2019T01]; STU Scientific Research Foundation for Talents [NTF17006]; Central Public-interest Scientific Institution Basal Research Foundation, CAFS [2016RC-LX04]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); special research grant for the National Non-profit Institute (East China Sea Fisheries Research Institute); STU Scientific Research Foundation for Talents; Central Public-interest Scientific Institution Basal Research Foundation, CAFS	This work was financially supported by the National Natural Science Foundation of China (No. 31772886), the special research grant for the National Non-profit Institute (East China Sea Fisheries Research Institute) (No. 2019T01), the STU Scientific Research Foundation for Talents (No. NTF17006), and the Central Public-interest Scientific Institution Basal Research Foundation, CAFS (No. 2016RC-LX04).	Bessa Pereira C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00416; Bi WJ, 2015, DEV COMP IMMUNOL, V51, P10, DOI 10.1016/j.dci.2015.02.001; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; Burkard C, 2018, J VIROL, V92, DOI [10.1128/JVI.00415-18, 10.1128/jvi.00415-18]; Burkard C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006206; Canton J, 2013, NAT REV IMMUNOL, V13, P621, DOI 10.1038/nri3515; Christophides GK, 2004, IMMUNOL REV, V198, P127, DOI 10.1111/j.0105-2896.2004.0127.x; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Martinez VG, 2011, PHARMACOL REV, V63, P967, DOI 10.1124/pr.111.004523; Herre J, 2004, CRIT REV IMMUNOL, V24, P193, DOI 10.1615/CritRevImmunol.v24.i3.30; Hildebrandt A, 2015, DEV BIOL, V400, P237, DOI 10.1016/j.ydbio.2015.02.008; Jozefowski S, 2005, J IMMUNOL, V175, P8032, DOI 10.4049/jimmunol.175.12.8032; Kim SG, 2017, INSECT BIOCHEM MOLEC, V89, P31, DOI 10.1016/j.ibmb.2017.08.007; Kong TT, 2018, FISH SHELLFISH IMMUN, V78, P79, DOI 10.1016/j.fsi.2018.04.027; Li FH, 2013, DEV COMP IMMUNOL, V39, P11, DOI 10.1016/j.dci.2012.03.016; Liu L, 2011, DEV COMP IMMUNOL, V35, P227, DOI 10.1016/j.dci.2010.09.010; Loker ES, 2004, IMMUNOL REV, V198, P10, DOI 10.1111/j.0105-2896.2004.0117.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mukhopadhyay S, 2004, IMMUNOBIOLOGY, V209, P39, DOI 10.1016/j.imbio.2004.02.004; Mukhopadhyay S, 2011, BLOOD, V117, P1319, DOI 10.1182/blood-2010-03-276733; Nakamoto M, 2012, IMMUNITY, V36, P658, DOI 10.1016/j.immuni.2012.03.003; Nakamura K, 2001, BBA-GENE STRUCT EXPR, V1522, P53, DOI 10.1016/S0167-4781(01)00284-6; PrabhuDas MR, 2017, J IMMUNOL, V198, P3775, DOI 10.4049/jimmunol.1700373; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Sankala M, 2002, J BIOL CHEM, V277, P33378, DOI 10.1074/jbc.M204494200; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Shi XZ, 2013, DEV COMP IMMUNOL, V40, P311, DOI 10.1016/j.dci.2013.03.011; SODERHALL K, 1983, DEV COMP IMMUNOL, V7, P229, DOI 10.1016/0145-305X(83)90004-6; Tassanakajon A, 2018, DEV COMP IMMUNOL, V80, P81, DOI 10.1016/j.dci.2017.05.009; Vasta GR, 2012, ANN NY ACAD SCI, V1253, pE14, DOI 10.1111/j.1749-6632.2012.06698.x; Wang H, 2018, DEV COMP IMMUNOL, V84, P1, DOI 10.1016/j.dci.2018.01.021; Wang XW, 2014, J BIOL CHEM, V289, P2405, DOI 10.1074/jbc.M113.528885; Wang XW, 2013, FISH SHELLFISH IMMUN, V34, P981, DOI 10.1016/j.fsi.2012.08.008; Wang XW, 2009, DEV COMP IMMUNOL, V33, P1039, DOI 10.1016/j.dci.2009.05.004; Wang Y, 2018, FISH SHELLFISH IMMUN, V75, P346, DOI 10.1016/j.fsi.2018.02.026; Watson FL, 2005, SCIENCE, V309, P1874, DOI 10.1126/science.1116887; Wu YM, 2017, FISH SHELLFISH IMMUN, V70, P426, DOI 10.1016/j.fsi.2017.09.034; Xu JD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01928; Yoshimoto R, 2011, CARDIOVASC DRUG THER, V25, P379, DOI 10.1007/s10557-011-6324-6; Zani IA, 2015, CELLS-BASEL, V4, P178, DOI 10.3390/cells4020178; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zhang XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep29924; Zhou J, 2017, DEV COMP IMMUNOL, V74, P154, DOI 10.1016/j.dci.2017.04.017	45	1	1	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2019	10								1992	10.3389/fimmu.2019.01992	http://dx.doi.org/10.3389/fimmu.2019.01992			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IS8TJ	31507600	Green Published, gold			2022-12-18	WOS:000482422100001
J	Deng, J; Fan, CF; Gao, X; Zeng, QX; Guo, RR; Wei, YB; Chen, ZA; Chen, YN; Gong, DC; Feng, J; Xia, Y; Xiang, SF; Gong, SS; Yuan, L; Shen, W; Shen, WY; Lin, L; Jiang, T; He, DY; Lu, LJ; Chen, XX; Yu, D				Deng, Jun; Fan, Chaofan; Gao, Xin; Zeng, Qunxiong; Guo, Ruru; Wei, Yunbo; Chen, Zhian; Chen, Yanan; Gong, Dongcheng; Feng, Jia; Xia, Yan; Xiang, Shifei; Gong, Shushi; Yuan, Lin; Shen, Wei; Shen, Wenyan; Lin, Lin; Jiang, Ting; He, Dongyi; Lu, Liangjing; Chen, Xiaoxiang; Yu, Di			Signal Transducer and Activator of Transcription 3 Hyperactivation Associates With Follicular Helper T Cell Differentiation and Disease Activity in Rheumatoid Arthritis (vol 9, 1226, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						rheumatoid arthritis; patient; follicular helper T cells; signal transducer and activator of transcription 3; phosphorylation; IL-6			[Deng, Jun; Gao, Xin; Zeng, Qunxiong; Chen, Zhian; Gong, Dongcheng; Yu, Di] Shanghai Jiao Tong Univ, China Australia Ctr Personalised Immunol, Renji Hosp, Sch Med, Shanghai, Peoples R China; [Deng, Jun; Fan, Chaofan; Gao, Xin; Zeng, Qunxiong; Guo, Ruru; Chen, Yanan; Gong, Dongcheng; Lu, Liangjing; Chen, Xiaoxiang; Yu, Di] Shanghai Jiao Tong Univ, Dept Rheumatol, Shanghai Inst Rheumatol, Renji Hosp,Sch Med, Shanghai, Peoples R China; [Deng, Jun; Yu, Di] Hubei Univ Nationalities, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Affiliated Hosp, Enshi, Peoples R China; [Gao, Xin; Chen, Zhian; Yu, Di] Australian Natl Univ, Dept Immunol & Infect Dis, John Curtin Sch Med Res, Canberra, ACT, Australia; [Wei, Yunbo; Yu, Di] Qilu Univ Technol, Shandong Acad Sci, Shandong Anal & Test Ctr, Lab Immunol Environm & Hlth, Jinan, Shandong, Peoples R China; [Feng, Jia; Xia, Yan; Xiang, Shifei; Gong, Shushi] Hubei Univ Nationalities, Dept Rheumatol, Affiliated Hosp, Enshi, Peoples R China; [Shen, Wei; Shen, Wenyan] Shanghai Jiao Tong Univ, Dept Lab Med, Renji Hosp, Sch Med, Shanghai, Peoples R China; [Lin, Lin] Shanghai Jiao Tong Univ, Dept Lab Med, Ruijin Hosp, Sch Med, Shanghai, Peoples R China; [Jiang, Ting; He, Dongyi] Guanghua Hosp Integrat Chinese & Western Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Hubei Minzu University; Australian National University; John Curtin School of Medical Research; Qilu University of Technology; Hubei Minzu University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, D (corresponding author), Shanghai Jiao Tong Univ, China Australia Ctr Personalised Immunol, Renji Hosp, Sch Med, Shanghai, Peoples R China.; Lu, LJ; Chen, XX; Yu, D (corresponding author), Shanghai Jiao Tong Univ, Dept Rheumatol, Shanghai Inst Rheumatol, Renji Hosp,Sch Med, Shanghai, Peoples R China.; Yu, D (corresponding author), Hubei Univ Nationalities, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Affiliated Hosp, Enshi, Peoples R China.; Yu, D (corresponding author), Australian Natl Univ, Dept Immunol & Infect Dis, John Curtin Sch Med Res, Canberra, ACT, Australia.; Yu, D (corresponding author), Qilu Univ Technol, Shandong Acad Sci, Shandong Anal & Test Ctr, Lab Immunol Environm & Hlth, Jinan, Shandong, Peoples R China.	lu__liangjing@163.com; xiaoxiang0721@126.com; di.yu@anu.edu.au	Wei, Yunbo/AHE-8248-2022; Chen, Zhian/ABA-6813-2021	Chen, Zhian/0000-0003-0073-2941; Deng, Jun/0000-0002-8916-6503				Deng J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01226	1	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 22	2019	10								2008	10.3389/fimmu.2019.02008	http://dx.doi.org/10.3389/fimmu.2019.02008			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IS5LU	31485214	gold, Green Published			2022-12-18	WOS:000482194900002
J	Sayegh, S; El Atat, O; Diallo, K; Rauwel, B; Degboe, Y; Cavaignac, E; Constantin, A; Cantagrel, A; Trak-Smayra, V; Alaaeddine, N; Davignon, JL				Sayegh, Souraya; El Atat, Oula; Diallo, Katy; Rauwel, Benjamin; Degboe, Yannick; Cavaignac, Etienne; Constantin, Arnaud; Cantagrel, Alain; Trak-Smayra, Viviane; Alaaeddine, Nada; Davignon, Jean-Luc			Rheumatoid Synovial Fluids Regulate the Immunomodulatory Potential of Adipose-Derived Mesenchymal Stem Cells Through a TNF/NF-kappa B-Dependent Mechanism (vol 10, 1482, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						mesenchymal stem cells; rheumatoid arthritis; synovial fluid; immunomodulation; TNF; NF-kappa B; Tregs; macrophages			[Sayegh, Souraya; Diallo, Katy; Rauwel, Benjamin; Degboe, Yannick; Constantin, Arnaud; Cantagrel, Alain; Davignon, Jean-Luc] INSERM, Ctr Physiopathol Toulouse Purpan, UMR 1043, Toulouse, France; [Sayegh, Souraya; Diallo, Katy; Constantin, Arnaud; Cantagrel, Alain] Univ Paul Sabatier Toulouse III, Toulouse, France; [Sayegh, Souraya; El Atat, Oula; Trak-Smayra, Viviane] Univ St Joseph, Fac Med, Beirut, Lebanon; [El Atat, Oula; Degboe, Yannick; Constantin, Arnaud; Cantagrel, Alain; Davignon, Jean-Luc] CHU Toulouse, Ctr Rhumatol, Toulouse, France; [Cavaignac, Etienne] CHU Toulouse, Ctr Chirurg Orthoped & Traumatol, Toulouse, France; [Alaaeddine, Nada] Lebanese Univ, Neurosci Res Ctr, Fac Med Sci, Beirut, Lebanon	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Saint Joseph University Beirut; CHU de Toulouse; CHU de Toulouse; Lebanese University	Davignon, JL (corresponding author), INSERM, Ctr Physiopathol Toulouse Purpan, UMR 1043, Toulouse, France.; Davignon, JL (corresponding author), CHU Toulouse, Ctr Rhumatol, Toulouse, France.; Alaaeddine, N (corresponding author), Lebanese Univ, Neurosci Res Ctr, Fac Med Sci, Beirut, Lebanon.	nada.aladdin@gmail.com; jean-luc.davignon@inserm.fr	atat, oula el/AAH-7689-2019	atat, oula el/0000-0003-1341-0204; DAVIGNON, Jean-Luc/0000-0002-8365-6552				Sayegh S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01482	1	1	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2019	10								1961	10.3389/fimmu.2019.01961	http://dx.doi.org/10.3389/fimmu.2019.01961			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IR9OZ	31475016	Green Published, gold			2022-12-18	WOS:000481776000001
J	Sloboda, N; Sorlin, A; Valduga, M; Beri-Dexheimer, M; Bilbault, C; Fouyssac, F; Becker, A; Lambert, L; Bonnet, C; Leheup, B				Sloboda, Natacha; Sorlin, Arthur; Valduga, Mylene; Beri-Dexheimer, Mylene; Bilbault, Claire; Fouyssac, Fanny; Becker, Aurelie; Lambert, Laetitia; Bonnet, Celine; Leheup, Bruno			Deletion of chr7p22 and chr15q11: Two Familial Cases of Immune Deficiency: Extending the Phenotype Toward Dysimmunity	FRONTIERS IN IMMUNOLOGY			English	Article						7p22; vasculitis; hypogammaglobulinemia; CGH array; dysimmunity	11 CARD11; LYMPHOCYTE; CARMA1	Background: We report here two new familial cases of associated del15q11 and del7p22, with the latter underlining the clinical variability of this deletion. Two siblings patients presented a similar familial imbalanced translocation, originating from a balanced maternal translocation, with deletions of 7p22 and of 15q11 [arr[GRCh37] 7p22.3-p22.2(42976-3736851)x1, 15q11.1-q11.2(20172544-24979427)x1]. Methods: We used aCGH array, FISH, and karyotype for studying the phenotype of the two patients. Results: The 7p22 deletion (3.5 Mb) contained 58 genes, including several OMIM genes. Patients 1 and 2 exhibited acquisition delays, morphological particularities, and hypogammaglobulinemia, which was more severe in patient 1. Patient 1 presented also with cerebral vasculitis. Conclusion: We discuss here how the PDGFa, CARD11, LFNG, GPER1, and MAFK genes, included in the deletion 7p22, could be involved in the clinical and biological features of the two patients.	[Sloboda, Natacha; Sorlin, Arthur; Lambert, Laetitia; Leheup, Bruno] CHRU Nancy, Children Hosp, Clin Genet Dept, Nancy, France; [Valduga, Mylene; Beri-Dexheimer, Mylene; Becker, Aurelie; Bonnet, Celine] CHRU Nancy, Genet Lab, Nancy, France; [Bilbault, Claire] CHRU Nancy, Children Hosp, Infantile Med Dept Neuropediat, Nancy, France; [Fouyssac, Fanny] CHRU Nancy, Children Hosp, Infantile Med Dept Hematopediat, Nancy, France	CHU de Nancy; CHU de Nancy; CHU de Nancy; CHU de Nancy	Sloboda, N (corresponding author), CHRU Nancy, Children Hosp, Clin Genet Dept, Nancy, France.	natacha.sloboda@icbud.com	BONNET, Céline/AAY-2674-2021	BONNET, Céline/0000-0002-6799-0438				Askalan R, 2001, STROKE, V32, P1257, DOI 10.1161/01.STR.32.6.1257; Cote M, 2015, NEUROBIOL DIS, V82, P99, DOI 10.1016/j.nbd.2015.05.017; Dadi H, 2018, J ALLERGY CLIN IMMUN, V141, P1818, DOI 10.1016/j.jaci.2017.06.047; Dhillon NK, 2007, J IMMUNOL, V179, P2722, DOI 10.4049/jimmunol.179.5.2722; Dorjbal B, 2019, J ALLERGY CLIN IMMUN, V143, P1482, DOI 10.1016/j.jaci.2018.08.013; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gambin T, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0472-7; Gilden DH, 1998, J NEUROL SCI, V159, P140, DOI 10.1016/S0022-510X(98)00153-1; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Huang N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001154; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Ma CA, 2017, NAT GENET, V49, P1192, DOI 10.1038/ng.3898; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Ochiai K, 2008, INT IMMUNOL, V20, P453, DOI 10.1093/intimm/dxn005; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Pryshchep O, 2008, CIRCULATION, V118, P1276, DOI 10.1161/CIRCULATIONAHA.108.789172; Rettew JA, 2010, MOL CELL ENDOCRINOL, V328, P87, DOI 10.1016/j.mce.2010.07.017; Rodenas M.C., 2017, BIOMED HUB, V2, P454981, DOI [10.1159/000454981, DOI 10.1159/000454981]; Samocha KE, 2014, NAT GENET, V46, P944, DOI 10.1038/ng.3050; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Song YH, 2016, J IMMUNOL, V196, P232, DOI 10.4049/jimmunol.1402421; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Ueno M, 2002, BRAIN DEV-JPN, V24, P106, DOI 10.1016/S0387-7604(02)00005-0; Visan I, 2006, NAT IMMUNOL, V7, P634, DOI 10.1038/ni1345; Yu AC, 2017, AM J MED GENET A, V173, P1593, DOI 10.1002/ajmg.a.38241	26	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2019	10								1871	10.3389/fimmu.2019.01871	http://dx.doi.org/10.3389/fimmu.2019.01871			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IR4ZM	31474980	Green Published, gold			2022-12-18	WOS:000481442800001
J	Joseph, H; Tan, QY; Mazhari, R; Eriksson, EM; Schofield, L				Joseph, Hayley; Tan, Qiao Ye; Mazhari, Ramin; Eriksson, Emily M.; Schofield, Louis			Vaccine-Induced Carbohydrate-Specific Memory B Cells Reactivate During Rodent Malaria Infection	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; B cell immunity; vaccines; memory failure; glycosylphosphatidylinositol (GPI)	VASCULAR ENDOTHELIAL-CELLS; GLYCOSYLPHOSPHATIDYLINOSITOL TOXIN; CAPSULAR POLYSACCHARIDE; PLASMODIUM-FALCIPARUM; PROTEIN; EXPRESSION; RESPONSES; EFFICACY; IMMUNITY; IL-12	A long-standing challenge in malaria is the limited understanding of B cell immunity, previously hampered by lack of tools to phenotype rare antigen-specific cells. Our aim was to develop a method for identifying carbohydrate-specific B cells within lymphocyte populations and to determine whether a candidate vaccine generated functional memory B cells (MBCs) that reactivated upon challenge with Plasmodium (pRBCs). To this end, a new flow cytometric probe was validated and used to determine the kinetics of B cell activation against the candidate vaccine glycosylphosphatidylinositol conjugated to Keyhole Limpet Haemocyanin (GPI-KLH). Additionally, immunized C57BL/6 mice were rested (10 weeks) and challenged with pRBCs or GPI-KLH to assess memory B cell recall against foreign antigen. We found that GPI-specific B cells were detectable in GPI-KLH vaccinated mice, but not in Plasmodium-infected mice. Additionally, in previously vaccinated mice GPI-specific IgG1 MBCs were reactivated against both pRBCs and synthetic GPI-KLH, which resulted in increased serum levels of anti-GPI IgG in both challenge approaches. Collectively our findings contribute to the understanding of B cell immunity in malaria and have important clinical implications for inclusion of carbohydrate conjugates in malaria vaccines.	[Joseph, Hayley; Tan, Qiao Ye; Mazhari, Ramin; Eriksson, Emily M.; Schofield, Louis] Walter & Eliza Hall Inst Med Res, Div Populat Hlth & Immun, Melbourne, Vic, Australia; [Joseph, Hayley; Tan, Qiao Ye; Mazhari, Ramin; Eriksson, Emily M.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Schofield, Louis] James Cook Univ, Australian Inst Trop Hlth & Med, Townsville, Qld, Australia	University of Melbourne; James Cook University	Eriksson, EM (corresponding author), Walter & Eliza Hall Inst Med Res, Div Populat Hlth & Immun, Melbourne, Vic, Australia.; Eriksson, EM (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.	eriksson@wehi.edu.au		Eriksson, Emily/0000-0002-7851-973X	National Health and Medical Research Council [GNT1052580, GNT1093311]; Bill and Melinda Gates Foundation [OPP1136441]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work was supported by the National Health and Medical Research Council [GNT1052580 to HJ and GNT1093311] and the Bill and Melinda Gates Foundation [OPP1136441].	Berhe S, 1999, MOL BIOCHEM PARASIT, V103, P273, DOI 10.1016/S0166-6851(99)00125-5; Buchanan RM, 1998, J IMMUNOL, V161, P5525; Burda PC, 2017, MBIO, V8, DOI [10.1128/mBio.00139-17, 10.1128/mbio.00139-17]; Campo JJ, 2014, VACCINE, V32, P2209, DOI 10.1016/j.vaccine.2014.02.042; Changrob S, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1967-9; Cheng Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35581; Fisher CR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006469; Franca CT, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2042-2; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Janeway C., 2008, JANEWAY IMMUNOBIOL; Jaurigue JA, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00248; Kalia V, 2006, CURR OPIN IMMUNOL, V18, P255, DOI 10.1016/j.coi.2006.03.020; Kapoor N, 2018, BIOCHEMISTRY-US, V57, P516, DOI 10.1021/acs.biochem.7b01099; Keitany GJ, 2016, CELL REP, V17, P3193, DOI 10.1016/j.celrep.2016.11.060; Krishnamurty AT, 2016, IMMUNITY, V45, P402, DOI 10.1016/j.immuni.2016.06.014; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; Lopaticki S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00571-y; Mamchak AA, 2000, IMMUNOL CELL BIOL, V78, P142, DOI 10.1046/j.1440-1711.2000.00896.x; Mathias DK, 2014, INFECT GENET EVOL, V28, P635, DOI 10.1016/j.meegid.2014.05.025; MCGREGOR IA, 1987, ANN TROP MED PARASIT, V81, P647, DOI 10.1080/00034983.1987.11812166; Moens L, 2015, INFECT IMMUN, V83, P2889, DOI 10.1128/IAI.00068-15; Ridderstad A, 1998, J IMMUNOL, V160, P4688; Rubinstein LJ, 1998, INFECT IMMUN, V66, P5450, DOI 10.1128/IAI.66.11.5450-5456.1998; Schmidt A, 1998, EXP PARASITOL, V88, P95, DOI 10.1006/expr.1998.4241; Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937; Schofield L, 1996, J IMMUNOL, V156, P1886; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; Schofield L, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0883-8; Shinde R, 2014, J IMMUNOL, V192; Tachado SD, 1996, J IMMUNOL, V156, P1897; Tamborrini M, 2010, BIOORGAN MED CHEM, V18, P3747, DOI 10.1016/j.bmc.2010.04.059; Tetsutani K, 2007, PARASITOLOGY, V134, P923, DOI 10.1017/S0031182007002326; Vekemans J, 2016, VACCINE BOOK, 2ND EDITION, P385, DOI 10.1016/B978-0-12-802174-3.00019-9; Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912; Wipasa J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000770	35	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 9	2019	10								1840	10.3389/fimmu.2019.01840	http://dx.doi.org/10.3389/fimmu.2019.01840			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IP7VX	31447848	Green Accepted, Green Published, gold			2022-12-18	WOS:000480257200001
J	Lutz, P; Jeffery, HC; Jones, N; Birtwistle, J; Kramer, B; Nattermann, J; Spengler, U; Strassburg, CP; Adams, DH; Oo, YH				Lutz, Philipp; Jeffery, Hannah C.; Jones, Nicholas; Birtwistle, Jane; Kraemer, Benjamin; Nattermann, Jacob; Spengler, Ulrich; Strassburg, Christian P.; Adams, David H.; Oo, Ye H.			NK Cells in Ascites From Liver Disease Patients Display a Particular Phenotype and Take Part in Antibacterial Immune Response	FRONTIERS IN IMMUNOLOGY			English	Article						ascites; Escherichia coli; liver; lymphocyte; NK cells; peritoneal cavity; spontaneous bacterial peritonitis	NATURAL-KILLER-CELLS; SPONTANEOUS BACTERIAL PERITONITIS; CIRRHOTIC-PATIENTS; HOST-DEFENSE; MACROPHAGES; BLOOD; FLUID; TRAFFICKING; EXPRESSION; PROTEIN	Background and Aims: Ascites and spontaneous bacterial peritonitis (SBP) are frequent complications of liver cirrhosis. In spite of the clinical impact, knowledge about ascites as an immune cell compartment in liver disease is limited. Therefore, we analyzed NK cells in blood, ascites, and liver. Methods: Mononuclear cells from blood, ascites, and liver explants of patients with advanced liver disease were extracted by density gradient centrifugation. Phenotyping and analysis of functional responses were carried out using flow cytometry. Migratory potential was investigated with transwell chamber assays. NK cell metabolism was assessed by Seahorse technology. Results: NK cell frequency was increased in uninfected ascites compared to blood, but not to liver. Ascites NK cells were predominantly CD16(positive). CD56(bright) ascites NK cells did not share the typical phenotype of their liver counterparts. In contrast to the inhibitory receptor NKG2A, expression of the activating receptor NKG2D was decreased on ascites and liver CD16(positive) NK cells. Ascites NK cells expressed higher levels of CXCR3 than blood or liver NK cells, corresponding to increased ascites levels of CXCL10. Blood NK cells migrated toward ascites. Stimulation of mononuclear cells with Escherichia coli led to downregulation of NKG2D expression and IL-12 and IL-18 mediated secretion of interferon-gamma by ascites and liver, but not blood NK cells. In-vivo, ascites NK cells expressed higher levels of the activation marker CD69 and lower levels of NKG2D during SBP compared to uninfected ascites. Conclusion: Ascites NK cells display a particular phenotype and are implicated in local immune defense against translocating bacteria.	[Lutz, Philipp; Jeffery, Hannah C.; Adams, David H.; Oo, Ye H.] Univ Birmingham, Inst Immunol & Immunotherapy, Liver Res Ctr, Natl Inst Hlth Res,Liver Biomed Res Unit Birmingh, Birmingham, W Midlands, England; [Lutz, Philipp; Kraemer, Benjamin; Nattermann, Jacob; Spengler, Ulrich; Strassburg, Christian P.] Univ Bonn, Dept Internal Med 1, Bonn, Germany; [Lutz, Philipp; Kraemer, Benjamin; Nattermann, Jacob; Spengler, Ulrich; Strassburg, Christian P.] Univ Bonn, German Ctr Infect Res, Bonn, Germany; [Jones, Nicholas] Swansea Univ, Med Sch, Inst Life Sci, Swansea, W Glam, Wales; [Birtwistle, Jane] Univ Birmingham, Human Biomat Resource Ctr, Birmingham, W Midlands, England; [Adams, David H.; Oo, Ye H.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England	University of Birmingham; University of Bonn; German Center for Infection Research; University of Bonn; Swansea University; University of Birmingham; University of Birmingham	Lutz, P (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Liver Res Ctr, Natl Inst Hlth Res,Liver Biomed Res Unit Birmingh, Birmingham, W Midlands, England.; Lutz, P (corresponding author), Univ Bonn, Dept Internal Med 1, Bonn, Germany.; Lutz, P (corresponding author), Univ Bonn, German Ctr Infect Res, Bonn, Germany.	philipp.lutz@ukbonn.de	Oo, Ye Htun/AFC-8888-2022; Adams, David H/C-9092-2009; Krämer, Benjamin/AAC-9618-2019	Adams, David H/0000-0001-6776-0336; Krämer, Benjamin/0000-0002-1385-9709; Oo, Ye Htun/0000-0002-0495-6734; Lutz, Philipp/0000-0002-4921-200X; Jones, Nicholas/0000-0003-4846-5117	EASL; German Liver Foundation; Hector foundation [M89]; Medical Research Council Clinician Scientist Award [G1002552]; Sir Jules Thorn Trust Biomedical Research Award; National Institute of Health Research Birmingham Biomedical Research Centre, Birmingham; Queen Elizabeth Hospital Birmingham Charity; DFG [SFB TR57, SPP 1937]; MRC [G0300102, G0300101, G0700301, MC_PC_14123, G0400496, G0802577, MR/M009157/1] Funding Source: UKRI	EASL; German Liver Foundation; Hector foundation; Medical Research Council Clinician Scientist Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sir Jules Thorn Trust Biomedical Research Award; National Institute of Health Research Birmingham Biomedical Research Centre, Birmingham; Queen Elizabeth Hospital Birmingham Charity; DFG(German Research Foundation (DFG)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by a Physician-Scientist-Fellowship by EASL and a Vernetzungsstipendium by German Liver Foundation to PL. JN was funded by DFG SFB TR57, SPP 1937, and Hector foundation M89. YO received funding from Medical Research Council Clinician Scientist Award (G1002552), Sir Jules Thorn Trust Biomedical Research Award, National Institute of Health Research Birmingham Biomedical Research Centre, Birmingham, Queen Elizabeth Hospital Birmingham Charity.	Abdel-Razik A, 2015, EUR J GASTROEN HEPAT, V27, P1087, DOI 10.1097/MEG.0000000000000400; Badgwell B, 2002, SURGERY, V132, P205, DOI 10.1067/msy.2002.125311; Bamias A, 2007, GYNECOL ONCOL, V106, P75, DOI 10.1016/j.ygyno.2007.02.029; Bi JC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00760; Chao YQ, 2011, APPL MICROBIOL BIOT, V92, P381, DOI 10.1007/s00253-011-3551-5; Cuff AO, 2016, J IMMUNOL, V197, P4283, DOI 10.4049/jimmunol.1601424; da Silva RF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050856; Etogo AO, 2008, J IMMUNOL, V180, P6334, DOI 10.4049/jimmunol.180.9.6334; Fagan KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120642; Frances R, 2004, GUT, V53, P860, DOI 10.1136/gut.2003.027425; Guo Y, 2018, IMMUNOLOGY, V153, P190, DOI 10.1111/imm.12854; Gur C, 2013, CELL HOST MICROBE, V14, P664, DOI 10.1016/j.chom.2013.11.004; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Herzig DS, 2014, CRIT CARE, V18, DOI 10.1186/cc13902; Herzig DS, 2012, CRIT CARE, V16, DOI 10.1186/cc11642; Herzig DS, 2012, AM J RESP CRIT CARE, V185, P291, DOI 10.1164/rccm.201108-1560OC; Hoogstad-van Evert Janneke S, 2018, Oncotarget, V9, P34810, DOI 10.18632/oncotarget.26199; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Jeffery HC, 2016, J HEPATOL, V64, P1118, DOI 10.1016/j.jhep.2015.12.017; Ruiz-Alcaraz AJ, 2016, MOL IMMUNOL, V72, P28, DOI 10.1016/j.molimm.2016.02.012; Kiyici M, 2006, J GASTROEN HEPATOL, V21, P963, DOI 10.1111/j.1440-1746.2006.04229.x; Kloss M, 2008, J IMMUNOL, V181, P6711, DOI 10.4049/jimmunol.181.10.6711; Kramer B, 2013, INFECT IMMUN, V81, P690, DOI [10.1128/IAI.00895-12, 10.1128/IAI.00895]; LAMPERI S, 1988, AM J KIDNEY DIS, V11, P225, DOI 10.1016/S0272-6386(88)80154-9; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Lozano-Ruiz B, 2015, J HEPATOL, V62, P64, DOI 10.1016/j.jhep.2014.08.027; Lukesova S, 2015, WSPOLCZESNA ONKOL, V19, P290, DOI 10.5114/wo.2015.54388; Lutz P, 2015, CLIN CHEM LAB MED, V53, P2031, DOI 10.1515/cclm-2015-0284; Male V, 2017, TRENDS IMMUNOL, V38, P307, DOI 10.1016/j.it.2017.02.008; Mayer L, 2014, GUT, V63, P442, DOI 10.1136/gutjnl-2012-303424; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Nham T, 2018, CANCER IMMUNOL IMMUN, V67, P575, DOI 10.1007/s00262-017-2112-x; Oo YH, 2012, J HEPATOL, V57, P1044, DOI 10.1016/j.jhep.2012.07.008; Peng H, 2017, SEMIN IMMUNOL, V31, P3, DOI 10.1016/j.smim.2017.07.006; Rogers GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074884; Tandon P, 2013, AM J GASTROENTEROL, V108, P1473, DOI 10.1038/ajg.2013.204; Tapia-Abellan A, 2013, LIVER INT, V33, P552, DOI 10.1111/liv.12072; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Walzer T, 2007, NAT IMMUNOL, V8, P1337, DOI 10.1038/ni1523; Wesselkamper SC, 2008, J IMMUNOL, V181, P5481, DOI 10.4049/jimmunol.181.8.5481; Yeang HXA, 2017, J IMMUNOL, V198, P1417, DOI 10.4049/jimmunol.1601818; Yunusova NV, 2018, CENT EUR J IMMUNOL, V43, P26, DOI 10.5114/ceji.2018.74870; Zhang JJ, 2017, KIDNEY INT, V92, P179, DOI 10.1016/j.kint.2017.01.017; Zhang L, 2013, EXP THER MED, V6, P1189, DOI 10.3892/etm_2013.1281; 2018, J HEPATOL, V69, P406	45	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2019	10								1838	10.3389/fimmu.2019.01838	http://dx.doi.org/10.3389/fimmu.2019.01838			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IO2OQ	31440239	gold, Green Published			2022-12-18	WOS:000479222100001
J	Lee, CK; Bluyssen, HAR				Lee, Chien-Kuo; Bluyssen, Hans A. R.			Editorial: STATs and IRFs in Innate Immunity: From Transcriptional Regulators to Therapeutic Targets	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						STAT; IRF; innate immunity; transcription regulation; therapeutic target			[Lee, Chien-Kuo] Natl Taiwan Univ, Coll Med, Grad Inst Immunol, Taipei, Taiwan; [Bluyssen, Hans A. R.] Adam Mickiewicz Univ, Inst Mol Biol & Biotechnol, Dept Human Mol Genet, Fac Biol, Poznan, Poland	National Taiwan University; Adam Mickiewicz University	Lee, CK (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Immunol, Taipei, Taiwan.; Bluyssen, HAR (corresponding author), Adam Mickiewicz Univ, Inst Mol Biol & Biotechnol, Dept Human Mol Genet, Fac Biol, Poznan, Poland.	leeck@ntu.edu.tw; h.bluyss@amu.edu.pl	Lee, Chien-Kuo/AAZ-1039-2020	Lee, Chien-Kuo/0000-0001-8189-6045; Bluyssen, Hans/0000-0002-4568-6259	Polish National Science Center [OPUS grant] [UMO-2015-17-B-NZ2-00967, UMO-2016-17-B-NZ2-00623]; KNOWRNA Research Center in Poznan, Poland [01/KNOW2/2014]; Ministry of Science and Technology, Taiwan [MOST 102-2320-B-002-030-MY3, MOST 105-2320-B-002-040-MY3]; National Health Research Institutes, Taiwan [NHRI-EX108-10632SI]	Polish National Science Center [OPUS grant]; KNOWRNA Research Center in Poznan, Poland; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	This study was supported by research grants from the Polish National Science Center (http://www.ncn.gov.pl/) [OPUS grant numbers: UMO-2015-17-B-NZ2-00967 and UMO-2016-17-B-NZ2-00623] and the KNOWRNA Research Center in Poznan (http://know-rna.amu.edu.pl/en/) [grant number 01/KNOW2/2014], Poland to HARB and the Ministry of Science and Technology, Taiwan (MOST 102-2320-B-002-030-MY3) and (MOST 105-2320-B-002-040-MY3) and National Health Research Institutes, Taiwan (NHRI-EX108-10632SI) to C-KL.		0	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2019	10								1829	10.3389/fimmu.2019.01829	http://dx.doi.org/10.3389/fimmu.2019.01829			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IN8KE	31447843	Green Published, gold			2022-12-18	WOS:000478928200001
J	Yang, R; Yao, L; Shen, L; Sha, W; Modlin, RL; Shen, HB; Chen, ZW				Yang, Rui; Yao, Lan; Shen, Ling; Sha, Wei; Modlin, Robert L.; Shen, Hongbo; Chen, Zheng W.			IL-12 Expands and Differentiates Human V gamma 2V delta 2 T Effector Cells Producing Antimicrobial Cytokines and Inhibiting Intracellular Mycobacterial Growth (vol 10, 913, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						IL-12; V gamma 2V delta 2 T cells; proliferation; differentiation; anti-tuberculosis			[Yang, Rui; Yao, Lan; Sha, Wei; Shen, Hongbo] Tongji Univ, Sch Med, Shanghai Pulm Hosp,Inst Adv Study, Shanghai Key Lab TB,Clin & Res Ctr TB, Shanghai, Peoples R China; [Shen, Ling; Chen, Zheng W.] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Ctr Primate Biomed Res, Chicago, IL 60612 USA; [Modlin, Robert L.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; [Modlin, Robert L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA	Tongji University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sha, W; Shen, HB (corresponding author), Tongji Univ, Sch Med, Shanghai Pulm Hosp,Inst Adv Study, Shanghai Key Lab TB,Clin & Res Ctr TB, Shanghai, Peoples R China.	shfksw@126.com; hongboshen109@hotmail.com			Clinical Research Plan of SHDC [16CR1028B]; National Institutes of Health R01 grants [OD015092/RR13601, HL64560, HL129887];  [2018ZX10731301-006001];  [2013ZX10003009-002]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312, R01AR073252] Funding Source: NIH RePORTER	Clinical Research Plan of SHDC; National Institutes of Health R01 grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Program Project Grants 2018ZX10731301-006001 (HS/SPH), 2013ZX10003009-002 (HS/IPS), Clinical Research Plan of SHDC 16CR1028B (WS/SPH), and the National Institutes of Health R01 grants OD015092/RR13601, HL64560, and HL129887 (ZC).	Yang R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00913	1	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2019	10								1742	10.3389/fimmu.2019.01742	http://dx.doi.org/10.3389/fimmu.2019.01742			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IM1VN	31404161	Green Published, gold			2022-12-18	WOS:000477779900001
J	Ramirez, GA; Rovere-Querini, P; Blasi, M; Sartorelli, S; Di Chio, MC; Baldini, M; De Lorenzo, R; Bozzolo, EP; Leone, R; Mantovani, A; Manfredi, AA; Tombetti, E				Ramirez, Giuseppe A.; Rovere-Querini, Patrizia; Blasi, Miriam; Sartorelli, Silvia; Di Chio, Maria Chiara; Baldini, Mattia; De Lorenzo, Rebecca; Bozzolo, Enrica P.; Leone, Roberto; Mantovani, Alberto; Manfredi, Angelo A.; Tombetti, Enrico			PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases (vol 10, 1135, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Ramirez, Giuseppe A.; Rovere-Querini, Patrizia; Blasi, Miriam; Sartorelli, Silvia; Di Chio, Maria Chiara; Baldini, Mattia; De Lorenzo, Rebecca; Manfredi, Angelo A.; Tombetti, Enrico] Univ Vita Salute San Raffaele, Milan, Italy; [Ramirez, Giuseppe A.; Bozzolo, Enrica P.; Manfredi, Angelo A.; Tombetti, Enrico] IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy; [Ramirez, Giuseppe A.; Rovere-Querini, Patrizia; Blasi, Miriam; Baldini, Mattia; De Lorenzo, Rebecca; Manfredi, Angelo A.; Tombetti, Enrico] IRCCS Osped San Raffaele, Div Immunol Transplantat & Infect Immun, Milan, Italy; [Leone, Roberto; Mantovani, Alberto] IRCCS, Humanitas Res Ctr, Rozzano, Italy; [Mantovani, Alberto] Humanitas Univ, Rozzano, Italy; [Mantovani, Alberto] Queen Mary Univ London, William Harvey Res Inst, London, England	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Humanitas Research Hospital; Humanitas University; IRCCS Humanitas Research Hospital; University of London; Queen Mary University London	Manfredi, AA (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.; Manfredi, AA (corresponding author), IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy.; Manfredi, AA (corresponding author), IRCCS Osped San Raffaele, Div Immunol Transplantat & Infect Immun, Milan, Italy.	manfredi.angelo@hsr.it	Ramirez, Giuseppe Alvise/K-4923-2018; Leone, Roberto/HGE-8714-2022; Mantovani, Alberto/HCI-7449-2022; Rovere-Querini, Patrizia/J-2340-2012	Ramirez, Giuseppe Alvise/0000-0002-2889-366X; Leone, Roberto/0000-0003-4978-7847; Mantovani, Alberto/0000-0001-5578-236X; De Lorenzo, Rebecca/0000-0002-1281-7996	Cluster Alisei [MEDINTECH CTN01_00177_962865]; MIUR [2015MGBEM2_002]; Ministero della Salute [RF_2013_02358715]; PR-Q; European Research Council (ERC) [69415]; Fondazione Cariplo [2015-0564]	Cluster Alisei; MIUR(Ministry of Education, Universities and Research (MIUR)); Ministero della Salute(Ministry of Health, Italy); PR-Q; European Research Council (ERC)(European Research Council (ERC)); Fondazione Cariplo(Fondazione Cariplo)	In the original article, we neglected to include the funder "Cluster Alisei (MEDINTECH CTN01_00177_962865)" to Alberto Mantovani.; This work was supported by grants from the MIUR (2015MGBEM2_002), and the Ministero della Salute (RF_2013_02358715) to AAM as well as the PR-Q and European Research Council (ERC -No 69415), Fondazione Cariplo (Contract no. 2015-0564) and Cluster Alisei (MEDINTECH CTN01_00177_962865) to AM.	Ramirez GA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01135	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2019	10								1755	10.3389/fimmu.2019.01755	http://dx.doi.org/10.3389/fimmu.2019.01755			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IL0HC	31396240	gold, Green Published			2022-12-18	WOS:000476976600002
J	Tabellini, G; Patrizi, O; Dobbs, K; Lougaris, V; Baronio, M; Coltrini, D; Plebani, A; Badolato, R; Notarangelo, LD; Parolini, S				Tabellini, Giovanna; Patrizi, Ornella; Dobbs, Kerry; Lougaris, Vassilios; Baronio, Manuela; Coltrini, Daniela; Plebani, Alessandro; Badolato, Raffaele; Notarangelo, Luigi D.; Parolini, Silvia			From Natural Killer Cell Receptor Discovery to Characterization of Natural Killer Cell Defects in Primary Immunodeficiencies	FRONTIERS IN IMMUNOLOGY			English	Review						natural killer cells; primary immunodeficiencies; monoclonal antibodies; functional assays; signaling transduction	LINKED LYMPHOPROLIFERATIVE-DISEASE; NK CELLS; SURFACE-MOLECULE; 2B4; CYTOTOXICITY; IDENTIFICATION; MUTATIONS; INNATE; GENE; DEFICIENCY	Alessandro Moretta was Professor of Histology at University of Brescia from 1994 to 1997. It was in that period that we met and started a collaboration that continued in the years to follow. He immediately involved us in the production of monoclonal antibodies (mAbs) that allowed the identification and fine characterization of novel receptor molecules that were able to activate or inhibit human Natural Killer cell function, including several antibodies specific for Natural Cytotoxicity Receptor (NCR) and Killer-cell Immunoglobulin-like Receptor (KIR) molecules. These reagents, generated in our laboratory in Brescia, contributed to complete the studies aimed to characterize innate lymphoid NK cells, that had been initiated by Alessandro and his brother Lorenzo in Genoa. Soon, we identified an anti-KIR3DL2 that was subsequently shown to be helpful for the diagnosis and treatment of various forms of cutaneous T cell lymphoma. While in Brescia, Alessandro established a partnership with those of us who were working in the Department of Pediatrics; together, in short time we tackled the goal of studying the role of NK cells in patients with primary immunodeficiencies. This collaboration led to novel discoveries that shed light on the critical role played by NK cells in the immune response against virus and tumors in humans, as best exemplified by our characterization of the molecular mechanisms of impaired control of Epstein-Barr Virus (EBV) infection in patients with X-linked lymphoproliferative (XLP) disease. After Alessandro left Brescia to return to Genoa, our collaboration continued with the same enthusiasm, and even from a distance he remained an extraordinary example of an inspirational and generous mentor. This review is a sign of our gratitude to a mentor and a friend whom we deeply miss.	[Tabellini, Giovanna; Patrizi, Ornella; Coltrini, Daniela; Parolini, Silvia] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Dobbs, Kerry; Notarangelo, Luigi D.] NIAID, Lab Host Defenses, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lougaris, Vassilios; Baronio, Manuela; Plebani, Alessandro; Badolato, Raffaele] Univ Brescia, Dept Expt & Clin Sci, Brescia, Italy	University of Brescia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Brescia	Parolini, S (corresponding author), Univ Brescia, Dept Mol & Translat Med, Brescia, Italy.	silvia.parolini@unibs.it	Badolato, Raffaele/A-8081-2010; Patrizi, Ornella/ABC-5102-2020	Badolato, Raffaele/0000-0001-7375-5410; PAROLINI, Silvia/0000-0003-1968-7765; Dobbs, Kerry/0000-0002-3432-3137	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Innate Pharma SA	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Innate Pharma SA	LN was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. SP had received funding from Innate Pharma SA.	Aoukaty A, 2002, J BIOL CHEM, V277, P13331, DOI 10.1074/jbc.M112029200; Augugliaro R, 2003, EUR J IMMUNOL, V33, P1235, DOI 10.1002/eji.200323896; Badolato R, 2007, J ALLERGY CLIN IMMUN, V120, P735, DOI 10.1016/j.jaci.2007.08.039; Badolato R, 2012, BLOOD, V119, P3185, DOI 10.1182/blood-2012-01-404350; Beziat V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011966; Biassoni R, 2001, IMMUNOL REV, V181, P203, DOI 10.1034/j.1600-065X.2001.1810117.x; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Bottino C, 2001, ADV EXP MED BIOL, V495, P63; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Cantoni C, 1999, J EXP MED, V189, P787, DOI 10.1084/jem.189.5.787; Carlin LM, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001729; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Dobbs K, 2015, NEW ENGL J MED, V372, P2409, DOI 10.1056/NEJMoa1413462; Dobbs K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00798; Dotta L, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-168; Eissmann P, 2005, BLOOD, V105, P4722, DOI 10.1182/blood-2004-09-3796; Fontana S, 2006, BLOOD, V107, P4857, DOI 10.1182/blood-2005-11-4398; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Jacobs R, 2001, EUR J IMMUNOL, V31, P3121, DOI 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Karo JM, 2015, EUR J IMMUNOL, V45, P1906, DOI 10.1002/eji.201445339; Karo JM, 2014, CELL, V159, P94, DOI 10.1016/j.cell.2014.08.026; Kerr WG, 2011, J INNATE IMMUN, V3, P249, DOI 10.1159/000323920; Lam VC, 2017, CURR OPIN IMMUNOL, V44, P43, DOI 10.1016/j.coi.2016.11.003; Lopez-Botet M, 2014, SEMIN IMMUNOL, V26, P145, DOI 10.1016/j.smim.2014.03.002; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Lorenzi L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080131; Lougaris V, 2017, CLIN IMMUNOL, V175, P99, DOI 10.1016/j.clim.2016.11.012; Lougaris V, 2016, J ALLERGY CLIN IMMUN, V138, P605, DOI 10.1016/j.jaci.2016.01.026; Lougaris V, 2015, CLIN IMMUNOL, V159, P33, DOI 10.1016/j.clim.2015.04.014; Lougaris V, 2015, J ALLERGY CLIN IMMUN, V135, P1641, DOI 10.1016/j.jaci.2014.11.038; Mace EM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00445; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; Marcenaro E, 2011, IMMUNOTHERAPY-UK, V3, P1075, DOI [10.2217/IMT.11.99, 10.2217/imt.11.99]; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Montaldo E, 2013, CYTOM PART A, V83A, P702, DOI 10.1002/cyto.a.22302; Moretta A, 2008, CELL DEATH DIFFER, V15, P226, DOI 10.1038/sj.cdd.4402170; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta A, 2001, CURR OPIN ALLERGY CL, V1, P513, DOI 10.1097/00130832-200112000-00004; Moretta L, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00087; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Olbrich P, 2016, PEDIAT ALLERG IMM-UK, V27, P640, DOI 10.1111/pai.12585; Pai SY, 2014, CURR OPIN ALLERGY CL, V14, P521, DOI 10.1097/ACI.0000000000000115; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Renoux VM, 2015, IMMUNITY, V43, P394, DOI 10.1016/j.immuni.2015.07.011; Rolle A, 2016, TRENDS IMMUNOL, V37, P233, DOI 10.1016/j.it.2016.01.005; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Sivori S, 2000, EUR J IMMUNOL, V30, P787, DOI 10.1002/1521-4141(200003)30:3<787::AID-IMMU787>3.0.CO;2-I; Tabellini G, 2017, J ALLERGY CLIN IMMUN, V140, P553, DOI 10.1016/j.jaci.2016.10.051; Upshaw JL, 2006, NAT IMMUNOL, V7, P524, DOI 10.1038/ni1325; Vairo D, 2011, BLOOD, V118, P1806, DOI 10.1182/blood-2011-01-330571; Vitale M, 2001, EUR J IMMUNOL, V31, P233, DOI 10.1002/1521-4141(200101)31:1<233::AID-IMMU233>3.3.CO;2-W; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wechsler A, 2003, J PATHOL, V199, P77, DOI 10.1002/path.1251	64	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2019	10								1757	10.3389/fimmu.2019.01757	http://dx.doi.org/10.3389/fimmu.2019.01757			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IL0HD	31396241	gold, Green Published			2022-12-18	WOS:000476976700001
J	Mohanty, MC; Madkaikar, MR; Desai, M; Aluri, J; Varose, SY; Taur, P; Sharma, DK; Nalavade, UP; Rane, SV; Gupta, M; Shabarish, S; Dalvi, A; Deshpande, JM				Mohanty, Madhu Chhanda; Madkaikar, Manisha Ranjan; Desai, Mukesh; Aluri, Jahnavi; Varose, Swapnil Yashwant; Taur, Prasad; Sharma, Deepa Kailash; Nalavade, Uma Prajwal; Rane, Sneha Vijay; Gupta, Maya; Shabarish, Snehal; Dalvi, Aparna; Deshpande, Jagadish Mohanrao			Natural Clearance of Prolonged VDPV Infection in a Child With Primary Immunodeficiency Disorder	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency disorder; oral polio vaccine; vaccine-derived polioviruses; severe combined immune-deficiency; leaky SCID; inflammatory cytokines	VACCINE-DERIVED POLIOVIRUSES; POLIO-ERADICATION; EXCRETION; WORLDWIDE; DISEASE	The emergence of immunodeficiency-associated vaccine-derived polioviruses (iVDPV) from children with primary immunodeficiency disorders poses a threat to the eradication program. Herein, we report a patient with severe combined immunodeficiency (SCID), identified as a prolonged serotype 3 iVDPV (iVDPV3) excreter with 13 VDPV3 isolates and a maximum of 10.33% nucleotide divergence, who abruptly cleared infection after a period of 2 years. Occurrence of an episode of norovirus diarrhea associated with increased activated oligoclonal cytotoxic T cells, inverse CD4: CD8 ratio, significantly elevated pro-inflammatory cytokines, and subsequent clearance of the poliovirus suggests a possible link between inflammatory diarrheal illness and clearance of iVDPV. Our findings suggest that in the absence of B cells and sufficiently activated T/NK cells, macrophages and other T cells may produce auto-inflammatory conditions by TLR/RLR ligands expressed by previous/ongoing bacterial or viral infections to clear VDPV infection. The study highlights the need to screen all the patients with combined immunodeficiency for poliovirus excretion and intermittent follow-up of their immune parameters if found positive, in order to manage the risk of iVDPV excretion in the polio eradication endgame strategy.	[Mohanty, Madhu Chhanda; Varose, Swapnil Yashwant; Sharma, Deepa Kailash; Nalavade, Uma Prajwal; Rane, Sneha Vijay; Deshpande, Jagadish Mohanrao] ICMR Natl Inst Virol, Mumbai Unit, Mumbai, Maharashtra, India; [Mohanty, Madhu Chhanda; Varose, Swapnil Yashwant; Sharma, Deepa Kailash; Nalavade, Uma Prajwal; Rane, Sneha Vijay; Deshpande, Jagadish Mohanrao] Indian Council Med Res, Enterovirus Res Ctr, Mumbai, Maharashtra, India; [Madkaikar, Manisha Ranjan; Aluri, Jahnavi; Gupta, Maya; Shabarish, Snehal; Dalvi, Aparna] Indian Council Med Res, KEM Hosp, ICMR Natl Inst Immunohaematol, Mumbai, Maharashtra, India; [Desai, Mukesh; Taur, Prasad] Bai Jer Bai Wadia Childrens Hosp, Mumbai, Maharashtra, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Virology (NIV); ICMR - Enterovirus Research Centre; Indian Council of Medical Research (ICMR); ICMR - National Institute of Immunohaemotology (NIIH)	Mohanty, MC (corresponding author), ICMR Natl Inst Virol, Mumbai Unit, Mumbai, Maharashtra, India.	madhuerc@gmail.com	Aluri, Jahnavi/AAB-3570-2022; Mohanty, Madhu Chhanda/ABA-4809-2021	Mohanty, Madhu Chhanda/0000-0001-6942-2875; shabrish, snehal/0000-0002-6407-5082; Deshpande, Jagadish/0000-0001-5194-0375; Madkaikar, Manisha/0000-0001-6380-3116	Indian Council of Medical Research (ICMR)	Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR))	This work was supported by the Indian Council of Medical Research (ICMR).	Aghamohammadi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00685; Alexander JP, 2009, J INFECT DIS, V199, P391, DOI 10.1086/596052; Asturias EJ, 2006, BIOLOGICALS, V34, P109, DOI 10.1016/j.biologicals.2006.03.002; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Burns CC, 2014, J INFECT DIS, V210, pS283, DOI 10.1093/infdis/jiu295; Dotzauer Andreas, 2012, World J Virol, V1, P91, DOI 10.5501/wjv.v1.i3.91; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Driss N, 2012, CLIN VACCINE IMMUNOL, V19, P1684, DOI 10.1128/CVI.00293-12; Dunn G, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005114; Gong X, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-224; Kew Olen M., 2012, Morbidity and Mortality Weekly Report, V61, P741; Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625; Kew OM, 1998, J CLIN MICROBIOL, V36, P2893, DOI 10.1128/JCM.36.10.2893-2899.1998; Khetsuriani N, 2003, J INFECT DIS, V188, P1845, DOI 10.1086/379791; Kilpatrick DR, 2011, J VIROL METHODS, V174, P128, DOI 10.1016/j.jviromet.2011.03.020; Li M, 2014, J BIOL CHEM, V289, P17647, DOI 10.1074/jbc.M114.572420; MacCallum F O, 1971, Spec Rep Ser Med Res Counc (G B), V310, P72; MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3; Martin J, 2002, J VIROL, V76, P5339, DOI 10.1128/JVI.76.11.5339-5349.2002; Minor PD, 2012, J GEN VIROL, V93, P457, DOI 10.1099/vir.0.036988-0; Mohanty MC, 2014, T ROY SOC TROP MED H, V108, P258, DOI 10.1093/trstmh/tru041; Mohanty MC, 2017, EMERG INFECT DIS, V23, P1664, DOI 10.3201/eid2310.170724; Morales M, 2016, MMWR-MORBID MORTAL W, V65, P470, DOI 10.15585/mmwr.mm6518a4; Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61; Shaghaghi M, 2018, J CLIN IMMUNOL, V38, P610, DOI 10.1007/s10875-018-0521-z; Shaghaghi M, 2018, VACCINE, V36, P1711, DOI 10.1016/j.vaccine.2018.02.059; Shaghaghi M, 2016, EMERG INFECT DIS, V22, P1712, DOI 10.3201/eid2210.151071; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Sutter RW, 1994, INFECT MED, V11, P426; Tebbens RJD, 2006, RISK ANAL, V26, P1471, DOI 10.1111/j.1539-6924.2006.00827.x; Tebbens RJD, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1112-8; Vreugdenhil GR, 2000, CYTOKINE, V12, P1793, DOI 10.1006/cyto.2000.0786; Wahid R, 2005, J VIROL, V79, P5988, DOI 10.1128/JVI.79.10.5988-5995.2005; Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8; WHO, 2004, POL LAB MAN; World Hlth Org, 2017, VACCINE, V35, P1197, DOI 10.1016/j.vaccine.2016.11.017	36	1	3	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2019	10								1567	10.3389/fimmu.2019.01567	http://dx.doi.org/10.3389/fimmu.2019.01567			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IK7DB	31396204	Green Published, gold			2022-12-18	WOS:000476747700001
J	Shih, T; De, S; Barnes, BJ				Shih, Tiffany; De, Saurav; Barnes, Betsy J.			RNAi Transfection Optimized in Primary Naive B Cells for the Targeted Analysis of Human Plasma Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						IRF4; AID; siRNA knockdown; plasmablast; antibody secreting cells; B cell	INTERFERON REGULATORY FACTOR-4; VERSUS-HOST-DISEASE; THERAPEUTIC TARGET; ANTIBODY-RESPONSES; ACTIVATION; IRF4; GENE; LEUKEMIA; RECEPTOR; STAT3	Upon antigen recognition, naive B cells undergo rapid proliferation followed by differentiation to specialized antibody secreting cells (ASCs), called plasma cells. Increased circulating plasma cells are reported in patients with B cell-associated malignancies, chronic graft-vs.-host disease, and autoimmune disorders. Our aim was to optimize an RNAi-based method that efficiently and reproducibly knocks-down genes of interest in human primary peripheral B cells for the targeted analysis of ASC differentiation. The unique contributions of transcriptional diversity in species-specific regulatory networks and the mechanisms of gene function need to be approached directly in human B cells with tools to hone our basic inferences from animal models to human biology. To date, methods for gene knockdown in human primary B cells, which tend to be more refractory to transfection than immortalized B cell lines, have been limited by losses in cell viability and ineffective penetrance. Our single-step siRNA nucleofector-based approach for human primary naive B cells demonstrates reproducible knockdown efficiency (similar to 40-60%). We focused on genes already known to play key roles in murine ASC differentiation, such as interferon regulatory factor 4 (IRF4) and AID. This study reports a validated non-viral method of siRNA delivery into human primary B cells that can be applied to study gene regulatory networks that control human ASC differentiation.	[Shih, Tiffany; De, Saurav; Barnes, Betsy J.] Northwell Hlth, Feinstein Inst Med Res, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Manhasset, NY 11030 USA; [De, Saurav] Rutgers State Univ, Grad Sch Biomed Sci, Newark, NJ USA; [Barnes, Betsy J.] Northwell Hlth, Zucker Sch Med Hofstra, Dept Mol Med, Hempstead, NY 11550 USA; [Barnes, Betsy J.] Northwell Hlth, Zucker Sch Med Hofstra, Dept Pediat, Hempstead, NY 11550 USA	Northwell Health; Rutgers State University Newark; Rutgers State University New Brunswick; Northwell Health; Northwell Health	Barnes, BJ (corresponding author), Northwell Hlth, Feinstein Inst Med Res, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Manhasset, NY 11030 USA.; Barnes, BJ (corresponding author), Northwell Hlth, Zucker Sch Med Hofstra, Dept Mol Med, Hempstead, NY 11550 USA.; Barnes, BJ (corresponding author), Northwell Hlth, Zucker Sch Med Hofstra, Dept Pediat, Hempstead, NY 11550 USA.	bbarnes1@northwell.edu			Lupus Research Alliance; National Institutes of Health NIAMS [AR065959-01]; DOD [W81XWH-18-1-0674]; New Jersey Commission on Cancer Research	Lupus Research Alliance; National Institutes of Health NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); DOD(United States Department of Defense); New Jersey Commission on Cancer Research	This work was supported by grants from the Lupus Research Alliance (BB), National Institutes of Health NIAMS AR065959-01 (BB), DOD Lupus Research Program W81XWH-18-1-0674 (BB), and the New Jersey Commission on Cancer Research (SD).	Agarwal A, 2016, METHODS MOL BIOL, V1470, P85, DOI 10.1007/978-1-4939-6337-9_7; Agrawal S, 2011, J CLIN IMMUNOL, V31, P472, DOI [10.1007/s10875-010-9507-1, 10.1007/s10875-010-9456-8]; Aleman LM, 2007, RNA, V13, P385, DOI 10.1261/rna.352507; Allen JL, 2014, BLOOD, V123, P2108, DOI 10.1182/blood-2013-10-533562; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Azam S, 2008, J BIOL CHEM, V283, P30632, DOI 10.1074/jbc.M801401200; Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439; Berglund LJ, 2013, BLOOD, V122, P3940, DOI 10.1182/blood-2013-06-506865; Biswas PS, 2012, J EXP MED, V209, P581, DOI 10.1084/jem.20111195; Chiche J, 2019, CELL METAB, V29, P1243, DOI 10.1016/j.cmet.2019.02.002; De S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01938; Deenick EK, 2013, J EXP MED, V210, P2739, DOI 10.1084/jem.20130323; Delker RK, 2009, NAT IMMUNOL, V10, P1147, DOI 10.1038/ni.1799; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779; Hipp N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01475-7; Hong SW, 2014, NUCLEIC ACID THER, V24, P192, DOI 10.1089/nat.2013.0466; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Huggins J, 2007, BLOOD, V109, P1611, DOI 10.1182/blood-2006-03-008441; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Indrevaer RL, 2015, J IMMUNOL, V195, P2601, DOI 10.4049/jimmunol.1500250; Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010; Jacobson CA, 2014, BIOL BLOOD MARROW TR, V20, P668, DOI 10.1016/j.bbmt.2014.01.021; Johnson MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30358-0; Kardava L, 2011, J CLIN INVEST, V121, P2614, DOI 10.1172/JCI45685; Kharfan-Dabaja MA, 2011, INT J HEMATOL, V93, P578, DOI 10.1007/s12185-011-0855-2; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Kim S, 2018, GENOME RES, V28, P367, DOI 10.1101/gr.231936.117; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; Koff JL, 2016, EXPERT REV HEMATOL, V9, P553, DOI 10.1080/17474086.2016.1180972; Kurosawa A, 2012, GENE, V492, P305, DOI 10.1016/j.gene.2011.11.003; Ma SB, 2008, BLOOD, V111, P1396, DOI 10.1182/blood-2007-08-110106; Ma SB, 2006, J IMMUNOL, V177, P7898, DOI 10.4049/jimmunol.177.11.7898; Maarof G, 2010, BLOOD, V115, P1718, DOI 10.1182/blood-2009-05-220251; Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161; Maxson JE, 2013, NEW ENGL J MED, V368, P1781, DOI 10.1056/NEJMoa1214514; Meng ZJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00331; Migliaccio N, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0202-4; Miklos DB, 2005, BLOOD, V105, P2973, DOI 10.1182/blood-2004-09-3660; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Mocellin Simone, 2004, J Transl Med, V2, P39, DOI 10.1186/1479-5876-2-39; Moens L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00065; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Ochiai K, 2012, NAT IMMUNOL, V13, P300, DOI 10.1038/ni.2210; Phadke MS, 2009, J PHARMACOL EXP THER, V331, P77, DOI 10.1124/jpet.109.155671; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Ramiro Almudena, 2007, Adv Immunol, V94, P75, DOI 10.1016/S0065-2776(06)94003-6; Richard ML, 2018, LUPUS SCI MED, V5, DOI 10.1136/lupus-2016-000199; Sarantopoulos S, 2015, BIOL BLOOD MARROW TR, V21, P16, DOI 10.1016/j.bbmt.2014.10.029; Sarantopoulos S, 2011, BLOOD, V117, P2275, DOI 10.1182/blood-2010-10-307819; Sarantopoulos S, 2009, BLOOD, V113, P3865, DOI 10.1182/blood-2008-09-177840; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Sciammas R, 2006, IMMUNITY, V25, P225, DOI 10.1016/j.immuni.2006.07.009; Seiffert M, 2007, LEUKEMIA, V21, P1977, DOI 10.1038/sj.leu.2404863; Smith I, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2003213; Somasundaram R, 2015, BLOOD, V126, P144, DOI 10.1182/blood-2014-12-575688; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; Tyner J, 2009, CELL CYCLE, V8, P2144; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Willis SN, 2014, J IMMUNOL, V192, P3200, DOI 10.4049/jimmunol.1303216; Wu CAM, 2018, J IMMUNOL METHODS, V457, P33, DOI 10.1016/j.jim.2018.03.009; Zhang JY, 2015, CANCER BIOL MED, V12, P10, DOI 10.7497/j.issn.2095-3941.2014.0019	64	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2019	10								1652	10.3389/fimmu.2019.01652	http://dx.doi.org/10.3389/fimmu.2019.01652			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IK7DP	31396212	Green Published, gold			2022-12-18	WOS:000476749200001
J	Vidal-Castineira, JR; Corte-Iglesias, V; Sobrino-Diaz, L; Perez-Fernandez, S; Melon, S; Lopez-Larrea, C; Diaz-Corte, C				Ramon Vidal-Castineira, Jose; Corte-Iglesias, Viviana; Sobrino-Diaz, Lucia; Perez-Fernandez, Sonia; Melon, Santiago; Lopez-Larrea, Carlos; Diaz-Corte, Carmen			Effect of Type of Dialysis on CMV-Specific CD8+T Cells in Kidney Transplant Candidates	FRONTIERS IN IMMUNOLOGY			English	Article						CMV; hemodialysis; peritoneal dialysis; CMV-specific CD8+T cells; dextramers	HUMAN CYTOMEGALOVIRUS; RECIPIENTS; INFECTION; RISK; REPLICATION; IMPAIRMENT; SECRETION; MORTALITY; RESPONSES; MODALITY	Background: Dialysis is the first procedure to partially replace renal function in end-stage renal diseases, despite several adverse side effects, such as infections. The primary aim of this study was to evaluate the levels of immune CMV-specific CD8+ T cells in a representative cohort of pre-transplant patients receiving hemodialysis (HD) or peritoneal dialysis (PD). The secondary aim was to monitor the CMV-specific CD8+ T cells in kidney transplant recipients undergoing different types of dialysis during the first year following their transplant. Methods: Sixty-nine patients were enrolled and examined with respect to the type of dialysis they received. HLA class I dextramers for CMV were used to determine the quantity of CMV-specific CD8+ T cells. The CMV DNA viral load was also determined. Forty-two of the patients enrolled in the study underwent solid organ transplantation and were analyzed during their first year post-transplantation. Results: Patients receiving HD had fewer CMV-specific CD8+ T cells than those in PD (p < 0.05). We also observed that patients in PD had more CMV-specific CD8+ T cells during the follow-up period than those in HD (p < 0.05), independently of the CMV DNA. Finally, PD patients had a higher frequency of CD8+ Effector-Memory RA T cells (TEMRA) and a lower frequency of central memory T cells (TCM) than did HD patients. Conclusions: These results indicate the better status of CMV-specific T cell immunity in PD patients. The use of CMV T cell dextramers would be advantageous formonitoring the CD8+ T-specific response, enabling the use of prophylactic treatment to be optimized.	[Ramon Vidal-Castineira, Jose; Corte-Iglesias, Viviana; Lopez-Larrea, Carlos] Hosp Univ Cent Asturias, Translat Immunol Lab, Hlth Res Inst Principal Asturias, Oviedo, Spain; [Sobrino-Diaz, Lucia; Diaz-Corte, Carmen] Hosp Univ Cent Asturias, Serv Nephrol, Oviedo, Spain; [Perez-Fernandez, Sonia] Univ Oviedo, Dept Stat & Operat Res & Math Didact, Oviedo, Spain; [Melon, Santiago] Hosp Univ Cent Asturias, Microbiol Serv, Oviedo, Spain; [Lopez-Larrea, Carlos] Hosp Univ Cent Asturias, Serv Immunol, Oviedo, Spain	Central University Hospital Asturias; Central University Hospital Asturias; University of Oviedo; Central University Hospital Asturias; Central University Hospital Asturias	Lopez-Larrea, C (corresponding author), Hosp Univ Cent Asturias, Translat Immunol Lab, Hlth Res Inst Principal Asturias, Oviedo, Spain.; Lopez-Larrea, C (corresponding author), Hosp Univ Cent Asturias, Serv Immunol, Oviedo, Spain.	inmuno@hca.es	Melón García, Santiago/AHE-7360-2022; Pérez-Fernández, Sonia/Z-4839-2019; Melón, Santiago/AAY-1466-2021	Melón García, Santiago/0000-0001-5770-7902; Pérez-Fernández, Sonia/0000-0002-2767-6399; Melón, Santiago/0000-0001-5770-7902; Vidal-Castineira, Jose Ramon/0000-0003-4877-3566	ISCIII (Spanish Institute of Health Carlos III) [PI16/01318, PI17/01244]; Gobierno del Principado de Asturias [IDI/2018/144, BP16118]; European Union; Red Espanola de Investigacion Renal (REDinREN) [RD16/0009/0020, RD16/0009/0021]	ISCIII (Spanish Institute of Health Carlos III); Gobierno del Principado de Asturias(Principality of Asturias); European Union(European Commission); Red Espanola de Investigacion Renal (REDinREN)	This work was supported by the Plan Nacional de I+D+I 2013-2016 ISCIII (Spanish Institute of Health Carlos III; grant numbers PI16/01318 and PI17/01244); Gobierno del Principado de Asturias, PCTI-Plan de Ciencia, Tecnologia e Innovacion 2013-2017, (grant number IDI/2018/144); FEDER Funding Program of the European Union; and the Red Espanola de Investigacion Renal (REDinREN, grant numbers RD16/0009/0020 and RD16/0009/0021). SP-F was supported by Severo Ochoa grant BP16118 (Gobierno del Principado de Asturias).	Cai KD, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0394-4; Cantisan S, 2015, AM J TRANSPLANT, V15, P715, DOI 10.1111/ajt.13012; Cantisan S, 2013, AM J TRANSPLANT, V13, P738, DOI 10.1111/ajt.12049; Crough T, 2009, CLIN MICROBIOL REV, V22, P76, DOI 10.1128/CMR.00034-08; Eleftheriadis T, 2007, SEMIN DIALYSIS, V20, P440, DOI 10.1111/J.1525-139X.2007.00283.x; Engstrand M, 2003, CLIN EXP IMMUNOL, V132, P96, DOI 10.1046/j.1365-2249.2003.02098.x; Eshraghi H, 2015, TRANSPL P, V47, P1136, DOI 10.1016/j.transproceed.2014.11.066; Ferreira VH, 2019, TRANSPLANTATION, V103, P613, DOI 10.1097/TP.0000000000002373; Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928; Gordon CL, 2017, J EXP MED, V214, P651, DOI 10.1084/jem.20160758; Humar A, 2006, AM J TRANSPLANT, V6, P262, DOI 10.1111/j.1600-6143.2005.01207.x; Humar A, 2010, AM J TRANSPLANT, V10, P1228, DOI 10.1111/j.1600-6143.2010.03074.x; Kaminski H, 2016, AM J TRANSPLANT, V16, P2254, DOI 10.1111/ajt.13791; Klenerman P, 2016, NAT REV IMMUNOL, V16, P367, DOI 10.1038/nri.2016.38; Lukowsky LR, 2013, CLIN J AM SOC NEPHRO, V8, P619, DOI 10.2215/CJN.04810512; Mattes FM, 2008, AM J TRANSPLANT, V8, P990, DOI 10.1111/j.1600-6143.2008.02191.x; McDonald SP, 2009, J AM SOC NEPHROL, V20, P155, DOI 10.1681/ASN.2007111188; Molina M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01221; Razonable RR, 2018, CURR OPIN ORGAN TRAN, V23, P388, DOI 10.1097/MOT.0000000000000541; Reddan DN, 2003, NEPHROL DIAL TRANSPL, V18, P1167, DOI 10.1093/ndt/gfg066; Satoh S, 2004, INT J UROL, V11, P825, DOI 10.1111/j.1442-2042.2004.00915.x; Schachtner T, 2017, TRANSPLANTATION, V101, pE315, DOI 10.1097/TP.0000000000001825; Sester U, 2005, AM J TRANSPLANT, V5, P1483, DOI 10.1111/j.1600-6143.2005.00871.x; Solana R, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-23; Yang R, 2008, TRANSPL P, V40, P3500, DOI 10.1016/j.transproceed.2008.03.176	25	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2019	10								1680	10.3389/fimmu.2019.01680	http://dx.doi.org/10.3389/fimmu.2019.01680			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IK7BP	31379868	Green Published, gold			2022-12-18	WOS:000476743700001
J	Nim, HT; Connelly, K; Vincent, FB; Petitjean, F; Hoi, A; Koelmeyer, R; Boyd, SE; Morand, EF				Nim, Hieu T.; Connelly, Kathryn; Vincent, Fabien B.; Petitjean, Francois; Hoi, Alberta; Koelmeyer, Rachel; Boyd, Sarah E.; Morand, Eric F.			Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; biomarkers; clustering; longitudinal analysis; regression models		Objective: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. SLE is characterized by high inter-patient variability, including fluctuations over time, a factor which most biomarker studies omit from consideration. We investigated relationships between disease activity and biomarker expression in SLE, using novel methods to control for time-dependent variability, in a proof-of-concept study to evaluate whether doing so revealed additional information. Methods: We measured 4 serum biomarkers (MIF, CCL2, CCL19, and CXCL10) and 13 routine clinical laboratory parameters, alongside disease activity measured by the SLE disease activity index-2k (SLEDAI-2k), collected longitudinally. We analyzed these data with unsupervised learning methods via ensemble clustering, incorporating temporal relationships using dynamic time warping for distance metric calculation. Results: Data from 843 visits in 110 patients (median age 47, 83% female) demonstrated highly heterogeneous time-dependent relationships between disease activity and biomarkers. Unbiased magnitude-based hierarchical clustering of biomarker expression levels isolated a patient subset (n = 9) with distinctively heterogeneous expression of the 17 biological parameters, and who had MIF, CCL2, CCL19, and CXCL10 levels that were higher and more strongly associated with disease activity, based on leave-one-out cross-validated regression analysis. In the remaining subgroup, a time-dependent regression model revealed significantly stronger predictive power of biomarkers for disease activity, compared to a time-agnostic regression model. Despite no significant difference in simple magnitude, using dynamic time warping analysis to align longitudinal profiles revealed a large subset (n = 69) with significantly stronger associations between biological parameters and disease activity. This subgroup had significantly lower flare rates, disease activity and damage scores, suggesting this clustering is clinically meaningful. Conclusions: These results suggest associations between biological parameters and disease activity in SLE exist in a multi-dimensional time-dependent pattern, with implications for the analysis of biomarkers in SLE often used to identify therapeutic targets. Novelmethods to analyse high-dimensional data and control for time-dependent variability may have broad utility in the study complex relationships between clinical and biological parameters.	[Nim, Hieu T.; Petitjean, Francois] Monash Univ, Fac Informat Technol, Data Sci & AI, Clayton, Vic, Australia; [Nim, Hieu T.; Connelly, Kathryn; Vincent, Fabien B.; Hoi, Alberta; Koelmeyer, Rachel; Boyd, Sarah E.; Morand, Eric F.] Monash Univ, Sch Clin Sci Monash Hlth, Ctr Inflammatory Dis, Melbourne, Vic, Australia; [Nim, Hieu T.] Monash Univ, Fac Sci, Sch Biol Sci, Clayton, Vic, Australia	Monash University; Monash University; Monash University	Morand, EF (corresponding author), Monash Univ, Sch Clin Sci Monash Hlth, Ctr Inflammatory Dis, Melbourne, Vic, Australia.	eric.morand@monash.edu	Morand, Eric F/I-4718-2013; Vincent, Fabien B./A-2834-2012; Morand, Eric/AAT-3259-2021	Morand, Eric F/0000-0002-9507-3338; Vincent, Fabien B./0000-0001-7220-0800; Morand, Eric/0000-0002-9507-3338; Hoi, Alberta/0000-0002-9416-7383	Monash Interdisciplinary Research (IDR) Grant; Richard Pratt Fellowships in Prostate Cancer by the Victorian Cancer Agency; Australian Government [DE170100037]	Monash Interdisciplinary Research (IDR) Grant; Richard Pratt Fellowships in Prostate Cancer by the Victorian Cancer Agency; Australian Government(Australian GovernmentCGIAR)	The work reported on this manuscript was supported by a Monash Interdisciplinary Research (IDR) Grant to EM and SB. HN is supported by the Richard Pratt Fellowships in Prostate Cancer by the Victorian Cancer Agency. FP is the recipient of the Discovery Early Career Award DE170100037 funded by the Australian Government.	Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Barturen G, 2018, NAT REV RHEUMATOL, V14, P75, DOI 10.1038/nrrheum.2017.220; Bauer JW, 2009, ARTHRITIS RHEUM-US, V60, P3098, DOI 10.1002/art.24803; Connelly KL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29909; Dolgin E, 2019, NAT BIOTECHNOL, V37, P6; Furie R, 2017, ARTHRITIS RHEUMATOL, V69, P376, DOI 10.1002/art.39962; Golder V, 2013, LUPUS, V22, P1425, DOI 10.1177/0961203313500547; Handelman GS, 2018, J INTERN MED, V284, P603, DOI 10.1111/joim.12822; Jorge AM, 2018, RHEUMATOLOGY, V57, P337, DOI 10.1093/rheumatology/kex412; Lu C, 2017, IMPLEMENT SCI, V12; Morand EF, 2018, ANN RHEUM DIS, V77, P706, DOI 10.1136/annrheumdis-2017-212504; Mosca M, 2010, ANN RHEUM DIS, V69, P1269, DOI 10.1136/ard.2009.117200; O'Neill S, 2017, MED J AUSTRALIA, V206, P194, DOI 10.5694/mja16.01282; Petri M, 2009, LUPUS, V18, P980, DOI 10.1177/0961203309105529; Ratanamahatana CA, 2005, SIAM PROC S, P506; Ronan T, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1932; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Toro-Dominguez D, 2018, ARTHRITIS RHEUMATOL, V70, P2025, DOI 10.1002/art.40653; Vincent FB, 2013, LUPUS, V22, P873, DOI 10.1177/0961203313496302; Vincent FB, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4277; Wallace DJ, 2015, NAT REV RHEUMATOL, V11, P616, DOI 10.1038/nrrheum.2015.86	21	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2019	10								1649	10.3389/fimmu.2019.01649	http://dx.doi.org/10.3389/fimmu.2019.01649			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IJ3TM	31379847	Green Published, gold			2022-12-18	WOS:000475827400001
J	Schmaljohn, AL; Orlandi, C; Lewis, GK				Schmaljohn, Alan L.; Orlandi, Chiara; Lewis, George K.			Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models	FRONTIERS IN IMMUNOLOGY			English	Review						virus; antibody; Fc; FcR; neutralization; ADCC; animal models	COMPLEMENT-DEPENDENT CYTOTOXICITY; EFFECTOR FUNCTION; GAMMA RECEPTORS; MOUSE MODEL; NONNEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; PROTECTIVE IMMUNITY; CD20 ANTIBODY; ENV EPITOPES; IGG-FC	Longstanding discordances and enigmas persist as to the specificities and other properties of antibodies (Abs) most effective in preventing or limiting many viral infections in mammals; in turn, failure to decipher key complexities has added to headwinds for both Ab-based therapeutic approaches and rational vaccine design. More recently, experimental approaches have emerged-and continue to emerge-for discerning the functional role of Ab structure, especially the Fc portion of antibody, in combating viral infections in vivo. A wide range of in vitro measures of antibody activity, from neutralization to antibody-dependent cell mediated cytotoxicity (ADCC)-each of these terms representing only an operational notion defined by the particulars of a given assay-are poised for assignment of both relevance and reliability in forecasting outcomes of infection. Of the several emergent technical opportunities for clarity, attention here is drawn to three realms: the increasing array of known modifications that can be engineered into Abs to affect their in vivo activities; the improvement of murine models involving knockouts and knock-ins of host genes including Fc receptors; and the development of additional virological design tools to differentiate Abs that act primarily by inhibiting viral entry from antibodies that mainly target viral antigens (Ags) on cell surfaces. To illustrate some of the opportunities with either zoonotic (emerging, spillover) or ancient human-adapted viruses, we draw examples from a wide range of viruses that affect humans.	[Schmaljohn, Alan L.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Schmaljohn, Alan L.; Orlandi, Chiara; Lewis, George K.] Univ Maryland, Sch Med, Inst Human Virol, Div Vaccine Res, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Schmaljohn, AL (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.; Schmaljohn, AL (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Div Vaccine Res, Baltimore, MD 21201 USA.	aschmaljohn@som.umaryland.edu			Bill and Melinda Gates Foundation [OPP1017606]; NIAID/NIH [P01AI120756]; DOD [HDTRA115-C-058]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI120756] Funding Source: NIH RePORTER	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DOD(United States Department of Defense); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for authors was provided by the following grants and contracts: NIAID/NIH P01AI120756; DOD HDTRA115-C-058; and Grant #OPP1017606, The Bill and Melinda Gates Foundation.	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14; Ben Mkaddem S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00811; Bournazos S, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0045-2016; Bournazos S, 2015, IMMUNOL REV, V268, P88, DOI 10.1111/imr.12343; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Carter PJ, 2018, NAT REV DRUG DISCOV, V17, P197, DOI 10.1038/nrd.2017.227; Casey E, 2018, LEUKEMIA, V32, P547, DOI 10.1038/leu.2017.293; Chung KM, 2007, J VIROL, V81, P9551, DOI 10.1128/JVI.00879-07; Cleary KLS, 2017, J IMMUNOL, V198, P3999, DOI 10.4049/jimmunol.1601473; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cook EM, 2016, J IMMUNOL, V197, P1762, DOI 10.4049/jimmunol.1600648; Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Dorner M, 2013, NATURE, V501, P237, DOI 10.1038/nature12427; Dorner M, 2011, NATURE, V474, P208, DOI 10.1038/nature10168; Farre D, 2017, EUR J IMMUNOL, V47, P780, DOI 10.1002/eji.201746984; Golding H, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028902; Hayes JM, 2016, J INFLAMM RES, V9, P209, DOI 10.2147/JIR.S121233; Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362; Hinton PR, 2006, J IMMUNOL, V176, P346, DOI 10.4049/jimmunol.176.1.346; Horwitz JA, 2017, CELL, V170, P637, DOI 10.1016/j.cell.2017.06.048; Kellner C, 2017, TRANSFUS MED HEMOTH, V44, P327, DOI 10.1159/000479980; Kiyoshi M, 2017, INT IMMUNOL, V29, P311, DOI 10.1093/intimm/dxx038; Latvala S, 2017, J HISTOCHEM CYTOCHEM, V65, P321, DOI 10.1369/0022155417705095; Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI [10.1056/NEJMoa1410863, 10.1056/nejmoa1410863]; Lee CH, 2017, NAT IMMUNOL, V18, P889, DOI 10.1038/ni.3770; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; Leist SR, 2018, TRENDS GENET, V34, P777, DOI 10.1016/j.tig.2018.07.005; Lewis GK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01025; Lewis GK, 2015, VIRUSES-BASEL, V7, P5115, DOI 10.3390/v7092856; Lewis GK, 2014, IMMUNOLOGY, V142, P46, DOI 10.1111/imm.12232; Lewis GK, 2014, CURR OPIN HIV AIDS, V9, P263, DOI 10.1097/COH.0000000000000055; Lewis GK, 2013, CURR HIV RES, V11, P354, DOI 10.2174/1570162X113116660060; Li TZ, 2017, P NATL ACAD SCI USA, V114, P3485, DOI 10.1073/pnas.1702173114; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Mamidi S, 2017, IMMUNOBIOLOGY, V222, P45, DOI 10.1016/j.imbio.2015.11.008; Marshall MJE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01245; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn Falk, 2012, Cancer Immun, V12, P13; Olson JK, 1997, J VIROL, V71, P110, DOI 10.1128/JVI.71.1.110-119.1997; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Pollara J, 2013, CURR HIV RES, V11, P378, DOI 10.2174/1570162X113116660059; Rodgers KR, 2016, BIOTECHNOL ADV, V34, P1149, DOI 10.1016/j.biotechadv.2016.07.004; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Saxena A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00580; Schmaljohn A, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw021; Schmaljohn AL, 2013, CURR HIV RES, V11, P345, DOI 10.2174/1570162X113116660057; Seeling M, 2015, CANCER CELL, V27, P427, DOI 10.1016/j.ccell.2015.03.011; Sondermann P, 2016, CURR OPIN IMMUNOL, V40, P78, DOI 10.1016/j.coi.2016.03.005; Sullivan NJ, 2009, NAT REV MICROBIOL, V7, P393, DOI 10.1038/nrmicro2129; Taylor RP, 2017, CLIN IMMUNOL, V181, P24, DOI 10.1016/j.clim.2017.05.016; Taylor RP, 2016, SEMIN IMMUNOL, V28, P309, DOI 10.1016/j.smim.2016.03.003; Taylor RP, 2015, BLOOD, V125, P762, DOI 10.1182/blood-2014-10-569244; Tolbert WD, 2017, STRUCTURE, V25, P1719, DOI 10.1016/j.str.2017.09.009; van der Poel CE, 2017, NAT IMMUNOL, V18, P874, DOI 10.1038/ni.3797; Vaughan AT, 2015, PHARMACOL RES, V99, P269, DOI 10.1016/j.phrs.2015.07.003; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Weiskopf K, 2015, MABS-AUSTIN, V7, P303, DOI 10.1080/19420862.2015.1011450; Wieland A, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao3125; Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664; Wirt T, 2017, TRANSFUS MED HEMOTH, V44, P292, DOI 10.1159/000479978; Yamada S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001034; Yang DL, 2017, MABS-AUSTIN, V9, P1231, DOI 10.1080/19420862.2017.1367074; Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111; Zhao J, 2019, MABS-AUSTIN, V11, P58, DOI 10.1080/19420862.2018.1522178	68	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2019	10								1602	10.3389/fimmu.2019.01602	http://dx.doi.org/10.3389/fimmu.2019.01602			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IJ3TH	31379822	Green Published, gold			2022-12-18	WOS:000475826900001
J	Lisco, A; Wong, CS; Price, S; Ye, PY; Niemela, J; Anderson, M; Richards, E; Manion, M; Mystakelis, H; Similuk, M; Lo, B; Stoddard, J; Rosenzweig, S; Vanpouille, C; Rupert, A; Maric, I; Perez-Diez, A; Parenti, D; Burbelo, PD; Rao, VK; Sereti, I				Lisco, Andrea; Wong, Chun-Shu; Price, Susan; Ye, Peiying; Niemela, Julie; Anderson, Megan; Richards, Elizabeth; Manion, Maura; Mystakelis, Harry; Similuk, Morgan; Lo, Bernice; Stoddard, Jennifer; Rosenzweig, Sergio; Vanpouille, Christophe; Rupert, Adam; Maric, Irina; Perez-Diez, Ainhoa; Parenti, David; Burbelo, Peter D.; Rao, V. Koneti; Sereti, Irini			Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS) (vol 10, pg 1193, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						CD4 lymphopenia; follicular T helper cells; ALPS-FAS; autoimmune cytopenia; apoptosis			[Lisco, Andrea; Wong, Chun-Shu; Ye, Peiying; Anderson, Megan; Richards, Elizabeth; Manion, Maura; Mystakelis, Harry; Perez-Diez, Ainhoa; Sereti, Irini] NIAID, Lab Immunoregulat, NIH, Bldg 10, Bethesda, MD 20892 USA; [Price, Susan; Rao, V. Koneti] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Niemela, Julie; Stoddard, Jennifer; Rosenzweig, Sergio] NIH, Immunol Serv, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA; [Similuk, Morgan] NIAID, Clin Genom Program, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lo, Bernice] NIAID, Lab Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA; [Vanpouille, Christophe] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD USA; [Rupert, Adam] Leidos Biomed Res, AIDS Monitoring Lab, Frederick, MD USA; [Maric, Irina] NIH, Hematol Serv, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA; [Parenti, David] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Burbelo, Peter D.] Natl Inst Dent & Craniofacial Res, Dent Clin Res Core, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Lisco, A; Sereti, I (corresponding author), NIAID, Lab Immunoregulat, NIH, Bldg 10, Bethesda, MD 20892 USA.	andrea.lisco@nih.gov; irini.sereti@nih.gov	Perez-Diez, Ainhoa/AAR-1630-2020; Rao, V. Koneti/AAR-2171-2020; Lo, Bernice/H-7538-2017	Perez-Diez, Ainhoa/0000-0001-8948-554X; Rao, V. Koneti/0000-0002-7881-6902; Lo, Bernice/0000-0002-1087-6845; Mystakelis, Harry A./0000-0001-9618-2782; Lisco, Andrea/0000-0002-1475-356X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000732] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Lisco A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01193	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 4	2019	10								1552	10.3389/fimmu.2019.01552	http://dx.doi.org/10.3389/fimmu.2019.01552			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IH0UQ	31333676	Green Published, gold			2022-12-18	WOS:000474208500002
J	Finsterer, J				Finsterer, Josef			Commentary: New Variant of MELAS Syndrome With Executive Dysfunction, Heteroplasmic Point Mutation in the MT-ND4 Gene (m.12015T > C; p.Leu419Pro) and Comorbid Polyglandular Autoimmune Syndrome Type 2	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						heteroplasmy; mtDNA; oxidative phosphorylation; MELAS; stroke-like episode	MITOCHONDRIAL; PHENOTYPE		[Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria	Rudolfstiftung Hospital	Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.	fifigs1@yahoo.de						Afroze B, 2014, BRAIN DEV-JPN, V36, P924, DOI 10.1016/j.braindev.2013.12.009; Duran GP, 2012, JIMD REP, V3, P5, DOI 10.1007/8904_2011_33; Endres D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00412; Finsterer J, 2019, J NEUROL SCI, V400, P135, DOI 10.1016/j.jns.2019.03.021; Finsterer J, 2018, PEDIATR NEUROL, V80, P8, DOI 10.1016/j.pediatrneurol.2017.12.005; Southgate HJ, 2000, ANN CLIN BIOCHEM, V37, P805, DOI 10.1258/0004563001900002; Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196	7	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2019	10								1333	10.3389/fimmu.2019.01333	http://dx.doi.org/10.3389/fimmu.2019.01333			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IE6DV	31293567	Green Published, gold			2022-12-18	WOS:000472467500001
J	Faraj, TA; Stover, C; Erridge, C				Faraj, Tola A.; Stover, Cordula; Erridge, Clett			Dietary Toll-Like Receptor Stimulants Promote Hepatic Inflammation and Impair Reverse Cholesterol Transport in Mice via Macrophage-Dependent Interleukin-1 Production	FRONTIERS IN IMMUNOLOGY			English	Article						microbiota; inflammation; innate immunity; cholesterol metabolism; cardiovascular disease; diet	FATTY LIVER-DISEASE; CARDIOVASCULAR-DISEASE; DENSITY-LIPOPROTEIN; MEAT CONSUMPTION; INDUCED OBESITY; PROCESSED MEAT; ATHEROSCLEROSIS; ENDOTOXIN; CONTRIBUTES; PROGRESSION	Background: The mechanisms connecting dietary intake of processed foods with systemic inflammatory markers and cardiovascular risk remain poorly defined. We sought to compare the abundance of pro-inflammatory stimulants of innate immune receptors in processed foods with those produced by the murine ileal and caecal microbiota, and to explore the impact of their ingestion on systemic inflammation and lipid metabolism in vivo. Methods and results: Calibrated receptor-dependent reporter assays revealed that many processed foods, particularly those based on minced meats, contain pro-inflammatory stimulants of Toll-like receptor (TLR)-2 and TLR4 at concentrations which greatly exceed those produced by the endogenous murine ileal microbiota. Chronic dietary supplementation with these stimulants, at concentrations relevant to those measured in the Western diet, promoted hepatic inflammation and reduced several markers of reverse cholesterol transport (RCT) in mice. Hepatocytes were found to be insensitive to TLR2- and TLR4-stimulants directly, but their secretion of functional cholesterol acceptors was impaired by interleukin (IL)-1 beta released by TLR-responsive hepatic macrophages. Hepatic macrophage priming by high-fat diet enhanced the impairment of RCT by ingested endotoxin, and this was reversed by macrophage depletion via clodronate liposome treatment, or genetic deficiency in the IL-1 receptor. Conclusion: These findings reveal an unexpected mechanism connecting processed food consumption with cardiovascular risk factors, and introduce the food microbiota as a potential target for therapeutic regulation of lipid metabolism.	[Faraj, Tola A.; Erridge, Clett] Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester, Leics, England; [Faraj, Tola A.] Hawler Med Univ, Dept Pharmacognosy, Erbil, Iraq; [Stover, Cordula] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Erridge, Clett] Anglia Ruskin Univ, Sch Life Sci, Cambridge, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Hawler Medical University; University of Leicester; Anglia Ruskin University	Erridge, C (corresponding author), Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester, Leics, England.; Erridge, C (corresponding author), Anglia Ruskin Univ, Sch Life Sci, Cambridge, England.	clett.erridge@anglia.ac.uk	Stefanadis, Christodoulos/ABH-2232-2020	Stefanadis, Christodoulos/0000-0001-5974-6454	Wellcome Trust Institutional Strategic Support Fund award [097828/Z/11/A]; University of Leicester College of Life Sciences Research fellowship; Iraq Higher Committee for Education Development [D-11-242]	Wellcome Trust Institutional Strategic Support Fund award(Wellcome Trust); University of Leicester College of Life Sciences Research fellowship; Iraq Higher Committee for Education Development	This work was supported by a Wellcome Trust Institutional Strategic Support Fund award (097828/Z/11/A), and a University of Leicester College of Life Sciences Research fellowship, awarded to CE. TF was supported by a studentship funded by the Iraq Higher Committee for Education Development (D-11-242).	Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Alhawi M, 2009, J MED MICROBIOL, V58, P1015, DOI 10.1099/jmm.0.009936-0; Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159; Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Bertola A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013577; Brandsma E, 2019, CIRC RES, V124, P94, DOI 10.1161/CIRCRESAHA.118.313234; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; Carvalho FA, 2012, CELL HOST MICROBE, V12, P139, DOI 10.1016/j.chom.2012.07.004; Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039; Copeland S, 2005, CLIN DIAGN LAB IMMUN, V12, P60, DOI 10.1128/CDLI.12.1.60-67.2005; d'Hennezel E, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00046-17; De Gregoris TB, 2011, J MICROBIOL METH, V86, P351, DOI 10.1016/j.mimet.2011.06.010; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; EMANCIPATOR K, 1992, INFECT IMMUN, V60, P596, DOI 10.1128/IAI.60.2.596-601.1992; Erridge C, 2008, J BIOL CHEM, V283, P24748, DOI 10.1074/jbc.M800352200; Erridge C, 2011, J FOOD SCI, V76, pH72, DOI 10.1111/j.1750-3841.2010.02018.x; Erridge C, 2011, BRIT J NUTR, V105, P15, DOI 10.1017/S0007114510003004; Erridge C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009125; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fretts AM, 2012, AM J CLIN NUTR, V95, P752, DOI 10.3945/ajcn.111.029942; Fu JY, 2015, CIRC RES, V117, P817, DOI 10.1161/CIRCRESAHA.115.306807; Fung TT, 2001, AM J CLIN NUTR, V73, P61; Harper MS, 2011, FOOD CHEM TOXICOL, V49, P1770, DOI 10.1016/j.fct.2011.04.025; Herieka M, 2016, NUTR METAB CARDIOVAS, V26, P194, DOI 10.1016/j.numecd.2015.12.001; Huang Hong, 2007, J Inflamm (Lond), V4, P22; Hughes SD, 1997, ARTERIOSCL THROM VAS, V17, P1725, DOI 10.1161/01.ATV.17.9.1725; Imajo K, 2012, CELL METAB, V16, P44, DOI 10.1016/j.cmet.2012.05.012; Jay JM, 2003, INT J FOOD MICROBIOL, V81, P105, DOI 10.1016/S0168-1605(02)00189-7; Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689; Kless C, 2015, MOL NUTR FOOD RES, V59, P968, DOI 10.1002/mnfr.201400840; Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029; Luchtefeld M, 2007, J EXP MED, V204, P1935, DOI 10.1084/jem.20070120; McGillicuddy FC, 2009, CIRCULATION, V119, P1135, DOI 10.1161/CIRCULATIONAHA.108.810721; Micha R, 2010, CIRCULATION, V121, P2271, DOI 10.1161/CIRCULATIONAHA.109.924977; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Mirea AM, 2018, TRENDS MOL MED, V24, P458, DOI 10.1016/j.molmed.2018.03.005; Moore RE, 2005, CIRC RES, V97, P763, DOI 10.1161/01.RES.0000185320.82962.F7; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Park JW, 2007, J GASTROEN HEPATOL, V22, P491, DOI 10.1111/j.1440-1746.2006.04758.x; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Rohrmann S, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-63; Romics L, 2004, HEPATOLOGY, V40, P555, DOI 10.1002/hep.20350; Severgnini M, 2012, CYTOTECHNOLOGY, V64, P187, DOI 10.1007/s10616-011-9407-0; Skye SM, 2018, CIRC RES, V123, P1164, DOI 10.1161/CIRCRESAHA.118.313142; Sydora BC, 2007, INFLAMM BOWEL DIS, V13, P947, DOI 10.1002/ibd.20155; Tamai H, 2000, ALCOHOL CLIN EXP RES, V24, P390, DOI 10.1111/j.1530-0277.2000.tb04629.x; THRIFT RN, 1986, J LIPID RES, V27, P236; UCHIDA K, 1987, AGR BIOL CHEM TOKYO, V51, P3107; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Weston CJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00893; Zelber-Sagi S, 2017, LIVER INT, V37, P936, DOI 10.1111/liv.13435; Zhu WH, 2018, NATURE, V553, P208, DOI 10.1038/nature25172	61	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 20	2019	10								1404	10.3389/fimmu.2019.01404	http://dx.doi.org/10.3389/fimmu.2019.01404			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IE2MH	31316501	Green Published, gold, Green Accepted			2022-12-18	WOS:000472217900001
J	de Aguiar, GPCG; Leite, CMGD; Dias, B; Vasconcelos, SMM; de Moraes, RA; de Moraes, MEA; Vallinoto, ACR; Macedo, DS; Cavalcanti, LPD; Miyajima, F				Costa Gomes de Aguiar, Gabriella Pequeno; Goncalves da Silva Leite, Claudio Manuel; Dias, Beatriz; Mendes Vasconcelos, Silvania Maria; de Moraes, Renata Amaral; Amaral de Moraes, Maria Elisabete; Rosario Vallinoto, Antonio Carlos; Macedo, Danielle Silveira; de Goes Cavalcanti, Luciano Pamplona; Miyajima, Fabio			Evidence for Host Epigenetic Signatures Arising From Arbovirus Infections: A Systematic Review	FRONTIERS IN IMMUNOLOGY			English	Review						systematic review; host epigenetics; microRNAs; histone modifications; arbovirus	JAPANESE ENCEPHALITIS-VIRUS; DENGUE-VIRUS; MICRORNA EXPRESSION; ANTIVIRAL ACTIVITY; RNA INTERFERENCE; PROTECTIVE ROLE; ACUTE-PHASE; REPLICATION; CHIKUNGUNYA; MECHANISM	Background: Arbovirus infections have steadily become a major pandemic threat. This study aimed at investigating the existence of host epigenetic markers arising from the principal arboviruses infections impacting on human health. We set to systematically review all published evidence describing any epigenetic modifications associated with infections from arboviruses, including, but not limited to, microRNAs, DNA methylation, and histone modifications. Methods: A comprehensive search was conducted using the electronic databases PubMed, Science Direct and Cochrane Library from inception to January 4th, 2018. We included reports describing original in vivo or in vitro studies investigating epigenetic changes related to arbovirus infections in either clinical subjects or human cell lines. Studies investigating epigenetic modifications related to the virus or the arthropod vector were excluded. A narrative synthesis of the findings was conducted, contextualizing comparative evidence from in vitro and in vivo studies. Results: A total of 853 unique references were identified and screened by two independent researchers. Thirty-two studiesmet the inclusion criteria and were reviewed. The evidence was centered mainly on microRNA and DNA methylation signatures implicated with secondary Dengue fever. Evidence for recent epidemic threats, such as the infections by Zika or Chikungunya viruses is still scant. Conclusions: Major epigenetic alterations found on arboviruses infections were miR-146, miR-30e and the Dicer complex. However, existing studies frequently tested distinct hypotheses resulting in a heterogeneity of methodological approaches. Whilst epigenetic signatures associated with arbovirus infections have been reported, existing studies have largely focused on a small number of diseases, particularly dengue. Validation of epigenetic signatures have an untapped potential, but concerted investigations are certainly required to deliver robust candidates of clinical utility for diagnosis, staging and prognosis of specific arboviral diseases.	[Costa Gomes de Aguiar, Gabriella Pequeno; Amaral de Moraes, Maria Elisabete] Univ Fed Ceara, Fac Med, Postgrad Programme Med & Surg Sci, Fortaleza, Ceara, Brazil; [Goncalves da Silva Leite, Claudio Manuel; Mendes Vasconcelos, Silvania Maria; Amaral de Moraes, Maria Elisabete; Macedo, Danielle Silveira; Miyajima, Fabio] Univ Fed Ceara, Fac Med, Postgrad Programme Pharmacol, Fortaleza, Ceara, Brazil; [Dias, Beatriz; de Moraes, Renata Amaral; de Goes Cavalcanti, Luciano Pamplona] Unichristus Univ Ctr, Fac Med, Fortaleza, Ceara, Brazil; [Mendes Vasconcelos, Silvania Maria; de Moraes, Renata Amaral; Amaral de Moraes, Maria Elisabete; Macedo, Danielle Silveira] Univ Fed Ceara, Fac Med, Ctr Drug Res & Dev NPDM, Fortaleza, Ceara, Brazil; [de Moraes, Renata Amaral] Sao Jose Hosp Infect Dis, Fortaleza, Ceara, Brazil; [Rosario Vallinoto, Antonio Carlos] Fed Univ Para, Inst Biol Sci, Lab Virol, Belem, Para, Brazil; [de Goes Cavalcanti, Luciano Pamplona] Univ Fed Ceara, Fac Med, Dept Community Hlth, Fortaleza, Ceara, Brazil; [Miyajima, Fabio] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England; [Miyajima, Fabio] Univ Fed Ceara, Fac Med, Postgrad Programme Med Sci, Fortaleza, Ceara, Brazil; [Miyajima, Fabio] Oswaldo Cruz Fdn Fiocruz, Branch Ceara, Eusebio, Brazil	Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Ceara; Universidade Federal do Para; Universidade Federal do Ceara; University of Liverpool; Universidade Federal do Ceara; Fundacao Oswaldo Cruz	Miyajima, F (corresponding author), Univ Fed Ceara, Fac Med, Postgrad Programme Pharmacol, Fortaleza, Ceara, Brazil.; Miyajima, F (corresponding author), Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.; Miyajima, F (corresponding author), Univ Fed Ceara, Fac Med, Postgrad Programme Med Sci, Fortaleza, Ceara, Brazil.; Miyajima, F (corresponding author), Oswaldo Cruz Fdn Fiocruz, Branch Ceara, Eusebio, Brazil.	fabio.miyajima@fiocruz.br	Patologia, Programa/AAI-4877-2021; Vallinoto, Antonio Carlos/AAL-9501-2020; de Góes Cavalcanti, Luciano Pamplona/N-4391-2015; Vasconcelos, Silvânia M/N-4470-2017; Macedo, Danielle/E-3424-2014	Vallinoto, Antonio Carlos/0000-0003-1135-6507; de Góes Cavalcanti, Luciano Pamplona/0000-0002-3440-1182; Vasconcelos, Silvânia M/0000-0003-1478-0127; Macedo, Danielle/0000-0001-8980-9970				Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003; Andrade BB, 2005, AN ACAD BRAS CIENC, V77, P665, DOI 10.1590/S0001-37652005000400008; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Balakrishnan L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110346; Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]; Bayer A, 2018, PLACENTA, V61, P33, DOI 10.1016/j.placenta.2017.11.004; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Gomes AVBT, 2016, J MED VIROL, V88, P1297, DOI 10.1002/jmv.24478; Bogerd HP, 2014, J VIROL, V88, P8065, DOI 10.1128/JVI.00985-14; Bruscella P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00824; Casseb Alexandre do Rosario, 2013, Veterinaria e Zootecnia, V20, P391; Casseb SMM, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027891; Charrel RN, 2007, NEW ENGL J MED, V356, P769, DOI 10.1056/NEJMp078013; Chen RF, 2014, J INFECTION, V69, P366, DOI 10.1016/j.jinf.2014.05.013; Coffey LL, 2008, P NATL ACAD SCI USA, V105, P6970, DOI 10.1073/pnas.0712130105; Colpitts TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024365; Corridoni D, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00032; Cavalcanti LPD, 2018, REV SOC BRAS MED TRO, V51, P63, DOI 10.1590/0037-8682-0440-2017; Demir ZC, 2017, J MED VIROL, V89, P417, DOI 10.1002/jmv.24667; Devhare P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.517; Diosa-Toro M, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005981; Escalera-Cueto M, 2015, VIRUS RES, V196, P105, DOI 10.1016/j.virusres.2014.11.010; Gould E, 2017, ONE HEALTH-AMSTERDAM, V4, P1, DOI 10.1016/j.onehlt.2017.06.001; Grassmann R, 2008, BBA-GENE REGUL MECH, V1779, P706, DOI 10.1016/j.bbagrm.2008.05.005; Gunther VJ, 2011, VACCINE, V29, P3895, DOI 10.1016/j.vaccine.2011.03.038; Jeewandara C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003673; Jiang LL, 2012, J CLIN INVEST, V122, P33, DOI 10.1172/JCI58849; Kakumani PK, 2016, GENE, V586, P7, DOI 10.1016/j.gene.2016.03.053; Kakumani PK, 2015, BIOCHEM J, V471, P89, DOI 10.1042/BJ20150445; Kakumani PK, 2013, J VIROL, V87, P8870, DOI 10.1128/JVI.02774-12; Kanokudom S, 2017, ANTIVIR RES, V142, P169, DOI 10.1016/j.antiviral.2017.03.020; KOZAK RA, 2017, VIRUSES-BASEL, V9, DOI DOI 10.3390/V9100297; Kumari B, 2016, SCI REP-UK, V6, DOI 10.1038/srep20263; Lichinchi G, 2016, CELL HOST MICROBE, V20, P666, DOI 10.1016/j.chom.2016.10.002; Liu SY, 2016, CELL MOL IMMUNOL, V13, P700, DOI 10.1038/cmi.2015.52; Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020; Meltzer E, 2012, INFECT DIS CLIN N AM, V26, P479, DOI 10.1016/j.idc.2012.02.003; Milavetz BI, 2015, METHODS MOL BIOL, V1238, P569, DOI 10.1007/978-1-4939-1804-1_30; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Olson KE, 2015, CURR OPIN VIROL, V15, P119, DOI 10.1016/j.coviro.2015.10.001; Ouyang XX, 2016, INT J MED SCI, V13, P195, DOI 10.7150/ijms.13996; Pham AM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002465; Pierro A., 2015, New Microbes and New Infections, V7, P23, DOI 10.1016/j.nmni.2015.04.002; Pu JY, 2017, ARCH VIROL, V162, P3645, DOI 10.1007/s00705-017-3516-9; Qi YM, 2013, MOL MED REP, V7, P791, DOI 10.3892/mmr.2013.1288; Rastogi M, 2018, J MED VIROL, V90, P648, DOI 10.1002/jmv.24995; Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578; Saxena T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079886; Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137; Selvamani SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103624; Sharma N, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0249-0; Slonchak A, 2016, J VIROL, V90, P2388, DOI 10.1128/JVI.02608-15; Tambyah PA, 2016, ANN CLIN BIOCHEM, V53, P466, DOI 10.1177/0004563215604001; Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; Wu N, 2014, MICROBES INFECT, V16, P911, DOI 10.1016/j.micinf.2014.08.011; Wu SY, 2013, J INFECTION, V67, P329, DOI 10.1016/j.jinf.2013.05.003; Zhu B, 2015, J IMMUNOL, V195, P2251, DOI 10.4049/jimmunol.1500370; Zhu X, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003088	59	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2019	10								1207	10.3389/fimmu.2019.01207	http://dx.doi.org/10.3389/fimmu.2019.01207			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IB3NI	31214179	gold, Green Published			2022-12-18	WOS:000470173800003
J	Dam, EM; Maier, AC; Hocking, AM; Carlin, J; Ng, B; Buckner, JH				Dam, Elizabeth M.; Maier, Alison C.; Hocking, Anne M.; Carlin, Jeffrey; Ng, Bernard; Buckner, Jane H.			Increased Binding of Specificity Protein 1 to the IL21R Promoter in B Cells Results in Enhanced B Cell Responses in Rheumatoid Arthritis (vol 9, 1978, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						rheumatoid arthritis; B cells; IL-21R; specificity protein 1; IL-6			[Dam, Elizabeth M.; Maier, Alison C.; Hocking, Anne M.; Buckner, Jane H.] Benaroya Res Inst, Translat Res Program, Seattle, WA 98101 USA; [Carlin, Jeffrey] Virginia Mason Med Ctr, Div Rheumatol, Seattle, WA 98101 USA; [Ng, Bernard] VA Puget Sound Hlth Care Syst, Rheumatol Sect, Seattle, WA USA; [Ng, Bernard] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA	Benaroya Research Institute; Virginia Mason Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Buckner, JH (corresponding author), Benaroya Res Inst, Translat Res Program, Seattle, WA 98101 USA.	jbuckner@benaroyaresearch.org						Dam EM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01978	1	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2019	10								1122	10.3389/fimmu.2019.01122	http://dx.doi.org/10.3389/fimmu.2019.01122			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HY4RA	31156654	Green Published, gold			2022-12-18	WOS:000468114400001
J	Farazuddin, M; Goel, RR; Kline, NJ; Landers, JJ; O'Konek, JJ; Baker, JR				Farazuddin, Mohammad; Goel, Rishi R.; Kline, Nicholas J.; Landers, Jeffrey J.; O'Konek, Jessica J.; Baker, James R., Jr.			Nanoemulsion Adjuvant Augments Retinaldehyde Dehydrogenase Activity in Dendritic Cells via MyD88 Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						nanoemulsion; epithelial cells; dendritic cells; retinaldehyde dehydrogenase; gut homing; MyD88 pathway	RETINOIC ACID; VITAMIN-A; T-CELLS; IMMUNITY; IMMUNIZATION; ANTIBODIES; RESPONSES	Mucosal surfaces are the primary point of entry for many infectious agents and mucosal immune responses serve as the primary defense to these pathogens. In order to mount an effective mucosal immune response, it is important to induce T cell homing to mucosal surfaces. Conventional vaccine adjuvants induce strong systemic immunity but often fail to produce mucosal immunity. We have developed an oil-in-water nanoemulsion (NE) adjuvant that provides mucosal immunity and efficient protection against mucosal pathogens when administered as part of an intranasal vaccine. In the present study, we demonstrate that intranasal immunization with NE indirectly activates the retinaldehyde dehydrogenase (RALDH) activity in dendritic cells through epithelial cell activity leading to SIgA as well as potent cellular responses and expression of alpha 4 beta 7 and CCR9 gut homing receptors on T cells. Confirming these findings, ex-vivo stimulation of splenocytes from NE nasally immunized animals showed increase in Th1/Th17 cytokines while suppressing Th2 responses. In examining mechanisms underlying this activation NE activated RALDH via MyD88 dependent pathways in DCs but did not activate the retinoic acid receptor directly. These results suggest that RALDH immune activities can be achieved by epithelial activation without direct RAR activation, which has significant implications for understanding mucosal immunity and the design of mucosal vaccines.	[Farazuddin, Mohammad; Goel, Rishi R.; Kline, Nicholas J.; Landers, Jeffrey J.; O'Konek, Jessica J.; Baker, James R., Jr.] Univ Michigan, Michigan Nanotechnol Inst Med & Biol Sci, Mary H Weiser Food Allergy Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Michigan Nanotechnol Inst Med & Biol Sci, Mary H Weiser Food Allergy Ctr, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu	Farazuddin, Mohammad/AAI-2580-2021	Kline, Nick/0000-0002-1991-6049; Goel, Rishi/0000-0003-1715-5191	William Davidson Foundation [1573998.0]	William Davidson Foundation	This research work was supported by funding from William Davidson Foundation under grant no 1573998.0 and a gift from the Vondell Family.	Basson A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00290; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148; Bielinska AU, 2016, VACCINE, V34, P4017, DOI 10.1016/j.vaccine.2016.06.043; Bielinska AU, 2014, J IMMUNOL, V192, P2722, DOI 10.4049/jimmunol.1301424; Bimczok D, 2015, MUCOSAL IMMUNOL, V8, P533, DOI 10.1038/mi.2014.86; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Dawson HD, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-27; Gyongyosi A, 2013, J LIPID RES, V54, P2458, DOI 10.1194/jlr.M038984; Hacini-Rachinel F, 2018, J ALLERGY CLIN IMMUN, V141, P163, DOI 10.1016/j.jaci.2017.02.022; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Iwata M, 2003, INT IMMUNOL, V15, P1017, DOI 10.1093/intimm/dxg101; Jackson EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041529; Kunisawa J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00189; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Levine MM, 2000, J PEDIATR GASTR NUTR, V31, P336, DOI 10.1097/00005176-200010000-00003; Makidon PE, 2012, EUR J IMMUNOL, V42, P2073, DOI 10.1002/eji.201142346; Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954; Manicassamy S, 2009, NAT MED, V15, P401, DOI 10.1038/nm.1925; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Menning A, 2010, EUR J IMMUNOL, V40, P2539, DOI 10.1002/eji.200939938; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; O'Konek JJ, 2018, J ALLERGY CLIN IMMUN, V141, P2121, DOI 10.1016/j.jaci.2018.01.042; Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001; Ohoka Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096512; Bono MR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060349; Wang S, 2011, J IMMUNOL, V187, P141, DOI 10.4049/jimmunol.1003740; Wong PT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126120; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yokota A, 2009, INT IMMUNOL, V21, P361, DOI 10.1093/intimm/dxp003; Zeng R, 2013, MUCOSAL IMMUNOL, V6, P847, DOI 10.1038/mi.2012.123	32	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 8	2019	10								916	10.3389/fimmu.2019.00916	http://dx.doi.org/10.3389/fimmu.2019.00916			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX4BW	31134057	Green Published, gold			2022-12-18	WOS:000467340500001
J	Koenderman, L				Koenderman, Leo			Inside-Out Control of Fc-Receptors (vol 10, 544, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						inside-out control; immunoglobulins; priming; activation; phagocytes; Fc-receptors			[Koenderman, Leo] Univ Med Ctr Utrecht, Dept Resp Med, Utrecht, Netherlands; [Koenderman, Leo] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Koenderman, L (corresponding author), Univ Med Ctr Utrecht, Dept Resp Med, Utrecht, Netherlands.; Koenderman, L (corresponding author), Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands.	l.koenderman@umcutrecht.nl						Koenderman L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00544	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2019	10								971	10.3389/fimmu.2019.00971	http://dx.doi.org/10.3389/fimmu.2019.00971			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX4BB	31134069	Green Published, gold			2022-12-18	WOS:000467338300001
J	Stobutzki, N; Schlickeiser, S; Streitz, M; Stanko, K; Truong, KL; Akyuez, L; Vogt, K; Appelt, C; Pascher, A; Blau, O; Gerlach, UA; Sawitzki, B				Stobutzki, Nadja; Schlickeiser, Stephan; Streitz, Mathias; Stanko, Katarina; Truong, Kim-Long; Akyuez, Levent; Vogt, Katrin; Appelt, Christine; Pascher, Andreas; Blau, Olga; Gerlach, Undine A.; Sawitzki, Birgit			Long-Term Signs of T Cell and Myeloid Cell Activation After Intestinal Transplantation With Cellular Rejections Contributing to Further Increase of CD16(+) Cell Subsets	FRONTIERS IN IMMUNOLOGY			English	Article						intestinal transplantation; T cells; Myeloid cells; flow cytometry; gene expression; cytokines; epigenetics	IMMUNE-RESPONSES; INNATE; EXPRESSION; RECIPIENTS; LIVER; RATIO	The intestine mediates a delicate balance between tolerogenic and inflammatory immune responses. The continuous pathogen encounter might also augment immune cell responses contributing to complications observed upon intestinal transplantation (ITx). We thus hypothesized that ITx patients show persistent signs of immune cell activation affecting both the adaptive and innate immune cell compartment. Information on the impact of intestinal grafts on immune cell composition, however, especially in the long-term is sparse. We here assessed activated and differentiated adaptive and innate immune subsets according to time, previous experience of cellular or antibody-mediated rejections or type of transplant after ITx applying multi-parametric flow cytometry, gene expression, serum cytokine and chemokine profiling. ITx patients showed an increase in CD16 expressing monocytes and myeloid dendritic cells (DCs) compared to healthy controls. This was even detectable in patients who were transplanted more than 10 years ago. Also, conventional CD4(+) and CD8(+) T cells showed persistent signs of activation counterbalanced by increased activated CCR4(+) regulatory T cells. Patients with previous cellular rejections had even higher proportions of CD16(+) monocytes and DCs, whereas transplanting higher donor mass with multi-visceral grafts was associated with increased T cell activation. The persistent inflammation and innate immune cell activation might contribute to unsatisfactory results after ITx.	[Stobutzki, Nadja; Schlickeiser, Stephan; Streitz, Mathias; Stanko, Katarina; Truong, Kim-Long; Akyuez, Levent; Vogt, Katrin; Appelt, Christine; Sawitzki, Birgit] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Stobutzki, Nadja; Schlickeiser, Stephan; Streitz, Mathias; Stanko, Katarina; Truong, Kim-Long; Akyuez, Levent; Vogt, Katrin; Appelt, Christine; Pascher, Andreas; Blau, Olga; Gerlach, Undine A.; Sawitzki, Birgit] Free Univ Berlin, Berlin, Germany; [Stobutzki, Nadja; Schlickeiser, Stephan; Streitz, Mathias; Stanko, Katarina; Truong, Kim-Long; Akyuez, Levent; Vogt, Katrin; Appelt, Christine; Pascher, Andreas; Blau, Olga; Gerlach, Undine A.; Sawitzki, Birgit] Humboldt Univ, Berlin, Germany; [Stobutzki, Nadja; Schlickeiser, Stephan; Streitz, Mathias; Stanko, Katarina; Truong, Kim-Long; Akyuez, Levent; Vogt, Katrin; Appelt, Christine; Pascher, Andreas; Blau, Olga; Gerlach, Undine A.; Sawitzki, Birgit] Berlin Inst Hlth, Berlin, Germany; [Schlickeiser, Stephan; Akyuez, Levent; Sawitzki, Birgit] Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany; [Pascher, Andreas; Gerlach, Undine A.] Charite Univ Med Berlin, Dept Surg, Berlin, Germany; [Blau, Olga] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sawitzki, B (corresponding author), Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany.; Sawitzki, B (corresponding author), Free Univ Berlin, Berlin, Germany.; Sawitzki, B (corresponding author), Humboldt Univ, Berlin, Germany.; Sawitzki, B (corresponding author), Berlin Inst Hlth, Berlin, Germany.; Sawitzki, B (corresponding author), Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.	birgit.sawitzki@charite.de	Gerlach, Undine/ABA-3565-2020	Schlickeiser, Stephan/0000-0003-3142-2890; Sawitzki, Birgit/0000-0001-8166-8579	German Research Foundation (DFG) [SFB650]; Bundesministerium fur Bildung und Forschung (BMBF)	German Research Foundation (DFG)(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF))	The work was supported by the German Research Foundation (DFG) SFB650 and Bundesministerium fur Bildung und Forschung (BMBF, e:Kid).	Ashokkumar C, 2017, TRANSPLANTATION, V101, P131, DOI 10.1097/TP.0000000000001076; Ashokkumar C, 2012, TRANSPLANTATION, V93, P561, DOI 10.1097/TP.0b013e3182449189; Ashokkumar C, 2009, SURGERY, V146, P166, DOI 10.1016/j.surg.2009.04.006; Benham H, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4317; Berger M, 2012, AM J TRANSPLANT, V12, pS2, DOI 10.1111/j.1600-6143.2012.04332.x; Ceulemans LJ, 2016, AM J TRANSPLANT, V16, P2973, DOI 10.1111/ajt.13815; Colvin RB, 2005, NAT REV IMMUNOL, V5, P807, DOI 10.1038/nri1702; Cosmi L, 2014, CYTOM PART A, V85A, P36, DOI 10.1002/cyto.a.22348; Crespo M, 2015, AM J TRANSPLANT, V15, P806, DOI 10.1111/ajt.13010; Danese S, 2016, DIGEST DIS, V34, P43, DOI 10.1159/000442925; Garg M, 2011, J GASTROEN HEPATOL, V26, P1221, DOI 10.1111/j.1440-1746.2011.06783.x; Gerlach UA, 2014, TRANSPL INT, V27, P280, DOI 10.1111/tri.12250; Gerlach UA, 2017, TRANSPLANTATION, V101, P1036, DOI 10.1097/TP.0000000000001469; Gerlach UA, 2017, TRANSPLANTATION, V101, P141, DOI 10.1097/TP.0000000000001439; Greer M, 2013, AM J TRANSPLANT, V13, P911, DOI 10.1111/ajt.12155; Gupta A, 2010, TRANSPLANTATION, V89, P55, DOI 10.1097/TP.0b013e3181bc5d9e; Halloran PF, 2014, KIDNEY INT, V85, P258, DOI 10.1038/ki.2013.300; Koo J, 2016, CLIN TRANSPLANT, V30, P1433, DOI 10.1111/ctr.12836; Kroemer Alexander, 2016, Curr Gastroenterol Rep, V18, P56, DOI 10.1007/s11894-016-0530-0; Kverneland AH, 2016, CYTOM PART A, V89A, P543, DOI 10.1002/cyto.a.22855; Lauro A, 2016, CURR OPIN ORGAN TRAN, V21, P165, DOI 10.1097/MOT.0000000000000279; Loo L, 2017, CURR OPIN GASTROEN, V33, P203, DOI 10.1097/MOG.0000000000000358; Mathew JM, 2015, TRANSPLANTATION, V99, P1273, DOI 10.1097/TP.0000000000000491; Matta BM, 2010, EUR J IMMUNOL, V40, P2667, DOI 10.1002/eji.201040839; Mazariegos GV, 2005, AM J TRANSPLANT, V5, P314, DOI 10.1111/j.1600-6143.2004.00672.x; Nakamoto N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00221; Parkes MD, 2017, TRANSPLANTATION, V101, pE102, DOI 10.1097/TP.0000000000001586; Powell N, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12430; Ramirez R, 2011, CONTRIB NEPHROL, V171, P57, DOI 10.1159/000327134; Ranganathan S, 2015, TRANSPLANTATION, V99, P890, DOI 10.1097/TP.0000000000000445; Ruiz P, 2006, TRANSPLANT P, V38, P1683, DOI 10.1016/j.transproceed.2006.05.017; Seki E, 2012, J PHYSIOL-LONDON, V590, P447, DOI 10.1113/jphysiol.2011.219691; Silva JT, 2016, AM J TRANSPLANT, V16, P951, DOI 10.1111/ajt.13535; Sindhi R, 2012, PEDIATR TRANSPLANT, V16, P83, DOI 10.1111/j.1399-3046.2011.01617.x; Steger U, 2008, TRANSPLANTATION, V85, P1339, DOI 10.1097/TP.0b013e31816dd64a; Streitz M, 2013, TRANSPLANT RES, V2, DOI 10.1186/2047-1440-2-17; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Talayero P, 2017, EXP MOL PATHOL, V103, P163, DOI 10.1016/j.yexmp.2017.08.008; Weiner J, 2017, TRANSPLANTATION, V101, P2449, DOI 10.1097/TP.0000000000001593; Wu Guo-Sheng, 2016, World J Transplant, V6, P719, DOI 10.5500/wjt.v6.i4.719; Yapici U, 2011, TRANSPL INT, V24, P1008, DOI 10.1111/j.1432-2277.2011.01302.x; Zuber J, 2015, AM J TRANSPLANT, V15, P2691, DOI 10.1111/ajt.13325; Zuber J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah3732; 2006, ARCH PATHOL LAB MED, V130, P1489, DOI DOI 10.1043/1543-2165(2006)130[1489:EOCSIL]2.0.CO;2; 2003, TRANSPLANTATION, V75, P1241, DOI DOI 10.1097/01.TP.0000062840.49159.2F	45	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2019	10								866	10.3389/fimmu.2019.00866	http://dx.doi.org/10.3389/fimmu.2019.00866			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX4AJ	31134051	gold, Green Published			2022-12-18	WOS:000467336500001
J	Tang, CL; Pan, Q; Xie, YP; Xiong, Y; Zhang, RH; Huang, J				Tang, Chun-lian; Pan, Qun; Xie, Ya-ping; Xiong, Ying; Zhang, Rong-hui; Huang, Jin			Effect of Cytotoxic T-Lymphocyte Antigen-4 on the Efficacy of the Fatty Acid-Binding Protein Vaccine Against Schistosoma japonicum	FRONTIERS IN IMMUNOLOGY			English	Article						Schistosoma japonicum; fatty acid-binding protein; regulatory T cells; cytotoxic T-lymphocyte antigen-4; granuloma	MANSONI INFECTION; DNA VACCINE; CTLA-4; CELLS; ANTI-CTLA-4; ENHANCEMENT; COMBINATION; INHIBITION; ANTIBODY; IMMUNITY	The present study evaluated the impact of blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4) activity on the protective effect elicited by the fatty acid binding protein (FABP) vaccine against Schistosoma japonicum infection. Mice were randomly divided into uninfected, infected control, anti-CTLA-4 monoclonal antibody (anti-CTLA-4 mAb), FABP, and combination (anti-CTLA-4 mAb and FABP) groups. An assessment of the S. japonicum worm and egg burden in the infected mice revealed that the worm reduction-rate induced by FABP administration was increased from 26.58 to 54.61% by co-administration of the monoclonal anti-CTLA antibody (anti-CTLA-4 mAb). Furthermore, the regulatory T cell (Treg) percentage was significantly increased in mice after administration of the anti-CTLA-4 mAb, but not the FABP vaccine, and elevated levels of the cytokines interferon (IFN)-gamma, interleukin (IL)-2, IL-4, and IL-5 were observed in infected mice that were administered the anti-CTLA-4 mAb. Notably, the diameter of egg granulomas in the anti-CTLA-4 mAb and combination groups was significantly increased compared to that observed in the infected control group. Together, these results suggest that co-administering the FABP vaccine and anti-CTLA-4 treatment may have synergistically increased the immunoprotective effect of the FABP vaccine by promoting T-helper 1-type immune responses, while incurring increased tissue damage.	[Tang, Chun-lian; Pan, Qun; Xie, Ya-ping; Xiong, Ying; Zhang, Rong-hui] Wuhan Univ Sci & Technol, Wuchang Hosp, Wuhan, Hubei, Peoples R China; [Huang, Jin] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Hosp 4, Dept Clin Lab,Puai Hosp, Wuhan, Hubei, Peoples R China	Wuhan University of Science & Technology; Huazhong University of Science & Technology	Zhang, RH (corresponding author), Wuhan Univ Sci & Technol, Wuchang Hosp, Wuhan, Hubei, Peoples R China.; Huang, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Hosp 4, Dept Clin Lab,Puai Hosp, Wuhan, Hubei, Peoples R China.	zhangronghui_123@163.com; huangjintjmu@163.com			Health and Family Planning Commission of Wuhan Municipality [WX17A08]; Hubei Provincial Planning Commission Joint Fund project [WJ2018H0129]; Hubei Provincial Natural Science Foundation [2017CFB570]	Health and Family Planning Commission of Wuhan Municipality; Hubei Provincial Planning Commission Joint Fund project; Hubei Provincial Natural Science Foundation	This research was funded by the Scientific Research Subject of the Health and Family Planning Commission of Wuhan Municipality [grant number WX17A08]; Hubei Provincial Planning Commission Joint Fund project [grant number WJ2018H0129]; and Hubei Provincial Natural Science Foundation project [grant number 2017CFB570].	Ahn JB, 2016, KOREAN J PARASITOL, V54, P163, DOI 10.3347/kjp.2016.54.2.163; Aly I, 2018, EXP PARASITOL, V194, P53, DOI 10.1016/j.exppara.2018.09.018; Bueno LL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009623; Cheng YL, 2008, PARASITOL RES, V102, P1129, DOI 10.1007/s00436-008-0880-0; Colley DG, 2014, PARASITE IMMUNOL, V36, P347, DOI 10.1111/pim.12087; Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Fahmy O, 2016, MED HYPOTHESES, V92, P57, DOI 10.1016/j.mehy.2016.04.037; Gannavaram S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00187; Ha D, 2019, P NATL ACAD SCI USA, V116, P609, DOI 10.1073/pnas.1812186116; Haque A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001221; Kadono Takafumi, 2017, Nihon Rinsho Meneki Gakkai Kaishi, V40, P83, DOI 10.2177/jsci.40.83; Li B, 2009, J IMMUNOL, V182, P7625, DOI 10.4049/jimmunol.0804192; Li MJ, 2011, EXP PARASITOL, V128, P427, DOI 10.1016/j.exppara.2011.05.012; Li YH, 2000, J NANJING MED U, V20, P442, DOI [10.3969/j.issn.1007-4368.2000.06.033, DOI 10.3969/J.ISSN.1007-4368.2000.06.033]; Liu LN, 2018, MOL THER, V26, P45, DOI 10.1016/j.ymthe.2017.10.020; Mo HM, 2007, EXP PARASITOL, V116, P385, DOI 10.1016/j.exppara.2007.02.009; Pietruczuk M, 2012, J BIOL REG HOMEOS AG, V26, P627; Raina OK, 2004, VET PARASITOL, V124, P65, DOI 10.1016/j.vetpar.2004.04.013; Rowe JH, 2009, IMMUNOLOGY, V128, pe471, DOI 10.1111/j.1365-2567.2008.03001.x; Rowshanravan B, 2018, BLOOD, V131, P58, DOI 10.1182/blood-2017-06-741033; Santini-Oliveira M, 2016, VACCINE, V34, P586, DOI 10.1016/j.vaccine.2015.10.027; Savoia P, 2016, HUM VACC IMMUNOTHER, V12, P1092, DOI 10.1080/21645515.2015.1129478; Son CH, 2017, ONCOL LETT, V13, P3781, DOI 10.3892/ol.2017.5933; Sun LP, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-017-0271-9; Tang CL, 2019, PARASITOL RES, V118, P559, DOI 10.1007/s00436-018-6186-y; Tang CL, 2017, PARASITOL RES, V116, P2727, DOI 10.1007/s00436-017-5581-0; Tang CL, 2014, EXP PARASITOL, V136, P74, DOI 10.1016/j.exppara.2013.11.001; Tang CL, 2011, PARASITOL RES, V108, P477, DOI 10.1007/s00436-010-2089-2; Taylor MD, 2007, J IMMUNOL, V179, P4626, DOI 10.4049/jimmunol.179.7.4626; Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269; Tendler M, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3040121; Vicente B, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1500-y; Walsh CM, 2007, PARASITE IMMUNOL, V29, P293, DOI 10.1111/j.1365-3024.2007.00947.x; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wei F, 2008, VACCINE, V26, P4145, DOI 10.1016/j.vaccine.2008.05.034; 2019, CLIN CANCER RES, V25, P1233, DOI DOI 10.1158/1078-0432.CCR-18-0762	38	1	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2019	10								1022	10.3389/fimmu.2019.01022	http://dx.doi.org/10.3389/fimmu.2019.01022			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX4BN	31134084	Green Published, gold			2022-12-18	WOS:000467339500001
J	Duarte-Neto, AN; Croda, J; Pagliari, C; Soriano, FG; Nicodemo, AC; Duarte, MIS				Duarte-Neto, Amaro Nunes; Croda, Julio; Pagliari, Carla; Soriano, Francisco Garcia; Nicodemo, Antonio Carlos; Seixas Duarte, Maria Irma			Severe Leptospirosis Features in the Spleen Indicate Cellular Immunosuppression Similar to That Found in Septic Shock	FRONTIERS IN IMMUNOLOGY			English	Article						leptospirosis; Weil's disease; severe pulmonary hemorrhage syndrome; intensive care; spleen; sepsis-related immunosuppression	NECROSIS-FACTOR-ALPHA; SEVERE SEPSIS; WHOLE-BLOOD; INTERROGANS ACTIVATION; PROFOUND DEPLETION; INTERFERON-GAMMA; DENDRITIC CELLS; DOWN-REGULATION; RELEASE; DISEASE	Objectives: To compare microscopic and immunologic features in the spleens of patients who died of pulmonary hemorrhage and shock caused by leptospirosis (11 cases) or Gram-positive/-negative bacterial septic shock (10 cases) to those from control spleens (12 cases from splenectomy). Methodology: Histological features in the red pulp and white pulp were analyzed using archived samples by a semi quantitative score. Immunohistochemistry was used for the recognition of immune cell markers, cytokines, caspase-3 and Leptospira antigens. Results: The control group differed significantly from the leptospirosis and septic shock patients which demonstrate strong similarities: diffuse congestion in the red pulp with a moderate to intense infiltration of plasma cells and polymorphonuclear cells; follicles with marked atrophy; high density of CD20(+) cells; low density of NK, TCD4(+) and active caspase-3 positive cells and strong expression of IL-10; leptospirosis patients had higher S100 and TNF-alpha positive cells in the spleen than the other groups. Conclusion: The results suggest that an immunosuppressive state develops at the terminal stage of severe leptospirosis with pulmonary hemorrhage and shock similar to that of patients with septic shock, with diffuse endothelial activation in the spleen, splenitis, and signs of disturbance in the innate and adaptive immunity in the spleen. The presence of leptospiral antigens in 73% of the spleens of the leptospirosis patients suggests the etiological agent contributes directly to the pathogenesis of the lesions. Our results support therapeutic approaches involving antibiotic and immunomodulatory treatments for leptospirosis patients and suggest that leptospirosis patients, which are usually young men with no co-morbidities, form a good group for studying sepsis and septic shock.	[Duarte-Neto, Amaro Nunes; Pagliari, Carla; Seixas Duarte, Maria Irma] Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil; [Duarte-Neto, Amaro Nunes; Soriano, Francisco Garcia] Univ Sao Paulo, Fac Med, Discipline Emergencies Clin, Sao Paulo, Brazil; [Croda, Julio] Univ Fed Mato Grosso do Sul, Fac Med, Campo Grande, Brazil; [Croda, Julio] Fundacao Oswald Cruz, Campo Grande, Brazil; [Soriano, Francisco Garcia] Univ Sao Paulo, Hosp Univ, Unidade Terapia Intens, Sao Paulo, Brazil; [Nicodemo, Antonio Carlos] Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal de Mato Grosso do Sul; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Universidade de Sao Paulo	Duarte-Neto, AN (corresponding author), Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil.; Duarte-Neto, AN (corresponding author), Univ Sao Paulo, Fac Med, Discipline Emergencies Clin, Sao Paulo, Brazil.	amaro.ndneto@hc.fm.usp.br	Soriano, Francisco/C-3382-2012; Croda, Julio/I-5172-2013; Pagliari, Carla/AAY-4773-2020	Soriano, Francisco/0000-0003-4898-0135; Croda, Julio/0000-0002-6665-6825; Pagliari, Carla/0000-0001-6210-6917				Abbas AK, 2012, CELL MOL IMMUNOL, V9th, P225; Adiga Deepa Sowkur Anandarama, 2017, J Clin Diagn Res, V11, pEC21, DOI 10.7860/JCDR/2017/25706.9836; ALVES VAF, 1986, REV I MED TROP, V28, P170, DOI 10.1590/S0036-46651986000300006; Andrade L, 2007, CLIN J AM SOC NEPHRO, V2, P739, DOI 10.2215/CJN.00680207; AREAN VM, 1962, AM J PATHOL, V40, P393; Athanazio DA, 2008, ACTA TROP, V105, P95, DOI 10.1016/j.actatropica.2007.09.004; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Burberry A, 2014, CELL HOST MICROBE, V15, P779, DOI 10.1016/j.chom.2014.05.004; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; Chen HI, 2007, PATHOLOGY, V39, P339, DOI 10.1080/00313020701329740; Cinco M, 1996, FEMS MICROBIOL LETT, V138, P211, DOI 10.1016/0378-1097(96)00109-7; COMBY F, 1969, Bulletin de la Societe de Pathologie Exotique, V62, P92; De Fost M, 2007, CLIN MICROBIOL INFEC, V13, P433, DOI 10.1111/j.1469-0691.2006.01640.x; de Fost M, 2003, CLIN DIAGN LAB IMMUN, V10, P332, DOI 10.1128/CDLI.10.2.332-335.2003; De Silva Nipun Lakshitha, 2014, Int Arch Med, V7, P31, DOI 10.1186/1755-7682-7-31; DEBRITO T, 1987, ANN TROP MED PARASIT, V81, P207; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207; Diament D, 2002, INFECT IMMUN, V70, P1677, DOI 10.1128/IAI.70.4.1677-1683.2002; Dorigatti F, 2005, BRAZ J MED BIOL RES, V38, P909, DOI 10.1590/S0100-879X2005000600013; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; Friedland JS, 1996, CRIT CARE MED, V24, P1775, DOI 10.1097/00003246-199611000-00003; Gaudart N, 2008, FEMS IMMUNOL MED MIC, V53, P359, DOI 10.1111/j.1574-695X.2008.00437.x; GIAMARELLOSBOURBOU, 2006, CRIT CARE, V10; Goeijenbier M, 2015, J INFECTION, V71, P437, DOI 10.1016/j.jinf.2015.05.016; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Golub R, 2018, TRENDS IMMUNOL, V39, P503, DOI 10.1016/j.it.2018.02.007; Guidugli Fabio, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P47, DOI 10.1590/S0036-46652000000100008; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2005, CLIN INFECT DIS, V41, pS465, DOI 10.1086/431998; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hotchkiss RS, 2002, J IMMUNOL, V168, P2493, DOI 10.4049/jimmunol.168.5.2493; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Isogai E, 1998, J VET MED B, V45, P529, DOI 10.1111/j.1439-0450.1998.tb00824.x; Junt T, 2008, NAT REV IMMUNOL, V8, P764, DOI 10.1038/nri2414; Karp CL, 1998, EUR J IMMUNOL, V28, P3128, DOI 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-T; Klimpel GR, 2003, J IMMUNOL, V171, P1447, DOI 10.4049/jimmunol.171.3.1447; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kox WJ, 1997, ARCH INTERN MED, V157, P389, DOI 10.1001/archinte.157.4.389; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Lowanitchapat A, 2010, COMP IMMUNOL MICROB, V33, P423, DOI 10.1016/j.cimid.2009.05.001; Maciel EAP, 2006, ACTA TROP, V100, P256, DOI 10.1016/j.actatropica.2006.11.006; Marinho M, 2009, AM J TROP MED HYG, V80, P832, DOI 10.4269/ajtmh.2009.80.832; Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8; Muensoongnoen Jittima, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P720; Naiman BM, 2002, INFECT IMMUN, V70, P6147, DOI 10.1128/IAI.70.11.6147-6157.2002; Naiman BM, 2001, INFECT IMMUN, V69, P7550, DOI 10.1128/IAI.69.12.7550-7558.2001; Nicodemo AC, 1997, AM J TROP MED HYG, V56, P181, DOI 10.4269/ajtmh.1997.56.181; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; Raffray L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165716; Rajan G, 1997, INTENS CARE MED, V23, P1187, DOI 10.1007/s001340050482; Reis EAG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002457; Resendes AR, 2004, VET IMMUNOL IMMUNOP, V99, P203, DOI 10.1016/j.vetimm.2004.02.001; Romero Eliete Caló, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P245, DOI 10.1590/S0036-46652003000500002; Secretaria da Saude do Estado de Sao Paulo, 2018, DAD EST; SHINZATO M, 1995, BIOTECH HISTOCHEM, V70, P114, DOI 10.3109/10520299509108327; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Spichler A, 2007, AM J TROP MED HYG, V77, P1111, DOI 10.4269/ajtmh.2007.77.1111; Tajiki MH, 1996, CLIN INFECT DIS, V23, P1177, DOI 10.1093/clinids/23.5.1177; Tang BM, 2018, ORIGIN IMMUNOLOGICAL, P13; Tinsley KW, 2003, J IMMUNOL, V171, P909, DOI 10.4049/jimmunol.171.2.909; Tuero I, 2010, J INFECT DIS, V201, P420, DOI 10.1086/650300; UIP DE, 1992, REV I MED TROP, V34, P375, DOI 10.1590/S0036-46651992000500001; van der Poll T, 2008, LANCET INFECT DIS, V8, P32, DOI 10.1016/S1473-3099(07)70265-7; Vernel-Pauillac F, 2006, INFECT IMMUN, V74, P4172, DOI 10.1128/IAI.00447-06; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wagenaar JFP, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000453; Wen HT, 2006, AM J PATHOL, V168, P1940, DOI 10.2353/ajpath.2006.051155; YAMASHIROKANASHIRO EH, 1991, AM J TROP MED HYG, V45, P138, DOI 10.4269/ajtmh.1991.45.138; 1998, EXP TOXICOL PATHOL, V50, P191, DOI DOI 10.1016/S0940-2993(98)80083-3	73	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2019	10								920	10.3389/fimmu.2019.00920	http://dx.doi.org/10.3389/fimmu.2019.00920			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HW1SW	31114579	Green Published, gold			2022-12-18	WOS:000466463800001
J	Costain, AH; MacDonald, AS; Smits, HH				Costain, Alice H.; MacDonald, Andrew S.; Smits, Hermelijn H.			Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses (vol 9, 3042, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						Schistosoma mansoni; intestine; endothelium; type 2 immunity; immune modulation			[Costain, Alice H.; Smits, Hermelijn H.] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands; [Costain, Alice H.; MacDonald, Andrew S.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Manchester	Smits, HH (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.	h.h.smits@lumc.nl	Smits, Hermelijn/V-4216-2018	Smits, Hermelijn/0000-0001-9279-2890	MRC [MR/N013751/1]; BBSRC [BB/P504543/1]	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	In the original article, we neglected to include the funders the "MRC, MR/N013751/1" and the "BBSRC, BB/P504543/1" to AM.	Costain AH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03042	1	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2019	10								749	10.3389/fimmu.2019.00749	http://dx.doi.org/10.3389/fimmu.2019.00749			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HT0TZ	31031753	Green Published, gold			2022-12-18	WOS:000464278800001
J	Qin, Y; Lee, Y; Seo, J; Kim, T; Shin, JH; Park, SH				Qin, Yingyu; Lee, Yuna; Seo, Jaeho; Kim, Taehyun; Shin, Jung Hoon; Park, Se-Ho			NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs	FRONTIERS IN IMMUNOLOGY			English	Article						NIH3T3-CM; cytotoxic T lymphocytes; memory precursor; memory CD8(+) T cells; adoptive cell therapy	CD8(+) T-CELLS; CUTTING EDGE; STEM-CELLS; EFFECTOR; FIBROBLASTS; BET; BLIMP-1; LYMPHOCYTES; ACTIVATION	Memory CD8(+) T cells have long been considered a promising population for adoptive cell therapy (ACT) due to their long-term persistence and robust re-stimulatory response. NIH3T3 is an immortalized mouse embryonic fibroblast cell line. We report that NIH3T3-conditioned medium (CM) can augment effector functions of CTLs following antigen priming and confer phenotypic and transcriptional properties of central memory cells. After NIH3T3-CM-educated CTLs were infused into naive mice, they predominantly developed to central memory cells. A large number of NIH3T3-CM-educated CTLs with high functionality persisted and infiltrated to tumor mass. In addition, NIH3T3-CM inhibited CTLs expression of PD-1 in vitro and repressed their high expression of PD-1 in tumor microenvironment after adoptive transfer. Consequently, established tumor models showed that infusion of NIH3T3-CM-educated CTLs dramatically improved CTL mediated-antitumor immunity. Furthermore, NIH3T3-CM also promoted human CD8(+) T cells differentiation into memory cells. These results suggest that NIH3T3-CM-programmed CTLs are good candidates for adoptive transfer in tumor therapy.	[Qin, Yingyu; Park, Se-Ho] Korea Univ, Dept Life Sci & Biotechnol, Seoul, South Korea; [Lee, Yuna; Seo, Jaeho; Kim, Taehyun; Shin, Jung Hoon] Korea Univ, ImmunoMax Co Ltd, Seoul, South Korea	Korea University; Korea University	Park, SH (corresponding author), Korea Univ, Dept Life Sci & Biotechnol, Seoul, South Korea.	sehopark@korea.ac.kr			Basic Science Research Program of the National Research Foundation of Korea [NRF-2018R1A2A2A05023297]	Basic Science Research Program of the National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by a grant (NRF-2018R1A2A2A05023297) of the Basic Science Research Program of the National Research Foundation of Korea.	Abu Eid R, 2017, CANCER RES, V77, P4135, DOI 10.1158/0008-5472.CAN-16-1925; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Bally APR, 2016, J IMMUNOL, V196, P2431, DOI 10.4049/jimmunol.1502643; Banerjee A, 2010, J IMMUNOL, V185, P4988, DOI 10.4049/jimmunol.1002042; Barnas JL, 2010, CANCER MICROENVIRON, V3, P29, DOI 10.1007/s12307-010-0044-5; Barnas JL, 2010, J IMMUNOL, V185, P2681, DOI 10.4049/jimmunol.1000896; Baruch EN, 2017, CANCER-AM CANCER SOC, V123, P2154, DOI 10.1002/cncr.30491; Boisvert M, 2007, MOL IMMUNOL, V44, P3732, DOI 10.1016/j.molimm.2007.04.003; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Crompton JG, 2015, CANCER RES, V75, P296, DOI 10.1158/0008-5472.CAN-14-2277; Crotty S, 2010, NAT IMMUNOL, V11, P114, DOI 10.1038/ni.1837; Fu SH, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0354-8; Gerritsen B, 2016, IMMUNOL CELL BIOL, V94, P236, DOI 10.1038/icb.2015.118; Haniffa MA, 2007, J IMMUNOL, V179, P1595, DOI 10.4049/jimmunol.179.3.1595; Hyde H, 1997, BLOOD, V89, P2453, DOI 10.1182/blood.V89.7.2453; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Jiang T, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1163462; Jiang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.162; Jones S, 2007, J IMMUNOL, V179, P2824, DOI 10.4049/jimmunol.179.5.2824; Joshi NS, 2008, J IMMUNOL, V180, P1309, DOI 10.4049/jimmunol.180.3.1309; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kallies A, 2017, TRENDS IMMUNOL, V38, P287, DOI 10.1016/j.it.2017.02.003; Kallies A, 2009, IMMUNITY, V31, P283, DOI 10.1016/j.immuni.2009.06.021; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Kondo T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15338; Lakins MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03347-0; Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3; Lu PY, 2014, J EXP MED, V211, P515, DOI 10.1084/jem.20130208; Lu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038825; Mescher MF, 2007, SEMIN CANCER BIOL, V17, P299, DOI 10.1016/j.semcancer.2007.06.008; Mohammed RN, 2016, CELL REP, V14, P760, DOI 10.1016/j.celrep.2015.12.090; Mousset CM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1488565; Obar JJ, 2010, INT IMMUNOL, V22, P619, DOI 10.1093/intimm/dxq053; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Qin Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00685; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Saito H, 2016, CANCER RES, V76, P3473, DOI 10.1158/0008-5472.CAN-15-1742; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; SCOTT S, 1990, J EXP MED, V172, P1873, DOI 10.1084/jem.172.6.1873; Sturm A, 2004, J IMMUNOL, V173, P3889, DOI 10.4049/jimmunol.173.6.3889; Takemoto N, 2006, J IMMUNOL, V177, P7515, DOI 10.4049/jimmunol.177.11.7515; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Trott J, 2017, STEM CELL REP, V8, P1675, DOI 10.1016/j.stemcr.2017.05.019; William Y, 2002, J CLIN INVEST, V110, P1415, DOI [10.1172/JCI0217214, DOI 10.1172/JCI0217214]; Xin A, 2016, NAT IMMUNOL, V17, P422, DOI 10.1038/ni.3410; Yang JC, 2015, ADV IMMUNOL, V130, P279, DOI [10.5041/RMMJ.10179, DOI 10.5041/RMMJ.10179]	49	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 11	2019	10								761	10.3389/fimmu.2019.00761	http://dx.doi.org/10.3389/fimmu.2019.00761			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HT0UE	31031760	Green Published, gold			2022-12-18	WOS:000464279300001
J	Perdijk, O; van Baarlen, P; Fernandez-Gutierrez, MM; van den Brink, E; Schuren, FHJ; Brugman, S; Savelkoul, HFJ; Kleerebezem, M; van Neerven, RJJ				Perdijk, Olaf; van Baarlen, Peter; Fernandez-Gutierrez, Marcela M.; van den Brink, Erik; Schuren, Frank H. J.; Brugman, Sylvia; Savelkoul, Huub F. J.; Kleerebezem, Michiel; van Neerven, R. J. Joost			Sialyllactose and Galactooligosaccharides Promote Epithelial Barrier Functioning and Distinctly Modulate Microbiota Composition and Short Chain Fatty Acid Production In Vitro (vol 10, 94, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						epithelium; galactooligosaccharides; microbiota; short chain fatty acids; sialyllactose			[Perdijk, Olaf; van den Brink, Erik; Brugman, Sylvia; Savelkoul, Huub F. J.; van Neerven, R. J. Joost] Wageningen Univ & Res, Cell Biol & Immunol Grp, Wageningen, Netherlands; [van Baarlen, Peter; Fernandez-Gutierrez, Marcela M.; Kleerebezem, Michiel] Wageningen Univ & Res, Host Microbe Interact Grp, Wageningen, Netherlands; [Schuren, Frank H. J.] Netherlands Org Appl Sci Res, Microbiol & Syst Biol, Zeist, Netherlands; [van Neerven, R. J. Joost] FrieslandCampina, Amersfoort, Netherlands	Wageningen University & Research; Wageningen University & Research; Netherlands Organization Applied Science Research	van Neerven, RJJ (corresponding author), Wageningen Univ & Res, Cell Biol & Immunol Grp, Wageningen, Netherlands.; van Neerven, RJJ (corresponding author), FrieslandCampina, Amersfoort, Netherlands.	joost.vanneerven@wur.nl	Kleerebezem, Michiel/AAT-2078-2021; van Neerven, Joost/GWZ-3214-2022	van Neerven, R.J.Joost/0000-0002-3991-5297; Perdijk, Olaf/0000-0002-1843-8858; van Baarlen, Peter/0000-0003-3530-5472; Kleerebezem, Michiel/0000-0001-8552-2235				Perdijk O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00094	1	1	1	8	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 10	2019	10								762	10.3389/fimmu.2019.00762	http://dx.doi.org/10.3389/fimmu.2019.00762			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HT0TF	31024573	gold, Green Published			2022-12-18	WOS:000464276800001
J	Kendrick, F; Evans, ND; Berlanga, O; Harding, SJ; Chappell, MJ				Kendrick, Felicity; Evans, Neil D.; Berlanga, Oscar; Harding, Stephen J.; Chappell, Michael J.			Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans	FRONTIERS IN IMMUNOLOGY			English	Article						biological systems; lumped-parameter systems; immunoglobulin G; neonatal Fc receptor; parameter estimation; structural identifiability	MONOCLONAL-ANTIBODY PHARMACOKINETICS; PBPK MODEL; DIFFERENTIAL EVOLUTION; BINDING-AFFINITY; DISPOSITION; IGG; METABOLISM; CATABOLISM; KINETICS; DISEASE	Salvage of endogenous immunoglobulin G (IgG) by the neonatal Fc receptor (FcRn) is implicated in many clinical areas, including therapeutic monoclonal antibody kinetics, patient monitoring in IgG multiple myeloma, and antibody-mediated transplant rejection. There is a clear clinical need for a fully parameterized model of FcRn-mediated recycling of endogenous IgG to allow for predictive modeling, with the potential for optimizing therapeutic regimens for better patient outcomes. In this paper we study a mechanism-based model incorporating nonlinear FcRn-IgG binding kinetics. The aim of this study is to determine whether parameter values can be estimated using the limited in vivo human data, available in the literature, from studies of the kinetics of radiolabeled IgG in humans. We derive mathematical descriptions of the experimental observations-timecourse data and fractional catabolic rate (FCR) data-based on the underlying physiological model. Structural identifiability analyses are performed to determine which, if any, of the parameters are unique with respect to the observations. Structurally identifiable parameters are then estimated from the data. It is found that parameter values estimated from timecourse data are not robust, suggesting that the model complexity is not supported by the available data. Based upon the structural identifiability analyses, a new expression for the FCR is derived. This expression is fitted to the FCR data to estimate unknown parameter values. Using these parameter estimates, the plasma IgG response is simulated under clinical conditions. Finally a suggestion is made for a reduced-order model based upon the newly derived expression for the FCR. The reduced-order model is used to predict the plasma IgG response, which is compared with the original four-compartment model, showing good agreement. This paper shows how techniques for compartmental model analysis-structural identifiability analysis, linearization, and reparameterization-can be used to ensure robust parameter identification.	[Kendrick, Felicity; Evans, Neil D.; Chappell, Michael J.] Univ Warwick, Sch Engn, Coventry, W Midlands, England; [Berlanga, Oscar; Harding, Stephen J.] Binding Site Grp Ltd, Dept Res & Dev, Birmingham, W Midlands, England	University of Warwick; Binding Site Group Limited	Chappell, MJ (corresponding author), Univ Warwick, Sch Engn, Coventry, W Midlands, England.	m.j.chappell@warwick.ac.uk			Biotechnology and Biological Sciences Research Council (BBSRC) studentship, through the Midlands Integrative Biosciences Training Partnership (MIBTP); Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Account (IAA) award	Biotechnology and Biological Sciences Research Council (BBSRC) studentship, through the Midlands Integrative Biosciences Training Partnership (MIBTP)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Account (IAA) award	This research was supported by a Biotechnology and Biological Sciences Research Council (BBSRC) studentship, through the Midlands Integrative Biosciences Training Partnership (MIBTP), and an Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Account (IAA) award.	Anderson DH., 1983, COMPARTMENTAL MODELI; BELLMAN R, 1970, Mathematical Biosciences, V7, P329, DOI 10.1016/0025-5564(70)90132-X; Biswal PC, 2008, NUMERICAL ANAL; CHEN K, 1991, PHYS MED BIOL, V36, P1183, DOI 10.1088/0031-9155/36/9/003; Chen Y, 2012, AAPS J, V14, P850, DOI 10.1208/s12248-012-9395-9; Cobelli C., 2002, TRACER KINETICS BIOM; Deng R, 2012, MABS-AUSTIN, V4, P101, DOI 10.4161/mabs.4.1.18543; Fang LY, 2008, DRUG METAB DISPOS, V36, P1153, DOI 10.1124/dmd.107.019182; Ferl GZ, 2005, ANN BIOMED ENG, V33, P1640, DOI 10.1007/s10439-005-7410-3; Fronton L, 2014, J PHARMACOKINET PHAR, V41, P87, DOI 10.1007/s10928-014-9349-1; Garg A, 2007, J PHARMACOKINET PHAR, V34, P687, DOI 10.1007/s10928-007-9065-1; Ghosh S, 2014, COMPUT BIOL MED, V46, P51, DOI 10.1016/j.compbiomed.2013.12.014; Hall A, 2010, IMMUNOLOGY; Hansen RJ, 2003, J PHARM SCI-US, V92, P1206, DOI 10.1002/jps.10364; Hattersley JG, 2013, COMPUT METH PROG BIO, V109, P126, DOI 10.1016/j.cmpb.2011.12.013; Hattersley J. G., 2009, THESIS; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kappel F, 2017, J INVERSE ILL-POSE P, V25, P499, DOI 10.1515/jiip-2016-0024; Kendrick F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00149; Kim J, 2007, CLIN IMMUNOL, V122, P146, DOI 10.1016/j.clim.2006.09.001; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Li LZ, 2014, AAPS J, V16, P1097, DOI 10.1208/s12248-014-9640-5; Mills JR, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.75; Ng CM, 2014, EUR J PHARM SCI, V51, P51, DOI 10.1016/j.ejps.2013.08.033; OriginLab Corporation, 2016, ORIGINPRO 2016; Raue A, 2009, BIOINFORMATICS, V25, P1923, DOI 10.1093/bioinformatics/btp358; Routh E., 1877, TREATISE STABILITY G; Shah DK, 2012, J PHARMACOKINET PHAR, V39, P67, DOI 10.1007/s10928-011-9232-2; SOLOMON A, 1963, J LAB CLIN MED, V62, P1; Storn R, 1997, J GLOBAL OPTIM, V11, P341, DOI 10.1023/A:1008202821328; Thomaseth K, 1999, ANN BIOMED ENG, V27, P607, DOI 10.1114/1.207; Urva SR, 2010, J PHARM SCI-US, V99, P1582, DOI 10.1002/jps.21918; WALDMANN TA, 1990, J CLIN INVEST, V86, P2093, DOI 10.1172/JCI114947; WALDMANN TA, 1969, PROG ALLERGY, V13, P1, DOI 10.1159/000287491; Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170; Wolfram Research Inc., 2017, MATH VERS 11 1; Xiao JJ, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/282989; Yan XY, 2018, CLIN PHARMACOKINET, V57, P529, DOI 10.1007/s40262-017-0598-1; Yan XY, 2012, J PHARMACOKINET PHAR, V39, P543, DOI 10.1007/s10928-012-9267-z	39	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2019	10								674	10.3389/fimmu.2019.00674	http://dx.doi.org/10.3389/fimmu.2019.00674			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HS3ZP	31024535	gold, Green Published			2022-12-18	WOS:000463801500001
J	Reed, AM; Crowson, CS; Dvergsten, JA				Reed, Ann Marie; Crowson, Cynthia S.; Dvergsten, Jeffrey Arthur			A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy	FRONTIERS IN IMMUNOLOGY			English	Article						juvenile myositis/deratomyositis; outcomes; myositis; predictive model; biomarkers	INDUCIBLE GENE-EXPRESSION; VALIDATED DISEASE-ACTIVITY; INCLUSION-BODY MYOSITIS; ASSESSMENT SCALE CMAS; DAMAGE INDEXES; CLINICAL IMPROVEMENT; DERMATOMYOSITIS JDM; CHILDHOOD ARTHRITIS; MUSCLE-FIBERS; BLOOD	Humans have an innate desire to observe and subsequently dissect an event into component pieces in an effort to better characterize the event. We then examine these pieces individually and in combinations using this information to determine the outcome of future similar events and the likelihood of their recurrence. Practically, this attempt to foretell an occurrence and predict its outcomes is evident in multiple disciplines ranging from meteorology to sociologic studies. In this manuscript we share the historical and present-day tools to predict course and outcome in juvenile idiopathic inflammatory myopathy including clinical features, testing, and biomarkers. Further we discuss considerations for building more complex predictive models of outcome especially in diseases such as juvenile idiopathic inflammatory myopathy where patients numbers are low. Many of the barriers to developing risk prediction models for juvenile idiopathic inflammatory myopathy outcomes have improved with many remaining challenges being addressed.	[Reed, Ann Marie] Duke Univ, Sch Med, Durham, NC 27708 USA; [Reed, Ann Marie; Dvergsten, Jeffrey Arthur] Duke Univ, Dept Pediat, Div Pediat Rheumatol, Durham, NC 27706 USA; [Crowson, Cynthia S.] Mayo Clin, Rochester, MN USA	Duke University; Duke University; Mayo Clinic	Reed, AM (corresponding author), Duke Univ, Sch Med, Durham, NC 27708 USA.; Reed, AM (corresponding author), Duke Univ, Dept Pediat, Div Pediat Rheumatol, Durham, NC 27706 USA.	ann.reed@duke.edu						Aggarwal R, 2016, RHEUMATOLOGY, V55, P1710, DOI 10.1093/rheumatology/kew275; Aggarwal R, 2014, ARTHRITIS RHEUMATOL, V66, P740, DOI 10.1002/art.38270; ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206; Baechler EC, 2007, MOL MED, V13, P59, DOI 10.2119/2006-00085.Baechler; Betteridge Z, 2016, J INTERN MED, V280, P8, DOI 10.1111/joim.12451; Betteridge ZE, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3275; Bilgic H, 2009, ARTHRITIS RHEUM-US, V60, P3436, DOI 10.1002/art.24936; BOWYER SL, 1983, J PEDIATR-US, V103, P882, DOI 10.1016/S0022-3476(83)80706-9; Challa D, 2018, CLIN RHEUMATOL, V37, P1011, DOI 10.1007/s10067-017-3901-5; Chen YW, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-43; De Padilla CML, 2015, CLIN EXP RHEUMATOL, V33, P655; De Padilla CML, 2017, J RHEUMATOL, V44, DOI 10.3899/jrheum.160293; Deakin CT, 2018, ARTHRITIS RHEUMATOL, V70, P785, DOI 10.1002/art.40418; Enders FB, 2014, ARTHRITIS RHEUMATOL, V66, P2281, DOI 10.1002/art.38676; Gao SM, 2017, AUTOIMMUN REV, V16, P1044, DOI 10.1016/j.autrev.2017.07.021; Greenberg SA, 2012, GENES IMMUN, V13, P207, DOI 10.1038/gene.2011.61; Greenberg SA, 2005, NEUROLOGY, V65, P1782, DOI 10.1212/01.wnl.0000187124.92826.20; Huber AM, 2018, PEDIATR CLIN N AM, V65, P739, DOI 10.1016/j.pcl.2018.04.006; Huber AM, 2017, J RHEUMATOL, V44, DOI 10.3899/jrheum.160688; Huber AM, 2012, ARTHRIT CARE RES, V64, P546, DOI 10.1002/acr.20695; Huber AM, 2000, ARTHRITIS RHEUM, V43, P541, DOI 10.1002/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T; Huber AM, 2001, J RHEUMATOL, V28, P1106; Isenberg DA, 2004, RHEUMATOLOGY, V43, P49, DOI 10.1093/rheumatology/keg427; Kim S, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-016-0134-0; Kleisiaris CF, 2014, J MED ETHICS HIST ME, V7; Kuru S, 2003, ACTA NEUROPATHOL, V105, P217, DOI 10.1007/s00401-002-0632-4; Lam CG, 2011, ANN RHEUM DIS, V70, P2089, DOI 10.1136/ard.2011.153718; Liao AP, 2011, ANN RHEUM DIS, V70, P831, DOI 10.1136/ard.2010.139949; Lovell DJ, 1999, ARTHRITIS RHEUM-US, V42, P2213, DOI 10.1002/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8; Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x; McCann LJ, 2018, ANN RHEUM DIS, V77, P241, DOI 10.1136/annrheumdis-2017-212141; McCann LJ, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0784-0; Nagaraju K, 2005, CURR OPIN RHEUMATOL, V17, P725, DOI 10.1097/01.bor.0000179947.58271.9a; Olazagasti J, 2015, OPEN J RHEUMATOL AUT, V5, P68, DOI [10.4236/ojra.2015, DOI 10.4236/OJRA.2015]; Petri M, 2009, LUPUS, V18, P980, DOI 10.1177/0961203309105529; Reed A, 2010, ARTHRITIS RHEUM, V62, P1376; Reed AM, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0710-3; Rider LG, 1997, ARTHRITIS RHEUM-US, V40, P1976, DOI 10.1002/art.1780401109; Rider LG, 1998, ARTHRITIS RHEUM, V41, P710, DOI 10.1002/1529-0131(199804)41:4<710::AID-ART19>3.0.CO;2-K; Rider LG, 2017, ARTHRITIS RHEUMATOL, V69, P911, DOI 10.1002/art.40060; Rider LG, 2011, ARTHRIT CARE RES, V63, pS118, DOI 10.1002/acr.20532; Rider LG, 2010, ARTHRIT CARE RES, V62, P465, DOI 10.1002/acr.20035; Ruperto N, 2003, RHEUMATOLOGY, V42, P1452, DOI 10.1093/rheumatology/keg403; Salaiegheh M, 2010, ANN NEUROL, V67, P53, DOI 10.1002/ana.21805; Sanner H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092171; Sato S, 2013, MOD RHEUMATOL, V23, P496, DOI 10.1007/s10165-012-0663-4; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stringer E, 2010, J RHEUMATOL, V37, P1953, DOI 10.3899/jrheum.090953; Suarez-Calvet X, 2014, J PATHOL, V233, P258, DOI 10.1002/path.4346; Sun C, 2015, PEDIATR NEONATOL, V56, P31, DOI 10.1016/j.pedneo.2014.02.006; Szodoray P, 2010, RHEUMATOLOGY, V49, P1867, DOI 10.1093/rheumatology/keq151; Tansley SL, 2017, J AUTOIMMUN, V84, P55, DOI 10.1016/j.jaut.2017.06.007; Tezak Z, 2002, J IMMUNOL, V168, P4154, DOI 10.4049/jimmunol.168.8.4154; Tournadre A, 2013, NAT REV RHEUMATOL, V9, P438, DOI 10.1038/nrrheum.2013.26; van Dijkhuizen EHP, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1687-8; van Dijkhuizen EHP, 2019, STAT METHODS MED RES, V28, P35, DOI 10.1177/0962280217713233; Varnier GC, 2018, ARTHRIT CARE RES, V70, P1312, DOI 10.1002/acr.23491; Vogenberg FR, 2009, AM HEALTH DRUG BENEF, V2, P218; Walsh RJ, 2007, ARTHRITIS RHEUM, V56, P3784, DOI 10.1002/art.22928; Wu Q, 2017, BEST PRACT RES CL RH, V31, P535, DOI 10.1016/j.berh.2017.12.003; Zhou XD, 2004, MED SCI MONITOR, V10, pBR191	62	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 2	2019	10								638	10.3389/fimmu.2019.00638	http://dx.doi.org/10.3389/fimmu.2019.00638			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HR3ZR	31001260	gold, Green Published			2022-12-18	WOS:000463083200001
J	Schaefer, S; Hettinga, KA; Cullor, J; German, JB; Henrick, BM				Schaefer, Sara; Hettinga, Kasper Arthur; Cullor, James; German, J. Bruce; Henrick, Bethany M.			Use of UV Treated Milk Powder to Increase Vaccine Efficacy in the Elderly (vol 9, 2254, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						nutritional supplementation; dairy proteins; immune response; vaccines; UV-C treatment			[Schaefer, Sara; Cullor, James; German, J. Bruce; Henrick, Bethany M.] Univ Calif Davis, Foods Hlth Inst, Dept Food Sci & Technol, Davis, CA 95616 USA; [Hettinga, Kasper Arthur] Wageningen Univ & Res, Wageningen, Netherlands; [Cullor, James] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA; [Henrick, Bethany M.] Univ Nebraska, Food Sci & Technol Dept, Lincoln, NE USA	University of California System; University of California Davis; Wageningen University & Research; University of California System; University of California Davis; University of Nebraska System; University of Nebraska Lincoln	Schaefer, S (corresponding author), Univ Calif Davis, Foods Hlth Inst, Dept Food Sci & Technol, Davis, CA 95616 USA.	seschaefer@ucdavis.edu						Schaefer S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02254	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2019	10								427	10.3389/fimmu.2019.00427	http://dx.doi.org/10.3389/fimmu.2019.00427			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HP3LF	30936865	Green Published, gold			2022-12-18	WOS:000461577500001
J	Marlin, R; Nugeyre, MT; Tchitchek, N; Parenti, M; Lefebvre, C; Hocini, H; Benjelloun, F; Cannou, C; Nozza, S; Dereuddre-Bosquet, N; Levy, Y; Barre-Sinoussi, F; Scarlatti, G; Le Grand, R; Menu, E				Marlin, Romain; Nugeyre, Marie-Therese; Tchitchek, Nicolas; Parenti, Matteo; Lefebvre, Cecile; Hocini, Hakim; Benjelloun, Fahd; Cannou, Claude; Nozza, Silvia; Dereuddre-Bosquet, Nathalie; Levy, Yves; Barre-Sinoussi, Francoise; Scarlatti, Gabriella; Le Grand, Roger; Menu, Elisabeth			Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae	FRONTIERS IN IMMUNOLOGY			English	Article						female reproductive tract (FRT); seminal plasma; vaccine; mucosa; HIV-1	LEUKOCYTE RECRUITMENT; VAGINAL TRANSMISSION; CELLULAR-IMMUNITY; DENDRITIC CELLS; EARLY-PREGNANCY; ACTIVIN-A; SEMEN; CYTOKINE; HIV-1; EXPRESSION	HIV-1 sexual transmission occurs mainly via mucosal semen exposures. In the female reproductive tract (FRT), seminal plasma (SP) induces physiological modifications, including inflammation. An effective HIV-1 vaccine should elicit mucosal immunity, however, modifications of vaccine responses by the local environment remain to be characterized. Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we characterized the impact of HIV-1(+) SP intravaginal exposure on the local immune responses of non-human primates. Multiple HIV-1(+) SP exposures did not impact the anti-MVA antibody responses. However, SP exposures revealed an anti-MVA responses mediated by CD4(+) T cells, which was not observed in the control group. Furthermore, the frequency and the quality of specific anti-MVA CD8(+) T cell responses increased in the FRT exposed to SP. Multi-parameter approaches clearly identified the cervix as the most impacted compartment in the FRT. SP exposures induced a local cell recruitment of antigen presenting cells, especially CD11c(+) cells, and CD8(+) T cell recruitment in the FRT draining lymph nodes. CD11c(+) cell recruitment was associated with upregulation of inflammation-related gene expression after SP exposures in the cervix. We thus highlight the fact that physiological conditions, such as SP exposures, should be taken into consideration to test and to improve vaccine efficacy against HIV-1 and other sexually transmitted infections.	[Marlin, Romain; Nugeyre, Marie-Therese; Tchitchek, Nicolas; Parenti, Matteo; Benjelloun, Fahd; Cannou, Claude; Dereuddre-Bosquet, Nathalie; Le Grand, Roger; Menu, Elisabeth] Univ Paris Sud, IDMIT Dept, Immunol Vral Infect & Autoimmune Dis IMVA U1184, CEA,IBFJ,Inserm, Fontenay Aux Roses, France; [Marlin, Romain; Nugeyre, Marie-Therese; Benjelloun, Fahd; Cannou, Claude; Menu, Elisabeth] Inst Pasteur, Dept Vrol, MISTIC Grp, Paris, France; [Marlin, Romain; Nugeyre, Marie-Therese; Parenti, Matteo; Lefebvre, Cecile; Hocini, Hakim; Levy, Yves; Barre-Sinoussi, Francoise; Scarlatti, Gabriella; Le Grand, Roger; Menu, Elisabeth] Hop Henri Mondor, VRI, Crete, France; [Lefebvre, Cecile; Hocini, Hakim; Levy, Yves] Inst Mondor Rech Biomed, INSERM U955, Equipe Physiopathol & Immunotherapies Infect HIV, Creteil, France; [Nozza, Silvia] Ist Sci San Raffaele, Infect Dis Dept, Milan, Italy; [Levy, Yves] AP HP, Serv Immunol Clin, Grp Henri Mondor Albert Chenevier, Crete, France; [Barre-Sinoussi, Francoise] Inst Pasteur, Int Div, Paris, France; [Scarlatti, Gabriella] Ist Sci San Raffaele, Viral Evolut & Transmiss Unit, Milan, Italy	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Menu, E (corresponding author), Univ Paris Sud, IDMIT Dept, Immunol Vral Infect & Autoimmune Dis IMVA U1184, CEA,IBFJ,Inserm, Fontenay Aux Roses, France.; Menu, E (corresponding author), Inst Pasteur, Dept Vrol, MISTIC Grp, Paris, France.; Menu, E (corresponding author), Hop Henri Mondor, VRI, Crete, France.	elisabeth.menu@pasteur.fr	NOZZA, SILVIA/AAC-5445-2022; MENU, Elisabeth/B-2886-2010	MENU, Elisabeth/0000-0001-8844-9328; Scarlatti, Gabriella/0000-0003-2316-2689; Tchitchek, Nicolas/0000-0003-3307-0446	ANRS (France Recherche Nord & Sud Sida-HIV Hepatites); ANRS; Sidaction; Institut Carnot-Pasteur, Microbes Sante; Programme Investissement d'Avenir (PIA) [ANR-11-INBS0008, ANR-10-EQPX-02-01, ANR-10-LABX77-01]	ANRS (France Recherche Nord & Sud Sida-HIV Hepatites)(French National Research Agency (ANR)); ANRS(ANRSFrench National Research Agency (ANR)); Sidaction; Institut Carnot-Pasteur, Microbes Sante; Programme Investissement d'Avenir (PIA)	NT held a fellowship from the ANRS (France Recherche Nord & Sud Sida-HIV Hepatites). FB held fellowships from the ANRS, Sidaction and Institut Carnot-Pasteur, Microbes & Sante. This work was supported by the Programme Investissement d'Avenir (PIA) managed by the ANR under reference ANR-11-INBS0008, funding the Infectious Disease Models and Innovative Therapies (IDMIT, Fontenay-aux-Roses, France) infrastructure, the ANR-10-EQPX-02-01, funding the FlowCyTech facility (IDMIT, Fontenay-aux-Roses, France) and the ANR-10-LABX77-01 funding the Vaccine Research Institute (VRI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson DJ, 2010, AIDS, V24, P163, DOI 10.1097/QAD.0b013e32833424c8; Anderson RA, 1998, HUM REPROD, V13, P3319, DOI 10.1093/humrep/13.12.3319; Bouvet Jean-Pierre, 1997, Clin Microbiol Infect, V3, P19; Chen JC, 2014, HUM REPROD, V29, P1255, DOI 10.1093/humrep/deu047; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Doncel GF, 2014, AM J REPROD IMMUNOL, V71, P564, DOI 10.1111/aji.12231; Guenounou S, 2013, CYTOM PART A, V83A, P182, DOI 10.1002/cyto.a.22233; Gupta P, 2002, J VIROL, V76, P9868, DOI 10.1128/JVI.76.19.9868-9876.2002; Hladik F, 2010, ANTIVIR RES, V88, pS3, DOI 10.1016/j.antiviral.2010.09.011; Johansson M, 2004, IMMUNOLOGY, V112, P290, DOI 10.1111/j.1365-2567.2004.01876.x; Joseph T, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.101956; Kafka JK, 2012, AIDS, V26, P27, DOI 10.1097/QAD.0b013e32834e57b2; Kaizu M, 2006, J INFECT DIS, V194, P912, DOI 10.1086/507308; Katoh M, 2002, INT J MOL MED, V10, P221; Khanna KV, 2002, J CLIN INVEST, V109, P205; Kim KA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-55; Lisco A, 2012, AM J REPROD IMMUNOL, V68, P515, DOI 10.1111/aji.12015; Marlin R, 2017, J IMMUNOL, V199, P1923, DOI 10.4049/jimmunol.1700320; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Meuleman T, 2015, J REPROD IMMUNOL, V110, P109, DOI 10.1016/j.jri.2015.01.012; Moldenhauer LM, 2010, J IMMUNOL, V185, P7085, DOI 10.4049/jimmunol.1001374; Mudie S, 2014, CELL CYCLE, V13, P3878, DOI 10.4161/15384101.2014.972889; O'Leary S, 2004, REPRODUCTION, V128, P237, DOI 10.1530/rep.1.00160; Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104; PANDYA IJ, 1985, FERTIL STERIL, V43, P417; Petkovic V, 2004, J BIOL CHEM, V279, P23357, DOI 10.1074/jbc.M309283200; Platt CD, 2010, P NATL ACAD SCI USA, V107, P4287, DOI 10.1073/pnas.0910609107; Pudney J, 2005, BIOL REPROD, V73, P1253, DOI 10.1095/biolreprod.105.043133; Robertson SA, 1996, J REPROD FERTIL, V107, P265, DOI 10.1530/jrf.0.1070265; Robertson SA., 1998, PLACENTA, V19, P101, DOI [10.1016/S0143-4004(9880009-X, DOI 10.1016/S0143-4004(9880009-X, DOI 10.1016/S0143-4004(98)80009-X]; Robertson SA, 2009, BIOL REPROD, V80, P1036, DOI 10.1095/biolreprod.108.074658; Robson NC, 2008, BLOOD, V111, P2733, DOI 10.1182/blood-2007-03-080994; Rodriguez-Martinez H, 2011, AM J REPROD IMMUNOL, V66, P11, DOI 10.1111/j.1600-0897.2011.01033.x; Rolland AD, 2013, HUM REPROD, V28, P199, DOI 10.1093/humrep/des360; Salle B, 2010, J INFECT DIS, V202, P337, DOI 10.1086/653619; Schulkens IA, 2014, J VASC RES, V51, P231, DOI 10.1159/000365550; Selva KJ, 2017, AIDS, V31, P333, DOI 10.1097/QAD.0000000000001319; Sharkey DJ, 2007, MOL HUM REPROD, V13, P491, DOI 10.1093/molehr/gam028; Sharkey DJ, 2012, J IMMUNOL, V189, P1024, DOI 10.4049/jimmunol.1200005; Sharkey DJ, 2012, J IMMUNOL, V188, P2445, DOI 10.4049/jimmunol.1102736; Sharkey DJ, 2008, REPROD FERT DEVELOP, V20, P101, DOI [10.1071/SRB08Abs421, DOI 10.1071/SRB08ABS421]; Southern PJ, 2013, TRENDS MICROBIOL, V21, P245, DOI 10.1016/j.tim.2013.02.002; THOMPSON LA, 1992, AM J REPROD IMMUNOL, V28, P85, DOI 10.1111/j.1600-0897.1992.tb00765.x; Wijayarathna R, 2016, HUM REPROD UPDATE, V22, P342, DOI 10.1093/humupd/dmv058	44	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 12	2019	10								430	10.3389/fimmu.2019.00430	http://dx.doi.org/10.3389/fimmu.2019.00430			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO7AA	30915079	Green Published, gold			2022-12-18	WOS:000461084800001
J	Chen, DM; Zhang, ML; Shi, ZQ; Li, CQ; Wang, Q; Song, JP; Xu, Q; Li, H; Zeng, QP				Chen, Dong-Mei; Zhang, Meng-Le; Shi, Zhu-Qing; Li, Chang-Qing; Wang, Qi; Song, Jian-Ping; Xu, Qin; Li, He; Zeng, Qing-Ping			Anti-inflammatory and Anti-infectious Dietary Paradigms May Be Crucial for Visceral Weight Reduction	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						obesity; weight loss; inflammation; infection; nutritional immunology	LOW-CARBOHYDRATE DIETS; CHAIN FATTY-ACID; GUT MICROBIOTA; KETOGENIC DIET; INSULIN-RESISTANCE; OBESITY; INFLAMMATION; INHIBITION; PREVENTS; BARRIER		[Chen, Dong-Mei; Li, Chang-Qing; Song, Jian-Ping; Xu, Qin; Zeng, Qing-Ping] Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou, Guangdong, Peoples R China; [Zhang, Meng-Le; Li, He] Guangdong Pharmaceut Univ, Sch Basic Course, Guangzhou, Guangdong, Peoples R China; [Shi, Zhu-Qing] Guangzhou Univ Chinese Med, Sci & Technol Ind Pk, Guangzhou, Guangdong, Peoples R China; [Wang, Qi] Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangdong Pharmaceutical University; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Zeng, QP (corresponding author), Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou, Guangdong, Peoples R China.	qpzeng@163.com			National Natural Science Foundation of China (NSFC) [81273620, 81774041, 81673861, 81873218]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (NSFC, No. 81273620 and 81774041 to Q-PZ, No. 81673861 to C-QL and 81873218 to J-PS).	Abbasi J, 2018, JAMA-J AM MED ASSOC, V319, P215, DOI 10.1001/jama.2017.20639; Al-Harbi NO, 2018, INT IMMUNOPHARMACOL, V58, P24, DOI 10.1016/j.intimp.2018.02.023; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Bae HR, 2016, ONCOTARGET, V7, P66444, DOI 10.18632/oncotarget.12119; Belei O, 2017, J PEDIATR ENDOCR MET, V30, P1161, DOI 10.1515/jpem-2017-0252; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Brouns F, 2018, EUR J NUTR, V57, P1301, DOI 10.1007/s00394-018-1636-y; Bueno NB, 2013, BRIT J NUTR, V110, P1178, DOI 10.1017/S0007114513000548; Caricilli AM, 2014, CURR OPIN CLIN NUTR, V17, P312, DOI 10.1097/MCO.0000000000000067; Chriett Sabrina, 2015, World J Biol Chem, V6, P223, DOI 10.4331/wjbc.v6.i3.223; Clemente-Postigo M, 2019, AM J PHYSIOL-ENDOC M, V316, pE319, DOI 10.1152/ajpendo.00277.2018; De-Lima JC, 2019, EBIOMEDICINE, V39, P436, DOI 10.1016/j.ebiom.2018.11.041; Deng ZJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00069; Eckel N, 2018, LANCET DIABETES ENDO, V6, P714, DOI 10.1016/S2213-8587(18)30137-2; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; Goss AM, 2017, FASEB J, V31; Grabacka M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122093; Hales CM, 2018, JAMA-J AM MED ASSOC, V319, P1723, DOI 10.1001/jama.2018.3060; Ijssennagger N, 2015, P NATL ACAD SCI USA, V112, P10038, DOI 10.1073/pnas.1507645112; Jarris PE, 2013, J PUBLIC HEALTH MAN, V19, P610, DOI 10.1097/PHH.0b013e3182a8f8c4; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Kimura I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2852; Knudsen KEB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101499; Kotzbeck P, 2018, J LIPID RES, V59, P784, DOI 10.1194/jlr.M079665; Lang F, 2017, KIDNEY BLOOD PRESS R, V42, P483, DOI 10.1159/000479640; Lavie CJ, 2018, LANCET DIABETES ENDO, V6, P678, DOI 10.1016/S2213-8587(18)30143-8; Lee YS, 2014, CELL, V157, P1339, DOI 10.1016/j.cell.2014.05.012; Li C, 2007, OBESITY, V15, P216, DOI 10.1038/oby.2007.505; Li QOY, 2017, ADIPOCYTE, V6, P161, DOI 10.1080/21623945.2017.1297346; Miletta MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107388; Newell C, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0099-3; Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004; Olson CA, 2018, CELL, V173, P1728, DOI [10.1016/j.cell.2018.04.027, 10.1016/j.cell.2018.06.051]; Park Mi-Young, 2016, J Cancer Prev, V21, P95, DOI 10.15430/JCP.2016.21.2.95; Peterson JT, 2007, INT J EXERC SCI, V39, pS373, DOI [10.1249/01.mss.0000274464.50186.ed, DOI 10.1249/01.MSS.0000274464.50186.ED]; Pindjakova J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01157; Rey FE, 2013, P NATL ACAD SCI USA, V110, P13582, DOI 10.1073/pnas.1312524110; Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005; Rothenberg DO, 2018, MOLECULES, V23, DOI 10.3390/molecules23051176; Sellami M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02187; Shen FG, 2016, J AGR FOOD CHEM, V64, P1111, DOI 10.1021/acs.jafc.5b05415; Snodgrass RG, 2016, J BIOL CHEM, V291, P413, DOI 10.1074/jbc.M115.686709; Soro-Arnaiz I, 2016, CELL REP, V16, P2991, DOI 10.1016/j.celrep.2016.08.041; Stefan N, 2018, LANCET DIABETES ENDO, V6, P249, DOI 10.1016/S2213-8587(17)30292-9; Tagliabue A, 2017, CLIN NUTR ESPEN, V17, P33, DOI 10.1016/j.clnesp.2016.11.003; Veech RL, 2017, IUBMB LIFE, V69, P305, DOI 10.1002/iub.1627; Vella CA, 2018, OBES RES CLIN PRACT, V12, P534, DOI 10.1016/j.orcp.2018.08.002; Wang DT, 2015, PEERJ, V3, DOI 10.7717/peerj.822; Wang Q, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01955; World Health Organization (WHO), FACT SHEET OB OV; Xia JY, 2015, CELL METAB, V22, P266, DOI 10.1016/j.cmet.2015.06.007; Ye JZ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01967; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zhao LP, 2018, SCIENCE, V359, P1151, DOI 10.1126/science.aao5774; Zheng XJ, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0462-7	56	1	1	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2019	10								422	10.3389/fimmu.2019.00422	http://dx.doi.org/10.3389/fimmu.2019.00422			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO1VN	30906298	gold, Green Published			2022-12-18	WOS:000460699700001
J	Dwivedi, A; Karulkar, A; Ghosh, S; Rafiq, A; Purwar, R				Dwivedi, Alka; Karulkar, Atharva; Ghosh, Sarbari; Rafiq, Afrin; Purwar, Rahul			Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells (vol 9, pg 3180, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						chimeric antigen receptor; cancer unotherapy; immunoregulation; anti-tumor efficacy; cytokines			[Dwivedi, Alka; Karulkar, Atharva; Ghosh, Sarbari; Rafiq, Afrin; Purwar, Rahul] Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Purwar, R (corresponding author), Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, Maharashtra, India.	purwarrahul@iitb.ac.in						DWIVEDI A, 2019, FRONT IMMUNOL, V9, P3180, DOI DOI 10.3389/(IMMU.2018.03180	1	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2019	10								401	10.3389/fimmu.2019.00401	http://dx.doi.org/10.3389/fimmu.2019.00401			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO1VK	30906295	gold, Green Published			2022-12-18	WOS:000460699300001
J	Milner, JD; Zhu, JF; Paul, M				Milner, Joshua D.; Zhu, Jinfang; Paul, Marilyn			Editorial: Continued Fascination-A Tribute to a Giant in Immunology, Dr. William E. Paul	FRONTIERS IN IMMUNOLOGY			English	Biographical-Item						T cell differentiation; interleukin; William Paul; T cell; B cell			[Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Zhu, Jinfang] NIAID, Lab Immune Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Milner, JD (corresponding author), NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Zhu, JF (corresponding author), NIAID, Lab Immune Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	joshua.milner@nih.gov; jfzhu@niaid.nih.gov; marilyn.paul.58@gmail.com	Zhu, Jinfang/B-7574-2012	Zhu, Jinfang/0000-0002-0117-4745	Intramural Research Program of the NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001169] Funding Source: NIH RePORTER	Intramural Research Program of the NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Intramural Research Program of the NIAID.		0	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2019	10								354	10.3389/fimmu.2019.00354	http://dx.doi.org/10.3389/fimmu.2019.00354			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO1VD	30906292	gold, Green Published			2022-12-18	WOS:000460698600001
J	Bennett, CL; Ambler, CA				Bennett, Clare L.; Ambler, Carrie A.			Editorial: Langerhans Cells and How Skin Pathology Reshapes the Local Immune Environment	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						langherans cells; skin; graft vs. host disease; psoriasis; pathology			[Bennett, Clare L.] UCL, Inst Immun & Transplantat, London, England; [Ambler, Carrie A.] Univ Durham, Biosci Dept, Durham, England	University of London; University College London; Durham University	Bennett, CL (corresponding author), UCL, Inst Immun & Transplantat, London, England.; Ambler, CA (corresponding author), Univ Durham, Biosci Dept, Durham, England.	c.bennett@ucl.ac.uk; c.a.ambler@durham.ac.uk		Ambler, Carrie/0000-0002-2697-7376	BBSRC [BB/L001608/1] Funding Source: UKRI	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Romani N, 2012, J INVEST DERMATOL, V132, P872, DOI 10.1038/jid.2011.437	1	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2019	10								139	10.3389/fimmu.2019.00139	http://dx.doi.org/10.3389/fimmu.2019.00139			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HK6EY	30792712	Green Published, gold			2022-12-18	WOS:000458066600001
J	Zijlstra, JG; van Meurs, M; Moser, J				Zijlstra, Jan G.; van Meurs, Matijs; Moser, Jill			Commentary: Precision Immunotherapy for Sepsis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sepsis; immunotherapy; immunosupression; immunoparalysis; endotypes; hyperinflammtion	IMPROVES BACTERIAL CLEARANCE; INTENSIVE-CARE-UNIT; MORTALITY; PRETREATMENT		[Zijlstra, Jan G.; van Meurs, Matijs; Moser, Jill] Univ Groningen, Dept Crit Care, Univ Med Ctr Groningen, Groningen, Netherlands	University of Groningen	Moser, J (corresponding author), Univ Groningen, Dept Crit Care, Univ Med Ctr Groningen, Groningen, Netherlands.	j.moser@umcg.nl	Moser, Jill/H-8893-2012; Zijlstra, Jan/E-6782-2011	Moser, Jill/0000-0002-9614-2577; Zijlstra, Jan/0000-0001-9079-0795	Department of Critical Care Research Foundation, University Medical Center Groningen	Department of Critical Care Research Foundation, University Medical Center Groningen	This work is supported by the Department of Critical Care Research Foundation, University Medical Center Groningen.	Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Leentjens J, 2012, AM J RESP CRIT CARE, V186, P838, DOI 10.1164/rccm.201204-0645OC; Murphey ED, 2008, SHOCK, V29, P512, DOI 10.1097/SHK.0b013e318150776f; Murphey ED, 2008, MICROBES INFECT, V10, P1244, DOI 10.1016/j.micinf.2008.07.021; Sweeney TE, 2018, CRIT CARE MED, V46, P915, DOI 10.1097/CCM.0000000000003084; van Vught LA, 2017, AM J RESP CRIT CARE, V196, P458, DOI [10.1164/rccm.201606-1225OC, 10.1164/rccm.201606-1225oc]; van Vught LA, 2016, JAMA-J AM MED ASSOC, V315, P1469, DOI 10.1001/jama.2016.2691; Zhang Y, 2010, CRIT CARE, V14, DOI 10.1186/cc9354	9	1	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2019	10								20	10.3389/fimmu.2019.00020	http://dx.doi.org/10.3389/fimmu.2019.00020			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HJ7EV	30766529	Green Published, gold			2022-12-18	WOS:000457358400001
J	Al-Daccak, R; Charron, D				Al-Daccak, Reem; Charron, Dominique			Editorial: Alloimmune Response From Regenerative Medicine	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						stem cells; allogeneic; autologous; bioengineered tissues and organs; immuno-monitoring; stem cells derived extracellular vesicles/exosomes; stem cells repair and regeneration	BENEFIT		[Al-Daccak, Reem; Charron, Dominique] Univ Paris Diderot, Hop St Louis, AP HP, INSERM,UMRS 976, Paris, France; [Al-Daccak, Reem; Charron, Dominique] Labex Transplantex Unistra, Strasbourg, France; [Charron, Dominique] Shanghai Jiao Tong Univ, Shanghai, Peoples R China	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Shanghai Jiao Tong University	Al-Daccak, R (corresponding author), Univ Paris Diderot, Hop St Louis, AP HP, INSERM,UMRS 976, Paris, France.; Al-Daccak, R (corresponding author), Labex Transplantex Unistra, Strasbourg, France.	reem.al-daccak@inserm.fr	Al-Daccak, Reem/L-8804-2018	Al-Daccak, Reem/0000-0002-6146-2845; Charron, Dominique/0000-0001-7689-8038				Al-Daccak R, 2015, TISSUE ANTIGENS, V86, P155, DOI 10.1111/tan.12614; Boukouaci W, 2014, CARDIOVASC RES, V104, P290, DOI 10.1093/cvr/cvu208; Hocine HR, 2017, SCI REP-UK, V7, DOI 10.1038/srep41125; Lauden L, 2013, CIRC RES, V112, P451, DOI 10.1161/CIRCRESAHA.112.276501; Ochando J, 2017, CURR OPIN ORGAN TRAN, V22, P79, DOI 10.1097/MOT.0000000000000378	5	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 18	2019	9								3121	10.3389/fimmu.2018.03121	http://dx.doi.org/10.3389/fimmu.2018.03121			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HH8NP	30713534	Green Published, gold			2022-12-18	WOS:000455989200001
J	Wang, LL; Zhang, W; Lin, LY; Li, X; Saksena, NK; Wu, JH; Wang, SY; Joyce, JG; Zhang, XQ; Yang, HM; Wang, J; Wang, IM; Liu, X				Wang, Longlong; Zhang, Wei; Lin, Liya; Li, Xiao; Saksena, Nitin K.; Wu, Jinghua; Wang, Shiyu; Joyce, Joseph G.; Zhang, Xiuqing; Yang, Huanming; Wang, Jian; Wang, I-Ming; Liu, Xiao			A Comprehensive Analysis of the T and B Lymphocytes Repertoire Shaped by HIV Vaccines (vol 9, 2194, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						HIV; vaccine; T cell receptors repertoire; B cell receptors repertoire; gp41			[Wang, Longlong; Wang, Shiyu; Zhang, Xiuqing] Univ Chinese Acad Sci, BGI Educ Ctr, Shenzhen, Peoples R China; [Wang, Longlong; Zhang, Wei; Lin, Liya; Li, Xiao; Saksena, Nitin K.; Wu, Jinghua; Wang, Shiyu; Zhang, Xiuqing; Yang, Huanming; Wang, Jian; Liu, Xiao] BGI Shenzhen, Shenzhen, Peoples R China; [Wang, Longlong; Zhang, Wei; Lin, Liya; Li, Xiao; Saksena, Nitin K.; Wu, Jinghua; Wang, Shiyu; Liu, Xiao] BGI Shenzhen, China Natl GeneBank, Shenzhen, Peoples R China; [Joyce, Joseph G.; Wang, I-Ming] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Yang, Huanming; Wang, Jian] James D Watson Inst Genome Sci, Hangzhou, Zhejiang, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Beijing Genomics Institute (BGI); Beijing Genomics Institute (BGI); Merck & Company	Liu, X (corresponding author), BGI Shenzhen, Shenzhen, Peoples R China.; Liu, X (corresponding author), BGI Shenzhen, China Natl GeneBank, Shenzhen, Peoples R China.; Wang, IM (corresponding author), Merck & Co Inc, Kenilworth, NJ 07033 USA.	imingwang0828@gmail.com; liuxiao@genomics.cn	Liu, Xiao/P-2732-2015	Liu, Xiao/0000-0002-8073-0534; Zhang, Wei/0000-0002-6968-6974				Wang LL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02194	1	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2018	9								2931	10.3389/fimmu.2018.02931	http://dx.doi.org/10.3389/fimmu.2018.02931			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HE4SB	30588237	Green Published, gold			2022-12-18	WOS:000453355800001
J	Yu, HJ; Liu, Y; Wang, HW; Wan, XY; Huang, JQ; Yan, WM; Xi, D; Luo, XP; Shen, GX; Ning, Q				Yu, Haijing; Liu, Yang; Wang, Hongwu; Wan, Xiaoyang; Huang, Jiaquan; Yan, Weiming; Xi, Dong; Luo, Xiaoping; Shen, Guanxin; Ning, Qin			Clara Cell 10 kDa Protein Alleviates Murine Hepatitis Virus Strain 3-Induced Fulminant Hepatitis by Inhibiting Fibrinogen-Like Protein 2 Expression	FRONTIERS IN IMMUNOLOGY			English	Article						CC10; Fgl2; hepatitis; MHV-3; macrophage	VIRAL-HEPATITIS; 10-KD PROTEIN; TNF-ALPHA; PROTHROMBINASE; FGL2; CONTRIBUTES; ACTIVATION; FGL2/FIBROLEUKIN; TRANSCRIPTION; ASSOCIATION	Background: Fulminant hepatitis (FH) is a serious threat to human life, accompanied by massive and rapid necroinflammation. Kupffer cells, the major immune cell population involved in innate immune responses, are considered to be central for FH. Fibrinogen-like protein 2 (Fgl2) is a pro-coagulant protein that is substantially induced in macrophages upon viral infection, and Fgl2 depletion represses murine hepatitis virus strain 3 (MHV-3) infection. Clara cell 10 kDa (CC10) protein is a secretory protein with anti-inflammatory properties in allergic rhinitis and asthma. However, its mechanisms of action and pathogenic roles in other disease are still unclear. In this study, we aimed to determine the role of CC10 in FH and the regulation of Fgl2 by CC10. Methods: A mouse FH model was established by peritoneal injection of MHV-3. The mice received CC10 protein through tail vein injection before viral infection. Survival rate, liver function, liver histology, fibrin deposition, and necrosis were examined. The regulatory effect of CC10 on Fgl2 expression was investigated using THP-1 cells and mouse peritoneal macrophages in vitro. Results: In the mouse FH model induced by MHV-3, the survival rate increased from 0 to 12.5% in the CC10 group compared to that in the saline-only control group. Meanwhile, the levels of ALT and AST in serum were significantly decreased and liver damage was reduced. Furthermore, hepatic Fgl2, TNF-alpha, and IL-1 beta expression was obviously downregulated together with fibrin deposition, and hepatocyte apoptosis was reduced after administration of CC10 protein. In vitro, CC10 was found to significantly inhibit the expression of Fgl2 in IFN-gamma-treated THP-1 cells and MHV-3-infected mouse peritoneal macrophages by western blot and real-time PCR. However, there was no direct interaction between CC10 and Fgl2 as shown by co-immunoprecipitation. Microarray investigations suggested that HMG-box transcription factor 1 (HBP1) was significantly low in CC10-treated and IFN-gamma-primed THP-1 cells. HBP1-siRNA treatment abrogated the inhibitory effect of CC10 on Fgl2 expression in Human Umbilical Vein Endothelial cells (HUVECs). Conclusion: CC10 protects against MHV-3-induced FH via suppression of Fgl2 expression in macrophages. Such effects may be mediated by the transcription factor HBP1.	[Yu, Haijing; Wang, Hongwu; Wan, Xiaoyang; Huang, Jiaquan; Yan, Weiming; Xi, Dong; Ning, Qin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan, Hubei, Peoples R China; [Liu, Yang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Luo, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pediat, Wuhan, Hubei, Peoples R China; [Shen, Guanxin] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Ning, Q (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan, Hubei, Peoples R China.	qning@vip.sina.com			National Natural Science Foundation of China (NSFC) [81571989, 81500452, 81770982]; Thirteenth Five-Year Plan National Major Science and Technology Special Project on Major Communicable Diseases [2017ZX10202201]; Innovation Team Development Plan of the Ministry of Education [IRT_14R20]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Thirteenth Five-Year Plan National Major Science and Technology Special Project on Major Communicable Diseases; Innovation Team Development Plan of the Ministry of Education	This study was supported by the National Natural Science Foundation of China (NSFC) (81571989, 81500452 and 81770982), the Thirteenth Five-Year Plan National Major Science and Technology Special Project on Major Communicable Diseases (2017ZX10202201), and the Innovation Team Development Plan of the Ministry of Education (IRT_14R20).	Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Benson M, 2007, ALLERGY, V62, P178, DOI 10.1111/j.1398-9995.2006.01264.x; Chen T, 2013, CLIN IMMUNOL, V146, P207, DOI 10.1016/j.clim.2012.12.013; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; Ding JW, 1998, ADV EXP MED BIOL, V440, P609; Guo S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005155; Han MF, 2008, J BIOL CHEM, V283, P32715, DOI 10.1074/jbc.M806769200; Hancock WW, 2004, P NATL ACAD SCI USA, V101, P3005, DOI 10.1073/pnas.0308369101; Levy GA, 2000, AM J PATHOL, V156, P1217, DOI 10.1016/S0002-9440(10)64992-9; Liu JJ, 2015, J HEPATOL, V62, P354, DOI 10.1016/j.jhep.2014.08.050; Liu M, 2001, Expert Rev Mol Med, V2001, P1, DOI 10.1017/S1462399401002812; Liu MF, 2006, J IMMUNOL, V176, P7028, DOI 10.4049/jimmunol.176.11.7028; Liu Y, 2010, CLIN EXP ALLERGY, V40, P1632, DOI 10.1111/j.1365-2222.2010.03549.x; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P387, DOI 10.1016/j.jaci.2012.11.027; Liu Z, 2009, ALLERGY, V64, P149, DOI 10.1111/j.1398-9995.2008.01847.x; Lu YL, 2012, MOL IMMUNOL, V52, P229, DOI 10.1016/j.molimm.2012.05.017; Marsden PA, 2003, J CLIN INVEST, V112, P58, DOI 10.1172/JCI200318114; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Ning Q, 1999, J BIOL CHEM, V274, P9930, DOI 10.1074/jbc.274.15.9930; PARR RL, 1995, J VIROL, V69, P5033, DOI 10.1128/JVI.69.8.5033-5038.1995; Shalev I, 2009, HEPATOLOGY, V49, P387, DOI 10.1002/hep.22684; Sun XH, 2015, MOL CELL BIOCHEM, V403, P139, DOI 10.1007/s11010-015-2344-z; VANVYVE T, 1995, J ALLERGY CLIN IMMUN, V95, P60, DOI 10.1016/S0091-6749(95)70153-2; Wang H, 2013, CURR OPIN ALLERGY CL, V13, P25, DOI 10.1097/ACI.0b013e32835a5b35; Wang H, 2010, AM J RESP CRIT CARE, V181, P908, DOI 10.1164/rccm.200904-0597OC; Wang HW, 2013, J HUAZHONG U SCI-MED, V33, P463, DOI 10.1007/s11596-013-1143-6; Wang XJ, 2014, EXCLI J, V13, P1131; Wang XJ, 2012, CELL IMMUNOL, V280, P76, DOI 10.1016/j.cellimm.2012.11.010; Wu D, 2016, IMMUNOL RES, V64, P518, DOI 10.1007/s12026-015-8727-0; Wu H, 2016, GUT, V65, P1850, DOI 10.1136/gutjnl-2014-308430; Wu ZG, 2010, LIVER INT, V30, P782, DOI 10.1111/j.1478-3231.2010.02262.x; Xi D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082330; Xu GL, 2014, HEPATOLOGY, V60, P114, DOI 10.1002/hep.27114; Zhu CL, 2006, HUM GENE THER, V17, P589, DOI 10.1089/hum.2006.17.589; Zou Y, 2010, J IMMUNOL, V184, P466, DOI 10.4049/jimmunol.0900687	35	1	1	0	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 13	2018	9								2935	10.3389/fimmu.2018.02935	http://dx.doi.org/10.3389/fimmu.2018.02935			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HE4IF	30619295	Green Published, gold			2022-12-18	WOS:000453328900001
J	Pereira, L; Oliveira, F; Townsend, S; Metangmo, S; Meneses, C; Moore, IN; Brodskyn, CI; Valenzuela, JG; Magez, S; Kamhawi, S				Pereira, Lais; Oliveira, Fabiano; Townsend, Shannon; Metangmo, Sonia; Meneses, Claudio; Moore, Ian N.; Brodskyn, Claudia I.; Valenzuela, Jesus G.; Magez, Stefan; Kamhawi, Shaden			Coinfection With Trypanosoma brucei Confers Protection Against Cutaneous Leishmaniasis	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania major; Trypanosoma brucei; coinfection; inflammation; cellular immunity; humoral immunity; cutaneous leishmaniasis; protection	HIV COINFECTION; AFRICAN TRYPANOSOMIASIS; VISCERAL LEISHMANIASIS; CONSEQUENCES; PARASITE; VIRUS; BITES; CELLS	Infection with certain bacteria, parasites, and viruses alters the host immune system to Leishmania major influencing disease outcome. Here, we determined the outcome of a chronic infection with Trypanosoma brucei brucei on cutaneous leishmaniasis (CL) caused by L. major. C57BL/6 mice infected with T. b. brucei were given a sub-curative treatment with diminazene aceturate then coinfected with L. major by vector bites. Our results revealed that infection with T. b. brucei controls CL pathology. Compared to controls, coinfected mice showed a significant decrease in lesion size (P < 0.05) up to 6 weeks post-infection and a significant decrease in parasite burden (P < 0.0001) at 3 weeks post-infection. Protection against L. major resulted from a non-specific activation of T cells by trypanosomes. This induced a strong immune response characterized by IFN-gamma production at the site of bites and systemically, creating a hostile inflammatory environment for L. major parasites and conferring protection from CL.	[Pereira, Lais; Oliveira, Fabiano; Townsend, Shannon; Metangmo, Sonia; Meneses, Claudio; Valenzuela, Jesus G.; Kamhawi, Shaden] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; [Moore, Ian N.] NIAID, Infect Dis Pathogenesis Sect, Comparat Med Branch, NIH, Rockville, MD USA; [Brodskyn, Claudia I.] Fiocruz MS, Lab Interacao Parasita Hospedeito & Epidemiol, Inst Pesquisas Goncalo Moniz, Salvador, BA, Brazil; [Magez, Stefan] Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium; [Magez, Stefan] Ghent Univ Global Campus, Incheon, South Korea; [Pereira, Lais] NIAID, Vaccine Res Ctr, Cellular Immunol Sect, NIH, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fundacao Oswaldo Cruz; Vrije Universiteit Brussel; Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kamhawi, S (corresponding author), NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.	skamhawi@niaid.nih.gov	Brodskyn, Cláudia/AAO-3288-2021; Oliveira, Fabiano/AAG-5388-2019; Magez, Stefan/AAC-5682-2021	Brodskyn, Cláudia/0000-0003-3367-5365; Oliveira, Fabiano/0000-0002-7924-8038; Magez, Stefan/0000-0003-3760-7968; Townsend, Shannon/0000-0001-9171-8031	Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000932] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases.	Adam AOA, 2014, ANN SAUDI MED, V34, P143, DOI 10.5144/0256-4947.2014.143; Aksoy S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005454; Al-Salem W, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1743-7; [Anonymous], 2014, GLOB BRIEF VECT BORN; Budischak SA, 2015, INT J PARASITOL, V45, P455, DOI 10.1016/j.ijpara.2015.02.005; Carvalho BM, 2017, B ENTOMOL RES, V107, P419, DOI 10.1017/S0007485316001097; Cnops J, 2015, PARASITOLOGY, V142, P417, DOI 10.1017/S0031182014001838; Cota GF, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002816; Crosby EJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003970; da Silva RC, 2015, REV SOC BRAS MED TRO, V48, P224, DOI 10.1590/0037-8682-0284-2014; Davarpanah M, 2015, CASE REP INFECT DIS, V2015, DOI 10.1155/2015/563851; Dey R, 2018, CELL HOST MICROBE, V23, P134, DOI 10.1016/j.chom.2017.12.002; Dincer E, 2015, AM J TROP MED HYG, V92, P690, DOI 10.4269/ajtmh.14-0322; Diro E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002869; Dominguez-Pinilla N, 2015, J POSTGRAD MED, V61, P44, DOI 10.4103/0022-3859.147052; Dostalova A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-276; Eckersall PD, 2001, PARASITOL INT, V50, P15, DOI 10.1016/S1383-5769(00)00065-9; Franco JAR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005585; Gomes R, 2012, J INVEST DERMATOL, V132, P2735, DOI 10.1038/jid.2012.205; Griffiths EC, 2011, J INFECTION, V63, P200, DOI 10.1016/j.jinf.2011.06.005; Jennings F W, 1983, Contrib Microbiol Immunol, V7, P147; Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351; Kamhawi S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005529; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Keita M, 1997, EXP PARASITOL, V85, P183, DOI 10.1006/expr.1996.4136; Krawczak FD, 2015, REV SOC BRAS MED TRO, V48, P64, DOI 10.1590/0037-8682-0291-2014; Kuriakose SM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00181; La Flamme AC, 2002, PARASITE IMMUNOL, V24, P339, DOI 10.1046/j.1365-3024.2002.00473.x; Lindoso JAL, 2016, HIV AIDS-RES PALLIAT, V8, P147, DOI 10.2147/HIV.S93789; Lindoso JA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003136; Magez S, 1998, J IMMUNOL, V160, P1949; Monge-Maillo B, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003021; Moore S, 2012, J R SOC INTERFACE, V9, P817, DOI 10.1098/rsif.2011.0654; Nothelfer K, 2015, NAT REV MICROBIOL, V13, P173, DOI 10.1038/nrmicro3415; Pigott DM, 2014, ELIFE, V3, DOI 10.7554/eLife.04395; Radwanska M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000078; Scott P, 2004, IMMUNOL REV, V201, P318, DOI 10.1111/j.0105-2896.2004.00198.x; Serafim TD, 2018, NAT MICROBIOL, V3, P548, DOI 10.1038/s41564-018-0125-7; Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331; Vaumourin E, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1167-9; Wu H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01105	41	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2018	9								2855	10.3389/fimmu.2018.02855	http://dx.doi.org/10.3389/fimmu.2018.02855			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HD9DB	30619253	Green Published, gold			2022-12-18	WOS:000452859900001
J	Smed-Sorensen, A; Oh, DY; Oshiumi, H; Hsu, ACY				Smed-Sorensen, Anna; Oh, Ding Yuan; Oshiumi, Hiroyuki; Hsu, Alan Chen-Yu			Emerging Viruses: Host Immunity and Novel Therapeutic Interventions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						influenza virus; coronavirus; MERS coronavirus; Ebola; Flavivirus; Hantavirus; vaccines; antiviral drugs			[Smed-Sorensen, Anna] Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Immunol & Allergy, Stockholm, Sweden; [Oh, Ding Yuan] Federat Univ, Sch Hlth & Life Sci, Gippsland, Vic, Australia; [Oshiumi, Hiroyuki] Kumamoto Univ, Dept Immunol, Fac Life Sci, Kumamoto, Japan; [Hsu, Alan Chen-Yu] Hunter Med Res Inst, Vaccines & Asthma, Infect Immun, Viruses, Newcastle, NSW, Australia; [Hsu, Alan Chen-Yu] Univ Newcastle, Fac Hlth & Med, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia	Karolinska Institutet; Karolinska University Hospital; Federation University Australia; Kumamoto University; Hunter Medical Research Institute; University of Newcastle; University of Newcastle	Hsu, ACY (corresponding author), Hunter Med Res Inst, Vaccines & Asthma, Infect Immun, Viruses, Newcastle, NSW, Australia.; Hsu, ACY (corresponding author), Univ Newcastle, Fac Hlth & Med, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia.	alan.hsu@newcastle.edu.au	Hsu, Alan/A-3144-2012	Hsu, Alan/0000-0002-6640-0846; Oshiumi, Hiroyuki/0000-0003-1567-8722					0	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2018	9								2828	10.3389/fimmu.2018.02828	http://dx.doi.org/10.3389/fimmu.2018.02828			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HC6OC	30555490	gold, Green Published			2022-12-18	WOS:000451920100002
J	Hunter, KS; Davies, SJ				Hunter, Kasandra S.; Davies, Stephen J.			Host Adaptive Immune Status Regulates Expression of the Schistosome AMP-Activated Protein Kinase	FRONTIERS IN IMMUNOLOGY			English	Article						Schistosoma mansoni; schistosome; adaptive immunity; AMP-activated protein kinase; energy metabolism; development	THERAPEUTIC TARGET; ENERGY HOMEOSTASIS; LIFE-SPAN; MANSONI; MECHANISMS; METFORMIN; DISEASES; PATHWAY; STIMULATION; METABOLISM	Schistosomes exhibit profound developmental adaptations in response to the immune status of their mammalian host, including significant attenuation of parasite growth, development and reproduction in response to deficits in host adaptive immunity. These observations led us to hypothesize that schistosomes regulate the utilization of energy resources in response to immunological conditions within the host. To test this hypothesis, we identified and characterized the Schistosoma mansoni AMP-activated protein kinase (AMPK), a heterotrimeric enzyme complex that is central to regulating energy metabolism at the cellular and organismal level in eukaryotes. We show that expression of the catalytic alpha subunit is developmentally regulated during the parasite life cycle, with peak expression occurring in adult worms. However, the protein is present and phosphorylated in all life cycle stages examined, suggesting a need for active regulation of energy resources throughout the life cycle. In contrast, transcription of the AMPK alpha gene is down-regulated in cercariae and schistosomula, suggesting that the protein in these life cycle stages is pre-synthesized in the sporocyst and that expression must be re-initiated once inside the mammalian host. We also show that schistosome AMPK alpha activity in adult worms is sensitive to changes in the parasite's environment, suggesting a mechanism by which schistosome metabolism may be responsive to host immune factors. Finally, we show that AMPK alpha expression is significantly down-regulated in parasites isolated from immunodeficient mice, suggesting that modulation of parasite energy metabolism may contribute to the attenuation of schistosome growth and reproduction in immunodeficient hosts. These findings provide insights into the molecular interactions between schistosomes and their vertebrate hosts and suggest that parasite energy metabolism may represent a novel target for anti-schistosome interventions.	[Hunter, Kasandra S.; Davies, Stephen J.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Davies, SJ (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA.	stephen.davies@usuhs.edu		Hunter, Kasandra/0000-0001-6343-885X	U.S. Department of Defense/USUHS award [R073305515]	U.S. Department of Defense/USUHS award	This work was supported by U.S. Department of Defense/USUHS award R073305515 to SD.	Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Adenowo AF, 2015, BRAZ J INFECT DIS, V19, P196, DOI 10.1016/j.bjid.2014.11.004; Alexander A, 2011, FEBS LETT, V585, P952, DOI 10.1016/j.febslet.2011.03.010; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160; Bland ML, 2010, DEV BIOL, V344, P293, DOI 10.1016/j.ydbio.2010.05.010; BUEDING E, 1950, J GEN PHYSIOL, V33, P475, DOI 10.1085/jgp.33.5.475; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Coughlan KA, 2014, DIABET METAB SYND OB, V7, P241, DOI 10.2147/DMSO.S43731; Coutinho EM, 2004, MEM I OSWALDO CRUZ, V99, P85, DOI 10.1590/S0074-02762004000900015; Davies SJ, 2003, INT J PARASITOL, V33, P1277, DOI 10.1016/S0020-7519(03)00161-9; Davies SJ, 2001, SCIENCE, V294, P1358, DOI 10.1126/science.1064462; Dawaki S, 2016, REV INST MED TROP SP, V58, DOI 10.1590/S1678-9946201658054; Day EA, 2017, TRENDS ENDOCRIN MET, V28, P545, DOI 10.1016/j.tem.2017.05.004; DOENHOFF MJ, 1986, T ROY SOC TROP MED H, V80, P503, DOI 10.1016/0035-9203(86)90126-4; Egawa M, 2008, PLACENTA, V29, P1003, DOI 10.1016/j.placenta.2008.09.008; Fenwick A, 2012, PUBLIC HEALTH, V126, P233, DOI 10.1016/j.puhe.2011.11.015; Fenwick A, 2003, TRENDS PARASITOL, V19, P509, DOI 10.1016/j.pt.2003.09.005; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Garcia-Salcedo R, 2014, FEBS J, V281, P1901, DOI 10.1111/febs.12753; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hardie DG, 2014, CELL METAB, V20, P939, DOI 10.1016/j.cmet.2014.09.013; Hardie DG, 2013, DIABETES, V62, P2164, DOI 10.2337/db13-0368; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; HARRISON RA, 1983, PARASITOLOGY, V86, P429, DOI 10.1017/S0031182000050629; Hsu JW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8840; Huang SCC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002996; Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537; Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Lamb EW, 2007, INT J PARASITOL, V37, P405, DOI 10.1016/j.ijpara.2006.11.001; Lamb EW, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000892; Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579; Marchler-Bauer A, 2017, NUCLEIC ACIDS RES, V45, pD200, DOI 10.1093/nar/gkw1129; Mbabazi PS, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001396; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; MIKHAIL MM, 1976, CLIN CHIM ACTA, V71, P207, DOI 10.1016/0009-8981(76)90532-5; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; O'Neill HM, 2013, DIABETES METAB J, V37, P1, DOI 10.4093/dmj.2013.37.1.1; Pearce EJ, 2015, CELL MICROBIOL, V17, P796, DOI 10.1111/cmi.12444; Riner DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003708; Roquis D, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003853; Santos TM, 1999, MOL BIOCHEM PARASIT, V103, P79, DOI 10.1016/S0166-6851(99)00100-0; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SHAPIRO TA, 1982, EXP PARASITOL, V54, P379, DOI 10.1016/0014-4894(82)90047-9; Simon GG, 2016, INT J INFECT DIS, V42, P54, DOI 10.1016/j.ijid.2015.11.006; Skelly PJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004246; SKELLY PJ, 1993, MOL BIOCHEM PARASIT, V60, P93, DOI 10.1016/0166-6851(93)90032-S; Sousa-Figueiredo JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033189; Swierczewski BE, 2010, INT J PARASITOL, V40, P929, DOI 10.1016/j.ijpara.2010.01.001; Uno M, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.10; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yao F, 2016, ACTA PHARM SIN B, V6, P20, DOI 10.1016/j.apsb.2015.07.009; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; You H, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00176; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhang CS, 2016, CELL METAB, V24, P521, DOI 10.1016/j.cmet.2016.09.003	61	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2018	9								2699	10.3389/fimmu.2018.02699	http://dx.doi.org/10.3389/fimmu.2018.02699			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HB1TO	30519243	Green Published, gold			2022-12-18	WOS:000450809400001
J	Arbogast, F; Gros, F				Arbogast, Florent; Gros, Frederic			Lymphocyte Autophagy in Homeostasis, Activation, and Inflammatory Diseases (vol 9, 1801, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						autophagy; mitophagy; metabolism; unfolded protein response; autoimmunity; lymphocytes			[Arbogast, Florent; Gros, Frederic] Inst Biol Mol & Cellulaire, CNRS UPR3572, Immunol Immunopathol & Therapeut Chem, Lab Excellence MEDALIS, Strasbourg, France; [Arbogast, Florent; Gros, Frederic] Univ Strasbourg, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gros, F (corresponding author), Inst Biol Mol & Cellulaire, CNRS UPR3572, Immunol Immunopathol & Therapeut Chem, Lab Excellence MEDALIS, Strasbourg, France.; Gros, F (corresponding author), Univ Strasbourg, Strasbourg, France.	f.gros@ibmc-cnrs.unistra.fr	GROS, Frédéric/G-6332-2013	GROS, Frédéric/0000-0002-6252-4323				Arbogast F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01801; Chen M, 2014, NAT MED, V20, P507, DOI 10.1038/nm.3521; Vargas TR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00468-w	3	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2018	9								2627	10.3389/fimmu.2018.02627	http://dx.doi.org/10.3389/fimmu.2018.02627			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HA7OF	30515153	gold, Green Published			2022-12-18	WOS:000450471300001
J	Yang, Z; Liu, X; Sun, ZH; Li, JJ; Tan, WG; Yu, WY; Zhang, MY				Yang, Zheng; Liu, Xi; Sun, Zehua; Li, Jingjing; Tan, Weiguo; Yu, Weiye; Zhang, Meiyun			Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity	FRONTIERS IN IMMUNOLOGY			English	Article						antibody; HIV; ADCC; epitope; gp41; MPER	IMMUNODEFICIENCY-VIRUS TYPE-1; VACCINE EFFICACY TRIAL; MEDIATED CYTOTOXICITY; CONFORMATIONAL EPITOPE; DISEASE PROGRESSION; INFLUENZA-VIRUS; ADCC ACTIVITY; FC-RECEPTOR; NEUTRALIZATION; GP41	Antibody-Dependent Cellular Cytotoxicity (ADCC) is a major mechanism of protection against viral infections in vivo. Identification of HIV-1-specific monoclonal antibodies (mAbs) with potent ADCC activity may help develop an effective HIV-1 vaccine. In present study, we isolated such human mAb, designated E10, from an HIV-1-infected patient sample by single B cell sorting and single cell PCR. E10 bound to gp140 trimer and linear peptides derived from gp41 membrane proximal external region (MPER). E10 epitope (QEKNEQELLEL) overlapped with mAb 2F5 epitope. However, E10 differentiated from 2F5 in neutralization breadth and potency, as well as ADCC activity. E10 showed low neutralization activity and narrow spectrum of neutralization compared to 2F5, but it mediated higher ADCC activity than 2F5 at low antibody concentration. Fine mapping of E10 epitope may potentiate MPER-based subunit vaccine development.	[Yang, Zheng; Tan, Weiguo; Yu, Weiye] Shenzhen Ctr Chron Dis Control, Dept TB Prevent, Shenzhen, Peoples R China; [Yang, Zheng; Li, Jingjing; Zhang, Meiyun] Univ Hong Kong, AIDS Inst, Dept Microbiol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China; [Liu, Xi] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 5, Zhuhai, Peoples R China; [Sun, Zehua] Natl Jewish Hlth, Denver, CO USA	University of Hong Kong; Sun Yat Sen University; National Jewish Health	Yu, WY (corresponding author), Shenzhen Ctr Chron Dis Control, Dept TB Prevent, Shenzhen, Peoples R China.; Zhang, MY (corresponding author), Univ Hong Kong, AIDS Inst, Dept Microbiol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.	yuweiye2002@126.com; zhangmy2014@hotmail.com	Li, Jing/GYU-5036-2022	Yang, Zheng/0000-0003-0217-6694	National Natural Science Foundation of China [31500719, 81672027]; Shenzhen Science and Technology Grant [JCYJ201604273000160, JCYJ20150402111430643, JSGG20140701164558078]; Science and Technology Project of Zhuhai [20161027E030031]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Grant; Science and Technology Project of Zhuhai	This work was funded by the National Natural Science Foundation of China (grant No. 31500719; 81672027), the Shenzhen Science and Technology Grant (grant No. JCYJ201604273000160; JCYJ20150402111430643; JSGG20140701164558078), and the Science and Technology Project of Zhuhai (grant No. 20161027E030031).	Acharya P, 2014, J VIROL, V88, P12895, DOI 10.1128/JVI.02194-14; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; Baum LL, 1996, J IMMUNOL, V157, P2168; Bolhassani A, 2015, IMMUNOL LETT, V168, P366, DOI 10.1016/j.imlet.2015.10.012; Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12; BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; Chung AW, 2011, JAIDS-J ACQ IMM DEF, V58, P127, DOI 10.1097/QAI.0b013e31822c62b9; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Ferrari G, 2017, J INFECT DIS, V215, pS152, DOI 10.1093/infdis/jiw555; Ferrari G, 2011, J VIROL, V85, P7029, DOI 10.1128/JVI.00171-11; Gohain N, 2015, J VIROL, V89, P8840, DOI 10.1128/JVI.01232-15; Gomez-Roman VR, 2005, J IMMUNOL, V174, P2185, DOI 10.4049/jimmunol.174.4.2185; Gustchina E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001182; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433; Hwang KK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090725; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Kunert R, 2004, AIDS RES HUM RETROV, V20, P755, DOI 10.1089/0889222041524571; Lee WS, 2016, J VIROL, V90, P2021, DOI 10.1128/JVI.02717-15; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Luftig MA, 2006, NAT STRUCT MOL BIOL, V13, P740, DOI 10.1038/nsmb1127; Luo M, 2006, VACCINE, V24, P435, DOI 10.1016/j.vaccine.2005.08.006; Mabuka J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002739; Milligan C, 2015, CELL HOST MICROBE, V17, P500, DOI 10.1016/j.chom.2015.03.002; Murray MK, 2015, J VIROL, V89, P10707, DOI 10.1128/JVI.01642-15; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Pollara J, 2013, CURR HIV RES, V11, P378, DOI 10.2174/1570162X113116660059; Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003; Richard J, 2016, EBIOMEDICINE, V12, P208, DOI 10.1016/j.ebiom.2016.09.004; Sabin C, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001195; Shang H, 2011, J BIOL CHEM, V286, P14531, DOI 10.1074/jbc.M111.224527; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; Srivastava V, 2013, J VIROL, V87, P5831, DOI 10.1128/JVI.00273-13; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Sun ZH, 2018, VIRUS RES, V243, P75, DOI 10.1016/j.virusres.2017.10.011; Sun ZH, 2017, J GEN VIROL, V98, P791, DOI 10.1099/jgv.0.000706; Sun ZH, 2015, ANTIVIR RES, V118, P1, DOI 10.1016/j.antiviral.2015.02.006; Sun ZW, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.86; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tolbert WD, 2016, STRUCTURE, V24, P697, DOI 10.1016/j.str.2016.03.005; Tudor D, 2011, AIDS, V25, P751, DOI 10.1097/QAD.0b013e32834507bd; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Wren LH, 2013, IMMUNOLOGY, V138, P116, DOI 10.1111/imm.12016; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126428; Zaritskaya L, 2010, EXPERT REV VACCINES, V9, P601, DOI [10.1586/erv.10.49, 10.1586/ERV.10.49]; Zhang MY, 2008, J VIROL, V82, P6869, DOI 10.1128/JVI.00033-08; Zhang MY, 2010, MABS-AUSTIN, V2, P266, DOI 10.4161/mabs.2.3.11416	54	1	1	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 16	2018	9								2613	10.3389/fimmu.2018.02613	http://dx.doi.org/10.3389/fimmu.2018.02613			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HA7NU	30519238	Green Published, gold			2022-12-18	WOS:000450470100001
J	Foung, SKH; Baumert, TF				Foung, Steven K. H.; Baumert, Thomas F.			Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hepatitis (C) virus; virus neutralization; vaccine; monoclonal abs; epitopes; humoral immunity			[Foung, Steven K. H.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Baumert, Thomas F.] INSERM, U1110, Inst Rech Malad Virales & Hepat, Strasbourg, France; [Baumert, Thomas F.] Univ Strasbourg, Strasbourg, France; [Baumert, Thomas F.] Hop Univ Strasbourg, Inst Hosp Univ, Pole Hepatodigestif, Strasbourg, France; [Baumert, Thomas F.] Inst Univ France, Paris, France	Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut Universitaire de France	Foung, SKH (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.; Baumert, TF (corresponding author), INSERM, U1110, Inst Rech Malad Virales & Hepat, Strasbourg, France.; Baumert, TF (corresponding author), Univ Strasbourg, Strasbourg, France.; Baumert, TF (corresponding author), Hop Univ Strasbourg, Inst Hosp Univ, Pole Hepatodigestif, Strasbourg, France.; Baumert, TF (corresponding author), Inst Univ France, Paris, France.	sfoung@stanford.edu; thomas.baumert@unistra.fr	Baumert, Thomas/ABF-4718-2020	Baumert, Thomas/0000-0002-8864-2168; Foung, Steven/0000-0001-7149-6160	National Institutes of Health [U19AI123862, R21AI126582, R01AI132213, R21CA209940, R03AI131066]; European Union [ERC-AdG-2014-671231-HEPCIR, EU H2020-667273-HEPCAR, FP7 HEPAMAB GAN 305600]; ANR [LABEX ANR-10-LABX-0028_HEPSYS]; ARC, Paris; IHU Strasbourg [TheraHCC IHUARC IHU201301187]; NATIONAL CANCER INSTITUTE [R21CA209940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI123862, R03AI131066, R21AI126582, R01AI132213] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union(European Commission); ANR(French National Research Agency (ANR)); ARC, Paris; IHU Strasbourg; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors acknowledge research support by the National Institutes of Health U19AI123862 (SF and TB), R21AI126582 (SF), R01AI132213 (SF), R21CA209940 (TB), and R03AI131066 (TB). In addition, TB is supported by European Union (ERC-AdG-2014-671231-HEPCIR, EU H2020-667273-HEPCAR, FP7 HEPAMAB GAN 305600), ANR (LABEX ANR-10-LABX-0028_HEPSYS), ARC, Paris and IHU Strasbourg (TheraHCC IHUARC IHU201301187). The authors would like to thank Dr. Florian Wrensch, Inserm U1110 for assisting in manuscript editing.	Baumert TE, 2016, J HEPATOL, V64, P968, DOI 10.1016/j.jhep.2015.12.021; Baumert TF, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0815-7; Chhatwal J, 2016, HEPATOLOGY, V64, P1442, DOI 10.1002/hep.28571; Edlin Brian R, 2016, Lancet Infect Dis, V16, pe196, DOI 10.1016/S1473-3099(16)30005-6; Liang TJ, 2018, NEW ENGL J MED, V378, P1169, DOI 10.1056/NEJMp1716871; Zibbell JE, 2015, MMWR-MORBID MORTAL W, V64, P453	6	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 9	2018	9								2577	10.3389/fimmu.2018.02577	http://dx.doi.org/10.3389/fimmu.2018.02577			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GZ7JB	30473699	gold, Green Published			2022-12-18	WOS:000449653800001
J	Ferreira, CM; Williams, JW; Tong, J; Rayon, C; Blaine, KM; Sperling, AI				Ferreira, Caroline M.; Williams, Jesse W.; Tong, Jiankun; Rayon, Crystal; Blaine, Kelly M.; Sperling, Anne, I			Allergen Exposure in Lymphopenic Fas-Deficient Mice Results in Persistent Eosinophilia Due to Defects in Resolution of Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						Th1/Th2 cells; eosinophils; apoptosis; lung; inflammation; asthma; lymphopenia	RESPIRATORY VIRAL-INFECTIONS; T-CELL APOPTOSIS; AIRWAY INFLAMMATION; IMMUNE-RESPONSES; PERIPHERAL-BLOOD; MURINE MODEL; ASTHMA; EXPRESSION; LYMPHOCYTES; RHINOVIRUS	Asthma is characterized by chronic airway type-2 inflammation and eosinophilia, yet the mechanisms involved in chronic, non-resolving inflammation remain poorly defined. Previously, our group has found that when Rag-deficient mice were reconstituted with Fas-deficient B6 LPR T cells and sensitized and challenged, the mice developed a prolonged type-2-mediated airway inflammation that continued for more than 6 weeks after the last antigen exposure. Surprisingly, no defect in resolution was found when intact B6 LPR mice or T cell specific Fas-conditional knockout mice were sensitized and challenged. We hypothesize that the homeostatic proliferation induced by adoptive transfer of T cells into Rag-deficient mice may be an important mechanism involved in the lack of resolution. To investigate the role of homeostatic proliferation, we induced lymphopenia in the T cell-specific Fas-conditional knockout mice by non-lethal irradiation and sensitized them when T cells began to repopulate. Interestingly, we found that defective Fas signaling on T cells plus antigen exposure during homeostatic proliferation was sufficient to induce prolonged eosinophilic airway inflammation. In conclusion, our data show that the combination of transient lymphopenia, abnormal Fas-signaling, and antigen exposure leads to the development of a prolonged airway eosinophilic inflammatory phase in our mouse model of experimental asthma.	[Ferreira, Caroline M.; Rayon, Crystal; Blaine, Kelly M.; Sperling, Anne, I] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Williams, Jesse W.; Sperling, Anne, I] Univ Chicago, Comm Mol Pathol & Mol Med, Chicago, IL 60637 USA; [Williams, Jesse W.; Tong, Jiankun] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Sperling, Anne, I] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Sperling, AI (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.; Sperling, AI (corresponding author), Univ Chicago, Comm Mol Pathol & Mol Med, Chicago, IL 60637 USA.; Sperling, AI (corresponding author), Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.	asperlin@uchicago.edu	Ferreira, Caroline M/D-3949-2012; Sperling, Anne/ACZ-2351-2022	Williams, Jesse/0000-0003-3815-0891; Sperling, Anne I./0000-0002-4265-9212	AHA [0630292N]; FAPESP [2012/50410-8]; NIH [R01 AI125644]; University of Chicago Cancer Research Center Flow Cytometry Facility [P30-CA14599];  [R01 AI46549]; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI125644, R01AI046549] Funding Source: NIH RePORTER	AHA(American Heart Association); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Chicago Cancer Research Center Flow Cytometry Facility; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to Alexander Chervonsky for providing Fas <SUP>fl/fl</SUP> lck-cre for this study. We also thank The University of Chicago Cancer Research Center Flow Cytometry Facility, Bryan S. Clay and Tamson V. Moore. This work was supported by R01 AI46549 to AS, AHA 0630292N to JT, FAPESP 2012/50410-8 to CF, and NIH R01 AI125644 to AS. The University of Chicago Cancer Research Center Flow Cytometry Facility is supported in part by P30-CA14599.	Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263, DOI 10.1164/ajrccm.160.4.9812025; Ajamian F, 2015, CLIN EXP ALLERGY, V45, P644, DOI 10.1111/cea.12498; ANDERSON LJ, 1985, J INFECT DIS, V151, P626, DOI 10.1093/infdis/151.4.626; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brightling CE, 2004, AM J RESP CRIT CARE, V169, P131, DOI 10.1164/ajrccm.169.1.955; Chen DY, 2017, EXP THER MED, V14, P6222, DOI 10.3892/etm.2017.5297; Criscitiello C, 2016, ONCOTARGET, V7, P51184, DOI 10.18632/oncotarget.9966; De Rose V, 2004, J LEUKOCYTE BIOL, V76, P423, DOI 10.1189/jlb.0503247; Desvignes L, 2009, IMMUNITY, V31, P974, DOI 10.1016/j.immuni.2009.10.007; Faustino L, 2014, MUCOSAL IMMUNOL, V7, P1199, DOI 10.1038/mi.2014.9; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Fortner KA, 2017, J AUTOIMMUN, V82, P47, DOI 10.1016/j.jaut.2017.05.003; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; Hamzaoui A, 1999, MEDIAT INFLAMM, V8, P237, DOI 10.1080/09629359990405; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; HIRSCH RL, 1984, CLIN IMMUNOL IMMUNOP, V31, P1, DOI 10.1016/0090-1229(84)90184-3; Holtzman MJ, 2000, APOPTOSIS, V5, P459, DOI 10.1023/A:1009657321461; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Jayaraman S, 1999, J IMMUNOL, V162, P1717; Kantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044; Kelly JT, 2008, J ALLERGY CLIN IMMUN, V122, P671, DOI 10.1016/j.jaci.2008.08.013; Kodama T, 1998, CLIN EXP ALLERGY, V28, P1435; Koetz K, 2000, P NATL ACAD SCI USA, V97, P9203, DOI 10.1073/pnas.97.16.9203; Kopf M, 1995, IMMUNOL REV, V148, P45, DOI 10.1111/j.1600-065X.1995.tb00093.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Martorano LM, 2018, EUR J IMMUNOL, V48, P407, DOI 10.1002/eji.201747052; McClain MT, 2013, J CLIN VIROL, V58, P689, DOI 10.1016/j.jcv.2013.09.015; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Min B, 2004, P NATL ACAD SCI USA, V101, P3874, DOI 10.1073/pnas.0400606101; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Sharma SK, 2012, ALLERGY, V67, P328, DOI 10.1111/j.1398-9995.2011.02763.x; SMITH RP, 1993, LANCET, V341, P772, DOI 10.1016/0140-6736(93)90555-U; Spinozzi F, 1998, ANN INTERN MED, V128, P363, DOI 10.7326/0003-4819-128-5-199803010-00004; Stranges PB, 2007, IMMUNITY, V26, P629, DOI 10.1016/j.immuni.2007.03.016; Takeda K, 2015, J ALLERGY CLIN IMMUN, V135, P451, DOI 10.1016/j.jaci.2014.08.014; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tesciuba AG, 2001, J IMMUNOL, V167, P1996, DOI 10.4049/jimmunol.167.4.1996; Tong JK, 2006, J EXP MED, V203, P1173, DOI 10.1084/jem.20051680; Tong JK, 2010, AM J RESP CELL MOL, V43, P342, DOI 10.1165/rcmb.2008-0454OC; Tumes DJ, 2008, MOL IMMUNOL, V45, P3609, DOI 10.1016/j.molimm.2008.05.002; Tumpey TM, 2000, J VIROL, V74, P6105, DOI 10.1128/JVI.74.13.6105-6116.2000; Vignola AM, 2000, APOPTOSIS, V5, P473, DOI 10.1023/A:1009661406440; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Yang PL, 2010, P NATL ACAD SCI USA, V107, P798, DOI 10.1073/pnas.0913498107; Yang W, 2011, J MOL MED, V89, P399, DOI 10.1007/s00109-010-0711-5; Yao YA, 2012, J INTERF CYTOK RES, V32, P534, DOI 10.1089/jir.2012.0016; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	51	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2018	9								2395	10.3389/fimmu.2018.02395	http://dx.doi.org/10.3389/fimmu.2018.02395			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GY5XR	30425708	gold, Green Published			2022-12-18	WOS:000448657800001
J	Bernard, I; Sacquin, A; Kassem, S; Benamar, M; Colacios, C; Gador, M; Perals, C; Fazilleau, N; Saoudi, A				Bernard, Isabelle; Sacquin, Antoine; Kassem, Sahar; Benamar, Mehdi; Colacios, Celine; Gador, Mylene; Perals, Corine; Fazilleau, Nicolas; Saoudi, Abdelhadi			A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire	FRONTIERS IN IMMUNOLOGY			English	Article						myasthenia gravis; T cells; Vav1; animal models; T cell repertoire	EXCHANGE FACTOR VAV; IFN-GAMMA; POLYMORPHISM; AUTOANTIBODIES; ASSOCIATION; EXPRESSION; SELECTION; IL-17; RISK; GENE	The guanine nucleotide exchange factor Vav1 is essential for transducing T cell receptor (TCR) signals and plays an important role in T cell development and activation. Previous genetic studies identified a natural variant of Vav1 characterized by the substitution of an arginine (R) residue by a tryptophane (W) at position 63 (Vav1(R63W)). This variant impacts Vav1 adaptor functions and controls susceptibility to T cell-mediated neuroinflammation. To assess the implication of this Vav1 variant on the susceptibility to antibody-mediated diseases, we used the animal model of myasthenia gravis, experimental autoimmune myasthenia gravis (EAMG). To this end, we generated a knock-in (KI) mouse model bearing a R to W substitution in the Vav1 gene (Vav1R63W) and immunized it with either torpedo acetylcholine receptor (tAChR) or the alpha 146-162 immunodominant peptide. We observed that the Vav1(R63W) conferred increased susceptibility to EAMG, revealed by a higher AChR loss together with an increased production of effector cytokines (IFN-gamma, IL-17A, GM-CSF) by antigen-specific CD4(+) T cells, as well as an increased frequency of antigen-specific CD4(+) T cells. This correlated with the emergence of a dominant antigen-specific T cell clone in KI mice that was not present in wild-type mice, suggesting an impact on thymic selection and/or a different clonal selection threshold following antigen encounter. Our results highlight the key role of Vav1 in the pathophysiology of EAMG and this was associated with an impact on the TCR repertoire of AChR reactive T lymphocytes.	[Bernard, Isabelle; Sacquin, Antoine; Kassem, Sahar; Benamar, Mehdi; Colacios, Celine; Gador, Mylene; Perals, Corine; Fazilleau, Nicolas; Saoudi, Abdelhadi] Univ Toulouse, CNRS, INSERM, UPS,Ctr Physiopathol Toulouse Purpan, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Saoudi, A (corresponding author), Univ Toulouse, CNRS, INSERM, UPS,Ctr Physiopathol Toulouse Purpan, Toulouse, France.	abdelhadi.saoudi@inserm.fr	SAOUDI, Abdelhadi/K-6719-2014; Colacios, Céline clc/P-2646-2014; Fazilleau, Nicolas/J-9883-2014	SAOUDI, Abdelhadi/0000-0001-7015-8178; Colacios, Céline clc/0000-0002-7509-0675; Benamar, Mehdi/0000-0003-1532-8642; Kassem, Sahar/0000-0001-9353-2927; Bernard, Isabelle/0000-0002-5847-1281; Fazilleau, Nicolas/0000-0002-3574-5614	INSERM; Fight-MG [FP7-Health-2009-242210]; Agence Nationale de la Recherche; Aninfimip; EquipEx program (Equipement d'Excellence) - French government through the Investments for the Future program [ANR-11-EQPX-0003]; Centre National de la Recherche Scientifique; Association Francaise contre les Myopathies	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fight-MG; Agence Nationale de la Recherche(French National Research Agency (ANR)); Aninfimip; EquipEx program (Equipement d'Excellence) - French government through the Investments for the Future program; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	We sincerely thank Anne S. Dejean, Anne Astier, Daniel Dunia and Roland Liblau for their helpful suggestions and Bernard Malissen for generating the Vav1R63W KI mice. We acknowledge the technical assistance provided by the personnel of Inserm US006 Anexplo/creffre animal facility. Flow cytometry experiments have been done at the CPTP-INSERM U1043 core facility connected to Toulouse Reseau Imagerie network. We thank Fatima-Ezzahra L'Faqihi, Valerie Duplan and Anne-Laure Iscache for technical assistance and/or for cell sorting. This work was supported by INSERM, Association Francaise contre les Myopathies, Fight-MG (FP7-Health-2009-242210), the Agence Nationale de la Recherche and the Aninfimip, an EquipEx program (Equipement d'Excellence) supported by the French government through the Investments for the Future program (ANR-11-EQPX-0003). AS is supported by Centre National de la Recherche Scientifique.	Aguilo-Seara G, 2017, CYTOKINE, V96, P279, DOI 10.1016/j.cyto.2017.05.008; Avidan N, 2014, ANN CLIN TRANSL NEUR, V1, P329, DOI 10.1002/acn3.51; Balasa B, 1997, J EXP MED, V186, P385, DOI 10.1084/jem.186.3.385; Berrih-Aknin S, 2014, J AUTOIMMUN, V48-49, P143, DOI 10.1016/j.jaut.2014.01.003; Cao YH, 2016, J IMMUNOL, V196, P2075, DOI 10.4049/jimmunol.1501339; Chuang WY, 2005, ANN NEUROL, V58, P644, DOI 10.1002/ana.20577; Colacios C, 2011, J EXP MED, V208, P2183, DOI 10.1084/jem.20102191; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Delpy L, 2005, J IMMUNOL, V175, P5050, DOI 10.4049/jimmunol.175.8.5050; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Giraud M, 2008, ANN NY ACAD SCI, V1132, P180, DOI 10.1196/annals.1405.027; Gregersen PK, 2012, ANN NEUROL, V72, P927, DOI 10.1002/ana.23691; Greve B, 2009, HUM IMMUNOL, V70, P540, DOI 10.1016/j.humimm.2009.04.027; Guerreiro-Cacais AO, 2017, GENES IMMUN, V18, P48, DOI 10.1038/gene.2016.49; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; Huang DR, 2001, EUR J IMMUNOL, V31, P225, DOI 10.1002/1521-4141(200101)31:1<225::AID-IMMU225>3.3.CO;2-S; Jagodic M, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000278; Jorritsma PJ, 2003, J IMMUNOL, V170, P2427, DOI 10.4049/jimmunol.170.5.2427; Kassem S, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006185; Kordas G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108327; Lindstrom J, 1981, Methods Enzymol, V74 Pt C, P432; Liu XL, 2004, NAT IMMUNOL, V5, P280, DOI 10.1038/ni1040; Moiola M, 1998, EUR J IMMUNOL, V28, P2487, DOI 10.1002/(SICI)1521-4141(199808)28:08<2487::AID-IMMU2487>3.0.CO;2-Y; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; Pevzner A, 2012, J NEUROL, V259, P427, DOI 10.1007/s00415-011-6194-7; Phillips William D, 2016, F1000Res, V5, DOI 10.12688/f1000research.8206.1; Renton AE, 2015, JAMA NEUROL, V72, P396, DOI 10.1001/jamaneurol.2014.4103; Roche JC, 2011, MUSCLE NERVE, V44, P278, DOI 10.1002/mus.22070; Saoudi A, 1999, J IMMUNOL, V162, P7189; Saveliev A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000420; Schaffert H, 2015, EUR J IMMUNOL, V45, P1339, DOI 10.1002/eji.201445064; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tubo NJ, 2014, TRENDS IMMUNOL, V35, P591, DOI 10.1016/j.it.2014.09.008; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; van Panhuys N, 2014, IMMUNITY, V41, P63, DOI 10.1016/j.immuni.2014.06.003; Vandiedonck C, 2006, ANN NEUROL, V59, P404, DOI 10.1002/ana.20751; Vincent A, 2002, NAT REV IMMUNOL, V2, P797, DOI 10.1038/nri916; Wang W, 2004, J IMMUNOL, V172, P97, DOI 10.4049/jimmunol.172.1.97; Wang XB, 2002, GENES IMMUN, V3, P46, DOI 10.1038/sj.gene.6363816; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yamane H, 2013, IMMUNOL REV, V252, P12, DOI 10.1111/imr.12032; Zhang B, 2012, ARCH NEUROL-CHICAGO, V69, P445, DOI 10.1001/archneurol.2011.2393; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	45	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2018	9								2399	10.3389/fimmu.2018.02399	http://dx.doi.org/10.3389/fimmu.2018.02399			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GY0TL	30410484	Green Published, gold			2022-12-18	WOS:000448234400001
J	de Bree, LCJ; Marijnissen, RJ; Kel, JM; Huber, SKR; Aaby, P; Benn, CS; Wijnands, MVW; Diavatopoulos, DA; van Crevel, R; Joosten, LAB; Netea, MG; Dulos, J				de Bree, L. Charlotte J.; Marijnissen, Renoud J.; Kel, Junda M.; Huber, Sietske K. Rosendahl; Aaby, Peter; Benn, Christine Stabell; Wijnands, Marcel V. W.; Diavatopoulos, Dimitri A.; van Crevel, Reinout; Joosten, Leo A. B.; Netea, Mihai G.; Dulos, John			Bacillus Calmette-Guerin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice (vol 9, 869, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						avian influenza A/Anhui/1/2013 (H7N9); bacillus Calmette-Guerin; trained immunity; innate immune memory; oseltamivir			[de Bree, L. Charlotte J.; van Crevel, Reinout; Joosten, Leo A. B.; Netea, Mihai G.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands; [de Bree, L. Charlotte J.; Diavatopoulos, Dimitri A.; van Crevel, Reinout; Joosten, Leo A. B.; Netea, Mihai G.] Radboud Univ Nijmegen, Radboud Ctr Infect Dis RCI, Med Ctr, Nijmegen, Netherlands; [de Bree, L. Charlotte J.; Aaby, Peter; Benn, Christine Stabell] Statens Serum Inst, Res Ctr Vitamins & Vaccines, Bandim Hlth Project, Copenhagen, Denmark; [de Bree, L. Charlotte J.; Benn, Christine Stabell] Univ Southern Denmark, Odense Patient Data Explorat Network, Odense Univ Hosp, Odense, Denmark; [Marijnissen, Renoud J.; Kel, Junda M.; Huber, Sietske K. Rosendahl; Wijnands, Marcel V. W.] Triskelion BV, Dept Immunol, Zeist, Netherlands; [Diavatopoulos, Dimitri A.] Radboud Univ Nijmegen, Med Ctr, Lab Pediat Infect Dis, Radboud Inst Mol Life Sci, Nijmegen, Netherlands; [Netea, Mihai G.] Univ Bonn, Dept Genom & Immunoregulat, Life & Med Sci Inst LIMES, Bonn, Germany; [Dulos, John] Aduro Biotech Europe, Oss, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Statens Serum Institut; University of Southern Denmark; Odense University Hospital; Radboud University Nijmegen; University of Bonn	Marijnissen, RJ (corresponding author), Triskelion BV, Dept Immunol, Zeist, Netherlands.	rjmarijnissen@gmail.com	Netea, Mihai/N-5155-2014; Joosten, Leo AB/H-3138-2015; Diavatopoulos, Dimitri A/L-4269-2015	Joosten, Leo AB/0000-0001-6166-9830; Diavatopoulos, Dimitri A/0000-0001-7065-7807				de Bree CLCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00869	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2018	9								2471	10.3389/fimmu.2018.02471	http://dx.doi.org/10.3389/fimmu.2018.02471			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GY0TF	30393473	Green Published, gold			2022-12-18	WOS:000448233800001
J	Hegen, H; Walde, J; Bsteh, G; Auer, M; Wurth, S; Zinganell, A; Di Pauli, F; Deisenhammer, F; Berger, T				Hegen, Harald; Walde, Janette; Bsteh, Gabriel; Auer, Michael; Wurth, Sebastian; Zinganell, Anne; Di Pauli, Franziska; Deisenhammer, Florian; Berger, Thomas			Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						JC virus; anti-JCV antibody index; natalizumab; interferon beta; glatiramer acetate; multiple sclerosis; seroconversion; longitudinal	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIRUS SEROPREVALENCE; RISK STRATIFICATION; COHORT; PLASMA; SERUM	Background: Risk of natalizumab-related progressive multifocal leukoencephalopathy is associated with the presence of anti-JC-virus (JCV) antibodies. Objective: To investigate the impact of disease-modifying treatments (DMT) on the longitudinal evolution of anti-JCV antibody index. Methods: Patients with multiple sclerosis who had serum sampling at intervals of 6 +/- 3 months over up to 6 years and who either started DMT (interferon-beta, glatiramer acetate or natalizumab) during the observation period with at least one serum sample available before and after treatment initiation or received no DMT during the observation period were included. Anti-JCV antibody serological status and index were determined by 2-step second-generation anti-JCV antibody assay. Results: A total of 89 patients were followed for a median time of 55.2 months. Of those, 62 (69.7%) started DMT and 27 (30.3%) were without therapy during the observation period. Variation of longitudinal anti-JCV antibody index ranged from 9 to 15% and was similar in patients with and without DMT. Applying a mixed model considering the combined effects of treatment and time as well as individual heterogeneity did not show a significant change of anti-JCV antibody index by the start of treatment with interferon-b, glatiramer acetate, or natalizumab. Conclusion: Evaluated DMTs do not impact longitudinal anti-JCV antibody index evolution.	[Hegen, Harald; Bsteh, Gabriel; Auer, Michael; Wurth, Sebastian; Zinganell, Anne; Di Pauli, Franziska; Deisenhammer, Florian; Berger, Thomas] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Walde, Janette] Univ Innsbruck, Fac Econ & Stat, Dept Stat, Innsbruck, Austria	Medical University of Innsbruck; University of Innsbruck	Berger, T (corresponding author), Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria.	thomas.berger@i-med.ac.at	Walde, Janette/HCH-4003-2022	Walde, Janette/0000-0002-1241-5292	Biogen	Biogen(Biogen)	The study was supported by Biogen.	Aladro Y, 2016, J NEUROL SCI, V365, P16, DOI 10.1016/j.jns.2016.03.050; Alroughani R, 2016, J NEUROL SCI, V360, P61, DOI 10.1016/j.jns.2015.11.044; Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829; Bozic C, 2011, ANN NEUROL, V70, P713, DOI 10.1002/ana.22606; Correia I, 2017, J CLIN NEUROSCI, V45, P257, DOI 10.1016/j.jocn.2017.08.006; Dominguez-Mozo MI, 2017, EUR J CLIN INVEST, V47, P158, DOI 10.1111/eci.12721; Gorelik L, 2010, ANN NEUROL, V68, P295, DOI 10.1002/ana.22128; Hegen H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174005; Kolasa M, 2016, ACTA NEUROL SCAND, V133, P391, DOI 10.1111/ane.12475; Lee P, 2013, J CLIN VIROL, V57, P141, DOI 10.1016/j.jcv.2013.02.002; Olsson T, 2013, MULT SCLER J, V19, P1533, DOI 10.1177/1352458513477925; Plavina T, 2014, ANN NEUROL, V76, P802, DOI 10.1002/ana.24286; R Core Team, LANG ENV STAT COMP; Raffel J, 2015, MULT SCLER J, V21, P1833, DOI 10.1177/1352458515599681; Salmen A, 2016, Mult Scler J Exp Transl Clin, V2, p2055217316630008, DOI 10.1177/2055217316630008; Schwab N, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000195; Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5; Trampe AK, 2012, NEUROLOGY, V78, P1736, DOI 10.1212/WNL.0b013e3182583022; Vennegoor A, 2016, EUR J NEUROL, V23, P1079, DOI 10.1111/ene.12988	19	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2018	9								2435	10.3389/fimmu.2018.02435	http://dx.doi.org/10.3389/fimmu.2018.02435			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GY0TM	30410486	Green Published, gold			2022-12-18	WOS:000448234500001
J	Saxena, A; Dagur, PK; Desai, A; Mccoy, JP				Saxena, Ankit; Dagur, Pradeep K.; Desai, Alisha; McCoy, John Philip, Jr.			Ultrasensitive Quantification of Cytokine Proteins in Single Lymphocytes From Human Blood Following ex-vivo Stimulation	FRONTIERS IN IMMUNOLOGY			English	Article						IFN-gamma; TNF-alpha; T cell; SiMoA; flow cytometry	MOLECULE SENSITIVITY; CELL TECHNOLOGIES; T-CELLS; EXPRESSION; SURFACE; HETEROGENEITY; TRANSCRIPTOME; SYSTEM; CD4	In this study we demonstrate the feasibility of direct, quantitative measurement of cytokine proteins in single human CD8 lymphocytes from fresh peripheral blood of healthy donors following a brief ex vivo stimulation. Cytokine-secreting cells were identified using cell surface "catch" reagents and single cell data were obtained by sorting of individual cytokine-secreting cells into 96 well plates containing lysis buffer followed by analysis using ultrasensitive immunoassays for interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha). CD8 cells negative for cytokine production, as determined by the cell surface catch reagents were used as negative controls. Furthermore, studies were undertaken to compare the mean fluorescence intensity (MFI) values of cytokine staining by flow cytometry with the quantification of cytokines using the current method. This study demonstrates that it is feasible to quantify cytokines from individual primary cells. A shift from qualitative to quantitative determinations of cytokine protein levels in single cells will permit more precise and reproducible studies of heterogeneity in the immune system and can be accomplished with readily available instrumentation.	[Saxena, Ankit; Dagur, Pradeep K.; Desai, Alisha; McCoy, John Philip, Jr.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Mccoy, JP (corresponding author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.	mccoyjp@mail.nih.gov	mccoy, john philip/ABD-9348-2021		Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZICHL005905] Funding Source: NIH RePORTER	Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding for this study was provided by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.	Abbaspourrad A, 2015, SCI REP-UK, V5, DOI 10.1038/srep12756; ANDERSON SJ, 1993, J IMMUNOL, V151, P5123; Andreasson U, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00179; Bueno C, 2002, J IMMUNOL METHODS, V264, P77, DOI 10.1016/S0022-1759(02)00083-2; Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; Chen X, 2016, NAT BIOTECHNOL, V34, P1111, DOI 10.1038/nbt.3721; Cheng Y, 2016, ADV IMMUNOL, V131, P101, DOI 10.1016/bs.ai.2016.02.002; Cheow LF, 2016, NAT METHODS, V13, P833, DOI 10.1038/nmeth.3961; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Hoppe PS, 2014, NAT CELL BIOL, V16, P919, DOI 10.1038/ncb3042; Huang B, 2007, SCIENCE, V315, P81, DOI 10.1126/science.1133992; Klein CA, 2002, NAT BIOTECHNOL, V20, P387, DOI 10.1038/nbt0402-387; Li JJ, 2015, SCIENCE, V347, P1066, DOI 10.1126/science.aaa8332; Lo CA, 2015, CELL REP, V13, P2634, DOI 10.1016/j.celrep.2015.11.048; Ma C, 2011, NAT MED, V17, P738, DOI 10.1038/nm.2375; O'Neil-Andersen NJ, 2002, CLIN DIAGN LAB IMMUN, V9, P243, DOI 10.1128/CDLI.9.2.243-250.2001; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; Proserpio V, 2016, IMMUNOLOGY, V147, P133, DOI 10.1111/imm.12553; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; Satija R, 2014, TRENDS IMMUNOL, V35, P219, DOI 10.1016/j.it.2014.03.004; Schubert SM, 2016, ANAL CHEM, V88, P2952, DOI 10.1021/acs.analchem.6b00146; Taniguchi Y, 2010, SCIENCE, V329, P533, DOI 10.1126/science.1188308; Thompson AM, 2014, ANAL CHEM, V86, P12308, DOI 10.1021/ac5035924; Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580; Zhu H, 2009, ANAL CHEM, V81, P8150, DOI 10.1021/ac901390j	27	1	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2018	9								2462	10.3389/fimmu.2018.02462	http://dx.doi.org/10.3389/fimmu.2018.02462			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX7RV	30405640	gold, Green Published			2022-12-18	WOS:000447974300001
J	Srdic-Rajic, T; Kohler, H; Jurisic, V; Metlas, R				Srdic-Rajic, Tatjana; Kohler, Heinz; Jurisic, Vladimir; Metlas, Radmila			Antibody Epitope Specificity for dsDNA Phosphate Backbone Is an Intrinsic Property of the Heavy Chain Variable Germline Gene Segment Used	FRONTIERS IN IMMUNOLOGY			English	Article						anti-DNA antibodies; anti-PC antibodies; VH germline genes; Characterization of antibody specificity by ISM; dsDNA reactive antibodies	COMPLEMENTARITY-DETERMINING REGION; DNA ANTIBODIES; SOMATIC MUTATION; IMMUNE-RESPONSE; T15 IDIOTYPE; CANONICAL STRUCTURES; STRANDED-DNA; BINDING; PHOSPHORYLCHOLINE; AUTOANTIBODIES	Analysis of protein sequences by the informational spectrum method (ISM) enables characterization of their specificity according to encoded information represented with defined frequency (F). Our previous data showed that F(0.367) is characteristic for variable heavy chain (VH) domains (a combination of variable (V), diversity (D) and joining (J) gene segments) of the anti-phosphocholine (PC) T15 antibodies and mostly dependent on the CDR2 region, a site for PC phosphate group binding. Because the T15 dsDNA-reactive U4 mutant also encodes F(0.367), we hypothesized that the same frequency may also be characteristic for anti-DNA antibodies. Data obtained from an analysis of 60 spontaneously produced anti-DNA antibody VH domain sequences supported our hypothesis only for antibodies, which use V gene segment in germline configuration, such as S57(VH31), MRL-DNA22, and VH11, members of the VH1 (J558) and VH7 (S107) gene families. The important finding is that out of seven V gene segments used by spontaneous anti-DNA antibodies, F(0.367) is only expressed by the germline configuration of these three V gene segments. The data suggest that antibody specificity for the phosphate group moiety delineated as F(0.367) is the intrinsic property of the V germline gene segments used, whereas paratope/epitope interaction with antigens bearing this epitope, such as PC or dsDNA, requires corresponding antibody VH conformation that is susceptible to somatic mutation(s).	[Srdic-Rajic, Tatjana] Natl Canc Res Ctr, Dept Expt Pharmacol, Belgrade, Serbia; [Kohler, Heinz] Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; [Jurisic, Vladimir] Univ Kragujevac, Fac Med Sci, Kragujevac, Serbia; [Metlas, Radmila] Univ Belgrade, Vinca Inst Nucl Sci, Belgrade, Serbia	University of Kentucky; University of Kragujevac; University of Belgrade	Metlas, R (corresponding author), Univ Belgrade, Vinca Inst Nucl Sci, Belgrade, Serbia.	metlas.r@sbb.rs	Jurisic, Vladimir/H-7452-2019; Srdic-Rajic, Tatjana/P-2552-2018	Jurisic, Vladimir/0000-0001-6525-128X; Srdic-Rajic, Tatjana/0000-0001-9840-6970	Ministry of Education, Science and Technological Development of the Republic of Serbia [175056]	Ministry of Education, Science and Technological Development of the Republic of Serbia	This work was supported by a grant from the Ministry of Education, Science and Technological Development of the Republic of Serbia (Grant No. 175056).	AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ANDRES CM, 1981, J EXP MED, V154, P1584, DOI 10.1084/jem.154.5.1584; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; Chang S, 2009, MOL IMMUNOL, V46, P3420, DOI 10.1016/j.molimm.2009.07.014; CHEN C, 1992, J EXP MED, V176, P855, DOI 10.1084/jem.176.3.855; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; CLAFLIN JL, 1974, J EXP MED, V139, P58, DOI 10.1084/jem.139.1.58; CLARKE SH, 1982, P NATL ACAD SCI-BIOL, V79, P3280, DOI 10.1073/pnas.79.10.3280; COSIC I, 1994, IEEE T BIO-MED ENG, V41, P1101, DOI 10.1109/10.335859; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; Detanico T, 2015, J AUTOIMMUN, V58, P67, DOI 10.1016/j.jaut.2015.01.006; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; EILAT D, 1988, J IMMUNOL, V141, P1745; FUNG J, 1980, J EXP MED, V152, P1262, DOI 10.1084/jem.152.5.1262; Guth AM, 2003, J IMMUNOL, V171, P6260, DOI 10.4049/jimmunol.171.11.6260; Holodick NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00872; ISENBERG DA, 1994, ARTHRITIS RHEUM-US, V37, P169, DOI 10.1002/art.1780370204; Jang YJ, 2003, CELL MOL LIFE SCI, V60, P309, DOI 10.1007/s000180300026; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KATZ MS, 1993, J CLIN INVEST, V91, P402, DOI 10.1172/JCI116214; KOFLER R, 1988, J CLIN INVEST, V82, P852, DOI 10.1172/JCI113689; KOHLER H, 1975, TRANSPLANT REV, V27, P24; Kohler H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00106; LAFER EM, 1981, J EXP MED, V153, P897, DOI 10.1084/jem.153.4.897; Li ZD, 2000, EUR J IMMUNOL, V30, P2015, DOI 10.1002/1521-4141(200007)30:7<2015::AID-IMMU2015>3.0.CO;2-5; Liang ZY, 2009, MOL IMMUNOL, V46, P2671, DOI 10.1016/j.molimm.2008.12.034; LIEBERMAN R, 1974, J EXP MED, V139, P983, DOI 10.1084/jem.139.4.983; Maranhao AQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072625; Metlas R, 2018, IMMUNOL LETT, V200, P52, DOI 10.1016/j.imlet.2018.07.002; Nguyen TTT, 2016, CRIT REV IMMUNOL, V36, P163, DOI 10.1615/CritRevImmunol.2016018175; OHNO S, 1985, P NATL ACAD SCI USA, V82, P2945, DOI 10.1073/pnas.82.9.2945; PADLAN EA, 1976, IMMUNOCHEMISTRY, V13, P945, DOI 10.1016/0019-2791(76)90239-1; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Rekvig OP, 2015, NAT REV RHEUMATOL, V11, P530, DOI 10.1038/nrrheum.2015.69; RUDIKOFF S, 1976, P NATL ACAD SCI USA, V73, P2109, DOI 10.1073/pnas.73.6.2109; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SIGAL NH, 1977, J EXP MED, V146, P933, DOI 10.1084/jem.146.4.933; Srdic-Rajic T, 2013, INT IMMUNOL, V25, P345, DOI 10.1093/intimm/dxs156; TILLMAN DM, 1992, J EXP MED, V176, P761, DOI 10.1084/jem.176.3.761; Veljkovic N, 2008, CURR PROTEIN PEPT SC, V9, P493, DOI 10.2174/138920308785915245; VELJKOVIC V, 1988, CANCER BIOCHEM BIOPH, V10, P91; VELJKOVIC V, 1987, CANCER BIOCHEM BIOPH, V9, P139; VELJKOVIC V, 1985, IEEE T BIO-MED ENG, V32, P337, DOI 10.1109/TBME.1985.325549; VELJKOVIC V, 1972, PHYS REV LETT, V29, P105, DOI 10.1103/PhysRevLett.29.105; Veljkovic V., 1980, THEORETICAL APPROACH; Willis JR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003045; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	49	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2018	9								2378	10.3389/fimmu.2018.02378	http://dx.doi.org/10.3389/fimmu.2018.02378			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX2YM	30405605	gold, Green Published			2022-12-18	WOS:000447587300001
J	Ghosh, S; Drexler, I; Bhatia, S; Adler, H; Gennery, AR; Borkhardt, A				Ghosh, Sujal; Drexler, Ingo; Bhatia, Sanil; Adler, Heiko; Gennery, Andrew R.; Borkhardt, Arndt			Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight? (vol 9, 979, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						Epstein-Barr virus-related malignancies; combined immunodeficiency; Interleukin-2-inducible T-cell kinase; lymphoproliferative disorders; primary immunodeficiency			[Ghosh, Sujal; Bhatia, Sanil; Borkhardt, Arndt] Heinrich Heine Univ, Ctr Child & Adolescent Hlth, Fac Med, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Drexler, Ingo] Heinrich Heine Univ Dusseldorf, Fac Med, Inst Virol, Dusseldorf, Germany; [Adler, Heiko] Helmholtz Zentrum Munchen, Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Comprehens Pneumol Ctr, Res Unit Lung Repair & Regenerat, Munich, Germany; [Adler, Heiko] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Munich, Germany; [Adler, Heiko] German Ctr Lung Res DZL, Giessen, Germany; [Gennery, Andrew R.] Newcastle Univ, Paediat Immunol & HSCT, Newcastle Upon Tyne, Tyne & Wear, England; [Gennery, Andrew R.] Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Newcastle University - UK	Ghosh, S (corresponding author), Heinrich Heine Univ, Ctr Child & Adolescent Hlth, Fac Med, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany.	sujal.ghosh@med.uni-duesseldorf.de		Bhatia, Sanil/0000-0001-6494-7744				Ghosh S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00979	1	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2018	9								2197	10.3389/fimmu.2018.02197	http://dx.doi.org/10.3389/fimmu.2018.02197			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GV4JL	30323808	gold, Green Published			2022-12-18	WOS:000446065000001
J	Giri, SS; Yun, S; Jun, JW; Kim, HJ; Kim, SG; Kang, JW; Kim, SW; Han, SJ; Sukumaran, V; Park, SC				Giri, Sib Sankar; Yun, Saekil; Jun, Jin Woo; Kim, Hyoun Joong; Kim, Sang Guen; Kang, Jeong Woo; Kim, Sang Wha; Han, Se Jin; Sukumaran, V.; Park, Se Chang			Therapeutic Effect of Intestinal Autochthonous Lactobacillus reuteri P16 Against Waterborne Lead Toxicity in Cyprinus carpio (vol 9, 1824, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						probiotics; lactic acid bacteria; Pb; common carp; oxidative stress; immune parameters; gene expression			[Giri, Sib Sankar; Yun, Saekil; Jun, Jin Woo; Kim, Hyoun Joong; Kim, Sang Guen; Kang, Jeong Woo; Kim, Sang Wha; Han, Se Jin; Park, Se Chang] Seoul Natl Univ, Res Inst Vet Sci, Coll Vet Med, Lab Aquat Biomed, Seoul, South Korea; [Giri, Sib Sankar; Sukumaran, V.] Periyar Maniammai Univ, Dept Biotechnol, Thanjavur, India; [Sukumaran, V.] Kundavai Nachiyar Govt Arts Coll Women Autonomous, Dept Zool, Thanjavur, Tamil Nadu, India	Seoul National University (SNU); Periyar Maniammai Institute of Science & Technology	Park, SC (corresponding author), Seoul Natl Univ, Res Inst Vet Sci, Coll Vet Med, Lab Aquat Biomed, Seoul, South Korea.; Sukumaran, V (corresponding author), Periyar Maniammai Univ, Dept Biotechnol, Thanjavur, India.; Sukumaran, V (corresponding author), Kundavai Nachiyar Govt Arts Coll Women Autonomous, Dept Zool, Thanjavur, Tamil Nadu, India.	drvsukumar@gmail.com; parksec@snu.ac.kr	kim, sang guen/AAT-9683-2021; Park, Chang/AAT-3439-2021; Giri, Sib Sankar/AAK-8909-2021	Park, Chang/0000-0001-9821-387X; 	Cooperative Research Program for Agriculture Science and Technology Development (Supportive managing project of Center for Companion Animals Research) by Rural Development Administration [PJ013985032018]	Cooperative Research Program for Agriculture Science and Technology Development (Supportive managing project of Center for Companion Animals Research) by Rural Development Administration	The correct number for the Cooperative Research Program for Agriculture Science and Technology Development (Supportive managing project of Center for Companion Animals Research) by Rural Development Administration is PJ013985032018.	Giri SS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01824	1	1	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 26	2018	9								2208	10.3389/fimmu.2018.02208	http://dx.doi.org/10.3389/fimmu.2018.02208			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GU9JY	30310385	gold, Green Published			2022-12-18	WOS:000445663000001
J	Sunagar, R; Kumar, S; Rosa, SJ; Hazlett, KRO; Gosselin, EJ				Sunagar, Raju; Kumar, Sudeep; Rosa, Sarah J.; Hazlett, Karsten R. O.; Gosselin, Edmund J.			Differential In Vitro cultivation of Francisella tularensis influences live Vaccine Protective efficacy by altering the immune response	FRONTIERS IN IMMUNOLOGY			English	Article						Francisella tularensis; live vaccine; brain hear infusion medium; biodefense; mucosal vaccines	ANTIBODY-BASED DETECTION; MYCOBACTERIUM-BOVIS BCG; INTRACELLULAR BACTERIUM; LISTERIA-MONOCYTOGENES; RESPIRATORY TULAREMIA; CULTURE-MEDIUM; C57BL/6 MICE; T-CELLS; INFECTION; STRAIN	Francisella tularensis (Ft) is a biothreat agent for which there is no FDA-approved human vaccine. Currently, there are substantial efforts underway to develop both vaccines and improved tools to assess these vaccines. Ft expresses distinct sets of antigens (Ags) in vivo as compared to those expressed in vitro. Importantly, Ft grown in brain-heart infusion medium (BHIM) more closely mimics the antigenic profile of macrophage-grown Ft when compared to Mueller-Hinton medium (MHM)-grown Ft. Thus, we predicted that when used as a live vaccine BHIM-grown Ft (BHIM-Ft) would provide better protection, as compared to MHM-Ft. We first determined if there was a difference in growth kinetics between BHIM and MHM-Ft. We found that BHIM-Ft exhibited an initial growth advantage ex vivo that manifests as slightly hastened intracellular replication as compared to MHM-Ft. We also observed that BHIM-Ft exhibited an initial growth advantage in vivo represented by rapid bacterial expansion and systemic dissemination associated with a slightly shorter mean survival time of naive animals. Next, using two distinct strains of Ft LVS (WT and sodB), we observed that mice vaccinated with live BHIM-Ft LVS exhibited significantly better protection against Ft SchuS4 respiratory challenge compared to MHM-Ft-immunized mice. This enhanced protection correlated with lower bacterial burden, reduced tissue inflammation, and reduced pro-inflammatory cytokine production late in infection. Splenocytes from BHIM-Ft sodB-immunized mice contained more CD4(+), effector, memory T-cells, and were more effective at limiting intracellular replication of Ft LVS in vitro. Concurrent with enhanced killing of Ft LVS, BHIM-Ft sodB-immune splenocytes produced significantly higher levels of IFN-gamma and IL-17A cytokines than their MHM-Ft sodB-immunized counterparts indicating development of a more effective T cell memory response when immunizing mice with BHIM-Ft.	[Sunagar, Raju; Kumar, Sudeep; Rosa, Sarah J.; Hazlett, Karsten R. O.; Gosselin, Edmund J.] Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA; [Sunagar, Raju] Ella Fdn, Hyderabad, India	Albany Medical College	Gosselin, EJ (corresponding author), Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA.	gossele@amc.edu		Kumar, Sudeep/0000-0003-0960-8162	National Institutes of Health [P01 AI056320, RO1 AI100138, RO1 AI123129]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100138, P01AI056320, R01AI123129] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The National Institutes of Health (P01 AI056320-EG & KH, RO1 AI100138-EG & KH, and RO1 AI123129-KH) funded these studies. The funders had no role in study design, data collection, and analysis, or the decision to publish this study.	Anderson RV, 2010, VACCINE, V28, P6562, DOI 10.1016/j.vaccine.2010.07.072; Bakshi CS, 2008, VACCINE, V26, P5276, DOI 10.1016/j.vaccine.2008.07.051; Bakshi CS, 2006, J BACTERIOL, V188, P6443, DOI 10.1128/JB.00266-06; Bina XR, 2010, PLASMID, V64, P156, DOI 10.1016/j.plasmid.2010.07.001; Bonquist L, 2008, INFECT IMMUN, V76, P3502, DOI 10.1128/IAI.00226-08; CHAMBERL.RE, 1965, APPL MICROBIOL, V13, P232, DOI 10.1128/AEM.13.2.232-235.1965; Chiavolini D, 2008, INFECT IMMUN, V76, P486, DOI 10.1128/IAI.00862-07; Cloete TE, 2001, CURR MICROBIOL, V42, P305, DOI 10.1007/s002840010221; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Elkins KL, 2003, MICROBES INFECT, V5, P135, DOI 10.1016/S1286-4579(02)00084-9; Faith SA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00126; Firstova VV, 2014, ADV EXP MED BIOL, V808, P15, DOI 10.1007/978-81-322-1774-9_2; Florio W, 2006, MICROBES INFECT, V8, P434, DOI 10.1016/j.micinf.2005.07.013; Geng T, 2006, J FOOD PROTECT, V69, P1879, DOI 10.4315/0362-028X-69.8.1879; Golovliov I, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00152; Griffin AJ, 2015, CLIN VACCINE IMMUNOL, V22, P119, DOI 10.1128/CVI.00648-14; Hahm BK, 2006, J APPL MICROBIOL, V100, P1017, DOI 10.1111/j.1365-2672.2006.02814.x; Hazlett KRO, 2008, INFECT IMMUN, V76, P4479, DOI 10.1128/IAI.00610-08; Holland KM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01158; Hume EBH, 2005, IMMUNOL CELL BIOL, V83, P294, DOI 10.1111/j.1440-1711.2005.01326.x; Guzman-de la Garza FJ, 2013, CLINICS, V68, P1034, DOI 10.6061/clinics/2013(07)23; Khader SA, 2010, VIRULENCE, V1, P423, DOI 10.4161/viru.1.5.12862; Kirimanjeswara GS, 2008, IMMUNOL REV, V225, P244, DOI 10.1111/j.1600-065X.2008.00689.x; Kirimanjeswara GS, 2007, J IMMUNOL, V179, P532, DOI 10.4049/jimmunol.179.1.532; Kumar S, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00677; Law HT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104881; Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025; Mahawar M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061539; Molins CR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010205; Rawool DB, 2008, J IMMUNOL, V180, P5548, DOI 10.4049/jimmunol.180.8.5548; Roberts AD, 2005, J EXP MED, V202, P123, DOI 10.1084/jem.20050137; Roberts LM, 2014, VACCINE, V32, P3595, DOI 10.1016/j.vaccine.2014.05.013; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sebastian S, 2009, VACCINE, V27, P597, DOI 10.1016/j.vaccine.2008.10.079; Shen H, 2004, VACCINE, V22, P2116, DOI 10.1016/j.vaccine.2003.12.003; Skyberg JA, 2013, INFECT IMMUN, V81, P3099, DOI 10.1128/IAI.00203-13; Sunagar Raju, 2016, Vaccine (Auckl), V6, P9; Sunagar R, 2016, VACCINE, V34, P3396, DOI 10.1016/j.vaccine.2016.04.054; Twine SM, 2006, MICROB PATHOGENESIS, V40, P133, DOI 10.1016/j.micpath.2005.12.004; Twine S, 2012, VACCINE, V30, P3634, DOI 10.1016/j.vaccine.2012.03.036; Venkataswamy MM, 2012, VACCINE, V30, P1038, DOI 10.1016/j.vaccine.2011.12.044; Walsh EJ, 1997, J APPL MICROBIOL, V83, P67, DOI 10.1046/j.1365-2672.1997.00164.x; Zarrella TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022335	43	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 10	2018	9								1594	10.3389/fimmu.2018.01594	http://dx.doi.org/10.3389/fimmu.2018.01594			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GM4MA	30042767	Green Published, gold			2022-12-18	WOS:000438093300003
J	Hens, J; Goovaerts, O; Ceulemans, A; Jennes, W; Kestens, L				Hens, Jef; Goovaerts, Odin; Ceulemans, Ann; Jennes, Wim; Kestens, Luc			Impact of the Variable Killer Ig-Like Receptor-Human Leukocyte Antigen Interactions on Natural Killer Cell Cytotoxicity Toward Foreign CD4 T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic natural killer cell responses; killer Ig-like receptor-human leukocyte antigen ligand mismatch; in vitro natural killer-CD4 cocultures; human immunodeficiency virus-1 patients; HIV transmission	MHC CLASS-I; IMMUNOGLOBULIN-LIKE RECEPTORS; HUMAN NK CELLS; INHIBITORY RECEPTORS; SURFACE-MOLECULE; ACUTE-LEUKEMIA; COMPLEX; HLA; RECOGNITION; RESPONSIVENESS	Background: Natural killer (NK) cells are known to mount a response against foreign target cells, where the absence of the dominant inhibitory killer Ig-like receptor (KIR)-human leukocyte antigen (HLA) interaction immensely lowers the threshold for NK cell activation. NK cells could thus constitute a vital part in the mucosal defense against cell-associated sexually transmitted diseases. Here, we performed a detailed analysis of hitherto unexplored KIR-HLA-incompatible NK cell interactions. Methods and findings: In vitro, healthy NK cells were cocultured with CD4+ T cells derived from human immunodeficiency virus-1 patients, and the KIR-specific NK cell cytotoxicity was measured using flow cytometry. Genotyping of KIR and HLA predicted the KIR-HLA interactions occurring during these 124 allogeneic encounters. KIR2DL1+ NK cells were seen as the strongest intrinsic responders in the absence of their ligand with a 3.2-fold increase in KIR2DL1+ NK cells in the total NK cell response. An association between the size of the alloreactive NK cell population and the amount of CD4+ T cell death (p = 0.0023) and NK cell degranulation (p = 0.0036) was only present in NK cell donors with an activating KIR haplotype. conclusion: We demonstrate differences in the activating effect of KIR-HLA incompatibility according to the KIR involved, with KIR2DL1 as the strongest responder. An activating KIR haplotype optimized the contribution of KIR-HLA-incompatible NK cells in the total NK cell response.	[Hens, Jef; Goovaerts, Odin; Ceulemans, Ann; Jennes, Wim; Kestens, Luc] Inst Trop Med, Dept Biomed Sci, Antwerp, Belgium; [Hens, Jef; Kestens, Luc] Univ Antwerp, Dept Biomed, Antwerp, Belgium	Institute of Tropical Medicine (ITM); University of Antwerp	Hens, J (corresponding author), Inst Trop Med, Dept Biomed Sci, Antwerp, Belgium.; Hens, J (corresponding author), Univ Antwerp, Dept Biomed, Antwerp, Belgium.	jhens@itg.be			Unit of Immunology, Instituut voor Tropsiche Geneeskunde	Unit of Immunology, Instituut voor Tropsiche Geneeskunde	The experiments were achieved through internal funding at the Unit of Immunology, Instituut voor Tropsiche Geneeskunde.	Anderson DJ, 2010, AIDS, V24, P163, DOI 10.1097/QAD.0b013e32833424c8; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Aversa F, 2005, J CLIN ONCOL, V23, P3447, DOI 10.1200/JCO.2005.09.117; Bari R, 2016, SCI REP-UK, V6, DOI 10.1038/srep23689; Beziat V, 2013, BLOOD, V121, P2678, DOI 10.1182/blood-2012-10-459545; Brodin P, 2009, BLOOD, V113, P2434, DOI 10.1182/blood-2008-05-156836; Carr WH, 2007, J IMMUNOL, V178, P647, DOI 10.4049/jimmunol.178.2.647; Carroll IR, 1998, MOL IMMUNOL, V35, P1171, DOI 10.1016/S0161-5890(98)00107-2; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Gillespie GMA, 2007, AIDS RES HUM RETROV, V23, P451, DOI 10.1089/aid.2006.0165; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; Hens J, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0099-6; Hilton HG, 2015, J IMMUNOL, V195, P3160, DOI 10.4049/jimmunol.1501358; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; Horowitz A, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1672; Ivarsson MA, 2013, J CLIN INVEST, V123, P3889, DOI 10.1172/JCI68989; Jennes W, 2013, BLOOD, V121, P1157, DOI 10.1182/blood-2012-09-455352; Joncker NT, 2009, J IMMUNOL, V182, P4572, DOI 10.4049/jimmunol.0803900; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kim S, 2008, P NATL ACAD SCI USA, V105, P3053, DOI 10.1073/pnas.0712229105; Korner C, 2014, EUR J IMMUNOL, V44, P2938, DOI 10.1002/eji.201444751; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Manser AR, 2015, IMMUNOL REV, V267, P178, DOI 10.1111/imr.12316; Moesta AK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00336; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Moretta L, 2004, CURR OPIN IMMUNOL, V16, P626, DOI 10.1016/j.coi.2004.07.010; O'Connor GM, 2015, J VIROL, V89, P5213, DOI 10.1128/JVI.03586-14; Palmieri G, 1999, J IMMUNOL, V162, P7181; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sim MJW, 2016, EUR J IMMUNOL, V46, P185, DOI 10.1002/eji.201545757; Sips M, 2012, MUCOSAL IMMUNOL, V5, P30, DOI 10.1038/mi.2011.40; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102; Sutherland CL, 2001, IMMUNOL REV, V181, P185, DOI 10.1034/j.1600-065X.2001.1810115.x; Tsamadou C, 2017, HAEMATOLOGICA, V102, P1947, DOI 10.3324/haematol.2017.169805; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Winter CC, 1998, J IMMUNOL, V161, P571; Yawata M, 2006, J EXP MED, V203, P633, DOI 10.1084/jem.20051884	45	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 9	2018	9								1588	10.3389/fimmu.2018.01588	http://dx.doi.org/10.3389/fimmu.2018.01588			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GM2BO	30038628	Green Published, gold			2022-12-18	WOS:000437882800001
J	Valanne, S; Vesala, L; Ramet, M				Valanne, Susanna; Vesala, Laura; Ramet, Mika			Commentary: Drosophila GATA Factor Serpent Establishes Phagocytic Ability of Embryonic Macrophages	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						phagocytosis; Drosophila melanogaster; apoptosis; innate immune response; plasmatocyte	CELL-DEATH; RECEPTOR; GENES		[Valanne, Susanna; Vesala, Laura; Ramet, Mika] Univ Tampere, Lab Expt Immunol, Fac Med & Life Sci, BioMediTech Inst, Tampere, Finland; [Ramet, Mika] Univ Oulu, Med Res Ctr Oulu, PEDEGO Res Unit, Oulu, Finland; [Ramet, Mika] Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland	Tampere University; University of Oulu; University of Oulu	Ramet, M (corresponding author), Univ Tampere, Lab Expt Immunol, Fac Med & Life Sci, BioMediTech Inst, Tampere, Finland.; Ramet, M (corresponding author), Univ Oulu, Med Res Ctr Oulu, PEDEGO Res Unit, Oulu, Finland.; Ramet, M (corresponding author), Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland.	mika.ramet@uta.fi	Valanne, Susanna/GZK-2381-2022	Valanne, Susanna/0000-0003-0898-8423				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Anderl I, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005746; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Freeman MR, 2003, NEURON, V38, P567, DOI 10.1016/S0896-6273(03)00289-7; Irving P, 2005, CELL MICROBIOL, V7, P335, DOI 10.1111/j.1462-5822.2004.00462.x; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; Kurucz E, 2007, CURR BIOL, V17, P649, DOI 10.1016/j.cub.2007.02.041; Kuuluvainen E, 2014, J BIOL CHEM, V289, P16252, DOI 10.1074/jbc.M113.541904; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Shlyakhover E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00266; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Tsuzuki S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5628; Ulvila J, 2011, J LEUKOCYTE BIOL, V89, P649, DOI 10.1189/jlb.0410195; Ulvila J, 2011, APMIS, V119, P651, DOI 10.1111/j.1600-0463.2011.02792.x	17	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 6	2018	9								1582	10.3389/fimmu.2018.01582	http://dx.doi.org/10.3389/fimmu.2018.01582			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GL9YU	30034400	Green Published, gold			2022-12-18	WOS:000437700700001
J	Gutierrez-Rivas, M; Jimenez-Sousa, MA; Rallon, N; Jimenez, JL; Restrepo, C; Leon, A; Montero-Alonso, M; Gonzalez-Garcia, J; Munoz-Fernandez, MA; Benito, JM; Resino, S				Gutierrez-Rivas, Monica; Angeles Jimenez-Sousa, Maria; Rallon, Norma; Luis Jimenez, Jose; Restrepo, Clara; Leon, Agathe; Montero-Alonso, Marta; Gonzalez-Garcia, Juan; Angeles Munoz-Fernandez, Maria; Miguel Benito, Jose; Resino, Salvador		ECRIS Integrated Spanish AIDS Res	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control	FRONTIERS IN IMMUNOLOGY			English	Article						human immunodeficiency virus; elite controllers; inflammation; plasma biomarkers; acquired immune deficiency syndrome; progression	TUMOR-NECROSIS-FACTOR; T-CELL-ACTIVATION; IMMUNE ACTIVATION; ANTIRETROVIRAL THERAPY; HIV-1 INFECTION; DISEASE PROGRESSION; CYTOKINE; PATHOGENESIS; INDIVIDUALS; CHEMOKINES	Our aim was to analyze the relationship between plasma inflammatory biomarkers and CD4+ T-cells evolution in human immunodeficiency virus (HIV) elite controllers (HIV-ECs) with a suppressed viremia. We carried out a retrospective study in 30 HIV-ECs classified into two groups: those showing no significant loss of CD4+ T-cells during the observation period (stable CD4+, n = 19) and those showing a significant decrease of CD4+ T-cells (decline CD4+, n = 11). Baseline plasma biomarkers were measured using a multiplex immunoassay: sTNF-R1, TRAIL, sFas (APO), sFasL, TNF-alpha, IL-beta, IL-18, IL-6, IL-10, IP-10, MCP-1, MIP-1 alpha, MIP-1 beta, RANTES, SDF1 alpha, GRO-alpha, and CCL11. Baseline levels of sTNF-R1 and CCL11 and sTNF-R1 TTNF-alpha ratio correlated with the slope of CD4+ T-cells (cells/mu l/year) during follow-up [r = -0.370 (p = 0.043), r = -0.314 (p = 0.091), and r = -0.381 (p = 0.038); respectively]. HIV-ECs with declining CD4+ T-cells had higher baseline plasma levels of sTNF-R1 [1,500.7 (555.7; 2,060.7) pg/ml vs. 450.8 (227.9; 1,263.9) pg/ml; p = 0.018] and CCL11 [29.8 (23.5; 54.9) vs. 19.2 (17.8; 29.9) pg/ml; p = 0.041], and sTNF-R1/TNF-alpha ratio [84.7 (33.2; 124.2) vs. 25.9 (16.3; 75.1); p = 0.012] than HIV-1 ECs with stable CD4+ T-cells. The area under the receiver operating characteristic (ROC) curve [area under ROC curve (AUROC)] were 0.758 +/- 0.093 (sTNF-R1), 0.727 +/- 0.096 (CCL11), and 0.777 +/- 0.087 (sTNF-R1/TNF-alpha). The cut-off of 75th percentile (high values) for these biomarkers had 71.4% positive predictive value and 73.9% negative predictive value for anticipating the evolution of CD4+ T-cells. In conclusion, the loss of CD4+ T-cells in HIV-ECs was associated with higher levels of two plasma inflammatory biomarkers (sTNF-R1 and CCL11), which were also reasonably accurate for the prediction of the CD4+ T-cells loss.	[Gutierrez-Rivas, Monica; Angeles Jimenez-Sousa, Maria; Resino, Salvador] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Infecc Viral & Inmunidad, Majadahonda, Spain; [Rallon, Norma; Restrepo, Clara; Miguel Benito, Jose] UAM, IIS FJD, Madrid, Spain; [Rallon, Norma; Restrepo, Clara; Miguel Benito, Jose] Hosp Univ Rey Juan Carlos, Mostoles, Spain; [Luis Jimenez, Jose] Hosp Gen Univ Gregorio Maranon, Plataforma Lab, Madrid, Spain; [Luis Jimenez, Jose; Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Secc Inmunol, Madrid, Spain; [Leon, Agathe] Hosp Clin IDIBAPS, Serv Enfermedades Infecciosas, Barcelona, Spain; [Montero-Alonso, Marta] Hosp Univ & Politecn La Fe, Unidad Enfermedades Infecciosas, Valencia, Spain; [Gonzalez-Garcia, Juan] Hosp Univ La Paz, Serv Med Interna, Madrid, Spain; [Angeles Munoz-Fernandez, Maria] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Autonomous University of Madrid; Fundacion Jimenez Diaz; General University Gregorio Maranon Hospital; General University Gregorio Maranon Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitari i Politecnic La Fe; Hospital Universitario La Paz	Rallon, N; Benito, JM (corresponding author), UAM, IIS FJD, Madrid, Spain.; Rallon, N; Benito, JM (corresponding author), Hosp Univ Rey Juan Carlos, Mostoles, Spain.	normaibon@yahoo.com; jbenito1@hotmail.com	Jiménez-Sousa, Maria A./I-8725-2012; Montero, Marta/H-7555-2017; , Felipe/F-4242-2014; Benito, Jose/AAC-4554-2020; Valenzuela-Fernández, Agustín/P-1638-2019; Jiménez, José Luis/AAK-6193-2020; Resino, Salvador/B-2430-2008; Leon, Agathe/K-9851-2015; Rivas, Mónica Gutiérrez/G-9713-2016	Jiménez-Sousa, Maria A./0000-0002-1945-6169; Montero, Marta/0000-0002-3432-5394; , Felipe/0000-0001-7658-5832; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Jiménez, José Luis/0000-0001-6187-6223; Resino, Salvador/0000-0001-8783-0450; Leon, Agathe/0000-0002-1198-5090; Rivas, Mónica Gutiérrez/0000-0001-9752-7498; Nogueras, Maria-Mercedes/0000-0001-5925-1929; Munoz-Fernandez/0000-0002-0813-4500; Gonzalez-Garcia, Juan/0000-0002-3652-002X; Rallon, Norma/0000-0002-4643-247X; Benito, Jose/0000-0002-7172-049X	Health Research and Development Strategy, State Plan for Scientific and Technical Research and Innovation [RD12/0017/0037, RD12/0017/0031, RD12/0017/0024, RD16CIII/0002/0002, RD16/0025/0019, RD16/0025/0013]; Institute of Health Carlos III, ISCIII-Sub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF) [RETIC PT13/0010/0028]; Fondo de Investigacion Sanitaria (FIS) [PI13/02016, PI16/01863, PI14/00882, PI14CIII/00011, CYTED 214RT0482]; VI National RDI Plan; Iniciativa Ingenio; Consolider Program; CIBER Actions; Instituto de Salud Carlos III; Marie Curie International Research Staff Exchange Scheme Fellowship within the seventh European Community Framework Program [PIRSES-GA-2012-316730 NANOGENE]; Polish Ministry of Science and Higher Education [W21/7PR/2013]; Institute of Health Carlos III [CD13/00013, CP14/00198]	Health Research and Development Strategy, State Plan for Scientific and Technical Research and Innovation; Institute of Health Carlos III, ISCIII-Sub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF)(European Commission); Fondo de Investigacion Sanitaria (FIS)(Instituto de Salud Carlos III); VI National RDI Plan; Iniciativa Ingenio(Spanish Government); Consolider Program(Spanish Government); CIBER Actions; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Marie Curie International Research Staff Exchange Scheme Fellowship within the seventh European Community Framework Program; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Institute of Health Carlos III(Instituto de Salud Carlos III)	This work has been (partially) funded by the RD12/0017/0037, RD12/0017/0031, RD12/0017/0024, RD16CIII/0002/0002, and RD16/0025/0019 and RD16/0025/0013 project as part of the Health Research and Development Strategy, State Plan for Scientific and Technical Research and Innovation (2008-2011; 2013-2016) and cofinanced by Institute of Health Carlos III, ISCIII-Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF), RETIC PT13/0010/0028, Fondo de Investigacion Sanitaria (FIS) (grant number PI13/02016; PI16/01863, PI14/00882, PI14CIII/00011), CYTED 214RT0482. EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. This work was supported partially by a Marie Curie International Research Staff Exchange Scheme Fellowship within the seventh European Community Framework Program, project No. PIRSES-GA-2012-316730 NANOGENE, co-financed by the Polish Ministry of Science and Higher Education (grant No. W21/7PR/2013). "Programa de Investigacion de la Consejeria de Sanidad de la Comunidad de Madrid" to JJ. MJ-S and NR are supported by Institute of Health Carlos III (grant numbers CD13/00013 and CP14/00198, respectively), CR was funded by project RD12/0017/0031 and is currently funded by project RD16/0025/0013.	ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; Barqasho B, 2009, HIV MED, V10, P94, DOI 10.1111/j.1468-1293.2008.00657.x; Blanpain C, 1999, BLOOD, V94, P1899; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Crowell TA, 2015, J VIRUS ERAD, V1, P72; Dagenais-Lussier X, 2015, CYTOKINE GROWTH F R, V26, P603, DOI 10.1016/j.cytogfr.2015.09.001; Doitsh G, 2016, CELL HOST MICROBE, V19, P280, DOI 10.1016/j.chom.2016.02.012; Foley JF, 2005, J IMMUNOL, V174, P4892, DOI 10.4049/jimmunol.174.8.4892; Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27; Groves KC, 2012, JAIDS-J ACQ IMM DEF, V61, P407, DOI 10.1097/QAI.0b013e318269c414; Hatano H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003691; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1; Krishnan S, 2014, J INFECT DIS, V209, P931, DOI 10.1093/infdis/jit581; Kumar SB, 2012, AIDS, V26, P685, DOI 10.1097/QAD.0b013e3283519b00; Leon A, 2016, AIDS, V30, P1209, DOI 10.1097/QAD.0000000000001050; Li JZ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofu117; Nakayama K, 2012, AIDS RES HUM RETROV, V28, P702, DOI [10.1089/aid.2011.0073, 10.1089/AID.2011.0073]; Noel N, 2014, AIDS, V28, P467, DOI 10.1097/QAD.0000000000000174; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Okulicz JF, 2011, CURR OPIN HIV AIDS, V6, P163, DOI 10.1097/COH.0b013e328344f35e; Pasquereau S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040064; Pereyra F, 2012, AIDS, V26, P2409, DOI 10.1097/QAD.0b013e32835a9950; Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446; Pernas M, 2018, J VIROL, V92, DOI 10.1128/JVI.01805-17; Platten M, 2016, AIDS RES HUM RETROV, V32, P579, DOI [10.1089/aid.2015.0226, 10.1089/AID.2015.0226]; Promadej-Lanier N, 2010, JAIDS-J ACQ IMM DEF, V53, P574, DOI 10.1097/QAI.0b013e3181d3521f; Richert Q, 2017, CYTOKINE, V91, P74, DOI 10.1016/j.cyto.2016.12.010; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Sanchez JL, 2015, J INFECT DIS, V211, P1068, DOI 10.1093/infdis/jiu586; Song W, 2011, AIDS RES HUM RETROV, V27, P639, DOI [10.1089/aid.2010.0161, 10.1089/AID.2010.0161]; Vaidya SA, 2014, J INFECT DIS, V210, P1042, DOI 10.1093/infdis/jiu206; Wang XL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00474; Younas M, 2016, HIV MED, V17, P89, DOI 10.1111/hiv.12310; Younas M, 2017, AIDS, V31, P171, DOI 10.1097/QAD.0000000000001311; Zeng M, 2011, J CLIN INVEST, V121, P998, DOI 10.1172/JCI45157	36	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2018	9								1399	10.3389/fimmu.2018.01399	http://dx.doi.org/10.3389/fimmu.2018.01399			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GJ6LZ	29967620	Green Published, gold			2022-12-18	WOS:000435497000001
J	Varesano, S; Zocchi, MR; Poggi, A				Varesano, Serena; Zocchi, Maria Raffaella; Poggi, Alessandro			Zoledronate Triggers V delta 2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures (vol 9, 998, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						CRC; spheroid; gamma delta T cells; epidermal growth factor receptor; antibody-dependent cellular cytotoxicity; zoledronate			[Varesano, Serena; Poggi, Alessandro] Osped Policlin San Martino, Mol Oncol & Angiogenesis Unit, Genoa, Italy; [Zocchi, Maria Raffaella] Ist Sci San Raffaele, Div Immunol Transplants & Infect Dis, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Poggi, A (corresponding author), Osped Policlin San Martino, Mol Oncol & Angiogenesis Unit, Genoa, Italy.; Zocchi, MR (corresponding author), Ist Sci San Raffaele, Div Immunol Transplants & Infect Dis, Milan, Italy.	zocchi.maria@hsr.it; alessandro.poggi@hsanmartino.it	Varesano, Serena/AAB-4449-2021; Poggi, Alessandro/K-6664-2016	Varesano, Serena/0000-0002-0967-7347; Poggi, Alessandro/0000-0002-1860-430X	AIRC [IG15483, IG17074]; 5xmille 2012 Ministero della Salute; 5xmille 2013 Ministero della Salute; 5xmille 2014 Ministero della Salute; 5xmille 2015 Ministero della Salute	AIRC(Fondazione AIRC per la ricerca sul cancro); 5xmille 2012 Ministero della Salute; 5xmille 2013 Ministero della Salute; 5xmille 2014 Ministero della Salute; 5xmille 2015 Ministero della Salute	This work has been partially supported by grants from AIRC to AP (IG15483) and AIRC to MZ (IG17074) and from 5xmille 2012 Ministero della Salute, 5xmille 2013 Ministero della Salute, 5xmille 2014 Ministero della Salute, and 5xmille 2015 Ministero della Salute to AP. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.	Varesano S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00998	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 13	2018	9								1343	10.3389/fimmu.2018.01343	http://dx.doi.org/10.3389/fimmu.2018.01343			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GJ2NP	29930560	Green Published, gold			2022-12-18	WOS:000435108300001
J	Vivier, E; Olive, D				Vivier, Eric; Olive, Daniel			A Tribute to Alessandro Moretta (1953-2018). Living Without Alessandro	FRONTIERS IN IMMUNOLOGY			English	Biographical-Item						NK; innate immunity; immunology; Medicine; cancer immunotherapy; immmunopathology			[Vivier, Eric] Innate Pharma, Marseille, France; [Vivier, Eric] Aix Marseille Univ, Marseille, France; [Vivier, Eric] Assistance Publ Hop Marseille, Marseille, France; [Olive, Daniel] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Olive, D (corresponding author), Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France.	daniel.olive@inserm.fr	Vivier, Eric/F-8939-2010; olive, daniel/B-9702-2012	Vivier, Eric/0000-0001-7022-8287; olive, daniel/0000-0003-1299-4113				MORETTA A, PUBLICATION LIST	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2018	9								1292	10.3389/fimmu.2018.01292	http://dx.doi.org/10.3389/fimmu.2018.01292			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GI5LH		gold, Green Published			2022-12-18	WOS:000434411500001
J	Kishore, U				Kishore, Uday			Editorial: Macromolecular Structure Underlying Recognition in Innate Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						pattern recognition; innate immunity; host-pathogen interactions; protein-protein interaction; HIV-1; malaria; zebrafish model system	C1Q		[Kishore, Uday] Brunel Univ London, Coll Hlth & Life Sci, Biosci, Uxbridge, Middx, England	Brunel University	Kishore, U (corresponding author), Brunel Univ London, Coll Hlth & Life Sci, Biosci, Uxbridge, Middx, England.	ukishore@hotmail.com						Dam TK, 2010, GLYCOBIOLOGY, V20, P270, DOI 10.1093/glycob/cwp186; Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Kouser L, 2016, MOL IMMUNOL, V73, P76, DOI 10.1016/j.molimm.2016.03.005; Kouser L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00093	5	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 15	2018	9								980	10.3389/fimmu.2018.00980	http://dx.doi.org/10.3389/fimmu.2018.00980			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GF9QM	29867958	Green Published, gold			2022-12-18	WOS:000432313200001
J	Zhu, JF				Zhu, Jinfang			Seventeen-Year Journey Working With a Master	FRONTIERS IN IMMUNOLOGY			English	Article						GATA3 transcription factor; T helper cells; innate lymphoid cells; cytokines; T cell differentiation; T cell development	INNATE LYMPHOID-CELLS; TRANSCRIPTION FACTOR GATA-3; REGULATORY T-CELLS; DOWN-REGULATION; TH1 DEVELOPMENT; FACTOR BCL11B; TGF-BETA; DIFFERENTIATION; EXPRESSION; INFLAMMATION	It had been a great honor for me to work with the late Dr. William E. Paul for 17 years in the Laboratory of Immunology (LI) from 1998 until his passing in 2015. He was such a master in the immunology field. Under his outstanding guidance, my research has been focusing on transcriptional regulation of T helper (Th) cell differentiation, especially, on the role of a master transcription factor GATA3 during Th2 cell differentiation. Just as enormous scientific contributions of Dr. Paul (we all call him Bill) to the immunology community are far beyond his serving as the Chief of the LI, GATA3 also plays important roles in different lymphocytes at various developmental stages besides its critical functions in Th2 cells. In this special review dedicated to the memory of Bill, I will summarize the research that I have carried out in Bill's lab working on GATA3 in the context of related studies by other groups in the field of T cell differentiation and innate lymphoid cell (ILC) development. These include the essential role of GATA3 in regulating Th2/ILC2 differentiation/development and their functions, the critical role of GATA3 during the development of T cells and innate lymphoid cells, and dynamic and quantitative expression of GATA3 in controlling lymphocyte homeostasis and functions.	[Zhu, Jinfang] NIAID, Mol & Cellular Immunoregulat Sect, Lab Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zhu, JF (corresponding author), NIAID, Mol & Cellular Immunoregulat Sect, Lab Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jfzhu@niaid.nih.gov	Zhu, Jinfang/B-7574-2012	Zhu, Jinfang/0000-0002-0117-4745	Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA [1-ZIA-AI001169]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001169] Funding Source: NIH RePORTER	Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	JZ is supported by the Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA (grant number 1-ZIA-AI001169).	Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Califano D, 2015, IMMUNITY, V43, P354, DOI 10.1016/j.immuni.2015.07.005; Chandele A, 2008, J IMMUNOL, V180, P5309, DOI 10.4049/jimmunol.180.8.5309; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Diefenbach A, 2014, IMMUNITY, V41, P354, DOI 10.1016/j.immuni.2014.09.005; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fang DF, 2018, J EXP MED, V215, P1449, DOI 10.1084/jem.20171127; Fang DF, 2017, J EXP MED, V214, P1861, DOI 10.1084/jem.20170494; Furusawa J, 2013, J IMMUNOL, V191, P1818, DOI 10.4049/jimmunol.1300379; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hernandez-Hoyos G, 2003, IMMUNITY, V19, P83, DOI 10.1016/S1074-7613(03)00176-6; Ho IC, 2009, NAT REV IMMUNOL, V9, P125, DOI 10.1038/nri2476; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hu GQ, 2013, NAT IMMUNOL, V14, P1190, DOI 10.1038/ni.2712; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Jenner RG, 2009, P NATL ACAD SCI USA, V106, P17876, DOI 10.1073/pnas.0909357106; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kanhere A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2260; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim PJ, 2006, J IMMUNOL, V177, P6650, DOI 10.4049/jimmunol.177.10.6650; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Koues OI, 2016, CELL, V165, P1134, DOI 10.1016/j.cell.2016.04.014; Lee YJ, 2013, NAT IMMUNOL, V14, P1146, DOI 10.1038/ni.2731; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Li L, 2010, SCIENCE, V329, P89, DOI 10.1126/science.1188989; McKenzie ANJ, 2014, IMMUNITY, V41, P366, DOI 10.1016/j.immuni.2014.09.006; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Pai SY, 2003, IMMUNITY, V19, P863, DOI 10.1016/S1074-7613(03)00328-5; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Peine M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001633; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Samson SI, 2003, IMMUNITY, V19, P701, DOI 10.1016/S1074-7613(03)00294-2; Sano T, 2015, CELL, V163, P381, DOI 10.1016/j.cell.2015.08.061; Seehus CR, 2015, NAT IMMUNOL, V16, P599, DOI 10.1038/ni.3168; Sharma Suveena, 2014, Curr Protoc Immunol, V105, DOI 10.1002/0471142735.im1034s105; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shih HY, 2016, CELL, V165, P1120, DOI 10.1016/j.cell.2016.04.029; Shikhagaie MM, 2017, NAT REV RHEUMATOL, V13, P164, DOI 10.1038/nrrheum.2016.218; Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966; Tindemans I, 2014, IMMUNITY, V41, P191, DOI 10.1016/j.immuni.2014.06.006; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Usui T, 2006, J EXP MED, V203, P755, DOI 10.1084/jem.20052165; Usui T, 2003, IMMUNITY, V18, P415, DOI 10.1016/S1074-7613(03)00057-8; Vosshenrich CAJ, 2006, NAT IMMUNOL, V7, P1217, DOI 10.1038/ni1395; Walker JA, 2015, J EXP MED, V212, P875, DOI 10.1084/jem.20142224; Wang L, 2008, NAT IMMUNOL, V9, P1122, DOI 10.1038/ni.1647; Wang YQ, 2013, NAT IMMUNOL, V14, P714, DOI 10.1038/ni.2623; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wei G, 2011, IMMUNITY, V35, P299, DOI 10.1016/j.immuni.2011.08.007; Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yagi R, 2010, IMMUNITY, V32, P507, DOI 10.1016/j.immuni.2010.04.004; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yang Q, 2015, NAT IMMUNOL, V16, P1044, DOI 10.1038/ni.3248; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Yu F, 2015, NAT IMMUNOL, V16, P197, DOI 10.1038/ni.3053; Yu Y, 2015, J EXP MED, V212, P865, DOI 10.1084/jem.20142318; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhong C, 2016, NAT IMMUNOL, V17, P169, DOI 10.1038/ni.3318; Zhong Chao, 2015, J Exp Med, V212, P828, DOI 10.1084/jem.2126insight1; Zhu JF, 2000, J EXP MED, V192, P1125, DOI 10.1084/jem.192.8.1125; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5; Zhu JF, 2001, J IMMUNOL, V166, P7276, DOI 10.4049/jimmunol.166.12.7276; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154; Zhu JF, 2006, P NATL ACAD SCI USA, V103, P18214, DOI 10.1073/pnas.0608981103; Zhu JF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01571; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zhu JF, 2009, J EXP MED, V206, P329, DOI 10.1084/jem.20081666; Zook EC, 2016, NAT IMMUNOL, V17, P775, DOI 10.1038/ni.3481	92	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2018	9								960	10.3389/fimmu.2018.00960	http://dx.doi.org/10.3389/fimmu.2018.00960			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GE4PM	29770140	Green Published, gold			2022-12-18	WOS:000431198300001
J	Zhou, Y; Leng, X; He, Y; Li, Y; Liu, Y; Liu, Y; Zou, Q; Shi, GX; Wang, YT				Zhou, Yan; Leng, Xiao; He, Yan; Li, Yan; Liu, Yuan; Liu, Yang; Zou, Qiang; Shi, Guixiu; Wang, Yantang			Loss of Perp in T Cells Promotes Resistance to Apoptosis of T Helper 17 Cells and Exacerbates the Development of Experimental Autoimmune Encephalomyelitis in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Perp; T helper 17 cell; activation-induced cell death; experimental autoimmune encephalomyelitis/multiple sclerosis; caspase activation	MULTIPLE-SCLEROSIS; TH17 CELLS; UVEAL MELANOMA; P53; ACTIVATION; LYMPHOCYTES; EXPRESSION; ARTHRITIS; DISEASE; DEATH	T helper 17 (Th17) cells are crucial for the pathogenesis of multiple sclerosis (MS) in humans and experimental autoimmune encephalomyelitis (EAE) in animals. High frequency of Th17 cells and low sensitivity to activation-induced cell death (AICD) are detected in MS patients. However, the mechanisms underlying apoptosis resistance of T cells remain unclear. Perp is an apoptosis-associated target of p53 and implicated in the development of cancers. Here, we show that loss of Perp in T cells does not affect Th1, Th17, or Treg cell differentiation, but does significantly increase the resistance of Perp Th17 cells to AICD and anti-Fas in Lck-Cre x Perpm mice by inhibiting the caspase-dependent apoptotic pathway. Moreover, Lck-Cre x Perp" mice exhibited earlier onset of EAE and severe spinal cord inflammation and demyelination, accompanied by increased levels of pro-inflammatory cytokines and enlarged population of Th17 cells. Therefore, Perp deletion promoted Th17 responses and exacerbated the development and severity of EAE.	[Zhou, Yan] Sichuan Univ, Dept Emergency, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China; [Zhou, Yan] Sichuan Univ, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Sichuan, Peoples R China; [Leng, Xiao; Liu, Yang; Zou, Qiang; Wang, Yantang] Chengdu Med Coll, Dept Immunol, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China; [He, Yan; Li, Yan; Liu, Yuan; Shi, Guixiu] Xiamen Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Xiamen, Peoples R China	Sichuan University; Sichuan University; Chengdu Medical College; Xiamen University	Wang, YT (corresponding author), Chengdu Med Coll, Dept Immunol, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China.; Shi, GX (corresponding author), Xiamen Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Xiamen, Peoples R China.	guixiu.shi@gmaii.com; yt-wang@hotmail.com	Li, Yan/AAF-3839-2019	Zhou, Yan/0000-0001-6685-2634; shi, guixiu/0000-0003-4044-3394; Wang, Yantang/0000-0003-0854-4988	National Natural Science Foundation of China [NSFC 81202363]; Research Fund of Development and Regeneration Key Laboratory of Sichuan Province [SYS16-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund of Development and Regeneration Key Laboratory of Sichuan Province	This study was supported by the grants from the National Natural Science Foundation of China (NSFC 81202363 to YW) and the Research Fund of Development and Regeneration Key Laboratory of Sichuan Province (SYS16-002 to YW).	Attardi LD, 2000, GENE DEV, V14, P704; Awais R, 2016, BRIT J CANCER, V115, P983, DOI 10.1038/bjc.2016.269; Banuelos J, 2016, ALLERGY, V71, P640, DOI 10.1111/all.12840; Cencioni MT, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.100; Chen K, 2011, CANCER BIOL THER, V12, P1114, DOI 10.4161/cbt.12.12.18435; Davies L, 2009, J CELL MOL MED, V13, P1995, DOI 10.1111/j.1582-4934.2008.00590.x; Durelli L, 2009, ANN NEUROL, V65, P499, DOI 10.1002/ana.21652; Dusek RL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3171; Fray MA, 2014, IMMUNITY, V40, P633, DOI 10.1016/j.immuni.2014.05.001; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Guo Beichu, 2016, J Clin Cell Immunol, V7; Hallstrom KN, 2015, CELL MICROBIOL, V17, P843, DOI 10.1111/cmi.12406; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jadidi-Niaragh F, 2011, SCAND J IMMUNOL, V74, P1, DOI 10.1111/j.1365-3083.2011.02536.x; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kroenke MA, 2008, J EXP MED, V205, P1535, DOI 10.1084/jem.20080159; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Leech M, 2008, CLIN EXP IMMUNOL, V152, P345, DOI 10.1111/j.1365-2249.2008.03629.x; Liu XB, 2010, NAT MED, V16, P191, DOI 10.1038/nm.2077; Luchtman DW, 2014, CYTOKINE GROWTH F R, V25, P403, DOI 10.1016/j.cytogfr.2014.07.013; Ma LL, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/605704; Mishra MK, 2016, NAT REV NEUROL, V12, P539, DOI 10.1038/nrneurol.2016.110; Moreno M, 2014, J NEUROIMMUNOL, V272, P51, DOI 10.1016/j.jneuroim.2014.04.007; Murugaiyan G, 2015, J CLIN INVEST, V125, P1069, DOI 10.1172/JCI74347; Reppert S, 2015, EUR J IMMUNOL, V45, P1426, DOI 10.1002/eji.201445150; Richter GHS, 2009, SCAND J IMMUNOL, V70, P206, DOI 10.1111/j.1365-3083.2009.02281.x; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Shi GP, 2009, J IMMUNOL, V183, P7547, DOI 10.4049/jimmunol.0900519; Simelyte E, 2005, ARTHRITIS RHEUM-US, V52, P1876, DOI 10.1002/ART.21099; Tabarkiewicz J, 2015, ARCH IMMUNOL THER EX, V63, P435, DOI 10.1007/s00005-015-0344-z; Takatori H, 2014, CRIT REV IMMUNOL, V34, P509, DOI 10.1615/CritRevImmunol.2014012193; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Yang J, 2009, ARTHRITIS RHEUM-US, V60, P1472, DOI 10.1002/art.24499; Yazid S, 2015, J AUTOIMMUN, V58, P1, DOI 10.1016/j.jaut.2014.12.004; Zhang SZ, 2011, FASEB J, V25, P2387, DOI 10.1096/fj.10-175299; Zhang X, 2015, J IMMUNOL, V194, P5139, DOI 10.4049/jimmunol.1401680	40	1	3	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2018	9								842	10.3389/fimmu.2018.00842	http://dx.doi.org/10.3389/fimmu.2018.00842			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GD5TF	29740445	Green Published, gold			2022-12-18	WOS:000430568800001
J	Ogasawara, T; Kohashi, Y; Ikari, J; Taniguchi, T; Tsuruoka, N; Watanabe-Takano, H; Fujimura, L; Sakamoto, A; Hatano, M; Hirata, H; Fukushima, Y; Fukuda, T; Kurasawa, K; Tatsumi, K; Tokuhisa, T; Arima, M				Ogasawara, Takashi; Kohashi, Yuko; Ikari, Jun; Taniguchi, Toshibumi; Tsuruoka, Nobuhide; Watanabe-Takano, Haruko; Fujimura, Lisa; Sakamoto, Akemi; Hatano, Masahiko; Hirata, Hirokuni; Fukushima, Yasutsugu; Fukuda, Takeshi; Kurasawa, Kazuhiro; Tatsumi, Koichiro; Tokuhisa, Takeshi; Arima, Masafumi			Allergic T(H)2 Response Governed by B-Cell Lymphoma 6 Function in Naturally Occurring Memory Phenotype CD4(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						B-cell lymphoma 6; naturally occurring memory phenotype T cells; allergy; T(H)2 cells; asthma	GERMINAL-CENTER FORMATION; TH2 DIFFERENTIATION; BCL6 EXPRESSION; TRANSCRIPTION; INFLAMMATION; STIMULATION; GENERATION; IMMUNITY; GENES; BC16	Transcriptional repressor B-cell lymphoma 6 (Bcl6) appears to regulate T(H)2 immune responses in allergies, but its precise role is unclear. We previously reported that Bcl6 suppressed IL-4 production in naive CD4(+) T cell-derived memory T(H)2 cells. To investigate Bcl6 function in allergic responses in naturally occurring memory phenotype CD4(+) T (MPT) cells and their derived T(H)2 (MPT(H)2) cells, Bcl6-manipulated mice, highly conserved intron enhancer (hcIE)-deficient mice, and reporter mice for conserved noncoding sequence 2 (CNS2) 3' distal enhancer region were used to elucidate Bcl6 function in MPT cells. The molecular mechanisms of Bcl6-mediated T(H)2 cytokine gene regulation were elucidated using cellular and molecular approaches. Bcl6 function in MPT cells was determined using adoptive transfer to naive mice, which were assessed for allergic airway inflammation. Bcl6 suppressed IL-4 production in MPT and MPT(H)2 cells by suppressing CNS2 enhancer activity. Bcl6 downregulated Il4 expression in MPT(H)2 cells, but not MPT cells, by suppressing hcIE activity. The inhibitory functions of Bcl6 in MPT and MPT(H)2 cells attenuated allergic responses. Bcl6 is a critical regulator of IL-4 production by MPT and MPT(H)2 cells in T(H)2 immune responses related to the pathogenesis of allergies.	[Ogasawara, Takashi; Ikari, Jun; Tatsumi, Koichiro] Chiba Univ, Grad Sch Med, Dept Respirol B2, Chiba, Japan; [Kohashi, Yuko; Taniguchi, Toshibumi; Watanabe-Takano, Haruko; Sakamoto, Akemi; Hatano, Masahiko; Arima, Masafumi] Chiba Univ, Grad Sch Med, Dept Biomed Sci M14, Chiba, Japan; [Tsuruoka, Nobuhide] Chiba Univ, Grad Sch Med, Dept Reprod Med G4, Chiba, Japan; [Fujimura, Lisa] Chiba Univ, Biomed Res Ctr, Chiba, Japan; [Hirata, Hirokuni; Fukushima, Yasutsugu] Dokkyo Med Univ, Koshigaya Hosp, Dept Resp Med & Clin Immunol, Koshigaya, Japan; [Fukuda, Takeshi] Dokkyo Med Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan; [Kurasawa, Kazuhiro; Arima, Masafumi] Dokkyo Med Univ, Sch Med, Dept Rheumatol, Mibu, Tochigi, Japan; [Tokuhisa, Takeshi] Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba, Japan	Chiba University; Chiba University; Chiba University; Chiba University; Dokkyo Medical University; Dokkyo Medical University; Dokkyo Medical University; Chiba University	Arima, M (corresponding author), Chiba Univ, Grad Sch Med, Dept Biomed Sci M14, Chiba, Japan.; Arima, M (corresponding author), Dokkyo Med Univ, Sch Med, Dept Rheumatol, Mibu, Tochigi, Japan.	masaa@dokkyomed.ac.jp	Arima, Masafumi/L-1951-2018	Arima, Masafumi/0000-0002-5169-7536	Japan Society for the Promotion of Science [JP17K10005, JP24591460]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors thank S. Satake for technical support and S. Nakamura for secretarial services. This work was supported in part by Grants-in-Aid for Scientific Research (C) (JP17K10005: MA; JP24591460: MA) from the Japan Society for the Promotion of Science.	Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Arguni E, 2006, INT IMMUNOL, V18, P1079, DOI 10.1093/intimm/dxl041; Arima M, 2002, J IMMUNOL, V169, P829, DOI 10.4049/jimmunol.169.2.829; BYRNE JA, 1994, J IMMUNOL, V152, P3098; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dobber R, 1992, Dev Immunol, V2, P141, DOI 10.1155/1992/57057; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Harada Y, 2012, IMMUNITY, V36, P188, DOI 10.1016/j.immuni.2012.02.002; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hatzi K, 2015, J EXP MED, V212, P539, DOI 10.1084/jem.20141380; Hirose K, 2017, IMMUNOL REV, V278, P145, DOI 10.1111/imr.12540; Huang T, 2005, CLIN IMMUNOL, V117, P221, DOI 10.1016/j.clim.2005.09.012; Ichii H, 2004, J IMMUNOL, V173, P883, DOI 10.4049/jimmunol.173.2.883; Ichii H, 2002, NAT IMMUNOL, V3, P558, DOI 10.1038/ni802; Ichii H, 2007, INT IMMUNOL, V19, P427, DOI 10.1093/intimm/dxm007; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; Kubo M, 2017, IMMUNOL REV, V278, P162, DOI 10.1111/imr.12557; Liao W, 2014, P NATL ACAD SCI USA, V111, P3508, DOI 10.1073/pnas.1301138111; Liu XD, 2016, CELL REP, V14, P1735, DOI 10.1016/j.celrep.2016.01.038; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Ogasawara T, 2017, P NATL ACAD SCI USA, V114, pE741, DOI 10.1073/pnas.1613528114; Paul WE, 2010, IMMUNOL CELL BIOL, V88, P236, DOI 10.1038/icb.2010.2; Sakano D, 2010, DEV CELL, V18, P450, DOI 10.1016/j.devcel.2009.12.023; Sofi MH, 2011, J IMMUNOL, V186, P2792, DOI 10.4049/jimmunol.1003353; Szabolcs P, 2003, EXP HEMATOL, V31, P708, DOI 10.1016/S0301-472X(03)00160-7; Tanaka S, 2006, IMMUNITY, V24, P689, DOI 10.1016/j.immuni.2006.04.009; Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Tough DF, 2000, VACCINE, V18, P1642, DOI 10.1016/S0264-410X(99)00500-9; Valls E, 2017, CANCER DISCOV, V7, P506, DOI 10.1158/2159-8290.CD-16-1189; VOS Q, 1992, J IMMUNOL, V149, P1204; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yoshida T, 1999, CARDIOVASC RES, V42, P670, DOI 10.1016/S0008-6363(99)00007-3; Younes SA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001171; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Zhou M, 2003, IMMUNOL RES, V28, P25, DOI 10.1385/IR:28:1:25; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	39	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 10	2018	9								750	10.3389/fimmu.2018.00750	http://dx.doi.org/10.3389/fimmu.2018.00750			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GC2AB	29696026	Green Published, gold			2022-12-18	WOS:000429583300001
J	Kanellopoulou, C; Muljo, SA				Kanellopoulou, Chrysi; Muljo, Stefan A.			Posttranscriptional (Re) programming of Cell Fate: Examples in Stem Cells, Progenitor, and Differentiated Cells	FRONTIERS IN IMMUNOLOGY			English	Review						posttranscriptional regulation; RNA-binding protein; microRNA; embryonic stem cell; Th17; fetal hematopoiesis; gene regulatory network; hematopoietic stem and progenitor cells	DEVELOPMENTAL REGULATORS; GENE-EXPRESSION; TH17 CELLS; JARID2; PRC2; TRANSCRIPTION; PLURIPOTENCY; MOUSE; LYMPHOPOIESIS; MIR-155	How a single genome can give rise to many different transcriptomes and thus all the different cell lineages in the human body is a fundamental question in biology. While signaling pathways, transcription factors, and chromatin architecture, to name a few determinants, have been established to play critical roles, recently, there is a growing appreciation of the roles of non-coding RNAs and RNA-binding proteins in controlling cell fates posttranscriptionally. Thus, it is vital that these emerging players are also integrated into models of gene regulatory networks that underlie programs of cellular differentiation. Sometimes, we can leverage knowledge about such posttranscriptional circuits to reprogram patterns of gene expression in meaningful ways. Here, we review three examples from our work.	[Kanellopoulou, Chrysi; Muljo, Stefan A.] NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kanellopoulou, C; Muljo, SA (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	chrysi.kanellopoulou@nih.gov; stefan.mugo@nih.gov	Muljo, Stefan A/F-5671-2015	Muljo, Stefan A/0000-0003-1013-446X	NIH Intramural Research Program of the NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001131] Funding Source: NIH RePORTER	NIH Intramural Research Program of the NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Bill Paul for his leadership, mentorship, friendship and supporting these studies. Ryan Kissinger and Austin Athman (NIAID Visual and Medical Arts) illustrated Figures 1 and 2, respectively. This research was funded by the NIH Intramural Research Program of the NIAID.	Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Bianconi E, 2013, ANN HUM BIOL, V40, P463, DOI 10.3109/03014460.2013.807878; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; CRICK F, 1970, NATURE, V227, P561, DOI 10.1038/227561a0; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Escobar T, 2013, INVEST OPHTH VIS SCI, V54, P4017, DOI 10.1167/iovs.13-11937; Escobar TM, 2014, IMMUNITY, V40, P865, DOI 10.1016/j.immuni.2014.03.014; Graham B, 2016, STEM CELL REP, V6, P635, DOI 10.1016/j.stemcr.2016.03.005; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kanellopoulou C, 2015, STEM CELL REP, V5, P971, DOI 10.1016/j.stemcr.2015.10.001; Kim BM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039239; Landeira D, 2010, NAT CELL BIOL, V12, P618, DOI 10.1038/ncb2065; Lee YT, 2013, BLOOD, V122, P1034, DOI 10.1182/blood-2012-12-472308; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Miyazaki H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003897; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Pereira CF, 2010, CELL STEM CELL, V6, P547, DOI 10.1016/j.stem.2010.04.013; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Witte S, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1905-6; Witte Steven, 2014, JAKSTAT, V3, pe28055, DOI 10.4161/jkst.28055; Yuan J, 2012, SCIENCE, V335, P1195, DOI 10.1126/science.1216557; Zhou Y, 2015, J EXP MED, V212, P569, DOI 10.1084/jem.20141510	31	1	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2018	9								715	10.3389/fimmu.2018.00715	http://dx.doi.org/10.3389/fimmu.2018.00715			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GC0LP	29686685	gold, Green Published			2022-12-18	WOS:000429469100003
J	Cheedarla, N; Hemalatha, B; Anangi, B; Muthuramalingam, K; Selvachithiram, M; Sathyamurthi, P; Kailasam, N; Varadarajan, R; Swaminathan, S; Tripathy, SP; Vaniambadi, SK; Vadakkupattu, DR; Hanna, LE				Cheedarla, Narayanaiah; Hemalatha, Babu; Anangi, Brahmaiah; Muthuramalingam, Kannan; Selvachithiram, Murugesan; Sathyamurthi, Pattabiraman; Kailasam, Nandagopal; Varadarajan, Raghavan; Swaminathan, Soumya; Tripathy, Srikanth Prasad; Vaniambadi, S. Kalyanaraman; Vadakkupattu, D. Ramanathan; Hanna, Luke Elizabeth			Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains	FRONTIERS IN IMMUNOLOGY			English	Article						human immunodeficiency virus type 1; broadly neutralizing antibodies; Indian HIV-1 subtype C infection; evolution of neutralization response; CD4-binding site; glycan-dependent neutralization	IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 BINDING-SITE; CONFORMATIONAL EPITOPE; ANTIBODY-RESPONSES; ELITE NEUTRALIZER; ENVELOPE PROTEIN; FOUNDER VIRUS; IN-VIVO; DESIGN; IDENTIFICATION	Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-infected individuals. However, only 10-30% of infected individuals produce broadly neutralizing antibodies (bNAbs). Identification and characterization of these bNAbs and understanding their evolution dynamics are critical for obtaining useful clues for the development of an effective HIV vaccine. Very recently, we published a study in which we identified 12 HIV-1 subtype C-infected individuals from India whose plasma showed potent and broad cross-clade neutralization (BCN) ability (1). In the present study, we report our findings on the evolution of host bNAb response over a period of 4 years in a subset of these individuals. Three of the five individuals (NAB033, NAB059, and NAB065) demonstrated a significant increase (p < 0.05) in potency. Interestingly, two of the three samples also showed a significant increase in CD4 binding site-specific antibody response, maintained stable CD4+ T cell counts (> 350 cells/mm(3)) and continued to remain ART-naive for more than 10 years after initial diagnosis, implying a strong clinical correlation with the development and evolution of broadly neutralizing antibody response against HIV-1.	[Cheedarla, Narayanaiah; Hemalatha, Babu; Muthuramalingam, Kannan; Selvachithiram, Murugesan; Sathyamurthi, Pattabiraman; Swaminathan, Soumya; Tripathy, Srikanth Prasad; Vadakkupattu, D. Ramanathan; Hanna, Luke Elizabeth] Natl Inst Res TB, Dept HIV AIDS, Madras, Tamil Nadu, India; [Anangi, Brahmaiah] Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Mol Virol Lab, Bangalore, Karnataka, India; [Kailasam, Nandagopal] Kilpauk Med Coll & Hosp, ART Ctr, Madras, Tamil Nadu, India; [Varadarajan, Raghavan] Indian Inst Sci, Mol Biophys Unit, Bangalore, Karnataka, India; [Vaniambadi, S. Kalyanaraman] Adv Biosci Labs Inc, Rockville, MD USA	Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Hanna, LE (corresponding author), Natl Inst Res TB, Dept HIV AIDS, Madras, Tamil Nadu, India.	hanna@nirt.res.in	Cheedarla, Narayanaiah/ABC-5652-2021	Tripathy, Srikanth/0000-0002-8363-2606	University Grants Commission (UGC) India; Indian Council of Medical Research (ICMR); the National Institute for Research in Tuberculosis, ICMR; National Institutes of Health [R01A1118366-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118366] Funding Source: NIH RePORTER	University Grants Commission (UGC) India(University Grants Commission, India); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR)); the National Institute for Research in Tuberculosis, ICMR; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	NC received fellowship from University Grants Commission (UGC) India for the period of 2010 to 2015, and Senior Research Fellowship from the Indian Council of Medical Research (ICMR) from 2016 onward. The work was carried out with intramural research funds from the National Institute for Research in Tuberculosis, ICMR. This work was supported in part by National Institutes of Health Grant R01A1118366-01to RV.	Almeida DV, 2013, AIDS RES HUM RETROV, V29, P488, DOI [10.1089/aid.2012.0052, 10.1089/AID.2012.0052]; Bachu M, 2012, J BIOL CHEM, V287, P44714, DOI 10.1074/jbc.M112.397158; Bhattacharyya S, 2013, J BIOL CHEM, V288, P9815, DOI 10.1074/jbc.M112.425959; Bhattacharyya S, 2010, J BIOL CHEM, V285, P27100, DOI 10.1074/jbc.M110.152272; Bhiman JN, 2015, NAT MED, V21, P1332, DOI 10.1038/nm.3963; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Bruel T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10844; Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158; Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Cheedarla N, 2017, SCI REP-UK, V7, DOI 10.1038/srep46557; Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805; de Almeida DV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167690; Euler Z, 2012, J VIROL, V86, P2045, DOI 10.1128/JVI.06091-11; Gray ES, 2007, J VIROL, V81, P6187, DOI 10.1128/JVI.00239-07; Gray ES, 2011, J VIROL, V85, P7719, DOI 10.1128/JVI.00563-11; Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11; He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041; Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106; Huang JH, 2016, IMMUNITY, V45, P1108, DOI 10.1016/j.immuni.2016.10.027; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; KENNEDY RC, 1986, SCIENCE, V232, P220, DOI 10.1126/science.3952505; Klein F, 2012, J EXP MED, V209, P1469, DOI 10.1084/jem.20120423; Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012; Landais E, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005369; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Lynch RM, 2012, J VIROL, V86, P7588, DOI 10.1128/JVI.00734-12; Montefiori D.C., 2005, CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735.IM1211S64; Moody MA, 2015, CELL HOST MICROBE, V18, P354, DOI 10.1016/j.chom.2015.08.006; Morris L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023532; Nimmerjahn Falk, 2012, Cancer Immun, V12, P13; Pancera M, 2005, VIROLOGY, V332, P145, DOI 10.1016/j.virol.2004.10.042; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; Patil S, 2016, J VIROL, V90, P3446, DOI 10.1128/JVI.03090-15; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Priya RS, 2015, J BIOL CHEM, V290, P9195, DOI 10.1074/jbc.M114.621185; Rusert P, 2016, NAT MED, V22, P1260, DOI 10.1038/nm.4187; Saha P, 2012, BIOCHEMISTRY-US, V51, P1836, DOI 10.1021/bi300003v; Sattentau Quentin J, 2010, F1000 Biol Rep, V2, P60, DOI 10.3410/B2-60; Shankarappa R, 1998, VIROLOGY, V241, P251, DOI 10.1006/viro.1997.8996; Shaw GM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006965; Shcherbakov DN, 2015, ACTA NATURAE, V7, P11, DOI 10.32607/20758251-2015-7-4-11-21; Simonich CA, 2016, CELL, V166, P77, DOI 10.1016/j.cell.2016.05.055; Stamatatos L, 2012, CURR OPIN IMMUNOL, V24, P316, DOI 10.1016/j.coi.2012.04.006; Steckbeck JD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015261; Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Tudor D, 2011, AIDS, V25, P751, DOI 10.1097/QAD.0b013e32834507bd; Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	56	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 27	2018	9								618	10.3389/fimmu.2018.00618	http://dx.doi.org/10.3389/fimmu.2018.00618			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GA6DB	29662494	Green Published, Green Accepted, gold			2022-12-18	WOS:000428422000001
J	Pastor-Vargas, C; Esteban, V				Pastor-Vargas, Carlos; Esteban, Vanesa			Editorial: New insights in anaphylaxis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						anaphylaxis; drug and food allergy; molecular signaling; augmentine factors; endothelial cells			[Pastor-Vargas, Carlos; Esteban, Vanesa] UAM, Inst Invest Sanitaria Hosp Univ Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain	Autonomous University of Madrid; Fundacion Jimenez Diaz	Esteban, V (corresponding author), UAM, Inst Invest Sanitaria Hosp Univ Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain.	vesteban@fjd.es	Pastor Vargas, Carlos/B-4112-2010; Esteban, Vanesa/J-8075-2012	Pastor Vargas, Carlos/0000-0002-4678-7967; Esteban, Vanesa/0000-0002-7500-6277	Spanish Council Ministry of Science and Innovation (Ramon y Cajal Program) [RyC-12880-2013]; Fundacion Merck Salud; program LOREAL for women in science; Instituto de Salud Carlos III [PI16/00888]; RETIC ARADYAL [RD16/0006/0013]; FEDER grants	Spanish Council Ministry of Science and Innovation (Ramon y Cajal Program); Fundacion Merck Salud; program LOREAL for women in science; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); RETIC ARADYAL; FEDER grants	This work was supported by the Spanish Council Ministry of Science and Innovation (Ramon y Cajal Program RyC-12880-2013), the Fundacion Merck Salud, and the program LOREAL for women in science 2016 (for VE). This work was also supported by grants from the Instituto de Salud Carlos III (PI16/00888) and RETIC ARADYAL (RD16/0006/0013), co-supported by FEDER grants.		0	1	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 14	2018	9								506	10.3389/fimmu.2018.00506	http://dx.doi.org/10.3389/fimmu.2018.00506			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FZ2JU	29593740	Green Published, gold			2022-12-18	WOS:000427404900001
J	Kremer, L; Garcia-Sanz, JA				Kremer, Leonor; Garcia-Sanz, Jose A.			Editorial: is the recent Burst of therapeutic anti-tumor antibodies the tip of an iceberg?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antitumor therapeutic antibodies; antibodies in combinations; effective cancer therapies; therapeutic antibodies; immunotherapy			[Kremer, Leonor] CSIC, Spanish Natl Res Council, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain; [Garcia-Sanz, Jose A.] CSIC, Spanish Natl Res Council, Ctr Invest Biol, Canc Genet & Canc Stem Cell Lab,Dept Mol Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Kremer, L (corresponding author), CSIC, Spanish Natl Res Council, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain.; Garcia-Sanz, JA (corresponding author), CSIC, Spanish Natl Res Council, Ctr Invest Biol, Canc Genet & Canc Stem Cell Lab,Dept Mol Biomed, Madrid, Spain.	lkremer@cnb.csic.es; jasanz@cib.csic.es	Garcia-Sanz, Jose A./AAA-2956-2019; Garcia-Sanz, Jose A/E-7684-2011; Kremer, Leonor/L-5445-2015	Garcia-Sanz, Jose A./0000-0002-1153-6025; Garcia-Sanz, Jose A/0000-0002-1153-6025; Kremer, Leonor/0000-0002-2235-2010	CSIC - FEDER funds from the EU [PIE-201420E109, PIE-201720E092]; PN-A from the ISCIII (FEDER funds from the EU, Operative program on Intelligent Growth) - FEDER funds from the EU; Spanish Ministry of Economy, Industry and Competitiveness - FEDER funds from the EU [RTC-2015-3786-1, RTC2015-3846-1]; PN-A from the ISCIII [PI14/00703]	CSIC - FEDER funds from the EU; PN-A from the ISCIII (FEDER funds from the EU, Operative program on Intelligent Growth) - FEDER funds from the EU; Spanish Ministry of Economy, Industry and Competitiveness - FEDER funds from the EU; PN-A from the ISCIII	The work in the author's laboratories was partially supported by grants from the CSIC (PIE-201420E109 and PIE-201720E092, to LK), the PN2014-A from the ISCIII (PI14/00703, cofinanced by FEDER funds from the EU, Operative program on Intelligent Growth 2014-2020, to LK), and from the Spanish Ministry of Economy, Industry and Competitiveness (RTC-2015-3786-1 to LK and JG-S and RTC2015-3846-1 to JG-S), both cofinanced by FEDER funds from the EU.	Callahan MK, 2013, J LEUKOCYTE BIOL, V94, P41, DOI 10.1189/jlb.1212631; Prieto PA, 2016, CANCER J, V22, P138, DOI 10.1097/PPO.0000000000000182; Romano G, 2017, DRUG TODAY, V53, P103, DOI 10.1358/dot.2017.53.2.2592798	3	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2018	9								442	10.3389/fimmu.2018.00442	http://dx.doi.org/10.3389/fimmu.2018.00442			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FY3NS	29556241	Green Published, gold			2022-12-18	WOS:000426727400001
J	van Balen, P; van der Zouwen, B; Kruisselbrink, AB; Eefting, M; Szuhai, K; Jordanova, ES; Falkenburg, JHF; Jedema, I				van Balen, Peter; van der Zouwen, Boris; Kruisselbrink, Alwine B.; Eefting, Matthijs; Szuhai, Karoly; Jordanova, Ekaterina S.; Falkenburg, J. H. F.; Jedema, Inge			Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-cell Interaction	FRONTIERS IN IMMUNOLOGY			English	Article						HLA class II; tissue damage; allogeneic stem cell transplantation; graft-versus-host disease; macrophages; skin	VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; DONOR LYMPHOCYTE INFUSION; HLA-CLASS-II; COMPLETE REMISSION; DENDRITIC CELLS; SKIN; ACTIVATION; EXPRESSION	Introduction: Conditioning regimens preceding allogeneic stem cell transplantation (alloSCT) can cause tissue damage and acceleration of the development of graft-versus-host disease (GVHD). T-cell-depleted alloSCT with postponed donor lymphocyte infusion (DLI) may reduce GVHD, because tissue injury can be restored at the time of DLI. In this study, we investigated the presence of tissue injury and inflammation in skin during the period of hematologic recovery and immune reconstitution after alloSCT. Methods: Skin biopsies were immunohistochemically stained for HLA class II, CD1a, CD11c, CD40, CD54, CD68, CD86, CD206, CD3, and CD8. HLA class II-expressing cells were characterized as activated T-cells, antigen-presenting cells (APCs), or tissue repairing macrophages. In sex-mismatched patient and donor couples, origin of cells was determined by multiplex analysis combining XY-FISH and fluorescent immunohistochemistry. Results: No inflammatory environment due to pretransplant conditioning was detected at the time of alloSCT, irrespective of the conditioning regimen. An increase in HLA class II-positive macrophages and CD3 T-cells was observed 12-24 weeks after myeloablative alloSCT, but these macrophages did not show signs of interaction with the co-localized T-cells. In contrast, during GVHD, an increase in HLA class II-expressing cells coinciding with T-cell interaction was observed, resulting in an overt inflammatory reaction with the presence of activated APC, activated donor T-cells, and localized upregulation of HLA class II expression on epidermal cells. In the absence of GVHD, patient derived macrophages were gradually replaced by donor-derived macrophages although patient-derived macrophages were detectable even 24 weeks after alloSCT. Conclusion: Conditioning regimens cause tissue damage in the skin, but this does not result in a local increase of activated APC. In contrast to the inflamed situation in GVHD, when interaction takes place between activated APC and donor T-cells, the tissue damage caused by myeloablative alloSCT results in dermal recruitment of HLA class II-positive tissue repairing macrophages co-existing with increased numbers of patient- and donor-derived T-cells, but without signs of specific interaction and initiation of an immune response. Thus, the local skin damage caused by the conditioning regimen appears to be insufficient as single factor to provoke GVHD induction.	[van Balen, Peter; van der Zouwen, Boris; Kruisselbrink, Alwine B.; Eefting, Matthijs; Falkenburg, J. H. F.; Jedema, Inge] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands; [Kruisselbrink, Alwine B.; Jordanova, Ekaterina S.] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; [Szuhai, Karoly] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands; [Jordanova, Ekaterina S.] Vrije Univ Amsterdam Med Ctr, Ctr Gynaecol Oncol Amsterdam, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	van Balen, P (corresponding author), Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands.	p.van_balen@lumc.nl	Szuhai, Karoly/A-1100-2008	Szuhai, Karoly/0000-0002-1228-4245; Van Balen, Peter/0000-0002-9670-4664				Ali N, 2017, IMMUNOLOGY, V152, P372, DOI 10.1111/imm.12791; Barge RMY, 2006, BONE MARROW TRANSPL, V37, P1129, DOI 10.1038/sj.bmt.1705385; Bayraktar UD, 2013, BIOL BLOOD MARROW TR, V19, P898, DOI 10.1016/j.bbmt.2013.02.018; BESCHORNER WE, 1987, TRANSPLANTATION, V44, P237, DOI 10.1097/00007890-198708000-00013; Boeck S, 2006, BONE MARROW TRANSPL, V37, P57, DOI 10.1038/sj.bmt.1705217; Cantoni N, 2010, BIOL BLOOD MARROW TR, V16, P1309, DOI 10.1016/j.bbmt.2010.03.020; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Durakovic N, 2007, BLOOD, V109, P4564, DOI 10.1182/blood-2006-09-048124; Eefting M, 2014, BONE MARROW TRANSPL, V49, P287, DOI 10.1038/bmt.2013.111; Eefting M, 2016, HAEMATOLOGICA, V101, P506, DOI 10.3324/haematol.2015.136846; Favre A, 1997, AM J SURG PATHOL, V21, P23, DOI 10.1097/00000478-199701000-00003; Fehres CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143519; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Kottaridis PD, 2000, BLOOD, V96, P2419; Mclellan AD, 1999, IMMUNOLOGY, V98, P171; Miller HK, 2017, BIOL BLOOD MARROW TR, V23, P522, DOI 10.1016/j.bbmt.2016.12.630; Novak ML, 2013, J LEUKOCYTE BIOL, V93, P875, DOI 10.1189/jlb.1012512; Ochoa MT, 2008, J INVEST DERMATOL, V128, P2225, DOI 10.1038/jid.2008.56; Pasquini MC, 2012, J CLIN ONCOL, V30, P3194, DOI 10.1200/JCO.2012.41.7071; Peggs KS, 2004, BLOOD, V103, P1548, DOI 10.1182/blood-2003-05-1513; Stevanovic S, 2013, BLOOD, V122, P1963, DOI 10.1182/blood-2012-12-470872; Toubai T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00539; van der Zouwen B, 2012, BIOL BLOOD MARROW TR, V18, P1353, DOI 10.1016/j.bbmt.2012.06.017; von dem Borne Peter A, 2009, Curr Opin Oncol, V21 Suppl 1, pS27, DOI 10.1097/01.cco.0000357472.76337.0e; Xu P, 2017, INFLAMMATION, V40, P1416, DOI 10.1007/s10753-017-0585-6; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225	26	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 27	2018	9								331	10.3389/fimmu.2018.00331	http://dx.doi.org/10.3389/fimmu.2018.00331			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FX6OF	29535719	Green Published, gold			2022-12-18	WOS:000426204300001
J	Ten Brinke, A; Marek-Trzonkowska, N; Mansilla, MJ; Turksma, AW; Piekarska, K; Iwaszkiewicz-Grzes, D; Passerini, L; Locafaro, G; Punet-Ortiz, J; van Ham, SM; Hernandez-Fuentes, MP; Martinez-Caceres, EM; Gregori, S				Ten Brinke, Anja; Marek-Trzonkowska, Natalia; Mansilla, Maria J.; Turksma, Annelies W.; Piekarska, Karolina; Iwaszkiewicz-Grzes, Dorota; Passerini, Laura; Locafaro, Grazia; Punet-Ortiz, Joan; van Ham, S. Marieke; Hernandez-Fuentes, Maria P.; Martinez-Caceres, Eva M.; Gregori, Silvia			Monitoring T-Cell Responses in Translational Studies: Optimization of Dye-Based Proliferation Assay for Evaluation of Antigen-Specific Responses (vol 8, 1870, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						tolerance; monitoring; proliferation; antigen-specific; T cells; transplantation; autoimmune diseases; immune-therapies			[Ten Brinke, Anja; Turksma, Annelies W.; van Ham, S. Marieke] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; [Ten Brinke, Anja; Turksma, Annelies W.; van Ham, S. Marieke] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, Amsterdam, Netherlands; [Marek-Trzonkowska, Natalia; Piekarska, Karolina] Med Univ Gdansk, Dept Family Med, Lab Immunoregulat & Cellular Therapies, Gdansk, Poland; [Mansilla, Maria J.; Punet-Ortiz, Joan; Martinez-Caceres, Eva M.] Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp & Res Inst, Immunol Div, Dept Cellular Biol,Physiol & Immunol, Barcelona, Spain; [Iwaszkiewicz-Grzes, Dorota] Med Univ Gdansk, Dept Clin Immunol & Transplantol, Gdansk, Poland; [Passerini, Laura; Locafaro, Grazia; Gregori, Silvia] IRCCS, San Raffaele Telethon Inst Gene Therapy SR Tiget, Div Regenerat Med Stem Cells & Gene Therapy, San Raffaele Sci Inst, Milan, Italy; [Hernandez-Fuentes, Maria P.] Kings Coll London, MRC, Ctr Transplantat, London, England; [Hernandez-Fuentes, Maria P.] UCB Pharma, Slough, Berks, England	University of Amsterdam; Academic Medical Center Amsterdam; Fahrenheit Universities; Medical University Gdansk; Autonomous University of Barcelona; Fahrenheit Universities; Medical University Gdansk; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; King's College London; UCB Pharma SA	Ten Brinke, A (corresponding author), Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands.; Ten Brinke, A (corresponding author), Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, Amsterdam, Netherlands.	a.tenbrinke@sanquin.nl	Passerini, Laura/J-7791-2016; Martinez-Caceres, Eva/R-5990-2019; Iwaszkiewicz-Grzes, Dorota/AAP-7476-2020; Fuentes, Maria/HGA-8617-2022; Iwaszkiewicz-Grzes, Dorota/U-1205-2018; Maria, Hernandez-Fuentes/B-5011-2010; Piekarska, Karolina/T-7440-2018	Passerini, Laura/0000-0002-4020-7386; Martinez-Caceres, Eva/0000-0002-6762-8025; Iwaszkiewicz-Grzes, Dorota/0000-0003-1177-1874; Maria, Hernandez-Fuentes/0000-0002-7558-9441; Marek- Trzonkowska, Natalia/0000-0003-1201-295X; Piekarska, Karolina/0000-0001-7197-0395				BRINKE AT, 2017, FRONT IMMUNOL, V8	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2018	9								343	10.3389/fimmu.2018.00343	http://dx.doi.org/10.3389/fimmu.2018.00343			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FX0WH	29493663	gold, Green Published			2022-12-18	WOS:000425767600001
J	Martinez-Guzman, MA; Alvarado-Navarro, A; Delgado-Rizo, V; Garcia-Orozco, A; Mayorga-Rodriguez, JA; Pereira-Suarez, AL; Fafutis-Morris, M				Alonso Martinez-Guzman, Marco; Alvarado-Navarro, Anabell; Delgado-Rizo, Vidal; Garcia-Orozco, Alejandra; Arturo Mayorga-Rodriguez, Jorge; Laura Pereira-Suarez, Ana; Fafutis-Morris, Mary			Serum Levels of Migration Inhibitory Factor (MIF) and In Situ Expression of MIF and Its Receptor CD74 in Lepromatous Leprosy Patients: A Preliminary Report	FRONTIERS IN IMMUNOLOGY			English	Article						leprosy; lepromatous leprosy; skin; serum cytokines; migration inhibitory factor; CD74	INVARIANT CHAIN; MACROPHAGE; SKIN; CELLS; IMMUNITY	Leprosy is a chronic disease caused by Mycobacterium leprae that affects the skin and peripheral nerves. It may present as one of two distinct poles: the self-limiting tuberculoid leprosy and the highly infectious lepromatous leprosy (LL) characterized by M. leprae-specific absence of cellular immune response. The pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) enhance the bactericide activities of macrophages after interaction with its receptor, CD74. Importantly, MIF also possesses chemoattractant properties, and it is a key factor in situ for the activation of macrophages and in blood to promote leukocytes migration. MIF-mediated activation of macrophages is a key process for the elimination of pathogens such as Mycobacterium tuberculosis; however, its participation for the clearance of M. leprae is unclear. The aim of this study was to evaluate the serum levels of MIF as well as MIF and CD74 expression in skin lesions of LL and compare it with healthy skin (HSk) taken from subjects attending to dermatological consult. Samples of serum and skin biopsies were taken from 39 LL patients and compared with 36 serum samples of healthy subjects (HS) and 10 biopsies of HSk. Serum samples were analyzed by ELISA and skin biopsies by immunohistochemistry (IHC). IHC smears were observed in 12 100x microscopic fields, in which percentage of stained cells and staining intensity were evaluated. Both variables were used to calculate a semi-quantitative expression score that ranged from 0 to 3+. We found no differences in MIF levels between LL patients and HS in sera. In addition, MIF was observed in over 75% of cells with high intensity in the skin of patients and HSk. Although we found no differences in MIF expression between the groups, a CD74 score statistically higher was found in LL skin than HSk (p < 0.001); this was the result of a higher percentage of cells positive for CD74 (p < 0.001). As a conclusion, we found that CD74-positive cells are intensely recruited to the skin with LL lesions. In this manner, MIF signaling may be enhanced in the skin of LL patients due to increased expression of its receptor, but further studies are required.	[Alonso Martinez-Guzman, Marco; Garcia-Orozco, Alejandra] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Fisiol, Ciencias Biomed Orientac Inmunol, Guadalajara, Mexico; [Alonso Martinez-Guzman, Marco; Alvarado-Navarro, Anabell; Garcia-Orozco, Alejandra; Fafutis-Morris, Mary] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Fisiol, Ctr Invest Inmunol & Dermatol, Guadalajara, Mexico; [Delgado-Rizo, Vidal; Laura Pereira-Suarez, Ana] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Fisiol, Lab Inmunol, Guadalajara, Mexico; [Arturo Mayorga-Rodriguez, Jorge] Inst Dermatol Jalisco Dr Jose Barba Rubio, Lab Micol, Zapopan, Mexico	Universidad de Guadalajara; Universidad de Guadalajara; Universidad de Guadalajara	Fafutis-Morris, M (corresponding author), Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Fisiol, Ctr Invest Inmunol & Dermatol, Guadalajara, Mexico.	mfafutis@gmail.com	Fafutis-Morris, Mary/AGG-1618-2022; Pereira, Ana Laura/AAE-6652-2020	Pereira, Ana Laura/0000-0002-6310-3715; Alvarado Navarro, Anabell/0000-0002-5719-1712				Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; Bansal F, 2017, INDIAN J DERMATOL VE, DOI [10.4103/ijdvl.IJDVL, DOI 10.4103/IJDVL.IJDVL]; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Brocks T, 2017, FASEB J, V31, P526, DOI 10.1096/fj.201600860R; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2003, J INFECT DIS, V187, pS385, DOI 10.1086/374752; Das R, 2013, P NATL ACAD SCI USA, V110, pE2997, DOI 10.1073/pnas.1301128110; de Sousa JR, 2017, J CLIN PATHOL, V70, P521, DOI 10.1136/jclinpath-2016-204110; de Sousa JR, 2016, ACTA TROP, V157, P108, DOI 10.1016/j.actatropica.2016.01.008; Hashimoto K, 2002, INFECT IMMUN, V70, P5167, DOI 10.1128/IAI.70.9.5167-5176.2002; Holowka T, 2016, FASEB J, V30, P2249, DOI 10.1096/fj.201500189R; Juttner S, 1998, J IMMUNOL, V161, P2383; Landsverk OJB, 2009, SCAND J IMMUNOL, V70, P184, DOI 10.1111/j.1365-3083.2009.02301.x; Lastoria JC, 2014, AN BRAS DERMATOL, V89, P205, DOI 10.1590/abd1806-4841.20142450; Lee DJ, 2007, J IMMUNOL, V179, P8128, DOI 10.4049/jimmunol.179.12.8128; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Li YX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118391; Liang YY, 2015, METABOLISM, V64, P1682, DOI 10.1016/j.metabol.2015.09.007; Martinez-Guzman MA, 2016, HUM IMMUNOL, V77, P985, DOI 10.1016/j.humimm.2016.07.006; da Silva VPM, 2013, AN BRAS DERMATOL, V88, P105, DOI 10.1590/abd1806-4841.20132050; Massone C, 2015, CLIN DERMATOL, V33, P38, DOI 10.1016/j.clindermatol.2014.10.003; Salem SA, 2016, INT J DERMATOL, V55, P1357, DOI 10.1111/ijd.13344; Schroder B, 2016, BBA-MOL CELL RES, V1863, P1269, DOI 10.1016/j.bbamcr.2016.03.026; Steinhoff M, 1999, BRIT J DERMATOL, V141, P1061, DOI 10.1046/j.1365-2133.1999.03206.x; Tillmann S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00115; World Health Organization, 2017, WEEKL EP REC REL EP; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yang DG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004335	28	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 13	2018	9								246	10.3389/fimmu.2018.00246	http://dx.doi.org/10.3389/fimmu.2018.00246			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FV9MP	29487601	Green Published, gold			2022-12-18	WOS:000424912700002
J	Di Rosa, F; Rocha, B				Di Rosa, Francesca; Rocha, Benedita			Commentary: Maintenance of CD8(+) T Memory Lymphocytes in the Spleen but Not in the Bone Marrow Is Dependent on Proliferation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunological memory; CD8 T cells; bone marrow; homeostatic proliferation; Cyclophosphamide	HOMEOSTATIC PROLIFERATION; IN-VIVO; IL-7R-ALPHA EXPRESSION; CELLS; CYCLOPHOSPHAMIDE; NAIVE; PHENOTYPE; SELECTION; DYNAMICS; KINETICS		[Di Rosa, Francesca] Sapienza Univ, Inst Mol Biol & Pathol, Dept Mol Med, CNR, Rome, Italy; [Rocha, Benedita] Inst Pasteur, CNRS URA 196, Populat Biol Unit, Paris, France; [Rocha, Benedita] Univ Paris 05, CNRS, Inst Necker Enfants Malades, INSERM,U1151,UMR8253, Paris, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Di Rosa, F (corresponding author), Sapienza Univ, Inst Mol Biol & Pathol, Dept Mol Med, CNR, Rome, Italy.	francesca.dirosa@uniroma1.it	Di Rosa, Francesca/AAW-8612-2020	Di Rosa, Francesca/0000-0003-0252-9138	Ministero dell'Universita e delle Ricerca (MIUR) [CTN01_00177_962865]	Ministero dell'Universita e delle Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	FD is supported by CTN01_00177_962865 (Medintech) grant from Ministero dell'Universita e delle Ricerca (MIUR).	Ahlmann M, 2016, CANCER CHEMOTH PHARM, V78, P661, DOI 10.1007/s00280-016-3152-1; Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; Alp OS, 2015, EUR J IMMUNOL, V45, P975, DOI 10.1002/eji.201445295; Becker TC, 2005, J IMMUNOL, V174, P1269, DOI 10.4049/jimmunol.174.3.1269; Cassese G, 2007, BLOOD, V110, P1960, DOI 10.1182/blood-2006-09-045807; Di Rosa F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00102; Di Rosa F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00596; Di Rosa F, 2016, TRENDS IMMUNOL, V37, P503, DOI 10.1016/j.it.2016.05.004; Di Rosa F, 2016, NAT REV IMMUNOL, V16, P271, DOI 10.1038/nri.2016.31; FREITAS AA, 1986, IMMUNOL REV, V91, P5, DOI 10.1111/j.1600-065X.1986.tb01482.x; FREITAS AA, 1982, J IMMUNOL, V128, P54; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Goncalves P, 2017, MOL IMMUNOL, V85, P66, DOI 10.1016/j.molimm.2017.01.026; Kalia V, 2015, IMMUNITY, V42, P1116, DOI 10.1016/j.immuni.2015.05.023; Klonowski KD, 2004, IMMUNITY, V20, P551, DOI 10.1016/S1074-7613(04)00103-7; Maeda Y, 2010, INT IMMUNOL, V22, P515, DOI 10.1093/intimm/dxq036; Nolte MA, 2017, EUR J IMMUNOL, V47, P1875, DOI 10.1002/eji.201747249; PABST R, 1986, IMMUNOLOGY, V59, P217; Paiardini M, 2009, BLOOD, V113, P612, DOI 10.1182/blood-2008-06-159442; Parretta E, 2005, J IMMUNOL, V174, P7654, DOI 10.4049/jimmunol.174.12.7654; Parretta E, 2008, J IMMUNOL, V180, P7230, DOI 10.4049/jimmunol.180.11.7230; Quinci AC, 2012, EUR J IMMUNOL, V42, P1129, DOI 10.1002/eji.201142019; Schiavoni G, 2000, BLOOD, V95, P2024, DOI 10.1182/blood.V95.6.2024; Schiavoni G, 2011, CANCER RES, V71, P768, DOI 10.1158/0008-5472.CAN-10-2788; Sercan-Alp O, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00329; Siracusa F, 2017, EUR J IMMUNOL, V47, P1900, DOI 10.1002/eji.201747063; Skirecki T, 2017, J IMMUNOL, V198; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; White JT, 2017, NAT REV IMMUNOL, V17, P391, DOI 10.1038/nri.2017.34; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048	30	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2018	9								122	10.3389/fimmu.2018.00122	http://dx.doi.org/10.3389/fimmu.2018.00122			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FU4IN	29449844	Green Published, gold			2022-12-18	WOS:000423816800001
J	Bekele, Y; Graham, RL; Soeria-Atmadja, S; Nasi, A; Zazzi, M; Vicenti, I; Naver, L; Nilsson, A; Chiodi, F				Bekele, Yonas; Graham, Rebecka Lantto; Soeria-Atmadja, Sandra; Nasi, Aikaterini; Zazzi, Maurizio; Vicenti, Ilaria; Naver, Lars; Nilsson, Anna; Chiodi, Francesca			Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults A Tool to Reduce the Size of HIV-1 Reservoirs?	FRONTIERS IN IMMUNOLOGY			English	Article						vaccination; hepatitis B virus; hepatitis A virus; HI V-1 reservoirs; anti-retroviral therapy; immune activation; T-cell proliferation	CD8(+) T-CELLS; SUPPRESSIVE ANTIRETROVIRAL THERAPY; INFLUENZA VACCINATION; VIRAL LOAD; LATENT RESERVOIR; IMMUNE-RESPONSE; INFECTION; REPLICATION; CHILDREN; TRIAL	During anti-retroviral therapy (ART) HIV-1 persists in cellular reservoirs, mostly represented by CD4+ memory T cells. Several approaches are currently being undertaken to develop a cure for HIV-1 infection through elimination (or reduction) of these reservoirs. Few studies have so far been conducted to assess the possibility of reducing the size of HIV-1 reservoirs through vaccination in virologically controlled HIV-1-infected children. We recently conducted a vaccination study with a combined hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccine in 22 HIV-1-infected children. We assessed the size of the virus reservoir, measured as total HIV-1 DNA copies in blood cells, pre-and postvaccination. In addition, we investigated by immunostaining whether the frequencies of CD4+ and CD8+ T cells and parameters of immune activation and proliferation on these cells were modulated by vaccination. At 1 month from the last vaccination dose, we found that 20 out of 22 children mounted a serological response to HBV; a majority of children had antibodies against HAV at baseline. The number of HIV-1 DNA copies in blood at 1 month postvaccination was reduced in comparison to baseline although this reduction was not statistically significant. A significant reduction of HIV-1 DNA copies in blood following vaccination was found in 12 children. The frequencies of CD4+ (naive, effector memory) and CD8+ (central memory) T-cell subpopulations changed following vaccinations and a reduction in the activation and proliferation pattern of these cells was also noticed. Multivariate linear regression analysis revealed that the frequency of CD8+ effector memory T cells prior to vaccination was strongly predictive of the reduction of HIV-1 DNA copies in blood following vaccination of the 22 HIV-1-infected children. The results of this study suggest a beneficial effect of vaccination to reduce the size of virus reservoir in HIV-1-infected children receiving ART. A reduced frequency of activated CD4+ cells and an increase in central memory CD8+ T cells were associated with this finding. Further studies should assess whether vaccination is a possible tool to reduce HIV-1 reservoirs.	[Bekele, Yonas; Graham, Rebecka Lantto; Nasi, Aikaterini; Chiodi, Francesca] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Soeria-Atmadja, Sandra; Naver, Lars] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden; [Soeria-Atmadja, Sandra; Naver, Lars] Karolinska Univ Hosp, Dept Pediat, Stockholm, Sweden; [Zazzi, Maurizio; Vicenti, Ilaria] Univ Siena, Dept Med Biotechnol, Siena, Italy; [Nilsson, Anna] Karolinska Inst, Dept Womens & Children Hlth, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Siena; Karolinska Institutet	Chiodi, F (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.	francesca.chiodi@ki.se	Bekele, Yonas/AAN-6710-2021; Zazzi, Maurizio/K-3422-2018; , ilariavicenti/AAU-6986-2020; Navér, Lars/E-5085-2013; Vicenti, Ilaria/AAP-9663-2020	Zazzi, Maurizio/0000-0002-0344-6281; Vicenti, Ilaria/0000-0002-4306-2960; Chiodi, Francesca/0000-0002-1385-8343; Nilsson, Anna/0000-0001-5885-7101; Naver, Lars/0000-0001-6027-0211	Swedish Medical Research Council [2011-03375]; Karolinska Institutet	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet(Karolinska Institutet)	The study was supported with grants from the Swedish Medical Research Council (grant number 2011-03375). Yonas Bekele is the recipient of a PhD scholarship from the Karolinska Institutet.	Amu S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003738; Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286; Besson GJ, 2014, CLIN INFECT DIS, V59, P1312, DOI 10.1093/cid/ciu585; Bruner KM, 2015, TRENDS MICROBIOL, V23, P192, DOI 10.1016/j.tim.2015.01.013; Buckheit RW, 2012, J VIROL, V86, P13679, DOI 10.1128/JVI.02439-12; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Comber JD, 2014, HEPAT RES TREAT, V2014, DOI [DOI 10.1155/2014/860562, 10.1155/2014/860562]; Cotton MF, 2013, LANCET, V382, P1555, DOI 10.1016/S0140-6736(13)61409-9; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Delagreverie HM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw189; Desmond CP, 2008, ANTIVIR THER, V13, P161; Elliott JH, 2015, LANCET HIV, V2, pE520, DOI 10.1016/S2352-3018(15)00226-X; FERRARI C, 1990, J IMMUNOL, V145, P3442; Frange P, 2016, LANCET HIV, V3, pE49, DOI 10.1016/S2352-3018(15)00232-5; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; Goulder PJ, 2016, NAT REV IMMUNOL, V16, P259, DOI 10.1038/nri.2016.19; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Gunthard HF, 2000, J INFECT DIS, V181, P522, DOI 10.1086/315260; Hosmane NN, 2017, J EXP MED, V214, P959, DOI 10.1084/jem.20170193; Hurst J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9495; Jones RB, 2016, J CLIN INVEST, V126, P455, DOI 10.1172/JCI80566; Kiselinova M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005472; Leth S, 2016, LANCET HIV, V3, pE463, DOI 10.1016/S2352-3018(16)30055-8; Matthews PC, 2016, J INFECT DIS, V213, P1248, DOI 10.1093/infdis/jiv592; McManus M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154391; OBRIEN WA, 1995, BLOOD, V86, P1082; Offit PA, 2008, VACCINES-BASEL, V2, P17, DOI 10.1016/b978-1-4557-0090-5.00004-5; Rasmussen TA, 2014, LANCET HIV, V1, pE13, DOI 10.1016/S2352-3018(14)70014-1; Resino S, 2003, J CLIN IMMUNOL, V23, P279, DOI 10.1023/A:1024536816684; Rosenblatt HM, 2005, J INFECT DIS, V192, P445, DOI 10.1086/431597; Rudy BJ, 2015, JAIDS-J ACQ IMM DEF, V69, P52, DOI 10.1097/QAI.0000000000000549; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Said ZNA, 2015, WORLD J HEPATOL, V7, P1660, DOI 10.4254/wjh.v7.i12.1660; Sereti I, 2017, CLIN INFECT DIS, V64, P124, DOI 10.1093/cid/ciw683; Spivak AM, 2016, TRENDS MOL MED, V22, P10, DOI 10.1016/j.molmed.2015.11.004; Spivak AM, 2014, CLIN INFECT DIS, V58, P883, DOI 10.1093/cid/cit813; Vicenti I, 2018, CLIN CHEM LAB MED, V56, pE75, DOI 10.1515/cclm-2017-0587; Violari A, 2017, 9 IAS C HIV SCI PAR; Wagner TA, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0135-1; Yamamoto T, 2012, J VIROL, V86, P5877, DOI 10.1128/JVI.00315-12	43	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2018	8								1966	10.3389/fimmu.2017.01966	http://dx.doi.org/10.3389/fimmu.2017.01966			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FS3WK		Green Published, gold			2022-12-18	WOS:000419714700001
J	Angelini, C; Varano, B; Puddu, P; Fiori, M; Baldassarre, A; Masotti, A; Gessani, S; Conti, L				Angelini, Costanza; Varano, Barbara; Puddu, Patrizia; Fiori, Maurizio; Baldassarre, Antonella; Masotti, Andrea; Gessani, Sandra; Conti, Lucia			Direct and Intestinal Epithelial Cell-Mediated Effects of TLR8 Triggering on Human Dendritic Cells, CD14(+)CD16(+) Monocytes and gamma delta T Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Article						cell activation; pathogen recognition; inflammation; microenvironment; adjuvant	TOLL-LIKE RECEPTORS; PATTERN-RECOGNITION RECEPTORS; INFLAMMATORY-BOWEL-DISEASE; RESPONSE MODIFIER R-848; IMMUNE-RESPONSES; CROHNS-DISEASE; TLR7/8 LIGAND; TNF-ALPHA; DIFFERENTIATION; IMMUNOTHERAPY	Toll-like receptor (TLR) 7/8 plays a crucial role in host recognition/response to viruses and its mucosal expression directly correlates with intestinal inflammation. The aim of this study was to investigate the role of TLR7/8 stimulation of intestinal epithelium in shaping the phenotype and functions of innate immunity cell subsets, and to define direct and/or epithelial cell-mediated mechanisms of the TLR7/8 agonist R848 immunomodulatory activity. We describe novel, TLR8-mediated, pro(-) and anti-inflammatory effects of R848 on ex vivo cultured human blood monocytes and gamma delta T lymphocytes, either induced by direct immune cell stimulation or mediated by intestinal epithelial cells (IEC). Apical stimulation with R848 led to its transport across normal polarized epithelial cell monolayer and resulted in the inhibition of monocyte differentiation toward immunostimulatory dendritic cells and Th1 type response. Furthermore, gamma delta T lymphocyte activation was promoted following direct exposure of these cells to the agonist. Conversely, a selective enrichment of the CD14(+)CD16(+) monocyte subpopulation was observed, which required a CCL2-mediated inflammatory response of normal epithelial cells to R848. Of note, a TLR-mediated activation of control gamma delta T lymphocytes was promoted by inflamed intestinal epithelium from active Crohn's disease patients. This study unravels a novel regulatory mechanism linking the activation of the TLR8 pathway in IEC to the monocyte-mediated inflammatory response, and highlights the capacity of the TLR7/8 agonist R848 to directly enhance the activation of gamma delta T lymphocytes. Overall these results expand the range of cell targets and immune responses controlled by TLR8 triggering that may contribute to the antiviral response, to chronic inflammation, as well as to the adjuvant activity of TLR8 agonists, highlighting the role of intestinal epithelium microenvironment in shaping TLR agonist-induced responses.	[Angelini, Costanza; Varano, Barbara; Puddu, Patrizia; Gessani, Sandra; Conti, Lucia] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy; [Varano, Barbara; Gessani, Sandra; Conti, Lucia] Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy; [Fiori, Maurizio] Ist Super Sanita, Dept Food Safety Nutr & Vet Publ Hlth, Rome, Italy; [Baldassarre, Antonella; Masotti, Andrea] Bambino Gesu Childrens Hosp IRCCS, Res Labs, Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); IRCCS Bambino Gesu	Conti, L (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy.; Conti, L (corresponding author), Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy.	lucia.conti@iss.it	Masotti, Andrea/D-5306-2009; Angelini, Costanza/AAA-7211-2019; Gessani, Sandra/K-5151-2016; Conti, Lucia/K-2723-2016; Varano, Barbara/ABA-3112-2021	Masotti, Andrea/0000-0002-2511-5088; Gessani, Sandra/0000-0002-8451-0758; Conti, Lucia/0000-0001-9439-081X; Varano, Barbara/0000-0002-8780-3775; Angelini, Costanza/0000-0002-9662-4066	ISS Italy-NIH USA collaborative project [11US/13]	ISS Italy-NIH USA collaborative project	This work was supported by the ISS Italy-NIH USA collaborative project 11US/13 (Italian Ministry of Health) to SG.	Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707; Ahonen CL, 1999, CELL IMMUNOL, V197, P62, DOI 10.1006/cimm.1999.1555; Ahout IML, 2016, PEDIATR INFECT DIS J, V35, pE89, DOI 10.1097/INF.0000000000001007; Artursson P, 2001, ADV DRUG DELIVER REV, V46, P27, DOI 10.1016/S0169-409X(00)00128-9; Assier E, 2007, J LEUKOCYTE BIOL, V81, P221, DOI 10.1189/jlb.0705385; Butchar JP, 2010, CLIN CANCER RES, V16, P2065, DOI 10.1158/1078-0432.CCR-09-2591; Conti L, 2005, J IMMUNOL, V174, P252, DOI 10.4049/jimmunol.174.1.252; Craft N, 2014, CLIN VACCINE IMMUNOL, V21, P1314, DOI 10.1128/CVI.00338-14; Diebold SS, 2008, ADV DRUG DELIVER REV, V60, P813, DOI 10.1016/j.addr.2007.11.004; Engel Abbi L, 2011, Expert Rev Clin Pharmacol, V4, P275, DOI 10.1586/ecp.11.5; Feng AL, 2011, CLIN EXP IMMUNOL, V164, P57, DOI 10.1111/j.1365-2249.2011.04321.x; Fukata M, 2013, MUCOSAL IMMUNOL, V6, P451, DOI 10.1038/mi.2013.13; Grasa L, 2015, MICROB ECOL, V70, P835, DOI 10.1007/s00248-015-0613-8; Gupta V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057136; Hackstein H, 2011, CELL IMMUNOL, V271, P401, DOI 10.1016/j.cellimm.2011.08.008; Hannani D, 2012, TRENDS IMMUNOL, V33, P199, DOI 10.1016/j.it.2012.01.006; Helminen O, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1127495; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Karlsson A, 2008, BIOCHEM BIOPH RES CO, V367, P242, DOI 10.1016/j.bbrc.2007.12.046; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Koch S, 2010, CLIN EXP IMMUNOL, V161, P332, DOI 10.1111/j.1365-2249.2010.04177.x; Kwissa M, 2012, BLOOD, V119, P2044, DOI 10.1182/blood-2011-10-388579; Latha TS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00571; MARY JY, 1989, GUT, V30, P983, DOI 10.1136/gut.30.7.983; McCarthy NE, 2015, J CLIN INVEST, V125, P3215, DOI 10.1172/JCI80840; Nisini R, 2007, J LEUKOCYTE BIOL, V82, P1136, DOI 10.1189/jlb.0307160; Ohto U, 2014, MICROBES INFECT, V16, P273, DOI 10.1016/j.micinf.2014.01.007; Pietschmann K, 2009, SCAND J IMMUNOL, V70, P245, DOI 10.1111/j.1365-3083.2009.02290.x; Poggi A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00575; Sanchez-Munoz F, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-138; Seidelin JB, 2003, AM J PHYSIOL-GASTR L, V285, pG1122, DOI 10.1152/ajpgi.00533.2002; Steenholdt C, 2009, SCAND J GASTROENTERO, V44, P195, DOI 10.1080/00365520802495529; Vasilakos JP, 2013, EXPERT REV VACCINES, V12, P809, DOI 10.1586/14760584.2013.811208; Vasilakos JP, 2000, CELL IMMUNOL, V204, P64, DOI 10.1006/cimm.2000.1689; Wagner TL, 1999, CELL IMMUNOL, V191, P10, DOI 10.1006/cimm.1998.1406; Wong KC, 2012, INT COMP CRIM JUST, P1; Yokogawa M, 2014, ARTHRITIS RHEUMATOL, V66, P694, DOI 10.1002/art.38298; Yrlid U, 2006, EUR J IMMUNOL, V36, P2639, DOI 10.1002/eji.200636426; Yrlid U, 2006, J IMMUNOL, V176, P5205, DOI 10.4049/jimmunol.176.9.5205; Zhang JW, 2016, INT J BIOL MACROMOL, V93, P506, DOI 10.1016/j.ijbiomac.2016.07.095; Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510	41	1	1	1	10	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2017	8								1813	10.3389/fimmu.2017.01813	http://dx.doi.org/10.3389/fimmu.2017.01813			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FQ8LW	29312324	gold, Green Published			2022-12-18	WOS:000418615300002
J	Casals, E; Gusta, MF; Piella, J; Casals, G; Jimenez, W; Puntes, V				Casals, Eudald; Gusta, Muriel F.; Piella, Jordi; Casals, Gregori; Jimenez, Wladimiro; Puntes, Victor			Intrinsic and Extrinsic Properties Affecting Innate Immune Responses to Nanoparticles: The Case of Cerium Oxide (vol 8, 970, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						nanoparticles; cerium oxide; nanoparticle evolution; nanoparticle agglomeration; ion leaching; antioxidant activity; inflammation; immune response			[Casals, Eudald; Gusta, Muriel F.; Puntes, Victor] VHIR, Barcelona, Spain; [Piella, Jordi; Puntes, Victor] CSIC, Barcelona Inst Sci & Technol, ICN2, Campus UAB, Barcelona, Spain; [Casals, Gregori; Jimenez, Wladimiro] Hosp Clin Univ, CIBERehd, IDIBAPS, Biochem & Mol Genet Serv, Barcelona, Spain; [Jimenez, Wladimiro] Univ Barcelona, Dept Biomed, Barcelona, Spain; [Puntes, Victor] ICREA, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Barcelona Institute of Science & Technology; Catalan Institute of Nanoscience & Nanotechnology (ICN2); Consejo Superior de Investigaciones Cientificas (CSIC); CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; ICREA	Puntes, V (corresponding author), VHIR, Barcelona, Spain.; Puntes, V (corresponding author), CSIC, Barcelona Inst Sci & Technol, ICN2, Campus UAB, Barcelona, Spain.; Puntes, V (corresponding author), ICREA, Barcelona, Spain.	victor.puntes@vhir.org	Casals, Eudald/P-2382-2016; Povedano, Wladimiro Jiménez/Q-1496-2018; Casals, Gregori/F-6506-2012; Puntes, Victor/AAL-6081-2021	Casals, Eudald/0000-0002-2900-7295; Casals, Gregori/0000-0002-3271-1371; Puntes, Victor/0000-0001-8996-9499; Jimenez, Wladimiro/0000-0002-9376-0214	European Community [604602]	European Community(European Commission)	A correction has been made to the text in the Funding: "Financial support from the FutureNanoNeeds Project (GA: 604602) financed by the European Community under the FP7 Programme (FP7-NMP-2013-LARGE-7) is gratefully acknowledged."	Casals E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00970	1	1	1	0	13	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2017	8								1891	10.3389/fimmu.2017.01891	http://dx.doi.org/10.3389/fimmu.2017.01891			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FQ8MT	29285024	Green Published, gold			2022-12-18	WOS:000418617600002
J	Heinzow, HS; Heinzow, BGJ				Heinzow, Hauke Sebastian; Heinzow, Birger Gustav John			Commentary: Severe Sequelae to Mold-Related Illness As Demonstrated in Two Finnish Cohorts	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mould-related diseases; exposure; allergic reactions; mold; health effects	RESPIRATORY SYMPTOMS; DAMPNESS; BUILDINGS; EXPOSURE; CHILDREN; SCHOOLS; HEALTH		[Heinzow, Hauke Sebastian] Univ Hosp Muenster, Dept Med B, Munster, Germany; [Heinzow, Birger Gustav John] State Off Social Serv, Dept Environm Hlth Protect, Kiel, Germany	University of Munster	Heinzow, HS (corresponding author), Univ Hosp Muenster, Dept Med B, Munster, Germany.	heinzow@hotmail.com						Abrams B, 2013, MMWR RECOMM REP, V62, P1; Annila Petri J., 2017, Case Studies in Construction Materials, V6, P103, DOI 10.1016/j.cscm.2017.01.003; Annila PJ, 2016, BUILD PATHOL REHABIL, V5, P1, DOI 10.1007/978-981-10-0466-7_1; Bornehag CG, 2001, INDOOR AIR, V11, P72; Borras-Santos A, 2013, OCCUP ENVIRON MED, V70, P681, DOI 10.1136/oemed-2012-101286; Ferrari SM, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00050; Institute of Medicine, 2004, DAMP IND SPAC HLTH; Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]; Meklin T, 2002, INDOOR AIR, V12, P175, DOI 10.1034/j.1600-0668.2002.00169.x; Mendell MJ, 2017, INDOOR AIR, V27, P506, DOI 10.1111/ina.12342; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Nielsen KF, 2003, FUNGAL GENET BIOL, V39, P103, DOI 10.1016/S1087-1845(03)00026-4; Palaty C, 2012, HLTH EFFECTS MOULD E; Palomaki E, 2008, SCAND J WORK ENV HEA, P35; Park JH, 2004, INDOOR AIR, V14, P425, DOI 10.1111/j.1600-0668.2004.00291.x; Quansah R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047526; Rasimus-Sahari S, 2015, APPL ENVIRON MICROB, V81, P2939, DOI 10.1128/AEM.03430-14; World Health Organization (WHO), 2009, GUID IND AIR QUAL DA; World Health Organization (WHO), 2009, DAMP MOULD HLTH RISK	19	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2017	8								1694	10.3389/fimmu.2017.01694	http://dx.doi.org/10.3389/fimmu.2017.01694			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FO9XE	29270170	Green Published, gold			2022-12-18	WOS:000417250900001
J	Giwa, A; Ahmed, R; Donner, T; Yagita, H; Hamad, ARA				Giwa, Adebola; Ahmed, Rizwan; Donner, Thomas; Yagita, Hideo; Hamad, Abdel Rahim A.			Editorial: Ying and Yang Members of the tumor Necrosis Factor Superfamily: Friends or Foes in immune-Mediated diseases and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Fas pathway; type 1 diabetes; CD95L; FasL; tumor necrosis factor	TNF SUPERFAMILY		[Giwa, Adebola; Ahmed, Rizwan; Hamad, Abdel Rahim A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Giwa, Adebola] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Donner, Thomas; Hamad, Abdel Rahim A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Juntendo University	Hamad, ARA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.; Hamad, ARA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	ahamad@jhmi.edu	AHMED, RIZWAN/ABH-5089-2020		NIH [1R01AI099027-01A1]; Norman Raab Foundation; Helmsley Charitable Trust [2015PG-T1D052]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD044355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI099027] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Norman Raab Foundation; Helmsley Charitable Trust; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work is supported in part by the NIH - Grant 1R01AI099027-01A1, the Norman Raab Foundation, a gift from Dr. J. Edlow, and the Helmsley Charitable Trust (George Eisenbarth nPOD Award for Team Science, 2015PG-T1D052 (A.P)).	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22; Martina MN, 2015, IMMUNOL CELL BIOL, V93, P305, DOI 10.1038/icb.2014.99; Saxena A, 2015, CYTOKINE, V74, P27, DOI 10.1016/j.cyto.2014.10.031; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Xiao ZX, 2011, AM J PATHOL, V179, P725, DOI 10.1016/j.ajpath.2011.04.016	6	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2017	8								1584	10.3389/fimmu.2017.01584	http://dx.doi.org/10.3389/fimmu.2017.01584			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FN4YE	29218044	Green Published, gold			2022-12-18	WOS:000416012000001
J	Sarker, S; Wang, YN; Warren-Smith, B; Helbig, KJ				Sarker, Subir; Wang, Yinan; Warren-Smith, Brenden; Helbig, Karla J.			Dynamic changes in host gene expression following In Vitro Viral Mimic stimulation in crocodile cells	FRONTIERS IN IMMUNOLOGY			English	Article						crocodile; RNA-sequencing; transcriptome analysis; virus; immune response; innate immunity; interferon; reptile	INNATE IMMUNE-RESPONSE; RNA-SEQ; VIRUS; RECOGNITION; VERTEBRATES; PHOSPHORYLATION; REVEALS; EVASION; INSIGHT; VIPERIN	The initial control of viral infection in a host is dominated by a very well orchestrated early innate immune system; however, very little is known about the ability of a host to control viral infection outside of mammals. The reptiles offer an evolutionary bridge between the fish and mammals, with the crocodile having evolved from the archosauria clade that included the dinosaurs, and being the largest living reptile species. Using an RNA-seq approach, we have defined the dynamic changes of a passaged primary crocodile cell line to stimulation with both RNA and DNA viral mimics. Cells displayed a marked upregulation of many genes known to be involved in the mammalian response to viral infection, including viperin, Mx1, IRF7, IRF1, and RIG-I with approximately 10% of the genes being uncharacterized transcripts. Both pathway and genome analysis suggested that the crocodile may utilize the main known mammalian TLR and cytosolic antiviral RNA signaling pathways, with the pathways being responsible for sensing DNA viruses less clear. Viral mimic stimulation upregulated the type I interferon, IFN-Omega, with many known antiviral interferon-stimulated genes also being upregulated. This work demonstrates for the first time that reptiles show functional regulation of many known and unknown antiviral pathways and effector genes. An enhanced knowledge of these ancient antiviral pathways will not only add to our understanding of the host antiviral innate response in non-mammalian species, but is critical to fully comprehend the complexity of the mammalian innate immune response to viral infection.	[Sarker, Subir; Warren-Smith, Brenden; Helbig, Karla J.] La Trobe Univ, Sch Life Sci, Dept Physiol Anat & Microbiol, Melbourne, Vic, Australia; [Wang, Yinan] La Trobe Univ, Genom Res Platform, Melbourne, Vic, Australia	La Trobe University; La Trobe University	Helbig, KJ (corresponding author), La Trobe Univ, Sch Life Sci, Dept Physiol Anat & Microbiol, Melbourne, Vic, Australia.	k.helbig@latrobe.edu.au	Sarker, Subir/U-8444-2019; Helbig, Karla/AAC-5515-2019	Sarker, Subir/0000-0002-2685-8377; Helbig, Karla/0000-0001-6306-2821	La Trobe University	La Trobe University	The authors would like to thank the Berrimah Veterinary Laboratory (Department of Primary Industry and Resources, Government of Northern Territory, Australia) for providing the C. porosus liver cell line (LV-1) used in this experiment. The authors also like to thank La Trobe University for the financial support under Start Up Grant to SS and KH.	Ablasser A, 2009, NAT IMMUNOL, V10, P1065, DOI 10.1038/ni.1779; Andrews S, 2016, FASTQC QUALITY CONTR; Barber GN, 2011, CURR OPIN IMMUNOL, V23, P10, DOI 10.1016/j.coi.2010.12.015; Bolen CR, 2014, HEPATOLOGY, V59, P1262, DOI 10.1002/hep.26657; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436; Brochu CA, 2003, ANNU REV EARTH PL SC, V31, P357, DOI 10.1146/annurev.earth.31.100901.141308; Brownlie R, 2009, MOL IMMUNOL, V46, P3163, DOI 10.1016/j.molimm.2009.06.002; Buenviaje GN, 1998, AUST VET J, V76, P357, DOI 10.1111/j.1751-0813.1998.tb12368.x; Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491; Castanier C, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-44; Chan YK, 2016, NAT REV MICROBIOL, V14, P360, DOI 10.1038/nrmicro.2016.45; Chen SN, 2016, DEV COMP IMMUNOL, V61, P208, DOI 10.1016/j.dci.2016.04.004; Chen S, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-82; Ding Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00343; El-Zaatari M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00051; Ertl R, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-52; Glennon NB, 2015, J VIROL, V89, P7550, DOI 10.1128/JVI.00302-15; Grayfer L, 2014, J VIROL, V88, P5766, DOI 10.1128/JVI.00223-14; Helbig KJ, 2014, J MOL BIOL, V426, P1210, DOI 10.1016/j.jmb.2013.10.019; Hoffmann HH, 2015, TRENDS IMMUNOL, V36, P124, DOI 10.1016/j.it.2015.01.004; Jensen S, 2012, J VIROL, V86, P2900, DOI 10.1128/JVI.05738-11; Jones M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003896; Katibah GE, 2014, P NATL ACAD SCI USA, V111, P12025, DOI 10.1073/pnas.1412842111; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Klotman ME, 2006, NAT REV IMMUNOL, V6, P447, DOI 10.1038/nri1860; Lamontagne J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005438; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lisnic VJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003611; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Lorna M, 2012, HUNTING VIRUSES CROC; Marschang RE, 2011, VIRUSES-BASEL, V3, P2087, DOI 10.3390/v3112087; Mason CP, 2015, MOLECULES, V20, P2229, DOI 10.3390/molecules20022229; McCowan C, 2004, AUST VET J, V82, P375, DOI 10.1111/j.1751-0813.2004.tb11109.x; Mehrbod P, 2015, METHODS MOL BIOL, V1282, P241, DOI 10.1007/978-1-4939-2438-7_20; Mei B, 2014, GENE, V551, P255, DOI 10.1016/j.gene.2014.08.062; Milic NL, 2015, DEV COMP IMMUNOL, V51, P108, DOI 10.1016/j.dci.2015.03.001; Miyashita M, 2011, MOL CELL BIOL, V31, P3802, DOI 10.1128/MCB.01368-10; Moriya Y, 2007, NUCLEIC ACIDS RES, V35, pW182, DOI 10.1093/nar/gkm321; Paludan SR, 2013, IMMUNITY, V38, P870, DOI 10.1016/j.immuni.2013.05.004; Panne D, 2007, J BIOL CHEM, V282, P22816, DOI 10.1074/jbc.M703019200; Park SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16512; Priyam M, 2016, VET IMMUNOL IMMUNOP, V172, P26, DOI 10.1016/j.vetimm.2016.03.002; Qi ZT, 2010, J IMMUNOL, V184, P5038, DOI 10.4049/jimmunol.0903374; Quinn K, 2009, J VIROL, V83, P10176, DOI 10.1128/JVI.00422-09; Rahnenfuhrer J, 2016, TOPGO ENRICHMENT ANA; Romo MR, 2016, IMMUNOLOGY, V148, P125, DOI 10.1111/imm.12597; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Santhakumar D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00049; Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008; Sen GC, 2007, CURR TOP MICROBIOL, V316, P233; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Shilton CM, 2016, J VET DIAGN INVEST, V28, P279, DOI 10.1177/1040638716642268; St John JA, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-1-415; Veneman W, 2015, IMMUNOGENETICS, V67, P135, DOI 10.1007/s00251-014-0820-3; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484	61	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2017	8								1634	10.3389/fimmu.2017.01634	http://dx.doi.org/10.3389/fimmu.2017.01634			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FN4XX	29213275	Green Published, gold			2022-12-18	WOS:000416011200001
J	Elhadad, S; Della Bella, S				Elhadad, Sonia; Della Bella, Silvia			Editorial: Cross talk between lymph Node lymphatic Endothelial Cells and t-Cells during inflammation and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; lymphatic vessels; lymphatic endothelial cells; inflammation; cancer; antigen presenting cells; atypical chemokine receptors; microRNAs			[Elhadad, Sonia] Weill Cornell Med, Dept Med, New York, NY 10065 USA; [Della Bella, Silvia] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy; [Della Bella, Silvia] Humanitas Clin & Res Ctr, Lab Clin & Expt Immunol, Rozzano, Italy	Cornell University; University of Milan; IRCCS Humanitas Research Hospital	Elhadad, S (corresponding author), Weill Cornell Med, Dept Med, New York, NY 10065 USA.	soe2003@med.cornell.edu	Elhadad, Sonia/GRF-6466-2022; Bella, Silvia Della/AAB-7904-2019	Elhadad, Sonia/0000-0002-0139-6487; Della Bella, Silvia/0000-0003-0818-5049	Department of Medical Biotechnologies and Translational Medicine, University of Milan	Department of Medical Biotechnologies and Translational Medicine, University of Milan	This work was supported by institutional funding from the Department of Medical Biotechnologies and Translational Medicine, University of Milan, grant 2016 to SDB.	Calcaterra F, 2017, J INVEST DERMATOL, V137, P1533, DOI 10.1016/j.jid.2017.02.979; Colombo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066734; Elhadad S., 2013, J IMMUNOTHER CANC S1, V1, P184, DOI [10.1186/2051-1426-1-S1-P184, DOI 10.1186/2051-1426-1-S1-P184]	3	1	1	0	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2017	8								1421	10.3389/fimmu.2017.01421	http://dx.doi.org/10.3389/fimmu.2017.01421			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FN0ON	29209307	Green Published, gold			2022-12-18	WOS:000415677900001
J	Bonnet, M; Sarmento, LM; Martins, AC; Sobral, D; Silva, J; Demengeot, J				Bonnet, Marie; Sarmento, Leonor Morais; Martins, Ana C.; Sobral, Daniel; Silva, Joana; Demengeot, Jocelyne			iRAGu: A Novel Inducible and Reversible Mouse Model for Ubiquitous Recombinase Activity	FRONTIERS IN IMMUNOLOGY			English	Article						recombination activating gene; transgenic mouse model; 4-hydroxytamoxifen induction; estrogen receptor; lymphocyte development; V(D)J recombination	CENTRAL-NERVOUS-SYSTEM; V(D)J RECOMBINATION; CELL DEVELOPMENT; DEFICIENT MICE; RAG PROTEINS; GENE; REARRANGEMENT; EXPRESSION; REPAIR; REPERTOIRE	Developing lymphocytes express the recombination activating genes (RAGs) 1 and 2 products that form a site specific recombinase complex (RAG), introducing double strand DNA breaks (DSBs) at recombination signal sequences (RSSs) flanking the V, D, and J gene segments in the antigen receptor loci. The subsequent steps in the reaction consist in the ligation of DSBs by ubiquitous enzymes of the non-homologous end joining DNA repair pathway. This mutagenesis process is responsible for the generation of the very large clonal diversity of T and B lymphocytes, itself allowing the recognition of a virtually open-ended antigenic universe. Sequences resembling RSS are found at high frequency all over the genome, and involved in RAG mediated illegitimate recombination and translocations. Hence, natural and induced ectopic activity of RAG is a threat to the genome only recently underscored. Here, we report and characterize a novel mouse transgenic system for which ubiquitous expression of the recombinase is inducible. In this system, the RAG1 protein is constitutively expressed and functional, while the RAG2 protein, coupled to the estrogen receptor, becomes functionally active upon 4-hydroxytamoxifen (TAM) administration. We describe two transgenic lines. The first one, when introgressed into an endogenous Rag2(-/-) genetic background is faithfully recapitulating lymphocyte development, repertoire dynamics and cryptic rearrangements, in a TAM-dependent manner. In this model, deprivation of TAM is followed by lymphocyte development arrest, evidencing the reversibility of the system. The second transgenic line is leaky, as the transgenes promote lymphocyte differentiation in absence of TAM treatment. Upon TAM-induction defects in lymphocytes composition and global health reveals the deleterious effect of uncontrolled RAG activity. Overall, this novel transgenic model provides a tool where RAG activity can be specifically manipulated to assess the dynamics of lymphocyte differentiation and the challenges imposed by the recombinase on the vertebrate genome.	[Bonnet, Marie; Sarmento, Leonor Morais; Martins, Ana C.; Sobral, Daniel; Silva, Joana; Demengeot, Jocelyne] Inst Gulbenkian Ciencias, Oeiras, Portugal	Instituto Gulbenkian de Ciencia	Demengeot, J (corresponding author), Inst Gulbenkian Ciencias, Oeiras, Portugal.	jocelyne@igc.gulbenkian.pt	Sobral, Daniel/B-4786-2014; demengeot, jocelyne/K-8072-2014; Sobral, Daniel/K-3097-2019; Martins, Ana-Catarina VC/L-3911-2014	Sobral, Daniel/0000-0003-3955-0117; demengeot, jocelyne/0000-0002-4761-614X; Sobral, Daniel/0000-0003-3955-0117; Martins, Ana-Catarina VC/0000-0002-8786-9424; Di Placido, Marie/0000-0002-8299-5595	Fundacao para a Ciencia e a Tecnologia [PTDC/BJA-GEN/116830/2010]; Portuguese League Against Cancer; Terry Fox Foundation; Fundação para a Ciência e a Tecnologia [PTDC/BIA-GEN/116830/2010] Funding Source: FCT	Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Portuguese League Against Cancer; Terry Fox Foundation; Fundação para a Ciência e a Tecnologia	This work was supported by the Fundacao para a Ciencia e a Tecnologia through the grant PTDC/BJA-GEN/116830/2010 to Jocelyne Demengeol and fellowships to Marie Bonnet and Leonor M. Sarmento, and by the Portuguese League Against Cancer in association with The Terry Fox Foundation through a prize awarded to Leonor M. Sarmento. We thank Manuel Rebelo's team for animal care, Jorg Becker's team for HTS and Vasco M. Barreto, Alekos Alhanasiadis, and Jorge Carneiro for helpful discussions.	AOKI T, 1991, BIOCHEM BIOPH RES CO, V181, P151, DOI 10.1016/S0006-291X(05)81394-4; Barreto V, 2001, EUR J IMMUNOL, V31, P3763, DOI 10.1002/1521-4141(200112)31:12<3763::AID-IMMU3763>3.0.CO;2-Y; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bolotin DA, 2013, NAT METHODS, V10, P813, DOI [10.1038/nmeth.2555, 10.1038/NMETH.2555]; Bonnet M, 2009, J IMMUNOL, V183, P7939, DOI 10.4049/jimmunol.0902179; Champagne DP, 2014, MUTAT RES-FUND MOL M, V761, P34, DOI 10.1016/j.mrfmmm.2014.01.007; Chen ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022913; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Corneo B, 2007, NATURE, V449, P483, DOI 10.1038/nature06168; Cui XP, 2007, P NATL ACAD SCI USA, V104, P17046, DOI 10.1073/pnas.0610928104; Desiderio S, 2010, SEMIN IMMUNOL, V22, P362, DOI 10.1016/j.smim.2010.09.001; Dik WA, 2007, BLOOD, V110, P388, DOI 10.1182/blood-2006-12-064816; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gopalakrishnan S, 2013, P NATL ACAD SCI USA, V110, pE3206, DOI 10.1073/pnas.1304048110; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hayakawa S, 1996, IMMUNOL CELL BIOL, V74, P52, DOI 10.1038/icb.1996.7; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; Liu YM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013533; Mancini S, 1999, J IMMUNOL, V163, P6053; Marculescu R, 2006, DNA REPAIR, V5, P1246, DOI 10.1016/j.dnarep.2006.05.015; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mostoslavsky R, 2004, CELL, V118, P539, DOI 10.1016/j.cell.2004.08.023; Onozawa M, 2012, GENE CHROMOSOME CANC, V51, P525, DOI 10.1002/gcc.21942; Passagem-Santos D, 2016, GENOME BIOL EVOL, V8, P3364, DOI 10.1093/gbe/evw261; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; PETRIE HT, 1993, J EXP MED, V178, P615, DOI 10.1084/jem.178.2.615; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; Schlissel MS, 2006, GENE DEV, V20, P1539, DOI 10.1101/gad.1446506; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shockett PE, 2004, MOL IMMUNOL, V40, P813, DOI 10.1016/j.molimm.2003.09.009; Swanson PC, 2009, ADV EXP MED BIOL, V650, P1; Talukder SR, 2004, NUCLEIC ACIDS RES, V32, P4539, DOI 10.1093/nar/gkh778; Teng G, 2015, CELL, V162, P751, DOI 10.1016/j.cell.2015.07.009; Trancoso I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00110; Vanura K, 2007, PLOS BIOL, V5, P515, DOI 10.1371/journal.pbio.0050043; Vasseur F, 2001, EUR J IMMUNOL, V31, P3038, DOI 10.1002/1521-4141(2001010)31:10<3038::AID-IMMU3038>3.0.CO;2-3; Zelenay S, 2007, INT IMMUNOL, V19, P11, DOI 10.1093/intimm/dxl116; Zhang L, 2011, IMMUNITY, V34, P163, DOI 10.1016/j.immuni.2011.02.003	43	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 10	2017	8								1525	10.3389/fimmu.2017.01525	http://dx.doi.org/10.3389/fimmu.2017.01525			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FM2TM	29176980	Green Published, gold			2022-12-18	WOS:000414853000001
J	Eisenhut, M				Eisenhut, Michael			Commentary: Cytokine-Regulation of Na+-K+-Cl- Cotransporter 1 and Cystic Fibrosis Transmembrane Conductance Regulator-Potential Role in Pulmonary Inflammation and Edema Formation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cystic fibrosis transmembrane conductance regulator; Na+-K+-Cl- cotransporter 1; sweat chloride; sweat sodium; nasal potential difference; pulmonary edema; sodium; chloride	EXHALED BREATH CONDENSATE; CHLORIDE		[Eisenhut, Michael] Luton & Dunstable Univ Hosp NHS Fdn Trust, Paediat Dept, Luton, Beds, England		Eisenhut, M (corresponding author), Luton & Dunstable Univ Hosp NHS Fdn Trust, Paediat Dept, Luton, Beds, England.	michael.eisenhut@talk21.com						Carter SR, 2012, RESP MED, V106, P601, DOI 10.1016/j.rmed.2012.02.003; Eisenhut M, 2006, PEDIATR CRIT CARE ME, V7, P119, DOI 10.1097/01.PCC.0000200944.98424.E0; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; NAKAMURA H, 1992, FEBS LETT, V314, P366, DOI 10.1016/0014-5793(92)81507-I; Weidenfeld S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00393; Zacharasiewicz A, 2004, PEDIATR PULM, V37, P273, DOI 10.1002/ppul.10431	6	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 6	2017	8								1490	10.3389/fimmu.2017.01490	http://dx.doi.org/10.3389/fimmu.2017.01490			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FL7NO	29163549	Green Published, gold			2022-12-18	WOS:000414435300001
J	Richards, AL; Howie, HL; Kapp, LM; Hendrickson, JE; Zimring, JC; Hudson, KE				Richards, Amanda L.; Howie, Heather L.; Kapp, Linda M.; Hendrickson, Jeanne E.; Zimring, James C.; Hudson, Krystalyn E.			Innate B-1 B Cells Are Not Enriched in Red Blood Cell Autoimmune Mice: Importance of B Cell Receptor Transgenic Selection	FRONTIERS IN IMMUNOLOGY			English	Article						B cell tolerance; red blood cells; autoimmunity; autoimmunity models; autoantibodies	HEMOLYTIC-ANEMIA; PERITONEAL-CAVITY; SELF-ANTIGEN; BONE-MARROW; ELIMINATION; MEMBRANE; TOLERANCE; LYMPHOCYTES; SYMPTOMS; LUPUS	Autoimmune hemolytic anemia (AIHA) results from breakdown of humoral tolerance to RBC antigens. Past analyses of B-cell receptor transgenic (BCR-Tg) mice that recognize RBC autoantigens led to a paradigm in which autoreactive conventional B-2 B cells are deleted whereas extramedullary B-1 B cells escape deletion due to lack of exposure to RBCs. However, BCR-Tg mice utilized to shape the current paradigm were unable to undergo receptor editing or class-switching. Given the importance of receptor editing as mechanism to tolerize autoreactive B cells during central tolerance, we hypothesized that expansion of autoreactive B-1 B cells is a consequence of the inability of the autoreactive BCR to receptor edit. To test this hypothesis, we crossed two separate strains of BCR-Tg mice with transgenic mice expressing the BCR target on RBCs. Both BCR-Tg mice express the same immunoglobulin and, thus, secrete antibodies with identical specificity, but one strain (SwHEL) has normal receptor editing, whereas the other (IgHEL) does not. Similar to other AIHA models, the autoreactive IgHEL strain showed decreased B-2 B cells, an enrichment of B-1 B cells, and detectable anti-RBC autoantibodies and decreased RBC hematocrit and hemoglobin values. However, autoreactive SwHEL mice had induction of tolerance in both B-2 and B-1 B cells with anti-RBC autoantibody production without anemia. These data generate new understanding and challenge the existing paradigm of B cell tolerance to RBC autoantigens. Furthermore, these findings demonstrate that immune responses vary when BCR-Tg do not retain BCR editing and class-switching functions.	[Richards, Amanda L.; Howie, Heather L.; Kapp, Linda M.; Zimring, James C.; Hudson, Krystalyn E.] Bloodworks Northwest Res Inst, Seattle, WA 98102 USA; [Hendrickson, Jeanne E.] Yale Univ, Dept Lab Med & Pediat, New Haven, CT USA; [Zimring, James C.] Univ Washington, Dept Lab Med, Div Hematol, Seattle, WA 98195 USA; [Zimring, James C.] Univ Washington, Div Hematol, Dept Internal Med, Seattle, WA 98195 USA	Yale University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hudson, KE (corresponding author), Bloodworks Northwest Res Inst, Seattle, WA 98102 USA.	krystalh@bloodworksnw.org			National Blood Foundation	National Blood Foundation	This work was supported, in part, by the National Blood Foundation.	ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; Arason GJ, 2010, SCAND J IMMUNOL, V71, P317, DOI 10.1111/j.1365-3083.2010.02386.x; BRINK R, 1992, J EXP MED, V176, P991, DOI 10.1084/jem.176.4.991; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; Chan TD, 2012, IMMUNITY, V37, P893, DOI 10.1016/j.immuni.2012.07.017; Coutelier JP, 2007, ANN NY ACAD SCI, V1109, P151, DOI 10.1196/annals.1398.018; Desmarets M, 2009, BLOOD, V114, P2315, DOI 10.1182/blood-2009-04-214387; Ekland EH, 2004, J IMMUNOL, V172, P4700, DOI 10.4049/jimmunol.172.8.4700; Gehrs BC, 2002, AM J HEMATOL, V69, P258, DOI 10.1002/ajh.10062; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Grimaldi C, 2005, J IMMUNOL, V174, P1775, DOI 10.4049/jimmunol.174.4.1775; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hoffman Philip C, 2009, Hematology Am Soc Hematol Educ Program, P80, DOI 10.1182/asheducation-2009.1.80; Hudson KE, 2012, HAEMATOL-HEMATOL J, V97, P1836, DOI 10.3324/haematol.2012.065144; Hudson KE, 2010, BLOOD, V115, P3989, DOI 10.1182/blood-2009-08-238568; Ito T, 2004, J IMMUNOL, V172, P3628, DOI 10.4049/jimmunol.172.6.3628; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Lang J, 2000, EUR J IMMUNOL, V30, P689, DOI 10.1002/1521-4141(200002)30:2<689::AID-IMMU689>3.0.CO;2-I; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Moon H, 2012, J KOREAN MED SCI, V27, P27, DOI 10.3346/jkms.2012.27.1.27; Murakami M, 1996, Semin Immunol, V8, P3, DOI 10.1006/smim.1996.0002; MURAKAMI M, 1994, J EXP MED, V180, P111, DOI 10.1084/jem.180.1.111; MURAKAMI M, 1995, INT IMMUNOL, V7, P877, DOI 10.1093/intimm/7.5.877; Murakami M, 1995, ANN NY ACAD SCI, V764, P402; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; Oliveira GGD, 1996, CLIN EXP IMMUNOL, V105, P313, DOI 10.1046/j.1365-2249.1996.d01-772.x; Phan TG, 2003, J EXP MED, V197, P845, DOI 10.1084/jem.20022144; Salomao M, 2008, P NATL ACAD SCI USA, V105, P8026, DOI 10.1073/pnas.0803225105; Shi ZT, 1999, J CLIN INVEST, V103, P331, DOI 10.1172/JCI3858; Teague BN, 2007, J IMMUNOL, V178, P7511, DOI 10.4049/jimmunol.178.12.7511; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Zimring JC, 2009, TRANSFUS MED REV, V23, P189, DOI 10.1016/j.tmrv.2009.03.002; Zimring JC, 2005, BLOOD, V106, P1105, DOI 10.1182/blood-2005-03-1040	36	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 3	2017	8								1366	10.3389/fimmu.2017.01366	http://dx.doi.org/10.3389/fimmu.2017.01366			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FL5PR	29163471	Green Published, gold			2022-12-18	WOS:000414298400001
J	Verna, AE; Franceschi, V; Tebaldi, G; Macchi, F; Menozzi, V; Pastori, C; Lopalco, L; Ottonello, S; Cavirani, S; Donofrio, G				Verna, Andrea Elizabeth; Franceschi, Valentina; Tebaldi, Giulia; Macchi, Francesca; Menozzi, Valentina; Pastori, Claudia; Lopalco, Lucia; Ottonello, Simone; Cavirani, Sandro; Donofrio, Gaetano			Induction of Antihuman C-C Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector	FRONTIERS IN IMMUNOLOGY			English	Article						bovine herpesvirus 4; gene delivery vector; human CCR5; recombinant virus; antihuman CCR5 antibodies	CCR5-REACTIVE ANTIBODIES; CCR5; MOUSE; INFECTION; LOOP	Bovine herpesvirus 4 (BoHV-4) is a promising vector for the delivery and intracellular expression of recombinant antigens and can thus be considered as a new prototype vaccine formulation system. An interesting, and actively pursued, antigen in the context of human immunodeficiency virus (HIV) infection prophylaxis (and therapy) is the C-C chemokine receptor type 5 (CCR5) co-receptor, whose blockage by specific antibodies has been shown to inhibit both viral entry and cell-to-cell transmission of the virus. Building on our previous work on the BoHV-4 vector system, we have engineered and tested a replication-competent derivative of BoHV-4 (BoHV-4-CMV-hCCR5.TK) bearing a human CCR5 (hCCR5) expression cassette. We show here that CCR5 is indeed expressed at high levels in multiple types of BoHV-4-CMV-hCCR5.TK-infected cells. More importantly, two intravenous inoculations of CCR5-expressing BoHV-4 virions into rabbits led to the production of anti-CCR5 antibodies capable of reacting with the CCR5 receptor exposed on the surface of HEK293T cells through specific recognition of the amino-terminal region (aa 14-34) of the protein. Given the growing interest for antiCCR5 immunization as an HIV control strategy and the many advantages of virus-based immunogen formulations (especially for poorly immunogenic or self-antigens), the results reported in this study provide preliminary validation of BoHV-4 as a safe viral vector suitable for CCR5 vaccination.	[Verna, Andrea Elizabeth; Franceschi, Valentina; Tebaldi, Giulia; Macchi, Francesca; Menozzi, Valentina; Cavirani, Sandro; Donofrio, Gaetano] Univ Parma, Dept Med Vet Sci, Parma, Italy; [Pastori, Claudia; Lopalco, Lucia] Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Milan, Italy; [Ottonello, Simone] Univ Parma, Dept Life Sci, Biochem & Mol Biol Unit, Lab Funct Genom & Prot Engn, Parma, Italy	University of Parma; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Parma	Donofrio, G (corresponding author), Univ Parma, Dept Med Vet Sci, Parma, Italy.	gaetano.donofrio@unipr.it	franceschi, valentina/AAR-5566-2020; , Lopalco/AAN-2429-2020	Donofrio, Gaetano/0000-0002-8984-0377; franceschi, valentina/0000-0003-3945-2285	Italian Ministry of University and Scientific Research (Italian National Grant MIUR, PRIN)	Italian Ministry of University and Scientific Research (Italian National Grant MIUR, PRIN)(Ministry of Education, Universities and Research (MIUR))	This work was supported by Italian Ministry of University and Scientific Research (Italian National Grant MIUR, PRIN 2010-2011).	Barassi C, 2005, J VIROL, V79, P6848, DOI 10.1128/JVI.79.11.6848-6858.2005; Barassi C, 2004, BLOOD, V104, P2205, DOI 10.1182/blood-2004-06-2134; Bomsel M, 2007, AIDS, V21, P13, DOI 10.1097/QAD.0b013e328011049b; Chackerian B, 1999, P NATL ACAD SCI USA, V96, P2373, DOI 10.1073/pnas.96.5.2373; Donofrio G, 2008, VACCINE, V26, P6031, DOI 10.1016/j.vaccine.2008.09.023; Donofrio G, 2002, J VIROL METHODS, V101, P49, DOI 10.1016/S0166-0934(01)00419-0; Donofrio G, 2006, J VIROL METHODS, V136, P126, DOI 10.1016/j.jviromet.2006.04.008; Donofrio G, 2006, MICROBES INFECT, V8, P898, DOI 10.1016/j.micinf.2005.10.016; Donofrio G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052758; Donofrio G, 2011, VACCINE, V29, P867, DOI 10.1016/j.vaccine.2010.11.048; Donofrio G, 2009, CLIN VACCINE IMMUNOL, V16, P1675, DOI 10.1128/CVI.00224-09; Donofrio G, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-68; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Franceschi V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003850; Franceschi V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105643; Franceschi V, 2011, VACCINE, V29, P3074, DOI 10.1016/j.vaccine.2011.01.075; Izquierdo SM, 2016, MICROSCOPY-JPN, V65, P341, DOI 10.1093/jmicro/dfw014; Jacca S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1082705; Jo M, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.105; Joshi A, 2011, J BIOL CHEM, V286, P29861, DOI 10.1074/jbc.M111.241521; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; Lopalco L, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S4; Lopalco L, 2010, VIRUSES-BASEL, V2, P574, DOI 10.3390/v2020574; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Pastori C, 2008, J VIROL, V82, P4125, DOI 10.1128/JVI.02232-07; Pastori C, 2006, BLOOD, V107, P4825, DOI 10.1182/blood-2005-06-2463; Pastori C, 2014, J VIROL, V88, P3623, DOI 10.1128/JVI.03663-13; Redaelli M, 2012, NEURO-ONCOLOGY, V14, P288, DOI 10.1093/neuonc/nor219; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035	31	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2017	8								1402	10.3389/fimmu.2017.01402	http://dx.doi.org/10.3389/fimmu.2017.01402			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FK5QS	29118763	Green Published, gold			2022-12-18	WOS:000413555900001
J	Sharma, S; Malmestrom, C; Lindberg, C; Meisel, S; Schon, K; Verolin, M; Lycke, NY				Sharma, Sapna; Malmestrom, Clas; Lindberg, Christopher; Meisel, Sarah; Schon, Karin; Verolin, Martina; Lycke, Nils Yngve			A Sensitive Method for Detecting Peptide-specific CD4(+) T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis	FRONTIERS IN IMMUNOLOGY			English	Article						myasthenia gravis; acetylcholine receptor; autoimmune disease; dendritic cells; CD4(+) T cells; peripheral blood and peptide	MUSCLE ACETYLCHOLINE-RECEPTOR; CYCLOSPORINE MICROEMULSION; MULTIPLE-SCLEROSIS; EXTRACELLULAR PART; MONONUCLEAR-CELLS; CHAIN PEPTIDES; ALPHA-CHAIN; HLA DQ; RECOGNITION; EAMG	Myasthenia gravis (MG) is an autoimmune neurological disorder typified by skeletal muscle fatigue and most often production of autoantibodies against the nicotinic acetylcholine receptor (AChR). The present study was undertaken to assess the extent of AChR-peptide recognition in MG patients using co-culturing (DC:TC) of autologous monocyte-derived dendritic cells (moDCs) and highly enriched CD4(+) T cells from the blood as compared to the traditional whole peripheral blood mononuclear cell (PBMC) cultures. We found that the DC:TC cultures were highly superior to the PBMC cultures for detection of reactivity toward HLA-DQ/DR-restricted AChR-peptides. In fact, whereas DC:TC cultures identified recognition in all MG patients the PBMC cultures failed to detect responsiveness in around 40% of the patients. Furthermore, reactivity to multiple peptides was evident in DC:TC cultures, while PBMC cultures mostly exhibited reactivity to a single peptide. No healthy control (HC) CD4(+) T cells responded to the peptides in either culture system. Interestingly, whereas spontaneous production of IFN. and IL-17 was observed in the DC:TC cultures from MG patients, recall responses to peptides enhanced IL-10 production in 9/13 MG patients, while little increase in IFN. and IL-17 was seen. HCs did not produce cytokines to peptide stimulations. We conclude that the DC:TC culture system is significantly more sensitive and better identifies the extent of responsiveness in MG patients to AChR-peptides than traditional PBMC cultures.	[Sharma, Sapna; Meisel, Sarah; Schon, Karin; Lycke, Nils Yngve] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Gothenburg, Sweden; [Malmestrom, Clas] Sahlgrens Univ Hosp, Lab Clin Immunol, Gothenburg, Sweden; [Malmestrom, Clas; Lindberg, Christopher] Sahlgrens Univ Hosp, Dept Neurol, Gothenburg, Sweden; [Verolin, Martina] Toleranzia AB, Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Lycke, NY (corresponding author), Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Gothenburg, Sweden.	nils.lycke@microbio.gu.se	Malmeström, Clas/A-8749-2012	Malmeström, Clas/0000-0003-2477-0088	Sahlgrenska University Hospital [LUA/ALF ALFGBG-531021]; Lundberg foundation [LUA/ALF ALFGBG-531021]; Swedish Cancer Foundation; Swedish Research Council; Vinnova; Eurostars project [E9480]	Sahlgrenska University Hospital; Lundberg foundation(European Commission); Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Vinnova(Vinnova); Eurostars project	NL provided financial support through a grant from the LUA/ALF ALFGBG-531021 at Sahlgrenska University Hospital and the Lundberg foundation, the Swedish Cancer Foundation, The Swedish Research Council and a Eurostars project E9480 TolerizeMG, for which Toleranzia received funding from Vinnova.	Aarli JA, 1999, ARCH NEUROL-CHICAGO, V56, P25, DOI 10.1001/archneur.56.1.25; Alahgholi-Hajibehzad M, 2015, EXPERT REV CLIN IMMU, V11, P859, DOI 10.1586/1744666X.2015.1047345; Aruna BV, 2006, J NEUROIMMUNOL, V177, P63, DOI 10.1016/j.jneuroim.2006.04.018; Aruna BV, 2006, IMMUNOLOGY, V118, P413, DOI 10.1111/j.1365-2567.2006.02398.x; ATASSI MZ, 1992, P NATL ACAD SCI USA, V89, P5852, DOI 10.1073/pnas.89.13.5852; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Ching KH, 2011, NEUROMUSCULAR DISORD, V21, P204, DOI 10.1016/j.nmd.2010.12.003; COMPSTON DAS, 1980, BRAIN, V103, P579, DOI 10.1093/brain/103.3.579; Conti-Fine BM, 1998, ANN NY ACAD SCI, V841, P283, DOI 10.1111/j.1749-6632.1998.tb10936.x; Danikowski KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0892-8; Deitiker PR, 2011, INT J IMMUNOGENET, V38, P55, DOI 10.1111/j.1744-313X.2010.00979.x; Deitiker P, 2012, CRIT REV IMMUNOL, V32, P193, DOI 10.1615/CritRevImmunol.v32.i3.10; Deitiker PR, 2006, AUTOIMMUNITY, V39, P277, DOI 10.1080/08916930600738581; Dejaco C, 2006, IMMUNOLOGY, V117, P289, DOI 10.1111/j.1365-2567.2005.02317.x; Furukawa Y, 2008, J NEUROIMMUNOL, V195, P108, DOI 10.1016/j.jneuroim.2007.12.008; Galgani M, 2016, J IMMUNOL, V197, P2567, DOI 10.4049/jimmunol.1600242; Garber K, 2014, NATURE, V507, P418, DOI 10.1038/507418a; Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3; Gregersen PK, 2012, ANN NEUROL, V72, P927, DOI 10.1002/ana.23691; Gu M, 2008, CLIN IMMUNOL, V128, P374, DOI 10.1016/j.clim.2008.05.006; Huang WX, 2000, EUR J NEUROL, V7, P195, DOI 10.1046/j.1468-1331.2000.00056.x; Huang YM, 1999, CLIN EXP IMMUNOL, V118, P304; Im SH, 1999, J CLIN INVEST, V104, P1723, DOI 10.1172/JCI8121; Kalb B, 2002, NEUROEPIDEMIOLOGY, V21, P221, DOI 10.1159/000065639; Karni A, 1997, NEUROLOGY, V48, P1638, DOI 10.1212/WNL.48.6.1638; Kirshner SL, 1997, CELL IMMUNOL, V180, P20, DOI 10.1006/cimm.1997.1171; LuoPhd J, 2010, ANN NEUROL, V67, P441, DOI 10.1002/ana.21901; Maniaol AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036603; Masuda M, 2010, EUR J PHARMACOL, V627, P325, DOI 10.1016/j.ejphar.2009.10.040; Melzer N, 2016, J NEUROL, V263, P1473, DOI 10.1007/s00415-016-8045-z; Meriggioli MN, 2009, LANCET NEUROL, V8, P475, DOI 10.1016/S1474-4422(09)70063-8; Milani M, 2003, ANN NY ACAD SCI, V998, P284, DOI 10.1196/annals.1254.032; Nagane Y, 2010, EUR NEUROL, V64, P186, DOI 10.1159/000319172; Nessi V, 2010, J IMMUNOL, V185, P5656, DOI 10.4049/jimmunol.0903183; Ng THS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00129; Oksenberg JR, 2004, AM J HUM GENET, V74, P160, DOI 10.1086/380997; Oshima M, 2000, AUTOIMMUNITY, V32, P45, DOI 10.3109/08916930008995987; Oshima M, 2005, HUM IMMUNOL, V66, P32, DOI 10.1016/j.humimm.2004.09.015; Oshima M, 1998, AUTOIMMUNITY, V27, P79, DOI 10.3109/08916939809008038; OSHIMA M, 1990, EUR J IMMUNOL, V20, P2563, DOI 10.1002/eji.1830201206; Oshima M, 2012, AUTOIMMUNITY, V45, P153, DOI 10.3109/08916934.2011.611550; Phillips William D, 2016, F1000Res, V5, DOI 10.12688/f1000research.8206.1; PROTTI MP, 1992, J CLIN INVEST, V90, P1558, DOI 10.1172/JCI116024; Raimondi G, 2006, J IMMUNOL, V176, P4012, DOI 10.4049/jimmunol.176.7.4012; Robertson NP, 1998, J NEUROL NEUROSUR PS, V65, P492, DOI 10.1136/jnnp.65.4.492; Sakai Waka, 2016, eNeurologicalSci, V2, P17, DOI 10.1016/j.ensci.2016.02.004; Shi FD, 1998, CLIN EXP IMMUNOL, V111, P506; Sinmaz N, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0678-4; Spence A, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0807-6; Testi M, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/541760; Utsugisawa K, 2008, EUR J NEUROL, V15, P598, DOI 10.1111/j.1468-1331.2008.02130.x; Vaughan K, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/403915; Velaga S, 2017, EXP HEMATOL, V45, P27, DOI 10.1016/j.exphem.2016.09.008; Wang XB, 2008, J INTERN MED, V263, P61, DOI 10.1111/j.1365-2796.2007.01879.x; Wang Z, 2012, SCAND J IMMUNOL, V76, P54, DOI 10.1111/j.1365-3083.2012.02703.x; Wang ZY, 1998, NEUROLOGY, V50, P1045, DOI 10.1212/WNL.50.4.1045; Wang ZY, 2000, J NEUROIMMUNOL, V108, P29, DOI 10.1016/S0165-5728(00)00250-2; Wang ZY, 1998, ANN NY ACAD SCI, V841, P329, DOI 10.1111/j.1749-6632.1998.tb10940.x; Wolfe GI, 2016, NEW ENGL J MED, V375, P511, DOI 10.1056/NEJMoa1602489; Wylam ME, 2003, J PEDIATR-US, V143, P674, DOI 10.1067/S0022-3476(03)00300-7; Yi JS, 2014, J AUTOIMMUN, V52, P130, DOI 10.1016/j.jaut.2013.12.005; YI Q, 1994, J NEUROIMMUNOL, V50, P177, DOI 10.1016/0165-5728(94)90044-2; Yilmaz V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123546; Yoshikawa H, 2002, J CLIN NEUROSCI, V9, P133, DOI 10.1054/jocn.2001.1028; Zagoriti Z, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/404053	66	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 24	2017	8								1370	10.3389/fimmu.2017.01370	http://dx.doi.org/10.3389/fimmu.2017.01370			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FK5HC	29114250	Green Published, gold			2022-12-18	WOS:000413527600001
J	Fierz, W				Fierz, Walter			Age-Related Macular Degeneration: A Connection between Human Herpes Virus-6A-Induced CD46 Downregulation and Complement Activation?	FRONTIERS IN IMMUNOLOGY			English	Article						human herpes virus-6A; age-related macular degeneration; CD46; complement system proteins; autophagy; parainflammation; inflammaging	PIGMENT EPITHELIAL-CELLS; BETA-CHEMOKINE RECEPTOR; COFACTOR PROTEIN CD46; FACTOR-H POLYMORPHISM; MULTIPLE-SCLEROSIS; HUMAN CYTOMEGALOVIRUS; CHRONIC INFLAMMATION; GEOGRAPHIC ATROPHY; SEQUENCE VARIATION; CELLULAR RECEPTOR	Viruses are able to interfere with the immune system by docking to receptors on host cells that are important for proper functioning of the immune system. A well-known example is the human immunodeficiency virus that uses CD4 cell surface molecules to enter host lymphocytes and thereby deleteriously destroying the helper cell population of the immune system. A more complicated mechanism is seen in multiple sclerosis (MS) where human herpes virus-6A (HHV-6A) infects astrocytes by docking to the CD46 surface receptor. Such HHV-6A infection in the brain of MS patients has recently been postulated to enable Epstein-Barr virus (EBV) to transform latently infected B-lymphocytes in brain lesions leading to the well-known phenomenon of oligoclonal immunoglobulin production that is widely used in the diagnosis of MS. The cellular immune response to HHV-6A and EBV is one part of the pathogenic mechanisms in MS. A more subtle pathogenic mechanism can be seen in the downregulation of CD46 on astrocytes by the infecting HHV-6A. Since CD46 is central in regulating the complement system, a lack of CD46 can lead to hyperactivation of the complement system. In fact, activation of the complement system in brain lesions is a well-known pathogenic mechanism in MS. In this review, it is postulated that a similar mechanism is central in the development of age-related macular degeneration (AMD). One of the earliest changes in the retina of AMD patients is the loss of CD46 expression in the retinal pigment epithelial (RPE) cells in the course of geographic atrophy. Furthermore, CD46 deficient mice spontaneously develop dry-type AMD-like changes in their retina. It is also well known that certain genetic polymorphisms in the complement-inhibiting pathways correlate with higher risks of AMD development. The tenet is that HHV-6A infection of the retina leads to downregulation of CD46 and consequently to hyperactivation of the complement system in the eyes of susceptible individuals.	[Fierz, Walter] Lab Med Zentrum Dr Risch, Vaduz, Liechtenstein		Fierz, W (corresponding author), Lab Med Zentrum Dr Risch, Vaduz, Liechtenstein.	w.f@swissonline.ch						Ablashi D, 2014, ARCH VIROL, V159, P863, DOI 10.1007/s00705-013-1902-5; Agut H, 2017, MED MALADIES INFECT, V47, P83, DOI 10.1016/j.medmal.2016.09.004; Ahlqvist J, 2006, J MED VIROL, V78, P1542, DOI 10.1002/jmv.20737; Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018; Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413; Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003; Bates M, 2009, J MED VIROL, V81, P779, DOI 10.1002/jmv.21455; Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223; Caselli E, 2017, VIROL J, V14, DOI 10.1186/s12985-016-0672-6; Caselli E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002951; Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0; Chatziralli I, 2017, BIOMED HUB, V2, P1, DOI [10.1159/000454706, DOI 10.1159/000454706]; Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R; Clark DA, 2000, REV MED VIROL, V10, P155, DOI 10.1002/(SICI)1099-1654(200005/06)10:3&lt;155::AID-RMV277&gt;3.0.CO;2-6; Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692; Crane IJ, 1998, CELL IMMUNOL, V184, P37, DOI 10.1006/cimm.1997.1235; Dagna L, 2013, FUTURE VIROL, V8, P273, DOI 10.2217/FVL.13.7; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dvashi Z, 2014, INVEST OPHTH VIS SCI, V55, P5679, DOI 10.1167/iovs.14-14349; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140; Fierz W, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0719-3; Franceschi C, 2017, TRENDS ENDOCRIN MET, V28, P199, DOI 10.1016/j.tem.2016.09.005; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Francis PJ, 2008, MOL VIS, V14, P1395; Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610; Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2; Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203; Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735; GORDON DL, 1992, J NEUROIMMUNOL, V36, P199, DOI 10.1016/0165-5728(92)90051-L; Green AJ, 2010, BRAIN, V133, P1591, DOI 10.1093/brain/awq080; Green YA, 2016, BIOCHEM CELL BIOL, V94, P188, DOI 10.1139/bcb-2015-0120; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; He J, 1996, J VIROL, V70, P1296, DOI 10.1128/JVI.70.2.1296-1300.1996; Ingram G, 2009, CLIN EXP IMMUNOL, V155, P128, DOI 10.1111/j.1365-2249.2008.03830.x; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037; Joubert PE, 2009, CELL HOST MICROBE, V6, P354, DOI 10.1016/j.chom.2009.09.006; Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8; Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x; Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8; Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960; Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073; Knox KK, 1996, J ACQ IMMUN DEF SYND, V11, P370, DOI 10.1097/00042560-199604010-00007; KNOX KK, 1995, J ACQ IMMUN DEF SYND, V9, P69; KOJIMA A, 1993, J IMMUNOL, V151, P1519; Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2; Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003; Leibovitch EC, 2014, CURR OPIN VIROL, V9, P127, DOI 10.1016/j.coviro.2014.09.016; Liao X, 2016, ARCH GERONTOL GERIAT, V64, P123, DOI 10.1016/j.archger.2016.01.011; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; Lusso P, 2006, J CLIN VIROL, V37, pS4, DOI 10.1016/S1386-6532(06)70004-X; Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021; Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592; Maeki T, 2012, ADV VIROL, V2012, DOI 10.1155/2012/384069; McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032; McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813; Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303; Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12; Mori Y, 2002, J VIROL, V76, P6750, DOI 10.1128/JVI.76.13.6750-6761.2002; Murakami Y, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-91; Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671; Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025; Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607; Pedersen SM, 2006, VIROLOGY, V356, P1, DOI 10.1016/j.virol.2006.07.028; QAVI HB, 1995, INVEST OPHTH VIS SCI, V36, P2040; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Santoro F, 2003, J BIOL CHEM, V278, P25964, DOI 10.1074/jbc.M302373200; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; SPEAR GT, 1995, J IMMUNOL, V155, P4376; Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje; Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002; Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1	80	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2017	8								1314	10.3389/fimmu.2017.01314	http://dx.doi.org/10.3389/fimmu.2017.01314			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FJ8QR	29093709	Green Published, gold			2022-12-18	WOS:000413034200001
J	Gerstner, C; Dubnovitsky, A; Sandin, C; Kozhukh, G; Uchtenhagen, H; James, EA; Ronnelid, J; Ytterberg, AJ; Pieper, J; Reed, E; Tandre, K; Rieck, M; Zubarev, RA; Ronnblom, L; Sandalova, T; Buckner, JH; Achour, A; Malmstrom, V				Gerstner, Christina; Dubnovitsky, Anatoly; Sandin, Charlotta; Kozhukh, Genadiy; Uchtenhagen, Hannes; James, Eddie A.; Ronnelid, Johan; Ytterberg, Anders Jimmy; Pieper, Jennifer; Reed, Evan; Tandre, Karolina; Rieck, Mary; Zubarev, Roman A.; Ronnblom, Lars; Sandalova, Tatyana; Buckner, Jane H.; Achour, Adnane; Malmstrom, Vivianne			Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted alpha-Enolase T Cell Epitope in Rheumatoid Arthritis (vol 7, 494, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						rheumatoid arthritis; HLA-DR4/alpha-enolase; neo-antigen; CD4(+) T cell; autoimmunity; cytokines; crystal structures			[Gerstner, Christina; Sandin, Charlotta; Kozhukh, Genadiy; Uchtenhagen, Hannes; Ytterberg, Anders Jimmy; Pieper, Jennifer; Reed, Evan; Malmstrom, Vivianne] Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Rheumatol Unit,Dept Med Solna, Stockholm, Sweden; [Dubnovitsky, Anatoly] Karolinska Inst, Neuroimmunol Unit, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden; [Dubnovitsky, Anatoly; Kozhukh, Genadiy; Sandalova, Tatyana; Achour, Adnane] Karolinska Inst, Dept Med Solna, Sci Life Lab, Stockholm, Sweden; [Uchtenhagen, Hannes; Rieck, Mary; Buckner, Jane H.] BRI Virginia Mason, Translat Res Program, Seattle, WA USA; [James, Eddie A.] BRI Virginia Mason, Tetramer Core, Seattle, WA USA; [Ronnelid, Johan] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Ytterberg, Anders Jimmy; Zubarev, Roman A.] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Tandre, Karolina; Ronnblom, Lars] Uppsala Univ, Sci Life Lab, Dept Med Sci, Rheumatol, Uppsala, Sweden; [Sandalova, Tatyana; Achour, Adnane] Karolinska Univ Hosp Solna, Dept Infect Dis, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Virginia Mason Medical Center; Virginia Mason Medical Center; Uppsala University; Karolinska Institutet; Uppsala University; Karolinska Institutet; Karolinska University Hospital	Gerstner, C (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Rheumatol Unit,Dept Med Solna, Stockholm, Sweden.	christina.gerstner@ki.se	James, Eddie/V-4929-2019; Zubarev, Roman A/W-7891-2018	James, Eddie/0000-0002-7217-5729; Zubarev, Roman A/0000-0001-9839-2089; Achour, Adnane/0000-0003-0432-710X; Kozhukh, Genadiy/0000-0003-4624-269X				Gerstner C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00494	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2017	8								1236	10.3389/fimmu.2017.01236	http://dx.doi.org/10.3389/fimmu.2017.01236			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI9FY	29018454	Green Published, gold			2022-12-18	WOS:000412312200001
J	Consuegra-Fernandez, M; Isamat, M; Lozano, F				Consuegra-Fernandez, Marta; Isamat, Marcos; Lozano, Francisco			Commentary: CD6 as a Potential target for treating multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CD6; multiple sclerosis; itolizumab; UMCD6; experimental autoimmune encephalomyelitis; collagen-induced arthritis; cGvHD-induced lupus-like disease	T-CELL RESPONSES; ITOLIZUMAB; TOLERANCE		[Consuegra-Fernandez, Marta; Isamat, Marcos; Lozano, Francisco] Inst Invest Biomed August Pi & Sunyer, Immunoreceptors Innate & Adapt Syst, Barcelona, Spain; [Lozano, Francisco] Hosp Clin Barcelona, Serv Immunol, Ctr Diagnost Biomed, Barcelona, Spain; [Lozano, Francisco] Univ Barcelona, Dept Biomed, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona	Lozano, F (corresponding author), Inst Invest Biomed August Pi & Sunyer, Immunoreceptors Innate & Adapt Syst, Barcelona, Spain.; Lozano, F (corresponding author), Hosp Clin Barcelona, Serv Immunol, Ctr Diagnost Biomed, Barcelona, Spain.; Lozano, F (corresponding author), Univ Barcelona, Dept Biomed, Barcelona, Spain.	flozano@clinic.ub.es	LOZANO, FRANCISCO/AAB-7888-2019	LOZANO, FRANCISCO/0000-0003-1119-4368; Consuegra-Fernandez, Marta/0000-0002-5894-2768	Worldwide Cancer Research [14-1275]; Fundacio La Marato TV3 [201319-30]; Ministerio de Economia y Competitividad [SAF2013-46151-R, SAF2016-80535-R]; European Development Regional Fund "A way to achieve Europe" ERDF	Worldwide Cancer Research; Fundacio La Marato TV3; Ministerio de Economia y Competitividad(Spanish Government); European Development Regional Fund "A way to achieve Europe" ERDF(European Commission)	The work to FL was supported by Worldwide Cancer Research (14-1275), Fundacio La Marato TV3 (201319-30), and Ministerio de Economia y Competitividad (SAF2013-46151-R; SAF2016-80535-R), co-financed by European Development Regional Fund "A way to achieve Europe" ERDF.	Aira LE, 2016, MABS-AUSTIN, V8, P187, DOI 10.1080/19420862.2015.1105416; Chatenoud L, 2005, CURR OPIN IMMUNOL, V17, P632, DOI 10.1016/j.coi.2005.09.011; Consuegra-Fernandez M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00594; Hernandez P, 2016, CURR DRUG TARGETS, V17, P666, DOI 10.2174/1389450117666160201114308; Kofler DM, 2016, CURR DRUG TARGETS, V17, P651, DOI 10.2174/1389450117666160201105934; Li Y, 2017, P NATL ACAD SCI USA, V114, P2687, DOI 10.1073/pnas.1615253114; Orta-Mascaro M, 2016, J EXP MED, V213, P1387, DOI 10.1084/jem.20151785; Santos RF, 2016, CURR DRUG TARGETS, V17, P630, DOI 10.2174/1389450116666150531152439; Singer NG, 1997, IMMUNOL LETT, V58, P9, DOI 10.1016/S0165-2478(97)02707-7	9	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2017	8								1217	10.3389/fimmu.2017.01217	http://dx.doi.org/10.3389/fimmu.2017.01217			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI4RK	29033937	Green Published, gold			2022-12-18	WOS:000411961000001
J	Zhou, AC; Snell, LM; Wortzman, ME; Watts, TH				Zhou, Angela C.; Snell, Laura M.; Wortzman, Michael E.; Watts, Tania H.			CD30 Is Dispensable for T-Cell Responses to Influenza Virus and Lymphocytic Choriomeningitis Virus Clone 13 but Contributes to Age-Associated T-Cell Expansion in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						CD30; viral; influenza; lymphocytic choriomeningitis virus; T cells; age-dependent T-cell expansion	KAPPA-B ACTIVATION; HODGKINS-LYMPHOMA; VIRAL-INFECTION; FAMILY-MEMBERS; MEMORY; OX40; IMMUNITY; RECEPTOR; DISEASE; LIGAND	CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans. A limited number of studies have assessed the physiological role of CD30/CD30 ligand interactions in control of infection in mice. Here, we assess the role of CD30 in T-cell immunity to acute influenza and chronic lymphocytic choriomeningitis virus (LCMV) clone 13 infection, two viral infections in which other members of the TNFR superfamily are important for T-cell responses. We show that CD30 is expressed on activated but not resting CD4 and CD8 T cells in vitro, as well as on regulatory T cells and marginally on T helper 1 cells in vivo during influenza infection. Despite this, CD4 and CD8 T-cell expansion in response to influenza virus was comparable in CD30(+/+) and CD30(-/-) littermates, with no discernable role for the pathway in the outcome of influenza infection. Similarly, during persistent infection with LCMV clone 13, CD30 plays no obvious role in CD4 or CD8 T-cell responses, the level of T-cell exhaustion or viral control. In contrast, in the steady state, we observed increased numbers of total CD4 and CD8 T cells as well as increased numbers of regulatory T cells in unimmunized older (similar to 8 months) CD30(+/+) but not in CD30(-/-) age-matched littermates. Naive T-cell numbers were unchanged in the aged CD30(+/+) mice compared to their CD30(-/-) littermate controls, rather the T-cell expansions were explained by an increase in CD4(+) and CD8(+) CD44(mid-hi)CD62L-effector memory cells, with a similar trend in the central memory T-cell compartment. In contrast, CD30 did not impact the numbers of T cells in young mice. These data suggest a role for CD30 in the homeostatic regulation of T cells during aging, contributing to memory T-cell expansions, which may have relevance for CD30 expression in human T-cell lymphoproliferative diseases.	[Zhou, Angela C.; Snell, Laura M.; Wortzman, Michael E.; Watts, Tania H.] Univ Toronto, Dept Immunol, Fac Med, Toronto, ON, Canada; [Snell, Laura M.] Princess Margaret Canc Ctr, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Watts, TH (corresponding author), Univ Toronto, Dept Immunol, Fac Med, Toronto, ON, Canada.	tania.watts@utoronto.ca		Snell, Laura/0000-0001-9890-6588	Canadian Institutes of Health Research (CIHR) [MOP-133443, FDN-143250]; Queen Elizabeth II/Aventis Graduate Scholarship; Ontario Graduate Scholarship (OGS); CIHR Doctoral Award	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Queen Elizabeth II/Aventis Graduate Scholarship; Ontario Graduate Scholarship (OGS)(Ontario Graduate Scholarship); CIHR Doctoral Award(Canadian Institutes of Health Research (CIHR))	This study was funded by Canadian Institutes of Health Research (CIHR) grants MOP-133443 and FDN-143250 to THW. THW holds the Sanofi Pasteur Chair in Human Immunology at the University of Toronto. ACZ was funded by a Queen Elizabeth II/Aventis Graduate Scholarship, Ontario Graduate Scholarship (OGS) and a CIHR Doctoral Award.	ALZONA M, 1994, J IMMUNOL, V153, P2861; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Ansieau S, 1997, P NATL ACAD SCI USA, V94, P12732; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; Bekiaris V, 2009, EUR J IMMUNOL, V39, P2120, DOI 10.1002/eji.200939424; Boettler T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002913; Bowen MA, 1996, J IMMUNOL, V156, P442; Clouthier DL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004517; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; de Leval L, 2010, HAEMATOL-HEMATOL J, V95, P1627, DOI 10.3324/haematol.2010.029256; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; Florido M, 2004, J LEUKOCYTE BIOL, V76, P1039, DOI 10.1189/jlb.1103572; Gaspal F, 2008, J IMMUNOL, V180, P2824, DOI 10.4049/jimmunol.180.5.2824; Gaspal FMC, 2005, J IMMUNOL, V174, P3891, DOI 10.4049/jimmunol.174.7.3891; Gilfillan MC, 1998, J IMMUNOL, V160, P2180; Guo Y, 2013, INFECT IMMUN, V81, P3923, DOI 10.1128/IAI.00887-13; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hendriks J, 2005, J IMMUNOL, V175, P1665, DOI 10.4049/jimmunol.175.3.1665; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601; Humphreys IR, 2007, J IMMUNOL, V179, P2195, DOI 10.4049/jimmunol.179.4.2195; Kim MY, 2003, IMMUNITY, V18, P643, DOI 10.1016/S1074-7613(03)00110-9; Kopf M, 1999, IMMUNITY, V11, P699, DOI 10.1016/S1074-7613(00)80144-2; Lane PJL, 2005, NAT REV IMMUNOL, V5, P655, DOI 10.1038/nri1665; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lin GHY, 2009, J IMMUNOL, V182, P934, DOI 10.4049/jimmunol.182.2.934; Marin ND, 2017, TUBERCULOSIS, V102, P8, DOI 10.1016/j.tube.2016.10.006; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; Nishimura H, 2005, J IMMUNOL, V175, P4627, DOI 10.4049/jimmunol.175.7.4627; Panus JF, 2002, P NATL ACAD SCI USA, V99, P8348, DOI 10.1073/pnas.122238599; Pierce JMR, 2017, EXPERT REV HEMATOL, V10, P29, DOI 10.1080/17474086.2017.1270202; Podack ER, 2002, ANN NY ACAD SCI, V975, P101, DOI 10.1111/j.1749-6632.2002.tb05945.x; Pulko V, 2016, NAT IMMUNOL, V17, P966, DOI 10.1038/ni.3483; Saraiva M, 2002, J EXP MED, V196, P829, DOI 10.1084/jem.20020319; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; Snell LM, 2010, J IMMUNOL, V185, P7223, DOI 10.4049/jimmunol.1001912; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; Stein H, 2000, BLOOD, V96, P3681; Sun X, 2010, J IMMUNOL, V185, P7671, DOI 10.4049/jimmunol.1002229; Sun X, 2010, J IMMUNOL, V185, P2222, DOI 10.4049/jimmunol.1000024; Tang C, 2008, J IMMUNOL, V181, P6316, DOI 10.4049/jimmunol.181.9.6316; Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237; van Gisbergen KPJM, 2009, J IMMUNOL, V182, P5352, DOI 10.4049/jimmunol.0802809; Wang C, 2012, J EXP MED, V209, P77, DOI 10.1084/jem.20110675; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wortzman ME, 2013, IMMUNOL REV, V255, P125, DOI 10.1111/imr.12086	49	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2017	8								1156	10.3389/fimmu.2017.01156	http://dx.doi.org/10.3389/fimmu.2017.01156			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI0ET	28993768	gold, Green Published			2022-12-18	WOS:000411596800001
J	Budding, K; van Setten, J; van de Graaf, EA; van Rossum, OA; Kardol-Hoefnagel, T; Oudijk, EJD; Hack, CE; Otten, HG				Budding, Kevin; van Setten, Jessica; van de Graaf, Eduard A.; van Rossum, Oliver A.; Kardol-Hoefnagel, Tineke; Oudijk, Erik-Jan D.; Hack, C. Erik; Otten, Henderikus G.			Association between a Single Donor TARC/CCL17 Promotor Polymorphism and Obstructive Chronic Lung Allograft Dysfunction after Lung Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						lung transplantation; thymus and activation-regulated chemokine; chronic lung allograft dysfunction; bronchiolitis obliterans syndrome; chronic rejection	BRONCHIOLITIS-OBLITERANS-SYNDROME; ACTIVATION-REGULATED CHEMOKINE; BRONCHIAL EPITHELIAL-CELLS; GENOME-WIDE ASSOCIATION; INTERFERON-GAMMA GENE; RECEPTORS CCR4; BINDING-SITES; T-CELLS; EXPRESSION; TARC	Lung transplantation (LTx) outcome is hampered by development of chronic rejection, often manifested as the bronchiolitis obliterans syndrome (BOS). Low serum levels of thymus and activation-regulated chemokine (TARC/CCL17), a chemoattractant, measured during the first month post-LTx are predictive for BOS development. Since TARC/CCL17 promotor polymorphisms correlate with serum TARC/CCL17 levels, we investigated seven single-nucleotide polymorphisms (SNPs) within this region and their potential association with LTx outcome. We analyzed donor and patient SNP configurations and haplotypes and observed a trend between a donor SNP (rs223899) configuration and patient TARC/CCL17 serum levels post-LTx (p = 0.066). Interestingly, this SNP configuration in patients did not show any correlation with pre-LTx TARC/CCL17 serum levels (p = 0.776). Survival analysis showed that receiving a graft from a donor heterozygous for rs223899 has a disadvantageous impact on transplantation outcome. When stratified per donor SNP genotype, patients receiving a transplant from a heterozygous donor showed a lower BOS-free survival (p = 0.023) and survival rate (p = 0.0079). Since rs223899 is located within a NF kappa B binding site, heterozygosity at this position could result in a reduced TARC/CCL17 expression. Our data indicate that a single TARC/CCL17 promotor SNP in the donor correlates with lower serum TARC/CCL17 levels measured 1 month after LTx and affects clinical outcome after LTx.	[Budding, Kevin; van Rossum, Oliver A.; Kardol-Hoefnagel, Tineke; Hack, C. Erik; Otten, Henderikus G.] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [van Setten, Jessica] Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands; [van de Graaf, Eduard A.] Univ Med Ctr Utrecht, Dept Resp Med, Utrecht, Netherlands; [Oudijk, Erik-Jan D.] St Antonius Hosp, Ctr Interstitial Lung Dis, Nieuwegein, Netherlands; [Hack, C. Erik] Univ Med Ctr Utrecht, Dept Rheumatol, Utrecht, Netherlands; [Hack, C. Erik] Univ Med Ctr Utrecht, Dept Dermatol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; St. Antonius Hospital Utrecht; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Budding, K (corresponding author), Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands.	k.budding@umcutrecht.nl	Levi, Marcel/AAZ-8559-2020					Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Anderson CA, 2010, NAT PROTOC, V5, P1564, DOI 10.1038/nprot.2010.116; Awad M, 1999, HUM IMMUNOL, V60, P343, DOI 10.1016/S0198-8859(98)00133-5; Berastegui C, 2013, TRANSPL P, V45, P3163, DOI 10.1016/j.transproceed.2013.06.013; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Budding K, 2016, AM J TRANSPLANT, V16, P987, DOI 10.1111/ajt.13497; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; El-Gamel A, 1999, J HEART LUNG TRANSPL, V18, P517, DOI 10.1016/S1053-2498(98)00024-2; Estenne M, 2002, J HEART LUNG TRANSPL, V21, P297, DOI 10.1016/S1053-2498(02)00398-4; Flicek P, 2014, NUCLEIC ACIDS RES, V42, pD749, DOI 10.1093/nar/gkt1196; Francioli LC, 2014, NAT GENET, V46, P818, DOI 10.1038/ng.3021; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Hennessy SA, 2010, ANN THORAC SURG, V89, P1555, DOI 10.1016/j.athoracsur.2010.01.060; Huang SP, 2013, EUR J CANCER, V49, P3729, DOI 10.1016/j.ejca.2013.07.012; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Karczewski J, 2008, TRANSPL P, V40, P3390, DOI 10.1016/j.transproceed.2008.07.125; Kawashima T, 2010, J DERMATOL SCI, V60, P52, DOI 10.1016/j.jdermsci.2010.07.012; Keating BJ, 2015, TRANSPLANTATION, V99, P2401, DOI 10.1097/TP.0000000000000913; Lee CP, 2013, PEDIATR RES, V74, P545, DOI 10.1038/pr.2013.134; Leung TF, 2004, J ALLERGY CLIN IMMUN, V114, P199, DOI 10.1016/j.jaci.2004.03.048; Li YR, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0211-x; Lu KC, 2002, TRANSPLANTATION, V74, P1297, DOI 10.1097/00007890-200211150-00017; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Miyazaki E, 2002, AM J RESP CRIT CARE, V165, P1125, DOI 10.1164/ajrccm.165.8.2106110; Monick MM, 2007, J IMMUNOL, V179, P1648, DOI 10.4049/jimmunol.179.3.1648; Munster JM, 2008, TRANSPLANTATION, V86, P1857, DOI 10.1097/TP.0b013e31819064b8; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Paantjens AWM, 2008, CLIN EXP IMMUNOL, V154, P202, DOI 10.1111/j.1365-2249.2008.03764.x; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Ruttens D, 2015, ANN MED, V47, P106, DOI 10.3109/07853890.2015.1004359; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Sekiya T, 2003, IMMUNOGENETICS, V54, P742, DOI 10.1007/s00251-002-0520-2; Shiels MS, 2013, JNCI-J NATL CANCER I, V105, P1871, DOI 10.1093/jnci/djt309; Snyder LD, 2006, J HEART LUNG TRANSPL, V25, P1330, DOI 10.1016/j.healun.2006.07.001; Tay SS, 2009, CURR OPIN ORGAN TRAN, V14, P16, DOI 10.1097/MOT.0b013e32831ebdf5; Todd JL, 2011, CHEST, V140, P502, DOI 10.1378/chest.10-2838; Verleden GM, 2014, J HEART LUNG TRANSPL, V33, P127, DOI 10.1016/j.healun.2013.10.022; Wirnsberger G, 2006, EUR J IMMUNOL, V36, P1882, DOI 10.1002/eji.200635972; Yusen RD, 2014, J HEART LUNG TRANSPL, V33, P1009, DOI 10.1016/j.healun.2014.08.004	42	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2017	8								1109	10.3389/fimmu.2017.01109	http://dx.doi.org/10.3389/fimmu.2017.01109			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FG0RN	28932229	Green Published, gold			2022-12-18	WOS:000409474600001
J	Oliveira, L; Carmo, AM				Oliveira, Liliana; Carmo, Alexandre M.			Response: Commentory: The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						scavenger receptor cisteine-rich; CD6; bacteria; pattern recognition receptors; surface plasmon resonance	CD6; BINDS		[Oliveira, Liliana; Carmo, Alexandre M.] Univ Porto, i3S, Oporto, Portugal; [Oliveira, Liliana; Carmo, Alexandre M.] IBMC, Oporto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto	Carmo, AM (corresponding author), Univ Porto, i3S, Oporto, Portugal.; Carmo, AM (corresponding author), IBMC, Oporto, Portugal.	acarmo@ibmc.up.pt	Oliveira, Liliana/AAX-9115-2021; Oliveira, Liliana/K-5859-2013; Carmo, Alexandre M./B-5191-2011	Oliveira, Liliana/0000-0001-5222-7600; Oliveira, Liliana/0000-0001-5222-7600; Carmo, Alexandre M./0000-0002-2508-9799	National Funds through FCT-Fundacao para a Ciencia e a Tecnologia under the project SRecognite [Infect-ERA/0003/2015]; Norte Portugal Regional Operational Programme (NORTE) under the PORTUGAL Partnership Agreement, through the European Regional Development Fund [Norte-01-0145-FEDER-000012]	National Funds through FCT-Fundacao para a Ciencia e a Tecnologia under the project SRecognite; Norte Portugal Regional Operational Programme (NORTE) under the PORTUGAL Partnership Agreement, through the European Regional Development Fund	This work is funded by National Funds through FCT-Fundacao para a Ciencia e a Tecnologia under the project SRecognite Infect-ERA/0003/2015, by the project Norte-01-0145-FEDER-000012-structured program on bioengineered therapies for infectious diseases and tissue regeneration, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund.	Bessa Pereira C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00416; Carmo AM, 2016, CURR DRUG TARGETS, V17, P618, DOI 10.2174/138945011706160324153314; Fabriek BO, 2009, BLOOD, V113, P887, DOI 10.1182/blood-2008-07-167064; Goncalves CM, 2009, MOL IMMUNOL, V46, P2585, DOI 10.1016/j.molimm.2009.05.006; Martinez-Florensa M, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01391-16; Oliveira MI, 2012, EUR J IMMUNOL, V42, P195, DOI 10.1002/eji.201040528; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; Sarrias MR, 2007, P NATL ACAD SCI USA, V104, P11724, DOI 10.1073/pnas.0702815104; Sarrias MR, 2005, J BIOL CHEM, V280, P35391, DOI 10.1074/jbc.M505042200	9	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2017	8								1004	10.3389/fimmu.2017.01004	http://dx.doi.org/10.3389/fimmu.2017.01004			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FE5AQ	28878773	Green Published, gold			2022-12-18	WOS:000408224800001
J	Zhou, CY; Wang, RN; Wen, Q; He, WT; Zhang, SM; Du, XL; Yang, JH; Ma, L				Zhou, Chao-Ying; Wang, Rui-Ning; Wen, Qian; He, Wen-Ting; Zhang, Shi-Meng; Du, Xia-Lin; Yang, Jia-Hui; Ma, Li			Alanine Mutagenesis in the Complementarity Determining Region 3 of the MTB and HIV-1 Peptide-Bispecific T Cell Receptor Beta Chain Affects Ligand Recognition	FRONTIERS IN IMMUNOLOGY			English	Article						alanine scanning mutagenesis; complementarity determining region 3 beta; bispecific T cell receptor; MTB/HI V coinfection; adoptive immunotherapy	ANTIGEN RECOGNITION; HIGH-AFFINITY; HUMAN CD4; BINDING; CANCER; MHC; TUBERCULOSIS; ACTIVATION; MELANOMA; EPITOPES	Mycobacterium tuberculosis/human immunodeficiency virus (MTB/HIV) coinfection presents a special challenge to the prevention and treatment of tuberculosis and HIV/AIDS. Adoptive transfer of high-affinity T cell receptor (TCR) gene-modified T cells against MTB and HIV antigens is a promising approach to treating MTB/HIV coinfected patients whose cellular immunity is obviously disordered. We have previously successfully identified that a bispecific TCR screened out from peripheral blood mononuclear cells of a HLA-A*0201(+) healthy individual using the complementarity determining region 3 (CDR3) spectratype analysis recognizes both MTB Ag85B(199-207) and HIV-1 Env(120-128) peptide. However, it has not been known how residues on CDR3 loops, which have been shown to play a leading role in antigen binding and specificity contribute to the bispecific TCR contact with the peptide-major histocompatibility complex (MHC) complexes. In this study, we provided an extensive investigation of residues in the predicted CDR3 of the bispecific TCR beta (beta) chain using alanine scanning mutagenesis. Our data showed that three of the five substituted residues (G115A, T116A, A117G) in CDR3 beta of the bispecific TCR caused a significantly diminished T cell response to antigen, whereas the remaining two substituted residues (D114A, S118A) resulted in completely eliminated response, thus identifying the two residues that were particularly critical for the recognition of peptide-MHC in the bispecific TCR. These findings will provide an imperative foundation for generating an improved high-affinity bispecific TCR for use in T cell adoptive immunotherapy for MTB/HIV coinfected individuals.	[Zhou, Chao-Ying; Wang, Rui-Ning; Wen, Qian; He, Wen-Ting; Zhang, Shi-Meng; Du, Xia-Lin; Yang, Jia-Hui; Ma, Li] Southern Med Univ, Inst Mol Immunol, Sch Lab Med & Biotechnol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Ma, L (corresponding author), Southern Med Univ, Inst Mol Immunol, Sch Lab Med & Biotechnol, Guangzhou, Guangdong, Peoples R China.	maryhmz@126.com		Ma, Li/0000-0001-5847-2375; Zhou, Chao-ying/0000-0002-4188-9630	National Natural Science Foundation of China [81571951, 81371764]; National Science and Technology Key Projects on Major Infectious Diseases [2017ZX10201301-008]; Guangdong Natural Science Foundation [2016A030311001]; Science and Technology Project of Guangdong Province [2017A020212007]; Science and Technology Project of Guangzhou [201707010215]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; China Postdoctoral Science Foundation [2016M600661]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Key Projects on Major Infectious Diseases; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Science and Technology Project of Guangdong Province; Science and Technology Project of Guangzhou; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81571951, 81371764), National Science and Technology Key Projects on Major Infectious Diseases (2017ZX10201301-008), Guangdong Natural Science Foundation (2016A030311001), Science and Technology Project of Guangdong Province (2017A020212007), Science and Technology Project of Guangzhou (201707010215), the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2012), and the China Postdoctoral Science Foundation (2016M600661).	Berger C, 2009, CURR OPIN IMMUNOL, V21, P224, DOI 10.1016/j.coi.2009.02.010; Bruchfeld J, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017871; Burkovitz A, 2016, MABS-AUSTIN, V8, P278, DOI 10.1080/19420862.2015.1123365; Carpenter SM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005380; Chinnasamy N, 2011, J IMMUNOL, V186, P685, DOI 10.4049/jimmunol.1001775; Chlewicki LK, 2005, J MOL BIOL, V346, P223, DOI 10.1016/j.jmb.2004.11.057; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; Cole DK, 2007, J IMMUNOL, V178, P5727, DOI 10.4049/jimmunol.178.9.5727; Dudley ME, 2003, J IMMUNOTHER, V26, P332, DOI 10.1097/00002371-200307000-00005; Feng D, 2007, NAT IMMUNOL, V8, P975, DOI 10.1038/ni1502; Frigstad T, 2013, SCAND J IMMUNOL, V78, P345, DOI 10.1111/sji.12098; Gottschalk S, 2005, LEUKEMIA LYMPHOMA, V46, P1, DOI 10.1080/10428190400002202; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; Hughes MS, 2005, HUM GENE THER, V16, P457, DOI 10.1089/hum.2005.16.457; Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848; KASIBHATLA S, 1993, J IMMUNOL, V151, P3140; Lai RPJ, 2016, SEMIN IMMUNOPATHOL, V38, P185, DOI 10.1007/s00281-015-0532-2; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; Laugel B, 2007, J BIOL CHEM, V282, P23799, DOI 10.1074/jbc.M700976200; Manning TC, 1999, IMMUNOL TODAY, V20, P417, DOI 10.1016/S0167-5699(99)01508-X; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Paletta D, 2015, EUR J IMMUNOL, V45, P2122, DOI 10.1002/eji.201545534; Parkhurst MR, 2009, CLIN CANCER RES, V15, P169, DOI 10.1158/1078-0432.CCR-08-1638; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Savage PA, 2001, IMMUNITY, V14, P243, DOI 10.1016/S1074-7613(01)00106-6; Schub A, 2009, J IMMUNOL, V183, P6819, DOI 10.4049/jimmunol.0902233; Smith LL, 2015, J ALLER CL IMM-PRACT, V3, P438, DOI 10.1016/j.jaip.2014.12.004; Spear TT, 2016, CANCER IMMUNOL IMMUN, V65, P293, DOI 10.1007/s00262-016-1800-2; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Varela-Rohena A, 2008, NAT MED, V14, P1390, DOI 10.1038/nm.1779; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wilgenhof S, 2016, J CLIN ONCOL, V34, P1330, DOI 10.1200/JCO.2015.63.4121; World Health Organisation (WHO), 2016, GLOB TUB REP 2016; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Yang HB, 2016, MOL THER, V24, P1913, DOI 10.1038/mt.2016.114; Zeh HJ, 1999, J IMMUNOL, V162, P989; Zha XF, 2016, ONCOTARGET, V7, P84246, DOI 10.18632/oncotarget.12441; Zhou CY, 2016, J CELL MOL MED, V20, P1984, DOI 10.1111/jcmm.12878	42	1	1	1	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2017	8								983	10.3389/fimmu.2017.00983	http://dx.doi.org/10.3389/fimmu.2017.00983			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FE0ON	28861087	Green Published, gold			2022-12-18	WOS:000407919700001
J	Maghazachi, AA				Maghazachi, Azzam A.			Editorial: immunomodulatory Effects of drugs for treatment of immune-related diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer; multiple sclerosis; chemokines; autophagy; adjuvants; natural killer cells			[Maghazachi, Azzam A.] Univ Sharjah, Coll Med, Dept Clin Med, Sharjah, U Arab Emirates; [Maghazachi, Azzam A.] Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates	University of Sharjah; University of Sharjah	Maghazachi, AA (corresponding author), Univ Sharjah, Coll Med, Dept Clin Med, Sharjah, U Arab Emirates.; Maghazachi, AA (corresponding author), Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates.	amagazachi@sharjah.ac.ae		Maghazachi, Azzam/0000-0002-3310-678X	University of Sharjah [1601010902009-P, 16010901010-P]	University of Sharjah	The author is supported by grants no. 1601010902009-P and 16010901010-P from the University of Sharjah.	Maghazachi AA, 1998, FASEB J, V12, P913, DOI 10.1096/fasebj.12.11.913	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2017	8								969	10.3389/fimmu.2017.00969	http://dx.doi.org/10.3389/fimmu.2017.00969			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FD4PO	28848562	gold, Green Published			2022-12-18	WOS:000407513200001
J	Vilen, LK; Atosuo, J; Lilius, EM				Vilen, Liisa K.; Atosuo, Janne; Lilius, Esa-Matti			The Response of Phagocytes Indoor Air Toxicity	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils response; mold; indoor air pollution; toxicity tests; immuno response	COMPLEMENT RECEPTORS; SCHOOLS; NEUTROPHILS; EXPRESSION; DAMPNESS; DUST; IGG; BACTERIAL; SYMPTOMS; RELEASE	This perspective presents a viewpoint on potential methods assessing toxicity of indoor air. Until recently, the major techniques to document moldy environment have been microbial isolation using conventional culture techniques for fungi and bacteria as well as in some instances polymerase chain reaction to detect microbial genetic components. However, it has become increasingly evident that bacterial and fungal toxins, their metabolic products, and volatile organic substances emitted from corrupted constructions are the major health risks. Here, we illustrate how phagocytes, especially neutrophils can be used as a toxicological probe. Neutrophils can be used either in vitro as probe cells, directly exposed to the toxic agent studied, or they can act as in vivo indicators of the whole biological system exposed to the agent. There are two convenient methods assessing the responses, one is to measure chemiluminescence emission from activated phagocytes and the other is to measure quantitatively by flow cytometry the expression of complement and immunoglobulin receptors on the phagocyte surface.	[Vilen, Liisa K.; Atosuo, Janne; Lilius, Esa-Matti] Univ Turku, Dept Biochem, Turku, Finland	Finland National Institute for Health & Welfare; University of Turku	Lilius, EM (corresponding author), Univ Turku, Dept Biochem, Turku, Finland.	esalil@utu.fi		Atosuo, Timo Janne/0000-0002-1100-4838	Finnish Work Environment Fund [TSR 116050]	Finnish Work Environment Fund	The Finnish Work Environment Fund (TSR 116050) funded the project.	Andersen B, 2003, MYCOLOGIA, V95, P1227, DOI 10.2307/3761923; Borras-Santos A, 2013, OCCUP ENVIRON MED, V70, P681, DOI 10.1136/oemed-2012-101286; Campbell AW, 2004, ADV APPL MICROBIOL, V55, P375, DOI 10.1016/S0065-2164(04)55015-3; Etzov E, 2015, ANAL CHEM, V87, P3655, DOI 10.1021/ac5038208; Gordon S, 2016, IMMUNITY, V44, P463, DOI 10.1016/j.immuni.2016.02.026; Han YH, 2008, ONCOL REP, V20, P689, DOI 10.3892/or_00000061; Haverinen-Shaughnessy U, 2008, SCI TOTAL ENVIRON, V399, P19, DOI 10.1016/j.scitotenv.2008.03.033; Hohenthal U, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-11; Huttunen K, 2016, INDOOR AIR, V26, P380, DOI 10.1111/ina.12223; Isolauri E, 1997, J ALLERGY CLIN IMMUN, V99, P707, DOI 10.1016/S0091-6749(97)70034-4; Jaakkola MS, 2002, CLIN EXP IMMUNOL, V129, P107, DOI 10.1046/j.1365-2249.2002.01884.x; Jacobs J, 2014, OCCUP ENVIRON MED, V71, P704, DOI 10.1136/oemed-2014-102246; Jonsson M, 2015, TOXICOL LETT, V233, P38, DOI 10.1016/j.toxlet.2014.11.006; Kieser T., 2000, PRACTICAL STREPTOMYC, V291; Kildeso J, 2003, INDOOR AIR, V13, P148, DOI 10.1034/j.1600-0668.2003.00172.x; Leino L, 1997, CLIN EXP IMMUNOL, V107, P37, DOI 10.1046/j.1365-2249.1997.d01-899.x; Lilius E, 2016, IND AIR P GHENT; LILIUS EM, 1992, EXPERIENTIA, V48, P1082, DOI 10.1007/BF01947995; Lilius EM, 2012, SCI WORLD J, DOI 10.1100/2012/527347; Lilius EME, 2006, LUMINESCENCE, V21, P148, DOI 10.1002/bio.899; Nuutila J, 2005, CYTOM PART A, V65A, P93, DOI 10.1002/cyto.a.20139; Salin JT, 2017, ENVIRON RES, V154, P234, DOI 10.1016/j.envres.2017.01.015; Salminen E, 2001, ANTICANCER RES, V21, P2049; Schmechel D, 2006, J IMMUNOL METHODS, V309, P150, DOI 10.1016/j.jim.2005.12.001; Suominen E, 2016, IND AIR P 2016 GHENT; Verdier T, 2014, BUILD ENVIRON, V80, P136, DOI 10.1016/j.buildenv.2014.05.030	26	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2017	8								887	10.3389/fimmu.2017.00887	http://dx.doi.org/10.3389/fimmu.2017.00887			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FB9RO	28804487	gold, Green Published			2022-12-18	WOS:000406476900001
J	Ho, PC; Hess, C				Ho, Ping-Chih; Hess, Christoph			Editorial: Immunometabolic Regulations in Adaptive and Innate Immune Cells Shapes and Re-Directs Host Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunometabolism; metabolic reprogramming; tumor microenvironment; autoimmunity; immune suppression			[Ho, Ping-Chih] Univ Lausanne, Dept Fundamental Oncol, Lausanne, Switzerland; [Ho, Ping-Chih] Univ Lausanne, Ludwig Ctr Canc Res, Lausanne, Switzerland; [Hess, Christoph] Univ Basel, Dept Biomed, Immunobiol, Basel, Switzerland	University of Lausanne; University of Lausanne; University of Basel	Ho, PC (corresponding author), Univ Lausanne, Dept Fundamental Oncol, Lausanne, Switzerland.; Ho, PC (corresponding author), Univ Lausanne, Ludwig Ctr Canc Res, Lausanne, Switzerland.; Hess, C (corresponding author), Univ Basel, Dept Biomed, Immunobiol, Basel, Switzerland.	ping-chih.ho@unil.ch; christoph.hess@usb.ch							0	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2017	8								852	10.3389/fimmu.2017.00852	http://dx.doi.org/10.3389/fimmu.2017.00852			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FB6AZ	28791013	Green Published, gold			2022-12-18	WOS:000406224900002
J	Spiegel, H; Boes, A; Fendel, R; Reimann, A; Schillberg, S; Fischer, R				Spiegel, Holger; Boes, Alexander; Fendel, Rolf; Reimann, Andreas; Schillberg, Stefan; Fischer, Rainer			Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candiate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRpm2 Does Not Improve the In Vitro Efficacy	FRONTIERS IN IMMUNOLOGY			English	Article						agroinfiltration; growth inhibition assay; plant molecular farming; Plasmodium falciparum; strain-transcending immune responses; surface plasmon resonance spectroscopy; calibration-free concentration analysis	MONOCLONAL-ANTIBODIES; AMA1-RON2 INTERACTION; ERYTHROCYTE INVASION; PFAMA1 ALLELES; AMA1; INHIBITION; RESPONSES; COCKTAIL; PHASE-1; TRIAL	The blood-stage malaria vaccine candidate Plasmodium falciparum apical membrane antigen 1 (PfAMA1) can induce strong parasite growth-inhibitory antibody responses in animals but has not achieved the anticipated efficacy in clinical trials. Possible explanations in humans are the insufficient potency of the elicited antibody responses, as well as the high degree of sequence polymorphisms found in the field. Several strategies have been developed to improve the cross-strain coverage of PfAMA1-based vaccines, whereas innovative concepts to increase the potency of PfAMA1-specific IgG responses have received little attention even though this may be an essential requirement for protective efficacy. A previous study has demonstrated that immunization with a complex of PyAMA1 and PyRON2, a ligand with an essential functional role in erythrocyte invasion, leads to protection from lethal Plasmodium yoelli challenge in an animal model and suggested to extend this strategy toward improved strain coverage by using multiple PfAMA1 alleles in combination with PfRon2L. As an alternative approach along this line, we decided to use PfRon2L in combination with three PfAMA1 diversity covering variants (DiCo) to investigate the potential of this complex to induce more potent parasite growth inhibitory immune response in combination with better cross-strain-specific efficacy. Within the limits of the study design, the ability of the PfAMA1 DiCo-Mix to induce cross-strain-specific antibodies was not affected in all immunization groups, but the DiCo-PfRon2L complexes did not improve the potency of PfAMA1-specific IgG responses.	[Spiegel, Holger; Boes, Alexander; Fendel, Rolf; Reimann, Andreas; Schillberg, Stefan; Fischer, Rainer] IME, Fraunhofer Inst Mol Biol & Appl Ecol, Aachen, Germany; [Schillberg, Stefan] Justus Liebig Univ Giessen, Inst Phytopathol & Appl Zool, Giessen, Germany; [Fischer, Rainer] Rhein Westfal TH Aachen, Inst Mol Biotechnol, Aachen, Germany; [Fischer, Rainer] IBRI, Indianapolis, IN USA	Fraunhofer Gesellschaft; Justus Liebig University Giessen; RWTH Aachen University	Spiegel, H (corresponding author), IME, Fraunhofer Inst Mol Biol & Appl Ecol, Aachen, Germany.	holger.spiegel@ime.fraunhofer.de	Schillberg, Stefan/K-4211-2019; Fendel, Rolf/K-3985-2013	Fendel, Rolf/0000-0003-4716-0311; Boes, Alexander/0000-0001-7722-692X	"Fraunhofer-Zukunftsstiftung"	"Fraunhofer-Zukunftsstiftung"	We thank Dr. Richard M. Twyman for manuscript editing. We are grateful for the BG98 standard, which was kindly provided by BPRC (Rijswijk, the Netherlands). Plasmodium falciparum 3D7A, MRA-151, deposited by D. Walliker; Plasmodium falciparum HB3, MRA-155, deposited by T. E. Wellems; and Plas-modium falciparum FCR-3/Gambia Subline F-86, MRA-731, deposited by W. Trager, were obtained through the MR4 as part of the BEI Resources Repository, NIAID, NIH. We also would like to thank Anh-Tuan Pham for technical help performing the culture of Plasmodium falciparum parasites and the growth inhibitions assays. This work was supported by the "Fraunhofer-Zukunftsstiftung."	Anders RF, 1998, VACCINE, V16, P240, DOI 10.1016/S0264-410X(97)88331-4; Bai T, 2005, P NATL ACAD SCI USA, V102, P12736, DOI 10.1073/pnas.0501808102; Barry AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00359; Biswas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020977; Boes A, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1328-0; Boes A, 2016, METHODS MOL BIOL, V1404, P597, DOI 10.1007/978-1-4939-3389-1_39; Boes A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131456; Boes A, 2015, PLANT BIOTECHNOL J, V13, P222, DOI 10.1111/pbi.12255; Coley AM, 2006, INFECT IMMUN, V74, P2628, DOI 10.1128/IAI.74.5.2628-2636.2006; Coley AM, 2001, PROTEIN ENG, V14, P691, DOI 10.1093/protein/14.9.691; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; Dicko A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001563; Dutta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003840; Ellis RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046094; Faber BW, 2013, INFECT IMMUN, V81, P1479, DOI 10.1128/IAI.01267-12; Harris KS, 2014, INFECT IMMUN, V82, P4707, DOI 10.1128/IAI.02061-14; Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x; Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Kusi KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015391; Kusi KA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-40; Kusi KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008110; Lamarque M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001276; Lim SS, 2014, BIOCHEMISTRY-US, V53, P7310, DOI 10.1021/bi5012089; Maskus DJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep39462; Maskus DJ, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0797-x; Miura K, 2013, INFECT IMMUN, V81, P1491, DOI 10.1128/IAI.01414-12; Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000; Osier FHA, 2010, INFECT IMMUN, V78, P4625, DOI 10.1128/IAI.00576-10; Ouattara A, 2015, VACCINE, V33, P7506, DOI 10.1016/j.vaccine.2015.09.110; Ouattara A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-175; Payne RO, 2016, J INFECT DIS, V213, P1743, DOI 10.1093/infdis/jiw039; Pierce MA, 2010, VACCINE, V28, P2236, DOI 10.1016/j.vaccine.2009.12.049; Pihan E, 2015, J COMPUT AID MOL DES, V29, P525, DOI 10.1007/s10822-015-9842-7; Pol E, 2007, J MOL RECOGNIT, V20, P22, DOI 10.1002/jmr.804; Polley SD, 2003, GENETICS, V165, P555; Polley SD, 2001, GENETICS, V158, P1505; Remarque EJ, 2008, INFECT IMMUN, V76, P2660, DOI 10.1128/IAI.00170-08; Remarque EJ, 2008, TRENDS PARASITOL, V24, P74, DOI 10.1016/j.pt.2007.12.002; Remarque EJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038898; Sedegah M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106241; Spiegel H, 2015, BIOTECHNOL J, V10, P1651, DOI 10.1002/biot.201500055; Srinivasan P, 2014, P NATL ACAD SCI USA, V111, P10311, DOI 10.1073/pnas.1409928111; Srinivasan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3261; Srinivasan P, 2011, P NATL ACAD SCI USA, V108, P13275, DOI 10.1073/pnas.1110303108; Thera MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001465; Vulliez-Le Normand B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123567; Vulliez-Le Normand B, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002755; Wang GQ, 2016, J MOL BIOL, V428, P3986, DOI 10.1016/j.jmb.2016.07.001; Wang Guiyang, 2014, Oxid Med Cell Longev, V2014, P273692, DOI 10.1155/2014/273692; WHO, 2016, WORLD MAL REP 2016	52	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 27	2017	8								743	10.3389/fimmu.2017.00743	http://dx.doi.org/10.3389/fimmu.2017.00743			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EY6CQ	28702028	Green Published, gold			2022-12-18	WOS:000404070500001
J	Uri, A; Werner, S; Luhder, F; Hunig, T; Kerkau, T; Beyersdorf, N				Uri, Anna; Werner, Sandra; Luehder, Fred; Huenig, Thomas; Kerkau, Thomas; Beyersdorf, Niklas			Protection of Mice from Acute Graft-versus-Host Disease Requires CD28 Co-stimulation on Donor CD4(+) Foxp3(+) Regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						acute graft-versus-host disease; CD28; co-stimulation; regulatory T cells; inducible deletion	NEGATIVE SELECTION; CUTTING EDGE; COSTIMULATION; DIFFERENTIATION; HOMEOSTASIS; ACTIVATION; TOLERANCE; PROLIFERATION; THYMOCYTES; EXPRESSION	Acute graft-versus-host disease (aGvHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell plus T cell transplantation (allo-HSCT). In this study, we investigated the requirement for CD28 co-stimulation of donor CD4(+) conventional (CD4(+)CD25-Foxp3(-), Tconv) and regulatory (CD4(+)CD25(+)Foxp3(+), Treg) T cells in aGvHD using tamoxifen-inducible CD28 knockout (iCD28KO) or wild-type (wt) littermates as donors of CD4(+) Tconv and Treg. In the highly inflammatory C57BL/6 into BALB/c allo-HSCT transplantation model, CD28 depletion on donor CD4(+) Tconv reduced clinical signs of aGvHD, but did not significantly prolong survival of the recipient mice. Selective depletion of CD28 on donor Treg did not abrogate protection of recipient mice from aGvHD until about day 20 after allo-HSCT. Later, however, the pool of CD28-depleted Treg drastically declined as compared to wt Treg. Consequently, only wt, but not CD28-deficient, Treg were able to continuously suppress aGvHD and induce long-term survival of the recipient mice. To our knowledge, this is the first study that specifically evaluates the impact of CD28 expression on donor Treg in aGvHD. Moreover, the delayed kinetics of aGvHD lethality after transplantation of iCD28KO Treg provides a novel animal model for similar disease courses found in patients after allo-HSCT.	[Uri, Anna; Werner, Sandra; Huenig, Thomas; Kerkau, Thomas; Beyersdorf, Niklas] Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany; [Luehder, Fred] Univ Med Ctr Gottingen, Inst Multiple Sclerosis Res & Neuroimmunol, Gottingen, Germany	University of Wurzburg; University of Gottingen	Kerkau, T; Beyersdorf, N (corresponding author), Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany.	kerkau@mail.uni-wuerzburg.de; niklas.beyersdorf@vim.uni-wuerzburg.de	Beyersdorf, Niklas/S-3845-2016; Kerkau, Thomas/ABE-8007-2020	Beyersdorf, Niklas/0000-0002-9236-5415; 	Jose Carreras Leukamie-Stiftung [R 13/25]; German Research Foundation (DFG); University of Wuerzburg	Jose Carreras Leukamie-Stiftung; German Research Foundation (DFG)(German Research Foundation (DFG)); University of Wuerzburg	This work was supported by a grant from the Jose Carreras Leukamie-Stiftung (R 13/25). The publication of this study was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.	Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390; Beyersdorf N, 2008, BLOOD, V112, P4328, DOI 10.1182/blood-2008-03-146662; Beyersdorf N, 2015, EUR J IMMUNOL, V45, P1997, DOI 10.1002/eji.201445317; Beyersdorf N, 2009, BLOOD, V114, P4575, DOI 10.1182/blood-2009-04-218248; Blazar BR, 1999, J IMMUNOL, V162, P6368; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; Briones Javier, 2011, Bone Marrow Res, V2011, P976793, DOI 10.1155/2011/976793; Chen X, 2007, BLOOD, V110, P3804, DOI 10.1182/blood-2007-05-091074; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Cooke KR, 1998, J CLIN INVEST, V102, P1882, DOI 10.1172/JCI4285; Drobyski WR, 1998, J IMMUNOL, V161, P2610; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Edinger M, 2011, CURR OPIN IMMUNOL, V23, P679, DOI 10.1016/j.coi.2011.06.006; Esensten JH, 2016, IMMUNITY, V44, P973, DOI 10.1016/j.immuni.2016.04.020; Ewing P, 2007, EXP HEMATOL, V35, P155, DOI 10.1016/j.exphem.2006.09.012; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Franckaert D, 2015, IMMUNOL CELL BIOL, V93, P417, DOI 10.1038/icb.2014.108; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Gogishvili T, 2013, EUR J IMMUNOL, V43, P188, DOI 10.1002/eji.201242824; Gogishvili T, 2012, J ALLERGY CLIN IMMUN, V130, P1394, DOI 10.1016/j.jaci.2012.08.049; Guo F, 2008, J IMMUNOL, V181, P2285, DOI 10.4049/jimmunol.181.4.2285; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Holtan SG, 2016, BLOOD, V128, P2350, DOI 10.1182/blood-2015-09-669846; Kerstan A, 2004, J IMMUNOL, V172, P1341, DOI 10.4049/jimmunol.172.3.1341; Kishimoto H, 1999, J EXP MED, V190, P65, DOI 10.1084/jem.190.1.65; Kitazawa Y, 2009, CELL TRANSPLANT, V18, P627, DOI 10.1177/096368970901805-619; Levine JE, 2011, INT J HEMATOL, V93, P571, DOI 10.1007/s12185-011-0803-1; Li N, 2010, CELL MOL IMMUNOL, V7, P133, DOI 10.1038/cmi.2009.120; Liu ZJ, 2001, J IMMUNOL, V167, P1830, DOI 10.4049/jimmunol.167.3.1830; Maekawa Y, 2015, NAT MED, V21, P55, DOI 10.1038/nm.3758; Magenau JM, 2010, BIOL BLOOD MARROW TR, V16, P907, DOI 10.1016/j.bbmt.2010.02.026; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9; Nguyen VH, 2007, BLOOD, V109, P2649, DOI 10.1182/blood-2006-08-044529; Paterson AM, 2015, J EXP MED, V212, P1603, DOI 10.1084/jem.20141030; Poirier N, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000116; Punt JA, 1997, J EXP MED, V186, P1911, DOI 10.1084/jem.186.11.1911; Reddy P, 2003, HEMATOL ONCOL, V21, P149, DOI 10.1002/hon.716; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sellami MH, 2011, HUM IMMUNOL, V72, P139, DOI 10.1016/j.humimm.2010.11.008; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; Speiser DE, 1997, TRANSPLANTATION, V63, P1042, DOI 10.1097/00007890-199704150-00028; Sun T, 2008, CANCER RES, V68, P7025, DOI 10.1158/0008-5472.CAN-08-0806; Tai XG, 2005, NAT IMMUNOL, V6, P152, DOI 10.1038/ni1160; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Trenado A, 2003, J CLIN INVEST, V112, P1688, DOI 10.1172/JCI17702; Vacchio MS, 2005, EUR J IMMUNOL, V35, P418, DOI 10.1002/eji.200424918; Vogtenhuber C, 2010, BLOOD, V116, P466, DOI 10.1182/blood-2009-11-252825; Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108; Wang B, 2000, J IMMUNOL, V164, P1216, DOI 10.4049/jimmunol.164.3.1216; Watkins B, 2014, BLOOD, V124, P2425; Weijtens M, 2002, HUM GENE THER, V13, P187, DOI 10.1089/10430340252769725; Yu XZ, 2004, J CLIN INVEST, V113, P1624, DOI 10.1172/JCI200420940; Yu XZ, 1998, BLOOD, V92, P2963, DOI 10.1182/blood.V92.8.2963.420k13_2963_2970; Zhang R, 2015, J IMMUNOL, V195, P4154, DOI 10.4049/jimmunol.1500945; Zhang R, 2013, J CLIN INVEST, V123, P580, DOI 10.1172/JCI65013; Zhao J, 2010, CLIN EXP IMMUNOL, V160, P479, DOI 10.1111/j.1365-2249.2010.04089.x	60	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2017	8								721	10.3389/fimmu.2017.00721	http://dx.doi.org/10.3389/fimmu.2017.00721			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EY4LL	28690612	Green Published, gold			2022-12-18	WOS:000403949400002
J	Jumat, NR; Chong, MY; Seman, Z; Jamaluddin, R; Wong, NK; Abdullah, M				Jumat, Nur Ramziahrazanah; Chong, Mun Yee; Seman, Zainina; Jamaluddin, Rosita; Wong, Nyet Kui; Abdullah, Maha			Sexual Dimorphic Responses in Lymphocytes of Healthy Individuals after Carica papaya Consumption	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer cells; T cells; CD25; CD69; CD107a; sex hormones; Carica papaya	REGULATORY T-CELLS; HORMONE REPLACEMENT THERAPY; IMMUNE-RESPONSES; DENDRITIC CELL; SUBSET; EXPRESSION; CD69; MODULATION; ACTIVATION; DYNAMICS	Sexual dimorphism in immune response is widely recognized, but few human studies have observed this distinction. Food with endo-immunomodulatory potential may reveal novel sex-biased in vivo interactions. Immunomodulatory effects of Carica papaya were compared between healthy male and female individuals. Volunteers were given fixed meals supplemented with papaya for 2 days. Changes in blood immune profiles and hormone levels were determined. In females, total natural killer (NK) cell percentages decreased (12.7 +/- 4.4 vs 14.6 +/- 5.8%, p = 0.018, n = 18) while B cells increased (15.2 +/- 5.5 vs 14.5 +/- 5.0, p = 0.037, n = 18) after papaya consumption. Increased 17A-estradiol (511.1 +/- 579.7 vs 282.7 +/- 165.0 pmol/l, p = 0.036, n = 9) observed in females may be crucial to this change. Differentiation markers (CD45RA, CD69, CD25) analyzed on lymphocytes showed nave (CD45RA(+)) non-CD4(+) lymphocytes were reduced in females (40.7 +/- 8.1 vs 46.8 +/- 5.4%, p = 0.012, n = 8) but not males. A general suppressive effect of papaya on CD69(+) cells, and higher percentage of CD69(+) populations in females and non-CD4 lymphocytes, may be relevant. CD107a(+) NK cells were significantly increased in males (16.8 +/- 7.0 vs 14.7 +/- 4.8, p = 0.038, n = 9) but not females. Effect in females may be disrupted by the action of progesterone, which was significantly correlated with this population (R = 0.771, p = 0.025, n = 8) after papaya consumption. In males, total T helper cells were increased (33.4 +/- 6.4 vs 32.4 +/- 6.1%, p = 0.040, n = 15). Strong significant negative correlation between testosterone and CD25(+) CD4(+) lymphocytes, may play a role in the lower total CD4(+) T cells reported in males. Thus, dissimilar immune profiles were elicited in the sexes after papaya consumption and may have sex hormone influence.	[Jumat, Nur Ramziahrazanah; Chong, Mun Yee; Abdullah, Maha] Univ Putra Malaysia, Dept Pathol, Immunol Unit, Serdang, Malaysia; [Seman, Zainina] Univ Putra Malaysia, Dept Pathol, Hematol Unit, Serdang, Malaysia; [Jamaluddin, Rosita] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Dietet & Nutr, Serdang, Malaysia; [Wong, Nyet Kui] Univ Malaysia Sabah, Fac Sci & Nat Resources, Biotechnol Program, Kota Kinabalu, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Kebangsaan Malaysia; Universiti Malaysia Sabah	Abdullah, M (corresponding author), Univ Putra Malaysia, Dept Pathol, Immunol Unit, Serdang, Malaysia.	maha@upm.edu.my		JUMAT, NUR RAMZIAHRAZANAH/0000-0003-3758-5017	Universiti Putra Malaysia Research Grant [04-01-11-1333RU]	Universiti Putra Malaysia Research Grant	This work was supported by a Universiti Putra Malaysia Research Grant (Project No: 04-01-11-1333RU).	Abdullah M, 2012, CELL IMMUNOL, V272, P214, DOI 10.1016/j.cellimm.2011.10.009; Abdullah M, 2011, MOL NUTR FOOD RES, V55, P803, DOI 10.1002/mnfr.201100087; Allegra M, 2007, P PHYSL SOC; Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brenchley JM, 2002, CLIN EXP IMMUNOL, V130, P431, DOI 10.1046/j.1365-2249.2002.02015.x; Cortes JR, 2014, J AUTOIMMUN, V55, P51, DOI 10.1016/j.jaut.2014.05.007; Craston R, 1997, J IMMUNOL METHODS, V209, P37, DOI 10.1016/S0022-1759(97)00143-9; del Corno M, 2016, CRIT REV FOOD SCI, V56, P737, DOI 10.1080/10408398.2012.713046; Deng YY, 2014, MOLECULES, V19, P13432, DOI 10.3390/molecules190913432; Fischer J, 2015, INFECTION, V43, P399, DOI 10.1007/s15010-015-0791-9; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Flanagan KL, 2014, T ROY SOC TROP MED H, V108, P385, DOI 10.1093/trstmh/tru079; Gabory A, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-5; Garenne M, 2015, J INFECT DIS, V211, P331, DOI 10.1093/infdis/jiu448; Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326; Giltay EJ, 2000, J CLIN ENDOCR METAB, V85, P1648, DOI 10.1210/jc.85.4.1648; Ginwala R, 2016, J NEUROIMMUNE PHARM, V11, P36, DOI 10.1007/s11481-015-9617-x; Grigorova IL, 2010, P NATL ACAD SCI USA, V107, P20447, DOI 10.1073/pnas.1009968107; Guo W, 2012, AM J REPROD IMMUNOL, V67, P463, DOI 10.1111/j.1600-0897.2012.01114.x; Gutsol AA, 2014, CELL TISS BIOL, V8, P473, DOI [10.1134/S1990519X14060030, DOI 10.1134/S1990519X14060030]; Han YM, 2009, J IMMUNOL, V182, P111, DOI 10.4049/jimmunol.182.1.111; Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409; Hooper L, 2009, HUM REPROD UPDATE, V15, P423, DOI 10.1093/humupd/dmp010; Ikram EHK, 2015, J FOOD COMPOS ANAL, V41, P201, DOI 10.1016/j.jfca.2015.02.010; JOHANNISSON A, 1995, CYTOMETRY, V19, P343, DOI 10.1002/cyto.990190409; Kamada M, 2000, J ENDOCRINOL INVEST, V23, P376, DOI 10.1007/BF03343741; Kapoor R, 2015, NUTR CANCER, V67, P1113, DOI 10.1080/01635581.2015.1073756; KIESS W, 1991, ACTA ENDOCRINOL-COP, V124, P399, DOI 10.1530/acta.0.1240399; Kissick HT, 2014, P NATL ACAD SCI USA, V111, P9887, DOI 10.1073/pnas.1402468111; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Li SS, 2014, CELL MOL IMMUNOL, V11, P326, DOI 10.1038/cmi.2014.25; Mahattanatawee K, 2006, J AGR FOOD CHEM, V54, P7355, DOI 10.1021/jf060566s; Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006; Marzio R, 1999, IMMUNOPHARM IMMUNOT, V21, P565, DOI 10.3109/08923979909007126; McCombe PA, 2009, CURR MOL MED, V9, P1058, DOI 10.2174/156652409789839116; McMurray RW, 2001, PATHOBIOLOGY, V69, P44, DOI 10.1159/000048757; Miean KH, 2001, J AGR FOOD CHEM, V49, P3106, DOI 10.1021/jf000892m; Miller VM, 2012, LANCET, V379, P873, DOI 10.1016/S0140-6736(12)60200-1; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Monforte MT, 2014, J MED FOOD, V17, P455, DOI 10.1089/jmf.2012.0262; Nakayama T, 2002, J IMMUNOL, V168, P87, DOI 10.4049/jimmunol.168.1.87; Niu XL, 2015, EUR J PHARMACOL, V750, P8, DOI 10.1016/j.ejphar.2015.01.017; Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022; Page ST, 2006, AM J PHYSIOL-ENDOC M, V290, pE856, DOI 10.1152/ajpendo.00484.2005; Pekalski ML, 2013, J IMMUNOL, V190, P2554, DOI 10.4049/jimmunol.1202914; Percival SS, 2009, J NUTR, V139, p1801S, DOI 10.3945/jn.109.108324; Porter VR, 2001, EXP GERONTOL, V36, P311, DOI 10.1016/S0531-5565(00)00195-9; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Schliep KC, 2013, AM J CLIN NUTR, V97, P621, DOI 10.3945/ajcn.111.024752; Schoenberger SP, 2012, P NATL ACAD SCI USA, V109, P8358, DOI 10.1073/pnas.1204616109; Sprent J, 2001, IMMUNOL CELL BIOL, V79, P199, DOI 10.1046/j.1440-1711.2001.00999.x; Triplett TA, 2012, EUR J IMMUNOL, V42, P1893, DOI 10.1002/eji.201242444; Walecki M, 2015, MOL BIOL CELL, V26, P2845, DOI 10.1091/mbc.E14-08-1323; Zhang W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130926	56	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2017	8								680	10.3389/fimmu.2017.00680	http://dx.doi.org/10.3389/fimmu.2017.00680			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EX0LP	28649252	Green Published, gold			2022-12-18	WOS:000402912500001
J	Garcia, V; Feldman, MW				Garcia, Victor; Feldman, Marcus W.			Within-Epitope Interactions Can Bias CTL Escape Estimation in Early HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						cytotoxic T lymphocytes (CTL); human immunodeficiency virus (HIV); escape; genetic interference; population genetics	IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ESCAPE; IN-VIVO; BENEFICIAL MUTATIONS; REVERSE-TRANSCRIPTASE; ASEXUAL POPULATIONS; GENERATION TIME; ADAPTATION; EVOLUTION; DYNAMICS	As human immunodeficiency virus (HIV) begins to replicate within hosts, immune responses are elicited against it. Escape mutations in viral epitopes immunogenic peptide parts presented on the surface of infected cells allow HIV to partially evade these responses, and thus rapidly go to fixation. The faster they go to fixation, i.e., the higher their escape rate, the larger the selective pressure exerted by the immune system is assumed to be. This relation underpins the rationale for using escapes to assess the strength of immune responses. However, escape rate estimates are often obtained by employing an aggregation procedure, where several mutations that affect the same epitope are aggregated into a single, composite epitope mutation. The aggregation procedure thus rests upon the assumption that all within-epitope mutations have indistinguishable effects on immune recognition. In this study, we investigate how violation of this assumption affects escape rate estimates. To this end, we extend a previously developed simulation model of HIV that accounts for mutation, selection, and recombination to include different distributions of fitness effects (DFEs) and inter mutational genomic distances. We use this discrete time Wright Fisher based model to simulate early within-host evolution of HIV for DFEs and apply standard estimation methods to infer the escape rates. We then compare true with estimated escape rate values. We also compare escape rate values obtained by applying the aggregation procedure with values estimated without use of that procedure. We find that across the DFEs analyzed, the aggregation procedure alters the detectability of escape mutations: large-effect mutations are overrepresented while small-effect mutations are concealed. The effect of the aggregation procedure is similar to extracting the largest-effect mutation appearing within an epitope. Furthermore, the more pronounced the over-exponential decay of the DFEs, the more severely true escape rates are underestimated. We conclude that the aggregation procedure has two main consequences. On the one hand, it leads to a misrepresentation of the DFE of fixed mutations. On the other hand, it conceals within-epitope interactions that may generate irregularities in mutation frequency trajectories that are thus left unexplained.	[Garcia, Victor; Feldman, Marcus W.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA	Stanford University	Garcia, V (corresponding author), Stanford Univ, Dept Biol, Stanford, CA 94305 USA.	victor.garcia_palencia@alumni.ethz.ch			Swiss National Science Foundation [P2EZP3_162257]; Stanford Center for Computational, Evolutionary and Human Genomics; Morrison Institute for Population and Resource Studies	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Stanford Center for Computational, Evolutionary and Human Genomics; Morrison Institute for Population and Resource Studies	VG gratefully acknowledges funding by the Swiss National Science Foundation (grant number P2EZP3_162257). MF was supported in part by The Stanford Center for Computational, Evolutionary and Human Genomics and by the Morrison Institute for Population and Resource Studies.	Althaus CL, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000103; Asquith B, 2006, PLOS BIOL, V4, P583, DOI 10.1371/journal.pbio.0040090; Batorsky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003878; Bimber BN, 2009, J VIROL, V83, P8247, DOI 10.1128/JVI.00897-09; Boutwell CL, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-S3-P399; Boutwell CL, 2010, J INFECT DIS, V202, pS309, DOI 10.1086/655653; Cale EM, 2011, J VIROL, V85, P3746, DOI 10.1128/JVI.02420-10; da Silva J, 2012, GENETICS, V190, P1087, DOI 10.1534/genetics.111.136366; Desai MM, 2007, GENETICS, V176, P1759, DOI 10.1534/genetics.106.067678; du Plessis L, 2016, MOL BIOL EVOL, V33, P2454, DOI 10.1093/molbev/msw097; Elemans M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003534; Fernandez CS, 2005, J VIROL, V79, P5721, DOI 10.1128/JVI.79.9.5721-5731.2005; Fischer W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012303; Fogle CA, 2008, GENETICS, V180, P2163, DOI 10.1534/genetics.108.090019; Ganusov VV, 2006, PLOS COMPUT BIOL, V2, P182, DOI 10.1371/journal.pcbi.0020024; Ganusov VV, 2013, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2013/01/P01010; Ganusov VV, 2011, J VIROL, V85, P10518, DOI 10.1128/JVI.00655-11; Garcia V, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004721; Garcia V, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00661; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Good BH, 2012, P NATL ACAD SCI USA, V109, P4950, DOI 10.1073/pnas.1119910109; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529; Hinkley T, 2011, NAT GENET, V43, P487, DOI 10.1038/ng.795; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084/jem.20040511; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Kessinger TA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00252; Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038; Leviyang S, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004492; Leviyang S, 2013, GENETICS, V194, P737, DOI 10.1534/genetics.113.150862; Liu MKP, 2013, J CLIN INVEST, V123, P380, DOI 10.1172/JCI65330; Liu Y, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015639, 10.1371/journal.pone.0022241]; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Markowitz M, 2003, J VIROL, V77, P5037, DOI 10.1128/JVI.77.8.5037-5038.2003; McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674; Mostowy R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016052; Murray JM, 2011, J VIROL, V85, P10798, DOI 10.1128/JVI.05095-11; Neher RA, 2013, ANNU REV ECOL EVOL S, V44, P195, DOI 10.1146/annurev-ecolsys-110512-135920; Neher RA, 2011, REV MOD PHYS, V83, DOI 10.1103/RevModPhys.83.1283; Neher RA, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000660; O'Connor SL, 2012, J VIROL, V86, P605, DOI 10.1128/JVI.05511-11; Orr HA, 2003, GENETICS, V163, P1519; Pandit A, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-56; Perelson AS, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-96; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; R Development Core Team, 2012, R LANG ENV STAT COMP; Ribeiro RM, 2010, J VIROL, V84, P6096, DOI 10.1128/JVI.00127-10; Roberts HE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004914; Rodrigo AG, 1999, P NATL ACAD SCI USA, V96, P2187, DOI 10.1073/pnas.96.5.2187; Rouzine IM, 2013, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2013/01/P01009; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Schiffels S, 2011, GENETICS, V189, P1361, DOI 10.1534/genetics.111.132027; Schneidewind A, 2008, J VIROL, V82, P5594, DOI 10.1128/JVI.02356-07; Turnbull EL, 2009, J IMMUNOL, V182, P7131, DOI 10.4049/jimmunol.0803658; van Deutekom HWM, 2013, J IMMUNOL, V191, P3277, DOI 10.4049/jimmunol.1300962; Zanini F, 2012, BIOINFORMATICS, V28, P3332, DOI 10.1093/bioinformatics/bts633	57	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 1	2017	8								423	10.3389/fimmu.2017.00423	http://dx.doi.org/10.3389/fimmu.2017.00423			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ET5IM	28507544	gold, Green Published			2022-12-18	WOS:000400317400001
J	Minigo, G; Flanagan, KL; Slattery, RM; Plebanski, M				Minigo, Gabriela; Flanagan, Katie L.; Slattery, Robyn M.; Plebanski, Magdalena			Vaccination with altered Peptide ligands of a Plasmodium berghei circumsporozoite Protein cD8 T-cell epitope: a Model to generate T cells resistant to immune interference by Polymorphic epitopes	FRONTIERS IN IMMUNOLOGY			English	Article						cross-reactivity; altered peptide ligand; antagonism; T cell; dendritic cell; vaccine; Plasmodium; malaria	MALARIA VACCINE; EFFICACY; ANTIGEN	Many pathogens, including the malaria parasite Plasmodium falciparum, display high levels of polymorphism within T-cell epitope regions of proteins associated with protective immunity. The T-cell epitope variants are often non-cross-reactive. Herein, we show in a murine model, which modifies a protective CD8 T-cell epitope from the circumsporozoite protein (CS) of Plasmodium berghei (SYIPSAEKI), that simultaneous or sequential co-stimulation with two of its putative similarly non-cross-reactive altered peptide ligand (APL) epitopes (SYIPSAEDI or SYIPSAEAI) has radically different effects on immunity. Hence, co-immunization or sequential stimulation in vivo of SYIPSAEKI with its APL antagonist SYIPSAEDI decreases immunity to both epitopes. By contrast, co-immunization with SYIPSAEAI has no apparent initial effect, but it renders the immune response to SYIPSAEKI resistant to being turned off by subsequent immunization with SYIPSAEDI. These results suggest a novel strategy for vaccines that target polymorphic epitopes potentially capable of mutual immune interference in the field, by initiating an immune response by co-immunization with the desired index epitope, together with a carefully selected "potentiator" APL peptide.	[Minigo, Gabriela; Flanagan, Katie L.; Plebanski, Magdalena] Monash Univ, Dept Pathol & Immunol, Vaccine & Infect Dis Lab, Melbourne, Vic, Australia; [Minigo, Gabriela] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia; [Flanagan, Katie L.] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [Slattery, Robyn M.] Monash Univ, Dept Pathol & Immunol, Diabet Lab, Melbourne, Vic, Australia	Monash University; Charles Darwin University; Menzies School of Health Research; University of Tasmania; Monash University	Plebanski, M (corresponding author), Monash Univ, Dept Pathol & Immunol, Vaccine & Infect Dis Lab, Melbourne, Vic, Australia.	magdalena.plebanski@monash.edu	Minigo, Gabriela/S-2582-2019; Plebanski, Magdalena/AAU-3144-2021	Minigo, Gabriela/0000-0001-5158-7700; , Magdalena/0000-0001-6889-3667; Flanagan, Katie/0000-0002-1575-1953	Melbourne International Research Scholarship; Melbourne International Fee Remission Scholarship	Melbourne International Research Scholarship; Melbourne International Fee Remission Scholarship	GM was supported by a Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship. MP is an NHMRC Senior Research Fellow.	BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; Candia M, 2016, INT ARCH ALLERGY IMM, V170, P211, DOI 10.1159/000448756; Flanagan KL, 2016, EXPERT REV VACCINES, V15, P389, DOI 10.1586/14760584.2016.1125785; Gascoigne NRJ, 2004, CURR OPIN IMMUNOL, V16, P114, DOI 10.1016/j.coi.2003.11.008; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Kester KE, 2014, VACCINE, V32, P6683, DOI 10.1016/j.vaccine.2014.06.033; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Krishnarjuna B, 2016, SCI REP-UK, V6, DOI 10.1038/srep20613; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Neafsey DE, 2015, NEW ENGL J MED, V373, P2025, DOI 10.1056/NEJMoa1505819; Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3; Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4345::AID-IMMU4345&gt;3.0.CO;2-P; Plebanski M, 1999, NAT MED, V5, P565, DOI 10.1038/8444; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; Unanue ER, 2011, J IMMUNOL, V186, P7, DOI 10.4049/jimmunol.1090118; Wilson KL, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00303	18	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2017	8								115	10.3389/fimmu.2017.00115	http://dx.doi.org/10.3389/fimmu.2017.00115			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EK4SA	28261200	Green Published, gold, Green Accepted			2022-12-18	WOS:000393915900001
J	Maffia, P; Doring, Y; Biessen, EAL; Mallat, Z				Maffia, Pasquale; Doering, Yvonne; Biessen, Erik A. L.; Mallat, Ziad			Commentary: Indoleamine 2,3-Dioxygenase-expressing aortic Plasmacytoid Dendritic Cells Protect against atherosclerosis by Induction of regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						atherosclerosis; plasmacytoid dendritic cells; aorta; antigen presentation; regulatory T cells; type I interferon; indoleamine 2,3-dioxygenase	DIPHTHERIA-TOXIN; EXPRESSION		[Maffia, Pasquale] Univ Glasgow, Coll Med Vet & Life Sci, Ctr Immunobiol, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Maffia, Pasquale] Univ Glasgow, Coll Med Vet & Life Sci, BHF Ctr Excellence Vasc Sci & Med, Glasgow, Lanark, Scotland; [Maffia, Pasquale] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Doering, Yvonne] Univ Munich, Inst Cardiovasc Prevent Ludwig Maximilians, Munich, Germany; [Doering, Yvonne] DZHK, German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany; [Biessen, Erik A. L.] Maastricht Univ, Med Ctr, CARIM, Dept Pathol,Expt Vasc Pathol Grp, Maastricht, Netherlands; [Biessen, Erik A. L.] RWTH Klinikum Aachen, Inst Mol Cardiovasc Res, Aachen, Germany; [Mallat, Ziad] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Cardiovasc Med, Cambridge, England; [Mallat, Ziad] Paris Cardiovasc Res Ctr, INSERM, Unit 970, Paris, France	University of Glasgow; University of Glasgow; University of Naples Federico II; University of Munich; German Centre for Cardiovascular Research; Munich Heart Alliance; Maastricht University; Maastricht University Medical Centre (MUMC); RWTH Aachen University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Maffia, P (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Ctr Immunobiol, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland.; Maffia, P (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, BHF Ctr Excellence Vasc Sci & Med, Glasgow, Lanark, Scotland.; Maffia, P (corresponding author), Univ Naples Federico II, Dept Pharm, Naples, Italy.; Mallat, Z (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Cardiovasc Med, Cambridge, England.; Mallat, Z (corresponding author), Paris Cardiovasc Res Ctr, INSERM, Unit 970, Paris, France.	pasquale.maffia@glasgow.ac.uk; zm255@medchl.cam.ac.uk	Mallat, Ziad/D-4041-2012; Döring, Yvonne/E-9414-2017; Doring, Yvonne/E-1796-2013; Döring, Yvonne/AAA-3018-2022	Mallat, Ziad/0000-0003-0443-7878; Döring, Yvonne/0000-0001-9307-3396; Biessen, Erik/0000-0002-6454-8548	British Heart Foundation [PG/12/81/29897, RE/13/5/30177]; Deutsche Forschungsgemeinschaft [SFB1054, B4]; British Heart Foundation [RG/15/11/31593] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); British Heart Foundation(British Heart Foundation)	Our work was supported by the British Heart Foundation grants PG/12/81/29897 and RE/13/5/30177 and the Deutsche Forschungsgemeinschaft (SFB1054, B4).	Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762; Clement M, 2015, J AUTOIMMUN, V63, P59, DOI 10.1016/j.jaut.2015.07.001; Daissormont ITMN, 2011, CIRC RES, V109, P1387, DOI 10.1161/CIRCRESAHA.111.256529; Davison LM, 2015, ARTHRITIS RHEUMATOL, V67, P1012, DOI 10.1002/art.38989; Doring Y, 2012, CIRCULATION, V125, P1673, DOI 10.1161/CIRCULATIONAHA.111.046755; Grassia G, 2013, PHARMACOL THERAPEUT, V137, P172, DOI 10.1016/j.pharmthera.2012.10.001; Horste GMZ, 2010, J IMMUNOL METHODS, V354, P80, DOI 10.1016/j.jim.2010.01.012; Hu DS, 2015, IMMUNITY, V42, P1100, DOI 10.1016/j.immuni.2015.05.015; Klingenberg R, 2013, J CLIN INVEST, V123, P1323, DOI 10.1172/JCI63891; Kretzschmar D, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/450957; MacRitchie N, 2012, ARTERIOSCL THROM VAS, V32, P2569, DOI 10.1161/ATVBAHA.112.251314; Mandl M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134176; Rai V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154802; Sage AP, 2014, CIRCULATION, V130, P1363, DOI 10.1161/CIRCULATIONAHA.114.011090; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Tittel AP, 2012, NAT METHODS, V9, P385, DOI [10.1038/NMETH.1905, 10.1038/nmeth.1905]; Wu PP, 2008, CLIN IMMUNOL, V129, P40, DOI 10.1016/j.clim.2008.06.004; You HN, 2013, AM J PHYSIOL-RENAL, V305, pF1719, DOI 10.1152/ajprenal.00141.2013; Yun TJ, 2016, CELL METAB, V24, P886, DOI 10.1016/j.cmet.2016.11.008; Yun TJ, 2016, CELL METAB, V23, P852, DOI 10.1016/j.cmet.2016.04.010	21	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 13	2017	8								140	10.3389/fimmu.2017.00140	http://dx.doi.org/10.3389/fimmu.2017.00140			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EK3LQ	28243244	Green Published, gold			2022-12-18	WOS:000393828300002
J	Calderwood, SK; Murshid, A; Borges, TJ				Calderwood, Stuart K.; Murshid, Ayesha; Borges, Thiago J.			Editorial: HSPs-Ambiguous Mediators of Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						heat shock protein; immunity; vaccine; mycobacterial Hsp65; transplant; arthritis	HEAT-SHOCK PROTEINS; RESPONSES; CHAPERONE		[Calderwood, Stuart K.; Murshid, Ayesha; Borges, Thiago J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Borges, Thiago J.] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Porto Alegre, RS, Brazil	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pontificia Universidade Catolica Do Rio Grande Do Sul	Calderwood, SK (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.	scalderw@bidmc.harvard.edu	Borges, Thiago/Q-3711-2019	Borges, Thiago/0000-0002-6554-0169				Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Ellis RJ, 2007, ADV EXP MED BIOL, V594, P1; Gong JL, 2010, J IMMUNOL, V184, P488, DOI 10.4049/jimmunol.0902255; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Srivastava PK, 2000, DRUG NEWS PERSPECT, V13, P517, DOI 10.1358/dnp.2000.13.9.858479; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Van Eden W, 2007, ANN NY ACAD SCI, V1113, P217, DOI 10.1196/annals.1391.020; Wang XY, 2003, INT J CANCER, V105, P226, DOI 10.1002/ijc.11058	8	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 26	2016	7								639	10.3389/fimmu.2016.00639	http://dx.doi.org/10.3389/fimmu.2016.00639			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EF6YM	28082978	gold, Green Published			2022-12-18	WOS:000390477200001
J	Pandiyan, P; Lavelle, EC				Pandiyan, Pushpa; Lavelle, Ed C.			Editorial: Immune Cells in the Mucosa	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mucosal immunity; infection; HIV; periodontitis; IBD			[Pandiyan, Pushpa] Case Western Reserve Univ, Sch Dent Med, Dept Biol Sci, Cleveland, OH 44106 USA; [Lavelle, Ed C.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Adjuvant Res Grp, Dublin, Ireland	Case Western Reserve University; Trinity College Dublin	Pandiyan, P (corresponding author), Case Western Reserve Univ, Sch Dent Med, Dept Biol Sci, Cleveland, OH 44106 USA.	pxp226@case.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK097948] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK097948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 26	2016	7								657	10.3389/fimmu.2016.00657	http://dx.doi.org/10.3389/fimmu.2016.00657			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EF6YZ	28082991	Green Published, gold			2022-12-18	WOS:000390478600001
J	Schmitt, MER; Sitte, S; Voehringer, D				Schmitt, Michaels E. R.; Sitte, Selina; Voehringer, David			CD4 T Helper Cells Instruct Lymphopenia-Induced Memory-Like CD8 T Cells for Control of Acute LCMV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						lymphopenia; memory-like T cells; lymphocytic choriomeningitis virus; PD-1; KLRG1	CHRONIC VIRAL-INFECTION; HOMEOSTATIC PROLIFERATION; VIRUS-INFECTIONS; MICE LACKING; DIVERSITY; RESPONSES; EXPANSION; NAIVE; PD-1; REPERTOIRE	Lymphopenic conditions lead to expansion of memory-like T cells (T-ML), which develop from naive T cells by spontaneous proliferation. T-ML cells are often increased in the elderly population, AIDS patients, and patients recovering from radio- or chemotherapy. At present, it is unclear whether T-ML cells can efficiently respond to foreign antigen and participate in antiviral immunity. To address this question, we analyzed the immune response during acute low-dose infection with lymphocytic choriomeningitis virus-WE in T cell lymphopenic CD4Cre/R-diphtheria toxin alpha (DTA) mice in which most peripheral T cells show a T-ML phenotype. On day 8 after infection, the total number of effector T cells and polyfunctional IFN-gamma and TNF-alpha producing CD8 T cells were three- to fivefold reduced in CD4Cre/R-DTA mice as compared to controls. Viral clearance and the humoral immune response were severely impaired in CD4Cre/R-DTA mice although CTLs efficiently killed transferred target cells in vivo. Transfer of naive CD4 T cells but not anti-PD-L1 blockade restored the expansion of antigen-specific polyfunctional CD8 T cells and resulted in lower viral titers. This finding indicates that under lymphopenic conditions endogenous CD4 T-ML cell lack the capacity to promote expansion of CTLs. However, CD8 T-ML cells retain sufficient functional plasticity to participate in antiviral immunity in the presence of appropriate help by fully functional CD4 T cells. This capacity might be exploited to develop treatments for improvement of CD8 T cell functions under various clinical settings of lymphopenia.	[Schmitt, Michaels E. R.; Sitte, Selina; Voehringer, David] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Infect Biol, Erlangen, Germany	University of Erlangen Nuremberg	Voehringer, D (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Infect Biol, Erlangen, Germany.	david.voehringer@uk-erlangen.de	Voehringer, David/K-2776-2019		Deutsche Forschungsgemeinschaft grant [SFB643_B15]	Deutsche Forschungsgemeinschaft grant(German Research Foundation (DFG))	This work was funded in part by the Deutsche Forschungsgemeinschaft grant SFB643_B15 to DV.	Bachmann MF, 2004, EUR J IMMUNOL, V34, P317, DOI 10.1002/eji.200324717; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; CALLAHAN JE, 1993, J IMMUNOL, V151, P6657; Cheung KP, 2009, J IMMUNOL, V183, P3364, DOI 10.4049/jimmunol.0900641; Ciurea A, 2001, IMMUNOGENETICS, V53, P185, DOI 10.1007/s002510100314; Do JS, 2009, P NATL ACAD SCI USA, V106, P20394, DOI 10.1073/pnas.0909954106; Dudani R, 2008, J IMMUNOL, V181, P1700, DOI 10.4049/jimmunol.181.3.1700; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Goldrath AW, 2004, P NATL ACAD SCI USA, V101, P16885, DOI 10.1073/pnas.0407417101; Goronzy JJ, 2005, CURR OPIN IMMUNOL, V17, P468, DOI 10.1016/j.coi.2005.07.020; Guy B, 2010, J COMP PATHOL, V141, pS133, DOI [10.1016/j.jepa.2009.09.009, 10.1016/j.jcpa.2009.09.009]; Haluszczak C, 2009, J EXP MED, V206, P435, DOI 10.1084/jem.20081829; Hamilton SE, 2008, P NATL ACAD SCI USA, V105, P18484, DOI 10.1073/pnas.0806487105; Hamilton SE, 2006, NAT IMMUNOL, V7, P475, DOI 10.1038/ni1326; Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783; Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107; King C, 2004, CELL, V117, P265, DOI 10.1016/S0092-8674(04)00335-6; Kotturi MF, 2008, J IMMUNOL, V181, P2124, DOI 10.4049/jimmunol.181.3.2124; Le Campion A, 2009, BLOOD, V114, P1784, DOI 10.1182/blood-2008-12-192120; Le Saout C, 2008, P NATL ACAD SCI USA, V105, P19414, DOI 10.1073/pnas.0807743105; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Lin SJ, 2007, J EXP MED, V204, P2321, DOI 10.1084/jem.20062150; Makedonas G, 2006, SPRINGER SEMIN IMMUN, V28, P209, DOI 10.1007/s00281-006-0025-4; Min B, 2004, P NATL ACAD SCI USA, V101, P3874, DOI 10.1073/pnas.0400606101; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Odorizzi PM, 2015, J EXP MED, V212, P1125, DOI 10.1084/jem.20142237; Pewe LL, 2004, J IMMUNOL, V172, P3151, DOI 10.4049/jimmunol.172.5.3151; Prlic M, 2001, J IMMUNOL, V167, P5664, DOI 10.4049/jimmunol.167.10.5664; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Seedhom MO, 2009, J VIROL, V83, P12907, DOI 10.1128/JVI.01722-09; Selin LK, 1999, IMMUNITY, V11, P733, DOI 10.1016/S1074-7613(00)80147-8; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; vandenBroek MF, 1995, IMMUNOL REV, V148, P5; Voehringer D, 2001, J IMMUNOL, V167, P4838, DOI 10.4049/jimmunol.167.9.4838; Voehringer D, 2002, BLOOD, V100, P3698, DOI 10.1182/blood-2002-02-0657; Voehringer D, 2008, J IMMUNOL, V180, P4742, DOI 10.4049/jimmunol.180.7.4742; West EE, 2013, J CLIN INVEST, V123, P2604, DOI 10.1172/JCI67008; Zandman-Goddard Gisele, 2002, Autoimmunity Reviews, V1, P329, DOI 10.1016/S1568-9972(02)00086-1	40	1	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 21	2016	7								622	10.3389/fimmu.2016.00622	http://dx.doi.org/10.3389/fimmu.2016.00622			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EF2KI	28066432	Green Published, gold			2022-12-18	WOS:000390153000001
J	Ramirez, GA; Weyand, C; Vaglio, A; Manfredi, AA				Ramirez, Giuseppe A.; Weyand, Cornelia; Vaglio, Augusto; Manfredi, Angelo A.			Editorial: Vascular inflammation in Systemic Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vascular inflammation; autoimmunity; vasculitis; systemic inflammation; remodeling	BOWEL-DISEASE		[Ramirez, Giuseppe A.; Manfredi, Angelo A.] IRCCS Osped San Raffaele, Unit Internal Med & Immunol, Milan, Italy; [Ramirez, Giuseppe A.; Manfredi, Angelo A.] Univ Vita Salute San Raffaele, Milan, Italy; [Weyand, Cornelia] Stanford Univ, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; [Vaglio, Augusto] Univ Hosp Parma, Nephrol Unit, Parma, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Stanford University; University of Parma; University Hospital of Parma	Ramirez, GA (corresponding author), IRCCS Osped San Raffaele, Unit Internal Med & Immunol, Milan, Italy.; Ramirez, GA (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.	ramirez.giuseppealvise@hsr.it	Manfredi, Angelo A./C-7018-2014; Weyand, Cornelia/AAH-3343-2021; Ramirez, Giuseppe Alvise/K-4923-2018; Vaglio, Augusto/AHE-8117-2022	Manfredi, Angelo A./0000-0001-8370-6970; Ramirez, Giuseppe Alvise/0000-0002-2889-366X; Vaglio, Augusto/0000-0002-3814-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL129941] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL129941] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amre DK, 2009, ALIMENT PHARM THER, V29, P1025, DOI 10.1111/j.1365-2036.2009.03953.x; Carmona FD, 2015, CURR OPIN RHEUMATOL, V27, P10, DOI 10.1097/BOR.0000000000000124; de Chambrun MP, 2012, AUTOIMMUN REV, V11, P687, DOI 10.1016/j.autrev.2011.11.026; Libby P, 2016, J AM COLL CARDIOL, V67, P1091, DOI 10.1016/j.jacc.2015.12.048; Loof TG, 2011, J INNATE IMMUN, V3, P34, DOI 10.1159/000321641; Ramirez GA, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0528-2; Vrij AA, 2000, EUR J CLIN INVEST, V30, P188; Vrij AA, 2003, PATHOPHYSIOL HAEMO T, V33, P75, DOI 10.1159/000073850; Zhou ZY, 2012, AUTOIMMUN REV, V11, P699, DOI 10.1016/j.autrev.2011.12.005	9	1	1	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2016	7								471	10.3389/fimmu.2016.00471	http://dx.doi.org/10.3389/fimmu.2016.00471			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EC4TN	27917171	Green Published, gold			2022-12-18	WOS:000388126900001
J	Haanstra, KG; Jonker, M; 't Hart, BA				Haanstra, Krista G.; Jonker, Margreet; 't Hart, Bert A.			An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates	FRONTIERS IN IMMUNOLOGY			English	Article						overview; EU projects; non-human primates; preclinical research; translational research	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; B-CELL DEPLETION; COLLAGEN-INDUCED ARTHRITIS; KIDNEY ALLOGRAFT SURVIVAL; PROTECTS RHESUS-MONKEYS; CENTRAL-NERVOUS-SYSTEM; COMMON MARMOSETS; MONOCLONAL-ANTIBODY; MULTIPLE-SCLEROSIS; CALLITHRIX-JACCHUS	Aging western societies are facing an increasing prevalence of chronic inflammatory and degenerative diseases for which often no effective treatments exist, resulting in increasing health-care expenditure. Despite high investments in drug development, the number of promising new drug candidates decreases. We propose that preclinical research in non-human primates can help to bridge the gap between drug discovery and drug prescription. Translational research covers various stages of drug development of which preclinical efficacy tests in valid animal models is usually the last stage. Preclinical research in non-human primates may be essential in the evaluation of new drugs or therapies when a relevant rodent model is not available. Non-human primate models for life-threatening or severely debilitating diseases in humans are available at the Biomedical Primate Research Centre (BPRC). These have been instrumental in translational research for several decades. In order to stimulate European health research and innovation from bench to bedside, the European Commission has invested heavily in access to non-human primate research for more than 20 years. BPRC has hosted European users in a series of transnational access programs covering a wide range of research areas with the common theme being immune-mediated inflammatory disorders. We present an overview of the results and give an account of the studies performed as part of European Union Framework Programme (EU FP)-funded translational non-human primate research performed at the BPRC. These data illustrate the value of translational non-human primate research for the development of new therapies and emphasize the importance of EU FP funding in drug development.	[Haanstra, Krista G.; Jonker, Margreet; 't Hart, Bert A.] Biomed Primate Res Ctr, Dept Immunobiol, Rijswijk, Netherlands; [Jonker, Margreet] Leiden Univ, Med Ctr, Dept Immunohematol, Leiden, Netherlands; ['t Hart, Bert A.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Groningen	Haanstra, KG (corresponding author), Biomed Primate Res Ctr, Dept Immunobiol, Rijswijk, Netherlands.	haanstra@bprc.nl						Arrowsmith J, 2013, NAT REV DRUG DISCOV, V12, P568, DOI 10.1038/nrd4090; Bajramovic JJ, 2008, EUR J IMMUNOL, V38, P1452, DOI 10.1002/eji.200737164; Bessis N, 2007, JOINT BONE SPINE, V74, P48, DOI 10.1016/j.jbspin.2006.09.010; Boon L, 2001, J IMMUNOL, V167, P2942, DOI 10.4049/jimmunol.167.5.2942; Brok HPM, 2000, J IMMUNOL, V165, P1093, DOI 10.4049/jimmunol.165.2.1093; Brok HPM, 2002, J IMMUNOL, V169, P6554, DOI 10.4049/jimmunol.169.11.6554; Broug E, 2010, NAT BIOTECHNOL, V28, P123, DOI 10.1038/nbt0210-123; Burm SM, 2014, ALTEX-ALTERN ANIM EX, V31, P520, DOI 10.14573/altex.1406231; Burm SM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0605-8; de Rosbo NK, 2000, J NEUROIMMUNOL, V110, P83, DOI 10.1016/S0165-5728(00)00306-4; De Vos AF, 2005, J NEUROIMMUNOL, V161, P29, DOI 10.1016/j.jneuroim.2004.12.002; de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Doxiadis GGM, 1998, TISSUE ANTIGENS, V51, P321; Dunham J, 2016, J NEUROIMMUNE PHARM, V11, P73, DOI 10.1007/s11481-015-9629-6; Goossens PH, 2000, CLIN EXP RHEUMATOL, V18, P547; Goossens PH, 1999, HUM GENE THER, V10, P1139, DOI 10.1089/10430349950018139; Haanstra KG, 2007, AM J TRANSPLANT, V7, P2236, DOI 10.1111/j.1600-6143.2007.01917.x; Haanstra KG, 2005, TRANSPLANTATION, V79, P1623, DOI 10.1097/01.TP.0000158426.64631.ED; Haanstra KG, 2003, TRANSPLANTATION, V75, P637, DOI 10.1097/01.TP.0000054835.58014.C2; Haanstra KG, 2006, TRANSPLANTATION, V82, P1194, DOI 10.1097/01.tp.0000235910.47214.67; Haanstra KG, 2015, J IMMUNOL, V194, P1454, DOI 10.4049/jimmunol.1402563; Haegel-Kronenberger H, 2004, GENE THER, V11, P241, DOI 10.1038/sj.gt.3302152; Ingelman-Sundberg HM, 2015, HAEMATOLOGICA, V100, pE158, DOI 10.3324/haematol.2014.116111; Jagessar SA, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0378-5; Jagessar SA, 2012, J NEUROIMMUNE PHARM, V7, P557, DOI 10.1007/s11481-012-9384-x; Jagessar SA, 2012, J NEUROPATH EXP NEUR, V71, P716, DOI 10.1097/NEN.0b013e3182622691; Jagessar SA, 2012, J NEUROIMMUNE PHARM, V7, P253, DOI 10.1007/s11481-011-9320-5; Jagessar SA, 2010, J NEUROPATH EXP NEUR, V69, P372, DOI 10.1097/NEN.0b013e3181d5d053; Jonker M, 2005, TRANSPLANTATION, V80, P385, DOI 10.1097/01.tp.0000166920.18998.15; Jonker M, 2002, TRANSPLANTATION, V73, P874, DOI 10.1097/00007890-200203270-00008; Jonker M, 2002, TRANSPLANTATION, V73, pS23, DOI 10.1097/00007890-200201151-00009; Jonker M, 2015, INFLAMMATION, V38, P2191, DOI 10.1007/s10753-015-0202-5; Jonker M, 2013, INFLAMM RES, V62, P181, DOI 10.1007/s00011-012-0564-1; Kap YS, 2014, J IMMUNOL, V192, P4242, DOI 10.4049/jimmunol.1303125; Kap YS, 2011, J NEUROPATH EXP NEUR, V70, P992, DOI 10.1097/NEN.0b013e318234d421; Kap YS, 2011, J NEUROIMMUNE PHARM, V6, P341, DOI 10.1007/s11481-010-9238-3; Kap YS, 2010, J IMMUNOL, V185, P3990, DOI 10.4049/jimmunol.1001393; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Kraan MC, 1998, ARTHRITIS RHEUM, V41, P1481, DOI 10.1002/1529-0131(199808)41:8<1481::AID-ART19>3.0.CO;2-O; Laman JD, 2002, EUR J IMMUNOL, V32, P2218, DOI 10.1002/1521-4141(200208)32:8<2218::AID-IMMU2218>3.0.CO;2-0; Laman JD, 1998, J NEUROIMMUNOL, V86, P30, DOI 10.1016/S0165-5728(98)00024-1; Liew FY, 2002, ANN RHEUM DIS, V61, P100; LOHSE AW, 1993, J AUTOIMMUN, V6, P121, DOI 10.1006/jaut.1993.1010; Mancardi G, 2001, J NEUROL SCI, V184, P41, DOI 10.1016/S0022-510X(00)00490-1; MEINL E, 1995, INT IMMUNOL, V7, P1489, DOI 10.1093/intimm/7.9.1489; Meinl E, 1997, VIROLOGY, V229, P175, DOI 10.1006/viro.1996.8427; Meinl E, 1997, AM J PATHOL, V150, P445; Ossevoort MA, 1999, J IMMUNOTHER, V22, P381, DOI 10.1097/00002371-199909000-00001; Ossevoort MA, 1999, TRANSPLANTATION, V68, P1010, DOI 10.1097/00007890-199910150-00019; Ossevoort MA, 1998, TRANSPLANT P, V30, P2165, DOI 10.1016/S0041-1345(98)00576-4; Otten HG, 2003, CANCER IMMUNOL IMMUN, V52, P569, DOI 10.1007/s00262-003-0401-z; Philippens IH, 2017, J ALZHEIMERS DIS, V55, P101, DOI 10.3233/JAD-160673; Philippens IHCHM, 2013, J NEUROIMMUNE PHARM, V8, P715, DOI 10.1007/s11481-013-9450-z; Plater-Zyberk C, 2011, TRANSPL IMMUNOL, V25, P133, DOI 10.1016/j.trim.2011.06.003; Pluchino S, 2009, ANN NEUROL, V66, P343, DOI 10.1002/ana.21745; Poliani PL, 2001, HUM GENE THER, V12, P905, DOI 10.1089/104303401750195872; Ringers J, 2002, TRANSPLANTATION, V73, P862, DOI 10.1097/00007890-200203270-00006; Sachs DH, 2003, J CLIN INVEST, V111, P1819, DOI 10.1172/JCI200318926; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schuurman HJ, 2001, TRANSPLANT INT, V14, P320, DOI 10.1111/j.1432-2277.2001.tb00066.x; 't Hart BA, 2005, J NEUROIMMUNOL, V163, P31, DOI 10.1016/j.jneuroim.2005.02.005; 't Hart BA, 2003, J NEUROL SCI, V212, P21, DOI 10.1016/S0022-510X(03)00080-7; 't Hart BA, 1998, AM J PATHOL, V153, P649, DOI 10.1016/S0002-9440(10)65606-4; 't Hart BA, 2002, TRENDS IMMUNOL, V23, P165, DOI 10.1016/S1471-4906(01)02148-2; 't Hart BA, 2015, EUR J PHARMACOL, V759, P69, DOI 10.1016/j.ejphar.2015.03.023; 't Hart BA, 2014, DRUG DISCOV TODAY, V19, P1394, DOI 10.1016/j.drudis.2014.03.023; 't Hart BA, 2013, DRUG DISCOV TODAY, V18, P372, DOI 10.1016/j.drudis.2012.11.010; t'Hart BA, 1998, BRIT J RHEUMATOL, V37, P314; Tak PP, 1999, RHEUMATOLOGY, V38, P362, DOI 10.1093/rheumatology/38.4.362; tHart B, 1996, IMMUNOL TODAY, V17, P400; Thiruvalluvan A, 2016, STEM CELL TRANSL MED, V5, P1550, DOI 10.5966/sctm.2016-0024; van Meer PJK, 2013, NAT BIOTECHNOL, V31, P882, DOI 10.1038/nbt.2709; van Meer PJK, 2012, REGUL TOXICOL PHARM, V64, P345, DOI 10.1016/j.yrtph.2012.09.002; Vierboom M, 2006, TRANSPL INT, V19, P396, DOI 10.1111/j.1432-2277.2006.00299.x; Vierboom MPM, 2016, CLIN EXP IMMUNOL, V183, P405, DOI 10.1111/cei.12739; Vierboom MPM, 2003, TRANSPL IMMUNOL, V11, P215, DOI 10.1016/S0966-3274(03)00009-1; von Herrath MG, 2005, J EXP MED, V202, P1159, DOI 10.1084/jem.20051224; Waring MJ, 2015, NAT REV DRUG DISCOV, V14, P475, DOI 10.1038/nrd4609; Williams MA, 2002, J IMMUNOL, V169, P5387, DOI 10.4049/jimmunol.169.10.5387	80	1	1	0	7	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 7	2016	7								462	10.3389/fimmu.2016.00462	http://dx.doi.org/10.3389/fimmu.2016.00462			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EA9YS	27872622	gold, Green Published			2022-12-18	WOS:000387001200001
J	Rijkers, GT				Rijkers, Ger T.			Fixing a Hole: Preventing Pneumococcal Pneumonia by Vaccination	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Streptococcus pneumoniae; polysaccharide; vaccination; infants; elderly; inflammation	COMMUNITY-ACQUIRED PNEUMONIA; CAPSULAR POLYSACCHARIDE; CHILDHOOD PNEUMONIA; ANTIBODY-RESPONSE; COMPLEMENT; FUTURE; ADULTS; TRIAL		[Rijkers, Ger T.] Univ Coll Roosevelt, Dept Sci, Middelburg, Netherlands; [Rijkers, Ger T.] St Antonius Hosp, Lab Med Microbiol & Immunol, Nieuwegein, Netherlands	St. Antonius Hospital Utrecht	Rijkers, GT (corresponding author), Univ Coll Roosevelt, Dept Sci, Middelburg, Netherlands.; Rijkers, GT (corresponding author), St Antonius Hosp, Lab Med Microbiol & Immunol, Nieuwegein, Netherlands.	g.rijkers@ucr.nl	Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019	Rijkers, Ger/0000-0001-6948-6123				Avery OT, 1929, J EXP MED, V50, P533, DOI 10.1084/jem.50.4.533; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Burnet M., 1962, NATURAL HIST INFECT; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; GRIFFIOEN AW, 1993, CLIN IMMUNOL IMMUNOP, V69, P1, DOI 10.1006/clin.1993.1142; LEE CJ, 1991, CRIT REV MICROBIOL, V18, P89, DOI 10.3109/10408419109113510; Levine OS, 2012, CLIN INFECT DIS, V54, pS93, DOI 10.1093/cid/cir1052; Meijvis SCA, 2011, LANCET, V377, P2023, DOI 10.1016/S0140-6736(11)60607-7; Mitsuyoshi JK, 2005, INFECT IMMUN, V73, P7311, DOI 10.1128/IAI.73.11.7311-7316.2005; PATON JC, 1986, AM J DIS CHILD, V140, P135, DOI 10.1001/archpedi.1986.02140160053031; Pozdnyakova O, 2003, J IMMUNOL, V170, P84, DOI 10.4049/jimmunol.170.1.84; Revest M, 2016, J THORAC DIS, V8, pE288, DOI 10.21037/jtd.2016.03.34; Rijkers GT, 2010, EXPERT REV VACCINES, V9, P1241, DOI 10.1586/ERV.10.127; Rodgers GL, 2009, VACCINE, V27, P3802, DOI 10.1016/j.vaccine.2009.04.021; Spellberg B, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-3; Steel HC, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/490346; Timens W, 2000, J BIOL REG HOMEOS AG, V14, P292; van Werkhoven CH, 2015, FUTURE MICROBIOL, V10, P1405, DOI [10.2217/FMB.15.80, 10.2217/fmb.15.80]; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; WATSON DA, 1993, CLIN INFECT DIS, V17, P913, DOI 10.1093/clinids/17.5.913; Whitney Cynthia G, 2004, Semin Pediatr Infect Dis, V15, P86, DOI 10.1053/j.spid.2004.01.011	21	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2016	7								349	10.3389/fimmu.2016.00349	http://dx.doi.org/10.3389/fimmu.2016.00349			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DV5NN	27679637	Green Published, gold			2022-12-18	WOS:000382974700001
J	Chirumbolo, S				Chirumbolo, Salvatore			Commentary: The Expression of CD123 Can Decrease with Basophil Activation: Implications for the Gating Strategy of the Basophil Activation Test	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						basophils; CD123; CD203c; bias; flow cytometry	FLOW-CYTOMETRY; MARKER; CCR3		[Chirumbolo, Salvatore] Univ Verona, Dept Neurosci Biomed & Movement, Verona, Italy	University of Verona	Chirumbolo, S (corresponding author), Univ Verona, Dept Neurosci Biomed & Movement, Verona, Italy.	salvatore.chirumbolo@univr.it						Chirumbolo S, 2016, EUR ANN ALLERGY CLIN, V48, P107; Chirumbolo S, 2011, CYTOM PART A, V79A, P102, DOI 10.1002/cyto.a.21008; Chirumbolo S, 2014, CYTOM PART A, V85, P382, DOI 10.1002/cyto.a.22466; Chirumbolo Salvatore, 2008, Clin Mol Allergy, V6, P12, DOI 10.1186/1476-7961-6-12; Hausmann OV, 2011, ALLERGY, V66, P85, DOI 10.1111/j.1398-9995.2010.02431.x; Khanolkar A, 2013, AM J CLIN PATHOL, V140, P293, DOI 10.1309/AJCPLSN0RQKHJX1A; Kim Z, 2016, ANN LAB MED, V36, P28, DOI 10.3343/alm.2016.36.1.28; Santos AF, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0100-4; Sharma M, 2013, SCI REP-UK, V3, DOI 10.1038/srep01188	9	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2016	7								260	10.3389/fimmu.2016.00260	http://dx.doi.org/10.3389/fimmu.2016.00260			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DQ3RD	27456009	Green Published, gold			2022-12-18	WOS:000379118900001
J	Kelly, BC				Kelly, Brian C.			Reconsidering "Unprotected" and HIV Risk in the Twenty-First Centry	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						risk assessment; HIV; MSM/Ms; condoms; unprotected sex	ANTIRETROVIRAL THERAPY; INFECTION; MEN		[Kelly, Brian C.] Purdue Univ, Sociol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kelly, BC (corresponding author), Purdue Univ, Sociol, W Lafayette, IN 47907 USA.	bckelly@purdue.edu						[Anonymous], 1981, MORBIDITY MORTALITY, V30, P250; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1600693, 10.1056/NEJMoa1105243]; Hutchinson AB, 2016, JAIDS-J ACQ IMM DEF, V71, P323, DOI 10.1097/QAI.0000000000000838; Jin FY, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00086; Jin FY, 2009, AIDS, V23, P243, DOI 10.1097/QAD.0b013e32831fb51a; Kwan CK, 2016, PUBLIC HEALTH REP, V131, P311, DOI 10.1177/003335491613100215; Phillips AN, 2015, AIDS, V29, P1855, DOI 10.1097/QAD.0000000000000767; Rodger A., 2014, C RETR OPP INF	8	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 8	2016	7								209	10.3389/fimmu.2016.00209	http://dx.doi.org/10.3389/fimmu.2016.00209			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DO1AU	27377578	Green Published, gold			2022-12-18	WOS:000377511400001
J	Koudriavtseva, T				Koudriavtseva, Tatiana			Commentary: acute Hemorrhagic leukoencephalitis (Weston-Hurst Syndrome) in a Patient with relapse-remitting multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						interferon-beta; multiple sclerosis; acute hemorrhagic leukoencephalitis; tumefactive demyelination; hemorrhage			[Koudriavtseva, Tatiana] Tor Vergata Univ, Dept Syst Med, Multiple Sclerosis Clin & Res Unit, Rome, Italy	University of Rome Tor Vergata	Koudriavtseva, T (corresponding author), Tor Vergata Univ, Dept Syst Med, Multiple Sclerosis Clin & Res Unit, Rome, Italy.	tatiana.koud@gmail.com	Koudriavtseva, Tatiana/H-8866-2017	Koudriavtseva, Tatiana/0000-0001-9984-1827				Bardehle S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00354; Dastgir J, 2009, J CHILD NEUROL, V24, P431, DOI 10.1177/0883073808324769; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Horstman LL, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-10; Johnson HL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-60; Koudriavtseva T, 2015, NEUROL SCI, V36, P2263, DOI 10.1007/s10072-015-2348-1; Le Bon A, 2006, J IMMUNOL, V176, P4682, DOI 10.4049/jimmunol.176.8.4682; Niederwieser G, 2001, EUR J NEUROL, V8, P363, DOI 10.1046/j.1468-1331.2001.00227.x; Rivadeneyra L, 2015, THROMB HAEMOSTASIS, V114, P982, DOI 10.1160/TH14-11-0951; Yildiz O, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0398-1; Zivadinov R, RADIOLOGY	11	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2016	7								207	10.3389/fimmu.2016.00207	http://dx.doi.org/10.3389/fimmu.2016.00207			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	VF6CX	27252706	Green Published, gold			2022-12-18	WOS:000443244900001
J	Weinberg, A; Curtis, D; Ning, MF; Claypool, DJ; Jalbert, E; Patterson, J; Frank, DN; Ir, D; Armon, C				Weinberg, Adriana; Curtis, Donna; Ning, Mariangeli Freitas; Claypool, David Jeremy; Jalbert, Emilie; Patterson, Julie; Frank, Daniel N.; Ir, Diana; Armon, Carl			Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						LAIV; influenza vaccine; HIV infection; children; cell-mediated immunity; ELISPOT; neutralization	BLOOD MONONUCLEAR-CELLS; VIRUS VACCINE; ANTIBODY-RESPONSES; SEASONAL INFLUENZA; YOUNG-CHILDREN; UNITED-STATES; IMMUNOGENICITY; TRIVALENT; EFFICACY; SAFETY	The live-attenuated influenza vaccine (LAIV) has generally been more efficacious than the inactivated vaccine in children. However, LAIV is not recommended for HIV-infected children because of insufficient data. We compared cellular, humoral, and mucosal immune responses to the 2013-2014 LAIV quadrivalent (LAIV4) in HIV-infected and uninfected children 2-25 years of age (yoa). We analyzed the responses to the vaccine H1N1 (H1N1-09), to the circulating H1N1 (H1N1 14). which had significant mutations compared to H1N1-09 and to B Yamagata (BY), which had the highest effectiveness in 2013-2014. Forty-six HIV-infected and 56 uninfected participants with prior influenza immunization had blood and nasal swabs collected before and after LAIV4 for IFN gamma T and IgG/IgA memory B-cell responses (ELISPOT), plasma antibodies [hemagglutination inhibition (HAI) and microneutralization (MN)], and mucosal IgA (ELISA). The HIV-infected participants had median CD4+ T cells = 645 cells/mu L and plasma HIV RNA = 20 copies/mL. Eighty-four percent were on combination anti-retroviral therapy. Regardless of HIV status, significant increases in T-cell responses were observed against BY, but not against H1N1-09. H1N1-09 T-cell immunity was higher than H1N1-14 both before and after vaccination. LAIV4 significantly increased memory IgG B-cell immunity against H1N1-14 and BY in uninfected, but not in HIV-infected participants. Regardless of HIV status, H1N1-09 memory IgG B-cell immunity was higher than H1N1-14 and lower than BY. There were significant HAI titer increases after vaccination in all groups and against all viruses. However, H1N1-14 MN titers were significantly lower than H1N1-09 before and after vaccination overall and in HIV-uninfected vaccinees. Regardless of HIV status, LAIV4 increased nasal IgA concentrations against all viruses. The fold-increase in H1N1-09 IgA was lower than BY. Overall, participants <9 yoa had decreased BY-specific HAI and nasal IgA responses to LAIV4. In conclusion, HIV-infected and uninfected children and youth had comparable responses to LAIV4. H1N1-09 immune responses were lower than BY and higher than H1N1-14, suggesting that both antigenic mismatches between circulating and vaccine H1N1 and lower immunogenicity of the H1N1 vaccine strain may have contributed to the decreased H1N1 effectiveness of 2013-2014 LAIV4.	[Weinberg, Adriana; Curtis, Donna; Ning, Mariangeli Freitas; Claypool, David Jeremy; Jalbert, Emilie; Patterson, Julie] Univ Colorado Denver, Div Infect Dis, Dept Pediat, Aurora, CO USA; [Frank, Daniel N.; Ir, Diana] Univ Colorado Denver, Div Infect Dis, Dept Med, Aurora, CO USA; [Armon, Carl] Childrens Hosp Colorado, Aurora, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado	Weinberg, A (corresponding author), Univ Colorado Denver, Div Infect Dis, Dept Pediat, Aurora, CO USA.	adriana.weinberg@ucdenver.edu		Jalbert, Emilie/0000-0001-7056-5275	MedImsnune through an Investigator-Initiated Study	MedImsnune through an Investigator-Initiated Study	This study was supported by MedImsnune through an Investigator-Initiated Study grant to AW. This work was conducted under IND 15564.	Abzug MJ, 2013, CLIN INFECT DIS, V56, P1488, DOI 10.1093/cid/cit057; Ambrose CS, 2014, VACCINE, V32, P5546, DOI 10.1016/j.vaccine.2014.07.097; Ambrose CS, 2012, VACCINE, V30, P6794, DOI 10.1016/j.vaccine.2012.09.018; Ambrose CS, 2011, INFLUENZA OTHER RESP, V5, P67, DOI 10.1111/j.1750-2659.2010.00183.x; Belshe RB, 2000, J INFECT DIS, V181, P1133, DOI 10.1086/315323; Belshe RB, 2000, J PEDIATR-US, V136, P168, DOI 10.1016/S0022-3476(00)70097-7; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Bull M, 2007, J IMMUNOL METHODS, V322, P57, DOI 10.1016/j.jim.2007.02.003; Curtis D, 2015, VACCINE, V33, P4790, DOI 10.1016/j.vaccine.2015.07.082; Faix DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034581; Flannery B, 2014, MMWR-MORBID MORTAL W, V63, P137; Flynn PM, 2012, J INFECT DIS, V206, P421, DOI 10.1093/infdis/jis360; Forrest BD, 2008, CLIN VACCINE IMMUNOL, V15, P1042, DOI 10.1128/CVI.00397-07; Hancock K., 2011, IMMUNOLOGY PATHOGENE, P1; Jacobsen MC, 2008, J INFECT DIS, V198, P481, DOI 10.1086/590215; King JC, 2000, J INFECT DIS, V181, P725, DOI 10.1086/315246; Klein EY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093632; Lanthier PA, 2011, VACCINE, V29, P7849, DOI 10.1016/j.vaccine.2011.07.093; Levesque MC, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000107; Levin MJ, 2008, VACCINE, V26, P4210, DOI 10.1016/j.vaccine.2008.05.054; Linderman SL, 2014, P NATL ACAD SCI USA, V111, P15798, DOI 10.1073/pnas.1409171111; Madhi SA, 2013, AIDS, V27, P369, DOI 10.1097/QAD.0b013e32835ab5b2; Pass RF, 2013, J PEDIATR INFECT DIS, V2, P352, DOI 10.1093/jpids/pit040; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; STIVER HG, 1973, NEW ENGL J MED, V289, P1267, DOI 10.1056/NEJM197312132892402; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031; Weinberg A, 2010, J IMMUNOL METHODS, V363, P42, DOI 10.1016/j.jim.2010.09.032; Weinberg A, 2010, JAIDS-J ACQ IMM DEF, V55, P189, DOI 10.1097/QAI.0b013e3181e46308; Weinberg A, 2009, CLIN VACCINE IMMUNOL, V16, P1176, DOI 10.1128/CVI.00342-08; Yasugi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077892	31	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2016	7								142	10.3389/fimmu.2016.00142	http://dx.doi.org/10.3389/fimmu.2016.00142			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DJ3VD	27148262	gold, Green Published			2022-12-18	WOS:000374133900001
J	Arapovic, M; Brizic, I; Popovic, B; Jurkovic, S; Jordan, S; Krmpotic, A; Arapovic, J; Jonjic, S				Arapovic, Maja; Brizic, Ilija; Popovic, Branka; Jurkovic, Slaven; Jordan, Stefan; Krmpotic, Astrid; Arapovic, Jurica; Jonjic, Stipan			Intrinsic Contribution of Perforin to NK-Cell Homeostasis during Mouse Cytomegalovirus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						mouse cytomegalovirus; perforin; NK cells; bone-marrow chimera; Ly49H; m157; proliferationIN	NATURAL-KILLER-CELLS; MURINE CYTOMEGALOVIRUS; T-CELLS; ACTIVATION RECEPTOR; VIRAL-INFECTION; VIRUS; RECOGNITION; RESPONSES; CYTOTOXICITY; IMMUNITY	In addition to their role as effector cells in virus control, natural killer (NK) cells have an immunoregulatory function in shaping the antiviral T-cell response. This function is further pronounced in perforin-deficient mice that show the enhanced NK-cell proliferation and cytokine secretion upon mouse cytomegalovirus (MCMV) infection. Here, we confirmed that stronger activation and maturation of NK cells in perforin-deficient mice correlates with higher MCMV load. To further characterize the immunoregulatory potential of perforin, we compared the response of NK cells that express or do not express perforin using bone-marrow chimeras. Our results demonstrated that the enhanced proliferation and maturation of NK cells in MCMV-infected bone-marrow chimeras is an intrinsic property of perforin-deficient NK cells. Thus, in addition to confirming that NK-cell proliferation is virus load dependent, our data extend this notion demonstrating that perforin plays an intrinsic role as a feedback mechanism in the regulation of NK-cell proliferation during viral infections.	[Arapovic, Maja; Popovic, Branka; Krmpotic, Astrid; Arapovic, Jurica; Jonjic, Stipan] Univ Rijeka, Fac Med, Dept Histol & Embryol, Rijeka, Croatia; [Brizic, Ilija; Jonjic, Stipan] Univ Rijeka, Fac Med, Ctr Prote, Rijeka, Croatia; [Jurkovic, Slaven] Clin Hosp Rijeka, Dept Med Phys, Rijeka, Croatia; [Jordan, Stefan] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Jordan, Stefan] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Arapovic, Jurica] Univ Mostar, Fac Med, Mostar, Bosnia & Herceg	University of Rijeka; University of Rijeka; University of Rijeka; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Mostar	Jonjic, S (corresponding author), Univ Rijeka, Fac Med, Dept Histol & Embryol, Rijeka, Croatia.; Jonjic, S (corresponding author), Univ Rijeka, Fac Med, Ctr Prote, Rijeka, Croatia.	stipan.jonjic@medri.uniri.hr	Arapović, Maja/GLT-1529-2022; Arapovic, Jurica/J-9374-2014; Arapovic, Jurica/AGS-4105-2022; Jordan, Stefan/AAI-1073-2021; Brizic, Ilija/N-4052-2015; Brizić, Ilija/O-4776-2018; Jordan, Stefan/AAH-8261-2021; Jordan, Stefan/G-6243-2011; Jonjic, Stipan/C-5657-2016; Krmpotic, Astrid/U-6224-2017	Arapović, Maja/0000-0001-6043-3666; Arapovic, Jurica/0000-0002-7674-6795; Arapovic, Jurica/0000-0002-7674-6795; Jordan, Stefan/0000-0001-9330-1715; Brizić, Ilija/0000-0001-8839-7839; Jordan, Stefan/0000-0001-9330-1715; Jordan, Stefan/0000-0001-9330-1715; Jonjic, Stipan/0000-0001-5003-3108; Krmpotic, Astrid/0000-0001-5470-5370; Popovic, Branka/0000-0002-2416-4793	European Research Council (ERC) Advanced Grant [322693]; Helmholtz Virtual Institute "Viral strategies of immune evasion" [VH VI-424]; Croatian Science Foundation [7132]	European Research Council (ERC) Advanced Grant(European Research Council (ERC)); Helmholtz Virtual Institute "Viral strategies of immune evasion"; Croatian Science Foundation	Stipan Jonjic is supported by the European Research Council (ERC) Advanced Grant (Grant number: 322693) and by the Helmholtz Virtual Institute "Viral strategies of immune evasion" (VH VI-424). This work has been supported in part by the Croatian Science Foundation under the project 7132 (AK).	Andrews DM, 2010, J EXP MED, V207, P1333, DOI 10.1084/jem.20091193; Arapovic J, 2015, MED MICROBIOL IMMUN, V204, P335, DOI 10.1007/s00430-015-0409-y; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Babic M, 2010, J EXP MED, V207, P2663, DOI 10.1084/jem.20100921; Biron CA, 2012, P NATL ACAD SCI USA, V109, P1814, DOI 10.1073/pnas.1120528109; Brizic I, 2014, SEMIN IMMUNOPATHOL, V36, P641, DOI 10.1007/s00281-014-0441-9; Brown MG, 2001, SCIENCE, V292, P934, DOI 10.1126/science.1060042; Bubic I, 2004, J VIROL, V78, P7536, DOI 10.1128/JVI.78.14.7536-7544.2004; Cao XF, 2007, IMMUNITY, V27, P635, DOI 10.1016/j.immuni.2007.08.014; Crouse J, 2014, IMMUNITY, V40, P961, DOI 10.1016/j.immuni.2014.05.003; Dokun AO, 2001, NAT IMMUNOL, V2, P951, DOI 10.1038/ni714; French AR, 2004, IMMUNITY, V20, P747, DOI 10.1016/j.immuni.2004.05.006; Hengel H, 1999, IMMUNOL REV, V168, P167, DOI 10.1111/j.1600-065X.1999.tb01291.x; Huntington ND, 2007, J IMMUNOL, V178, P4764, DOI 10.4049/jimmunol.178.8.4764; Jenkins MR, 2015, J EXP MED, V212, P307, DOI 10.1084/jem.20140964; Jonjic Stipan, 2008, V415, P127, DOI 10.1007/978-1-59745-570-1_8; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; Lanier LL, 2008, NAT REV IMMUNOL, V8, P259, DOI 10.1038/nri2276; Lee SH, 2009, J EXP MED, V206, P2235, DOI 10.1084/jem.20082387; Lee SH, 2001, NAT GENET, V28, P42, DOI 10.1038/88247; Lisnic B, 2015, CURR OPIN VIROL, V15, P9, DOI 10.1016/j.coviro.2015.07.001; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Madera S, 2016, J EXP MED, V213, P225, DOI 10.1084/jem.20150712; Matloubian M, 1999, J VIROL, V73, P2527, DOI 10.1128/JVI.73.3.2527-2536.1999; Mitrovic M, 2012, MED MICROBIOL IMMUN, V201, P487, DOI 10.1007/s00430-012-0263-0; Mitrovic M, 2012, J VIROL, V86, P2165, DOI 10.1128/JVI.06042-11; Robbins SH, 2007, PLOS PATHOG, V3, P1152, DOI 10.1371/journal.ppat.0030123; Robbins SH, 2004, J IMMUNOL, V173, P259, DOI 10.4049/jimmunol.173.1.259; Sad S, 1996, J EXP MED, V184, P1543, DOI 10.1084/jem.184.4.1543; Scalzo AA, 2008, CURR TOP MICROBIOL, V321, P101; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Sumaria N, 2009, IMMUNOL CELL BIOL, V87, P559, DOI 10.1038/icb.2009.41; Taniguchi RT, 2007, BLOOD, V110, P2020, DOI 10.1182/blood-2007-02-076927; Tay CH, 1997, J VIROL, V71, P267, DOI 10.1128/JVI.71.1.267-275.1997; Wagner M, 1999, J VIROL, V73, P7056, DOI 10.1128/JVI.73.8.7056-7060.1999; Yokoyama Wayne M., 2008, V415, P179, DOI 10.1007/978-1-59745-570-1_11	37	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2016	7								133	10.3389/fimmu.2016.00133	http://dx.doi.org/10.3389/fimmu.2016.00133			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DI3UQ	27092144	gold, Green Published			2022-12-18	WOS:000373424400001
J	Robinson, MW; Hughes, J; Wilkie, GS; Swann, R; Barclay, ST; Mills, PR; Patel, AH; Thomson, EC; McLauchlan, J				Robinson, Mark W.; Hughes, Joseph; Wilkie, Gavin S.; Swann, Rachael; Barclay, Stephen T.; Mills, Peter R.; Patel, Arvind H.; Thomson, Emma C.; McLauchlan, John			Tracking TCR beta Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region	FRONTIERS IN IMMUNOLOGY			English	Article						T cell receptor; high-throughput sequencing; complementarity determining region 3; hepatitis C virus; TRBV; TBRJ; clonotype expansion	HEPATITIS-C VIRUS; VIRAL CLEARANCE; CELL RESPONSES; RIBAVIRIN TREATMENT; IMMUNE REPERTOIRES; HCV INFECTION; INTERFERON; IMMUNOGLOBULIN; DIVERSITY; GENOTYPE	To maintain a persistent infection viruses such as hepatitis C virus (HCV) employ a range of mechanisms that subvert protective T cell responses. The suppression of antigen-specific T cell responses by HCV hinders efforts to profile T cell responses during chronic infection and antiviral therapy. Conventional methods of detecting antigen-specific T cells utilize either antigen stimulation (e.g., ELISpot, proliferation assays, cytokine production) or antigen loaded tetramer staining. This limits the ability to profile T cell responses during chronic infection due to suppressed effector function and the requirement for prior knowledge of antigenic viral peptide sequences. Recently, high-throughput sequencing (HTS) technologies have been developed for the analysis of T cell repertoires. In the present study, we have assessed the feasibility of HTS of the TCR beta complementarity determining region (CDR)3 to track T cell expansions in an antigen-independent manner. Using sequential blood samples from HCV-infected individuals undergoing antiviral therapy, we were able to measure the population frequencies of >35,000 TCR beta sequence clonotypes in each individual over the course of 12 weeks. TRBV/TRBJ gene segment usage varied markedly between individuals but remained relatively constant within individuals across the course of therapy. Despite this stable TRBV/TRBJ gene segment usage, a number of TCR beta sequence clonotypes showed dramatic changes in read frequency. These changes could not be linked to therapy outcomes in the present study; however, the TCR beta CDR3 sequences with the largest fold changes did include sequences with identical TRBV/TRBJ gene segment usage and high junction region homology to previously published CDR3 sequences from HCV-specific T cells targeting the HLA-B*0801-restricted 1396HSKKKCDEL14 3 and HLA-A*0101-restricted (143)bATDALMTGY(1443) epitopes. The pipeline developed in this proof of concept study provides a platform for the design of future experiments to accurately address the question of whether T cell responses contribute to SVR upon antiviral therapy. This pipeline represents a novel technique to analyze T cell dynamics in situations where conventional antigen-dependent methods are limited due to suppression of T cell functions and highly diverse antigenic sequences.	[Robinson, Mark W.; Hughes, Joseph; Wilkie, Gavin S.; Swann, Rachael; Patel, Arvind H.; Thomson, Emma C.; McLauchlan, John] Univ Glasgow, Inst Infect Immun & Inflammat, MRC Univ Glasgow Ctr Virus Res, Glasgow, Lanark, Scotland; [Robinson, Mark W.] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland; [Swann, Rachael; Mills, Peter R.] NHS Greater Glasgow & Clyde, Gartnavel Gen Hosp, Glasgow, Lanark, Scotland; [Barclay, Stephen T.] NHS Greater Glasgow & Clyde, Glasgow Royal Infirm, Glasgow, Lanark, Scotland	University of Glasgow; Trinity College Dublin; University of Glasgow	Thomson, EC; McLauchlan, J (corresponding author), Univ Glasgow, Inst Infect Immun & Inflammat, MRC Univ Glasgow Ctr Virus Res, Glasgow, Lanark, Scotland.	emma.thomson@glasgow.ac.uk; john.mclauchlan@glasgow.ac.uk	Hughes, Joseph/B-7711-2009; Thomson, Emma C/M-8690-2017	Hughes, Joseph/0000-0003-2556-2563; Thomson, Emma C/0000-0003-1482-0889; Swann, Rachael/0000-0002-3945-2253	UK Medical Research Council through a MRC Centenary Award [4050295596, MC_UU_I 2014/2]; Wellcome Trust [102789/Z/13/Z]; MRC [MC_UU_12014/12, G0801822, MC_UU_12014/2, MC_UU_12014/1] Funding Source: UKRI; Medical Research Council [MC_UU_12014/12, MC_UU_12014/2, G0801822, 1272048, MC_UU_12014/1] Funding Source: researchfish	UK Medical Research Council through a MRC Centenary Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors wish to acknowledge Dr. Richard Reeve and Prof. Daniel Haydon, University of Glasgow, for helpful discussions. This work was supported by the UK Medical Research Council through a MRC Centenary Award (MR), Intramural Programme Grants, grant no: 4050295596 (JM) and MC_UU_I 2014/2 (AP), and by the Wellcome Trust, grant no: 102789/Z/13/Z (ET).	Aberle JH, 2007, J INFECT DIS, V195, P1315, DOI 10.1086/513278; Attaf M, 2015, CELL MOL IMMUNOL, V12, P391, DOI 10.1038/cmi.2014.134; Barnes E, 2009, J INFECT DIS, V199, P819, DOI 10.1086/597072; Barrett S, 1999, J HEPATOL, V30, P979, DOI 10.1016/S0168-8278(99)80249-9; Caetano J, 2008, J VIROL, V82, P7567, DOI 10.1128/JVI.02175-07; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749; Cramp ME, 2000, GASTROENTEROLOGY, V118, P346, DOI 10.1016/S0016-5085(00)70217-4; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Dieterich DT, 2003, CLIN INFECT DIS, V37, P533, DOI 10.1086/376971; Egorov ES, 2015, J IMMUNOL, V194, P6155, DOI 10.4049/jimmunol.1500215; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Fitzmaurice K, 2015, GUT, V64, P813, DOI 10.1136/gutjnl-2013-306287; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Greiff V, 2015, TRENDS IMMUNOL, V36, P738, DOI 10.1016/j.it.2015.09.006; Honegger JR, 2013, NAT MED, V19, P1529, DOI 10.1038/nm.3351; Kim AY, 2011, GASTROENTEROLOGY, V140, P686, DOI 10.1053/j.gastro.2010.09.042; La Gruta NL, 2014, TRENDS IMMUNOL, V35, P396, DOI 10.1016/j.it.2014.06.004; Larrubia JR, 2013, CELL IMMUNOL, V286, P31, DOI 10.1016/j.cellimm.2013.11.001; Laydon DJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0291; Li S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3333; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Martin B, 2014, J HEPATOL, V61, P538, DOI 10.1016/j.jhep.2014.05.043; McKiernan SM, 2004, HEPATOLOGY, V40, P108, DOI 10.1002/hep.20261; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; Miles JJ, 2011, J IMMUNOL, V186, P901, DOI 10.4049/jimmunol.1003167; Neumann-Haefelin C, 2010, HEPATOLOGY, V51, P54, DOI 10.1002/hep.23275; Park SH, 2014, IMMUNITY, V40, P13, DOI 10.1016/j.immuni.2013.12.010; Pilli M, 2007, GASTROENTEROLOGY, V133, P1132, DOI 10.1053/j.gastro.2007.06.059; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Robinson MW, 2015, J VIRAL HEPATITIS, V22, P384, DOI 10.1111/jvh.12310; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Thursz M, 1999, LANCET, V354, P2119, DOI 10.1016/S0140-6736(99)91443-5; Turner SJ, 2009, CURR OPIN IMMUNOL, V21, P286, DOI 10.1016/j.coi.2009.05.004; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478; Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x; Woollard DJ, 2003, HEPATOLOGY, V38, P1297, DOI 10.1053/jhep.2003.50478	38	1	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2016	7								131	10.3389/fimmu.2016.00131	http://dx.doi.org/10.3389/fimmu.2016.00131			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DI2QF	27092143	gold, Green Published, Green Accepted			2022-12-18	WOS:000373340800001
J	Catalan, D; Pino-Lagos, K				Catalan, Diego; Pino-Lagos, Karina			Editorial: Searching for immune tolerance Manipulating New Molecules and Exploiting New Concepts on lymphocyte Biology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune tolerance; regulatory T cells; B cell tolerance; dendritic cells; transplantation; autoimmunity; costimulatory molecules; cytokines			[Catalan, Diego] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Disciplinario Inmunol, Santiago 7, Chile; [Catalan, Diego] Inst Milenio Inmunol & Inmunoterapia, Santiago, Chile; [Pino-Lagos, Karina] Univ Los Andes, Fac Med, Ctr Invest Biomed, Santiago, Chile	Universidad de Chile; Universidad de los Andes - Chile	Pino-Lagos, K (corresponding author), Univ Los Andes, Fac Med, Ctr Invest Biomed, Santiago, Chile.	karina.p.lagos@gmail.com	Catalán, Diego/AAN-3241-2020; Pino-Lagos, Karina/C-9583-2017; Catalán, Diego F/H-7983-2013; Pino-Lagos, Karina/H-7581-2013	Catalán, Diego/0000-0002-4353-1229; Pino-Lagos, Karina/0000-0002-4070-6169; Catalán, Diego F/0000-0002-4353-1229; Pino-Lagos, Karina/0000-0002-4070-6169					0	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2016	7								27	10.3389/fimmu.2016.00027	http://dx.doi.org/10.3389/fimmu.2016.00027			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DC3HT	26870042	gold, Green Published			2022-12-18	WOS:000369111100001
J	Padovan, E; Martin, SF				Padovan, Elisabetta; Martin, Stefan F.			Editorial: innate immune Cell determinants of T Cell immunity: From Basic Mechanisms to Clinical implications	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate immunity; T cell memory; antigen presentation; vaccines; human diseases	PERIPHERAL LYMPHOID ORGANS; IDENTIFICATION; MICE		[Padovan, Elisabetta] Univ Basel, Dept Biomed, Univ Basel Hosp, Inst Surg Res, Basel, Switzerland; [Martin, Stefan F.] Univ Freiburg, Med Ctr, Allergy Res Grp, Dept Dermatol, Freiburg, Germany	University of Basel; University of Freiburg	Padovan, E (corresponding author), Univ Basel, Dept Biomed, Univ Basel Hosp, Inst Surg Res, Basel, Switzerland.	elisabetta.padovan@unibas.ch		Padovan, Elisabetta/0000-0002-8212-508X				STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1974, J EXP MED, V139, P380, DOI 10.1084/jem.139.2.380	2	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 14	2016	6								664	10.3389/fimmu.2015.00664	http://dx.doi.org/10.3389/fimmu.2015.00664			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DB3SR	26834741	gold, Green Published			2022-12-18	WOS:000368432400002
J	Arsenijevic, D; Montani, JP				Arsenijevic, Denis; Montani, Jean-Pierre			Uninephrectomy in Rats on a Fixed Food Intake Potentiates Both Anorexia and Circulating Cytokine Subsets in Response to LPS	FRONTIERS IN IMMUNOLOGY			English	Article						uninephrectomy; LPS; brain; cytokines; neuropeptides; anorexia; rats; Sprague-Dawley	CHRONIC KIDNEY-DISEASE; ACYLATION-STIMULATING PROTEIN; PITUITARY-ADRENAL AXIS; INTERFERON-GAMMA; PROINFLAMMATORY CYTOKINES; TOXOPLASMA-GONDII; SUBFORNICAL ORGAN; MESSENGER-RNAS; RENAL-DISEASE; LIPOPOLYSACCHARIDE	Recent human studies have suggested that mild reduction in kidney function can alter immune response and increase susceptibility to infection. The role of mild reduction in kidney function in altering susceptibility to bacterial lipopolysaccharide (LPS) responses was investigated in uninephrectomized rats compared to Sham-operated controls rats 4 weeks after surgery. Throughout the 4 weeks, all rats were maintained under mild food restriction at 90% of ad libitum intake to ensure the same caloric intake in both groups. In comparison to Sham, uninephrectomy (UniNX) potentiated LPS-induced anorexia by 2.1-fold. The circulating anorexigenic cytokines granulocyte-macrophage colony stimulating factor, interferon-gamma, tumor necrosis factor-alpha, and complement-derived acylation-stimulating protein were elevated after LPS in UniNX animals compared to Sham animals. Interleukin(IL)1 beta and IL6 pro-inflammatory cytokines were transiently increased. Anti-inflammatory cytokines IL4 and IL10 did not differ or had a tendency to be lower in UniNX group compared to Sham animals. LPS-induced anorexia was associated with increased anorexigenic neuropeptides m RNA for pro-opiomelanocortin, corticotrophin-releasing factor, and cocaine amphetamine-regulated transcript in the hypothalamus of both Sham and UniNX groups, but at higher levels in the UniNX group. Melanocortin-4-receptor mRNA was markedly increased in the UniNX group, which may have contributed to the enhanced anorexic response to LPS of the UniNX group. In summary, UniNX potentiates pro-inflammatory cytokine production, anorexia, and selected hypothalamic anorexigenic neuropeptides in response to LPS.	[Arsenijevic, Denis; Montani, Jean-Pierre] Univ Fribourg, Dept Med, Div Physiol, CH-1700 Fribourg, Switzerland; [Arsenijevic, Denis; Montani, Jean-Pierre] Natl Ctr Competence Res Kidney Control Homeostasi, Zurich, Switzerland	University of Fribourg	Arsenijevic, D (corresponding author), Univ Fribourg, Dept Med, Div Physiol, CH-1700 Fribourg, Switzerland.	denis.arsenijevic@unifr.ch	Arsenijevic, Denis/O-8315-2016	Arsenijevic, Denis/0000-0001-5741-9652	Swiss National Center of Competence in Research (NCCR-Kidney.CH) grant	Swiss National Center of Competence in Research (NCCR-Kidney.CH) grant	The study was supported by Swiss National Center of Competence in Research (NCCR-Kidney.CH) grant to J-PM.	Akchurin OM, 2015, BLOOD PURIFICAT, V39, P84, DOI 10.1159/000368940; Arsenijevic D, 1998, AM J PHYSIOL-ENDOC M, V274, pE439, DOI 10.1152/ajpendo.1998.274.3.E439; Arsenijevic D, 2000, EUR CYTOKINE NETW, V11, P662; Arsenijevic D, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00195; Barsoum Rashad S, 2004, Exp Clin Transplant, V2, P258; Bellavance MA, 2012, IMMUNOL REV, V248, P36, DOI 10.1111/j.1600-065X.2012.01129.x; Borges BC, 2011, AM J PHYSIOL-ENDOC M, V300, pE858, DOI 10.1152/ajpendo.00558.2010; Cao CY, 2001, EUR J NEUROSCI, V13, P1781, DOI 10.1046/j.0953-816x.2001.01551.x; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Cheung WW, 2012, AM J PHYSIOL-RENAL, V303, pF1315, DOI 10.1152/ajprenal.00341.2012; Delfanti F, 2000, CLIN IMMUNOL, V97, P102, DOI 10.1006/clim.2000.4923; DIAMOND JR, 1990, AM J PHYSIOL, V258, pF1, DOI 10.1152/ajprenal.1990.258.1.F1; Duan KP, 2015, CLIN ENDOCRINOL, V82, P695, DOI 10.1111/cen.12610; Ernanuela M, 2007, BIOMED PHARMACOTHER, V61, P360, DOI 10.1016/j.biopha.2007.03.002; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; Francis K, 2008, J ENDOCRINOL, V199, P417, DOI 10.1677/JOE-08-0110; Fujita T, 2013, DIABETES-METAB RES, V29, P220, DOI 10.1002/dmrr.2380; Fuzesi T, 2008, J NEUROENDOCRINOL, V20, P1058, DOI 10.1111/j.1365-2826.2008.01758.x; Gai ZB, 2014, AM J PHYSIOL-RENAL, V306, pF130, DOI 10.1152/ajprenal.00114.2013; Gayle D, 1998, BRAIN RES, V795, P77, DOI 10.1016/S0006-8993(98)00280-7; Grinevich V, 2001, J NEUROENDOCRINOL, V13, P711, DOI 10.1046/j.1365-2826.2001.00684.x; Hrupka BJ, 2001, PHARMACOL BIOCHEM BE, V68, P355, DOI 10.1016/S0091-3057(00)00463-9; Inui A, 1999, CANCER RES, V59, P4493; Johnson RW, 1997, J ANIM SCI, V75, P1244; Joshi PC, 2006, AM J PHYSIOL-LUNG C, V291, pL1150, DOI 10.1152/ajplung.00150.2006; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Keller CR, 2007, KIDNEY INT, V71, P239, DOI 10.1038/sj.ki.5002042; Li XF, 2007, ENDOCRINOLOGY, V148, P5984, DOI 10.1210/en.2007-0710; Lopez N, 2010, PEPTIDES, V31, P1361, DOI 10.1016/j.peptides.2010.03.028; Mak RH, 2005, PEDIATR NEPHROL, V20, P427, DOI 10.1007/s00467-004-1789-1; Mathew R, 2014, EXPERT REV VACCINES, V13, P285, DOI 10.1586/14760584.2014.874950; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Minakata K, 2014, CIRC J, V78, P2225, DOI 10.1253/circj.CJ-14-0328; Naeini AE, 2012, SAUDI J KIDNEY DIS T, V23, P677, DOI 10.4103/1319-2442.98110; Ortega L., 2010, INT J INTERFERON CYT, V2, P49, DOI [10.2147/IJICMR.S10111, DOI 10.2147/IJICMR.S10111]; Ozata M, 2002, J CLIN ENDOCR METAB, V87, P853, DOI 10.1210/jc.87.2.853; Park SW, 2011, LAB INVEST, V91, P63, DOI 10.1038/labinvest.2010.151; Plata-Salaman CR, 1998, ANN NY ACAD SCI, V856, P160, DOI 10.1111/j.1749-6632.1998.tb08324.x; PLATASALAMAN CR, 1992, AM J PHYSIOL, V263, pR1222, DOI 10.1152/ajpregu.1992.263.6.R1222; Reed JA, 2005, J CLIN INVEST, V115, P3035, DOI 10.1172/JCI25681; Rivest S, 2001, PSYCHONEUROENDOCRINO, V26, P761, DOI 10.1016/S0306-4530(01)00064-6; Rorato R, 2008, HORM BEHAV, V54, P134, DOI 10.1016/j.yhbeh.2008.02.011; Roy C, 2011, AM J PHYSIOL-ENDOC M, V301, pE232, DOI 10.1152/ajpendo.00476.2010; Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1046/j.1523-1755.2000.00337.x; Sartin JL, 2008, J ANIM SCI, V86, P2557, DOI 10.2527/jas.2008-0916; Sergeyev V, 2001, MOL BRAIN RES, V90, P93, DOI 10.1016/S0169-328X(01)00088-2; Stoving RK, 1999, J PSYCHIATR RES, V33, P139, DOI 10.1016/S0022-3956(98)00049-1; Summermatter S, 2009, DIABETES, V58, P2228, DOI 10.2337/db08-1793; Tang JH, 2008, PEDIATR NEPHROL, V23, P959, DOI 10.1007/s00467-007-0738-1; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; Utsuyama M, 2002, EXP GERONTOL, V37, P411, DOI 10.1016/S0531-5565(01)00208-X; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; von Meyenburg C, 2003, PHARMACOL BIOCHEM BE, V74, P1025, DOI 10.1016/S0091-3057(03)00030-3; Wang Y, 2010, GLIA, V58, P195, DOI 10.1002/glia.20912; Wei SG, 2015, HYPERTENSION, V65, P1126, DOI 10.1161/HYPERTENSIONAHA.114.05112; Wei SG, 2013, HYPERTENSION, V62, P118, DOI 10.1161/HYPERTENSIONAHA.113.01404	58	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2015	6								641	10.3389/fimmu.2015.00641	http://dx.doi.org/10.3389/fimmu.2015.00641			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CZ4FN	26734008	Green Published, gold			2022-12-18	WOS:000367059000001
J	Vermijlen, D; Prinz, I				Vermijlen, David; Prinz, Immo			Ontogeny of Innate T Lymphocytes - Some Innate Lymphocytes Are More Innate Than Others (vol 5, 486, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Vermijlen, David] ULB, Fac Phys, Brussels, Belgium; [Prinz, Immo] Hannover Med Sch, Inst Immunol, Hannover, Germany	Universite Libre de Bruxelles; Hannover Medical School	Vermijlen, D (corresponding author), ULB, Fac Phys, Brussels, Belgium.	dvermijl@ulb.ac.be	Prinz, Immo/A-3026-2010	Prinz, Immo/0000-0002-8789-9578				Vermijlen D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00486	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2015	6								624	10.3389/fimmu.2015.00624	http://dx.doi.org/10.3389/fimmu.2015.00624			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CZ1BQ	26697018	Green Published, gold			2022-12-18	WOS:000366841100003
J	Wijeyewickrema, LC; Duncan, RC; Pike, RN				Wijeyewickrema, Lakshmi Carmel; Duncan, Renee Charlene; Pike, Robert Neil			The role of tne Lys628 (192) residue of the complement protease, C1s, in interacting with peptide and protein substrates	FRONTIERS IN IMMUNOLOGY			English	Article						complement; C1s; C4; substrate; protease; serine protease	CATALYTIC DOMAIN; SERINE-PROTEASE; COMPONENT C4; SYSTEM; MASP-2; SPECIFICITY; RECOGNITION; THROMBIN; CLEAVAGE; SUBSITES	The C1s protease of the classical complement pathway propagates the initial activation of this pathway of the system by cleaving and thereby activating the C4 and C2 complement components. This facilitates the formation of the classical pathway C3 convertase (C4bC2a). C1s has a Lys residue located at position 628 (192 in chymotrypsin numbering) of the SP domain that has the potential to partially occlude the S2-S2' positions of the active site. The 192 residue of serine proteases generally plays an important role in interactions with substrates. We therefore investigated the role of Lys628 (192) in interactions with C4 by altering the Lys residue to either a Gln (found in many other serine proteases) or an Ala residue. The mutant enzymes had altered specificity profiles for a combinatorial peptide substrate library, suggesting that this residue does influence the active site specificity of the protease. Generally, the K628Q mutant had greater activity than wild type enzyme against peptide substrates, while the K628A residue had lowered activity, although this was not always the case. Against peptide substrates containing physiological substrate sequences, the K628Q mutant once again had generally higher activity, but the activity of the wild type and mutant enzymes against a C4 P4-P4' substrate were similar. Interestingly, alteration of the K628 residue in C1s had a marked effect on the cleavage of C4, reducing cleavage efficiency for both mutants about fivefold. This indicates that this residue plays a different role in cleaving protein versus peptide substrates and that the Lys residue found in the wild type enzyme plays an important role in interacting with the C4 substrate. Understanding the basis of the interaction between C1s and its physiological substrates is likely to lead to insights that can be used to design efficient inhibitors of the enzyme for use in treating diseases caused by inflammation as result of over-activity of the classical complement pathway.	[Wijeyewickrema, Lakshmi Carmel; Duncan, Renee Charlene; Pike, Robert Neil] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Pike, RN (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.	rob.pike@monash.edu	Wijeyewickrema, Lakshmi/A-9676-2015	Wijeyewickrema, Lakshmi/0000-0001-6084-4887; Pike, Robert/0000-0002-2083-0269	National Health and Medical Research Council of Australia [490900]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Usha Koul for excellent technical assistance. The work was supported by National Health and Medical Research Council of Australia funding (Program Grant 490900).	Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; Andersson MK, 2010, FEBS J, V277, P2255, DOI 10.1111/j.1742-4658.2010.07642.x; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Duncan RC, 2008, BIOCHIMIE, V90, P387, DOI 10.1016/j.biochi.2007.07.023; Duncan RC, 2012, J IMMUNOL, V189, P2365, DOI 10.4049/jimmunol.1201085; Duncan RC, 2012, MOL IMMUNOL, V49, P593, DOI 10.1016/j.molimm.2011.10.006; Forneris F, 2012, CURR OPIN STRUC BIOL, V22, P333, DOI 10.1016/j.sbi.2012.04.001; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; Harmat V, 2004, J MOL BIOL, V342, P1533, DOI 10.1016/j.jmb.2004.07.014; Kerr FK, 2005, J BIOL CHEM, V280, P39510, DOI 10.1074/jbc.M506131200; Kidmose RT, 2012, P NATL ACAD SCI USA, V109, P15425, DOI 10.1073/pnas.1208031109; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Marque PE, 2000, J BIOL CHEM, V275, P809, DOI 10.1074/jbc.275.2.809; Mollnes Tom E., 2002, Trends in Immunology, V23, P61, DOI 10.1016/S1471-4906(01)02129-9; O'Brien G, 2003, BIOCHEMISTRY-US, V42, P14939, DOI 10.1021/bi035507b; Perry AJ, 2013, J BIOL CHEM, V288, P15821, DOI 10.1074/jbc.M113.464545; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rossi V, 2005, J BIOL CHEM, V280, P41811, DOI 10.1074/jbc.M503813200; Tang J, 2005, J BIOL CHEM, V280, P41077, DOI 10.1074/jbc.M506766200; Tang YQ, 2013, J BIOL CHEM, V288, P28307, DOI 10.1074/jbc.A113.483875	21	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2015	5								444	10.3389/fimmu.2014.00444	http://dx.doi.org/10.3389/fimmu.2014.00444			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0SE	25278939	Green Published, gold			2022-12-18	WOS:000354447400001
J	Gerard, NP; Gerard, C				Gerard, Norma P.; Gerard, Craig			Cloning of the human C5a anaphylatoxin receptor, and more	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						C5aR/C5R1; 7-TMS receptors; complement anaphylatoxin; C5a; G protein coupled receptor	INTERLEUKIN-8 RECEPTOR; MOLECULAR-CLONING; FUNCTIONAL CDNA; NEUTROPHILS; RANTES; CELLS; BETA		[Gerard, Norma P.; Gerard, Craig] Harvard Univ, Childrens Hosp, Ina Sue Perlmutter Lab, Sch Med,Dept Med,Div Resp Dis, Boston, MA 02115 USA; [Gerard, Norma P.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Gerard, C (corresponding author), Harvard Univ, Childrens Hosp, Ina Sue Perlmutter Lab, Sch Med,Dept Med,Div Resp Dis, Boston, MA 02115 USA.	craig.gerard@childrens.harvard.edu						BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FELTNER DE, 1986, J IMMUNOL, V137, P1961; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	14	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2015	6						1	3	445	10.3389/fimmu.2015.00445	http://dx.doi.org/10.3389/fimmu.2015.00445			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CQ1BX	26388870	Green Published, gold			2022-12-18	WOS:000360333400001
J	Sauer, K; Okkenhaug, K				Sauer, Karsten; Okkenhaug, Klaus			Editorial: Lipid signaling in T cell development and function	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lipid; PI3K; T cell; inositol; eicosanoid; vitamin D-3; adipokine; TNF			[Sauer, Karsten] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Sauer, Karsten] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA USA; [Okkenhaug, Klaus] Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge, England	Scripps Research Institute; Scripps Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Sauer, K (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	ksauer@scripps.edu	Okkenhaug, Klaus/H-3154-2019	Okkenhaug, Klaus/0000-0002-9432-4051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100785] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM100785] Funding Source: Medline; Wellcome Trust [095691] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Blagosklonny MV, 2015, ONCOTARGET; Chen JH, 2015, NAT MED, V21, P327, DOI 10.1038/nm.3831; Choudhuri K, 2014, NATURE, V507, P118, DOI 10.1038/nature12951; Dustin ML, 2011, NAT REV IMMUNOL, V11, P672, DOI 10.1038/nri3066; Jun JE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00239; Kongsbak M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00148; Krishna S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00178; Lone AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00130; Nicolaou A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00075; Nunes JA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00080; Okkenhaug K, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00557; Patrussi L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00213; Procaccini C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00332; Sauer K, 2010, NAT REV IMMUNOL, V10, P257, DOI 10.1038/nri2745; Siegemund S, 2015, BLOOD, V125, P2786, DOI 10.1182/blood-2014-06-583187; So T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00139; Srivastava N, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00288; van der Merwe PA, 2011, NAT REV IMMUNOL, V11, P47, DOI 10.1038/nri2887; Veldhoen M, 2015, NAT MED, V21, P709, DOI 10.1038/nm.3894; Wang XX, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00117; Wu W, 2015, PROG BIOPHYS MOL BIO, V118, P130, DOI 10.1016/j.pbiomolbio.2015.04.004	21	1	1	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2015	6								410	10.3389/fimmu.2015.00410	http://dx.doi.org/10.3389/fimmu.2015.00410			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CO9DC	26322043	Green Published, gold			2022-12-18	WOS:000359471800001
J	Best, K; Chain, B; Watkins, C				Best, Katharine; Chain, Benny; Watkins, Chris			Immune tolerance maintained by cooperative interactions between T cells and antigen presenting cells shapes a diverse TCR repertoire	FRONTIERS IN IMMUNOLOGY			English	Article						immune tolerance; T cell population; dendritic cells; TCR repertoire; linear programming	DENDRITIC CELLS; FAS LIGAND; SELF; SELECTION; MODEL; MAINTENANCE; MECHANISM; DANGER	The T cell population in an individual needs to avoid harmful activation by self peptides while maintaining the ability to respond to an unknown set of foreign peptides. This property is acquired by a combination of thymic and extra-thymic mechanisms. We extend current models for the development of self/non-self discrimination to consider the acquisition of self-tolerance as an emergent system level property of the overall T cell receptor repertoire. We propose that tolerance is established at the level of the antigen presenting cell/T cell cluster, which facilitates and integrates cooperative interactions between T cells of different specificities. The threshold for self-reactivity is therefore imposed at a population level, and not at the level of the individual T cell/antigen encounter. Mathematically, the model can be formulated as a linear programing optimization problem that can be implemented as a multiplicative update algorithm, which shows a rapid convergence to a stable state. The model constrains self-reactivity within a predefined threshold, but maintains repertoire diversity and cross reactivity which are key characteristics of human T cell immunity. We show further that the size of individual clones in the model repertoire becomes heterogeneous, and that new clones can establish themselves even when the repertoire has stabilized. Our study combines the salient features of the "danger" model of self/non-self discrimination with the concepts of quorum sensing, and extends repertoire generation models to encompass the establishment of tolerance. Furthermore, the dynamic and continuous repertoire reshaping, which underlies tolerance in this model, suggests opportunities for therapeutic intervention to achieve long-term tolerance following transplantation.	[Best, Katharine; Chain, Benny] UCL, Div Infect & Immun, London, England; [Best, Katharine] UCL, Ctr Math Phys & Engn Life Sci & Expt Biol CoMPLEX, London, England; [Watkins, Chris] Univ London, Dept Comp Sci, London, England	University of London; University College London; University of London; University College London; University of London	Chain, B (corresponding author), Div Infect & Immun, Cruciform Bldg,Gower St, London WC1E 6BT, England.	b.chain@ucl.ac.uk	Watkins, Christopher/E-5811-2013	Watkins, Christopher/0000-0001-9020-4530; Chain, Benny/0000-0002-7417-3970	Engineering and Physical Sciences Research Council [1079579] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Abdi K, 2012, J IMMUNOL, V188, P5981, DOI 10.4049/jimmunol.1102868; Alexander HK, 2011, B MATH BIOL, V73, P33, DOI 10.1007/s11538-010-9519-2; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Arora Sanjeev, 2012, THEOR COMPUT, V8, P121; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Bains I, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003102; Beltman JB, 2007, J EXP MED, V204, P771, DOI 10.1084/jem.20061278; Berkley AM, 2014, J IMMUNOL, V193, P3262, DOI 10.4049/jimmunol.1401870; Birnbaum ME, 2014, CELL, V157, P1073, DOI 10.1016/j.cell.2014.03.047; Britanova OV, 2014, J IMMUNOL, V192, P2689, DOI 10.4049/jimmunol.1302064; Burnet F M, 1976, CA Cancer J Clin, V26, P119, DOI 10.3322/canjclin.26.2.119; Butler TC, 2013, P NATL ACAD SCI USA, V110, P11833, DOI 10.1073/pnas.1222467110; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; Carneiro J, 2007, IMMUNOL REV, V216, P48; Creusot RJ, 2003, J IMMUNOL, V171, P240, DOI 10.4049/jimmunol.171.1.240; DEBOER RJ, 1994, J THEOR BIOL, V169, P375, DOI 10.1006/jtbi.1994.1160; Gascoigne NRJ, 2015, CURR OPIN IMMUNOL, V33, P86, DOI 10.1016/j.coi.2015.01.020; Hogquist KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; IBRAHIM MAA, 1995, IMMUNOL TODAY, V16, P181, DOI 10.1016/0167-5699(95)80118-9; Izawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048798; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Khailaie S, 2014, J IMMUNOL, V193, P5983, DOI 10.4049/jimmunol.1400889; Krogsgaard M, 2005, NAT IMMUNOL, V6, P239, DOI 10.1038/ni1173; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Moore JR, 2014, J THEOR BIOL, V357, P86, DOI 10.1016/j.jtbi.2014.04.034; Naderi N, 2011, TRANSPL P, V43, P3913, DOI 10.1016/j.transproceed.2011.10.040; Palmer E, 2009, NAT REV IMMUNOL, V9, P206, DOI 10.1038/nri2469; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Stepanek O, 2014, CELL, V159, P333, DOI 10.1016/j.cell.2014.08.042; Stirk ER, 2008, J THEOR BIOL, V255, P237, DOI 10.1016/j.jtbi.2008.07.017; Stirk ER, 2010, J THEOR BIOL, V265, P396, DOI 10.1016/j.jtbi.2010.05.004; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Thomas N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045262; Wooldridge L, 2012, J BIOL CHEM, V287, P1168, DOI 10.1074/jbc.M111.289488; Xu XF, 2012, J IMMUNOL, V188, P1168, DOI 10.4049/jimmunol.1101696; Zangi L, 2012, BLOOD, V120, P1647, DOI 10.1182/blood-2012-02-410803	44	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 7	2015	6								360	10.3389/fimmu.2015.00360	http://dx.doi.org/10.3389/fimmu.2015.00360			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CO8ZR	26300880	Green Published, gold			2022-12-18	WOS:000359461900001
J	Barrio, MM; Levy, EM; Mordoh, J				Marcela Barrio, Maria; Mariel Levy, Estrella; Mordoh, Jose			Editorial: "Cancer immunotherapy: lights and shadows"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer immunotherapy; immune checkpoint blockade; melanoma; mouse models; vaccines	CELLS		[Marcela Barrio, Maria; Mariel Levy, Estrella; Mordoh, Jose] Fdn Canc FUCA, Ctr Invest Oncol, Buenos Aires, DF, Argentina; [Mordoh, Jose] Fdn Inst Leloir, Buenos Aires, DF, Argentina; [Mordoh, Jose] Inst Alexander Fleming, Buenos Aires, DF, Argentina	Leloir Institute	Mordoh, J (corresponding author), Fdn Canc FUCA, Ctr Invest Oncol, Buenos Aires, DF, Argentina.	jmordoh@leloir.org.ar						Aris M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00144; Aris M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00046; Aris M, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/192719; Barrio MM, 2006, J IMMUNOTHER, V29, P444, DOI 10.1097/01.cji.0000208258.79005.5f; Beer TM, 2011, CLIN CANCER RES, V17, P4558, DOI 10.1158/1078-0432.CCR-10-3223; Pampena MB, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00013; Di Stasi A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00036; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Germain C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00067; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Mac Keon S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00243; Rowdo FPM, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00127; Pizzurro GA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00091; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Vela M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00012	16	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2015	6								350	10.3389/fimmu.2015.00350	http://dx.doi.org/10.3389/fimmu.2015.00350			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CN0XR	26217342	Green Published, gold			2022-12-18	WOS:000358138800002
J	Owens, BMJ; Steevels, TAM; Dudek, M; Walcott, D; Sun, MY; Mayer, A; Allan, P; Simmons, A				Owens, Benjamin M. J.; Steevels, Tessa A. M.; Dudek, Michael; Walcott, David; Sun, Mei-Yi; Mayer, Alice; Allan, Philip; Simmons, Alison			CD90(+) stromal cells are non-professional innate immune effectors of the human colonic mucosa (vol 4, 307, 2013)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Owens, Benjamin M. J.; Steevels, Tessa A. M.; Dudek, Michael; Walcott, David; Allan, Philip; Simmons, Alison] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Translat Gastroenterol Unit,Expt Med Div, Oxford OX3 9DU, England; [Sun, Mei-Yi; Mayer, Alice; Simmons, Alison] Univ Oxford, John Radcliffe Hosp, MRC Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Simmons, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Translat Gastroenterol Unit,Expt Med Div, Oxford OX3 9DU, England.	annabel.gordon@ndm.ox.ac.uk	Mayer, A/AAM-2083-2021	Mayer, A/0000-0002-6859-0612; Allan, Philip/0000-0003-2682-772X; Owens, Benjamin/0000-0003-4710-6841				Owens BMJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00307	1	1	1	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2015	6								325	10.3389/fimmu.2015.00325	http://dx.doi.org/10.3389/fimmu.2015.00325			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CL9EG	26157441	gold, Green Published			2022-12-18	WOS:000357277800001
J	Hafler, DA; Astier, AL				Hafler, David A.; Astier, Anne L.			Editorial: T cell regulation by the environment	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; environment; metabolism; microbiome; vitamin D; regulatory T cells; pathogens	AUTOIMMUNE-DISEASE; IMMUNE CHECKPOINTS		[Hafler, David A.] Yale Univ, Sch Med, New Haven, CT USA; [Astier, Anne L.] Univ Edinburgh, MRC, Ctr Inflammat Res, Edinburgh EH8 9YL, Midlothian, Scotland	Yale University; University of Edinburgh	Astier, AL (corresponding author), Univ Edinburgh, MRC, Ctr Inflammat Res, Edinburgh EH8 9YL, Midlothian, Scotland.	a.astier@ed.ac.uk	Astier, Anne L/A-1641-2008	Astier, Anne L/0000-0002-0144-3431				Appleby LJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00051; Bour-Jordan H, 2011, IMMUNOL REV, V241, P180, DOI 10.1111/j.1600-065X.2011.01011.x; Byersdorfer CA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00641; Chapman NM, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00686; Churlaud G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00171; Hayes CE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00100; Hoeppli RE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00061; Joller N, 2012, IMMUNOL REV, V248, P122, DOI 10.1111/j.1600-065X.2012.01136.x; Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868; Palmer CS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00001; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Phetsouphanh C, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00681; Pollizzi KN, 2014, NAT REV IMMUNOL, V14, P435, DOI 10.1038/nri3701; Ramsay G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00099; Schneider H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00619; Sharpe AH, 2009, IMMUNOL REV, V229, P5, DOI 10.1111/j.1600-065X.2009.00784.x	16	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2015	6								229	10.3389/fimmu.2015.00229	http://dx.doi.org/10.3389/fimmu.2015.00229			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CJ2NT	26029214	gold, Green Published			2022-12-18	WOS:000355322400002
J	Knopf, PM; Suri, PB				Knopf, Paul Mark; Suri, Parmjeet Behl			S. mansoni trapping in lungs contributes to resistance to reinfection	FRONTIERS IN IMMUNOLOGY			English	Review						S. mansoni; portacaval shunt; self-cure; resistance-to-reinfection; F2x (sera from twice-infected Fisher rats); W2x (sera from twice-infected Wistar-Furth rats); permissive vs. non-permissive hosts	SCHISTOSOMA-MANSONI; ADULT WORMS; VACCINE; INFECTION; RATS; ANTIBODIES; CERCARIAE; RECOVERY; PEPTIDE; EPITOPE	Worm transplantation studies show that physiological and reproductive status of the worm is influenced by the microenvironment of the host and critical for vaccine design. Worm migration studies in rats with Se-75-methionine labeled cercariae demonstrated that resistance to reinfection (R/R) requires a host immune response resulting in worm death. In permissive hosts, inflammation due to anti eggs immunity leads to host death, whereas in non-permissive hosts this is not the case due to reduced egg burdens. Eggs-induced pathology and inflammatory debris resulting from immune attack on worms are important for vaccine design. Protective immune responses are perhaps induced when naive hosts are vaccinated with either schistosome-derived molecules or attenuated cercariae as suggested by the induction of protective anti-parasite antibodies and monoclonals. However, these immunological strategies rarely produce 85-90% R/R as is achievable by portal-caval shunting. Alternatively, induction of anti -schistosoma immunity may induce portacaval shunting, seems highly unlikely although not yet tested. Differential screening with sera from twice-infected rats, protective (F2x) from Fisher vs. non-protective (W2x) from Wistar Furth rats, was used to identify candidate vaccine antigens.	[Knopf, Paul Mark] Brown Univ, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; [Suri, Parmjeet Behl] BCR Diagnost, Chandler, AZ USA	Brown University	Suri, PB (corresponding author), 77 Beechwood Dr, Cranston, RI 02921 USA.	pammisuri@gmail.com			Rockefeller Foundation; Edna McConnell Clark Foundation; WHO; NIH	Rockefeller Foundation; Edna McConnell Clark Foundation; WHO(World Health Organization); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We wish to thank Donato Cioli and Jonathan Kurtis for their invaluable insight in critiquing this manuscript; Sean Suri and Ami Shah with technical support. Without the financial grant support from Rockefeller Foundation, Edna McConnell Clark Foundation, WHO, NIH over the years, this project would not be possible.	CIOLI D, 1976, J IMMUNOL, V117, P59; Dougall AM, 2014, HUM VACC IMMUNOTHER, V10, P399, DOI 10.4161/hv.27057; ELSAGHIER AAF, 1989, PARASITOLOGY, V99, P365, DOI 10.1017/S0031182000059084; ELSHERBEINI M, 1990, EXP PARASITOL, V70, P72, DOI 10.1016/0014-4894(90)90087-S; Figueiredo BCP, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00022; Fuaad AAHA, 2015, BIOORGAN MED CHEM, V23, P1307, DOI 10.1016/j.bmc.2015.01.033; Fukushige M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00085; KNOPF PM, 1980, INT J PARASITOL, V10, P13, DOI 10.1016/0020-7519(80)90058-2; KNOPF PM, 1986, AM J TROP MED HYG, V35, P1173, DOI 10.4269/ajtmh.1986.35.1173; KNOPF PM, 1977, EXP PARASITOL, V41, P74, DOI 10.1016/0014-4894(77)90131-X; KNOPF PM, 1985, J PARASITOL, V71, P422, DOI 10.2307/3281532; KNOPF PM, 1980, INT J PARASITOL, V10, P197, DOI 10.1016/0020-7519(80)90049-1; LICHTENBERG FV, 1977, AM J PATHOL, V87, P105; MANGOLD BL, 1978, J PARASITOL, V64, P813, DOI 10.2307/3279508; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; Mo AX, 2014, AM J TROP MED HYG, V90, P54, DOI 10.4269/ajtmh.13-0467; Nguyen KB, 1997, VACCINES, V97, P213; Nixon CP, 2005, TRANSFUSION, V45, p81S, DOI 10.1111/j.1537-2995.2005.00540.x; Oliveira CR, 2012, SCI WORLD J, DOI 10.1100/2012/938457; Petzke MM, 2000, PARASITE IMMUNOL, V22, P381, DOI 10.1046/j.1365-3024.2000.00316.x; Pinheiro CS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/503068; PLATT J, 1969, SCIENCE, V166, P1115, DOI 10.1126/science.166.3909.1115; Siddiqui AA, 2011, HUM VACCINES, V7, P1192, DOI 10.4161/hv.7.11.17017; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; Suri PK, 1997, PARASITE IMMUNOL, V19, P515, DOI 10.1046/j.1365-3024.1997.d01-160.x; Wilson AR, 1989, PARASITOLOGY, V99, P283; Wilson RA, 2008, IMMUNOLOGY, V63, P173, DOI [10.1371/journal.pntd.0000290, DOI 10.1371/JOURNAL.PNTD.0000290]; Zhang WD, 2014, PARASITOL RES, V113, P2239, DOI 10.1007/s00436-014-3879-8	28	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2015	6								186	10.3389/fimmu.2015.00186	http://dx.doi.org/10.3389/fimmu.2015.00186			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI7IF	25954278	Green Published, gold			2022-12-18	WOS:000354935800001
J	Vanderberg, JP				Vanderberg, Jerome P.			Commentary on: Antibody and B cell responses to Plasmodium sporozoites	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						malaria; plasmodium; sporozoite; immunity; antibodies; blood; liver; mosquitoes	BERGHEI SPOROZOITES; CIRCUMSPOROZOITE PROTEIN; CULTURED-CELLS; FALCIPARUM; MALARIA; MACROPHAGES; MOSQUITOS; INVITRO; RELEASE; ENTRY		NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Vanderberg, JP (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.	vandej01@nyumc.org						Baer K, 2007, CELL MICROBIOL, V9, P397, DOI [10.1111/j.1462-5822.2006.00798.x, DOI 10.1111/J.1462-5822.2006.00798.X]; BEIER JC, 1992, EXP PARASITOL, V75, P248, DOI 10.1016/0014-4894(92)90185-D; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; DANFORTH HD, 1980, J PROTOZOOL, V27, P193, DOI 10.1111/j.1550-7408.1980.tb04680.x; Dups JN, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00625; GOLENDA CF, 1992, PARASITOL RES, V78, P563, DOI 10.1007/BF00936453; HOLLINGDALE MR, 1984, J IMMUNOL, V132, P909; HOLLINGDALE MR, 1982, J IMMUNOL, V128, P1929; Kebaier C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000399; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; NUSSENZWEIG RS, 1972, EXP PARASITOL, V31, P88, DOI 10.1016/0014-4894(72)90051-3; Pradel G, 2001, HEPATOLOGY, V33, P1154, DOI 10.1053/jhep.2001.24237; SEGUIN MC, 1989, J IMMUNOL, V143, P1716; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; VANDERBERG J, 1969, MIL MED, V134, P1183; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1990, J PROTOZOOL, V37, P528, DOI 10.1111/j.1550-7408.1990.tb01260.x	18	1	1	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2015	6								113	10.3389/fimmu.2015.00113	http://dx.doi.org/10.3389/fimmu.2015.00113			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI5QR	25852685	Green Published, gold			2022-12-18	WOS:000354814200001
J	Fredenburg, KM; Chan, EKL				Fredenburg, Kristianna M.; Chan, Edward K. L.			Our journey from the study of human autoantibodies to the microRNA world	FRONTIERS IN IMMUNOLOGY			English	Article						microRNA; autoantibody; GW body; endotoxin tolerance; IL-1 beta	GW BODIES; AUTOIMMUNITY; MICE	Our discovery of a novel cytoplasmic domain in HEp-2 cells recognized by the autoimmune serum of a patient led us on a journey into the world of microRNAs (miRNA). Our journey began with the identification and cloning of the novel glycine (G) tryptophan (W)-rich protein, GW182, and its close interaction with the miRNA-binding protein, argonaute2 (Ago2). Discovering the important relevance of GW182 with miRNA function was the igniting force that steered us toward understanding the role of miRNAs in autoimmunity and the innate immune response. This brief paper highlights our journey and key findings.	[Fredenburg, Kristianna M.; Chan, Edward K. L.] Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Chan, EKL (corresponding author), Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA.	echan@ufl.edu	Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503				Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Ceribelli A, 2012, CURR OPIN IMMUNOL, V24, P686, DOI 10.1016/j.coi.2012.07.011; Ceribelli A, 2011, FEBS LETT, V585, P3667, DOI 10.1016/j.febslet.2011.05.020; Chan EKL, 2013, ANN RHEUM DIS, V72, P90, DOI 10.1136/annrheumdis-2012-202203; Fritzler MJ, 2013, ADV EXP MED BIOL, V768, P5, DOI 10.1007/978-1-4614-5107-5_2; Nahid MA, 2015, J INNATE IM IN PRESS; Nahid MA, 2013, J IMMUNOL, V190, P1250, DOI 10.4049/jimmunol.1103060; Pauley KM, 2010, IMMUNOL CELL BIOL, V88, P205, DOI 10.1038/icb.2009.84; Remenyi J, 2010, BIOCHEM J, V428, P281, DOI 10.1042/BJ20100024; Satoh M, 2013, ADV EXP MED BIOL, V768, P45, DOI 10.1007/978-1-4614-5107-5_4; Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783; Stinton LM, 2011, CLIN EXP IMMUNOL, V163, P147, DOI 10.1111/j.1365-2249.2010.04288.x; Stittrich AB, 2010, NAT IMMUNOL, V11, P1057, DOI 10.1038/ni.1945; Yao B, 2013, ADV EXP MED BIOL, V768, P71, DOI 10.1007/978-1-4614-5107-5_6; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108	15	1	2	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2015	6								110	10.3389/fimmu.2015.00110	http://dx.doi.org/10.3389/fimmu.2015.00110			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI5QE	25814992	gold, Green Published			2022-12-18	WOS:000354812700001
J	Furuya, Y; Ludewick, HP; Mullbacher, A				Furuya, Yoichi; Ludewick, Herbert P.; Muellbacher, Arno			Mysteries of type I IFN response: benefits versus detriments	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						type I interferons; vaccine adjuvant; viral; bacterial	FRANCISELLA-TULARENSIS		[Furuya, Yoichi; Ludewick, Herbert P.] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; [Muellbacher, Arno] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol, Canberra, ACT 2601, Australia	Albany Medical College; Australian National University; John Curtin School of Medical Research	Furuya, Y (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA.	furuyay@mail.amc.edu		Ludewick, Herbert/0000-0001-5398-5112				Babb R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00267; Dhariwala MO, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00545; Eshleman EM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00431; Furuya AKM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00419; Furuya Y, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00355; Furuya Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025765; Henry T, 2010, J IMMUNOL, V184, P3755, DOI 10.4049/jimmunol.0902065; Metzger DW, 2007, ANN NY ACAD SCI, V1105, P266, DOI 10.1196/annals.1409.007; Tomasello E, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00526; Wijesundara DK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00412	10	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2015	6								21	10.3389/fimmu.2015.00021	http://dx.doi.org/10.3389/fimmu.2015.00021			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI2UW	25674090	gold, Green Published			2022-12-18	WOS:000354603800001
J	Gu, SY; Nawrocka, W; Adams, EJ				Gu, Siyi; Nawrocka, Wioletta; Adams, Erin J.			Sensing of pyrophosphate metabolites by V gamma 9 delta 2T cells	FRONTIERS IN IMMUNOLOGY			English	Review						V gamma 9V delta 2; phosphoantigens; T cells; T cell receptor; butyrophilins; B30.2	DELTA T-CELLS; NONPEPTIDIC MYCOBACTERIAL LIGANDS; RECEPTOR GAMMA-DELTA; ISOPRENOID BIOSYNTHESIS; MEVALONATE PATHWAY; (E)-4-HYDROXY-3-METHYL-BUT-2-ENYL PYROPHOSPHATE; PHOSPHORYLATED ANTIGENS; V-GAMMA-2V-DELTA-2 TCR; PRENYL PYROPHOSPHATES; BIOLOGICAL-ACTIVITY	The predominant population of gamma delta T cells in human blood express a T cell receptor (TCR) composed of a V gamma 9 (Vy2 in an alternate nomenclature) and V delta 2 domains. These cells came into the limelight when it was discovered they can respond to certain microbial infections and tumorigenic cells through the detection of small, pyrophosphate containing organic molecules collectively called "phosphoantigens" or "pAgs." These molecules are intermediates in both eukaryotic and prokaryotic metabolic pathways. Chemical variants of these intermediates have been used in the clinic to treat a range of different cancers, however, directed optimization of these molecules requires a full understanding of their mechanism of action on target cells. We and others have identified a subclass of butyrophilin-related molecules (BTN3A1-3) that are directly involved in pAg sensing in the target cell, leading to engagement and activation of the T cell through the TCR. Our data and that of others support the pAg binding site to be the intracellular B30.2 domain of BTN3A1, which is the only isoform capable of mediating pAg-dependent stimulation of V gamma 9V delta 2T cells. Here, we review the data demonstrating pAg binding to the B30.2 domain and our studies of the structural conformations of the BTN3A extracellular domains. Finally, we synthesize a model linking binding of pAg to the intracellular domain with T cell detection via the extracellular domains in an "inside-out" signaling mechanism of the type characterized first for integrin molecule signaling. We also explore the role of V gamma 9V delta 2 TCR variability in the CDR3 gamma and delta loops and how this may modulate V gamma 9V delta 2 cells as a population in surveillance of human health and disease.	[Gu, Siyi; Nawrocka, Wioletta; Adams, Erin J.] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; [Adams, Erin J.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; [Adams, Erin J.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Adams, EJ (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 929 E 57thStreet,GCISW236, Chicago, IL 60637 USA.	ejadams@uchicago.edu	Gu, Siyi/AAI-2910-2020	Gu, Siyi/0000-0002-0711-7442	National Institutes of Health (NIH) [R56_AI097386, ROI_AI073922]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health (NIH) grants R56_AI097386 and ROI_AI073922 to Erin J. Adams.	Abeler-Dorner L, 2012, TRENDS IMMUNOL, V33, P34, DOI 10.1016/j.it.2011.09.007; Altincicek B, 2001, J IMMUNOL, V166, P3655, DOI 10.4049/jimmunol.166.6.3655; Arnett HA, 2014, NAT REV IMMUNOL, V14, P559, DOI 10.1038/nri3715; Asslan R, 1999, BIOCHEM BIOPH RES CO, V260, P699, DOI 10.1006/bbrc.1999.0945; Belmant C, 2000, FASEB J, V14, P1669, DOI 10.1096/fj.99-0909fje; Boedec A, 2008, J MED CHEM, V51, P1747, DOI 10.1021/jm701101g; Born WK, 2013, CELL MOL IMMUNOL, V10, P13, DOI 10.1038/cmi.2012.45; Bukowski JF, 1998, J IMMUNOL, V161, P286; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; Chen ZW, 2013, CELL MOL IMMUNOL, V10, P58, DOI 10.1038/cmi.2012.46; Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Davey MS, 2014, J IMMUNOL, V193, P3704, DOI 10.4049/jimmunol.1401018; Davey MS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002040; Decaup E, 2014, IMMUNOL LETT, V161, P133, DOI 10.1016/j.imlet.2014.05.011; Devilder MC, 2006, J IMMUNOL, V176, P1386, DOI 10.4049/jimmunol.176.3.1386; Dieli F, 2000, EUR J IMMUNOL, V30, P1512, DOI 10.1002/(SICI)1521-4141(200005)30:5<1512::AID-IMMU1512>3.0.CO;2-3; Eberl M, 2003, FEBS LETT, V544, P4, DOI 10.1016/S0014-5793(03)00483-6; Espinosa E, 2001, J BIOL CHEM, V276, P18337, DOI 10.1074/jbc.M100495200; Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500; Grunder C, 2012, BLOOD, V120, P5153, DOI 10.1182/blood-2012-05-432427; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; Hintz M, 2001, FEBS LETT, V509, P317, DOI 10.1016/S0014-5793(01)03191-X; Hsiao CHC, 2014, CHEM BIOL, V21, P945, DOI 10.1016/j.chembiol.2014.06.006; James LC, 2007, P NATL ACAD SCI USA, V104, P6200, DOI 10.1073/pnas.0609174104; Karunakaran MM, 2014, IMMUNOGENETICS, V66, P243, DOI 10.1007/s00251-014-0763-8; KAUR I, 1993, J IMMUNOL, V150, P2046; Kazen AR, 2011, P NATL ACAD SCI USA, V108, pE332, DOI 10.1073/pnas.1105105108; Kisielow J, 2013, CURR OPIN IMMUNOL, V25, P181, DOI 10.1016/j.coi.2013.03.002; Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914; LANG F, 1995, J IMMUNOL, V154, P5986; Li JQ, 2009, J IMMUNOL, V182, P8118, DOI 10.4049/jimmunol.0900101; Lombard J, 2011, MOL BIOL EVOL, V28, P87, DOI 10.1093/molbev/msq177; Luoma AM, 2014, TRENDS IMMUNOL, V35, P613, DOI 10.1016/j.it.2014.09.003; Miyagawa F, 2001, J IMMUNOL, V167, P6773, DOI 10.4049/jimmunol.167.12.6773; Morita CT, 2000, SPRINGER SEMIN IMMUN, V22, P191, DOI 10.1007/s002810000042; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; Morita CT, 2001, J IMMUNOL, V167, P36, DOI 10.4049/jimmunol.167.1.36; Nedellec S, 2010, SEMIN IMMUNOL, V22, P199, DOI 10.1016/j.smim.2010.04.004; Palakodeti A, 2012, J BIOL CHEM, V287, P32780, DOI 10.1074/jbc.M112.384354; Poquet Y, 1996, EUR J IMMUNOL, V26, P2344, DOI 10.1002/eji.1830261011; Puan KJ, 2007, INT IMMUNOL, V19, P657, DOI 10.1093/intimm/dxm031; Rhodes DA, 2005, IMMUNOLOGY, V116, P411, DOI 10.1111/j.1365-2567.2005.02248.x; Rhodes DA, 2001, GENOMICS, V71, P351, DOI 10.1006/geno.2000.6406; Riano F, 2014, EUR J IMMUNOL, V44, P2571, DOI 10.1002/eji.201444712; Rojas RE, 2002, INFECT IMMUN, V70, P4019, DOI 10.1128/IAI.70.8.4019-4027.2002; Salio M, 2014, ANNU REV IMMUNOL, V32, P323, DOI 10.1146/annurev-immunol-032713-120243; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Scotet E, 2005, IMMUNITY, V22, P71, DOI 10.1016/j.immuni.2004.11.012; Silva MT, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00071; STURM E, 1992, IMMUNOGENETICS, V36, P294; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; Thompson K, 2006, BLOOD, V107, P651, DOI 10.1182/blood-2005-03-1025; Vantourout P, 2008, MOL IMMUNOL, V45, P485, DOI 10.1016/j.molimm.2007.05.026; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Vavassori S, 2013, NAT IMMUNOL, V14, P908, DOI 10.1038/ni.2665; Wang H, 2013, J IMMUNOL, V191, P1029, DOI 10.4049/jimmunol.1300658; Wang H, 2010, J IMMUNOL, V184, P6209, DOI 10.4049/jimmunol.1000231; Wei HY, 2008, J IMMUNOL, V181, P4798, DOI 10.4049/jimmunol.181.7.4798	61	1	1	1	20	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 22	2015	5						1	10		10.3389/fimmu.2014.00688	http://dx.doi.org/10.3389/fimmu.2014.00688			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI2UH		Green Published, gold			2022-12-18	WOS:000354602200001
J	Takatsu, K				Takatsu, Kiyoshi			Revisiting the identification and ciNA cloning of T cell-replacing factor/interleukin-5	FRONTIERS IN IMMUNOLOGY			English	Article						B cell differentiation factor; eosinophil differentiation factor; B cell growth factor; TRF; IL-5	GROWTH FACTOR-II; FACTOR TRF; COMPLEMENTARY-DNA; ENHANCING FACTOR; LYMPHOCYTES-B; CDNA; INTERLEUKIN-2; ESTABLISHMENT; EXPRESSION; DISTINCT	This is a perspective based on the paper "Cloning of complementary DNA encoding T cell-replacing factor and identity with B cell growth factor II," by Kinashi et al. (1). We have been interested in understanding the molecular basis of T-B cell cooperation for antibody formation. Although many investigators had described a number of different soluble factors that appeared to have biological relevance to T-B cell interactions, molecular basis of such active substances remained unknown for a long period of time. In this perspective, I will briefly summarize the history of the initial discovery of T cell-replacing factor/B cell growth factor II that appeared to be involved in B cell growth and differentiation, and outline the discovery and characterization of interleukin-5. Studies of interleukin-5 have provided strong evidence that a single cytokine exerts a variety of activities on diverse target cells.	[Takatsu, Kiyoshi] Toyama Prefectural Inst Pharmaceut Res, Imizu, Toyama, Japan; [Takatsu, Kiyoshi] Grad Sch Med & Pharmaceut Sci, Dept Immunobiol & Pharmacol Genet, Toyama, Toyama, Japan		Takatsu, K (corresponding author), Toyama Prefectural Inst Pharmaceut Res, Imizu, Toyama, Japan.	kiyoshi.takastu@pref.toyama.lg.jp			MEXT of the Japanese Government; Japan Society for the Promotion of Science; Japan Science and Technology Agency	MEXT of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	This work is partly supported by Grant-in-Aid for Scientific Research from MEXT of the Japanese Government; Grants from the Japan Society for the Promotion of Science and Japan Science and Technology Agency. The author thanks Toyama Prefecture for continued support of our laboratory.	[Anonymous], PROG IMMUNOL, DOI DOI 10.1016/B978-0-12-057550-3.50033-8; HARADA N, 1987, P NATL ACAD SCI USA, V84, P4581, DOI 10.1073/pnas.84.13.4581; HARADA N, 1985, J IMMUNOL, V134, P3944; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; KINASHI T, 1986, NATURE, V324, P70, DOI 10.1038/324070a0; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OGARRA A, 1986, P NATL ACAD SCI USA, V83, P5228, DOI 10.1073/pnas.83.14.5228; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; RAJEWSKY K, 1969, J EXP MED, V129, P1131, DOI 10.1084/jem.129.6.1131; SANO Y, 1984, J IMMUNOL, V133, P629; SCHIMPL A, 1972, NATURE-NEW BIOL, V237, P15, DOI 10.1038/newbio237015a0; SWAIN SL, 1982, J EXP MED, V156, P1821, DOI 10.1084/jem.156.6.1821; TAKAHASHI T, 1990, MOL IMMUNOL, V27, P911, DOI 10.1016/0161-5890(90)90158-V; TAKATSU K, 1980, J IMMUNOL, V124, P2414; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAKATSU K, 1980, J IMMUNOL, V125, P2646; TAKATSU K, 1974, IMMUNOCHEMISTRY, V11, P107, DOI 10.1016/0019-2791(74)90324-3; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388	21	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2014	5								639	10.3389/fimmu.2014.00639	http://dx.doi.org/10.3389/fimmu.2014.00639			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1YF	25566252	Green Published, gold			2022-12-18	WOS:000354540400001
J	Roy, AL; Roeder, RG				Roy, Ananda L.; Roeder, Robert G.			Cnromatin and transcriptional tango on the immune dance floor	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune response; transcription; promoter; enhancer; chromatin	CELL DEVELOPMENT; CHROMATIN; RECOMBINATION; MECHANISMS; GENES; LOCUS		[Roy, Ananda L.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Programs Immunol & Genet, Boston, MA 02111 USA; [Roeder, Robert G.] Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10021 USA	Tufts University; Rockefeller University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Programs Immunol & Genet, Boston, MA 02111 USA.	ananda.roy@tufts.edu; roeder@mail.rockefeller.edu						Atchison ML, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00045; Bhatt D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00071; Birshtein BK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00163; Bossen C, 2012, ANNU REV IMMUNOL, V30, P337, DOI 10.1146/annurev-immunol-020711-075003; Chao J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00100; Chaumeil J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00423; Choi NM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00049; Choukrallah MA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00156; Corcoran L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00108; Devaiah BN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00476; Fowler T, 2011, MOL CELL, V44, P348, DOI 10.1016/j.molcel.2011.09.014; Guertin MJ, 2013, CURR OPIN GENET DEV, V23, P116, DOI 10.1016/j.gde.2012.11.008; Hamel KM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00139; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Johnson K, 2009, ADV EXP MED BIOL, V650, P133; Kato L, 2012, J IMMUNOL, V188, P3559, DOI 10.4049/jimmunol.1102397; Kenter AL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00500; Kurosaki T, 2010, ANNU REV IMMUNOL, V28, P21, DOI 10.1146/annurev.immunol.021908.132541; Levin-Klein R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00240; Li GD, 2013, TRENDS IMMUNOL, V34, P460, DOI 10.1016/j.it.2013.03.006; Naito T, 2011, INT IMMUNOL, V23, P661, DOI 10.1093/intimm/dxr078; Ratliff ML, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00113; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Roy AL, 2011, TRENDS IMMUNOL, V32, P532, DOI 10.1016/j.it.2011.06.012; Rudolf R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00021; Santos PM, 2011, CURR OPIN IMMUNOL, V23, P163, DOI 10.1016/j.coi.2010.11.014; Sleckman BP, 2012, J IMMUNOL, V188, P7, DOI 10.4049/jimmunol.1103195; Smale ST, 2014, ANNU REV IMMUNOL, V32, P489, DOI 10.1146/annurev-immunol-031210-101303; Vaidyanathan B, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00120; Zhang YB, 2013, NATURE, V504, P306, DOI 10.1038/nature12716	30	1	1	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 15	2014	5								631	10.3389/fimmu.2014.00631	http://dx.doi.org/10.3389/fimmu.2014.00631			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1WW	25566246	Green Published, gold			2022-12-18	WOS:000354536800001
J	Gery, I				Gery, Igal			The definition of lymphocyte activating factor: giving a Helping Hand to Serendipity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						interleukin-1; lymphocyte activating factor; cytokines; macrophages; thymocytes	DELAYED HYPERSENSITIVITY; POTENTIATION; VITRO; MITOGENS; MEDIATOR(S); RESPONSES; MECHANISM; CELLS		NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Gery, I (corresponding author), NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	geryi@nei.nih.gov						Bach F H, 1970, Cell Immunol, V1, P219, DOI 10.1016/0008-8749(70)90009-2; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; DAVID JR, 1964, J IMMUNOL, V93, P264; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; GERSHON RK, 1974, J IMMUNOL, V112, P215; GERY I, 1974, CELL IMMUNOL, V11, P162, DOI 10.1016/0008-8749(74)90016-1; GERY I, 1972, J EXP MED, V136, P128, DOI 10.1084/jem.136.1.128; GERY I, 1972, J IMMUNOL, V108, P1088; GERY I, 1971, J IMMUNOL, V107, P1778; GERY I, 1972, J EXP MED, V136, P143, DOI 10.1084/jem.136.1.143; GORDON J, 1965, NATURE, V208, P795, DOI 10.1038/208795a0; KASAKURA S, 1965, NATURE, V208, P794, DOI 10.1038/208794a0; RUDDLE NH, 1968, J EXP MED, V128, P1267, DOI 10.1084/jem.128.6.1267; SMITH KA, 1980, J EXP MED, V151, P1551, DOI 10.1084/jem.151.6.1551	14	1	1	2	4	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 28	2014	5								610	10.3389/fimmu.2014.00610	http://dx.doi.org/10.3389/fimmu.2014.00610			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1VD	25506345	Green Published, gold			2022-12-18	WOS:000354532100001
J	Zhang, GL; Keskin, DB; Lin, HN; Lin, HH; DeLuca, DS; Leppanen, S; Milford, EL; Reinherz, EL; Brusic, V				Zhang, Guang Lan; Keskin, Derin B.; Lin, Hsin-Nan; Lin, Hong Huang; DeLuca, David S.; Leppanen, Scott; Milford, Edgar L.; Reinherz, Ellis L.; Brusic, Vladimir			Human leukocyte antigen typing using a knowledge base coupled with a high-throughput oligonucleotide probe array analysis	FRONTIERS IN IMMUNOLOGY			English	Article						HLA typing; HLA disease association; population typing	STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; HLA CLASS-I; INDUCED HYPERSENSITIVITY REACTIONS; HLA-B-ASTERISK-1502 ALLELE; RISK-FACTOR; CARBAMAZEPINE; LOCI; SUSCEPTIBILITY; ASSOCIATION	Human leukocyte antigens (HLA) are important biomarkers because multiple diseases, drug toxicity, and vaccine responses reveal strong HLA associations. Current clinical HLA typing is an elimination process requiring serial testing. We present an alternative in situ synthesized DNA-based microarray method that contains hundreds of thousands of probes representing a complete overlapping set covering 1,610 clinically relevant HLA class I alleles accompanied by computational tools for assigning HLA type to 4-digit resolution. Our proof-of-concept experiment included 21 blood samples, 18 cell lines, and multiple controls. The method is accurate, robust, and amenable to automation. Typing errors were restricted to homozygous samples or those with very closely related alleles from the same locus, but readily resolved by targeted DNA sequencing validation of flagged samples. High-throughput HLA typing technologies that are effective, yet inexpensive, can be used to analyze the world's populations, benefiting both global public health and personalized health care.	[Zhang, Guang Lan; Keskin, Derin B.; Lin, Hsin-Nan; Lin, Hong Huang; DeLuca, David S.; Reinherz, Ellis L.; Brusic, Vladimir] Harvard Univ, Sch Med, Canc Vaccine Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA; [Zhang, Guang Lan; Brusic, Vladimir] Boston Univ, Dept Comp Sci, Metropolitan Coll, Boston, MA 02215 USA; [Keskin, Derin B.; Milford, Edgar L.; Reinherz, Ellis L.; Brusic, Vladimir] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Keskin, Derin B.; Reinherz, Ellis L.] Dana Farber Canc Inst, Dept Med Oncol, Immunobiol Lab, Boston, MA 02115 USA; [Lin, Hsin-Nan] Acad Sinica, Inst Informat Sci, Taipei, Taiwan; [Lin, Hong Huang] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Leppanen, Scott] Agilent Technol, Santa Clara, CA USA; [Milford, Edgar L.] Brigham & Womens Hosp, Histocompatibil & Tissue Typing Lab, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Boston University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Academia Sinica - Taiwan; Boston University; Agilent Technologies; Harvard University; Brigham & Women's Hospital	Brusic, V (corresponding author), Harvard Univ, Sch Med, Canc Vaccine Ctr, Dana Farber Canc Inst, 77 Ave Louis Pasteur,HIM 401, Boston, MA 02115 USA.	vladimir_brusic@dfci.harvard.edu	Lin, Hsin-Nan/AFL-1244-2022; Lin, Honghuang/A-3269-2019; Lin, Hsin-Nan/AFI-7411-2022; Brusic, Vladimir/B-1478-2008	Lin, Honghuang/0000-0003-3043-3942; Lin, Hsin-Nan/0000-0001-7225-7161; Brusic, Vladimir/0000-0003-0523-5266	NIH [U01 AI90043, U01 AI089859]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the NIH grants U01 AI90043 and U01 AI089859.	Agilent SurePrint Technology, 0000 CONT CTR MICR D; Albayrak A, 2011, BIOCHEM GENET, V49, P258, DOI 10.1007/s10528-010-9404-6; Alfirevic A, 2010, PHARMACOGENOMICS, V11, P497, DOI [10.2217/pgs.10.12, 10.2217/PGS.10.12]; Amiel J.L, 1967, HISTOCOMPAT TEST, V1967, P79; Boegel S, 2012, GENOME MED, V4, DOI 10.1186/gm403; Boisgerault F, 1996, J CLIN INVEST, V98, P2764, DOI 10.1172/JCI119102; Bray RA, 2008, BIOL BLOOD MARROW TR, V14, P45, DOI 10.1016/j.bbmt.2008.06.014; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Consolandi C, 2003, HUM IMMUNOL, V64, P168, DOI 10.1016/S0198-8859(02)00685-7; Dettling M, 2007, PHARMACOGENOMICS J, V7, P325, DOI 10.1038/sj.tpj.6500423; DURANDY A, 1982, PRENATAL DIAG, V2, P109, DOI 10.1002/pd.1970020206; Feng C, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-85; Fernandez-Vina MA, 2013, BLOOD, V121, P4603, DOI 10.1182/blood-2013-02-481945; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; Guo Z, 1999, Rev Immunogenet, V1, P220; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]; Ikeda H, 2010, EPILEPSIA, V51, P297, DOI 10.1111/j.1528-1167.2009.02269.x; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Itoh Y, 2005, IMMUNOGENETICS, V57, P717, DOI 10.1007/s00251-005-0048-3; Kaneko K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-454; Kaniwa N, 2010, EPILEPSIA, V51, P2461, DOI 10.1111/j.1528-1167.2010.02766.x; Keresztury L, 2003, AM J FOREN MED PATH, V24, P70; Kibbe WA, 2007, NUCLEIC ACIDS RES, V35, pW43, DOI 10.1093/nar/gkm234; Kim SH, 2010, PHARMACOGENOMICS, V11, P879, DOI [10.2217/pgs.10.54, 10.2217/PGS.10.54]; Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x; Lam TH, 2013, HEREDITY, V111, P131, DOI 10.1038/hdy.2013.27; Lank SM, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-378; Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386; Lin BK, 2006, AM J EPIDEMIOL, V164, P1, DOI 10.1093/aje/kwj175; Lin LC, 2009, KAOHSIUNG J MED SCI, V25, P82, DOI 10.1016/S1607-551X(09)70045-2; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; McKusick VA, 2007, AM J HUM GENET, V80, P588, DOI 10.1086/514346; Nakaoka H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060793; Ovsyannikova IG, 2012, VACCINE, V30, P2146, DOI 10.1016/j.vaccine.2012.01.038; Ozeki T, 2011, HUM MOL GENET, V20, P1034, DOI 10.1093/hmg/ddq537; Palmisano GL, 2005, AUTOIMMUN REV, V4, P510, DOI 10.1016/j.autrev.2005.04.011; PANAYI GS, 1978, BMJ-BRIT MED J, V2, P1326, DOI 10.1136/bmj.2.6148.1326; Pellicano R, 1997, J AM ACAD DERMATOL, V36, P782, DOI 10.1016/S0190-9622(97)80347-7; Pirmohamed M, 2006, AAPS J, V8, pE20, DOI 10.1208/aapsj080103; Prugnolle F, 2005, CURR BIOL, V15, P1022, DOI 10.1016/j.cub.2005.04.050; Robinson J, 2013, NUCLEIC ACIDS RES, V41, pD1222, DOI 10.1093/nar/gks949; ROUJEAU JC, 1987, ARCH DERMATOL, V123, P1171, DOI 10.1001/archderm.123.9.1171; Shiina T, 2009, J HUM GENET, V54, P15, DOI 10.1038/jhg.2008.5; Solberg OD, 2008, HUM IMMUNOL, V69, P443, DOI 10.1016/j.humimm.2008.05.001; Spellman SR, 2012, BLOOD, V120, P259, DOI 10.1182/blood-2012-03-379032; Theseira M, 2011, GENET ENG BIOTECHN N, V31, P66; Vina MAF, 2012, PHILOS T R SOC B, V367, P820, DOI 10.1098/rstb.2011.0320; Wang CL, 2012, P NATL ACAD SCI USA, V109, P8676, DOI 10.1073/pnas.1206614109; Woolhouse MEJ, 2002, NAT GENET, V32, P569, DOI 10.1038/ng1202-569	58	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2014	5						1	12	597	10.3389/fimmu.2014.00597	http://dx.doi.org/10.3389/fimmu.2014.00597			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1UX	25505899	Green Published, gold			2022-12-18	WOS:000354531500001
J	Smith, KA				Smith, Kendall A.			On discovering thymus-marrow synergism	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						thymus; bone marrow; sheep red blood cells; stem cells; thymus-marrow synergism	CELL		Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA.							CLAMAN HN, 1966, P SOC EXP BIOL MED, V122, P1167; Good R.A., 1964, THYMUS IMMUNOBIOLOGY; Miller JFAP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00411; MILLER JF, 1961, LANCET, V2, P748; MILLER JFAP, 1962, PROC R SOC SER B-BIO, V156, P415, DOI 10.1098/rspb.1962.0048; MITCHELL GF, 1968, J EXP MED, V128, P821, DOI 10.1084/jem.128.4.821; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MITCHISON N A, 1971, European Journal of Immunology, V1, P10, DOI 10.1002/eji.1830010103; Mitchison NA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00377	9	1	1	1	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2014	5								588	10.3389/fimmu.2014.00588	http://dx.doi.org/10.3389/fimmu.2014.00588			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1TO	25484885	Green Published, gold			2022-12-18	WOS:000354527700001
J	Huang, FP				Huang, Fang-Ping			Autoimmuno-anti-tumor immunity - understanding the immune responses against "self" and "altered-self"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmunity; cancer; inflammation; tumorigenesis; immune regulation; immunosuppression; anti-tumor immunity; tumor immunotherapy	INFLAMMATION; CANCER; IMMUNOTHERAPY; IL-10		[Huang, Fang-Ping] Univ London Imperial Coll Sci Technol & Med, London, England; [Huang, Fang-Ping] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of Hong Kong	Huang, FP (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.	fp.huang@imperial.ac.uk			Arthritis Research UK [18523] Funding Source: Medline; Versus Arthritis [18523] Funding Source: Medline	Arthritis Research UK(Versus Arthritis); Versus Arthritis(Versus Arthritis)		Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Chen YX, 2007, J IMMUNOL, V179, P6009, DOI 10.4049/jimmunol.179.9.6009; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Huang FP, 2011, EUR J IMMUNOL, V41, P18, DOI 10.1002/eji.201040543; Ling GS, 2011, RHEUMATOLOGY, V50, P1773, DOI 10.1093/rheumatology/ker198; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Yang L, 2014, CELL DEATH DIFFER, V21, P1677, DOI 10.1038/cdd.2014.131; 1986, N ENGL J MED	11	1	1	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 14	2014	5								582	10.3389/fimmu.2014.00582	http://dx.doi.org/10.3389/fimmu.2014.00582			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1SM	25452757	Green Published, gold			2022-12-18	WOS:000354524700001
J	Lmamura, K; Akimitsu, N				Lmamura, Katsutoshi; Akimitsu, Nobuyoshi			Long non-cocing RNAs involved in immuune responses	FRONTIERS IN IMMUNOLOGY			English	Review						long non-coding RNA (IncRNA); innate immune response; NEAT1; translational repression	NONCODING RNA; MICRORNA REGULATION; TNF-ALPHA; EXPRESSION; GENE; ACTIVATION; IDENTIFICATION; TRANSCRIPTION; RELOCATION; POLYCOMB	A large number of human RNA transcripts, which do not encode proteins are defined as non-coding RNAs (ncRNAs).These ncRNAs are divided into two classes of different lengths; short and long ncRNAs. MicroRNAs are a major class of short ncRNAs, 22 nucleotides in length that regulate gene expression at the post-transcriptional level. Long non-coding RNAs (IncRNAs) are more than 200 nucleotides in length and play roles in various biological pathways. In this review, we summarize the functions of IncRNAs which regulate immune responses.	[Lmamura, Katsutoshi; Akimitsu, Nobuyoshi] Univ Tokyo, Radioisotope Ctr, Tokyo 1130032, Japan	University of Tokyo	Akimitsu, N (corresponding author), Univ Tokyo, Radioisotope Ctr, 2-11-16 Yayot, Tokyo 1130032, Japan.	akimitsu@ric.u-tokyo.ac.jp						Aguilo F, 2011, CANCER RES, V71, P5365, DOI 10.1158/0008-5472.CAN-10-4379; Brockdorff N, 2013, RNA, V19, P429, DOI 10.1261/rna.037598.112; Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925; Chen LL, 2010, CURR OPIN CELL BIOL, V22, P357, DOI 10.1016/j.ceb.2010.03.003; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Cui HC, 2014, EUR J IMMUNOL, V44, P2085, DOI 10.1002/eji.201344126; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Gomes AQ, 2013, INT J MOL SCI, V14, P16010, DOI 10.3390/ijms140816010; Gomez JA, 2013, CELL, V152, P743, DOI 10.1016/j.cell.2013.01.015; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gurtan AM, 2013, J MOL BIOL, V425, P3582, DOI 10.1016/j.jmb.2013.03.007; He ZS, 2014, RNA, V20, P1103, DOI 10.1261/rna.043075.113; Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39; Iacobazzi V, 2005, BIOCHEM J, V391, P613, DOI 10.1042/BJ20050776; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Iyengar BR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00047; Jeker LT, 2013, IMMUNOL REV, V253, P65, DOI 10.1111/imr.12061; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Li ZH, 2014, P NATL ACAD SCI USA, V111, P1002, DOI 10.1073/pnas.1313768111; Naganuma T, 2012, EMBO J, V31, P4020, DOI 10.1038/emboj.2012.251; Nagpal N, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00099; Olivieri F, 2014, CURR OPIN IMMUNOL, V29, P29, DOI 10.1016/j.coi.2014.03.006; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Primo MN, 2012, CYTOKINE, V60, P741, DOI 10.1016/j.cyto.2012.07.031; Saha S, 2006, J GEN VIROL, V87, P3285, DOI 10.1099/vir.0.82107-0; Sasaki YTF, 2009, P NATL ACAD SCI USA, V106, P2525, DOI 10.1073/pnas.0807899106; Scaria Vinod, 2013, Frontiers in Genetics, V3, P308, DOI 10.3389/fgene.2012.00308; Shi XF, 2015, MOL CARCINOGEN, V54, pE1, DOI 10.1002/mc.22120; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Song X, 2005, P NATL ACAD SCI USA, V102, P16905; Sonkoly E, 2008, CLIN EXP DERMATOL, V33, P312, DOI 10.1111/j.1365-2230.2008.02804.x; Sunwoo H, 2009, GENOME RES, V19, P347, DOI 10.1101/gr.087775.108; Vigneau S, 2003, J VIROL, V77, P5632, DOI 10.1128/JVI.77.10.5632-5638.2003; Witwer KW, 2010, J IMMUNOL, V184, P2369, DOI 10.4049/jimmunol.0902712; Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054; Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024; Zhang Q, 2013, MBIO, V4, DOI 10.1128/mBio.00596-12	39	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2014	5								573	10.3389/fimmu.2014.00573	http://dx.doi.org/10.3389/fimmu.2014.00573			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1SG		gold, Green Published			2022-12-18	WOS:000354524100002
J	Mattila, JT; Thomas, AC				Mattila, Joshua T.; Thomas, Anita C.			Nitric oxide synthase: non-canonical expression patterns	FRONTIERS IN IMMUNOLOGY			English	Article						NOS1; NOS2; NOS3; iNOS; eNOS; nNOS; nitric oxide; nitric oxide synthase	HUMAN NOS2 GENE; INOS; MACROPHAGES; ISOFORMS; CANCER; ANGIOGENESIS; TUBERCULOSIS; ACTIVATION; GRANULOMAS; EPITHELIUM	Science can move ahead by questioning established or canonical views and, so it may be with the enzymes, nitric oxide synthases (NOS). Nitric oxide (NO) is generated by NOS iso-forms that are often described by their tissue-specific expression patterns. NOS1 (nNOS) is abundant in neural tissue, NOS2 is upregulated in activated macrophages and known as inducible NOS (NOS), and NOS3 (eNOS) is abundant in endothelium where it regulates vascular tone.These isoforms are described as constitutive or inducible, but in this perspective we question the broad application of these labels. Are there instances where "constitutive" NOS (NOS1 and NOS3) are inducibly expressed; conversely, are there instances where NOS2 is constitutively expressed? NOS1 and NOS3 inducibility may be linked to post-translational regulation, making their actual patterns activity much more difficult to detect. Constitutive NOS2 expression has been observed in several tissues, especially the human pulmonary epithelium where it may regulate airway tone. These data suggest that expression of the three NOS enzymes may include non-established patterns. Such information should be useful in designing strategies to modulate these important enzymes in different disease states.	[Mattila, Joshua T.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA; [Thomas, Anita C.] Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England; [Thomas, Anita C.] Univ Bristol, Bristol Royal Infirm, Bristol CardioVasc, Bristol, Avon, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Bristol Royal Infirmary; University of Bristol; Bristol Royal Infirmary; University of Bristol	Mattila, JT (corresponding author), Univ Pittsburgh, Dept Microbiol & Mol Genet, 5065 Biomed Sci Tower 3,3501 Fifth Ave, Pittsburgh, PA 15260 USA.	jmattila@pitt.edu	Thomas, Anita C/E-1743-2011	Thomas, Anita C/0000-0002-3792-2653	NIH [RO1A103785]; Bill and Melinda Gates Foundation; British Heart Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); British Heart Foundation(British Heart Foundation)	We gratefully acknowledge JoAnne L. Flynn (University of Pittsburgh, Pittsburgh, PA, USA) for permission to image data on cynomolgus macaque lung. Joshua T. Matti la is supported in part by NIH RO1A103785 (JoAnne L. Flynn) and grants from the Bill and Melinda Gates Foundation (JoAnne L. Flynn). Anita C. Thomas is supported by funding from the British Heart Foundation.	ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954; Brennan PA, 2008, HEAD NECK-J SCI SPEC, V30, P208, DOI 10.1002/hed.20675; Choi HS, 2002, AM J RESP CRIT CARE, V166, P178, DOI 10.1164/rccm.2201023; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; Connelly L, 2003, J BIOL CHEM, V278, P26480, DOI 10.1074/jbc.M302238200; Crowell JA, 2003, MOL CANCER THER, V2, P815; DiGirolamo G, 2003, BRIT J PHARMACOL, V139, P1164, DOI 10.1038/sj.bjp.0705315; Esaki T, 1997, ATHEROSCLEROSIS, V128, P39, DOI 10.1016/S0021-9150(96)05976-X; Evans DM, 1996, J BONE MINER RES, V11, P300; Fitzpatrick B, 2008, NITRIC OXIDE-BIOL CH, V19, P217, DOI 10.1016/j.niox.2008.05.001; Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304; Forstermann U, 1998, FASEB J, V12, P773; Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532; Grimm EA, 2008, NITRIC OXIDE-BIOL CH, V19, P133, DOI 10.1016/j.niox.2008.04.009; Gross TJ, 2014, J IMMUNOL, V192, P2326, DOI 10.4049/jimmunol.1301758; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Huang Z, 2012, J BIOL CHEM, V287, P4492, DOI 10.1074/jbc.M111.315598; Jungi TW, 1996, VET IMMUNOL IMMUNOP, V54, P323, DOI 10.1016/S0165-2427(96)05690-5; Klotz T, 1998, CANCER, V82, P1897, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1897::AID-CNCR12>3.0.CO;2-O; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Lechner M, 2005, SEMIN CANCER BIOL, V15, P277, DOI 10.1016/j.semcancer.2005.04.004; Lewko B, 2001, MED SCI MONITOR, V7, P218; Lowenstein CJ, 2004, J CELL SCI, V117, P2865, DOI 10.1242/jcs.01166; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mattila JT, 2013, J IMMUNOL, V191, P773, DOI 10.4049/jimmunol.1300113; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Musicki B, 2009, J ANDROL, V30, P352, DOI 10.2164/jandrol.108.006999; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Obermajer N, 2013, J EXP MED, V210, P1433, DOI 10.1084/jem.20121277; Perner A, 2002, SCAND J GASTROENTERO, V37, P944, DOI 10.1080/003655202760230919; Pessanha AP, 2012, FEMS IMMUNOL MED MIC, V66, P265, DOI 10.1111/j.1574-695X.2012.01012.x; Roberts PJ, 2001, J CLIN PATHOL, V54, P293, DOI 10.1136/jcp.54.4.293; Ruscheweyh R, 2006, NEUROSCIENCE, V141, P977, DOI 10.1016/j.neuroscience.2006.04.010; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; Schmidt N, 2010, BIOCHEM PHARMACOL, V79, P722, DOI 10.1016/j.bcp.2009.10.012; Schneemann M, 2002, NAT IMMUNOL, V3, P102, DOI 10.1038/ni0202-102a; Schneemann M, 2007, J LEUKOCYTE BIOL, V81, P579, DOI 10.1189/jlb.1106702; Tang QB, 2007, EUR J NEUROSCI, V25, P2964, DOI 10.1111/j.1460-9568.2007.05576.x; Vakkala M, 2000, CLIN CANCER RES, V6, P2408; Venema RC, 2002, INT IMMUNOPHARMACOL, V2, P1755, DOI 10.1016/S1567-5769(02)00185-6; Vitek MP, 2006, ANTIOXID REDOX SIGN, V8, P893, DOI 10.1089/ars.2006.8.893; Weinberg JB, 1998, MOL MED, V4, P557, DOI 10.1007/BF03401758; Wilson KT, 1998, CANCER RES, V58, P2929; Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550; Wolf H, 2000, VIRCHOWS ARCH, V437, P662, DOI 10.1007/s004280000296; Wu J, 1998, EXP BRAIN RES, V118, P457, DOI 10.1007/s002210050302; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133	51	1	1	0	6	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 9	2014	5						1	5		10.3389/fimmu.2014.00478	http://dx.doi.org/10.3389/fimmu.2014.00478			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1GK		Green Published, gold			2022-12-18	WOS:000354491300001
J	Szomolay, B; Williams, T; Wooldridge, L; van den Berg, HA				Szomolay, Barbara; Williams, Tamsin; Wooldridge, Linda; van den Berg, Hugo Antonius			Co-receptor CD8-mediated modulation of T-cell receptor functional sensitivity and epitope recognition degeneracy (vol 4, pg 329, 2013)	FRONTIERS IN IMMUNOLOGY			English	Correction						corrigendum; T cell; T cell receptor; T cell repertoire; T cell response			[Szomolay, Barbara; van den Berg, Hugo Antonius] Univ Warwick, Coventry CV4 7AL, W Midlands, England; [Williams, Tamsin] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF10 3AX, S Glam, Wales; [Wooldridge, Linda] Univ Bristol, Fac Med & Vet Sci, Bristol, Avon, England	University of Warwick; Cardiff University; University of Bristol	van den Berg, HA (corresponding author), Univ Warwick, Coventry CV4 7AL, W Midlands, England.	hugo@maths.warwick.ac.uk						Szomolay B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00329	1	1	1	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2014	5								443	10.3389/fimmu.2014.00443	http://dx.doi.org/10.3389/fimmu.2014.00443			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0RW		gold, Green Accepted			2022-12-18	WOS:000354446600002
J	ten Brinke, A; Joosten, I; van Ham, SM; van Kooten, C; Prakken, BJ				ten Brinke, Anja; Joosten, Irma; van Ham, S. Marieke; van Kooten, Cees; Prakken, Berent Jan			Redefining strategies to introduce tolerance-inducing cellular therapy in human beings to combat autoimmunit and transplantation reactions	FRONTIERS IN IMMUNOLOGY			English	Article						tolerance; regulatory T cells; dendritic cells; regulatory agencies; autoimmunity; transplantation	VERSUS-HOST-DISEASE; DENDRITIC CELLS; REGULATORY CELLS; MICE; IMMUNOTHERAPY; INFUSION	Clinical translation of tolerance-inducing cell therapies requires a novel approach focused on innovative networks, patient involvement, and, foremost, a fundamental paradigm shift in thinking from both Academia, and Industry and Regulatory Agencies. Tolerance-inducing cell products differ essentially from conventional drugs. They are personalized and target interactive immunological networks to shift the balance toward tolerance. The human cell products are often absent or fundamentally different in animals. This creates important limitations of pre-clinical animal testing for safety and efficacy of these products and calls for novel translational approaches, which require the combined efforts of the different parties involved. Dedicated international and multidisciplinary consortia that focus on clinical translation are of utmost importance. They can help in informing and educating regulatory policy makers on the unique requirements for these cell products, ranging from preclinical studies in animals to in vitro human studies. In addition, they can promote reliable immunomonitoring tools. The development of tolerance-inducing cell products requires not only bench-to-bedside but also reverse translation, from bedside back to the bench.	[ten Brinke, Anja; van Ham, S. Marieke] Univ Amsterdam, Acad Med Ctr, Sanquin Blood Supply, Dept Immunopathol,Div Res, NL-1105 AZ Amsterdam, Netherlands; [ten Brinke, Anja; van Ham, S. Marieke] Univ Amsterdam, Acad Med Ctr, Sanquin Blood Supply, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Joosten, Irma] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Med Immunol, NL-6525 ED Nijmegen, Netherlands; [van Kooten, Cees] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; [Prakken, Berent Jan] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Ctr Mol & Cellular Immunol, Lab Translat Immunol, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	ten Brinke, A (corresponding author), Sanquin Blood Supply, Dept Immunopathol, Div Res, POB 9190, NL-1006 AD Amsterdam, Netherlands.	a.tenbrinke@sanquin.nl	van Kooten, Cees/E-5694-2018; Joosten, Irma/N-4418-2013	van Kooten, Cees/0000-0002-6257-0899; Joosten, Irma/0000-0003-2950-4977; ten Brinke, Anja/0000-0002-0135-7496	Sanquin Blood Supply; Landsteiner Foundation for Blood Transfusion Research; Dutch Kidney Foundation; Netherlands Organization of Scientific Research (NWO); European Union; Dutch Top Institute Pharma; Leo Pharma (Denmark); Dutch Arthritis Foundation; Child Health program of the UMC Utrecht; STW technology development; EU FP7 Framework program; European grant for European cooperation in science and technology	Sanquin Blood Supply; Landsteiner Foundation for Blood Transfusion Research; Dutch Kidney Foundation; Netherlands Organization of Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); European Union(European Commission); Dutch Top Institute Pharma; Leo Pharma (Denmark); Dutch Arthritis Foundation; Child Health program of the UMC Utrecht; STW technology development; EU FP7 Framework program; European grant for European cooperation in science and technology	The views expressed are inspired by an international symposium organized by the authors entitled: "Lessons learned from immune regulation; toward tolerance-inducing cellular therapies" held at the Royal Netherlands Academy of Arts and Sciences in Amsterdam on 16 and 17 October 2013. The authors received the grants for their work from Sanquin Blood Supply (internal not-for-profit grant) (Anja ten Brinke, S. Marieke van Ham), not-for-profit Landsteiner Foundation for Blood Transfusion Research (S. Marieke van Ham), Dutch Kidney Foundation (Cees van Kooten, Irma Joosten), the Netherlands Organization of Scientific Research (NWO) (Cees van Kooten), the European Union (Cees van Kooten, Berent Jan Prakken), Dutch Top Institute Pharma (Irma Joosten) and Leo Pharma (Denmark) (Irma Joosten), the Dutch Arthritis Foundation (Berent Jan Prakken), the Child Health program of the UMC Utrecht (Berent Jan Prakken), STW technology development (Berent Jan Prakken), the EU FP7 Framework program (Berent Jan Prakken), and European grant for European cooperation in science and technology (Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies) (Anja ten Brinke, S. Marieke van Ham).	Bonham CA, 2002, J IMMUNOL, V169, P3382, DOI 10.4049/jimmunol.169.6.3382; Braun S, 2013, J GENE MED, V15, P397, DOI 10.1002/jgm.2747; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Di IM, 2011, BLOOD, V117, P3921, DOI [10.1182/blood-2010-10-311894, DOI 10.1182/BLOOD-2010-10-311894]; Feldmann M, 2008, IMMUNOL REV, V223, P7, DOI 10.1111/j.1600-065X.2008.00626.x; Geissler EK, 2012, TRANSPLANT RES, V1, DOI [10.1186/2047-1440-1-10, 10.1186/2047-1440-1-11]; Gordon JR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00007; Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731; Hutchinson JA, 2011, J IMMUNOL, V187, P2072, DOI 10.4049/jimmunol.1100762; Ledford H, 2008, NATURE, V453, P843, DOI 10.1038/453843a; Marek-Trzonkowska N, 2013, PEDIATR DIABETES, V14, P322, DOI 10.1111/pedi.12029; Martin S, 2001, NEW ENGL J MED, V345, P1036, DOI 10.1056/NEJMoa010465; Moreau A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00218; Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011; Pfoertner S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r54; Robles-Carrillo L, 2010, J IMMUNOL, V185, P1577, DOI 10.4049/jimmunol.0903888; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Singer BD, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00046; Stenger EO, 2012, BLOOD, V119, P5088, DOI 10.1182/blood-2011-11-364091; Sung NS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004719; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	23	1	1	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 15	2014	5								392	10.3389/fimmu.2014.00392	http://dx.doi.org/10.3389/fimmu.2014.00392			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH9ZZ	25177323	Green Published, gold			2022-12-18	WOS:000354396600001
J	Selmi, C; Cavaciocchi, F; Lleo, A; Cheroni, C; De Francesco, R; Lombardi, SA; De Santis, M; Meda, F; Raimondo, MG; Crotti, C; Folci, M; Zammataro, L; Mayo, MJ; Bach, N; Shimoda, S; Gordon, SC; Miozzo, M; Invernizzi, P; Podda, M; Scavelli, R; Martin, MR; Seldin, MF; LaSalle, JM; Gershwin, ME				Selmi, Carlo; Cavaciocchi, Francesca; Lleo, Ana; Cheroni, Cristina; De Francesco, Raffaele; Lombardi, Simone A.; De Santis, Maria; Meda, Francesca; Raimondo, Maria Gabriella; Crotti, Chiara; Folci, Marco; Zammataro, Luca; Mayo, Marlyn J.; Bach, Nancy; Shimoda, Shinji; Gordon, Stuart C.; Miozzo, Monica; Invernizzi, Pietro; Podda, Mauro; Scavelli, Rossana; Martin, Michelle R.; Seldin, Michael F.; LaSalle, Janine M.; Gershwin, M. Eric			Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis (vol 5, pg 128, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction						autoimmune cholangitis; epigenetics; environment; DNA methylation; PBC			[Selmi, Carlo; Cavaciocchi, Francesca; Lombardi, Simone A.; De Santis, Maria; Meda, Francesca; Raimondo, Maria Gabriella; Crotti, Chiara; Folci, Marco; Zammataro, Luca; Podda, Mauro] Humanitas Clin & Res Ctr, Div Rheumatol & Clin Immunol, Milan, Italy; [Selmi, Carlo; Gershwin, M. Eric] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Cavaciocchi, Francesca; De Santis, Maria] Univ Milan, BIOMETRA Dept, Milan, Italy; [Lleo, Ana; Invernizzi, Pietro] Humanitas Clin & Res Ctr, Liver Unit, Milan, Italy; [Lleo, Ana; Invernizzi, Pietro] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Milan, Italy; [Cheroni, Cristina; De Francesco, Raffaele; Scavelli, Rossana] Natl Inst Mol Genet INGM, Milan, Italy; [Mayo, Marlyn J.] Univ Texas Southwestern, Dallas, TX USA; [Bach, Nancy] Mt Sinai Univ, New York, NY USA; [Shimoda, Shinji] Natl Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan; [Gordon, Stuart C.] Henry Ford Hosp, Detroit, MI 48202 USA; [Miozzo, Monica] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Miozzo, Monica] Ca Granda Osped Maggiore Policlin, Div Pathol, Fdn IRCCS, Milan, Italy; [Martin, Michelle R.; LaSalle, Janine M.] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; [Martin, Michelle R.; LaSalle, Janine M.] Univ Calif Davis, MIND Inst, Davis, CA 95616 USA; [Seldin, Michael F.] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA; [Seldin, Michael F.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA	University of California System; University of California Davis; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Texas System; University of Texas Southwestern Medical Center Dallas; Icahn School of Medicine at Mount Sinai; Henry Ford Health System; Henry Ford Hospital; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Selmi, C (corresponding author), Humanitas Clin & Res Ctr, Div Rheumatol & Clin Immunol, Milan, Italy.	carlo.selmi@unimi.it	Invernizzi, Pietro/AAB-8367-2022; Lleo, Ana/AAA-5759-2019; De Santis, Maria/K-2644-2018; Marco, Folci/ABB-9609-2021; Cheroni, Cristina/AAO-2316-2020; Miozzo, Monica Rosa/AAC-6401-2022; Selmi, Carlo/ABG-4899-2021; De Francesco, Raffaele/J-6003-2012; LaSalle, Janine M./A-4643-2008	Invernizzi, Pietro/0000-0003-3262-1998; Lleo, Ana/0000-0002-0561-7902; De Santis, Maria/0000-0002-3196-1336; Marco, Folci/0000-0001-5618-2876; Miozzo, Monica Rosa/0000-0002-6523-4575; Selmi, Carlo/0000-0002-0323-0376; De Francesco, Raffaele/0000-0001-8754-5123; LaSalle, Janine M./0000-0002-3480-2031; Zammataro, Luca/0000-0002-4348-6341				Selmi C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00128	1	1	1	0	7	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 14	2014	5								371	10.3389/fimmu.2014.00371	http://dx.doi.org/10.3389/fimmu.2014.00371			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH9ZW		Green Published, gold			2022-12-18	WOS:000354396300001
J	van der Burg, M; van Zelm, MC				van der Burg, Miriam; van Zelm, Menno C.			Clinical spectrum of SCID: the key is in the thymus?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						severe combined immunodeficiency; Omenn syndrome; thymic epithelial cells; hypomotphic mutation; T-cell; immune deregulation	T-CELL DEVELOPMENT; OMENN-SYNDROME; RAG MUTATIONS; DEFECTS; IMMUNODEFICIENCY; MATURATION; LEADS; MICE		[van der Burg, Miriam; van Zelm, Menno C.] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	van der Burg, M (corresponding author), Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands.	m.vanderburg@erasmusmc.nl; m.vanzelm@erasmusmc.nl	van Zelm, Menno C/O-4404-2015	van Zelm, Menno C/0000-0003-4161-1919				Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; Datta S, 2009, TRENDS IMMUNOL, V30, P430, DOI 10.1016/j.it.2009.06.002; Dik WA, 2005, J EXP MED, V201, P1715, DOI 10.1084/jem.20042524; IJspeert H, 2014, J ALLERGY CLIN IMMUN, V133, P1124, DOI 10.1016/j.jaci.2013.11.028; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Rucci F, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00015; Rucci F, 2010, P NATL ACAD SCI USA, V107, P3024, DOI 10.1073/pnas.0914865107; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Yu XM, 2014, J ALLERGY CLIN IMMUN, V133, P1109, DOI 10.1016/j.jaci.2013.11.018	14	1	1	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2014	5								111	10.3389/fimmu.2014.00111	http://dx.doi.org/10.3389/fimmu.2014.00111			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH5GE	24678313	Green Published, gold			2022-12-18	WOS:000354062600002
J	Larkin, J; Ahmed, CM; Wilson, TD; Johnson, HM				Larkin, Joseph, III; Ahmed, Chulbul M.; Wilson, Tenisha D.; Johnson, Howard M.			Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells (vol 4, 469, 2013)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Larkin, Joseph, III; Ahmed, Chulbul M.; Wilson, Tenisha D.; Johnson, Howard M.] Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Larkin, J (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.	jlarkin3@ufl.edu		Larkin, Joseph/0000-0003-2066-6814				Larkin J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00469	1	1	1	0	0	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2014	5								88	10.3389/fimmu.2014.00088	http://dx.doi.org/10.3389/fimmu.2014.00088			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH5EB		Green Published, Green Accepted, gold			2022-12-18	WOS:000354056700001
J	De Riva, A; Busch, R				De Riva, Alessandra; Busch, Robert			MHC class II protein turnover in vivo and its relevance for autoimmunity in non-obese diabetic mice	FRONTIERS IN IMMUNOLOGY			English	Review						autoimmune pathogenesis; type 1 diabetes mellitus; major histocompatibility complex class II; antigen-presenting cell; protein turnover; mass spectrometry	COMPLEX CLASS-II; HUMAN DENDRITIC CELLS; INVARIANT-CHAIN; PEPTIDE BINDING; B-CELLS; SURFACE EXPRESSION; AMINO-ACIDS; T-CELLS; MOLECULE; I-A(G7)	Major histocompatibility complex class II (MHCII) proteins are loaded with endosomal peptides and reside at the surface of antigen-presenting cells (APCs) for a time before being degraded. In vitro, MHCII protein levels and turnover are affected by peptide loading and by rates of ubiquitin-dependent internalization from the cell surface, which is in turn affected by APC type and activation state. Prior work suggested that fast turnover of disease-associated MHCII alleles may contribute to autoimmunity. We recently developed novel stable isotope tracer techniques to test this hypothesis in vivo. In non-obese diabetic (NOD) mice, a model of type 1 diabetes (T1D), MHCII turnover was affected by APC type, but unaffected by disease-associated structural polymorphism. Differences in MHCII turnover were observed between NOD colonies with high and low T1D incidence, but fast turnover was dispensable for autoimmunity. Moreover, NOD mice with gene knockouts of peptide loading cofactors do not develop T1D. Thus, fast turnover does not appear pathogenic, and conventional antigen presentation is critical for autoimmunity in NOD mice. However, shared environmental factors may underpin colony differences in MHCII protein turnover, immune regulation, and pathogenesis.	[De Riva, Alessandra; Busch, Robert] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England	University of Cambridge	Busch, R (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Box 157 Level 5,Hills Rd, Cambridge CB2 0QQ, England.	rb468@medschl.cam.ac.uk		Busch, Robert/0000-0002-4132-0751	Arthritis Research UK [20648]; Diabetes UK; Cambridge Arthritis Research Endeavor; Cambridge Biomedical Research Centre of the National Institute of Health Research;  [18543]; Diabetes UK [12/0004572] Funding Source: researchfish; Versus Arthritis [20648, 18543] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); Diabetes UK(Diabetes UK); Cambridge Arthritis Research Endeavor; Cambridge Biomedical Research Centre of the National Institute of Health Research; ; Diabetes UK(Diabetes UK); Versus Arthritis(Versus Arthritis)	Robert Busch holds a Research Progression Award from Arthritis Research UK (Ref.: 20648). The work discussed herein was supported primarily by a Senior Research Fellowship (Ref.: 18543, to Robert Busch), and further by grants from Diabetes UK, Cambridge Arthritis Research Endeavor, and the Cambridge Biomedical Research Centre of the National Institute of Health Research. We thank Prof. Elizabeth D. Mellins, Dr. Timo Burster, Prof. Anne Cooke, and Dr. Mike Decry for collaborations.	Bhatnagar A, 2001, J IMMUNOL, V166, P4490, DOI 10.4049/jimmunol.166.7.4490; Burster T, 2010, IMMUNOLOGY, V130, P436, DOI 10.1111/j.1365-2567.2010.03247.x; Busch R, 2005, IMMUNOL REV, V207, P242, DOI 10.1111/j.0105-2896.2005.00306.x; Busch R, 2007, NAT PROTOC, V2, P3045, DOI 10.1038/nprot.2007.420; Busch R, 2006, BBA-GEN SUBJECTS, V1760, P730, DOI 10.1016/j.bbagen.2005.12.023; Busch R, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/erm.2012.9; CarrascoMarin E, 1996, J IMMUNOL, V156, P450; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; COMMERFORD SL, 1983, RADIAT RES, V94, P151, DOI 10.2307/3575870; Corper AL, 2000, SCIENCE, V288, P505, DOI 10.1126/science.288.5465.505; De Gassart A, 2008, P NATL ACAD SCI USA, V105, P3491, DOI 10.1073/pnas.0708874105; De Riva A, 2013, J IMMUNOL, V190, P5961, DOI 10.4049/jimmunol.1300551; De Riva A, 2010, ANAL BIOCHEM, V403, P1, DOI 10.1016/j.ab.2010.04.018; Delong T, 2012, DIABETES, V61, P3239, DOI 10.2337/db12-0112; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; Ettinger RA, 1998, J IMMUNOL, V161, P6439; Galbas T, 2012, CYTOKINE, V59, P27, DOI 10.1016/j.cyto.2012.03.015; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; Hausmann DHF, 1999, J EXP MED, V189, P1723, DOI 10.1084/jem.189.11.1723; Herath K, 2011, ANAL BIOCHEM, V415, P197, DOI 10.1016/j.ab.2011.04.031; Herrmann TL, 2007, J LEUKOCYTE BIOL, V82, P686, DOI 10.1189/jlb.0107045; Hou Tieying, 2013, Methods Mol Biol, V960, P411, DOI 10.1007/978-1-62703-218-6_31; Hou TY, 2011, J IMMUNOL, V187, P2442, DOI 10.4049/jimmunol.1100255; Jahnke M, 2012, J BIOL CHEM, V287, P28779, DOI 10.1074/jbc.M112.381541; Kanagawa O, 1998, P NATL ACAD SCI USA, V95, P1721, DOI 10.1073/pnas.95.4.1721; Koonce CH, 2004, J IMMUNOL, V173, P3271, DOI 10.4049/jimmunol.173.5.3271; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Krawczyk M, 2006, TISSUE ANTIGENS, V67, P183, DOI 10.1111/j.1399-0039.2006.00557.x; Kruger M, 2008, CELL, V134, P353, DOI 10.1016/j.cell.2008.05.033; Lapaque N, 2009, J BIOL CHEM, V284, P7007, DOI 10.1074/jbc.M805736200; Latek RR, 2000, IMMUNITY, V12, P699, DOI 10.1016/S1074-7613(00)80220-4; Levisetti MG, 2008, DIABETES, V57, P1852, DOI 10.2337/db08-0068; Ma JK, 2012, P NATL ACAD SCI USA, V109, P8820, DOI 10.1073/pnas.1202977109; Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067; Martin-Fontecha Alfonso, 2009, Handb Exp Pharmacol, P31, DOI 10.1007/978-3-540-71029-5_2; Matsuki Y, 2007, EMBO J, V26, P846, DOI 10.1038/sj.emboj.7601556; Mellanby RJ, 2006, J IMMUNOL, V177, P7588, DOI 10.4049/jimmunol.177.11.7588; Morgan MAJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071974, 10.1371/journal.pone.0056738, 10.1371/journal.pone.0069936]; Munz C, 2002, EUR J IMMUNOL, V32, P2105, DOI 10.1002/1521-4141(200208)32:8<2105::AID-IMMU2105>3.0.CO;2-Q; Obst R, 2007, P NATL ACAD SCI USA, V104, P15460, DOI 10.1073/pnas.0707331104; Peterson M, 1998, J IMMUNOL, V161, P2961; POZZILLI P, 1993, IMMUNOL TODAY, V14, P193, DOI 10.1016/0167-5699(93)90160-M; Price JC, 2012, ANAL BIOCHEM, V420, P73, DOI 10.1016/j.ab.2011.09.007; Rachdaoui N, 2009, MOL CELL PROTEOMICS, V8, P2653, DOI 10.1074/mcp.M900026-MCP200; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Reizis B, 1997, INT IMMUNOL, V9, P43, DOI 10.1093/intimm/9.1.43; Ridgway WM, 1998, J EXP MED, V188, P2267, DOI 10.1084/jem.188.12.2267; Rinderknecht CH, 2010, IMMUNOLOGY, V131, P18, DOI 10.1111/j.1365-2567.2010.03282.x; Rinderknecht CH, 2010, INT IMMUNOL, V22, P705, DOI 10.1093/intimm/dxq056; Shin JS, 2006, NATURE, V444, P115, DOI 10.1038/nature05261; Stadinski BD, 2010, P NATL ACAD SCI USA, V107, P10978, DOI 10.1073/pnas.1006545107; Stratmann T, 2000, J IMMUNOL, V165, P3214, DOI 10.4049/jimmunol.165.6.3214; Suri A, 2005, J CLIN INVEST, V115, P2268, DOI 10.1172/JCI25350; Thibodeau J, 2008, EUR J IMMUNOL, V38, P1225, DOI 10.1002/eji.200737902; Viret C, 1999, Rev Immunogenet, V1, P91; Walseng E, 2010, P NATL ACAD SCI USA, V107, P20465, DOI 10.1073/pnas.1010990107; Yi W, 2010, J CLIN INVEST, V120, P1324, DOI 10.1172/JCI40220; Young LJ, 2008, NAT IMMUNOL, V9, P1244, DOI 10.1038/ni.1665	59	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								399	10.3389/fimmu.2013.00399	http://dx.doi.org/10.3389/fimmu.2013.00399			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	24324466	Green Published, gold			2022-12-18	WOS:000209374100387
J	Guthmann, MD; Venier, C; Toledo, D; Segatori, VI; Alonso, DF; Fainboim, L; Vazquez, AM; Ostrowski, H				Guthmann, Marcelo D.; Venier, Cecilia; Toledo, Darien; Segatori, Valeria I.; Alonso, Daniel F.; Fainboim, Leonardo; Vazquez, Ana M.; Ostrowski, Hector			Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3	FRONTIERS IN IMMUNOLOGY			English	Article						NeuGcGM3; racotumomab; anti-idiotype antibody; leghorn chickens; antibody responses; tumor antigens		Bacotumomab is a murine anti-idiotype cancer vaccine targeting NeuGcGM3 on melanoma, breast, and lung cancer. In order to characterize the immunogenicity of alum-adsorbed racotumomab in a non-clinical setting, Leghorn chickens were immunized in dose levels ranging from 25 mu g to 1600 mu g. Racotumornab was administered subcutaneously in the birds' neck with three identical boosters and serum samples were collected before, during and after the immunization schedule. A strong antibody response was obtained across the evaluated dose range, confirming the immunogenicity of racotumomab even at dose levels as low as 25 mu g. As previously observed when using Freund's adjuvant, alum adsorbed racotumomab induced an idiotype-specific response in all the immunized birds and ganglioside-specific antibodies in 60-100% of the animals. In contrast to the rapid induction anti-idiotype response, detection of ganglioside-specific antibodies in responsive animals may require repeated boosting. Kinetics of anti-NeuGcGM3 antibody titers showed a slight decline 2 weeks after each booster, arguing in favor of repeated immunizations in order to maintain antibody titer. Interestingly, the intensity of the anti-NeuGcGM3 response paralleled that of anti-mucin antibodies and anti-tumor antibodies, suggesting that the in vitro detection of anti-ganglioside antibodies might be a surrogate for an in vivo activity of racotumomab. Taken together, these results suggest that Leghorn chicken immunization might become the means to test the biological activity of racotumomab intended for clinical use	[Guthmann, Marcelo D.; Ostrowski, Hector] ELEA Labs, Buenos Aires, DF, Argentina; [Venier, Cecilia; Fainboim, Leonardo] Consejo Nacl Invest Cient & Tecn, INIGEM, Immunogenet Lab, RA-1033 Buenos Aires, DF, Argentina; [Toledo, Darien; Vazquez, Ana M.] Ctr Mol Immunol, Havana, Cuba; [Segatori, Valeria I.; Alonso, Daniel F.] Natl Univ Quilmes, Mol Oncol Lab, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Guthmann, MD (corresponding author), Lab Elea, Sanabria 2353, RA-1417 Buenos Aires, DF, Argentina.	guthmanm@elea.com	Segatori, Valeria Inés/AAC-2650-2022	Segatori, Valeria Inés/0000-0002-3913-3658; Fainboim, Leonardo/0000-0002-8907-0341; Alonso, Daniel F./0000-0002-0601-613X				Alfonso M, 2002, J IMMUNOL, V168, P2523, DOI 10.4049/jimmunol.168.5.2523; Berezin VE, 2010, VET PARASITOL, V167, P28, DOI 10.1016/j.vetpar.2009.09.045; Blanco Rances, 2012, Patholog Res Int, V2012, P235418, DOI 10.1155/2012/235418; Boffey J, 2005, J NEUROIMMUNOL, V165, P92, DOI 10.1016/j.jneuroim.2005.04.011; Chabicovsky M, 2006, REGUL TOXICOL PHARM, V44, P226, DOI 10.1016/j.yrtph.2006.01.002; de Paula VS, 2011, J VIROL METHODS, V171, P102, DOI 10.1016/j.jviromet.2010.10.008; Diaz A, 2003, CLIN IMMUNOL, V107, P80, DOI 10.1016/S1521-6616(03)00036-6; European Medicines Agency (EMA), 2005, GUID ADJ VACC HUM US; Fassbinder-Orth CA, 2009, AVIAN DIS, V53, P502, DOI 10.1637/8688-031009-Reg.1; FDA, 2011, GUID IND CLIN CONS T; Guthmann MD, 2006, J IMMUNOTHER, V29, P215, DOI 10.1097/01.cji.0000188502.11348.34; Hernandez AM, 2005, IMMUNOBIOLOGY, V210, P11, DOI 10.1016/j.imbio.2005.02.002; Jansen T, 2007, AVIAN PATHOL, V36, P361, DOI 10.1080/03079450701567395; Machado YJ, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-112; Hernandez AM, 2011, J IMMUNOL, V186, P3735, DOI 10.4049/jimmunol.1000609; Mayo SL, 2005, IN VIVO, V19, P375; Mesa C, 2004, IMMUNOL CELL BIOL, V82, P644, DOI 10.1111/j.0818-9641.2004.01279.x; Neninger E, 2007, CANCER BIOL THER, V6, P145, DOI 10.4161/cbt.6.2.3574; Scursoni AM, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/245181; Scursoni AM, 2010, PEDIATR DEVEL PATHOL, V13, P18, DOI 10.2350/08-10-0544.1; Talavera A, 2009, MOL IMMUNOL, V46, P3466, DOI 10.1016/j.molimm.2009.07.032; van Cruijsen H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-180; Vazquez AM, 2000, ONCOL REP, V7, P751	23	1	1	0	3	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	3								422	10.3389/fimmu.2012.00422	http://dx.doi.org/10.3389/fimmu.2012.00422			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WR	23335925	Green Published, gold			2022-12-18	WOS:000209374000026
J	Lycke, NV				Lycke, Nils V.			IgA B cell responses to gut mucosal antigens: do we know it all?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						IgA; intestinal; germinal centers; Peyer's patches; gut lamina propria	MICROBIOTA		Univ Gothenburg, Dept Microbiol & Immunol, Inst Biomed, Gothenburg, Sweden	University of Gothenburg	Lycke, NV (corresponding author), Univ Gothenburg, Dept Microbiol & Immunol, Inst Biomed, Gothenburg, Sweden.	nils.lycke@microbio.gu.se						Barone F, 2011, GASTROENTEROLOGY, V140, P947, DOI 10.1053/j.gastro.2010.12.005; Benckert J, 2011, J CLIN INVEST, V121, P1946, DOI 10.1172/JCI44447; Bergqvist P, 2013, MUCOSAL IMMUNOL, V6, P122, DOI 10.1038/mi.2012.56; Brandtzaeg P, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00222; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Lindner C, 2012, J EXP MED, V209, P365, DOI 10.1084/jem.20111980; Maruya M, 2013, GUT MICROBES, V4, P165, DOI 10.4161/gmic.23595; Pabst O, 2012, NAT REV IMMUNOL, V12, P821, DOI 10.1038/nri3322; Rehman A, 2011, GUT, V60, P1354, DOI 10.1136/gut.2010.216259; Wei M, 2011, NAT IMMUNOL, V12, P264, DOI 10.1038/ni.1991; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x	11	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								368	10.3389/fimmu.2013.00368	http://dx.doi.org/10.3389/fimmu.2013.00368			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	24312091	Green Published, gold			2022-12-18	WOS:000209374100359
J	Miyazaki, Y; Tsumiyama, K; Yamane, T; Ito, M; Shiozawa, S				Miyazaki, Yumi; Tsumiyama, Ken; Yamane, Takashi; Ito, Mitsuhiro; Shiozawa, Shunichi			Self-organized criticality theory and the expansion of PD-1-positive effector CD4 T cells: search for autoantibody-inducing CD4 T cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Miyazaki, Yumi; Tsumiyama, Ken; Shiozawa, Shunichi] Kyushu Univ, Beppu Hosp, Dept Med, Beppu, Oita, Japan; [Yamane, Takashi] Konan Kakogawa Hosp, Ctr Rheumat Dis, Kakogawa, Hyogo, Japan; [Ito, Mitsuhiro] Kobe Univ, Grad Sch Hlth Sci, Dept Biophys, Kobe, Hyogo 657, Japan; [Shiozawa, Shunichi] Global Ctr Excellence, Tokyo, Japan	Kyushu University; Kobe University	Shiozawa, S (corresponding author), Kyushu Univ, Beppu Hosp, Dept Med, Beppu, Oita, Japan.	shiozawa@beppu.kyushu-u.ac.jp	Shiozawa, Shunichi/W-2992-2019		Grants-in-Aid for Scientific Research [23591388] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Bertsias GK, 2009, ARTHRITIS RHEUM-US, V60, P207, DOI 10.1002/art.24227; Duraiswamy J, 2011, J IMMUNOL, V186, P4200, DOI 10.4049/jimmunol.1001783; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Fu SM, 2011, J AUTOIMMUN, V37, P104, DOI 10.1016/j.jaut.2011.05.004; Guo WZ, 2010, J EXP MED, V207, P2225, DOI 10.1084/jem.20092712; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; Jin HT, 2011, CURR TOP MICROBIOL, V350, P17, DOI 10.1007/82_2010_116; Kasagi S, 2010, J IMMUNOL, V184, P2337, DOI 10.4049/jimmunol.0901652; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Liu MF, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/406136; McKinstry KK, 2007, J EXP MED, V204, P2199, DOI 10.1084/jem.20070041; Miyazaki Y., 2013, KOBE J MED SCI; Nurieva R, 2006, EMBO J, V25, P2623, DOI 10.1038/sj.emboj.7601146; Perry D, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/271694; Riella LV, 2012, AM J TRANSPLANT, V12, P2575, DOI 10.1111/j.1600-6143.2012.04224.x; Shiozawa S, 2012, JOINT BONE SPINE, V79, P428, DOI 10.1016/j.jbspin.2012.03.010; Shiozawa S, 2011, EXPERT REV CLIN IMMU, V7, P715, DOI [10.1586/ECI.11.54, 10.1586/eci.11.54]; Tsumiyama K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008382; Wang Y, 2007, CELL RES, V17, P858, DOI 10.1038/cr.2007.81; Weinstein JS, 2012, IMMUNOL REV, V247, P160, DOI 10.1111/j.1600-065X.2012.01122.x	20	1	1	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 87	10.3389/fimmu.2013.00087	http://dx.doi.org/10.3389/fimmu.2013.00087			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23596442	gold, Green Published			2022-12-18	WOS:000209374100086
J	Nehete, PN; Singh, S; Sastry, KJ				Nehete, Pramod N.; Singh, Shailbala; Sastry, K. Jagannatha			Lessons on non-progression of HIV disease from monkeys	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Nehete, Pramod N.; Sastry, K. Jagannatha] Univ Texas MD Anderson Canc Ctr, Dept Vet Sci, Bastrop, TX 78602 USA; [Singh, Shailbala; Sastry, K. Jagannatha] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sastry, KJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Vet Sci, Bastrop, TX 78602 USA.	jsastry@mdanderson.org		Nehete, Pramod/0000-0002-2815-2677				Barry AP, 2007, J IMMUNOL, V178, P8002, DOI 10.4049/jimmunol.178.12.8002; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Cecchinato V, 2010, CURR OPIN HIV AIDS, V5, P141, DOI 10.1097/COH.0b013e32833653ec; Dandekar S, 2010, CURR OPIN HIV AIDS, V5, P173, DOI 10.1097/COH.0b013e328335eda3; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295; Fellay J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000791; Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; He H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019607; Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kanwar B, 2010, CURR OPIN HIV AIDS, V5, P151, DOI 10.1097/COH.0b013e328335c0c1; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006; Loffredo JT, 2008, J VIROL, V82, P1723, DOI 10.1128/JVI.02084-07; Mercier GT, 2007, VACCINE, V25, P8687, DOI 10.1016/j.vaccine.2007.10.030; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Milush JM, 2011, J CLIN INVEST, V121, P1102, DOI 10.1172/JCI44876; Mudd PA, 2012, NATURE, V491, P129, DOI 10.1038/nature11443; Nehete PN, 2005, VACCINE, V23, P2154, DOI 10.1016/j.vaccine.2005.01.052; Nehete PN, 2001, VACCINE, V20, P813, DOI 10.1016/S0264-410X(01)00408-X; Nehete PN, 1998, VIRAL IMMUNOL, V11, P119, DOI 10.1089/vim.1998.11.119; Nehete PN, 2008, VIROLOGY, V370, P130, DOI 10.1016/j.virol.2007.08.022; Premkumar DRD, 1996, AIDS RES HUM RETROV, V12, P337, DOI 10.1089/aid.1996.12.337; Saksena NK, 2007, AIDS REV, V9, P195; Sette A, 2005, IMMUNOGENETICS, V57, P53, DOI 10.1007/s00251-004-0749-z; Silvestri G, 2005, J VIROL, V79, P4043, DOI 10.1128/JVI.79.7.4043-4054.2005; Weaver EA, 2009, VIRUSES-BASEL, V1, P920, DOI 10.3390/v1030920	32	1	1	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 64	10.3389/fimmu.2013.00064	http://dx.doi.org/10.3389/fimmu.2013.00064			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23495354	Green Published, gold			2022-12-18	WOS:000209374100064
J	Ottaiano, A; Capuozzo, M; Nasti, G; Maiolino, P; De Angelis, V; Scala, S; Iaffaioli, RV				Ottaiano, Alessandro; Capuozzo, Maurizio; Nasti, Guglielmo; Maiolino, Piera; De Angelis, Valentina; Scala, Stefania; Iaffaioli, Rosario V.			Prediction of response to anti-EGFR antibocies in metastatic colorectal cancer: looking beyond EGFR inhibition	FRONTIERS IN IMMUNOLOGY			English	Editorial Material							POLYMORPHISMS; ANTIBODIES; MUTATIONS; IMPACT; KRAS		[Ottaiano, Alessandro; Nasti, Guglielmo; Iaffaioli, Rosario V.] G Pascale Fdn, Natl Canc Inst, Dept Colorectal Oncol, Naples, Italy; [Capuozzo, Maurizio] ALS Naples 3, Dept Pharm, Ercolano, NA, Italy; [Maiolino, Piera] G Pascale Fdn, Natl Canc Inst, Dept Pharm, Naples, Italy; [De Angelis, Valentina] Inst Psychol & System Med, Naples, Italy; [Scala, Stefania] G Pascale Fdn, Natl Canc Inst, Dept Canc Immunol, Naples, Italy	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Ottaiano, A (corresponding author), G Pascale Fdn, Natl Canc Inst, Dept Colorectal Oncol, Via M Semmola, Naples, Italy.	ale.otto@libero.it	Scala, Stefania/K-1380-2016	Scala, Stefania/0000-0001-9524-2616; nasti, guglielmo/0000-0002-3590-382X				Ashraf SQ, 2012, P NATL ACAD SCI USA, V109, P21046, DOI 10.1073/pnas.1218750110; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Calemma R, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-232; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Eng C, 2010, ONCOLOGIST, V15, P73, DOI 10.1634/theoncologist.2009-0167; Kohrt HE, 2012, IMMUNOTHERAPY-UK, V4, P511, DOI [10.2217/IMT.12.38, 10.2217/imt.12.38]; Matsumoto I, 2005, ARTHRITIS RES THER, V7, pR1183, DOI 10.1186/ar1802; Pander J, 2011, CLIN CANCER RES, V17, P5668, DOI 10.1158/1078-0432.CCR-11-0239; Tsuchiya N, 2007, CURR MED CHEM, V14, P431, DOI 10.2174/092986707779941041; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021	10	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	3								409	10.3389/fimmu.2012.00409	http://dx.doi.org/10.3389/fimmu.2012.00409			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WR	23316197	Green Published, gold			2022-12-18	WOS:000209374000013
J	Fernandes, RA; Huo, JD; Lui, Y; Felce, JH; Davis, SJ				Fernandes, Ricardo A.; Huo, Jiandong; Lui, Yuan; Felce, James H.; Davis, Simon J.			On the control of TCR phosphorylation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Fernandes, Ricardo A.; Huo, Jiandong; Lui, Yuan; Felce, James H.; Davis, Simon J.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, MRC Human Immunol Unit, Oxford OX3 9DU, England	University of Oxford	Davis, SJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, MRC Human Immunol Unit, Oxford OX3 9DU, England.	simon.davis@ndm.ox.ac.uk	Fernandes, Ricardo/AAB-8165-2019	Fernandes, Ricardo/0000-0001-5343-3334; Felce, James/0000-0001-5531-9244	MRC [MC_UU_12010/4] Funding Source: UKRI; Medical Research Council [MC_UU_12010/4] Funding Source: researchfish; Wellcome Trust [098274] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Bernado P, 2008, J MOL BIOL, V376, P492, DOI 10.1016/j.jmb.2007.11.066; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Chung I, 2010, NATURE, V464, P783, DOI 10.1038/nature08827; Davis SJ, 2006, NAT IMMUNOL, V7, P803, DOI 10.1038/ni1369; Davis SJ, 2011, TRENDS IMMUNOL, V32, P1, DOI 10.1016/j.it.2010.11.003; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DeFord-Watts LM, 2009, J IMMUNOL, V183, P1055, DOI 10.4049/jimmunol.0900404; Domingo-Sananes MR, 2011, PHILOS T R SOC B, V366, P3584, DOI 10.1098/rstb.2011.0087; Dushek O, 2011, BIOPHYS J, V100, P1189, DOI 10.1016/j.bpj.2011.01.060; Eggeling C, 2009, NATURE, V457, P1159, DOI 10.1038/nature07596; Fernandes RA, 2010, CELL, V142, P668, DOI 10.1016/j.cell.2010.08.018; Filippakopoulos P, 2009, CURR OPIN STRUC BIOL, V19, P643, DOI 10.1016/j.sbi.2009.10.001; FISCHER EH, 1992, CIBA F SYMP, V164, P132; Gagnon E, 2010, CELL, V142, P669, DOI 10.1016/j.cell.2010.08.019; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; He HT, 2008, EMBO REP, V9, P525, DOI 10.1038/embor.2008.78; Hermiston ML, 2009, IMMUNOL REV, V228, P288, DOI 10.1111/j.1600-065X.2008.00752.x; Huse M, 2007, IMMUNITY, V27, P76, DOI 10.1016/j.immuni.2007.05.017; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; James JR, 2007, P NATL ACAD SCI USA, V104, P17662, DOI 10.1073/pnas.0700411104; James JR, 2006, NAT METHODS, V3, P1001, DOI 10.1038/nmeth978; James JR, 2011, J BIOL CHEM, V286, P31993, DOI 10.1074/jbc.M111.219212; Kleiman LB, 2011, MOL CELL, V43, P723, DOI 10.1016/j.molcel.2011.07.014; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Nika K, 2007, J BIOL CHEM, V282, P36000, DOI 10.1074/jbc.M702779200; Nika K, 2010, IMMUNITY, V32, P766, DOI 10.1016/j.immuni.2010.05.011; PATEL MD, 1987, J BIOL CHEM, V262, P5831; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Williams A. F., 1986, HDB EXPT IMMUNOLOGY, P221; Xu CQ, 2008, CELL, V135, P702, DOI 10.1016/j.cell.2008.09.044; Yamada T, 2002, J BIOL CHEM, V277, P28830, DOI 10.1074/jbc.M201781200; Yang SC, 2010, P NATL ACAD SCI USA, V107, P15757, DOI 10.1073/pnas.1004569107; Yu C, 2011, J BIOL CHEM, V286, P6685, DOI 10.1074/jbc.M110.182394; Zhang H, 2011, P NATL ACAD SCI USA, V108, P19323, DOI 10.1073/pnas.1108052108	42	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2012	3								92	10.3389/fimmu.2012.00092	http://dx.doi.org/10.3389/fimmu.2012.00092			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TQ	22566970	gold, Green Published			2022-12-18	WOS:000209501300089
J	Kurts, C; Wagner, H				Kurts, Christian; Wagner, Hermann			Grand challenges in molecular antigen-presenting cell-biology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Kurts, Christian] Univ Bonn, Inst Mol Med & Expt Immunol, Bonn, Germany; [Wagner, Hermann] Tech Univ Munich, Fac Med, D-80290 Munich, Germany	University of Bonn; Technical University of Munich	Kurts, C (corresponding author), Univ Bonn, Inst Mol Med & Expt Immunol, Bonn, Germany.	ckurts@uni-bonn.de; hermann.wagner@mikrobio.med.tum.de							0	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2								8	10.3389/fimmu.2011.00008	http://dx.doi.org/10.3389/fimmu.2011.00008			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566799	Green Published, gold			2022-12-18	WOS:000209501400008
J	Chen, M; Nie, ZY; Huang, DG; Gao, YH; Cao, H; Zheng, LL; Zhang, SF				Chen, Mei; Nie, Zhenyu; Huang, Denggao; Gao, Yuanhui; Cao, Hui; Zheng, Linlin; Zhang, Shufang			Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						polyamine metabolism; clear cell renal cell carcinoma; immunotherapy; immune escape; multi-omics; prognosis	T-CELLS; PROLIFERATION; METABOLISM; IDENTIFICATION	BackgroundsPolyamine metabolism (PM) is closely related to the tumor microenvironment (TME) and is involved in antitumor immunity. Clear cell renal cell carcinoma (ccRCC) not only has high immunogenicity but also has significant metabolic changes. However, the role of PM in the immune microenvironment of ccRCC remains unclear. This study aimed to reveal the prognostic value of PM-related genes (PMRGs) expression in ccRCC and their correlation with the TME. MethodsThe expression levels PMRGs in different cells were characterized with single-cell sequencing analysis. The PMRG expression pattern of 777 ccRCC patients was evaluated based on PMRGs. Unsupervised clustering analysis was used in identifying PMRG expression subtypes, and Lasso regression analysis was used in developing polyamine gene expression score (PGES), which was validated in external and internal data sets. The predictive value of PGES for immunotherapy was validated in the IMvigor210 cohort. Multiple algorithms were used in analyzing the correlation between PGES and immune cells. The sensitivity of PGES to chemotherapeutic drugs was analyzed with the "pRRophetic" package. We validated the genes that develop PGES in tissue samples. Finally, weighted gene co-expression network analysis was used in identifying the key PMRGs closely related to ccRCC, and cell function experiments were carried out. ResultsPMRGs were abundantly expressed on tumor cells, and PMRG expression was active in CD8(+) T cells and fibroblasts. We identified three PMRG expression subtypes. Cancer and immune related pathways were active in PMRG expression cluster A, which had better prognosis. PGES exhibited excellent predictive value. The high-PGES group was characterized by high immune cell infiltration, high expression of T cell depletion markers, high tumor mutation burden and tumor immune dysfunction and exclusion, was insensitive to immunotherapy but sensitive to sunitinib, temsirolimus, and rapamycin, and had poor prognosis. Spermidine synthetase (SRM) has been identified as a key gene and is highly expressed in ccRCC at RNA and protein levels. SRM knockdown can inhibit ccRCC cell proliferation, migration, and invasion. ConclusionsWe revealed the biological characteristics of PMRG expression subtypes and developed PGES to accurately predict the prognosis of patients and response to immunotherapy.	[Chen, Mei; Nie, Zhenyu; Huang, Denggao; Gao, Yuanhui; Cao, Hui; Zheng, Linlin; Zhang, Shufang] Cent South Univ, Affiliated Haikou Hosp, Cent Lab, Xiangya Med Coll, Haikou, Peoples R China		Zhang, SF (corresponding author), Cent South Univ, Affiliated Haikou Hosp, Cent Lab, Xiangya Med Coll, Haikou, Peoples R China.	zsf66189665@126.com			Hainan Provincial Natural Science Foundation of China; Finance science and technology project of Hainan province; National Science Foundation of China; health department of Hainan province;  [2017CXTD010];  [ZDYF2019163];  [ZDYF2021SHFZ249];  [82160531];  [81760465];  [19A200184]	Hainan Provincial Natural Science Foundation of China; Finance science and technology project of Hainan province; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); health department of Hainan province; ; ; ; ; ; 	Funding The research is supported with fund from Hainan Provincial Natural Science Foundation of China (2017CXTD010), Finance science and technology project of Hainan province (ZDYF2019163 and ZDYF2021SHFZ249), the National Science Foundation of China (82160531 and 81760465), and the health department of Hainan province (19A200184).	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Bian XY, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.352; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Chai XY, 2020, FASEB J, V34, P12907, DOI 10.1096/fj.202001222R; Chen M, 2021, PATHOL ONCOL RES, V27, DOI 10.3389/pore.2021.598460; Chen M, 2019, ONCOTARGETS THER, V12, P10771, DOI 10.2147/OTT.S229332; Chen Q, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00506-z; Chia TY, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11050896; Chiu PKF, 2021, PROSTATE CANCER P D, V24, P542, DOI 10.1038/s41391-020-00312-1; Christensen BR, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-020-00814-z; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Czystowska-Kuzmicz M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10979-3; Diaz-Montero CM, 2020, NAT REV NEPHROL, V16, P721, DOI 10.1038/s41581-020-0316-3; Dunston TT, 2020, ACTA NATURAE, V12, P140, DOI 10.32607/actanaturae.10992; Efremova M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02424-0; Forshell TP, 2010, CANCER PREV RES, V3, P140, DOI 10.1158/1940-6207.CAPR-09-0166; Gao HY, 2022, EXP CELL RES, V417, DOI 10.1016/j.yexcr.2022.113235; Gatto F, 2014, P NATL ACAD SCI USA, V111, pE866, DOI 10.1073/pnas.1319196111; Grzywa TM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00938; Guo T, 2019, CANCER MED-US, V8, P7754, DOI 10.1002/cam4.2637; Guo TJ, 2022, GENES-BASEL, V13, DOI 10.3390/genes13040620; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Hamouda NN, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.013908; Han WK, 2022, BMC NEPHROL, V23, DOI 10.1186/s12882-022-02801-y; Hiasa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06836; Holbert CE, 2022, NAT REV CANCER, V22, P467, DOI 10.1038/s41568-022-00473-2; Huang ZH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-998; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jorgensen MA, 2021, CANCER IMMUNOL RES, V9, P1316, DOI 10.1158/2326-6066.CIR-21-0280; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kaminski L, 2019, CANCER RES, V79, P3268, DOI 10.1158/0008-5472.CAN-18-2043; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Kwon OK, 2020, CANCER GENOM PROTEOM, V17, P195, DOI 10.21873/cgp.20180; Lopez-Contreras AJ, 2010, AMINO ACIDS, V38, P603, DOI 10.1007/s00726-009-0419-4; Mai SJ, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12960; Miska J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abc8929; Moriyama Y, 2020, BBA-BIOMEMBRANES, V1862, DOI 10.1016/j.bbamem.2020.183208; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Munder M, 2009, EUR J IMMUNOL, V39, P2161, DOI 10.1002/eji.200839041; Murata T, 2019, BREAST CANCER RES TR, V177, P591, DOI 10.1007/s10549-019-05330-9; Nakkina SP, 2021, CANCERS, V13, DOI 10.3390/cancers13246391; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Niu FL, 2022, BIOMED PHARMACOTHER, V149, DOI 10.1016/j.biopha.2022.112840; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7; Puleston DJ, 2021, CELL, V184, P4186, DOI 10.1016/j.cell.2021.06.007; Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586-021-03442-1; Rhodes CJ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02350-2020; Ruan YB, 2011, J BIOL CHEM, V286, P29417, DOI 10.1074/jbc.M111.274647; Sari IN, 2021, ONCOGENE, V40, P603, DOI 10.1038/s41388-020-01547-x; Sekhar V, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-07712-4; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Su XM, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145296; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1597-y; Thakur VS, 2019, ONCOGENE, V38, P6794, DOI 10.1038/s41388-019-0917-0; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Urabe F, 2020, CANCER SCI, V111, P3258, DOI 10.1111/cas.14535; van Veen S, 2020, NATURE, V578, P419, DOI 10.1038/s41586-020-1968-7; Wagner A, 2021, CELL, V184, P4168, DOI 10.1016/j.cell.2021.05.045; Wang X, 2014, INT J MOL MED, V34, P1606, DOI 10.3892/ijmm.2014.1961; Wu RH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4275; Wu X., 2022, J IMMUNOL RES, V2022, DOI [10.1155/2022/614936969, DOI 10.1155/2022/614936969]; Xu LJ, 2020, CARCINOGENESIS, V41, P214, DOI 10.1093/carcin/bgz098; Xu SX, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.938259; Yang JS, 2021, CHINESE MED J-PEKING, V134, P28, DOI 10.1097/CM9.0000000000001216; Yang LJ, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10462; Ye Z, 2019, ONCOTARGETS THER, V12, P4081, DOI 10.2147/OTT.S198341; Yeon A, 2018, THERANOSTICS, V8, P4520, DOI 10.7150/thno.25130; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang T, 2021, MOLECULES, V26, DOI 10.3390/molecules26071990; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zhu YM, 2022, GENOMICS, V114, P125, DOI 10.1016/j.ygeno.2021.11.028	77	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1048204	10.3389/fimmu.2022.1048204	http://dx.doi.org/10.3389/fimmu.2022.1048204			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U9VX	36505496	gold, Green Published			2022-12-18	WOS:000894709000001
J	Chowdhury, CS; Wareham, E; Xu, JY; Kumar, S; Kofron, M; Lakshmikanthan, S; Chrzanowska, M; Filippi, MD				Chowdhury, Chanchal Sur; Wareham, Elizabeth; Xu, Juying; Kumar, Sachin; Kofron, Matthew; Lakshmikanthan, Sribalaji; Chrzanowska, Magdalena; Filippi, Marie-Dominique			Rap1b-loss increases neutrophil lactate dehydrogenase activity to enhance neutrophil migration and acute inflammation in vivo	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; inflammation; Ldha; migration; vascular leakage	TRANSCELLULAR DIAPEDESIS; MECHANISM; ACIDIFICATION; ANGIOGENESIS; INHIBITION; METABOLISM; ACTIVATION; BIOMARKERS; PROTEIN	IntroductionNeutrophils are critical for host immune defense; yet, aberrant neutrophil tissue infiltration triggers tissue damage. Neutrophils are heterogeneous functionally, and adopt 'normal' or 'pathogenic' effector function responses. Understanding neutrophil heterogeneity could provide specificity in targeting inflammation. We previously identified a signaling pathway that suppresses neutrophilmediated inflammation via integrin-mediated Rap1b signaling pathway. MethodsHere, we used Rap1-deficient neutrophils and proteomics to identify pathways that specifically control pathogenic neutrophil effector function. ResultsWe show neutrophil acidity is normally prevented by Rap1b during normal immune response with loss of Rap1b resulting in increased neutrophil acidity via enhanced Ldha activity and abnormal neutrophil behavior. Acidity drives the formation of abnormal invasive-like protrusions in neutrophils, causing a shift to transcellular migration through endothelial cells. Acidity increases neutrophil extracellular matrix degradation activity and increases vascular leakage in vivo. Pathogenic inflammatory condition of ischemia/reperfusion injury is associated with increased neutrophil transcellular migration and vascular leakage. Reducing acidity with lactate dehydrogenase inhibition in vivo limits tissue infiltration of pathogenic neutrophils but less so of normal neutrophils, and reduces vascular leakage. DiscussionAcidic milieu renders neutrophils more dependent on Ldha activity such that their effector functions are more readily inhibited by small molecule inhibitor of Ldha activity, which offers a therapeutic window for antilactate dehydrogenase treatment in specific targeting of pathogenic neutrophils in vivo.	[Chowdhury, Chanchal Sur; Wareham, Elizabeth; Xu, Juying; Kumar, Sachin; Filippi, Marie-Dominique] Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Chowdhury, Chanchal Sur; Wareham, Elizabeth; Xu, Juying; Kumar, Sachin; Filippi, Marie-Dominique] Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA; [Kofron, Matthew] Cincinnati Childrens Res Fdn, Div Dev Biol, Cincinnati, OH USA; [Lakshmikanthan, Sribalaji; Chrzanowska, Magdalena] Versiti Blood Res Inst, Milwaukee, WI USA; [Chrzanowska, Magdalena] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI USA; [Chrzanowska, Magdalena] Med Coll Wisconsin, Cardiovasc Ctr, Milwaukee, WI USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Medical College of Wisconsin; Medical College of Wisconsin	Filippi, MD (corresponding author), Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.; Filippi, MD (corresponding author), Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA.	Marie-Dominique.Filippi@cchmc.org			National Institutes of Health;  [GM112792];  [HL111582]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; 	Funding The work was supported by National Institutes of Health (GM112792 to M-DF; HL111582 to MC).	ADAMS PL, 1980, KIDNEY INT, V18, P68, DOI 10.1038/ki.1980.111; Adeva-Andany M, 2014, MITOCHONDRION, V17, P76, DOI 10.1016/j.mito.2014.05.007; Alarcon P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00975; Attanasio F, 2011, EUR J CELL BIOL, V90, P115, DOI 10.1016/j.ejcb.2010.05.004; Awasthi D, 2019, BBA-MOL BASIS DIS, V1865, DOI 10.1016/j.bbadis.2019.165542; Behnen M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00184; Beppu K, 2014, NEURON, V81, P314, DOI 10.1016/j.neuron.2013.11.011; Beyrau M, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120134; Bruijnzeel PLB, 2015, J LEUKOCYTE BIOL, V98, P549, DOI 10.1189/jlb.3VMR1214-600RR; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Cao SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137221; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Carman CV, 2009, J CELL SCI, V122, P3025, DOI 10.1242/jcs.047522; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; Di Carlo A, 2009, AGE AGEING, V38, P4, DOI 10.1093/ageing/afn282; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Everts B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00203; Faix JD, 2013, CRIT REV CL LAB SCI, V50, P23, DOI 10.3109/10408363.2013.764490; Filippi MD, 2007, BLOOD, V109, P1257, DOI 10.1182/blood-2006-04-017731; Filippi MD, 2016, ADV IMMUNOL, V129, P25, DOI 10.1016/bs.ai.2015.09.001; Goh CC, 2016, JOVE-J VIS EXP, DOI 10.3791/54956; He PN, 2010, CARDIOVASC RES, V87, P281, DOI 10.1093/cvr/cvq140; JENSEN JA, 1986, LAB INVEST, V54, P574; KANNO T, 1988, CLIN CHIM ACTA, V173, P89, DOI 10.1016/0009-8981(88)90359-2; Karon BS, 2017, CLIN BIOCHEM, V50, P956, DOI 10.1016/j.clinbiochem.2017.05.014; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Khatib-Massalha E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17402-2; Kominsky DJ, 2010, J IMMUNOL, V184, P4062, DOI 10.4049/jimmunol.0903002; Kumar S, 2014, J EXP MED, V211, P1741, DOI 10.1084/jem.20131706; Lakshmikanthan S, 2011, BLOOD, V118, P2015, DOI 10.1182/blood-2011-04-349282; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; MAEKAWA M, 1990, BIOCHEM BIOPH RES CO, V168, P677, DOI 10.1016/0006-291X(90)92374-9; Margaroli Camilla, 2016, Mol Cell Pediatr, V3, P38; Martinez D, 2006, J IMMUNOL, V176, P1163, DOI 10.4049/jimmunol.176.2.1163; MULLANE KM, 1984, J PHARMACOL EXP THER, V228, P510; Petri B, 2011, BLOOD, V117, P942, DOI 10.1182/blood-2010-02-270561; Phillipson M, 2011, NAT MED, V17, P1381, DOI 10.1038/nm.2514; Rodriguez-Espinosa O, 2015, IMMUNOLOGY, V145, P213, DOI 10.1111/imm.12437; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Schofield ZV, 2013, SHOCK, V40, P463, DOI 10.1097/SHK.0000000000000044; Swamydas M, 2013, JOVE-J VIS EXP, DOI 10.3791/50586; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Trabold O, 2003, WOUND REPAIR REGEN, V11, P504, DOI 10.1046/j.1524-475X.2003.11621.x; Trevani AS, 1999, J IMMUNOL, V162, P4849; VANHEEL B, 1990, AM J PHYSIOL, V259, pC169, DOI 10.1152/ajpcell.1990.259.1.C169; Walenta S, 1997, AM J PATHOL, V150, P409; Wang SJ, 2006, J EXP MED, V203, P1519, DOI 10.1084/jem.20051210; Wang Yingchun, 2007, Sci STKE, V2007, ppl4, DOI 10.1126/stke.4002007pl4; Wang Yingchun, 2007, Methods Mol Biol, V370, P55; Woodfin A, 2011, NAT IMMUNOL, V12, P761, DOI 10.1038/ni.2062; Wright HL, 2010, RHEUMATOLOGY, V49, P1618, DOI 10.1093/rheumatology/keq045	54	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1061544	10.3389/fimmu.2022.1061544	http://dx.doi.org/10.3389/fimmu.2022.1061544			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U4YN	36505495	gold, Green Published			2022-12-18	WOS:000894374300001
J	Hu, J; Huang, Z; Yu, M; Zhang, P; Xia, ZK; Gao, CL				Hu, Jian; Huang, Zhen; Yu, Min; Zhang, Pei; Xia, Zhengkun; Gao, Chunlin			Caspase-8 activation in neutrophils facilitates autoimmune kidney vasculitis through regulating CD4(+) effector memory T cells	FRONTIERS IN IMMUNOLOGY			English	Article						anti-neutrophil cytoplasmic antibody (ANCA); kidney vasculitis; single-cell transcriptome; neutrophil; caspase-8; immunity	ANCA-ASSOCIATED VASCULITIS; COMPLEMENTARY; AUTOANTIBODY; PATHOGENESIS; ASSOCIATION; CYTOKINE; GENES	Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are closely associated with neutrophil recruitment and activation, but the impact of the neutrophil apoptosis process in autoimmune disease has been rarely explained. Here, by integrating and analyzing single-cell transcriptome datasets, we found that the caspase-8-associated pathway in neutrophils was highly activated in the kidney rather than in the blood. To verify the function of caspase-8 in neutrophils on AAVs progression, we constructed neutrophil-specific caspase-8 knockout mice combined with an AAVs model induced by human ANCA from AAVs patients, a rapid and powerful model developed in this study. Our results show that caspase-8 activation of neutrophils up-regulates the expression of several inflammatory and immunoregulatory factors, especially IL23A, regulating the activation and differentiation of tissue-resident CD4(+) effector memory T cells. This study reveals that the activation of caspase-8 in neutrophils can worsen glomerulonephritis of AAVs by regulating inflammation and immunity.	[Hu, Jian; Yu, Min; Xia, Zhengkun; Gao, Chunlin] Nanjing Med Univ, Jinling Hosp, Dept Pediat, Nanjing, Jiangsu, Peoples R China; [Huang, Zhen] Sichuan Univ, West China Second Univ Hosp, State Key Lab Biotherapy, Key Lab Birth Defects & Related Dis Women & Childr, Chengdu, Peoples R China; [Zhang, Pei] Nanjing Univ, Affiliated Jinling Hosp, Dept Pediat, Med Sch, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Sichuan University; Nanjing University	Xia, ZK; Gao, CL (corresponding author), Nanjing Med Univ, Jinling Hosp, Dept Pediat, Nanjing, Jiangsu, Peoples R China.	njxzk@126.com; shuangmu345@hotmail.com			Natural Science Foundation & Youth Fund Plan of Jiangsu Province; China Postdoctoral Foundation; Postdoctoral Fund of Jiangsu Province;  [BK20190251];  [2018M643888];  [2018K089B]	Natural Science Foundation & Youth Fund Plan of Jiangsu Province; China Postdoctoral Foundation(China Postdoctoral Science Foundation); Postdoctoral Fund of Jiangsu Province; ; ; 	Funding This study was supported by the Natural Science Foundation & Youth Fund Plan of Jiangsu Province (BK20190251); China Postdoctoral Foundation (2018M643888); Postdoctoral Fund of Jiangsu Province (2018K089B).	Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bautz DJ, 2008, J AM SOC NEPHROL, V19, P2421, DOI 10.1681/ASN.2008030270; Beisner DR, 2005, J IMMUNOL, V175, P3469, DOI 10.4049/jimmunol.175.6.3469; Bosch X, 2006, LANCET, V368, P404, DOI 10.1016/S0140-6736(06)69114-9; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Der E, 2019, NAT IMMUNOL, V20, P915, DOI 10.1038/s41590-019-0386-1; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Garcia-Alonso L, 2021, NAT GENET, V53, P1698, DOI 10.1038/s41588-021-00972-2; Grayson PC, 2018, ANN RHEUM DIS, V77, P1227, DOI 10.1136/annrheumdis-2017-212935; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Hamour SM, 2011, KIDNEY INT, V79, P699, DOI 10.1038/ki.2010.558; Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hewins P, 2006, KIDNEY INT, V69, P605, DOI 10.1038/sj.ki.5000167; Hutton HL, 2017, SEMIN NEPHROL, V37, P418, DOI 10.1016/j.semnephrol.2017.05.016; Huugen D, 2006, CLIN J AM SOC NEPHRO, V1, P1100, DOI 10.2215/CJN.02181205; Jagiello P, 2004, HUM GENET, V114, P468, DOI 10.1007/s00439-004-1092-z; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Kain R, 2008, NAT MED, V14, P1088, DOI 10.1038/nm.1874; Kerstein A, 2017, Z RHEUMATOL, V76, P14, DOI 10.1007/s00393-016-0053-y; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Kettritz R, 2001, J AM SOC NEPHROL, V12, P37, DOI 10.1681/ASN.V12137; Kitching AR, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0204-y; Kong FH, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.767618; Krebs CF, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba4163; Lane SE, 2003, ARTHRITIS RHEUM-US, V48, P814, DOI 10.1002/art.10830; Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009; Little MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028626; Mandal R, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188357; McCall AS, 2018, J AM SOC NEPHROL, V29, P2619, DOI 10.1681/ASN.2018050519; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moschen AR, 2019, NAT REV GASTRO HEPAT, V16, P185, DOI 10.1038/s41575-018-0084-8; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Pendergraft WF, 2004, NAT MED, V10, P72, DOI 10.1038/nm968; Pendergraft WF, 2014, CURR OPIN RHEUMATOL, V26, P42, DOI 10.1097/BOR.0000000000000014; Ramos RN, 2022, CELL, V185, P1189, DOI 10.1016/j.cell.2022.02.021; Schreiber A, 2006, J AM SOC NEPHROL, V17, P3355, DOI 10.1681/ASN.2006070718; Schreiber A, 2012, J AM SOC NEPHROL, V23, P470, DOI 10.1681/ASN.2010080892; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194; Shochet L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00525; Simon A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147091; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stewart BJ, 2019, SCIENCE, V365, P1461, DOI 10.1126/science.aat5031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Summers SA, 2010, KIDNEY INT, V78, P1263, DOI 10.1038/ki.2010.327; Suzuki K, 2014, NEPHROL DIAL TRANSPL, V29, P1168, DOI 10.1093/ndt/gft469; Tang R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645988; Tummers B, 2017, IMMUNOL REV, V277, P76, DOI 10.1111/imr.12541; Watts RA, 2015, NEPHROL DIAL TRANSPL, V30, pi14, DOI 10.1093/ndt/gfv022; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wilson PC, 2019, P NATL ACAD SCI USA, V116, P19619, DOI 10.1073/pnas.1908706116; Xiao H, 2014, J AM SOC NEPHROL, V25, P225, DOI 10.1681/ASN.2013020143; Zappia L, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy083	57	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1038134	10.3389/fimmu.2022.1038134	http://dx.doi.org/10.3389/fimmu.2022.1038134			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U9KK	36505410	Green Published, gold			2022-12-18	WOS:000894679000001
J	Liu, H; Varvel, S; Chen, G; McConnell, J; Caffrey, R; Galdzicka, M; Shabahang, S				Liu, Hong; Varvel, Stephen; Chen, Ge; McConnell, Joseph; Caffrey, Rebecca; Galdzicka, Marzena; Shabahang, Shahrokh			Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; neutralizing antibodies; omicron subvariants; flow cytometry; clinical		IntroductionNeutralizing antibodies (NAbs) have been recognized as surrogates of protection against SARS-CoV-2; however, the emergence of variants/subvariants escaping neutralization suggests that laboratory assessments of NAbs against the ancestral/wild type (WT) antigens likely overestimate the degree of protection. MethodsA novel flow cytometry-based multiplex test system was developed for the simultaneous detection of NAbs of multiple SARS-CoV-2 variants. SARS-CoV-2 antibodies (Abs) including IgG, IgM, IgA isotypes were measured in the same system. Samples from negative, convalesced, vaccinated, boosted, and breakthrough infection (BTI) populations were tested for both NAbs and Abs. ResultsNAbs induced by WT showed neutralization activity that correlated strongly to all variants (R-2 > 0.85) except omicron BA.1/BA.2 (R-2 <0.50). Two doses of vaccine elicited very little protective immunity against BA.1/BA.2, though a booster dose significantly improved NAbs for all variants. NAbs/Abs increased more following BTI than after a booster, suggesting that hybrid immunity (vaccination + natural immunity) was more robust to all variants including BA.1/BA.2. BTIs occurring in the omicron era led to stronger NAb responses against BA.1/BA.2 than did older BTIs. In all comparisons, the RBD antigens demonstrated greater differences between WT and BA.1/BA.2 than the spike antigens. DiscussionTaken together, we demonstrated that both Ab and NAb against multiple SARS-CoV-2 variants/subvariants can be reliably detected on the same multiplex platform. Distinguishing NAbs to the appropriate antigenic target of prevalent variants offers the best correlate of protection and aids individual decisions about the appropriateness and cadence of vaccine boosters and other exposure mitigation strategies.	[Liu, Hong; Varvel, Stephen; Chen, Ge; McConnell, Joseph; Caffrey, Rebecca; Galdzicka, Marzena; Shabahang, Shahrokh] Aditxt Inc, Richmond, VA 23219 USA		Varvel, S (corresponding author), Aditxt Inc, Richmond, VA 23219 USA.	svarvel@aditxt.com						Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1101/2021.12.12.472269, 10.1038/s41586-021-04386-2]; Cao Y, 2021, NUMER LINEAR ALGEBR, V28, DOI [10.1002/nla.2362, 10.1038/s41586-021-04385-3]; Cao YL, 2022, NATURE, V608, P593, DOI 10.1038/s41586-022-04980-y; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1; Cheng SMS, 2022, NAT MED, V28, P486, DOI 10.1038/s41591-022-01704-7; Dejnirattisai W, 2022, CELL, V185, P467, DOI 10.1016/j.cell.2021.12.046; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Garcia-Beltran Wilfredo F, 2020, medRxiv, DOI [10.1016/j.cell.2020.12.015, 10.1101/2020.10.15.20213512]; Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lambrou Anastasia S, 2022, MMWR Morb Mortal Wkly Rep, V71, P206, DOI 10.15585/mmwr.mm7106a4; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mendiola-Pastrana IR, 2022, LIFE-BASEL, V12, DOI 10.3390/life12020170; Seaman MS, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.159944; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Wang Q, 2022, NATURE, V608, P603, DOI 10.1038/s41586-022-05053-w; Yu JY, 2022, NEW ENGL J MED, V386, DOI 10.1056/NEJMc2201849	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1039163	10.3389/fimmu.2022.1039163	http://dx.doi.org/10.3389/fimmu.2022.1039163			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U3XC	36505453	gold, Green Published			2022-12-18	WOS:000894300900001
J	Shang, SP; Wang, MZ; Xing, ZY; He, NN; Li, SY				Shang, Shipeng; Wang, Mi-zhou; Xing, Zhiyuan; He, Ningning; Li, Shangyong			Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						lactate regulator; lung adenocarcinoma; cancer prognosis; risk model; immunotherapy	CANCER; EXPRESSION; CELLS	BackgroundLactic acid, as a product of glycolysis, increases tumor cell migration and the invasion of tumor cells in the tumor microenvironment. Besides this, lactic acid promotes the expression of programmed death-1 expression (PD-1) in regulatory T cells, which could cause the failure of PD-1 blockade therapy. However, the implications of lactic acid in the tumor microenvironment of lung adenocarcinoma (LUAD) remain largely unclear. MethodsWe performed unsupervised consensus clustering to identify lactic-associated subtypes using expression profile of lactate regulators in LUAD. Differentially expressed genes (DEGs) associated with lactic-associated subtypes was used to construct lactate signature (LaSig) using LASSO regression algorithm. Immune infiltration analysis was conducted by ESTIMATER and drug sensitivity was estimated by R package called "pRRophetic". The difference between two groups was calculated using Wilcox rank sum test and correlation analysis was calculated using Pearson correlation coefficient. ResultsIn this study, we evaluated DNA methylation and the mutation frequency of lactate regulators and found lactate regulators showed low mutation frequency in the TCGA-LUAD cohort, except TP53. At the RNA level, the expression level of lactate regulators was significantly associated with the immune cell component. In particular, expression of LDHA was positively correlated with CD4 T cell, CD8 T cell, M1 macrophages, and the enrichment score of multiple immune pathways. Two clusters were defined using the gene expression level of lactate regulators, and LDHA was significantly upregulated in cluster 1 with poor overall survival. A lactate signature (LaSig) had a robust performance in predicting the survival rate and immunotherapy response of LUAD patients. Moreover, patients in the high LaSig group may be more likely to benefit from these drugs (Cisplatin, Erlotinib, Gemcitabine, and Vinblastine) than those in the low LaSig group. ConclusionIn summary, our study explores the role of lactate regulators in guiding the clinical treatment of lung adenocarcinoma and provides additional help to supplement traditional molecular subtypes.	[Shang, Shipeng; Wang, Mi-zhou; Xing, Zhiyuan; He, Ningning; Li, Shangyong] Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China; [Wang, Mi-zhou] Affiliated Qingdao Municipal Hosp Qingdao Univ, Anesthesia Operating Dept, Qingdao, Peoples R China; [Xing, Zhiyuan] Qingdao Cent Hosp Qingdao Univ, Dept Abdominal Tumor Surg, Qingdao, Peoples R China	Qingdao University	He, NN; Li, SY (corresponding author), Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China.	heningning@qdu.edu.cn; lisy@qdu.edu.cn			Shandong Provincial Youth Entrepreneurship Program for Colleges and Universities;  [2021KJ075]	Shandong Provincial Youth Entrepreneurship Program for Colleges and Universities; 	Funding This study was supported by the Shandong Provincial Youth Entrepreneurship Program for Colleges and Universities (2021KJ075).	Baxi S, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k793; Berglund A, 2020, J CLIN INVEST, V130, P974, DOI 10.1172/JCI131234; Bohn T, 2018, NAT IMMUNOL, V19, P1319, DOI 10.1038/s41590-018-0226-8; Brown TP, 2020, ONCOGENE, V39, P3292, DOI 10.1038/s41388-020-1216-5; Brown TP, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107451; Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000957; Chen FJ, 2019, J CLIN INVEST, V129, P2056, DOI 10.1172/JCI99538; Chen LH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231911943; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Franke AJ, 2019, JNCI-J NATL CANCER I, V111, P1131, DOI 10.1093/jnci/djz093; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jardim DL, 2021, CANCER CELL, V39, P154, DOI 10.1016/j.ccell.2020.10.001; Kumagai S, 2022, CANCER CELL, V40, P201, DOI 10.1016/j.ccell.2022.01.001; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Ma KY, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121387; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ngwa VM, 2019, CANCER RES, V79, P4003, DOI 10.1158/0008-5472.CAN-19-0617; Qian J, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-020-00667-x; Sheppard S, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109210; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Updegraff BL, 2018, CELL REP, V25, P2223, DOI 10.1016/j.celrep.2018.10.100; Watson MJ, 2021, NATURE, V591, P645, DOI 10.1038/s41586-020-03045-2; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Xie M, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04124-6; Yang XG, 2020, CANCER IMMUNOL RES, V8, P1440, DOI 10.1158/2326-6066.CIR-20-0111; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1024925	10.3389/fimmu.2022.1024925	http://dx.doi.org/10.3389/fimmu.2022.1024925			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1PL	36505423	Green Published, gold			2022-12-18	WOS:000894142200001
J	Tang, LL; Liu, L; Sun, XH; Hu, P; Zhang, H; Wang, BH; Zhang, XA; Jiang, JJ; Zhao, X; Shi, XL				Tang, Lingling; Liu, Li; Sun, Xianhong; Hu, Po; Zhang, Hui; Wang, Bohan; Zhang, Xiaona; Jiang, Jinjin; Zhao, Xia; Shi, Xiaolu			BMAL1/FOXA2-induced rhythmic fluctuations in IL-6 contribute to nocturnal asthma attacks	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; nocturnal symptom; circadian; inflammatory; airway epithelial cell	CIRCADIAN GENE-EXPRESSION; PROTEIN BMAL1; NITRIC-OXIDE; CLOCK; TRANSCRIPTION; LIGHT; FOXA2; INFLAMMATION; BIOLOGY; CELLS	The circadian clock is closely associated with inflammatory reactions. Increased inflammatory cytokine levels have been detected in the airways of nocturnal asthma. However, the mechanisms that contribute to the nocturnal increase in inflammatory responses and the relationship with circadian clock remain unknown. MethodsInflammatory cytokine levels were measured in asthma patients with and without nocturnal symptoms. Allergic airway disease was induced in mice by ovalbumin (OVA), and different periods of light/dark cycles were used to induce circadian rhythm disorders. Serum shock was used to stimulate the rhythmic expression in human bronchial epidermal cells (16HBE). The expression and oscillation of circadian clock genes and inflammatory cytokines in 16HBE cells subjected to brain and muscle ARNT-like protein-1 (BMAL1) and Forkhead Box A2 (FOXA2) knockdown and treatment with a FOXA2 overexpression plasmid were assessed. ResultsSerum IL-6 was found to be significantly higher in asthmatic patients with nocturnal symptoms than those without nocturnal symptoms. The OVA-induced asthma model with a circadian rhythm disorder and 16HBE cells treated with serum shock showed an increase in IL-6 levels and a negative correlation with BMAL1 and FOXA2. The knockdown of BMAL1 resulted in a lower correlation between IL-6 and other rhythm clock genes. Furthermore, knockdown of the BMAL1 and FOXA2 in 16HBE cells reduced the expression and rhythmic fluctuations of IL-6. ConclusionsOur findings suggest that there are increased IL-6 levels in nocturnal asthma resulting from inhibition of the BMAL1/FOXA2 signalling pathway in airway epithelial cells.	[Tang, Lingling; Sun, Xianhong; Wang, Bohan; Zhang, Xiaona; Shi, Xiaolu] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China; [Liu, Li] Nanjing Univ Chinese Med, Dept Cent lab, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China; [Hu, Po] Changzhou Hosp Tradit Chinese Med, Dept Resp, Changzhou, Jiangsu, Peoples R China; [Zhang, Hui] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Resp, Nanjing, Jiangsu, Peoples R China; [Jiang, Jinjin; Zhao, Xia] Nanjing Univ Chinese Med, Inst Pediat, Jiangsu Key Lab Pediat Resp Dis, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Shi, XL (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.; Zhao, X (corresponding author), Nanjing Univ Chinese Med, Inst Pediat, Jiangsu Key Lab Pediat Resp Dis, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.	Zhaoxiahy@njucm.edu.cn; fsyy00721@njucm.edu.cn			National Natural Science Foundation of China; General project of Jiangsu Natural Science Foundation; Graduate Research and Practice Innovation Plan of Graduate Education Innovation Project in Jiangsu Province; 2020 Nanjing Traditional Chinese Medicine Young Talents Training Project;  [82004265];  [82004304];  [BK20211391];  [SJCX21-0742];  [NJSZYYQNRC-2020-ZH]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); General project of Jiangsu Natural Science Foundation; Graduate Research and Practice Innovation Plan of Graduate Education Innovation Project in Jiangsu Province; 2020 Nanjing Traditional Chinese Medicine Young Talents Training Project; ; ; ; ; 	Funding This work was financially supported by National Natural Science Foundation of China 82004265, 82004304, and General project of Jiangsu Natural Science Foundation BK20211391, and Graduate Research and Practice Innovation Plan of Graduate Education Innovation Project in Jiangsu Province SJCX21-0742. 2020 Nanjing Traditional Chinese Medicine Young Talents Training Project NJSZYYQNRC-2020-ZH.	Abdo M, 2021, J ASTHMA ALLERGY, V14, P897, DOI 10.2147/JAA.S313572; Annamneedi VP, 2021, BIOMOL THER, V29, P31, DOI 10.4062/biomolther.2020.215; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Boden MJ, 2010, REPRODUCTION, V139, P1077, DOI 10.1530/REP-09-0523; Chen G, 2010, J IMMUNOL, V184, P6133, DOI 10.4049/jimmunol.1000223; Chen HC, 2021, J ASTHMA ALLERGY, V14, P371, DOI 10.2147/JAA.S302508; Chiou YY, 2016, P NATL ACAD SCI USA, V113, pE6072, DOI 10.1073/pnas.1612917113; Durrington HJ, 2014, THORAX, V69, P90, DOI 10.1136/thoraxjnl-2013-203482; Ehlers A, 2018, MUCOSAL IMMUNOL, V11, P97, DOI 10.1038/mi.2017.24; Engeland WC, 2018, ENDOCRINOLOGY, V159, P3950, DOI 10.1210/en.2018-00769; Fagnano M, 2011, ACAD PEDIATR, V11, P493, DOI 10.1016/j.acap.2011.05.006; Fonken LK, 2014, ENDOCR REV, V35, P648, DOI 10.1210/er.2013-1051; Francisco Cristina de Oliveira, 2019, Porto Biomed J, V4, pe40, DOI 10.1097/j.pbj.0000000000000040; Froy O, 2013, AGEING RES REV, V12, P931, DOI 10.1016/j.arr.2013.09.002; Gallardo A, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900535; Global Initiative for Asthma, 2022, GLOB STRAT ASTHM MAN; Haspel JA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5753; Horner CC, 2016, J ALLERGY CLIN IMMUN, V138, P1196, DOI 10.1016/j.jaci.2016.01.054; Lawther Adam J, 2022, Brain Behav Immun Health, V21, P100428, DOI 10.1016/j.bbih.2022.100428; Lehtimaki L, 2002, EUR RESPIR J, V20, P841, DOI 10.1183/09031936.02.00202002; Lemos DR, 2007, ENDOCRINOLOGY, V148, P5811, DOI 10.1210/en.2007-0610; Li F, 2022, INT J BIOL SCI, V18, P2597, DOI 10.7150/ijbs.71719; Liu Peter Y., 2021, Neurobiology of Sleep and Circadian Rhythms, V10, P100063, DOI 10.1016/j.nbscr.2021.100063; Luo Q, 2015, ALLERGY ASTHMA IMMUN, V7, P458, DOI 10.4168/aair.2015.7.5.458; MACKAY TW, 1994, THORAX, V49, P257, DOI 10.1136/thx.49.3.257; Marone G, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01387; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Mattes J, 2002, PEDIATR RES, V51, P190, DOI 10.1203/00006450-200202000-00011; Mehra R, 2014, AM J RESP CRIT CARE, V190, P243, DOI 10.1164/rccm.201406-1130ED; Mei M, 2020, AM J TRANSL RES, V12, P5563; Mieda M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00055; Moustafa A, 2020, INT J ENDOCRINOL, V2020, DOI 10.1155/2020/1426846; Nakazato R, 2017, GLIA, V65, P198, DOI 10.1002/glia.23087; Ono D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12310; OOSTERHOFF Y, 1995, J ALLERGY CLIN IMMUN, V96, P219, DOI 10.1016/S0091-6749(95)70011-0; Park SW, 2009, AM J RESP CRIT CARE, V180, P603, DOI 10.1164/rccm.200811-1768OC; Polidarova L, 2011, CHRONOBIOL INT, V28, P204, DOI 10.3109/07420528.2010.548615; Reddel HK, 2022, AM J RESP CRIT CARE, V205, P17, DOI 10.1164/rccm.202109-2205PP; Studer P, 2015, CELL DEATH DIFFER, V22, P2068, DOI 10.1038/cdd.2015.52; Sundar IK, 2015, AM J PHYSIOL-LUNG C, V309, pL1056, DOI 10.1152/ajplung.00152.2015; Sussman W, 2019, AM J PHYSIOL-CELL PH, V317, pC492, DOI 10.1152/ajpcell.00058.2019; Swanson GR, 2022, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.770491; Tamaru T, 2000, J NEUROSCI, V20, P7525; Tang LL, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.922003; Tang XJ, 2013, AM J RESP CELL MOL, V49, P960, DOI 10.1165/rcmb.2013-0122OC; Timmons GA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.700431; Tough SC, 1998, J ASTHMA, V35, P657, DOI 10.3109/02770909809048968; Valladares M, 2015, J PHYSIOL BIOCHEM, V71, P855, DOI 10.1007/s13105-015-0447-3; Van Hoecke L, 2017, JOVE-J VIS EXP, DOI 10.3791/55398; West AC, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009097; Xu LR, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.712903; Yang GR, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125133; Zaslona Z, 2017, AM J PHYSIOL-LUNG C, V312, pL855, DOI 10.1152/ajplung.00072.2017; Zhang R, 2014, P NATL ACAD SCI USA, V111, P16219, DOI 10.1073/pnas.1408886111	54	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								947067	10.3389/fimmu.2022.947067	http://dx.doi.org/10.3389/fimmu.2022.947067			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U9XQ	36505412	gold, Green Published			2022-12-18	WOS:000894713500001
J	Zhang, YY; Li, XW; Li, XD; Zhou, TT; Chen, C; Liu, JW; Wang, L; Jiang, X; Wang, L; Liu, M; Zhao, YG; Li, SD				Zhang, Yao-Yu; Li, Xiao-Wei; Li, Xiao-Dong; Zhou, Ting-Ting; Chen, Chao; Liu, Ji-Wen; Wang, Li; Jiang, Xin; Wang, Liang; Liu, Ming; Zhao, You-Guang; Li, Sha-dan			Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						bladder cancer; lncRNA; anoikis; prognostic model; bioinformatics; immune status	STEM-CELLS; METASTASIS; LANDSCAPE; PATHWAYS	BackgroundAnoikis is a form of programmed cell death or programmed cell death(PCD) for short. Studies suggest that anoikis involves in the decisive steps of tumor progression and cancer cell metastasis and spread, but what part it plays in bladder cancer remains unclear. We sought to screen for anoikis-correlated long non-coding RNA (lncRNA) so that we can build a risk model to understand its ability to predict bladder cancer prognosis and the immune landscape. MethodsWe screened seven anoikis-related lncRNAs (arlncRNAs) from The Cancer Genome Atlas (TCGA) and designed a risk model. It was validated through ROC curves and clinicopathological correlation analysis, and demonstrated to be an independent factor of prognosis prediction by uni- and multi-COX regression. In the meantime, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, immune infiltration, and half-maximal inhibitory concentration prediction (IC50) were implemented with the model. Moreover, we divided bladder cancer patients into three subtypes by consensus clustering analysis to further study the differences in prognosis, immune infiltration level, immune checkpoints, and drug susceptibility. ResultWe designed a risk model of seven arlncRNAs, and proved its accuracy using ROC curves. COX regression indicated that the model might be an independent prediction factor of bladder cancer prognosis. KEGG enrichment analysis showed it was enriched in tumors and immune-related pathways among the people at high risk. Immune correlation analysis and drug susceptibility results indicated that it had higher immune infiltration and might have a better immunotherapy efficacy for high-risk groups. Of the three subtypes classified by consensus clustering analysis, cluster 3 revealed a positive prognosis, and cluster 2 showed the highest level of immune infiltration and was sensitive to most chemistries. This is helpful for us to discover more precise immunotherapy for bladder cancer patients. ConclusionIn a nutshell, we found seven arlncRNAs and built a risk model that can identify different bladder cancer subtypes and predict the prognosis of bladder cancer patients. Immune-related and drug sensitivity researches demonstrate it can provide individual therapeutic schedule with greater precision for bladder cancer patients.	[Zhang, Yao-Yu; Li, Xiao-Wei; Li, Xiao-Dong; Zhou, Ting-Ting; Chen, Chao; Liu, Ji-Wen; Wang, Li; Jiang, Xin; Wang, Liang; Zhao, You-Guang; Li, Sha-dan] Gen Hosp Western Theater Command, Dept Urol, Chengdu, Peoples R China; [Zhang, Yao-Yu; Li, Xiao-Dong; Li, Sha-dan] Southwest Med Univ, Affiliated Hosp, Dept Urol, Luzhou, Peoples R China; [Liu, Ming] Xuanhan Chinese Med Hosp, Dept Urol, Dazhou, Peoples R China	Southwest Medical University	Zhao, YG; Li, SD (corresponding author), Gen Hosp Western Theater Command, Dept Urol, Chengdu, Peoples R China.; Li, SD (corresponding author), Southwest Med Univ, Affiliated Hosp, Dept Urol, Luzhou, Peoples R China.	Zhaoyg717@126.com; lishadan2005@126.com			General Hospital of Western Theater Command [2021-XZYG-A11]; urology department of The General Hospital of WTC	General Hospital of Western Theater Command; urology department of The General Hospital of WTC	This study was supported by The General Hospital of Western Theater Command (grant no. 2021-XZYG-A11) and the urology department of The General Hospital of WTC.	Ahluwalia P, 2021, CANCERS, V13, DOI 10.3390/cancers13010155; Bersanelli M, 2021, CRIT REV ONCOL HEMAT, V159, DOI 10.1016/j.critrevonc.2021.103241; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bunea F, 2011, NEUROIMAGE, V55, P1519, DOI 10.1016/j.neuroimage.2010.12.028; Cao Zheng, 2016, Critical Reviews in Oncogenesis, V21, P155, DOI 10.1615/CritRevOncog.2016016955; Chen S, 2021, J ONCOL, V2021, DOI 10.1155/2021/3375297; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Deng ZD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.606817; Fang D, 2018, INT J UROL, V25, P7, DOI 10.1111/iju.13404; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Garg M, 2015, CANCER METAST REV, V34, P691, DOI 10.1007/s10555-015-9589-6; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Hong WF, 2020, MOL THER-NUCL ACIDS, V22, P937, DOI 10.1016/j.omtn.2020.10.002; Hu FF, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa176; Jang I, 2019, CANCERS, V11, DOI 10.3390/cancers11050721; Kim Yong-Nyun, 2012, Int J Cell Biol, V2012, P306879, DOI 10.1155/2012/306879; Liu D, 2020, CLIN TRANSL ONCOL, V22, P1687, DOI 10.1007/s12094-020-02330-w; Liu L, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.811269; Lu YL, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.862741; Lv WC, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.745719; Meng T, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00270; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; PROUT GR, 1956, CANCER, V9, P551, DOI 10.1002/1097-0142(195605/06)9:3<551::AID-CNCR2820090319>3.0.CO;2-2; Robinson EK, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194419; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007; Su XJ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.664393; Tan K, 2013, J CANCER RES CLIN, V139, P1795, DOI 10.1007/s00432-013-1482-5; Tran LD, 2021, NAT REV CANCER, V21, P104, DOI 10.1038/s41568-020-00313-1; Vishnubalaji R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94514-9; Zhang XQ, 2020, DNA CELL BIOL, V39, P299, DOI 10.1089/dna.2019.5161	31	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1055304	10.3389/fimmu.2022.1055304	http://dx.doi.org/10.3389/fimmu.2022.1055304			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U8WS	36505486	gold, Green Published			2022-12-18	WOS:000894643300001
J	Zhang, Y; Duan, CJ; Wu, SW; Ma, JC; Liu, YM; Li, WP; Wang, TT; Yang, L; Cheng, K; Zhuang, R				Zhang, Yuan; Duan, Chujun; Wu, Shuwen; Ma, Jingchang; Liu, Yongming; Li, Wenpeng; Wang, Tingting; Yang, Lu; Cheng, Kun; Zhuang, Ran			Knockout of IL-6 mitigates cold water-immersion restraint stress-induced intestinal epithelial injury and apoptosis	FRONTIERS IN IMMUNOLOGY			English	Article						IL-6; distress; intestinal mucosal barrier; KO mice; apoptosis	ION SECRETION; PERMEABILITY; EXPRESSION; INTERLEUKIN-6; DEFENSINS; MODELS; CELLS	BackgroundInterleukin-6 (IL-6) is essential for maintaining intestinal epithelial homeostasis. Although cold water-immersion restraint (CWIR) stress is commonly used to induce in vivo gastric injury, it also affects intestinal epithelial permeability. Although IL-6 is increased in response to acute physiological and psychological stress, its exact effects on the pathophysiology of the intestinal epithelium in response to acute CWIR stress remain unknown. MethodsWe used IL-6 knockout (KO) mice with acute CWIR modeling to investigate the effect of IL-6 deficiency on intestinal epithelial morphology and pathological damage using histological staining assays under the acute stress. We detected jejunal epithelial apoptosis using TUNEL and standard molecular experiments. ResultsCWIR caused intestinal epithelial damage, which was alleviated by the absence of IL-6, as evidenced by morphological changes and goblet cell and intestinal permeability alteration. IL-6 KO also reduced CWIR-mediated inflammatory levels and improved stress defense. Meanwhile, IL-6 deficiency decreased the intestinal epithelial apoptosis induced by CWIR administration. This IL-6 KO-led effect depended more on mitochondrial AIF signaling rather than the traditional caspase pathway. ConclusionAs a result, we concluded that acute CWIR-induced severe intestinal damage and jejunal epithelium apoptosis could be alleviated by IL-6 deficiency, implying a protective effect of IL-6 deficiency on the intestines under acute stress. The findings shed new light on treating CWIR-induced intestinal disorders by inhibiting IL-6 signaling.	[Zhang, Yuan; Wu, Shuwen; Zhuang, Ran] Northwestern Polytech Univ, Inst Med Res, Xian, Shaanxi, Peoples R China; [Duan, Chujun; Ma, Jingchang; Wang, Tingting; Yang, Lu; Cheng, Kun; Zhuang, Ran] Fourth Mil Med Univ, Dept Immunol, Xian, Shaanxi, Peoples R China; [Liu, Yongming; Li, Wenpeng] Fourth Mil Med Univ, Orthoped Dept, Tangdu Hosp, Xian, Shaanxi, Peoples R China	Northwestern Polytechnical University; Air Force Military Medical University; Air Force Military Medical University	Zhuang, R (corresponding author), Northwestern Polytech Univ, Inst Med Res, Xian, Shaanxi, Peoples R China.; Zhuang, R (corresponding author), Fourth Mil Med Univ, Dept Immunol, Xian, Shaanxi, Peoples R China.	fmmuzhr@fmmu.edu.cn			Natural Science Basic Research Program of Shaanxi; Fourth Military Medical University;  [2021JM-081];  [2018HKPY02];  [2020rcfczr]	Natural Science Basic Research Program of Shaanxi; Fourth Military Medical University; ; ; 	Funding This work was supported by the Natural Science Basic Research Program of Shaanxi (Program No. 2021JM-081) and the funds provided by Fourth Military Medical University (Grant Nos. 2018HKPY02 and 2020rcfczr).	Ataka K, 2003, DIGEST DIS SCI, V48, P1303, DOI 10.1023/A:1024155125366; Bano D, 2018, EBIOMEDICINE, V30, P29, DOI 10.1016/j.ebiom.2018.03.016; Bautista MV, 2009, J IMMUNOL, V183, P2159, DOI 10.4049/jimmunol.0803022; Bevins CL, 2013, DIGEST DIS, V31, P299, DOI 10.1159/000354681; Darcy J, 2020, CELL METAB, V32, P152, DOI 10.1016/j.cmet.2020.07.011; Di Cerbo A, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00427; Ding XQ, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10020185; Gadekar R, 2010, Pharmacogn Rev, V4, P136, DOI 10.4103/0973-7847.70906; Garcia-Hernandez V, 2017, ANN NY ACAD SCI, V1397, P66, DOI 10.1111/nyas.13360; Gipson IK, 2016, PROG RETIN EYE RES, V54, P49, DOI 10.1016/j.preteyeres.2016.04.005; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Guzman-Mejia F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105095; Jaggi AS, 2011, NEUROL SCI, V32, P993, DOI 10.1007/s10072-011-0770-6; Jarczak J, 2013, HUM IMMUNOL, V74, P1069, DOI 10.1016/j.humimm.2013.05.008; Jeffery V, 2017, J IMMUNOL, V199, P304, DOI 10.4049/jimmunol.1600960; Jin XL, 2010, GUT, V59, P186, DOI 10.1136/gut.2008.151175; Johansson MEV, 2011, CELL MOL LIFE SCI, V68, P3635, DOI 10.1007/s00018-011-0822-3; Kuhn KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114195; Landeira-Fernandez J, 2004, PHYSIOL BEHAV, V82, P827, DOI 10.1016/j.physbeh.2004.06.016; Landeira-Fernandez J, 2015, PHYSIOL BEHAV, V140, P209, DOI 10.1016/j.physbeh.2014.12.038; Li BR, 2018, JOVE-J VIS EXP, DOI 10.3791/57032; Li YS, 2020, J CELL MOL MED, V24, P7873, DOI 10.1111/jcmm.15420; Mohamed-Ali V, 2001, J CLIN ENDOCR METAB, V86, P5864, DOI 10.1210/jc.86.12.5864; Monnikes H, 2001, DIGEST DIS, V19, P201, DOI 10.1159/000050681; Norberg E, 2010, BIOCHEM BIOPH RES CO, V396, P95, DOI 10.1016/j.bbrc.2010.02.163; Pluske JR, 1996, BRIT J NUTR, V76, P409, DOI 10.1079/BJN19960046; Qing H, 2020, CELL, V182, P372, DOI 10.1016/j.cell.2020.05.054; Rohleder N, 2012, ANN NY ACAD SCI, V1261, P88, DOI 10.1111/j.1749-6632.2012.06634.x; Rose-John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415; Sae-khow K, 2020, J INFLAMM RES, V13, P719, DOI 10.2147/JIR.S273329; Saunders PR, 2002, DIGEST DIS SCI, V47, P208, DOI 10.1023/A:1013204612762; SAUNDERS PR, 1994, AM J PHYSIOL-GASTR L, V267, pG794, DOI 10.1152/ajpgi.1994.267.5.G794; Saxena B, 2017, DRUG DISCOV THER, V11, P98, DOI 10.5582/ddt.2016.01081; SIRONI M, 1989, J IMMUNOL, V142, P549; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Suzuki T, 2011, J BIOL CHEM, V286, P31263, DOI 10.1074/jbc.M111.238147; Tanaka T, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028456; Wang YF, 2009, EXP NEUROL, V218, P193, DOI 10.1016/j.expneurol.2009.03.020; Wu SW, 2022, CYTOKINE, V153, DOI 10.1016/j.cyto.2022.155841; Xiao YT, 2016, CYTOKINE, V83, P189, DOI 10.1016/j.cyto.2016.04.012; Yaribeygi H, 2017, EXCLI J, V16, P1057, DOI 10.17179/excli2017-480; Zhang MM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201471; Zhang Y, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.706849	43	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								936689	10.3389/fimmu.2022.936689	http://dx.doi.org/10.3389/fimmu.2022.936689			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6V0HI	36505466	Green Published, gold			2022-12-18	WOS:000894738700001
J	Zhao, YD; He, W; Wang, CC; Cui, NA; Yang, CJ; You, ZR; Shi, BS; Xia, L; Chen, XS				Zhao, Yudong; He, Wei; Wang, Chenchen; Cui, Nana; Yang, Changjie; You, Zhengrui; Shi, Bisheng; Xia, Lei; Chen, Xiaosong			Characterization of intrahepatic B cells in acute-on-chronic liver failure	FRONTIERS IN IMMUNOLOGY			English	Article						acute on chronic liver failure; atypical memory B cells; plasma cells; intrahepatic B cells; dysfunction	T-HELPER-CELLS; PLASMA-CELL; DIFFERENTIATION; ACTIVATION; INFECTION; CIRRHOSIS; IMMUNITY; RECEPTOR	Background and objectivesAcute on chronic liver failure (ACLF) is characterized by the immunologic dissonance during the prolonged pathogenic development. Both abnormal innate immune response and adaptive T-cell response have been reported in patients with ACLF; however, less is known regarding B cells in ACLF pathogenesis. Previous reports were only based on immunophenotyping of peripheral blood samples. Here, we aim to dissect liver-infiltrating B-cell subpopulation in ACLF. MethodsPaired liver perfusate and peripheral blood were freshly collected from healthy living donors and recipients during liver transplantation. Liver tissues were obtained from patients with ACLF, cirrhosis, and healthy controls. Flow cytometry was used to characterize the phenotypic and functional alterations in intrahepatic and circulating B-cell populations from ACLF, cirrhosis, and healthy controls. The expression of CD19(+) and CD138(+) on liver tissues was examined by immunohistochemistry staining. ResultsIn this study, we first deciphered the intrahepatic B cells subsets of patients with ACLF. We found that the ACLF liver harbored reduced fraction of naive B cells and elevated percentage of CD27(+)CD21(-) activated memory B cells (AM), CD27(-)CD21(-) atypical memory B cells (atMBC), CD27(+)IgD(-)IgM(+)(IgM(+) memory B cells), and CD27(+)CD38(++) plasma cells than cirrhosis and healthy controls. Moreover, these B subpopulations demonstrated enhanced activation and altered effector functions. Specifically, the ACLF liver was abundant in atMBC expressing higher CD11c and lower CD80 molecule, which was significantly correlated to alanine aminotransferase and aspartate aminotransferase. In addition, we found that intrahepatic CD27(+)CD38(++)plasma cells were preferentially accumulated in ACLF, which expressed more CD273 (PD-L2) and secreted higher granzyme B and IL-10. Finally, the enriched hepatic plasma B cells were in positive association with disease severity indices including alkaline phosphatase and gamma-glutamyl transferase. ConclusionsIn this pilot study, we showed an intrahepatic B-cell landscape shaped by the ACLF liver environment, which was distinct from paired circulating B-cell subsets. The phenotypic and functional perturbation in atMBC and plasma cells highlighted the unique properties of infiltrating B cells during ACLF progression, thereby denoting the potential of B-cell intervention in ACLF therapy.	[Zhao, Yudong; Wang, Chenchen; Yang, Changjie; Xia, Lei; Chen, Xiaosong] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Liver Surg, Shanghai, Peoples R China; [He, Wei; Cui, Nana; You, Zhengrui] Shanghai Jiao Tong Univ, Renji Hosp, Natl Hlth Council NHC, Div Gastroenterol & Hepatol,Key Lab Gastroenterol, Shanghai, Peoples R China; [Shi, Bisheng] Shanghai Jiao tong Univ, Renji Hosp, Sch Med, Dept Lab Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xia, L; Chen, XS (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Liver Surg, Shanghai, Peoples R China.; Shi, BS (corresponding author), Shanghai Jiao tong Univ, Renji Hosp, Sch Med, Dept Lab Med, Shanghai, Peoples R China.	shibisheng@renji.com; drxialei@hotmail.com; chenxiaosong@renji.com			National Natural Science Foundation of China (NSFC); Shanghai Yangfan Program;  [81902366];  [19YF1429000]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Yangfan Program; ; 	Funding This work was supported by the National Natural Science Foundation of China (NSFC) grants (#81902366 to CW) and Shanghai Yangfan Program (19YF1429000 to CW).	Arroyo V, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.41; Barnas JL, 2021, J IMMUNOL, V207, P2660, DOI 10.4049/jimmunol.2100339; Barrow F, 2021, HEPATOLOGY, V74, P2277, DOI 10.1002/hep.31889; Basho K, 2021, J HEPATOL, V74, P649, DOI 10.1016/j.jhep.2020.10.012; Bernsmeier C, 2018, GUT, V67, P1155, DOI 10.1136/gutjnl-2017-314184; Brasher NA, 2020, J HEPATOL, V72, P670, DOI 10.1016/j.jhep.2019.11.011; Burton AR, 2018, J CLIN INVEST, V128, P4588, DOI [10.1172/jci121960, 10.1172/JCI121960]; Cardoso CC, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2021.101698; Choi JK, 2021, METHODS MOL BIOL, V2270, P437, DOI 10.1007/978-1-0716-1237-8_23; Dong XJ, 2013, LIVER INT, V33, P1517, DOI 10.1111/liv.12248; Du BY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641362; Fu YJ, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109344; Golinski ML, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00032; Gronbaek H, 2016, J HEPATOL, V64, P813, DOI 10.1016/j.jhep.2015.11.021; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Hipp N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01475-7; Hollister Kristin, 2018, Liver Res, V2, P52, DOI 10.1016/j.livres.2018.02.001; Hua ZL, 2013, CELL MOL IMMUNOL, V10, P103, DOI 10.1038/cmi.2012.61; Keller B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abh0891; Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58870-2; Knox JJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92943; Le Bert N, 2020, J HEPATOL, V72, P34, DOI 10.1016/j.jhep.2019.07.015; Le Gallou S, 2012, J IMMUNOL, V189, P161, DOI 10.4049/jimmunol.1200301; Liang XS, 2014, WORLD J GASTROENTERO, V20, P8558, DOI 10.3748/wjg.v20.i26.8558; Liu FF, 2016, CLIN RES HEPATOL GAS, V40, P605, DOI 10.1016/j.clinre.2016.01.004; Maini MK, 2018, LANCET GASTROENTEROL, V3, P192, DOI 10.1016/S2468-1253(18)30007-4; Mendoza A, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi4710; Mezzano G, 2022, GUT, V71, P148, DOI 10.1136/gutjnl-2020-322161; Moreau R, 2021, J HEPATOL, V75, pS27, DOI 10.1016/j.jhep.2020.11.047; Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; Ogega Clinton O, 2022, PLoS Pathog, V18, pe1010179, DOI 10.1371/journal.ppat.1010179; Ouyang FZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13453; Papillion A, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw7636; Poonia B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33719-x; Reincke ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.535784; Rubtsov AV, 2015, J IMMUNOL, V195, P71, DOI 10.4049/jimmunol.1500055; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Sarin SK, 2019, HEPATOL INT, V13, P353, DOI 10.1007/s12072-019-09946-3; Shen GJ, 2020, HEPATOL INT, V14, P47, DOI 10.1007/s12072-019-10008-x; Shimabukuro-Vornhagen A, 2017, J LEUKOCYTE BIOL, V101, P577, DOI 10.1189/jlb.5A0416-182R; Song WZ, 2022, IMMUNITY, V55, P290, DOI 10.1016/j.immuni.2022.01.002; Wan ZH, 2016, DIGEST LIVER DIS, V48, P528, DOI 10.1016/j.dld.2016.01.008; Wu W, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620365; Xiang XG, 2020, J HEPATOL, V72, P736, DOI 10.1016/j.jhep.2019.11.013; You ZR, 2021, HEPATOLOGY, DOI 10.1002/hep.31739; Zhao JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01915; Zhao S, 2020, J GASTROEN HEPATOL, V35, P689, DOI 10.1111/jgh.14866	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1041176	10.3389/fimmu.2022.1041176	http://dx.doi.org/10.3389/fimmu.2022.1041176			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U9VV	36505417	gold, Green Published			2022-12-18	WOS:000894708700001
J	Zhou, W; Zhang, CY; Zhuang, ZW; Zhang, J; Zhong, CL				Zhou, Wei; Zhang, Chunyu; Zhuang, Zhongwei; Zhang, Jing; Zhong, Chunlong			Identification of two robust subclasses of sepsis with both prognostic and therapeutic values based on machine learning analysis	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; clustering; LASSO; logistic regression; clinical outcomes		BackgroundSepsis is a heterogeneous syndrome with high morbidity and mortality. Optimal and effective classifications are in urgent need and to be developed. Methods and resultsA total of 1,936 patients (sepsis samples, n=1,692; normal samples, n=244) in 7 discovery datasets were included to conduct weighted gene co-expression network analysis (WGCNA) to filter out candidate genes related to sepsis. Then, two subtypes of sepsis were classified in the training sepsis set (n=1,692), the Adaptive and Inflammatory, using K-means clustering analysis on 90 sepsis-related features. We validated these subtypes using 617 samples in 5 independent datasets and the merged 5 sets. Cibersort method revealed the Adaptive subtype was related to high infiltration levels of T cells and natural killer (NK) cells and a better clinical outcome. Immune features were validated by single-cell RNA sequencing (scRNA-seq) analysis. The Inflammatory subtype was associated with high infiltration of macrophages and a disadvantageous prognosis. Based on functional analysis, upregulation of the Toll-like receptor signaling pathway was obtained in Inflammatory subtype and NK cell-mediated cytotoxicity and T cell receptor signaling pathway were upregulated in Adaptive group. To quantify the cluster findings, a scoring system, called, risk score, was established using four datasets (n=980) in the discovery cohorts based on least absolute shrinkage and selection operator (LASSO) and logistic regression and validated in external sets (n=760). Multivariate logistic regression analysis revealed the risk score was an independent predictor of outcomes of sepsis patients (OR [odds ratio], 2.752, 95% confidence interval [CI], 2.234-3.389, P<0.001), when adjusted by age and gender. In addition, the validation sets confirmed the performance (OR, 1.638, 95% CI, 1.309-2.048, P<0.001). Finally, nomograms demonstrated great discriminatory potential than that of risk score, age and gender (training set: AUC=0.682, 95% CI, 0.643-0.719; validation set: AUC=0.624, 95% CI, 0.576-0.664). Decision curve analysis (DCA) demonstrated that the nomograms were clinically useful and had better discriminative performance to recognize patients at high risk than the age, gender and risk score, respectively. ConclusionsIn-depth analysis of a comprehensive landscape of the transcriptome characteristics of sepsis might contribute to personalized treatments and prediction of clinical outcomes.	[Zhou, Wei] Zhejiang Univ, Huzhou Cent Hosp, Affiliated Huzhou Hosp, Dept Anesthesiol,Sch Med, Huzhou, Zhejiang, Peoples R China; [Zhang, Chunyu; Zhuang, Zhongwei; Zhong, Chunlong] Nanjing Med Univ, Shanghai East Hosp, Dept Neurosurg, Nanjing, Peoples R China; [Zhang, Chunyu; Zhang, Jing; Zhong, Chunlong] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China; [Zhang, Jing] Tongji Univ, Inst Adv Study, Shanghai, Peoples R China	Huzhou University; Zhejiang University; Nanjing Medical University; Tongji University; Tongji University	Zhong, CL (corresponding author), Nanjing Med Univ, Shanghai East Hosp, Dept Neurosurg, Nanjing, Peoples R China.; Zhang, J; Zhong, CL (corresponding author), Tongji Univ, Shanghai East Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.; Zhang, J (corresponding author), Tongji Univ, Inst Adv Study, Shanghai, Peoples R China.	gjingwt@tongji.eol; drchunlongzhong@tongji.edu.cn			Medical Discipline Construction Project of Pudong Health Committee of Shanghai; Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai;  [2021-07];  [PWR12018-07]	Medical Discipline Construction Project of Pudong Health Committee of Shanghai; Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai; ; 	Funding This work was supported by the Medical Discipline Construction Project of Pudong Health Committee of Shanghai (PWYgy 2021-07) and the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (PWR12018-07).	Antcliffe DB, 2019, AM J RESP CRIT CARE, V199, P980, DOI 10.1164/rccm.201807-1419OC; Arts RJW, 2017, J LEUKOCYTE BIOL, V101, P151, DOI 10.1189/jlb.4MR0216-066R; Baghela A, 2022, EBIOMEDICINE, V75, DOI 10.1016/j.ebiom.2021.103776; Barcella M, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2242-3; Bhavani SV, 2019, AM J RESP CRIT CARE, V200, P327, DOI 10.1164/rccm.201806-1197OC; Burnham KL, 2017, AM J RESP CRIT CARE, V196, P328, DOI 10.1164/rccm.201608-1685OC; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Chen XS, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107791; Cohen J, 2015, LANCET INFECT DIS, V15, P581, DOI 10.1016/S1473-3099(15)70112-X; Davenport EE, 2016, LANCET RESP MED, V4, P259, DOI 10.1016/S2213-2600(16)00046-1; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hortova-Kohoutkova M, 2020, J CELL MOL MED, V24, P12504, DOI 10.1111/jcmm.15791; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hu Q, 2021, ACTA PHARM SIN B, V11, P1493, DOI 10.1016/j.apsb.2020.12.014; Jiang WQ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03329-z; Jiang YL, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135678; Kong XL, 2019, INT J BIOL MACROMOL, V125, P892, DOI 10.1016/j.ijbiomac.2018.12.146; Ljungstrom L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225700; Oczenski W, 2003, INTENS CARE MED, V29, P1253, DOI 10.1007/s00134-003-1826-8; Opal SM, 2005, CLIN INFECT DIS, V41, pS504, DOI 10.1086/432007; Peters-Sengers H, 2022, INTENS CARE MED, V48, P92, DOI 10.1007/s00134-021-06574-0; Prescott HC, 2018, JAMA-J AM MED ASSOC, V319, P62, DOI 10.1001/jama.2017.17687; Prescott HC, 2016, AM J RESP CRIT CARE, V194, P147, DOI 10.1164/rccm.201512-2544CP; Reel PS, 2021, BIOTECHNOL ADV, V49, DOI 10.1016/j.biotechadv.2021.107739; Reisinger AC, 2021, NUTRIENTS, V13, DOI 10.3390/nu13093106; Rimmele T, 2016, SHOCK, V45, P282, DOI 10.1097/SHK.0000000000000495; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Scicluna BP, 2017, LANCET RESP MED, V5, P816, DOI 10.1016/S2213-2600(17)30294-1; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shindo Y, 2017, J SURG RES, V208, P33, DOI 10.1016/j.jss.2016.08.099; Soussi S, 2022, CRIT CARE, V26, DOI 10.1186/s13054-022-03972-8; Sun JX, 2022, FRONT SURG, V9, DOI 10.3389/fsurg.2022.814293; Sweeney TE, 2017, CRIT CARE MED, V45, P1, DOI 10.1097/CCM.0000000000002021; van der Poll T, 2021, IMMUNITY, V54, P2450, DOI 10.1016/j.immuni.2021.10.012; Wong HR, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-34; Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141; Xu JJ, 2021, J MICROBIOL IMMUNOL, V54, P404, DOI 10.1016/j.jmii.2019.10.006; Xu ZX, 2022, CRIT CARE, V26, DOI 10.1186/s13054-022-04071-4; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhang CY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.717601; Zhang CY, 2021, J CANCER, V12, P2912, DOI 10.7150/jca.51643; Zhang CY, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-07972-9; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900; Zhang Y, 2010, CRIT CARE, V14, DOI 10.1186/cc9354; Zhang YY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00816-9; Zhang ZH, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103081	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 25	2022	13								1040286	10.3389/fimmu.2022.1040286	http://dx.doi.org/10.3389/fimmu.2022.1040286			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U9ZK	36505503	Green Published, gold			2022-12-18	WOS:000894718100001
J	Barnes, SA; Audsley, KM; Newnes, HV; Fernandez, S; de Jong, E; Waithman, J; Foley, B				Barnes, Samantha A.; Audsley, Katherine M.; Newnes, Hannah V.; Fernandez, Sonia; de Jong, Emma; Waithman, Jason; Foley, Bree			Type I interferon subtypes differentially activate the anti-leukaemic function of natural killer cells	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer cells; leukemia; interferon subtypes; adoptive cell therapy; immunotherapy	NK-CELLS; STAT3; CYTOTOXICITY; INFECTION; AFFINITY; IFNAR1	Natural killer (NK) cells have an intrinsic ability to detect and eliminate leukaemic cells. Cellular therapies using cytokine-activated NK cells have emerged as promising treatments for patients with advanced leukaemia. However, not all patients respond to current NK cell therapies, and thus improvements in efficacy are required. Type I interferons (IFN-I) are a family of potent immunomodulatory cytokines with a known ability to modulate NK cell responses against cancer. Although the human IFN-I family comprises 16 distinct subtypes, only IFN alpha 2 has been widely explored as an anti-cancer agent. Here, we investigated the individual immunomodulatory effects each IFN alpha subtype and IFN beta had on NK cell functionality to determine whether a particular subtype confers enhanced effector activity against leukaemia. Importantly, IFN alpha 14 and IFN beta were identified as superior activators of NK cell effector function in vitro. To test the ability of these subtypes to enhance NK cell activity in vivo, IFN-I stimulation was overlaid onto a standard ex vivo expansion protocol to generate NK cells for adoptive cell therapy. Interestingly, infusion of NK cells pre-activated with IFN alpha 14, but not IFN beta, significantly prolonged survival in a preclinical model of leukaemia compared to NK cells expanded without IFN-I. Collectively, these results highlight the diverse immunomodulatory potencies of individual IFN-I subtypes and support further investigation into the use of IFN alpha 14 to favourably modulate NK cells against leukaemia.	[Barnes, Samantha A.; Audsley, Katherine M.; Newnes, Hannah V.; de Jong, Emma; Waithman, Jason; Foley, Bree] Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia; [Barnes, Samantha A.; Audsley, Katherine M.; Newnes, Hannah V.; Fernandez, Sonia; Waithman, Jason] Univ Western Australia, Sch Biomed Sci, Crawley, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Foley, B (corresponding author), Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia.	bree.foley@telethonkids.org.au	Fernandez, Sonia/H-9176-2014	Fernandez, Sonia/0000-0001-8753-466X; de Jong, Emma/0000-0002-2501-6119	Australian Government Research Training Program Scholarship at The University of Western Australia; Lions Cancer Institute Karen & Joshua Chinnery PhD Top Up Scholarship administered by Cancer Council WA; Richard Walter Gibbon Medical Research Scholarship in Paediatric Cancer Research; Government of Western Australia Department of Health, Cancer Council WA, Brady Cancer Support Foundation; Children's Leukaemia and Cancer Research Foundation	Australian Government Research Training Program Scholarship at The University of Western Australia(Australian Government); Lions Cancer Institute Karen & Joshua Chinnery PhD Top Up Scholarship administered by Cancer Council WA; Richard Walter Gibbon Medical Research Scholarship in Paediatric Cancer Research; Government of Western Australia Department of Health, Cancer Council WA, Brady Cancer Support Foundation; Children's Leukaemia and Cancer Research Foundation	This work was supported by the Australian Government Research Training Program Scholarship at The University of Western Australia and the Lions Cancer Institute Karen & Joshua Chinnery PhD Top Up Scholarship administered by Cancer Council WA (scholarships to SB and HN), the Richard Walter Gibbon Medical Research Scholarship and Rachel Kierath Top-Up Scholarship in Paediatric Cancer Research (scholarships to KA), and funding from the Government of Western Australia Department of Health, Cancer Council WA, Brady Cancer Support Foundation, and the Children's Leukaemia and Cancer Research Foundation (research funding to BF).	Au-Yeung Nancy, 2013, JAKSTAT, V2, pe23931, DOI 10.4161/jkst.23931; Audsley KM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.735133; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Buzzai AC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00542; Cacalano NA, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00128; Cull VS, 2003, BLOOD, V101, P2727, DOI 10.1182/blood-2002-05-1521; de Weerd NA, 2013, NAT IMMUNOL, V14, P901, DOI 10.1038/ni.2667; Dickow J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02255; Foley B, 2011, BLOOD, V118, P2784, DOI 10.1182/blood-2011-04-347070; Francois-Newton V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022200; Genin P, 2009, CYTOKINE GROWTH F R, V20, P283, DOI 10.1016/j.cytogfr.2009.07.005; Ghofrani J, 2019, EUR J IMMUNOL, V49, P1153, DOI 10.1002/eji.201847931; Gibbert K, 2013, BRIT J PHARMACOL, V168, P1048, DOI 10.1111/bph.12010; Gotthardt D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02590; Gotthardt D, 2014, BLOOD, V124, P2370, DOI 10.1182/blood-2014-03-564450; Granzin M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00458; Guo KJ, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008986; Hansen ML, 2011, MOL IMMUNOL, V48, P2087, DOI 10.1016/j.molimm.2011.07.008; Jaitin DA, 2006, MOL CELL BIOL, V26, P1888, DOI 10.1128/MCB.26.5.1888-1897.2006; Jaks E, 2007, J MOL BIOL, V366, P525, DOI 10.1016/j.jmb.2006.11.053; Kalie E, 2008, J BIOL CHEM, V283, P32925, DOI 10.1074/jbc.M806019200; Karakoese Z, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.936918; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lavender KJ, 2016, J VIROL, V90, P6001, DOI 10.1128/JVI.00451-16; Lavoie TB, 2011, CYTOKINE, V56, P282, DOI 10.1016/j.cyto.2011.07.019; Liang SJ, 2003, CYTOKINE, V23, P190, DOI 10.1016/S1043-4666(03)00226-6; Madera S, 2016, J EXP MED, V213, P225, DOI 10.1084/jem.20150712; Miyagi T, 2007, J EXP MED, V204, P2383, DOI 10.1084/jem.20070401; Mizutani T, 2012, ONCOIMMUNOLOGY, V1, P1027, DOI 10.4161/onci.21284; Muller L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00304; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nielsen CM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00101; Ningrum RA, 2014, SCIENTIFICA, V2014, DOI 10.1155/2014/970315; Rautela J, 2017, CURR OPIN IMMUNOL, V44, P1, DOI 10.1016/j.coi.2016.10.004; Schuhenn J, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2111600119; Swann JB, 2007, J IMMUNOL, V178, P7540, DOI 10.4049/jimmunol.178.12.7540; Takaki R, 2005, J IMMUNOL, V175, P2167, DOI 10.4049/jimmunol.175.4.2167; Tu TC, 2015, J EXP MED, V212, P415, DOI 10.1084/jem.20131601; VERHAGEN A, 1990, NAT IMMUN CELL GROW, V9, P325; Zhu SG, 2014, BLOOD, V124, P403, DOI 10.1182/blood-2013-05-499707	42	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1050718	10.3389/fimmu.2022.1050718	http://dx.doi.org/10.3389/fimmu.2022.1050718			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1NG	36505400	Green Published, gold			2022-12-18	WOS:000894136000001
J	Chen, JL; Lou, RH; Zhou, F; Li, D; Peng, C; Lin, LG				Chen, Jiali; Lou, Ruohan; Zhou, Fei; Li, Dan; Peng, Cheng; Lin, Ligen			Sirtuins: Key players in obesity-associated adipose tissue remodeling	FRONTIERS IN IMMUNOLOGY			English	Review						Sirtuins; obesity; adipose tissue remodeling; inflammation; fibrosis	DIET-INDUCED OBESITY; NF-KAPPA-B; INSULIN-RESISTANCE; ADIPOCYTE DIFFERENTIATION; CALORIE RESTRICTION; RESVERATROL SUPPLEMENTATION; MACROPHAGE POLARIZATION; MITOCHONDRIAL-FUNCTION; NAD(+) BIOSYNTHESIS; SIRT1 EXPRESSION	Obesity, a complex disease involving an excessive amount of body fat and a major threat to public health all over the world, is the determining factor of the onset and development of metabolic disorders, including type 2 diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease. Long-term overnutrition results in excessive expansion and dysfunction of adipose tissue, inflammatory responses and over-accumulation of extracellular matrix in adipose tissue, and ectopic lipid deposit in other organs, termed adipose tissue remodeling. The mammalian Sirtuins (SIRT1-7) are a family of conserved NAD(+)-dependent protein deacetylases. Mounting evidence has disclosed that Sirtuins and their prominent substrates participate in a variety of physiological and pathological processes, including cell cycle regulation, mitochondrial biogenesis and function, glucose and lipid metabolism, insulin action, inflammatory responses, and energy homeostasis. In this review, we provided up-to-date and comprehensive knowledge about the roles of Sirtuins in adipose tissue remodeling, focusing on the fate of adipocytes, lipid mobilization, adipose tissue inflammation and fibrosis, and browning of adipose tissue, and we summarized the clinical trials of Sirtuin activators and inhibitors in treating metabolic diseases, which might shed light on new therapeutic strategies for obesity and its associated metabolic diseases.	[Chen, Jiali; Lou, Ruohan; Zhou, Fei; Lin, Ligen] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Macao, Peoples R China; [Li, Dan; Peng, Cheng] Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China; [Lin, Ligen] Univ Macau, Fac Hlth Sci, Dept Pharmaceut Sci & Technol, Taipa, Macao, Peoples R China	University of Macau; Chengdu University of Traditional Chinese Medicine; University of Macau	Lin, LG (corresponding author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Macao, Peoples R China.; Peng, C (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China.; Lin, LG (corresponding author), Univ Macau, Fac Hlth Sci, Dept Pharmaceut Sci & Technol, Taipa, Macao, Peoples R China.	pengchengchengdu@126.com; ligenl@um.edu.mo			Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China [2022ZYXK2011007]; National Natural Science Foundation of China [81872754, 82073715]; Research Fund of University of Macau [MYRG2020-00091-ICMS]; Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau [QRCM-IRG2022-014]; Science and Technology Development Fund, Macao SAR [FDCT 0064/2021/AGJ]	Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund of University of Macau; Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau; Science and Technology Development Fund, Macao SAR	Financial support by the Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China (2022ZYXK2011007), National Natural Science Foundation of China (81872754, 82073715), the Research Fund of University of Macau (MYRG2020-00091-ICMS), Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau (QRCM-IRG2022-014), and the Science and Technology Development Fund, Macao SAR (FDCT 0064/2021/AGJ), is gratefully acknowledged.	Asterholm IW, 2014, CELL METAB, V20, P103, DOI 10.1016/j.cmet.2014.05.005; Bang IH, 2021, AGING CELL, V20, DOI 10.1111/acel.13418; Bilal M, 2021, MOL METAB, V54, DOI 10.1016/j.molmet.2021.101328; Boutant M, 2015, MOL METAB, V4, P118, DOI 10.1016/j.molmet.2014.12.008; Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022; Chakrabarti P, 2011, J LIPID RES, V52, P1693, DOI 10.1194/jlr.M014647; Chalkiadaki A, 2012, CELL METAB, V16, P180, DOI 10.1016/j.cmet.2012.07.003; Chang HC, 2014, TRENDS ENDOCRIN MET, V25, P138, DOI 10.1016/j.tem.2013.12.001; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Chen Q, 2017, CELL REP, V18, P3155, DOI 10.1016/j.celrep.2017.03.006; Choe SS, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00030; Dai H, 2018, PHARMACOL THERAPEUT, V188, P140, DOI 10.1016/j.pharmthera.2018.03.004; de Pinho L, 2013, OBESITY, V21, P1830, DOI 10.1002/oby.20305; Escalona-Garrido C, 2020, MOL METAB, V42, DOI 10.1016/j.molmet.2020.101097; Fang J, 2017, P NATL ACAD SCI USA, V114, pE8352, DOI 10.1073/pnas.1706945114; Franczyk MP, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqab006; Fujitaka K, 2011, NUTR RES, V31, P842, DOI 10.1016/j.nutres.2011.09.028; Galli M, 2011, BIOCHEM PHARMACOL, V81, P569, DOI 10.1016/j.bcp.2010.12.010; Gao P, 2020, DIABETES, V69, P165, DOI 10.2337/db19-0526; Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580-018-0093-z; Gillum MP, 2011, DIABETES, V60, P3235, DOI 10.2337/db11-0616; Gillum MP, 2011, TRENDS MOL MED, V17, P8, DOI 10.1016/j.molmed.2010.09.005; Giralt A, 2011, J BIOL CHEM, V286, P16958, DOI 10.1074/jbc.M110.202390; Gomes P, 2015, TRENDS PHARMACOL SCI, V36, P756, DOI 10.1016/j.tips.2015.08.001; Grabner GF, 2021, NAT METAB, V3, P1445, DOI 10.1038/s42255-021-00493-6; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Han MS, 2013, SCIENCE, V339, P218, DOI 10.1126/science.1227568; Hong JY, 2020, GENOMICS, V112, P1065, DOI 10.1016/j.ygeno.2019.12.004; Hong JY, 2020, ARCH BIOCHEM BIOPHYS, V681, DOI 10.1016/j.abb.2020.108260; Hong JY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181705; Hui XY, 2017, EMBO REP, V18, P645, DOI 10.15252/embr.201643184; Hwang JW, 2013, FREE RADICAL BIO MED, V61, P95, DOI 10.1016/j.freeradbiomed.2013.03.015; Jang MJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0070-z; Jiang HF, 2014, DIABETOLOGIA, V57, P2393, DOI 10.1007/s00125-014-3350-5; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Jokinen R, 2017, REDOX BIOL, V12, P246, DOI 10.1016/j.redox.2017.02.011; Jukarainen S, 2016, J CLIN ENDOCR METAB, V101, P274, DOI 10.1210/jc.2015-3095; Jung YJ, 2020, STEM CELL RES, V44, DOI 10.1016/j.scr.2020.101771; Ka SO, 2015, J ENDOCRINOL, V224, P109, DOI 10.1530/JOE-14-0527; Kan Y, 2008, FEBS LETT, V582, P2417, DOI 10.1016/j.febslet.2008.06.005; Kanfi Y, 2008, FEBS LETT, V582, P543, DOI [10.1016/j.febslet.2008.01.019, 10.1016/j.febslet.2008.06.005]; Kanfi Y, 2010, AGING CELL, V9, P162, DOI 10.1111/j.1474-9726.2009.00544.x; Khanh VC, 2018, BIOCHEM BIOPH RES CO, V500, P682, DOI 10.1016/j.bbrc.2018.04.136; Khwatenge CN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.732913; Kim KE, 2018, BIOCHEM BIOPH RES CO, V499, P1025, DOI 10.1016/j.bbrc.2018.04.044; Kim MB, 2022, J NUTR BIOCHEM, V107, DOI 10.1016/j.jnutbio.2022.109058; Koenen M, 2021, CIRC RES, V128, P951, DOI 10.1161/CIRCRESAHA.121.318093; Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111; Krueger JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142081; Kuang JY, 2017, DIABETES, V66, P1159, DOI 10.2337/db16-1225; Kurylowicz A, 2016, INT J OBESITY, V40, P1635, DOI 10.1038/ijo.2016.131; Laurent G, 2013, MOL CELL, V50, P686, DOI 10.1016/j.molcel.2013.05.012; Lee Y, 2017, DIABETES, V66, P2659, DOI 10.2337/db16-1446; Li C, 2018, TRANSL RES, V191, P29, DOI 10.1016/j.trsl.2017.10.004; Li D, 2021, CRIT REV FOOD SCI, V61, P1947, DOI 10.1080/10408398.2020.1768044; Li Y, 2014, GASTROENTEROLOGY, V146, P539, DOI 10.1053/j.gastro.2013.10.059; Li ZL, 2020, FASEB J, V34, P4527, DOI 10.1096/fj.201902222R; Lin K, 2022, ACTA PHARMACOL SIN, V43, P2624, DOI 10.1038/s41401-022-00885-8; Lin QQ, 2012, CYTOKINE, V60, P447, DOI 10.1016/j.cyto.2012.05.025; Liu JX, 2019, ACTA PHARM SIN B, V9, P220, DOI 10.1016/j.apsb.2018.09.007; Liu L, 2020, OBES SURG, V30, P1392, DOI 10.1007/s11695-019-04295-4; Liu ZJ, 2017, ONCOTARGET, V8, P9267, DOI 10.18632/oncotarget.14035; Liu ZJ, 2016, J LIPID RES, V57, P1373, DOI 10.1194/jlr.M063537; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Luo T, 2016, DIABETES, V65, P2295, DOI 10.2337/db15-1122; Majeed Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87759-x; Marcelin G, 2019, J CLIN INVEST, V129, P4032, DOI 10.1172/JCI129192; Mariani S, 2017, ENDOCRINE, V57, P455, DOI 10.1007/s12020-016-1170-8; Martinez-Jimenez V, 2019, DIABETES METAB SYND, V13, P582, DOI 10.1016/j.dsx.2018.11.011; Mayoral R, 2015, MOL METAB, V4, P378, DOI 10.1016/j.molmet.2015.02.007; Molinari F, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051126; Moschen AR, 2013, J HEPATOL, V59, P1315, DOI 10.1016/j.jhep.2013.07.027; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nielsen KN, 2018, MOL METAB, V11, P178, DOI 10.1016/j.molmet.2018.02.014; Okabe K, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586179; Pardo R, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202000672; Perrini S, 2020, INT J OBESITY, V44, P307, DOI 10.1038/s41366-019-0436-7; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Porter LC, 2018, AM J PHYSIOL-ENDOC M, V315, pE520, DOI 10.1152/ajpendo.00057.2018; Pyrina I, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00644; Qiang L, 2012, CELL, V150, P620, DOI 10.1016/j.cell.2012.06.027; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Ramadori G, 2010, CELL METAB, V12, P78, DOI 10.1016/j.cmet.2010.05.010; Rappou E, 2016, J CLIN ENDOCR METAB, V101, P1263, DOI 10.1210/jc.2015-3054; Sands BE, 2016, INFLAMM BOWEL DIS, V22, P607, DOI 10.1097/MIB.0000000000000597; Schug TT, 2010, MOL CELL BIOL, V30, P4712, DOI 10.1128/MCB.00657-10; Serrano-Marco L, 2012, BBA-MOL CELL BIOL L, V1821, P1177, DOI 10.1016/j.bbalip.2012.05.006; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Shi T, 2010, J DIGEST DIS, V11, P55, DOI 10.1111/j.1751-2980.2009.00416.x; Shuai L, 2019, DIABETES, V68, P1449, DOI 10.2337/db18-1103; Smith GI, 2019, J CLIN INVEST, V129, P3978, DOI 10.1172/JCI129186; Song J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00724; Song Mi-Young, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0256-9; Song YS, 2013, DIABETES RES CLIN PR, V101, P341, DOI 10.1016/j.diabres.2013.07.002; Stromsdorfer KL, 2016, CELL REP, V16, P1851, DOI 10.1016/j.celrep.2016.07.027; Sussmuth SD, 2015, BRIT J CLIN PHARMACO, V79, P465, DOI 10.1111/bcp.12512; Sun Y, 2014, PHARMACOL RES, V89, P19, DOI 10.1016/j.phrs.2014.07.006; Tang Q, 2020, MOL METAB, V37, DOI 10.1016/j.molmet.2020.100994; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Trivanovic D, 2018, ARTIF CELL NANOMED B, V46, pS370, DOI 10.1080/21691401.2018.1494183; Vachharajani V, 2020, EXPERT OPIN THER TAR, V24, P489, DOI 10.1080/14728222.2020.1743268; Vachharajani VT, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8167273; Vijay J, 2020, NAT METAB, V2, P97, DOI 10.1038/s42255-019-0152-6; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang F, 2009, MOL BIOL CELL, V20, P801, DOI 10.1091/mbc.E08-06-0647; Wang GX, 2019, MOL CELL, V74, P844, DOI 10.1016/j.molcel.2019.03.021; Wei T, 2021, ARTERIOSCL THROM VAS, V41, P714, DOI 10.1161/ATVBAHA.120.315337; Wei T, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1834-4; Wei XJ, 2020, J NUTR BIOCHEM, V80, DOI 10.1016/j.jnutbio.2020.108377; Westerberg G, 2015, BRIT J CLIN PHARMACO, V79, P477, DOI 10.1111/bcp.12513; Wronska A, 2016, GERONTOLOGY, V62, P304, DOI 10.1159/000441603; Wu DD, 2021, EXP MOL MED, V53, P1298, DOI 10.1038/s12276-021-00664-1; Wu Y, 2018, EXP CELL RES, V367, P137, DOI 10.1016/j.yexcr.2018.03.030; Wu YT, 2018, FREE RADICAL RES, V52, P1398, DOI 10.1080/10715762.2018.1489130; Xiang DM, 2017, AM J PHYSIOL-RENAL, V312, pF689, DOI 10.1152/ajprenal.00584.2016; Xu C, 2015, DIABETES, V64, P1576, DOI 10.2337/db14-1180; Xu F, 2016, OBESITY, V24, P634, DOI 10.1002/oby.21393; Xu F, 2012, ENDOCRINOLOGY, V153, P1706, DOI 10.1210/en.2011-1667; Xu F, 2010, ENDOCRINOLOGY, V151, P2504, DOI 10.1210/en.2009-1013; Yamaguchi S, 2019, P NATL ACAD SCI USA, V116, P23822, DOI 10.1073/pnas.1909917116; Yao JF, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.977485; Yao L, 2017, CELL REP, V20, P641, DOI 10.1016/j.celrep.2017.06.069; Ye X, 2017, ONCOTARGET, V8, P1845, DOI 10.18632/oncotarget.12157; Yoshino J, 2012, CELL METAB, V16, P658, DOI 10.1016/j.cmet.2012.09.015; Yoshino J, 2011, CELL METAB, V14, P528, DOI 10.1016/j.cmet.2011.08.014; Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08; Yu JJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02806; Yu JJ, 2009, ANN NY ACAD SCI, V1173, pE10, DOI 10.1111/j.1749-6632.2009.04952.x; Zaganjor E, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109345; Zatterale F, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01607; Zhang T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020372; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zhou S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00748; Zullo A, 2021, WOUND REPAIR REGEN, V29, P650, DOI 10.1111/wrr.12943	135	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1068986	10.3389/fimmu.2022.1068986	http://dx.doi.org/10.3389/fimmu.2022.1068986			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2DX	36505468	gold, Green Published			2022-12-18	WOS:000894180600001
J	Chen, YS; Tang, L				Chen, Yusi; Tang, Li			The crosstalk between parenchymal cells and macrophages: A keeper of tissue homeostasis	FRONTIERS IN IMMUNOLOGY			English	Review						parenchymal cells; tissue-resident macrophages; cellular crosstalk; tissue-specific function; mammalian; tissue homeostasis	RESIDENT MACROPHAGES; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MESENCHYMAL TRANSITION; MICROGLIA; HETEROGENEITY; ATHEROSCLEROSIS; INFLAMMATION; POLARIZATION; PHYSIOLOGY	Non-parenchymal cells (NPCs) and parenchymal cells (PCs) collectively perform tissue-specific functions. PCs play significant roles and continuously adjust the intrinsic functions and metabolism of organs. Tissue-resident macrophages (TRMs) are crucial members of native NPCs in tissues and are essential for immune defense, tissue repair and development, and homeostasis maintenance. As a plastic-phenotypic and prevalent cluster of NPCs, TRMs dynamically assist PCs in functioning by producing cytokines, inflammatory and anti-inflammatory signals, growth factors, and proteolytic enzymes. Furthermore, the PCs of tissues modulate the functional activity and polarization of TRMs. Dysregulation of the PC-TRM crosstalk axis profoundly impacts many essential physiological functions, including synaptogenesis, gastrointestinal motility and secretion, cardiac pulsation, gas exchange, blood filtration, and metabolic homeostasis. This review focuses on the PC-TRM crosstalk in mammalian vital tissues, along with their interactions with tissue homeostasis maintenance and disorders. Thus, this review highlights the fundamental biological significance of the regulatory network of PC-TRM in tissue homeostasis.	[Chen, Yusi; Tang, Li] Beijing Inst Life, Natl Ctr Prot Sci, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China		Tang, L (corresponding author), Beijing Inst Life, Natl Ctr Prot Sci, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China.	tangli@ncpsb.org.cn			National Natural Science Foundation of China;  [31900632];  [31900666];  [82225009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; ; 	Funding This work was supported by the National Natural Science Foundation of China (Grant Nos. 31900632, 31900666, 82225009).	A-Gonzalez N, 2018, CELL IMMUNOL, V330, P151, DOI 10.1016/j.cellimm.2018.05.005; Aegerter Helena, 2022, Immunity, V55, P1564, DOI 10.1016/j.immuni.2022.08.010; Agudelo CW, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-01278-8; Aizarani N, 2019, NATURE, V572, P199, DOI 10.1038/s41586-019-1373-2; Alam Z, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107825; Arrese M, 2016, DIGEST DIS SCI, V61, P1294, DOI 10.1007/s10620-016-4049-x; Badimon A, 2020, NATURE, V586, P417, DOI 10.1038/s41586-020-2777-8; Backdahl J, 2021, CELL METAB, V33, P1869, DOI 10.1016/j.cmet.2021.07.018; Bain CC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02733; Bajpai G, 2019, CIRC RES, V124, P263, DOI 10.1161/CIRCRESAHA.118.314028; Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103; Bein K, 2013, AM J RESP CELL MOL, V49, P306, DOI 10.1165/rcmb.2012-0283OC; Bellomo A, 2021, IMMUNOL REV, V302, P104, DOI 10.1111/imr.12979; Bellomo A, 2020, IMMUNITY, V53, P127, DOI 10.1016/j.immuni.2020.06.008; Ben-Moshe S, 2019, NAT REV GASTRO HEPAT, V16, P395, DOI 10.1038/s41575-019-0134-x; Bennett LF, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aap7336; Bernardo BC, 2010, PHARMACOL THERAPEUT, V128, P191, DOI 10.1016/j.pharmthera.2010.04.005; Bi QQ, 2022, IMMUNITY, V55, P1466, DOI 10.1016/j.immuni.2022.06.018; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Bleriot C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02694; Block L, 2016, SCAND J PAIN, V10, P74, DOI 10.1016/j.sjpain.2015.10.002; Bonnardel J, 2019, IMMUNITY, V51, P638, DOI 10.1016/j.immuni.2019.08.017; Bottai D, 2020, CURR MED CHEM, V27, P4039, DOI 10.2174/0929867326666190506120213; Brykczynska U, 2020, CELL REP, V30, P1627, DOI 10.1016/j.celrep.2020.01.005; Cahill TJ, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.194563; Canadas O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103708; Chakarov S, 2022, J EXP MED, V219, DOI 10.1084/jem.20211948; Chen Q, 2021, EMBO REP, V22, DOI 10.15252/embr.202152835; Chiaranunt P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.749708; Chikina AS, 2020, CELL, V183, P411, DOI 10.1016/j.cell.2020.08.048; Cipriani G, 2019, CELL MOL GASTROENTER, V7, P689, DOI 10.1016/j.jcmgh.2019.01.005; Cox N, 2021, SCIENCE, V373, DOI 10.1126/science.abe9383; Cox N, 2021, ANNU REV IMMUNOL, V39, P313, DOI 10.1146/annurev-immunol-093019-111748; De Biase LM, 2019, NEUROSCIENTIST, V25, P314, DOI 10.1177/1073858418800996; De Schepper S, 2018, CELL, V175, P400, DOI 10.1016/j.cell.2018.07.048; Delfini M, 2022, IMMUNITY, V55, P1530, DOI 10.1016/j.immuni.2022.08.005; Demetz E, 2020, EUR HEART J, V41, P3949, DOI 10.1093/eurheartj/ehaa140; Ding C, 2016, MOL CELL PROTEOMICS, V15, P3190, DOI 10.1074/mcp.M116.060145; Eguchi A, 2014, DIGEST DIS, V32, P579, DOI 10.1159/000360509; Elmentaite R, 2021, NATURE, V597, P250, DOI 10.1038/s41586-021-03852-1; Engin AB, 2017, ADV EXP MED BIOL, V960, P327, DOI 10.1007/978-3-319-48382-5_14; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Frigolet ME, 2020, GAC MED MEX, V156, P142, DOI 10.24875/GMM.M20000356; Gao H, 2022, CELL METAB, V34, P978, DOI 10.1016/j.cmet.2022.05.008; Gavin KM, 2017, ADIPOCYTE, V6, P234, DOI 10.1080/21623945.2017.1314403; Ginhoux F, 2016, IMMUNITY, V44, P439, DOI 10.1016/j.immuni.2016.02.024; Golub R, 2018, TRENDS IMMUNOL, V39, P503, DOI 10.1016/j.it.2018.02.007; Greenhalgh AD, 2020, NAT REV NEUROSCI, V21, P139, DOI 10.1038/s41583-020-0263-9; Grosjean A, 2021, SEMIN CELL DEV BIOL, V119, P130, DOI 10.1016/j.semcdb.2021.09.002; Grune Jana, 2022, Nat Cardiovasc Res, V1, P649, DOI 10.1038/s44161-022-00094-w; Gschwend J, 2021, J EXP MED, V218, DOI 10.1084/jem.20210745; Guilliams M, 2022, CELL, V185, P379, DOI 10.1016/j.cell.2021.12.018; Guilliams M, 2020, IMMUNITY, V52, P434, DOI 10.1016/j.immuni.2020.02.015; Guilliams M, 2017, NAT REV IMMUNOL, V17, P451, DOI 10.1038/nri.2017.42; Hackett TA, 2018, ANAT REC, V301, P1882, DOI 10.1002/ar.23907; Halpern KB, 2017, NATURE, V542, P352, DOI 10.1038/nature21065; Hammond TR, 2019, IMMUNITY, V50, P253, DOI 10.1016/j.immuni.2018.11.004; Hao SY, 2019, BLOOD ADV, V3, P2205, DOI 10.1182/bloodadvances.2019000375; Hill DA, 2018, P NATL ACAD SCI USA, V115, pE5096, DOI 10.1073/pnas.1802611115; Hoeffel G, 2018, CELL IMMUNOL, V330, P5, DOI 10.1016/j.cellimm.2018.01.001; Holtman IR, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0203-5; Hoppstadter J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-124; Hou F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.753940; Hou JC, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135197; Hulsmans M, 2017, CELL, V169, P510, DOI 10.1016/j.cell.2017.03.050; Illes P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051108; Jaitin DA, 2019, CELL, V178, P686, DOI 10.1016/j.cell.2019.05.054; Jiang PC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183114; Khalil H, 2017, J CLIN INVEST, V127, P3770, DOI 10.1172/JCI94753; Kierdorf K, 2017, J CLIN INVEST, V127, P3201, DOI [10.1172/JCI90602, 10.1172/jci90602]; Kim SY, 2019, IMMUNOL CELL BIOL, V97, P258, DOI 10.1111/imcb.12236; Koc A, 2021, ADV EXP MED BIOL, V1312, P75, DOI 10.1007/5584_2020_576; Krenkel O, 2017, NAT REV IMMUNOL, V17, P306, DOI 10.1038/nri.2017.11; Kulikauskaite J, 2020, TRENDS IMMUNOL, V41, P864, DOI 10.1016/j.it.2020.08.008; Kunz HE, 2021, AM J PHYSIOL-ENDOC M, V321, pE105, DOI 10.1152/ajpendo.00070.2021; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Lee JW, 2019, AUTOPHAGY, V15, P753, DOI 10.1080/15548627.2018.1556946; Li PP, 2013, CELL, V155, P200, DOI 10.1016/j.cell.2013.08.054; Li QY, 2019, NEURON, V101, P207, DOI 10.1016/j.neuron.2018.12.006; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Li X, 2021, J ASTHMA ALLERGY, V14, P513, DOI 10.2147/JAA.S307165; Lindhorst A, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03872-9; Liu B, 2013, J IMMUNOL, V190, P4185, DOI 10.4049/jimmunol.1203091; Liu KL, 2021, CELL METAB, V3, P666, DOI 10.1016/j.cmet.2021.01.012; Loft A, 2022, CELL METAB, V34, P473, DOI 10.1016/j.cmet.2022.01.004; Lopez-Rodriguez E, 2017, CELL TISSUE RES, V367, P721, DOI 10.1007/s00441-016-2520-9; Luo JL, 2018, IMMUNITY, V49, P107, DOI 10.1016/j.immuni.2018.04.021; Lyu QP, 2020, BIOCHEM BIOPH RES CO, V522, P560, DOI 10.1016/j.bbrc.2019.11.077; Ma WD, 2019, J IMMUNOL, V203, P2689, DOI 10.4049/jimmunol.1900366; Mandal P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111221; Mangalmurti A, 2022, CURR OPIN NEUROBIOL, V75, DOI 10.1016/j.conb.2022.102575; Marinelli S, 2019, SEMIN CELL DEV BIOL, V94, P138, DOI 10.1016/j.semcdb.2019.05.017; Marrone J, 2021, BIOCHIMIE, V188, P12, DOI 10.1016/j.biochi.2021.03.016; Masuda T, 2019, NATURE, V566, P388, DOI 10.1038/s41586-019-0924-x; Medzhitov R, 2021, SCIENCE, V374, P1070, DOI 10.1126/science.abi5200; Meizlish ML, 2021, ANNU REV IMMUNOL, V39, P557, DOI 10.1146/annurev-immunol-061020-053734; Melo EM, 2021, INT J BIOCHEM CELL B, V141, DOI 10.1016/j.biocel.2021.106095; Miao WY, 2020, J IMMUNOL, V204, P1486, DOI 10.4049/jimmunol.1900909; Molofsky AB, 2015, IMMUNITY, V42, P1005, DOI 10.1016/j.immuni.2015.06.006; Muller PA, 2014, CELL, V158, P300, DOI 10.1016/j.cell.2014.04.050; Munshi NV, 2017, CELL, V169, P376, DOI 10.1016/j.cell.2017.04.002; Murano I, 2008, J LIPID RES, V49, P1562, DOI 10.1194/jlr.M800019-JLR200; Na YR, 2021, GUT, V70, P2249, DOI 10.1136/gutjnl-2020-322146; Na YR, 2019, NAT REV GASTRO HEPAT, V16, P531, DOI 10.1038/s41575-019-0172-4; Nawaz A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00231-1; Nguyen PT, 2020, CELL, V182, P388, DOI 10.1016/j.cell.2020.05.050; Nicolas-Avila JA, 2020, CELL, V183, P94, DOI 10.1016/j.cell.2020.08.031; Nobs SP, 2021, TRENDS IMMUNOL, V42, P495, DOI 10.1016/j.it.2021.04.007; Norris GT, 2019, J EXP MED, V216, P60, DOI 10.1084/jem.20180199; O'Farrell K, 2017, EUR J PHARMACOL, V810, P163, DOI 10.1016/j.ejphar.2017.07.008; Oh JS, 2015, CELL REP, V10, P1872, DOI 10.1016/j.celrep.2015.02.043; Oishi Y, 2017, CELL METAB, V25, P412, DOI 10.1016/j.cmet.2016.11.009; Okabe Y, 2016, NAT IMMUNOL, V17, P9, DOI 10.1038/ni.3320; Okumura R, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.20; Pan JJ, 2018, CELL IMMUNOL, V332, P111, DOI 10.1016/j.cellimm.2018.08.006; Pan Y, 2019, J CLIN INVEST, V129, P834, DOI 10.1172/JCI123069; Petkevicius K, 2021, FASEB J, V35, DOI 10.1096/fj.202001101R; Pirgova G, 2020, P NATL ACAD SCI USA, V117, P12295, DOI [10.1073/pnas.1921673117/-/DCSupplemental, 10.1073/pnas.1921673117]; Prinz M, 2017, NAT IMMUNOL, V18, P385, DOI 10.1038/ni.3703; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Puchalska P, 2019, CELL METAB, V29, P383, DOI 10.1016/j.cmet.2018.10.015; Qin YL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26408-3; Raffo-Romero A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124124; Raghuraman R, 2019, NEUROBIOL LEARN MEM, V163, DOI 10.1016/j.nlm.2019.107039; Rawji KS, 2020, ACTA NEUROPATHOL, V139, P893, DOI 10.1007/s00401-020-02129-7; Sakai M, 2019, IMMUNITY, V51, P655, DOI 10.1016/j.immuni.2019.09.002; Sarvari AK, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.579; Sawai CM, 2016, IMMUNITY, V45, P597, DOI 10.1016/j.immuni.2016.08.007; Schyns J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5160794; Sevenich L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00697; Shaw TN, 2018, J EXP MED, V215, P1507, DOI 10.1084/jem.20180019; Shen XL, 2018, PROG NEUROBIOL, V171, P50, DOI 10.1016/j.pneurobio.2018.09.007; Sierro F, 2017, IMMUNITY, V47, P374, DOI 10.1016/j.immuni.2017.07.018; Silva HM, 2019, J EXP MED, V216, P786, DOI 10.1084/jem.20181049; Skronska-Wasek W, 2022, EUR RESPIR J, V59, DOI 10.1183/13993003.02732-2020; Sominsky L, 2018, INT J BIOCHEM CELL B, V94, P56, DOI 10.1016/j.biocel.2017.11.012; Song M, 2018, CELL PHYSIOL BIOCHEM, V48, P1416, DOI 10.1159/000492252; Soucie EL, 2016, SCIENCE, V351, DOI 10.1126/science.aad5510; Stienstra R, 2010, HEPATOLOGY, V51, P511, DOI 10.1002/hep.23337; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Su L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0377-4; Subramanian S, 2022, NAT IMMUNOL, V23, P458, DOI 10.1038/s41590-022-01146-w; Sugita J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22178-0; Terada M, 2016, SCI REP-UK, V6, DOI 10.1038/srep34691; Toita R, 2016, BIOMATERIALS, V110, P81, DOI 10.1016/j.biomaterials.2016.09.018; Travaglini KJ, 2020, NATURE, V587, DOI 10.1038/s41586-020-2922-4; Vainchtein ID, 2018, SCIENCE, V359, P1269, DOI 10.1126/science.aal3589; Wang YN, 2021, NAT METAB, V3, P1536, DOI 10.1038/s42255-021-00482-9; Ween MP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82481-0; Wen YK, 2021, CELL MOL IMMUNOL, V18, P45, DOI 10.1038/s41423-020-00558-8; Westphalen K, 2014, NATURE, V506, P503, DOI 10.1038/nature12902; Winn NC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132964; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; Wong NR, 2021, IMMUNITY, V54, P2072, DOI 10.1016/j.immuni.2021.07.003; Wright-Jin EC, 2019, TRENDS MOL MED, V25, P967, DOI 10.1016/j.molmed.2019.08.013; Xie D, 2019, CNS NEUROSCI THER, V25, P1287, DOI 10.1111/cns.13257; Yang AM, 2017, J CLIN INVEST, V127, P2829, DOI 10.1172/JCI90562; Yang M, 2017, MOL MED REP, V16, P3482, DOI 10.3892/mmr.2017.6955; Yang ZP, 2018, P NATL ACAD SCI USA, V115, P11054, DOI 10.1073/pnas.1804094115; Yeh H, 2019, TRENDS MOL MED, V25, P96, DOI 10.1016/j.molmed.2018.11.004; Ying W, 2021, CELL METAB, V33, P781, DOI 10.1016/j.cmet.2020.12.019; Yip JLK, 2021, CELL MOL GASTROENTER, V12, P1701, DOI 10.1016/j.jcmgh.2021.08.021; Young AMH, 2021, NAT GENET, V53, P861, DOI 10.1038/s41588-021-00875-2; Zaman R, 2022, IMMUNITY, V55, P1549, DOI 10.1016/j.immuni.2022.08.009; Zhang LY, 2019, ARCH TOXICOL, V93, P3305, DOI 10.1007/s00204-019-02572-w; Zhao DY, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI150489; Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004	167	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1050188	10.3389/fimmu.2022.1050188	http://dx.doi.org/10.3389/fimmu.2022.1050188			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6V0SR	36505488	Green Published, gold			2022-12-18	WOS:000894768500001
J	Cohen, IJ; Pareja, F; Socci, ND; Shen, RL; Doane, AS; Schwartz, J; Khanin, R; Morris, EA; Sutton, EJ; Blasberg, RG				Cohen, Ivan J.; Pareja, Fresia; Socci, Nicholas D.; Shen, Ronglai; Doane, Ashley S.; Schwartz, Jazmin; Khanin, Raya; Morris, Elizabeth A.; Sutton, Elizabeth J.; Blasberg, Ronald G.			Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors	FRONTIERS IN IMMUNOLOGY			English	Article						tumor metabolism; immunotherapy; tumor microenvironment; solid tumors; glycolysis; immune infiltration	CELL LUNG-CANCER; NIVOLUMAB PLUS IPILIMUMAB; STAGE IV MELANOMA; BREAST-CANCER; PROTEOGENOMIC CHARACTERIZATION; ADJUVANT NIVOLUMAB; GENE SIGNATURE; DOUBLE-BLIND; OPEN-LABEL; AEROBIC GLYCOLYSIS	Response to immunotherapy across multiple cancer types is approximately 25%, with some tumor types showing increased response rates compared to others (i.e. response rates in melanoma and non-small cell lung cancer (NSCLC) are typically 30-60%). Patients whose tumors are resistant to immunotherapy often lack high levels of pre-existing inflammation in the tumor microenvironment. Increased tumor glycolysis, acting through glucose deprivation and lactic acid accumulation, has been shown to have pleiotropic immune suppressive effects using in-vitro and in-vivo models of disease. To determine whether the immune suppressive effect of tumor glycolysis is observed across human solid tumors, we analyzed glycolytic and immune gene expression patterns in multiple solid malignancies. We found that increased expression of a glycolytic signature was associated with decreased immune infiltration and a more aggressive disease across multiple tumor types. Radiologic and pathologic analysis of untreated estrogen receptor (ER)-negative breast cancers corroborated these observations, and demonstrated that protein expression of glycolytic enzymes correlates positively with glucose uptake and negatively with infiltration of CD3(+) and CD8(+) lymphocytes. This study reveals an inverse relationship between tumor glycolysis and immune infiltration in a large cohort of multiple solid tumor types.	[Cohen, Ivan J.; Blasberg, Ronald G.] Mem Sloan Kettering Canc Ctr, Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY 10065 USA; [Pareja, Fresia] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA; [Socci, Nicholas D.; Khanin, Raya] Mem Sloan Kettering Canc Ctr, Bioinformat Core, New York, NY USA; [Shen, Ronglai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA; [Doane, Ashley S.] Weill Cornell Med, Computat Biol & Med Tri Inst PhD Program, New York, NY USA; [Schwartz, Jazmin] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY USA; [Morris, Elizabeth A.; Sutton, Elizabeth J.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY USA; [Blasberg, Ronald G.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY USA; [Doane, Ashley S.; Blasberg, Ronald G.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Cohen, IJ (corresponding author), Mem Sloan Kettering Canc Ctr, Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY 10065 USA.	ivan.cohen@pennmedicine.upenn.edu			NCI [R01-CA215136]; Breast Research Fund at MSKCC; Cancer Center Support Grant [P30 CA008748]; NIH/NCI [P50 CA247749]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Research Fund at MSKCC; Cancer Center Support Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to acknowledge assistance from the NCI R01-CA215136 grant, the Breast Research Fund at MSKCC, and the Cancer Center Support Grant P30 CA008748. FP is partially funded by an NIH/NCI P50 CA247749 grant.	An YS, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.618705; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; [Anonymous], 2019, WHO CLASSIFICATION T; Ascierto PA, 2020, LANCET ONCOL, V21, P1465, DOI 10.1016/S1470-2045(20)30494-0; Bajorin DF, 2021, NEW ENGL J MED, V384, P2102, DOI 10.1056/NEJMoa2034442; Beloueche-Babari M, 2020, BRIT J CANCER, V122, P895, DOI 10.1038/s41416-019-0717-x; Borghaei H, 2019, J THORAC ONCOL, V14, P124, DOI 10.1016/j.jtho.2018.08.004; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Cao LW, 2021, CELL, V184, P5031, DOI 10.1016/j.cell.2021.08.023; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; Cohen IJ, 2017, BREAST CANCER-BASIC, V11, DOI 10.1177/1178223417731565; Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026; Eggermont AMM, 2021, LANCET ONCOL, V22, P643, DOI 10.1016/S1470-2045(21)00065-6; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Feng J, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01629-4; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gillette MA, 2020, CELL, V182, P200, DOI 10.1016/j.cell.2020.06.013; Haas R, 2016, TRENDS BIOCHEM SCI, V41, P460, DOI 10.1016/j.tibs.2016.02.003; Hakimi AA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17965-0; Halford SER, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2516; Hall A, 2013, ONCOTARGET, V4, P584, DOI 10.18632/oncotarget.965; Harbison R Alex, 2022, Cancer Res Commun, V2, P639, DOI 10.1158/2767-9764.crc-22-0061; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Jiang F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83628-9; Kelly RJ, 2021, NEW ENGL J MED, V384, P1191, DOI 10.1056/NEJMoa2032125; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Kraehenbuehl L, 2022, NAT REV CLIN ONCOL, V19, P37, DOI 10.1038/s41571-021-00552-7; Krug K, 2020, CELL, V183, P1436, DOI 10.1016/j.cell.2020.10.036; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leone RD, 2020, NAT REV CANCER, V20, P516, DOI 10.1038/s41568-020-0273-y; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu JH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01264-1; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Murakami W, 2020, EUR J RADIOL, V123, DOI 10.1016/j.ejrad.2019.108773; Orozco JM, 2020, NAT METAB, V2, P893, DOI 10.1038/s42255-020-0250-5; Osborne JR, 2010, J NUCL MED, V51, P543, DOI 10.2967/jnumed.108.060459; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Pareja F, 2020, MODERN PATHOL, V33, P1056, DOI 10.1038/s41379-019-0442-2; Pareja F, 2020, HISTOPATHOLOGY, V76, P865, DOI 10.1111/his.14057; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Satpathy S, 2021, CELL, V184, P4348, DOI 10.1016/j.cell.2021.07.016; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z; Serganova I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203965; Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shitara K, 2020, JAMA ONCOL, V6, P1571, DOI 10.1001/jamaoncol.2020.3370; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Subat S, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110419; Tang JN, 2020, AGING-US, V12, P24983, DOI 10.18632/aging.103806; Tang XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0415-9; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Walenta S, 2000, CANCER RES, V60, P916; Wang LB, 2021, CANCER CELL, V39, P509, DOI 10.1016/j.ccell.2021.01.006; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Warburg O., 1925, J CANCER RES CLIN, V9, P148, DOI [10.1158/jcr.1925.148, DOI 10.1158/JCR.1925.148]; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Watson MJ, 2021, NATURE, V591, P645, DOI 10.1038/s41586-020-03045-2; Wei JF, 2020, CANCERS, V12, DOI 10.3390/cancers12071788; WIKEHOOLEY JL, 1985, EUR J CANCER CLIN ON, V21, P785, DOI 10.1016/0277-5379(85)90216-0; Winer EP, 2021, LANCET ONCOL, V22, P499, DOI 10.1016/S1470-2045(20)30754-3; Wu Z, 2020, CLIN TRANSL ONCOL, V22, P631, DOI 10.1007/s12094-019-02187-8; Wu ZY, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000023836; Xu FS, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07702-7; Xu JY, 2020, CELL, V182, P245, DOI 10.1016/j.cell.2020.05.043; Xu K, 2021, SCIENCE, V371, P405, DOI 10.1126/science.abb2683; Yao J, 2021, J CANCER, V12, P885, DOI 10.7150/jca.50274; Yu SS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01778; Zappasodi R, 2021, NATURE, V591, P652, DOI 10.1038/s41586-021-03326-4; Zappasodi R, 2018, CURR HEMATOL MALIG R, V13, P383, DOI 10.1007/s11899-018-0471-9; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069; Zhang L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02173-2; Zimmer L, 2020, LANCET, V395, P1558, DOI 10.1016/S0140-6736(20)30417-7	102	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								880959	10.3389/fimmu.2022.880959	http://dx.doi.org/10.3389/fimmu.2022.880959			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1VB	36505421	gold, Green Published			2022-12-18	WOS:000894157500001
J	Deng, YL; Guo, K; Tang, ZF; Feng, YF; Cai, SH; Ye, JH; Xi, YX; Li, JC; Liu, R; Cai, C; Tan, ZH; Zhang, YX; Han, ZD; Zeng, GH; Zhong, WD				Deng, Yulin; Guo, Kai; Tang, Zhenfeng; Feng, Yuanfa; Cai, Shanghua; Ye, Jianheng; Xi, Yuanxue; Li, Jinchuang; Liu, Ren; Cai, Chao; Tan, Zeheng; Zhang, Yixun; Han, Zhaodong; Zeng, Guohua; Zhong, Weide			Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						tumor-infiltrating lymphocytes; long noncoding RNA; bioinformatics; clear cell renal cell carcinoma; prognostic	REGULATORY T-CELLS; CANCER STATISTICS; EXPRESSION; IMMUNITY	Clear cell renal cell carcinoma (ccRCC) is a common aggressive malignant tumor of the urinary system. Given the heterogeneity of the tumor microenvironment, immunotherapy may not fully exert its role in the treatment of advanced patients. Long noncoding RNA (lncRNA) has been reported to be critically associated with the differentiation and maturation of tumor-infiltrating lymphocytes (TILs), which work against tumor cells. In this study, we identified 10 TIL-related lncRNAs (AL590094.1, LINC02027, LINC00460, AC147651.1, AC026401.3, LINC00944, LINC01615, AP000439.2, AL162586.1, and AC084876.1) by Pearson correlation, univariate Cox regression, Lasso regression, and multivariate Cox regression based on The Cancer Genome Atlas (TCGA) database. A risk score model was established based on these lncRNAs. Next, a nomogram was constructed to predict the overall survival. By employing differentially expressed genes (DEGs) between groups with high and low risk scores, gene ontology (GO) enrichment analysis was performed to identify the major biological processes (BP) related to immune DEGs. We analyzed the mutation data of the groups and demonstrated that SETD2 and BAP1 had the highest mutation frequency in the high-risk group. The "CIBERSORT" R package was used to detect the abundance of TILs in the groups. The expression of lymphocyte markers was compared. We also determined the expression of two lncRNAs (AC084876.1 and AC026401.3) and their relationship with lymphocyte markers in the kidney tissue of ccRCC patients and showed that there was a positive correlation between AC084876.1 and FoxP3. Proliferation, migration, and invasion of AC084876.1-downregulated ccRCC cell lines were inhibited, and the expression of PD-L1 and TGF-beta secretion decreased. To our knowledge, this is the first bioinformatics study to establish a prognostic model for ccRCC using TIL-related lncRNAs. These lncRNAs were associated with T-cell activities and may serve as biomarkers of disease prognosis.	[Deng, Yulin; Tang, Zhenfeng; Feng, Yuanfa; Cai, Shanghua; Cai, Chao; Zeng, Guohua; Zhong, Weide] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Urol Res Inst, Dept Urol,Minimally Invas Surg Ctr,Guangdong Key L, Guangzhou, Guangdong, Peoples R China; [Guo, Kai; Tan, Zeheng] Southern Med Univ, Dept Urol, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China; [Cai, Shanghua; Zhong, Weide] Guangzhou Med Univ, Guangzhou Lab, Guangzhou, Guangdong, Peoples R China; [Ye, Jianheng; Xi, Yuanxue; Li, Jinchuang; Liu, Ren; Zhang, Yixun; Han, Zhaodong; Zhong, Weide] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Urol,Guangdong Key Lab Clin Mol Med & Diagnos, Guangzhou, Guangdong, Peoples R China; [Zhong, Weide] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Macau Sar, Peoples R China	Guangzhou Medical University; Southern Medical University - China; Guangzhou Medical University; South China University of Technology; Macau University of Science & Technology	Zeng, GH; Zhong, WD (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Urol Res Inst, Dept Urol,Minimally Invas Surg Ctr,Guangdong Key L, Guangzhou, Guangdong, Peoples R China.; Zhong, WD (corresponding author), Guangzhou Med Univ, Guangzhou Lab, Guangzhou, Guangdong, Peoples R China.; Han, ZD; Zhong, WD (corresponding author), South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Urol,Guangdong Key Lab Clin Mol Med & Diagnos, Guangzhou, Guangdong, Peoples R China.; Zhong, WD (corresponding author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Macau Sar, Peoples R China.	hanzhaodong@21cn.com; gzgyzgh@sina.vip.com; zhongwd2009@live.cn			National Natural Science Foundation of China [82072813]; Guangdong Basic and Applied Basic Research Foundation [2017A030310100, 2020A1515110792, 2022A1515010342]; Science and Technology Projects in Guangzhou [2020A1515110792]; Science and Technology Development Fund of Macau SAR [0031/2021/A]; Emergency Key Program of Guangzhou Laboratory [EKPG21-04]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Science and Technology Projects in Guangzhou; Science and Technology Development Fund of Macau SAR; Emergency Key Program of Guangzhou Laboratory	This work was supported by grants from the National Natural Science Foundation of China 82072813 (WZ); Guangdong Basic and Applied Basic Research Foundation 2017A030310100 (KG); Science and Technology Projects in Guangzhou 202201010726 (ZH); Science and Technology Development Fund of Macau SAR 0031/2021/A (WZ); Emergency Key Program of Guangzhou Laboratory EKPG21-04 (WZ); Guangdong Basic and Applied Basic Research Foundation 2020A1515110792, 2022A1515010342 (JY).	Atianand MK, 2014, TRENDS MOL MED, V20, P623, DOI 10.1016/j.molmed.2014.09.002; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Braun DA, 2020, NAT MED, V26, P909, DOI 10.1038/s41591-020-0839-y; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Considine B, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0779-1; Deleuze A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072532; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Giraldo NA, 2015, CLIN CANCER RES, V21, P3031, DOI 10.1158/1078-0432.CCR-14-2926; Gonzalez-Rodriguez P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2266-x; Grimm MO, 2019, EUR UROL, V76, P368, DOI 10.1016/j.eururo.2019.05.041; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu YF, 2017, CANCER DISCOV, V7, P900, DOI 10.1158/2159-8290.CD-17-0292; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jonasch E, 2021, NAT REV NEPHROL, V17, P245, DOI 10.1038/s41581-020-00359-2; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; Kanamori M, 2016, TRENDS IMMUNOL, V37, P803, DOI 10.1016/j.it.2016.08.012; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khorkova O, 2015, ADV DRUG DELIVER REV, V87, P15, DOI 10.1016/j.addr.2015.05.012; Li GP, 2021, NAT CELL BIOL, V23, P526, DOI 10.1038/s41556-021-00672-3; Li L, 2019, MOL CELL PROTEOMICS, V18, P437, DOI 10.1074/mcp.RA118.000957; Li YH, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1838141; Lin EY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.830220; Liu JN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02048; Liu KP, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.890641; Liu R, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01996-6; MacLennan S, 2012, EUR UROL, V62, P1097, DOI 10.1016/j.eururo.2012.07.028; Nair VS, 2018, IMMUNOL CELL BIOL, V96, P21, DOI 10.1111/imcb.1003; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ni C, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0129-7; Ohue Y, 2019, CANCER SCI, V110, P2080, DOI 10.1111/cas.14069; Paijens ST, 2021, CELL MOL IMMUNOL, V18, P842, DOI 10.1038/s41423-020-00565-9; Qi Y, 2020, CANCER IMMUNOL IMMUN, V69, P1565, DOI 10.1007/s00262-020-02563-2; Saleh R, 2020, SEMIN CANCER BIOL, V65, P13, DOI 10.1016/j.semcancer.2019.07.017; Saleh R, 2020, CANCER LETT, V490, P174, DOI 10.1016/j.canlet.2020.07.022; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Shitara K, 2018, ANN NY ACAD SCI, V1417, P104, DOI 10.1111/nyas.13625; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sun CC, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00773-y; Sun JX, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/8800358; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tang C, 2021, AGING-US, V13, P26046, DOI 10.18632/aging.203797; Vuong L, 2019, CANCER DISCOV, V9, P1349, DOI 10.1158/2159-8290.CD-19-0499; Wei BY, 2019, PATHOL RES PRACT, V215, P159, DOI 10.1016/j.prp.2018.10.032; Wu XK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.745945; Yu YF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2149; Zhang ZD, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9921466	46	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1046790	10.3389/fimmu.2022.1046790	http://dx.doi.org/10.3389/fimmu.2022.1046790			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1MP	36505457	gold, Green Published			2022-12-18	WOS:000894133900001
J	Dodd, KC; Menon, M				Dodd, Katherine C.; Menon, Madhvi			Sex bias in lymphocytes: Implications for autoimmune diseases	FRONTIERS IN IMMUNOLOGY			English	Review						lymphocytes; sex; sex-bias; T cells; B cells; estrogen; testosterone	REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HORMONE REPLACEMENT THERAPY; GONADOTROPIN-RELEASING-HORMONE; SUBTYPE-SELECTIVE AGONISTS; COLLAGEN-INDUCED ARTHRITIS; IFN-ALPHA PRODUCTION; B-CELLS; MULTIPLE-SCLEROSIS; MYASTHENIA-GRAVIS	Autoimmune diseases are characterized by a significant sex dimorphism, with women showing increased susceptibility to disease. This is, at least in part, due to sex-dependent differences in the immune system that are influenced by the complex interplay between sex hormones and sex chromosomes, with contribution from sociological factors, diet and gut microbiota. Sex differences are evident in the number and function of lymphocyte populations. Women mount a stronger pro-inflammatory response than males, with increased lymphocyte proliferation, activation and pro-inflammatory cytokine production, whereas men display expanded regulatory cell subsets. Ageing alters the immune landscape of men and women in differing ways, resulting in changes in autoimmune disease susceptibility. Here we review the current literature on sex differences in lymphocyte function, the factors that influence this, and the implications for autoimmune disease. We propose that improved understanding of sex bias in lymphocyte function can provide sex-specific tailoring of treatment strategies for better management of autoimmune diseases.	[Dodd, Katherine C.; Menon, Madhvi] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth,Div Immunol Immun Infect & Re, Manchester, England; [Dodd, Katherine C.] Salford Royal Hosp, Manchester Ctr Clin Neurosci, Salford, England	University of Manchester; Salford Royal NHS Foundation Trust; Salford Royal Hospital	Menon, M (corresponding author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth,Div Immunol Immun Infect & Re, Manchester, England.	madhvi.menon@manchester.ac.uk		Dodd, Katherine/0000-0002-0491-7030; Menon, Madhvi/0000-0003-2516-9438	Academy of Medical Sciences Springboard Award [SBF006\1165]; Asthma Lung UK [RP22F\6]; University of Manchester Presidential Fellowship; Myaware; Neuromuscular Study Group; Northern Care Alliance NHS Foundation Trust; Manchester Myasthenia Gravis Research Fund (NorthCare Charity Fund) [CS2041]	Academy of Medical Sciences Springboard Award; Asthma Lung UK; University of Manchester Presidential Fellowship; Myaware; Neuromuscular Study Group; Northern Care Alliance NHS Foundation Trust; Manchester Myasthenia Gravis Research Fund (NorthCare Charity Fund)	MM is funded by the Academy of Medical Sciences Springboard Award (SBF006\1165), Asthma & Lung UK (RP22F\6) and University of Manchester Presidential Fellowship. KD is undertaking a PhD funded by the Manchester Myasthenia Gravis Research Fund (NorthCare Charity Fund CS2041), with additional grants from Myaware and the Neuromuscular Study Group, and a salary from the Northern Care Alliance NHS Foundation Trust.	Aarli JA, 1999, ARCH NEUROL-CHICAGO, V56, P25, DOI 10.1001/archneur.56.1.25; Abdullah M, 2012, CELL IMMUNOL, V272, P214, DOI 10.1016/j.cellimm.2011.10.009; Afshan G, 2012, CLIN LAB, V58, P567; Agarwal SK, 1999, ANN ALLERG ASTHMA IM, V83, P222, DOI 10.1016/S1081-1206(10)62644-0; Aggelakopoulou M, 2016, J IMMUNOL, V196, P4947, DOI 10.4049/jimmunol.1600246; Alazwari A, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0264118; Altuwaijri S, 2009, MOL ENDOCRINOL, V23, P444, DOI 10.1210/me.2008-0106; Andersson A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0548-y; Angeloni B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073696; ARANEO BA, 1991, BLOOD, V78, P688, DOI 10.1182/blood.V78.3.688.688; Arruvito L, 2007, J IMMUNOL, V178, P2572, DOI 10.4049/jimmunol.178.4.2572; Asaba J, 2015, INT J BIOCHEM CELL B, V68, P42, DOI 10.1016/j.biocel.2015.08.012; Asmail A, 2019, INT J NEUROSCI, V129, P313, DOI 10.1080/00207454.2018.1529669; Barrett ELB, 2011, AGING CELL, V10, P913, DOI 10.1111/j.1474-9726.2011.00741.x; Bebo BF, 1999, J IMMUNOL, V162, P35; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Beckmann L, 2022, STROKE, V53, P381, DOI 10.1161/STROKEAHA.121.037537; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Behrens M, 2010, J AUTOIMMUN, V35, P1, DOI 10.1016/j.jaut.2009.12.007; Ben-Batalla I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01184; Bereshchenko O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01332; Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088; Berletch JB, 2011, HUM GENET, V130, P237, DOI 10.1007/s00439-011-1011-z; Blanco Luz P, 2013, J Immune Based Ther Vaccines Antimicrob, V2, P29, DOI 10.4236/jibtva.2013.23004; Bodhankar S, 2012, IMMUNOLOGY, V137, P282, DOI 10.1111/imm.12013; Borchers AT, 2012, AUTOIMMUN REV, V11, pA413, DOI 10.1016/j.autrev.2011.11.016; Bouman A, 2004, AM J REPROD IMMUNOL, V52, P19, DOI 10.1111/j.1600-0897.2004.00177.x; Brown MA, 2019, J IMMUNOL, V202, P1927, DOI 10.4049/jimmunol.1801403; Buskiewicz IA, 2016, SEX DIFFERENCES IN PHYSIOLOGY, P45, DOI 10.1016/B978-0-12-802388-4.00004-5; Bynoe MS, 2000, P NATL ACAD SCI USA, V97, P2703, DOI 10.1073/pnas.040577497; Bynote KK, 2008, GENES IMMUN, V9, P137, DOI 10.1038/sj.gene.6364458; Capellino S, 2007, ANN RHEUM DIS, V66, P53, DOI 10.1136/ard.2006.055483; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Castagnetta LA, 2003, J RHEUMATOL, V30, P2597; Chabchoub G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2759; Chatzileontiadou DSM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010073; Chuang WY, 2014, J AUTOIMMUN, V52, P122, DOI 10.1016/j.jaut.2013.12.006; Churov AV, 2020, IMMUNOL LETT, V226, P83, DOI 10.1016/j.imlet.2020.07.004; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Connect Immune Research, 2018, AR YOU AUT AW REP PA; Cooper LT, 2012, J CARD FAIL, V18, P28, DOI 10.1016/j.cardfail.2011.09.009; Correale J, 2010, J IMMUNOL, V185, P4948, DOI 10.4049/jimmunol.1000588; CUA DJ, 1995, J IMMUNOL, V155, P4052; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; Cutolo M, 2006, ANN NY ACAD SCI, V1069, P391, DOI 10.1196/annals.1351.037; D'Agostino P, 1999, ANN NY ACAD SCI, V876, P426, DOI 10.1111/j.1749-6632.1999.tb07667.x; da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664; Dalal M, 1997, J IMMUNOL, V159, P3; Dao KH, 2022, INT J WOMENS HEALTH, V14, P199, DOI 10.2147/IJWH.S282604; DASILVA JAP, 1992, BAILLIERE CLIN RHEUM, V6, P193, DOI 10.1016/S0950-3579(05)80344-9; Deguchi K, 2001, MENOPAUSE, V8, P266, DOI 10.1097/00042192-200107000-00008; Delpy L, 2005, J IMMUNOL, V175, P5050, DOI 10.4049/jimmunol.175.8.5050; Dema B, 2016, ANTIBODIES, V5, DOI 10.3390/antib5010002; Desdin-Mico G, 2020, SCIENCE, V368, P1371, DOI 10.1126/science.aax0860; Dosiou C, 2008, J ENDOCRINOL, V196, P67, DOI 10.1677/JOE-07-0317; Dresser L, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112235; Dunn SE, 2007, J EXP MED, V204, P321, DOI 10.1084/jem.20061839; Eames HL, 2016, TRANSL RES, V167, P167, DOI 10.1016/j.trsl.2015.06.018; Edwards M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00478; EIDINGER D, 1972, J EXP MED, V136, P1098, DOI 10.1084/jem.136.5.1098; Elbers JMH, 1997, J CLIN ENDOCR METAB, V82, P3267, DOI 10.1210/jc.82.10.3267; Elbourne KB, 1998, LUPUS, V7, P420, DOI 10.1191/096120398678920352; Elderman M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01018; Elkon KB, 2011, J INTERF CYTOK RES, V31, P803, DOI 10.1089/jir.2011.0045; Enghard P, 2009, ARTHRITIS RHEUM, V60, P199, DOI 10.1002/art.24136; Faas M, 2000, FERTIL STERIL, V74, P1008, DOI 10.1016/S0015-0282(00)01553-3; Fairweather D, 2008, AM J PATHOL, V173, P600, DOI 10.2353/ajpath.2008.071008; Fan HY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/814598; Feng F, 2010, CLIN IMMUNOL, V134, P226, DOI 10.1016/j.clim.2009.10.004; Fernanda Romo-Garcia M., 2020, RHEUMATOID ARTHRITIS, DOI [10.5772/intechopen.93371, DOI 10.5772/INTECHOPEN.93371]; FOX HS, 1991, J IMMUNOL, V146, P4362; Fransen F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00754; Freeman BM, 2014, J SURG RES, V190, P319, DOI 10.1016/j.jss.2014.03.017; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Fuseini H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02740; Ganesan K, 2008, CALCIFIED TISSUE INT, V83, P354, DOI 10.1007/s00223-008-9183-9; Garnier L, 2018, J IMMUNOL, V201, P3218, DOI 10.4049/jimmunol.1800417; Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326; Giltay EJ, 2000, J CLIN ENDOCR METAB, V85, P1648, DOI 10.1210/jc.85.4.1648; Giron-Gonzalez JA, 2000, EUR J ENDOCRINOL, V143, P31, DOI 10.1530/eje.0.1430031; Goetzl EJ, 2010, FASEB J, V24, P3580, DOI 10.1096/fj.10-160911; Gold SM, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-32; Goodin DS, 2014, HAND CLINIC, V122, P231, DOI 10.1016/B978-0-444-52001-2.00010-8; Gregersen PK, 2012, ANN NEUROL, V72, P927, DOI 10.1002/ana.23691; Greuter T, 2020, DIGESTION, V101, P98, DOI 10.1159/000504701; Griesbeck M, 2015, J IMMUNOL, V195, P5327, DOI 10.4049/jimmunol.1501684; Grimaldi CM, 2006, J IMMUNOL, V176, P2703, DOI 10.4049/jimmunol.176.5.2703; Grimaldi CM, 2005, MOL IMMUNOL, V42, P811, DOI 10.1016/j.molimm.2004.05.014; Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873; Grimaldi CM, 2001, J IMMUNOL, V167, P1886, DOI 10.4049/jimmunol.167.4.1886; Guggenmos J, 2004, J IMMUNOL, V172, P661, DOI 10.4049/jimmunol.172.1.661; Haddadi NS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.883375; Hagg D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063619; Hatakeyama C, 2004, CLIN GENET, V66, P327, DOI 10.1111/j.1399-0004.2004.00310.x; Hepworth MR, 2010, EUR J IMMUNOL, V40, P406, DOI 10.1002/eji.200939589; Herblot S, 2002, MOL CELL BIOL, V22, P886, DOI 10.1128/MCB.22.3.886-900.2002; Herz J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01696; Hewagama A, 2009, GENES IMMUN, V10, P509, DOI 10.1038/gene.2009.12; Hewagama A., 2013, RHEUMATOL CURR RES, V3, P118, DOI [10.4172/2161-1149.1000118, DOI 10.4172/2161-1149.1000118]; Hill L, 2011, MOL MED, V17, P211, DOI 10.2119/molmed.2010.00172; Hirokawa K, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-19; Holroyd CR, 2009, CLIMACTERIC, V12, P378, DOI 10.1080/13697130903025449; Huang N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01023; Huang ZH, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2023216118; HUBER SA, 1994, J VIROL, V68, P5126, DOI 10.1128/JVI.68.8.5126-5132.1994; Hughes GC, 2007, AUTOIMMUNITY, V40, P470, DOI 10.1080/08916930701464764; Hughes GC, 2014, NAT REV RHEUMATOL, V10, P740, DOI 10.1038/nrrheum.2014.144; Iannello A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03075; Itoh Y, 2019, J CLIN INVEST, V129, P3852, DOI 10.1172/JCI126250; JACOBSON JD, 1994, ENDOCRINOLOGY, V134, P2516, DOI 10.1210/en.134.6.2516; Jacobson JD, 2000, ANN NY ACAD SCI, V917, P809; Janer M, 1999, HUM IMMUNOL, V60, P909, DOI 10.1016/S0198-8859(99)00062-2; Janssen M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91655-9; JANSSON L, 1994, J NEUROIMMUNOL, V53, P203, DOI 10.1016/0165-5728(94)90030-2; Jansson-Knodell CL, 2018, DIGEST DIS SCI, V63, P184, DOI 10.1007/s10620-017-4835-0; Jenks SA, 2020, IMMUNITY, V52, P203, DOI 10.1016/j.immuni.2019.12.005; Jentsch-Ullrich K, 2005, CLIN IMMUNOL, V116, P192, DOI 10.1016/j.clim.2005.03.020; Jiwrajka N, 2022, J EXP MED, V219, DOI 10.1084/jem.20211487; Jones BG, 2019, INT IMMUNOL, V31, P141, DOI 10.1093/intimm/dxy074; Kamada M, 2000, J ENDOCRINOL INVEST, V23, P376, DOI 10.1007/BF03343741; Kamitaki N, 2020, NATURE, V582, P577, DOI 10.1038/s41586-020-2277-x; Kanaan SB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158550; Karpuzoglu E, 2007, MOL IMMUNOL, V44, P1808, DOI 10.1016/j.molimm.2006.08.005; Karpuzoglu-Sahin E, 2001, J REPROD IMMUNOL, V52, P113, DOI 10.1016/S0165-0378(01)00117-6; Keller ET, 1996, J BIOL CHEM, V271, P26267, DOI 10.1074/jbc.271.42.26267; Khan D, 2015, CELL IMMUNOL, V294, P70, DOI 10.1016/j.cellimm.2015.01.004; Kim SH, 1999, J IMMUNOL, V162, P5561; Kim YS, 2020, WORLD J MENS HEALTH, V38, P48, DOI 10.5534/wjmh.190009; Kissick HT, 2014, P NATL ACAD SCI USA, V111, P9887, DOI 10.1073/pnas.1402468111; Klein SL, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00301-y; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Klein SL, 2012, BIOESSAYS, V34, P1050, DOI 10.1002/bies.201200099; Koetzier SC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.642038; Kosyreva AM, 2018, J INFLAMM RES, V11, P431, DOI 10.2147/JIR.S178288; Kotimaa J, 2016, MOL IMMUNOL, V76, P13, DOI 10.1016/j.molimm.2016.06.004; Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018; Kronzer VL, 2021, EVOL APPL, V14, P629, DOI 10.1111/eva.13167; Kyto V, 2013, HEART, V99, P1681, DOI 10.1136/heartjnl-2013-304449; Lahore GF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25828-5; Lai JJ, 2012, AM J PATHOL, V181, P1504, DOI 10.1016/j.ajpath.2012.07.008; Lambert KC, 2005, J IMMUNOL, V175, P5716, DOI 10.4049/jimmunol.175.9.5716; Lang TJ, 2004, CLIN IMMUNOL, V113, P224, DOI 10.1016/j.clim.2004.05.011; Latham KA, 2003, J IMMUNOL, V171, P5820, DOI 10.4049/jimmunol.171.11.5820; Lee BW, 1996, CYTOMETRY, V26, P8, DOI 10.1002/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E; Lee JH, 2012, EUR J IMMUNOL, V42, P2683, DOI 10.1002/eji.201142317; Lee S, 2010, J IMMUNOL, V185, P756, DOI 10.4049/jimmunol.0904192; Lelu K, 2011, J IMMUNOL, V187, P2386, DOI 10.4049/jimmunol.1101578; Li J, 2007, CLIN IMMUNOL, V123, P219, DOI 10.1016/j.clim.2007.01.008; Li J, 2006, INT IMMUNOPHARMACOL, V6, P1413, DOI 10.1016/j.intimp.2006.04.019; Li Y, 2021, BIOMED REP, V15, DOI 10.3892/br.2021.1457; Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815; Lin HL, 2011, KAOHSIUNG J MED SCI, V27, P125, DOI 10.1016/j.kjms.2010.12.005; Liva SM, 2001, J IMMUNOL, V167, P2060, DOI 10.4049/jimmunol.167.4.2060; Loetscher P, 2002, ARTHRITIS RES, V4, P233, DOI 10.1186/ar412; Lu FX, 2002, CLIN EXP IMMUNOL, V128, P10, DOI 10.1046/j.1365-2249.2002.01780.x; Lu MC, 2013, CLIN EXP IMMUNOL, V171, P91, DOI 10.1111/j.1365-2249.2012.04676.x; Lu Q, 2007, J IMMUNOL, V179, P6352, DOI 10.4049/jimmunol.179.9.6352; Luckey D, 2012, AUTOIMMUNITY, V45, P364, DOI 10.3109/08916934.2012.665528; Ma SL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00318; Mackay IR, 2001, WESTERN J MED, V174, P118, DOI 10.1136/ewjm.174.2.118; Magyari M, 2014, MULT SCLER J, V20, P1244, DOI 10.1177/1352458514521515; Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210/jc.2003-031069; Mangalam AK, 2008, ADV IMMUNOL, V97, P65, DOI 10.1016/S0065-2776(08)00002-3; Manicardi V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162960; Manji N, 2006, J CLIN ENDOCR METAB, V91, P4873, DOI 10.1210/jc.2006-1402; Mao GP, 2010, ENDOCRINOLOGY, V151, P5477, DOI 10.1210/en.2010-0426; Maranini B, 2022, J PERS MED, V12, DOI 10.3390/jpm12030499; Maret A, 2003, EUR J IMMUNOL, V33, P512, DOI 10.1002/immu.200310027; Markle JGM, 2013, SCIENCE, V339, P1084, DOI 10.1126/science.1233521; Marquez EJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14396-9; Marttila S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066229; Marx A., 2018, MEDIASTINUM, V2, P66, DOI [DOI 10.21037/med.2018.12.04, 10.21037/med.2018.12.04, DOI 10.21037/MED.2018.12.04]; Marx A, 2010, J THORAC ONCOL, V5, pS266, DOI 10.1097/JTO.0b013e3181f1f63f; Maselli A, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0057-y; Massa MG, 2017, AM J PATHOL, V187, P1613, DOI 10.1016/j.ajpath.2017.03.006; Matalka KZ, 2003, NEUROENDOCRINOL LETT, V24, P185; McGee Jean S, 2021, Int J Womens Dermatol, V7, P533, DOI 10.1016/j.ijwd.2021.10.007; Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004; Michel L, 2012, J NEUROL NEUROSUR PS, V83, P796, DOI 10.1136/jnnp-2012-302235; Milan-Mattos JC, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20198392, 10.1590/1414-431x20198392]; Mohamad NV, 2019, AGING MALE, V22, P129, DOI 10.1080/13685538.2018.1482487; Mohammad I, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aap9415; Mokbel A, 2021, CLIN RHEUMATOL, V40, P3465, DOI 10.1007/s10067-021-05588-9; Molinie F, 2004, GUT, V53, P843, DOI 10.1136/gut.2003.025346; Mooney LA, 2001, CANCER EPIDEM BIOMAR, V10, P641; MORALE MC, 1991, ENDOCRINOLOGY, V128, P1073, DOI 10.1210/endo-128-2-1073; Morgan CP, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-22; Morgan CP, 2011, J NEUROSCI, V31, P11748, DOI 10.1523/JNEUROSCI.1887-11.2011; Moulton VR, 2012, MOL MED, V18, P370, DOI 10.2119/molmed.2011.00506; Nakashima Hitoshi, 2006, Rinsho Byori, V54, P706; Namazi MR, 2009, IRAN J ALLERGY ASTHM, V8, P65, DOI 08.01/ijaai.6569; Nancy P, 2005, ENDOCRINOLOGY, V146, P2345, DOI 10.1210/en.2004-1003; Navarro FC., 2017, GEND GENOME, V1, P1, DOI [10.1089/gg.2017.0014, DOI 10.1089/GG.2017.0014]; NEWSOMDAVIS J, 1987, ANN NY ACAD SCI, V505, P12, DOI 10.1111/j.1749-6632.1987.tb51279.x; Nicot A, 2009, FRONT BIOSCI-LANDMRK, V14, P4477, DOI 10.2741/3543; Olsen NJ, 2001, IMMUNOL RES, V23, P281, DOI 10.1385/IR:23:2-3:281; Ortolan A, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1705-x; Page ST, 2006, AM J PHYSIOL-ENDOC M, V290, pE856, DOI 10.1152/ajpendo.00484.2005; Palaszynski KM, 2004, J NEUROIMMUNOL, V146, P144, DOI 10.1016/j.jneuroim.2003.11.004; Panchanathan R, 2013, INT IMMUNOL, V25, P521, DOI 10.1093/intimm/dxt015; Panchanathan R, 2013, MOL IMMUNOL, V53, P15, DOI 10.1016/j.molimm.2012.06.013; Panchanathan R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010868; Papenfuss TL, 2011, J IMMUNOL, V186, P3346, DOI 10.4049/jimmunol.1001322; Park SR, 2009, NAT IMMUNOL, V10, P540, DOI 10.1038/ni.1725; Pauklin S, 2009, J IMMUNOL, V183, P1238, DOI 10.4049/jimmunol.0803915; Phiel KL, 2005, IMMUNOL LETT, V97, P107, DOI 10.1016/j.imlet.2004.10.007; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Pietschmann P, 2003, EXP GERONTOL, V38, P1119, DOI 10.1016/S0531-5565(03)00189-X; Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047; Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227; Prieto GA, 2006, IMMUNOLOGY, V118, P58, DOI 10.1111/j.1365-2567.2006.02339.x; Queiro R, 2014, RHEUMATOLOGY, V53, P1178, DOI 10.1093/rheumatology/ket363; Queiro R, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/482691; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Raine C, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.909879; Restellini S, 2020, DIGESTION, V101, P27, DOI 10.1159/000502886; Rettew JA, 2008, BIOL REPROD, V78, P432, DOI 10.1095/biolreprod.107.063545; Rezzani R, 2014, AGE, V36, P313, DOI 10.1007/s11357-013-9564-5; RHODES K, 1969, BRIT MED J, V3, P439, DOI 10.1136/bmj.3.5668.439; Rider Virginia, 2003, J Gend Specif Med, V6, P14; Rindfleisch JA, 2005, AM FAM PHYSICIAN, V72, P1037; Robinson George A, 2022, Lancet Rheumatol, V4, pe710, DOI 10.1016/S2665-9913(22)00198-9; Roden AC, 2004, J IMMUNOL, V173, P6098, DOI 10.4049/jimmunol.173.10.6098; Ronnblom L, 2006, ARTHRITIS RHEUM-US, V54, P408, DOI 10.1002/art.21571; Rosenzweig R, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105606; Rosser EC, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.910561; ROUBINIAN JR, 1977, J CLIN INVEST, V59, P1066, DOI 10.1172/JCI108729; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Rowe JH, 2012, NATURE, V490, P102, DOI 10.1038/nature11462; Rubtsov AV, 2010, AUTOIMMUN REV, V9, P494, DOI 10.1016/j.autrev.2010.02.008; Rubtsova K, 2015, J IMMUNOL, V195, P1933, DOI 10.4049/jimmunol.1501209; Rubtsova K, 2015, J CLIN INVEST, V125, P2187, DOI 10.1172/JCI78082; Rubtsova K, 2012, EXPERT REV CLIN IMMU, V8, P5, DOI [10.1586/ECI.11.83, 10.1586/eci.11.83]; Ruddy SC, 2014, MOL CANCER THER, V13, P1882, DOI 10.1158/1535-7163.MCT-13-1066; Rupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00794; Rusman T, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0744-2; SABAHI F, 1995, AM J REPROD IMMUNOL, V33, P381, DOI 10.1111/j.1600-0897.1995.tb00907.x; Sachinidis Athanasios, 2020, Mediterr J Rheumatol, V31, P311, DOI 10.31138/mjr.31.3.311; Sakiani S, 2013, NAT REV ENDOCRINOL, V9, P56, DOI 10.1038/nrendo.2012.206; Sakurai K, 2020, INTERNAL MED, V59, P3093, DOI 10.2169/internalmedicine.4839-20; SanchezGuerrero J, 1997, ARTHRITIS RHEUM, V40, P804, DOI 10.1002/art.1780400505; Sankaran-Walters S, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-10; Sardu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032487; Seillet C, 2013, J IMMUNOL, V190, P5459, DOI 10.4049/jimmunol.1203312; Sepulveda JIR, 2019, BIOL SEX DIFFER, V10, DOI 10.1186/s13293-019-0274-2; Shaukat F., 2019, J NEPHROPHARMACOL, V8, P9, DOI [10.15171/npj.2019.09, DOI 10.15171/NPJ.2019.09]; Shen H, 2010, J MOL CELL BIOL, V2, P284, DOI 10.1093/jmcb/mjq023; Shotan A, 2020, CARDIAC PROBLEMS IN PREGNANCY, 4TH EDITION, P107; Sicotte NL, 2007, ARCH NEUROL-CHICAGO, V64, P683, DOI 10.1001/archneur.64.5.683; Sicotte NL, 2002, ANN NEUROL, V52, P421, DOI 10.1002/ana.10301; Sims GP, 2001, J IMMUNOL, V167, P1935, DOI 10.4049/jimmunol.167.4.1935; Singh RP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.619268; Smyth A, 2010, CLIN J AM SOC NEPHRO, V5, P2060, DOI 10.2215/CJN.00240110; Souyris M, 2019, SEMIN IMMUNOPATHOL, V41, P153, DOI 10.1007/s00281-018-0712-y; Souyris M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8855; Spanier JA, 2015, J NEUROIMMUNOL, V286, P48, DOI 10.1016/j.jneuroim.2015.06.015; Spitzer JA, 1999, LUPUS, V8, P380, DOI 10.1177/096120339900800510; Steinmetz OM, 2009, J IMMUNOL, V183, P4693, DOI 10.4049/jimmunol.0802626; STEWARD MW, 1976, CLIN EXP IMMUNOL, V26, P363; STHOEGER ZM, 1988, J IMMUNOL, V141, P91; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Straub RH, 2006, ARTHRITIS RHEUM-US, V54, P2039, DOI 10.1002/art.21946; Subramanian S, 2011, IMMUNOLOGY, V132, P340, DOI 10.1111/j.1365-2567.2010.03380.x; Svenson JL, 2008, CLIN IMMUNOL, V128, P259, DOI 10.1016/j.clim.2008.03.508; Taneja V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01931; Taneja V, 2015, CYTOKINE, V75, P216, DOI 10.1016/j.cyto.2014.11.028; Tengstrand B, 2003, J RHEUMATOL, V30, P2338; Tingi E, 2016, J CLIN TRANSL ENDOCR, V6, P37, DOI 10.1016/j.jcte.2016.11.001; Torkildsen O, 2018, MULT SCLER RELAT DIS, V22, P38, DOI 10.1016/j.msard.2018.02.031; Tower C, 2011, NAT REV RHEUMATOL, V7, P124, DOI 10.1038/nrrheum.2010.124; Uppal SS, 2003, CYTOM PART B-CLIN CY, V52B, P32, DOI 10.1002/cyto.b.10011; Varyte G, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56020049; Versini M, 2014, AUTOIMMUN REV, V13, P981, DOI 10.1016/j.autrev.2014.07.001; Verthelyi D, 2001, INT IMMUNOPHARMACOL, V1, P983, DOI 10.1016/S1567-5769(01)00044-3; Voskuhl Rhonda, 2011, Biol Sex Differ, V2, P1, DOI 10.1186/2042-6410-2-1; Voskuhl RR, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00326-3; Voskuhl RR, 2018, MULT SCLER J, V24, P22, DOI 10.1177/1352458517737394; Vural P, 2006, PHARMACOL RES, V54, P298, DOI 10.1016/j.phrs.2006.06.006; Walecki M, 2015, MOL BIOL CELL, V26, P2845, DOI 10.1091/mbc.E14-08-1323; Wang C, 2009, IMMUNOLOGY, V126, P329, DOI 10.1111/j.1365-2567.2008.03051.x; Wang JL, 2016, P NATL ACAD SCI USA, V113, pE2029, DOI 10.1073/pnas.1520113113; Wang KX, 2018, AM J MED SCI, V356, P552, DOI 10.1016/j.amjms.2018.08.018; WEINSTEIN Y, 1984, J IMMUNOL, V132, P656; Wikby A, 2008, BIOGERONTOLOGY, V9, P299, DOI 10.1007/s10522-008-9138-6; Wilhelmson AS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04408-0; Wu MM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649882; Yacoub Wasef Sherif Z, 2004, Gend Med, V1, P12, DOI 10.1016/S1550-8579(04)80006-8; Yasui T, 2007, MATURITAS, V56, P396, DOI 10.1016/j.maturitas.2006.11.002; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Young NA, 2014, CLIN IMMUNOL, V151, P66, DOI 10.1016/j.clim.2014.01.006; Yurkovetskiy L, 2013, IMMUNITY, V39, P400, DOI 10.1016/j.immuni.2013.08.013; Yusipov I, 2020, AGING-US, V12, P24057, DOI 10.18632/aging.202251; Zhang J, 2015, J NEUROIMMUNOL, V285, P129, DOI 10.1016/j.jneuroim.2015.06.002; Zhang MA, 2012, P NATL ACAD SCI USA, V109, P9505, DOI 10.1073/pnas.1118458109; Zhou Y, 2009, CLIN IMMUNOL, V132, P362, DOI 10.1016/j.clim.2009.05.011; Zhu ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11350	296	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								945762	10.3389/fimmu.2022.945762	http://dx.doi.org/10.3389/fimmu.2022.945762			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1MR	36505451	gold, Green Published			2022-12-18	WOS:000894134100001
J	Feng, JF; Wang, L; Yang, X; Chen, QX; Cheng, XD				Feng, Jifeng; Wang, Liang; Yang, Xun; Chen, Qixun; Cheng, Xiangdong			The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study	FRONTIERS IN IMMUNOLOGY			English	Article						controlling nutritional status; esophageal squamous cell carcinoma; pathologic complete response; recurrence; neoadjuvant immunochemotherapy; disease-free survival	STATUS CONUT SCORE; INDEPENDENT PROGNOSTIC-FACTOR; CANCER STATISTICS; GASTRIC-CANCER; CHEMOTHERAPY; SURVIVAL; SAFETY; IMMUNOTHERAPY; COMPLICATIONS; RADIATION	BackgroundThe controlling nutritional status (CONUT) score, as an immune-nutritional index, has been reported to be related to prognosis in several cancers. Neoadjuvant immunochemotherapy (nICT) is an emerging pattern for cancer treatment in recent years. However, the usefulness of CONUT in esophageal squamous cell carcinoma (ESCC) with nICT has not been reported so far. This study attempted to clarify the usefulness of CONUT in predicting disease-free survival (DFS) in ESCC with nICT. MethodsTwo hundred sixteen ESCC patients receiving nICT between 2019 and 2021 were retrospectively enrolled. Based on CONUT, the patients were divided into two groups: low groups (score <= 2) and high (score >= 3) groups. The relationships between CONUT and clinical characteristics were estimated. Cox regression analyses with hazard ratios (HRs) and 95% confidence intervals (CIs) were also performed to evaluate the prognostic factors of DFS. ResultsFifty-nine (27.3%) patients achieved pathologic complete response (pCR), and 30 (13.9%) cases had a recurrence. There were 150 cases (69.4%) in low CONUT group and 66 cases (30.6%) in high CONUT group, respectively. The results revealed that vessel invasion (P = 0.037), postoperative pneumonia (P = 0.001), advanced ypT stage (P = 0.011), cTNM stage (P = 0.007), and ypTNM stage (P < 0.001) were significantly related to patients with a high CONUT score. A high pCR rate was found in patients with a low CONUT score (33.3% vs. 13.6%, P = 0.003), and a high recurrence rate was found in patients with a high CONUT score (24.2% vs. 9.3%, P = 0.004), respectively. Patients with a low CONUT score had a better 1-year DFS than those with a high CONUT score (90.7% vs. 75.8%, P = 0.004). Multivariate analyses indicated that the pretreatment CONUT score was an independent predictor regarding DFS (HR = 2.221, 95% CI: 1.067-4.625, P = 0.033). ConclusionA better response and a lower recurrence were found in ESCC patients with a lower pretreatment CONUT. As a useful index for immune-nutritional status, the CONUT might be a reliable prognostic indicator in ESCC patients with nICT.	[Feng, Jifeng; Wang, Liang; Yang, Xun; Chen, Qixun] Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Dept Thorac Oncol Surg, Hangzhou, Peoples R China; [Feng, Jifeng; Cheng, Xiangdong] Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Zhejiang Prov Res Ctr Upper Gastrointestinal Tract, Hangzhou, Peoples R China; [Feng, Jifeng] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China	Chinese Academy of Sciences; Zhejiang Cancer Hospital; Chinese Academy of Sciences; Zhejiang Cancer Hospital; Zhejiang Chinese Medical University	Chen, QX (corresponding author), Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Dept Thorac Oncol Surg, Hangzhou, Peoples R China.; Cheng, XD (corresponding author), Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Zhejiang Prov Res Ctr Upper Gastrointestinal Tract, Hangzhou, Peoples R China.	chenqix@yeah.net; chengxd516@126.com			Zhejiang TCM Science and Technology Project;  [2020ZB036];  [2021ZB034];  [2022ZB051]	Zhejiang TCM Science and Technology Project; ; ; 	Funding This study was supported by Zhejiang TCM Science and Technology Project (2020ZB036, 2021ZB034, and 2022ZB051).	Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Aoyama T, 2022, IN VIVO, V36, P942, DOI 10.21873/invivo.12784; Cao W, 2021, CHINESE MED J-PEKING, V134, P783, DOI 10.1097/CM9.0000000000001474; Chang Lele, 2022, J Immunother, V45, P415, DOI 10.1097/CJI.0000000000000438; Chirieac LR, 2005, CANCER-AM CANCER SOC, V103, P1347, DOI 10.1002/cncr.20916; Damen PJJ, 2021, INT J RADIAT ONCOL, V111, P936, DOI 10.1016/j.ijrobp.2021.07.1695; Du XX, 2019, BOSNIAN J BASIC MED, V19, P186, DOI 10.17305/bjbms.2019.3873; Feng JF, 2022, J INFLAMM RES, V15, P3783, DOI 10.2147/JIR.S367964; Goh SL, 2015, INTERACT CARDIOV TH, V20, P107, DOI 10.1093/icvts/ivu324; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Hao JT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00614; Hayama T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70252-2; Hikage M, 2019, ANN SURG ONCOL, V26, P4744, DOI 10.1245/s10434-019-07742-9; Hirahara N, 2018, AM J THER, V25, pE524, DOI 10.1097/MJT.0000000000000414; Jin HL, 2021, J GASTRIC CANCER, V21, P155, DOI 10.5230/jgc.2021.21.e14; Kang X., 2021, ANN ESOPHAGUS, V4, P33, DOI [10.21037/aoe-21-64, DOI 10.21037/AOE-21-64]; Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6; Kelly RJ, 2021, NEW ENGL J MED, V384, P1191, DOI 10.1056/NEJMoa2032125; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Li Y, 2020, INT J GYNECOL CANCER, V30, P74, DOI 10.1136/ijgc-2019-000865; Lin HN, 2020, INT J SURG, V80, P184, DOI 10.1016/j.ijsu.2020.06.046; Nemoto Y, 2021, IN VIVO, V35, P999, DOI 10.21873/invivo.12343; Rice TW, 2016, DIS ESOPHAGUS, V29, P897, DOI 10.1111/dote.12533; Ruan GT, 2021, J INFLAMM RES, V14, P5527, DOI 10.2147/JIR.S332408; Shen DJ, 2021, J GASTROINTEST ONCOL, V12, P1, DOI 10.21037/jgo-20-599; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Sun F, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01682-z; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Takagi K, 2020, ANTICANCER RES, V40, P5343, DOI 10.21873/anticanres.14541; Toyokawa T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2696-0; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Wu ZG, 2021, J THORAC DIS, V13, P3518, DOI 10.21037/jtd-21-340; Yang GZ, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3352; Yang WX, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003497; Yoshida N, 2017, LANGENBECK ARCH SURG, V402, P333, DOI 10.1007/s00423-017-1553-1; Yoshida N, 2016, WORLD J SURG, V40, P1910, DOI 10.1007/s00268-016-3549-3; Zhang T, 2020, INTERACT CARDIOV TH, V30, P812, DOI 10.1093/icvts/ivaa038; Zhou PT, 2018, CLIN CHIM ACTA, V477, P94, DOI 10.1016/j.cca.2017.11.039; Zhu YM, 2016, ONCOTARGETS THER, V9, P4187, DOI 10.2147/OTT.S104221	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1015365	10.3389/fimmu.2022.1015365	http://dx.doi.org/10.3389/fimmu.2022.1015365			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5TR	36505443	Green Published, gold			2022-12-18	WOS:000893743100001
J	Harabuchi, S; Khan, O; Bassiri, H; Yoshida, T; Okada, Y; Takizawa, M; Ikeda, O; Katada, A; Kambayashi, T				Harabuchi, Shohei; Khan, Omar; Bassiri, Hamid; Yoshida, Taku; Okada, Yohei; Takizawa, Masaomi; Ikeda, Osamu; Katada, Akihiro; Kambayashi, Taku			Manipulation of diacylglycerol and ERK-mediated signaling differentially controls CD8(+) T cell responses during chronic viral infection	FRONTIERS IN IMMUNOLOGY			English	Article						TCR T cell receptor; diacylglycerol kinase (DGK); ERK (extracellular signal-regulated kinase); chronic viral infection; T cell exhaustion	KINASE; ACTIVATION; PATHWAY; PERSISTENCE; EXHAUSTION; PHOSPHORYLATION; PROLIFERATION; DEGRADATION; EXPRESSION; INDUCTION	IntroductionActivation of T cell receptor (TCR) signaling is critical for clonal expansion of CD8+ T cells. However, the effects of augmenting TCR signaling during chronic antigen exposure is less understood. Here, we investigated the role of diacylglycerol (DAG)-mediated signaling downstream of the TCR during chronic lymphocytic choriomeningitis virus clone 13 (LCMV CL13) infection by blocking DAG kinase zeta (DGK zeta), a negative regulator of DAG. MethodsWe examined the activation, survival, expansion, and phenotype of virus-specific T cell in the acute and chronic phases of LCMV CL13-infected in mice after DGK zeta blockade or selective activation of ERK. ResultsUpon LCMV CL13 infection, DGK zeta deficiency promoted early short-lived effector cell (SLEC) differentiation of LCMV-specific CD8+ T cells, but this was followed by abrupt cell death. Short-term inhibition of DGK zeta with ASP1570, a DGK zeta-selective pharmacological inhibitor, augmented CD8+ T cell activation without causing cell death, which reduced virus titers both in the acute and chronic phases of LCMV CL13 infection. Unexpectedly, the selective enhancement of ERK, one key signaling pathway downstream of DAG, lowered viral titers and promoted expansion, survival, and a memory phenotype of LCMV-specific CD8+ T cells in the acute phase with fewer exhausted T cells in the chronic phase. The difference seen between DGK zeta deficiency and selective ERK enhancement could be potentially explained by the activation of the AKT/mTOR pathway by DGK zeta deficiency, since the mTOR inhibitor rapamycin rescued the abrupt cell death seen in virus-specific DGK zeta KO CD8+ T cells. DiscussionThus, while ERK is downstream of DAG signaling, the two pathways lead to distinct outcomes in the context of chronic CD8+ T cell activation, whereby DAG promotes SLEC differentiation and ERK promotes a memory phenotype.	[Harabuchi, Shohei; Kambayashi, Taku] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Harabuchi, Shohei; Katada, Akihiro] Asahikawa Med Univ, Dept Otolaryngol Head & Neck Surg, Asahikawa, Japan; [Khan, Omar] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA; [Bassiri, Hamid] Univ Penn, Dept Pediat, Div Infect Dis, Perelman Sch Med, Philadelphia, PA USA; [Yoshida, Taku; Okada, Yohei; Ikeda, Osamu] Astellas Pharma Inc, Immunooncol, Tsukuba, Japan; [Takizawa, Masaomi] Astellas Pharma Inc, Res Program Management Appl Res Management, Tokyo, Japan	University of Pennsylvania; Pennsylvania Medicine; Asahikawa Medical College; University of California System; University of California San Francisco; University of Pennsylvania; Pennsylvania Medicine; Astellas Pharmaceuticals; Astellas Pharmaceuticals	Kambayashi, T (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.	kambayat@pennmedicine.upenn.edu			Astellas Pharma; National Institutes of Health [R01HL111501, R01HL146645]; Ito Foundation; Society for Promotion of International Oto-Rhino-Laryngology (SPIO)	Astellas Pharma(Astellas Pharmaceuticals); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ito Foundation; Society for Promotion of International Oto-Rhino-Laryngology (SPIO)	This work was supported by funds from Astellas Pharma and the National Institutes of Health, R01HL111501 and R01HL146645 to TK and funds from The Ito Foundation and Society for Promotion of International Oto-Rhino-Laryngology (SPIO) to SH.	Allan LA, 2009, FEBS J, V276, P6063, DOI 10.1111/j.1742-4658.2009.07330.x; Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bergthaler A, 2010, P NATL ACAD SCI USA, V107, P21641, DOI 10.1073/pnas.1011998107; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; Chen ZY, 2019, IMMUNITY, V51, P840, DOI 10.1016/j.immuni.2019.09.013; D'Souza WN, 2008, J IMMUNOL, V181, P7617, DOI 10.4049/jimmunol.181.11.7617; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Gorentla BK, 2011, BLOOD, V117, P4022, DOI 10.1182/blood-2010-08-300731; Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080; Hayashi K, 2007, PHARMACOL RES, V55, P537, DOI 10.1016/j.phrs.2007.04.009; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hwang JR, 2020, EXP MOL MED, V52, P750, DOI 10.1038/s12276-020-0435-8; Joshi RP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004373; Joshi RP, 2013, INT J MOL SCI, V14, P6649, DOI 10.3390/ijms14046649; Kahan SM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020156; Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Little AS, 2012, BIOCHEM SOC T, V40, P73, DOI 10.1042/BST20110647; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Ngoi NYL, 2020, CANCERS, V12, DOI 10.3390/cancers12030574; Olenchock BA, 2006, NAT IMMUNOL, V7, P1174, DOI 10.1038/ni1400; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010; Riese MJ, 2011, J BIOL CHEM, V286, P5254, DOI 10.1074/jbc.M110.171884; Schmidt AM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004411; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Shin J, 2012, J IMMUNOL, V188, P2111, DOI 10.4049/jimmunol.1102265; Shulga YV, 2011, CHEM REV, V111, P6186, DOI 10.1021/cr1004106; Singh BK, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aax3332; Singh BK, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00096; Staron MM, 2014, IMMUNITY, V41, P802, DOI 10.1016/j.immuni.2014.10.013; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Torres-Ayuso P, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.22; Wesley Erin M, 2018, Immunohorizons, V2, P107, DOI 10.4049/immunohorizons.1700055; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958; Zhong XP, 2002, J BIOL CHEM, V277, P31089, DOI 10.1074/jbc.M203818200	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1032113	10.3389/fimmu.2022.1032113	http://dx.doi.org/10.3389/fimmu.2022.1032113			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U0NP		gold			2022-12-18	WOS:000894068100001
J	He, Y; Xia, D; Tong, YH; Shang, HJ; Liu, X; Peng, EJ; Huang, Q; Tang, K; Chen, ZQ				He, Yu; Xia, Ding; Tong, Yonghua; Shang, Haojie; Liu, Xiao; Peng, Ejun; Huang, Qiu; Tang, Kun; Chen, Zhiqiang			Predictive value of CD3(+) cells and interleukin 2 receptor in systemic inflammatory response syndrome after percutaneous nephrolithotomy	FRONTIERS IN IMMUNOLOGY			English	Article						CD3(+) cells; IL-2R; nomogram; percutaneous nephrolithotomy; systemic inflammatory response syndrome	INTERNATIONAL CONSENSUS DEFINITIONS; SOLUBLE IL-2 RECEPTOR; LYMPHOCYTE SUBSETS; RISK-FACTORS; MARKERS; SEPSIS	ObjectiveThe aim of the current study was to evaluate the risk factors that influence the development of postoperative systemic inflammatory response syndrome (SIRS) after percutaneous nephrolithotomy (PCNL), including cytokines and lymphocyte subsets. MethodsA total of 154 patients who underwent PCNL at our hospital between October 2019 and January 2022 were retrospectively reviewed. The development of post-PCNL SIRS was the primary endpoint of the study. Univariable analysis and multivariable logistic regression analysis were performed to identify independent risk factors of post-PCNL SIRS. A nomogram was constructed using the independent risk factors, and receiver operating characteristic (ROC) curves were drawn. ResultsThere were 50 patients (32.5%) who developed SIRS after PCNL. In multivariate analysis, positive urine culture (odds ratio [OR], 3.556; p = 0.048), long operation time (OR, 1.011; p = 0.027), high IL-2R (OR, 1.002; p = 0.018), low percentage of CD3(+) cells (OR 0.931; p = 0.006), and high white blood cell (WBC) count (OR, 1.282; p = 0.044) were independent risk factors for post-PCNL SIRS. These five significant variables were used to generate a nomogram that exhibited favorable fitting. The discrimination area under the ROC curves was 0.795. ConclusionsPatients with long operation times, positive urine cultures, high interleukin 2 receptor, high white blood cell counts, and low percentages of CD3(+) cells may be at a higher risk of developing SIRS after PCNL. In these patients, cautious and comprehensive preoperative evaluations and appropriate treatment strategies should be considered.	[He, Yu; Xia, Ding; Tong, Yonghua; Shang, Haojie; Liu, Xiao; Peng, Ejun; Huang, Qiu; Tang, Kun; Chen, Zhiqiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China	Huazhong University of Science & Technology	Tang, K; Chen, ZQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China.	tangsk1990@163.com; zhqchen8366@163.com			National Natural Science Foundation of China [81900645, 82170779, 82270804]; Natural Science Foundation of Hubei Province [2021CFB366]; Wuhan Yellow Crane Talent Program (Outstanding Young Talents); Tongji Hospital (HUST) Foundation for Excellent Young Scientist [2020YQ15]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province); Wuhan Yellow Crane Talent Program (Outstanding Young Talents); Tongji Hospital (HUST) Foundation for Excellent Young Scientist	Our research was funded by the National Natural Science Foundation of China (Nos. 81900645, 82170779, and 82270804), the Natural Science Foundation of Hubei Province (2021CFB366), 2019 Wuhan Yellow Crane Talent Program (Outstanding Young Talents), and the Tongji Hospital (HUST) Foundation for Excellent Young Scientist (No. 2020YQ15).	ACKERMANN D, 1989, Journal of Endourology, V3, P355, DOI 10.1089/end.1989.3.355; Akdeniz E, 2021, JCPSP-J COLL PHYSICI, V31, P410, DOI 10.29271/jcpsp.2021.04.410; Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123; Cheng W, 2020, INT J INFECT DIS, V96, P315, DOI 10.1016/j.ijid.2020.04.072; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Ding LL, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00128; EAU Guidelines, 2022, UR CIT INF; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Floege J, 2012, EUR J CELL BIOL, V91, P427, DOI 10.1016/j.ejcb.2012.01.003; Ganesan V, 2017, J ENDOUROL, V31, P638, DOI 10.1089/end.2016.0884; Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625; Holub M, 2003, CLIN MICROBIOL INFEC, V9, P202, DOI 10.1046/j.1469-0691.2003.00518.x; Jang DI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052719; Koras O, 2015, UROLITHIASIS, V43, P55, DOI 10.1007/s00240-014-0730-8; Kreydin EI, 2013, NAT REV UROL, V10, P598, DOI 10.1038/nrurol.2013.183; Lai Win Shun, 2018, Rev Urol, V20, P7, DOI 10.3909/riu0778; Liu JC, 2020, UROLITHIASIS, V48, P251, DOI 10.1007/s00240-019-01148-8; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; Moses RA, 2017, UROLOGY, V100, P33, DOI 10.1016/j.urology.2016.09.012; Omar M, 2016, J UROLOGY, V196, P109, DOI 10.1016/j.juro.2016.01.104; Onur ST, 2015, INFECT DIS-NOR, V47, P150, DOI 10.3109/00365548.2014.975278; Qi TG, 2021, UROLITHIASIS, V49, P367, DOI 10.1007/s00240-020-01237-z; Schneider DF, 2007, J BURN CARE RES, V28, P365, DOI 10.1097/BCR.0B013E318053D40B; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sorokin I, 2017, WORLD J UROL, V35, P1301, DOI 10.1007/s00345-017-2008-6; Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y; Toledo-Cornell C, 2014, J MED VIROL, V86, P315, DOI 10.1002/jmv.23711; URIBARRI J, 1989, ANN INTERN MED, V111, P1006, DOI 10.7326/0003-4819-111-12-1006; Xia QD, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/9927498; Xu HB, 2019, J ENDOUROL, V33, P1, DOI 10.1089/end.2018.0632; Zeng GH, 2022, EUR UROL FOCUS, V8, P588, DOI 10.1016/j.euf.2021.03.008; Zhang W, 2020, INT J INFECT DIS, V99, P92, DOI 10.1016/j.ijid.2020.06.079; Zhong W, 2008, J ENDOUROL, V22, P2147, DOI 10.1089/end.2008.0001; Zhu JF, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a030338	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1017219	10.3389/fimmu.2022.1017219	http://dx.doi.org/10.3389/fimmu.2022.1017219			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1ZO	36505430	Green Published, gold			2022-12-18	WOS:000894169200001
J	Hinrichs, AC; Kruize, AA; Leavis, HL; van Roon, JAG				Hinrichs, Anneline C.; Kruize, Aike A.; Leavis, Helen L.; van Roon, Joel A. G.			In patients with primary Sjogren's syndrome innate-like MAIT cells display upregulated IL-7R, IFN-gamma, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells	FRONTIERS IN IMMUNOLOGY			English	Article						Sjogren's syndrome (pSS); MAIT cells; CCR9; CXCR5 T cells; IL-7R alpha (CD127); IL-18R alpha	INVARIANT T-CELLS; ECTOPIC GERMINAL-CENTERS; LABIAL SALIVARY-GLANDS; B-CELLS; ACTIVATION; RECEPTOR; INTERLEUKIN-7; DIFFERENTIATION; HYPERACTIVITY; CXCL13	Introduction: Mucosal-associated invariant T (MAIT) cells might play a role in B cell hyperactivity and local inflammation in primary Sjogren's syndrome (pSS), just like previously studied mucosa-associated CCR9+ and CXCR5+ T helper cells. Here, we investigated expression of CCR9, CXCR5, IL-18R and IL-7R on MAIT cells in pSS, and assessed the capacity of DMARDs to inhibit the activity of MAIT cells. Methods: Circulating CD161+ and IL-18R alpha+ TCRV alpha 7.2+ MAIT cells from pSS patients and healthy controls (HC) were assessed using flow cytometry, and expression of CCR9, CXCR5, and IL-7R on MAIT cells was studied. Production of IFN-gamma and IL-21 by MAIT cells was measured upon IL-7 stimulation in the presence of leflunomide (LEF) and hydroxychloroquine (HCQ). Results: The numbers of CD161+ and IL-18R alpha+ MAIT cells were decreased in pSS patients compared to HC. Relative increased percentages of CD4 MAIT cells in pSS patients caused significantly higher CD4/CD8 ratios in MAIT cells. The numbers of CCR9 and CXCR5-expressing MAIT cells were significantly higher in pSS patients. IL-7R expression was higher in CD8 MAIT cells as compared to all CD8 T cells, and changes in IL-7R expression correlated to several clinical parameters. The elevated production of IL-21 by MAIT cells was significantly inhibited by LEF/HCQ treatment. Conclusion: Circulating CD161+ and IL-18R alpha+ MAIT cell numbers are decreased in pSS patients. Given their enriched CCR9/CXCR5 expression this may facilitate migration to inflamed salivary glands known to overexpress CCL25/CXCL13. Given the pivotal role of IL-7 and IL-21 in inflammation in pSS this indicates a potential role for MAIT cells in driving pSS immunopathology.	[Hinrichs, Anneline C.; Kruize, Aike A.; Leavis, Helen L.; van Roon, Joel A. G.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands; [Hinrichs, Anneline C.; van Roon, Joel A. G.] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van Roon, JAG (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands.; van Roon, JAG (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands.	J.vanroon@umcutrecht.nl			 [17-2-403]		Funding AH is supported by ReumaNederland, grant number 17-2-403.	Amft N, 2001, ARTHRITIS RHEUM-US, V44, P2633, DOI 10.1002/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9; Barone F, 2005, ARTHRITIS RHEUM-US, V52, P1773, DOI 10.1002/art.21062; Bennett MS, 2017, J LEUKOCYTE BIOL, V102, P1261, DOI 10.1189/jlb.4A0317-116R; Bikker A, 2012, ANN RHEUM DIS, V71, P1027, DOI 10.1136/annrheumdis-2011-200744; Bikker A, 2010, ARTHRITIS RHEUM-US, V62, P969, DOI 10.1002/art.27318; Blokland SLM, 2021, RHEUMATOLOGY, V60, P3072, DOI 10.1093/rheumatology/key438; Blokland SLM, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2018-000772; Blokland SLM, 2017, ARTHRITIS RHEUMATOL, V69, P2038, DOI 10.1002/art.40182; Bombardieri M, 2004, ARTHRITIS RES THER, V6, pR447, DOI 10.1186/ar1209; Bombardieri M, 2007, J IMMUNOL, V179, P4929, DOI 10.4049/jimmunol.179.7.4929; Booth JS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00466; Brito-Zeron P, 2017, ANN RHEUM DIS, V76, P1042, DOI 10.1136/annrheumdis-2016-209952; Brito-Zeron P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.47; Carrette F, 2012, SEMIN IMMUNOL, V24, P209, DOI 10.1016/j.smim.2012.04.010; Chiba A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01333; Chiba A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1257-5; Chiba A, 2012, ARTHRITIS RHEUM-US, V64, P153, DOI 10.1002/art.33314; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Dupre A, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen-2020-001442; Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339; Flament H, 2021, EUR J IMMUNOL, V51, P298, DOI 10.1038/s41590-021-00870-z; Gherardin NA, 2018, IMMUNOL CELL BIOL, V96, P507, DOI 10.1111/imcb.12021; Gong YZ, 2014, J AUTOIMMUN, V51, P57, DOI 10.1016/j.jaut.2013.11.003; Guggino G, 2017, EUR J IMMUNOL, V47, P2002, DOI 10.1002/eji.201747140; Hartgring SAY, 2009, ARTHRITIS RHEUM-US, V60, P2595, DOI 10.1002/art.24754; Henriques CM, 2010, BLOOD, V115, P3269, DOI 10.1182/blood-2009-10-246876; Hinrichs AC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.887972; Hinrichs AC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.702733; Jensen O, 2022, SCI IMMUNOL, V7, DOI 10.1126/sciimmunol.abe8931; Jiang J, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12858; Jin L, 2014, INT J CLIN EXP PATHO, V7, P1988; Kang KY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3504; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Kroese FGM, 2014, EXPERT REV CLIN IMMU, V10, P483, DOI 10.1586/1744666X.2014.891439; Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890; Li XY, 2012, BIOCHEM BIOPH RES CO, V422, P238, DOI 10.1016/j.bbrc.2012.04.133; Li YM, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.819992; Liang Y, 2022, INT IMMUNOPHARMACOL, V108, DOI 10.1016/j.intimp.2022.108758; Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113; Maehara T, 2012, CLIN EXP IMMUNOL, V169, P89, DOI 10.1111/j.1365-2249.2012.04606.x; Manoussakis MN, 2007, ARTHRITIS RHEUM-US, V56, P3977, DOI 10.1002/art.23073; Mariette X, 2018, NEW ENGL J MED, V378, P931, DOI 10.1056/NEJMcp1702514; Martin E, 2009, PLOS BIOL, V7, P525, DOI 10.1371/journal.pbio.1000054; McGuire HM, 2011, IMMUNITY, V34, P602, DOI 10.1016/j.immuni.2011.01.021; Murayama G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02681; Nel I, 2021, MUCOSAL IMMUNOL, V14, P803, DOI 10.1038/s41385-021-00391-w; Nocturne G, 2018, NAT REV RHEUMATOL, V14, P133, DOI 10.1038/nrrheum.2018.1; Pontarini E, 2020, ANN RHEUM DIS, V79, P1588, DOI 10.1136/annrheumdis-2020-217646; Reantragoon R, 2012, J EXP MED, V209, P761, DOI 10.1084/jem.20112095; Risselada AP, 2014, ANN RHEUM DIS, V73, P1537, DOI 10.1136/annrheumdis-2013-204634; Risselada AP, 2013, SEMIN ARTHRITIS RHEU, V42, P368, DOI 10.1016/j.semarthrit.2012.07.003; Riviere E, 2021, ARTHRITIS RHEUMATOL, V73, P631, DOI 10.1002/art.41558; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Sobkowiak MJ, 2019, EUR J IMMUNOL, V49, P133, DOI 10.1002/eji.201847759; Sundstrom P, 2015, J IMMUNOL, V195, P3472, DOI 10.4049/jimmunol.1500258; Szabo K, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/631787; Szabo K, 2013, CLIN IMMUNOL, V147, P95, DOI 10.1016/j.clim.2013.02.024; Tilloy F, 1999, J EXP MED, V189, P1907, DOI 10.1084/jem.189.12.1907; Ussher JE, 2018, IMMUNOL CELL BIOL, V96, P630, DOI 10.1111/imcb.12008; Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509; van der Heijden EHM, 2019, EXPERT REV CLIN IMMU, V15, P801, DOI 10.1080/1744666X.2019.1624527; van der Heijden EHM, 2020, LANCET RHEUMATOL, V2, pE260, DOI 10.1016/S2665-9913(20)30057-6; van Roon JAG, 2003, ANN RHEUM DIS, V62, P113, DOI 10.1136/ard.62.2.113; van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653; Verstappen GM, 2017, ARTHRITIS RHEUMATOL, V69, P1850, DOI 10.1002/art.40165; Wang JJ, 2016, EUR J IMMUNOL, V46, P2444, DOI 10.1002/eji.201646300	66	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1017157	10.3389/fimmu.2022.1017157	http://dx.doi.org/10.3389/fimmu.2022.1017157			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U5EK	36505431	gold, Green Published			2022-12-18	WOS:000894389600001
J	Huang, JH; Yuan, L; Huang, WQ; Liao, LW; Zhu, XD; Wang, XQ; Li, JX; Liang, WY; Wu, YT; Liu, XC; Yu, D; Zheng, YN; Guan, J; Zhan, YZ; Liu, LY				Huang, Jihong; Yuan, Lu; Huang, Wenqi; Liao, Liwei; Zhu, Xiaodi; Wang, Xiaoqing; Li, Jiaxin; Liang, Wenyu; Wu, Yuting; Liu, Xiaocheng; Yu, Dong; Zheng, Yunna; Guan, Jian; Zhan, Yongzhong; Liu, Laiyu			LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; prognosis; immune infiltration; tumor microenvironment; LUAD	REGULATORY T-CELLS; CHECKPOINTS	BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient biomarkers have been identified to distinguish patients who would respond to immunotherapy. The tumor microenvironment (TME) is reported to contribute to immunotherapy response, but details remain unknown. We aimed to construct a prognostic model based on the TME of lung adenocarcinoma (LUAD) to predict the prognosis and immunotherapy efficacy. MethodsWe integrated computational algorithms to describe the immune infiltrative landscape of LUAD patients. With the least absolute shrinkage and selection operator (LASSO) and Cox regression analyses, we developed a LUAD tumor microenvironment prognostic signature (LATPS). Subsequently, the immune characteristics and the benefit of immunotherapy in LATPS-defined subgroups were analyzed. RNA sequencing of tumor samples from 28 lung cancer patients treated with anti-PD-1 therapy was conducted to verify the predictive value of the LATPS. ResultsWe constructed the LATPS grounded on four genes, including UBE2T, KRT6A, IRX2, and CD3D. The LATPS-low subgroup had a better overall survival (OS) and tended to have a hot immune phenotype, which was characterized by an elevated abundance of immune cell infiltration and increased activity of immune-related pathways. Additionally, tumor immune dysfunction and exclusion (TIDE) score was markedly decreased in the LATPS-low subgroup, indicating an enhanced opportunity to benefit from immunotherapy. Survival analysis in 28 advanced lung cancer patients treated with an anti-PD-1 regimen at Nanfang hospital revealed that the LATPS-low subgroup had better immunotherapy benefit. ConclusionLATPS is an effective predictor to distinguish survival, immune characteristics, and immunotherapy benefit in LUAD patients.	[Huang, Jihong; Yuan, Lu; Huang, Wenqi; Liao, Liwei; Zhu, Xiaodi; Li, Jiaxin; Liang, Wenyu; Liu, Xiaocheng; Yu, Dong; Zheng, Yunna; Zhan, Yongzhong; Liu, Laiyu] Southern Med Univ, Nanfang Hosp, Dept Resp & Crit Care Med, Chron Airways Dis Lab, Guangzhou, Peoples R China; [Wang, Xiaoqing; Guan, Jian] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China; [Wu, Yuting] Ganzhou Peoples Hosp, Dept Blood Transfus, Ganzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China	Zhan, YZ; Liu, LY (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Resp & Crit Care Med, Chron Airways Dis Lab, Guangzhou, Peoples R China.; Guan, J (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China.	guanjian5461@163.com; 171290466@qq.com; liulaiyu@sina.com			National Natural Science Foundation of China; President Foundation of Nanfang Hospital, Southern Medical University; Clinical Research Program of Nanfang Hospital, Southern Medical University;  [81870026];  [2020C044];  [2018CR019];  [2018CR021];  [2020CR025]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); President Foundation of Nanfang Hospital, Southern Medical University; Clinical Research Program of Nanfang Hospital, Southern Medical University; ; ; ; ; 	Funding This work was supported by the National Natural Science Foundation of China [grant number 81870026], the President Foundation of Nanfang Hospital, Southern Medical University [grant number 2020C044], and the Clinical Research Program of Nanfang Hospital, Southern Medical University [grant numbers 2018CR019, 2018CR021, 2020CR025].	Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brahmer JR, 2013, CANCER IMMUNOL RES, V1, P85, DOI 10.1158/2326-6066.CIR-13-0078; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Che D, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.694071; Chen Y, 2021, CLIN CANCER RES, V27, P330, DOI 10.1158/1078-0432.CCR-20-2166; Cheng Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.665276; Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Faruki H, 2017, J THORAC ONCOL, V12, P943, DOI 10.1016/j.jtho.2017.03.010; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Garcia-Mulero S, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000491; Guo W, 2020, J CANCER RES CLIN, V146, P821, DOI 10.1007/s00432-020-03147-4; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hazra A, 2016, INDIAN J DERMATOL, V61, P251, DOI 10.4103/0019-5154.182416; He Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1002-1; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; Jacobs JFM, 2012, LANCET ONCOL, V13, pE32, DOI 10.1016/S1470-2045(11)70155-3; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Ke X, 2016, CANCER IMMUNOL IMMUN, V65, P587, DOI 10.1007/s00262-016-1825-6; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li XL, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0578-4; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Nishio M, 2021, J THORAC ONCOL, V16, P653, DOI 10.1016/j.jtho.2020.11.025; Pan Q, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9960905; Philip M, 2022, NAT REV IMMUNOL, V22, P209, DOI 10.1038/s41577-021-00574-3; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Reck M, 2021, J CLIN ONCOL, V39, P2339, DOI 10.1200/JCO.21.00174; Ren ZY, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.672904; Si JY, 2018, INT J CLIN EXP PATHO, V11, P4073; Simon N, 2011, J STAT SOFTW, V39, P1; Smit EF, 2016, NAT REV CLIN ONCOL, V13, P75, DOI 10.1038/nrclinonc.2015.223; Steven A, 2016, RESPIROLOGY, V21, P821, DOI 10.1111/resp.12789; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang YF, 2021, CANCER MANAG RES, V13, P5919, DOI 10.2147/CMAR.S320393; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Wu J, 2021, ONCOGENE, V40, P4413, DOI 10.1038/s41388-021-01853-y; Yang Y, 2020, IMMUNOTHERAPY-UK, V12, P25, DOI 10.2217/imt-2019-0145; Yi M, 2021, CANCER IMMUNOL IMMUN, V70, P1705, DOI 10.1007/s00262-020-02817-z; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yue C, 2019, PEERJ, V7, DOI 10.7717/peerj.8128; Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0; Zhu ZP, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20202898	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1064874	10.3389/fimmu.2022.1064874	http://dx.doi.org/10.3389/fimmu.2022.1064874			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5QZ	36505456	gold, Green Published			2022-12-18	WOS:000893735900001
J	Lei, Y; Cui, TJ; Wang, XH; Zhang, XM; Tang, C; Zheng, ZH				Lei, Yan; Cui, Tian-Jiao; Wang, Xiao-Hua; Zhang, Xue-Mei; Tang, Chun; Zheng, Zhi-Hua			Plasma adsorption in refractory chronic gouty arthritis flare: A case report	FRONTIERS IN IMMUNOLOGY			English	Article						case report; cytokines; gout; plasma adsorption; refractory gouty arthropathy; arthritis	HEMOADSORPTION; MECHANISMS; APHERESIS	BackgroundAlong with uric acid, which is the primary driving factor of gout, downstream inflammatory mediators have been shown to be involved in the pathogenesis of gouty arthritis flares. Extracorporeal haemadsorption is an emerging technology for the treatment of dysregulated inflammatory states by effectively removing cytokines from the bloodstream. Whether haemadsorption was effective in refractory gout flares has not been reported in the literature. Case summaryWe report the case of a 52-year-old male who presented with refractory gouty arthropathy for 30 years. His uric acid levels were poorly controlled due to poor diet and treatment compliance. Tophi were found to have precipitated in multiple joints and subcutaneous tissue. In the last 2 years, his incidents of gouty flares had become more frequent, and resistant to the medications, including colchicine, allopurinol, febuxostat, glucocorticoids, and NSAID analgesics. He had experienced a triad of chills, high fever and arthritis for the past 2 weeks. Therefore, he took 2 mg colchicine twice daily for 2 weeks with no improvement in his pain. Proinflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha), were found to be remarkably elevated. Given that conventional treatment was unsuccessful, we tried to employ plasma adsorption (PA) to remove inflammatory cytokines. After 4 sessions, symptoms, such as fever, joint swelling and pain, were greatly improved. Meanwhile, the levels of proinflammatory factors such as IL-6 and TNF-alpha were found to be decreased, while the anti-inflammatory factor IL-10 remained the same during the course. He was followed up for 8 months and arthritis have flared up twice in response to a high-purine diet. ConclusionOur study suggests that plasma adsorption (PA) may be a promising and feasible treatment for refractory gout when conventional treatments are unsatisfactory or contraindicated. However, more clinical trials are needed to verify the efficacy and safety of the treatment. Core tipChronic gouty arthritis flares are refractory to conventional treatment, such as uric acid-lowering drugs and NSAID analgesics. Due to the involvement of inflammatory cytokines, plasma adsorption was employed to alleviate flares by removing inflammatory mediators. Herein, we report a 52-year-old male who presented with refractory gouty arthropathy for 30 years, manifested with a triad of chills, high fever and arthritis. He underwent several sessions of plasma adsorption, and his symptoms soon improved, along with a drop in inflammatory mediators. We conclude that plasma adsorption may be a promising and feasible treatment for refractory gout when conventional treatments are unsatisfactory or contraindicated.	[Lei, Yan; Cui, Tian-Jiao; Wang, Xiao-Hua; Zhang, Xue-Mei; Tang, Chun; Zheng, Zhi-Hua] Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Nephrol & Urol, Dept Nephrol, Shenzhen, Peoples R China	Sun Yat Sen University	Zheng, ZH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Nephrol & Urol, Dept Nephrol, Shenzhen, Peoples R China.	zhzhihua@mail.sysu.edu.cn			Shenzhen Science and Technology Innovation Committee of Guangdong Province of China;  [JCYJ20180307150634856];  [JCYJ20210324123200003]	Shenzhen Science and Technology Innovation Committee of Guangdong Province of China; ; 	Funding Supported by the Shenzhen Science and Technology Innovation Committee of Guangdong Province of China (Grant No. JCYJ20180307150634856, JCYJ20210324123200003)	Berlot G, 2018, BLOOD PURIFICAT, V46, P274, DOI 10.1159/000490611; Bonavia A, 2018, BLOOD PURIFICAT, V46, P337, DOI 10.1159/000492379; Dumusc A, 2015, CURR OPIN RHEUMATOL, V27, P156, DOI 10.1097/BOR.0000000000000143; Hovland A, 2012, ACTA BIOMATER, V8, P2288, DOI 10.1016/j.actbio.2012.02.017; Kimmel JD, 2010, J BIOMED MATER RES B, V92B, P390, DOI 10.1002/jbm.b.31527; Kuo CF, 2015, NAT REV RHEUMATOL, V11, P649, DOI 10.1038/nrrheum.2015.91; Padmanabhan A, 2019, J CLIN APHERESIS, V34, P171, DOI 10.1002/jca.21705; Schultz P, 2021, J CRIT CARE, V64, P184, DOI 10.1016/j.jcrc.2021.04.011; Shukla R, 2007, J CUTAN MED SURG, V11, P31, DOI 10.2310/7750.2007.00002; So AK, 2017, NAT REV RHEUMATOL, V13, P639, DOI 10.1038/nrrheum.2017.155; Zhang BJ, 2021, J NEUROL SCI, V428, DOI 10.1016/j.jns.2021.117568	11	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1045982	10.3389/fimmu.2022.1045982	http://dx.doi.org/10.3389/fimmu.2022.1045982			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6KX	36505444	gold, Green Published			2022-12-18	WOS:000893787900001
J	Lemieux, W; Fleischer, D; Yang, AY; Niemann, M; Oualkacha, K; Klement, W; Richard, L; Polychronakos, C; Liwski, R; Claas, F; Gebel, HM; Keown, PA; Lewin, A; Sapir-Pichhadze, R; Genome Canada Transplant Consortium				Lemieux, William; Fleischer, David; Yang, Archer Yi; Niemann, Matthias; Oualkacha, Karim; Klement, William; Richard, Lucie; Polychronakos, Constantin; Liwski, Robert; Claas, Frans; Gebel, Howard M. M.; Keown, Paul A. A.; Lewin, Antoine; Sapir-Pichhadze, Ruth; Genome Canada Transplant Consortium			Dissecting the impact of molecular T-cell HLA mismatches in kidney transplant failure: A retrospective cohort study	FRONTIERS IN IMMUNOLOGY			English	Article						human leukocyte antigens; PIRCHE-II; death-censored graft failure; feature selection; network analysis	REGULARIZATION PATHS	IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo donor specific antibody development continues to negatively impact patients undergoing kidney transplantation. One of the recent advances in solid organ transplantation has been the definition of molecular mismatching between donors and recipients' Human Leukocyte Antigens (HLA). While not fully integrated in standard clinical care, cumulative molecular mismatch at the level of eplets (EMM) as well as the PIRCHE-II score have shown promise in predicting transplant outcomes. In this manuscript, we sought to study whether certain T-cell molecular mismatches (TcEMM) were highly predictive of death-censored graft failure (DCGF). MethodsWe studied a retrospective cohort of kidney donor:recipient pairs from the Scientific Registry of Transplant Recipients (2000-2015). Allele level HLA-A, B, C, DRB1 and DQB1 types were imputed from serologic types using the NMDP algorithm. TcEMMs were then estimated using the PIRCHE-II algorithm. Multivariable Accelerated Failure Time (AFT) models assessed the association between each TcEMM and DCGF. To discriminate between TcEMMs most predictive of DCGF, we fit multivariable Lasso penalized regression models. We identified co-expressed TcEMMs using weighted correlation network analysis (WGCNA). Finally, we conducted sensitivity analyses to address PIRCHE and IMGT/HLA version updates. ResultsA total of 118,309 donor:recipient pairs meeting the eligibility criteria were studied. When applying the PIRCHE-II algorithm, we identified 1,935 distinct TcEMMs at the population level. A total of 218 of the observed TcEMM were independently associated with DCGF by AFT models. The Lasso penalized regression model with post selection inference identified a smaller subset of 86 TcEMMs (56 and 30 TcEMM derived from HLA Class I and II, respectively) to be highly predictive of DCGF. Of the observed TcEMM, 38.14% appeared as profiles of highly co-expressed TcEMMs. In addition, sensitivity analyses identified that the selected TcEMM were congruent across IMGT/HLA versions. ConclusionIn this study, we identified subsets of TcEMMs highly predictive of DCGF and profiles of co-expressed mismatches. Experimental verification of these TcEMMs determining immune responses and how they may interact with EMM as predictors of transplant outcomes would justify their consideration in organ allocation schemes and for modifying immunosuppression regimens.	[Lemieux, William; Sapir-Pichhadze, Ruth] McGill Univ, Ctr Outcomes Res & Evaluat CORE, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Lemieux, William; Lewin, Antoine] Hema Quebec, Med Affairs & Innovat, Montreal, PQ, Canada; [Fleischer, David; Yang, Archer Yi] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada; [Niemann, Matthias] PIRCHE AG, Res & Dev, Berlin, Germany; [Oualkacha, Karim] Univ Quebec Montreal, Dept Math, Montreal, PQ, Canada; [Klement, William] Canadian Blood Serv, Div Organ Donat & Transplantat, Ottawa, ON, Canada; [Richard, Lucie] Hema Quebec, Transfus Med Reference Lab, Montreal, PQ, Canada; [Polychronakos, Constantin] McGill Univ, Res Inst, Hlth Ctr, Dept Pediat, Montreal, PQ, Canada; [Polychronakos, Constantin] Montreal Childrens Hosp, Montreal, PQ, Canada; [Liwski, Robert] Dalhousie Univ, Dept Pathol, Multiorgan Transplant Program, Hlth Ctr, Halifax, NS, Canada; [Claas, Frans] Leiden Univ Med Ctr, Dept Immunol, Leiden, PQ, Netherlands; [Gebel, Howard M. M.] Emory Univ, Pathol & Lab Med, Atlanta, GA USA; [Keown, Paul A. A.] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Lewin, Antoine] Univ Sherbrooke, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada; [Sapir-Pichhadze, Ruth] McGill Univ, Royal Victoria Hosp, Hlth Ctr, Div Nephrol, Montreal, PQ, Canada	McGill University; Hema-Quebec; McGill University; University of Quebec; University of Quebec Montreal; Canadian Blood Services; Hema-Quebec; McGill University; McGill University; Dalhousie University; Leiden University; Leiden University Medical Center (LUMC); Emory University; University of British Columbia; University of Sherbrooke; McGill University; Royal Victoria Hospital	Sapir-Pichhadze, R (corresponding author), McGill Univ, Ctr Outcomes Res & Evaluat CORE, Res Inst, Hlth Ctr, Montreal, PQ, Canada.; Sapir-Pichhadze, R (corresponding author), McGill Univ, Royal Victoria Hosp, Hlth Ctr, Div Nephrol, Montreal, PQ, Canada.	ruth.sapir-pichhadze@mcgill.ca			Genome Canada Large Scale Applied Research Program Award "Precision Medicine CanPREVENT AMR" - Genome Quebec; Genome British Columbia; Genome Alberta; Canadian Institutes of Health Research; Calcul Quebec; Compute Canada [RAC cna-921-ac]; MITACS Accelerate grant; Fonds de recherche du Quebec-Sante chercheur boursier clinicien award [254386]	Genome Canada Large Scale Applied Research Program Award "Precision Medicine CanPREVENT AMR" - Genome Quebec; Genome British Columbia; Genome Alberta; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Calcul Quebec; Compute Canada; MITACS Accelerate grant; Fonds de recherche du Quebec-Sante chercheur boursier clinicien award	This research was enabled thanks to support provided by Genome Canada Large Scale Applied Research Program Award "Precision Medicine CanPREVENT AMR" funded by Genome Quebec, Genome British Columbia, Genome Alberta, and Canadian Institutes of Health Research, Calcul Quebec (https://www.calculquebec.ca) and Compute Canada (https://www.computecanada.ca) through a Resource Allocation for Research groups (RAC cna-921-ac), and a MITACS Accelerate grant. RS-P is supported by Fonds de recherche du Quebec-Sante chercheur boursier clinicien award (grant no. 254386).	Alfaro R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.800968; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bestard O, 2021, AM J TRANSPLANT, V21, P2833, DOI 10.1111/ajt.16563; Black CK, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.09.68; D'Souza Y, 2018, HLA, V92, P33, DOI 10.1111/tan.13307; Do Nguyen H, 2014, TRANSPLANTATION, V97, P769, DOI 10.1097/01.TP.0000438639.36838.ac; Duquesnoy RJ, 2006, HUM IMMUNOL, V67, P847, DOI 10.1016/j.humimm.2006.08.001; Duquesnoy RJ, 2016, PEDIATR TRANSPLANT, V20, P884, DOI 10.1111/petr.12774; Duquesnoy RJ, 2001, TRANSPL P, V33, P493, DOI 10.1016/S0041-1345(00)02108-4; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gebel H, 2022, HUM IMMUNOL, V83, P197, DOI 10.1016/j.humimm.2022.01.012; Geneugelijk K, 2020, IMMUNOGENETICS, V72, P119, DOI 10.1007/s00251-019-01140-x; Geneugelijk K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00321; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Heidt S, 2019, AM J TRANSPLANT, V19, P2926, DOI 10.1111/ajt.15486; Kok G, 2022, LIVER TRANSPLANT, V28, P1356, DOI 10.1002/lt.26431; Krummey SM, 2022, HUM IMMUNOL, V83, P241, DOI 10.1016/j.humimm.2021.11.008; Lachmann N, 2017, AM J TRANSPLANT, V17, P3076, DOI 10.1111/ajt.14393; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Langfelder P, 2012, J STAT SOFTW, V46, P1; Lemieux W, 2021, INT J IMMUNOGENET, V48, P135, DOI 10.1111/iji.12525; Mangiola M, 2022, J HEART LUNG TRANSPL, V41, P952, DOI 10.1016/j.healun.2022.03.015; Marsh SGE, 2022, INT J IMMUNOGENET, DOI [10.1111/iji.12568, 10.1111/tan.14538, 10.1016/j.humimm.2022.01.011]; McCaughan JA, 2018, AM J TRANSPLANT, V18, P2924, DOI 10.1111/ajt.14951; Mohammadhassanzadeh H, 2021, KIDNEY INT REP, V6, P1567, DOI 10.1016/j.ekir.2021.03.877; Nettling M, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0767-x; Niemann M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.797360; Peereboom ETM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.784040; R Core Team, 2020, R LANG ENV STAT COMP; Sakamoto S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02000; Sapir-Pichhadze R, 2020, KIDNEY INT, V97, P778, DOI 10.1016/j.kint.2019.10.028; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Senev A, 2021, KIDNEY INT, V100, P401, DOI 10.1016/j.kint.2021.01.029; Simon N, 2011, J STAT SOFTW, V39, P1; Swanson Kurtis J, 2020, World J Transplant, V10, P230, DOI 10.5500/wjt.v10.i9.230; Tambur AR, 2019, AM J TRANSPLANT, V19, P2910, DOI 10.1111/ajt.15489; Therneau T. M., 2013, MODELING SURVIVAL DA, DOI 10.1007/978-1-4757-3294-8; Therneau Terry M, 2021, CRAN; Tibshirani Rob, 2019, CRAN; Wiebe C, 2019, AM J TRANSPLANT, V19, P1708, DOI 10.1111/ajt.15177; Zahran S, 2022, HUM IMMUNOL, V83, P225, DOI 10.1016/j.humimm.2021.11.007	41	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1067075	10.3389/fimmu.2022.1067075	http://dx.doi.org/10.3389/fimmu.2022.1067075			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1NJ	36505483	gold, Green Published			2022-12-18	WOS:000894136400001
J	Li, ZW; Hadlich, F; Wimmers, K; Murani, E				Li, Zhiwei; Hadlich, Frieder; Wimmers, Klaus; Murani, Eduard			Glucocorticoid receptor hypersensitivity enhances inflammatory signaling and inhibits cell cycle progression in porcine PBMCs	FRONTIERS IN IMMUNOLOGY			English	Article						glucocorticoid receptor hypersensitivity; transcriptome; porcine PBMCs; lipopolysaccharide; inflammatory signaling; cell cycle progression; pattern recognition receptors	INNATE IMMUNE-RESPONSES; RESISTANCE; EXPRESSION; PHOSPHORYLATION; DIMERIZATION; ACTIVATION; MECHANISMS; STRESS; MODELS	The consequences of glucocorticoid receptor (GR) hypersensitivity during infection have so far received little attention. We previously discovered that a natural gain-of-function Ala610Val substitution in the porcine GR aggravates response of pigs to lipopolysaccharide (LPS)-induced endotoxemia, which can be alleviated by dexamethasone (DEX) pretreatment. In this work, we investigated the relevant molecular basis of these phenotypes by transcriptomic profiling of porcine peripheral blood mononuclear cells (PBMCs) carrying different GR genotypes, in unstimulated conditions or in response to DEX and/or LPS in vitro. The Val allele differentially regulated abunda+nt genes in an additive-genetic manner. A subset of more than 200 genes was consistently affected by the substitution across treatments. This was associated with upregulation of genes related i.a. to endo-lysosomal system, lipid and protein catabolism, and immune terms including platelet activation, and antigen presentation, while downregulated genes were mainly involved in cell cycle regulation. Most importantly, the set of genes constitutively upregulated by Val includes members of the TLR4/LPS signaling pathway, such as LY96. Consequently, when exposing PBMCs to LPS treatment, the Val variant upregulated a panel of additional genes related to TLR4 and several other pattern recognition receptors, as well as cell death and lymphocyte signaling, ultimately amplifying the inflammatory responses. In contrast, when stimulated by DEX treatment, the Val allele orchestrated several genes involved in anti-inflammatory responses during infection. This study provides novel insights into the impact of GR hypersensitivity on the fate and function of immune cells, which may be useful for endotoxemia therapy.	[Li, Zhiwei; Hadlich, Frieder; Wimmers, Klaus; Murani, Eduard] Res Inst Farm Anim Biol FBN, Inst Genome Biol, Dummerstorf, Germany; [Wimmers, Klaus] Univ Rostock, Fac Agr & Environm Sci, Rostock, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); University of Rostock	Murani, E (corresponding author), Res Inst Farm Anim Biol FBN, Inst Genome Biol, Dummerstorf, Germany.	murani@fbn-dummerstorf.de			German Research Foundation (Deutsche Forschungsgemeinschaft (DFG)) [391382814]; FBN	German Research Foundation (Deutsche Forschungsgemeinschaft (DFG))(German Research Foundation (DFG)); FBN	The current study was funded by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft (DFG)-Project number 391382814), and matched funding from the FBN.	Amarante-Mendes GP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02379; Assinger A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01687; Bafica A, 2007, J IMMUNOL, V179, P5514, DOI 10.4049/jimmunol.179.8.5514; Blanes MG, 2007, J BIOL CHEM, V282, P10660, DOI 10.1074/jbc.M609048200; Blighe K, 2019, ENHANCEDVOLCANO PUBL; Bougarne N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01769; Casals C, 2007, J IMMUNOL, V178, P6307, DOI 10.4049/jimmunol.178.10.6307; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chang M, 2009, NAT IMMUNOL, V10, P1089, DOI 10.1038/ni.1777; Chen CJ, 2020, MOL PLANT, V13, P1194, DOI 10.1016/j.molp.2020.06.009; Chi F, 2022, EXP CELL RES, V412, DOI 10.1016/j.yexcr.2022.113035; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Cui HC, 2018, J IMMUNOL, V200, P3218, DOI 10.4049/jimmunol.1701571; Dejager L, 2010, J BIOL CHEM, V285, P31073, DOI 10.1074/jbc.M110.154484; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Dendoncker K, 2017, CYTOKINE GROWTH F R, V35, P85, DOI 10.1016/j.cytogfr.2017.04.002; Ding X., 2018, J IMMUNOL SCI, V2, P65, DOI [10.29245/2578-3009/2018/1.1121, DOI 10.29245/2578-3009/2018/1.1121]; Divanovic S, 2005, NAT IMMUNOL, V6, P571, DOI 10.1038/ni1198; Duval M, 2007, MOL BIOL CELL, V18, P4659, DOI 10.1091/mbc.E07-05-0467; Frank T, 2019, CELL DEATH DIFFER, V26, P2046, DOI 10.1038/s41418-019-0298-5; Futai M, 2019, P JPN ACAD B-PHYS, V95, P261, DOI 10.2183/pjab.95.018; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Gaudino SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00360; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108; Hutchins AP, 2013, BRIEF FUNCT GENOMICS, V12, P489, DOI 10.1093/bfgp/elt028; Jacobsen AV, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.386; Kader KN, 2000, TISSUE ENG, V6, P241, DOI 10.1089/10763270050044425; Kerrigan SW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01748; Kleiman A, 2012, FASEB J, V26, P722, DOI 10.1096/fj.11-192112; Kolde Raivo, 2019, CRAN; Lambden S, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0274-x; Li DY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00687-0; Li ZZ, 2018, CELL PHYSIOL BIOCHEM, V47, P2278, DOI 10.1159/000491538; Li ZW, 2021, VIRULENCE, V12, P1808, DOI 10.1080/21505594.2021.1948276; Li ZW, 2020, BRAIN BEHAV IMMUN, V90, P174, DOI 10.1016/j.bbi.2020.08.009; Lin RY, 2016, CANCER LETT, V381, P165, DOI 10.1016/j.canlet.2016.07.033; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu XG, 2011, NAT IMMUNOL, V12, P416, DOI 10.1038/ni.2015; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marshall JC, 2010, CONTRIB NEPHROL, V167, P1, DOI 10.1159/000315914; Martin-Fernandez M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126272; Mathiassen SG, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00051; Mazgaeen L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020379; Murani E, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150193; Murani E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045518; Opal SM, 2010, CONTRIB NEPHROL, V167, P14, DOI 10.1159/000315915; Pantano L, 2021, DEGREPORT REPORT DEG; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; Petrillo MG, 2016, HYPOTHALAMIC PITUITA, P43; Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Reichardt SD, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10112921; Reyer H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164628; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Rollins DA, 2015, MOL ENDOCRINOL, V29, P502, DOI 10.1210/me.2015-1005; Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100; Roworth AP, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970480; Sangiuliano B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/821043; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schrottmaier WC, 2015, THROMB HAEMOSTASIS, V114, P478, DOI 10.1160/TH14-11-0943; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sheldon LA, 2017, CELL CYCLE, V16, P2058, DOI 10.1080/15384101.2017.1338221; Silverman MN, 2013, MOL PSYCHIATR, V18, P1006, DOI 10.1038/mp.2012.131; Spiga F, 2014, COMPR PHYSIOL, V4, P1273, DOI 10.1002/cphy.c140003; Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074; Timmermans S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01545; Todkar K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00106; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Vandevyver S, 2014, ENDOCR REV, V35, P671, DOI 10.1210/er.2014-1010; Vandewalle J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01318; Wang XR, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.599281; Watts C, 2012, BBA-PROTEINS PROTEOM, V1824, P14, DOI 10.1016/j.bbapap.2011.07.006; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI 10.1007/978-3-319-24277-4; Wong CO, 2017, CELL HOST MICROBE, V21, P719, DOI 10.1016/j.chom.2017.05.002; Wyns H, 2015, VET IMMUNOL IMMUNOP, V166, P58, DOI 10.1016/j.vetimm.2015.06.001; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Yim WWY, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0141-7; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	81	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								976454	10.3389/fimmu.2022.976454	http://dx.doi.org/10.3389/fimmu.2022.976454			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1LE	36505401	gold, Green Published			2022-12-18	WOS:000894130200001
J	Malireddi, RKS; Bynigeri, RR; Kancharana, B; Sharma, BR; Burton, AR; Pelletier, S; Kanneganti, TD				Malireddi, R. K. Subbarao; Bynigeri, Ratnakar R.; Kancharana, Balabhaskararao; Sharma, Bhesh Raj; Burton, Amanda R.; Pelletier, Stephane; Kanneganti, Thirumala-Devi			Determining distinct roles of IL-1 alpha through generation of an IL-1 alpha knockout mouse with no defect in IL-1 beta expression	FRONTIERS IN IMMUNOLOGY			English	Article						PAMP; innate immunity; inflammation; inflammasome; IL-1 alpha; IL-1 beta; CXCL1; caspase-1	INTERLEUKIN-1 INDUCES INTERLEUKIN-1; INFLAMMATORY RESPONSE; MICE DEFICIENT; I RECEPTOR; SECRETION; CELLS; PROTEIN; IDENTIFICATION; INFLAMMASOMES; CANAKINUMAB	Interleukin 1 alpha (IL-1 alpha) and IL-1 beta are the founding members of the IL-1 cytokine family, and these innate immune inflammatory mediators are critically important in health and disease. Early studies on these molecules suggested that their expression was interdependent, with an initial genetic model of IL-1 alpha depletion, the IL-1 alpha KO mouse (Il1a-KOline1), showing reduced IL-1 beta expression. However, studies using this line in models of infection and inflammation resulted in contrasting observations. To overcome the limitations of this genetic model, we have generated and characterized a new line of IL-1 alpha KO mice (Il1a-KOline2) using CRISPR-Cas9 technology. In contrast to cells from Il1a-KOline1, where IL-1 beta expression was drastically reduced, bone marrow-derived macrophages (BMDMs) from Il1a-KOline2 mice showed normal induction and activation of IL-1 beta. Additionally, Il1a-KOline2 BMDMs showed normal inflammasome activation and IL-1 beta expression in response to multiple innate immune triggers, including both pathogen-associated molecular patterns and pathogens. Moreover, using Il1a-KOline2 cells, we confirmed that IL-1 alpha, independent of IL-1 beta, is critical for the expression of the neutrophil chemoattractant KC/CXCL1. Overall, we report the generation of a new line of IL-1 alpha KO mice and confirm functions for IL-1 alpha independent of IL-1 beta. Future studies on the unique functions of IL-1 alpha and IL-1 beta using these mice will be critical to identify new roles for these molecules in health and disease and develop therapeutic strategies.	[Malireddi, R. K. Subbarao; Bynigeri, Ratnakar R.; Kancharana, Balabhaskararao; Sharma, Bhesh Raj; Burton, Amanda R.; Pelletier, Stephane; Kanneganti, Thirumala-Devi] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kanneganti, TD (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA.	Thirumala-Devi.Kanneganti@StJude.org			US National Institutes of Health; American Lebanese Syrian Associated Charities;  [AI101935];  [AI124346];  [AI160179];  [AR056296];  [CA253095]	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); ; ; ; ; 	Funding Work from our laboratory is supported by the US National Institutes of Health (AI101935, AI124346, AI160179, AR056296, and CA253095 to T-DK) and the American Lebanese Syrian Associated Charities (to T-DK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Almog T, 2015, CYTOKINE, V73, P138, DOI 10.1016/j.cyto.2015.01.029; Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Berda-Haddad Y, 2011, P NATL ACAD SCI USA, V108, P20684, DOI 10.1073/pnas.1116848108; Boraschi D, 2018, IMMUNOL REV, V281, P197, DOI 10.1111/imr.12606; Caricchio R, 2021, JAMA-J AM MED ASSOC, V326, P230, DOI 10.1001/jama.2021.9508; Cassel SL, 2014, P NATL ACAD SCI USA, V111, P1072, DOI 10.1073/pnas.1318685111; Cavalli G, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102763; Copenhaver AM, 2015, P NATL ACAD SCI USA, V112, P7557, DOI 10.1073/pnas.1501289112; Dagvadorj J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2015632118; Di Paolo NC, 2009, IMMUNITY, V31, P110, DOI 10.1016/j.immuni.2009.04.015; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1974, J EXP MED, V139, P1369, DOI 10.1084/jem.139.6.1369; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Eigenbrod T, 2008, J IMMUNOL, V181, P8194, DOI 10.4049/jimmunol.181.12.8194; Eislmayr K, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abj7293; Fettelschoss A, 2011, P NATL ACAD SCI USA, V108, P18055, DOI 10.1073/pnas.1109176108; Glaccum MB, 1997, J IMMUNOL, V159, P3364; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Gross Olaf, 2012, Immunity, V36, P388, DOI 10.1016/j.immuni.2012.01.018; Gurung P, 2017, IMMUNITY, V46, P635, DOI 10.1016/j.immuni.2017.03.014; Gurung P, 2016, P NATL ACAD SCI USA, V113, P4452, DOI 10.1073/pnas.1601636113; Gurung P, 2012, J BIOL CHEM, V287, P34474, DOI 10.1074/jbc.M112.401406; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; Hsu LC, 2011, NAT IMMUNOL, V12, P144, DOI 10.1038/ni.1976; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; KAPLANSKI G, 1994, BLOOD, V84, P4242, DOI 10.1182/blood.V84.12.4242.bloodjournal84124242; Karki R, 2018, CELL, V173, P920, DOI 10.1016/j.cell.2018.02.055; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kono H, 2010, J IMMUNOL, V184, P4470, DOI 10.4049/jimmunol.0902485; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; Kyriazopoulou E, 2021, NAT MED, V27, P1752, DOI 10.1038/s41591-021-01499-z; Labow M, 1997, J IMMUNOL, V159, P2452; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; Lukens JR, 2014, NATURE, V516, P246, DOI 10.1038/nature13788; Lukens JR, 2014, P NATL ACAD SCI USA, V111, P1066, DOI 10.1073/pnas.1318688111; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315; Malik A, 2018, IMMUNOL REV, V281, P124, DOI 10.1111/imr.12615; Malik A, 2016, J CLIN INVEST, V126, P4469, DOI 10.1172/JCI88625; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Matsuki T, 2006, INT IMMUNOL, V18, P399, DOI 10.1093/intimm/dxh379; Pelletier S, 2015, IMMUNITY, V42, P18, DOI 10.1016/j.immuni.2015.01.004; Place DE, 2019, J EXP MED, V216, P1474, DOI 10.1084/jem.20181892; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Ridker PM, 2011, AM HEART J, V162, P597, DOI 10.1016/j.ahj.2011.06.012; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shornick LP, 1996, J EXP MED, V183, P1427, DOI 10.1084/jem.183.4.1427; SMITH JW, 1993, NEW ENGL J MED, V328, P756, DOI 10.1056/NEJM199303183281103; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; Tweedell RE, 2020, NAT PROTOC, V15, P3284, DOI 10.1038/s41596-020-0374-9; WARNER SJC, 1987, J IMMUNOL, V139, P1911	56	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1068230	10.3389/fimmu.2022.1068230	http://dx.doi.org/10.3389/fimmu.2022.1068230			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U6AH	36505497	Green Published, Green Submitted, gold			2022-12-18	WOS:000894446800001
J	Melsen, JE; van Ostaijen-ten Dam, MM; Schoorl, DJA; Schol, PJ; van den Homberg, DAL; Lankester, AC; Lugthart, G; Schilham, MW				Melsen, Janine E.; van Ostaijen-ten Dam, Monique M.; Schoorl, Dorenda J. A.; Schol, Pieter J.; van den Homberg, Daphne A. L.; Lankester, Arjan C.; Lugthart, Gertjan; Schilham, Marco W.			Single-cell transcriptomics in bone marrow delineates CD56(dim)GranzymeK(+) subset as intermediate stage in NK cell differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						spectral cytometry; single-cell RNA sequencing; natural killer cells (NK cells); bone marrow; pseudotime analysis	NATURAL-KILLER-CELLS; INNATE LYMPHOID-CELLS; UNIQUE SUBSET; HUMAN LIVER; IFN-GAMMA; HUMAN T; CD56(BRIGHT); EXPRESSION; IDENTIFICATION; NORMALIZATION	Human natural killer (NK) cells in lymphoid tissues can be categorized into three subsets: CD56(bright)CD16(+), CD56(dim)CD16(+) and CD69(+)CXCR6(+) lymphoid tissue-resident (lt)NK cells. How the three subsets are functionally and developmentally related is currently unknown. Therefore, we performed single-cell RNA sequencing combined with oligonucleotide-conjugated antibodies against CD56, CXCR6, CD117 and CD34 on fresh bone marrow NK cells. A minor CD56(dim)GzmK(+) subset was identified that shared features with CD56(bright) and CD56(dim)GzmK(-) NK cells based on transcriptome, phenotype (NKG2A(high)CD16(low)KLRG1(high)TIGIT(high)) and functional analysis in bone marrow and blood, supportive for an intermediate subset. Pseudotime analysis positioned CD56(bright), CD56(dim)GzmK(+) and CD56(dim)GzmK(-) cells in one differentiation trajectory, while ltNK cells were developmentally separated. Integrative analysis with bone marrow cells from the Human Cell Atlas did not demonstrate a developmental connection between CD34(+) progenitor and NK cells, suggesting absence of early NK cell stages in bone marrow. In conclusion, single-cell transcriptomics provide new insights on development and differentiation of human NK cells.	[Melsen, Janine E.; van Ostaijen-ten Dam, Monique M.; Schoorl, Dorenda J. A.; Schol, Pieter J.; van den Homberg, Daphne A. L.; Lankester, Arjan C.; Lugthart, Gertjan; Schilham, Marco W.] Leiden Univ, Willem Alexander Childrens Hosp, Lab Pediat Immunol, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Melsen, JE (corresponding author), Leiden Univ, Willem Alexander Childrens Hosp, Lab Pediat Immunol, Med Ctr, Leiden, Netherlands.	j.e.melsen@lumc.nl			Leiden University Medical Center; Nederlandse Organisatie voor Wetenschappelijk Onderzoek and Stichting Zeldzame Ziekten Fonds (SCID project)	Leiden University Medical Center; Nederlandse Organisatie voor Wetenschappelijk Onderzoek and Stichting Zeldzame Ziekten Fonds (SCID project)	JM was supported by funding from the Leiden University Medical Center, the graduate program of Nederlandse Organisatie voor Wetenschappelijk Onderzoek and Stichting Zeldzame Ziekten Fonds (SCID project).	A.Pfefferle, 2019, bioRxiv, DOI 10.1101/630657; Amand M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00699; Amezquita RA, 2020, NAT METHODS, V17, P137, DOI 10.1038/s41592-019-0654-x; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bayard C, 2016, EUR J IMMUNOL, V46, P1168, DOI 10.1002/eji.201546179; Bengsch B, 2018, J IMMUNOL METHODS, V453, P3, DOI 10.1016/j.jim.2017.03.009; Bergen V, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0591-3; Beziat V, 2011, J IMMUNOL, V186, P6753, DOI 10.4049/jimmunol.1100330; Bjorkstrom NK, 2011, J EXP MED, V208, P13, DOI 10.1084/jem.20100762; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Bjorkstrom NK, 2010, TRENDS IMMUNOL, V31, P401, DOI 10.1016/j.it.2010.08.003; Bouwman AC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677707; Bratke K, 2005, EUR J IMMUNOL, V35, P2608, DOI 10.1002/eji.200526122; Chan A, 2007, J IMMUNOL, V179, P89, DOI 10.4049/jimmunol.179.1.89; Chen LX, 2018, IMMUNITY, V49, P464, DOI 10.1016/j.immuni.2018.08.010; Cichocki F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02078; Collins PL, 2019, CELL, V176, P348, DOI 10.1016/j.cell.2018.11.045; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Crinier A, 2021, CELL MOL IMMUNOL, V18, P1290, DOI 10.1038/s41423-020-00574-8; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; Csardi G., 2006, INTERJOURNAL COMPLEX, V1695, P5; Cuff AO, 2016, J IMMUNOL, V197, P4283, DOI 10.4049/jimmunol.1601424; de Andrade LF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.133103; De Maria A, 2011, P NATL ACAD SCI USA, V108, P728, DOI 10.1073/pnas.1012356108; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Freud AG, 2006, J EXP MED, V203, P1033, DOI 10.1084/jem.20052507; Freud AG, 2005, IMMUNITY, V22, P295, DOI 10.1016/j.immuni.2005.01.013; Freud AG, 2016, CELL REP, V16, P379, DOI 10.1016/j.celrep.2016.05.095; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Gonzalez VD, 2009, J IMMUNOL, V183, P6612, DOI 10.4049/jimmunol.0901437; Goodridge JP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08384-x; Griffiths JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05083-x; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Haghverdi L, 2018, NAT BIOTECHNOL, V36, P421, DOI 10.1038/nbt.4091; Hahne F, 2010, CYTOM PART A, V77A, P121, DOI 10.1002/cyto.a.20823; Heemskerk B, 2006, J IMMUNOL, V177, P8851, DOI 10.4049/jimmunol.177.12.8851; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; humancellatlas, CENSUS IMMUNE CELLS; Juelke K, 2010, BLOOD, V116, P1299, DOI 10.1182/blood-2009-11-253286; Kolde Raivo, 2019, CRAN; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Lugthart G, 2017, J ALLERGY CLIN IMMUN, V140, P1466, DOI 10.1016/j.jaci.2017.06.039; Lugthart G, 2016, J IMMUNOL, V197, P78, DOI 10.4049/jimmunol.1502603; Lunemann S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06011-7; Marini F., 2022, R PACKAG VERSION 1 4; Marquardt N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11632-9; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; Martens JHA, 2013, HAEMATOLOGICA, V98, P1487, DOI 10.3324/haematol.2013.094243; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Mazzurana L, 2021, CELL RES, V31, P554, DOI 10.1038/s41422-020-00445-x; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; McInnes L., 2018, J OPEN SOURCE SOFTW, DOI [DOI 10.21105/JOSS.00861, 10.21105/joss.00861]; Melsen JE, 2022, J CLIN IMMUNOL, V42, P1205, DOI 10.1007/s10875-022-01279-5; Melsen JE, 2021, CELL MOL IMMUNOL, V18, P1348, DOI 10.1038/s41423-021-00653-4; Melsen JE, 2020, J IMMUNOL, V205, P864, DOI 10.4049/jimmunol.1901530; Melsen JE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01829; Melsen JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00262; MILLER JS, 1994, BLOOD, V83, P2594; Milush JM, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-158; Monaco G, 2016, BIOINFORMATICS, V32, P2473, DOI 10.1093/bioinformatics/btw191; Montaldo E, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00646; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Nguyen S, 2005, BLOOD, V105, P4135, DOI 10.1182/blood-2004-10-4113; Renoux VM, 2015, IMMUNITY, V43, P394, DOI 10.1016/j.immuni.2015.07.011; Romagnani C, 2007, J IMMUNOL, V178, P4947, DOI 10.4049/jimmunol.178.8.4947; Rue-Albrecht K., 2021, R PACKAGE VERSION 1; Scheiter M, 2013, MOL CELL PROTEOMICS, V12, P1099, DOI 10.1074/mcp.M112.024596; Scoville SD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00360; Seo S, 2022, CURR OPIN IMMUNOL, V74, P106, DOI 10.1016/j.coi.2021.11.001; Serafini N, 2015, NAT REV IMMUNOL, V15, P415, DOI 10.1038/nri3855; Silva A, 2008, INT IMMUNOL, V20, P625, DOI 10.1093/intimm/dxn022; Smith SL, 2020, BLOOD ADV, V4, P1388, DOI 10.1182/bloodadvances.2019000699; Sojka DK, 2014, ELIFE, V3, DOI 10.7554/eLife.01659; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Street K, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4772-0; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Urlaub D, 2017, J IMMUNOL, V198, P1944, DOI 10.4049/jimmunol.1601004; Van den Berge K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14766-3; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vossen MTM, 2008, J IMMUNOL, V180, P3739, DOI 10.4049/jimmunol.180.6.3739; Westendorf K, 2014, EUR J IMMUNOL, V44, P1866, DOI 10.1002/eji.201344323; Yang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11947-7; Yeang HXA, 2017, J IMMUNOL, V198, P1417, DOI 10.4049/jimmunol.1601818; Yu JH, 2010, BLOOD, V115, P274, DOI 10.1182/blood-2009-04-215491; Zimmer J, 2020, HEMASPHERE, V4, DOI 10.1097/HS9.0000000000000348	91	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1044398	10.3389/fimmu.2022.1044398	http://dx.doi.org/10.3389/fimmu.2022.1044398			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1HH	36505452	Green Published, gold			2022-12-18	WOS:000894119900001
J	Park, HE; Lee, W; Choi, S; Jung, M; Shin, MK; Shin, SJ				Park, Hyun-Eui; Lee, Wonsik; Choi, Sangwon; Jung, Myunghwan; Shin, Min-Kyoung; Shin, Sung Jae			Modulating macrophage function to reinforce host innate resistance against Mycobacterium avium complex infection	FRONTIERS IN IMMUNOLOGY			English	Review						nontuberculous mycobacteria; Mycobacterium avium complex; innate immunity; macrophage; host-directed therapy	CHRONIC GRANULOMATOUS-DISEASE; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; VITAMIN-D; NITRIC-OXIDE; IMMUNE-RESPONSES; CYSTIC-FIBROSIS; LUNG-DISEASE; URSOLIC ACID; VALPROIC ACID	Mycobacterium avium complex (MAC) is the main causative agent of infectious diseases in humans among nontuberculous mycobacteria (NTM) that are ubiquitous organisms found in environmental media such as soil as well as in domestic and natural waters. MAC is a primary causative agent of NTM-lung disease that threaten immunocompromised or structural lung disease patients. The incidence and the prevalence of M. tuberculosis infection have been reduced, while MAC infections and mortality rates have increased, making it a cause of global health concern. The emergence of drug resistance and the side effects of long-term drug use have led to a poor outcome of treatment regimens against MAC infections. Therefore, the development of host-directed therapy (HDT) has recently gained interest, aiming to accelerate mycobacterial clearance and reversing lung damage by employing the immune system using a novel adjuvant strategy to improve the clinical outcome of MAC infection. Therefore, in this review, we discuss the innate immune responses that contribute to MAC infection focusing on macrophages, chief innate immune cells, and host susceptibility factors in patients. We also discuss potential HDTs that can act on the signaling pathway of macrophages, thereby contributing to antimycobacterial activity as a part of the innate immune response during MAC infection. Furthermore, this review provides new insights into MAC infection control that modulates and enhances macrophage function, promoting host antimicrobial activity in response to potential HDTs and thus presenting a deeper understanding of the interactions between macrophages and MACs during infection.	[Park, Hyun-Eui; Jung, Myunghwan; Shin, Min-Kyoung] Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Microbiol & Convergence Med Sci, Jinju, South Korea; [Lee, Wonsik] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea; [Choi, Sangwon; Shin, Sung Jae] Yonsei Univ, Inst Immunol & Immunol Dis, Grad Sch Med Sci, Dept Microbiol,Brain Korea 21Project,Coll Med, Seoul, South Korea	Gyeongsang National University; Sungkyunkwan University (SKKU); Yonsei University; Yonsei University Health System	Shin, MK (corresponding author), Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Microbiol & Convergence Med Sci, Jinju, South Korea.; Shin, SJ (corresponding author), Yonsei Univ, Inst Immunol & Immunol Dis, Grad Sch Med Sci, Dept Microbiol,Brain Korea 21Project,Coll Med, Seoul, South Korea.	mkshin@gnu.ac.kr; sjshin@yuhs.ac			National Research Foundation of Korea (NRF) - Ministry of Education [2021R1I1A2045131]; NRF - Korea Government(MSIT) [2021R1C1C2012177]; Bio of Medical and Medical Technologyprogram of NRF - Korea Government(MSIT) [2020M3A9H5104234]	National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of Korea); NRF - Korea Government(MSIT)(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); Bio of Medical and Medical Technologyprogram of NRF - Korea Government(MSIT)	This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2021R1I1A2045131), by the NRF grant funded by the Korea Government(MSIT)(2021R1C1C2012177), and by the Bio of Medical and Medical Technologyprogram of NRF grant funded by the Korea Government(MSIT) (2020M3A9H5104234). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah Z, 2012, EMBO J, V31, P4153, DOI 10.1038/emboj.2012.274; Achari AE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061321; Agdestein A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-58; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ALBRIGHT JW, 1994, IMMUNOL LETT, V40, P279, DOI 10.1016/0165-2478(94)00066-2; ALLEN DM, 1993, J INFECTION, V26, P83, DOI 10.1016/0163-4453(93)97000-N; Amaral EP, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0872-7; Amini A, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0092-7; Andersson AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep28171; Andrejak C, 2013, THORAX, V68, P256, DOI 10.1136/thoraxjnl-2012-201772; Anjani G, 2020, GENES DIS, V7, P84, DOI 10.1016/j.gendis.2019.07.010; Aprahamian T, 2008, CLIN EXP IMMUNOL, V152, P448, DOI 10.1111/j.1365-2249.2008.03658.x; Aquilano K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00196; Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755; Arend SM, 2007, CLIN INFECT DIS, V45, P1470, DOI 10.1086/522993; Ashley D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072043; Awazawa M, 2011, CELL METAB, V13, P401, DOI 10.1016/j.cmet.2011.02.010; BACK HAE KYONG, 2020, [Korean Journal of Clinical Laboratory Science, 대한임상검사과학회지], V52, P349, DOI 10.15324/kjcls.2020.52.4.349; BAEHNER R L, 1990, Pediatric Pathology, V10, P143; Bai XY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01417; Bai XY, 2016, RESPIROLOGY, V21, P951, DOI 10.1111/resp.12762; Bai XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061925; Barua N, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11091278; Behar SM, 2011, MUCOSAL IMMUNOL, V4, P279, DOI 10.1038/mi.2011.3; Belchamber KBR, 2020, INT J CHRONIC OBSTR, V15, P3183, DOI 10.2147/COPD.S276792; BERMUDEZ LE, 1993, CLIN EXP IMMUNOL, V91, P277; Bhatt Kamlesh, 2021, Dis Model Mech, V14, DOI 10.1242/dmm.049018; Blanc L, 2017, P NATL ACAD SCI USA, V114, P11205, DOI 10.1073/pnas.1707840114; Blasi F, 2016, RESP MED, V117, P190, DOI 10.1016/j.rmed.2016.06.015; Boehmer ED, 2004, J LEUKOCYTE BIOL, V75, P342, DOI 10.1189/jlb.0803389; Boehmer ED, 2005, MECH AGEING DEV, V126, P1305, DOI 10.1016/j.mad.2005.07.009; Bolt HM, 2004, DRUG METAB REV, V36, P497, DOI 10.1081/DMR-200033432; Bonay M, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.22; BONFIELD TL, 1995, AM J RESP CRIT CARE, V152, P2111, DOI 10.1164/ajrccm.152.6.8520783; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Bouillon R, 2022, NAT REV ENDOCRINOL, V18, P96, DOI 10.1038/s41574-021-00593-z; Braverman J, 2016, J IMMUNOL, V197, P1287, DOI 10.4049/jimmunol.1600266; Byrne ST, 2007, J ANTIMICROB CHEMOTH, V59, P313, DOI 10.1093/jac/dkl486; Byrne ST, 2007, ANTIMICROB AGENTS CH, V51, P794, DOI 10.1128/AAC.01145-06; Caire-Brandli I, 2014, INFECT IMMUN, V82, P476, DOI 10.1128/IAI.01196-13; Cao RQ, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01132-18; Cardoso MS, 2015, INFECT IMMUN, V83, P3534, DOI 10.1128/IAI.00144-15; Carroll TP, 2010, J IMMUNOL, V184, P4538, DOI 10.4049/jimmunol.0802864; Carvalho NB, 2011, INFECT IMMUN, V79, P1638, DOI 10.1128/IAI.01030-10; Cervantes JL, 2020, J IMMUNOL, V204; Chan ED, 2007, SCAND J INFECT DIS, V39, P690, DOI 10.1080/00365540701225744; Chan ED, 2010, GENDER MED, V7, P5, DOI 10.1016/j.genm.2010.01.005; Cheng CY, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aaj1789; Cheng Y, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008569; Cheng Y, 2018, J EXP MED, V215, P2919, DOI 10.1084/jem.20180508; Chung C, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e12; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; Cichewicz RH, 2004, MED RES REV, V24, P90, DOI 10.1002/med.10053; Conti F, 2016, J ALLERGY CLIN IMMUN, V138, P241, DOI 10.1016/j.jaci.2015.11.041; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Critchley JA, 2013, LANCET INFECT DIS, V13, P223, DOI 10.1016/S1473-3099(12)70321-3; Danelishvili L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06700-3; Danelishvili L, 2015, MICROBES INFECT, V17, P628, DOI 10.1016/j.micinf.2015.05.005; Oliveira ALD, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121306; Degner NR, 2018, CLIN INFECT DIS, V66, P198, DOI 10.1093/cid/cix819; Guerra-De-Blas PD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02097; DELAFUENTE M, 1985, COMP BIOCHEM PHYS A, V81, P935, DOI 10.1016/0300-9629(85)90933-8; Deramaudt TB, 2013, MED MALADIES INFECT, V43, P100, DOI 10.1016/j.medmal.2013.02.004; Diel R, 2018, CHEST, V153, P888, DOI 10.1016/j.chest.2018.01.024; Dinauer Mary C, 2005, Hematology Am Soc Hematol Educ Program, P89; Dirac MA, 2012, AM J RESP CRIT CARE, V186, P684, DOI 10.1164/rccm.201205-0825OC; DOI T, 1993, INFECT IMMUN, V61, P1980, DOI 10.1128/IAI.61.5.1980-1989.1993; Donohue MJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05925-y; Dutta NK, 2020, J INFECT DIS, V221, P1079, DOI 10.1093/infdis/jiz517; Dutta NK, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00652-17; Dutta NK, 2016, J ANTIMICROB CHEMOTH, V71, P1570, DOI 10.1093/jac/dkw014; Early J, 2011, MICROB PATHOGENESIS, V50, P132, DOI 10.1016/j.micpath.2010.12.004; Fabri M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003045; Fadipe VO, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1818-9; Falkinham JO, 2015, CLIN CHEST MED, V36, P35, DOI 10.1016/j.ccm.2014.10.003; Farazi Aliasghar, 2015, Tuberc Res Treat, V2015, P205016, DOI 10.1155/2015/205016; Feng CG, 2003, J IMMUNOL, V171, P4758, DOI 10.4049/jimmunol.171.9.4758; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; FLESCH IEA, 1994, INT IMMUNOL, V6, P1751, DOI 10.1093/intimm/6.11.1751; Fomogne-Fodjo MCY, 2017, J ETHNOPHARMACOL, V195, P238, DOI 10.1016/j.jep.2016.11.027; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Fratazzi C, 1997, J IMMUNOL, V158, P4320; Frenkel JDH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73212-y; Fujita K, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012463, 10.1097/md.0000000000012463]; Fujita M, 2010, CLIN EXP IMMUNOL, V160, P457, DOI 10.1111/j.1365-2249.2010.04092.x; Gar RK, 2009, J NEUROL SCI, V285, pS184; Gelder CM, 2000, J INFECT DIS, V181, P2099, DOI 10.1086/315489; Genoula M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008929; Gerriets V., 2021, TUMOR NECROSIS FACTO; Gleeson LE, 2016, J IMMUNOL, V196, P2444, DOI 10.4049/jimmunol.1501612; Grab J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08405-9; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Gundavda MK, 2017, INDIAN J ORTHOP, V51, P205, DOI 10.4103/0019-5413.201718; Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321; Hay E, 2019, CHEM-BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108729; He L, 2009, CELL, V137, P635, DOI 10.1016/j.cell.2009.03.016; Henkle E, 2015, ANN AM THORAC SOC, V12, P642, DOI 10.1513/AnnalsATS.201412-559OC; Hewison M, 2012, RHEUM DIS CLIN N AM, V38, P125, DOI 10.1016/j.rdc.2012.03.012; Hojo M, 2012, RESPIROLOGY, V17, P185, DOI 10.1111/j.1440-1843.2011.02076.x; Honda JR, 2018, CURR OPIN IMMUNOL, V54, P66, DOI 10.1016/j.coi.2018.06.001; Hu WB, 2022, BIOLOGY-BASEL, V11, DOI 10.3390/biology11020246; Hui XY, 2015, CELL METAB, V22, P279, DOI 10.1016/j.cmet.2015.06.004; Ikeda Y, 2007, J IMMUNOL, V178, P4854, DOI 10.4049/jimmunol.178.8.4854; Islamoglu H, 2018, J CLIN MED, V7, DOI 10.3390/jcm7030040; Jackaman C, 2013, AGING CELL, V12, P345, DOI 10.1111/acel.12062; Jager S, 2009, MOLECULES, V14, P2016, DOI 10.3390/molecules14062016; Jang DI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052719; Jeon K, 2013, RESPIROLOGY, V18, P983, DOI 10.1111/resp.12109; Jiao XN, 2002, J IMMUNOL, V168, P1294, DOI 10.4049/jimmunol.168.3.1294; Jimenez-Arellanes A, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-258; Jo EK, 2010, CELL MICROBIOL, V12, P1026, DOI 10.1111/j.1462-5822.2010.01491.x; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430; Kennedy BK, 2016, CELL METAB, V23, P990, DOI 10.1016/j.cmet.2016.05.009; Kim H, 2017, IMMUNOLOGY, V151, P177, DOI 10.1111/imm.12721; Kim JH, 2010, CLIN NUTR, V29, P512, DOI 10.1016/j.clnu.2010.01.008; Kim RD, 2008, AM J RESP CRIT CARE, V178, P1066, DOI 10.1164/rccm.200805-686OC; Kim SJ, 2014, INT J TUBERC LUNG D, V18, P730, DOI 10.5588/ijtld.13.0792; Kim SY, 2016, INT J TUBERC LUNG D, V20, P1594, DOI 10.5588/ijtld.16.0347; Kim SJ, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0349-3; Kim S, 2021, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.609712; Kim YM, 2009, SCAND J INFECT DIS, V41, P656, DOI 10.1080/00365540903089468; Kimmey JM, 2015, NATURE, V528, P565, DOI 10.1038/nature16451; Klok MD, 2007, OBES REV, V8, P21, DOI 10.1111/j.1467-789X.2006.00270.x; Kocaadam B, 2017, CRIT REV FOOD SCI, V57, P2889, DOI 10.1080/10408398.2015.1077195; Koh WJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7-0024-2016; Kroesen VM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00772; Krotova K, 2017, AM J RESP CELL MOL, V57, P238, DOI 10.1165/rcmb.2016-0366OC; Ku JWK, 2021, REDOX BIOL, V44, DOI 10.1016/j.redox.2021.102012; Kumar K, 2022, EUR RESPIR REV, V31, DOI 10.1183/16000617.0212-2021; Kundu M, 2009, NAT IMMUNOL, V10, P918, DOI 10.1038/ni.1754; Kwon BS, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082524; Kwon YS, 2019, TUBERC RESPIR DIS, V82, P15, DOI 10.4046/trd.2018.0060; Lachmandas E, 2019, J INFECT DIS, V220, P139, DOI 10.1093/infdis/jiz064; Lange SM, 2019, J IMMUNOL, V202, P1747, DOI 10.4049/jimmunol.1801569; Laval T, 2021, IMMUNOL REV, V301, P84, DOI 10.1111/imr.12952; Lee HJ, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091298; Lee KI, 2016, SCI REP-UK, V6, DOI 10.1038/srep37804; Lee SK, 2013, LUNG, V191, P565, DOI 10.1007/s00408-013-9481-5; Lee YJ, 2018, KOREAN J INTERN MED, V33, P933, DOI 10.3904/kjim.2017.249; Li HX, 2015, J ETHNOPHARMACOL, V165, P148, DOI 10.1016/j.jep.2015.02.042; Li PW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147688; Lin CK, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023775; Lindez AAMI, 2021, CELL MOL LIFE SCI, V78, P5303, DOI 10.1007/s00018-021-03828-4; Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EUJMI-D-14-00035, 10.1556/EuJMI-D-14-00035]; Linehan E, 2014, AGING CELL, V13, P699, DOI 10.1111/acel.12223; Liu PT, 2007, J IMMUNOL, V179, P2060, DOI 10.4049/jimmunol.179.4.2060; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Lopez-Garcia S, 2015, MOLECULES, V20, P14348, DOI 10.3390/molecules200814348; Lu YG, 2011, J ATHEROSCLER THROMB, V18, P998; Luo Y, 2016, J MOL CELL BIOL, V8, P120, DOI 10.1093/jmcb/mjw012; Lv JZ, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0517-0; Mahbub S, 2012, J INTERF CYTOK RES, V32, P18, DOI 10.1089/jir.2011.0058; Malaguarnera L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11050946; Malhotra HS, 2009, ANN TROP MED PARASIT, V103, P625, DOI 10.1179/000349809X12502035776315; Mansour MR, 2015, BRIT J HAEMATOL, V168, P230, DOI 10.1111/bjh.13115; Franco JLM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108547; Marupuru S, 2017, BRAZ J INFECT DIS, V21, P312, DOI 10.1016/j.bjid.2017.01.001; Matsuyama M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10121861; Mattila JT, 2013, J IMMUNOL, V191, P773, DOI 10.4049/jimmunol.1300113; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Morris SM, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3135pe27; Mukherjee S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12771; Mustafa T, 2008, INDIAN J MED RES, V128, P691; Nakajima M, 2021, MBIO, V12, DOI 10.1128/mBio.01947-20; Naylor C, 2016, TRENDS MOL MED, V22, P88, DOI 10.1016/j.molmed.2015.12.001; Nieto-Patlan E, 2019, TUBERCULOSIS, V114, P123, DOI 10.1016/j.tube.2018.12.007; Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708; Ohga S, 1997, J INFECTION, V34, P147, DOI 10.1016/S0163-4453(97)92509-3; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550; Park SC, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0901-z; Park Y, 2020, KOREAN J INTERN MED, V35, P1424, DOI 10.3904/kjim.2019.395; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Phelan JJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00836; Pitaloka DAE, 2020, INFECT DIS REP, V12, P5, DOI 10.4081/idr.2020.8717; Podder B, 2015, J MICROBIOL BIOTECHN, V25, P738, DOI 10.4014/jmb.1407.07020; Prasla Z, 2020, AM J RESP CELL MOL, V63, P144, DOI 10.1165/rcmb.2019-0241TR; Prevots DR, 2010, AM J RESP CRIT CARE, V182, P970, DOI 10.1164/rccm.201002-0310OC; Qualls JE, 2012, CELL HOST MICROBE, V12, P313, DOI 10.1016/j.chom.2012.07.012; Ralph AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070032; Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002; Rao M, 2018, INT J INFECT DIS, V69, P78, DOI 10.1016/j.ijid.2018.02.021; Rapovy SM, 2015, J IMMUNOL, V195, P3293, DOI 10.4049/jimmunol.1500800; Ratnatunga CN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00303; Ravesloot-Chavez MM, 2021, ANNU REV IMMUNOL, V39, P611, DOI 10.1146/annurev-immunol-093019-010426; Reiner Z, 2013, NAT REV CARDIOL, V10, P453, DOI 10.1038/nrcardio.2013.80; Renda G, 2022, PHYTOCHEM REV, V21, P537, DOI 10.1007/s11101-021-09785-x; Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697; Rider NL, 2018, J PEDIAT INF DIS SOC, V7, pS2, DOI 10.1093/jpids/piy008; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Rodrigues MF, 2013, IMMUNOLOGY, V139, P503, DOI 10.1111/imm.12097; Rodrigues MF, 2009, IMMUNOLOGY, V128, pe691, DOI 10.1111/j.1365-2567.2009.03062.x; Rodriguez-Carlos A, 2020, MICROBES INFECT, V22, P111, DOI 10.1016/j.micinf.2019.10.002; Rohde K, 2007, IMMUNOL REV, V219, P37, DOI 10.1111/j.1600-065X.2007.00547.x; Rosain J, 2019, IMMUNOL CELL BIOL, V97, P360, DOI 10.1111/imcb.12210; Ruetz M, 2019, SCIENCE, V366, P589, DOI 10.1126/science.aay0934; Ryu YJ, 2007, EUR RESPIR J, V30, P736, DOI 10.1183/09031936.00039507; Ryu YJ, 2006, CLIN VACCINE IMMUNOL, V13, P818, DOI 10.1128/CVI.00025-06; Sadowska AM, 2012, THER ADV RESPIR DIS, V6, P127, DOI 10.1177/1753465812437563; Sano C, 1999, ANTIMICROB AGENTS CH, V43, P360, DOI 10.1128/AAC.43.2.360; Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002; Saxena S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10020096; Schoeman JF, 2011, J CHILD NEUROL, V26, P956, DOI 10.1177/0883073811398132; Schon T, 2003, EUR RESPIR J, V21, P483, DOI 10.1183/09031936.03.00090702; Shamaei M, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00812-20; Sharma S, 2007, CLIN EXP IMMUNOL, V147, P155, DOI 10.1111/j.1365-2249.2006.03257.x; Shiozawa A, 2020, MICROBES INFECT, V22, P567, DOI 10.1016/j.micinf.2020.08.003; Singhal A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009885; Skerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039680; Skolnik Kate, 2016, Curr Treat Options Infect Dis, V8, P259, DOI 10.1007/s40506-016-0092-6; Song Eunkyung, 2011, Clin Mol Allergy, V9, P10, DOI 10.1186/1476-7961-9-10; Sonnenberg P, 2000, EUR RESPIR J, V15, P291, DOI 10.1034/j.1399-3003.2000.15b12.x; Stoller JK, 2005, LANCET, V365, P2225, DOI 10.1016/S0140-6736(05)66781-5; Strausbaugh SD, 2007, CLIN CHEST MED, V28, P279, DOI 10.1016/j.ccm.2007.02.011; Tanaka G, 2007, EUR RESPIR J, V30, P90, DOI 10.1183/09031936.00042506; Tasaka S, 2010, RESPIRATION, V79, P383, DOI 10.1159/000231975; Tasneen R, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.00253-21; Teskey G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02069; To K, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.657775; To Kimberly, 2021, BioMolecular Concepts, V12, P16, DOI 10.1515/bmc-2021-0003; Torok ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027821; Tomson T, 2016, LANCET NEUROL, V15, P210, DOI [10.1016/S1474-4422(15)00398-1, 10.1016/S1474-4422(15)00314-2]; Tong BC, 2004, MINI-REV MED CHEM, V4, P823, DOI 10.2174/1389557043403305; Tran CD, 2010, SCAND J GASTROENTERO, V45, P1424, DOI 10.3109/00365521.2010.506245; Ulasov AV, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120111; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Uribe-Querol E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01368; Van de Weert-van Leeuwen PB, 2013, AM J RESP CELL MOL, V49, P463, DOI 10.1165/rcmb.2012-0502OC; Venketaraman V, 2008, MICROB PATHOGENESIS, V44, P255, DOI 10.1016/j.micpath.2007.09.002; Vidal CG, 2005, CLIN INFECT DIS, V40, P756, DOI 10.1086/427941; Vilaplana C, 2013, J INFECT DIS, V208, P199, DOI 10.1093/infdis/jit152; Wallace RJ, 2013, J CLIN MICROBIOL, V51, P1747, DOI 10.1128/JCM.00186-13; Wallis RS, 2021, LANCET RESP MED, V9, P897, DOI 10.1016/S2213-2600(20)30448-3; Wallis RS, 2009, CLIN INFECT DIS, V48, P1429, DOI 10.1086/598504; Wallis RS, 2004, CLIN INFECT DIS, V38, P1261, DOI 10.1086/383317; Walls RS, 2008, LANCET INFECT DIS, V8, P601, DOI 10.1016/S1473-3099(08)70227-5; Wang TY, 2000, J IMMUNOL, V165, P6308, DOI 10.4049/jimmunol.165.11.6308; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Winthrop KL, 2013, ANN RHEUM DIS, V72, P37, DOI 10.1136/annrheumdis-2011-200690; Winthrop KL, 2013, NAT REV RHEUMATOL, V9, P524, DOI 10.1038/nrrheum.2013.82; Winthrop KL, 2009, EMERG INFECT DIS, V15, P1556, DOI 10.3201/eid1510.090310; Wright AKA, 2009, J LEUKOCYTE BIOL, V86, P479, DOI 10.1189/jlb.1108699; Wu JJ, 2021, REDOX BIOL, V47, DOI 10.1016/j.redox.2021.102170; Wu UI, 2015, LANCET INFECT DIS, V15, P968, DOI 10.1016/S1473-3099(15)00089-4; Yamazaki Y, 1999, AM J RESP CRIT CARE, V160, P1851, DOI 10.1164/ajrccm.160.6.9902019; Yang H, 2020, ARCH BIOCHEM BIOPHYS, V694, DOI 10.1016/j.abb.2020.108612; Yang H, 2019, ARCH BIOCHEM BIOPHYS, V667, P49, DOI 10.1016/j.abb.2019.04.006; Yeh JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110922; Yim JJ, 2008, HUM IMMUNOL, V69, P572, DOI 10.1016/j.humimm.2008.06.003; Yoo JW, 2014, EUR RESPIR J, V44, P1289, DOI 10.1183/09031936.00063514; Yu W, 2012, J CELL BIOCHEM, V113, P752, DOI 10.1002/jcb.23431; Yuksel I, 2003, ENDOCR RES, V29, P257, DOI 10.1081/ERC-120025033; Zenk SF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678354; Zerin T, 2015, MOL CELLS, V38, P610, DOI 10.14348/molcells.2015.2328; Zhang PX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7221; Zhang PX, 2013, J IMMUNOL, V190, P5196, DOI 10.4049/jimmunol.1201607; Zheng C, 2013, QJM-INT J MED, V106, P307, DOI 10.1093/qjmed/hct022; Zhou J, 2017, EUR J INFLAMM, V15, P107, DOI 10.1177/1721727X17721829	262	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								931876	10.3389/fimmu.2022.931876	http://dx.doi.org/10.3389/fimmu.2022.931876			27	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1NI	36505429	Green Published, gold			2022-12-18	WOS:000894136300001
J	Qi, XW; Wan, ZX; Jiang, BH; Ouyang, YH; Feng, WJ; Zhu, HB; Tan, YR; He, RF; Xie, LM; Li, YH				Qi, Xiaowen; Wan, Zhixing; Jiang, Baohong; Ouyang, Yuhan; Feng, Wenjie; Zhu, Hongbo; Tan, Yeru; He, Rongfang; Xie, Liming; Li, Yuehua			Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer	FRONTIERS IN IMMUNOLOGY			English	Review						ferroptosis; breast cancer; therapy resistance; autophagy; chemotherapy; radiotherapy; nanoparticles	STRESS-INDUCED FERROPTOSIS; PHASE-II TRIAL; TUMOR MICROENVIRONMENT; GTP CYCLOHYDROLASE; ANTIOXIDANT ROLE; IRON-METABOLISM; OPEN-LABEL; GLUTATHIONE; P53; OXYGENASE-1	Breast cancer is the most common type of malignancy among women. Due to the iron-dependent character of breast cancer cells, they are more sensitive to ferroptosis compared to normal cells. It is possible to reverse tumor resistance by inducing ferroptosis in breast cancer cells, thereby improving tumor treatment outcomes. Ferroptosis is highly dependent on the balance of oxidative and antioxidant status. When ferroptosis occurs, intracellular iron levels are significantly increased, leading to increased membrane lipid peroxidation and ultimately triggering ferroptosis. Ferroptotic death is a form of autophagy-associated cell death. Synergistic use of nanoparticle-loaded ferroptosis-inducer with radiotherapy and chemotherapy achieves more significant tumor suppression and inhibits the growth of breast cancer by targeting cancer tissues, enhancing the sensitivity of cells to drugs, reducing the drug resistance of cancer cells and the toxicity of drugs. In this review, we present the current status of breast cancer and the mechanisms of ferroptosis. It is hopeful for us to realize effective treatment of breast cancer through targeted ferroptosis.	[Qi, Xiaowen; Wan, Zhixing; Ouyang, Yuhan; Feng, Wenjie; Zhu, Hongbo; Tan, Yeru; Xie, Liming; Li, Yuehua] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Med Oncol, Hengyang, Hunan, Peoples R China; [Jiang, Baohong] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pharm, Hengyang, Hunan, Peoples R China; [He, Rongfang] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pathol, Hengyang, Hunan, Peoples R China; [Li, Yuehua] Univ South China, Inst Pathogen Biol, Hengyang Med Coll, Hengyang, Peoples R China	University of South China; University of South China; University of South China; University of South China	Xie, LM; Li, YH (corresponding author), Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Med Oncol, Hengyang, Hunan, Peoples R China.; Li, YH (corresponding author), Univ South China, Inst Pathogen Biol, Hengyang Med Coll, Hengyang, Peoples R China.	xlmusc@163.com; liyuehua2020@stu.usc.edu.cn			National Natural Science Foundation of China [81902707]; Key Research Project of Hunan Provincial Education Department [21A0270]; China Postdoctoral Science Foundation [2022M711541]; Natural Science Foundation of Hunan Province [2019JJ80036, 2021SK51818]; Scientific Research Fund Project of Hunan Provincial Health Commission [B202303109577, D202303109450, 20201974, B20180052]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research Project of Hunan Provincial Education Department; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Scientific Research Fund Project of Hunan Provincial Health Commission	This study was supported by the National Natural Science Foundation of China (No.81902707, YL), the Key Research Project of Hunan Provincial Education Department (21A0270, YL), China Postdoctoral Science Foundation (2022M711541), YL the Natural Science Foundation of Hunan Province (2019JJ80036, RH, 2021SK51818, LX) and Scientific Research Fund Project of Hunan Provincial Health Commission (B202303109577, D202303109450, 20201974, B20180052).	Adedoyin O, 2018, AM J PHYSIOL-RENAL, V314, pF702, DOI 10.1152/ajprenal.00044.2017; Agmon E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23408-0; An PJ, 2019, ACS APPL MATER INTER, V11, P42988, DOI 10.1021/acsami.9b16124; Asleh K, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02476-1; Ayoubi M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13396-y; Bai YS, 2019, BIOCHEM BIOPH RES CO, V508, P997, DOI 10.1016/j.bbrc.2018.12.039; Bailey AP, 2015, CELL, V163, P340, DOI 10.1016/j.cell.2015.09.020; Baird L, 2013, P NATL ACAD SCI USA, V110, P15259, DOI 10.1073/pnas.1305687110; Basit F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.133; Bebber CM, 2020, CANCERS, V12, DOI 10.3390/cancers12010164; Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2; Birsen R, 2022, HAEMATOLOGICA, V107, P403, DOI 10.3324/haematol.2020.259531; Bonnefoi H, 2016, ANN ONCOL, V27, P812, DOI 10.1093/annonc/mdw067; Boylan JA, 2008, MOL MICROBIOL, V68, P786, DOI 10.1111/j.1365-2958.2008.06204.x; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; Burguin A, 2021, J PERS MED, V11, DOI 10.3390/jpm11080808; Ceder S, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03988-y; Chang LC, 2018, CANCER LETT, V416, P124, DOI 10.1016/j.canlet.2017.12.025; Chen CA, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03362-4; Chen GQ, 2020, CELL DEATH DIFFER, V27, P242, DOI 10.1038/s41418-019-0352-3; Chen JD, 2022, FEBS OPEN BIO, V12, P146, DOI 10.1002/2211-5463.13314; Chen LY, 2016, ONCOTARGET, V7, P9354, DOI 10.18632/oncotarget.6981; Chen X, 2021, CELL DEATH DIFFER, V28, P1135, DOI 10.1038/s41418-020-00728-1; Chen YP, 2020, HEPATOLOGY, V71, P1787, DOI 10.1002/hep.31116; Chiang JL, 2020, AGEING RES REV, V63, DOI 10.1016/j.arr.2020.101168; Clemente LP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102259; Cosialls E, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10112981; Crielaard BJ, 2017, NAT REV DRUG DISCOV, V16, P400, DOI 10.1038/nrd.2016.248; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dai EY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20154-8; Dai EY, 2020, AUTOPHAGY, V16, P2069, DOI 10.1080/15548627.2020.1714209; Damia G, 2014, CANCER TREAT REV, V40, P909, DOI 10.1016/j.ctrv.2014.05.008; de la Loza MDD, 2011, NUCLEIC ACIDS RES, V39, P6002, DOI 10.1093/nar/gkr193; Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Dixon SJ, 2015, ACS CHEM BIOL, V10, P1604, DOI 10.1021/acschembio.5b00245; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107; Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]; Duffy MJ, 2022, SEMIN CANCER BIOL, V79, P58, DOI 10.1016/j.semcancer.2020.07.005; Eaton JK, 2019, J AM CHEM SOC, V141, P20407, DOI 10.1021/jacs.9b10769; Ellington TD, 2022, MMWR-MORBID MORTAL W, V71, P43, DOI 10.15585/mmwr.mm7102a2; Fang XX, 2020, CIRC RES, V127, P486, DOI 10.1161/CIRCRESAHA.120.316509; Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116; Fu JK, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120537; Gao JJ, 2018, ACS CENTRAL SCI, V4, P960, DOI 10.1021/acscentsci.8b00112; Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042; Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gong Y, 2021, CELL METAB, V33, P51, DOI 10.1016/j.cmet.2020.10.012; Gorrini C, 2019, CANCER CELL, V35, P161, DOI 10.1016/j.ccell.2019.01.017; Gozzelino R, 2014, ANTIOXID REDOX SIGN, V20, P1754, DOI 10.1089/ars.2013.5666; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Han ST, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/3846217; Haque JA, 2010, LAB INVEST, V90, P1704, DOI 10.1038/labinvest.2010.112; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Harris IS, 2019, CELL METAB, V29, P1166, DOI 10.1016/j.cmet.2019.01.020; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hattori K, 2017, EMBO REP, V18, P2067, DOI 10.15252/embr.201744228; Hayano M, 2016, CELL DEATH DIFFER, V23, P270, DOI 10.1038/cdd.2015.93; Hill M, 2005, FASEB J, V19, P1957, DOI 10.1096/fj.05-3875com; Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366; Hou YF, 2021, ACTA BIOCH BIOPH SIN, V53, P333, DOI 10.1093/abbs/gmaa180; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Itoh K, 2010, ANTIOXID REDOX SIGN, V13, P1665, DOI 10.1089/ars.2010.3222; Jiang Y, 2017, THERANOSTICS, V7, P1036, DOI 10.7150/thno.18005; Jiang YZ, 2021, CELL RES, V31, P178, DOI 10.1038/s41422-020-0375-9; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]; Kajarabille N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194968; Kapralov AA, 2020, NAT CHEM BIOL, V16, P278, DOI 10.1038/s41589-019-0462-8; Kraft VAN, 2020, ACS CENTRAL SCI, V6, P41, DOI 10.1021/acscentsci.9b01063; Krainz T, 2016, ACS CENTRAL SCI, V2, P653, DOI 10.1021/acscentsci.6b00199; Kremer DM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24859-2; Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lee J, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101697; Lehmann BD, 2020, CLIN CANCER RES, V26, P2111, DOI 10.1158/1078-0432.CCR-19-2170; Lei G, 2022, NAT REV CANCER, V22, P381, DOI 10.1038/s41568-022-00459-0; Lei G, 2021, ONCOGENE, V40, P3533, DOI 10.1038/s41388-021-01790-w; Lei G, 2021, PROTEIN CELL, V12, P836, DOI 10.1007/s13238-021-00841-y; Lei G, 2020, CELL RES, V30, P146, DOI 10.1038/s41422-019-0263-3; Leone A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2597581; Li HP, 2021, BREAST CANCER RES TR, V189, P725, DOI 10.1007/s10549-021-06345-x; Li JH, 2022, MOL CANCER THER, V21, P535, DOI 10.1158/1535-7163.MCT-21-0728; Li RH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3469840; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Li ZHR, 2021, NANOSCALE RES LETT, V16, DOI 10.1186/s11671-021-03497-z; Lin CW, 2008, MOL CANCER THER, V7, P1195, DOI 10.1158/1535-7163.MCT-07-2199; Lin HY, 2021, CANCERS, V13, DOI 10.3390/cancers13184576; Lin YS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01226; Lin ZH, 2022, REDOX BIOL, V52, DOI 10.1016/j.redox.2022.102312; Lisboa BW, 1997, VIRCHOWS ARCH, V431, P375, DOI 10.1007/s004280050114; Liyanage PY, 2019, BBA-REV CANCER, V1871, P419, DOI 10.1016/j.bbcan.2019.04.006; Llombart-Cussac A, 2017, LANCET ONCOL, V18, P545, DOI 10.1016/S1470-2045(17)30021-9; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Ma S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.208; Ma SM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.723801; Ma SM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182921; Mandal PK, 2010, CANCER RES, V70, P9505, DOI 10.1158/0008-5472.CAN-10-1509; Mandal PK, 2010, J BIOL CHEM, V285, P22244, DOI 10.1074/jbc.M110.121327; Martin M, 2017, ONCOLOGIST, V22, P1301, DOI 10.1634/theoncologist.2017-0052; McRee AJ, 2018, CLIN BREAST CANCER, V18, P289, DOI 10.1016/j.clbc.2017.10.014; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Muller S, 2020, NAT CHEM, V12, P929, DOI 10.1038/s41557-020-0513-5; Mugoni V, 2013, CELL, V152, P504, DOI 10.1016/j.cell.2013.01.013; Nagpal A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1177-1; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Pickert G, 2013, INT J CANCER, V132, P591, DOI 10.1002/ijc.27706; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Prat A, 2020, LANCET ONCOL, V21, P33, DOI 10.1016/S1470-2045(19)30786-7; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Raninga PV, 2020, INT J CANCER, V146, P123, DOI 10.1002/ijc.32410; Rodriguez R, 2022, MOL CELL, V82, P728, DOI 10.1016/j.molcel.2021.12.001; Rojas K, 2016, CLIN OBSTET GYNECOL, V59, P651, DOI 10.1097/GRF.0000000000000239; Rossner P, 2009, J CELL MOL MED, V13, P3847, DOI 10.1111/j.1582-4934.2008.00553.x; Sahoo K, 2012, INVEST NEW DRUG, V30, P558, DOI 10.1007/s10637-010-9610-4; Santoro MM, 2020, CELL METAB, V31, P13, DOI 10.1016/j.cmet.2019.12.007; Saura C, 2019, LANCET ONCOL, V20, P1226, DOI 10.1016/S1470-2045(19)30334-1; Shahbandi A, 2020, TRENDS CANCER, V6, P98, DOI 10.1016/j.trecan.2020.01.007; Shimada K, 2016, NAT CHEM BIOL, V12, P497, DOI [10.1038/NCHEMBIO.2079, 10.1038/nchembio.2079]; Shin CS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15074; Shin D, 2018, FREE RADICAL BIO MED, V129, P454, DOI 10.1016/j.freeradbiomed.2018.10.426; Sica A, 2010, EUR J IMMUNOL, V40, P2131, DOI 10.1002/eji.201040736; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Sopik V, 2021, BREAST CANCER RES TR, V186, P497, DOI 10.1007/s10549-020-06003-8; Soula M, 2020, NAT CHEM BIOL, V16, P1351, DOI 10.1038/s41589-020-0613-y; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Synnott NC, 2017, INT J CANCER, V140, P234, DOI 10.1002/ijc.30425; Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422-020-00441-1; Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077; Tesfay L, 2019, CANCER RES, V79, P5355, DOI 10.1158/0008-5472.CAN-19-0369; Tessoulin B, 2014, BLOOD, V124, P1626, DOI 10.1182/blood-2014-01-548800; Torti SV, 2020, MOL ASPECTS MED, V75, DOI 10.1016/j.mam.2020.100860; Torti SV, 2011, CANCER RES, V71, P1511, DOI 10.1158/0008-5472.CAN-10-3614; van Raaij SEG, 2018, TOXICOL LETT, V295, P179, DOI 10.1016/j.toxlet.2018.06.1218; Verma N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8968; Wang SJ, 2016, CELL REP, V17, P366, DOI 10.1016/j.celrep.2016.09.022; Wang WM, 2019, NATURE, V569, P270, DOI 10.1038/s41586-019-1170-y; Wang YW, 2021, THERANOSTICS, V11, P4839, DOI 10.7150/thno.56747; Wei YP, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2020.129539; Wen Y, 2021, FREE RADICAL BIO MED, V173, P41, DOI 10.1016/j.freeradbiomed.2021.07.019; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Wu XH, 2020, MOL CELL BIOCHEM, V473, P217, DOI 10.1007/s11010-020-03821-8; Wu ZM, 2019, P NATL ACAD SCI USA, V116, P2996, DOI 10.1073/pnas.1819728116; Xiao Y, 2019, CLIN CANCER RES, V25, P5002, DOI 10.1158/1078-0432.CCR-18-3524; Xiao YW, 2022, CONNECT TISSUE RES, DOI [10.1038/s41422-022-00614-0, 10.1080/03008207.2022.2148527]; Xie Y, 2021, BIOORG CHEM, V109, DOI 10.1016/j.bioorg.2021.104744; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Xiong H, 2019, J CONTROL RELEASE, V309, P145, DOI 10.1016/j.jconrel.2019.07.029; Xu HJ, 2021, TRENDS MOL MED, V27, P856, DOI 10.1016/j.molmed.2021.06.014; Xu MY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2299-1; Yan HF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00428-9; Yang Fan, 2022, Cell Metab, DOI 10.1016/j.cmet.2022.09.021; Yang JJ, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02012-7; Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang Y, 2007, BIOCHEM PHARMACOL, V74, P372, DOI 10.1016/j.bcp.2007.02.003; Yao XX, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-01058-1; Ye LF, 2020, ACS CHEM BIOL, V15, P469, DOI 10.1021/acschembio.9b00939; Yoo SE, 2012, FREE RADICAL BIO MED, V52, P1820, DOI 10.1016/j.freeradbiomed.2012.02.043; Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17380-5; Yu HC, 2019, ONCOL REP, V42, P826, DOI 10.3892/or.2019.7189; Yu MY, 2019, CANCER SCI, V110, P3173, DOI 10.1111/cas.14181; Yuan Y, 2021, ONCOLOGIST, V26, DOI 10.1002/onco.13583; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang J, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120429; Zhang WJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI152067; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013	171	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1038225	10.3389/fimmu.2022.1038225	http://dx.doi.org/10.3389/fimmu.2022.1038225			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1SW	36505465	Green Published, gold			2022-12-18	WOS:000894151800001
J	Radwan, P; Tarnowska, A; Piekarska, K; Wisniewski, A; Krasinski, R; Radwan, M; Nowak, I				Radwan, Pawel; Tarnowska, Agnieszka; Piekarska, Karolina; Wisniewski, Andrzej; Krasinski, Rafal; Radwan, Michal; Nowak, Izabela			The impact of soluble HLA-G in IVF/ICSI embryo culture medium on implantation success	FRONTIERS IN IMMUNOLOGY			English	Article						SHLA-G; in vitro fertilization; embryo; reproductive success; ovarian stimulation	LEUKOCYTE ANTIGEN-G; G EXPRESSION; LONG-PROTOCOL; SHLA-G; FUNDAMENTAL PREREQUISITE; PREIMPLANTATION EMBRYOS; OVARIAN STIMULATION; HORMONE AGONIST; CLASS-I; PREGNANCY	The HLA-G molecule is widely accepted as an important factor for pregnancy success. Its expression has been detected in the extravillous trophoblasts. Soluble HLA-G (sHLA-G) was found in the genital tract, pre-implanted embryos as well as in seminal fluid. In this study, we investigated the concentration of sHLA-G (sHLA-G1 and sHLA-G5) in media from 344 single cultured embryos following in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). The level of sHLA-G (U/ml) was tested with a sandwich enzyme-linked immunosorbent assay (ELISA) kit. We correlated sHLA-G secretion with ovarian stimulation protocols, the type of embryo transfer (fresh or frozen cycle) and the quality of the embryos. The ovarian stimulation protocol affects the secretion of sHLA-G by the embryo. Embryos obtained from the long agonist protocol secreted more sHLA-G than those originating from the short antagonist protocol (p = 0.0001). Embryos whose transfer resulted in a clinical pregnancy and/or live birth secreted more sHLA-G compared to those whose transfer ended without pregnancy. This was particularly observable in embryos following the long ovarian stimulation protocol and from a frozen embryo cycle. In conclusion, sHLA-G secreted by the embryo has an impact on implantation and live birth and could be a developmental potential marker of the embryo. Its concentration depends on the ovarian stimulation protocol used.	[Radwan, Pawel; Krasinski, Rafal; Radwan, Michal] Dept Reprod Med, Gameta Hosp, Rzgow, Poland; [Tarnowska, Agnieszka; Piekarska, Karolina; Wisniewski, Andrzej; Nowak, Izabela] Polish Acad Sci, Ludw Hirszfeld Inst Immunol & Expt Therapy, Dept Clin Immunol, Lab Immunogenet & Tissue Immunol, Wroclaw, Poland	Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences	Nowak, I (corresponding author), Polish Acad Sci, Ludw Hirszfeld Inst Immunol & Expt Therapy, Dept Clin Immunol, Lab Immunogenet & Tissue Immunol, Wroclaw, Poland.	izabela.nowak@hirszfeld.pl			Polish National Science Centre [2014/13/B/NZ5/00273]	Polish National Science Centre	This study was funded by the Polish National Science Centre (grant no. 2014/13/B/NZ5/00273). Open access was covered by Organon, Poland. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Baczkowski Tomasz, 2004, Reprod Biol, V4, P5; Bosch E, 2020, HUM REPROD OPEN, V2020, DOI 10.1093/hropen/hoaa009; Castelli EC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02106-4; Criscuoli L, 2005, GYNECOL ENDOCRINOL, V20, P264, DOI 10.1080/09513590400027299; Dahl M, 2014, AM J REPROD IMMUNOL, V72, P89, DOI 10.1111/aji.12251; Desai N, 2006, REPROD BIOMED ONLINE, V13, P272, DOI 10.1016/S1472-6483(10)60626-8; Donadi EA, 2011, CELL MOL LIFE SCI, V68, P369, DOI 10.1007/s00018-010-0580-7; Ferreira LMR, 2016, P NATL ACAD SCI USA, V113, P5364, DOI 10.1073/pnas.1602886113; Fisch JD, 2007, FERTIL STERIL, V87, P757, DOI 10.1016/j.fertnstert.2006.08.088; Furukawa A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235947; Fuzzi B, 2002, EUR J IMMUNOL, V32, P311, DOI 10.1002/1521-4141(200202)32:2<311::AID-IMMU311>3.3.CO;2-#; Gardner DK, 2000, HUM REPROD, V15, P9; Heidari MH, 2011, ANAT CELL BIOL, V44, P331, DOI 10.5115/acb.2011.44.4.331; Hunt JS, 2006, IMMUNOL REV, V213, P36, DOI 10.1111/j.1600-065X.2006.00436.x; Jee BC, 2011, YONSEI MED J, V52, P967, DOI 10.3349/ymj.2011.52.6.967; Jurisicova A, 1996, P NATL ACAD SCI USA, V93, P161, DOI 10.1073/pnas.93.1.161; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Lambalk CB, 2017, HUM REPROD UPDATE, V23, P560, DOI 10.1093/humupd/dmx017; Larsen MH, 2011, MOL HUM REPROD, V17, P727, DOI 10.1093/molehr/gar052; Menezo Y, 2006, REPROD BIOMED ONLINE, V13, P763, DOI 10.1016/S1472-6483(10)61021-8; Menicucci A, 1999, HUM IMMUNOL, V60, P1054, DOI 10.1016/S0198-8859(99)00108-1; Mu ZN, 2019, LIBYAN J MED, V14, DOI 10.1080/19932820.2019.1652058; Niu ZR, 2017, REPROD BIOMED ONLINE, V34, P611, DOI 10.1016/j.rbmo.2017.03.002; Noci I, 2005, HUM REPROD, V20, P138, DOI 10.1093/humrep/deh572; Nowak I, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02982; Ou JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133887; Piekarska K, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.791399; Porto IOP, 2015, MOL IMMUNOL, V65, P230, DOI 10.1016/j.molimm.2015.01.030; Rebmann V, 2010, HUM REPROD, V25, P1691, DOI 10.1093/humrep/deq120; Rebmann V, 2007, HUM IMMUNOL, V68, P251, DOI 10.1016/j.humimm.2006.11.003; Rizzo R, 2007, HUM IMMUNOL, V68, P244, DOI 10.1016/j.humimm.2006.10.012; Diaz RR, 2019, ZYGOTE, V27, P78, DOI 10.1017/S0967199419000054; Sageshima N, 2007, J REPROD IMMUNOL, V75, P11, DOI 10.1016/j.jri.2007.02.010; Shaikly VR, 2008, J IMMUNOL, V180, P4330, DOI 10.4049/jimmunol.180.6.4330; Sher G, 2005, HUM REPROD, V20, P1359, DOI 10.1093/humrep/deh758; Sher G, 2005, FERTIL STERIL, V83, P1410, DOI 10.1016/j.fertnstert.2004.11.061; Sher G, 2004, REPROD BIOMED ONLINE, V9, P74, DOI 10.1016/S1472-6483(10)62113-X; Song JY, 2020, DRUG DES DEV THER, V14, P3673, DOI 10.2147/DDDT.S270519; Tabiasco J, 2009, REPROD BIOMED ONLINE, V18, P374, DOI 10.1016/S1472-6483(10)60096-X; TAN SL, 1992, FERTIL STERIL, V57, P810; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; TASDEMIR M, 1995, INT J FERTIL MENOP S, V40, P25; Thibodeau V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025185; van Lierop MJC, 2002, MOL HUM REPROD, V8, P776, DOI 10.1093/molehr/8.8.776; Vani V, 2021, AM J REPROD IMMUNOL, V86, DOI 10.1111/aji.13499; Yao YQ, 2005, J IMMUNOL, V175, P8379, DOI 10.4049/jimmunol.175.12.8379; Yie S, 2005, FERTIL STERIL, V83, P30, DOI 10.1016/j.fertnstert.2004.06.059; Yie SM, 2008, MOL HUM REPROD, V14, P649, DOI 10.1093/molehr/gan059; Zhuang BM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744324	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								982518	10.3389/fimmu.2022.982518	http://dx.doi.org/10.3389/fimmu.2022.982518			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1JU	36505440	Green Published, gold			2022-12-18	WOS:000894126600001
J	Rise, N; Touborg, T; Lundsted, DH; Dalager-Pedersen, M; Mogensen, TH				Rise, Nina; Touborg, Toke; Lundsted, Ditte Helene; Dalager-Pedersen, Michael; Mogensen, Trine H.			Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia	FRONTIERS IN IMMUNOLOGY			English	Article						Bruton's agammaglobulinemia; COVID-19; SARS-CoV-2; inborn error of immunity; viral Evolution; vaccination	X-LINKED AGAMMAGLOBULINEMIA	Despite several reports and small case series on the disease course of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI), including X-linked agammaglobulinemia (XLA), this topic remains incompletely described. Here we present the case of a 38-year-old unvaccinated man with XLA, who acquired SARS-CoV-2 infection and experienced a protracted disease course with 47 days of SARS-CoV-2 positivity, critical COVID-19 with respiratory insufficiency necessitating intensive care and ventilatory support, and prompting repeated intensified treatments with remdesivir, dexamethasone, and monoclonal antibodies to eventually control infection. We describe the disease course and treatment and review the current literature on COVID-19 susceptibility and evidence for vaccine efficacy in patients with XLA.	[Rise, Nina; Dalager-Pedersen, Michael] Aalborg Univ Hosp, Dept Infect Dis, Aalborg, Denmark; [Touborg, Toke; Mogensen, Trine H.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Lundsted, Ditte Helene] Aalborg Univ Hosp, Dept Clin Microbiol, Aalborg, Denmark; [Mogensen, Trine H.] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark	Aalborg University; Aalborg University Hospital; Aarhus University; Aalborg University; Aalborg University Hospital; Aarhus University	Mogensen, TH (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.; Mogensen, TH (corresponding author), Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark.	trine.mogensen@biomed.au.dk		Mogensen, Trine Hyrup/0000-0002-1853-9704	Independent Research Fund Denmark; NOVO Nordisk Foundation; Lundbeck Foundation;  [0134-00006B];  [NNF20OC0064890];  [NNF21OC0067157];  [R268-2016-3927]	Independent Research Fund Denmark; NOVO Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); ; ; ; 	Funding No funding was received specifically for this study. TM is funded by the Independent Research Fund Denmark (0134-00006B), the NOVO Nordisk Foundation (NNF20OC0064890; NNF21OC0067157), and the Lundbeck Foundation (R268-2016-3927).	Almontasheri A, 2021, AM J CASE REP, V22, DOI 10.12659/AJCR.929447; Boyd S, 2022, ANTIBIOTICS-BASEL, V11, DOI 10.3390/antibiotics11050632; Brown LAK, 2022, J ALLERGY CLIN IMMUN, V149, P557, DOI 10.1016/j.jaci.2021.10.031; BRUTON OC, 1952, PEDIATRICS, V9, P722; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Delmonte Ottavia M, 2022, Physiology (Bethesda), V37, P0, DOI 10.1152/physiol.00016.2022; Destras Gregory, 2022, Lancet Microbe, V3, pe559, DOI 10.1016/S2666-5247(22)00120-3; Giardino G, 2022, J CLIN IMMUNOL, V42, P935, DOI 10.1007/s10875-022-01264-y; Gupta S, 2022, J CLIN IMMUNOL, V42, P914, DOI 10.1007/s10875-022-01256-y; Gupta S, 2021, INT ARCH ALLERGY IMM, V182, P195, DOI 10.1159/000514193; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Hueso T, 2020, BLOOD, V136, P2290, DOI 10.1182/blood.2020008423; Iaboni A, 2021, J CLIN IMMUNOL, V41, P923, DOI 10.1007/s10875-021-00983-y; Kogoj R, 2022, PATHOGENS, V11, DOI 10.3390/pathogens11040462; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Milosevic I, 2020, J INFECT DEV COUNTR, V14, P1248, DOI 10.3855/jidc.13840; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Pham MN, 2022, J ALLERGY CLIN IMMUN, V149, P907, DOI 10.1016/j.jaci.2021.11.022; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Ponsford MJ, 2021, CURR OPIN ALLERGY CL, V21, P525, DOI 10.1097/ACI.0000000000000792; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110; Shillitoe B, 2017, CLIN IMMUNOL, V183, P54, DOI 10.1016/j.clim.2017.07.008; Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263; Taha Y, 2021, ANN CLIN MICROB ANTI, V20, DOI 10.1186/s12941-021-00491-2; van Leeuwen LPM, 2022, J ALLERGY CLIN IMMUN, V149, P1949, DOI 10.1016/j.jaci.2022.04.002	28	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1057065	10.3389/fimmu.2022.1057065	http://dx.doi.org/10.3389/fimmu.2022.1057065			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5RR	36505407	gold, Green Published			2022-12-18	WOS:000893737700001
J	Sachdeva, R; Pal, R				Sachdeva, Ruchi; Pal, Rahul			A pregnancy hormone-cell death link promotes enhanced lupus-specific immunological effects	FRONTIERS IN IMMUNOLOGY			English	Article						pregnancy; human chorionic gonadotropin; autoantibodies; systemic lupus erythematosus; autoimmunity; apoptotic bodies	HUMAN CHORIONIC-GONADOTROPIN; TOLL-LIKE RECEPTORS; APOPTOTIC CELLS; AUTOIMMUNE-DISEASE; DYING CELLS; ANTI-DNA; ERYTHEMATOSUS; EXPRESSION; TAMOXIFEN; ANTIBODIES	Women of reproductive age demonstrate an increased incidence of systemic lupus erythematosus, and reproductive hormones have been implicated in disease progression. Additionally, pregnancy can be associated with disease "flares", the reasons for which remain obscure. While apoptotic bodies are believed to provide an autoantigenic trigger in lupus, whether autoantigenic constituents vary with varying cellular insults, and whether such variations can be immunologically consequential in the context of pregnancy, remains unknown. As assessed by antigenicity and mass spectrometry, apoptotic bodies elicited by different drugs demonstrated the differential presence of lupus-associated autoantigens, and varied in the ability to elicit lupus-associated cytokines from lupus splenocytes and alter the phenotype of lupus B cells. Immunization of tamoxifen-induced apoptotic bodies in lupus-prone mice generated higher humoral autoreactive responses than did immunization with cisplatin-induced apoptotic bodies, and both apoptotic bodies were poorly immunogenic in healthy mice. Incubation of lupus splenocytes (but not healthy splenocytes) with the pregnancy hormone human chorionic gonadotropin (hCG) along with tamoxifen-induced apoptotic bodies (but not cisplatin-induced apoptotic bodies) induced increases in the secretion of lupus-associated cytokines and in the up-modulation of B cell phenotypic markers. In addition, levels of secreted autoantibodies (including of specificities linked to lupus pathogenesis) were enhanced. These events were associated with the heightened phosphorylation of several signaling intermediates. Observations suggest that hCG is a potential disease-promoting co-stimulant in a lupus-milieu; when combined with specific apoptotic bodies, it enhances the intensity of multiple lupus-associated events. These findings deepen mechanistic insight into the hormone's links with autoreactive responses in lupus-prone mice and humans.	[Sachdeva, Ruchi; Pal, Rahul] Jawaharlal Nehru Univ JNU Complex, Natl Inst Immunol, Immunoendocrinol Lab, Aruna Asaf Ali Marg, New Delhi, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Pal, R (corresponding author), Jawaharlal Nehru Univ JNU Complex, Natl Inst Immunol, Immunoendocrinol Lab, Aruna Asaf Ali Marg, New Delhi, India.	rahul@nii.ac.in			Department of Biotechnology, Government of India; National Institute of Immunology, New Delhi, India;  [BT/PR/15020/Med/30/587/2010]	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); National Institute of Immunology, New Delhi, India; 	Funding This work was supported by an extra-mural grant from the Department of Biotechnology, Government of India to RP (Grant number BT/PR/15020/Med/30/587/2010) and by core grants from the National Institute of Immunology, New Delhi, India.	Abu-Shakra M, 2001, ANN RHEUM DIS, V60, P433, DOI 10.1136/ard.60.5.433; Arkatkar T, 2017, J EXP MED, V214, P3207, DOI 10.1084/jem.20170580; Arora P, 2017, CLIN EXP IMMUNOL, V187, P353, DOI 10.1111/cei.12889; Barjaktarovic M, 2019, ULTRASOUND OBST GYN, V54, P477, DOI 10.1002/uog.20256; Becker-Merok A, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2070; Beebe AM, 2002, CYTOKINE GROWTH F R, V13, P403, DOI 10.1016/S1359-6101(02)00025-4; Bijl M, 2001, ANN RHEUM DIS, V60, P523, DOI 10.1136/ard.60.5.523; Bondanza A, 2004, ARTHRITIS RHEUM-US, V50, P1549, DOI 10.1002/art.20187; Casarini L, 2018, ENDOCR REV, V39, P549, DOI 10.1210/er.2018-00065; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Choi J, 2014, GYNECOL ENDOCRINOL, V30, P174, DOI 10.3109/09513590.2013.859670; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cocca BA, 2002, J IMMUNOL, V169, P159, DOI 10.4049/jimmunol.169.1.159; Cozzani E, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/321359; CREAMER P, 1994, BRIT J RHEUMATOL, V33, P583; Das J, 2008, EUR J IMMUNOL, V38, P3561, DOI 10.1002/eji.200838624; Dayan M, 1997, IMMUNOLOGY, V90, P101, DOI 10.1046/j.1365-2567.1997.00122.x; De A, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00742; Dulitzky M, 2002, FERTIL STERIL, V77, P463, DOI 10.1016/S0015-0282(01)03218-6; El-Baradie SMY, 2009, J OBSTET GYNAECOL CA, V31, P142, DOI 10.1016/S1701-2163(16)34098-1; Elbourne KB, 1998, LUPUS, V7, P420, DOI 10.1191/096120398678920352; Folzenlogen D, 1997, CLIN IMMUNOL IMMUNOP, V83, P199, DOI 10.1006/clin.1997.4353; Fransen JH, 2009, ARTHRITIS RHEUM-US, V60, P2304, DOI 10.1002/art.24719; Fumal I, 2005, DERMATOLOGY, V210, P251, DOI 10.1159/000083798; Gaipl US, 2007, J AUTOIMMUN, V28, P114, DOI 10.1016/j.jaut.2007.02.005; Gandhi R, 2006, CELL DEATH DIFFER, V13, P1715, DOI 10.1038/sj.cdd.4401866; Gigante A, 2011, EUR REV MED PHARMACO, V15, P15; Grootscholten C, 2003, ARTHRITIS RHEUM, V48, P1355, DOI 10.1002/art.10974; He Y, 2018, CURR OPIN RHEUMATOL, V30, P490, DOI 10.1097/BOR.0000000000000522; Jung JY, 2015, INT J RHEUM DIS, V18, P294, DOI 10.1111/1756-185X.12568; Katz U, 2010, AUTOIMMUN REV, V10, P46, DOI 10.1016/j.autrev.2010.07.005; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Khil LY, 2007, DIABETOLOGIA, V50, P2147, DOI 10.1007/s00125-007-0769-y; Kim JH, 2010, BIOCHEM PHARMACOL, V79, P373, DOI 10.1016/j.bcp.2009.09.008; Kovacs B, 1996, CLIN EXP RHEUMATOL, V14, P695; Li N, 2007, ARTHRITIS RHEUM, V56, P2211, DOI 10.1002/art.22737; LOPRINZI CL, 1993, J CLIN ONCOL, V11, P768, DOI 10.1200/JCO.1993.11.4.768; Mahajan A, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00035; Malik M, 2016, LUPUS, V25, P684, DOI 10.1177/0961203315624023; Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Maymon R, 2001, PRENATAL DIAG, V21, P143, DOI 10.1002/1097-0223(200102)21:2<143::AID-PD998>3.0.CO;2-B; Meng AH, 2014, EXP THER MED, V8, P1772, DOI 10.3892/etm.2014.2023; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Mohammed Mohammed EA., 2013, J DRUG METAB TOXICOL, V4, P1, DOI [10.4172/2157-7609.1000138, DOI 10.4172/2157-7609.1000138]; MONCAYO R, 1995, LUPUS, V4, P39, DOI 10.1177/096120339500400109; Murphy G, 2013, RHEUMATOLOGY, V52, P2108, DOI 10.1093/rheumatology/ket160; Nagafuchi H, 2003, CLIN EXP RHEUMATOL, V21, P71; Orvieto R, 2003, HUM REPROD, V18, P665, DOI 10.1093/humrep/deg166; Pal R, 2005, J IMMUNOL, V175, P7669, DOI 10.4049/jimmunol.175.11.7669; Peeva E, 2005, IMMUNOL LETT, V101, P123, DOI 10.1016/j.imlet.2005.05.014; Piccinni Marie-Pierre, 2016, Clin Mol Allergy, V14, P11, DOI 10.1186/s12948-016-0048-x; Postal M, 2011, CYTOKINE, V56, P537, DOI 10.1016/j.cyto.2011.08.026; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Rider V, 2001, INT IMMUNOPHARMACOL, V1, P1009, DOI 10.1016/S1567-5769(01)00046-7; Rudofsky UH, 1999, ENVIRON HEALTH PERSP, V107, P713, DOI 10.2307/3434332; Saha S, 2011, CLIN REV ALLERG IMMU, V40, P8, DOI 10.1007/s12016-009-8182-6; Santiago-Raber ML, 2009, J AUTOIMMUN, V33, P231, DOI 10.1016/j.jaut.2009.10.001; Schwartz MM, 2008, NEPHROL DIAL TRANSPL, V23, P1298, DOI 10.1093/ndt/gfm775; Seret G, 2015, J AUTOIMMUN, V61, P54, DOI 10.1016/j.jaut.2015.05.009; Shao WH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3206; Sthoeger ZM, 2003, ANN RHEUM DIS, V62, P341, DOI 10.1136/ard.62.4.341; STURGESS AD, 1984, J CLIN LAB IMMUNOL, V13, P11; Sui MS, 2013, J CLIN IMMUNOL, V33, P378, DOI 10.1007/s10875-012-9825-6; Toubi E, 2004, AUTOIMMUNITY, V37, P457, DOI 10.1080/08916930400002386; Weckerle CE, 2011, CLIN REV ALLERG IMMU, V40, P42, DOI 10.1007/s12016-009-8192-4; Wiegand UK, 2001, CELL DEATH DIFFER, V8, P734, DOI 10.1038/sj.cdd.4400867; Wu WM, 2000, SCAND J IMMUNOL, V52, P393, DOI 10.1046/j.1365-3083.2000.00789.x; Wu YW, 2015, ACTA PHARMACOL SIN, V36, P1395, DOI 10.1038/aps.2015.91; Yaniv G, 2015, AUTOIMMUN REV, V14, P75, DOI 10.1016/j.autrev.2014.10.003; Zhong L, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2091	71	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1051779	10.3389/fimmu.2022.1051779	http://dx.doi.org/10.3389/fimmu.2022.1051779			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5WG	36505418	gold, Green Published			2022-12-18	WOS:000893749800001
J	Sombetzki, M; Reinholdt, C; Winkelmann, F; Rabes, A; Koslowski, N; Reisinger, EC				Sombetzki, Martina; Reinholdt, Cindy; Winkelmann, Franziska; Rabes, Anne; Koslowski, Nicole; Reisinger, Emil C.			A one-year unisexual Schistosoma mansoni infection causes pathologic organ alterations and persistent non-polarized T cell-mediated inflammation in mice	FRONTIERS IN IMMUNOLOGY			English	Article						unisexual infection; non-polarzzed T-cell response; schistosoma mansoni; hepatitis (general); longterm infection	RESPONSES; FIBROSIS; HEPATITIS; DIAGNOSIS; PROTEINS; MODEL; IL-13	In exhibiting gonochorism and phenotypic sexual dimorphism, Schistosoma spp. are unique among trematodes. Only females mating with male schistosomes can produce the highly immunogenic parasite eggs which determine the clinical picture of the disease schistosomiasis. The strong immune-modulatory effect of the eggs masks the influence of the adult worms. To shed light on the complexity of the immune response triggered by adult worms of Schistosoma mansoni, we performed a long-term unisexual infection experiment in mice. We were able to demonstrate that both male and female schistosomes can survive unpaired for one year in the murine host. Furthermore, unisexual S. mansoni infection leads to pronounced inflammation of the liver characterized by a non-polarized Th1/Th2 immune response, regardless of worm sex.	[Sombetzki, Martina; Reinholdt, Cindy; Winkelmann, Franziska; Rabes, Anne; Koslowski, Nicole; Reisinger, Emil C.] Univ Med Ctr Rostock, Dept Trop Med Infect Dis & Nephrol, Rostock, Germany	University of Rostock	Sombetzki, M (corresponding author), Univ Med Ctr Rostock, Dept Trop Med Infect Dis & Nephrol, Rostock, Germany.	martina.sombetzki@uni-rostock.de			European Social Fund project Cardiiomics [ESF/14-BM-A55-0037/16]	European Social Fund project Cardiiomics	The skillful technical support of Daniel Wolter andMohamed Elhensheri (Department of Oral, Maxillofacial, andPlastic Surgery, University Medical Center Rostock) is gratefullyacknowledged. The work was funded by the European SocialFund project Card-ii-omics (ESF/14-BM-A55-0037/16).	Acharya S, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010064; Amacher DE, 1998, REGUL TOXICOL PHARM, V27, P119, DOI 10.1006/rtph.1998.1201; Andrade ZA, 2009, PARASITE IMMUNOL, V31, P656, DOI 10.1111/j.1365-3024.2009.01157.x; ARMSTRONG JC, 1965, J PARASITOL, V51, P605, DOI 10.2307/3276242; Basch P. F., 1991, Schistosomes: development, reproduction, and host relations.; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; Boissier J, 2004, THEOR POPUL BIOL, V66, P269, DOI 10.1016/j.tpb.2004.06.008; Boissier J, 2003, PARASITOL RES, V91, P144, DOI 10.1007/s00436-003-0943-1; Botros Mona, 2013, Clin Biochem Rev, V34, P117; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; Brunet LR, 1998, PARASITOL TODAY, V14, P422, DOI 10.1016/S0169-4758(98)01317-9; Cass CL, 2007, MOL BIOCHEM PARASIT, V155, P84, DOI 10.1016/j.molbiopara.2007.06.002; Cheever AW, 1997, PARASITOL RES, V83, P57, DOI 10.1007/s004360050208; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Clegg J A, 1972, Int J Parasitol, V2, P79, DOI 10.1016/0020-7519(72)90036-7; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Fraga LAD, 2010, J INFECT DIS, V201, P464, DOI 10.1086/649841; Deelder AM, 1996, PARASITOLOGY, V112, P21, DOI 10.1017/S0031182000065045; DERITIS F, 1957, CLIN CHIM ACTA, V2, P70, DOI 10.1016/0009-8981(57)90027-X; Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460; Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585; Figueiredo BCP, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00022; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; GBD, 2016, DALYS HALE COLL; Goodman ZD, 2007, J HEPATOL, V47, P598, DOI 10.1016/j.jhep.2007.07.006; Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004; Han ZG, 2009, ANNU REV GENOM HUM G, V10, P211, DOI 10.1146/annurev-genom-082908-150036; Hernandez DC, 2004, EXP PARASITOL, V106, P59, DOI 10.1016/j.exppara.2004.01.003; Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008; Keyser JW, 1987, HUMAN PLASMA PROTEIN, P77; Knuhr K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02293; Koslowski N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005595; Langenberg MCC, 2020, NAT MED, V26, P326, DOI 10.1038/s41591-020-0759-x; Lu DB, 2021, INT J PARASITOL, V51, P887, DOI 10.1016/j.ijpara.2021.03.005; McManus DP, 2020, SEMIN IMMUNOPATHOL, V42, P355, DOI 10.1007/s00281-020-00789-x; Meevissen MHJ, 2010, J PROTEOME RES, V9, P2630, DOI 10.1021/pr100081c; Pearce EJ, 2004, IMMUNOL REV, V201, P117, DOI 10.1111/j.0105-2896.2004.00187.x; Pearce EJ, 1998, ADV EXP MED BIOL, V452, P67; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Skelly PJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004246; Sombetzki Martina, 2019, Biomed Res Int, V2019, P1704238, DOI 10.1155/2019/1704238; Sombetzki M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00861; Sombetzki M, 2015, J HEPATOL, V62, P871, DOI 10.1016/j.jhep.2014.11.020; Truscott M, 2013, INFECT IMMUN, V81, P133, DOI 10.1128/IAI.00701-12; Vogel H., 1942, Zentralblatt fuer Bakteriologie u Parasit Jena Abt I Orig, V148, P29; Weerakoon KGAD, 2015, CLIN MICROBIOL REV, V28, P939, DOI 10.1128/CMR.00137-14; World Health Organisation, SCHISTOSOMIASIS; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1010932	10.3389/fimmu.2022.1010932	http://dx.doi.org/10.3389/fimmu.2022.1010932			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1MY	36505463	gold, Green Published			2022-12-18	WOS:000894135100001
J	Ung, S; Choochuen, P; Khopanlert, W; Maneechai, K; Sangkhathat, S; Terakura, S; Julamanee, J				Ung, Socheatraksmey; Choochuen, Pongsakorn; Khopanlert, Wannakorn; Maneechai, Kajornkiat; Sangkhathat, Surasak; Terakura, Seitaro; Julamanee, Jakrawadee			Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions	FRONTIERS IN IMMUNOLOGY			English	Article						gene expression profiling; CAR-T cell; CD79A; CD40; costimulatory domain; CD19	ACTIVATION; GROWTH; CD8(+)	CD19 chimeric antigen receptor (CAR) T-cells have demonstrated remarkable outcomes in B-cell malignancies. Recently, the novel CD19CAR-T cells incorporated with B-cell costimulatory molecules of CD79A/CD40 demonstrated superior antitumor activity in the B-cell lymphoma model compared with CD28 or 4-1BB. Here, we investigated the intrinsic transcriptional gene underlying the functional advantage of CD19.79A.40z CAR-T cells following CD19 antigen exposure using transcriptome analysis compared to CD28 or 4-1BB. Notably, CD19.79A.40z CAR-T cells up-regulated genes involved in T-cell activation, T-cell proliferation, and NF-kappa B signaling, whereas down-regulated genes associated with T-cell exhaustion and apoptosis. Interestingly, CD19.79A.40z CAR- and CD19.BBz CAR-T cells were enriched in almost similar pathways. Furthermore, gene set enrichment analysis demonstrated the enrichment of genes, which were previously identified to correlate with T-cell proliferation, interferon signaling pathway, and naive and memory T-cell signatures, and down-regulated T-cell exhaustion genes in CD79A/CD40, compared with the T-cell costimulatory domain. The CD19.79A.40z CAR-T cells also up-regulated genes related to glycolysis and fatty acid metabolism, which are necessary to drive T-cell proliferation and differentiation compared with conventional CD19CAR-T cells. Our study provides a comprehensive insight into the understanding of gene signatures that potentiates the superior antitumor functions by CD19CAR-T cells incorporated with the CD79A/CD40 costimulatory domain.	[Ung, Socheatraksmey; Khopanlert, Wannakorn; Maneechai, Kajornkiat; Julamanee, Jakrawadee] Prince Songkla Univ, Fac Med, Div Internal Med, Hematol Unit,Stem Cell Lab, Hat Yai, Songkhla, Thailand; [Ung, Socheatraksmey; Choochuen, Pongsakorn; Khopanlert, Wannakorn; Maneechai, Kajornkiat; Sangkhathat, Surasak] Prince Songkla Univ, Fac Med, Dept Biomed Sci & Biomed Engn, Hat Yai, Songkhla, Thailand; [Choochuen, Pongsakorn; Sangkhathat, Surasak] Prince Songkla Univ, Fac Med, Translat Med Res Ctr, Hat Yai, Songkhla, Thailand; [Terakura, Seitaro] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Japan	Prince of Songkla University; Prince of Songkla University; Prince of Songkla University; Nagoya University	Julamanee, J (corresponding author), Prince Songkla Univ, Fac Med, Div Internal Med, Hematol Unit,Stem Cell Lab, Hat Yai, Songkhla, Thailand.	jjakrawadee@gmail.com			National Science, Research and Innovation Fund (NSRF); Prince of Songkla University [1272/2552]; Higher Education Research Promotion; Thailand Scholarships of the Higher Education Commission;  [MED6505092S \]	National Science, Research and Innovation Fund (NSRF); Prince of Songkla University; Higher Education Research Promotion; Thailand Scholarships of the Higher Education Commission; 	This work was supported by the National Science, Research and Innovation Fund (NSRF) and Prince of Songkla University (Grant No. MED6505092S to JJ), the Higher Education Research Promotion, and the Thailand Scholarships of the Higher Education Commission (Grant No.1272/2552 to SU).	Almeida L, 2016, SEMIN IMMUNOL, V28, P514, DOI 10.1016/j.smim.2016.10.009; Ataide MA, 2020, NAT IMMUNOL, V21, P1397, DOI 10.1038/s41590-020-0786-2; Boroughs AC, 2020, MOL THER, V28, P2577, DOI 10.1016/j.ymthe.2020.07.023; Collinson-Pautz MR, 2019, LEUKEMIA, V33, P2195, DOI 10.1038/s41375-019-0417-9; Dang CV, 1999, MOL CELL BIOL, V19, P1; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Julamanee J, 2021, MOL THER, V29, P2677, DOI 10.1016/j.ymthe.2021.04.038; Kawalekar OU, 2016, IMMUNITY, V44, P712, DOI 10.1016/j.immuni.2016.02.023; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li GB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121322; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; O'Leary MC, 2019, CLIN CANCER RES, V25, P1142, DOI 10.1158/1078-0432.CCR-18-2035; Philipson BI, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8248; Powell MD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01299; Prinzing B, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136093; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Schuster SJ, 2017, NEW ENGL J MED, V377, P2545, DOI 10.1056/NEJMoa1708566; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Terakura S, 2012, BLOOD, V119, P72, DOI 10.1182/blood-2011-07-366419; van der Stegen SJC, 2015, NAT REV DRUG DISCOV, V14, P499, DOI 10.1038/nrd4597; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004; Zhong Q, 2018, ACTA HAEMATOL-BASEL, V140, P131, DOI 10.1159/000492146; Zou Y, 2022, CANCER LETT, V524, P121, DOI 10.1016/j.canlet.2021.10.016	30	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1064339	10.3389/fimmu.2022.1064339	http://dx.doi.org/10.3389/fimmu.2022.1064339			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1DJ	36505428	Green Published, gold			2022-12-18	WOS:000894109400001
J	Wang, Q; Yang, B; Wang, N; Gu, J				Wang, Qin; Yang, Bin; Wang, Nan; Gu, Jian			Tumor immunomodulatory effects of polyphenols	FRONTIERS IN IMMUNOLOGY			English	Review						polyphenols; tumor immunity; natural compounds; bioavailability; MPNs	NK CELL CYTOTOXICITY; REGULATORY T-CELLS; SUPPRESSOR-CELLS; IMMUNE-RESPONSE; BIOLOGICAL-ACTIVITIES; PLANT POLYPHENOLS; T-HELPER-1 CELLS; CANCER-CELLS; CURCUMIN; RESVERATROL	Polyphenols, commonly found in various plants, have attracted enormous attention due to their potential pharmacological activity, especially antitumor activity dependent on immune function. In recent years, the development of nanomedicine can counteract the low bioavailability of polyphenols and improve the effect of tumor treatment. Among them, metal-phenolic networks (MPNs), which utilize various metal ions and phenolic ligands for coordination binding, have now become candidates for polyphenol-based nanomedicine treatment of tumors. In this mini-review, we described the classification of polyphenols and their mechanisms in antitumor immune responses, and provided suggestions for the next steps of treating tumors with polyphenols.	[Wang, Qin; Yang, Bin; Wang, Nan; Gu, Jian] Southwest Minzu Univ, Sch Pharm, Chengdu, Sichuan, Peoples R China	Southwest Minzu University	Wang, Q; Gu, J (corresponding author), Southwest Minzu Univ, Sch Pharm, Chengdu, Sichuan, Peoples R China.	jiajiawangqin@163.com; gujiancd@163.com			Natural Science Foundation of Sichuan Province; Fundamental Research Funds for the Central Universities;  [2022NSFSC1735];  [ZYN2022094]	Natural Science Foundation of Sichuan Province; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); ; 	Funding The work was financially supported by the Natural Science Foundation of Sichuan Province (2022NSFSC1735) and the Fundamental Research Funds for the Central Universities (ZYN2022094).	Bachleda P, 2010, J CELL PHYSIOL, V225, P289, DOI 10.1002/jcp.22233; Bertleff-Zieschang N, 2017, CHEM COMMUN, V53, P1068, DOI 10.1039/c6cc08607a; Bhattacharya T, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081176; Bisht K, 2009, BIOCHEM BIOPH RES CO, V379, P632, DOI 10.1016/j.bbrc.2008.12.135; Bjorkstrom NK, 2022, NAT REV IMMUNOL, V22, P112, DOI 10.1038/s41577-021-00558-3; Blank C, 2005, CANCER IMMUNOL IMMUN, V54, P307, DOI 10.1007/s00262-004-0593-x; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; Brudno JN, 2020, NAT MED, V26, P270, DOI 10.1038/s41591-019-0737-3; Chandrasekara A, 2010, J AGR FOOD CHEM, V58, P6706, DOI 10.1021/jf100868b; Chauhan VP, 2013, NAT MATER, V12, P958, DOI 10.1038/nmat3792; Chen L, 2015, CELL BIOCHEM BIOPHYS, V72, P617, DOI 10.1007/s12013-015-0513-z; Clambey ET, 2014, J MOL MED, V92, P735, DOI 10.1007/s00109-014-1145-2; Dai Q, 2019, THERANOSTICS, V9, P3170, DOI 10.7150/thno.31847; Davis LE, 2019, CANCER BIOL THER, V20, P1366, DOI 10.1080/15384047.2019.1640032; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Duda-Chodak A, 2015, EUR J NUTR, V54, P325, DOI 10.1007/s00394-015-0852-y; Durgeau A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00014; Ejima H, 2017, NANO TODAY, V12, P136, DOI 10.1016/j.nantod.2016.12.012; Ejima H, 2013, SCIENCE, V341, P154, DOI 10.1126/science.1237265; Espinoza JL, 2013, CANCER SCI, V104, P657, DOI 10.1111/cas.12141; Forghani P, 2014, CANCER MED-US, V3, P215, DOI 10.1002/cam4.186; Fraga CG, 2019, FOOD FUNCT, V10, P514, DOI [10.1039/c8fo01997e, 10.1039/C8FO01997E]; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Galiniak S, 2019, ACTA BIOCHIM POL, V66, P13, DOI 10.18388/abp.2018_2749; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao XD, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585214; Ghiringhelli F, 2012, ANTI-CANCER AGENT ME, V12, P852, DOI 10.2174/187152012802650048; Guo JL, 2014, ANGEW CHEM INT EDIT, V53, P5546, DOI 10.1002/anie.201311136; Guo TL, 2007, CARCINOGENESIS, V28, P2560, DOI 10.1093/carcin/bgm223; Haverkamp JM, 2011, EUR J IMMUNOL, V41, P749, DOI 10.1002/eji.201041069; Houde V, 2006, J PERIODONTOL, V77, P1371, DOI 10.1902/jop.2006.050419; Huang SF, 2016, FOOD CHEM TOXICOL, V94, P1, DOI 10.1016/j.fct.2016.05.009; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jiang XG, 2008, ENDOCRINOLOGY, V149, P5366, DOI 10.1210/en.2008-0857; Joe B, 2000, MOL CELL BIOCHEM, V203, P153, DOI 10.1023/A:1007005605869; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kimura Y, 2016, NUTR CANCER, V68, P667, DOI 10.1080/01635581.2016.1158295; Kusmartsev S, 2003, CANCER RES, V63, P4441; Lee H, 2017, CLIN CANCER RES, V23, P4190, DOI 10.1158/1078-0432.CCR-16-3193; Li AN, 2014, NUTRIENTS, V6, P6020, DOI 10.3390/nu6126020; Li CL, 2008, P NATL ACAD SCI USA, V105, P3017, DOI 10.1073/pnas.0712310105; Li HG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092155; Li T, 2007, INT IMMUNOPHARMACOL, V7, P1221, DOI 10.1016/j.intimp.2007.05.008; Li W, 2019, MOLECULES, V24, DOI 10.3390/molecules24224062; Liu D, 2016, INT IMMUNOPHARMACOL, V39, P265, DOI 10.1016/j.intimp.2016.07.035; Long KB, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26860; Lu CC, 2010, J CELL PHYSIOL, V223, P343, DOI 10.1002/jcp.22043; Manach C, 2005, AM J CLIN NUTR, V81, p230S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Marzocchella L, 2011, RECENT PATENTS INFLA, V5, P200, DOI 10.2174/187221311797264937; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Min SY, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0097-9; Mohan A, 2013, ANTI-CANCER AGENT ME, V13, P281, DOI 10.2174/1871520611313020015; Momtazi-Borojeni AA, 2019, HEART FAIL REV, V24, P399, DOI 10.1007/s10741-018-09764-z; Mortezaee K, 2019, J CELL PHYSIOL, V234, P12537, DOI 10.1002/jcp.28122; Motallebnezhad M, 2016, TUMOR BIOL, V37, P1387, DOI 10.1007/s13277-015-4477-9; Mukherjee S, 2018, CANCER IMMUNOL IMMUN, V67, P761, DOI 10.1007/s00262-018-2130-3; Ostroumov D, 2018, CELL MOL LIFE SCI, V75, P689, DOI 10.1007/s00018-017-2686-7; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Pan SJ, 2020, ANGEW CHEM INT EDIT, V59, P275, DOI 10.1002/anie.201912296; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975; Podlaha O, 2012, TRENDS GENET, V28, P155, DOI 10.1016/j.tig.2012.01.003; Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044; Radwan FFY, 2012, LEUKEMIA LYMPHOMA, V53, P305, DOI 10.3109/10428194.2011.615423; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sang W, 2021, ADV SCI, V8, DOI 10.1002/advs.202003338; Santilli G, 2013, CLIN CANCER RES, V19, P1116, DOI 10.1158/1078-0432.CCR-12-2528; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sharma S, 2007, CLIN EXP IMMUNOL, V147, P155, DOI 10.1111/j.1365-2249.2006.03257.x; Shi JJ, 2017, NAT REV CANCER, V17, P20, DOI 10.1038/nrc.2016.108; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Sloas C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.783305; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sun LW, 2017, CELL IMMUNOL, V311, P86, DOI 10.1016/j.cellimm.2016.11.002; Tabrez S, 2020, NANOMEDICINE-UK, V15, P1147, DOI 10.2217/nnm-2019-0398; Trac NT, 2020, BIOACT MATER, V5, P92, DOI 10.1016/j.bioactmat.2020.01.006; Tu SP, 2012, CANCER PREV RES, V5, P205, DOI 10.1158/1940-6207.CAPR-11-0247; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108; Wolf NK, 2022, NAT REV IMMUNOL, DOI 10.1038/s41577-022-00732-1; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Xie LS, 2022, J AM CHEM SOC, V144, P787, DOI 10.1021/jacs.1c09753; Xu B, 2017, AM J TRANSL RES, V9, P1866; Xu L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0929-6; Xu Y, 2022, ACS NANO, V16, P984, DOI 10.1021/acsnano.1c08585; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8; Zhong ZF, 2022, MED RES REV, V42, P1246, DOI 10.1002/med.21876; Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515; Zou JY, 2018, J CELL BIOCHEM, V119, P1420, DOI 10.1002/jcb.26302	91	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1041138	10.3389/fimmu.2022.1041138	http://dx.doi.org/10.3389/fimmu.2022.1041138			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5TU	36505462	gold, Green Published			2022-12-18	WOS:000893743400001
J	Yang, GK; Liang, XM; Hu, JH; Li, CQ; Hu, WP; Li, KK; Chang, XL; Zhang, YM; Zhang, XD; Shen, YW; Meng, XL				Yang, Guokun; Liang, Xiaomin; Hu, Jihong; Li, Chengquan; Hu, Wenpan; Li, Keke; Chang, Xulu; Zhang, Yanmin; Zhang, Xindang; Shen, Yawei; Meng, Xiaolin			Feeding tea polysaccharides affects lipid metabolism, antioxidant capacity and immunity of common carp (Cyprinus carpio L.)	FRONTIERS IN IMMUNOLOGY			English	Article						tea polysaccharide; metabolism; antioxidant; immunity; common carp	GREEN TEA; BLACK TEA; PHYSICOCHEMICAL CHARACTERIZATION; DIETARY CARBOHYDRATE; ENHANCES ANTIOXIDANT; GLUCOSE-TOLERANCE; OXIDATIVE STRESS; BODY-COMPOSITION; GENE-EXPRESSION; RESISTANCE	Tea polysaccharides plays a role in lipid metabolism, antioxidant capacity and immunity of mammals. To investigate the functions of tea polysaccharides on fish, the common carp (Cyprinus carpio L.) was selected as the animal model in this study. In our study, the common carp (45 +/- 0.71g) were randomly divided into four groups and were fed fodder with 50% carbohydrate. The common carp were orally administrated with 0 mg/kg BW (control group), 200 mg/kg BW (low-dose group), 400 mg/kg BW (medium-dose group) and 800 mg/kg BW (high-dose group) tea polysaccharide for two week. At the end of experiment, the serum glucose, TG, MDA contents and antioxidase activities were measured by commercial kits. The serum immune factors levels were tested by ELISA. The genes expression levels related to antioxidant capacity, metabolism and immunity were measured by real-time PCR. The results showed that the glucose, TG and MDA contents in serum were significantly decreased by tea polysaccharides treatment. The serum activities of SOD were significantly increased by low-dose tea polysaccharides treatment. The serum activities of GPX were significantly increased by medium-dose tea polysaccharides treatment. The serum levels of IL-1 beta and TNF alpha were significantly decreased in the tea polysaccharides treatment group. In the high-dose treatment group, the serum level of TGF beta was significantly increased, and the serum level of IL-12 was markedly decreased. In the hepatopancreas, the expression of acc1, fas, srebp1c, lpl, gys and ppar gamma were significantly reduced, and the expression of pygl, cat, mnsod, ho-1 and gr were significantly up-regulated in the tea polysaccharides group. In the intestine, the expression of zo-1, occ and gip was significantly up-regulated in the high-dose treatment group. Moreover, the expression of glut2 and sglt1 were significantly down regulated. In the spleen, the expression of il-12, tnf alpha and il-6 were significantly decreased, and the expression of il-10 and tgf beta was significantly increased by the tea polysaccharides. In the spleen cells, the tea polysaccharides could relieve the LPS-induced immune damage. In conclusion, tea polysaccharides can improve antioxidant capacity, lipid metabolism and immunity of common carp.	[Yang, Guokun; Liang, Xiaomin; Hu, Jihong; Li, Chengquan; Chang, Xulu; Zhang, Yanmin; Zhang, Xindang; Shen, Yawei; Meng, Xiaolin] Henan Normal Univ, Coll Fisheries, Xinxiang, Peoples R China; [Yang, Guokun; Chang, Xulu; Zhang, Yanmin; Zhang, Xindang; Shen, Yawei; Meng, Xiaolin] Henan Normal Univ, Coll Fisheries Engn Technol Res Ctr Henan Prov Aqu, Xinxiang, Peoples R China; [Hu, Wenpan; Li, Keke] Henan JinBaiHe Biotechnol Co Ltd, Anyang, Peoples R China	Henan Normal University; Henan Normal University	Meng, XL (corresponding author), Henan Normal Univ, Coll Fisheries, Xinxiang, Peoples R China.; Meng, XL (corresponding author), Henan Normal Univ, Coll Fisheries Engn Technol Res Ctr Henan Prov Aqu, Xinxiang, Peoples R China.	mengxiaolinqdio@126.com			National Natural Science Foundation of China; Natural Science Foundation of Henan Province;  [U1904118];  [32273149];  [212300410174]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Henan Province; ; ; 	Funding This work was supported by the National Natural Science Foundation of China (U1904118, 32273149), the Natural Science Foundation of Henan Province (212300410174).	Barbosa V, 2021, FOOD CHEM TOXICOL, V152, DOI 10.1016/j.fct.2021.112218; Beliveau R, 2004, LANCET, V364, P1021, DOI 10.1016/S0140-6736(04)17076-1; Cao H, 2013, INT J BIOL MACROMOL, V62, P76, DOI 10.1016/j.ijbiomac.2013.08.033; Chen D, 2020, J FOOD SCI, V85, P1948, DOI 10.1111/1750-3841.15155; Chen D, 2019, J FUNCT FOODS, V61, DOI 10.1016/j.jff.2019.103470; Chen DJ, 2018, INT J FOOD SCI TECH, V53, P2335, DOI 10.1111/ijfs.13825; Chen GJ, 2016, CARBOHYD POLYM, V153, P663, DOI 10.1016/j.carbpol.2016.08.022; Chen HX, 2005, FOOD CHEM, V90, P17, DOI 10.1016/j.foodchem.2004.03.001; Chen N, 2009, NUTR RES, V29, P784, DOI 10.1016/j.nutres.2009.10.003; Chen XQ, 2014, CARBOHYD POLYM, V112, P77, DOI 10.1016/j.carbpol.2014.05.030; Chen XQ, 2010, CARBOHYD POLYM, V82, P28, DOI 10.1016/j.carbpol.2010.04.017; Church NA, 2021, BIOLOGIA, V76, P1535, DOI 10.1007/s11756-021-00697-x; Du LL, 2016, MOLECULES, V21, DOI 10.3390/molecules21111449; Fan SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051007; Feng JC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00904; Feng JC, 2019, INT J BIOL MACROMOL, V140, P477, DOI 10.1016/j.ijbiomac.2019.08.041; Guo L, 2011, FOOD HYDROCOLLOID, V25, P486, DOI 10.1016/j.foodhyd.2010.07.027; Koo MWL, 2004, EUR J PHARMACOL, V500, P177, DOI 10.1016/j.ejphar.2004.07.023; Lee YE, 2020, J SCI FOOD AGR, V100, P3979, DOI 10.1002/jsfa.10442; Li SQ, 2015, INT J BIOL MACROMOL, V81, P967, DOI 10.1016/j.ijbiomac.2015.09.037; Liang YR, 2015, TROP J PHARM RES, V14, P1943, DOI 10.4314/tjpr.v14i10.29; Lin SM, 2018, FISH SHELLFISH IMMUN, V78, P121, DOI 10.1016/j.fsi.2018.04.046; Liu LQ, 2018, J AGR FOOD CHEM, V66, P4384, DOI 10.1021/acs.jafc.8b00710; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu XS, 2013, FOOD CHEM, V141, P3415, DOI 10.1016/j.foodchem.2013.06.058; Mao Y, 2018, INT J FOOD SCI TECH, V53, P599, DOI 10.1111/ijfs.13633; Meng XL, 2021, AQUACULTURE, V530, DOI 10.1016/j.aquaculture.2020.735753; Nie SP, 2011, FOOD HYDROCOLLOID, V25, P144, DOI 10.1016/j.foodhyd.2010.04.010; Pu HY, 2017, ENGINEERING-PRC, V3, P731, DOI 10.1016/J.ENG.2017.03.017; Ren DY, 2015, FOOD FUNCT, V6, P3342, DOI 10.1039/c5fo00557d; Sotnikov A, 2023, AQUACULTURE, V562, DOI 10.1016/j.aquaculture.2022.738746; Sun YF, 2013, FOOD CHEM TOXICOL, V58, P184, DOI 10.1016/j.fct.2013.04.034; Tian C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053796; Tian J, 2020, AQUACULT NUTR, V26, P2135, DOI 10.1111/anu.13152; Wang DF, 2001, J AGR FOOD CHEM, V49, P507, DOI 10.1021/jf000029m; Wu CL, 2016, FISH SHELLFISH IMMUN, V49, P132, DOI 10.1016/j.fsi.2015.12.030; Wu T, 2016, FOOD FUNCT, V7, P2469, DOI 10.1039/c6fo00401f; Xiang LP, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080458; Xie X, 2022, FRONT VET SCI, V9, DOI 10.3389/fvets.2022.1036495; Xu AN, 2021, TRENDS FOOD SCI TECH, V114, P83, DOI 10.1016/j.tifs.2021.05.020; Xu P, 2014, J FUNCT FOODS, V6, P545, DOI 10.1016/j.jff.2013.11.021; Xu P, 2012, J FOOD SCI, V77, pH246, DOI 10.1111/j.1750-3841.2012.02950.x; Xu Y, 2015, FOOD FUNCT, V6, P297, DOI 10.1039/c4fo00970c; Yang GK, 2020, COMP BIOCHEM PHYS B, V242, DOI 10.1016/j.cbpb.2019.110394; Yang JJ, 2012, CARBOHYD POLYM, V90, P943, DOI 10.1016/j.carbpol.2012.06.024; Yuan CF, 2015, J SCI FOOD AGR, V95, P3211, DOI 10.1002/jsfa.7287; Zhai XC, 2017, FOOD FUNCT, V8, P2536, DOI [10.1039/C7FO00490G, 10.1039/c7fo00490g]; Zhao H, 2019, AQUACULTURE, V509, P149, DOI 10.1016/j.aquaculture.2019.05.029; Zhou CP, 2014, FISH SHELLFISH IMMUN, V41, P183, DOI 10.1016/j.fsi.2014.08.024; Zhu F, 2020, AQUACULTURE, V526, DOI 10.1016/j.aquaculture.2020.735422	51	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1074198	10.3389/fimmu.2022.1074198	http://dx.doi.org/10.3389/fimmu.2022.1074198			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5MB	36505461	Green Published, gold			2022-12-18	WOS:000893723100001
J	Yuan, XG; Li, X; Huang, YR; Jin, XL; Liu, H; Zhao, AQ; Zhang, WP; Qian, WB; Liang, Y				Yuan, Xianggui; Li, Xian; Huang, Yurong; Jin, Xueli; Liu, Hui; Zhao, Aiqi; Zhang, Weiping; Qian, Wenbin; Liang, Yun			Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						relapsed or refractory diffuse large B-cell lymphoma; zanubrutinib; Bruton's tyrosine kinase inhibitor; combination chemotherapy; TP53; chimeric antigen receptor T-cell (CAR-T)	RITUXIMAB-CHOP; IBRUTINIB; TRIAL; COMBINATION	IntroductionRelapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has poor clinical outcomes when treated with conventional salvage chemotherapy. Monotherapy using zanubrutinib, a selective Bruton's tyrosine kinase (BTK) inhibitor, has achieved modest antitumor effect in R/R DLBCL. Here we aimed to evaluate the efficacy and safety of zanubrutinib plus salvage chemotherapy in R/R DLBCL patients. MethodsWe retrospectively reviewed R/R DLBCL patients who were administered with zanubrutinib plus salvage chemotherapy in our center between January, 2019 and December, 2021. Targeted panel sequencing of 11 lymphoma-related genes was performed on 8 patients with poor responses to zanubrutinib-based chemotherapy. Results27 R/R DLBCL patients were enrolled. Median age at this study was 59 years (range, 15-72). The best overall response rate (ORR) was 74.1% and complete remission rate was 33.3%. With a median follow-up of 11 months (range, 1-17), the median progression-free survival (PFS) was 8.1 months, and the overall survival (OS) was not achieved. The most common grade-3/4 adverse events were neutropenia (70.4%), thrombocytopenia (66.7%), and febrile neutropenia (33.3%). In multivariate analysis, early treatment and overall response after chemotherapy were independent favorable prognostic factors for PFS. Overall response after chemotherapy was an independent favorable factor for OS. Among the 8 patients with poor response to zanubrutinib-based treatment, the majority of patients had NOTCH2 mutations (n=8, 100%) and TP53 mutations (n=7, 87.5%). However, these patients achieved an ORR of 75% at 3 months after CD19-CAR-T cell therapy (including 4 cases of complete remission and 2 cases of partial remission). With a median follow-up of 9 months from CAR-T cell infusion (range, 1-16 months), the median PFS was 14.5 months, and the median OS was not reached. ConclusionWith high efficacy and manageable tolerability, zanubrutinib plus salvage chemotherapy may be a potential treatment option for R/R DLBCL. CAR-T cell therapy may be a priority strategy for these poor responders to BTKi-based treatment.	[Yuan, Xianggui; Li, Xian; Huang, Yurong; Jin, Xueli; Liu, Hui; Zhao, Aiqi; Qian, Wenbin; Liang, Yun] Zhejiang Univ, Affiliated Hosp 2, Dept Hematol, Sch Med, Hangzhou, Peoples R China; [Zhang, Weiping] Zhejiang Chinese Med Univ, Dept Oncol, Affiliated Hosp 3, Hangzhou, Peoples R China; [Qian, Wenbin] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Hangzhou, Peoples R China	Zhejiang University; Zhejiang Chinese Medical University; Soochow University - China	Qian, WB; Liang, Y (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Hematol, Sch Med, Hangzhou, Peoples R China.; Zhang, WP (corresponding author), Zhejiang Chinese Med Univ, Dept Oncol, Affiliated Hosp 3, Hangzhou, Peoples R China.; Qian, WB (corresponding author), Soochow Univ, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Hangzhou, Peoples R China.	15325715566@163.com; qianwb@zju.edu.cn; liangyuan@zju.edu.cn			Translational Research Grant of HCRCH [2020ZKZC01]; National Natural Science Foundation of China [81830006]; Natural Science Foundation of Zhejiang Province of China [LY15H160038]	Translational Research Grant of HCRCH; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province of China(Natural Science Foundation of Zhejiang Province)	This work was supported by funds from Translational Research Grant of HCRCH (2020ZKZC01), the National Natural Science Foundation of China (No. 81830006), and the Natural Science Foundation of Zhejiang Province of China (No. LY15H160038).	Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Bartlett NL, 2018, BLOOD, V131, P182, DOI 10.1182/blood-2017-09-804641; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Collins GP, 2021, LEUKEMIA LYMPHOMA, V62, P2625, DOI 10.1080/10428194.2021.1938027; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Gauthier J, 2020, BLOOD, V135, P1650, DOI 10.1182/blood.2019002936; Gisselbrecht C, 2010, J CLIN ONCOL, V28, P4184, DOI 10.1200/JCO.2010.28.1618; Goy A, 2019, BLOOD, V134, P1024, DOI 10.1182/blood.2018891598; Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Herrera AF, 2020, AM J HEMATOL, V95, P18, DOI 10.1002/ajh.25659; Hillmen P, 2020, FUTURE ONCOL, V16, P517, DOI 10.2217/fon-2019-0844; Hodkinson BP, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100977; Jiang SY, 2020, INT J CANCER, V147, P2611, DOI 10.1002/ijc.33049; Ondrisova L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.591577; Porpaczy E, 2021, CANCERS, V13, DOI 10.3390/cancers13225592; Sauter CS, 2018, BLOOD, V131, P1805, DOI 10.1182/blood-2017-08-802561; Schaffer M, 2018, LEUKEMIA LYMPHOMA, V59, P931, DOI 10.1080/10428194.2017.1349899; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Sehn LH, 2021, NEW ENGL J MED, V384, P842, DOI 10.1056/NEJMra2027612; Shouval R, 2022, J CLIN ONCOL, V40, P369, DOI 10.1200/JCO.21.02143; Stewart CM, 2022, CLIN CANCER RES, V28, P45, DOI 10.1158/1078-0432.CCR-21-2183; Sun J, 2012, AM J CLIN PATHOL, V138, P429, DOI 10.1309/AJCP7YLTQPUSDQ5C; Tam CS, 2020, BLOOD, V136, P2038, DOI 10.1182/blood.2020006844; Tam CS, 2019, BLOOD, V134, P851, DOI 10.1182/blood.2019001160; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; Wang S, 2021, CANCER COMMUN, V41, P229, DOI 10.1002/cac2.12126; Wang YL, 2018, J MOL DIAGN, V20, P264, DOI 10.1016/j.jmoldx.2017.11.006; Wei J, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00924-0; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Yang HY, 2022, BLOOD ADV, V6, P1629, DOI 10.1182/bloodadvances.2020003698; Younes A, 2019, J CLIN ONCOL, V37, P1285, DOI 10.1200/JCO.18.02403; Zhang Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.760405; Zhou ZY, 2021, ANN HEMATOL, V100, P1509, DOI 10.1007/s00277-021-04535-7	36	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1015081	10.3389/fimmu.2022.1015081	http://dx.doi.org/10.3389/fimmu.2022.1015081			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1GI	36505470	Green Published, gold			2022-12-18	WOS:000894117200001
J	Zhang, C; Dang, D; Wang, HR; Shi, SY; Dai, JY; Yang, M				Zhang, Chuan; Dang, Dan; Wang, Hongrui; Shi, Shuyou; Dai, Jiayu; Yang, Ming			Acircadian rhythm-related gene signature for predicting survival and drug response in HNSC	FRONTIERS IN IMMUNOLOGY			English	Article						circadian rhythm; prognosis; head and neck squamous cell carcinoma; drug response; gene signature	TUMOR MICROENVIRONMENT; CANCER; PROGNOSIS; HEAD; CELL; DISRUPTION	Head and neck squamous cell carcinoma (HNSC) represents one of the most common malignant carcinomas worldwide. Because the 5-year survival rate of patients with HNSC is poor, it is necessary to develop an effective signature for predicting the risk of HNSC. To identify a circadian rhythm (CR)-related predictive signature, we analyzed the RNA-seq data of patients with HNSC from The Cancer Genome Atlas and Gene Expression Omnibus cohorts. Nine CR-related genes (PER2, PER3, GHRL, CSF2, HDAC3, KLF10, PRKAA2, PTGDS, and RORB) were identified to develop a CR-related signature. The area under the curve values for 5-year overall survival were 0.681, 0.700, and 0.729 in the training set, validation set, and an external independent test set (GSE41613), respectively. The Kaplan-Meier curve analysis showed that the high-risk group had a reduced relapse-free survival compared with the low-risk group in the training set, validation set, and test set (P < 0.05). Finally, we observed that the CR-related gene signature was associated with the tumor immune microenvironment, somatic nucleotide variation, and drug response in HNSC. In conclusion, we developed a circadian rhythm-related gene signature for predicting overall survival in HNSC.	[Zhang, Chuan] Jilin Univ, Dept Pediat Surg, Affiliated Hosp 1, Changchun, Peoples R China; [Dang, Dan] Jilin Univ, Dept Neonatol, Hosp 1, Changchun, Peoples R China; [Wang, Hongrui; Shi, Shuyou; Yang, Ming] Jilin Univ, Coll Basic Med Sci, Dept Mol Biol, Changchun, Jilin, Peoples R China; [Dai, Jiayu] Jilin Univ, Coll Clin Med, Changchun, Jilin, Peoples R China	Jilin University; Jilin University; Jilin University; Jilin University	Yang, M (corresponding author), Jilin Univ, Coll Basic Med Sci, Dept Mol Biol, Changchun, Jilin, Peoples R China.	myang48@jlu.edu.cn			National Natural Science Foundation of China; Natural Science Foundation of Jilin Province;  [81902111];  [20220101281JC]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jilin Province; ; 	Funding This project was supported by the National Natural Science Foundation of China (grant numbers. 81902111); the Natural Science Foundation of Jilin Province (grant numbers. 20220101281JC).	Aiello I, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4530; Bhat GR, 2021, ADV CANCER RES, V152, P67, DOI 10.1016/bs.acr.2021.05.002; Cai H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.690869; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Dong CY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.713001; Essegian D, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100128; Fortier EE, 2011, J IMMUNOL, V187, P6291, DOI 10.4049/jimmunol.1004030; Guo FY, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8587458; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hu FF, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa176; Li C, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8899337; Li M, 2021, J CANCER, V12, P2582, DOI 10.7150/jca.52454; Li YY, 2019, CHRONOBIOL INT, V36, P1723, DOI 10.1080/07420528.2019.1648486; Liao RC, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.780094; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Ling B, 2021, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.603701; Liu BL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.657002; Long SR, 2020, AGING-US, V12, P7112, DOI 10.18632/aging.103065; Mocchegiani E, 2004, EXP GERONTOL, V39, P775, DOI 10.1016/j.exger.2004.01.014; Mohanty V, 2021, CANCER BIOMARK, V31, P361, DOI 10.3233/CBM-203077; Papagiannakopoulos T, 2016, CELL METAB, V24, P324, DOI 10.1016/j.cmet.2016.07.001; Riva G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031402; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Thariat J, 2015, CRIT REV ONCOL HEMAT, V95, P397, DOI 10.1016/j.critrevonc.2015.03.005; Wendeu-Foyet MG, 2017, CANCER EPIDEM BIOMAR, V26, P985, DOI [10.1158/1055-9965.EPI-16-1030, 10.1158/1055-9965.epi-16-1030]; Wu YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02451; Xiao L, 2021, J CANCER, V12, P5231, DOI 10.7150/jca.58593; Xiong HG, 2018, INT J ONCOL, V52, P279, DOI 10.3892/ijo.2017.4180; Xu DF, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.109903; Xu ZB, 2019, ONCOTARGETS THER, V12, P11255, DOI 10.2147/OTT.S216829; Xuan WJ, 2021, TRENDS CELL BIOL, V31, P940, DOI 10.1016/j.tcb.2021.06.008; Yeh CM, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57010017; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang Y, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.570336; Zhou RR, 2021, AGING-US, V13, P25153, DOI 10.18632/aging.203733	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1029676	10.3389/fimmu.2022.1029676	http://dx.doi.org/10.3389/fimmu.2022.1029676			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5HF	36505439	gold, Green Published			2022-12-18	WOS:000893708800001
J	Zhang, YZ; Yang, Y; Chen, YR; Lin, W; Chen, XL; Liu, J; Huang, YY; Wang, HY; Teng, LS				Zhang, Yingzi; Yang, Yan; Chen, Yiran; Lin, Wu; Chen, Xiangliu; Liu, Jin; Huang, Yingying; Wang, Haiyong; Teng, Lisong			PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer	FRONTIERS IN IMMUNOLOGY			English	Review						gastric cancer; programmed death-ligand 1; immune checkpoint inhibitor (ICI); clinical trials; tumor microenvironment	EPSTEIN-BARR-VIRUS; INHIBITS TUMOR PROGRESSION; LIGAND 1 EXPRESSION; T-CELL APOPTOSIS; MICROSATELLITE INSTABILITY; ANTITUMOR IMMUNITY; GENE-EXPRESSION; STAGE-III; CHEMOTHERAPY; PROGNOSIS	Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune efficacy. Further understanding of the regulatory mechanism of PD-L1 in GC may bring substantial progress to the immunotherapy. In this review, we provide information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in GC. The malignant biological phenotypes caused by PD-L1 and the corresponding clinical combined treatment scheme have been reported. Identifying the biomarkers of the potential efficacy of immunotherapy and specifying the clinical immunotherapy scheme in combination with molecular characteristics of patients may maximize clinical benefits and better prognosis.	[Zhang, Yingzi; Yang, Yan; Chen, Yiran; Lin, Wu; Chen, Xiangliu; Liu, Jin; Huang, Yingying; Wang, Haiyong; Teng, Lisong] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Surg Oncol, Hangzhou, Peoples R China	Zhejiang University	Wang, HY; Teng, LS (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Surg Oncol, Hangzhou, Peoples R China.	lanceter1@zju.edu.cn; lsteng@zju.edu.cn			Science and Technology Program of Zhejiang Province; Natural Science Foundation of Zhejiang Province;  [2021c03119];  [LQ18H160012]	Science and Technology Program of Zhejiang Province; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); ; 	Funding This work was supported by Science and Technology Program of Zhejiang Province [2021c03119] and Natural Science Foundation of Zhejiang Province [LQ18H160012].	Amini M, 2021, GENE, V772, DOI 10.1016/j.gene.2020.145376; An JY, 2012, INT J CANCER, V131, P505, DOI 10.1002/ijc.26399; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Bang YJ, 2019, GASTRIC CANCER, V22, P828, DOI 10.1007/s10120-018-00909-5; Beghelli S, 2006, SURGERY, V139, P347, DOI 10.1016/j.surg.2005.08.021; Booth L, 2020, J CELL PHYSIOL, V235, P8098, DOI 10.1002/jcp.29464; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budczies J, 2016, GENE CHROMOSOME CANC, V55, P626, DOI 10.1002/gcc.22365; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chakrabarti Jayati, 2018, Oncotarget, V9, P37439, DOI 10.18632/oncotarget.26473; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen KY, 2016, ONCOTARGET, V7, P30772, DOI 10.18632/oncotarget.8956; Chen X, 2020, ACTA PHARMACOL SIN B, V10, P723, DOI 10.1016/j.apsb.2019.09.006; Chiaravalli AM, 2006, VIRCHOWS ARCH, V448, P344, DOI 10.1007/s00428-005-0066-4; Chiu YM, 2018, ANTICANCER RES, V38, P2069, DOI 10.21873/anticanres.12446; Chong LC, 2016, BLOOD, V128, P1206, DOI 10.1182/blood-2015-11-683003; Comprehensive molecular characterization of gastric adenocarcinoma, 2014, NATURE, V513, P202, DOI [10.1038/nature13480, DOI 10.1038/NATURE13480]; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258; Fan YB, 2018, EXP CELL RES, V373, P180, DOI 10.1016/j.yexcr.2018.10.011; Fang WL, 2012, WORLD J SURG, V36, P2131, DOI 10.1007/s00268-012-1652-7; Fu LC, 2022, ONCOGENE, V41, P1100, DOI 10.1038/s41388-021-02144-2; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Goding SR, 2013, J IMMUNOL, V190, P4899, DOI 10.4049/jimmunol.1300271; Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Grogg KL, 2003, MODERN PATHOL, V16, P641, DOI 10.1097/01.MP.0000076980.73826.C0; Guo J, 2018, MOL CELLS, V41, P653, DOI 10.14348/molcells.2018.0040; Guo TW, 2021, CANCER MANAG RES, V13, P2669, DOI 10.2147/CMAR.S275352; Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535; Herter-Sprie GS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87415; Huang LT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01453; Huang RY, 2015, ONCOTARGET, V6, P27359, DOI 10.18632/oncotarget.4751; Imai Y, 2020, ONCOL LETT, V20, P2161, DOI 10.3892/ol.2020.11757; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; Janjigian YY, 2018, J CLIN ONCOL, V36, P2836, DOI 10.1200/JCO.2017.76.6212; Jiang HP, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003635; Joshi Smita S, 2021, CA Cancer J Clin, V71, P264, DOI 10.3322/caac.21657; Ju XL, 2020, EXP CELL RES, V396, DOI 10.1016/j.yexcr.2020.112315; Kang BW, 2016, ANN ONCOL, V27, P494, DOI 10.1093/annonc/mdv610; Kang YK, 2022, LANCET ONCOL, V23, P234, DOI 10.1016/S1470-2045(21)00692-6; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kim H, 2011, J GASTROEN HEPATOL, V26, P585, DOI 10.1111/j.1440-1746.2010.06487.x; Kim JH, 2016, BRIT J CANCER, V115, P490, DOI 10.1038/bjc.2016.211; Kim KJ, 2014, HUM PATHOL, V45, P285, DOI 10.1016/j.humpath.2013.09.004; Kim R, 2022, CANCER DISCOV, V12, P984, DOI 10.1158/2159-8290.CD-21-0888; Kim SY, 2015, INT J CANCER, V137, P819, DOI 10.1002/ijc.29449; Kim W, 2021, GASTROENTEROLOGY, V160, P781, DOI 10.1053/j.gastro.2020.10.036; Kim YB, 2019, INT J CANCER, V145, P916, DOI 10.1002/ijc.32140; Koh V, 2021, CANCER LETT, V518, P59, DOI 10.1016/j.canlet.2021.06.007; Kotanides H, 2020, CANCER IMMUNOL RES, V8, P1300, DOI 10.1158/2326-6066.CIR-20-0304; Kubota Y, 2021, IN VIVO, V35, P1865, DOI 10.21873/invivo.12449; Li CF, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00548-x; Li J, 2017, CELL PHYSIOL BIOCHEM, V41, P907, DOI [10.1159/00460504, 10.1159/000460504]; Li P, 2020, MOL THER-NUCL ACIDS, V22, P615, DOI 10.1016/j.omtn.2020.08.020; Lin C, 2019, GUT, V68, P1764, DOI 10.1136/gutjnl-2018-316324; Liu J, 2021, CLIN TRANSL ONCOL, V23, P1782, DOI 10.1007/s12094-021-02579-9; Lu LG, 2021, HEPATOLOGY, V73, P821, DOI 10.1002/hep.31502; Lu XR, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22621; Lv JQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01067; Lv YP, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0530-3; Meric-Bernstam F, 2021, LANCET, V397, P1010, DOI 10.1016/S0140-6736(20)32598-8; Miliotis C, 2021, CANCER LETT, V518, P115, DOI 10.1016/j.canlet.2021.05.037; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Nakano H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81667-w; Ott PA, 2019, J CLIN ONCOL, V37, P318, DOI 10.1200/JCO.2018.78.2276; Park JW, 2017, BIOCHEM BIOPH RES CO, V484, P631, DOI 10.1016/j.bbrc.2017.01.153; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Prestipino A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7729; Reck M, 2021, J CLIN ONCOL, V39, P2339, DOI 10.1200/JCO.21.00174; Saeed A, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01034-0; Salas-Benito D, 2021, CANCER DISCOV, V11, P1353, DOI 10.1158/2159-8290.CD-20-1312; Sato H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01883-9; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Shevtsov M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00156; Shinozaki-Ushiku A, 2015, INT J ONCOL, V46, P1421, DOI 10.3892/ijo.2015.2856; Shitara K, 2020, JAMA ONCOL, V6, P1571, DOI 10.1001/jamaoncol.2020.3370; Shitara K, 2020, NEW ENGL J MED, V382, P2419, DOI 10.1056/NEJMoa2004413; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Smyth Elizabeth C, 2020, Lancet Oncol, V21, P204, DOI 10.1016/S1470-2045(20)30025-5; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun L, 2020, THERANOSTICS, V10, P11950, DOI 10.7150/thno.49717; Sun L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0988-9; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Taylor C, 2007, CLIN CANCER RES, V13, P5133, DOI 10.1158/1078-0432.CCR-07-0507; Telli TA, 2020, CANCER LETT, V469, P142, DOI 10.1016/j.canlet.2019.10.036; Van der Kraak L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0163-8; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wang B, 2018, CELL PHYSIOL BIOCHEM, V49, P260, DOI 10.1159/000492876; Wang JY, 2021, ONCOGENE, V40, P4894, DOI 10.1038/s41388-021-01840-3; Wang MN, 2019, BBA-REV CANCER, V1871, P199, DOI 10.1016/j.bbcan.2018.12.002; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; Wang WP, 2012, HUM MUTAT, V33, P480, DOI 10.1002/humu.22014; Wang XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1148-5; Wang ZR, 2021, ACTA PHARM SIN B, V11, P694, DOI 10.1016/j.apsb.2020.11.005; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wu LJ, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107443; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Xu D, 2019, ONCOTARGETS THER, V12, P10099, DOI 10.2147/OTT.S224053; Xu SJ, 2019, INT J NANOMED, V14, P17, DOI 10.2147/IJN.S175340; Xue YY, 2021, EXPERT OPIN DRUG DEL, V18, P187, DOI 10.1080/17425247.2021.1825376; Yan XL, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2020.10.015; Yang JH, 2019, GASTRIC CANCER, V22, P147, DOI 10.1007/s10120-018-0842-x; Yap TA, 2021, CANCER DISCOV, V11, P1368, DOI 10.1158/2159-8290.CD-20-1209; Yoon CJ, 2020, GASTRIC CANCER, V23, P780, DOI 10.1007/s10120-020-01059-3; Zhang DC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00071; Zhang M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00492	114	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1060497	10.3389/fimmu.2022.1060497	http://dx.doi.org/10.3389/fimmu.2022.1060497			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5SB	36505487	gold, Green Published			2022-12-18	WOS:000893738800001
J	Zhao, ZY; Ren, J; Xie, SP; Zou, LC; Zhao, QY; Zeng, S; Zha, DS				Zhao, Zhenyu; Ren, Jie; Xie, Siping; Zou, Longchun; Zhao, Qianyue; Zeng, Shan; Zha, Dingsheng			Identification of biomarkers associated with CD8+T cells in rheumatoid arthritis and their pan-cancer analysis	FRONTIERS IN IMMUNOLOGY			English	Article						CD8+T Cells(1); rheumatoid arthritis(2); WGCNA(3); Pan-Cancer(4); ssGSEA(5)	T-CELLS; GRANZYME; INFECTION	IntroductionRheumatoid arthritis (RA), a prevailing chronic progressive autoimmune disease, seriously affects the patient's quality of life. However, there is still a lack of precise treatment and management methods in clinical practice. Previous studies showed that CD8+ T cells take a lead in the progression of RA. MethodsGenes closely related to CD8+T cells in RA were identified through multiple RA datasets, CIBERSORT, and WGCNA algorithms. Further machine learning analysis were performed to identify CD8+T cell-related genes most closely related to RA. In addition, the relationship between these three key genes and 33 cancer species was also explored in this study. ResultsIn this study, 10 genes were identified to be closely related to CD8+T cells in RA. Machine learning analysis identified 3 CD8+T cell-related genes most closely related to RA: CD8A, GZMA, and PRF1. DiscussionOur research aims to provide new ideas for the clinical treatment of RA.	[Zhao, Zhenyu; Zha, Dingsheng] Jinan Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Peoples R China; [Ren, Jie; Zeng, Shan] Jinan Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China; [Xie, Siping] Jinan Univ, Affiliated Hosp 1, Dept Med Records, Guangzhou, Peoples R China; [Zou, Longchun] Jinan Univ, Sch Stomatol, Guangzhou, Peoples R China; [Zhao, Qianyue] Jinan Univ, Sch Basic Med & Publ Hlth, Guangzhou, Peoples R China	Jinan University; Jinan University; Jinan University; Jinan University; Jinan University	Zha, DS (corresponding author), Jinan Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Peoples R China.; Zeng, S (corresponding author), Jinan Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China.	zs870103@126.com; zdsuser@126.com			National Natural Science Foundation of China [81901650, 81401766]; Shenzhen Key Laboratory of Musculoskeletal Tissue Reconstruction and Function Restoration and Shenzhen People's Hospital [ZDSYS20200811143752005]; Guangzhou Science and Technology Project [201904010060]; fundamental research funds for the central universities [21619348]; Science and Technology Projects in Guangzhou [2021020200460]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Key Laboratory of Musculoskeletal Tissue Reconstruction and Function Restoration and Shenzhen People's Hospital; Guangzhou Science and Technology Project; fundamental research funds for the central universities(Fundamental Research Funds for the Central Universities); Science and Technology Projects in Guangzhou	This research is funded by the National Natural Science Foundation of China (Project number: 81901650), Shenzhen Key Laboratory of Musculoskeletal Tissue Reconstruction and Function Restoration and Shenzhen People's Hospital (Project number: ZDSYS20200811143752005), Guangzhou Science and Technology Project (Grant No. 201904010060, Effect and mechanism of S100A4 on collagen-induced arthritis (CIA) model in mice. National Natural Science Foundation of China (Project number:81401766), the fundamental research funds for the central universities (Project number:21619348), Funding by Science and Technology Projects in Guangzhou (Project number: 2021020200460).	Anthony DA, 2010, IMMUNOL REV, V235, P73, DOI 10.1111/j.0105-2896.2010.00907.x; Bassez A, 2021, NAT MED, V27, P820, DOI 10.1038/s41591-021-01323-8; Blum A, 2018, CELL, V173, P530, DOI 10.1016/j.cell.2018.03.059; Carvalheiro H, 2013, AUTOIMMUN REV, V12, P401, DOI 10.1016/j.autrev.2012.07.011; Chang MH, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109902; Fousteri G, 2020, MOL IMMUNOL, V119, P101, DOI 10.1016/j.molimm.2020.01.007; Gao CY, 2019, ARTHRITIS RHEUMATOL, V71, P121, DOI 10.1002/art.40676; Harris MA, 2006, NUCLEIC ACIDS RES, V34, pD322, DOI 10.1093/nar/gkj021; Hay SI, 2017, LANCET, V389, pE1; Higashioka K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654623; Hyndman IJ, 2017, INT J RHEUM DIS, V20, P417, DOI 10.1111/1756-185X.12823; Ishwaran H, 2010, STAT PROBABIL LETT, V80, P1056, DOI 10.1016/j.spl.2010.02.020; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Krishna C, 2021, CANCER CELL, V39, P662, DOI 10.1016/j.ccell.2021.03.007; Kumar LD, 2016, BIOMED PHARMACOTHER, V79, P52, DOI 10.1016/j.biopha.2016.02.001; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lees JR, 2020, CELL IMMUNOL, V357, DOI 10.1016/j.cellimm.2020.104212; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Long NP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010050; Qaiyum Z, 2019, ANN RHEUM DIS, V78, P1566, DOI 10.1136/annrheumdis-2019-215349; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sangro B, 2020, J HEPATOL, V73, P1460, DOI 10.1016/j.jhep.2020.07.026; Santiago L, 2017, ARTHRITIS RHEUMATOL, V69, P320, DOI 10.1002/art.39857; Smolen JS, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0168-y; Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Souto-Carneiro MM, 2020, ARTHRITIS RHEUMATOL, V72, P2050, DOI 10.1002/art.41420; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun YL, 2014, J IMMUNOL, V193, P860, DOI 10.4049/jimmunol.1400045; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; TSUBOTA K, 1994, AM J OPHTHALMOL, V117, P120, DOI 10.1016/S0002-9394(14)73032-6; Ungethuem U, 2010, PHYSIOL GENOMICS, V42A, P267, DOI 10.1152/physiolgenomics.00004.2010; Woetzel D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4526; Zander R, 2019, IMMUNITY, V51, P1028, DOI 10.1016/j.immuni.2019.10.009; Zhou S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.726747; Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548	38	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1044909	10.3389/fimmu.2022.1044909	http://dx.doi.org/10.3389/fimmu.2022.1044909			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1XR	36505419	gold, Green Published			2022-12-18	WOS:000894164300001
J	Zhou, H; Chen, YP; Xiao, Y; Wu, Q; Li, H; Li, Y; Su, GJ; Ke, LF; Wu, JX; Li, JL				Zhou, Han; Chen, Yanping; Xiao, Yu; Wu, Qian; Li, Hui; Li, Yi; Su, Guangjian; Ke, Longfeng; Wu, Junxin; Li, Jinluan			Evaluation of the ability of fatty acid metabolism signature to predict response to neoadjuvant chemoradiotherapy and prognosis of patients with locally advanced rectal cancer	FRONTIERS IN IMMUNOLOGY			English	Article						fatty acid metabolism; gut microbiome; metabolite; neoadjuvant chemoradiotherapy response; rectal cancer	COLORECTAL-CANCER; FUSOBACTERIUM-NUCLEATUM; EXPRESSION; RADIOTHERAPY; MICROBIOME; HALLMARKS; CHEMORADIATION; IMMUNOTHERAPY; CHEMOTHERAPY; STATISTICS	Neoadjuvant chemoradiotherapy (nCRT) is widely used to treat patients with locally advanced rectal cancer (LARC), and treatment responses vary. Fatty acid metabolism (FAM) is closely associated with carcinogenesis and cancer progression. In this study, we investigated the vital role of FAM on the gut microbiome and metabolism in the context of cancer. We screened 34 disease-free survival (DFS)-related, FAM-related, and radiosensitivity-related genes based on the Gene Expression Omnibus database. Subsequently, we developed a five-gene FAM-related signature using the least absolute shrinkage and selection operator Cox regression model. The FAM-related signature was also validated in external validation from Fujian Cancer Hospital for predicting nCRT response, DFS, and overall survival (OS). Notably, patients with a low-risk score were associated with pathological complete response and better DFS and OS outcomes. A comprehensive evaluation of the tumor microenvironment based on the FAM-related signature revealed that patients with high-risk scores were closely associated with activating type I interferon response and inflammation-promoting functions. In conclusion, our findings indicate the potential ability of FAM to predict nCRT response and the prognosis of DFS and OS in patients with LARC.	[Zhou, Han; Xiao, Yu; Wu, Qian; Li, Hui; Li, Yi; Wu, Junxin; Li, Jinluan] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Radiat Oncol, Fuzhou, Peoples R China; [Chen, Yanping; Ke, Longfeng] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Clin Pathol, Fuzhou, Peoples R China; [Su, Guangjian] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Clin Lab, Fuzhou, Peoples R China	Fujian Medical University; Fujian Medical University; Fujian Medical University	Wu, JX; Li, JL (corresponding author), Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Radiat Oncol, Fuzhou, Peoples R China.	junxinwufj@aliyun.com; lijinluan@pku.org.cn			Natural Foundation of Fujian Province [2021J01433]; Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare; National Clinical Key Specialty Construction Program, 2021; Startup Fund for scientific research, Fujian Medical University [2020QH2043]	Natural Foundation of Fujian Province; Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare; National Clinical Key Specialty Construction Program, 2021; Startup Fund for scientific research, Fujian Medical University	This work was supported by a grant (no. 2021J01433) from the Natural Foundation of Fujian Province, Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare, National Clinical Key Specialty Construction Program, 2021, and Startup Fund for scientific research, Fujian Medical University (grant number 2020QH2043).	Artemaki PI, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228568; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Benson A, 2020, J NATL COMPR CANC NE, V18, P807, DOI 10.6004/jnccn.2020.0032; Bian XL, 2021, J EXP MED, V218, DOI 10.1084/jem.20201606; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Butler LM, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0040-z; Chakrabarti S, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0483-4; Chan SL, 2020, PROG MOL BIOL TRANSL, V171, P301, DOI 10.1016/bs.pmbts.2020.04.004; Chen F, 2022, GUT, V71, P1315, DOI 10.1136/gutjnl-2020-323476; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Des Guetz G, 2021, CANCERS, V13, DOI 10.3390/cancers13236035; Ding CS, 2021, MOL THER-ONCOLYTICS, V20, P532, DOI 10.1016/j.omto.2021.02.010; Ding MM, 2022, CLIN COLORECTAL CANC, V21, pE12, DOI 10.1016/j.clcc.2021.11.009; Duvvuri U, 2012, CANCER RES, V72, P3270, DOI 10.1158/0008-5472.CAN-12-0475-T; Feng Y Y, 2021, Zhonghua Zhong Liu Za Zhi, V43, P1264, DOI 10.3760/cma.j.cn112152-20190923-00618; Fokas Emmanouil, 2019, J Clin Oncol, V37, P3212, DOI 10.1200/JCO.19.00308; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Graham K, 2018, INT J NANOMED, V13, P6049, DOI 10.2147/IJN.S140462; Guo MJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00354; Han SJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01201; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Huang EY, 2013, JPEN-PARENTER ENTER, V37, P746, DOI 10.1177/0148607113486931; Jang BS, 2020, INT J RADIAT ONCOL, V107, P736, DOI 10.1016/j.ijrobp.2020.04.015; Ji DB, 2018, CANCER IMMUNOL RES, V6, P1401, DOI 10.1158/2326-6066.CIR-17-0630; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kontos CK, 2010, BRIT J CANCER, V102, P1384, DOI 10.1038/sj.bjc.6605654; Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lauber K, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00116; Lawson PA, 2004, INT J SYST EVOL MICR, V54, P413, DOI 10.1099/ijs.0.02653-0; Lei G, 2020, CELL RES, V30, P146, DOI 10.1038/s41422-019-0263-3; Li F, 2017, PHARMACOL THERAPEUT, V178, P18, DOI 10.1016/j.pharmthera.2017.03.007; Liu XX, 2018, INT J CLIN EXP PATHO, V11, P2654; Lu P, 2019, CANCER MANAG RES, V11, P9057, DOI 10.2147/CMAR.S185766; Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377; Mokutani Y, 2016, ANN SURG ONCOL, V23, pS599, DOI 10.1245/s10434-016-5133-3; Murray GI, 1997, CANCER RES, V57, P3026; Park JH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102308; Patrone V, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5202-z; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng YR, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.704038; Peng Z, 2020, CANCER IMMUNOL RES, V8, P1251, DOI 10.1158/2326-6066.CIR-19-1014; Pitroda SP, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-68; Roy S, 2017, NAT REV CANCER, V17, P271, DOI 10.1038/nrc.2017.13; Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191; Saigusa S, 2016, INT J CLIN ONCOL, V21, P946, DOI 10.1007/s10147-016-0962-4; Sattler UGA, 2010, RADIOTHER ONCOL, V94, P102, DOI 10.1016/j.radonc.2009.11.007; Shimada T, 1996, CANCER RES, V56, P2979; Shimura T, 2014, RADIOTHER ONCOL, V112, P302, DOI 10.1016/j.radonc.2014.07.015; Shin A, 2020, CANCER RES TREAT, V52, P848, DOI 10.4143/crt.2019.550; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Singleton DC, 2015, ONCOGENE, V34, P4713, DOI 10.1038/onc.2014.396; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tan ZQ, 2018, THERANOSTICS, V8, P2329, DOI 10.7150/thno.21451; Trakarnsanga A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju248; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vassiliou AG, 2019, BIOCHIMIE, V160, P76, DOI 10.1016/j.biochi.2019.02.009; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Yi M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0592-6; Yi YX, 2021, CLIN CANCER RES, V27, P1329, DOI 10.1158/1078-0432.CCR-20-3445; Zhou SM, 2017, J AGR FOOD CHEM, V65, P6599, DOI 10.1021/acs.jafc.7b01803; Zhu J, 2020, J CLIN ONCOL, V38, P4231, DOI 10.1200/JCO.20.01932	68	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2022	13								1050721	10.3389/fimmu.2022.1050721	http://dx.doi.org/10.3389/fimmu.2022.1050721			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1DX	36505493	gold, Green Published			2022-12-18	WOS:000894110900001
J	Abe, N; Kono, M; Kono, M; Katsuyama, T; Ohmura, K; Sato, T; Karino, K; Fujieda, Y; Kato, M; Hasebe, R; Murakami, M; Atsumi, T				Abe, Nobuya; Kono, Michihiro; Kono, Michihito; Katsuyama, Takayuki; Ohmura, Kazumasa; Sato, Taiki; Karino, Kohei; Fujieda, Yuichiro; Kato, Masaru; Hasebe, Rie; Murakami, Masaaki; Atsumi, Tatsuya			Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study	FRONTIERS IN IMMUNOLOGY			English	Article						large vessel vasculitis; Takayasu arteritis; giant cell arteritis; proteomics; cytokine; chemokine; clustering; Janus-kinase inhibitor	GIANT-CELL ARTERITIS; TAKAYASU ARTERITIS; TH17	Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6-IL-17 axis and IL-12-IFN-gamma axis play critical roles in the disease development. We aimed to clarify the association between the disease state and cytokine/chemokine levels, to assess disease course as prognosis and to predict regulators in patients with LVV using the blood profiles of multiple cytokines/chemokines. This retrospective analysis comprised 35 LVV patients whose blood were collected, and multiplex cytokine/chemokine analysis with 28 analytes was performed. The differences of cytokines/chemokines corresponding disease status, upstream regulator analysis, pathway analysis and cluster analysis were conducted using the cytokines/chemokines profile. Relapse-free survival rate was calculated with Kaplan-Meier analysis in the classified clusters. In the robust analysis, IL-4, CCL2/MCP-1, TNFSF13/APRIL, TNFSF13B/BAFF, CHI3L1 and VEGF-A levels were significantly changed after treatment. Untreated LVV patients demonstrated activation of NF kappa B-related molecules and these patients are potentially treated with JAK/STAT inhibitors, anti-TNF-alpha inhibitors and IL-6 inhibitors. Cluster analysis in active LVV patients revealed two clusters including one with high blood levels of IL-1 beta, IL-6, IL-17, IL-23 and CCL20/MIP-3. A subgroup of the LVV patients showed activated IL-17 signature with high relapse frequency, and JAK/TyK2 inhibitors and IFN-gamma inhibitors were detected as potentially upstream inhibitors. Blood cytokine/chemokine profiles would be useful for prediction of relapse and potentially contributes to establish therapeutic strategy as precision medicine in LVV patients.	[Abe, Nobuya; Kono, Michihiro; Kono, Michihito; Ohmura, Kazumasa; Sato, Taiki; Karino, Kohei; Fujieda, Yuichiro; Kato, Masaru; Atsumi, Tatsuya] Hokkaido Univ, Fac Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Japan; [Abe, Nobuya; Kono, Michihiro; Kono, Michihito; Ohmura, Kazumasa; Sato, Taiki; Karino, Kohei; Fujieda, Yuichiro; Kato, Masaru; Atsumi, Tatsuya] Hokkaido Univ, Grad Sch Med, Sapporo, Japan; [Abe, Nobuya; Murakami, Masaaki] Hokkaido Univ, Inst Genet Med, Grad Sch Med, Div Mol Psychoimmunol, Sapporo, Japan; [Katsuyama, Takayuki] Okayama Univ, Grad Sch Med, Dept Nephrol Rheumatol Endocrinol & Metab, Okayama, Japan; [Hasebe, Rie] Hokkaido Univ, Inst Genet Med, Ctr Infect Canc, Sapporo, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Okayama University; Hokkaido University	Kono, M (corresponding author), Hokkaido Univ, Fac Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Japan.; Kono, M (corresponding author), Hokkaido Univ, Grad Sch Med, Sapporo, Japan.	m-kono@med.hokudai.ac.jp						Dong H, 2021, CYTOKINE, V143, DOI 10.1016/j.cyto.2021.155515; Grayson PC, 2012, ANN RHEUM DIS, V71, P1329, DOI 10.1136/annrheumdis-2011-200795; Hellmich B, 2020, ANN RHEUM DIS, V79, P19, DOI 10.1136/annrheumdis-2019-215672; James JA, 2020, RHEUMATOLOGY, V59, P860, DOI 10.1093/rheumatology/kez335; Kaiser M, 1998, ARTHRITIS RHEUM, V41, P623, DOI 10.1002/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kuwabara S, 2020, ANN RHEUM DIS, V79, P1125, DOI 10.1136/annrheumdis-2019-216606; Maksimowicz-McKinnon K, 2009, MEDICINE, V88, P221, DOI 10.1097/MD.0b013e3181af70c1; Mason JC, 2010, NAT REV RHEUMATOL, V6, P406, DOI 10.1038/nrrheum.2010.82; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Regnier P, 2020, ANN RHEUM DIS, V79, P951, DOI 10.1136/annrheumdis-2019-216900; Saadoun D, 2015, ARTHRITIS RHEUMATOL, V67, P1353, DOI 10.1002/art.39037; Sammel AM, 2021, INT J RHEUM DIS, V24, P781, DOI 10.1111/1756-185X.14111; Samson M, 2012, ARTHRITIS RHEUM-US, V64, P3788, DOI 10.1002/art.34647; Sanada A, 2022, RHEUMATOLOGY, V61, pE274, DOI 10.1093/rheumatology/keac203; Szodoray P, 2007, RHEUMATOLOGY, V46, P417, DOI 10.1093/rheumatology/kel306; Tombetti E, 2019, RHEUMATOLOGY, V58, P206, DOI 10.1093/rheumatology/key040; Wagner AD, 1996, AM J PATHOL, V148, P1925; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Weyand CM, 2003, NEW ENGL J MED, V349, P160, DOI 10.1056/NEJMra022694; Zhang H, 2018, CIRCULATION, V137, P1934, DOI 10.1161/CIRCULATIONAHA.117.030423	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1066916	10.3389/fimmu.2022.1066916	http://dx.doi.org/10.3389/fimmu.2022.1066916			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9TW	36505494	Green Published, gold			2022-12-18	WOS:000894016300001
J	Chen, SL; Zeng, XZ; Su, TH; Xiao, H; Lin, MX; Peng, ZW; Peng, S; Kuang, M				Chen, Shuling; Zeng, Xuezhen; Su, Tianhong; Xiao, Han; Lin, Manxia; Peng, Zhenwei; Peng, Sui; Kuang, Ming			Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective	FRONTIERS IN IMMUNOLOGY			English	Review						ablation; tumor immune microenvironment; immunotherapy; HCC; combination therapy	RADIOFREQUENCY THERMAL ABLATION; RANDOMIZED CONTROLLED-TRIAL; INDUCED KILLER-CELLS; MICROWAVE ABLATION; IRREVERSIBLE ELECTROPORATION; SURGICAL RESECTION; DENDRITIC CELLS; LIVER; CRYOABLATION; THERAPY	Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide. Local ablation, such as radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation, etc., are well established in elimination and control of HCC. However, high recurrence rate after local ablation remains the biggest challenge for HCC management. Novel and effective therapeutic strategies to improve long-term survival are urgently needed. Accumulating studies have reported the role of ablation in modulating the tumor signaling pathway and the immune microenvironment to both eliminate residual/metastatic tumor and promote tumor progression. Ablation has been shown to elicit tumor-specific immune responses by inducing massive cell death and releasing tumor antigen. Immunotherapies that unleash the immune system have the potential to enhance the anti-tumor immunity induced by ablation. Multiple combinatory strategies have been explored in preclinical and clinical studies. In this review, we comprehensively summarize the latest progress on different mechanisms underlying the effects of ablation on tumor cells and tumor microenvironment. We further analyze the clinical trials testing the combination of ablation and immunotherapies, and discuss the possible role of immunomodulation to boost the anti-tumor effects of ablation and prevent HCC recurrence.	[Chen, Shuling; Xiao, Han; Lin, Manxia] Sun Yat sen Univ, Affiliated Hosp 1, Inst Diagnost & Intervent Ultrasound, Guangzhou, Guangdong, Peoples R China; [Zeng, Xuezhen; Kuang, Ming] Sun Yat sen Univ, Affiliated Hosp 1, Ctr Hepatopancreato Biliary Surg, Guangzhou, Guangdong, Peoples R China; [Zeng, Xuezhen] Sun Yat sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Guangdong, Peoples R China; [Su, Tianhong] Sun Yat sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Peng, Zhenwei; Peng, Sui] Sun Yat sen Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China; [Kuang, Ming] Sun Yat sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Kuang, M (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Ctr Hepatopancreato Biliary Surg, Guangzhou, Guangdong, Peoples R China.; Kuang, M (corresponding author), Sun Yat sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.	kuangm@mail.sysu.edu.cn			State Key Program of National Natural Science of China [82130083]; National Science Fund for Distinguished Young Scholars [81825013]; National Science Fund for Young Scholars [82003105]; National Natural Science Foundation of China [82172047, 31970870]; Natural Science Foundation of Guangdong Province [2021A1515010450]; Natural Science Foundation for Distinguished Youths of Guangdong Province [2022B1515020060]; Joint Funds of the National Natural Science Foundation of China [U20A20370]	State Key Program of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Science Fund for Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Natural Science Foundation for Distinguished Youths of Guangdong Province; Joint Funds of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by State Key Program of National Natural Science of China (No. 82130083), The National Science Fund for Distinguished Young Scholars (No. 81825013), the National Science Fund for Young Scholars (No. 82003105), the National Natural Science Foundation of China (No. 82172047; No. 31970870), Natural Science Foundation of Guangdong Province (No. 2021A1515010450), Natural Science Foundation for Distinguished Youths of Guangdong Province (No. 2022B1515020060), the Joint Funds of the National Natural Science Foundation of China (No. U20A20370).	Ahmad F, 2010, LIVER INT, V30, P1305, DOI 10.1111/j.1478-3231.2010.02290.x; Ali MY, 2005, J HEPATOL, V43, P817, DOI 10.1016/j.jhep.2005.04.016; Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Behm B, 2016, GUT, V65, P134, DOI 10.1136/gutjnl-2014-308286; Breen DJ, 2015, NAT REV CLIN ONCOL, V12, P175, DOI 10.1038/nrclinonc.2014.237; Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672; Clark TWI, 2002, J VASC INTERV RADIOL, V13, pS245, DOI 10.1016/S1051-0443(07)61792-8; Cui JW, 2014, INT J CANCER, V134, P342, DOI 10.1002/ijc.28372; Dai ZH, 2021, CANCER LETT, V503, P1, DOI 10.1016/j.canlet.2021.01.001; den Brok MHMGM, 2006, BRIT J CANCER, V95, P896, DOI 10.1038/sj.bjc.6603341; den Brok MHMGM, 2004, CANCER RES, V64, P4024, DOI 10.1158/0008-5472.CAN-03-3949; Dromi SA, 2009, RADIOLOGY, V251, P58, DOI 10.1148/radiol.2511072175; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; FAJARDO LF, 1980, CANCER-AM CANCER SOC, V45, P613, DOI 10.1002/1097-0142(19800201)45:3<613::AID-CNCR2820450331>3.0.CO;2-E; Feng K, 2012, J HEPATOL, V57, P794, DOI 10.1016/j.jhep.2012.05.007; Gao XC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00774; Guan QL, 2015, BIOTECHNOL BIOTEC EQ, V29, P119, DOI 10.1080/13102818.2014.981776; Han JW, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091387; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Hiroishi K, 2010, J GASTROENTEROL, V45, P451, DOI 10.1007/s00535-009-0155-2; Hsiao CY, 2017, J MED ULTRASOUND, V25, P195, DOI 10.1016/j.jmu.2017.08.003; Huang SJ, 2022, INT J HYPERTHER, V39, P278, DOI 10.1080/02656736.2022.2032406; Iida N, 2010, CANCER RES, V70, P6556, DOI 10.1158/0008-5472.CAN-10-0096; Jansen MC, 2010, SURGERY, V147, P686, DOI 10.1016/j.surg.2009.10.053; Ji LL, 2017, INT J CLIN EXP PATHO, V10, P8715; Jia GQ, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01444-z; Jiang QC, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00783; Kole C, 2020, CANCERS, V12, DOI 10.3390/cancers12102859; Kong J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-230; Lee DH, 2014, RADIOLOGY, V270, P900, DOI 10.1148/radiol.13130940; Lee JH, 2015, GASTROENTEROLOGY, V148, P1383, DOI 10.1053/j.gastro.2015.02.055; Lehmann KS, 2016, J HEPATO-BIL-PAN SCI, V23, P508, DOI 10.1002/jhbp.370; Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718; Leuchte K, 2021, CANCER IMMUNOL IMMUN, V70, P893, DOI 10.1007/s00262-020-02734-1; Li XS, 2020, NAT REV CLIN ONCOL, V17, P657, DOI 10.1038/s41571-020-0410-2; Li ZL, 2021, CANCER BIOTHER RADIO, V36, P879, DOI 10.1089/cbr.2019.3541; Liu F, 2020, LIVER CANCER, V9, P397, DOI 10.1159/000505694; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Lubner MG, 2010, J VASC INTERV RADIOL, V21, pS192, DOI 10.1016/j.jvir.2010.04.007; Lyu N, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580241; Ma DN, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12795; Ma HQ, 2010, CANCER BIOL THER, V9, P903, DOI 10.4161/cbt.9.11.11697; Mizukoshi E, 2013, HEPATOLOGY, V57, P1448, DOI 10.1002/hep.26153; Mohkam K, 2018, J HEPATOL, V68, P1172, DOI 10.1016/j.jhep.2018.01.014; NAKASHIMA O, 1995, HEPATOLOGY, V22, P101, DOI 10.1002/hep.1840220116; Nikfarjam M, 2005, J SURG RES, V127, P208, DOI 10.1016/j.jss.2005.02.009; Nobuoka D, 2012, INT J ONCOL, V40, P63, DOI 10.3892/ijo.2011.1202; Peng S, 2022, CANCER IMMUNOL RES, V10, P728, DOI 10.1158/2326-6066.CIR-21-0931; Pinter M, 2021, JAMA ONCOL, V7, P113, DOI 10.1001/jamaoncol.2020.3381; Reig M, 2022, J HEPATOL, V76, P681, DOI 10.1016/j.jhep.2021.11.018; Rochigneux P, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1615818; Seror O, 2015, DIAGN INTERV IMAG, V96, P617, DOI 10.1016/j.diii.2015.04.007; Shiina S, 2012, AM J GASTROENTEROL, V107, P569, DOI 10.1038/ajg.2011.425; Su TH, 2021, HEPATOLOGY, V74, P1339, DOI 10.1002/hep.31766; Su TH, 2018, ONCOGENE, V37, P3514, DOI 10.1038/s41388-018-0169-4; Sutter O, 2017, RADIOLOGY, V284, P877, DOI 10.1148/radiol.2017161413; van den Bijgaart RJE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.617365; Vitale G, 2010, CANCER BIOL THER, V9, P694, DOI 10.4161/cbt.9.9.11691; Wang CP, 2015, HEPATOLOGY, V61, P1579, DOI 10.1002/hep.27548; Weng DS, 2008, J IMMUNOTHER, V31, P63, DOI 10.1097/CJI.0b013e31815a121b; Xu J, 2018, ANTICANCER RES, V38, P6381, DOI 10.21873/anticanres.12997; Xu WL, 2019, BMB REP, V52, P277, DOI 10.5483/BMBRep.2019.52.4.263; Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978; Yoon JS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5740-z; Zeng XZ, 2022, HEPATOLOGY, DOI 10.1002/hep.32585; Zeng Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023621; Zerbini A, 2006, CANCER RES, V66, P1139, DOI 10.1158/0008-5472.CAN-05-2244; Zerbini A, 2008, J IMMUNOTHER, V31, P271, DOI 10.1097/CJI.0b013e318160ff1c; Zerbini A, 2010, GASTROENTEROLOGY, V138, P1931, DOI 10.1053/j.gastro.2009.12.051; Zhang HW, 2017, MINIM INVASIV THER, V26, P207, DOI 10.1080/13645706.2017.1286356; Zhang N, 2019, J CANCER RES CLIN, V145, P895, DOI 10.1007/s00432-019-02852-z; Zhang N, 2017, J CANCER, V8, P3742, DOI 10.7150/jca.20816; Zhang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115949; Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1; Zhou T, 2020, J CANCER RES THER, V16, P1112, DOI 10.4103/jcrt.JCRT_12_20; Zhou Y, 2018, J CANCER RES THER, V14, P40, DOI 10.4103/jcrt.JCRT_775_17	77	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1033000	10.3389/fimmu.2022.1033000	http://dx.doi.org/10.3389/fimmu.2022.1033000			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9QW	36505437	Green Published, gold			2022-12-18	WOS:000894008400001
J	Comez, D; Glenn, J; Anbuhl, SM; Heukers, R; Smit, MJ; Hill, SJ; Kilpatrick, LE				Comez, Dehan; Glenn, Jacqueline; Anbuhl, Stephanie M. M.; Heukers, Raimond; Smit, Martine J. J.; Hill, Stephen J. J.; Kilpatrick, Laura E. E.			Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells	FRONTIERS IN IMMUNOLOGY			English	Article						EGFR; nanobody; BRET; NanoBiT; fluorescence	EPIDERMAL-GROWTH-FACTOR; EARLY/LATE ENDOCYTIC PATHWAY; FACTOR RECEPTOR EGFR; LUNG-CANCER; DIMERIZATION; ACTIVATION; COMPLEX; INHIBITION; DOMAIN	IntroductionThe Epidermal Growth Factor Receptor is a member of the Erb receptor tyrosine kinase family. It binds several ligands including EGF, betacellulin (BTC) and TGF-alpha, controls cellular proliferation and invasion and is overexpressed in various cancer types. Nanobodies (VHHs) are the antigen binding fragments of heavy chain only camelid antibodies. In this paper we used NanoBRET to compare the binding characteristics of fluorescent EGF or two distinct fluorescently labelled EGFR directed nanobodies (Q44c and Q86c) to full length EGFR. MethodsLiving HEK293T cells were stably transfected with N terminal NLuc tagged EGFR. NanoBRET saturation, displacement or kinetics experiments were then performed using fluorescently labelled EGF ligands (EGF-AF488 or EGF-AF647) or fluorescently labelled EGFR targeting nanobodies (Q44c-HL488 and Q86c-HL488). ResultsThese data revealed that the EGFR nanobody Q44c was able to inhibit EGF binding to full length EGFR, while Q86c was able to recognise agonist bound EGFR and act as a conformational sensor. The specific binding of fluorescent Q44c-HL488 and EGF-AF488 was inhibited by a range of EGFR ligands (EGF> BTC>TGF-alpha). DiscussionEGFR targeting nanobodies are powerful tools for studying the role of the EGFR in health and disease and allow real time quantification of ligand binding and distinct ligand induced conformational changes.	[Comez, Dehan; Glenn, Jacqueline; Hill, Stephen J. J.] Univ Nottingham, Sch Life Sci, Div Physiol Pharmacol & Neurosci, Pharmacol & Neurosci, Nottingham, Nottinghamshire, United Kingdom; [Comez, Dehan; Glenn, Jacqueline; Hill, Stephen J. J.; Kilpatrick, Laura E. E.] Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham, England; [Comez, Dehan; Glenn, Jacqueline; Hill, Stephen J. J.; Kilpatrick, Laura E. E.] Univ Nottingham, Nottingham, England; [Anbuhl, Stephanie M. M.; Heukers, Raimond; Smit, Martine J. J.] Vrije Univ VU, Amsterdam Inst Mol & Life Sci AIMMS, Div Med Chem, Amsterdam, Netherlands; [Anbuhl, Stephanie M. M.; Heukers, Raimond] QVQ Holding BV, Utrecht, Netherlands; [Kilpatrick, Laura E. E.] Univ Nottingham, Biodiscovery Inst, Sch Pharm, Div Bimol Sci & Med Chem, Nottingham, England	University of Nottingham; University of Birmingham; University of Nottingham; Vrije Universiteit Amsterdam; University of Nottingham	Hill, SJ (corresponding author), Univ Nottingham, Sch Life Sci, Div Physiol Pharmacol & Neurosci, Pharmacol & Neurosci, Nottingham, Nottinghamshire, United Kingdom.; Hill, SJ; Kilpatrick, LE (corresponding author), Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham, England.; Hill, SJ; Kilpatrick, LE (corresponding author), Univ Nottingham, Nottingham, England.; Kilpatrick, LE (corresponding author), Univ Nottingham, Biodiscovery Inst, Sch Pharm, Div Bimol Sci & Med Chem, Nottingham, England.	stephen.hill@nottingham.ac.uk; laura.kilpatrick@nottingham.ac.uk			MRC [MR/N020081/1, MR/W016176/1]; ONCORNET 2.0 (ONCOgenic Receptor Network of Excellence and Training 2.0) PhD training programme - European Commission [860229]; University of Nottingham Anne McLaren Research Fellowship	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ONCORNET 2.0 (ONCOgenic Receptor Network of Excellence and Training 2.0) PhD training programme - European Commission; University of Nottingham Anne McLaren Research Fellowship	Research was supported by MRC (grant numbers MR/N020081/1 and MR/W016176/1) and the ONCORNET 2.0 (ONCOgenic Receptor Network of Excellence and Training 2.0) PhD training programme (DC and SA) funded by the European Commission for a Marie Sklodowska Curie Actions<EM><STRONG> </STRONG></EM>(H2020-MSCA grant agreement 860229). LK is funded by a University of Nottingham Anne McLaren Research Fellowship.	Alvarado D, 2010, CELL, V142, P568, DOI 10.1016/j.cell.2010.07.015; Bessman NJ, 2014, CELL REP, V9, P1306, DOI 10.1016/j.celrep.2014.10.010; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Dixon AS, 2016, ACS CHEM BIOL, V11, P400, DOI 10.1021/acschembio.5b00753; Ferguson KM, 2020, PROTEIN SCI, V29, P1331, DOI 10.1002/pro.3871; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Heukers R, 2019, ANTIBODIES, V8, DOI 10.3390/antib8020026; Hofman EG, 2008, J CELL SCI, V121, P2519, DOI 10.1242/jcs.028753; Hofman EG, 2010, J BIOL CHEM, V285, P39481, DOI 10.1074/jbc.M110.164731; Huang YJ, 2021, ELIFE, V10, DOI [10.7554/eLife.73218, 10.7554/eLife.73218.sa0, 10.7554/eLife.73218.sa1, 10.7554/eLife.73218.sa2]; Kilpatrick LE, 2017, BIOCHEM PHARMACOL, V136, P62, DOI 10.1016/j.bcp.2017.04.006; Knudsen SLJ, 2014, GROWTH FACTORS, V32, P155, DOI 10.3109/08977194.2014.952410; Lay Charles S, 2022, Cell Chem Biol, V29, P19, DOI 10.1016/j.chembiol.2021.05.002; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liu P, 2012, P NATL ACAD SCI USA, V109, P10861, DOI 10.1073/pnas.1201114109; Low-Nam ST, 2011, NAT STRUCT MOL BIOL, V18, P1244, DOI 10.1038/nsmb.2135; Macdonald-Obermann JL, 2012, P NATL ACAD SCI USA, V109, P137, DOI 10.1073/pnas.1111316109; Macdonald-Obermann JL, 2009, J BIOL CHEM, V284, P13570, DOI 10.1074/jbc.M109.001487; Nevoltris D, 2015, ACS NANO, V9, P1388, DOI 10.1021/nn505752u; Nishimura Y, 2007, HISTOCHEM CELL BIOL, V127, P541, DOI 10.1007/s00418-007-0281-y; Nishimura Y, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-42; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Peach CJ, 2021, BRIT J PHARMACOL, V178, P2393, DOI 10.1111/bph.15426; Ronan T, 2016, J BIOL CHEM, V291, P5528, DOI 10.1074/jbc.M115.710087; Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4; Schihada H, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0072-0; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schmitz KR, 2013, STRUCTURE, V21, P1214, DOI 10.1016/j.str.2013.05.008; Singh M, 2018, DRUG DISCOV TODAY, V23, P745, DOI 10.1016/j.drudis.2017.10.004; Soave M, 2020, CELL CHEM BIOL, V27, P1250, DOI 10.1016/j.chembiol.2020.06.006; Soave M, 2020, SLAS DISCOV, V25, P186, DOI 10.1177/2472555219880475; Stoddart LA, 2015, NAT METHODS, V12, P661, DOI [10.1038/NMETH.3398, 10.1038/nmeth.3398]; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zanetti-Domingues LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06632-0; Zeronian MR, 2022, BMC MOL CELL BIOL, V23, DOI 10.1186/s12860-022-00412-x	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1006718	10.3389/fimmu.2022.1006718	http://dx.doi.org/10.3389/fimmu.2022.1006718			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U0KZ	36505413	gold, Green Published			2022-12-18	WOS:000894061300001
J	Dankers, W; Northcott, M; Bennett, T; D'Cruz, A; Sherlock, R; Gearing, LJ; Hertzog, P; Russ, B; Miceli, I; Scheer, S; Fujishiro, M; Hayakawa, K; Ikeda, K; Morand, EF; Jones, SA				Dankers, Wendy; Northcott, Melissa; Bennett, Taylah; D'Cruz, Akshay; Sherlock, Rochelle; Gearing, Linden J. J.; Hertzog, Paul; Russ, Brendan; Miceli, Iolanda; Scheer, Sebastian; Fujishiro, Maki; Hayakawa, Kunihiro; Ikeda, Keigo; Morand, Eric F. F.; Jones, Sarah A. A.			Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ)	FRONTIERS IN IMMUNOLOGY			English	Article						interferon; GILZ; glucocorticoid; STAT1; systemic lupus erythematosus (SLE); inflammation; autoimmunity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENE-EXPRESSION; CELL ACTIVATION; I INTERFERON; T-CELLS; INFLAMMATION; ANIFROLUMAB; INHIBITION; SIGNATURES; STAT5	SLE is a systemic multi-organ autoimmune condition associated with reduced life expectancy and quality of life. Glucocorticoids (GC) are heavily relied on for SLE treatment but are associated with detrimental metabolic effects. Type 1 interferons (IFN) are central to SLE pathogenesis and may confer GC insensitivity. Glucocorticoid-induced leucine zipper (GILZ) mediates many effects of GC relevant to SLE pathogenesis, but the effect of IFN on GC regulation of GILZ is unknown. We performed in vitro experiments using human PBMC to examine the effect of IFN on GILZ expression. JAK inhibitors tofacitinib and tosylate salt were used in vivo and in vitro respectively to investigate JAK-STAT pathway dependence of our observations. ChiP was performed to examine glucocorticoid receptor (GR) binding at the GILZ locus. Several public data sets were mined for correlating clinical data. High IFN was associated with suppressed GILZ and reduced GILZ relevant to GC exposure in a large SLE population. IFN directly reduced GILZ expression and suppressed the induction of GILZ by GC in vitro in human leukocytes. IFN actions on GILZ expression were dependent on the JAK1/Tyk2 pathway, as evidenced by loss of the inhibitory effect of IFN on GILZ in the presence of JAK inhibitors. Activation of this pathway led to reduced GR binding in key regulatory regions of the GILZ locus. IFN directly suppresses GILZ expression and GILZ upregulation by GC, indicating a potential mechanism for IFN-induced GC resistance. This work has important implications for the ongoing development of targeted GC-sparing therapeutics in SLE.	[Dankers, Wendy; Northcott, Melissa; Bennett, Taylah; D'Cruz, Akshay; Sherlock, Rochelle; Russ, Brendan; Miceli, Iolanda; Scheer, Sebastian; Morand, Eric F. F.; Jones, Sarah A. A.] Monash Univ, Ctr Inflammatory Dis, Melbourne, VIC, Australia; [Hertzog, Paul] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Melbourne, VIC, Australia; [Fujishiro, Maki; Hayakawa, Kunihiro; Ikeda, Keigo] Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Chiba, Japan; [Ikeda, Keigo] Juntendo Univ Urayasu Hosp, Dept Internal Med & Rheumatol, Chiba, Japan	Monash University; Hudson Institute of Medical Research; Juntendo University; Juntendo University	Jones, SA (corresponding author), Monash Univ, Ctr Inflammatory Dis, Melbourne, VIC, Australia.	sarah.a.jones@monash.edu						Apostolopoulos D, 2020, LANCET RHEUMATOL, V2, pE24, DOI 10.1016/S2665-9913(19)30105-5; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Ayroldi E, 2014, FASEB J, V28, P5055, DOI 10.1096/fj.14-254755; Barrat FJ, 2008, IMMUNOL REV, V223, P271, DOI 10.1111/j.1600-065X.2008.00630.x; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Chavele KM, 2011, FEBS LETT, V585, P3603, DOI 10.1016/j.febslet.2011.07.043; Cheng Q, 2013, J IMMUNOL, V191, P424, DOI 10.4049/jimmunol.1202662; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Felger JC, 2016, PHYSIOL BEHAV, V166, P14, DOI 10.1016/j.physbeh.2015.12.013; Fensome A, 2018, J MED CHEM, V61, P8597, DOI 10.1021/acs.jmedchem.8b00917; Furie R, 2017, ARTHRITIS RHEUMATOL, V69, P376, DOI 10.1002/art.39962; Guiducci C, 2010, NATURE, V465, P937, DOI 10.1038/nature09102; Hoffman RW, 2017, ARTHRITIS RHEUMATOL, V69, P643, DOI 10.1002/art.39950; Hu F, 2009, BRAIN BEHAV IMMUN, V23, P455, DOI 10.1016/j.bbi.2009.01.001; Ikeda K, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0225-9; Jones SA, 2016, ANN RHEUM DIS, V75, P739, DOI 10.1136/annrheumdis-2015-207744; Jones SA, 2015, J AUTOIMMUN, V61, P73, DOI 10.1016/j.jaut.2015.05.010; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Melo AKG, 2013, GENET MOL RES, V12, P2010, DOI 10.4238/2013.February.19.1; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Nataraja C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652800; Ngo D, 2013, ARTHRITIS RHEUM-US, V65, P1203, DOI 10.1002/art.37858; Northcott M, 2022, LUPUS SCI MED, V9, DOI 10.1136/lupus-2021-000625; Northcott M, 2021, LANCET RHEUMATOL, V3, pE357, DOI 10.1016/S2665-9913(21)00006-0; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Psarras A, 2017, RHEUMATOLOGY, V56, P1662, DOI 10.1093/rheumatology/kew431; Ronnblom L, 2019, LUPUS SCI MED, V6, DOI 10.1136/lupus-2018-000270; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232; Yang NL, 2015, FASEB J, V29, P3954, DOI 10.1096/fj.15-273664	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1034880	10.3389/fimmu.2022.1034880	http://dx.doi.org/10.3389/fimmu.2022.1034880			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9UL	36505447	Green Published, gold			2022-12-18	WOS:000894017800001
J	Jin, J; Duan, J; Du, LY; Xing, WL; Peng, XC; Zhao, QJ				Jin, Jing; Duan, Jian; Du, Leiya; Xing, Wenli; Peng, Xingchen; Zhao, Qijie			Inflammation and immune cell abnormalities in intracranial aneurysm subarachnoid hemorrhage (SAH): Relevant signaling pathways and therapeutic strategies	FRONTIERS IN IMMUNOLOGY			English	Review						subarachnoid hemorrhage (SAH); inflammation; immune cells; signaling pathways; therapeutic strategies	EARLY BRAIN-INJURY; NF-KAPPA-B; PROLONGED-RELEASE IMPLANTS; RATS POSSIBLE INVOLVEMENT; SMOOTH-MUSCLE-CELLS; REGULATORY T-CELLS; NEWTON NIMODIPINE MICROPARTICLES; DELAYED CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; NLRP3 INFLAMMASOME	Intracranial aneurysm subarachnoid hemorrhage (SAH) is a cerebrovascular disorder associated with high overall mortality. Currently, the underlying mechanisms of pathological reaction after aneurysm rupture are still unclear, especially in the immune microenvironment, inflammation, and relevant signaling pathways. SAH-induced immune cell population alteration, immune inflammatory signaling pathway activation, and active substance generation are associated with pro-inflammatory cytokines, immunosuppression, and brain injury. Crosstalk between immune disorders and hyperactivation of inflammatory signals aggravated the devastating consequences of brain injury and cerebral vasospasm and increased the risk of infection. In this review, we discussed the role of inflammation and immune cell responses in the occurrence and development of aneurysm SAH, as well as the most relevant immune inflammatory signaling pathways [PI3K/Akt, extracellular signal-regulated kinase (ERK), hypoxia-inducible factor-1 alpha (HIF-1 alpha), STAT, SIRT, mammalian target of rapamycin (mTOR), NLRP3, TLR4/nuclear factor-kappa B (NF-kappa B), and Keap1/nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/ARE cascades] and biomarkers in aneurysm SAH. In addition, we also summarized potential therapeutic drugs targeting the aneurysm SAH immune inflammatory responses, such as nimodipine, dexmedetomidine (DEX), fingolimod, and genomic variation-related aneurysm prophylactic agent sunitinib. The intervention of immune inflammatory responses and immune microenvironment significantly reduces the secondary brain injury, thereby improving the prognosis of patients admitted to SAH. Future studies should focus on exploring potential immune inflammatory mechanisms and developing additional therapeutic strategies for precise aneurysm SAH immune inflammatory regulation and genomic variants associated with aneurysm formation.	[Jin, Jing; Zhao, Qijie] Sichuan Univ, West China Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China; [Jin, Jing; Peng, Xingchen] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China; [Duan, Jian; Xing, Wenli] Suining Cent Hosp, Dept Cerebrovascular Dis, Suining, Sichuan, Peoples R China; [Du, Leiya] Second People Hosp Yibin, Dept Oncol 4, Yibin, Sichuan, Peoples R China	Sichuan University; Sichuan University	Zhao, QJ (corresponding author), Sichuan Univ, West China Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China.; Peng, XC (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China.	pxx2014@163.com; zhaoqijie77@163.com						Abboud T, 2015, ACTA NEUROCHIR, V157, P763, DOI 10.1007/s00701-015-2369-9; Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890; Akpinar O, 2017, BRAIN RES BULL, V130, P1, DOI 10.1016/j.brainresbull.2016.12.005; Albanna W, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.03.062; An JY, 2018, EXP THER MED, V15, P1330, DOI 10.3892/etm.2017.5539; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Aoki T, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah6037; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Ayer RE, 2013, ACTA NEUROCHIR SUPPL, V115, P259, DOI 10.1007/978-3-7091-1192-5_46; Balboa L, 2011, J LEUKOCYTE BIOL, V90, P69, DOI 10.1189/jlb.1010577; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Barth M, 2007, STROKE, V38, P330, DOI 10.1161/01.STR.0000254601.74596.0f; Bayerl SH, 2020, J NEUROSURG, V132, P465, DOI 10.3171/2018.9.JNS173085; Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123; Bela SR, 2012, INFECT IMMUN, V80, P4298, DOI 10.1128/IAI.00328-12; BENEDICT CR, 1978, STROKE, V9, P237, DOI 10.1161/01.STR.9.3.237; Biondi A, 2004, AM J NEURORADIOL, V25, P1067; Bonomi A, 2020, GENES IMMUN, V21, P100, DOI 10.1038/s41435-019-0090-z; Brait VH, 2012, J CEREBR BLOOD F MET, V32, P598, DOI 10.1038/jcbfm.2012.6; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8; Burmi RS, 2019, CANCER BIOL THER, V20, P21, DOI 10.1080/15384047.2018.1504718; Burton MD, 2012, BRAIN BEHAV IMMUN, V26, P732, DOI 10.1016/j.bbi.2011.10.008; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Chaudhry SR, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92873-x; Chaudhry SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122580; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Chen JY, 2014, J PINEAL RES, V57, P340, DOI 10.1111/jpi.12173; Chen JH, 2019, J CELL MOL MED, V23, P2256, DOI 10.1111/jcmm.14105; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Chen XX, 2018, NEUROTOXICOL TERATOL, V67, P65, DOI 10.1016/j.ntt.2018.03.004; Chenbhanich J, 2021, AM J MED GENET A, V185, P1430, DOI 10.1002/ajmg.a.62126; Choi HA, 2012, NEUROCRIT CARE, V16, P363, DOI 10.1007/s12028-012-9670-8; Chu HX, 2014, J CEREBR BLOOD F MET, V34, P450, DOI 10.1038/jcbfm.2013.217; Corovic A, 2018, INT J STROKE, V13, P257, DOI 10.1177/1747493017741569; Coulibaly AP, 2020, NEUROTHERAPEUTICS, V17, P436, DOI 10.1007/s13311-019-00829-x; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dong GP, 2021, ACS CHEM NEUROSCI, V12, P430, DOI 10.1021/acschemneuro.0c00611; Dong L, 2016, CNS NEUROSCI THER, V22, P661, DOI 10.1111/cns.12557; Dutzmann J, 2015, CARDIOVASC RES, V106, P365, DOI 10.1093/cvr/cvv103; Edvinsson L, 2014, TRANSL STROKE RES, V5, P365, DOI 10.1007/s12975-014-0331-4; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; Eyo UB, 2019, PROG NEUROBIOL, V179, DOI 10.1016/j.pneurobio.2019.04.003; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Feng D, 2014, NEUROSCIENCE, V268, P21, DOI 10.1016/j.neuroscience.2014.02.053; Fielding CA, 2008, J IMMUNOL, V181, P2189, DOI 10.4049/jimmunol.181.3.2189; Foreman PM, 2017, CLIN NEUROL NEUROSUR, V157, P65, DOI 10.1016/j.clineuro.2017.04.007; Foster A, 2020, CLIN GENET, V98, P19, DOI 10.1111/cge.13752; Frase S, 2022, NEUROCRIT CARE, V36, P279, DOI 10.1007/s12028-021-01299-w; Frosen J, 2004, STROKE, V35, P2287, DOI 10.1161/01.STR.0000140636.30204.da; Fujii M, 2014, J NEUROL SCI, V342, P101, DOI 10.1016/j.jns.2014.04.034; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; Gaab M R, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P93; Gaidt MM, 2018, J MOL BIOL, V430, P133, DOI 10.1016/j.jmb.2017.11.013; Galea J, 2012, J NEUROCHEM, V121, P785, DOI 10.1111/j.1471-4159.2012.07716.x; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; Gao YY, 2021, EXP NEUROL, V336, DOI 10.1016/j.expneurol.2020.113532; Gatti S, 2012, EXP NEUROL, V234, P230, DOI 10.1016/j.expneurol.2011.12.039; Gauthier T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.780839; Geraghty JR, 2021, NEUROSURGERY, V89, P1071, DOI 10.1093/neuros/nyab354; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Grage-Griebenow E, 2001, EUR J IMMUNOL, V31, P48; Graves DT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02530; Gris T, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1629-7; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; Gu X, 2017, AM J TRANSL RES, V9, P5643; Guo Mengdi, 2022, Handb Exp Pharmacol, V276, P213, DOI 10.1007/164_2021_542; Guyon A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00065; Hanggi D, 2015, NEUROCRIT CARE, V23, P274, DOI 10.1007/s12028-015-0112-2; Han YW, 2021, EUR J PHARMACOL, V893, DOI 10.1016/j.ejphar.2020.173811; Hao XK, 2014, BRAIN RES, V1587, P15, DOI 10.1016/j.brainres.2014.08.069; Harari OA, 2010, ANN NY ACAD SCI, V1207, P32, DOI 10.1111/j.1749-6632.2010.05735.x; Harno KSR, 1999, J TELEMED TELECARE, V5, P189, DOI 10.1258/1357633991933611; Hasegawa K, 2008, J NEUROSCI, V28, P8772, DOI 10.1523/JNEUROSCI.3052-08.2008; Hasegawa Y, 2010, STROKE, V41, P368, DOI 10.1161/STROKEAHA.109.568899; Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Hockel K, 2017, WORLD NEUROSURG, V101, P372, DOI 10.1016/j.wneu.2017.02.014; Hockel K, 2016, WORLD NEUROSURG, V88, P104, DOI 10.1016/j.wneu.2015.11.081; Hou CK, 2022, NEUROCHEM RES, V47, P701, DOI 10.1007/s11064-021-03478-9; Hu Q., 2014, ZHEJIANG XUE XUE BAO, V43, P58, DOI [10.3785/j.issn.1008-9292.2014.01.009, DOI 10.3785/J.ISSN.1008-9292.2014.01.009]; Hu Q, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.869546; Hu YW, 2021, J IMMUNOL, V207, P2933, DOI 10.4049/jimmunol.2100568; Huang C, 2016, NEUROSCIENCE, V331, P24, DOI 10.1016/j.neuroscience.2016.06.018; Huang XP, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00398; Hwang JW, 2013, FREE RADICAL BIO MED, V61, P95, DOI 10.1016/j.freeradbiomed.2013.03.015; Imai T, 2021, J CEREBR BLOOD F MET, V41, P1483, DOI 10.1177/0271678X20984565; Inta I, 2006, J NEUROSCI, V26, P12896, DOI 10.1523/JNEUROSCI.3670-06.2006; Intusoma U, 2019, PEDIATR NEUROL, V99, P23, DOI 10.1016/j.pediatrneurol.2019.06.005; Jabbarli R, 2018, STROKE, V49, P848, DOI 10.1161/STROKEAHA.117.020342; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P689, DOI 10.1097/00004647-200206000-00007; Kakehashi A, 2011, TOXICOL SCI, V119, P61, DOI 10.1093/toxsci/kfq307; Karasozen Y, 2019, AM J HUM GENET, V104, P968, DOI 10.1016/j.ajhg.2019.03.014; Kashiwada M, 2007, IMMUNOL RES, V39, P194, DOI 10.1007/s12026-007-0075-2; Kasuya H, 2002, STROKE, V33, P1011, DOI 10.1161/01.STR.0000014563.75483.22; Kawakita F, 2017, MOL NEUROBIOL, V54, P6624, DOI 10.1007/s12035-016-0178-7; Keogh B, 2011, TRENDS PHARMACOL SCI, V32, P435, DOI 10.1016/j.tips.2011.03.008; Khan N, 2018, INFLAMMOPHARMACOLOGY, V26, P77, DOI 10.1007/s10787-017-0401-9; Khey KMW, 2020, CELL MOL NEUROBIOL, V40, P675, DOI 10.1007/s10571-019-00767-4; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Korja M, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.228; Kourtzelis I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00553; Kox M, 2007, INTENS CARE MED, V33, P1303, DOI 10.1007/s00134-007-0664-5; Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483; Kreisl TN, 2008, NEUROLOGY, V70, P2314, DOI 10.1212/01.wnl.0000314648.82924.6f; Krishna M, 2008, CELL MOL LIFE SCI, V65, P3525, DOI 10.1007/s00018-008-8170-7; Kuai Feng, 2022, Neurol India, V70, P1517, DOI 10.4103/0028-3886.355128; Kurz K, 2009, PHARMACOL RES, V60, P508, DOI 10.1016/j.phrs.2009.07.009; Kusch A, 2009, CARDIOVASC RES, V83, P115, DOI 10.1093/cvr/cvp117; Kwan K, 2020, J NEUROSURG, V133, P1786, DOI 10.3171/2019.6.JNS19613; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Lazzaro MA, 2012, J NEUROINTERV SURG, V4, P22, DOI 10.1136/jnis.2010.004358; Leng W, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02156-1; Li JR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0959-6; Li JR, 2016, MOL NEUROBIOL, V53, P2668, DOI 10.1007/s12035-015-9318-8; Li L, 2015, EXP NEUROL, V272, P135, DOI 10.1016/j.expneurol.2014.12.020; Li PY, 2013, ANN NEUROL, V74, P458, DOI 10.1002/ana.23815; Li Q, 2018, BIOMED PHARMACOTHER, V99, P947, DOI 10.1016/j.biopha.2018.01.093; Li R, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1279-1; Li SL, 2019, INT J CLIN EXP PATHO, V12, P909; Li XG, 2019, NEURAL REGEN RES, V14, P721, DOI 10.4103/1673-5374.247476; Li YJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172784; Li YC, 2020, CELL MOL NEUROBIOL, V40, P629, DOI 10.1007/s10571-019-00760-x; Li ZG, 2018, BIOL CHEM, V399, P1339, DOI 10.1515/hsz-2018-0269; Liao Q, 2010, EUR J PHARMACOL, V641, P179, DOI 10.1016/j.ejphar.2010.05.024; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Liesz A, 2016, TRANSL STROKE RES, V7, P313, DOI 10.1007/s12975-016-0465-7; Lim HS, 2015, J IMMUNOL, V195, P5432, DOI 10.4049/jimmunol.1500707; Lin WB, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/3099409; Lindgren C, 2014, NEUROCRIT CARE, V21, P91, DOI 10.1007/s12028-013-9945-8; Lindner SH, 2010, J NEUROL NEUROSUR PS, V81, P116, DOI 10.1136/jnnp.2008.163063; Liu CY, 2015, EUR J IMMUNOL, V45, P142, DOI 10.1002/eji.201344429; Liu FY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1388-x; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Liu H, 2016, CELL PHYSIOL BIOCHEM, V38, P2323, DOI 10.1159/000445586; Liu JT, 2022, BIOCHEM BIOPH RES CO, V602, P27, DOI 10.1016/j.bbrc.2022.02.063; Liu LL, 2020, BMC IMMUNOL, V21, DOI 10.1186/s12865-020-00355-y; Liu L, 2021, AGING-US, V13, P11752, DOI 10.18632/aging.202869; Liu L, 2019, NEUROSCIENCE, V408, P105, DOI 10.1016/j.neuroscience.2019.03.038; Liu YZ, 2015, J NEUROSURG, V123, P915, DOI 10.3171/2014.11.JNS132348; Liu YX, 2011, NEUROPHARMACOLOGY, V60, P373, DOI 10.1016/j.neuropharm.2010.10.002; Lu Y, 2018, NEUROSCI LETT, V683, P13, DOI 10.1016/j.neulet.2018.06.016; Lu Y, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1118-4; Lucke-Wold BP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040497; Luo YJ, 2020, STROKE, V51, P3320, DOI 10.1161/STROKEAHA.120.029951; Lv HM, 2017, FREE RADICAL BIO MED, V106, P38, DOI 10.1016/j.freeradbiomed.2017.02.016; Ma CX, 2015, NEUROL MED-CHIR, V55, P878, DOI 10.2176/nmc.oa.2015-0077; Ma JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep23817; Ma M, 2020, MOL NEUROBIOL, V57, P3744, DOI 10.1007/s12035-020-01990-7; Ma YG, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/8889569; Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7; Maddahi A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-274; Maddahi A, 2011, J CEREBR BLOOD F MET, V31, P144, DOI 10.1038/jcbfm.2010.62; MALLOCH JA, 1988, NEW ZEAL MED J, V101, P614; Mao L, 2013, NEUROSCIENCE, V231, P272, DOI 10.1016/j.neuroscience.2012.11.050; Moreno-Navarrete JM, 2013, J NUTR BIOCHEM, V24, P1266, DOI 10.1016/j.jnutbio.2012.10.002; Mashaly Hazem Antar, 2008, Cleve Clin J Med, V75 Suppl 2, pS26; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; McMahon CJ, 2013, J NEUROINTERV SURG, V5, P512, DOI 10.1136/neurintsurg-2012-010386; Medvedev AE, 2015, IMMUNOL REV, V266, P109, DOI 10.1111/imr.12298; Mellanby RJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-248; Do MT, 2014, FREE RADICAL BIO MED, V74, P21, DOI [10.1016/j.freeradbiomed2014.06.010, 10.1016/j.freeradbiomed.2014.06.010]; Minogue AM, 2017, PROG NEURO-PSYCHOPH, V79, P15, DOI 10.1016/j.pnpbp.2017.02.008; Mirlekar B, 2015, BIOCHEM BIOPH RES CO, V464, P647, DOI 10.1016/j.bbrc.2015.07.028; Mohme M, 2020, TRANSL STROKE RES, V11, P1348, DOI 10.1007/s12975-019-00764-1; Moraes L, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0970-2; Morris KC, 2011, J CEREBR BLOOD F MET, V31, P1003, DOI 10.1038/jcbfm.2010.229; Muhammad S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.630381; Muhammad S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082709; Muller TB, 2013, NEUROSURGERY, V73, P256, DOI 10.1227/01.neu.0000430295.23799.16; Munshaw S, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI127884; Nabi B, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-018-1284-9; Naidech AM, 2011, AM J RESP CRIT CARE, V184, P998, DOI 10.1164/rccm.201103-0475CI; Nakura T, 2011, J NEUROL NEUROSUR PS, V82, P952, DOI 10.1136/jnnp.2009.197244; Neal M, 2018, GLIA, V66, P2137, DOI 10.1002/glia.23467; Nicholson LB, 2016, ESSAYS BIOCHEM, V60, P275, DOI 10.1042/EBC20160017; Nishikawa H, 2018, STROKE, V49, P2743, DOI 10.1161/STROKEAHA.118.021757; Nissinen L, 2014, BBA-GEN SUBJECTS, V1840, P2571, DOI 10.1016/j.bbagen.2014.03.007; Nowicki KW, 2018, J NEUROINTERV SURG, V10, P93, DOI 10.1136/neurintsurg-2016-012911; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Okada T, 2017, NEURAL REGEN RES, V12, P193, DOI 10.4103/1673-5374.200795; Okazaki T, 2018, J CRIT CARE, V44, P111, DOI 10.1016/j.jcrc.2017.10.034; Ott S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/970741; Pan H, 2011, NEUROCHEM RES, V36, P2434, DOI 10.1007/s11064-011-0571-6; Pang JW, 2018, TRANSL STROKE RES, V9, P654, DOI 10.1007/s12975-018-0665-4; Paudel YN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134609; Peng JH, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2019.101121; Peng YC, 2018, NEUROCHEM RES, V43, P785, DOI 10.1007/s11064-018-2480-4; Penn DL, 2015, J CLIN NEUROSCI, V22, P1, DOI 10.1016/j.jocn.2014.05.025; Penn DL, 2014, J CLIN NEUROSCI, V21, P28, DOI 10.1016/j.jocn.2013.07.004; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pfeilschifter Waltraud, 2011, Exp Transl Stroke Med, V3, P2, DOI 10.1186/2040-7378-3-2; Priego N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01314; Provencio JJ, 2013, ACTA NEUROCHIR SUPPL, V115, P233, DOI 10.1007/978-3-7091-1192-5_42; Pyne-Geithman GJ, 2013, ACTA NEUROCHIR SUPPL, V115, P267, DOI 10.1007/978-3-7091-1192-5_47; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Raghunath A, 2018, REDOX BIOL, V17, P297, DOI 10.1016/j.redox.2018.05.002; Ramagopalan SV, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-176; Rapoport RM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00303; Ren XY, 2016, J NEUROIMMUNE PHARM, V11, P238, DOI 10.1007/s11481-016-9658-9; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Roa JA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68861-y; Roethlisberger M, 2018, WORLD NEUROSURG, V111, pE192, DOI 10.1016/j.wneu.2017.12.046; Rohr J, 2016, LEUKEMIA, V30, P1062, DOI 10.1038/leu.2015.357; Rolland WB, 2011, ACTA NEUROCHIR SUPPL, V111, P213, DOI 10.1007/978-3-7091-0693-8_36; Roosen K, 2021, BRAIN RES, V1763, DOI 10.1016/j.brainres.2021.147446; Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af; Rustemi O, 2017, STROKE, V48, pe113, DOI 10.1161/STROKEAHA.116.016512; Saand AR, 2019, J CEREBR BLOOD F MET, V39, P959, DOI 10.1177/0271678X19841443; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Samraj AK, 2014, J CEREBR BLOOD F MET, V34, P759, DOI 10.1038/jcbfm.2014.15; Sandow N, 2016, NEUROCRIT CARE, V25, P29, DOI 10.1007/s12028-015-0230-x; Sansing LH, 2011, ACTA NEUROCHIR SUPPL, V111, P173, DOI 10.1007/978-3-7091-0693-8_29; Santiago-Sim T, 2016, STROKE, V47, P3005, DOI 10.1161/STROKEAHA.116.014161; Sarrafzadeh A, 2011, STROKE, V42, P53, DOI 10.1161/STROKEAHA.110.594705; Sasaki K, 2018, CLIN EXP PHARMACOL P, V45, P859, DOI 10.1111/1440-1681.12950; Schneider UC, 2018, CURR NEUROPHARMACOL, V16, P1385, DOI 10.2174/1570159X16666180412110919; Schneider UC, 2011, ACTA NEUROCHIR, V153, P2119, DOI 10.1007/s00701-011-1129-8; Schoch B, 2007, NEUROSURGERY, V60, P828, DOI 10.1227/01.NEU.0000255440.21495.80; Schumacher N, 2021, J HEPATOL, V74, DOI 10.1016/j.jhep.2020.09.021; SCRIABINE A, 1988, ANN NY ACAD SCI, V522, P698; Sehba FA, 2012, PROG NEUROBIOL, V97, P14, DOI 10.1016/j.pneurobio.2012.02.003; Shao ZW, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01079; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Shi H, 2021, NEUROTHERAPEUTICS, V18, P1905, DOI 10.1007/s13311-021-01066-x; Smith E.O., 1983, Progress in Clinical and Biological Research, V131, P1; Sokol B, 2015, J STROKE CEREBROVASC, V24, P1897, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.002; Solar P, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00018; Soliven B, 2011, NEUROLOGY, V76, pS9, DOI 10.1212/WNL.0b013e31820d9507; Solum EJ, 2015, CURR PHARM DESIGN, V21, P5453, DOI 10.2174/1381612821666151002112511; Son Y, 2020, MOL METAB, V39, DOI 10.1016/j.molmet.2020.101005; Song Y, 2019, J NEUROSURG ANESTH, V31, P342, DOI 10.1097/ANA.0000000000000504; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Sramek M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092599; STERN MJ, 1983, ARCH INTERN MED, V143, P1719, DOI 10.1001/archinte.143.9.1719; Stubelius A, 2011, CLIN IMMUNOL, V140, P37, DOI 10.1016/j.clim.2011.03.006; Sun J, 2019, BRAIN RES, V1719, P64, DOI 10.1016/j.brainres.2019.05.026; Sun Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-106; Suzuki H, 2003, STROKE, V34, P2796, DOI 10.1161/01.STR.0000103743.62248.12; Takenouchi T, 2021, AM J MED GENET A, V185, P999, DOI 10.1002/ajmg.a.62027; Tang JP, 2005, J NEUROCHEM, V94, P1342, DOI 10.1111/j.1471-4159.2005.03292.x; Tao CY, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00422; Tawk RG, 2021, MAYO CLIN PROC, V96, P1970, DOI 10.1016/j.mayocp.2021.01.005; Theus MH, 2017, J IMMUNOL, V199, P3547, DOI 10.4049/jimmunol.1700251; Tian Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.839796; Tong XP, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104485; TOWART R, 1979, BRIT J PHARMACOL, V67, pP409; Tschoe C, 2020, J STROKE, V22, P29, DOI 10.5853/jos.2019.02236; Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021; Usui F, 2015, ARTERIOSCL THROM VAS, V35, P127, DOI 10.1161/ATVBAHA.114.303763; Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415; van Baarsen K, 2018, J NEUROSURG, V129, P1407, DOI 10.3171/2017.8.JNS163085; van Donkelaar CE, 2016, CRIT CARE MED, V44, P966, DOI 10.1097/CCM.0000000000001569; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vellimana AK, 2020, EXP NEUROL, V334, DOI 10.1016/j.expneurol.2020.113484; Vellimana AK, 2018, NEUROSURGERY, V65, P1, DOI 10.1093/neuros/nyy201; Vikman P, 2007, J NEUROSURG, V107, P1015, DOI 10.3171/JNS-07/11/1015; Wagner KR, 2004, ANN NY ACAD SCI, V1012, P237, DOI 10.1196/annals.1306.020; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wahdan SA, 2019, N-S ARCH PHARMACOL, V392, P1331, DOI 10.1007/s00210-019-01673-8; Wan H, 2014, EXPERT OPIN PHARMACO, V15, P231, DOI 10.1517/14656566.2014.865724; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang J, 2008, NEUROSCIENCE, V155, P1133, DOI 10.1016/j.neuroscience.2008.07.004; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang JK, 2021, EXP BRAIN RES, V239, P2193, DOI 10.1007/s00221-021-06111-x; Wang L, 2020, NEUROSCIENCE, V441, P46, DOI 10.1016/j.neuroscience.2020.05.054; Wang Y, 2016, BRIT J ANAESTH, V116, P384, DOI 10.1093/bja/aev549; Wang Y, 2020, NEUROSCI LETT, V736, DOI 10.1016/j.neulet.2020.135250; Wang Z, 2010, ANN CLIN LAB SCI, V40, P233; Wei Boyang, 2022, Front Cell Neurosci, V16, P899484, DOI 10.3389/fncel.2022.899484; Wei SW, 2017, EXP CELL RES, V361, P342, DOI 10.1016/j.yexcr.2017.11.002; Wei Y, 2011, ANN NEUROL, V69, P119, DOI 10.1002/ana.22186; Wei YJ, 2017, CELL, V168, P224, DOI 10.1016/j.cell.2016.11.042; Weichhart T, 2015, NAT REV IMMUNOL, V15, P599, DOI 10.1038/nri3901; Weinstock MJ, 2016, THROMB RES, V140, pS60, DOI 10.1016/S0049-3848(16)30100-1; Wen J, 2018, EUR REV MED PHARMACO, V22, P2817, DOI 10.26355/eurrev_201805_14981; Wolf J, 2016, J BIOL CHEM, V291, P16186, DOI 10.1074/jbc.M116.718551; Wu C, 2013, BIOCHEM BIOPH RES CO, V437, P469, DOI 10.1016/j.bbrc.2013.06.107; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Wu XF, 2010, BIOCHEM BIOPH RES CO, V393, P514, DOI 10.1016/j.bbrc.2010.02.038; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xian XD, 2017, ELIFE, V6, DOI 10.75549/eLife.29292; Xie Y, 2017, BRAIN BEHAV IMMUN, V60, P346, DOI 10.1016/j.bbi.2016.11.004; Xie ZY, 2018, NEUROPHARMACOLOGY, V128, P142, DOI 10.1016/j.neuropharm.2017.09.040; Xiong XY, 2016, PROG NEUROBIOL, V142, P23, DOI 10.1016/j.pneurobio.2016.05.001; Xu HZ, 2017, BRAIN BEHAV IMMUN, V65, P125, DOI 10.1016/j.bbi.2017.04.020; Xu HL, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0234-7; Xu K, 2014, BBA-REV CANCER, V1846, P638, DOI 10.1016/j.bbcan.2014.10.007; Xu PF, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02226-8; Xu W, 2016, AM J TRANSL RES, V8, P2114; Xu XJ, 2018, INFLAMM RES, V67, P57, DOI 10.1007/s00011-017-1095-6; Xu ZJ, 2022, BIOENGINEERED, V13, P4235, DOI 10.1080/21655979.2022.2027175; Xue H, 2012, PULM PHARMACOL THER, V25, P208, DOI 10.1016/j.pupt.2012.02.006; Yamaguchi Tadashi, 2022, J Neurosurg, P1, DOI 10.3171/2022.4.JNS212945; Yamamoto S, 2019, BRAIN RES BULL, V144, P85, DOI 10.1016/j.brainresbull.2018.11.015; Yang L, 2020, NEUROSCI LETT, V735, DOI 10.1016/j.neulet.2020.135227; Yang SJ, 2018, CELL MOL NEUROBIOL, V38, P595, DOI 10.1007/s10571-017-0526-9; Yang S, 2018, MED SCI MONITOR, V24, P3804, DOI 10.12659/MSM.907734; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yasuno K, 2010, NAT GENET, V42, P420, DOI 10.1038/ng.563; Yin DP, 2018, BRAIN RES, V1698, P1, DOI 10.1016/j.brainres.2018.05.040; Yin J, 2016, INT J BIOCHEM CELL B, V75, P11, DOI 10.1016/j.biocel.2016.03.008; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Yu ZW, 2015, J NEUROSCI, V35, P6350, DOI 10.1523/JNEUROSCI.2468-14.2015; Yuan B, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/9069825; Zhan CP, 2021, CLIN CHIM ACTA, V513, P1, DOI 10.1016/j.cca.2020.12.006; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhang J, 2015, MOL NEUROBIOL, V52, P1527, DOI 10.1007/s12035-014-8939-7; Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011; Zhang LF, 2021, J NEUROCHEM, V158, P880, DOI 10.1111/jnc.15457; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang TY, 2019, EXP NEUROL, V317, P1, DOI 10.1016/j.expneurol.2019.02.009; Zhang TY, 2018, CELL MOL NEUROBIOL, V38, P1413, DOI 10.1007/s10571-018-0608-3; Zhang WG, 2012, EXP NEUROL, V233, P799, DOI 10.1016/j.expneurol.2011.11.046; Zhang XH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01073; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292; Zhang XS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081331; Zhang XS, 2018, FREE RADICAL BIO MED, V124, P504, DOI 10.1016/j.freeradbiomed.2018.06.035; Zhang YM, 2017, BRIT J PHARMACOL, V174, P2512, DOI 10.1111/bph.13862; Zhang ZY, 2021, EXP NEUROL, V336, DOI 10.1016/j.expneurol.2020.113535; Zhang ZH, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160100; Zhao CY, 2018, MAT SCI ENG C-MATER, V92, P1031, DOI 10.1016/j.msec.2018.02.004; Zhao L, 2017, MOL NEUROBIOL, V54, P1612, DOI 10.1007/s12035-016-9776-7; Zhao M, 2017, J NEUROL SCI, V381, P25, DOI 10.1016/j.jns.2017.08.011; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2007, J NEUROCHEM, V101, P652, DOI 10.1111/j.1471-4159.2006.04414.x; Zheng VZY, 2017, J CLIN NEUROSCI, V42, P7, DOI 10.1016/j.jocn.2017.02.001; Zheng ZV, 2022, STROKE VASC NEUROL, V7, P62, DOI 10.1136/svn-2021-001028; Zhong WY, 2017, TURK NEUROSURG, V27, P346, DOI 10.5137/1019-5149.JTN.16193-15.1; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831; Zhou SR, 2018, STROKE, V49, P780, DOI 10.1161/STROKEAHA.117.018152; Zhou XM, 2014, J NEUROSCI RES, V92, P714, DOI 10.1002/jnr.23359; Zhou YL, 2011, ACTA NEUROCHIR SUPPL, V110, P15, DOI 10.1007/978-3-7091-0353-1_3; Zhou Y, 2017, WORLD NEUROSURG, V108, P206, DOI 10.1016/j.wneu.2017.08.091; Zhu QQ, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1211-8; Ziai WC, 2019, CRIT CARE MED, V47, P1125, DOI 10.1097/CCM.0000000000003848; Ziai WC, 2013, STROKE, V44, pS74, DOI 10.1161/STROKEAHA.111.000662; Zolnourian A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6218239; Zuiderwijk-Sick EA, 2007, GLIA, V55, P1589, DOI 10.1002/glia.20572	344	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1027756	10.3389/fimmu.2022.1027756	http://dx.doi.org/10.3389/fimmu.2022.1027756			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2NX	36505409	gold, Green Published			2022-12-18	WOS:000894207000001
J	Lin, J; Liu, J; Hao, SG; Lan, B; Zheng, XB; Xiong, JN; Zhang, YQ; Gao, X; Chen, CB; Chen, L; Huang, YF; Luo, H; Yi, YT; Yi, X; Lu, JP; Zheng, XW; Chen, G; Wang, XF; Chen, Y				Lin, Jing; Liu, Jun; Hao, Shi-guang; Lan, Bin; Zheng, Xiao-bin; Xiong, Jia-ni; Zhang, Ying-qian; Gao, Xuan; Chen, Chuan-ben; Chen, Ling; Huang, Yu-fang; Luo, Hong; Yi, Yu-ting; Yi, Xin; Lu, Jian-ping; Zheng, Xiong-wei; Chen, Gang; Wang, Xue-feng; Chen, Yu			An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy	FRONTIERS IN IMMUNOLOGY			English	Article						EGFR L858R mutation; neoantigen vaccine; HLA A*33; 03; immunological features; Chinese NSCLC	IMMUNE ESCAPE; CHECKPOINT INHIBITORS; TUMOR-CELLS; CANCER; EXPRESSION; ACTIVATION; DOCETAXEL; NIVOLUMAB; BLOCKADE; TAP	BackgroundThis study aimed to develop a vaccine that targets mutation-derived neoantigen in Chinese non-small-cell lung cancer (NSCLC). MethodsA cohort of 1862 Chinese NSCLC patients who underwent targeted sequencing with a 1021-gene panel was investigated. HLA typing was done using OptiType v1.0 and neoantigens were predicted by netMHCpan v4.0. HLA LOH was inferred using the lohhla algorithm and TMB were quantified by counting the total number of non-synonymous ones based on our panel data. CIBERSORT was utilized to estimate the TME in different EGFR mutant subtype by using TCGA data. ResultsHLA-A*11:01(42.59%) was the top one allele and HLA-A*33:03(12.94%) ranked 12th. EGFR L858R (22.61%) was the most prevalent gene variant. The binding affinity (IC50 MT = 22.9 nM) and shared frequency (2.93%) of EGFR L858R in combination with HLA-A*33:03 were optimal. In a subsequent further analysis on immunological features of EGFR mutant subtypes, 63.1% HLA loss of heterozygosity LOH (HLA LOH) and 0.37% (7 of 1862) B2M aberrations were found in our population, both had no significant association with EGFR mutant subtypes suggesting that the process of antigen presentation involved HLA LOH and B2M mechanisms in EGFR L858R is working. Tumor mutation burden (TMB) was investigated by utilizing our panel and showed that EGFR L858R had the lowest TMB compared with other EGFR mutant subtypes. In addition, analysis of 22 immune cell types from The Cancer Genome Atlas (TCGA) data showed EGFR L858R was correlated with low level of CD8 T cells, activated CD4 memory T cells and elevated level of macrophage M2 suggesting an inhibited tumor microenvironment (TME). ConclusionOur study identified that EGFR L858R neoantigen had the potential to generate cancer vaccines in NSCLC patients with HLA A*33:03. The neoantigen-based vaccines may become an effective salvage regimen for EGFR L858R subgroup after targeted therapy or immune checkpoint inhibitors (ICIs) failure.	[Lin, Jing; Liu, Jun; Lan, Bin; Xiong, Jia-ni; Chen, Ling; Huang, Yu-fang; Luo, Hong; Wang, Xue-feng; Chen, Yu] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China; [Lin, Jing; Liu, Jun; Xiong, Jia-ni; Chen, Chuan-ben; Chen, Ling; Huang, Yu-fang; Luo, Hong; Lu, Jian-ping; Zheng, Xiong-wei; Chen, Gang; Chen, Yu] Fujian Med Univ, Fujian Canc Hosp, Canc Bioimmunotherapy Ctr, Clin Oncol Sch, Fuzhou, Peoples R China; [Hao, Shi-guang; Zhang, Ying-qian; Yi, Yu-ting; Yi, Xin] Geneplus Beijing Inst, Beijing, Peoples R China; [Lan, Bin; Zheng, Xiao-bin; Wang, Xue-feng] Fujian Med Univ, Fujian Canc Hosp, Fujian Prov Key Lab Tumor Biotherapy, Clin Oncol Sch, Fuzhou, Peoples R China; [Gao, Xuan] Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing, Peoples R China; [Gao, Xuan] GenePlus Shenzhen Clin Lab, Dept Translat Med, Shenzhen, Peoples R China; [Chen, Chuan-ben] Fujian Med Univ, Fujian Canc Hosp, Dept Radiat Oncol, Clin Oncol Sch, Fuzhou, Peoples R China; [Lu, Jian-ping; Zheng, Xiong-wei; Chen, Gang] Fujian Med Univ, Fujian Canc Hosp, Dept Pathol, Clin Oncol Sch, Fuzhou, Peoples R China; [Wang, Xue-feng] Soochow Univ, Affiliated Hosp 3, Inst Translat Med, Suzhou, Peoples R China	Fujian Medical University; Fujian Medical University; Fujian Medical University; Chinese Academy of Sciences; Institute of Microbiology, CAS; Fujian Medical University; Fujian Medical University; Soochow University - China	Wang, XF; Chen, Y (corresponding author), Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China.; Chen, Y (corresponding author), Fujian Med Univ, Fujian Canc Hosp, Canc Bioimmunotherapy Ctr, Clin Oncol Sch, Fuzhou, Peoples R China.; Wang, XF (corresponding author), Fujian Med Univ, Fujian Canc Hosp, Fujian Prov Key Lab Tumor Biotherapy, Clin Oncol Sch, Fuzhou, Peoples R China.; Wang, XF (corresponding author), Soochow Univ, Affiliated Hosp 3, Inst Translat Med, Suzhou, Peoples R China.	wangxuefeng2019@foxmail.com; cheyu1980@fjmu.edu.cn			Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy [2020Y2012]; National Natural Science Foundation of China [U1705282, 32000550]; Joint Funds for the Innovation of Science and Technology, Fujian province [2021Y9227]; Startup Fund for scientific research, Fujian Medical University [2019QH1200]	Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Joint Funds for the Innovation of Science and Technology, Fujian province; Startup Fund for scientific research, Fujian Medical University	The work was supported by Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy (Grant No. 2020Y2012), the National Natural Science Foundation of China (Grant No. U1705282, 32000550), Joint Funds for the Innovation of Science and Technology, Fujian province (Grant No. 2021Y9227) and Startup Fund for scientific research, Fujian Medical University (Grant No. 2019QH1200).	Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Chan TA, 2015, NEW ENGL J MED, V373, P1984, DOI 10.1056/NEJMc1508163; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; El Hage F, 2013, ANN NY ACAD SCI, V1283, P75, DOI 10.1111/j.1749-6632.2012.06777.x; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166; Gou LY, 2014, LUNG CANCER-TARGETS, V5, P1, DOI 10.2147/LCTT.S40817; Han JF, 2020, CANCER IMMUNOL RES, V8, P146, DOI 10.1158/2326-6066.CIR-19-0398; Hartmaier RJ, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0408-2; Hastings K, 2019, ANN ONCOL, V30, P1311, DOI 10.1093/annonc/mdz141; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hulpke S, 2013, TRENDS BIOCHEM SCI, V38, P412, DOI 10.1016/j.tibs.2013.06.003; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Leisegang M, 2016, CLIN CANCER RES, V22, P2734, DOI 10.1158/1078-0432.CCR-15-2361; Liang WH, 2019, CANCER SCI, V110, P2014, DOI 10.1111/cas.14032; Litchfield K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17526-5; Lu YC, 2016, SEMIN IMMUNOL, V28, P22, DOI 10.1016/j.smim.2015.11.002; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Matsushita H, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1338996; Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167; McGranahan N, 2017, CELL, V171, P1259, DOI 10.1016/j.cell.2017.10.001; Mhanna L, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.5_suppl.172; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Offin M, 2019, CLIN CANCER RES, V25, P1063, DOI 10.1158/1078-0432.CCR-18-1102; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Perea F, 2017, INT J CANCER, V140, P888, DOI 10.1002/ijc.30489; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reuben A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14273-0; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Sharma GG, 2018, CANCERS, V10, DOI 10.3390/cancers10030062; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Stinchcombe TE, 2016, CLIN LUNG CANCER, V17, P1, DOI 10.1016/j.cllc.2015.07.002; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Wang YT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00536; Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1; Yang HT, 2017, ONCOTARGET, V8, P23517, DOI 10.18632/oncotarget.15627; Zhang XC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09762-1	52	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1022598	10.3389/fimmu.2022.1022598	http://dx.doi.org/10.3389/fimmu.2022.1022598			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2YC	36505399	Green Published, gold			2022-12-18	WOS:000894233900001
J	Luo, ZQ; Hao, SY; Li, YX; Cheng, L; Zhou, XD; Gunes, EG; Liu, SY; Chen, J				Luo, Zhiqiang; Hao, Siyuan; Li, Yuxuan; Cheng, Lei; Zhou, Xuedong; Gunes, Emine Gulsen; Liu, Shiyu; Chen, Jing			The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis	FRONTIERS IN IMMUNOLOGY			English	Review						carcinoma; renal cell; antibiotics; immunotherapy; immune checkpoint inhibitors; meta-analysis	RENAL-CELL CARCINOMA; NIVOLUMAB; EFFICACY; IMPACT	Background: Microbiome dysbiosis is considered a predictive biomarker of clinical response in renal cell carcinoma (RCC), which can be regulated by antibiotics (ATB). Multiple studies have shown that concomitant ATB administration has inhibitory effects on immunotherapy in RCC. This review aimed to assess the impact of ATB on patient survival and tumor response in RCC with immunotherapy. Methods: Literature evaluating the effect of ATB on immunotherapy in RCC from Cochrane Ubrary (R), PubMed (R), Embase (R), Scopus (R), and Web of Science (R) were systematically searched. Hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for objective response rate (ORR) and primary progressive disease (PD) were pooled as effect sizes for clinical outcomes. Subgroup analysis was conducted to reveal the determinants of the effect of ATB on immunotherapy, including time windows of ATB exposure to immunotherapy initiation, ICIs treatment and study location. The leave-one-out approach was adopted to analyze the heterogeneity formulated. Cumulative meta-analysis adding by time was used to observe dynamic changes of the results. Results: Ten studies were included in the systematic review and six studies (with n=1,104 patients) were included in the meta-analysis, four studies were excluded for overlapping patients with subsequent larger studies and lack of unique patient-level data. ATB administration was significantly correlated with shorter PFS (HR=2.10, 95%CI [1.54; 2.85], I-2 = 2% after omitting study Derosa et al, 2021 detected by leave-one-out approach), shorter OS (HR=1.69, 95%CI [1.34; 2.12], I-2 = 25%) and worse ORR (OR=0.58, 95%CI [0.41; 0.84]), but no difference was observed in risk of PD (OR=1.18, 95%CI [0.97; 1.44]). No significant differences existed among the subgroups for determining the determinants of ATB inhibition. Conclusions: Concomitant ATB with immunotherapy was associated with worse PFS, OS and ORR in RCC. No publication bias was observed in this study.	[Luo, Zhiqiang; Hao, Siyuan; Cheng, Lei; Zhou, Xuedong; Chen, Jing] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Natl Clin Res Oral Dis, Chengdu, Peoples R China; [Li, Yuxuan] Dalian Med Univ, Sch Stomatol, Dalian, Peoples R China; [Cheng, Lei; Zhou, Xuedong; Chen, Jing] Sichuan Univ, West China Hosp Stomatol, Dept Operat Dent & Endodont, Chengdu, Peoples R China; [Gunes, Emine Gulsen] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Duarte, CA USA; [Liu, Shiyu] Zhejiang Univ, Canc Ctr, Stomatol Hosp, Sch Med,Sch Stomatol,Zhejiang Prov Clin Res Ctr Or, Hangzhou, Peoples R China	Sichuan University; Dalian Medical University; Sichuan University; City of Hope; Zhejiang University	Chen, J (corresponding author), Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Natl Clin Res Oral Dis, Chengdu, Peoples R China.; Chen, J (corresponding author), Sichuan Univ, West China Hosp Stomatol, Dept Operat Dent & Endodont, Chengdu, Peoples R China.; Liu, SY (corresponding author), Zhejiang Univ, Canc Ctr, Stomatol Hosp, Sch Med,Sch Stomatol,Zhejiang Prov Clin Res Ctr Or, Hangzhou, Peoples R China.	1203383220@qq.com; jinchen@scu.edu.cn			West China School/Hospital of Stomatology Sichuan University [RCDWJS2022-5]; fellowship of China Postdoctoral Science Foundation [2022M712239]	West China School/Hospital of Stomatology Sichuan University; fellowship of China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the Research Funding from West China School/Hospital of Stomatology Sichuan University, No. RCDWJS2022-5 (to JC), and the fellowship of China Postdoctoral Science Foundation 2022M712239 (to JC).	Adil M, 2018, CURR DRUG METAB, V19, P902, DOI 10.2174/1389200219666180329124130; Chambers LM, 2021, GYNECOL ONCOL, V161, P211, DOI 10.1016/j.ygyno.2021.01.015; Deluce J, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221122714; Derosa L, 2021, ANN ONCOL, V32, pS681, DOI 10.1016/j.annonc.2021.08.053; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Derosa L, 2020, EUR UROL, V78, P195, DOI 10.1016/j.eururo.2020.04.044; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elkrief A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1568812; Guven DC, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2021.100760; Iacovelli R, 2018, CANCER TREAT REV, V70, P112, DOI 10.1016/j.ctrv.2018.08.007; Jiang S, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.823705; Kato T, 2022, INT J CLIN ONCOL, V27, P1596, DOI 10.1007/s10147-022-02215-8; Kim SH, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00859; Kulkarni A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e20520; Kulkarni AA, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000803; Labadie BW, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02144-7; Lalani AKA, 2020, EUR UROL ONCOL, V3, P372, DOI 10.1016/j.euo.2019.09.001; Lurienne L, 2020, J THORAC ONCOL, V15, P1147, DOI 10.1016/j.jtho.2020.03.002; Martini A, 2021, WORLD J UROL, V39, P1369, DOI 10.1007/s00345-020-03550-z; Mollica V, 2022, TARGET ONCOL, V17, P61, DOI 10.1007/s11523-021-00861-y; Moscetti L, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000856; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Oh B, 2021, CANCERS, V13, DOI 10.3390/cancers13194824; Peters BA, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0672-4; Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1; PRISMA, 2022, PRISMA; RCore Team, 2022, R LANG ENV STAT COMP; Rini BI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0813-8; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Roviello G, 2022, PHARMACOL THERAPEUT, V231, DOI 10.1016/j.pharmthera.2021.107973; Salgia NJ, 2020, EUR UROL, V78, P498, DOI 10.1016/j.eururo.2020.07.011; Santoni M, 2022, TARGET ONCOL, V17, P571, DOI 10.1007/s11523-022-00907-9; Santoni M, 2022, EUR J CANCER, V172, P191, DOI 10.1016/j.ejca.2022.04.035; Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.1007/978-3-319-21416-0; Sidik K, 2005, J R STAT SOC C-APPL, V54, P367, DOI 10.1111/j.1467-9876.2005.00489.x; Singh D, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118632; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Su SC, 2021, CARCINOGENESIS, V42, P127, DOI 10.1093/carcin/bgaa062; Swami U, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9110740; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Tsikala-Vafea M, 2021, INT J INFECT DIS, V106, P142, DOI 10.1016/j.ijid.2021.03.063; Ueda K, 2019, ANTICANCER RES, V39, P6265, DOI 10.21873/anticanres.13836; Wang L, 2015, INT UROL NEPHROL, V47, P617, DOI 10.1007/s11255-015-0932-1; Wei W, 2022, MOL IMMUNOL, V149, P94, DOI 10.1016/j.molimm.2022.06.013; Wilson BE, 2020, CANCER IMMUNOL IMMUN, V69, P343, DOI 10.1007/s00262-019-02453-2; Xu HL, 2020, CRIT REV ONCOL HEMAT, V149, DOI 10.1016/j.critrevonc.2020.102909; Yang MX, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106876; Yin JY, 2022, CLIN GENITOURIN CANC, V20, P260, DOI 10.1016/j.clgc.2022.01.017; Zhou JX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.968729	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1065004	10.3389/fimmu.2022.1065004	http://dx.doi.org/10.3389/fimmu.2022.1065004			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T1YY	36505435	Green Published, gold			2022-12-18	WOS:000893478600001
J	Neidemire-Colley, L; Robert, J; Ackaoui, A; Dorrance, AM; Guimond, M; Ranganathan, P				Neidemire-Colley, Lotus; Robert, Jeremy; Ackaoui, Antoine; Dorrance, Adrienne. M. M.; Guimond, Martin; Ranganathan, Parvathi			Role of endothelial cells in graft-versus-host disease	FRONTIERS IN IMMUNOLOGY			English	Review						endothelial cell; endotheial dysfunction; GvHD; inflammation; integrins; selectins	BONE-MARROW-TRANSPLANTATION; VON-WILLEBRAND-FACTOR; DAMAGE-RELATED COMPLICATIONS; STRESS INDEX EASIX; CD8(+) T-CELLS; ACUTE GVHD; TRANSENDOTHELIAL MIGRATION; VASCULAR ENDOTHELIUM; ADHESION MOLECULES; BETA(2) INTEGRINS	To date, the only curative treatment for high-risk or refractory hematologic malignancies non-responsive to standard chemotherapy is allogeneic hematopoietic transplantation (allo-HCT). Acute graft-versus-host disease (GVHD) is a donor T cell-mediated immunological disorder that is frequently fatal and the leading cause of non-relapse mortality (NRM) in patients post allo-HCT. The pathogenesis of acute GVHD involves recognition of minor and/or major HLA mismatched host antigens by donor T cells followed by expansion, migration and finally end-organ damage due to combination of inflammatory cytokine secretion and direct cytotoxic effects. The endothelium is a thin layer of endothelial cells (EC) that line the innermost portion of the blood vessels and a key regulator in vascular homeostasis and inflammatory responses. Endothelial cells are activated by a wide range of inflammatory mediators including bacterial products, contents released from dying/apoptotic cells and cytokines and respond by secreting cytokines/chemokines that facilitate the recruitment of innate and adaptive immune cells to the site of inflammation. Endothelial cells can also be damaged prior to transplant as well as by alloreactive donor T cells. Prolonged EC activation results in dysfunction that plays a role in multiple post-transplant complications including but not limited to veno-occlusive disease (VOD), transplant associated thrombotic microangiopathy (TA-TMA), and idiopathic pneumonia syndrome. In this mini review, we summarize the biology of endothelial cells, factors regulating EC activation and the role of ECs in inflammation and GVHD pathogenesis.	[Neidemire-Colley, Lotus] Ohio State Univ, Biomed Sci Grad Program, Columbus, OH USA; [Neidemire-Colley, Lotus; Dorrance, Adrienne. M. M.; Ranganathan, Parvathi] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA; [Robert, Jeremy; Ackaoui, Antoine] Univ Montreal, Dept Microbiol, Infectiol & Immunol, Montreal, PQ, Canada; [Dorrance, Adrienne. M. M.; Ranganathan, Parvathi] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Guimond, Martin] Coll Bois Boulogne, Montreal, PQ, Canada	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Universite de Montreal; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ranganathan, P (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.; Ranganathan, P (corresponding author), Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA.	parvathi.ranganathan@osumc.edu			NIH [R01CA252469PR, RSG RSG-22-053-01-IBCD]; American Cancer Society [R01HL163849]; Cancer Research Society of Canada [24380]; Cancer Research Society; Leukemia Lymphoma Society of Canada [840026]; Andy & Lena Chabot Cancer Research Society Studentship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Cancer Research Society of Canada; Cancer Research Society; Leukemia Lymphoma Society of Canada; Andy & Lena Chabot Cancer Research Society Studentship	This work was supported by grants from NIH R01CA252469PR, American Cancer Society RSG RSG-22-053-01-IBCD (PR), NIH R01HL163849 (PR and AD), the American Cancer SocietyRSG-18-170-01-LIB (AD), the Cancer Research Society of Canada 24380 (MG), and Cancer Research Society and the Leukemia Lymphoma Society of Canada 840026 (MG). AA has received the Andy & Lena Chabot Cancer Research Society Studentship.	Abadier M, 2017, CELL REP, V21, P3885, DOI 10.1016/j.celrep.2017.11.099; Ali AJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00492; Alon R, 2009, MICROCIRCULATION, V16, P3, DOI 10.1080/10739680802026076; Apostolova P, 2016, HUM IMMUNOL, V77, P1037, DOI 10.1016/j.humimm.2016.02.005; Baaten BJG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00023; Bauer HC, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00392; Bhagwani A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00352; Biedermann BC, 2002, LANCET, V359, P2078, DOI 10.1016/S0140-6736(02)08907-9; Bunting M, 2002, CURR OPIN HEMATOL, V9, P30, DOI 10.1097/00062752-200201000-00006; Campbell ID, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004994; Chao CC, 1997, J IMMUNOL, V159, P1686; Cong X, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109485; Cooke KR., 2019, CHAPTER 18 CHEMOKINE, V2nd, P323; Cordes S, 2021, HAEMATOLOGICA, V106, P2147, DOI 10.3324/haematol.2020.253716; Cutler C, 2014, BLOOD, V124, P1372, DOI 10.1182/blood-2014-04-567164; Cutler C, 2010, BIOL BLOOD MARROW TR, V16, P1180, DOI 10.1016/j.bbmt.2010.02.016; Dai H, 2021, BONE MARROW TRANSPL, V56, P1573, DOI 10.1038/s41409-020-01186-6; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dietrich S, 2013, BIOL BLOOD MARROW TR, V19, P22, DOI 10.1016/j.bbmt.2012.09.018; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Dorrance AM, 2022, BLOOD ADV, V6, P2403, DOI [10.1182/bloodadvances.2021005498., 10.1182/bloodadvances.2021005498]; Duong CN, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00519; Eyrich M, 2005, BIOL BLOOD MARROW TR, V11, P371, DOI 10.1016/j.bbmt.2005.02.002; Federici AB., 2003, HAEMATOLOGICA, V88, pEREP02; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Filippi MD, 2016, ADV IMMUNOL, V129, P25, DOI 10.1016/bs.ai.2015.09.001; Fuke S, 2007, CIRC J, V71, P220, DOI 10.1253/circj.71.220; Gergoudis SC, 2020, BLOOD ADV, V4, P6098, DOI 10.1182/bloodadvances.2020003336; Giannoni L, 2020, BIOL BLOOD MARROW TR, V26, P1620, DOI 10.1016/j.bbmt.2020.05.014; Go SI, 2022, CANCER BIOMARK, V35, P217, DOI 10.3233/CBM-220032; Graham GJ, 2019, TRENDS IMMUNOL, V40, P472, DOI 10.1016/j.it.2019.03.009; Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962; Harjunpaa H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01078; Heidegger S, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00337; Hidalgo A, 2007, IMMUNITY, V26, P477, DOI 10.1016/j.immuni.2007.03.011; Hill GR, 2020, BLOOD, V136, P418, DOI 10.1182/blood.2019000952; Holtan SG., 2019, CHAPTER 21 ENDOTHELI, V2nd, P401; Hoskova L, 2017, PHYSIOL RES, V66, P167, DOI 10.33549/physiolres.933332; Jambusaria A, 2020, ELIFE, V9, DOI 10.7554/eLife.51413; Jeanmart H, 2002, J HEART LUNG TRANSPL, V21, P990, DOI 10.1016/S1053-2498(02)00429-1; Kappelmayer J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/6138145; Khakpour S, 2015, INNATE IMMUN-LONDON, V21, P827, DOI 10.1177/1753425915606525; Kim S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00722; Kong XH, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135468; Kornblit B, 2017, BONE MARROW TRANSPL, V52, P499, DOI 10.1038/bmt.2016.263; Kreisel D, 2002, NAT MED, V8, P233, DOI 10.1038/nm0302-233; Lelas A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676756; Lenting PJ, 2012, J THROMB HAEMOST, V10, P2428, DOI 10.1111/jth.12008; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liang Y, 2008, BLOOD, V111, P954, DOI 10.1182/blood-2007-05-089573; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Lockett AD, 2013, AM J RESP CELL MOL, V49, P143, DOI 10.1165/rcmb.2012-0515OC; Lu SX, 2010, J IMMUNOL, V185, P1912, DOI 10.4049/jimmunol.0903148; Luft T, 2020, BONE MARROW TRANSPL, V55, P553, DOI 10.1038/s41409-019-0703-1; Luft T, 2011, BLOOD, V118, P1685, DOI 10.1182/blood-2011-02-334821; Magenau JM, 2018, BLOOD, V131, P1372, DOI 10.1182/blood-2017-11-815746; Manes TD, 2008, J IMMUNOL, V180, P8386, DOI 10.4049/jimmunol.180.12.8386; Mannucci PM, 1998, ARTERIOSCL THROM VAS, V18, P1359, DOI 10.1161/01.ATV.18.9.1359; Marcondes AM, 2016, BIOL BLOOD MARROW TR, V22, P1596, DOI 10.1016/j.bbmt.2016.05.011; Martinez-Sanchez J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02339; Matsuda Y, 2001, BONE MARROW TRANSPL, V27, P977, DOI 10.1038/sj.bmt.1703026; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Merz A, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0247-z; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Milone G, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030623; Mir E, 2017, BONE MARROW TRANSPL, V52, P1317, DOI 10.1038/bmt.2017.121; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Muller WA, 2009, CIRC RES, V105, P223, DOI 10.1161/CIRCRESAHA.109.200717; Mysore V, 2022, J EXP MED, V219, DOI 10.1084/jem.20210562; Naserian S, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00564-3; Newell LF, 2020, BIOL BLOOD MARROW TR, V26, P606, DOI 10.1016/j.bbmt.2019.11.006; Nie DM, 2015, J HUAZHONG U SCI-MED, V35, P694, DOI 10.1007/s11596-015-1492-4; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Nomura S, 2017, TRANSPL IMMUNOL, V43-44, P27, DOI 10.1016/j.trim.2017.06.004; Palomo M, 2010, BIOL BLOOD MARROW TR, V16, P985, DOI 10.1016/j.bbmt.2010.02.008; Pinte S, 2016, J BIOL CHEM, V291, P24017, DOI 10.1074/jbc.M116.731331; Ramgolam Vinod S, 2011, J Signal Transduct, V2011, P635721, DOI 10.1155/2011/635721; Ribatti D, 2002, J HEMATOTH STEM CELL, V11, P81, DOI 10.1089/152581602753448559; Richardson PG, 2021, BONE MARROW TRANSPL, V56, P2889, DOI 10.1038/s41409-021-01383-x; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Rotz SJ, 2017, NEW ENGL J MED, V376, P1189, DOI 10.1056/NEJMc1700185; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Salat C, 1997, BONE MARROW TRANSPL, V19, P909, DOI 10.1038/sj.bmt.1700767; Schillemans M, 2019, J THROMB HAEMOST, V17, P6, DOI 10.1111/jth.14322; SHEN N, 1994, EUR J HAEMATOL, V52, P296; Sumransub N, 2022, BLOOD REV, V51, DOI 10.1016/j.blre.2021.100883; TANAKA T, 1995, INT IMMUNOL, V7, P1183, DOI 10.1093/intimm/7.8.1183; Tatekawa S, 2016, BIOL BLOOD MARROW TR, V22, P1573, DOI 10.1016/j.bbmt.2016.05.018; Tawara I, 2012, P NATL ACAD SCI USA, V109, P564, DOI 10.1073/pnas.1117665109; Tichelli A, 2008, BEST PRACT RES CL HA, V21, P139, DOI 10.1016/j.beha.2008.02.002; Toubai T, 2020, BLOOD, V136, P429, DOI 10.1182/blood.2019000953; Toubai T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00539; Toubai T, 2014, BLOOD, V123, P3512, DOI 10.1182/blood-2013-12-545335; Ueda N, 2014, BIOL BLOOD MARROW TR, V20, P1335, DOI 10.1016/j.bbmt.2014.04.030; Vander Lugt MT, 2013, NEW ENGL J MED, V369, P529, DOI 10.1056/NEJMoa1213299; Varma A, 2020, BIOL BLOOD MARROW TR, V26, P1013, DOI 10.1016/j.bbmt.2020.01.028; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908; Voisin MB, 2013, J INNATE IMMUN, V5, P336, DOI 10.1159/000346659; Wettschureck N, 2019, PHYSIOL REV, V99, P1467, DOI 10.1152/physrev.00037.2018; Wysocki CA, 2005, BLOOD, V105, P4191, DOI 10.1182/blood-2004-12-4726; Zeng L, 2010, TRANSPL P, V42, P2720, DOI 10.1016/j.transproceed.2010.04.024; Zihni C, 2016, NAT REV MOL CELL BIO, V17, P564, DOI 10.1038/nrm.2016.80	103	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1033490	10.3389/fimmu.2022.1033490	http://dx.doi.org/10.3389/fimmu.2022.1033490			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2XY	36505438	gold, Green Published			2022-12-18	WOS:000894233500001
J	Niizato, D; Isoda, T; Mitsuiki, N; Kaneko, S; Tomomasa, D; Kamiya, T; Takagi, M; Imai, K; Kajiwara, M; Shimizu, M; Morio, T; Kanegane, H				Niizato, Daiki; Isoda, Takeshi; Mitsuiki, Noriko; Kaneko, Shuya; Tomomasa, Dan; Kamiya, Takahiro; Takagi, Masatoshi; Imai, Kohsuke; Kajiwara, Michiko; Shimizu, Masaki; Morio, Tomohiro; Kanegane, Hirokazu			Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3	FRONTIERS IN IMMUNOLOGY			English	Article						cytokine; familial hemophagocytic lymphohistiocytosis (FHL); HLH; hematopoietic cell transplantation (HCT); janus kinase; ruxolitinib	CHILDREN; HLH; EMAPALUMAB; DEFECTS; BLIND; GAMMA	Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and fatal autosomal recessive immune disorder characterized by uncontrolled activation of T and NK cells, macrophages, and overproduction of inflammatory cytokines. Early hematopoietic cell transplantation (HCT) is required for long-term survival. Current therapy is based on the HLH-94/2004 protocol, but is insufficient to fully control disease activity. This case report describes an infant with FHL type 3 who, despite initial therapy with dexamethasone and etoposide, showed aberrant cytokine levels, including interleukin-18 (IL-18), chemokine ligand 9 (CXCL9), soluble interleukin-2 receptor (sIL-2R), and soluble tumor necrosis factor receptor type II (sTNF-RII). The Janus kinase inhibitor ruxolitinib was therefore coadministered. The patient was treated with dose-adjusted ruxolitinib guided by cytokine profiles, and was successfully prepared for HCT. The results demonstrate the effectiveness and safety of dose-adjusted ruxolitinib as a bridging therapy for FHL, and the value of monitoring cytokine levels, especially IL-18, CXCL9, sIL-2R, and sTNF-RII, as disease-activity markers for FHL.	[Niizato, Daiki; Isoda, Takeshi; Mitsuiki, Noriko; Kaneko, Shuya; Tomomasa, Dan; Takagi, Masatoshi; Morio, Tomohiro] Tokyo Med & Dent Univ TMDU, Dept Pediat & Dev Biol, Tokyo, Japan; [Kamiya, Takahiro] Tokyo Med & Dent Univ TMDU, Dept Clin Res Ctr, Tokyo, Japan; [Imai, Kohsuke] Tokyo Med & Dent Univ TMDU, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Imai, Kohsuke] Natl Def Med Coll, Dept Pediat, Tokorozawa, Japan; [Kajiwara, Michiko] Tokyo Med & Dent Univ Hosp, Ctr Blood Transfus & Cell Therapy, Tokyo, Japan; [Shimizu, Masaki; Kanegane, Hirokazu] Tokyo Med & Dent Univ TMDU, Dept Child Hlth & Dev, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Isoda, T (corresponding author), Tokyo Med & Dent Univ TMDU, Dept Pediat & Dev Biol, Tokyo, Japan.	tisoda.ped@tmd.ac.jp			JSPS KAKENHI [21H02878]; Takeda Science Foundation; Medical and Biological Laboratories Co., Ltd (MBL)	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Medical and Biological Laboratories Co., Ltd (MBL)	This work was supported in part by JSPS KAKENHI Grant Number (21H02878) and Takeda Science Foundation to TI and by the joint research grant with Medical and Biological Laboratories Co., Ltd (MBL) to MS. KAKENHI contributed an English editing fee. KAKENHI and Takeda Science Foundation contributed open access publication fee. The Joint research grant with MBL covered the reagents for cytokine monitoring. The funder, Medical and Biological Laboratories Co., Ltd, was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.	Albeituni S, 2019, BLOOD, V134, P147, DOI 10.1182/blood.2019000761; Amirifar P, 2021, PEDIAT ALLERG IMM-UK, V32, P186, DOI 10.1111/pai.13323; Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349; Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019; Diamond T, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0269553; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Felber M, 2020, BLOOD ADV, V4, P1998, DOI 10.1182/bloodadvances.2020001748; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fischer A, 2007, CURR OPIN IMMUNOL, V19, P348, DOI 10.1016/j.coi.2007.04.006; Gadoury-Levesque V, 2020, BLOOD ADV, V4, P2578, DOI 10.1182/bloodadvances.2020001605; Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Henter JI, 2020, NEW ENGL J MED, V383, P596, DOI 10.1056/NEJMc2020754; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; Hiejima E, 2018, CLIN IMMUNOL, V191, P63, DOI 10.1016/j.clim.2018.03.012; Hoshino A, 2020, J CLIN IMMUNOL, V40, P1196, DOI 10.1007/s10875-020-00863-x; Huarte E, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.650295; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Kohli S, 2019, J PEDIAT HEMATOL ONC, V41, pE158, DOI 10.1097/MPH.0000000000001265; Lin H, 2021, BLOOD ADV, V5, P3457, DOI 10.1182/bloodadvances.2021004287; Lipton JM, 2004, NEW ENGL J MED, V351, P1120, DOI 10.1056/NEJMcpc049019; Locatelli F, 2020, NEW ENGL J MED, V382, P1811, DOI 10.1056/NEJMoa1911326; Luo ZB, 2017, CYTOKINE, V97, P80, DOI 10.1016/j.cyto.2017.03.013; Mahlaoui N, 2007, PEDIATRICS, V120, pE622, DOI 10.1542/peds.2006-3164; Marois L, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28954; Marsh RA, 2013, PEDIATR BLOOD CANCER, V60, P101, DOI 10.1002/pbc.24188; Medina-Valencia D, 2021, J CLIN IMMUNOL, V41, P1172, DOI 10.1007/s10875-021-01009-3; Menager MM, 2007, NAT IMMUNOL, V8, P257, DOI 10.1038/ni1431; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; Ramanan KM, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28071; Salit RB, 2022, BONE MARROW TRANSPL, V57, P857, DOI 10.1038/s41409-022-01649-y; Shi JG, 2011, J CLIN PHARMACOL, V51, P1644, DOI 10.1177/0091270010389469; Sieni E, 2011, J MED GENET, V48, P343, DOI 10.1136/jmg.2010.085456; Takakura M, 2019, CLIN IMMUNOL, V208, DOI 10.1016/j.clim.2019.108252; Tomizawa D, 2013, INT J HEMATOL, V98, P578, DOI 10.1007/s12185-013-1429-2; Tomomasa D, 2022, CLIN IMMUNOL, V242, DOI 10.1016/j.clim.2022.109104; Tomomasa D, 2021, CLIN CASE REP, V9, DOI 10.1002/ccr3.5242; Triebwasser MP, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29026; Vannucchi AM, 2015, NEW ENGL J MED, V372, P426, DOI 10.1056/NEJMoa1409002; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Wada T, 2013, PEDIATR BLOOD CANCER, V60, pE46, DOI 10.1002/pbc.24480; Wang JS, 2020, HAEMATOLOGICA, V105, pE210, DOI 10.3324/haematol.2019.222471; Wei A, 2020, INT J HEMATOL, V112, P568, DOI 10.1007/s12185-020-02936-4; Yang Y, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027786; Zeiser R, 2021, NEW ENGL J MED, V385, P228, DOI 10.1056/NEJMoa2033122; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zhang Q, 2022, BLOOD, V139, P3493, DOI 10.1182/blood.2021014860; Zhang Q, 2021, BMC PEDIATR, V21, DOI 10.1186/s12887-021-02720-1; Zhao YM, 2020, BONE MARROW TRANSPL, V55, P824, DOI 10.1038/s41409-019-0577-2	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								977463	10.3389/fimmu.2022.977463	http://dx.doi.org/10.3389/fimmu.2022.977463			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U1TA	36505485	Green Published, gold			2022-12-18	WOS:000894152200001
J	Nikolic, T; Suwandi, JS; Wesselius, J; Laban, S; Joosten, AM; Sonneveld, P; Mul, D; Aanstoot, HJ; Kaddis, JS; Zwaginga, JJ; Roep, BO				Nikolic, Tatjana; Suwandi, Jessica S. S.; Wesselius, Joris; Laban, Sandra; Joosten, Antoinette M. M.; Sonneveld, Petra; Mul, Dick; Aanstoot, Henk-Jan; Kaddis, John S. S.; Zwaginga, Jaap Jan; Roep, Bart O. O.			Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; islet autoimmunity; clinical trial; immune intervention therapy; immunotherapy; tolerance induction; antigen-specific therapy	IMMUNOTHERAPY; CYTOMETRY; RESPONSES; DISEASE	IntroductionRestoration of immune tolerance may halt progression of autoimmune diseases. Tolerogenic dendritic cells (tolDC) inhibit antigen-specific proinflammatory T-cells, generate antigen-specific regulatory T-cells and promote IL-10 production in-vitro, providing an appealing immunotherapy to intervene in autoimmune disease progression. MethodsA placebo-controlled, dose escalation phase 1 clinical trial in nine adult patients with long-standing type 1 diabetes (T1D) demonstrated the safety and feasibility of two (prime-boost) vaccinations with tolDC pulsed with a proinsulin peptide. Immunoregulatory effects were monitored by antigen-specific T-cell assays and flow and mass cytometry. ResultsThe tolDC vaccine induced a profound and durable decline in pre-existing autoimmune responses to the vaccine peptide up to 3 years after therapy and temporary decline in CD4 and CD8+ T-cell responses to other islet autoantigens. While major leukocyte subsets remained stable, ICOS(+)CCR4(+)TIGIT(+) Tregs and CD103(+) tissue-resident and CCR6(+) effector memory CD4(+) T-cells increased in response to the first tolDC injection, the latter declining thereafter below baseline levels. DiscussionOur data identify immune correlates of mechanistic efficacy of intradermally injected tolDC reducing proinsulin autoimmunity in T1D.	[Nikolic, Tatjana; Suwandi, Jessica S. S.; Wesselius, Joris; Laban, Sandra; Joosten, Antoinette M. M.; Sonneveld, Petra; Zwaginga, Jaap Jan; Roep, Bart O. O.] Leiden Univ Med Ctr, Dept Internal Med, Leiden, Netherlands; [Mul, Dick; Aanstoot, Henk-Jan] Diabet Ctr, Diabeter Nederland, Rotterdam, Netherlands; [Kaddis, John S. S.] Beckman Res Inst, Arthur Riggs Diabet & Metab Res Inst, Dept Diabet & Canc Discovery Sci, Duarte, CA USA	Leiden University; Leiden University Medical Center (LUMC); City of Hope; Beckman Research Institute of City of Hope	Roep, BO (corresponding author), Leiden Univ Med Ctr, Dept Internal Med, Leiden, Netherlands.	boroep@lumc.nl			European Union [2020.10.011]; Dutch Diabetes Research Foundation; Stichting DON; Wanek Family Project for Type 1 Diabetes;  [241447]	European Union(European Commission); Dutch Diabetes Research Foundation; Stichting DON; Wanek Family Project for Type 1 Diabetes; 	This work was supported by the European Union (FP7-NAIMIT, Grant 241447), the Dutch Diabetes Research Foundation and Stichting DON (grant number 2020.10.011) and the Wanek Family Project for Type 1 Diabetes.	Adeegbe DO, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00190; Ali MA, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf7779; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Atkinson MA, 2019, LANCET DIABETES ENDO, V7, P52, DOI 10.1016/S2213-8587(18)30112-8; Beringer DX, 2015, NAT IMMUNOL, V16, P1153, DOI 10.1038/ni.3271; Beyrend G, 2018, COMPUT STRUCT BIOTEC, V16, P435, DOI 10.1016/j.csbj.2018.10.004; Ferreira GB, 2012, J PROTEOME RES, V11, P941, DOI 10.1021/pr200724e; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Gibson VB, 2015, CLIN EXP IMMUNOL, V182, P251, DOI 10.1111/cei.12687; Herndler-Brandstetter D, 2005, J IMMUNOL, V175, P1566, DOI 10.4049/jimmunol.175.3.1566; Hilbrands R, 2009, DIABETES, V58, P2267, DOI 10.2337/db09-0160; Honkanen J, 2010, J IMMUNOL, V185, P1959, DOI 10.4049/jimmunol.1000788; Kleijwegt FS, 2013, EUR J IMMUNOL, V43, P85, DOI 10.1002/eji.201242879; Kleijwegt FS, 2011, J IMMUNOL, V187, P6357, DOI 10.4049/jimmunol.1101638; Klicznik MM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav8995; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Li M, 2014, J CELL MOL MED, V18, P749, DOI 10.1111/jcmm.12270; Li YY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/638470; Nikolic T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00113; Nikolic T, 2020, LANCET DIABETES ENDO, V8, P470, DOI [10.1016/S2213-8587(20)30149-2, 10.1016/S2213-8587(20)30104-2]; Peakman M, 2001, IMMUNOLOGY, V104, P361, DOI 10.1046/j.1365-2567.2001.01335.x; Potzl J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002951; Povoleri GAM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00169; Roep BO, 2019, LANCET DIABETES ENDO, V7, P65, DOI 10.1016/S2213-8587(18)30109-8; Roep BO, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006103; ROEP BO, 1995, DIABETES, V44, P278, DOI 10.2337/diabetes.44.3.278; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Solt Laura A, 2015, Diabetes Manag (Lond), V5, P247; Staeva-Vieira T, 2007, CLIN EXP IMMUNOL, V148, P17, DOI 10.1111/j.1365-2249.2007.03328.x; Suwandi JS, 2020, J AUTOIMMUN, V107, DOI 10.1016/j.jaut.2019.102361; Suwandi JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01598; Thrower SL, 2009, CLIN EXP IMMUNOL, V155, P156, DOI 10.1111/j.1365-2249.2008.03814.x; Tian J, 2009, DIABETES, V58, P1939, DOI 10.2337/db09-0451; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Tree TIM, 2010, DIABETES, V59, P1451, DOI 10.2337/db09-0503; Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103; van Halteren AGS, 2004, J AUTOIMMUN, V23, P233, DOI 10.1016/j.jaut.2004.06.004; van Megen KM, 2021, CYTOTHERAPY, V23, P242, DOI 10.1016/j.jcyt.2020.12.003; van Unen V, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01689-9; van Unen V, 2016, IMMUNITY, V44, P1227, DOI 10.1016/j.immuni.2016.04.014; Velthuis JH, 2010, DIABETES, V59, P1721, DOI 10.2337/db09-1486; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862	43	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1054968	10.3389/fimmu.2022.1054968	http://dx.doi.org/10.3389/fimmu.2022.1054968			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9TX	36505460	gold, Green Published			2022-12-18	WOS:000894016400001
J	Oganesyan, A; Gregory, A; Malard, F; Ghahramanyan, N; Mohty, M; Kazandjian, D; Mekinian, A; Hakobyan, Y; MINHEMON				Oganesyan, Artem; Gregory, Andrew; Malard, Florent; Ghahramanyan, Nerses; Mohty, Mohamad; Kazandjian, Dickran; Mekinian, Arsene; Hakobyan, Yervand; MINHEMON			Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment	FRONTIERS IN IMMUNOLOGY			English	Review						monoclonal gammopathy; monoclonal gammopathy of clinical significance; MGUS; immunotherapy; monoclonal gammopathy of undetermined significance; MGCS	VON-WILLEBRAND-SYNDROME; ONSET NEMALINE MYOPATHY; CAPILLARY LEAK SYNDROME; SUBCORNEAL PUSTULAR DERMATOSIS; INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CRYSTAL-STORING HISTIOCYTOSIS; ACQUIRED CUTIS LAXA; RECALCITRANT NECROBIOTIC XANTHOGRANULOMA; SNEDDON-WILKINSON-DISEASE; STEM-CELL TRANSPLANTATION	Monoclonal gammopathy of clinical significance (MGCS) represents a new clinical entity referring to a myriad of pathological conditions associated with the monoclonal gammopathy of undetermined significance (MGUS). The establishment of MGCS expands our current understanding of the pathophysiology of a range of diseases, in which the M protein is often found. Aside from the kidney, the three main organ systems most affected by monoclonal gammopathy include the peripheral nervous system, skin, and eye. The optimal management of these MGUS-related conditions is not known yet due to the paucity of clinical data, the rarity of some syndromes, and limited awareness among healthcare professionals. Currently, two main treatment approaches exist. The first one resembles the now-established therapeutic strategy for monoclonal gammopathy of renal significance (MGRS), in which chemotherapy with anti-myeloma agents is used to target clonal lesion that is thought to be the culprit of the complex clinical presentation. The second approach includes various systemic immunomodulatory or immunosuppressive options, including intravenous immunoglobulins, corticosteroids, or biological agents. Although some conditions of the MGCS spectrum can be effectively managed with therapies aiming at the etiology or pathogenesis of the disease, evidence regarding other pathologies is severely limited to individual patient data from case reports or series. Future research should pursue filling the gap in knowledge and finding the optimal treatment for this novel clinical category.	[Oganesyan, Artem; Hakobyan, Yervand] Natl Inst Hlth, Dept Hematol & Transfus Med, Yerevan, Armenia; [Oganesyan, Artem; Ghahramanyan, Nerses; Hakobyan, Yervand] Hematol Ctr Prof R Yeolyan, Dept Adult Hematol, Yerevan, Armenia; [Gregory, Andrew] Wayne State Univ, Sch Med, Detroit, MI USA; [Malard, Florent; Mohty, Mohamad] Hop St Antoine, Assistance Publ Hop Paris, St Antoine Res Ctr, Dept Clin Hematol & Cellular Therapy,INSERM, Paris, France; [Kazandjian, Dickran] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA; [Mekinian, Arsene] Sorbonne Univ, Hop St Antoine, Assistance Publ Hop Paris, Dept Internal Med DMU i3, Paris, France; [Mekinian, Arsene] Natl Inst Hlth, French Armenian Clin Res Ctr, Yerevan, Armenia	Wayne State University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; University of Miami; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Oganesyan, A (corresponding author), Natl Inst Hlth, Dept Hematol & Transfus Med, Yerevan, Armenia.; Oganesyan, A (corresponding author), Hematol Ctr Prof R Yeolyan, Dept Adult Hematol, Yerevan, Armenia.	a.t.oganesyan@gmail.com						Abou-Ismail MY, 2021, RES PRACT THROMB HAE, V5, P356, DOI 10.1002/rth2.12481; Agarwal N, 2004, ANN INTERN MED, V141, P83, DOI 10.7326/0003-4819-141-1-200407060-00037; AGUZZI F, 1992, EUR J HAEMATOL, V48, P192; Ahn C, 2018, EXPERT REV CLIN IMMU, V14, P225, DOI 10.1080/1744666X.2018.1438269; Al-Musalhi Buthaina, 2016, Oman Med J, V31, P394, DOI 10.5001/omj.2016.79; Al-Niaimi FA, 2010, CLIN EXP DERMATOL, V35, P275, DOI 10.1111/j.1365-2230.2009.03447.x; Aline-Fardin A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001247; Alkhunaizi AM, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0347-0; Amini-Adle M, 2007, DERMATOLOGY, V214, P58, DOI 10.1159/000096914; Arbogast SD, 2007, J NEUROL NEUROSUR PS, V78, P1276, DOI 10.1136/jnnp.2007.120444; Arginelli F, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12583; Asahina A, 2010, CLIN EXP DERMATOL, V35, pe123, DOI 10.1111/j.1365-2230.2009.03746.x; Baek SH, 2019, J NEUROL NEUROSUR PS, V90, P674, DOI 10.1136/jnnp-2018-319758; Bashir Maaman, 2018, Case Rep Rheumatol, V2018, P7041576, DOI 10.1155/2018/7041576; BAYLE P, 1994, DERMATOLOGY, V189, P69, DOI 10.1159/000246788; Berk DR, 2012, J AM ACAD DERMATOL, V66, DOI 10.1016/j.jaad.2011.01.004; Bida JP, 2009, MAYO CLIN PROC, V84, P685, DOI 10.1016/S0025-6196(11)60518-1; Bork K, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1043-3; Bos R, 2011, RHEUMATOLOGY, V50, P1925, DOI 10.1093/rheumatology/ker209; Branellec A, 2012, J CLIN IMMUNOL, V32, P936, DOI 10.1007/s10875-012-9691-2; Bredin A, 2000, ACTA NEUROPATHOL, V100, P63, DOI 10.1007/s004010051193; Brunet-Possenti F, 2013, J AM ACAD DERMATOL, V69, P319, DOI 10.1016/j.jaad.2013.01.028; Canpolat F, 2010, J DERMATOL TREAT, V21, P114, DOI 10.3109/09546630902882071; Canueto J, 2012, EUR J HAEMATOL, V88, P450, DOI 10.1111/j.1600-0609.2012.01772.x; Cascavilla N, 2010, INT J IMMUNOPATH PH, V23, P633, DOI 10.1177/039463201002300226; CASTAMAN G, 1989, BLUT, V58, P211, DOI 10.1007/BF00320776; Chahin N, 2005, NEUROLOGY, V65, P1158, DOI 10.1212/01.wnl.0000180362.90078.dc; Chave TA, 2001, BRIT J DERMATOL, V144, P158, DOI 10.1046/j.1365-2133.2001.03967.x; Cheng S, 2008, CLIN EXP DERMATOL, V33, P229, DOI 10.1111/j.1365-2230.2008.02706.x; Chiang HH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008649; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380; Cicardi M, 2010, CURR MOL MED, V10, P354, DOI 10.2174/156652410791317066; CLARKSON B, 1960, AM J MED, V29, P193, DOI 10.1016/0002-9343(60)90018-8; Claveau JS, 2022, BLOOD CANCER J, V12, DOI 10.1038/s41408-022-00661-1; Cohen Yoon K, 2015, Dermatol Pract Concept, V5, P65, DOI 10.5826/dpc.0504a16; Contejean A, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-01364-2; Correia Cristina Pires, 2019, Eur J Case Rep Intern Med, V6, P001156, DOI 10.12890/2019_001156; Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001; Dalakas MC, 2010, CURR TREAT OPTION NE, V12, P71, DOI 10.1007/s11940-010-0065-x; Dane KE, 2021, BLOOD ADV, V5, P2813, DOI 10.1182/bloodadvances.2021004843; Davies MJ, 2017, ASIA-PAC J OPHTHALMO, V6, P435, DOI 10.22608/APO.2017246; de Chambrun MP, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.05.023; de Koning HD, 2006, ANN RHEUM DIS, V65, P542, DOI 10.1136/ard.2005.045245; de Koning HD, 2007, SEMIN ARTHRITIS RHEU, V37, P137, DOI 10.1016/j.semarthrit.2007.04.001; de Koning HD, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-41; de Larrea CF, 2009, EUR J HAEMATOL, V82, P154, DOI 10.1111/j.1600-0609.2008.01181.x; Delmont E, 2010, J NEUROL, V257, P655, DOI 10.1007/s00415-009-5412-z; Delval A, 2006, MUSCLE NERVE, V33, P274, DOI 10.1002/mus.20452; Dhir V, 2007, INTERNAL MED, V46, P899, DOI 10.2169/internalmedicine.46.6129; Dholaria BR, 2016, ANN HEMATOL, V95, P671, DOI 10.1007/s00277-016-2604-3; DINNEEN AM, 1995, J AM ACAD DERMATOL, V33, P37, DOI 10.1016/0190-9622(95)90007-1; Diral E, 2020, LEUKEMIA RES, V97, DOI 10.1016/j.leukres.2020.106441; Dispenzieri A, 2020, HEMATOL-AM SOC HEMAT, P380, DOI 10.1182/hematology.2020000122; Dogan S, 2012, HEAD NECK PATHOL, V6, P111, DOI 10.1007/s12105-011-0326-3; Donato ML, 2006, BLOOD, V107, P463, DOI 10.1182/blood-2004-12-4870; Doneddu PE, 2019, J NEUROL NEUROSUR PS, V90, P125, DOI 10.1136/jnnp-2018-318714; DRODER RM, 1992, AM J MED, V92, P523, DOI 10.1016/0002-9343(92)90749-2; Duquesne A, 2013, HUM PATHOL, V44, P927, DOI 10.1016/j.humpath.2012.10.012; Efebera Y, 2011, CL LYMPH MYELOM LEUK, V11, P298, DOI 10.1016/j.clml.2011.03.020; Efthimiou P, 2008, SEMIN ARTHRITIS RHEU, V38, P188, DOI 10.1016/j.semarthrit.2007.10.015; Eiling E, 2007, J AM ACAD DERMATOL, V57, P361, DOI 10.1016/j.jaad.2007.03.036; Elder SA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123414; Elner Victor M, 2005, Trans Am Ophthalmol Soc, V103, P69; Eton EA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01423-y; Eurelings M, 2002, ACTA NEUROPATHOL, V103, P107; Farhad K, 2016, MUSCLE NERVE, V53, P856, DOI 10.1002/mus.24969; Federici AB, 2006, SEMIN HEMATOL, V43, pS48, DOI 10.1053/j.seminhematol.2005.11.003; Federici AB, 1998, BLOOD, V92, P2707, DOI 10.1182/blood.V92.8.2707.420k25_2707_2711; Fermand JP, 2018, BLOOD, V132, P1478, DOI 10.1182/blood-2018-04-839480; Fett NM, 2011, AM J HEMATOL, V86, P893, DOI 10.1002/ajh.22131; Filosto M, 2012, NEUROLOGIST, V18, P378, DOI 10.1097/NRL.0b013e31826a99e9; FINAN MC, 1986, MEDICINE, V65, P376, DOI 10.1097/00005792-198611000-00003; Fleming KE, 2012, J CUTAN PATHOL, V39, P508, DOI 10.1111/j.1600-0560.2012.01882.x; Franchini M, 2020, HAEMATOLOGICA, V105, P2032, DOI 10.3324/haematol.2020.255117; Fremeaux-Bacchi V, 2002, AM J MED, V113, P194, DOI 10.1016/S0002-9343(02)01124-5; Frohman EM, 1996, ANN NEUROL, V39, P529, DOI 10.1002/ana.410390415; Gama Ivo, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-218031; Garcia-Santibanez R, 2018, J NEUROL, V265, P1402, DOI 10.1007/s00415-018-8853-4; Georgakis CDC, 2006, CLIN DERMATOL, V24, P493, DOI 10.1016/j.clindermatol.2006.07.011; Georgiou S, 1999, ACTA DERM-VENEREOL, V79, P86; Gobert D, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004363; Goede JS, 2007, ANN HEMATOL, V86, P303, DOI 10.1007/s00277-006-0231-0; Gonzalez DP, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01820-x; Gorson KC, 1997, NEUROLOGY, V48, P321, DOI 10.1212/WNL.48.2.321; GOUDEMAND J, 1988, BRIT J HAEMATOL, V68, P227, DOI 10.1111/j.1365-2141.1988.tb06194.x; Gousseff M, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00004; Grimaldi D, 2008, THROMB HAEMOSTASIS, V99, P782, DOI 10.1160/TH07-07-0456; Guarenti I, 2013, INT J DERMATOL, V52, P631, DOI 10.1111/j.1365-4632.2011.05030.x; Gumber R, 2018, KIDNEY INT, V94, P199, DOI 10.1016/j.kint.2018.02.020; Gusdorf L, 2018, ANN DERMATOL VENER, V145, P735, DOI 10.1016/j.annder.2018.06.010; Gusdorf L, 2017, ALLERGY, V72, P177, DOI 10.1111/all.13035; Hall RB, 2014, CAN J OPHTHALMOL, V49, P388, DOI 10.1016/j.jcjo.2014.04.011; Higgins LS, 2016, CL LYMPH MYELOM LEUK, V16, P447, DOI 10.1016/j.clml.2016.04.009; HISLER BM, 1991, J AM ACAD DERMATOL, V24, P854, DOI 10.1016/0190-9622(91)70132-L; Horiuchi H, 2019, J ATHEROSCLER THROMB, V26, P303, DOI 10.5551/jat.RV17031; Howard CR, 2014, BLOOD COAGUL FIBRIN, V25, P631, DOI 10.1097/MBC.0000000000000112; Hu XX, 2012, EUR J HAEMATOL, V89, P183, DOI 10.1111/j.1600-0609.2012.01800.x; Huang YH, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.894464; Inthasotti S, 2011, DERMAT RES PRACT, V2011, DOI 10.1155/2011/927852; Jann S, 2005, MUSCLE NERVE, V32, P351, DOI 10.1002/mus.20391; Jasim Sina, 2014, Clin Lymphoma Myeloma Leuk, V14, pe221, DOI 10.1016/j.clml.2014.07.004; Kalli F, 2020, J EUR ACAD DERMATOL, V34, P1092, DOI 10.1111/jdv.16136; Kapoor P, 2010, MAYO CLIN PROC, V85, P905, DOI 10.4065/mcp.2010.0159; Karakus Sezen, 2019, Am J Ophthalmol Case Rep, V15, P100471, DOI 10.1016/j.ajoc.2019.100471; Kasatkar P, 2013, J POSTGRAD MED, V59, P98, DOI 10.4103/0022-3859.113816; Kastritis E, 2008, CLIN LYMPHOMA MYELOM, V8, P359, DOI 10.3816/CLM.2008.n.053; Katz JS, 2000, NEUROLOGY, V54, P615, DOI 10.1212/WNL.54.3.615; KELLY JJ, 1981, NEUROLOGY, V31, P1480, DOI 10.1212/WNL.31.11.1480; Kenderian SS, 2015, LEUKEMIA, V29, P2414, DOI 10.1038/leu.2015.298; Kentley Jonathan, 2017, JAAD Case Rep, V3, P212, DOI 10.1016/j.jdcr.2017.02.007; Khan IJ, 2009, CAN J OPHTHALMOL, V44, P335, DOI 10.3129/i09-021; Khan Javed, 2014, BMC Hematol, V14, P11, DOI 10.1186/2052-1839-14-11; Kieffer C, 2009, MEDICINE, V88, P23, DOI 10.1097/MD.0b013e3181943f5e; Kim S, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13378; Kocabeyoglu S, 2014, INDIAN J OPHTHALMOL, V62, P938, DOI 10.4103/0301-4738.143933; Koo Hyun, 2011, Korean J Ophthalmol, V25, P202, DOI 10.3341/kjo.2011.25.3.202; Kourou K, 2006, J DERMATOL, V33, P64, DOI 10.1111/j.1346-8138.2006.00013.x; Krause K, 2012, ALLERGY, V67, P943, DOI 10.1111/j.1398-9995.2012.02843.x; Krause K, 2017, J ALLERGY CLIN IMMUN, V139, P1311, DOI 10.1016/j.jaci.2016.07.041; Krenn Martin, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2013-202545; Kreuter A, 2005, J AM ACAD DERMATOL, V53, P739, DOI 10.1016/j.jaad.2005.04.012; KREUZ W, 1992, EPILEPSIA, V33, P178, DOI 10.1111/j.1528-1157.1992.tb02303.x; Kuitwaard K, 2015, J NEUROL NEUROSUR PS, V86, P1331, DOI 10.1136/jnnp-2014-309042; Kuldeep C M, 2005, Indian J Dermatol Venereol Leprol, V71, P44; Kumar S, 2003, AM J HEMATOL, V72, P243, DOI 10.1002/ajh.10298; Kwok M, 2012, NEW ENGL J MED, V366, P1843, DOI 10.1056/NEJMc1202649; Kyle RA, 2010, LEUKEMIA, V24, P1121, DOI 10.1038/leu.2010.60; Kyle RA, 2006, NEW ENGL J MED, V354, P1362, DOI 10.1056/NEJMoa054494; Kyle RA, 2018, NEW ENGL J MED, V378, P241, DOI 10.1056/NEJMoa1709974; Lacy MQ, 2005, ARCH DERMATOL, V141, P1277, DOI 10.1001/archderm.141.10.1277; Landgren O, 2009, BLOOD, V114, P791, DOI 10.1182/blood-2008-12-191676; Larocca CA, 2012, CLIN RHEUMATOL, V31, P169, DOI 10.1007/s10067-011-1804-4; Lavin M, 2016, J THROMB HAEMOST, V14, P1200, DOI 10.1111/jth.13317; Lavorato FG, 2013, AN BRAS DERMATOL, V88, P32, DOI 10.1590/abd1806-4841.20132531; Le Cann M, 2020, BLOOD, V136, P2428, DOI 10.1182/blood.2020007092; Leung N, 2021, NEW ENGL J MED, V384, P1931, DOI 10.1056/NEJMra1810907; Leys A, 2001, ARCH OPHTHALMOL-CHIC, V119, P911; Liang SH, 2019, ANN HEMATOL, V98, P2447, DOI 10.1007/s00277-019-03761-4; Lipsker D, 2017, J EUR ACAD DERMATOL, V31, P45, DOI 10.1111/jdv.13847; Lisch Walter, 2016, Trans Am Ophthalmol Soc, V114, pT7; Lisch W, 2012, CORNEA, V31, P55, DOI 10.1097/ICO.0b013e31821ddd0c; Loscher WN, 2013, J NEUROL, V260, P1168, DOI 10.1007/s00415-013-6867-5; Lor M, 2020, JAMA DERMATOL, V156, P1379, DOI 10.1001/jamadermatol.2020.2668; Magy L, 2003, EUR J NEUROL, V10, P677, DOI 10.1046/j.1468-1331.2003.00687.x; Mahevas T, 2020, BLOOD, V135, P1101, DOI 10.1182/blood.2019002300; Mansour AM, 2014, OPHTHALMOLOGY, V121, P1925, DOI 10.1016/j.ophtha.2014.04.007; Marcoval J, 1998, J AM ACAD DERMATOL, V39, P439, DOI 10.1016/S0190-9622(98)70321-4; Marliere V, 1999, DERMATOLOGY, V199, P153, DOI 10.1159/000018224; Thomas VM, 2021, HAEMOPHILIA, V27, pE563, DOI 10.1111/hae.14323; Mathis S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004807; Matsumura M, 2007, INTERNAL MED, V46, P1585, DOI 10.2169/internalmedicine.46.0254; Maverakis E, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0213-x; Mehta Vandana, 2009, Indian J Dermatol, V54, P193, DOI 10.4103/0019-5154.53183; Meyer S, 2005, BRIT J DERMATOL, V153, P443, DOI 10.1111/j.1365-2133.2005.06737.x; Migkou M, 2011, LEUKEMIA RES, V35, pE209, DOI 10.1016/j.leukres.2011.07.021; Milman T, 2015, OPHTHALMOLOGY, V122, P1748, DOI 10.1016/j.ophtha.2015.05.029; Monforte M, 2018, J NEUROL, V265, P542, DOI 10.1007/s00415-018-8741-y; Montagnese F, 2015, MUSCLE NERVE, V51, P934, DOI 10.1002/mus.24545; Murota H, 2009, J AM ACAD DERMATOL, V61, P1070, DOI 10.1016/j.jaad.2008.12.040; Mygland A, 2003, ARCH NEUROL-CHICAGO, V60, P260, DOI 10.1001/archneur.60.2.260; Naddaf E, 2019, NEUROLOGY, V93, pE298, DOI 10.1212/WNL.0000000000007777; Nakagawa N, 2011, INTERNAL MED, V50, P597, DOI 10.2169/internalmedicine.50.4857; Neel A, 2014, AUTOIMMUN REV, V13, P1035, DOI 10.1016/j.autrev.2014.08.031; Nelson CA, 2020, JAMA DERMATOL, V156, P270, DOI 10.1001/jamadermatol.2019.4221; New HD, 2011, ARCH DERMATOL, V147, P323, DOI 10.1001/archdermatol.2011.26; Nofal A, 2017, J DTSCH DERMATOL GES, V15, P1081, DOI 10.1111/ddg.13350; Notermans NC, 1996, NEUROLOGY, V47, P1227, DOI 10.1212/WNL.47.5.1227; Notermans NC, 2000, MUSCLE NERVE, V23, P73, DOI 10.1002/(SICI)1097-4598(200001)23:1<73::AID-MUS9>3.0.CO;2-5; Oestreicher J, 2010, OPHTHAL PLAST RECONS, V26, P473, DOI 10.1097/IOP.0b013e3181d92955; Oh Shin J, 2019, J Clin Neuromuscul Dis, V21, P53, DOI 10.1097/CND.0000000000000247; Okhovat AA, 2021, NEUROMUSCULAR DISORD, V31, P29, DOI 10.1016/j.nmd.2020.11.004; Olson RM, 2018, CASE REP OPHTHALM, V9, P76, DOI 10.1159/000485913; Oostergo T, 2013, EUR J GASTROEN HEPAT, V25, P507, DOI 10.1097/MEG.0b013e32835c94ff; Pascart T, 2016, JOINT BONE SPINE, V83, P587, DOI 10.1016/j.jbspin.2015.06.011; PoerinkStockschlader ABJ, 1996, MED PEDIATR ONCOL, V26, P238, DOI 10.1002/(SICI)1096-911X(199604)26:4<238::AID-MPO3>3.0.CO;2-K; Posa A, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04230; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rao AAN, 2009, PEDIATR BLOOD CANCER, V53, P655, DOI 10.1002/pbc.22084; Ravindran A, 2020, MAYO CLIN PROC, V95, P944, DOI 10.1016/j.mayocp.2019.12.033; Reichrath J, 2005, J AM ACAD DERMATOL, V53, P273, DOI 10.1016/j.jaad.2004.10.006; Roccatello D, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0009-4; Rodriguez O, 2016, JAMA DERMATOL, V152, P589, DOI 10.1001/jamadermatol.2015.5151; Rongioletti F, 2013, J AM ACAD DERMATOL, V69, P66, DOI 10.1016/j.jaad.2013.01.007; Rosado FG, 2015, MODERN PATHOL, V28, P367, DOI 10.1038/modpathol.2014.117; Ryan E, 2012, AUSTRALAS J DERMATOL, V53, pE23, DOI 10.1111/j.1440-0960.2010.00710.x; Saffra N, 2013, CAN J OPHTHALMOL, V48, pE168, DOI 10.1016/j.jcjo.2013.07.018; Sagiv O, 2018, OPHTHAL PLAST RECONS, V34, pE24, DOI 10.1097/IOP.0000000000000988; Saigoh S, 2003, DERMATOLOGY, V207, P410, DOI 10.1159/000074127; Sansbury JC, 2004, J AM ACAD DERMATOL, V51, P126, DOI 10.1016/j.jaad.2004.01.058; Sanvito L, 2011, MUSCLE NERVE, V44, P451, DOI 10.1002/mus.22157; Schaudig Ulrich, 2004, Orbit, V23, P65, DOI 10.1076/orbi.23.1.65.28989; Schnitzler LJ, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0640-2; Schroyens W, 2012, NEW ENGL J MED, V367, P778, DOI 10.1056/NEJMc1205806; Shah S, 2014, SURV OPHTHALMOL, V59, P115, DOI 10.1016/j.survophthal.2013.03.002; Shalhout Sophia Z, 2020, Case Rep Dermatol Med, V2020, P7480607, DOI 10.1155/2020/7480607; Silveria L, 2013, AM J DERMATOPATH, V35, pE67, DOI 10.1097/DAD.0b013e31827bceaf; Smith SJ, 2020, OPHTHALMOL RETINA, V4, P300, DOI 10.1016/j.oret.2019.09.018; Sokumbi O, 2012, J AM ACAD DERMATOL, V67, P1289, DOI 10.1016/j.jaad.2012.04.027; Spraul CW, 2002, KLIN MONATSBL AUGENH, V219, P55, DOI 10.1055/s-2000-23502; Steiner N, 2017, ONCOTARGET, V8, P5081, DOI 10.18632/oncotarget.13861; Stiefel Hillary C, 2019, Am J Ophthalmol Case Rep, V13, P83, DOI 10.1016/j.ajoc.2018.12.010; Stockman A, 2002, DERMATOLOGY, V204, P351, DOI 10.1159/000063384; Stuijver DJF, 2014, HAEMOPHILIA, V20, P326, DOI 10.1111/hae.12275; Sun CY, 2021, BLOOD ADV, V5, P2563, DOI 10.1182/bloodadvances.2020003783; Sykes DB, 2020, BLOOD, V135, P1199, DOI 10.1182/blood.2019004216; Sykes DB, 2018, NEW ENGL J MED, V378, P2240, DOI 10.1056/NEJMc1804415; Sykes DB, 2011, NEW ENGL J MED, V365, P475, DOI 10.1056/NEJMc1106670; Szalat R, 2015, J AM ACAD DERMATOL, V73, P809, DOI 10.1016/j.jaad.2015.07.031; Szalat R, 2011, BLOOD, V118, P3777, DOI 10.1182/blood-2011-05-356907; Tagawa Y, 2000, MUSCLE NERVE, V23, P895; Tainsh LT, 2017, CORNEA, V36, P372, DOI 10.1097/ICO.0000000000001139; Tao Q, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5734-x; Terpos E, 2012, HAEMATOL-HEMATOL J, V97, P1699, DOI 10.3324/haematol.2012.067306; Therneau TM, 2012, MAYO CLIN PROC, V87, P1071, DOI 10.1016/j.mayocp.2012.06.014; Tinazzi E, 2011, AUTOIMMUN REV, V10, P404, DOI 10.1016/j.autrev.2011.01.003; Tohani A, 2014, ANN ALLERG ASTHMA IM, V112, P265, DOI 10.1016/j.anai.2013.12.024; Tschen JA, 1999, J AM ACAD DERMATOL, V40, P303, DOI 10.1016/S0190-9622(99)70471-8; Tzelikis Patrick F., 2005, Arq. Bras. Oftalmol., V68, P539, DOI 10.1590/S0004-27492005000400021; Uthamalingam P, 2017, INT J SURG PATHOL, V25, P458, DOI 10.1177/1066896917696746; van de Donk NWCJ, 2014, HAEMATOLOGICA, V99, P984, DOI 10.3324/haematol.2013.100552; Velasco-Tamariz V, 2017, INT WOUND J, V14, P1382, DOI 10.1111/iwj.12746; VENENCIE PY, 1995, J AM ACAD DERMATOL, V32, P666, DOI 10.1016/0190-9622(95)90370-4; Versini M, 2013, ANN DERMATOL VENER, V140, P797, DOI 10.1016/j.annder.2013.07.012; Villarreal-Villarreal CD, 2016, ACTAS DERMO-SIFILOGR, V107, P369, DOI 10.1016/j.ad.2015.12.001; Voermans NC, 2008, NEUROLOGY, V71, P532, DOI 10.1212/01.wnl.0000310814.54623.6f; Voermans NC, 2014, NEUROLOGY, V83, P2133, DOI 10.1212/WNL.0000000000001047; Voisin S, 2011, MEDICINE, V90, P404, DOI 10.1097/MD.0b013e3182397166; Wan XC, 2017, ANN ALLERG ASTHMA IM, V118, P631, DOI 10.1016/j.anai.2017.02.013; Wasielica-Poslednik J, 2018, OPHTHALMOLOGE, V115, P765, DOI 10.1007/s00347-017-0615-7; Wasielica-Poslednik J, 2018, Am J Ophthalmol Case Rep, V11, P87, DOI 10.1016/j.ajoc.2018.06.014; Watts PJ, 2016, AM J CLIN DERMATOL, V17, P653, DOI 10.1007/s40257-016-0202-8; Wei YH, 2015, DERMATOL THER, V28, P7, DOI 10.1111/dth.12179; Wilmas K., 2018, DERMATOL ONLINE J, V24, P1, DOI [10.5070/D3241037926, DOI 10.5070/D3241037926]; Wood AJ, 2009, ARCH DERMATOL, V145, P279, DOI 10.1001/archdermatol.2008.583; Xie ZH, 2012, BLOOD, V119, P4321, DOI 10.1182/blood-2011-08-375816; Yabe H, 2010, BLOOD, V115, P2723, DOI 10.1182/blood-2009-11-247056; Yeung CK, 2012, BRIT J HAEMATOL, V157, P411, DOI 10.1111/j.1365-2141.2012.09088.x; Young PA., 2021, DERMATOL ONLINE J, V27, P1, DOI [10.5070/D3274053153, DOI 10.5070/D3274053153]	239	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1045002	10.3389/fimmu.2022.1045002	http://dx.doi.org/10.3389/fimmu.2022.1045002			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2MS	36505449	gold, Green Published			2022-12-18	WOS:000894203900001
J	Ouyang, YL; Tu, YQ; Chen, SL; Min, H; Wen, ZX; Zheng, GH; Wan, T; Fan, H; Yang, WZ; Sun, GC				Ouyang, Yulong; Tu, Yuanqing; Chen, Shuilin; Min, Huan; Wen, Zhexu; Zheng, Guihao; Wan, Ting; Fan, Hao; Yang, Wenzhao; Sun, Guicai			Characterization of immune microenvironment infiltration and m(6)A regulator-mediated RNA methylation modification patterns in osteoarthritis	FRONTIERS IN IMMUNOLOGY			English	Article						m(6)A regulator; immune microenvironment; osteoarthritis; RNA methylation; immunocytes	GENE-EXPRESSION; INFLAMMATION; CANCER	BackgroundFew studies have been reported the potential role of N6-methyladenosine (m(6)A) modification in osteoarthritis (OA). We investigated the patterns of m(6)A modification in the immune microenvironment of OA. MethodsWe evaluated the m(6)A modification patterns based on 22 m(6)A regulators in 139 OA samples and systematically associated these modification patterns with immune cell infiltration characteristics. The function of m(6)A phenotype-related differentially expressed genes (DEGs) was investigated using gene enrichment analysis. An m(6)A score model was constructed using principal component analysis (PCA), and an OA prediction model was established based on the key m(6)A regulators. We used real-time PCR analysis to detect the changes of gene expression in the cell model of OA. ResultsHealthy and OA samples showed significant differences in the expression of m(6)A regulators. Nine key m(6)A regulators, two m(6)A modification patterns, m(6)A-related genes and two gene clusters were identified. Some m(6)A regulators had a strong correlation with each other. Gene clusters and m(6)A clusters have high similarity, and cluster A corresponds to a high m(6)A score. Immunocytes infiltration differed significantly between the two clusters, with the m(6)A cluster B and gene cluster B having more types of infiltrating immunocytes than cluster A. The predictive model can also predict the progression of OA through m(6)A regulators expression. The results of real-time PCR analysis showed that the gene expression in the cell model of OA is similar to that of the m(6)A cluster B. ConclusionsOur study reveals for the first time the potential regulatory mechanism of m(6)A modification in the immune microenvironment of OA. This study also sheds new light on the pathogenesis of OA.	[Ouyang, Yulong; Tu, Yuanqing; Chen, Shuilin; Wan, Ting; Fan, Hao; Yang, Wenzhao] Nanchang Univ, Nanchang, Jiangxi, Peoples R China; [Min, Huan] Jiangxi Prov Peoples Hosp, Nanchang, Jiangxi, Peoples R China; [Wen, Zhexu] Nanchang Univ, Affiliated Hosp 4, Nanchang, Jiangxi, Peoples R China; [Zheng, Guihao] Shangrao Peoples Hosp, Shangrao, Jiangxi, Peoples R China; [Sun, Guicai] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China	Nanchang University; Nanchang University; Nanchang University	Sun, GC (corresponding author), Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.	13657000633@139.com			National Natural Science Foundation of China;  [81960881]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	Funding This work was supported by the National Natural Science Foundation of China (NO.81960881), which was hosted by GS. The funders were not involved in the study design, data collection, statistical analysis or writing of the manuscript. The GSE48556 datasets were obtained from the GEO database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48556).	Bloomfield RA, 2019, IEEE T BIO-MED ENG, V66, P319, DOI 10.1109/TBME.2018.2837620; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Dai J, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0769-2; de Lange-Brokaar BJE, 2012, OSTEOARTHR CARTILAGE, V20, P1484, DOI 10.1016/j.joca.2012.08.027; Glyn-Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140-6736(14)60802-3; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Harvey ZH, 2018, MOL CELL, V69, P195, DOI 10.1016/j.molcel.2017.10.030; Huang XW, 2020, J CELL MOL MED, V24, P12706, DOI 10.1111/jcmm.15848; Hunter DJ, 2014, NAT REV RHEUMATOL, V10, P437, DOI 10.1038/nrrheum.2014.44; Jiang Y, 2022, OSTEOARTHR CARTILAGE, V30, P207, DOI 10.1016/j.joca.2021.11.009; Jin Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.637933; Legendre F, 2008, OSTEOARTHR CARTILAGE, V16, P105, DOI 10.1016/j.joca.2007.05.020; Li BL, 2019, CLIN CANCER RES, V25, P3528, DOI 10.1158/1078-0432.CCR-18-4085; Li HZ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.766020; Li KC, 2015, ADV HEALTHC MATER, V4, P948, DOI 10.1002/adhm.201400773; Li MZ, 2022, ACTA BIOMATER, V140, P23, DOI 10.1016/j.actbio.2021.12.006; Lin SJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.541401; Liu QB, 2019, BIOCHEM BIOPH RES CO, V516, P22, DOI 10.1016/j.bbrc.2019.05.168; Liu Y, 2020, J CELL PHYSIOL, V235, P6043, DOI 10.1002/jcp.29531; Liu ZX, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00089; Ma XQ, 2020, AM J TRANSL RES, V12, P8137; Nelson AE, 2018, OSTEOARTHR CARTILAGE, V26, P319, DOI 10.1016/j.joca.2017.11.014; Panoutsopoulou K, 2014, ANN RHEUM DIS, V73, P2082, DOI 10.1136/annrheumdis-2013-203772; Ramos YFM, 2014, ANN RHEUM DIS, V73, P1844, DOI 10.1136/annrheumdis-2013-203405; Ren JD, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-022-00890-0; Sang WL, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119528; Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768; Shen SP, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01362-2; Shulman Z, 2020, NAT IMMUNOL, V21, P501, DOI 10.1038/s41590-020-0650-4; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Sun DY, 2021, J CELL MOL MED, V25, P10236, DOI 10.1111/jcmm.16961; Teng PC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910592; Wang J, 2021, GENOMICS, V113, P1048, DOI 10.1016/j.ygeno.2021.02.016; Wang J, 2020, PEERJ, V8, DOI 10.7717/peerj.9880; Wang L, 2019, SCIENCE, V365, P656, DOI 10.1126/science.aav0758; Wang PZ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20203107; Woodell-May JE, 2020, J ORTHOP RES, V38, P253, DOI 10.1002/jor.24457; Wu HY, 2021, CLIN EXP PHARMACOL P, V48, P270, DOI 10.1111/1440-1681.13412; Xiong W, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.819080; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yi LL, 2020, MOL THER-NUCL ACIDS, V21, P299, DOI 10.1016/j.omtn.2020.06.001; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0; Zhang WC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00870; Zhang XQ, 2021, J CELL MOL MED, V25, P3634, DOI 10.1111/jcmm.16469	45	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1018701	10.3389/fimmu.2022.1018701	http://dx.doi.org/10.3389/fimmu.2022.1018701			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5CX	36505479	Green Published, gold			2022-12-18	WOS:000893697000001
J	Peng, B; Yang, M; Zhuang, Q; Li, JH; Zhang, PP; Liu, H; Cheng, K; Ming, YZ				Peng, Bo; Yang, Min; Zhuang, Quan; Li, Junhui; Zhang, Pengpeng; Liu, Hong; Cheng, Ke; Ming, Yingzi			Standardization of neutrophil CD64 and monocyte HLA-DR measurement and its application in immune monitoring in kidney transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						nCD64; mHLA-DR expression; infection; sepsis; kidney transplantation; immune monitoring; prognosis	GAMMA	BackgroundInfections cause high mortality in kidney transplant recipients (KTRs). The expressions of neutrophil CD64 (nCD64) and monocyte HLA-DR (mHLA-DR) provide direct evidence of immune status and can be used to evaluate the severity of infection. However, the intensities of nCD64 and mHLA-DR detected by flow cytometry (FCM) are commonly measured by mean fluorescence intensities (MFIs), which are relative values, thus limiting their application. We aimed to standardize nCD64 and mHLA-DR expression using molecules of equivalent soluble fluorochrome (MESF) and to explore their role in immune monitoring for KTRs with infection. MethodsThe study included 50 KTRs diagnosed with infection, 65 immunologically stable KTRs and 26 healthy controls. The blood samples were collected and measured simultaneously by four FCM protocols at different flow cytometers. The MFIs of nCD64 and mHLA-DR were converted into MESF by Phycoerythrin (PE) Fluorescence Quantitation Kit. The intraclass correlation coefficients (ICCs) and the Bland-Altman plots were used to evaluate the reliability between the four FCM protocols. MESFs of nCD64 and mHLA-DR, nCD64 index and sepsis index (SI) with the TBNK panel were used to evaluate the immune status. Comparisons among multiple groups were performed with ANOVA one-way analysis. Receiver operating characteristics (ROC) curve analysis was performed to diagnose infection or sepsis. Univariate and multivariate logistic analysis examined associations of the immune status with infection. ResultsMESFs of nCD64 and mHLA-DR measured by four protocols had excellent reliability (ICCs 0.993 and 0.957, respectively). The nCD64, CD64 index and SI in infection group were significantly higher than those of stable KTRs group. Patients with sepsis had lower mHLA-DR but higher SI than non-sepsis patients. ROC analysis indicated that nCD64 had the highest area under the curve (AUC) for infection, and that mHLA-DR had the highest AUC for sepsis. Logistic analysis indicated that nCD64 > 3089 and B cells counts were independent risk factors for infection. ConclusionThe standardization of nCD64 and mHLA-DR made it available for widespread application. MESFs of nCD64 and mHLA-DR had good diagnostic performance on infection and sepsis, respectively, which could be promising indicators for immune status of KTRs and contributed to individualized treatment.	[Peng, Bo; Yang, Min; Zhuang, Quan; Li, Junhui; Zhang, Pengpeng; Liu, Hong; Cheng, Ke; Ming, Yingzi] Cent South Univ, Xiangya Hosp 3, Transplantat Ctr, Changsha, Peoples R China; [Peng, Bo; Yang, Min; Zhuang, Quan; Li, Junhui; Zhang, Pengpeng; Liu, Hong; Cheng, Ke; Ming, Yingzi] Natl Hlth Commiss, Engn & Technol Res Ctr Transplantat Med, Changsha, Peoples R China	Central South University	Ming, YZ (corresponding author), Cent South Univ, Xiangya Hosp 3, Transplantat Ctr, Changsha, Peoples R China.; Ming, YZ (corresponding author), Natl Hlth Commiss, Engn & Technol Res Ctr Transplantat Med, Changsha, Peoples R China.	mingyz_china@csu.edu.cn			National Natural Science Foundation of China; Hunan Provincial Natural Science Foundation of China;  [81771722];  [2020JJ5863]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); ; 	Funding This study was supported by the National Natural Science Foundation of China (81771722) and the Hunan Provincial Natural Science Foundation of China (2020JJ5863). The funders had no role in study design, data collection, analysis and interpretation, writing and submission of the manuscript.	Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Alingrin J, 2018, TRANSPL IMMUNOL, V51, P6, DOI 10.1016/j.trim.2018.08.001; Bodinier M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.795052; Boix F, 2021, HUM IMMUNOL, V82, P414, DOI 10.1016/j.humimm.2021.03.007; Bottomley MJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.901273; Bourgoin P, 2021, CYTOM PART A, V99, P435, DOI 10.1002/cyto.a.24314; Bourgoin P, 2020, IMMUN INFLAMM DIS, V8, P106, DOI 10.1002/iid3.289; Carter MJ, 2020, NAT MED, V26, P1701, DOI 10.1038/s41591-020-1054-6; Coemans M, 2022, NEW ENGL J MED, V386, P497, DOI 10.1056/NEJMc2115207; Comins-Boo A, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.655785; Dendle C, 2019, TRANSPLANT REV-ORLAN, V33, P87, DOI 10.1016/j.trre.2018.10.001; Denstaedt SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02446; Dos Santos AR, 2022, MYCOPATHOLOGIA, V187, P15, DOI 10.1007/s11046-021-00598-2; Fernandez-Ruiz M, 2020, EXPERT REV ANTI-INFE, V18, P423, DOI 10.1080/14787210.2020.1733976; Gozalbo D, 2014, FRONT BIOSCI-LANDMRK, V19, P1279, DOI 10.2741/4281; Jackson KR, 2021, AM J TRANSPLANT, V21, P198, DOI 10.1111/ajt.16106; Kelesidis T, 2011, INT J INFECT DIS, V15, pE2, DOI 10.1016/j.ijid.2010.03.025; Leijte GP, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2830-x; Liu QQ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.905060; Liu QQ, 2020, J CELL MOL MED, V24, P13961, DOI 10.1111/jcmm.16004; Mittag A, 2009, J BIOPHOTONICS, V2, P470, DOI 10.1002/jbio.200910033; Nuutila J, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103724; Pandey G, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99276-y; Peng B, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02542-2; Pradhan R, 2016, CYTOM PART B-CLIN CY, V90, P295, DOI 10.1002/cyto.b.21244; Sacco KA, 2018, IMMUNOTHERAPY-UK, V10, P713, DOI 10.2217/imt-2017-0178; Sanju S, 2022, APPL BIOCHEM BIOTECH, DOI 10.1007/s12010-022-03819-6; Schachtner T, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12695; Shankar-Hari M, 2018, INTENS CARE MED, V44, P1836, DOI 10.1007/s00134-018-5389-0; Shen HP, 2016, INT J INFECT DIS, V48, P73, DOI 10.1016/j.ijid.2016.05.016; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Tamulyte S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00432; Tawfik DM, 2020, J INFECT DIS, V222, pS84, DOI 10.1093/infdis/jiaa248; Venet F, 2011, CRIT CARE, V15, DOI 10.1186/cc10333; Wang X, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0972-z	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1063957	10.3389/fimmu.2022.1063957	http://dx.doi.org/10.3389/fimmu.2022.1063957			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T4ZL	36505404	Green Published, gold			2022-12-18	WOS:000893687900001
J	Shu, MY; Zhao, LH; Shi, KL; Lei, WB; Yang, YW; Li, ZY				Shu, Mingyi; Zhao, Lanhua; Shi, Keliang; Lei, Wenbo; Yang, Yewei; Li, Zhongyu			Chitosan particle stabilized Pickering emulsion/interleukin-12 adjuvant system for Pgp3 subunit vaccine elicits immune protection against genital chlamydial infection in mice	FRONTIERS IN IMMUNOLOGY			English	Article						chlamydia trachomatis; Pgp3 protein; chitosan particle stabilized Pickering emulsion; interleukin (IL)-12; immune protection	OUTER-MEMBRANE PROTEIN; TRACHOMATIS INFECTION; CELL BIOLOGY; IN-VITRO; IMMUNIZATION; IL-12; TRACT; MURIDARUM; RESPONSES; INTERLEUKIN-12	Considering the shortcomings in current chlamydia infection control strategies, a major challenge in curtailing infection is the implementation of an effective vaccine. The immune response induced by C. trachomatis plasmid encoded Pgp3 was insufficient against C. trachomatis infection, which requires adjuvant applications to achieve the robust immune response induced by Pgp3. There is increasing promising in developing adjuvant systems relying on the delivery potential of Pickering emulsions and the immunomodulatory effects of interleukin (IL)-12. Here, owing to the polycationic nature, chitosan particles tended to absorb on the oil/water interphase to prepare the optimized chitosan particle-stabilized Pickering emulsion (CSPE), which was designed as a delivery system for Pgp3 protein and IL-12. Our results showed that the average droplets size of CSPE was 789.47 +/- 44.26 nm after a series of optimizations and about 90% antigens may be absorbed by CSPE owing to the positively charged surface (33.2 +/- 3mV), and CSPE promoted FITC-BSA proteins uptake by macrophages. Furthermore, as demonstrated by Pgp3-specific antibody production and cytokine secretion, CSPE/IL-12 system enhanced significantly higher levels of Pgp3-specific IgG, IgG1, IgG2a, sIgA and significant cytokines secretion of IFN-gamma, IL-2, TNF-alpha, IL-4. Similarly, vaginal chlamydial shedding and hydrosalpinx pathologies were markedly reduced in mice immunized with Pgp3/CSPE/IL-12. Collectively, vaccination with Pgp3/CSPE/IL-12 regimen elicited robust cellular and humoral immune response in mice resulting in an obvious reduction of live chlamydia load in the vaginal and inflammatory pathologies in the oviduct, which further propells the development of vaccines against C. trachomatis infection.	[Shu, Mingyi; Zhao, Lanhua; Shi, Keliang; Lei, Wenbo; Yang, Yewei; Li, Zhongyu] Univ South China, Inst Pathogen Biol, Hunan Prov Key Lab Special Pathogens Prevent & Con, Hengyang Med Sch, Hengyang, Peoples R China	University of South China	Li, ZY (corresponding author), Univ South China, Inst Pathogen Biol, Hunan Prov Key Lab Special Pathogens Prevent & Con, Hengyang Med Sch, Hengyang, Peoples R China.	lzhy1023@hotmail.com			National Natural Science Foundation of China; Hunan Provincial Natural Science Foundation of China; Key Program of Hunan Provincial Department of Education; Clinical Research Project of University of South China;  [32070189];  [81772210];  [2021JJ30594];  [20A421]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Key Program of Hunan Provincial Department of Education; Clinical Research Project of University of South China; ; ; ; 	Funding This work was supported by the National Natural Science Foundation of China (No. 32070189 and 81772210), Hunan Provincial Natural Science Foundation of China (No.2021JJ30594), the Key Program of Hunan Provincial Department of Education (No.20A421), Clinical Research Project of University of South China (No.USCKF201902K01).	AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Asfour MH, 2017, INT J PHARMACEUT, V534, P325, DOI 10.1016/j.ijpharm.2017.10.044; Boraschi D, 2017, SEMIN IMMUNOL, V34, P33, DOI 10.1016/j.smim.2017.08.013; Bousso P, 2008, NAT REV IMMUNOL, V8, P675, DOI 10.1038/nri2379; Brunham RC, 2005, J INFECT DIS, V192, P1836, DOI 10.1086/497341; Bufan B, 2020, EXP GERONTOL, V133, DOI 10.1016/j.exger.2020.110857; Chen CQ, 2015, INFECT IMMUN, V83, P1881, DOI 10.1128/IAI.03158-14; Chen H, 2021, MICROB PATHOGENESIS, V160, DOI 10.1016/j.micpath.2021.105137; Cheong HC, 2019, IMMUNOBIOLOGY, V224, P34, DOI 10.1016/j.imbio.2018.10.010; Conde J, 2015, ADV FUNCT MATER, V25, P4183, DOI 10.1002/adfm.201501283; Cruz-Fisher MI, 2011, INFECT IMMUN, V79, P246, DOI 10.1128/IAI.00626-10; de la Maza LM, 2021, EXPERT REV VACCINES, V20, P425, DOI 10.1080/14760584.2021.1899817; Del Vecchio M, 2007, CLIN CANCER RES, V13, P4677, DOI 10.1158/1078-0432.CCR-07-0776; Donati M, 2003, VACCINE, V21, P1089, DOI 10.1016/S0264-410X(02)00631-X; Elwell C, 2016, NAT REV MICROBIOL, V14, P385, DOI 10.1038/nrmicro.2016.30; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Gotz H, 2002, SCAND J INFECT DIS, V34, P28, DOI 10.1080/00365540110077001; Gurunathan S, 1998, NAT MED, V4, P1409, DOI 10.1038/4000; Headley MB, 2016, NATURE, V531, P513, DOI 10.1038/nature16985; Heffernan MJ, 2011, BIOMATERIALS, V32, P926, DOI 10.1016/j.biomaterials.2010.09.058; Hou SP, 2019, MICROBES INFECT, V21, P50, DOI 10.1016/j.micinf.2018.06.003; Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]; Jankovic D, 1997, J IMMUNOL, V159, P2409; Li Z, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-90; Li ZY, 2008, INFECT IMMUN, V76, P3415, DOI 10.1128/IAI.01377-07; Liu Y, 2014, INFECT IMMUN, V82, P5327, DOI 10.1128/IAI.02576-14; Luan XL, 2019, IMMUNOBIOLOGY, V224, P223, DOI 10.1016/j.imbio.2018.11.009; Maheshwari C, 2011, INT IMMUNOPHARMACOL, V11, P1516, DOI 10.1016/j.intimp.2011.05.007; Mestecky J, 2005, AM J REPROD IMMUNOL, V53, P208, DOI 10.1111/j.1600-0897.2005.00267.x; Murray SM, 2021, VACCINE, V39, P2965, DOI 10.1016/j.vaccine.2021.03.043; Murthy AK, 2011, INFECT IMMUN, V79, P2928, DOI 10.1128/IAI.05022-11; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; Olsen AW, 2014, VACCINE, V32, P685, DOI 10.1016/j.vaccine.2013.11.100; PAL S, 1994, INFECT IMMUN, V62, P3354, DOI 10.1128/IAI.62.8.3354-3362.1994; Pal S, 2005, INFECT IMMUN, V73, P8153, DOI 10.1128/IAI.73.12.8153-8160.2005; Pal S, 2001, INFECT IMMUN, V69, P6240, DOI 10.1128/IAI.69.10.6240-6247.2001; Pang B, 2021, ADV COLLOID INTERFAC, V296, DOI 10.1016/j.cis.2021.102522; Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210; Peng S, 2020, ADV MATER, V32, DOI 10.1002/adma.202004210; Portielje JEA, 2003, CANCER IMMUNOL IMMUN, V52, P133, DOI 10.1007/s00262-002-0356-5; Poston TB, 2019, VACCINE, V37, P7289, DOI 10.1016/j.vaccine.2017.01.023; Powell MD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50614-1; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Rao JB, 1996, J IMMUNOL, V156, P3357; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; SCHIJNS VECJ, 1995, J IMMUNOL, V155, P2525; Shao LL, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00429-17; Sharkawy A, 2020, CARBOHYD POLYM, V250, DOI 10.1016/j.carbpol.2020.116885; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Touati A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259274; Vannini A, 2021, ADV EXP MED BIOL, V1290, P67, DOI 10.1007/978-3-030-55617-4_4; Vasilevsky S, 2016, VIRULENCE, V7, P11, DOI 10.1080/21505594.2015.1111509; Verma SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00602; Wang C, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104256; Wang XY, 2016, LANGMUIR, V32, P929, DOI 10.1021/acs.langmuir.5b03556; Wang YX, 2020, CARBOHYD POLYM, V241, DOI 10.1016/j.carbpol.2020.116373; Wen YT, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.593295; Wen YT, 2020, BIOCHEM BIOPH RES CO, V527, P805, DOI 10.1016/j.bbrc.2020.04.117; Xia YF, 2018, NAT MATER, V17, P187, DOI 10.1038/NMAT5057; Yang CF, 2020, MBIO, V11, DOI 10.1128/mBio.01902-20; Yang CF, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00197-17; Zhou H, 2022, ASIAN J ANDROL, V24, P56, DOI 10.4103/aja.aja_54_21; Zou Y, 2019, MOL CELL BIOCHEM, V452, P167, DOI 10.1007/s11010-018-3422-9	64	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								989620	10.3389/fimmu.2022.989620	http://dx.doi.org/10.3389/fimmu.2022.989620			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S9FP	36505424	gold, Green Published			2022-12-18	WOS:000893289000001
J	Tang, Y; Yang, SY; Yao, MS; Yang, MX; Wei, LX; Chen, H; Lin, JY; Huang, Y; Lin, L; Qin, ZD				Tang, Ying; Yang, Shiyi; Yao, Minshan; Yang, Minxuan; Wei, Lixiang; Chen, Hong; Lin, Junyan; Huang, Yao; Lin, Li; Qin, Zhendong			Hemoglobin induces inflammation through NF-kB signaling pathway and causes cell oxidative damage in grass carp (Ctenopharyngodon idella)	FRONTIERS IN IMMUNOLOGY			English	Article						Ctenopharyngodon idella; Hb; ROS; inflammation response; NF-kappa B; apoptosis	ROS; APOPTOSIS; IRON	Hemolytic disease in grass carp (C. idella) leads to hemolysis in vivo, releasing damage-related molecular patterns (DAMPs) hemoglobin (Hb; which is rapidly oxidized to Hb-Fe3+ and Hb-Fe4+) and generating a high level of reactive oxygen species (ROS) that cause oxidative damage. However, the effect of cell-free Hb on tissue cells of grass carp has yet to be elucidated. In this study, western blotting (WB) and immunofluorescence analysis (IFA) results showed that PHZ-induced hemolysis caused Hb and iron accumulation, increased the production of ROS and resulted in apoptosis in head kidney and middle kidney of the grass carp. Quantitative real-time PCR (qRT-PCR), WB, and IFA revealed that PHZ-induced hemolysis significantly upregulated the expression of inflammation-related genes through activation of the NF-kappa B signaling pathway. To further explore the effect of Hb, three forms of Hb (Hb, MetHb, and FerrylHb) were prepared. The incubation with the different forms of Hb and heme markedly upregulated the expression of cytokine genes through NF-kappa B signaling pathway, which was further confirmed by a specific inhibitor (caffeic acid phenethyl ester, CAPE). Flow cytometry analysis data showed that the stimulation of different forms of Hb and heme increased the production of ROS, and resulted in apoptosis. In summary, our data suggest that the excess cell-free Hb released during hemolysis modulates the inflammatory response through activation of the NF-kappa B signaling pathway and causes cell oxidative damage and apoptosis.	[Tang, Ying; Yang, Shiyi; Yao, Minshan; Yang, Minxuan; Wei, Lixiang; Chen, Hong; Lin, Junyan; Huang, Yao; Lin, Li; Qin, Zhendong] Zhongkai Univ Agr & Engn, Coll Anim Sci & Technol, Guangdong Prov Water Environm & Aquat Prod Secur E, Guangzhou Key Lab Aquat Anim Dis & Waterfowl Breed, Guangzhou, Guangdong, Peoples R China	Zhongkai University of Agriculture & Engineering	Lin, L; Qin, ZD (corresponding author), Zhongkai Univ Agr & Engn, Coll Anim Sci & Technol, Guangdong Prov Water Environm & Aquat Prod Secur E, Guangzhou Key Lab Aquat Anim Dis & Waterfowl Breed, Guangzhou, Guangdong, Peoples R China.	linli@zhku.edu.cn; qinzhendongsc@163.com			National Natural Science Foundation of China; Key Project of Department of Education of Guangdong Province;  [31902409];  [31872606];  [31572657];  [U1701233];  [2020ZDZX1026]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of Department of Education of Guangdong Province; ; ; ; ; 	Funding This work was jointly supported by the National Natural Science Foundation of China (31902409, 31872606, 31572657, U1701233); Key Project of Department of Education of Guangdong Province (2020ZDZX1026).	AGAR NS, 1986, J CLIN INVEST, V77, P319, DOI 10.1172/JCI112294; Agyemang AA, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-020-02052-4; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; Bozza MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01323; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dong N, 2020, J CELL PHYSIOL, V235, P5525, DOI 10.1002/jcp.29452; Du RJ, 2010, EMBO J, V29, P632, DOI 10.1038/emboj.2009.380; Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115; El-Kenawi A, 2017, CANCER CELL, V32, P727, DOI 10.1016/j.ccell.2017.11.015; Gram M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0200-9; Hao K, 2018, FISH SHELLFISH IMMUN, V72, P199, DOI 10.1016/j.fsi.2017.10.060; JACOB HS, 1965, J CLIN INVEST, V44, P1187, DOI 10.1172/JCI105225; Jeney V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00379; Jeney V, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/703571; Kang RF, 2019, ENVIRON POLLUT, V251, P689, DOI 10.1016/j.envpol.2019.05.026; Kapralov A, 2009, J BIOL CHEM, V284, P30395, DOI 10.1074/jbc.M109.045567; Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705; Lontchi-Yimagou E, 2013, CURR DIABETES REP, V13, P435, DOI 10.1007/s11892-013-0375-y; Lu ZJ, 2022, DEV COMP IMMUNOL, V126, DOI 10.1016/j.dci.2021.104207; Lu ZJ, 2021, DEV COMP IMMUNOL, V123, DOI 10.1016/j.dci.2021.104160; Mele C, 2014, SEMIN IMMUNOPATHOL, V36, P399, DOI 10.1007/s00281-014-0416-x; Nader E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00454; Nagy E, 2010, ARTERIOSCL THROM VAS, V30, P1347, DOI 10.1161/ATVBAHA.110.206433; NaveenKumar SK, 2017, BIOCHEM BIOPH RES CO, V491, P183, DOI 10.1016/j.bbrc.2017.07.073; Nyakundi BB, 2019, BBA-MOL BASIS DIS, V1865, P464, DOI 10.1016/j.bbadis.2018.10.030; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; Qin ZD, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.843662; Rao YL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/670437; Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708; Shaver CM, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14589; Shen YB, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5872-1; Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070; Song XH, 2017, SCI REP-UK, V7, DOI 10.1038/srep40777; Sweeney SE, 2004, INT J BIOCHEM CELL B, V36, P372, DOI 10.1016/S1357-2725(03)00259-0; Toledo SLD, 2019, CLIN CHIM ACTA, V493, P129, DOI 10.1016/j.cca.2019.02.026; Van Avondt K, 2019, NAT REV NEPHROL, V15, P671, DOI 10.1038/s41581-019-0181-0; Wang Z, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090395; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Xu ZZ, 2021, FISH SHELLFISH IMMUN, V119, P96, DOI 10.1016/j.fsi.2021.10.001; Yang MX, 2021, FISH SHELLFISH IMMUN, V112, P159, DOI 10.1016/j.fsi.2020.09.036; Yang YC, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.766970; Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00312-6; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e; Zhao W, 2007, BRIT J RADIOL, V80, pS23, DOI 10.1259/bjr/18237646	47	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1044299	10.3389/fimmu.2022.1044299	http://dx.doi.org/10.3389/fimmu.2022.1044299			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U0SU	36505464	Green Published, gold			2022-12-18	WOS:000894081700001
J	Wang, P; Zhang, J				Wang, Peng; Zhang, Jing			Persistent expression of NLRP3 in spinal microglia promotes development of lumbar disc degeneration	FRONTIERS IN IMMUNOLOGY			English	Article						lumbar disc degeneration (LDD); microglia; inflammation; PYD domains-containing protein 3 (NLRP3); neuropathic pain	PAIN	IntroductionActivated microglia play a critical role in the development of lumbar disc degeneration (LDD), which is a severe disease that causes neuropathic pain in affected people. Interleukin 1 beta (IL-1 beta) is a proinflammatory cytokine produced and secreted by activated microglia to induce the inflammation and the subsequent degradation of the disease discs. Recent findings suggest that activation of IL-1 beta in cells usually requires the involvement of NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-induced formation of inflammasome. However, the importance of NLRP3 in spinal microglia in LDD is not known and thus addressed in the current study. MethodsNLRP3 expression was examined in the spinal discs. Correlation of NLRP3 levels in microglia with the pain score of the LDD patients or Thompson classification of the degeneration level of the patients was determined. The effects of persistent expression or depletion of NLRP3 on phagocytosis potential and production of proinflammatory cytokines in microglia were tested in vitro, while their effects on the severity of LDD and LDD-associated neuropathic pain were assessed in a mouse model for LDD. ResultsNLRP3 was exclusively expressed in microglia in the spinal discs. NLRP3 levels in microglia strongly correlated with the pain score of the LDD patients, and modestly correlated with the Thompson classification of the degeneration level of the patients. Persistent NLRP3 expression in microglia increased both their phagocytosis potential and production of proinflammatory cytokines, while NLRP3-depleted microglia decreased both their phagocytosis potential and production of proinflammatory cytokines. In a mouse model for LDD, persistent NLRP3 activation in microglia significantly increased the severity of LDD and LDD-associated neuropathic pain, while specific depletion of NLRP3 in microglia significantly attenuated the severity of LDD and reduced the LDD-associated neuropathic pain. ConclusionsPersistent activation of NLRP3 in spinal microglia promotes development of LDD, while suppression of NLRP3 in microglia could be a promising strategy for LDD therapy.	[Wang, Peng; Zhang, Jing] Shanghai Jiao Tong Univ, Dept Orthopaed, XinHua Hosp, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University	Zhang, J (corresponding author), Shanghai Jiao Tong Univ, Dept Orthopaed, XinHua Hosp, Sch Med, Shanghai, Peoples R China.	zhangjing@xinhuamed.com.cn						Boutilier AJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136995; Chen MY, 2021, INFLAMMATION, V44, P1229, DOI 10.1007/s10753-021-01439-6; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Hou Y, 2020, AGING-US, V12, P6558, DOI 10.18632/aging.102909; Ip WKE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7931; Kaiser T, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0448-18.2019; Kamali A, 2021, THERANOSTICS, V11, P27, DOI 10.7150/thno.48987; Katsumoto A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00978; Khan AN, 2017, ANN NY ACAD SCI, V1410, P68, DOI 10.1111/nyas.13551; Lin TY, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610492; Lu Xuan, 2022, Pain, DOI 10.1097/j.pain.0000000000002708; Lyu FJ, 2021, BONE RES, V9, DOI 10.1038/s41413-020-00125-x; Melgoza IP, 2021, JOR SPINE, V4, DOI 10.1002/jsp2.1164; Navone SE, 2018, OSTEOARTHR CARTILAGE, V26, P978, DOI 10.1016/j.joca.2018.04.013; Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Urban JPG, 2020, J BIOMECH, V102, DOI 10.1016/j.jbiomech.2019.109573; Wang HG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126560; Yang G, 2018, MOL PAIN, V14, DOI 10.1177/1744806918811238; Yang XY, 2020, SPINE J, V20, P754, DOI 10.1016/j.spinee.2019.11.002; Zhivaki D, 2021, TRENDS IMMUNOL, V42, P575, DOI 10.1016/j.it.2021.05.001; Zhong Y, 2018, NEUROPEPTIDES, V72, P30, DOI 10.1016/j.npep.2018.10.001	22	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1064303	10.3389/fimmu.2022.1064303	http://dx.doi.org/10.3389/fimmu.2022.1064303			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6VV	36505450	Green Published, gold			2022-12-18	WOS:000893816400001
J	Wang, Q; Qiao, WY; Zhang, HH; Liu, BY; Li, JJ; Zang, CR; Mei, TT; Zheng, JS; Zhang, YH				Wang, Qi; Qiao, Wenying; Zhang, Honghai; Liu, Biyu; Li, Jianjun; Zang, Chaoran; Mei, Tingting; Zheng, Jiasheng; Zhang, Yonghong			Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						nomogram; Lasso-Cox regression; hepatocellular carcinoma; prediction; recurrence	TRANSARTERIAL CHEMOEMBOLIZATION; ALBUMIN-BILIRUBIN; SURVIVAL; GRADE; LIVER; ALBI	PurposeTo investigate the risk factors for recurrence in patients with early-stage hepatocellular carcinoma (HCC) after minimally invasive treatment with curative intent, then to construct a prediction model based on Lasso-Cox regression and visualize the model built. MethodsClinical data were collected from 547 patients that received minimally invasive treatment in our hospital from January 1, 2012, to December 31, 2016. Lasso regression was used to screen risk factors for recurrence. Then we established Cox proportional hazard regression model and random survival forest model including several parameters screened by Lasso regression. An optimal model was selected by comparing the values of C-index, then the model was visualized and the nomogram was finally plotted. ResultsThe variables screened by Lasso regression including age, gender, cirrhosis, tumor number, tumor size, platelet-albumin-bilirubin index (PALBI), and viral load were incorporated in the Cox model and random survival forest model (P<0.05). The C-index of these two models in the training sets was 0.729 and 0.708, and was 0.726 and 0.700 in the validation sets, respectively. So we finally chose Lasso-Cox regression model, and the calibration curve in the validation set performed well, indicating that the model built has a better predictive ability. And then a nomogram was plotted based on the model chosen to visualize the results. ConclusionsThe present study established a nomogram for predicting recurrence in patients with early-stage HCC based on the Lasso-Cox regression model. This nomogram was of some guiding significance for screening populations at high risk of recurrence after treatment, by which doctors can formulate individualized follow-up strategies or treatment protocols according to the predicted risk of relapse for patients to improve the long-term prognosis.	[Wang, Qi; Qiao, Wenying; Liu, Biyu; Zang, Chaoran; Mei, Tingting; Zhang, Yonghong] Capital Med Univ, Beijing Youan Hosp, Res Ctr Biomed Resources, Beijing, Peoples R China; [Zhang, Honghai; Li, Jianjun; Zheng, Jiasheng; Zhang, Yonghong] Capital Med Univ, Beijing Youan Hosp, Intervent Therapy Ctr Oncol, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Zhang, YH (corresponding author), Capital Med Univ, Beijing Youan Hosp, Res Ctr Biomed Resources, Beijing, Peoples R China.; Zhang, YH (corresponding author), Capital Med Univ, Beijing Youan Hosp, Intervent Therapy Ctr Oncol, Beijing, Peoples R China.	zhangyh@ccmu.edu.cn			Beijing Municipal Natural Science Foundation [7191004]; Capital Health Development Project [2020-1-2182, 2020-2-1153]; Beijing Key Laboratory [BZ0373]; Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20181701]; Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals [ZYLX201711]; Beijing Municipal Administration of Hospitals' Incubating Program [PX2018059]; National Key R&D Program of China [2020YFE0202400]	Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation); Capital Health Development Project; Beijing Key Laboratory; Beijing Municipal Administration of Hospitals' Ascent Plan; Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals; Beijing Municipal Administration of Hospitals' Incubating Program; National Key R&D Program of China	This study was funded by a grant Beijing Municipal Natural Science Foundation (7191004), Capital Health Development Project (2020-1-2182 and 2020-2-1153), Beijing Key Laboratory (BZ0373), Beijing Municipal Administration of Hospitals' Ascent Plan (DFL20181701), Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals (ZYLX201711), and Beijing Municipal Administration of Hospitals' Incubating Program (PX2018059), and the National Key R & D Program of China (2020YFE0202400).	El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Hansmann J, 2017, J VASC INTERV RADIOL, V28, P1224, DOI 10.1016/j.jvir.2017.05.020; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Johnson PJ, 2015, J CLIN ONCOL, V33, P550, DOI 10.1200/JCO.2014.57.9151; Ladenheim MR, 2016, BMJ OPEN GASTROENTER, V3, DOI 10.1136/bmjgast-2016-000107; Lee SK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216173; Liu PH, 2017, J GASTROEN HEPATOL, V32, P879, DOI 10.1111/jgh.13608; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Roayaie S, 2015, HEPATOLOGY, V62, p631A; Schmucker DL, 1998, J GERONTOL A-BIOL, V53, pB315, DOI 10.1093/gerona/53A.5.B315; Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wen LT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.657039; Wong JSW, 2011, ALIMENT PHARM THER, V33, P1104, DOI 10.1111/j.1365-2036.2011.04634.x; Wu Eric M, 2018, Hepatoma Res, V4, DOI 10.20517/2394-5079.2018.87; Yang Y, 2021, EUR J RADIOL, V138, DOI 10.1016/j.ejrad.2021.109623; Zhang F, 2021, INT J HYPERTHER, V38, P1, DOI 10.1080/02656736.2020.1850885; Zhong WH, 2021, J ONCOL, V2021, DOI 10.1155/2021/6665267; ZOLI M, 1989, GERONTOLOGY, V35, P61, DOI 10.1159/000213000	23	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1019638	10.3389/fimmu.2022.1019638	http://dx.doi.org/10.3389/fimmu.2022.1019638			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U0HM	36505501	Green Published, gold			2022-12-18	WOS:000894051900001
J	Zhan, YX; Zhao, WP; Ni, KM; Liu, ZC; Su, YJ; Li, XC; Zhang, H; Zhang, CZ				Zhan, Yixiang; Zhao, Weipeng; Ni, Kemin; Liu, Zhaoce; Su, Yanjun; Li, Xichuan; Zhang, Heng; Zhang, Chunze			Case report: Camrelizumab associated with central retinal vein occlusion	FRONTIERS IN IMMUNOLOGY			English	Article						camrelizumab; immunotherapy; case report; vitreous hemorrhage; lung cancer; central retinal vein occlusion	LUNG-CANCER	Immunotherapy has revolutionized cancer treatment and become one of the five pillars of cancer therapy. The clinical applications of immunotherapy have been adapted to range from the management of melanoma to most tumor types. As the clinical applications of cancer immunotherapies expand, understanding the treatment-related adverse events of these drugs becomes critical in clinical practice. We report a rare case of ocular immune-related side effects associated with camrelizumab that resulted in vision loss. A 56-year-old male patient was diagnosed with small cell lung cancer. The tumor involved the porta pulmonis and mediastinum upon initial diagnosis; therefore, surgery was not possible. Upon receiving the 10th immunotherapy session with camrelizumab 200 mg, the patient's visual acuity began to decrease in his right eye and a central retinal vein occlusion. Optical coherence tomography revealed significant cystoid exudation in the macular area and vitreous hemorrhage. The patient underwent vitrectomy, phacoemulsification and intraocular lens implantation after symptom onset. Following surgery, the patient's vision was limitedly restored. This is the first clinical report in China of central retinal vein occlusion and vitreous hemorrhage associated with anti-PD-1 therapy, ultimately leading to blindness. Although rare, clinical practitioners should be concerned about ocular adverse events associated with anti-PD-1 immunotherapy and develop a high index of suspicion for this possibility since ophthalmic manifestations that are rapidly detected, closely monitored, and appropriately managed are treatable.	[Zhan, Yixiang; Ni, Kemin; Liu, Zhaoce; Zhang, Chunze] Tianjin Union Med Ctr, Dept Colorectal Surg, Tianjin, Peoples R China; [Zhan, Yixiang; Ni, Kemin; Liu, Zhaoce] Nankai Univ, Sch Med, Tianjin, Peoples R China; [Zhao, Weipeng] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Breast Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Su, Yanjun] Tianjin Med Univ Canc Inst & Hosp, Tianjin Lung Canc Ctr, Natl Clin Res Ctr Canc, Dept Lung Canc,Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Xichuan] Tianjin Normal Univ, Coll Life Sci, Tianjin Key Lab Anim & Plant Resistance, Tianjin, Peoples R China; [Zhang, Heng] Tianjin Union Med Ctr, Dept Oncol, Tianjin, Peoples R China; [Zhang, Chunze] Nankai Univ, Tianjin Union Med Ctr, Inst Translat Med, Tianjin, Peoples R China; [Zhang, Chunze] Tianjin Union Med Ctr, Tianjin Inst Coloproctol, Tianjin, Peoples R China	Nankai University; Tianjin Medical University; Tianjin Medical University; Tianjin Normal University; Nankai University	Zhang, CZ (corresponding author), Tianjin Union Med Ctr, Dept Colorectal Surg, Tianjin, Peoples R China.; Li, XC (corresponding author), Tianjin Normal Univ, Coll Life Sci, Tianjin Key Lab Anim & Plant Resistance, Tianjin, Peoples R China.; Zhang, H (corresponding author), Tianjin Union Med Ctr, Dept Oncol, Tianjin, Peoples R China.; Zhang, CZ (corresponding author), Nankai Univ, Tianjin Union Med Ctr, Inst Translat Med, Tianjin, Peoples R China.; Zhang, CZ (corresponding author), Tianjin Union Med Ctr, Tianjin Inst Coloproctol, Tianjin, Peoples R China.	xichuanli@tjnu.edu.cn; 13602018589@163.com; chunze.zhang@nankai.edu.cn			Natural Science Foundation of Tianjin [21JCYBJC00180]; Key R&D Projects in the Tianjin Science and Technology Pillar Program [19YFZCSY00420, 18ZXDBSY00040]; Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-044A]; National Natural Science Foundation of China [81872236, 81472183]; Scientific Research Project of Tianjin Educational Committee [2017ZD11]	Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Key R&D Projects in the Tianjin Science and Technology Pillar Program; Tianjin Key Medical Discipline (Specialty) Construction Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Project of Tianjin Educational Committee	This work was supported by the Natural Science Foundation of Tianjin (no. 21JCYBJC00180), Key R & D Projects in the Tianjin Science and Technology Pillar Program (no. 19YFZCSY00420 and no. 18ZXDBSY00040), Tianjin Key Medical Discipline (Specialty) Construction Project (no. TJYXZDXK-044A), the National Natural Science Foundation of China (no. 81872236 and no. 81472183), and Scientific Research Project of Tianjin Educational Committee (no. 2017ZD11).	Abdel-Wahab N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160221; Andrade AR, 2020, CASE REP OPHTHALM, V11, P161, DOI 10.1159/000507609; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Antoun J, 2016, CURR OPIN ONCOL, V28, P288, DOI 10.1097/CCO.0000000000000296; Arbour KC, 2019, JAMA-J AM MED ASSOC, V322, P764, DOI 10.1001/jama.2019.11058; Daxini A, 2018, CLIN RHEUMATOL, V37, P2579, DOI 10.1007/s10067-018-4177-0; Dermarkarian Christopher R, 2020, Am J Ophthalmol Case Rep, V18, P100691, DOI 10.1016/j.ajoc.2020.100691; Dulos J, 2012, J IMMUNOTHER, V35, P169, DOI 10.1097/CJI.0b013e318247a4e7; Fortes BH, 2021, BRIT J OPHTHALMOL, V105, P1263, DOI 10.1136/bjophthalmol-2020-316970; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Manusow JS, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0041-1; Nooreldeen R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168661; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Quach HT, 2021, J AM ACAD DERMATOL, V85, P956, DOI 10.1016/j.jaad.2020.09.054; Scott IU, 2020, LANCET, V396, P1927, DOI 10.1016/S0140-6736(20)31559-2; Shen L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621858; Sibaud V, 2018, AM J CLIN DERMATOL, V19, P345, DOI 10.1007/s40257-017-0336-3; Sun GS, 2022, INT J ONCOL, V60, DOI 10.3892/ijo.2022.5364; Tamura T, 2018, J THORAC ONCOL, V13, P1606, DOI 10.1016/j.jtho.2018.04.026; Theillac C, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0611-3; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Tsui E, 2020, OCUL IMMUNOL INFLAMM, V28, P868, DOI 10.1080/09273948.2019.1610460; Tugan BY, 2021, SEMIN OPHTHALMOL, V36, P794, DOI 10.1080/08820538.2021.1906916; Yang S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0736-3; Zhou L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701951	25	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1025125	10.3389/fimmu.2022.1025125	http://dx.doi.org/10.3389/fimmu.2022.1025125			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9WK	36505454	Green Published, gold			2022-12-18	WOS:000894022900001
J	Zhang, LS; Peng, M				Zhang, Lusi; Peng, Mou			Integrated bioinformatic analysis identified a novel prognostic pan-programmed cell death signature for bladder cancer	FRONTIERS IN IMMUNOLOGY			English	Article						pan-PCD; bladder cancer; immunotherapy; cell death; chemotherapy		Programmed cell death (PCD) refers to a molecularly regulated form of cell death that functions as an essential anticancer defense mechanism and serves as a target of anticancer therapies. Multiple types of PCD comprehensively regulate tumorigenesis and tumor progression and metastasis. However, a systemic exploration of the multiple types of PCD in cancers, especially bladder cancer, is lacking. In this study, we evaluated the expression pattern of genes associated with multiple types of PCD in bladder cancer using the "ssGSEA" method and conceptualized the multiple types of PCD as being collectively involved in "Pan-PCD". Based on the differentially expressed genes related to Pan-PCD, we developed a Pan-PCD-related prognostic signature (PPRPS) to predict patient prognosis via univariate and multivariate Cox regression analysis. The PPRPS is an independent prognostic factor, and the AUC (Area Under Curve) for 3-year overall survival was 0.748. Combined with age and stage, PPRPS displayed excellent predictive ability. Based on the PPRPS, higher levels of immune cell infiltration, tumor microenvironment, and immune checkpoint molecules were observed in the high-PPRPS group. Furthermore, PPRPS enabled accurate risk prediction for metastatic urothelial carcinoma after anti-PD-L1 monoclonal antibody treatment. Patients in the high-PPRPS group had poor prognoses. Docetaxel, staurosporine, and luminespib were identified as potentially effective drugs for high-PPRPS bladder cancer patients. In summary, we developed the Pan-PCD signature to improve the accuracy of bladder cancer prognostic predictions and to provide a novel classification method to guide treatment selection.	[Zhang, Lusi; Peng, Mou] Cent South Univ, Dept Urol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China; [Zhang, Lusi] Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China; [Peng, Mou] Cent South Univ, Natl Clin Res Ctr Metab Dis, Key Lab Diabet Immunol, Minist Educ, Changsha, Peoples R China	Central South University; Central South University; Central South University	Peng, M (corresponding author), Cent South Univ, Dept Urol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.; Peng, M (corresponding author), Cent South Univ, Natl Clin Res Ctr Metab Dis, Key Lab Diabet Immunol, Minist Educ, Changsha, Peoples R China.	pengmou@csu.edu.cn			Natural Science Foundation of Hunan Provincial; Natural Science Foundation of Changsha City;  [2022JJ30831];  [2021JJ40892];  [kq2202389]	Natural Science Foundation of Hunan Provincial; Natural Science Foundation of Changsha City; ; ; 	Funding This study was supported by the Natural Science Foundation of Hunan Provincial (2022JJ30831, 2021JJ40892) and the Natural Science Foundation of Changsha City (kq2202389).	Bagaev A, 2021, CANCER CELL, V39, P845, DOI 10.1016/j.ccell.2021.04.014; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bedoui S, 2020, NAT REV MOL CELL BIO, V21, P678, DOI 10.1038/s41580-020-0270-8; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brisuda A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23748-y; Bryan RT, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0042; Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1033-z; Eke I, 2015, SEMIN CANCER BIOL, V31, P65, DOI 10.1016/j.semcancer.2014.07.009; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Gao B, 2019, J HEPATOL, V70, P249, DOI 10.1016/j.jhep.2018.10.023; Geng Y, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.98; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Jin HL, 2021, AUTOPHAGY, V17, P840, DOI 10.1080/15548627.2020.1733262; Koren E, 2021, CANCER DISCOV, V11, P245, DOI 10.1158/2159-8290.CD-20-0789; Liu Q, 2022, FRONT GENET, V12, DOI 10.3389/fgene.2021.825109; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Liu X, 2019, AM J TRANSL RES, V11, P3972; Lu HC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.803355; Luo WJ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04296-1; Napoli JL, 2017, PHARMACOL THERAPEUT, V173, P19, DOI 10.1016/j.pharmthera.2017.01.004; Nie ZY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.789004; Oka S, 2011, CANCER SCI, V102, P677, DOI 10.1111/j.1349-7006.2011.01869.x; Peng F, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-01110-y; Peng M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.970885; Rabachini T, 2018, CELL DEATH DIFFER, V25, P706, DOI 10.1038/s41418-017-0008-0; Rosario SR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07232-8; Saginala Kalyan, 2020, Med Sci (Basel), V8, DOI 10.3390/medsci8010015; Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22; Seehawer M, 2018, NATURE, V562, P69, DOI 10.1038/s41586-018-0519-y; Serrano-del Valle A, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00050; Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5; Sugano K, 2006, NAT CLIN PRACT UROL, V3, P642, DOI 10.1038/ncpuro0649; Tang JE, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-130; Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17380-5; Zhang Y, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-15209-3	37	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2022	13								1030097	10.3389/fimmu.2022.1030097	http://dx.doi.org/10.3389/fimmu.2022.1030097			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T5ID	36505448	Green Published			2022-12-18	WOS:000893712200001
J	Aggarwal, P; Luo, W; Pehlivan, KC; Hoang, H; Rajappa, P; Cripe, TP; Cassady, KA; Lee, DA; Cairo, MS				Aggarwal, Payal; Luo, Wen; Pehlivan, Katherine C. C.; Hoang, Hai; Rajappa, Prajwal; Cripe, Timothy P. P.; Cassady, Kevin A. A.; Lee, Dean A. A.; Cairo, Mitchell S. S.			Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations	FRONTIERS IN IMMUNOLOGY			English	Review						high grade glioma; glioblastoma; pediatric; adult; immunotherapy	CENTRAL-NERVOUS-SYSTEM; PHASE-II TRIAL; RECURRENT MALIGNANT GLIOMA; WT1 PEPTIDE VACCINATION; BLOOD-BRAIN-BARRIER; CAR T-CELLS; PROGNOSTIC-SIGNIFICANCE; COMBINATION THERAPY; PROLONGED SURVIVAL; SUPPRESSOR-CELLS	High grade gliomas are identified as malignant central nervous tumors that spread rapidly and have a universally poor prognosis. Historically high grade gliomas in the pediatric population have been treated similarly to adult high grade gliomas. For the first time, the most recent classification of central nervous system tumors by World Health Organization has divided adult from pediatric type diffuse high grade gliomas, underscoring the biologic differences between these tumors in different age groups. The objective of our review is to compare high grade gliomas in the adult versus pediatric patient populations, highlighting similarities and differences in epidemiology, etiology, pathogenesis and therapeutic approaches. High grade gliomas in adults versus children have varying clinical presentations, molecular biology background, and response to chemotherapy, as well as unique molecular targets. However, increasing evidence show that they both respond to recently developed immunotherapies. This review summarizes the distinctions and commonalities between the two in disease pathogenesis and response to therapeutic interventions with a focus on immunotherapy.	[Aggarwal, Payal; Luo, Wen; Pehlivan, Katherine C. C.; Hoang, Hai; Cairo, Mitchell S. S.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA; [Luo, Wen; Cairo, Mitchell S. S.] New York Med Coll, Dept Pathol Microbiol & Immunol, Valhalla, NY 10595 USA; [Rajappa, Prajwal; Cripe, Timothy P. P.; Cassady, Kevin A. A.; Lee, Dean A. A.] Nationwide Childrens Hosp, Ctr Childhood Canc Res, Abigail Wexner Res Inst, Columbus, OH USA; [Cairo, Mitchell S. S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA; [Cairo, Mitchell S. S.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; New York Medical College; New York Medical College	Cairo, MS (corresponding author), New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA.; Cairo, MS (corresponding author), New York Med Coll, Dept Pathol Microbiol & Immunol, Valhalla, NY 10595 USA.; Cairo, MS (corresponding author), New York Med Coll, Dept Med, Valhalla, NY 10595 USA.; Cairo, MS (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.	Mitchell_Cairo@nymc.edu			Pediatric Cancer Research Foundation; Children's Cancer Fund;  [U54 (CA232561-01/A1)]	Pediatric Cancer Research Foundation; Children's Cancer Fund; 	This work was supported in part by grant U54 (CA232561-01/A1) (MC, TC, DL, KC), Pediatric Cancer Research Foundation (MC) and Children's Cancer Fund (MC).	Ahluwalia M, 2018, NEURO-ONCOLOGY, V20, P10; Akhavan D, 2019, IMMUNOL REV, V290, P60, DOI 10.1111/imr.12773; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Anderson MG, 2020, MOL CANCER THER, V19, P2117, DOI 10.1158/1535-7163.MCT-20-0149; Antonucci L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867154; Antunes ARP, 2020, ELIFE, V9, DOI 10.7554/eLife.52176; Arvanitis CD, 2020, NAT REV CANCER, V20, P26, DOI 10.1038/s41568-019-0205-x; Aziz-Bose R, 2019, CURR OPIN ONCOL, V31, P522, DOI 10.1097/CCO.0000000000000577; Barish ME, 2022, NEOPLASIA, V30, DOI 10.1016/j.neo.2022.100801; Bax DA, 2009, CLIN CANCER RES, V15, P5753, DOI 10.1158/1078-0432.CCR-08-3210; Berghoff AS, 2017, NEURO-ONCOLOGY, V19, P1460, DOI 10.1093/neuonc/nox054; Bielamowicz K, 2018, NEURO-ONCOLOGY, V20, P506, DOI 10.1093/neuonc/nox182; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Braun K, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0644-z; Buchroithner J, 2018, CANCERS, V10, DOI 10.3390/cancers10100372; Burger MC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02683; Cai DL, 2020, CELL MOL IMMUNOL, V17, P227, DOI 10.1038/s41423-019-0305-2; Cameron BJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006034; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen MH, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108734; CHEUNG NKV, 1987, J CLIN ONCOL, V5, P1430, DOI 10.1200/JCO.1987.5.9.1430; Chu YY, 2021, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-002267; Chu YY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1341031; Clarke JL, 2012, CANCER J, V18, P26, DOI 10.1097/PPO.0b013e318244d7c8; Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P410, DOI 10.1093/neuonc/noq205; Crotty E, 2021, EXPERT REV NEUROTHER, V21, P205, DOI 10.1080/14737175.2020.1855144; Cuoco JA, 2018, WORLD NEUROSURG, V120, P302, DOI 10.1016/j.wneu.2018.08.202; Da Ros M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102879; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; de Billy E, 2022, NEURO-ONCOLOGY, V24, P1150, DOI 10.1093/neuonc/noab300; De Vleeschouwer S, 2008, CLIN CANCER RES, V14, P3098, DOI 10.1158/1078-0432.CCR-07-4875; Donovan LK, 2020, NAT MED, V26, P720, DOI 10.1038/s41591-020-0827-2; Donson AM, 2007, PEDIATR BLOOD CANCER, V48, P403, DOI 10.1002/pbc.20803; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Fanelli GN, 2021, GENES-BASEL, V12, DOI 10.3390/genes12030445; Federico SM, 2017, CLIN CANCER RES, V23, P6441, DOI 10.1158/1078-0432.CCR-17-0379; Fernandes C, 2017, GLIOBLASTOMA, P197, DOI 10.15586/codon.glioblastoma.2017.ch11; Foster JB, 2019, NEURO-ONCOLOGY, V21, P1226, DOI 10.1093/neuonc/noz077; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Furman WL, 2019, CLIN CANCER RES, V25, P6320, DOI 10.1158/1078-0432.CCR-19-1452; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Perez-Larraya JG, 2022, NEW ENGL J MED, V386, P2471, DOI 10.1056/NEJMoa2202028; Gargini R, 2020, CANCERS, V12, DOI 10.3390/cancers12061622; Gauthier J, 2018, CURR RES TRANSL MED, V66, P50, DOI 10.1016/j.retram.2018.03.003; Gesundheit B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00702; Gieryng A, 2017, LAB INVEST, V97, P498, DOI 10.1038/labinvest.2017.19; Goff SL, 2019, J IMMUNOTHER, V42, P126, DOI 10.1097/CJI.0000000000000260; Golan I, 2018, CANCERS, V10, DOI 10.3390/cancers10120522; Golinelli G, 2020, CANCER GENE THER, V27, P558, DOI 10.1038/s41417-018-0062-x; Gururangan S, 2010, J CLIN ONCOL, V28, P3069, DOI 10.1200/JCO.2009.26.8789; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Haydar D, 2021, NEURO-ONCOLOGY, V23, P999, DOI 10.1093/neuonc/noaa278; Hegde M, 2016, J CLIN INVEST, V126, P3036, DOI 10.1172/JCI83416; Hirabayashi K, 2018, ANTICANCER RES, V38, P2227, DOI 10.21873/anticanres.12465; Hosseinalizadeh H, 2022, MED ONCOL, V39, DOI 10.1007/s12032-022-01724-w; Howie D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00409; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Iorio AL, 2017, ONCOTARGET, V8, P89595, DOI 10.18632/oncotarget.19875; Ishikawa E, 2004, ANTICANCER RES, V24, P1861; Iwami K, 2012, CYTOTHERAPY, V14, P733, DOI 10.3109/14653249.2012.666633; Izumoto S, 2008, J NEUROSURG, V108, P963, DOI 10.3171/JNS/2008/108/5/0963; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Jha P, 2019, NEUROPATHOLOGY, V39, P413, DOI 10.1111/neup.12594; Kamran N, 2018, IMMUNOTHERAPY-UK, V10, P317, DOI 10.2217/imt-2017-0122; Kamran N, 2017, MOL THER, V25, P232, DOI 10.1016/j.ymthe.2016.10.003; Kattner P, 2019, CANCER METAST REV, V38, P673, DOI 10.1007/s10555-019-09836-y; Kaufman HL, 2015, NAT REV DRUG DISCOV, V14, P642, DOI 10.1038/nrd4663; Kim SS, 2015, NANOMED-NANOTECHNOL, V11, P301, DOI 10.1016/j.nano.2014.09.005; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lakshmanachetty S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040893; Lam FC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04315-4; Lan FM, 2015, J NEUROCHEM, V134, P811, DOI 10.1111/jnc.13174; Lasky JL, 2013, ANTICANCER RES, V33, P2047; Lassman AB., 2022, NEURO-ONCOLOGY, pnoac173, DOI [10.1093/neuonc/noac173, DOI 10.1093/NEUONC/NOAC173]; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lee YH, 2017, CELL RES, V27, P1034, DOI 10.1038/cr.2017.90; Li G, 2012, J NEURO-ONCOL, V108, P395, DOI 10.1007/s11060-012-0842-3; Li H, 2017, J NEURO-ONCOL, V134, P145, DOI 10.1007/s11060-017-2499-4; Liau LM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1507-6; Lin GL, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0553-x; Lin YJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.817296; Liu YJ, 2017, ONCOTARGET, V8, P42495, DOI 10.18632/oncotarget.17205; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Lu HM, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1748991; Lu VCM, 2021, NEUROSURG FOCUS, V50, DOI 10.3171/2020.11.FOCUS20860; Ma R, 2021, CANCER RES, V81, P3635, DOI 10.1158/0008-5472.CAN-21-0035; Mackay A, 2018, CANCER CELL, V33, P829, DOI 10.1016/j.ccell.2018.04.004; Mackay A, 2017, CANCER CELL, V32, P520, DOI 10.1016/j.ccell.2017.08.017; Majzner RG, 2022, NATURE, V603, P934, DOI 10.1038/s41586-022-04489-4; Marchetti Luca, 2020, Vasc Biol, V2, pH1, DOI 10.1530/VB-19-0033; Martinez-Velez N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10043-0; Marx S, 2020, J NEURO-ONCOL, V147, P577, DOI 10.1007/s11060-020-03470-3; McKinnon C, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1560; Michaeli O, 2018, J KOREAN NEUROSURG S, V61, P319, DOI 10.3340/jkns.2018.0031; Mody R, 2020, J CLIN ONCOL, V38, P2160, DOI 10.1200/JCO.20.00203; Mody R, 2017, LANCET ONCOL, V18, P946, DOI 10.1016/S1470-2045(17)30355-8; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; Mount CW, 2018, NAT MED, V24, P572, DOI 10.1038/s41591-018-0006-x; Mueller S, 2020, J CLIN INVEST, V130, P6325, DOI 10.1172/JCI140378; Murphy MFG, 2013, MATURITAS, V76, P95, DOI 10.1016/j.maturitas.2013.05.017; Nabors LB, 2020, J NATL COMPR CANC NE, V18, P1537, DOI 10.6004/jnccn.2020.0052; Narayana A, 2010, NEURO-ONCOLOGY, V12, P985, DOI 10.1093/neuonc/noq033; Nayyar G, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00051; Nazha B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01000; Nehama D, 2019, EBIOMEDICINE, V47, P33, DOI 10.1016/j.ebiom.2019.08.030; Nitta Y, 2016, CANCER MED-US, V5, P486, DOI 10.1002/cam4.614; Nowosielski M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095830; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Ochs K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328340; Oji Y, 2016, INT J CANCER, V139, P1391, DOI 10.1002/ijc.30182; Omuro A, 2018, NEURO-ONCOLOGY, V20, P674, DOI 10.1093/neuonc/nox208; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/noab200, 10.1093/neuonc/noaa200, 10.1093/neuonc/nov189]; Ousman SS, 2012, NAT NEUROSCI, V15, P1096, DOI 10.1038/nn.3161; Parakh S, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.718590; Parakh S, 2016, EXPERT OPIN DRUG DEL, V13, P401, DOI 10.1517/17425247.2016.1124854; Patel NP, 2019, NEUROL RES, V41, P967, DOI 10.1080/01616412.2019.1638018; Patterson JD, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01582; Penas-Prado M, 2012, HAND CLINIC, V105, P485, DOI 10.1016/B978-0-444-53502-3.00004-5; Petersen CT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00069; Platten M, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0498-1; Pollack IF, 2016, J NEURO-ONCOL, V130, P517, DOI 10.1007/s11060-016-2245-3; Pollack IF, 2014, J CLIN ONCOL, V32, P2050, DOI 10.1200/JCO.2013.54.0526; Prasad G, 2011, NEURO-ONCOLOGY, V13, P384, DOI 10.1093/neuonc/noq193; Prinz M, 2021, ANNU REV IMMUNOL, V39, P251, DOI 10.1146/annurev-immunol-093019-110159; Raja J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0458-z; Reardona DA, 2017, NEURO-ONCOLOGY, V19, P21, DOI 10.1093/neuonc/nox036.071; Rehman H, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0158-5; Ring E, 2016, NEURO-ONCOLOGY, V18, P141; Rosenthal M, 2019, CANCER CHEMOTH PHARM, V84, P327, DOI 10.1007/s00280-019-03879-2; Ross JL, 2021, BRAIN, V144, P2594, DOI 10.1093/brain/awab155; Rudnick JD, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2059; Sabbah DA, 2020, CURR TOP MED CHEM, V20, P815, DOI 10.2174/1568026620666200303123102; SALEH MN, 1992, CANCER RES, V52, P4342; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Sampson JH, 2010, J CLIN ONCOL, V28, P4722, DOI 10.1200/JCO.2010.28.6963; Sampson JH, 2009, MOL CANCER THER, V8, P2773, DOI 10.1158/1535-7163.MCT-09-0124; Sampson JH, 2008, SEMIN IMMUNOL, V20, P267, DOI 10.1016/j.smim.2008.04.001; Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319; Sarkaria JN, 2018, NEURO-ONCOLOGY, V20, P184, DOI 10.1093/neuonc/nox175; Sawada A, 2016, PEDIATR BLOOD CANCER, V63, P234, DOI 10.1002/pbc.25792; Schaller TH, 2017, EXPERT REV VACCINES, V16, P27, DOI 10.1080/14760584.2016.1218762; Sippel TR, 2011, CLIN CANCER RES, V17, P6992, DOI 10.1158/1078-0432.CCR-11-1107; Soman G, 2012, MABS-AUSTIN, V4, P84, DOI 10.4161/mabs.4.1.18566; Soomro SH, 2017, J PAK MED ASSOC, V67, P1410; Souweidane MM, 2018, LANCET ONCOL, V19, P1040, DOI 10.1016/S1470-2045(18)30322-X; Stucklin ASG, 2016, NEUROPEDIATRICS, V47, P70, DOI 10.1055/s-0035-1570491; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Suri V, 2009, NEURO-ONCOLOGY, V11, P274, DOI 10.1215/15228517-2008-092; Tang X, 2019, MOL THER-ONCOLYTICS, V14, P279, DOI 10.1016/j.omto.2019.07.002; Thaci B, 2014, NEURO-ONCOLOGY, V16, P1304, DOI 10.1093/neuonc/nou045; Todo T, 2022, NAT MED, DOI 10.1038/s41591-022-01897-x; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsuboi A, 2019, CANCER IMMUNOL IMMUN, V68, P331, DOI 10.1007/s00262-018-2274-1; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; van Willigen WW, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1738814; Viana-Pereira M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020588; Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309; Wakefield A, 2015, J NEURO-ONCOL, V125, P307, DOI 10.1007/s11060-015-1905-z; Wang HY, 2017, J NEUROSURG, V126, P446, DOI 10.3171/2016.1.JNS152513; Wang J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107507118; Wang J, 2018, J MOL MED, V96, P903, DOI 10.1007/s00109-018-1679-9; Warren KE, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00205; Warren KE, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00239; Wei J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016195, 10.1371/journal.pone.0017868]; Wei X, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01243-1; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Wen PY, 2021, NEURO-ONCOLOGY, V23, P1215, DOI 10.1093/neuonc/noab120; Wen PY, 2019, CLIN CANCER RES, V25, P5799, DOI 10.1158/1078-0432.CCR-19-0261; Wilson Taylor A, 2014, Surg Neurol Int, V5, P64, DOI 10.4103/2152-7806.132138; Wirsching Hans-Georg, 2016, Handb Clin Neurol, V134, P381, DOI 10.1016/B978-0-12-802997-8.00023-2; Wollmann G, 2012, CANCER J, V18, P69, DOI 10.1097/PPO.0b013e31824671c9; Xiong LJ, 2014, INT J MOL SCI, V15, P17411, DOI 10.3390/ijms151017411; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang M, 2013, J NEURO-ONCOL, V115, P19, DOI 10.1007/s11060-013-1207-2; Yang ZX, 2021, CANCER MANAG RES, V13, P8755, DOI 10.2147/CMAR.S336213; Yu AL, 1998, J CLIN ONCOL, V16, P2169, DOI 10.1200/JCO.1998.16.6.2169; Zagzag D, 2005, LAB INVEST, V85, P328, DOI 10.1038/labinvest.3700233; Zhao HF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0670-3; Zhou WT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701006; Zhu X, 2017, J NEUROSURG-PEDIATR, V19, P249, DOI 10.3171/2016.8.PEDS16326	185	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1038096	10.3389/fimmu.2022.1038096	http://dx.doi.org/10.3389/fimmu.2022.1038096			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T4MI	36483545	Green Published, gold			2022-12-18	WOS:000893652100001
J	Brassington, K; Kanellakis, P; Cao, A; Toh, BH; Peter, K; Bobik, A; Kyaw, T				Brassington, Kurt; Kanellakis, Peter; Cao, Anh; Toh, Ban-Hock; Peter, Karlheinz; Bobik, Alex; Kyaw, Tin			Crosstalk between cytotoxic CD8+T cells and stressed cardiomyocytes triggers development of interstitial cardiac fibrosis in hypertensive mouse hearts	FRONTIERS IN IMMUNOLOGY			English	Article						cardiac fibrosis; CD8+T cells; perforin; NKG2D; cardiomyocytes; RAE-1; STING; TGF-beta 1	PRESERVED EJECTION FRACTION; T-CELLS; MYOCARDIAL FIBROSIS; APOPTOTIC CELLS; DIASTOLIC DYSFUNCTION; ACTIVATION; PROMOTE; FAILURE; MECHANISMS; FIBROBLAST	Aims: Cardiac fibrosis is central to heart failure (HF), especially HF with preserved ejection fraction (HFpEF), often caused by hypertension. Despite fibrosis causing diastolic dysfunction and impaired electrical conduction, responsible for arrhythmia-induced sudden cardiac death, the mechanisms are poorly defined and effective therapies are lacking. Here we show that crosstalk between cardiac cytotoxic memory CD8+ T cells and overly stressed cardiomyocytes is essential for development of non-ischemic hypertensive cardiac fibrosis. Methods and results: CD8 T cell depletion in hypertensive mice, strongly attenuated CF, reduced cardiac apoptosis and improved ventricular relaxation. Interaction between cytotoxic memory CD8+ T cells and overly stressed cardiomyocytes is highly dependent on the CD8+ T cells expressing the innate stress-sensing receptor NKG2D and stressed cardiomyocytes expressing the NKG2D activating ligand RAE-1. The interaction between NKG2D and RAE-1 results in CD8+ T cell activation, release of perforin, cardiomyocyte apoptosis, increased numbers of TGF-beta 1 expressing macrophages and fibrosis. Deleting NKG2D or perforin from CD8+ T cells greatly attenuates these effects. Activation of the cytoplasmic DNA-STING-TBK1-IRF3 signaling pathway in overly stressed cardiomyocytes is responsible for elevating RAE-1 and MCP-1, a macrophage attracting chemokine. Inhibiting STING activation greatly attenuates cardiomyocyte RAE-1 expression, the cardiomyocyte apoptosis, TGF-beta 1 and fibrosis. Conclusion: Our data highlight a novel pathway by which CD8 T cells contribute to an early triggering mechanism in CF development; preventing CD8+ T cell activation by inhibiting the cardiomyocyte RAE-1-CD8+ T cell-NKG2D axis holds promise for novel therapeutic strategies to limit hypertensive cardiac fibrosis.	[Brassington, Kurt; Kanellakis, Peter; Cao, Anh; Peter, Karlheinz; Bobik, Alex; Kyaw, Tin] Baker Heart & Diabet Inst, Inflammat & Cardiovasc Dis Lab, Melbourne, Vic, Australia; [Cao, Anh; Toh, Ban-Hock; Bobik, Alex; Kyaw, Tin] Monash Med Ctr, Ctr Inflammatory Dis, Dept Med, Clayton, Vic, Australia; [Peter, Karlheinz; Kyaw, Tin] Univ Melbourne, Baker Dept Cardiometab Hlth, Parkville, Vic, Australia; [Bobik, Alex] Monash Univ, Dept Immunol, Melbourne, Vic, Australia	Monash University; University of Melbourne; Monash University	Kyaw, T (corresponding author), Baker Heart & Diabet Inst, Inflammat & Cardiovasc Dis Lab, Melbourne, Vic, Australia.; Kyaw, T (corresponding author), Monash Med Ctr, Ctr Inflammatory Dis, Dept Med, Clayton, Vic, Australia.; Kyaw, T (corresponding author), Univ Melbourne, Baker Dept Cardiometab Hlth, Parkville, Vic, Australia.	tin.kyaw@baker.edu.au		Brassington, Kurt/0000-0001-5908-1114	National Health and Medical Research Council of Australia;  [APP1106151];  [APP1162251]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); ; 	Funding This work was supported by grants (APP1106151 to AB, B-HT, TK, APP1162251 to AB and B-HT) from the National Health and Medical Research Council of Australia.	Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; AGROTIS A, 1994, HYPERTENSION, V23, P593, DOI 10.1161/01.HYP.23.5.593; Baba T, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03587-x; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Bi XJ, 2021, ADV SCI, V8, DOI 10.1002/advs.202002738; Bottcher JP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9306; Booty MG, 2016, J IMMUNOL, V196, P1822, DOI 10.4049/jimmunol.1502206; Cho JH, 2018, CIRC-ARRHYTHMIA ELEC, V11, DOI 10.1161/CIRCEP.118.006452; Chu T, 2013, CELL REP, V3, P701, DOI 10.1016/j.celrep.2013.02.020; COMBATES NJ, 1995, CLIN IMMUNOL IMMUNOP, V77, P221, DOI 10.1006/clin.1995.1147; Cullen JG, 2019, P NATL ACAD SCI USA, V116, P4481, DOI 10.1073/pnas.1808849116; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Fang CJ, 2021, CELL MOL IMMUNOL, V18, P2211, DOI 10.1038/s41423-020-0456-1; Gao Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00630; Garg P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79729-6; Gasser R, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108790; Gonzalez A, 2002, HYPERTENSION, V39, P75, DOI 10.1161/hy0102.100788; Groschel C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02665; Haag SM, 2018, NATURE, V559, P269, DOI 10.1038/s41586-018-0287-8; Hansen AL, 2019, CELL MOL IMMUNOL, V16, P236, DOI 10.1038/s41423-019-0205-5; Hu D, 2020, AM J PHYSIOL-HEART C, V318, pH1525, DOI 10.1152/ajpheart.00097.2020; Hulsmans M, 2018, J EXP MED, V215, P423, DOI 10.1084/jem.20171274; Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010; Kanellakis P, 2012, CARDIOVASC RES, V95, P77, DOI 10.1093/cvr/cvs142; Kanellakis P, 2011, J HYPERTENS, V29, P1820, DOI 10.1097/HJH.0b013e328349c62d; Kanellakis P, 2010, BRIT J PHARMACOL, V160, P2085, DOI 10.1111/j.1476-5381.2010.00876.x; Khalil H, 2017, J CLIN INVEST, V127, P3770, DOI 10.1172/JCI94753; Kim TS, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0316-1; Kiriazis H, 2013, BRIT J PHARMACOL, V170, P352, DOI 10.1111/bph.12272; Komai Kyoko, 2021, Front Immunol, V12, P763647, DOI 10.3389/fimmu.2021.763647; Kourtzelis I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00553; Kuwahara F, 2002, CIRCULATION, V106, P130, DOI 10.1161/01.CIR.0000020689.12472.E0; Kuwahara F, 2004, HYPERTENSION, V43, P739, DOI 10.1161/01.HYP.0000118584.33350.7d; Kyaw T, 2013, CIRCULATION, V127, P1028, DOI 10.1161/CIRCULATIONAHA.112.001347; Lam AR, 2014, CANCER RES, V74, P2193, DOI 10.1158/0008-5472.CAN-13-1703; Lam CSP, 2018, EUR HEART J, V39, P1770, DOI 10.1093/eurheartj/ehy005; Laroumanie F, 2014, CIRCULATION, V129, P2111, DOI 10.1161/CIRCULATIONAHA.113.007101; Ma FF, 2014, J IMMUNOL, V192, P3365, DOI 10.4049/jimmunol.1301522; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; Midgley AC, 2013, J BIOL CHEM, V288, P14824, DOI 10.1074/jbc.M113.451336; Nacu N, 2008, J IMMUNOL, V180, P5036, DOI 10.4049/jimmunol.180.7.5036; Nevers T, 2017, J EXP MED, V214, P3311, DOI 10.1084/jem.20161791; Novy P, 2007, J IMMUNOL, V179, P8243, DOI 10.4049/jimmunol.179.12.8243; Ogilvie LM, 2020, AM J PHYSIOL-HEART C, V318, pH1139, DOI 10.1152/ajpheart.00705.2019; Okada K, 2004, CIRCULATION, V110, P705, DOI 10.1161/01.CIR.0000137836.95625.D4; Ortiz PA, 2001, HYPERTENSION, V38, P621, DOI 10.1161/hy09t1.093361; ROVIN BH, 1995, KIDNEY INT, V48, P1263, DOI 10.1038/ki.1995.410; Russo I, 2016, J MOL CELL CARDIOL, V90, P84, DOI 10.1016/j.yjmcc.2015.12.011; Sharma K, 2014, CIRC RES, V115, P79, DOI 10.1161/CIRCRESAHA.115.302922; Shen YJ, 2015, CELL REP, V11, P460, DOI 10.1016/j.celrep.2015.03.041; Sweeney M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910865; Takaishi H, 2003, BIOCHEM BIOPH RES CO, V305, P122, DOI 10.1016/S0006-291X(03)00712-5; TANAKA M, 1986, BRIT HEART J, V55, P575; Tanaka T, 2010, BIOCHEM BIOPH RES CO, V399, P677, DOI 10.1016/j.bbrc.2010.07.141; Tay C, 2018, ARTERIOSCL THROM VAS, V38, pE71, DOI 10.1161/ATVBAHA.117.310678; Teo LYL, 2016, CURR OPIN CARDIOL, V31, P410, DOI 10.1097/HCO.0000000000000292; Tokuyama M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002265; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Turner NA, 2016, J MOL CELL CARDIOL, V94, P189, DOI 10.1016/j.yjmcc.2015.11.002; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025; Xiong WP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072772; Xu JA, 2010, AM J PHYSIOL-HEART C, V299, pH1328, DOI 10.1152/ajpheart.00538.2010; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114; Yang J, 2018, AM J TRANSL RES, V10, P4350; Zander R, 2019, IMMUNITY, V51, P1028, DOI 10.1016/j.immuni.2019.10.009; Zhang CG, 2019, NATURE, V567, P394, DOI 10.1038/s41586-019-1000-2; Zhang Y, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110022	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1040233	10.3389/fimmu.2022.1040233	http://dx.doi.org/10.3389/fimmu.2022.1040233			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U5QY	36483558	gold, Green Published			2022-12-18	WOS:000894422400001
J	Dong, Q; Li, D; Xie, BB; Hu, LH; Huang, J; Jia, XX; Tang, YL; Liu, GH; Shen, NN; Yu, XB				Dong, Qiang; Li, Dan; Xie, Bi Bo; Hu, Li Hua; Huang, Jia; Jia, Xiao Xiao; Tang, Yan Li; Liu, Gan Hong; Shen, Ning Ning; Yu, Xiao Bing			IL-17A and TNF-alpha inhibitors induce multiple molecular changes in psoriasis	FRONTIERS IN IMMUNOLOGY			English	Article						proteomics; psoriasis; parallel reaction monitoring; data-independent acquisition mass spectrometry; biological agent; ingenuity pathway analysis; adalimumab; secukinumab	NECROSIS-FACTOR-ALPHA; MODERATE; ARCHITECTURE; EFFICACY; REVEALS; NETWORK; SAFETY	Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psoriatic lesions from patients treated with these drugs using data-independent acquisition mass spectrometry (DIA-MS). Thousands of differentially expressed proteins (DEPs) changed over 12 weeks of treatment. Network analysis showed that DEPs could interact and induce transformation in matrix components, metabolic regulation, and immune response. The results of parallel reaction monitoring (PRM) analysis suggested that S100s, STAT1, KRT2, TYMP, SOD2, HSP90AB1, TFRC, and COL5A1 were the most significantly changed proteins in both groups. There was a positive association between the Psoriasis Area and Severity Index (PASI) score and three proteins (TFRC, IMPDH2, KRT2). Our study findings suggest that inhibition of IL-17A and TNF-alpha can induce changes in multiple molecules in psoriatic lesions and have an overlapping influence on the immune response and process through direct or indirect effects.	[Dong, Qiang; Li, Dan; Xie, Bi Bo; Hu, Li Hua; Huang, Jia; Jia, Xiao Xiao; Tang, Yan Li; Liu, Gan Hong; Shen, Ning Ning; Yu, Xiao Bing] Dermatol Hosp Zhejiang Prov, Dept Dermatol, Huzhou, Zhejiang, Peoples R China		Dong, Q (corresponding author), Dermatol Hosp Zhejiang Prov, Dept Dermatol, Huzhou, Zhejiang, Peoples R China.	QiangDong.edu@outlook.com						Amin M, 2018, AM J CLIN DERMATOL, V19, P1, DOI 10.1007/s40257-017-0328-3; Armstrong AW, 2020, JAMA-J AM MED ASSOC, V323, P1945, DOI 10.1001/jama.2020.4006; Armstrong AW, 2020, JAMA DERMATOL, V156, P258, DOI 10.1001/jamadermatol.2019.4029; Azimi A, 2020, J INVEST DERMATOL, V140, P212, DOI 10.1016/j.jid.2019.06.128; Bolt JW, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020324; Caldarola G, 2020, EXPERT OPIN BIOL TH, V20, P665, DOI 10.1080/14712598.2020.1727439; Egeberg A, 2018, BRIT J DERMATOL, V178, P509, DOI 10.1111/bjd.16102; Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-191; Escoda-Ferran C, 2014, FEBS LETT, V588, P2805, DOI 10.1016/j.febslet.2014.05.064; Fischer JAA, 2015, ARTHRITIS RHEUMATOL, V67, P51, DOI 10.1002/art.38896; Foulkes AC, 2019, J INVEST DERMATOL, V139, P100, DOI 10.1016/j.jid.2018.04.041; Gerdes S, 2020, J EUR ACAD DERMATOL, V34, P533, DOI 10.1111/jdv.16004; Hansen RS, 2021, EXP DERMATOL, V30, P773, DOI 10.1111/exd.14302; Hu YS, 2017, MOL NEUROBIOL, V54, P4452, DOI 10.1007/s12035-016-9998-8; Khatri A, 2019, RHEUMATOLOGY, V58, P352, DOI 10.1093/rheumatology/key312; Koch Michael, 2022, J Invest Dermatol, DOI 10.1016/j.jid.2022.08.048; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Krueger JG, 2019, J ALLERGY CLIN IMMUN, V144, P750, DOI 10.1016/j.jaci.2019.04.029; Krupashankar DS, 2014, J AM ACAD DERMATOL, V71, P484, DOI 10.1016/j.jaad.2014.01.897; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Ludwig C, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178126; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Matsunaga Y, 2021, J DERMATOL, V48, P1518, DOI 10.1111/1346-8138.16032; Maurelli M, 2020, BRIT J DERMATOL, V182, P1502, DOI 10.1111/bjd.18807; Moran B, 2017, J INVEST DERMATOL, V137, P2389, DOI 10.1016/j.jid.2017.05.033; Navrazhina K, 2022, BRIT J DERMATOL, V187, P223, DOI 10.1111/bjd.21060; Nie X, 2021, CELL, V184, P775, DOI 10.1016/j.cell.2021.01.004; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Pappireddi N, 2019, CHEMBIOCHEM, V20, P1210, DOI 10.1002/cbic.201800650; Prassas I, 2015, NAT REV DRUG DISCOV, V14, P183, DOI 10.1038/nrd4534; Reich K, 2015, EXP DERMATOL, V24, P529, DOI 10.1111/exd.12710; Silfvast-Kaiser A, 2019, EXPERT OPIN BIOL TH, V19, P45, DOI 10.1080/14712598.2019.1555235; Sutaria N, 2021, J DERMATOL TREAT, V32, P617, DOI 10.1080/09546634.2019.1688756; Swindell WR, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0208-5; Taipale M, 2014, CELL, V158, P434, DOI 10.1016/j.cell.2014.05.039; Urbano PCM, 2018, J ALLERGY CLIN IMMUN, V142, P517, DOI 10.1016/j.jaci.2017.11.024; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Xu M, 2019, THERANOSTICS, V9, P2475, DOI 10.7150/thno.31144; Zhang JW, 2018, INT IMMUNOPHARMACOL, V65, P84, DOI 10.1016/j.intimp.2018.09.048; Zhu YN, 2017, J ALLERGY CLIN IMMUN, V140, P1310, DOI 10.1016/j.jaci.2017.01.025	41	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1015182	10.3389/fimmu.2022.1015182	http://dx.doi.org/10.3389/fimmu.2022.1015182			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T8VM	36483564	gold, Green Published			2022-12-18	WOS:000893952800001
J	Espino, A; Gouilly, J; Chen, Q; Colin, P; Guerby, P; Izopet, J; Amara, A; Tabiasco, J; Al-Daccak, R; El Costa, H; Jabrane-Ferrat, N				Espino, Ana; Gouilly, Jordi; Chen, Qian; Colin, Philippe; Guerby, Paul; Izopet, Jacques; Amara, Ali; Tabiasco, Julie; Al-Daccak, Reem; El Costa, Hicham; Jabrane-Ferrat, Nabila			The mechanisms underlying the immune control of Zika virus infection at the maternal-fetal interface	FRONTIERS IN IMMUNOLOGY			English	Article						Zika virus; infection; natural killer cells; maternal-fetal interface; inflammation	NATURAL-KILLER-CELLS; UTERINE NK CELLS; DIFFERENTIAL ROLES; IFN-LAMBDA; RECEPTORS; PHOSPHATIDYLSERINE; CYTOTOXICITY; IMMUNOLOGY; ACTIVATION; BINDS	Unlike other Flaviviruses, Zika virus (ZIKV) infection during the first trimester of pregnancy causes severe pregnancy outcomes including the devastating microcephaly and diseases associated with placental dysfunctions. We have previously reported that the maternal decidua basalis, the major maternal-fetal interface, serves as a replication platform enabling virus amplification before dissemination to the fetal compartment. However, the rate of congenital infection is quite low, suggesting the presence of a natural barrier against viral infection. Using primary cells from first-trimester pregnancy samples, we investigated in this study how the maternal decidua can interfere with ZIKV infection. Our study reveals that whether through their interactions with dNK cells, the main immune cell population of the first-trimester decidua, or their production of proinflammatory cytokines, decidual stromal cells (DSCs) are the main regulators of ZIKV infection during pregnancy. We also validate the functional role of AXL as a crucial receptor for ZIKV entry in DSCs and demonstrate that targeted inhibition of ligand-receptor interaction at the early stage of the infection is effective in drastically reducing virus pathogenesis at the maternal-fetal interface. Collectively, our results provide insights into the mechanisms through which ZIKV infection and spreading can be limited. The strategy of circumventing viral entry at the maternal-fetus interface limits virus dissemination to fetal tissues, thereby preventing congenital abnormalities.	[Espino, Ana; Gouilly, Jordi; Chen, Qian; Colin, Philippe; Guerby, Paul; Tabiasco, Julie; El Costa, Hicham; Jabrane-Ferrat, Nabila] Univ Toulouse III, Toulouse Inst Infect & Inflammatory Dis Infin, CNRS, INSERM,UMR1291,UMR5051, Toulouse, France; [Guerby, Paul] Paule Viguier Hosp, Dept Obstet & Gynecol, Toulouse, France; [Izopet, Jacques] Inst Fed Biol, Dept Virol, Toulouse, France; [Amara, Ali] Univ Paris Cite, Hop St Louis, CNRS 7212, INSERM,U944, Paris, France; [Al-Daccak, Reem] Univ Paris Cite, Hop St Louis, INSERM, UMRS976, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jabrane-Ferrat, N (corresponding author), Univ Toulouse III, Toulouse Inst Infect & Inflammatory Dis Infin, CNRS, INSERM,UMR1291,UMR5051, Toulouse, France.	nabila.jabrane-ferrat@inserm.fr		Colin, Philippe/0000-0002-5552-8908	INSERM-CNRS-University Toulouse III; Region Occitanie; Fondation pour la Recherche Medicale (FRM)	INSERM-CNRS-University Toulouse III; Region Occitanie(Region Occitanie); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	This work was supported by funds from the INSERM-CNRS-University Toulouse III, the Region Occitanie and the Fondation pour la Recherche Medicale (FRM).	Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Bruhns P, 1999, J IMMUNOL, V162, P3168; Carty M, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114316; Casazza RL, 2020, VIRAL IMMUNOL, V33, P3, DOI 10.1089/vim.2019.0076; Chaudhary V, 2017, J VIROL, V91, DOI 10.1128/JVI.00163-17; Chen Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16754-z; Crespo AC, 2020, CELL, V182, P1125, DOI 10.1016/j.cell.2020.07.019; Dukhovny A, 2019, J VIROL, V93, DOI 10.1128/JVI.00211-19; El Costa H, 2008, J IMMUNOL, V181, P3009, DOI 10.4049/jimmunol.181.5.3009; El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296; El Costa H, 2009, J REPROD IMMUNOL, V82, P142, DOI 10.1016/j.jri.2009.06.123; Gao DX, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI134529; Golden-Mason L, 2010, HEPATOLOGY, V52, P1581, DOI 10.1002/hep.23896; Guzeloglu-Kayisli O, 2020, J IMMUNOL, V205, P3083, DOI 10.4049/jimmunol.2000713; Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15; Hanna J, 2006, NAT MED, V12, P1065, DOI 10.1038/nm1452; Hershkovitz O, 2009, J IMMUNOL, V183, P2610, DOI 10.4049/jimmunol.0802806; Jabrane-Ferrat Nabila, 2022, Methods Mol Biol, V2407, P205, DOI 10.1007/978-1-0716-1871-4_15; Jabrane-Ferrat N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01397; Jabrane-Ferrat N, 2014, IMMUNOLOGY, V141, P490, DOI 10.1111/imm.12218; Jagger BW, 2017, CELL HOST MICROBE, V22, P366, DOI 10.1016/j.chom.2017.08.012; Jun Y, 2000, J IMMUNOL, V164, P805, DOI 10.4049/jimmunol.164.2.805; Kaiser BK, 2005, J IMMUNOL, V174, P2878, DOI 10.4049/jimmunol.174.5.2878; Kariolis MS, 2014, NAT CHEM BIOL, V10, P977, DOI [10.1038/NCHEMBIO.1636, 10.1038/nchembio.1636]; Kuchipudi SV, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/272359; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Lundberg R, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111024; Male V, 2011, EUR J IMMUNOL, V41, P3017, DOI 10.1002/eji.201141445; Manaster I, 2010, AM J REPROD IMMUNOL, V63, P434, DOI 10.1111/j.1600-0897.2009.00794.x; Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045; Meertens L, 2012, CELL HOST MICROBE, V12, P544, DOI 10.1016/j.chom.2012.08.009; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Moffett A, 2006, NAT REV IMMUNOL, V6, P584, DOI 10.1038/nri1897; Moffett A, 2014, J CLIN INVEST, V124, P1872, DOI 10.1172/JCI68107; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Nattermann J, 2005, ANTIVIR THER, V10, P95; Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Patel MV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.718380; Perera-Lecoin M, 2014, VIRUSES-BASEL, V6, P69, DOI 10.3390/v6010069; Quillay H, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0271-z; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schoggins JW, 2019, ANNU REV VIROL, V6, P567, DOI 10.1146/annurev-virology-092818-015756; Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006; Sen Santara S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2115410118; Siewiera J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003257; Szekeres-Bartho J, 2008, REPROD BIOMED ONLINE, V16, P211, DOI 10.1016/S1472-6483(10)60576-7; Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002; Weisblum Y, 2017, J VIROL, V91, DOI [10.1128/JVI.01905-16, 10.1128/jvi.01905-16]; Whitelaw PF, 1996, PLACENTA, V17, P533, DOI 10.1016/S0143-4004(96)80070-1; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Zhang XH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.728291	57	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1000861	10.3389/fimmu.2022.1000861	http://dx.doi.org/10.3389/fimmu.2022.1000861			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9FN	36483552	gold, Green Published			2022-12-18	WOS:000893978900001
J	Fan, TY; Lu, J; Niu, DL; Zhang, Y; Wang, B; Zhang, B; Zhang, ZG; He, XJI; Peng, N; Li, B; Fang, HL; Gong, Z; Zhang, L				Fan, Tianyu; Lu, Jian; Niu, Delei; Zhang, Yue; Wang, Bin; Zhang, Bei; Zhang, Zugui; He, Xinjiai; Peng, Nan; Li, Biao; Fang, Huilong; Gong, Zheng; Zhang, Li			Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						lung adenocarcinoma (LUAD); TCGA; scRNA-seq; immunotherapy; microenvironment	TUMOR-ASSOCIATED MACROPHAGES; BISPECIFIC ANTIBODY YM101; MICROENVIRONMENT; COMBINATION	Lung adenocarcinoma (LUAD) is the most common type of lung cancer and the leading cause of cancer incidence and mortality worldwide. Despite the improvement of traditional and immunological therapies, the clinical outcome of LUAD is still far from satisfactory. Patients given the same treatment regimen had different responses and clinical outcomes due to the heterogeneity of LUAD. How to identify the targets based on heterogeneity analysis is crucial for treatment strategies. Recently, the single-cell RNA-sequencing (scRNA-seq) technology has been used to investigate the tumor microenvironment (TME) based on cell-specific changes and shows prominently valuable for biomarker prediction. In this study, we systematically analyzed a meta-dataset from the multiple LUAD scRNA-seq datasets in LUAD, identified 15 main types of cells and 57 cell subgroups, and revealed a series of potential biomarkers in M2b, exhausted CD8(+)T, endothelial cells, fibroblast, and metabolic patterns in TME, which further validated with immunofluorescence in clinical cohorts of LUAD. In the prognosis analysis, M0 macrophage and T cell activation were shown correlated to a better prognosis (p<0.05). Briefly, our study provided insights into the heterogeneity of LUAD and assisted in novel therapeutic strategies for clinical outcome improvement.	[Fan, Tianyu; Zhang, Yue; Zhang, Bei; Zhang, Li] Qingdao Univ, Coll Basic Med, Dept Immunol, Qingdao, Shandong, Peoples R China; [Lu, Jian] Suzhou Sci & Technol Town Hosp, Dept Orthopaed, Suzhou, Jiangsu, Peoples R China; [Niu, Delei; Wang, Bin] Qingdao Univ, Coll Basic Med, Dept Pathogen Biol, Qingdao, Shandong, Peoples R China; [Zhang, Zugui] Christiana Care Hlth Syst, Value Inst, Newark, DE USA; [He, Xinjiai] Qingdao Univ, Dept Radiat Oncol, Affiliated Hosp, Qingdao, Shandong, Peoples R China; [Peng, Nan; Li, Biao; Fang, Huilong] Xiangnan Univ, Dept Pathogen Biol & Immunol, Chenzhou, Hunan, Peoples R China; [Gong, Zheng] Qingdao Univ, Sino Cell Biomed Inst Med Cell & Pharmaceut Prot, Qingdao, Shandong, Peoples R China; [Gong, Zheng] Xiangnan Univ, Dept Basic Med, Chenzhou, Hunan, Peoples R China	Qingdao University; Qingdao University; Christiana Care Health System; Qingdao University; Xiangnan University; Qingdao University; Xiangnan University	Zhang, L (corresponding author), Qingdao Univ, Coll Basic Med, Dept Immunol, Qingdao, Shandong, Peoples R China.; Gong, Z (corresponding author), Qingdao Univ, Sino Cell Biomed Inst Med Cell & Pharmaceut Prot, Qingdao, Shandong, Peoples R China.; Gong, Z (corresponding author), Xiangnan Univ, Dept Basic Med, Chenzhou, Hunan, Peoples R China.	xblong2000@gmail.com; 343918320@qq.com			Natural Science Foundation of Shandong Province, China [ZR2021MH138]; China Postdoctoral Science Foundation [2016M592142]; Wu Jieping Medical Foundation Clinical Research Special Fund [320.6750.2021-2-94]; Scientific Research Fund of Hunan Province Health Commission [202101062143]; National Innovation and Entrepreneurship Training Program for College Students [S202010545069S]; Innovation and Entrepreneurship Training Program for College Students of Hunan Province [3697]	Natural Science Foundation of Shandong Province, China(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Wu Jieping Medical Foundation Clinical Research Special Fund; Scientific Research Fund of Hunan Province Health Commission; National Innovation and Entrepreneurship Training Program for College Students; Innovation and Entrepreneurship Training Program for College Students of Hunan Province	This research was funded by Natural Science Foundation of Shandong Province, China grant number (No. ZR2021MH138), The China Postdoctoral Science Foundation grant number (No. 2016M592142), Wu Jieping Medical Foundation Clinical Research Special Fund (No. 320.6750.2021-2-94), The Scientific Research Fund of Hunan Province Health Commission (No. 202101062143), National Innovation and Entrepreneurship Training Program for College Students (No. S202010545069S) and Innovation and Entrepreneurship Training Program for College Students of Hunan Province (No. 3697).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Fu JQ, 2018, ENDOCR-RELAT CANCER, V25, P185, DOI 10.1530/ERC-17-0458; Gao YZ, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03395-7; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanley CJ, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx121; Huang GC, 2012, J SURG ONCOL, V105, P420, DOI 10.1002/jso.22033; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jahanban-Esfahlan R, 2018, J CELL PHYSIOL, V233, P2982, DOI 10.1002/jcp.26051; Jahanban-Esfahlan R, 2017, INT J HEMATOL, V105, P244, DOI 10.1007/s12185-016-2171-3; Jew B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15816-6; Jurisic V, 2020, J ONCOL, V2020, DOI 10.1155/2020/1973241; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Nasim F, 2019, MED CLIN N AM, V103, P463, DOI 10.1016/j.mcna.2018.12.006; Norden PR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235116; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]; Scott AC, 2019, NATURE, V571, P270, DOI 10.1038/s41586-019-1324-y; Taguchi A, 2014, CANCER RES, V74, P4694, DOI 10.1158/0008-5472.CAN-13-3725; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Wang F, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.877896; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wang RP, 2021, NAT MED, V27, P141, DOI 10.1038/s41591-020-1125-8; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Yi M, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01363-8; Yi M, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01155-6; Yi M, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01045-x; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang C, 2019, J THORAC ONCOL, V14, P1912, DOI 10.1016/j.jtho.2019.07.031; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900; Zhang YJ, 2021, J HEPATOL, V75, P1128, DOI 10.1016/j.jhep.2021.06.023; Zhu MC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.783495	37	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1046121	10.3389/fimmu.2022.1046121	http://dx.doi.org/10.3389/fimmu.2022.1046121			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T9CB	36483553	Green Published, gold			2022-12-18	WOS:000893969900001
J	Hou, WT; Yi, C; Zhu, H				Hou, Wanting; Yi, Cheng; Zhu, Hong			Predictive biomarkers of colon cancer immunotherapy: Present and future	FRONTIERS IN IMMUNOLOGY			English	Review						biomarker; immune checkpoint inhibitor (ICI); colon cancer; predictive; immunotherapy	CONSENSUS MOLECULAR SUBTYPES; TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC COLORECTAL-CANCER; MISMATCH REPAIR-DEFICIENT; CELL LUNG-CANCER; MICROSATELLITE INSTABILITY; PD-L1 EXPRESSION; MUTATIONAL BURDEN; PROGNOSTIC IMPACT; ADJUVANT THERAPY	Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors (ICIs) have shown clinical benefits for colon cancer patients, especially those with high microsatellite instability (MSI-H). In 2020, the US Food and Drug Administration (FDA)-approved ICI pembrolizumab as the first-line treatment for metastatic MSI-H colon cancer patients. Additionally, neoadjuvant immunotherapy has presented efficacy in treating early-stage colon cancer patients. Although MSI has been thought of as an effective predictive biomarker for colon cancer immunotherapy, only a small proportion of colon cancer patients were MSI-H, and certain colon cancer patients with MSI-H presented intrinsic or acquired resistance to immunotherapy. Thus, further search for predictive biomarkers to stratify patients is meaningful in colon cancer immunotherapy. Except for MSI, other biomarkers, such as PD-L1 expression level, tumor mutation burden (TMB), tumor-infiltrating lymphocytes (TILs), certain gut microbiota, ctDNA, and circulating immune cells were also proposed to be correlated with patient survival and ICI efficacy in some colon cancer clinical studies. Moreover, developing new diagnostic techniques helps identify accurate predictive biomarkers for colon cancer immunotherapy. In this review, we outline the reported predictive biomarkers in colon cancer immunotherapy and further discuss the prospects of technological changes for biomarker development in colon cancer immunotherapy.	[Hou, Wanting; Yi, Cheng; Zhu, Hong] Sichuan Univ, West China Hosp, Dept Med Oncol, Canc Ctr, Chengdu, Sichuan, Peoples R China	Sichuan University	Zhu, H (corresponding author), Sichuan Univ, West China Hosp, Dept Med Oncol, Canc Ctr, Chengdu, Sichuan, Peoples R China.	441695131@qq.com			Key research projects of Science & Technology of Sichuan Province; Fundamental Research Funds for the Central Universities;  [2022YFS0189];  [2022SCU12058]	Key research projects of Science & Technology of Sichuan Province; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); ; 	Funding This study was supported by grants from the Key research projects of Science & Technology of Sichuan Province (2022YFS0189) and the Fundamental Research Funds for the Central Universities (2022SCU12058).	Aguilar EJ, 2019, ANN ONCOL, V30, P1653, DOI 10.1093/annonc/mdz288; Ahn AR, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-2315; Allen J, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0621-2; Amato M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158726; Amodio V, 2021, CANCERS, V13, DOI 10.3390/cancers13112638; An HJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179414; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Bader JE, 2020, MOL CELL, V78, P1019, DOI 10.1016/j.molcel.2020.05.034; Bai WQ, 2019, CANCER MED-US, V8, P2157, DOI 10.1002/cam4.2111; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879; Berntsson J, 2016, INT J CANCER, V139, P1129, DOI 10.1002/ijc.30138; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Borowsky J, 2021, CLIN CANCER RES, V27, P2816, DOI 10.1158/1078-0432.CCR-20-4009; Bortolomeazzi M, 2021, GASTROENTEROLOGY, V161, P1179, DOI 10.1053/j.gastro.2021.06.064; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; BURKS RT, 1994, ONCOGENE, V9, P1163; Cabel L, 2017, ANN ONCOL, V28, P1996, DOI 10.1093/annonc/mdx212; Chakrabarti S, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.19.00055; Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chen EX, 2020, JAMA ONCOL, V6, P831, DOI 10.1001/jamaoncol.2020.0910; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen YF, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00402-3; Cheng Yi-Kan, 2022, Front Immunol, V13, P809971, DOI 10.3389/fimmu.2022.809971; Chida K, 2022, CLIN CANCER RES, V28, P2110, DOI 10.1158/1078-0432.CCR-22-0041; Clouthier DL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0541-0; Cohen R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001499; Cohen R, 2019, JAMA ONCOL, V5, P551, DOI 10.1001/jamaoncol.2018.4942; Coppola D, 2011, AM J PATHOL, V179, P37, DOI 10.1016/j.ajpath.2011.03.007; Corti F, 2021, EUR J CANCER, V150, P155, DOI 10.1016/j.ejca.2021.03.043; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; de Vries NL, 2020, GUT, V69, P691, DOI 10.1136/gutjnl-2019-318672; Di Caro G, 2014, CLIN CANCER RES, V20, P2147, DOI 10.1158/1078-0432.CCR-13-2590; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213; Dunne PD, 2016, CLIN CANCER RES, V22, P4095, DOI 10.1158/1078-0432.CCR-16-0032; El Sissy C, 2021, CANCERS, V13, DOI 10.3390/cancers13061281; Fancello L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0647-4; Ferrucci PF, 2015, BRIT J CANCER, V112, P1904, DOI 10.1038/bjc.2015.180; Flemer B, 2017, GUT, V66, P633, DOI 10.1136/gutjnl-2015-309595; Fontana E, 2019, ANN ONCOL, V30, P520, DOI 10.1093/annonc/mdz052; Foroutan M, 2021, CANCER IMMUNOL RES, V9, P1125, DOI 10.1158/2326-6066.CIR-21-0137; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Friedman CF, 2022, CANCER DISCOV, V12, P654, DOI 10.1158/2159-8290.CD-21-0450; Fujiyoshi K, 2017, ANTICANCER RES, V37, P239, DOI 10.21873/anticanres.11313; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao Yang, 2021, Front Oncol, V11, P748465, DOI 10.3389/fonc.2021.748465; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Gong J, 2022, MOL CLIN ONCOL, V16, DOI 10.3892/mco.2022.2533; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hamada T, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442999; Hamarsheh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19288-6; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Henriksen TV, 2022, MOL ONCOL, V16, P3654, DOI 10.1002/1878-0261.13294; Herrera M, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01367-x; Herting CJ, 2021, CANCER IMMUNOL IMMUN, V70, P3337, DOI 10.1007/s00262-021-02986-5; Ho HL, 2019, J CANCER RES CLIN, V145, P1785, DOI 10.1007/s00432-019-02942-y; Hou WT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.604227; Hu FJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.758776; Huyghe N, 2020, GASTROENTEROL REP, V8, P11, DOI 10.1093/gastro/goz061; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798; Jacquelot N, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1900508; Jardim DL, 2021, CANCER CELL, V39, P154, DOI 10.1016/j.ccell.2020.10.001; Jiang MS, 2021, J CONTROL RELEASE, V335, P408, DOI 10.1016/j.jconrel.2021.06.001; Joanito I, 2022, NAT GENET, V54, P963, DOI 10.1038/s41588-022-01100-4; Johnson B, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-005332; Kang K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.573141; Khaliq AM, 2022, GENOME BIOL, V23, DOI 10.1186/s13059-022-02677-z; Kikuchi T, 2020, CANCER IMMUNOL IMMUN, V69, P23, DOI 10.1007/s00262-019-02433-6; Kim JH, 2020, CANCER RES TREAT, V52, P1135, DOI 10.4143/crt.2020.218; Kitsou M, 2020, INT J ONCOL, V57, P237, DOI 10.3892/ijo.2020.5062; Klapholz M, 2022, J PATHOL, V257, P186, DOI 10.1002/path.5877; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Krijgsman D, 2019, CANCER IMMUNOL IMMUN, V68, P1011, DOI 10.1007/s00262-019-02343-7; Kuang CY, 2022, CLIN EPIGENETICS, V14, DOI 10.1186/s13148-021-01226-y; Lal N, 2018, CLIN CANCER RES, V24, P224, DOI 10.1158/1078-0432.CCR-17-1090; Laumont CM, 2022, NAT REV CANCER, V22, P414, DOI 10.1038/s41568-022-00466-1; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015; Li SKH, 2016, TRENDS MOL MED, V22, P274, DOI 10.1016/j.molmed.2016.02.003; Li Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00139; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Lichtenstern CR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030618; Lin AQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02039; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; Liu ZQ, 2022, INT IMMUNOPHARMACOL, V111, DOI 10.1016/j.intimp.2022.109173; Lizardo DY, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188447; Llosa NJ, 2019, CANCER IMMUNOL RES, V7, P1574, DOI 10.1158/2326-6066.CIR-18-0927; Loupakis F, 2020, ONCOLOGIST, V25, P481, DOI 10.1634/theoncologist.2019-0611; Luchini C, 2019, ANN ONCOL, V30, P1232, DOI 10.1093/annonc/mdz116; Luo WQ, 2022, INT J BIOL SCI, V18, P1773, DOI 10.7150/ijbs.69808; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Marcuello M, 2019, MOL ASPECTS MED, V69, P107, DOI 10.1016/j.mam.2019.06.002; Marie PK, 2021, CLIN CANCER RES, V27, P3039, DOI 10.1158/1078-0432.CCR-21-0163; Marisa L, 2021, CLIN CANCER RES, V27, P4768, DOI 10.1158/1078-0432.CCR-21-0529; Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915; Martini G, 2022, INT J CANCER, V151, P473, DOI 10.1002/ijc.34033; Masugi Y, 2017, GUT, V66, P1463, DOI 10.1136/gutjnl-2016-311421; McCarthy AJ, 2019, J PATHOL CLIN RES, V5, P115, DOI 10.1002/cjp2.120; McGrail DJ, 2021, ANN ONCOL, V32, P661, DOI 10.1016/j.annonc.2021.02.006; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mei ZB, 2017, CANCER TREAT REV, V58, P1, DOI 10.1016/j.ctrv.2017.05.005; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Mola S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186866; Mur P, 2020, GENET MED, V22, P2089, DOI 10.1038/s41436-020-0922-2; Naito Y, 1998, CANCER RES, V58, P3491; Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189; Ng HHM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000987; Nixon AB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0799-2; Oh CR, 2022, INT J CANCER, V150, P2038, DOI 10.1002/ijc.33966; Omura Y, 2020, CANCER IMMUNOL IMMUN, V69, P2533, DOI 10.1007/s00262-020-02645-1; Osumi H, 2019, CANCER SCI, V110, P1148, DOI 10.1111/cas.13972; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Pan D, 2021, J THORAC ONCOL, V16, P419, DOI 10.1016/j.jtho.2020.11.021; Pan HD, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.934221; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Paver EC, 2021, PATHOLOGY, V53, P141, DOI 10.1016/j.pathol.2020.10.007; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Peng QH, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001638; Peng Z, 2020, CANCER IMMUNOL RES, V8, P1251, DOI 10.1158/2326-6066.CIR-19-1014; Pessoa LS, 2020, CRIT REV ONCOL HEMAT, V155, DOI 10.1016/j.critrevonc.2020.103109; Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369; Posch F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1378844; Ravensbergen CJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10112935; Redman JM, 2022, ONCOLOGIST, V27, P198, DOI 10.1093/oncolo/oyab046; RHYU MG, 1994, ONCOGENE, V9, P29; Rodriguez-Salas N, 2017, CRIT REV ONCOL HEMAT, V109, P9, DOI 10.1016/j.critrevonc.2016.11.007; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Roth AD, 2012, JNCI-J NATL CANCER I, V104, P1635, DOI 10.1093/jnci/djs427; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Roxburgh CSD, 2012, CANCER TREAT REV, V38, P451, DOI 10.1016/j.ctrv.2011.09.001; Sahin IH, 2019, BRIT J CANCER, V121, P809, DOI 10.1038/s41416-019-0599-y; Saied A, 2014, CANCER GENE THER, V21, P457, DOI 10.1038/cgt.2014.50; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825; Schrock AB, 2019, ANN ONCOL, V30, P1096, DOI 10.1093/annonc/mdz134; Segal NH, 2021, CLIN CANCER RES, V27, P2200, DOI 10.1158/1078-0432.CCR-20-2474; Shao YF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.711776; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shin S, 2019, ONCOLOGIST, V24, pE835, DOI 10.1634/theoncologist.2018-0273; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Soyano AE, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0447-2; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Strickler JH, 2021, CLIN CANCER RES, V27, P1236, DOI 10.1158/1078-0432.CCR-20-3054; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1; Taieb J, 2019, ANN ONCOL, V30, P1466, DOI 10.1093/annonc/mdz208; Temraz S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174155; ten Hoorn S, 2022, JNCI-J NATL CANCER I, V114, P503, DOI 10.1093/jnci/djab106; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tie J, 2019, JAMA ONCOL, V5, P1710, DOI 10.1001/jamaoncol.2019.3616; Timmermann B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015661; Trimaglio G, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1790125; Turksma AW, 2016, CLIN CANCER RES, V22, P346, DOI 10.1158/1078-0432.CCR-13-2462; van Velzen MJM, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102024; Vega PN, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.878920; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viale G, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4719194; Wan RJ, 2021, CNS NEUROSCI THER, V27, P973, DOI 10.1111/cns.13654; Wang CJ, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.919389; Wang CK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.18416; Wang CK, 2020, ONCOLOGIST, V25, pE1188, DOI 10.1634/theoncologist.2020-0161; Wang F, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100383; Wang F, 2019, JAMA ONCOL, V5, P1504, DOI 10.1001/jamaoncol.2019.2963; Wang SX, 2021, INT J COLORECTAL DIS, V36, P117, DOI 10.1007/s00384-020-03734-4; Wang WM, 2019, NATURE, V569, P270, DOI 10.1038/s41586-019-1170-y; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wang YC, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.886949; Wennhold K, 2021, CANCER IMMUNOL RES, V9, P1098, DOI 10.1158/2326-6066.CIR-20-0949; Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022; Wu C, 2018, SURG ONCOL CLIN N AM, V27, P235, DOI 10.1016/j.soc.2017.11.001; Xu HJ, 2021, TRENDS MOL MED, V27, P856, DOI 10.1016/j.molmed.2021.06.014; Xu YX, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.901734; Xu YX, 2021, J ONCOL, V2021, DOI 10.1155/2021/2427427; Yang LZ, 2019, ONCOTARGETS THER, V12, P3671, DOI 10.2147/OTT.S190168; Yang YB, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/4846683; YEE CJ, 1994, CANCER RES, V54, P1641; Yeong J, 2020, J CLIN PATHOL, V73, P557, DOI 10.1136/jclinpath-2019-206252; Zeng Z, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.650481; Zhang HC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.855849; Zheng H, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02252-9; Zheng M, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731329; Zong YW, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.673724; Zou Q, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002671	192	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1032314	10.3389/fimmu.2022.1032314	http://dx.doi.org/10.3389/fimmu.2022.1032314			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T2LE	36483562	gold, Green Published			2022-12-18	WOS:000893510400001
J	Li, CY; Qin, DL; Hu, JR; Yang, Y; Hu, D; Yu, BL				Li, Chenyu; Qin, Donglu; Hu, Jiarui; Yang, Yang; Hu, Die; Yu, Bilian			Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction	FRONTIERS IN IMMUNOLOGY			English	Review						obesity; HFPEF; inflamed adipose tissue; NLRP3 inflammasome; inflammation	RIGHT-VENTRICULAR DYSFUNCTION; NATRIURETIC PEPTIDE LEVELS; NLRP3 INFLAMMASOME; DIASTOLIC DYSFUNCTION; INSULIN-RESISTANCE; CARDIAC-FUNCTION; NONINVASIVE ASSESSMENT; GENE-EXPRESSION; RAT MODEL; COLCHICINE	The incidence of heart failure with preserved ejection fraction is increasing in patients with obesity, diabetes, hypertension, and in the aging population. However, there is a lack of adequate clinical treatment. Patients with obesity-related heart failure with preserved ejection fraction display unique pathophysiological and phenotypic characteristics, suggesting that obesity could be one of its specific phenotypes. There has been an increasing recognition that overnutrition in obesity causes adipose tissue expansion and local and systemic inflammation, which consequently exacerbates cardiac remodeling and leads to the development of obese heart failure with preserved ejection fraction. Furthermore, overnutrition leads to cellular metabolic reprogramming and activates inflammatory signaling cascades in various cardiac cells, thereby promoting maladaptive cardiac remodeling. Growing evidence indicates that the innate immune response pathway from the NLRP3 inflammasome, to interleukin-1 to interleukin-6, is involved in the generation of obesity-related systemic inflammation and heart failure with preserved ejection fraction. This review established the existence of obese heart failure with preserved ejection fraction based on structural and functional changes, elaborated the inflammation mechanisms of obese heart failure with preserved ejection fraction, proposed that NLRP3 inflammasome activation may play an important role in adiposity-induced inflammation, and summarized the potential therapeutic approaches.	[Li, Chenyu; Qin, Donglu; Yang, Yang; Hu, Die; Yu, Bilian] Cent South Univ, Xiangya Hosp 2, Res Inst Blood Lipid & Atherosclerosis, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China; [Hu, Jiarui] Cent South Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China	Central South University; Central South University	Yu, BL (corresponding author), Cent South Univ, Xiangya Hosp 2, Res Inst Blood Lipid & Atherosclerosis, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China.	yubilian@csu.edu.cn			National Natural Science Foundation of China; Natural Science Foundation of Hunan Province of China;  [82170483];  [82100496];  [2020JJ4786]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province of China(Natural Science Foundation of Hunan Province); ; ; 	Funding This work was supported in whole or in part by the National Natural Science Foundation of China (No.82170483 to BY and No.82100496 to DH) and the Natural Science Foundation of Hunan Province of China (No.2020JJ4786 to JH).	Abhayaratna WP, 2006, HEART, V92, P1259, DOI 10.1136/hrt.2005.080150; Aizpurua AB, 2018, AM J PHYSIOL-HEART C, V315, pH1670, DOI 10.1152/ajpheart.00024.2018; Alex L, 2018, AM J PHYSIOL-HEART C, V315, pH934, DOI 10.1152/ajpheart.00238.2018; AMAD KH, 1965, CIRCULATION, V32, P740, DOI 10.1161/01.CIR.32.5.740; Amzulescu MS, 2019, EUR HEART J-CARD IMG, V20, P605, DOI 10.1093/ehjci/jez041; Anker SD, 2021, NEW ENGL J MED, V385, P1451, DOI 10.1056/NEJMoa2107038; [Anonymous], 2022, FARXIGA MET PRIMARY; Aschauer S, 2016, EUR J HEART FAIL, V18, P71, DOI 10.1002/ejhf.418; Baker AR, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-1; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Battiprolu PK, 2012, J CLIN INVEST, V122, P1109, DOI 10.1172/JCI60329; Bergman BC, 2016, DIABETOLOGIA, V59, P785, DOI 10.1007/s00125-015-3850-y; Borlaug BA, 2016, EUR HEART J, V37, P3294, DOI 10.1093/eurheartj/ehw241; Bostick B, 2015, AM J PHYSIOL-HEART C, V308, pH1126, DOI 10.1152/ajpheart.00898.2014; Bouabdallaoui N, 2020, EUR HEART J, V41, P4092, DOI 10.1093/eurheartj/ehaa659; Buettner C, 2008, NAT MED, V14, P667, DOI 10.1038/nm1775; Bursi F, 2006, JAMA-J AM MED ASSOC, V296, P2209, DOI 10.1001/jama.296.18.2209; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Carnicer R, 2017, CARDIOVASC RES, V113, P321, DOI 10.1093/cvr/cvx002; Castoldi A, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00637; Chahal H, 2012, CHEST, V141, P388, DOI 10.1378/chest.11-0172; Chirinos JA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004133; Claus P, 2015, JACC-CARDIOVASC IMAG, V8, P1444, DOI 10.1016/j.jcmg.2015.11.001; Cohen JB, 2020, JACC-HEART FAIL, V8, P172, DOI 10.1016/j.jchf.2019.09.009; Cohen JB, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0912-4; Collier P, 2011, EUR J HEART FAIL, V13, P1087, DOI 10.1093/eurjhf/hfr079; Conceicao G, 2016, NETH HEART J, V24, P275, DOI 10.1007/s12471-016-0815-9; Condorelli G, 2002, FASEB J, V16, P1732, DOI 10.1096/fj.02-0419com; Conway WC, 2009, ANN SURG ONCOL, V16, P1548, DOI 10.1245/s10434-009-0420-x; Cuijpers I, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0798-y; D'Amario D, 2021, CLIN RES CARDIOL, V110, P1531, DOI 10.1007/s00392-021-01828-9; Deftereos S, 2014, JACC-HEART FAIL, V2, P131, DOI 10.1016/j.jchf.2013.11.006; Demidowich AP, 2016, MED HYPOTHESES, V92, P67, DOI 10.1016/j.mehy.2016.04.039; Deng Y, 2021, CIRC RES, V128, P232, DOI 10.1161/CIRCRESAHA.120.317933; Dhingra S, 2009, CARDIOVASC RES, V82, P59, DOI 10.1093/cvr/cvp040; Doenst T, 2013, CIRC RES, V113, P709, DOI 10.1161/CIRCRESAHA.113.300376; Du WJ, 2018, THERANOSTICS, V8, P4155, DOI 10.7150/thno.26055; DUFLOU J, 1995, AM HEART J, V130, P306, DOI 10.1016/0002-8703(95)90445-X; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; Elsanhoury A, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.720690; Finucane OM, 2015, DIABETES, V64, P2116, DOI 10.2337/db14-1098; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Fusco-Allison G, 2021, ESC HEART FAIL, V8, P3643, DOI 10.1002/ehf2.13504; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global regional and national incidence prevalence and years lived with disability for 354 diseases and injuries for 195 countries and territories 1990-2017, 2018, LANCET LONDON ENGLAN, V392, P1789, DOI [10.1016/s0140-6736(18)32279-7, DOI 10.1016/S0140-6736(18)32279-7, DOI 10.1016/S0140-6736(18)31221-2]; Gentili A, 2017, TRANSL RES, V186, P52, DOI 10.1016/j.trsl.2017.06.001; Gonzalez N, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0528-4; Gorter TM, 2018, EUR HEART J, V39, P2825, DOI 10.1093/eurheartj/ehy331; Gorter TM, 2016, EUR J HEART FAIL, V18, P1472, DOI 10.1002/ejhf.630; Grebe A, 2018, CIRC RES, V122, P1722, DOI 10.1161/CIRCRESAHA.118.311362; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guidry UC, 2001, AM J RESP CRIT CARE, V164, P933, DOI 10.1164/ajrccm.164.6.2001092; Haass M, 2011, CIRC-HEART FAIL, V4, P324, DOI 10.1161/CIRCHEARTFAILURE.110.959890; Hamdani N, 2013, CIRC-HEART FAIL, V6, P1239, DOI 10.1161/CIRCHEARTFAILURE.113.000539; Harada T, 2020, HEART FAIL CLIN, V16, P357, DOI 10.1016/j.hfc.2020.02.004; Henri O, 2016, CIRCULATION, V133, P1484, DOI 10.1161/CIRCULATIONAHA.115.020143; Honsho S, 2009, CIRC RES, V105, P1149, DOI 10.1161/CIRCRESAHA.109.208199; Horwich TB, 2006, J AM COLL CARDIOL, V47, P85, DOI 10.1016/j.jacc.2005.08.050; Imazio M, 2021, EUR HEART J, V42, P2745, DOI 10.1093/eurheartj/ehab221; Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001; Jin CC, 2013, J ALLERGY CLIN IMMUN, V132, P287, DOI 10.1016/j.jaci.2013.06.022; Joffe II, 1999, J AM COLL CARDIOL, V34, P2111, DOI 10.1016/S0735-1097(99)00436-2; KASPER EK, 1992, AM J CARDIOL, V70, P921, DOI 10.1016/0002-9149(92)90739-L; Kim JH, 2019, DIABETES OBES METAB, V21, P801, DOI 10.1111/dom.13577; Kiran S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.680944; KOEHLER B, 1989, Materia Medica Polona, V21, P131; KRUTZFELDT A, 1990, J MOL CELL CARDIOL, V22, P1393, DOI 10.1016/0022-2828(90)90984-A; Kumar AA, 2019, CIRCULATION, V139, P1435, DOI 10.1161/CIRCULATIONAHA.118.036259; Lafuse WP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010051; Lam CSP, 2007, CIRCULATION, V115, P1982, DOI 10.1161/CIRCULATIONAHA.106.659763; Lee CJ, 2021, HEART FAIL CLIN, V17, P337, DOI 10.1016/j.hfc.2021.02.002; Levine JA, 2022, OBESITY, V30, P358, DOI 10.1002/oby.23341; Li PP, 2015, NAT MED, V21, P239, DOI 10.1038/nm.3800; Libby P, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040951; Loganathan R, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-7; Louch WE, 2011, J MOL CELL CARDIOL, V51, P288, DOI 10.1016/j.yjmcc.2011.06.012; Lu S, 2020, CIRC RES, V126, pE80, DOI 10.1161/CIRCRESAHA.119.316288; Maack C, 2018, EUR HEART J, V39, P4243, DOI 10.1093/eurheartj/ehy596; Mali VR, 2014, EXP BIOL MED, V239, P610, DOI 10.1177/1535370213520109; Mann DL, 2002, CIRC RES, V91, P988, DOI 10.1161/01.RES.0000043825.01705.1B; Martinez GJ, 2018, ATHEROSCLEROSIS, V269, P262, DOI 10.1016/j.atherosclerosis.2017.12.027; Masaidi M, 2009, BLOOD PRESSURE, V18, P23, DOI 10.1080/08037050902850226; Mehlhorn U, 2001, EUR J CARDIO-THORAC, V20, P1220, DOI 10.1016/S1010-7940(01)01031-4; Mehra MR, 2004, J AM COLL CARDIOL, V43, P1590, DOI 10.1016/j.jacc.2003.10.066; Meyer TE, 2006, J AM COLL CARDIOL, V47, P398, DOI 10.1016/j.jacc.2005.08.069; Mills RJ, 2019, APL BIOENG, V3, DOI 10.1063/1.5070106; Mohammed SF, 2015, CIRCULATION, V131, P550, DOI 10.1161/CIRCULATIONAHA.114.009625; Mouton AJ, 2020, CIRC RES, V126, P789, DOI 10.1161/CIRCRESAHA.119.312321; Nachar W, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220707; Narayan P, 2022, CYTOKINE, V151, DOI 10.1016/j.cyto.2022.155811; Nassif ME, 2021, NAT MED, V27, P1954, DOI 10.1038/s41591-021-01536-x; Neeland IJ, 2018, CIRCULATION, V137, P1391, DOI 10.1161/CIRCULATIONAHA.117.029617; Nidorf SM, 2020, NEW ENGL J MED, V383, P1838, DOI 10.1056/NEJMoa2021372; Nidorf SM, 2013, J AM COLL CARDIOL, V61, P404, DOI 10.1016/j.jacc.2012.10.027; Nikolaidis N, 2016, MED HYPOTHESES, V95, P34, DOI 10.1016/j.mehy.2016.08.006; Nishida K, 2017, CARDIOVASC RES, V113, P389, DOI 10.1093/cvr/cvx012; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; Obokata M, 2017, CIRCULATION, V136, P6, DOI 10.1161/CIRCULATIONAHA.116.026807; Olsen MB, 2022, JACC-BASIC TRANSL SC, V7, P84, DOI 10.1016/j.jacbts.2021.08.006; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Pabel S, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.752370; Packer M, 2018, CIRCULATION, V137, P1614, DOI 10.1161/CIRCULATIONAHA.117.032474; PALMER JN, 1995, J CLIN INVEST, V95, P2555, DOI 10.1172/JCI117956; Pan Y, 2014, DIABETES, V63, P3497, DOI 10.2337/db13-1577; Park S, 2013, J IMMUNOL, V191, P4358, DOI 10.4049/jimmunol.1301170; Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pieske B, 2019, EUR HEART J, V40, P3297, DOI 10.1093/eurheartj/ehz641; Prochnicki T, 2017, CELL METAB, V26, P71, DOI 10.1016/j.cmet.2017.06.018; Qin FZ, 2012, CIRCULATION, V125, P1757, DOI 10.1161/CIRCULATIONAHA.111.067801; Querejeta R, 2004, CIRCULATION, V110, P1263, DOI 10.1161/01.CIR.0000140973.60992.9A; Raichur S, 2014, CELL METAB, V20, P687, DOI 10.1016/j.cmet.2014.09.015; Rain S, 2013, CIRCULATION, V128, P2016, DOI 10.1161/CIRCULATIONAHA.113.001873; RANDLE PJ, 1963, LANCET, V1, P785; Reddy YNV, 2018, CIRCULATION, V138, P861, DOI 10.1161/CIRCULATIONAHA.118.034646; Ren J, 2021, PHYSIOL REV, V101, P1745, DOI 10.1152/physrev.00030.2020; Rider OJ, 2015, INT J CARDIOVAS IMAG, V31, P339, DOI 10.1007/s10554-014-0548-z; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Riehle C, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-018-0711-0; Russo C, 2011, J AM COLL CARDIOL, V57, P1368, DOI 10.1016/j.jacc.2010.10.042; Russo S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.746151; Sabbah MS, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.119.006414; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sanders-van Wijk S, 2020, CIRCULATION, V142, P2029, DOI 10.1161/CIRCULATIONAHA.120.045810; SCAGLIONE R, 1992, EUR HEART J, V13, P738, DOI 10.1093/oxfordjournals.eurheartj.a060249; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Schauer A, 2020, ESC HEART FAIL, V7, P2123, DOI 10.1002/ehf2.12915; Schiattarella GG, 2019, NATURE, V568, P351, DOI 10.1038/s41586-019-1100-z; Schulz R, 2009, CIRCULATION, V119, P1355, DOI 10.1161/CIRCULATIONAHA.108.846105; Sciacqua A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020412; Sehgal A, 2021, ENVIRON SCI POLLUT R, V28, P43102, DOI 10.1007/s11356-021-14904-4; Shah AS, 2011, DIABETOLOGIA, V54, P722, DOI 10.1007/s00125-010-1974-7; Shah SJ, 2016, CIRCULATION, V134, P73, DOI 10.1161/CIRCULATIONAHA.116.021884; Sharp TE, 2021, JACC-BASIC TRANSL SC, V6, P154, DOI 10.1016/j.jacbts.2020.11.012; Shen JL, 2020, J CARDIOVASC PHARM, V76, P276, DOI 10.1097/FJC.0000000000000858; Smart N, 2006, CARDIOVASC RES, V69, P164, DOI 10.1016/j.cardiores.2005.08.017; Sotomi Y, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018574; SPAHR R, 1989, MOL CELL BIOCHEM, V88, P59; Spartalis Michael, 2019, Cardiovascular & Hematological Agents in Medicinal Chemistry, V16, P74, DOI 10.2174/1871525717666181211110332; STERNLICHT H, 1979, J BIOL CHEM, V254, P540; Stienstra R, 2011, P NATL ACAD SCI USA, V108, P15324, DOI 10.1073/pnas.1100255108; STODDARD MF, 1992, AM HEART J, V124, P694, DOI 10.1016/0002-8703(92)90280-9; Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054; Sutherland G R, 1994, J Am Soc Echocardiogr, V7, P441; Takatsu M, 2013, HYPERTENSION, V62, P957, DOI 10.1161/HYPERTENSIONAHA.113.02093; Tamaki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068893; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Tong D, 2019, CIRCULATION, V140, P1769, DOI 10.1161/CIRCULATIONAHA.119.042267; Valero-Munoz Maria, 2017, JACC Basic Transl Sci, V2, P770, DOI 10.1016/j.jacbts.2017.07.013; Van den Bergh A, 2006, EUR J HEART FAIL, V8, P777, DOI 10.1016/j.ejheart.2006.03.001; van den Dorpel MMP, 2018, INT J CARDIOVAS IMAG, V34, P743, DOI 10.1007/s10554-017-1287-8; van Empel VPM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001293; van Kimmenade R, 2006, J AM COLL CARDIOL, V47, P886, DOI 10.1016/j.jacc.2005.11.022; Van Tassell BW, 2018, CIRC-HEART FAIL, V11, DOI 10.1161/CIRCHEARTFAILURE.118.005036; Van Tassell BW, 2014, AM J CARDIOL, V113, P321, DOI 10.1016/j.amjcard.2013.08.047; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; VEILLE JC, 1994, AM J OBSTET GYNECOL, V171, P980, DOI 10.1016/0002-9378(94)90018-3; Versari D, 2009, BRIT J PHARMACOL, V157, P527, DOI 10.1111/j.1476-5381.2009.00240.x; Wang TJ, 2004, CIRCULATION, V109, P594, DOI 10.1161/01.CIR.0000112582.16683.EA; Warbrick I, 2019, OBES REV, V20, P701, DOI 10.1111/obr.12828; Wei Michael, 2003, Heart Lung Circ, V12, P44, DOI 10.1046/j.1444-2892.2003.00160.x; Weir JM, 2013, J LIPID RES, V54, P2898, DOI 10.1194/jlr.P035808; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Wenzl FA, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.742178; Westermann D, 2011, CIRC-HEART FAIL, V4, P44, DOI 10.1161/CIRCHEARTFAILURE.109.931451; Whayne TF, 2021, AM J CARDIOVASC DRUG, V21, P1, DOI 10.1007/s40256-020-00408-y; Wijk SSV, 2015, EUR J HEART FAIL, V17, P1006, DOI 10.1002/ejhf.414; Withaar C, 2021, EUR HEART J, V42, P4420, DOI 10.1093/eurheartj/ehab389; Withaar C, 2021, CARDIOVASC RES, V117, P2108, DOI 10.1093/cvr/cvaa256; Wohlfahrt P, 2014, JACC-HEART FAIL, V2, P489, DOI 10.1016/j.jchf.2014.03.014; Wong CY, 2006, J AM COLL CARDIOL, V47, P611, DOI 10.1016/j.jacc.2005.11.015; Wong CY, 2004, CIRCULATION, V110, P3081, DOI 10.1161/01.CIR.0000147184.13872.0F; World Health Organization, OB OV FACTS; Xiao WS, 2021, CIRC RES, V129, P9, DOI 10.1161/CIRCRESAHA.120.318805; Yang HJ, 2020, EXP PHYSIOL, V105, P966, DOI 10.1113/EP088390; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Yu XY, 2012, MOL BIOL REP, V39, P8891, DOI 10.1007/s11033-012-1756-z; Zawieja SD, 2016, AM J PHYSIOL-HEART C, V310, pH385, DOI 10.1152/ajpheart.00664.2015; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1; Zhang HL, 2018, J CELL MOL MED, V22, P4437, DOI 10.1111/jcmm.13743; Zhang NJ, 2017, HEART LUNG CIRC, V26, P251, DOI 10.1016/j.hlc.2016.06.1212; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zile MR, 2015, CIRCULATION, V131, P1247, DOI 10.1161/CIRCULATIONAHA.114.013215	184	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								947147	10.3389/fimmu.2022.947147	http://dx.doi.org/10.3389/fimmu.2022.947147			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T3WI	36483560	Green Published, gold			2022-12-18	WOS:000893609300001
J	Nasiri, F; Kazemi, M; Mirarefin, SMJ; Kancha, MM; Najafabadi, MA; Salem, F; Shokoohi, SD; Bakhshi, SE; Kozani, PS; Kozani, PS				Nasiri, Fatemeh; Kazemi, Mehrasa; Mirarefin, Seyed Mohamad Javad; Mahboubi Kancha, Maral; Ahmadi Najafabadi, Milad; Salem, Faeze; Dashti Shokoohi, Setareh; Evazi Bakhshi, Sahar; Safarzadeh Kozani, Pouya; Safarzadeh Kozani, Pooria			CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil	FRONTIERS IN IMMUNOLOGY			English	Review						triple-negative breast cancer; chimeric antigen receptor; solid tumors; cancer immunotherapy; adoptive cell therapy; T-cell therapy	CHIMERIC ANTIGEN RECEPTORS; ENDOTHELIAL MARKER 8; TUMOR-INFILTRATING LYMPHOCYTES; SULFATE PROTEOGLYCAN 4; ANTITUMOR-ACTIVITY; SOLID TUMORS; FOLATE RECEPTOR; CHECKPOINT BLOCKADE; STEM-CELLS; IN-VITRO	Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine and HER2-specific antibody therapies. To date, surgery, radiotherapy, and systemic chemotherapy remain the principal therapy options for TNBC treatment. However, in numerous cases, these approaches either result in minimal clinical benefit or are nonfunctional, resulting in disease recurrence and poor prognosis. Nowadays, chimeric antigen receptor T cell (CAR-T) therapy is becoming more established as an option for the treatment of various types of hematologic malignancies. CAR-Ts are genetically engineered T lymphocytes that employ the body's immune system mechanisms to selectively recognize cancer cells expressing tumor-associated antigens (TAAs) of interest and efficiently eliminate them. However, despite the clinical triumph of CAR-T therapy in hematologic neoplasms, CAR-T therapy of solid tumors, including TNBC, has been much more challenging. In this review, we will discuss the success of CAR-T therapy in hematological neoplasms and its caveats in solid tumors, and then we summarize the potential CAR-T targetable TAAs in TNBC studied in different investigational stages.	[Nasiri, Fatemeh; Ahmadi Najafabadi, Milad; Salem, Faeze; Dashti Shokoohi, Setareh; Safarzadeh Kozani, Pooria] Tarbiat Modares Univ, Fac Med Sci, Dept Med Biotechnol, Tehran, Iran; [Nasiri, Fatemeh] Natl Res Council Canada, Human Hlth Therapeut Res Ctr, Dept Prod Platforms & Analyt, Montreal, PQ, Canada; [Kazemi, Mehrasa] Mazandaran Univ Med Sci, Hemoglobinopathy Inst, Thalassemia Res Ctr, Dept Lab Med, Sari, Iran; [Mirarefin, Seyed Mohamad Javad] Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, Tehran, Iran; [Mahboubi Kancha, Maral] Shahroud Univ Med Sci, Sch Med, Dept Med Nanotechnol, Shahroud, Iran; [Evazi Bakhshi, Sahar] Guilan Univ Med Sci, Sch Med, Dept Anat Sci, Rasht, Iran; [Safarzadeh Kozani, Pouya] Guilan Univ Med Sci, Fac Paramedicine, Dept Med Biotechnol, Rasht, Iran	Tarbiat Modares University; National Research Council Canada; Mazandaran University Medical Sciences; Tarbiat Modares University; Shahroud University Medical Sciences	Kozani, PS (corresponding author), Tarbiat Modares Univ, Fac Med Sci, Dept Med Biotechnol, Tehran, Iran.	pooriasafarzadeh@modares.ac.ir						Aalipour A, 2020, MOL THER-ONCOLYTICS, V17, P232, DOI 10.1016/j.omto.2020.03.018; Alabanza L, 2017, MOL THER, V25, P2452, DOI 10.1016/j.ymthe.2017.07.013; Alizadeh D, 2019, CANCER IMMUNOL RES, V7, P759, DOI 10.1158/2326-6066.CIR-18-0466; Amoury M, 2016, INT J CANCER, V139, P916, DOI 10.1002/ijc.30119; Anurathapan U, 2014, MOL THER, V22, P623, DOI 10.1038/mt.2013.262; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Barazzuol L, 2020, MOL ONCOL, V14, P1538, DOI 10.1002/1878-0261.12750; Bardia A, 2019, NEW ENGL J MED, V380, P741, DOI 10.1056/NEJMoa1814213; Battula VL, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-1766; Battula VL, 2012, J CLIN INVEST, V122, P2066, DOI 10.1172/JCI59735; Beard RE, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-25; Bedoya DM, 2019, CYTOTHERAPY, V21, pS11, DOI 10.1016/j.jcyt.2019.03.570; Beyer I, 2011, MOL THER, V19, P479, DOI 10.1038/mt.2010.256; Bocca P, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1378843; Boogerd LSF, 2016, ONCOTARGET, V7, P17442, DOI 10.18632/oncotarget.7856; Bouchkouj N, 2019, CLIN CANCER RES, V25, P1702, DOI 10.1158/1078-0432.CCR-18-2743; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751; Byrd TT, 2018, CANCER RES, V78, P489, DOI 10.1158/0008-5472.CAN-16-1911; Calmes-Miller J, 2018, CANCER DISCOV, V8, P5, DOI 10.1158/2159-8290.CD-NB2017-155; Canestrari E, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/3616120; Caruso HG, 2019, J NEURO-ONCOL, V145, P429, DOI 10.1007/s11060-019-03311-y; Chan JD, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1157; Chaudhary A, 2012, CANCER CELL, V21, P212, DOI 10.1016/j.ccr.2012.01.004; Chavez AT, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0804-9; Che YX, 2020, CANCER IMMUNOL IMMUN, V69, P2651, DOI 10.1007/s00262-020-02651-3; Chen Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201900192; Chmielewski M, 2015, EXPERT OPIN BIOL TH, V15, P1145, DOI 10.1517/14712598.2015.1046430; Chmielewski M, 2011, CANCER RES, V71, P5697, DOI 10.1158/0008-5472.CAN-11-0103; Choi BD, 2019, NAT BIOTECHNOL, V37, P1049, DOI 10.1038/s41587-019-0192-1; Choi BD, 2011, EXPERT OPIN BIOL TH, V11, P843, DOI 10.1517/14712598.2011.572874; Cobb DA, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003816; Constantinescu C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000742; Danylesko I, 2020, CURR RES TRANSL MED, V68, P17, DOI 10.1016/j.retram.2019.12.001; Davies G, 2006, INT J ONCOL, V29, P1311; Davis RJ, 2016, ORAL ONCOL, V58, P59, DOI 10.1016/j.oraloncology.2016.05.002; Del Bano J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01593; Deng CW, 2020, MOL THER, V28, P75, DOI 10.1016/j.ymthe.2019.10.010; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dhillon S, 2015, DRUGS, V75, P923, DOI 10.1007/s40265-015-0399-5; Di Stasi A, 2009, BLOOD, V113, P6392, DOI 10.1182/blood-2009-03-209650; Dieci MV, 2014, ANN ONCOL, V25, P611, DOI 10.1093/annonc/mdt556; DiNofia AM, 2021, NAT REV CLIN ONCOL, V18, P195, DOI 10.1038/s41571-021-00485-1; Duell J, 2010, BLOOD, V116, P866; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Feneyrolles C, 2014, MOL CANCER THER, V13, P2141, DOI 10.1158/1535-7163.MCT-13-1083; Feng YX, 2018, GENES DIS, V5, P77, DOI 10.1016/j.gendis.2018.05.001; Fernando S, 2009, CANCER RES, V69, P5126, DOI [10.1158/0008-5476.CAN-09-0725, 10.1158/0008-5472.CAN-09-0725]; Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17; Ferreira LMR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.766220; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fousek K, 2021, LEUKEMIA, V35, P75, DOI 10.1038/s41375-020-0792-2; Fousek K, 2017, BLOOD, V130; Fowler NH, 2022, NAT MED, V28, P325, DOI 10.1038/s41591-021-01622-0; Frey NV, 2022, BLOOD, V140, P11, DOI 10.1182/blood.2021014892; Frey NV, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01892; Frigault MJ, 2015, CANCER IMMUNOL RES, V3, P356, DOI 10.1158/2326-6066.CIR-14-0186; Fu S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011203; Fujiwara K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051182; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Geldres C, 2014, CLIN CANCER RES, V20, P962, DOI 10.1158/1078-0432.CCR-13-2218; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Ghassemi S, 2020, CYTOTHERAPY, V22, pS133; Ghassemi S, 2020, MOL THER-METH CLIN D, V18, P595, DOI 10.1016/j.omtm.2020.07.008; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Giuffrida L, 2020, MOL THER, V28, P2379, DOI 10.1016/j.ymthe.2020.07.018; Gohil S, 2017, LANCET, V389, P40; Gohil SH, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.3361.3361; Goldenberg David M, 2018, Oncotarget, V9, P28989, DOI 10.18632/oncotarget.25615; Grosser R, 2019, CANCER CELL, V36, P471, DOI 10.1016/j.ccell.2019.09.006; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Guo P, 2014, P NATL ACAD SCI USA, V111, P14710, DOI 10.1073/pnas.1408556111; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Gutierrez R, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.e14513; Gutwein LG, 2011, ANTICANCER RES, V31, P3417; Halpin-Veszeleiova K, 2020, CURR OPIN PHARMACOL, V53, P84, DOI 10.1016/j.coph.2020.07.005; Han KL, 2017, AAPS J, V19, P527, DOI 10.1208/s12248-016-0029-5; Han YL, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0635-z; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0122-z, 10.1038/s41572-019-0111-2]; Hatfield SM, 2014, J MOL MED, V92, P1283, DOI 10.1007/s00109-014-1189-3; Heng G, 2020, CLIN CANCER RES, V26, P1606, DOI 10.1158/1078-0432.CCR-19-1339; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hu WH, 2019, CANCER IMMUNOL IMMUN, V68, P365, DOI 10.1007/s00262-018-2281-2; Hu ZW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59736-3; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Ilieva KM, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01911; Jacobson CA, 2022, LANCET ONCOL, V23, P91, DOI 10.1016/S1470-2045(21)00591-X; Jia HY, 2017, DRUG RESIST UPDATE, V32, P1, DOI 10.1016/j.drup.2017.07.002; Jin LC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11869-4; Juillerat A, 2017, SCI REP-UK, V7, DOI 10.1038/srep39833; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kagoya Y, 2018, NAT MED, V24, P352, DOI 10.1038/nm.4478; Kailayangiri S, 2020, CANCERS, V12, DOI 10.3390/cancers12051075; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Kim MS, 2015, J AM CHEM SOC, V137, P2832, DOI 10.1021/jacs.5b00106; Kim YJ, 2014, INT J CANCER, V134, P2424, DOI 10.1002/ijc.28566; Klampatsa A, 2021, EXPERT OPIN BIOL TH, V21, P473, DOI 10.1080/14712598.2021.1843628; Ko HJ, 2009, J IMMUNOL, V182, P1818, DOI 10.4049/jimmunol.0802430; Kozani PS, 2022, FRONT MED-PRC, V16, P322, DOI 10.1007/s11684-021-0901-2; Kozani PS, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101079; Kozani PS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.795164; Kumar CC, 2003, CURR DRUG TARGETS, V4, P123, DOI 10.2174/1389450033346830; Landoni E, 2021, CANCER IMMUNOL RES, V9, P441, DOI 10.1158/2326-6066.CIR-20-0451; Lanitis E, 2013, CANCER IMMUNOL RES, V1, P43, DOI 10.1158/2326-6066.CIR-13-0008; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Li GC, 2021, MOL THER-ONCOLYTICS, V22, P507, DOI 10.1016/j.omto.2021.07.003; Li H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0238-6; Li J, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0568-6; Li X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02293; Li ZH, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1514-7; Lim M, 2005, HUM PATHOL, V36, P665, DOI 10.1016/j.humpath.2005.03.014; Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036; Liu HC, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003468; Liu Y, 2019, AGING-US, V11, P11054, DOI 10.18632/aging.102510; Liu YF, 2018, J IMMUNOTHER, V41, P406, DOI 10.1097/CJI.0000000000000243; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Louis CU, 2011, BLOOD, V118, P6050, DOI 10.1182/blood-2011-05-354449; Lumachi Franco, 2015, World J Biol Chem, V6, P231, DOI 10.4331/wjbc.v6.i3.231; Luo CY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.919072; Ly S, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001197; Ma L, 2019, SCIENCE, V365, P162, DOI 10.1126/science.aav8692; Magalhaes Isabelle, 2019, Expert Opin Biol Ther, V19, P811, DOI 10.1080/14712598.2019.1608179; Majzner RG, 2020, CANCER DISCOV, V10, P702, DOI 10.1158/2159-8290.CD-19-0945; Makki J, 2015, CLIN MED INSIGHTS-PA, V8, DOI 10.4137/CPath.S31563; Malhotra GK, 2010, CANCER BIOL THER, V10, P955, DOI 10.4161/cbt.10.10.13879; Marra A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1326-5; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mayor P, 2018, GYNECOL ONCOL, V150, P361, DOI 10.1016/j.ygyno.2018.05.024; Mei H, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01170-7; Miller IC, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-021-00781-2; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Monsuez JJ, 2010, INT J CARDIOL, V144, P3, DOI 10.1016/j.ijcard.2010.03.003; Morisaki T, 2012, ANTICANCER RES, V32, P2241; Muller N, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01251; Mullard A, 2022, NAT REV DRUG DISCOV, V21, P249, DOI 10.1038/d41573-022-00048-8; Mullard A, 2021, NAT REV DRUG DISCOV, V20, P332, DOI 10.1038/d41573-021-00063-1; Mullard A, 2021, NAT REV DRUG DISCOV, V20, P166, DOI 10.1038/d41573-021-00031-9; Mullard A, 2017, NAT REV DRUG DISCOV, V16, P669, DOI 10.1038/nrd.2017.196; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; Muller YD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639818; Murad JM, 2018, CYTOTHERAPY, V20, P952, DOI 10.1016/j.jcyt.2018.05.001; Nakai K, 2016, AM J CANCER RES, V6, P1609; Nellan A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0340-z; Newick K, 2016, CANCER IMMUNOL RES, V4, P541, DOI 10.1158/2326-6066.CIR-15-0263; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; O'Shannessy DJ, 2012, SPRINGERPLUS, V1, DOI 10.1186/2193-1801-1-22; Opoku-Darko M, 2011, CANCER INVEST, V29, P676, DOI 10.3109/07357907.2011.626474; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parinyanitikul N, 2013, CLIN BREAST CANCER, V13, P378, DOI 10.1016/j.clbc.2013.05.001; Park AK, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz1863; Park S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14749-3; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patel S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00196; Patel SR, 2001, CANCER, V92, P1347, DOI 10.1002/1097-0142(20010901)92:5<1347::AID-CNCR1456>3.0.CO;2-0; Paul Symonds R., 2006, CURR OBSTET GYNAECOL, V16, P100, DOI [10.1016/j.curobgyn.2006.01.006, DOI 10.1016/J.CUROBGYN.2006.01.006]; Pernas S, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919833519; Petrovic K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224015; Pfeifer R., 2018, EVALUATION SSEA 4 CA; Porter CE, 2020, MOL THER, V28, P1251, DOI 10.1016/j.ymthe.2020.02.016; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Posey AD, 2016, IMMUNITY, V44, P1444, DOI 10.1016/j.immuni.2016.05.014; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; Poznansky MC, 2002, J CLIN INVEST, V109, P1101, DOI 10.1172/JCI200213853; Prasad V, 2018, NAT REV CLIN ONCOL, V15, P11, DOI 10.1038/nrclinonc.2017.156; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607; Reinhard K, 2020, SCIENCE, V367, P446, DOI 10.1126/science.aay5967; Rose M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.564601; Russnes HG, 2017, AM J PATHOL, V187, P2152, DOI 10.1016/j.ajpath.2017.04.022; Kozani PS, 2022, CRIT REV BIOTECHNOL, V42, P1079, DOI 10.1080/07388551.2021.1988509; Kozani PS, 2022, BIOMARK RES, V10, DOI 10.1186/s40364-022-00371-7; Kozani PS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.765097; Kozani PS, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02595-0; Salazar MD, 2007, CANCER METAST REV, V26, P141, DOI 10.1007/s10555-007-9048-0; Sallman DA, 2018, HAEMATOLOGICA, V103, pE424, DOI 10.3324/haematol.2017.186742; Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817; Schmid P, 2020, LANCET ONCOL, V21, P44, DOI 10.1016/S1470-2045(19)30689-8; Schnell O, 2008, BRAIN PATHOL, V18, P378, DOI 10.1111/j.1750-3639.2008.00137.x; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Seitz CM, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1683345; Shah PD, 2020, J CLIN ONCOL, V38; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Shvartsur Anna, 2015, Genes Cancer, V6, P84; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Slaney CY, 2017, CLIN CANCER RES, V23, P2478, DOI 10.1158/1078-0432.CCR-16-1860; Song DG, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0285-y; Song DG, 2011, CANCER RES, V71, P4617, DOI 10.1158/0008-5472.CAN-11-0422; Specht JM, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-P2-09-13; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Sterner RM, 2019, BLOOD, V133, P697, DOI 10.1182/blood-2018-10-881722; Stoner Alyssa, 2020, Crit Care Explor, V2, pe0093, DOI 10.1097/CCE.0000000000000093; Tanaka M, 2017, CLIN CANCER RES, V23, P3499, DOI 10.1158/1078-0432.CCR-16-2138; Tang XY, 2020, CANCER LETT, V487, P1, DOI 10.1016/j.canlet.2020.05.013; Tchou J, 2017, CANCER IMMUNOL RES, V5, P1152, DOI 10.1158/2326-6066.CIR-17-0189; Tchou J, 2012, BREAST CANCER RES TR, V133, P799, DOI 10.1007/s10549-012-2018-4; Theruvath J, 2020, NAT MED, V26, P712, DOI 10.1038/s41591-020-0821-8; Toffoli G, 1997, INT J CANCER, V74, P193, DOI 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F; Tokarew N, 2019, BRIT J CANCER, V120, P26, DOI 10.1038/s41416-018-0325-1; Tozbikian G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114900; van der Stegen SJC, 2015, NAT REV DRUG DISCOV, V14, P499, DOI 10.1038/nrd4597; Vedvyas Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46938-7; Voelker R, 2020, JAMA-J AM MED ASSOC, V324, P832, DOI 10.1001/jama.2020.15456; Voeller J, 2019, J PEDIAT HEMATOL ONC, V41, P163, DOI 10.1097/MPH.0000000000001369; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Wallstabe L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126345; Wallstabe Lars, 2018, Adv Cell Gene Ther, V1, DOI 10.1002/acg2.11; Wang J, 2017, CLIN EXP PHARMACOL P, V44, P79, DOI 10.1111/1440-1681.12672; Wang N, 2020, BLOOD, V135, P17, DOI 10.1182/blood.2019000017; Wang WJ, 2021, NEURO-ONCOLOGY, V23, P63, DOI 10.1093/neuonc/noaa206; Wei J, 2018, CELL IMMUNOL, V331, P49, DOI 10.1016/j.cellimm.2018.05.004; Whilding LM, 2019, CANCERS, V11, DOI 10.3390/cancers11050674; Wick W, 2016, NEURO-ONCOLOGY, V18, P315, DOI 10.1093/neuonc/nov180; Wing A, 2018, CANCER IMMUNOL RES, V6, P605, DOI 10.1158/2326-6066.CIR-17-0314; Wu MR, 2019, CYTOTHERAPY, V21, P659, DOI 10.1016/j.jcyt.2019.03.313; Wu Y, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax9364; Xia L, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1135; Xia W, 2010, J MED CHEM, V53, P6811, DOI 10.1021/jm100509v; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Xue JL, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108921; Yang Y., 2019, CANCER RES, V79, P2322, DOI [10.1158/1538-7445.AM2019-2322, DOI 10.1158/1538-7445.AM2019-2322]; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Yeku OO, 2016, BIOCHEM SOC T, V44, P412, DOI 10.1042/BST20150291; Yoon DH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020340; Young A, 2016, CANCER CELL, V30, P391, DOI 10.1016/j.ccell.2016.06.025; Yu L, 2019, J CANCER RES CLIN, V145, P941, DOI 10.1007/s00432-019-02867-6; Zeichner SB, 2016, BREAST CANCER-BASIC, V10, DOI 10.4137/BCBCR.S32783; Zhai XC, 2021, AM J CANCER RES, V11, P79; Zhang T, 2005, BLOOD, V106, P1544, DOI 10.1182/blood-2004-11-4365; Zhang YJ, 2021, J CANCER RES CLIN, V147, P3725, DOI 10.1007/s00432-021-03613-7; Zhao W, 2019, AM J CANCER RES, V9, P1846; Zhao XX, 2017, ONCOTARGET, V8, P56758, DOI 10.18632/oncotarget.18142; Zhao ZH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4795171; Zhong XS, 2010, MOL THER, V18, P413, DOI 10.1038/mt.2009.210; Zhou JT, 2020, CANCER MANAG RES, V12, P8893, DOI 10.2147/CMAR.S260915; Zhou R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01149	249	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1018786	10.3389/fimmu.2022.1018786	http://dx.doi.org/10.3389/fimmu.2022.1018786			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T2KN	36483567	Green Published, gold			2022-12-18	WOS:000893508700001
J	Pan, SY; Tian, HM; Zhu, Y; Gu, WJ; Zou, H; Wu, XQ; Cheng, RJ; Yang, Z				Pan, Shu-Yue; Tian, Hui-Min; Zhu, Yong; Gu, Wei-Jie; Zou, Hao; Wu, Xu-Qiang; Cheng, Rui-Juan; Yang, Zhi			Cardiac damage in autoimmune diseases: Target organ involvement that cannot be ignored	FRONTIERS IN IMMUNOLOGY			English	Review						autoimmune disease; cardiac damage; rheumatoid arthritis; systemic lupus erythematosus; polymyositis; dermatomyositis; Sjogren's Syndrome; systemic sclerosis	SYSTEMIC-LUPUS-ERYTHEMATOSUS; IDIOPATHIC INFLAMMATORY MYOPATHIES; CARDIOVASCULAR RISK-FACTORS; VALVULAR HEART-DISEASE; RHEUMATOID-ARTHRITIS; CONSTRICTIVE PERICARDITIS; DIASTOLIC FUNCTION; SCLEROSIS; DYSFUNCTION; RO	Autoimmune diseases are diseases that cause damage to the body's own tissues as a result of immune dysfunction, often involving multiple organs and systems. The heart is one of the common target organs of autoimmune diseases. The whole structure of the heart can be affected, causing microcirculatory disorders, arrhythmias, pericardial damage, myocarditis, myocardial fibrosis, and impaired valvular function. However, early clinical manifestations of autoimmune heart damage are often overlooked because they are insidious or have no typical features. The damage is often severe and irreversible when symptoms are apparent, even life-threatening. Therefore, early detection and treatment of heart damage in autoimmune diseases is particularly important. Herein, we review the clinical features and mechanisms of cardiac damage in common rheumatic diseases.	[Pan, Shu-Yue; Tian, Hui-Min; Zhu, Yong; Gu, Wei-Jie; Zou, Hao; Wu, Xu-Qiang] Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 5, Dept Rheumatol & Immunol, Peoples Hosp 5, Chengdu, Peoples R China; [Cheng, Rui-Juan] Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, Chengdu, Sichuan, Peoples R China; [Yang, Zhi] Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 5, Dept Radiol, Peoples Hosp 5, Chengdu, Peoples R China	Chengdu University of Traditional Chinese Medicine; Sichuan University; Chengdu University of Traditional Chinese Medicine	Cheng, RJ (corresponding author), Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, Chengdu, Sichuan, Peoples R China.; Yang, Z (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 5, Dept Radiol, Peoples Hosp 5, Chengdu, Peoples R China.	orange411@qq.com; yangzhicdwy@qq.com			Seedling project of science and Technology Department of Sichuan Province;  [2021JDRC0153]	Seedling project of science and Technology Department of Sichuan Province; 	Funding Seedling project of science and Technology Department of Sichuan Province (Project no. 2021JDRC0153) to S-YP.	Avina-Zubieta JA, 2017, ARTHRIT CARE RES, V69, P849, DOI 10.1002/acr.23018; BULKLEY BH, 1976, CIRCULATION, V53, P483, DOI 10.1161/01.CIR.53.3.483; Cannarile F, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2014.12.12; Casian M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.865373; Castaneda S, 2018, CURR PHARM DESIGN, V24, P262, DOI 10.2174/1381612824666180123102632; CERVERA R, 1992, ANN RHEUM DIS, V51, P156, DOI 10.1136/ard.51.2.156; Chang JC, 2018, LUPUS, V27, P2146, DOI 10.1177/0961203318804889; Cooper LT, 2009, NEW ENGL J MED, V360, P1526, DOI 10.1056/NEJMra0800028; Dai H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007320; Damoiseaux J, 2015, AUTOIMMUN REV, V14, P555, DOI 10.1016/j.autrev.2015.01.017; Danieli MG, 2016, AUTOIMMUN REV, V15, P462, DOI 10.1016/j.autrev.2016.01.015; Davis JM, 2008, ARTHRITIS RHEUM, V58, P2603, DOI 10.1002/art.23798; Dhir Teena, 2013, Int J Biomed Sci, V9, P107; Di Franco M, 2000, ANN RHEUM DIS, V59, P227, DOI 10.1136/ard.59.3.227; Espinola Zavaleta Nilda, 1997, Archivos del Instituto de Cardiologia de Mexico, V67, P114; Fairley JL, 2022, RHEUMATOLOGY, V61, P103, DOI 10.1093/rheumatology/keab573; Ferri C, 2002, MEDICINE, V81, P139, DOI 10.1097/00005792-200203000-00004; Finkelstein Y, 1997, ANN MED INTERNE, V148, P205; Gabriel SE, 2008, AM J MED, V121, P9, DOI 10.1016/j.amjmed.2008.06.011; Gasparyan AY, 2012, RHEUMATOL INT, V32, P461, DOI 10.1007/s00296-009-1318-4; Talepoor AG, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.945016; Gonzalez A, 2008, ANN RHEUM DIS, V67, P64, DOI 10.1136/ard.2006.059980; Gupta S, 2020, CUREUS, V12, DOI 10.7759/cureus.11256; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Holmstrom M, 2016, CLIN EXP RHEUMATOL, V34, P416; Hughes M, 2015, ANN RHEUM DIS, V74, P795, DOI 10.1136/annrheumdis-2014-206812; Jain D, 2009, J CLIN PATHOL, V62, P584, DOI 10.1136/jcp.2009.064311; Jia ET, 2019, IRISH J MED SCI, V188, P801, DOI 10.1007/s11845-018-1934-7; Jordan AD, 2011, HEART LUNG CIRC, V20, P24, DOI 10.1016/j.hlc.2010.08.014; Kessler J, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105494; Koivuniemi R, 2013, SCAND J RHEUMATOL, V42, P131, DOI 10.3109/03009742.2012.723747; Kurmann RD, 2021, J RHEUMATOL, V48, P1047, DOI 10.3899/jrheum.201005; Lazzerini PE, 2007, AM J CARDIOL, V100, P1029, DOI 10.1016/j.amjcard.2007.04.048; Lazzerini PE, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010595; Lazzerini PE, 2017, NAT REV CARDIOL, V14, P521, DOI 10.1038/nrcardio.2017.61; Lazzerini PE, 2017, EUR HEART J, V38, P1717, DOI 10.1093/eurheartj/ehw208; Lindop R, 2012, IMMUNOL CELL BIOL, V90, P304, DOI 10.1038/icb.2011.108; LOGAR D, 1990, ANN RHEUM DIS, V49, P627, DOI 10.1136/ard.49.8.627; Lundberg IE, 2006, RHEUMATOLOGY, V45, P18, DOI 10.1093/rheumatology/kel311; Maceira AM, 2006, J CARDIOVASC MAGN R, V8, P417, DOI 10.1080/10976640600572889; Mantel A, 2017, J AM COLL CARDIOL, V69, P1275, DOI 10.1016/j.jacc.2016.12.033; Mavrogeni S, 2017, LUPUS, V26, P227, DOI 10.1177/0961203316671810; Mavrogeni S, 2013, SEMIN ARTHRITIS RHEU, V43, P314, DOI 10.1016/j.semarthrit.2013.05.001; MULLINS PA, 1991, AM HEART J, V122, P242, DOI 10.1016/0002-8703(91)90789-K; Myasoedova E, 2011, J RHEUMATOL, V38, P983, DOI 10.3899/jrheum.101133; Nurmohamed MT, 2009, AUTOIMMUN REV, V8, P663, DOI 10.1016/j.autrev.2009.02.015; Panchal L, 2006, J POSTGRAD MED, V52, P5; Parkes JE, 2015, CURR OPIN RHEUMATOL, V27, P608, DOI 10.1097/BOR.0000000000000225; Petersen LE, 2015, NEUROIMMUNOMODULAT, V22, P130, DOI 10.1159/000358437; QUISMORIO FP, 1980, ARCH INTERN MED, V140, P112, DOI 10.1001/archinte.140.1.112; Rawla Prashanth, 2019, Reumatologia (Warsaw), V57, P27, DOI 10.5114/reum.2019.83236; Riviere E, 2017, J NEUROL, V264, P1218, DOI 10.1007/s00415-017-8519-7; Roldan CA, 1996, NEW ENGL J MED, V335, P1424, DOI 10.1056/NEJM199611073351903; Roubille C, 2015, ANN RHEUM DIS, V74, P480, DOI 10.1136/annrheumdis-2014-206624; SHAPIRO RF, 1977, ANN RHEUM DIS, V36, P508, DOI 10.1136/ard.36.6.508; Shazzad M N, 2013, Mymensingh Med J, V22, P736; Shirakawa K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092435; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Suthahar Navin, 2017, Curr Heart Fail Rep, V14, P235, DOI 10.1007/s11897-017-0343-y; Tariq S, 2018, ARCH MED SCI, V14, P460, DOI 10.5114/aoms.2017.68692; THADANI U, 1975, MEDICINE, V54, P261, DOI 10.1097/00005792-197505000-00006; Toh N, 2010, HYPERTENSION, V55, P1150, DOI 10.1161/HYPERTENSIONAHA.109.137760; Tsai YD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022326; Turiel M, 2009, REUMATISMO, V61, P244, DOI 10.4081/reumatismo.2009.244; Turk SA, 2017, J RHEUMATOL, V44, P580, DOI 10.3899/jrheum.161184; Van Laecke S, 2018, TRANSPL INT, V31, P689, DOI 10.1111/tri.13160; Voskuyl AE, 2006, RHEUMATOLOGY, V45, P4, DOI 10.1093/rheumatology/kel313; Wang YA, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.942796; Yong WC, 2019, CLIN RHEUMATOL, V38, P447, DOI 10.1007/s10067-018-4265-1; Zhou Z, 2020, CLIN EXP RHEUMATOL, V38, P203, DOI 10.55563/clinexprheumatol/6kxs1o	70	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1056400	10.3389/fimmu.2022.1056400	http://dx.doi.org/10.3389/fimmu.2022.1056400			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T1JP	36483559	Green Published			2022-12-18	WOS:000893438500001
J	Pang, QD; Chen, H; Wu, H; Wang, Y; An, CY; Lai, SH; Xu, J; Wang, RQ; Zhou, J; Xiao, HY				Pang, Qidan; Chen, Hong; Wu, Hang; Wang, Yong; An, Changyong; Lai, Suhe; Xu, Jia; Wang, Ruiqiong; Zhou, Juan; Xiao, Hanyu			N6-methyladenosine regulators-related immune genes enable predict graft loss and discriminate T-cell mediate rejection in kidney transplantation biopsies for cause	FRONTIERS IN IMMUNOLOGY			English	Article						N6-methyladenosine (m6A); kidney transplantation; alloimmunity; graft loss; T-cell mediate rejection; biopsies for cause; prediction model	EXPRESSION; DIAGNOSIS; CYTOSCAPE; SURVIVAL; FAILURE; PATHWAY; FUTURE; INJURY	ObjectiveThe role of m6A modification in kidney transplant-associated immunity, especially in alloimmunity, still remains unknown. This study aims to explore the potential value of m6A-related immune genes in predicting graft loss and diagnosing T cell mediated rejection (TCMR), as well as the possible role they play in renal graft dysfunction. MethodsRenal transplant-related cohorts and transcript expression data were obtained from the GEO database. First, we conducted correlation analysis in the discovery cohort to identify the m6A-related immune genes. Then, lasso regression and random forest were used respectively to build prediction models in the prognosis and diagnosis cohort, to predict graft loss and discriminate TCMR in dysfunctional renal grafts. Connectivity map (CMap) analysis was applied to identify potential therapeutic compounds for TCMR. ResultsThe prognostic prediction model effectively predicts the prognosis and survival of renal grafts with clinical indications (P< 0.001) and applies to both rejection and non-rejection situations. The diagnostic prediction model discriminates TCMR in dysfunctional renal grafts with high accuracy (area under curve = 0.891). Meanwhile, the classifier score of the diagnostic model, as a continuity index, is positively correlated with the severity of main pathological injuries of TCMR. Furthermore, it is found that METTL3, FTO, WATP, and RBM15 are likely to play a pivotal part in the regulation of immune response in TCMR. By CMap analysis, several small molecular compounds are found to be able to reverse TCMR including fenoldopam, dextromethorphan, and so on. ConclusionsTogether, our findings explore the value of m6A-related immune genes in predicting the prognosis of renal grafts and diagnosis of TCMR.	[Pang, Qidan; Wu, Hang; Xu, Jia; Wang, Ruiqiong; Zhou, Juan] Chongqing Med Univ, Dept Nephrol, Bishan Hosp, Chongqing, Peoples R China; [Chen, Hong; Wang, Yong; An, Changyong; Lai, Suhe; Xiao, Hanyu] Chongqing Med Univ, Dept Gen Surg Gastrointestinal Surg, Bishan Hosp, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Zhou, J (corresponding author), Chongqing Med Univ, Dept Nephrol, Bishan Hosp, Chongqing, Peoples R China.; Xiao, HY (corresponding author), Chongqing Med Univ, Dept Gen Surg Gastrointestinal Surg, Bishan Hosp, Chongqing, Peoples R China.	zj604050129@163.com; xiaohanyu3399@foxmail.com						Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026-014-8516-1; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Dedeoglu B, 2018, AM J TRANSPLANT, V18, P341, DOI 10.1111/ajt.14480; Donato R, 2017, CELL MOL LIFE SCI, V74, P2749, DOI 10.1007/s00018-017-2526-9; Dorotea D, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0053-x; Einecke G, 2010, J CLIN INVEST, V120, P1862, DOI 10.1172/JCI41789; El-Zoghby ZM, 2009, AM J TRANSPLANT, V9, P527, DOI 10.1111/j.1600-6143.2008.02519.x; Furness PN, 2003, AM J SURG PATHOL, V27, P805, DOI 10.1097/00000478-200306000-00012; Gillies MA, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1166-4; Gu XF, 2020, CELL SIGNAL, V69, DOI 10.1016/j.cellsig.2020.109553; Halloran PF, 2013, AM J TRANSPLANT, V13, P2352, DOI 10.1111/ajt.12387; Halloran PF, 2010, AM J TRANSPLANT, V10, P1126, DOI 10.1111/j.1600-6143.2010.03053.x; Halloran PF, 2018, AM J TRANSPLANT, V18, P785, DOI 10.1111/ajt.14600; Halloran PF, 2016, NAT REV NEPHROL, V12, P534, DOI 10.1038/nrneph.2016.85; Hariharan S, 2021, NEW ENGL J MED, V385, P729, DOI 10.1056/NEJMra2014530; Ito-Kureha T, 2022, NAT IMMUNOL, V23, P1208, DOI 10.1038/s41590-022-01268-1; Jiang XL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00450-x; Kazakov AS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249473; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lei H, 2021, AM J TRANSL RES, V13, P4376; Li HB, 2017, NATURE, V548, P338, DOI 10.1038/nature23450; Li XX, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01558-0; Li Y, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa225; Loupy A, 2020, AM J TRANSPLANT, V20, P2318, DOI 10.1111/ajt.15898; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ponticelli C, 2014, NEPHROL DIAL TRANSPL, V29, P1134, DOI 10.1093/ndt/gft488; Rabant M, 2015, J AM SOC NEPHROL, V26, P2840, DOI 10.1681/ASN.2014080797; Reeve J, 2013, AM J TRANSPLANT, V13, P645, DOI 10.1111/ajt.12079; Reeve J, 2019, AM J TRANSPLANT, V19, P2719, DOI 10.1111/ajt.15351; Reeve J, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94197; Roshanravan H, 2016, DIABETES, V65, P3139, DOI 10.2337/db16-0209; Schiffer L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102552; Schinstock CA, 2019, AM J TRANSPLANT, V19, P123, DOI 10.1111/ajt.14979; Seki Y, 2007, J IMMUNOL, V178, P262, DOI 10.4049/jimmunol.178.1.262; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shulman Z, 2020, NAT IMMUNOL, V21, P501, DOI 10.1038/s41590-020-0650-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Tang LP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.630358; Tong JY, 2018, CELL RES, V28, P253, DOI 10.1038/cr.2018.7; Van Loon E, 2020, TRANSPLANTATION, V104, pE46, DOI 10.1097/TP.0000000000003012; Van Loon E, 2019, EBIOMEDICINE, V46, P463, DOI 10.1016/j.ebiom.2019.07.028; Wang HM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09903-6; Wekerle T, 2017, LANCET, V389, P2152, DOI 10.1016/S0140-6736(17)31283-7; Williams WW, 2012, NAT REV NEPHROL, V8, P110, DOI 10.1038/nrneph.2011.213; Winkler R, 2019, NAT IMMUNOL, V20, P173, DOI 10.1038/s41590-018-0275-z; Yao YP, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21594-6; Yilmaz MI, 2009, CLIN TRANSPLANT, V23, P241, DOI 10.1111/j.1399-0012.2008.00921.x	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1039013	10.3389/fimmu.2022.1039013	http://dx.doi.org/10.3389/fimmu.2022.1039013			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T7TW	36483557	Green Published, gold			2022-12-18	WOS:000893879200001
J	Shen, Y; Meng, XK; Wang, LL; Wang, XX; Chang, H				Shen, Yue; Meng, Xiangkai; Wang, Lili; Wang, Xiaoxiao; Chang, Hua			Advanced primary vaginal squamous cell carcinoma: A case report and literature review	FRONTIERS IN IMMUNOLOGY			English	Review						vaginal squamous cell carcinoma; chemotherapy; radiotherapy; immune checkpoint inhibitors; tyrosine kinase inhibitors; case report	ADVANCED CERVICAL-CANCER; RADIATION-THERAPY; SINGLE-ARM; ANLOTINIB	BackgroundVaginal carcinoma is a gynecological malignancy with low incidence, and there are few relevant and specific guidelines for vaginal cancer in our country and abroad. Here, we report the case who was diagnosed with advanced, primary vaginal squamous cell carcinoma and underwent integrated treatment successfully. Case introductionA 64-year-old Chinese woman underwent subtotal hysterectomy for uterine fibroids in 1998 and laparoscopic extensive residual cervical resection, bilateral ovarian salpingectomy, and pelvic lymph node dissection for residual cervical adenocarcinoma (stage IB1) in the First Affiliated Hospital of China Medical University in 2018. There was no postoperative review. The patient experienced vaginal discharge in March 2020, and vaginal bleeding occurred in July 2020. Our patient was diagnosed with stage IVA vaginal squamous cell carcinoma, based on a gynecological examination, colposcopy biopsy with histopathological examination, computed tomography scan, and tumor marker levels by two professors. After three phases of treatment (sequential treatment with chemotherapy plus radiotherapy, chemotherapy combined with immune checkpoint inhibitors, and immune checkpoint inhibitors combined with tyrosine kinase inhibitors therapy), her condition improved. Her current state is generally good, and she has achieved complete remission. ConclusionWe report a rare case of a patient with primary advanced vaginal carcinoma combined with cervical adenocarcinoma. The patient was treated for approximately 2 years, and her personalized treatment showed promising results. We will continue to follow up with the patient and monitor her response to the current treatment process.	[Shen, Yue; Meng, Xiangkai; Wang, Lili; Wang, Xiaoxiao; Chang, Hua] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Liaoning, Peoples R China	China Medical University	Chang, H (corresponding author), China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Liaoning, Peoples R China.	changhuafck1@163.com			Liaoning Provincial Department of Education Fund [ZF2019007]	Liaoning Provincial Department of Education Fund	Liaoning Provincial Department of Education Fund Project: Project Number: ZF2019007.	Adams TS, 2018, INT J GYNECOL OBSTET, V143, P14, DOI 10.1002/ijgo.12610; Adhikari P., 2017, DIAGN HISTOPATHOL, V23, P28, DOI [10.1016/j.mpdhp.2016.11.006, DOI 10.1016/J.MPDHP.2016.11.006]; [Anonymous], 2009, INT J GYNECOL OBSTET, V105, P3; Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265; Colombo N, 2021, NEW ENGL J MED, V385, P1856, DOI 10.1056/NEJMoa2112435; de Crevoisier R, 2007, RADIOTHER ONCOL, V85, P362, DOI 10.1016/j.radonc.2007.09.015; Di Donato V, 2012, CRIT REV ONCOL HEMAT, V81, P286, DOI 10.1016/j.critrevonc.2011.04.004; Frank SJ, 2005, INT J RADIAT ONCOL, V62, P138, DOI 10.1016/j.ijrobp.2004.09.032; Gadducci A, 2015, CRIT REV ONCOL HEMAT, V93, P211, DOI 10.1016/j.critrevonc.2014.09.002; He MY, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202002104; Hiniker SM, 2013, GYNECOL ONCOL, V131, P380, DOI 10.1016/j.ygyno.2013.08.012; Jhingran A, 2022, INT J GYNECOL CANCER, V32, P344, DOI 10.1136/ijgc-2021-002517; Naumann RW, 2019, J CLIN ONCOL, V37, P2825, DOI 10.1200/JCO.19.00739; P.D.Q.A.T.E National Board of Transport Safety Vaginal Cancer Treatment (PDQ(R), 2002, HLTH PROFESSIONAL VE; Rajagopalan MS, 2014, GYNECOL ONCOL, V135, P495, DOI 10.1016/j.ygyno.2014.09.018; Rajaram S, 2015, BEST PRACT RES CL OB, V29, P822, DOI 10.1016/j.bpobgyn.2015.01.006; Serrano B, 2015, EUR J CANCER, V51, P1732, DOI 10.1016/j.ejca.2015.06.001; Sha CM, 2020, RADIOTHER ONCOL, V151, P141, DOI 10.1016/j.radonc.2020.07.035; Shan YL, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2581; Shen GS, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0664-7; Sherman JF, 2008, GYNECOL ONCOL, V110, P396, DOI 10.1016/j.ygyno.2008.05.015; Shi YK, 2019, LANCET HAEMATOL, V6, pE12, DOI 10.1016/S2352-3026(18)30192-3; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; The American Cancer Society Medical and Editorial Content Team, KEY STAT VAG CANC; Wu XH, 2020, J CLIN ONCOL, V38; Xu Q, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.5524; Yang J, 2020, GYNECOL ONCOL, V159, P456, DOI 10.1016/j.ygyno.2020.08.036; Yang YL, 2020, CANCER IMMUNOL IMMUN, V69, P2523, DOI 10.1007/s00262-020-02641-5; Yi M, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01489-2; Zhu J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.720343	30	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1007462	10.3389/fimmu.2022.1007462	http://dx.doi.org/10.3389/fimmu.2022.1007462			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T7VC	36483563	Green Published, gold			2022-12-18	WOS:000893882500001
J	Vadevoo, SMP; Gunassekaran, GR; Yoo, JD; Kwon, TH; Hur, K; Chae, S; Lee, B				Vadevoo, Sri Murugan Poongkavithai; Gunassekaran, Gowri Rangaswamy; Yoo, Jae Do; Kwon, Tae-Hwan; Hur, Keun; Chae, Sehyun; Lee, Byungheon			Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p	FRONTIERS IN IMMUNOLOGY			English	Article						5-aza-2'-deoxycytidine; epigenetic therapy; macrophage reprogramming; miR-7083-5p; trichostatin A	EXPRESSION; POLARIZATION; RESPONSES; PROGRESSION; ACTIVATION; CANCER; CELLS; CD43	Reprogramming M2-type, pro-tumoral tumor-associated macrophages (TAMs) into M1-type, anti-tumoral macrophages is a key strategy in cancer therapy. In this study, we exploited epigenetic therapy using the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) and the histone deacetylation inhibitor trichostatin A (TSA), to reprogram M2-type macrophages into an M1-like phenotype. Treatment of M2-type macrophages with the combination of 5-aza-dC and TSA decreased the levels of M2 macrophage cytokines while increasing those of M1 macrophage cytokines, as compared to the use of either therapy alone. Conditioned medium of M2 macrophages treated with the combination of 5-aza-dC and TSA sensitized the tumor cells to paclitaxel. Moreover, treatment with the combination inhibited tumor growth and improved anti-tumor immunity in the tumor microenvironment. Depletion of macrophages reduced the anti-tumor growth activity of the combination therapy. Profiling of miRNAs revealed that the expression of miR-7083-5p was remarkably upregulated in M2 macrophages, following treatment with 5-aza-dC and TSA. Transfection of miR-7083-5p reprogrammed the M2-type macrophages towards an M1-like phenotype, and adoptive transfer of M2 macrophages pre-treated with miR-7083-5p into mice inhibited tumor growth. miR-7083-5p inhibited the expression of colony-stimulating factor 2 receptor alpha and CD43 as candidate targets. These results show that epigenetic therapy upon treatment with the combination of 5-aza-dC and TSA skews M2-type TAMs towards the M1-like phenotype by upregulating miR-7083-5p, which contributes to the inhibition of tumor growth.	[Vadevoo, Sri Murugan Poongkavithai; Gunassekaran, Gowri Rangaswamy; Yoo, Jae Do; Kwon, Tae-Hwan; Hur, Keun; Lee, Byungheon] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Daegu, South Korea; [Vadevoo, Sri Murugan Poongkavithai; Gunassekaran, Gowri Rangaswamy; Yoo, Jae Do; Kwon, Tae-Hwan; Hur, Keun; Lee, Byungheon] Kyungpook Natl Univ, Cell & Matrix Res Inst CMRI, Daegu, South Korea; [Kwon, Tae-Hwan; Hur, Keun; Lee, Byungheon] Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea; [Chae, Sehyun] Korea Brain Res Inst KBRI, Daegu, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Korea Brain Research Institute (KBRI)	Lee, B (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Daegu, South Korea.; Lee, B (corresponding author), Kyungpook Natl Univ, Cell & Matrix Res Inst CMRI, Daegu, South Korea.; Lee, B (corresponding author), Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea.	leebh@knu.ac.kr			National Research Foundation [2021R1A5A2021614]; Bio & Medical Technology Development Program - Ministry of Science and ICT of Korea [2017M3A9G8083382, 2020M3A9I4039539]	National Research Foundation; Bio & Medical Technology Development Program - Ministry of Science and ICT of Korea	This work was supported by a National Research Foundation grant [2021R1A5A2021614] and the Bio & Medical Technology Development Program [2017M3A9G8083382 and 2020M3A9I4039539] funded by the Ministry of Science and ICT of Korea.	Ali SR, 2015, DRUG DEVELOP RES, V76, P296, DOI 10.1002/ddr.21268; Alvarez-Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Curtale G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00799; de Groot Amber E, 2018, Oncotarget, V9, P20908, DOI 10.18632/oncotarget.24556; Gunassekaran GR, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121137; Hercus TR, 2012, GROWTH FACTORS, V30, P63, DOI 10.3109/08977194.2011.649919; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang XY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5363; Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620; Ivashkiv LB, 2013, TRENDS IMMUNOL, V34, P216, DOI 10.1016/j.it.2012.11.001; Kadaja-Saarepuu L, 2012, INT J ONCOL, V40, P567, DOI 10.3892/ijo.2011.1208; Kalinowski FC, 2014, INT J BIOCHEM CELL B, V54, P312, DOI 10.1016/j.biocel.2014.05.040; Karagoz K, 2015, OMICS, V19, P115, DOI 10.1089/omi.2014.0135; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li XL, 2021, ONCOGENE, V40, P1836, DOI 10.1038/s41388-020-01636-x; Li YS, 2015, SCI REP-UK, V5, DOI 10.1038/srep18648; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu ZH, 2020, NATURE, V579, P284, DOI 10.1038/s41586-020-2054-x; Mathsyaraja H, 2015, ONCOGENE, V34, P3651, DOI 10.1038/onc.2014.294; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Osella M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00345; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Serrat N, 2012, EUR J IMMUNOL, V42, P3028, DOI 10.1002/eji.201242413; Shi RC, 2022, THERANOSTICS, V12, P875, DOI 10.7150/thno.66420; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Tuccillo FM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/742831; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Zabuawala T, 2010, CANCER RES, V70, P1323, DOI 10.1158/0008-5472.CAN-09-1474; Zhang BC, 2009, J CELL BIOCHEM, V107, P134, DOI 10.1002/jcb.22110; Zhao ZN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045133; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								976196	10.3389/fimmu.2022.976196	http://dx.doi.org/10.3389/fimmu.2022.976196			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T7NM	36483544	gold, Green Published			2022-12-18	WOS:000893862300001
J	Wang, MG; Wu, SQ; Zhang, MM; He, JQ				Wang, Ming-Gui; Wu, Shou-Quan; Zhang, Meng-Meng; He, Jian-Qing			Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study	FRONTIERS IN IMMUNOLOGY			English	Article						metabolomic; microbiome; anti-tuberculosis drug-induced liver injury (ATB-DILI); machine learning; cohort; updated RUCAM	INDUCED HEPATOTOXICITY; PLASMA; CHROMATOGRAPHY; ACID; RATS	BackgroundAnti-tuberculosis drug-induced liver injury (ATB-DILI) is one of the most common adverse reactions that brings great difficulties to the treatment of tuberculosis. Thus, early identification of individuals at risk for ATB-DILI is urgent. We conducted a prospective cohort study to analyze the urinary metabolic and microbial profiles of patients with ATB-DILI before drug administration. And machine learning method was used to perform prediction model for ATB-DILI based on metabolomics, microbiome and clinical data. MethodsA total of 74 new TB patients treated with standard first-line anti-TB treatment regimens were enrolled from West China Hospital of Sichuan University. Only patients with an updated RUCAM score of 6 or more were accepted in this study. Nontargeted metabolomics and microbiome analyses were performed on urine samples prior to anti-tuberculosis drug ingestion to screen the differential metabolites and microbes between the ATB-DILI group and the non-ATB-DILI group. Integrating electronic medical records, metabolomics, and microbiome data, four machine learning methods was used, including random forest algorithm, artificial neural network, support vector machine with the linear kernel and radial basis function kernel. ResultsOf all included patients, 69 patients completed follow-up, with 16 (23.19%) patients developing ATB-DILI after antituberculosis treatment. Finally, 14 ATB-DILI patients and 30 age- and sex-matched non-ATB-DILI patients were subjected to urinary metabolomic and microbiome analysis. A total of 28 major differential metabolites were screened out, involving bile secretion, nicotinate and nicotinamide metabolism, tryptophan metabolism, ABC transporters, etc. Negativicoccus and Actinotignum were upregulated in the ATB-DILI group. Multivariate analysis also showed significant metabolic and microbial differences between the non-ATB-DILI and severe ATB-DILI groups. Finally, the four models showed high accuracy in predicting ATB-DILI, with the area under the curve of more than 0.85 for the training set and 1 for the validation set. ConclusionThis study characterized the metabolic and microbial profile of ATB-DILI risk individuals before drug ingestion for the first time. Metabolomic and microbiome characteristics in patient urine before anti-tuberculosis drug ingestion may predict the risk of liver injury after ingesting anti-tuberculosis drugs. Machine learning algorithms provides a new way to predict the occurrence of ATB-DILI among tuberculosis patients.	[Wang, Ming-Gui; Wu, Shou-Quan; Zhang, Meng-Meng; He, Jian-Qing] Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Peoples R China; [Wang, Ming-Gui] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Emergency Med, Chengdu, Peoples R China	Sichuan University; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China	He, JQ (corresponding author), Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Peoples R China.	Jianqhe@gmail.com			National Natural Science Foundation of China;  [81870015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	Funding This work was supported by the National Natural Science Foundation of China (Grant No. 81870015).	Araujo AM, 2017, CRIT REV TOXICOL, V47, P633, DOI 10.1080/10408444.2017.1309638; Boobier S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19594-z; Bowerman KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19701-0; Brewer CT, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071654; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; C.S.o.T.o.C.M. Association, 2019, CHINESE J TUBERCULOS, V42, P343, DOI [10.3760/cma.j.issn.1001-0939.2019.05.007, DOI 10.3760/CMA.J.ISSN.1001-0939.2019.05.007]; Cao J, 2018, BIOCHEM BIOPH RES CO, V497, P485, DOI 10.1016/j.bbrc.2018.02.030; Clarke CJ, 2008, TOXICOL PATHOL, V36, P140, DOI 10.1177/0192623307310947; Crestani E, 2020, J ALLERGY CLIN IMMUN, V145, P897, DOI 10.1016/j.jaci.2019.10.014; Danan G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010014; Dara L, 2016, LIVER INT, V36, P158, DOI 10.1111/liv.12988; Dominguez-Bello MG, 2019, GUT, V68, P1108, DOI 10.1136/gutjnl-2018-317503; Duan JY, 2020, J PROTEOMICS, V221, DOI 10.1016/j.jprot.2020.103767; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; El Hamdouni M, 2020, INFECTION, V48, P43, DOI 10.1007/s15010-019-01324-3; Gilbert K, 2019, J TRAUMA ACUTE CARE, V86, P431, DOI 10.1097/TA.0000000000002152; Gong SH, 2018, J HEPATOL, V69, P51, DOI 10.1016/j.jhep.2018.02.024; Gottschick C, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0305-3; Harsch Igor Alexander, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6020032; Hussein AA, 2021, UROL ONCOL-SEMIN ORI, V39, DOI 10.1016/j.urolonc.2020.12.011; Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787; Jin JS, 2018, ANAEROBE, V52, P29, DOI 10.1016/j.anaerobe.2018.05.010; Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9; Khazoom F, 2020, J TRAUMA ACUTE CARE, V89, P1076, DOI 10.1097/TA.0000000000002868; Lai NH, 2020, COMPUT METH PROG BIO, V188, DOI 10.1016/j.cmpb.2019.105307; Lang R, 2008, J AGR FOOD CHEM, V56, P11114, DOI 10.1021/jf802838s; Lee K, 2009, GLOB INST, P1; Lee Y, 2017, EXP NEUROBIOL, V26, P307, DOI 10.5607/en.2017.26.5.307; Li ZQ, 2020, J PROTEOMICS, V213, DOI 10.1016/j.jprot.2019.103603; Liu FP, 2017, ONCOTARGET, V8, P3798, DOI 10.18632/oncotarget.14028; Liu LS, 2020, EXPERT OPIN DRUG MET, V16, P527, DOI 10.1080/17425255.2020.1758060; Ma ZH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016717; Nahid P, 2016, CLIN INFECT DIS, V63, pe147, DOI 10.1093/cid/ciw376; Pickard JM, 2017, IMMUNOL REV, V279, P70, DOI 10.1111/imr.12567; Pradhan-Sundd T, 2018, GASTROENTEROLOGY, V155, P1218, DOI 10.1053/j.gastro.2018.06.048; Rawat A, 2018, HUM EXP TOXICOL, V37, P373, DOI 10.1177/0960327117705426; Ren YJ, 2019, TRANSL LUNG CANCER R, V8, P235, DOI 10.21037/tlcr.2019.06.11; Ren ZG, 2021, GUT, V70, P1253, DOI 10.1136/gutjnl-2020-323826; Ruan LY, 2018, TOXICOL LETT, V295, P256, DOI 10.1016/j.toxlet.2018.05.032; Sarafian MH, 2014, ANAL CHEM, V86, P5766, DOI 10.1021/ac500317c; Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST; Schauer N, 2006, TRENDS PLANT SCI, V11, P508, DOI 10.1016/j.tplants.2006.08.007; Schneider KM, 2021, NAT METAB, V3, P1228, DOI 10.1038/s42255-021-00452-1; Sergeev IN, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010222; Shang PH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021836; Sheyn D, 2020, FEMALE PELVIC MED RE, V26, P644, DOI 10.1097/SPV.0000000000000639; Shoji H, 2020, J MATERN-FETAL NEO M, V33, P230, DOI 10.1080/14767058.2018.1488165; Slopianka M, 2017, TOXICOLOGY, V386, P1, DOI 10.1016/j.tox.2017.05.009; Sun J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03327-1; Teschke R, 2021, TRANSL GASTROENT HEP, V6, DOI 10.21037/tgh-20-149; Teschke R, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11030458; Teschke Rolf, 2020, Medicines (Basel), V7, DOI 10.3390/medicines7100062; Tostmann A, 2008, J GASTROEN HEPATOL, V23, P192, DOI 10.1111/j.1440-1746.2007.05207.x; van Laarhoven A, 2018, LANCET INFECT DIS, V18, P526, DOI 10.1016/S1473-3099(18)30053-7; Vats R, 2020, HEPATOLOGY, V72, P2165, DOI 10.1002/hep.31239; Wang M, 2020, HEPATOLOGY, V72, P1617, DOI 10.1002/hep.31197; Wang ST, 2020, J INT MED RES, V48, DOI 10.1177/0300060518811512; Wen B, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1579-y; Wu D, 2020, INT J ACCOUNT INF MA, V28, P184, DOI [10.1016/j.ijid.2020.03.004, 10.1108/IJAIM-12-2018-0148]; Wu SQ, 2022, ARCH BIOCHEM BIOPHYS, V716, DOI 10.1016/j.abb.2022.109118; Wu SQ, 2019, THERAPIE, V74, P399, DOI 10.1016/j.therap.2018.07.003; Xiao Q, 2020, CHEM-BIOL INTERACT, V324, DOI 10.1016/j.cbi.2020.109062; Xie ZY, 2019, J PROTEOME RES, V18, P2514, DOI 10.1021/acs.jproteome.9b00047; Yu MQ, 2017, CAN J GASTROENTEROL, V2017, DOI 10.1155/2017/8467192; Zhang AH, 2012, J PROTEOMICS, V75, P1079, DOI 10.1016/j.jprot.2011.10.027; Zhang D, 2020, J CLIN PHARM THER, V45, P561, DOI 10.1111/jcpt.13097; Zhang L, 2020, ARCH TOXICOL, V94, P245, DOI 10.1007/s00204-019-02595-3; Zhang T, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010086; Zhao H, 2017, TOXICOL RES-UK, V6, P17, DOI 10.1039/c6tx00245e	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1002126	10.3389/fimmu.2022.1002126	http://dx.doi.org/10.3389/fimmu.2022.1002126			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T3LS	36483548	Green Published, gold			2022-12-18	WOS:000893580900001
J	Wu, X; Dong, N; Yu, LQ; Liu, MR; Jiang, JH; Tang, TY; Zhao, HR; Fang, Q				Wu, Xuan; Dong, Nan; Yu, Liqiang; Liu, Meirong; Jiang, Jianhua; Tang, Tieyu; Zhao, Hongru; Fang, Qi			Identification of immune-related features involved in Duchenne muscular dystrophy: A bidirectional transcriptome and proteome-driven analysis	FRONTIERS IN IMMUNOLOGY			English	Article						Duchenne muscular dystrophy; transcriptome; proteome; immune; differentially expressed mRNAs; differentially expressed proteins	MICE	BackgroundWe aimed to investigate the biological mechanism and feature genes of Duchenne muscular dystrophy (DMD) by multi-omics and experimental verification strategy. MethodsWe integrated the transcriptomic and proteomic methods to find the differentially expressed mRNAs (DEMs) and proteins (DEPs) between DMD and Control groups. Weighted gene co-expression network analysis (WGCNA) was then used to identify modules of highly correlated genes and hub genes. In the following steps, the immune and stromal cells infiltrations were accomplished by xCELL algorithm. Furthermore, TF and miRNA prediction were performed with Networkanalyst. ELISA, western blot and external datasets were performed to verify the key proteins/mRNAs in DMD patient and mouse. Finally, a nomogram model was established based on the potential biomarkers. Results4515 DEMs and 56 DEPs were obtained from the transcriptomic and proteomic study respectively. 14 common genes were identified, which is enriched in muscle contraction and inflammation-related pathways. Meanwhile, we observed 33 significant differences in the infiltration of cells in DMD. Afterwards, a total of 22 miRNAs and 23 TF genes interacted with the common genes, including TFAP2C, MAX, MYC, NFKB1, RELA, hsa-miR-1255a, hsa-miR-130a, hsa-miR-130b, hsa-miR-152, and hsa-miR-17. In addition, three genes (ATP6AP2, CTSS, and VIM) showed excellent diagnostic performance on discriminating DMD in GSE1004, GSE3307, GSE6011 and GSE38417 datasets (all AUC > 0.8), which is validated in patients (10 DMD vs. 10 controls), DMD with exon 55 mutations, mdx mouse, and nomogram model. ConclusionTaken together, ATP6AP2, CTSS, and VIM play important roles in the inflammatory response in DMD, which may serve as diagnostic biomarkers and therapeutic targets.	[Wu, Xuan; Dong, Nan; Yu, Liqiang; Liu, Meirong; Jiang, Jianhua; Zhao, Hongru; Fang, Qi] Soochow Univ, Affiliated Hosp 1, Dept Neurol, Suzhou, Peoples R China; [Wu, Xuan; Tang, Tieyu] Yangzhou Univ, Affiliated Hosp, Dept Neurol, Yangzhou, Peoples R China	Soochow University - China; Yangzhou University	Zhao, HR; Fang, Q (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurol, Suzhou, Peoples R China.	tiantan11@163.com; fangqi_008@126.com			National Natural Science Foundation of China [GSWS2020002]; National Key R&D Program Key Special Project for Intergovernmental Cooperation in International Science and Technology Innovation [82071300]; Introduction of Clinical Medicine Team Project in Suzhou [2017YFE0103700]; Suzhou Gusu Health Talents Program Training Project [SZYJTD201802]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program Key Special Project for Intergovernmental Cooperation in International Science and Technology Innovation; Introduction of Clinical Medicine Team Project in Suzhou; Suzhou Gusu Health Talents Program Training Project	General Project of National Natural Science Foundation of China (82071300); National Key R&D Program Key Special Project for Intergovernmental Cooperation in International Science and Technology Innovation (2017YFE0103700); Introduction of Clinical Medicine Team Project in Suzhou (SZYJTD201802; Suzhou Gusu Health Talents Program Training Project (GSWS2020002).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Baban D, 2008, NEUROMUSCULAR DISORD, V18, P239, DOI 10.1016/j.nmd.2007.11.011; Bhattarai S, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28531-1; Capitanio D, 2020, J CACHEXIA SARCOPENI, V11, P547, DOI 10.1002/jcsm.12527; Chadwick JA, 2017, AM J PHYSIOL-CELL PH, V312, pC155, DOI 10.1152/ajpcell.00269.2016; Cordova G, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00114; Duan DS, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00248-3; Estrellas KM, 2018, J BIOL CHEM, V293, P15594, DOI 10.1074/jbc.RA118.004417; Frohlich T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33362; Hirose T, 2019, J CLIN INVEST, V129, P2145, DOI 10.1172/JCI79990; Howard ZM, 2021, AM J PATHOL, V191, P730, DOI 10.1016/j.ajpath.2021.01.008; Kinouchi K, 2010, CIRC RES, V107, P30, DOI 10.1161/CIRCRESAHA.110.224667; Kolwicz SC, 2019, JACC-BASIC TRANSL SC, V4, P778, DOI 10.1016/j.jacbts.2019.06.006; Lafreniere JF, 2006, EXP CELL RES, V312, P1127, DOI 10.1016/j.yexcr.2006.01.002; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee JD, 2021, SEMIN IMMUNOPATHOL, V43, P817, DOI 10.1007/s00281-021-00895-4; Li LT, 2020, J ADV RES, V24, P13, DOI 10.1016/j.jare.2020.01.005; Licata L, 2020, NUCLEIC ACIDS RES, V48, pD504, DOI 10.1093/nar/gkz949; Lim KRQ, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2112546119; Ling C, 2020, HUM MUTAT, V41, P668, DOI 10.1002/humu.23953; Liu ZP, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav095; Markham LW, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0257-2; Mercuri E, 2007, J MAGN RESON IMAGING, V25, P433, DOI 10.1002/jmri.20804; Mercuri E, 2019, LANCET, V394, P2025, DOI 10.1016/S0140-6736(19)32910-1; Moratal C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35429-w; Mu HQ, 2020, BIOMARK MED, V14, P353, DOI 10.2217/bmm-2019-0318; Pang ZQ, 2021, NUCLEIC ACIDS RES, V49, pW388, DOI 10.1093/nar/gkab382; Petrof BJ, 2022, J PHYSIOL-LONDON, V600, P3455, DOI 10.1113/JP281673; Poyatos-Garcia J, 2022, ANN NEUROL, V92, P793, DOI 10.1002/ana.26461; Smyth P, 2022, MOL ASPECTS MED, V88, DOI 10.1016/j.mam.2022.101106; Sun CM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11080837; Sun CS, 2020, EXP NEUROL, V323, DOI 10.1016/j.expneurol.2019.113086; Tibshirani R, 2012, J R STAT SOC B, V74, P245, DOI 10.1111/j.1467-9868.2011.01004.x; Tidball JG, 2018, COMPR PHYSIOL, V8, P1313, DOI 10.1002/cphy.c170052; Tjondrokoesoemo A, 2016, J BIOL CHEM, V291, P9920, DOI 10.1074/jbc.M116.719054; Tripodi L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9101447; Van Pelt DW, 2021, CONNECT TISSUE RES, V62, P24, DOI 10.1080/03008207.2020.1791103; Waldrop MA, 2019, CURR OPIN NEUROL, V32, P722, DOI 10.1097/WCO.0000000000000739; Wang JR, 2022, EVID-BASED COMPL ALT, V2022, DOI 10.1155/2022/2056630; Wein N, 2015, PEDIATR CLIN N AM, V62, P723, DOI 10.1016/j.pcl.2015.03.008; White Z, 2022, J CACHEXIA SARCOPENI, V13, P544, DOI 10.1002/jcsm.12879; Yang MD, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.524663; Zhao KK, 2020, CANCER MANAG RES, V12, P10449, DOI 10.2147/CMAR.S270024; Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240; Zhou YY, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0113-2; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1017423	10.3389/fimmu.2022.1017423	http://dx.doi.org/10.3389/fimmu.2022.1017423			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T8RJ	36483550	Green Published, gold			2022-12-18	WOS:000893942000001
J	Zeng, Z; Hao, HX; Bi, XY; Lin, YJ; Yang, L; Wang, SY; Shen, G; Chang, M; Jiang, TT; Deng, W; Lu, HH; Sun, FF; Lu, Y; Gao, YJ; Liu, RY; Xu, MJ; Chen, XX; Hu, LP; Zhang, L; Li, MH; Xie, Y				Zeng, Zhan; Hao, Hongxiao; Bi, Xiaoyue; Lin, Yanjie; Yang, Liu; Wang, Shiyu; Shen, Ge; Chang, Min; Jiang, Tingting; Deng, Wen; Lu, Huihui; Sun, Fangfang; Lu, Yao; Gao, Yuanjiao; Liu, Ruyu; Xu, Mengjiao; Chen, Xiaoxue; Hu, Leiping; Zhang, Lu; Li, Minghui; Xie, Yao			Study on liver histopathology of chronic HBV infected patients with different normal ALT values	FRONTIERS IN IMMUNOLOGY			English	Article						chronic HBV-infection; ALT value; HBV therapy; liver histopathology; clinical indicators	CHRONIC HEPATITIS-B	AimsComparison of liver histopathological findings to explore the occurrence of liver inflammation in patients with chronic hepatitis B (CHB) under different alanine aminotransferase (ALT) normal values. MethodsThe patients who were diagnosed as chronic hepatitis B virus (HBV) infection by liver histopathology at the Department of Pathology, Beijing Ditan Hospital due to clinical difficulty in defining the degree of liver inflammation or fibrosis were retrospectively enrolled from May 2008 to November 2020. Study of the incidence of significant hepatic histopathology in enrolled patients according to different ALT normal values. Using logistic regression to investigate the relevant factors of significant hepatic histopathology. ResultsA total of 1474 patients were enrolled, 56.20% of the patients were male, and the overall patients' age was 36.80 +/- 10.60 years. 39.00% of patients had liver inflammation grade G > 1, 34.70% liver fibrosis stage S > 1, and 48.17% patients had significant hepatic histopathology (G > 1 and/or S > 1). Among patients with normal ALT values, 36.40% and 40.40% had significant hepatic histopathology by American Association for the Study of Liver Diseases (AASLD) criteria and Chinese guideline criteria, respectively, but the difference was not statistically significant (chi(2 =)3.38, P =0.066). In contrast, among patients with abnormal ALT values, 58.90% and 62.20% of patients had significant hepatic histopathology by AASLD criteria and Chinese guideline criteria, respectively, with no significant difference (chi(2 =)2.28, P =0.131). ALT (P <0.001, OR=1.019), hepatitis B surface antigen (HBsAg) (P <0.001, OR=0.665) and hepatitis B e antigen (HBeAg) status (P <0.001, OR=2.238) were relevant factors in the occurrence of significant hepatic histopathology. ALT was positively corelated with grade of inflammation G (r =0.194, P <0.001) and negatively correlated with liver fibrosis stage S (r =-0.066, P =0.021). ConclusionsOur study found no statistically significant differences in the presence of significant hepatic histopathology under the two ALT criteria. ALT, HBsAg and HBeAg status were related to the occurrence of significant hepatic histopathology.	[Zeng, Zhan; Hao, Hongxiao; Bi, Xiaoyue; Yang, Liu; Wang, Shiyu; Shen, Ge; Chang, Min; Jiang, Tingting; Deng, Wen; Lu, Huihui; Sun, Fangfang; Lu, Yao; Gao, Yuanjiao; Liu, Ruyu; Xu, Mengjiao; Chen, Xiaoxue; Hu, Leiping; Zhang, Lu; Li, Minghui; Xie, Yao] Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol Div 2, Beijing, Peoples R China; [Zeng, Zhan] Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China; [Lin, Yanjie; Li, Minghui; Xie, Yao] Peking Univ, Ditan Teaching Hosp, Dept Hepatol Div 2, Beijing, Peoples R China	Capital Medical University; Peking University; Peking University	Li, MH; Xie, Y (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol Div 2, Beijing, Peoples R China.; Li, MH; Xie, Y (corresponding author), Peking Univ, Ditan Teaching Hosp, Dept Hepatol Div 2, Beijing, Peoples R China.	wumh2000@sina.com; xieyao00120184@sina.com			Digestive Medical Coordinated Development Center of Beijing Hospitals Authority [XXZ0302, XXT28]; Beijing science and technology commission [Z211100002921059]; High-level Public Health Technical Personnel Training Program of Beijing Municipal Health Commission [2022-3-050]; National Science and Technology Major Project of China [2017ZX10201201-001-006, 2017ZX10201201-002-006, 2018ZX10715-005-003-005]; capital health research and development of special [2022-1-2172]; Beijing Hospitals Authority Clinical Medicine Development [XMLX 202127]; National Key R&D Program of China [2022YFC2603500]	Digestive Medical Coordinated Development Center of Beijing Hospitals Authority; Beijing science and technology commission; High-level Public Health Technical Personnel Training Program of Beijing Municipal Health Commission; National Science and Technology Major Project of China; capital health research and development of special; Beijing Hospitals Authority Clinical Medicine Development; National Key R&D Program of China	The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (XXZ0302 and XXT28). Project supported by Beijing science and technology commission (Z211100002921059). High- level Public Health Technical Personnel Training Program of Beijing Municipal Health Commission (2022-3-050). National Science and Technology Major Project of China ( 2017ZX10201201-001- 006, 2017ZX10201201-002- 006, 2018ZX10715-005-003-005). The capital health research and development of special (2022-12172). Beijing Hospitals Authority Clinical Medicine Development of special funding support (XMLX 202127). National Key R&D Program of China (2022YFC2603500)	Andreani T, 2007, CLIN GASTROENTEROL H, V5, P636, DOI 10.1016/j.cgh.2007.01.005; Brahmania M, 2019, CLIN GASTROENTEROL H, V17, P2541, DOI 10.1016/j.cgh.2019.02.005; Chang ML, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031552; Chinese Society of Hepatology Chinese Medical Association, 2022, Zhonghua Gan Zang Bing Za Zhi, V30, P131, DOI 10.3760/cma.j.cn501113-20220209-00060; Chinese Society of Infectious Diseases Chinese Medical Association, 2019, Zhonghua Gan Zang Bing Za Zhi, V27, P938, DOI 10.3760/cma.j.issn.1007-3418.2019.12.007; Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Ghany MG, 2020, LANCET GASTROENTEROL, V5, P406, DOI 10.1016/S2468-1253(19)30344-9; Hu A R, 2021, Zhonghua Nei Ke Za Zhi, V60, P891, DOI 10.3760/cma.j.cn112138-20201211-01005; Jeng WJ, 2021, CLIN GASTROENTEROL H, V19, P2006, DOI 10.1016/j.cgh.2020.04.091; Jiang XY, 2021, WORLD J GASTROENTERO, V27, P1101, DOI 10.3748/wjg.v27.i11.1101; Kim HJ, 2020, KOREAN J INTERN MED, V35, P320, DOI 10.3904/kjim.2018.214; Kumar M, 2008, GASTROENTEROLOGY, V134, P1376, DOI 10.1053/j.gastro.2008.02.075; Lee HA, 2020, ALIMENT PHARM THER, V52, P196, DOI 10.1111/apt.15741; Lesmana CRA, 2011, J DIGEST DIS, V12, P476, DOI 10.1111/j.1751-2980.2011.00540.x; Li MH, 2017, BIOMED ENVIRON SCI, V30, P177, DOI 10.3967/bes2017.025; Li MingHui, 2021, Journal of Clinical Hepatology, V37, P783, DOI 10.3969/j.issn.1001-5256.2021.04.011; Li MH, 2021, VIROL SIN, V36, P311, DOI 10.1007/s12250-020-00290-7; Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Zeng Zhan, 2022, Journal of Clinical Hepatology, V38, P1030	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2022	13								1069752	10.3389/fimmu.2022.1069752	http://dx.doi.org/10.3389/fimmu.2022.1069752			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T4LI	36483546	Green Published, gold			2022-12-18	WOS:000893649400001
J	Cousins, K; DeFelice, N; Jeong, S; Feng, J; Lee, ASE; Rotella, K; Sanchez, D; Jaber, F; Agarwal, S; Ho, HE; Cunningham-Rundles, C				Cousins, Kimberley; DeFelice, Nicholas; Jeong, Stephanie; Feng, Jin; Lee, Ashley Sang Eun; Rotella, Karina; Sanchez, David; Jaber, Faris; Agarwal, Shradha; Ho, Hsi-en; Cunningham-Rundles, Charlotte			SARS-COV-2 infections in inborn errors of immunity: A single center study	FRONTIERS IN IMMUNOLOGY			English	Article						coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); inborn errors of immunity (IEI); primary immunodeficiency (PID); common variable immunodeficiency (CVID); X-linked agammaglobulinemia (XLA); covid vaccination; monoclonal therapy		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). One of the main topics of conversation in these past months in the world of immunology has been the issue of how patients with immune defects will fare if they contract this infection. To date there has been limited data on larger cohorts of patients with Inborn Errors of Immunity (IEI) diagnosed with COVID-19. Here, we review the data of COVID-19 infections in a single center cohort of 113 patients from the Mount Sinai Immunodeficiency program, who had 132 infections between January 2020 and June 2022. This included 56 males and 57 females, age range 2 - 84 (median 42). The mortality rate was 3%. Comparison between admitted patients revealed a significantly increased risk of hospitalization amongst the unvaccinated patients, 4% vaccinated vs 40% unvaccinated; odds ratio 15.0 (95% CI 4.2 - 53.4; p <0.00001). Additionally, COVID anti-spike antibody levels, determined in 36 of these patients post vaccination and before infection, were highly variable.	[Cousins, Kimberley; Jeong, Stephanie; Feng, Jin; Lee, Ashley Sang Eun; Rotella, Karina; Sanchez, David; Jaber, Faris; Agarwal, Shradha; Ho, Hsi-en; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol, New York, NY 10029 USA; [DeFelice, Nicholas] Icahn Sch Med Mt Sinai, Div Environm Med & Publ Hlth, New York, NY USA; [DeFelice, Nicholas] Icahn Sch Med Mt Sinai, Inst Expos Res, New York, NY USA; [DeFelice, Nicholas] Icahn Sch Med Mt Sinai, Arnold Inst Global Hlth, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Cousins, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol, New York, NY 10029 USA.	Kimberley.cousins@mssm.edu						Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barmettler S, 2022, J ALLER CL IMM-PRACT, V10, P1622, DOI 10.1016/j.jaip.2022.03.017; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Castano-Jaramillo LM, 2021, J CLIN IMMUNOL, V41, P1463, DOI 10.1007/s10875-021-01077-5; Center JsHUoMCR, 2022, MORT AN; Cousins K., ANN ALLERGY ASTHMA I, V127, pS6, DOI [10.1016/j.anai.2021.08.029, DOI 10.1016/J.ANAI.2021.08.029]; Delavari S, 2021, J CLIN IMMUNOL, V41, P345, DOI 10.1007/s10875-020-00928-x; Esenboga S, 2021, J CLIN IMMUNOL, V41, P1515, DOI 10.1007/s10875-021-01065-9; Giardino G, 2022, J CLIN IMMUNOL, V42, P935, DOI 10.1007/s10875-022-01264-y; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Harada K, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108803; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hirsiger Julia R, 2022, J Allergy Clin Immunol Pract, V10, P2452, DOI 10.1016/j.jaip.2022.06.020; Ho HE, 2021, J ALLER CL IMM-PRACT, V9, DOI 10.1016/j.jaip.2020.09.052; Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X; Hygiene NDoHaM, 2022, COR DIS 2019 COVID 1; Jalil M, 2022, ALLERGY RHINOL, V13, DOI 10.1177/21526575221096044; Lang-Meli J, 2022, J CLIN IMMUNOL, V42, P253, DOI 10.1007/s10875-021-01193-2; Lee K, 2009, GLOB INST, P1; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Moss P, 2022, NAT IMMUNOL, V23, P186, DOI 10.1038/s41590-021-01122-w; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sanyaolu Adekunle, 2020, SN Compr Clin Med, V2, P1069, DOI 10.1007/s42399-020-00363-4; Stadnytskyi V, 2020, P NATL ACAD SCI USA, V117, P11875, DOI 10.1073/pnas.2006874117; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; Wen W, 2022, ANN MED, V54, P516, DOI 10.1080/07853890.2022.2034936; Worldometer, COR COVID 19 MORT RA; Yao Y, 2020, CLIN EXP ALLERGY, V50, P1313, DOI 10.1111/cea.13746; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10	32	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1035571	10.3389/fimmu.2022.1035571	http://dx.doi.org/10.3389/fimmu.2022.1035571			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2TF	36479106	Green Published, gold			2022-12-18	WOS:000894220800001
J	Deng, J; Zhao, N; Lv, LP; Ma, P; Zhang, YY; Xu, JB; Zhou, XP; Chen, ZA; Zhang, YY				Deng, Jiang; Zhao, Ning; Lv, Li-ping; Ma, Ping; Zhang, Yang-yang; Xu, Jin-bo; Zhou, Xi-peng; Chen, Zi-an; Zhang, Yan-yu			Integrated analysis of multiple microarray studies to establish differential diagnostic models of Crohn's disease and ulcerative colitis based on a metalloproteinase-associated module	FRONTIERS IN IMMUNOLOGY			English	Article						crohn's disease; ulcerative colitis; robust rank aggregation; microarray; metalloproteinases; differential diagnostic models	INFLAMMATORY-BOWEL-DISEASE; EVIDENCE-BASED CONSENSUS; MATRIX METALLOPROTEINASES; EXTRACELLULAR VESICLES; COLONIC INFLAMMATION; ENHANCED EXPRESSION; ANNEXIN A1; INHIBITOR; ONSET; METHOTREXATE	BackgroundThe ulcerative colitis (UC) and Crohn's disease (CD) subtypes of inflammatory bowel disease (IBD) are autoimmune diseases influenced by multiple complex factors. The clinical treatment strategies for UC and CD often differ, indicating the importance of improving their discrimination. MethodsTwo methods, robust rank aggregation (RRA) analysis and merging and intersection, were applied to integrate data from multiple IBD cohorts, and the identified differentially expressed genes (DEGs) were used to establish a protein-protein interaction (PPI) network. Molecular complex detection (MCODE) was used to identify important gene sets. Two differential diagnostic models to distinguish CD and UC were established via a least absolute shrinkage and selection operator (LASSO) logistic regression, and model evaluation was performed in both the training and testing groups, including receiver operating characteristic (ROC) curves, calibration plots and decision curve analysis (DCA). The potential value of MMP-associated genes was further verified using different IBD cohorts and clinical samples. ResultsFour datasets (GSE75214, GSE10616, GSE36807, and GSE9686) were included in the analysis. Both data integration methods indicated that the activation of the MMP-associated module was significantly elevated in UC. Two LASSO models based on continuous variable (Model_1) and binary variable (Model_2) MMP-associated genes were established to discriminate CD and UC. The results showed that Model_1 exhibited good discrimination in the training and testing groups. The calibration analysis and DCA showed that Model_1 exhibited good performance in the training group but failed in the testing group. Model_2 exhibited good discrimination, calibration and DCA results in the training and testing groups and exhibited greater diagnostic value. The effects of Model_1 and Model_2 were further verified in a new IBD cohort of GSE179285. The MMP genes exhibited high value as biomarkers for the discrimination of IBD patients using published cohort and immunohistochemistry (IHC) staining data. The MMP-associated gene levels were statistically significantly positively correlated with the levels of the differentially expressed cell types, indicating their potential value in differential diagnosis. The single-cell analysis confirmed that the expression of ANXA1 in UC was higher than that in CD. ConclusionMMP-associated modules are the main differential gene sets between CD and UC. The established Model_2 overcomes batch differences and has good clinical applicability. Subsequent in-depth research investigating how MMPs are involved in the development of different IBD subtypes is necessary.	[Deng, Jiang; Zhao, Ning; Lv, Li-ping; Ma, Ping; Zhang, Yang-yang; Xu, Jin-bo; Zhou, Xi-peng; Zhang, Yan-yu] Inst Hlth Serv & Transfus Med, Beijing, Peoples R China; [Deng, Jiang; Zhao, Ning; Lv, Li-ping; Ma, Ping; Zhang, Yang-yang; Xu, Jin-bo; Zhou, Xi-peng; Zhang, Yan-yu] Beijing Key Lab Blood Safety & Supply Technol, Beijing, Peoples R China; [Chen, Zi-an] Hebei Med Univ, Hosp 2, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China; [Chen, Zi-an] Hebei Clin Res Ctr Digest Dis, Hebei Inst Gastroenterol, Hebei Key Lab Gastroenterol, Shijiazhuang, Hebei, Peoples R China	Hebei Medical University	Zhang, YY (corresponding author), Inst Hlth Serv & Transfus Med, Beijing, Peoples R China.; Zhang, YY (corresponding author), Beijing Key Lab Blood Safety & Supply Technol, Beijing, Peoples R China.; Chen, ZA (corresponding author), Hebei Med Univ, Hosp 2, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China.; Chen, ZA (corresponding author), Hebei Clin Res Ctr Digest Dis, Hebei Inst Gastroenterol, Hebei Key Lab Gastroenterol, Shijiazhuang, Hebei, Peoples R China.	chenzian@hb2h.com; swgczhyy@126.com			National Natural Science Foundation of China; Medical Science Research Projects of Hebei Province;  [81902055];  [82200738];  [20220990]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Research Projects of Hebei Province; ; ; 	Funding This study was funded by the National Natural Science Foundation of China (Grant No. 81902055, Grant No. 82200738) and the Medical Science Research Projects of Hebei Province (Grant No. 20220990).	Abraham BP, 2012, J CLIN GASTROENTEROL, V46, P581, DOI 10.1097/MCG.0b013e318247c32f; Annese V, 2013, J CROHNS COLITIS, V7, P982, DOI 10.1016/j.crohns.2013.09.016; Appleby TC, 2017, J BIOL CHEM, V292, P6810, DOI 10.1074/jbc.M116.760579; Arihiro S, 2001, HISTOPATHOLOGY, V39, P50, DOI 10.1046/j.1365-2559.2001.01142.x; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Burisch J, 2014, GUT, V63, P588, DOI 10.1136/gutjnl-2013-304636; Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1038/bjc.2014.639, 10.1161/CIRCULATIONAHA.114.014508, 10.1186/s12916-014-0241-z, 10.1002/bjs.9736, 10.7326/M14-0698, 10.1016/j.jclinepi.2014.11.010, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025]; de Souza HSP, 2016, NAT REV GASTRO HEPAT, V13, P13, DOI [10.1038/nrgastro.2016.186, 10.1038/nrgastro.2015.186]; Derkacz A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051122; Di Sebastiano P, 2001, DIGESTION, V63, P234, DOI 10.1159/000051895; Dignass A, 2010, J CROHNS COLITIS, V4, P28, DOI 10.1016/j.crohns.2009.12.002; Dignass A, 2012, J CROHNS COLITIS, V6, P991, DOI 10.1016/j.crohns.2012.09.002; Dobre M, 2018, J IMMUNOL RES, V2018, DOI [10.1155/2018/9208271, 10.1155/2018/9208274]; Feagan BG, 2000, NEW ENGL J MED, V342, P1627, DOI 10.1056/NEJM200006013422202; Feakins RM, 2014, HISTOPATHOLOGY, V64, P317, DOI 10.1111/his.12263; Gill SE, 2016, AM J RESP CELL MOL, V55, P243, DOI 10.1165/rcmb.2015-0193OC; Gisbert JP, 2011, WORLD J GASTROENTERO, V17, P3467, DOI 10.3748/wjg.v17.i30.3467; Hendrickson BA, 2002, CLIN MICROBIOL REV, V15, P79, DOI 10.1128/CMR.15.1.79-94.2002; Henriksen M, 2006, SCAND J GASTROENTERO, V41, P1037, DOI 10.1080/00365520600554527; Heuschkel RB, 2000, GUT, V47, P57, DOI 10.1136/gut.47.1.57; James JP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217893; Jimbo K, 2014, PEDIATR INT, V56, P873, DOI 10.1111/ped.12362; Kirkegaard T, 2004, GUT, V53, P701, DOI 10.1136/gut.2003.017442; Kornbluth A, 2004, AM J GASTROENTEROL, V99, P1371, DOI 10.1111/j.1572-0241.2004.40036.x; Kugathasan S, 2008, NAT GENET, V40, P1211, DOI 10.1038/ng.203; Laharie D, 2011, ALIMENT PHARM THER, V33, P714, DOI 10.1111/j.1365-2036.2010.04569.x; Leoni G, 2015, J CLIN INVEST, V125, P1215, DOI 10.1172/JCI76693; Leoni G, 2013, J CLIN INVEST, V123, P443, DOI 10.1172/JCI65831; Lim WC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008870; Louis E, 2000, CLIN EXP IMMUNOL, V120, P241, DOI 10.1046/j.1365-2249.2000.01227.x; Magro F, 2013, J CROHNS COLITIS, V7, P827, DOI 10.1016/j.crohns.2013.06.001; Makitalo L, 2010, SCAND J GASTROENTERO, V45, P862, DOI 10.3109/00365520903583863; Manuc M, 2020, J GASTROINTEST LIVER, V29, P159, DOI 10.15403/jgld-576; Marcello PW, 1997, DIS COLON RECTUM, V40, P263, DOI 10.1007/BF02050413; Maronek M, 2021, J INFLAMM RES, V14, P1029, DOI 10.2147/JIR.S288280; Martin GR, 2008, AM J PHYSIOL-GASTR L, V294, pG764, DOI 10.1152/ajpgi.00531.2007; Matsuno K, 2003, J GASTROENTEROL, V38, P348, DOI 10.1007/s005350300062; Melmed GY, 2007, CLIN GASTROENTEROL H, V5, P602, DOI 10.1016/j.cgh.2007.02.015; Meucci G, 1999, EUR J GASTROEN HEPAT, V11, P909, DOI 10.1097/00042737-199908000-00018; Mitsialis V, 2020, GASTROENTEROLOGY, V159, P591, DOI 10.1053/j.gastro.2020.04.074; Montero-Melendez T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076235; MYREN J, 1988, SCAND J GASTROENTERO, V23, P11; Newell KJ, 2002, MOL CARCINOGEN, V34, P59, DOI 10.1002/mc.10049; Nuij VJAA, 2013, INFLAMM BOWEL DIS, V19, P2215, DOI 10.1097/MIB.0b013e3182961626; O'Sullivan S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050808; Pender SLF, 1997, J IMMUNOL, V158, P1582; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Rath T, 2006, INFLAMM BOWEL DIS, V12, P1025, DOI 10.1097/01.mib.0000234133.97594.04; Rath T, 2010, SCAND J GASTROENTERO, V45, P1186, DOI 10.3109/00365521.2010.499961; Rymarz A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84662-3; SaarialhoKere UK, 1996, AM J PATHOL, V148, P519; Saibeni S, 2012, DIGEST LIVER DIS, V44, P123, DOI 10.1016/j.dld.2011.09.015; Salmela MT, 2004, SCAND J GASTROENTERO, V39, P1095, DOI 10.1080/00365520410003470; Salmela MT, 2002, GUT, V51, P540, DOI 10.1136/gut.51.4.540; Sandborn WJ, 2016, ALIMENT PHARM THER, V44, P157, DOI 10.1111/apt.13653; Sandborn WJ, 2018, J CROHNS COLITIS, V12, P1021, DOI 10.1093/ecco-jcc/jjy049; Schreiber S, 2018, J CROHNS COLITIS, V12, P1014, DOI 10.1093/ecco-jcc/jjy070; Seyedian Seyed Saeid, 2019, J Med Life, V12, P113, DOI 10.25122/jml-2018-0075; Shen QC, 2022, J ADV RES, V37, P221, DOI 10.1016/j.jare.2021.07.002; Sipos F, 2014, EUR J CANCER PREV, V23, P336, DOI 10.1097/CEJ.0000000000000058; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Sykes AP, 1999, ALIMENT PHARM THER, V13, P1535; Tontini GE, 2015, WORLD J GASTROENTERO, V21, P21, DOI 10.3748/wjg.v21.i1.21; Tun GSZ, 2018, CLIN MED, V18, P231, DOI 10.7861/clinmedicine.18-3-231; Uzzan M, 2022, NAT MED, V28, P766, DOI 10.1038/s41591-022-01680-y; Vancamelbeke M, 2017, INFLAMM BOWEL DIS, V23, P1718, DOI 10.1097/MIB.0000000000001246; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Vong L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039244; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang H, 2021, COMPUT STRUCT BIOTEC, V19, P4603, DOI 10.1016/j.csbj.2021.08.019	71	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1022850	10.3389/fimmu.2022.1022850	http://dx.doi.org/10.3389/fimmu.2022.1022850			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6TF	36479126	gold, Green Published			2022-12-18	WOS:000893809500001
J	Halimi, H; Farjadian, S				Halimi, Hossein; Farjadian, Shirin			Cholesterol: An important actor on the cancer immune scene	FRONTIERS IN IMMUNOLOGY			English	Review						cholesterol; immune cells; cancer; anticholesteremic agents; immunometabolism	SERUM-CHOLESTEROL; LIPOPROTEIN CHOLESTEROL; DIETARY-CHOLESTEROL; SIGNALING PATHWAY; DENDRITIC CELLS; LUNG-CANCER; HIGH-GRADE; STATIN USE; RECEPTOR; RISK	Based on the structural and signaling roles of cholesterol, which are necessary for immune cell activity, high concentrations of cholesterol and its metabolites not only trigger malignant cell activities but also impede immune responses against cancer cells. To proliferate and evade immune responses, tumor cells overcome environmental restrictions by changing their metabolic and signaling pathways. Overexpression of mevalonate pathway enzymes and low-density lipoprotein receptor cause elevated cholesterol synthesis and uptake, respectively. Accordingly, cholesterol can be considered as both a cause and an effect of cancer. Variations in the effects of blood cholesterol levels on the outcome of different types of cancer may depend on the stage of cancer. However, positive effects of cholesterol-lowering drugs have been reported in the treatment of patients with some malignancies.	[Halimi, Hossein; Farjadian, Shirin] Shiraz Univ Med Sci, Sch Med, Dept Immunol, Shiraz, Iran	Shiraz University of Medical Science	Farjadian, S (corresponding author), Shiraz Univ Med Sci, Sch Med, Dept Immunol, Shiraz, Iran.	shirinenator@gmail.com						Abdulla N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.728325; Afonso MS, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060760; Ahern TP, 2011, JNCI-J NATL CANCER I, V103, P1461, DOI 10.1093/jnci/djr291; Al-Khami AA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1344804; Amirkhani Z, 2022, IRAN J IMMUNOL, V19, P71, DOI [10.22034/iji.2022.92648.2163, 10.22034/IJI.2022.92648.2163]; Antalis CJ, 2010, BREAST CANCER RES TR, V122, P661, DOI 10.1007/s10549-009-0594-8; Ashouri E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86964-y; Ayyagari VN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228024; Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z; Baroni S, 1996, ACTA HAEMATOL-BASEL, V96, P24; Beckwitt CH, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1066-z; Beckwitt CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197422; Behranvand N, 2022, CANCER IMMUNOL IMMUN, V71, P507, DOI 10.1007/s00262-021-03013-3; BRICKER LA, 1972, J CLIN INVEST, V51, P206, DOI 10.1172/JCI106805; Brown MS, 2018, ANNU REV BIOCHEM, V87, P783, DOI 10.1146/annurev-biochem-062917-011852; Cao W, 2014, J IMMUNOL, V192, P2920, DOI 10.4049/jimmunol.1302801; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Castellano BM, 2017, SCIENCE, V355, P1306, DOI 10.1126/science.aag1417; Cendrowicz E, 2021, CANCERS, V13, DOI 10.3390/cancers13081946; CHANG AK, 1995, PREV MED, V24, P557, DOI 10.1006/pmed.1995.1089; Chen HQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08243; Chen L, 2017, BIOCHEM BIOPH RES CO, V484, P857, DOI 10.1016/j.bbrc.2017.02.003; Chen QF, 2018, J CELL PHYSIOL, V233, P6722, DOI 10.1002/jcp.26351; Chen WCY, 2019, CANCER EPIDEM BIOMAR, V28, P363, DOI 10.1158/1055-9965.EPI-18-0421; Chen YF, 2001, INT J CANCER, V91, P41, DOI 10.1002/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2; Chimento A, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00807; Chow S, 2016, LEUKEMIA LYMPHOMA, V57, P797, DOI 10.3109/10428194.2015.1088651; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; Deng CF, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.803473; Dillard PR, 2008, MOL CELL ENDOCRINOL, V295, P115, DOI 10.1016/j.mce.2008.08.013; dos Santos CR, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-16; Ehmsen S, 2019, CELL REP, V27, P3927, DOI 10.1016/j.celrep.2019.05.104; Esfahani K, 2020, CURR ONCOL, V27, pS87, DOI 10.3747/co.27.5223; Farooqi MAM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209486; Fritsche KL, 2015, ADV NUTR, V6, p293S, DOI 10.3945/an.114.006940; Garcia-Bermudez J, 2019, NATURE, V567, P118, DOI 10.1038/s41586-019-0945-5; Giacomini I, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.682911; Gill S, 2011, CELL METAB, V13, P260, DOI 10.1016/j.cmet.2011.01.015; Goossens P, 2019, CELL METAB, V29, P1376, DOI 10.1016/j.cmet.2019.02.016; Granchi C, 2018, EUR J MED CHEM, V157, P1276, DOI 10.1016/j.ejmech.2018.09.001; Gray RT, 2016, CANCER EPIDEMIOL, V45, P71, DOI 10.1016/j.canep.2016.10.004; Guillaumond F, 2015, P NATL ACAD SCI USA, V112, P2473, DOI 10.1073/pnas.1421601112; He MY, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0490-8; Hedrick CC, 2022, NAT REV IMMUNOL, V22, P173, DOI 10.1038/s41577-021-00571-6; Helzlsouer KJ, 1996, JNCI-J NATL CANCER I, V88, P32, DOI 10.1093/jnci/88.1.32; Herber DL, 2010, NAT MED, V16, P880, DOI 10.1038/nm.2172; HIRAYAMA C, 1979, CLIN CHIM ACTA, V91, P53, DOI 10.1016/0009-8981(79)90470-4; Huang BL, 2020, NAT METAB, V2, P132, DOI 10.1038/s42255-020-0174-0; Huang PX, 2016, CELL, V166, P1176, DOI 10.1016/j.cell.2016.08.003; J Welsh, 2020, J Biomed Phys Eng, V10, P537, DOI 10.31661/jbpe.v0i0.1066; Jamnagerwalla J, 2018, PROSTATE CANCER P D, V21, P252, DOI 10.1038/s41391-017-0030-9; Jhunjhunwala S, 2021, NAT REV CANCER, V21, P298, DOI 10.1038/s41568-021-00339-z; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Kim HY, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10081908; King RJ, 2022, TRENDS IMMUNOL, V43, P78, DOI 10.1016/j.it.2021.11.007; Kitahara CM, 2011, J CLIN ONCOL, V29, P1592, DOI 10.1200/JCO.2010.31.5200; Kobayashi E, 2022, CANCERS, V14, DOI 10.3390/cancers14122826; Komiya Yuko, 2008, Organogenesis, V4, P68; Kondo A, 2017, CELL REP, V18, P2228, DOI 10.1016/j.celrep.2017.02.006; Lash TL, 2017, AM J EPIDEMIOL, V186, P679, DOI 10.1093/aje/kww245; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Li CK, 2016, NUTR RES, V36, P627, DOI 10.1016/j.nutres.2016.04.009; Li J, 2016, ONCOGENE, V35, P6378, DOI 10.1038/onc.2016.168; Li JR, 2015, INT J CLIN EXP PATHO, V8, P11877; Lin CY, 2015, NAT REV CANCER, V15, P216, DOI 10.1038/nrc3912; Liu J, 2013, ONCOTARGET, V4, P1804, DOI 10.18632/oncotarget.1364; Liu K, 2018, CANCER MANAG RES, V10, P143, DOI 10.2147/CMAR.S144619; Liu YP, 2015, CANCER EPIDEM BIOMAR, V24, P1086, DOI 10.1158/1055-9965.EPI-14-1329; Luchetti G, 2016, ELIFE, V5, DOI 10.7554/eLife.20304; Lyu Z Y, 2018, Zhonghua Liu Xing Bing Xue Za Zhi, V39, P604, DOI 10.3760/cma.j.issn.0254-6450.2018.05.012; Ma XZ, 2019, CELL METAB, V30, P143, DOI 10.1016/j.cmet.2019.04.002; Malhotra P, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00467; MATTICK WALTER L., 1928, JOUR CANCER RES, V12, P236; Mayengbam SS, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101043; Mostaghel EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030062; NAGASU T, 1995, CANCER RES, V55, P5310; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; NEUGUT AI, 1986, JAMA-J AM MED ASSOC, V255, P365, DOI 10.1001/jama.255.3.365; NIENDORF A, 1995, INT J CANCER, V61, P461, DOI 10.1002/ijc.2910610405; Novelli G, 2012, J INHERIT METAB DIS, V35, P917, DOI 10.1007/s10545-011-9445-y; Okoye I, 2017, ONCOTARGET, V8, P98215, DOI 10.18632/oncotarget.21003; Onwuka JU, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6679-9; Park J, 2015, CELL REP, V10, P1614, DOI 10.1016/j.celrep.2015.02.024; Poirier S, 2009, J BIOL CHEM, V284, P28856, DOI 10.1074/jbc.M109.037085; Raccosta L, 2013, J EXP MED, V210, P1711, DOI 10.1084/jem.20130440; Raza S, 2015, MOL CELL BIOCHEM, V410, P187, DOI 10.1007/s11010-015-2551-7; Relja B, 2010, INT J MOL MED, V26, P733, DOI 10.3892/ijmm_00000520; Ricoult SJH, 2016, ONCOGENE, V35, P1250, DOI 10.1038/onc.2015.179; Rudd-Schmidt JA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13385-x; Sankanagoudar Shrimanjunath, 2017, Asian Pac J Cancer Prev, V18, P23; Schorghofer D, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0087-z; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Shafique K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-25; Shao JYH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001801; Sharma B, 2019, BBA-MOL CELL BIOL L, P1314, DOI 10.1016/j.bbalip.2019.06.008; SHEKELLE RB, 1991, AM J EPIDEMIOL, V134, P480, DOI 10.1093/oxfordjournals.aje.a116119; Sheng R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5393; Sheng R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2221; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Singh G, 2017, INDIAN J MED RES, V146, P38, DOI 10.4103/ijmr.IJMR_1639_15; Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756; Soncini M, 2016, P NATL ACAD SCI USA, V113, pE6219, DOI 10.1073/pnas.1613332113; Spampanato C, 2012, INT J ONCOL, V40, P935, DOI 10.3892/ijo.2011.1273; Stopsack KH, 2017, CARCINOGENESIS, V38, P806, DOI 10.1093/carcin/bgx058; Swamy M, 2016, IMMUNITY, V44, P1091, DOI 10.1016/j.immuni.2016.04.011; Vaquero J, 2017, ONCOGENE, V36, P3067, DOI 10.1038/onc.2016.462; Venturini I, 1999, ITAL J GASTROENTEROL, V31, P61; Villablanca EJ, 2010, NAT MED, V16, P98, DOI 10.1038/nm.2074; Vona R, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.622908; Wang CH, 2017, CELL PHYSIOL BIOCHEM, V42, P729, DOI 10.1159/000477890; Wang J, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12452; Webb J., 1901, LANCET, V158, P976, DOI [10.1016/S0140-6736(01)73258-8, DOI 10.1016/S0140-6736(01)73258-8]; Wylie B, 2019, CANCERS, V11, DOI 10.3390/cancers11040521; Yan AW, 2020, INT J ONCOL, V57, P1103, DOI 10.3892/ijo.2020.5124; Yang YH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01371; Yarmolinsky J, 2020, JAMA-J AM MED ASSOC, V323, P646, DOI 10.1001/jama.2020.0150; Yavasoglu I, 2017, J NATL MED ASSOC, V109, P23, DOI 10.1016/j.jnma.2016.11.006; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang HX, 2021, ONCOTARGETS THER, V14, P3803, DOI 10.2147/OTT.S315998; Zhang X, 2014, WORLD J GASTROENTERO, V20, P8646, DOI 10.3748/wjg.v20.i26.8646; Zhong SL, 2015, CANCER TREAT REV, V41, P554, DOI 10.1016/j.ctrv.2015.04.005; Zhou PT, 2018, CLIN CHIM ACTA, V477, P94, DOI 10.1016/j.cca.2017.11.039; Zhu DM, 2016, TOXICOL LETT, V264, P79, DOI 10.1016/j.toxlet.2016.11.006; Zou ZL, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00396-1	126	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1057546	10.3389/fimmu.2022.1057546	http://dx.doi.org/10.3389/fimmu.2022.1057546			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T0VN	36479100	Green Published, gold			2022-12-18	WOS:000893401600001
J	Holcomb, EA; Pearson, AN; Jungles, KM; Tate, A; James, J; Jiang, L; Huber, AK; Green, MD				Holcomb, Erin A. A.; Pearson, Ashley N. N.; Jungles, Kassidy M. M.; Tate, Akshay; James, Jadyn; Jiang, Long; Huber, Amanda K. K.; Green, Michael D. D.			High-content CRISPR screening in tumor immunology	FRONTIERS IN IMMUNOLOGY			English	Review						CRISPR screen; tumor immunology; cancer immunotherapy; transcriptomic readout; epigenetic readout; proteomic readout; genomic imaging	THROUGHPUT FUNCTIONAL GENOMICS; SEQUENCE-SPECIFIC CONTROL; PRIMARY IMMUNE CELLS; CAS9 PROTEIN; POOLED SCREENS; RNAI SCREENS; T-CELLS; TARGET; CANCER; DNA	CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions. Pooled CRISPR screens have enabled discovery of innate and adaptive immune response regulators in the setting of viral infection and cancer. Emerging methods couple pooled CRISPR screens with parallel high-content readouts at the transcriptomic, epigenetic, proteomic, and optical levels. These approaches are illuminating cancer immune evasion mechanisms as well as nominating novel targets that augment T cell activation, increase T cell infiltration into tumors, and promote enhanced T cell cytotoxicity. This review details recent methodological advances in high-content CRISPR screens and highlights the impact this technology is having on tumor immunology.	[Holcomb, Erin A. A.; Pearson, Ashley N. N.; Green, Michael D. D.] Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI 48109 USA; [Holcomb, Erin A. A.; Pearson, Ashley N. N.; Tate, Akshay; James, Jadyn; Jiang, Long; Huber, Amanda K. K.; Green, Michael D. D.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI USA; [Green, Michael D. D.] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Jiang, Long] Hefei Comprehens Natl Sci Ctr, Inst Hlth & Med, Hefei, Peoples R China; [Green, Michael D. D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Green, Michael D. D.] Vet Affairs Ann Arbor Healthcare Syst, Dept Radiat Oncol, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Green, MD (corresponding author), Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI 48109 USA.; Green, MD (corresponding author), Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.; Green, MD (corresponding author), Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.; Green, MD (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.; Green, MD (corresponding author), Vet Affairs Ann Arbor Healthcare Syst, Dept Radiat Oncol, Ann Arbor, MI 48105 USA.	migr@med.umich.edu			Immunology Training Program; Pharmacological Sciences Training Program (PSTP) T32 Training Grant [GM007767]; Rackham Merit Fellowship; Rackham Graduate School Research Grant; NIAID Training Grant [T32 (AI007413)]; Lung Precision Oncology Program [VA 150CU000182]; LUNGevity; Veterans Affairs [I01 BX005267]; Melanoma Research Alliance [MRA689853]; NCI [CA252010]; Breast Cancer Research Foundation	Immunology Training Program; Pharmacological Sciences Training Program (PSTP) T32 Training Grant; Rackham Merit Fellowship; Rackham Graduate School Research Grant; NIAID Training Grant; Lung Precision Oncology Program; LUNGevity; Veterans Affairs(US Department of Veterans Affairs); Melanoma Research Alliance; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation	Funding was provided to EH by the Immunology Training Program. Funding was provided to KJ by the Pharmacological Sciences Training Program (PSTP) T32 Training Grant (GM007767), the Rackham Merit Fellowship, and the Rackham Graduate School Research Grant. Funding was provided to AP by NIAID Training Grant T32 (AI007413). Funding was provided to MG by the Lung Precision Oncology Program (VA 150CU000182), LUNGevity, Veterans Affairs (I01 BX005267), Melanoma Research Alliance (MRA689853), NCI (CA252010), and the Breast Cancer Research Foundation.	Adamson B., 2018, BIORXIV, V298349, DOI [10.1101/298349, DOI 10.1101/298349]; Adamson B, 2016, CELL, V167, P1867, DOI 10.1016/j.cell.2016.11.048; Alghadban S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74960-7; Banskota S, 2022, CELL, V185, P250, DOI 10.1016/j.cell.2021.12.021; Barry T, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02545-2; Basu A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669474; Belk JA, 2022, CANCER CELL, V40, P768, DOI 10.1016/j.ccell.2022.06.001; Berger G, 2011, NAT PROTOC, V6, P806, DOI 10.1038/nprot.2011.327; Bikard D, 2013, NUCLEIC ACIDS RES, V41, P7429, DOI 10.1093/nar/gkt520; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Bodapati S, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-01972-x; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Buquicchio FA, 2021, TRENDS IMMUNOL, V42, P432, DOI 10.1016/j.it.2021.03.003; Burkhardt DB, 2021, NAT BIOTECHNOL, V39, P619, DOI 10.1038/s41587-020-00803-5; Burkhardt JK, 2008, ANNU REV IMMUNOL, V26, P233, DOI 10.1146/annurev.immunol.26.021607.090347; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen SD, 2015, CELL, V160, P1246, DOI 10.1016/j.cell.2015.02.038; Chen XZ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.939090; Chen ZY, 2021, CELL, V184, P1262, DOI 10.1016/j.cell.2021.02.019; Chiarle R, 2011, CELL, V147, P107, DOI 10.1016/j.cell.2011.07.049; Cho SW, 2013, GENETICS, V195, P1177, DOI 10.1534/genetics.113.155853; Choi JG, 2016, GENE THER, V23, P627, DOI 10.1038/gt.2016.27; Colic M, 2021, EMERG TOP LIFE SCI, V5, P779, DOI 10.1042/ETLS20210222; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Cortez JT, 2020, NATURE, V582, P416, DOI 10.1038/s41586-020-2246-4; Covarrubias S, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108541; Crosetto N, 2013, NAT METHODS, V10, P361, DOI 10.1038/nmeth.2408; Crotty S, 2015, TRENDS IMMUNOL, V36, P315, DOI 10.1016/j.it.2015.03.007; Dann E, 2022, NAT BIOTECHNOL, V40, P245, DOI 10.1038/s41587-021-01033-z; Datlinger P, 2017, NAT METHODS, V14, P297, DOI [10.1038/NMETH.4177, 10.1038/nmeth.4177]; Dhainaut M, 2022, CELL, V185, P1223, DOI 10.1016/j.cell.2022.02.015; Diaz AA, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1197; Dixit A, 2016, CELL, V167, P1853, DOI 10.1016/j.cell.2016.11.038; Doench JG, 2018, NAT REV GENET, V19, P67, DOI 10.1038/nrg.2017.97; Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026; Dong MB, 2019, CELL, V178, P1189, DOI 10.1016/j.cell.2019.07.044; Dong W, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071288; Duan B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10216-x; Duan JL, 2021, BIOINFORMATICS, V37, P4266, DOI 10.1093/bioinformatics/btab375; Echeverri CJ, 2006, NAT METHODS, V3, P777, DOI 10.1038/nmeth1006-777; Blaeschke F, 2022, bioRxiv, DOI 10.1101/2022.07.27.501186; Feldman D, 2022, NAT PROTOC, V17, P476, DOI 10.1038/s41596-021-00653-8; Feldman D, 2019, CELL, V179, P787, DOI 10.1016/j.cell.2019.09.016; Ferretti JJ., 2016, STREPTOCOCCUS PYOGEN; Frangieh CJ, 2021, NAT GENET, V53, P332, DOI 10.1038/s41588-021-00779-1; Frock RL, 2015, NAT BIOTECHNOL, V33, P179, DOI 10.1038/nbt.3101; Galy ASD, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe8219; Gee P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14957-y; Ghaffari S, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02076-5; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Giuliano Christopher J, 2019, Curr Protoc Mol Biol, V128, pe100, DOI 10.1002/cpmb.100; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; Gurusamy D, 2020, CANCER CELL, V37, P818, DOI 10.1016/j.ccell.2020.05.004; Hamilton JR, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109207; Hamilton JR., 2022, BIORXIV, DOI [10.1101/2022.08.24.505004, DOI 10.1101/2022.08.24.505004]; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hendel A, 2015, NAT BIOTECHNOL, V33, P985, DOI 10.1038/nbt.3290; Henkel L, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00905-1; Henriksson J, 2019, CELL, V176, P882, DOI 10.1016/j.cell.2018.11.044; Herrera A, 2021, BLOOD, V138, P1456, DOI 10.1182/blood.2020009346; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Indikova I, 2020, NUCLEIC ACIDS RES, V48, P8178, DOI 10.1093/nar/gkaa561; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jaitin DA, 2016, CELL, V167, P1883, DOI 10.1016/j.cell.2016.11.039; Jiang ML, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00916-z; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Jost M, 2021, ELIFE, V10, DOI 10.7554/eLife.65856; Kamber RA, 2021, NATURE, V597, P549, DOI 10.1038/s41586-021-03879-4; Kampmann M, 2018, ACS CHEM BIOL, V13, P406, DOI 10.1021/acschembio.7b00657; Kim S, 2014, GENOME RES, V24, P1012, DOI 10.1101/gr.171322.113; Klein K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.798235; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; LaFleur MW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09656-2; Larson MH, 2013, NAT PROTOC, V8, P2180, DOI 10.1038/nprot.2013.132; Lee YW, 2019, ADV THER-GERMANY, V2, DOI 10.1002/adtp.201900041; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Liang XQ, 2015, J BIOTECHNOL, V208, P44, DOI 10.1016/j.jbiotec.2015.04.024; Lin S, 2014, ELIFE, V3, DOI 10.7554/eLife.04766; Lin YN, 2014, NUCLEIC ACIDS RES, V42, P7473, DOI 10.1093/nar/gku402; Lino CA, 2018, DRUG DELIV, V25, P1234, DOI 10.1080/10717544.2018.1474964; Liscovitch-Brauer N, 2021, NAT BIOTECHNOL, V39, P1270, DOI 10.1038/s41587-021-00902-x; Listgarten J, 2018, NAT BIOMED ENG, V2, P38, DOI 10.1038/s41551-017-0178-6; Long LY, 2021, NATURE, V600, P308, DOI 10.1038/s41586-021-04109-7; Loo CS, 2020, IMMUNITY, V53, P143, DOI 10.1016/j.immuni.2020.06.011; Lu Y, 2020, NAT MED, V26, P732, DOI 10.1038/s41591-020-0840-5; Luteijn RD, 2019, NATURE, V573, P434, DOI 10.1038/s41586-019-1553-0; Lyu P, 2020, LIFE-BASEL, V10, DOI 10.3390/life10120366; Lyu P, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz605; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mangeot PE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07845-z; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Mehta A, 2020, J PHARM SCI-US, V109, P62, DOI 10.1016/j.xphs.2019.10.003; Mimitou EP, 2019, NAT METHODS, V16, P409, DOI 10.1038/s41592-019-0392-0; Mitani K., 2002, Current Gene Therapy, V2, P135, DOI 10.2174/1566523024605591; Moraes L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867195; Morgens DW, 2016, NAT BIOTECHNOL, V34, P634, DOI 10.1038/nbt.3567; Navarro-Guerrero E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82137-z; Norman TM, 2019, SCIENCE, V365, P786, DOI 10.1126/science.aax4438; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Papalexi E, 2021, NAT GENET, V53, P322, DOI 10.1038/s41588-021-00778-2; Parnas O, 2015, CELL, V162, P675, DOI 10.1016/j.cell.2015.06.059; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Pierce SE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23213-w; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299; Replogle Joseph M, 2022, Cell, V185, P2559, DOI 10.1016/j.cell.2022.05.013; Replogle JM, 2020, NAT BIOTECHNOL, V38, P954, DOI 10.1038/s41587-020-0470-y; Roth TL, 2020, CELL, V181, P728, DOI 10.1016/j.cell.2020.03.039; Rubin AJ, 2019, CELL, V176, P361, DOI 10.1016/j.cell.2018.11.022; Satpathy AT, 2019, NAT BIOTECHNOL, V37, P925, DOI 10.1038/s41587-019-0206-z; Schmidt R, 2022, SCIENCE, V375, P513, DOI 10.1126/science.abj4008; Schraivogel D, 2020, NAT METHODS, V17, P629, DOI 10.1038/s41592-020-0837-5; Schumann K, 2015, P NATL ACAD SCI USA, V112, P10437, DOI 10.1073/pnas.1512503112; Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shang WJ, 2018, P NATL ACAD SCI USA, V115, pE4051, DOI 10.1073/pnas.1801340115; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Simeonov DR, 2017, NATURE, V549, P111, DOI 10.1038/nature23875; Singh N, 2020, CANCER DISCOV, V10, P552, DOI 10.1158/2159-8290.CD-19-0813; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/NMETH.4380, 10.1038/nmeth.4380]; Theisen DJ, 2018, SCIENCE, V362, P694, DOI 10.1126/science.aat5030; Ting PY, 2018, NAT METHODS, V15, P941, DOI 10.1038/s41592-018-0149-1; Tong JY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd4742; Tsai SQ, 2016, NAT REV GENET, V17, P300, DOI 10.1038/nrg.2016.28; Tsai SQ, 2015, NAT BIOTECHNOL, V33, P187, DOI 10.1038/nbt.3117; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Chu VT, 2016, P NATL ACAD SCI USA, V113, P12514, DOI 10.1073/pnas.1613884113; Vredevoogd DW, 2019, CELL, V178, P585, DOI 10.1016/j.cell.2019.06.014; Wang LF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26682-1; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wang WB, 2016, J GENET GENOMICS, V43, P319, DOI 10.1016/j.jgg.2016.02.004; Wasels F, 2017, J MICROBIOL METH, V140, P5, DOI 10.1016/j.mimet.2017.06.010; Wei J, 2019, NATURE, V576, P471, DOI 10.1038/s41586-019-1821-z; Wroblewska A, 2018, CELL, V175, P1141, DOI 10.1016/j.cell.2018.09.022; Xie SQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198635; Xie SQ, 2017, MOL CELL, V66, P285, DOI 10.1016/j.molcel.2017.03.007; Xu YX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.848327; Yang L, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1928-4; Ye LP, 2019, NAT BIOTECHNOL, V37, P1302, DOI 10.1038/s41587-019-0246-4; Yeung ATY, 2019, MBIO, V10, DOI 10.1128/mBio.02169-19; Yip BH, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060839; Zalatan JG, 2015, CELL, V160, P339, DOI 10.1016/j.cell.2014.11.052; Zhu SY, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1628-0; Zhu SY, 2017, METHODS MOL BIOL, V1656, P175, DOI 10.1007/978-1-4939-7237-1_11	147	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1041451	10.3389/fimmu.2022.1041451	http://dx.doi.org/10.3389/fimmu.2022.1041451			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T2JK	36479127	gold, Green Published			2022-12-18	WOS:000893505800001
J	Khattab, A; Rezola, M; Barroso, M; Kyrklund, M; Pihlajamaa, T; Freitag, TL; van Gemert, GJ; Bousema, T; Permi, P; Turunen, O; Sauerwein, R; Luty, AJF; Meri, S				Khattab, Ayman; Rezola, Mikel; Barroso, Marta; Kyrklund, Mikael; Pihlajamaa, Tero; Freitag, Tobias L.; van Gemert, Geert-Jan; Bousema, Teun; Permi, Perttu; Turunen, Ossi; Sauerwein, Robert; Luty, Adrian J. F.; Meri, Seppo			Hijacking the human complement inhibitor C4b-binding protein by the sporozoite stage of the Plasmodium falciparum parasite	FRONTIERS IN IMMUNOLOGY			English	Article						complement evasion; Plasmodium; sporozoites; circumsporozoite protein; C4b binding protein	CIRCUMSPOROZOITE PROTEIN; MALARIA SPOROZOITES; FACTOR-H; INFECTION; BINDING; RECRUITMENT; MOSQUITO; REGION; LYSIS; SERUM	The complement system is considered the first line of defense against pathogens. Hijacking complement regulators from blood is a common evasion tactic of pathogens to inhibit complement activation on their surfaces. Here, we report hijacking of the complement C4b-binding protein (C4bp), the regulator of the classical and lectin pathways of complement activation, by the sporozoite (SPZ) stage of the Plasmodium falciparum parasite. This was shown by direct binding of radiolabeled purified C4bp to live SPZs as well as by binding of C4bp from human serum to SPZs in indirect immunofluorescence assays. Using a membrane-bound peptide array, peptides from the N-terminal domain (NTD) of P. falciparum circumsporozoite protein (CSP) were found to bind C4bp. Soluble biotinylated peptide covering the same region on the NTD and a recombinantly expressed NTD also bound C4bp in a dose-dependent manner. NTD-binding site on C4bp was mapped to the CCP1-2 of the C4bp alpha-chain, a common binding site for many pathogens. Native CSP was also co-immunoprecipitated with C4bp from human serum. Preventing C4bp binding to the SPZ surface negatively affected the SPZs gliding motility in the presence of functional complement and malaria hyperimmune IgG confirming the protective role of C4bp in controlling complement activation through the classical pathway on the SPZ surface. Incorporating the CSP-C4bp binding region into a CSP-based vaccine formulation could induce vaccine-mediated immunity that neutralizes this immune evasion region and increases the vaccine efficacy.	[Khattab, Ayman; Rezola, Mikel; Barroso, Marta; Kyrklund, Mikael; Freitag, Tobias L.; Meri, Seppo] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland; [Khattab, Ayman; Rezola, Mikel; Barroso, Marta; Kyrklund, Mikael; Freitag, Tobias L.; Meri, Seppo] Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland; [Khattab, Ayman] Genet Engn & Biotechnol Res Inst, Dept Nucl Acid Res, City Sci Res & Technol Applicat, Alexandria, Egypt; [Kyrklund, Mikael; Turunen, Ossi] Aalto Univ, Dept Bioprod & Biosyst, Espoo, Finland; [Pihlajamaa, Tero] Helsinki Univ Hosp, HUS Diagnost Ctr, Dept Clin Chem, HUSLAB, Helsinki, Finland; [van Gemert, Geert-Jan; Bousema, Teun] Radboudumc, Dept Med Microbiol, Nijmegen, Netherlands; [Permi, Perttu] Univ Jyvaskyla, Nanosci Ctr, Dept Chem, Jyvaskyla, Finland; [Permi, Perttu] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland; [Turunen, Ossi] Univ Eastern Finland, Sch Forest Sci, Joensuu, Finland; [Sauerwein, Robert] TropIQ Hlth Sci, Dept Biomed Sci, Nijmegen, Netherlands; [Luty, Adrian J. F.] Univ Paris, MERIT, IRD, Paris, France; [Meri, Seppo] Helsinki Univ Cent Hosp, HUSLAB Diagnost Ctr, Helsinki, Finland	University of Helsinki; University of Helsinki; Egyptian Knowledge Bank (EKB); City of Scientific Research & Technological Applications (SRTA-City); Aalto University; University of Helsinki; Helsinki University Central Hospital; Radboud University Nijmegen; University of Jyvaskyla; University of Jyvaskyla; University of Eastern Finland; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; University of Helsinki; Helsinki University Central Hospital	Khattab, A (corresponding author), Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland.; Khattab, A (corresponding author), Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland.; Khattab, A (corresponding author), Genet Engn & Biotechnol Res Inst, Dept Nucl Acid Res, City Sci Res & Technol Applicat, Alexandria, Egypt.	ayman.khattab@helsinki.fi			Jane and Aatos Erkko foundation [1323237]; Academy of Finland [4705080]; Sigrid Juselius Foundation [TYH2019311]; Helsinki University Hospital Funds [860044]; EU MSCA project CORVOS;  [4706167]	Jane and Aatos Erkko foundation; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Helsinki University Hospital Funds; EU MSCA project CORVOS; 	Research funding to SM and AK was provided by the Jane and Aatos Erkko foundation (4706167), the Academy of Finland (1323237), the Sigrid Juselius Foundation (4705080), and the Helsinki University Hospital Funds (TYH2019311). MR was supported by funds of the EU MSCA project CORVOS 860044.	Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Amino R, 2007, NAT PROTOC, V2, P1705, DOI 10.1038/nprot.2007.120; Ancsin JB, 2004, J BIOL CHEM, V279, P21824, DOI 10.1074/jbc.M401979200; Andre I, 2006, BIOCHEMISTRY-US, V45, P4559, DOI 10.1021/bi052455c; Behet MC, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00920-17, 10.1128/iai.00920-17]; Blom AM, 2008, VACCINE, V26, pI49, DOI 10.1016/j.vaccine.2008.11.049; Bongfen SE, 2009, VACCINE, V27, P328, DOI 10.1016/j.vaccine.2008.09.097; Chatterjee D, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108996; Coppi A, 2005, J EXP MED, V201, P27, DOI 10.1084/jem.20040989; Feng GQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21998-4; Friberg N, 2008, MOL IMMUNOL, V45, P4171, DOI 10.1016/j.molimm.2008.08.227; Hofmeyer T, 2013, J MOL BIOL, V425, P1302, DOI 10.1016/j.jmb.2012.12.017; Hopp CS, 2015, ELIFE, V4, DOI 10.7554/eLife.07789; Hovingh ES, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02004; KAWAMOTO Y, 1992, EXP PARASITOL, V75, P361, DOI 10.1016/0014-4894(92)90249-A; Kennedy AT, 2017, J IMMUNOL, V198, P4728, DOI 10.4049/jimmunol.1700067; Kennedy AT, 2016, J IMMUNOL, V196, P1239, DOI 10.4049/jimmunol.1501581; Khattab A, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-21; Kisalu NK, 2018, NAT MED, V24, P408, DOI 10.1038/nm.4512; Kurtovic L, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1054-2; Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205; Mejia P, 2016, J INFECT DIS, V213, P80, DOI 10.1093/infdis/jiv439; Meri S, 2016, FEBS LETT, V590, P2418, DOI 10.1002/1873-3468.12284; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Morgan BP., 1999, COMPLEMENT REGULATOR; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; Persson J, 2005, J IMMUNOL METHODS, V297, P83, DOI 10.1016/j.jim.2004.11.024; Rathore D, 2005, J BIOL CHEM, V280, P20524, DOI 10.1074/jbc.M414254200; Shao S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00532; Simon N, 2013, CELL HOST MICROBE, V13, P29, DOI 10.1016/j.chom.2012.11.013; Singh N, 2016, PARASITOL INT, V65, P552, DOI 10.1016/j.parint.2015.12.003; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; Tan J, 2018, NAT MED, V24, P401, DOI 10.1038/nm.4513; TOURAY MG, 1994, EXP PARASITOL, V78, P294, DOI 10.1006/expr.1994.1031; Vaughan AM, 2008, CELL HOST MICROBE, V4, P209, DOI 10.1016/j.chom.2008.08.010; Vera IM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002197; VERHAVE JP, 1988, PARASITE IMMUNOL, V10, P17, DOI 10.1111/j.1365-3024.1988.tb00200.x; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1051161	10.3389/fimmu.2022.1051161	http://dx.doi.org/10.3389/fimmu.2022.1051161			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2JI	36479121	gold, Green Published			2022-12-18	WOS:000894195000001
J	Li, X; Ye, YY; Peng, KL; Zeng, Z; Chen, L; Zeng, YH				Li, Xia; Ye, Youyuan; Peng, Kailan; Zeng, Zhuo; Chen, Li; Zeng, Yanhua			Histones: The critical players in innate immunity	FRONTIERS IN IMMUNOLOGY			English	Review						histones; innate immunity; DAMPs; AMPs; histone modification	NEUTROPHIL EXTRACELLULAR TRAPS; ANTIMICROBIAL PROTEINS; SKIN SECRETIONS; RAINBOW-TROUT; RICH HISTONES; CELL-DEATH; PEPTIDE; H2B; INFLAMMATION; ACTIVATION	The highly conserved histones in different species seem to represent a very ancient and universal innate host defense system against microorganisms in the biological world. Histones are the essential part of nuclear matter and act as a control switch for DNA transcription. However, histones are also found in the cytoplasm, cell membranes, and extracellular fluid, where they function as host defenses and promote inflammatory responses. In some cases, extracellular histones can act as damage-associated molecular patterns (DAMPs) and bind to pattern recognition receptors (PRRs), thereby triggering innate immune responses and causing initial organ damage. Histones and their fragments serve as antimicrobial peptides (AMPs) to directly eliminate bacteria, viruses, fungi, and parasites in vitro and in vivo. Histones are also involved in phagocytes-related innate immune response as components of neutrophil extracellular traps (NETs), neutrophil activators, and plasminogen receptors. In addition, as a considerable part of epigenetic regulation, histone modifications play a vital role in regulating the innate immune response and expression of corresponding defense genes. Here, we review the regulatory role of histones in innate immune response, which provides a new strategy for the development of antibiotics and the use of histones as therapeutic targets for inflammatory diseases, sepsis, autoimmune diseases, and COVID-19.	[Li, Xia; Ye, Youyuan; Peng, Kailan; Zeng, Zhuo; Chen, Li; Zeng, Yanhua] Univ South China, Inst Pathogen Biol, Hengyang Med Coll, Hunan Prov Key Lab Special Pathogens Prevent & Con, Hengyang, Hunan, Peoples R China; [Zeng, Yanhua] Univ South China, Affiliated Hosp 1, Dept Dermatol & Venereol, Hengyang, Hunan, Peoples R China	University of South China; University of South China	Zeng, YH (corresponding author), Univ South China, Inst Pathogen Biol, Hengyang Med Coll, Hunan Prov Key Lab Special Pathogens Prevent & Con, Hengyang, Hunan, Peoples R China.; Zeng, YH (corresponding author), Univ South China, Affiliated Hosp 1, Dept Dermatol & Venereol, Hengyang, Hunan, Peoples R China.	zengyihua21cn@126.com			National Natural Science Foundation of China;  [31370207];  [81871256]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; 	Funding This study was supported by the National Natural Science Foundation of China (NO: 31370207, 81871256).	Ackermann M, 2021, CELL DEATH DIFFER, V28, P3125, DOI 10.1038/s41418-021-00805-z; Allam R, 2013, EUR J IMMUNOL, V43, P3336, DOI 10.1002/eji.201243224; Allam R, 2012, J AM SOC NEPHROL, V23, P1375, DOI 10.1681/ASN.2011111077; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; Anand P, 2012, ELIFE, V1, DOI 10.7554/eLife.00003; Arnaud M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094527; Ashar HK, 2018, AM J PATHOL, V188, P135, DOI 10.1016/j.ajpath.2017.09.014; Athira PP, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205-020-02455-3; Augusto LA, 2003, BIOCHEMISTRY-US, V42, P3929, DOI 10.1021/bi0268394; Aymonnier K, 2022, BLOOD ADV, V6, P2001, DOI 10.1182/bloodadvances.2021005949; Beato M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041351; Bergsson G, 2005, FEBS J, V272, P4960, DOI 10.1111/j.1742-4658.2005.04906.x; Block H, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11121919; Bode KA, 2007, IMMUNOLOGY, V122, P596, DOI 10.1111/j.1365-2567.2007.02678.x; Bouchard BA, 2022, VASC PHARMACOL, V142, DOI 10.1016/j.vph.2021.106950; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bustillo ME, 2014, BBA-BIOMEMBRANES, V1838, P2228, DOI 10.1016/j.bbamem.2014.04.010; Byun S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14384-z; Cai XF, 2021, THROMB HAEMOSTASIS, V121, P1448, DOI 10.1055/s-0041-1726093; Carson WF, 2017, ADV PROTEIN CHEM STR, V106, P191, DOI 10.1016/bs.apcsb.2016.08.004; Cavalli G, 2019, NATURE, V571, P489, DOI 10.1038/s41586-019-1411-0; Chen R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.337; Chen RC, 2016, ONCOTARGET, V7, P61728, DOI 10.18632/oncotarget.11226; Chen XP, 2009, J BIOL CHEM, V284, P27857, DOI 10.1074/jbc.M109.000950; Cheng ZX, 2019, CRIT CARE MED, V47, pE677, DOI 10.1097/CCM.0000000000003839; Cho JH, 2009, BBA-BIOMEMBRANES, V1788, P1564, DOI 10.1016/j.bbamem.2008.10.025; Conceicao-Silva F, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081891; Das R, 2007, BLOOD, V110, P3763, DOI 10.1182/blood-2007-03-079392; Daskalaki MG, 2018, J CELL PHYSIOL, V233, P6495, DOI 10.1002/jcp.26497; De Lucca AJ, 2011, J AGR FOOD CHEM, V59, P6933, DOI 10.1021/jf201646x; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Doolin T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17699-z; Doyle HA, 2013, AUTOIMMUNITY, V46, P6, DOI 10.3109/08916934.2012.710859; Duong L, 2020, MICROB CELL, V7, P309, DOI 10.15698/mic2020.11.736; Eilenberg W, 2021, TRANSL RES, V233, P32, DOI 10.1016/j.trsl.2021.02.003; Ekaney ML, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0543-8; Elsharkawy AM, 2010, J HEPATOL, V53, P519, DOI 10.1016/j.jhep.2010.03.025; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fang TC, 2012, J EXP MED, V209, P661, DOI 10.1084/jem.20112343; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fernandes JMO, 2002, BIOCHEM J, V368, P611, DOI 10.1042/BJ20020980; Fernandes JMO, 2004, DEV COMP IMMUNOL, V28, P127, DOI 10.1016/S0145-305X(03)00120-4; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Frydman GH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61309-3; Fu BY, 2020, MAR DRUGS, V18, DOI 10.3390/md18030133; Gschwandtner M, 2014, J INVEST DERMATOL, V134, P2192, DOI 10.1038/jid.2014.165; Herren T, 2006, BIOCHEMISTRY-US, V45, P9463, DOI 10.1021/bi060756w; HIEMSTRA PS, 1993, INFECT IMMUN, V61, P3038, DOI 10.1128/IAI.61.7.3038-3046.1993; HIRSCH JG, 1958, J EXP MED, V108, P925, DOI 10.1084/jem.108.6.925; Hoeksema M, 2015, INNATE IMMUN-LONDON, V21, P736, DOI 10.1177/1753425915593794; Howell SJ, 2003, PEPTIDES, V24, P1763, DOI 10.1016/j.peptides.2003.07.028; Hsieh IN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247605; Hsieh IN, 2021, J LEUKOCYTE BIOL, V109, P763, DOI 10.1002/JLB.3A0620-342R; Huang H, 2013, J IMMUNOL, V191, P2665, DOI 10.4049/jimmunol.1202733; Huckriede J, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.694186; Ioannou M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-32320-1; Ito T, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0348-y; Jacobsen F, 2005, J ANTIMICROB CHEMOTH, V55, P735, DOI 10.1093/jac/dki067; Jiang Q, 2020, STEM CELLS, V38, P960, DOI 10.1002/stem.3188; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Johnstone AL, 2021, ADDICT BIOL, V26, DOI 10.1111/adb.12816; KASHIMA M, 1991, Journal of Dermatology (Tokyo), V18, P695, DOI 10.1111/j.1346-8138.1991.tb03160.x; Kaur BP, 2021, IMMUNOL ALLERGY CLIN, V41, P535, DOI 10.1016/j.iac.2021.07.003; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawano H, 2014, LAB INVEST, V94, P569, DOI 10.1038/labinvest.2014.46; Kim HS, 2002, J IMMUNOL, V168, P2356, DOI 10.4049/jimmunol.168.5.2356; Kimura H, 2021, HISTOPATHOLOGY, V78, P520, DOI 10.1111/his.14247; Kobiyama K, 2010, J VIROL, V84, P822, DOI 10.1128/JVI.01339-09; Koo YS, 2008, PEPTIDES, V29, P1102, DOI 10.1016/j.peptides.2008.02.019; Kozlowski HN, 2016, AIDS, V30, P2043, DOI 10.1097/QAD.0000000000001159; Lagedal R, 2022, J CLIN MED, V11, DOI 10.3390/jcm11123419; Lai JJ, 2020, IMMUNITY, V52, P123, DOI 10.1016/j.immuni.2019.11.013; Lee DY, 2009, J INVEST DERMATOL, V129, P2489, DOI 10.1038/jid.2009.106; Lemaire S, 2008, FEBS J, V275, P5286, DOI 10.1111/j.1742-4658.2008.06659.x; Li GH, 2007, J PEPT SCI, V13, P368, DOI 10.1002/psc.851; Li M, 2020, CANCERS, V12, DOI 10.3390/cancers12113424; Li YQ, 2014, SURGERY, V156, P229, DOI 10.1016/j.surg.2014.04.009; Li YP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.650184; Liao YT, 2021, PATHOG DIS, V79, DOI 10.1093/femspd/ftab053; Ligi D, 2022, CRIT CARE, V26, DOI 10.1186/s13054-022-04138-2; Luders T, 2005, ANTIMICROB AGENTS CH, V49, P2399, DOI 10.1128/AAC.49.6.2399-2406.2005; Meegan JE, 2018, BIOCHEM BIOPH RES CO, V503, P1498, DOI 10.1016/j.bbrc.2018.07.069; Mehta S, 2015, IMMUNOL CELL BIOL, V93, P233, DOI 10.1038/icb.2014.101; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Miller BF, 1942, SCIENCE, V96, P428, DOI 10.1126/science.96.2497.428; Moores RC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00602; Ondracek AS, 2021, ARTERIOSCL THROM VAS, V41, P995, DOI 10.1161/ATVBAHA.120.315633; Pakala SB, 2017, J BIOL CHEM, V292, P4764, DOI 10.1074/jbc.A117.139469; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pasupuleti M, 2012, CRIT REV BIOTECHNOL, V32, P143, DOI 10.3109/07388551.2011.594423; Patat SA, 2004, EUR J BIOCHEM, V271, P4825, DOI 10.1111/j.1432-1033.2004.04448.x; Pentagna N, 2021, DEV COMP IMMUNOL, V114, DOI 10.1016/j.dci.2020.103840; Qiao Y, 2013, IMMUNITY, V39, P454, DOI 10.1016/j.immuni.2013.08.009; Ramasubramanian B, 2022, FASEB J, V36, DOI 10.1096/fj.202200303RR; Roger T, 2011, BLOOD, V117, P1205, DOI 10.1182/blood-2010-05-284711; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; Rubio-Tomas T, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e07387; Scheer S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00429; Shah M, 2022, CARDIOVASC RES, V118, P1115, DOI 10.1093/cvr/cvab139; Shakespear MR, 2011, TRENDS IMMUNOL, V32, P335, DOI 10.1016/j.it.2011.04.001; Sharma N, 2022, J THROMB HAEMOST, V20, P1485, DOI 10.1111/jth.15706; Shaw RJ, 2021, HAEMATOLOGICA, V106, P2493, DOI 10.3324/haematol.2021.278492; Shi L, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251726; Shrestha B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02535; Silk E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.52; Silphaduang U, 2006, BIOCHEM BIOPH RES CO, V340, P648, DOI 10.1016/j.bbrc.2005.12.054; Silvestre-Roig C, 2019, NATURE, V569, P236, DOI 10.1038/s41586-019-1167-6; Sim S, 2017, FEBS LETT, V591, P706, DOI 10.1002/1873-3468.12574; Song Y, 2019, ADV MATER, V31, DOI 10.1002/adma.201807436; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Sun WY, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120633; Swindle CS, 1998, J VIROL, V72, P1994, DOI 10.1128/JVI.72.3.1994-2001.1998; Tagai C, 2011, PEPTIDES, V32, P2003, DOI 10.1016/j.peptides.2011.09.005; Tamura M, 2003, ARCH VIROL, V148, P1659, DOI 10.1007/s00705-003-0143-4; Tan CY, 2021, J LEUKOCYTE BIOL, V110, P797, DOI 10.1002/JLB.3RU0620-375R; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Tian YZ, 2021, INFECTION, V49, P83, DOI 10.1007/s15010-020-01528-y; Tsourouktsoglou TD, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107602; Ueki N, 2008, ONCOGENE, V27, P300, DOI 10.1038/sj.onc.1210654; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Urusov AE, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169182; Venkatesh S, 2015, NAT REV MOL CELL BIO, V16, P178, DOI 10.1038/nrm3941; Wang YW, 2011, INFECT IMMUN, V79, P1124, DOI 10.1128/IAI.00658-10; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Westman J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005319; Williams WM, 1996, CLIN EXP IMMUNOL, V104, P18, DOI 10.1046/j.1365-2249.1996.d01-633.x; Xia M, 2013, IMMUNITY, V39, P470, DOI 10.1016/j.immuni.2013.08.016; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Yoo HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163982; Zhang Q, 2021, ANNU REV IMMUNOL, V39, P279, DOI 10.1146/annurev-immunol-093019-123619; Zhang XX, 2019, PROTEIN CELL, V10, P864, DOI 10.1007/s13238-019-0653-9; Zhao ZY, 2020, ADV SCI, V7, DOI 10.1002/advs.202002680; Zhong YY, 2019, MOL IMMUNOL, V114, P179, DOI 10.1016/j.molimm.2019.07.011; Zhou W, 2008, MOL CELL, V29, P69, DOI 10.1016/j.molcel.2007.11.002; Zhu CR, 2019, J TRAUMA ACUTE CARE, V87, P614, DOI 10.1097/TA.0000000000002387	136	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1030610	10.3389/fimmu.2022.1030610	http://dx.doi.org/10.3389/fimmu.2022.1030610			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6UN	36479112	Green Published, gold			2022-12-18	WOS:000893813000001
J	Li, YJ; Wang, BB; Sun, WZ; Kong, C; Li, GW; Chen, XL; Lu, SB				Li, Yongjin; Wang, Baobao; Sun, Wenzhi; Kong, Chao; Li, Guowang; Chen, Xiaolong; Lu, Shibao			Screening the immune-related circRNAs and genes in mice of spinal cord injury by RNA sequencing	FRONTIERS IN IMMUNOLOGY			English	Article						spinal cord injury; RNA-sequencing; circular RNA; immune; inflammation	EXPRESSION; RECOVERY	Spinal cord injury (SCI) is a pathological condition that leading to serious nerve damage, disability and even death. Increasing evidence have revealed that circular RNAs (circRNAs) and mRNA are widely involved in the regulation of the pathological process of neurological diseases by sponging microRNAs (miRNAs). Nevertheless, the potential biological functions and regulatory mechanisms of circRNAs in the subacute stage of SCI remain unclear. We analyzed the expression and regulatory patterns of circRNAs and mRNAs in SCI mice models using RNA-sequencing and bioinformatics analysis. A total of 24 circRNAs and 372 mRNAs were identified to be differentially expressed. Then we identifying the immune-related genes (IRGs) from them. The protein-protein interaction network were constructed based on the STRING database and Cytoscape software. Furthermore, Go and KEGG enrichment analysis were conducted to predict the functions of the IRGs and host genes of DECs. These findings will contribute to elucidate the pathophysiology of SCI and provide effective therapeutic targets for SCI patients.	[Li, Yongjin; Wang, Baobao; Sun, Wenzhi; Kong, Chao; Chen, Xiaolong; Lu, Shibao] Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China; [Li, Guowang] Tianjin Med Univ, Grad Sch, Tianjin, Peoples R China	Capital Medical University; Tianjin Medical University	Chen, XL; Lu, SB (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China.	chensmalldragon@163.com; spinelu@163.com			National key RD plan [2020YFC2004905]; R&D Program of Beijing Municipal Education Commission [KZ/KM/SZ/SM2022100250]; Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project [2019-2]	National key RD plan; R&D Program of Beijing Municipal Education Commission; Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project	This research was funded by National key R & D plan(2020YFC2004905) R & D Program of Beijing Municipal Education Commission (KZ/KM/SZ/SM2022100250**), and Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project (Capital Medical Research No. 2019-2).	Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Bie F, 2021, BIOMED PHARMACOTHER, V141, DOI 10.1016/j.biopha.2021.111826; Bunday KL, 2012, CURR BIOL, V22, P2355, DOI 10.1016/j.cub.2012.10.046; Buzoianu-Anguiano V, 2021, CELLS-BASEL, V10, DOI [10.3390/cells10102783, 10.1111/j.1768-322X.2004.tb01416.x]; Chen JN, 2022, NEURAL REGEN RES, V17, P144, DOI 10.4103/1673-5374.314114; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Chio JCT, 2021, EXP NEUROL, V341, DOI 10.1016/j.expneurol.2021.113704; Ge L, 2019, WORLD NEUROSURG, V122, pE1551, DOI 10.1016/j.wneu.2018.11.099; Ge L, 2018, WORLD NEUROSURG, V111, pE411, DOI 10.1016/j.wneu.2017.12.008; Grassner L, 2022, J NEUROTRAUM, DOI 10.1089/neu.2021.0448; Gucluler G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171003; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Lee BS, 2022, SPINAL CORD, V60, P268, DOI 10.1038/s41393-021-00695-5; Li XY, 2021, FASEB J, V35, DOI 10.1096/fj.202100993R; Liu T, 2012, NEUROSCI BULL, V28, P131, DOI 10.1007/s12264-012-1219-5; Martirosyan NL, 2021, NEUROSURG CLIN N AM, V32, P389, DOI 10.1016/j.nec.2021.03.010; O'Shea TM, 2017, J CLIN INVEST, V127, P3265, DOI 10.1172/JCI90608; Orr MB, 2018, NEUROTHERAPEUTICS, V15, P541, DOI 10.1007/s13311-018-0631-6; Panni S, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194417; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Patop IL, 2019, EMBO J, V38, DOI 10.15252/embj.2018100836; Qin C, 2019, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00497; Quadri SA, 2020, NEUROSURG REV, V43, P425, DOI 10.1007/s10143-018-1008-3; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Shi LL, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3532-x; Sun YP, 2021, CELL CYCLE, V20, P1828, DOI 10.1080/15384101.2021.1962634; Sweis R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0715-4; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Vismara I, 2017, TRENDS MOL MED, V23, P831, DOI 10.1016/j.molmed.2017.07.005; Wang Q, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3586; Wang WZ, 2021, NEURAL REGEN RES, V16, P2048, DOI 10.4103/1673-5374.308100; Wang WZ, 2021, AGING-US, V13, P13211, DOI 10.18632/aging.203002; Yan L, 2022, BMC NEUROSCI, V23, DOI 10.1186/s12868-022-00737-5; Yang L, 2022, ANNU REV CELL DEV BI, V38, P263, DOI 10.1146/annurev-cellbio-120420-125117; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao JW, 2020, BIOCHEM BIOPH RES CO, V528, P359, DOI 10.1016/j.bbrc.2020.02.108; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zhou ZB, 2019, J NEUROTRAUM, V36, P2287, DOI 10.1089/neu.2018.6366; Zhu LL, 2017, CELL PHYSIOL BIOCHEM, V44, P388, DOI 10.1159/000484919	47	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1060290	10.3389/fimmu.2022.1060290	http://dx.doi.org/10.3389/fimmu.2022.1060290			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6V0LO	36479123	gold, Green Published			2022-12-18	WOS:000894749900001
J	Li, YJ; Wang, BB; Sun, WZ; Kong, C; Li, GW; Chen, XL; Lu, SB				Li, Yongjin; Wang, Baobao; Sun, Wenzhi; Kong, Chao; Li, Guowang; Chen, Xiaolong; Lu, Shibao			Screening the immune-related circRNAs and genes in mice of spinal cord injury by RNA sequencing	FRONTIERS IN IMMUNOLOGY			English	Article						spinal cord injury; RNA-sequencing; circular RNA; immune; inflammation	EXPRESSION; RECOVERY; SUBACUTE	Spinal cord injury (SCI) is a pathological condition that leading to serious nerve damage, disability and even death. Increasing evidence have revealed that circular RNAs (circRNAs) and mRNA are widely involved in the regulation of the pathological process of neurological diseases by sponging microRNAs (miRNAs). Nevertheless, the potential biological functions and regulatory mechanisms of circRNAs in the subacute stage of SCI remain unclear. We analyzed the expression and regulatory patterns of circRNAs and mRNAs in SCI mice models using RNA-sequencing and bioinformatics analysis. A total of 24 circRNAs and 372 mRNAs were identified to be differentially expressed. Then we identifying the immune-related genes (IRGs) from them. The proteinprotein interaction network were constructed based on the STRING database and Cytoscape software. Furthermore, Go and KEGG enrichment analysis were conducted to predict the functions of the IRGs and host genes of DECs. These findings will contribute to elucidate the pathophysiology of SCI and provide effective therapeutic targets for SCI patients.	[Li, Yongjin; Wang, Baobao; Sun, Wenzhi; Kong, Chao; Chen, Xiaolong; Lu, Shibao] Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China; [Li, Guowang] Tianjin Med Univ, Grad Sch, Tianjin, Peoples R China	Capital Medical University; Tianjin Medical University	Chen, XL; Lu, SB (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China.	chensmalldragon@163.com; spinelu@163.com			National key RD plan [2020YFC2004905]; R&D Program of Beijing Municipal Education Commission [KZ/KM/SZ/SM2022100250**]; Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project [2019-2]	National key RD plan; R&D Program of Beijing Municipal Education Commission; Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project	This research was funded by National key R&D plan (2020YFC2004905) R&D Program of Beijing Municipal Education Commission (KZ/KM/SZ/SM2022100250**), and Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project (Capital Medical Research No. 2019-2).	Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Bie F, 2021, BIOMED PHARMACOTHER, V141, DOI 10.1016/j.biopha.2021.111826; Bunday KL, 2012, CURR BIOL, V22, P2355, DOI 10.1016/j.cub.2012.10.046; Buzoianu-Anguiano V, 2021, CELLS-BASEL, V10, DOI [10.3390/cells10102783, 10.1111/j.1768-322X.2004.tb01416.x]; Chen JN, 2022, NEURAL REGEN RES, V17, P144, DOI 10.4103/1673-5374.314114; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Chio JCT, 2021, EXP NEUROL, V341, DOI 10.1016/j.expneurol.2021.113704; Ge L, 2019, WORLD NEUROSURG, V122, pE1551, DOI 10.1016/j.wneu.2018.11.099; Ge L, 2018, WORLD NEUROSURG, V111, pE411, DOI 10.1016/j.wneu.2017.12.008; Grassner L, 2022, J NEUROTRAUM, DOI 10.1089/neu.2021.0448; Gucluler G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171003; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Lee BS, 2022, SPINAL CORD, V60, P268, DOI 10.1038/s41393-021-00695-5; Li XY, 2021, FASEB J, V35, DOI 10.1096/fj.202100993R; Liu T, 2012, NEUROSCI BULL, V28, P131, DOI 10.1007/s12264-012-1219-5; Martirosyan NL, 2021, NEUROSURG CLIN N AM, V32, P389, DOI 10.1016/j.nec.2021.03.010; O'Shea TM, 2017, J CLIN INVEST, V127, P3265, DOI 10.1172/JCI90608; Orr MB, 2018, NEUROTHERAPEUTICS, V15, P541, DOI 10.1007/s13311-018-0631-6; Panni S, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194417; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Patop IL, 2019, EMBO J, V38, DOI 10.15252/embj.2018100836; Qin C, 2019, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00497; Quadri SA, 2020, NEUROSURG REV, V43, P425, DOI 10.1007/s10143-018-1008-3; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Shi LL, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3532-x; Sun YP, 2021, CELL CYCLE, V20, P1828, DOI 10.1080/15384101.2021.1962634; Sweis R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0715-4; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Vismara I, 2017, TRENDS MOL MED, V23, P831, DOI 10.1016/j.molmed.2017.07.005; Wang Q, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3586; Wang WZ, 2021, NEURAL REGEN RES, V16, P2048, DOI 10.4103/1673-5374.308100; Wang WZ, 2021, AGING-US, V13, P13211, DOI 10.18632/aging.203002; Yan L, 2022, BMC NEUROSCI, V23, DOI 10.1186/s12868-022-00737-5; Yang L, 2022, ANNU REV CELL DEV BI, V38, P263, DOI 10.1146/annurev-cellbio-120420-125117; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao JW, 2020, BIOCHEM BIOPH RES CO, V528, P359, DOI 10.1016/j.bbrc.2020.02.108; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zhou ZB, 2019, J NEUROTRAUM, V36, P2287, DOI 10.1089/neu.2018.6366; Zhu LL, 2017, CELL PHYSIOL BIOCHEM, V44, P388, DOI 10.1159/000484919	47	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13									10.3389/fimmu.2022.1060290	http://dx.doi.org/10.3389/fimmu.2022.1060290			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6Q1UP	36479123	gold, Green Published			2022-12-18	WOS:000891404500001
J	Liu, C; Lin, H; Cao, LM; Wang, KQ; Sui, JX				Liu, Chang; Lin, Hong; Cao, Limin; Wang, Kaiqiang; Sui, Jianxin			Research progress on unique paratope structure, antigen binding modes, and systematic mutagenesis strategies of single-domain antibodies	FRONTIERS IN IMMUNOLOGY			English	Review						single-domain antibody; structure; binding modes; mutagenesis; epitope; paratope	SHARK IGNAR ANTIBODY; PROTEIN-STRUCTURE PREDICTION; HEAVY-CHAIN ANTIBODIES; AFFINITY MATURATION; VARIABLE DOMAINS; ENZYME-IMMUNOASSAY; CRYSTAL-STRUCTURE; RIBOSOME DISPLAY; PHAGE DISPLAY; NURSE SHARK	Single-domain antibodies (sdAbs) showed the incredible advantages of small molecular weight, excellent affinity, specificity, and stability compared with traditional IgG antibodies, so their potential in binding hidden antigen epitopes and hazard detection in food, agricultural and veterinary fields were gradually explored. Moreover, its low immunogenicity, easy-to-carry target drugs, and penetration of the blood-brain barrier have made sdAbs remarkable achievements in medical treatment, toxin neutralization, and medical imaging. With the continuous development and maturity of modern molecular biology, protein analysis software and database with different algorithms, and next-generation sequencing technology, the unique paratope structure and different antigen binding modes of sdAbs compared with traditional IgG antibodies have aroused the broad interests of researchers with the increased related studies. However, the corresponding related summaries are lacking and needed. Different antigens, especially hapten antigens, show distinct binding modes with sdAbs. So, in this paper, the unique paratope structure of sdAbs, different antigen binding cases, and the current maturation strategy of sdAbs were classified and summarized. We hope this review lays a theoretical foundation to elucidate the antigen-binding mechanism of sdAbs and broaden the further application of sdAbs.	[Liu, Chang; Lin, Hong; Cao, Limin; Wang, Kaiqiang; Sui, Jianxin] Ocean Univ China, Coll Food Sci & Engn, Qingdao, Shandong, Peoples R China	Ocean University of China	Sui, JX (corresponding author), Ocean Univ China, Coll Food Sci & Engn, Qingdao, Shandong, Peoples R China.	suijianxin@ouc.edu.cn			National Natural Science Foundation of China; National Key R&D Program of China; Fundamental Research Funds for the Central Universities;  [32072308];  [2018YFD0901005];  [202042011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); ; ; 	Funding This work was financially supported by the National Natural Science Foundation of China (No. 32072308), the National Key R&D Program of China (2018YFD0901005) and the Fundamental Research Funds for the Central Universities (No.202042011).	Akiba H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50722-y; Anderson GP, 2017, TOXICON, V129, P68, DOI 10.1016/j.toxicon.2017.02.008; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Barelle C, 2009, ADV EXP MED BIOL, V655, P49, DOI 10.1007/978-1-4419-1132-2_6; Bond CJ, 2003, J MOL BIOL, V332, P643, DOI 10.1016/S0022-2836(03)00967-7; Bystroff Christopher, 2002, Bioinformatics, V18 Suppl 1, pS54; Cabanillas-Bernal O, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213394; Cheong WS, 2020, INT J BIOL MACROMOL, V147, P369, DOI 10.1016/j.ijbiomac.2020.01.039; Chi SW, 2007, P NATL ACAD SCI USA, V104, P9230, DOI 10.1073/pnas.0701279104; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Crouch K, 2013, FISH SHELLFISH IMMUN, V34, P1158, DOI 10.1016/j.fsi.2013.01.025; D'Angelo S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00395; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; De Genst E, 2004, J BIOL CHEM, V279, P53593, DOI 10.1074/jbc.M407843200; De Genst EJ, 2010, J MOL BIOL, V402, P326, DOI 10.1016/j.jmb.2010.07.001; De Vlieger D, 2018, ANTIBODIES, V8, DOI 10.3390/antib8010001; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Diaz M, 1999, INT IMMUNOL, V11, P825, DOI 10.1093/intimm/11.5.825; Diaz M, 2002, IMMUNOGENETICS, V54, P501, DOI 10.1007/s00251-002-0479-z; Ding LL, 2019, FEBS LETT, V593, P1248, DOI 10.1002/1873-3468.13398; Dobson CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep38644; Dooley H, 2006, DEV COMP IMMUNOL, V30, P43, DOI 10.1016/j.dci.2005.06.022; Dooley H, 2006, P NATL ACAD SCI USA, V103, P1846, DOI 10.1073/pnas.0508341103; Doyle PJ, 2008, MOL IMMUNOL, V45, P3703, DOI 10.1016/j.molimm.2008.06.005; Du ZY, 2021, NAT PROTOC, V16, P5634, DOI 10.1038/s41596-021-00628-9; Ebrahimizadeh W, 2015, APPL BIOCHEM BIOTECH, V176, P1985, DOI 10.1007/s12010-015-1695-y; English Hejiao, 2020, Antib Ther, V3, P1, DOI 10.1093/abt/tbaa001; Fanning SW, 2011, PROTEIN SCI, V20, P1196, DOI 10.1002/pro.648; Feng Mingqian, 2019, Antib Ther, V2, P1, DOI 10.1093/abt/tby011; Fennell BJ, 2010, J MOL BIOL, V400, P155, DOI 10.1016/j.jmb.2010.04.061; Flajnik MF, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001120; GARNIER J, 1990, BIOCHIMIE, V72, P513, DOI 10.1016/0300-9084(90)90115-W; Gaylord ST, 2015, ANAL CHEM, V87, P6570, DOI 10.1021/acs.analchem.5b00322; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Goldman ER, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00865; Gonzalez-Sapienza G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00977; GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0; Hagihara Y, 2007, J BIOL CHEM, V282, P36489, DOI 10.1074/jbc.M707078200; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Harmsen MM, 2006, APPL MICROBIOL BIOT, V72, P544, DOI 10.1007/s00253-005-0300-7; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; He T, 2014, ANAL CHEM, V86, P8873, DOI 10.1021/ac502390c; Henry KA, 2018, MABS-AUSTIN, V10, P815, DOI 10.1080/19420862.2018.1489633; HINDS KR, 1986, NATURE, V320, P546, DOI 10.1038/320546a0; Hoey RJ, 2019, EXP BIOL MED, V244, P1568, DOI 10.1177/1535370219881129; Irving RA, 2001, J IMMUNOL METHODS, V248, P31, DOI 10.1016/S0022-1759(00)00341-0; Jiao LX, 2017, APPL MICROBIOL BIOT, V101, P6071, DOI 10.1007/s00253-017-8347-9; Juma SN, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051140; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Khalid Z, 2022, FISH SHELLFISH IMMUN, V121, P467, DOI 10.1016/j.fsi.2022.01.027; King MT, 2018, J BIOL CHEM, V293, P13626, DOI 10.1074/jbc.RA118.003888; Kirchhofer A, 2010, NAT STRUCT MOL BIOL, V17, P133, DOI 10.1038/nsmb.1727; Kobayashi N, 2009, ANAL BIOCHEM, V387, P257, DOI 10.1016/j.ab.2009.01.004; Konning D, 2017, CURR OPIN STRUC BIOL, V45, P10, DOI 10.1016/j.sbi.2016.10.019; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Koide A, 2007, J MOL BIOL, V373, P941, DOI 10.1016/j.jmb.2007.08.027; Kontermann RE, 2012, MABS-AUSTIN, V4, P182, DOI 10.4161/mabs.4.2.19000; Kopsidas G, 2006, IMMUNOL LETT, V107, P163, DOI 10.1016/j.imlet.2006.09.004; Kovaleva M, 2014, EXPERT OPIN BIOL TH, V14, P1527, DOI 10.1517/14712598.2014.937701; Kubala MH, 2010, PROTEIN SCI, V19, P2389, DOI 10.1002/pro.519; Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3; Leow CH, 2017, DIAGNOSTICS, V7, DOI 10.3390/diagnostics7040052; Lesne J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38752-y; Lim CC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081861; Lindstedt PR, 2021, CELL CHEM BIOL, V28, P70, DOI 10.1016/j.chembiol.2020.11.002; Lippow SM, 2007, NAT BIOTECHNOL, V25, P1171, DOI 10.1038/nbt1336; Lippow SM, 2007, CURR OPIN BIOTECH, V18, P305, DOI 10.1016/j.copbio.2007.04.009; Liu JL, 2007, MOL IMMUNOL, V44, P1775, DOI 10.1016/j.molimm.2006.07.299; Liu JL, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0837-z; Liu X, 2017, TALANTA, V164, P154, DOI 10.1016/j.talanta.2016.11.039; Lohr T, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12050718; Maass DR, 2007, J IMMUNOL METHODS, V324, P13, DOI 10.1016/j.jim.2007.04.008; Marshall SA, 2005, PROTEIN SCI, V14, P1293, DOI 10.1110/ps.041259105; Matz H, 2021, DEV COMP IMMUNOL, V115, DOI 10.1016/j.dci.2020.103873; Mishra AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00117; Mitchell LS, 2018, PROTEIN ENG DES SEL, V31, P267, DOI 10.1093/protein/gzy017; Mitchell LS, 2018, PROTEINS, V86, P697, DOI 10.1002/prot.25497; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; Nie JF, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111328; Nuttall SD, 2001, MOL IMMUNOL, V38, P313, DOI 10.1016/S0161-5890(01)00057-8; Nuttall SD, 2004, PROTEINS, V55, P187, DOI 10.1002/prot.20005; Nuttall SD, 2008, CURR OPIN PHARMACOL, V8, P609, DOI 10.1016/j.coph.2008.06.007; Qiu YL, 2016, ANAL BIOANAL CHEM, V408, P895, DOI 10.1007/s00216-015-9181-5; Rabia LA, 2018, BIOCHEM ENG J, V137, P365, DOI 10.1016/j.bej.2018.06.003; Ragland SA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006512; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Rosenberg M, 2006, CURR PHARM DESIGN, V12, P3973, DOI 10.2174/138161206778743655; Roux KH, 1998, P NATL ACAD SCI USA, V95, P11804, DOI 10.1073/pnas.95.20.11804; Rubinstein ND, 2008, MOL IMMUNOL, V45, P3477, DOI 10.1016/j.molimm.2007.10.016; Schneider C, 2022, NUCLEIC ACIDS RES, V50, pD1368, DOI 10.1093/nar/gkab1050; Sefid F, 2019, INT J PEPT RES THER, V25, P273, DOI 10.1007/s10989-017-9670-9; Shan GM, 2004, CHEM RES TOXICOL, V17, P218, DOI 10.1021/tx034220c; Sheedy C, 2006, J AGR FOOD CHEM, V54, P3668, DOI 10.1021/jf060219i; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Soler MA, 2019, CHEM COMMUN, V55, P14043, DOI 10.1039/c9cc06182g; Spinelli S, 2000, BIOCHEMISTRY-US, V39, P1217, DOI 10.1021/bi991830w; Spinelli S, 2001, J MOL BIOL, V311, P123, DOI 10.1006/jmbi.2001.4856; Stanfield RL, 2004, SCIENCE, V305, P1770, DOI 10.1126/science.1101148; Stanfield RL, 2007, J MOL BIOL, V367, P358, DOI 10.1016/j.jmb.2006.12.045; Stave JW, 2013, J IMMUNOL, V191, P1428, DOI 10.4049/jimmunol.1203198; Steeland S, 2016, DRUG DISCOV TODAY, V21, P1076, DOI 10.1016/j.drudis.2016.04.003; Streltsov VA, 2004, P NATL ACAD SCI USA, V101, P12444, DOI 10.1073/pnas.0403509101; Streltsov VA, 2005, PROTEIN SCI, V14, P2901, DOI 10.1110/ps.051709505; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Swindells MB, 2017, J MOL BIOL, V429, P356, DOI 10.1016/j.jmb.2016.08.019; Tabares-da Rosa S, 2019, J MOL RECOGNIT, V32, DOI 10.1002/jmr.2755; Tabasinezhad M, 2019, IMMUNOL LETT, V212, P106, DOI 10.1016/j.imlet.2019.06.009; Tiller KE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00986; Turner Kendrick B, 2015, Biotechnol Rep (Amst), V6, P27, DOI 10.1016/j.btre.2015.01.001; Vishwakarma P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073721; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; Wang K, 2019, ANAL CHEM, V91, P1532, DOI 10.1021/acs.analchem.8b04653; Wang XR, 2020, INT J BIOL MACROMOL, V151, P312, DOI [10.1016/j.ijbiomac.2020.02.180, 10.16/j.ijbiomac.2020.02.180]; Waxman EA, 2009, BBA-MOL BASIS DIS, V1792, P616, DOI 10.1016/j.bbadis.2008.09.013; Wesolowski J, 2009, MED MICROBIOL IMMUN, V198, P157, DOI 10.1007/s00430-009-0116-7; Wilton EE, 2018, ACS SYNTH BIOL, V7, P2480, DOI 10.1021/acssynbio.8b00407; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Xi X, 2020, MOL IMMUNOL, V128, P165, DOI 10.1016/j.molimm.2020.10.014; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yau KYF, 2005, J IMMUNOL METHODS, V297, P213, DOI 10.1016/j.jim.2004.12.005; Zavrtanik U, 2018, J MOL BIOL, V430, P4369, DOI 10.1016/j.jmb.2018.09.002; Zhang WJ, 2020, FISH SHELLFISH IMMUN, V102, P140, DOI 10.1016/j.fsi.2020.04.037; Zielonka S, 2015, MAR BIOTECHNOL, V17, P386, DOI 10.1007/s10126-015-9642-z; Zielonka S, 2015, MABS-AUSTIN, V7, P15, DOI 10.4161/19420862.2015.989032; Zielonka S, 2014, J BIOTECHNOL, V191, P236, DOI 10.1016/j.jbiotec.2014.04.023	131	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1059771	10.3389/fimmu.2022.1059771	http://dx.doi.org/10.3389/fimmu.2022.1059771			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6SI	36479130	gold, Green Published			2022-12-18	WOS:000893807200001
J	Liu, C; Xiao, HT; Cui, LY; Fang, L; Han, SL; Ruan, YL; Zhao, WY; Zhang, YQ				Liu, Chao; Xiao, Huiting; Cui, Luying; Fang, Lin; Han, Shuling; Ruan, Yuli; Zhao, Wenyuan; Zhang, Yanqiao			Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint inhibitor therapy; biomarker; microsatellite-stable; colorectal cancer; epigenetic-related gene mutations	METHYLATION; PROFILE; TRIAL	BackgroundCombination therapy with immune checkpoint inhibitors (ICIs) may benefit approximately 10-20% of microsatellite-stable colorectal cancer (MSS-CRC) patients. However, there is a lack of optimal biomarkers. This study aims to understand the predictive value of epigenetic-related gene mutations in ICIs therapy in MSS-CRC patients. MethodsWe analyzed DNA sequences and gene expression profiles from The Cancer Genome Atlas (TCGA) to examine their immunological features. The Harbin Medical University Cancer Hospital (HMUCH) clinical cohort of MSS-CRC patients was used to validate the efficacy of ICIs in patients with epigenetic-related gene mutations (Epigenetic_Mut). ResultsIn TCGA, 18.35% of MSS-CRC patients (78/425) had epigenetic-related gene mutations. The Epigenetic_Mut group had a higher tumor mutation burden (TMB) and frameshift mutation (FS_mut) rates. In all MSS-CRC samples, Epigenetic_Mut was elevated in the immune subtype (CMS1) and had a strong correlation with immunological features. Epigenetic_Mut was also associated with favorable clinical outcomes in MSS-CRC patients receiving anti-PD-1-based therapy from the HMUCH cohort. Using immunohistochemistry and flow cytometry, we demonstrated that Epigenetic_Mut samples were associated with increased anti-tumor immune cells both in tumor tissues and peripheral blood. ConclusionMSS-CRC patients with epigenetic regulation impairment exhibit an immunologically active environment and may be more susceptible to treatment strategies based on ICIs.	[Liu, Chao; Cui, Luying; Fang, Lin; Han, Shuling; Ruan, Yuli; Zhang, Yanqiao] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China; [Liu, Chao; Cui, Luying; Fang, Lin; Han, Shuling; Ruan, Yuli; Zhang, Yanqiao] Harbin Med Univ Canc Hosp, Clin Res Ctr Colorectal Canc Heilongjiang, Harbin, Peoples R China; [Liu, Chao; Cui, Luying; Fang, Lin; Han, Shuling; Ruan, Yuli; Zhang, Yanqiao] Harbin Med Univ Canc Hosp, Key Lab Tumor Immunol Heilongjiang, Harbin, Peoples R China; [Xiao, Huiting; Zhao, Wenyuan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China; [Zhang, Yanqiao] Heilongjiang Acad Med Sci, Translat Med Res & Cooperat Ctr Northern China, Harbin, Peoples R China	Harbin Medical University	Zhang, YQ (corresponding author), Harbin Med Univ Canc Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China.; Zhang, YQ (corresponding author), Harbin Med Univ Canc Hosp, Clin Res Ctr Colorectal Canc Heilongjiang, Harbin, Peoples R China.; Zhang, YQ (corresponding author), Harbin Med Univ Canc Hosp, Key Lab Tumor Immunol Heilongjiang, Harbin, Peoples R China.; Zhao, WY (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.; Zhang, YQ (corresponding author), Heilongjiang Acad Med Sci, Translat Med Res & Cooperat Ctr Northern China, Harbin, Peoples R China.	zhaowenyuan@ems.hrbmu.edu.cn; yanqiaozhang@ems.hrbmu.edu.cn			National Natural Science Foundation of China [82102858]; Natural Science Funding of Heilongjiang [YQ2022H017]; Excellent Discipline Construction Program; Basic scientific research projects of universities in Heilongjiang Province [2020-KYYWF-1465]; Top Young Talents Project of HMUCH [BJQN2021-01]; Haiyan Research Fund of Harbin Medical University Cancer Hospital [JJMS2022-04]; Beijing Science and Technology Innovation Medical Development Foundation [KC2021-JX-0186-102, KC2021-JX-0186-69]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Funding of Heilongjiang; Excellent Discipline Construction Program; Basic scientific research projects of universities in Heilongjiang Province; Top Young Talents Project of HMUCH; Haiyan Research Fund of Harbin Medical University Cancer Hospital; Beijing Science and Technology Innovation Medical Development Foundation	This work was supported by grants from the National Natural Science Foundation of China (No. 82102858), the Natural Science Funding of Heilongjiang (No. YQ2022H017), nN10 Excellent Discipline Construction Program ( No. Hepatobiliary and Pancreatic Tumor 2017); Basic scientific research projects of universities in Heilongjiang Province (No. 2020-KYYWF-1465); Top Young Talents Project of HMUCH (No. BJQN2021-01); Haiyan Research Fund of Harbin Medical University Cancer Hospital (No. JJMS2022-04), and Beijing Science and Technology Innovation Medical Development Foundation (No. KC2021-JX-0186-102, KC2021-JX-0186-69).	Arai H, 2021, CLIN CANCER RES, V27, P3234, DOI 10.1158/1078-0432.CCR-20-3635; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bortolomeazzi M, 2021, GASTROENTEROLOGY, V161, P1179, DOI 10.1053/j.gastro.2021.06.064; Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0; Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Gomez-Roca CA, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3564; Goswami S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc4220; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Heeke AL, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00286; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hu GY, 2020, CANCER LETT, V473, P148, DOI 10.1016/j.canlet.2020.01.001; Jansz N, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02357-4; Kassiotis G, 2014, J IMMUNOL, V192, P1343, DOI 10.4049/jimmunol.1302972; Kaur J, 2019, CURR MOL PHARMACOL, V12, P215, DOI 10.2174/1874467212666190215112915; Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107; Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848; Ott PA, 2019, J CLIN ONCOL, V37, P318, DOI 10.1200/JCO.2018.78.2276; Panarelli NC, 2015, AM J SURG PATHOL, V39, P313, DOI 10.1097/PAS.0000000000000380; Pietrantonio F, 2021, ANN ONCOL, V32, pS530, DOI 10.1016/j.annonc.2021.08.905; Qin Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00689; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sarshekeh AM, 2021, CLIN CANCER RES, V27, P1663, DOI 10.1158/1078-0432.CCR-20-2404; Song YP, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.549777; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Valencia AM, 2019, NAT CELL BIOL, V21, P152, DOI 10.1038/s41556-018-0258-1; Wang F, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100383; Wang F, 2019, JAMA ONCOL, V5, P1504, DOI 10.1001/jamaoncol.2019.2963; Wang GC, 2020, CANCER DISCOV, V10, P1912, DOI 10.1158/2159-8290.CD-19-1448; Wang L, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110626; Wu HX, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0737-3; Yuki S, 2020, J CLIN ONCOL, V38; Zhang P, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01050-0; Zhou Pei, 2020, Aging (Albany NY), V13, P2365, DOI 10.18632/aging.202267	43	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1039631	10.3389/fimmu.2022.1039631	http://dx.doi.org/10.3389/fimmu.2022.1039631			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U3FS	36479108	Green Published, gold			2022-12-18	WOS:000894254100001
J	Luo, JH; Liu, K; Wang, Y; Li, HG				Luo, Jianheng; Liu, Ke; Wang, Yong; Li, Hongge			Divergent roles of PD-L1 in immune regulation during ischemia-reperfusion injury	FRONTIERS IN IMMUNOLOGY			English	Review						PD-L1; ischemia-reperfusion injury; costimulatory molecules; immune response; immune checkpoints	BRAIN-BARRIER BREAKDOWN; MIDDLE CEREBRAL-ARTERY; HOMOLOG 1 EXPRESSION; T-CELL; PROGRAMMED DEATH-1; NEUTROPHIL INFILTRATION; DENDRITIC CELLS; INNATE IMMUNITY; SOLUBLE PD-1; MOUSE-LIVER	Ischemia-reperfusion (I/R) injury is a type of pathological injury that commonly arises in various diseases. Various forms of immune response are involved in the process of I/R injury. As a member of the B7 costimulatory molecule family, programmed death 1-ligand 1 (PD-L1) is an important target for immune regulation. Therefore, PD-L1 may be implicated in the regulation of I/R injury. This review briefly describes the immune response during I/R injury and how PD-L1 is involved in its regulation by focusing on findings from various I/R models. Despite the limited number of studies in this field of research, PD-L1 has shown sufficient potential as a clinical therapeutic target.	[Luo, Jianheng; Liu, Ke; Wang, Yong; Li, Hongge] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Wang, Y; Li, HG (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Hubei, Peoples R China.	370687495@qq.com; hgeli0609@163.com			National Natural Science Foundation of China;  [81801181]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	Funding This work was supported by a grant from the National Natural Science Foundation of China (Grant No. 81801181).	Alvarez IB, 2010, J INFECT DIS, V202, P524, DOI 10.1086/654932; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Ballanti E, 2013, IMMUNOL RES, V56, P477, DOI 10.1007/s12026-013-8422-y; Bamboat ZM, 2010, J CLIN INVEST, V120, P559, DOI 10.1172/JCI40008; Bodhankar S, 2015, STROKE, V46, P2926, DOI 10.1161/STROKEAHA.115.010592; Bodhankar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-111; Bodhankar S, 2013, METAB BRAIN DIS, V28, P375, DOI 10.1007/s11011-013-9413-3; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Campbell BCV, 2020, LANCET, V396, P129, DOI 10.1016/S0140-6736(20)31179-X; Carroll MC, 2005, ADV IMMUNOL, V86, P137, DOI 10.1016/S0065-2776(04)86004-8; Casey SC, 2016, SCIENCE, V353, P229; Cassol C, 2019, KIDNEY INT REP, V4, P1152, DOI 10.1016/j.ekir.2019.06.001; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Chaudhri A, 2018, CANCER IMMUNOL RES, V6, P921, DOI 10.1158/2326-6066.CIR-17-0316; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen YJ, 2011, CYTOKINE, V56, P231, DOI 10.1016/j.cyto.2011.06.004; Cho HY, 2009, IMMUNOL LETT, V127, P39, DOI 10.1016/j.imlet.2009.08.011; Chung C, 2018, CLIN CANCER RES, V24, DOI 10.1158/1557-3265.AACRIASLC18-B05; Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251; Daneman R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020412; Day YJ, 2006, J IMMUNOL, V176, P3108, DOI 10.4049/jimmunol.176.5.3108; de Dios E, 2021, INT IMMUNOPHARMACOL, V95, DOI 10.1016/j.intimp.2021.107490; Diepenhorst GMP, 2009, ANN SURG, V249, P889, DOI 10.1097/SLA.0b013e3181a38f45; Dong HD, 1999, NAT MED, V5, P1365; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Engelhardt B, 2017, NAT IMMUNOL, V18, P123, DOI 10.1038/ni.3666; Forteza MJ, 2014, INT J CARDIOL, V177, P8, DOI 10.1016/j.ijcard.2014.09.114; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Frigola X, 2012, IMMUNOL LETT, V142, P78, DOI 10.1016/j.imlet.2011.11.001; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Guiteras J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031216; Haile ST, 2013, J IMMUNOL, V191, P2829, DOI 10.4049/jimmunol.1202777; Haile ST, 2011, J IMMUNOL, V186, P6822, DOI 10.4049/jimmunol.1003682; Hakroush S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.624547; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106; Jaworska K, 2015, J IMMUNOL, V194, P325, DOI 10.4049/jimmunol.1400497; Ji HF, 2010, HEPATOLOGY, V52, P1380, DOI 10.1002/hep.23843; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kinsey GR, 2012, J AM SOC NEPHROL, V23, P1528, DOI 10.1681/ASN.2012010070; Kreisel D, 2011, J CLIN INVEST, V121, P265, DOI 10.1172/JCI42596; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Lazar-Molnar E, 2010, P NATL ACAD SCI USA, V107, P13402, DOI 10.1073/pnas.1007394107; Lee J, 2009, J MOL CELL CARDIOL, V46, P169, DOI 10.1016/j.yjmcc.2008.10.028; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Li PY, 2014, STROKE, V45, P857, DOI 10.1161/STROKEAHA.113.004100; Li SH, 2015, CORONARY ARTERY DIS, V26, P598, DOI 10.1097/MCA.0000000000000282; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lin Z, 2022, BIOACT MATER, V13, P300, DOI 10.1016/j.bioactmat.2021.10.042; Liu LF, 2020, CIRCULATION, V141, P464, DOI 10.1161/CIRCULATIONAHA.119.042501; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Mentzelopoulos SD, 2017, RESUSCITATION, V121, pA12, DOI 10.1016/j.resuscitation.2017.10.013; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Ozkaynak E, 2002, J IMMUNOL, V169, P6546, DOI 10.4049/jimmunol.169.11.6546; Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975; Patsoukis N, 2013, MOL CELL BIOL, V33, P3091, DOI 10.1128/MCB.00319-13; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Powers KA, 2006, J EXP MED, V203, P1951, DOI 10.1084/jem.20060943; Powles T, 2020, NEW ENGL J MED, V383, P1218, DOI 10.1056/NEJMoa2002788; Prestipino A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7729; Ren XF, 2011, STROKE, V42, P2578, DOI 10.1161/STROKEAHA.111.613182; Rifa'i M, 2004, J EXP MED, V200, P1123, DOI 10.1084/jem.20040395; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Rui YX, 2013, P NATL ACAD SCI USA, V110, P16073, DOI 10.1073/pnas.1315828110; Ryan S, 2005, CIRCULATION, V112, P2660, DOI 10.1161/CIRCULATIONAHA.105.556746; Satpute SR, 2009, J IMMUNOL, V183, P984, DOI 10.4049/jimmunol.0801928; SCHROETER M, 1994, J NEUROIMMUNOL, V55, P195, DOI 10.1016/0165-5728(94)90010-8; Shen XF, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117923; Shen XD, 2009, HEPATOLOGY, V50, P1537, DOI 10.1002/hep.23153; Shi BM, 2013, METABOLISM, V62, P778, DOI 10.1016/j.metabol.2012.12.005; Subudhi SK, 2004, J CLIN INVEST, V113, P694, DOI 10.1172/JCI200419210; Sumiyoshi M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184188; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun YF, 2020, CLIN CHIM ACTA, V505, P26, DOI 10.1016/j.cca.2020.02.019; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tampe D, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.902256; Theodoraki MN, 2018, CLIN CANCER RES, V24, P896, DOI 10.1158/1078-0432.CCR-17-2664; Ueki S, 2011, HEPATOLOGY, V54, P216, DOI 10.1002/hep.24360; Wallace KL, 2010, BLOOD, V116, P5010, DOI 10.1182/blood-2010-06-290643; Weyand CM, 2018, J LEUKOCYTE BIOL, V103, P565, DOI 10.1189/jlb.3MA0717-283; Xu J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03139-9; Xue J, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172541; Yang Y, 2018, CELL RES, V28, P862, DOI 10.1038/s41422-018-0060-4; Yang ZQ, 2005, CIRCULATION, V111, P2190, DOI 10.1161/01.CIR.0000163586.62253.A5; Yao S, 2009, BLOOD, V113, P5811, DOI 10.1182/blood-2009-02-203141; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI [DOI 10.1056/NEJMRA071667, 10.1056/NEJMra071667]; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; Zak KM, 2017, STRUCTURE, V25, P1163, DOI 10.1016/j.str.2017.06.011; Zhang M, 2006, J EXP MED, V203, P141, DOI 10.1084/jem.20050390; Zhang XY, 2018, DIGEST DIS SCI, V63, P3307, DOI 10.1007/s10620-018-5282-2; Zhang XY, 2015, DIGEST DIS SCI, V60, P2662, DOI 10.1007/s10620-015-3684-y; Zhu XX, 2017, ONCOTARGET, V8, P97671, DOI 10.18632/oncotarget.18311; Zozulya AL, 2009, EUR J IMMUNOL, V39, P1536, DOI 10.1002/eji.200839165	102	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1021452	10.3389/fimmu.2022.1021452	http://dx.doi.org/10.3389/fimmu.2022.1021452			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S9CM	36479124	gold, Green Published			2022-12-18	WOS:000893280300001
J	Nicholas, B; Lee, HH; Guo, JE; Cicmil, M; Blume, C; Malefyt, RD; Djukanovic, R				Nicholas, Ben; Lee, Hyun-Hee; Guo, Jane; Cicmil, Milenko; Blume, Cornelia; Malefyt, Rene De Waal; Djukanovic, Ratko			Immunomodulatory regulator blockade in a viral exacerbation model of severe asthma	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; allergy; immuno-modulation; viral; exacerbation	IMMUNE CHECKPOINT BLOCKADE; CD8 T-CELLS; PD-1 EXPRESSION; RESTORATION; INFECTION; LIGANDS; PATHWAY; VIRUS	Asthmatics are more susceptible to viral infections than healthy individuals and are known to have impaired innate anti-viral defences. Influenza A virus causes significant morbidity and mortality in this population. Immuno-modulatory regulators (IMRs) such as PD-1 are activated on T cells following viral infection as part of normal T cell activation responses, and then subside, but remain elevated in cases of chronic exposure to virus, indicative of T cell exhaustion rather than activation. There is evidence that checkpoint inhibition can enhance anti-viral responses during acute exposure to virus through enhancement of CD8+T cell function. Although elevated PD-1 expression has been described in pulmonary tissues in other chronic lung diseases, the role of IMRs in asthma has been relatively unexplored as the basis for immune dysfunction. We first assessed IMR expression in the peripheral circulation and then quantified changes in IMR expression in lung tissue in response to ex-vivo influenza infection. We found that the PD-1 family members are not significantly altered in the peripheral circulation in individuals with severe asthma but are elevated in pulmonary tissues following ex-vivo influenza infection. We then applied PD-1 Mab inhibitor treatment to bronchial biopsy tissues infected with influenza virus and found that PD-1 inhibition was ineffective in asthmatics, but actually increased infection rates in healthy controls. This study, therefore, suggests that PD-1 therapy would not produce harmful side-effects when applied in people with severe asthma, but could have important, as yet undescribed, negative effects on anti-viral responses in healthy individuals that warrant further investigation.	[Nicholas, Ben; Blume, Cornelia; Djukanovic, Ratko] Univ Southampton, Southampton Gen Hosp, Div Clin & Expt Sci, Fac Med, Southampton, England; [Lee, Hyun-Hee; Guo, Jane; Cicmil, Milenko] Merck Res Labs, Oncol & Immunol Discovery, Boston, MA USA; [Malefyt, Rene De Waal] Merck Res Labs, Palo Alto, CA USA	University of Southampton; Merck & Company; Merck & Company	Nicholas, B (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Clin & Expt Sci, Fac Med, Southampton, England.	B.L.Nicholas@soton.ac.uk			University of Southampton; Merck Co Inc	University of Southampton; Merck Co Inc(Merck & Company)	This work was supported by a collaboration between the University of Southampton and Merck & Co Inc. Merck & CoInc. assisted in the design of the work and the collection,analysis, and interpretation of data. The manuscript wasconceived and written by the University of Southampton co-authors and was approved by co-authors from Merck & Co Inc.	Bally APR, 2015, J IMMUNOL, V194, P4545, DOI 10.4049/jimmunol.1402550; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bardhan K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53463-0; British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Bengsch B, 2014, J HEPATOL, V61, P1212, DOI 10.1016/j.jhep.2014.07.005; Bratke K, 2017, CLIN EXP ALLERGY, V47, P1417, DOI 10.1111/cea.13017; Chen W, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.33; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Fisicaro P, 2010, GASTROENTEROLOGY, V138, P682, DOI 10.1053/j.gastro.2009.09.052; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106; Huber S, 2010, BLOOD, V116, P3311, DOI 10.1182/blood-2010-02-271981; Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487; Kolle J, 2020, IMMUN INFLAMM DIS, V8, P310, DOI 10.1002/iid3.307; McKendry RT, 2016, AM J RESP CRIT CARE, V193, P642, DOI 10.1164/rccm.201504-0782OC; Nakamoto N, 2008, GASTROENTEROLOGY, V134, P1927, DOI 10.1053/j.gastro.2008.02.033; Nakamoto N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000313; Nicholas B, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1009894; Nicholas B, 2017, J ALLERGY CLIN IMMUN, V140, P309, DOI 10.1016/j.jaci.2016.12.964; Nicholas B, 2015, J IMMUNOL, V194, P6144, DOI 10.4049/jimmunol.1402283; Nicholas BL, 2010, AM J RESP CRIT CARE, V181, P1049, DOI 10.1164/rccm.200906-0857OC; Raziorrouh B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105703; Rodriguez-Garcia M, 2011, J LEUKOCYTE BIOL, V89, P507, DOI 10.1189/jlb.0610327; Shen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep38362; Stanciu LA, 2006, J INFECT DIS, V193, P404, DOI 10.1086/499275; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Tang ZS, 2016, MOL MED REP, V14, P1107, DOI 10.3892/mmr.2016.5396; Van der Sluis RM, 2020, J IMMUNOL, V204, P1242, DOI 10.4049/jimmunol.1901191; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Yamazaki T, 2002, J IMMUNOL, V169, P5538, DOI 10.4049/jimmunol.169.10.5538	30	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								973673	10.3389/fimmu.2022.973673	http://dx.doi.org/10.3389/fimmu.2022.973673			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S9FU	36479132	Green Published, gold			2022-12-18	WOS:000893289600001
J	Sun, XJ; Zhang, Z; Wang, ZQ; Xie, R; Yi, CX; Liu, HY; Chi, XW; Li, TC; Liu, HT; Han, Y; Pang, XC; Cui, YM; Liu, ZM				Sun, Xiaojiao; Zhang, Zhuo; Wang, Zhiqi; Xie, Ran; Yi, Chuxiao; Liu, Huiyu; Chi, Xiaowei; Li, Tiancheng; Liu, Haitao; Han, Yi; Pang, Xiaocong; Cui, Yimin; Liu, Zhenming			The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer	FRONTIERS IN IMMUNOLOGY			English	Article						angiogenesis; remodeling; tumor microenvironment; immunotherapy; pan-cancer	ENDOTHELIAL GROWTH-FACTOR; TUMOR; EXCLUSION; CELLS	BackgroundAngiogenesis and remodeling (AR) is necessary for the growth and metastasis of cancers. Although AR related genes involved in this process are reported, the correlation between AR and clinical outcome, immune cell infiltration, and immunotherapy is still unknown in diverse cancers. This study aimed to investigate the role of AR in the tumor immune microenvironment (TIME) in pan-cancer, and explore its values in prognostic prediction and therapeutic responses. MethodsFirstly, AR genes (including angiogenesis genes and blood vessel remodeling genes) are collected from MsigDB database. The differential expression, and prognostic value of AR genes were studied in 33 tumor types based on TCGA and GTEx data. The AR score of each sample was calculated using the "ssGSEA" function of R package "GSVA" in pan-cancer. The correlation of the AR score with TIME index, such as the amount of stromal and immune components and the immune cell infiltration, was evaluated via integrating multiple computational methods. And we also utilized IMvigor210 and GSE78220 data to explore the prediction value of the AR score on the immunotherapy response. ResultsSignificant differences in AR gene expression between tumors and adjacent normal tissues were found in most cancer types. The AR score varied depending on the types of tumors, and high score was related to worse survival in various tumors, such as pancreatic and stomach adenocarcinoma and so on. Moreover, the AR score was further explored to be positively correlated with proportions and pathways of immune and stromal in TIME. And the AR score was positively correlated with immunosuppressive cells, including TAMs and iTregs, while negatively with CD8+ T cells. Further analysis revealed that patients with high AR had worse therapy efficacy and survival status in bladder cancer and melanomas. ConclusionsOur systematic analysis revealed that AR is closely associated TIME, and prognosis, and clinical characteristics in multiple cancers. Targeting AR genes may activate immune microenvironment and increase the efficacy of immunotherapy.	[Sun, Xiaojiao; Wang, Zhiqi; Yi, Chuxiao; Chi, Xiaowei; Liu, Zhenming] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China; [Zhang, Zhuo; Xie, Ran; Pang, Xiaocong; Cui, Yimin] Peking Univ First Hosp, Dept Pharm, Beijing, Peoples R China; [Zhang, Zhuo; Liu, Haitao; Pang, Xiaocong; Cui, Yimin] Peking Univ, Inst Clin Pharmacol, Beijing, Peoples R China; [Liu, Huiyu; Li, Tiancheng] Peking Univ First Hosp, Dept Otorhinolaryngol Head, Beijing, Peoples R China; [Liu, Huiyu; Li, Tiancheng] Peking Univ First Hosp, Dept Neck Surg, Beijing, Peoples R China; [Han, Yi] Beijing Thorac Hosp, Dept Thorac Surg, Beijing, Peoples R China	Peking University; Peking University; Peking University	Liu, ZM (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China.; Pang, XC; Cui, YM (corresponding author), Peking Univ First Hosp, Dept Pharm, Beijing, Peoples R China.; Pang, XC; Cui, YM (corresponding author), Peking Univ, Inst Clin Pharmacol, Beijing, Peoples R China.	Pangpangxiaocong1227@163.com; cui.pharm@pkufh.com; zmliu@bjmu.edu.cn			National Key R&D Program of China [2021YFC2500400, 2020YFC2008304]; National High Level Hospital Clinical Research (Science and Technology Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital) [2022CX11]; National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) [2022CR36]; National Natural Science Foundation of China [81973320, 81903714]	National Key R&D Program of China; National High Level Hospital Clinical Research (Science and Technology Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital); National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was funded by the National Key R & D Program of China (grant No. 2021YFC2500400, 2020YFC2008304), National High Level Hospital Clinical Research (Science and Technology Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital) (2022CX11), National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) (no. 2022CR36), and National Natural Science Foundation of China (grant No. 81973320 and No. 81903714).	Albini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00527; Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Bleve A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165845; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169; Choi GH, 2021, WORLD J GASTROENTERO, V27, P4453, DOI 10.3748/wjg.v27.i27.4453; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Farnsworth RH, 2014, ONCOGENE, V33, P3496, DOI 10.1038/onc.2013.304; Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29; Gong Z, 2020, CANCER MED-US, V9, P9052, DOI 10.1002/cam4.3505; Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434; Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Karimi-Shahri M, 2021, IRAN J BASIC MED SCI, V24, P1307, DOI 10.22038/IJBMS.2021.58227.12934; Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265-014-0302-9; Keskin Serkan, 2019, Asian Pac J Cancer Prev, V20, P733; Khan KA, 2018, NAT REV CLIN ONCOL, V15, P310, DOI 10.1038/nrclinonc.2018.9; Kim HJ, 2022, ARCH PHARM RES, V45, P401, DOI 10.1007/s12272-022-01389-z; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Lopes-Coelho F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073765; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Phillips D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26974-6; Qing X, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.843077; Rahma OE, 2019, CLIN CANCER RES, V25, P5449, DOI 10.1158/1078-0432.CCR-18-1543; Rodriguez-Garcia A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20893-2; Rossi A, 2017, EXPERT OPIN DRUG SAF, V16, P471, DOI 10.1080/14740338.2017.1297795; Scheiner B, 2022, J HEPATOL, V76, P353, DOI 10.1016/j.jhep.2021.09.035; Sopo M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241484; Stockmann C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00069; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Varney ML, 2005, MELANOMA RES, V15, P417, DOI 10.1097/00008390-200510000-00010; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Wada J, 2009, ANTICANCER RES, V29, P881; Wallin JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12624; Yi M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0974-6; Yu GY, 2021, CANCERS, V13, DOI 10.3390/cancers13236092; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zirlik K, 2018, ONCOL RES TREAT, V41, P166, DOI 10.1159/000488087	41	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1033967	10.3389/fimmu.2022.1033967	http://dx.doi.org/10.3389/fimmu.2022.1033967			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T0UI	36479101	gold, Green Published			2022-12-18	WOS:000893398500001
J	Wang, RQ; Cui, W; Cai, JY; Sun, YH				Wang, Rui-Qi; Cui, Wei; Cai, Jiayi; Sun, Yihao			Integrative analysis indicates the prognostic value of circadian rhythm disruption in liver cancer: Potential for therapeutic targeting	FRONTIERS IN IMMUNOLOGY			English	Article						circadian rhythm disruption; liver cancer; single-cell transcriptomic analysis; prognostic factor; systematic analysis	HEPATOCELLULAR-CARCINOMA; MOLECULAR SUBTYPES; IN-VITRO; CELL; ARID1A; CLOCK; MYC; P53; EXPRESSION; MUTATIONS	Circadian rhythms regulate various biological processes, such as cell division and metabolism. Circadian rhythm disruption (CRD) is often associated with malignant tumor progression and poor prognosis. However, the effect of CRD on liver cancer prognosis has not been systematically analyzed or fully elucidated. Here, we developed a method to quantify and assess intratumoral CRD in a single-cell transcriptomic analysis of liver cancer and systematically analyzed the role of CRD in tumor progression and prognosis. Furthermore, a LASSO-Cox regression model based on 14 CRD genes was used to predict overall patient survival across multiple datasets. We found that malignant cells with high CRD scores were enriched in specific metabolic pathways, such as fatty acid metabolism and the trichloroacetic acid cycle. Intercellular communication analysis suggested that CRD regulates chemokine-mediated interactions. With the bulk transcriptomic datasets, we determined that LiverCRD scores were significantly correlated with macrophage infiltration levels and could guide targeted immunotherapy and chemotherapy strategies. In addition, LiverCRD is also associated with the mutational landscape-for example, TP53 mutation frequency was higher in high-CRD samples. Finally, the 14-gene-based LASSO-Cox regression model could accurately predict overall patient survival across datasets. In conclusion, Our proposed analysis reflects the relationship between CRD and the immune environment in liver cancer, suggesting that CRD may serve as a potential prognostic indicator. Our results may help guide targeted anti-tumor strategies.	[Wang, Rui-Qi; Sun, Yihao] Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Dept Pharm, Zhuhai, Guangdong, Peoples R China; [Cui, Wei] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Intervent Radiol, Guangzhou, Guangdong, Peoples R China; [Cai, Jiayi] Zunyi Med Univ, Sch Stomatol, Zunyi, Guizhou, Peoples R China; [Sun, Yihao] Jinan Univ, Zhuhai Peoples Hosp, Zhuhai Precis Med Ctr, Zhuhai Intervent Med Ctr,Zhuhai Hosp, Zhuhai, Peoples R China	Jinan University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Zunyi Medical University; Jinan University	Sun, YH (corresponding author), Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Dept Pharm, Zhuhai, Guangdong, Peoples R China.; Sun, YH (corresponding author), Jinan Univ, Zhuhai Peoples Hosp, Zhuhai Precis Med Ctr, Zhuhai Intervent Med Ctr,Zhuhai Hosp, Zhuhai, Peoples R China.	syh@alumni.tongji.edu.cn			Guangdong Basic and Applied Basic Research Foundation; Xiangshan Talented Scientific Research Foundation of Zhuhai People's Hospital; National Natural Science Foundation of China;  [2020A1515110057];  [2020XSYC-07];  [2021XSYC-02];  [32100561];  [82102163]	Guangdong Basic and Applied Basic Research Foundation; Xiangshan Talented Scientific Research Foundation of Zhuhai People's Hospital; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; ; ; ; 	Funding This study was supported by the Guangdong Basic and Applied Basic Research Foundation [2020A1515110057], the Xiangshan Talented Scientific Research Foundation of Zhuhai People's Hospital [2020XSYC-07; 2021XSYC-02], the National Natural Science Foundation of China (32100561, 82102163).	Aiello I, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4530; Akashi M, 2000, GENE DEV, V14, P645; Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144; Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y; Blakeman V, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0743-z; Burchett JB, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147761; Cao RF, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00367; Casper RF, 2014, FERTIL STERIL, V102, P319, DOI 10.1016/j.fertnstert.2014.04.053; Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; D'Esposito V, 2016, ONCOTARGET, V7, P24495, DOI 10.18632/oncotarget.8336; Ding XX, 2017, ONCOTARGET, V8, P55715, DOI 10.18632/oncotarget.18382; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Faivre S, 2020, J HEPATOL, V72, P342, DOI 10.1016/j.jhep.2019.09.010; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; He PJ, 2007, J ENDOCRINOL, V193, P413, DOI 10.1677/JOE-07-0044; Hovestadt V, 2019, NATURE, V572, P74, DOI 10.1038/s41586-019-1434-6; Jiang P, 2021, NAT METHODS, V18, P1181, DOI 10.1038/s41592-021-01274-5; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kinouchi K, 2020, NAT REV CANCER, V20, P645, DOI 10.1038/s41568-020-0291-9; Krishnaiah SY, 2017, CELL METAB, V25, P961, DOI 10.1016/j.cmet.2017.03.019; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee JS, 2017, EXP CELL RES, V355, P67, DOI 10.1016/j.yexcr.2017.03.056; Leng Y, 2019, LANCET NEUROL, V18, P307, DOI 10.1016/S1474-4422(18)30461-7; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu CD, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.597860; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma LC, 2019, CANCER CELL, V36, P418, DOI 10.1016/j.ccell.2019.08.007; Mercadante AA., 2022, GENETICS CANC CELL C; Miller JE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00108; Mun SH, 2020, EXP MOL MED, V52, P1239, DOI 10.1038/s12276-020-0484-z; Okazaki F, 2010, CANCER RES, V70, P6238, DOI 10.1158/0008-5472.CAN-10-0184; Pizarro A, 2013, NUCLEIC ACIDS RES, V41, pD1009, DOI 10.1093/nar/gks1161; Rida Padmashree, 2019, Front Biosci (Schol Ed), V11, P178; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Savvidis C, 2012, MOL MED, V18, P1249, DOI 10.2119/molmed.2012.00077; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Sheng YR, 2021, TISSUE CELL, V70, DOI 10.1016/j.tice.2021.101495; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sun DQ, 2021, NUCLEIC ACIDS RES, V49, pD1420, DOI 10.1093/nar/gkaa1020; Villanueva A, 2014, NAT REV CLIN ONCOL, V11, P73, DOI [10.1038/nrclinonc.2013.227, 10.1038/nrclinonc.2013.243]; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Voronov E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00177; Waldmann TA, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028472; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang LL, 2020, J CLIN INVEST, V130, P5951, DOI 10.1172/JCI130445; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yarchoan M, 2017, CLIN CANCER RES, V23, P7333, DOI 10.1158/1078-0432.CCR-17-0950; Ye YQ, 2018, CELL SYST, V6, P314, DOI 10.1016/j.cels.2018.01.013; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao LQ, 2020, AGING-US, V12, P14556, DOI 10.18632/aging.103502; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6; Zhu Y, 2008, MED HYPOTHESES, V70, P788, DOI 10.1016/j.mehy.2007.07.040	62	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1011264	10.3389/fimmu.2022.1011264	http://dx.doi.org/10.3389/fimmu.2022.1011264			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6UY		gold			2022-12-18	WOS:000893814100001
J	Wei, H; Li, YQ; Guo, ZB; Ma, XX; Li, Y; Wei, XY; Han, D; Zhang, T; Chen, X; Yan, CH; Zhou, JH; Pang, QS; Wang, P; Zhang, WC				Wei, Hui; Li, Yanqi; Guo, Zhoubo; Ma, Xiaoxue; Li, Yang; Wei, Xiaoying; Han, Dong; Zhang, Tian; Chen, Xi; Yan, Cihui; Zhou, Jiahuan; Pang, Qingsong; Wang, Ping; Zhang, Wencheng			Comparison of dynamic changes in the peripheral CD8(+) T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						CD8+T cells; PD-1; radiotherapy; immunotherapy; chemoradiotherapy; ESCC	CHECKPOINT BLOCKADE; CLINICAL ACTIVITY; TH1; THERAPY; SAFETY; MEMORY; ROLES; BLOOD; BET	ObjectiveThe systematic immune status of cancer patients undergoing immunotherapy is little known. We prospectively identified the function and differentiation traits of peripheral CD8(+) T cells based on our phase 1b clinical trial (NCT03222440) of radiotherapy combined with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma (ESCC) and compared it with concurrent chemoradiotherapy (CCRT). Methods19 and 18 patients were included in the cohort of radiotherapy plus camrelizumab and cohort of CCRT treatment. By using flow cytometry, we evaluated the expression levels of PD-1, Eomes, T-bet and IFN-gamma (function), CD38 and HLA-DR (activation), and differentiation subsets classified according to the expression levels of CD45RA and CD62L in peripheral CD8(+) T cells before and during treatment. ResultsEffective binding of anti-PD-1 antibody camrelizumab with PD-1 on CD8(+) T cells was detected during treatment. Both two treatments elevated the expression levels of activation molecules CD38 and HLA-DR on CD8(+) T cells. PD-1(+)CD8(+) T cells had more activation features than PD-1(-)CD8(+) T cells in two groups and the treatments did not alter these differences. The two treatments activated both PD-1(+) and PD-1(-) CD8(+) T cells. PD-1(+)CD8(+) T cells had less Naive and TEMRA but more Tcm and Tem than PD-1(-)CD8(+) T cells in two groups and both two treatments changed the ratio of memory T cells in PD-1(+) and PD-1(-) cells. RT plus camrelizumab treatment reduced Naive T cells and TEMRA subsets both in PD-1(+) and PD-1(-) CD8(+) T cells while elevated Tcm subset in PD-1(+)CD8(+) T cells and Tem subset in PD-1(-)CD8(+) T cells. CCRT elevated Tcm subset and reduced TEMRA subset in PD-1(-)CD8(+) T cells while did not change any subset in PD-1(+)CD8(+) T cells. Furthermore, patients undergoing radiotherapy plus immunotherapy were found to obtain better prognosis than those receiving CCRT. ConclusionsThis study identified the dynamic changes of systematic immune status of patients undergoing treatment. The two treatments had similar activation effects on peripheral CD8(+) T cells with different PD-1 properties but had different effects on their differentiation status. These results provided potential clues to the reasons underlying the difference in prognosis of the two treatments.	[Wei, Hui; Li, Yanqi; Guo, Zhoubo; Ma, Xiaoxue; Li, Yang; Wei, Xiaoying; Han, Dong; Zhang, Tian; Chen, Xi; Pang, Qingsong; Wang, Ping; Zhang, Wencheng] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Radiat Oncol,Key L, Tianjin, Peoples R China; [Yan, Cihui] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Immunol,Key Lab Ca, Tianjin, Peoples R China; [Zhou, Jiahuan] Jiangsu Hengrui Pharmaceut Co Ltd, Dept Clin Res & Dev, Shanghai, Peoples R China	Tianjin Medical University; Tianjin Medical University	Pang, QS; Wang, P; Zhang, WC (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Radiat Oncol,Key L, Tianjin, Peoples R China.	pangqingsong@tjmuch.com; wangping@tjmuch.com; wczhang@tmu.edu.cn			National Natural Science Foundation of China [82073348, 81602565, 81872462]; Chinese National Key Research and Development Project [2018YFC1315601]; Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-009A]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National Key Research and Development Project; Tianjin Key Medical Discipline (Specialty) Construction Project	This work was supported by the National Natural Science Foundation of China [grant number 82073348, 81602565 and 81872462], Chinese National Key Research and Development Project [2018YFC1315601] and Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-009A].	Abbas G, 2017, ANN CARDIOTHORAC SUR, V6, P131, DOI 10.21037/acs.2017.03.03; Baecher-Allan C, 2006, J IMMUNOL, V176, P4622, DOI 10.4049/jimmunol.176.8.4622; Bannard O, 2009, EUR J IMMUNOL, V39, P2083, DOI 10.1002/eji.200939555; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Fernandez-Poma SM, 2017, CANCER RES, V77, P3672, DOI 10.1158/0008-5472.CAN-17-0236; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Golubovskaya V, 2016, CANCERS, V8, DOI 10.3390/cancers8030036; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Hogan KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01187; Hu X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02354; Huang J, 2020, LANCET ONCOL, V21, P832, DOI 10.1016/S1470-2045(20)30110-8; Jing WQ, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0256-z; Kamphorst AO, 2017, P NATL ACAD SCI USA, V114, P4993, DOI 10.1073/pnas.1705327114; Liu C, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1872-9; Luke JJ, 2018, J CLIN ONCOL, V36, P1611, DOI 10.1200/JCO.2017.76.2229; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Pan CQ, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1883890; Papaioannou VE, 2014, DEVELOPMENT, V141, P3819, DOI 10.1242/dev.104471; Peng M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1055-6; Pilones KA, 2015, SEMIN RADIAT ONCOL, V25, P28, DOI 10.1016/j.semradonc.2014.07.004; Ren DX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1144-6; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Shah MA, 2019, JAMA ONCOL, V5, P546, DOI 10.1001/jamaoncol.2018.5441; Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Simon S, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001631; Suto A, 2006, J IMMUNOL, V177, P3721, DOI 10.4049/jimmunol.177.6.3721; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Theelen WSME, 2019, JAMA ONCOL, V5, P1276, DOI 10.1001/jamaoncol.2019.1478; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Van Cutsem E, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100517; Wang ZX, 2022, CANCER CELL, V40, P277, DOI 10.1016/j.ccell.2022.02.007; Yang Y, 2008, J IMMUNOL, V181, P8700, DOI 10.4049/jimmunol.181.12.8700; Zhang JS, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8635381; Zhang WC, 2021, ONCOLOGIST, V26, pE1110, DOI 10.1002/onco.13797	38	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1060695	10.3389/fimmu.2022.1060695	http://dx.doi.org/10.3389/fimmu.2022.1060695			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2KO	36479110	gold, Green Published			2022-12-18	WOS:000894198300001
J	Wei, YH; Zhao, Z; Ma, XL				Wei, Yuhao; Zhao, Zhen; Ma, Xuelei			Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment	FRONTIERS IN IMMUNOLOGY			English	Review						human papillomavirus; clustered regularly interspaced short palindromic repeat; CRISPR-associated nuclease 9; gene editing; cancer treatment; tumor microenvironment	CERVICAL-CANCER; CRISPR/CAS9 SYSTEM; DNA DETECTION; HPV INFECTION; IN-VITRO; E6 GENE; CELLS; E7; INACTIVATION; EXPRESSION	Human papillomaviruses (HPVs) have been recognized as the etiologic agents of various cancers and are called HPV-driven cancers. Concerning HPV-mediated carcinogenic action, gene therapy can cure cancer at the molecular level by means of the correction of specific genes or sites. CRISPR-Cas9, as a novel genetic editing technique, can correct errors in the genome and change the gene expression and function in cells efficiently, quickly, and with relative ease. Herein, we overviewed studies of CRISPR-mediated gene remedies for HPV-driven cancers and summarized the potential applications of CRISPR-Cas9 in gene therapy for cancer.	[Wei, Yuhao; Zhao, Zhen; Ma, Xuelei] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China; [Wei, Yuhao; Zhao, Zhen] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University	Ma, XL (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China.	drmaxuelei@gmail.com						Abboodi F, 2021, VIROLOGY, V554, P9, DOI 10.1016/j.virol.2020.12.005; Aghamiri S, 2020, EXPERT OPIN DRUG DEL, V17, P753, DOI 10.1080/17425247.2020.1747429; Ajiro M, 2015, MBIO, V6, DOI 10.1128/mBio.02068-14; Alsbeih G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00065; Bachtiary B, 2002, INT J CANCER, V102, P237, DOI 10.1002/ijc.10708; Batista AC, 2018, J MICROBIOL METH, V152, P98, DOI 10.1016/j.mimet.2018.07.024; Beerheide W, 2000, BIOORGAN MED CHEM, V8, P2549, DOI 10.1016/S0968-0896(00)00193-0; Beerheide W, 1999, J NATL CANCER I, V91, P1211, DOI 10.1093/jnci/91.14.1211; Bortnik V, 2021, J MICROBIOL IMMUNOL, V54, P733, DOI 10.1016/j.jmii.2020.07.010; Broutian TR, 2020, CANCER LETT, V476, P23, DOI 10.1016/j.canlet.2020.01.012; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; Chen R, 2019, SMALL, V15, DOI 10.1002/smll.201902686; Cheng YX, 2018, CURR MED SCI, V38, P212, DOI 10.1007/s11596-018-1868-3; Chiang C, 2018, J VIROL, V92, DOI 10.1128/JVI.01737-17; Choi JH, 2021, ACS NANO, V15, P13475, DOI 10.1021/acsnano.1c03975; Cui ZF, 2021, MOL THER-NUCL ACIDS, V26, P1466, DOI 10.1016/j.omtn.2021.08.008; Das D, 2017, J VIROL, V91, DOI 10.1128/JVI.00102-17; Dok R, 2020, INT J CANCER, V146, P1075, DOI 10.1002/ijc.32558; Ehrhardt A, 2002, BLOOD, V99, P3923, DOI 10.1182/blood.V99.11.3923; Ehrke-Schulz E, 2020, CANCERS, V12, DOI 10.3390/cancers12071934; Ehrke-Schulz E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17180-w; Fang J, 2011, AM J MED SCI, V342, P198, DOI 10.1097/MAJ.0b013e31821335a9; Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623; Medhin MTG, 2021, BIOL-TARGETS THER, V15, P199, DOI 10.2147/BTT.S310312; Gao C, 2022, CANCER GENE THER, V29, P466, DOI 10.1038/s41417-021-00366-w; Gao JL, 2021, J MOL DIAGN, V23, P46, DOI 10.1016/j.jmoldx.2020.10.004; Gao XQ, 2020, J CONTROL RELEASE, V321, P654, DOI 10.1016/j.jconrel.2020.02.045; Goncalves BC, 2021, FUND CLIN PHARMACOL, V35, P305, DOI 10.1111/fcp.12609; Guo CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017734; Hatterschide J, 2020, J VIROL, V94, DOI 10.1128/JVI.01024-20; Hsu DS, 2018, FUTURE VIROL, V13, P475, DOI 10.2217/fvl-2018-0010; Hu Z, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/612823; Hyakusoku H, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0284-4; Imahorn E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71889-9; Inturi R, 2021, VIROLOGY, V562, P92, DOI 10.1016/j.virol.2021.07.005; Ishida Y, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061376; James CD, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00858-20; James CD, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00448-19; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Jubair L, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0223288; Jubair L, 2019, MOL THER, V27, P2091, DOI 10.1016/j.ymthe.2019.08.012; Kantor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176240; Karimian A, 2019, J CELL PHYSIOL, V234, P12267, DOI 10.1002/jcp.27972; Kennedy EM, 2014, J VIROL, V88, P11965, DOI 10.1128/JVI.01879-14; Kim EJ, 2017, KOREAN J INTERN MED, V32, P42, DOI 10.3904/kjim.2016.198; Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946; Lao YH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700540; Leung THY, 2019, MOL CANCER RES, V17, P1867, DOI 10.1158/1541-7786.MCR-19-0068; Leung THY, 2018, J PATHOL, V244, P151, DOI 10.1002/path.4991; Lin Y, 2018, ADV SCI, V5, DOI 10.1002/advs.201700611; Ling KJ, 2020, HUM GENE THER, V31, P297, DOI 10.1089/hum.2019.246; Liu YC, 2016, ASIAN J ANDROL, V18, P475, DOI 10.4103/1008-682X.157399; Lu Y, 2020, NAT MED, V26, P732, DOI 10.1038/s41591-020-0840-5; Makarova KS, 2015, NAT REV MICROBIOL, V13, P722, DOI 10.1038/nrmicro3569; Mingozzi F, 2011, NAT REV GENET, V12, P341, DOI 10.1038/nrg2988; Mittal S, 2017, MUTAT RES-REV MUTAT, V772, P23, DOI 10.1016/j.mrrev.2016.08.001; MUNGER K, 1989, J VIROL, V63, P4417; Noroozi Z, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-06025-w; Nunez JK, 2014, NAT STRUCT MOL BIOL, V21, P528, DOI 10.1038/nsmb.2820; Pal A, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03116; Perez-Benavente B, 2013, ONCOGENE, V32, P2189, DOI 10.1038/onc.2012.235; Pirouzfar M, 2020, EXCLI J, V19, P170, DOI 10.17179/excli2019-1957; Rodriguez-Rodriguez DR, 2019, INT J MOL MED, V43, P1559, DOI 10.3892/ijmm.2019.4112; Ratan ZA, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834018755089; Sun YZ, 2018, J DERMATOL SCI, V91, P256, DOI 10.1016/j.jdermsci.2018.05.006; Teng M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050779; Thatte J, 2017, J VIROL, V91, DOI 10.1128/JVI.01390-17; Tian R, 2022, MOL THER-ONCOLYTICS, V24, P171, DOI 10.1016/j.omto.2021.12.011; Wang J, 2018, INT J CLIN EXP PATHO, V11, P4230; Wang Q, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32329-x; Wu W, 2019, MED SCI MONITOR, V25, P8651, DOI 10.12659/MSM.917867; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Xia AL, 2019, J MED GENET, V56, P4, DOI 10.1136/jmedgenet-2018-105422; Xiong JF, 2021, INT J NANOMED, V16, P7609, DOI 10.2147/IJN.S335277; Xu XH, 2020, CRISPR J, V3, P487, DOI 10.1089/crispr.2020.0041; Yang W, 2013, IMMUNOLOGY, V139, P513, DOI 10.1111/imm.12101; Yosef I, 2012, NUCLEIC ACIDS RES, V40, P5569, DOI 10.1093/nar/gks216; Yoshiba T, 2019, ONCOL LETT, V17, P2197, DOI 10.3892/ol.2018.9815; Yu L, 2017, ONCOTARGETS THER, V10, P2835, DOI [10.2147/OTT.S64092, 10.2147/OTT.S142877]; Zhan TZ, 2019, SEMIN CANCER BIOL, V55, P106, DOI 10.1016/j.semcancer.2018.04.001; Zhang BB, 2018, ANAL BIOANAL CHEM, V410, P2889, DOI 10.1007/s00216-018-0873-5; Zhang F, 2014, HUM MOL GENET, V23, pR40, DOI 10.1093/hmg/ddu125; Zhang Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06920-7; Zhang XH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.37; Zhang YZ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.716344; Zhen S, 2020, CANCER GENE THER, V27, P168, DOI 10.1038/s41417-019-0131-9; Zhen S, 2017, CELL PHYSIOL BIOCHEM, V44, P2455, DOI 10.1159/000486168; Zhen S, 2016, TRANSL ONCOL, V9, P498, DOI 10.1016/j.tranon.2016.10.002; Zhen S, 2014, BIOCHEM BIOPH RES CO, V450, P1422, DOI 10.1016/j.bbrc.2014.07.014; Zheng R, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.261; Zhong SS, 2019, ONCOTARGETS THER, V12, P2137, DOI 10.2147/OTT.S195655; Zhou LY, 2020, CLIN CANCER RES, V26, P290, DOI 10.1158/1078-0432.CCR-19-1351	95	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1037124	10.3389/fimmu.2022.1037124	http://dx.doi.org/10.3389/fimmu.2022.1037124			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U2KS	36479105	gold, Green Published			2022-12-18	WOS:000894198700001
J	Yasseen, BA; Elkhodiry, AA; El-Messiery, RM; El-sayed, H; Elbenhawi, MW; Kamel, AG; Gad, SA; Zidan, M; Hamza, MS; Al-ansary, M; Abdel-Rahman, EA; Ali, SS				Yasseen, Basma A.; Elkhodiry, Aya A.; El-Messiery, Riem M.; El-sayed, Hajar; Elbenhawi, Malak W.; Kamel, Azza G.; Gad, Shaimaa A.; Zidan, Mona; Hamza, Marwa S.; Al-ansary, Mohamed; Abdel-Rahman, Engy A.; Ali, Sameh S.			Platelets' morphology, metabolic profile, exocytosis, and heterotypic aggregation with leukocytes in relation to severity and mortality of COVID-19-patients	FRONTIERS IN IMMUNOLOGY			English	Article						Critically ill COVID-19 patients; COVID-19 severity; platelet activation; leukocyte-platelet aggregation; metabolism; mitochondrial function; exocytosis	INFLAMMATION; CALCIUM; CELL; ACTIVATION; EVOLUTION; COVID-19	Roles of platelets during infections surpass the classical thrombus function and are now known to modulate innate immune cells. Leukocyte-platelet aggregations and activation-induced secretome are among factors recently gaining interest but little is known about their interplay with severity and mortality during the course of SARS-Cov-2 infection. The aim of the present work is to follow platelets' bioenergetics, redox balance, and calcium homeostasis as regulators of leukocyte-platelet interactions in a cohort of COVID-19 patients with variable clinical severity and mortality outcomes. We investigated COVID-19 infection-related changes in platelet counts, activation, morphology (by flow cytometry and electron microscopy), bioenergetics (by Seahorse analyzer), mitochondria function (by high resolution respirometry), intracellular calcium (by flow cytometry), reactive oxygen species (ROS, by flow cytometry), and leukocyte-platelet aggregates (by flow cytometry) in non-intensive care unit (ICU) hospitalized COVID-19 patients (Non-ICU, n=15), ICU-survivors of severe COVID-19 (ICU-S, n=35), non-survivors of severe COVID-19 (ICU-NS, n=60) relative to control subjects (n=31). Additionally, molecular studies were carried out to follow gene and protein expressions of mitochondrial electron transport chain complexes (ETC) in representative samples of isolated platelets from the studied groups. Our results revealed that COVID-19 infection leads to global metabolic depression especially in severe patients despite the lack of significant impacts on levels of mitochondrial ETC genes and proteins. We also report that severe patients' platelets exhibit hyperpolarized mitochondria and significantly lowered intracellular calcium, concomitantly with increased aggregations with neutrophil. These changes were associated with increased populations of giant platelets and morphological transformations usually correlated with platelets activation and inflammatory signatures, but with impaired exocytosis. Our data suggest that hyperactive platelets with impaired exocytosis may be integral parts in the pathophysiology dictating severity and mortality in COVID-19 patients.	[Yasseen, Basma A.; Elkhodiry, Aya A.; El-sayed, Hajar; Elbenhawi, Malak W.; Kamel, Azza G.; Zidan, Mona; Abdel-Rahman, Engy A.; Ali, Sameh S.] Childrens Canc Hosp Egypt, Res Dept, Cairo, Egypt; [El-Messiery, Riem M.] Cairo Univ, Fac Med, Internal Med Dept, Infect Dis Unit, Cairo, Egypt; [Gad, Shaimaa A.] Natl Res Ctr, Med Res & Clin Studies Inst, Pharmacol Dept, Cairo, Egypt; [Hamza, Marwa S.] British Univ Egypt, Fac Pharm, Dept Clin Pharm Practice, Cairo, Egypt; [Al-ansary, Mohamed] Cairo Univ, Fac Med, Dept Intens Care, Cairo, Egypt; [Abdel-Rahman, Engy A.] Assiut Univ, Fac Med, Pharmacol Dept, Assiut, Egypt	Children's Cancer Hospital 57357; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian Knowledge Bank (EKB); British University in Egypt; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Assiut University	Abdel-Rahman, EA; Ali, SS (corresponding author), Childrens Canc Hosp Egypt, Res Dept, Cairo, Egypt.; Abdel-Rahman, EA (corresponding author), Assiut Univ, Fac Med, Pharmacol Dept, Assiut, Egypt.	engy.ahmed@57357.org; sameh.ali@57357.org						Abdel-Rahman EA, 2021, FREE RADICAL RES, V55, P26, DOI 10.1080/10715762.2020.1856376; Aibibula M, 2018, J THROMB HAEMOST, V16, P2300, DOI 10.1111/jth.14274; Ali Ramadan A, 2015, Curr Trends Immunol, V16, P65; Badawy MA, 2021, ELIFE, V10, DOI [10.7554/eLife.69417, 10.7554/eLife.69417.sa0, 10.7554/eLife.69417.sa1, 10.7554/eLife.69417.sa2]; Barale C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413638; Barclay JW, 2005, CELL CALCIUM, V38, P343, DOI 10.1016/j.ceca.2005.06.012; Bashash D, 2020, ARCH ACAD EMERG MED, V8, DOI 10.22037/aaem.v8i1.828; Ben Jemaa A, 2022, INT IMMUNOPHARMACOL, V109, DOI 10.1016/j.intimp.2022.108781; Cardenes N, 2014, BLOOD, V123, P2864, DOI 10.1182/blood-2013-09-529420; Choo HJ, 2017, ARTERIOSCL THROM VAS, V37, P1503, DOI 10.1161/ATVBAHA.117.309473; Choo HJ, 2012, ARTERIOSCL THROM VAS, V32, P2946, DOI 10.1161/ATVBAHA.112.300433; Choudhary OP, 2021, ANN MED SURG, V70, DOI 10.1016/j.amsu.2021.102895; Christe Martine, 2013, ISRN Obes, V2013, P826027, DOI 10.1155/2013/826027; Chu SG, 2010, J THROMB HAEMOST, V8, P148, DOI 10.1111/j.1538-7836.2009.03584.x; Clarke A, 2010, BIOL REV, V85, P703, DOI 10.1111/j.1469-185X.2010.00122.x; Connor D, 2022, PLATELETS, V33, P1139, DOI 10.1080/09537104.2022.2052035; Danwang C, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00217-0; Don-Doncow N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030537; Fitch-Tewfik Jennifer L, 2013, Front Endocrinol (Lausanne), V4, P77, DOI 10.3389/fendo.2013.00077; Fu G, 2021, SHOCK, V55, P156, DOI 10.1097/SHK.0000000000001619; Garcia-Souza LF, 2014, INT J BIOCHEM CELL B, V50, P156, DOI 10.1016/j.biocel.2014.02.015; Gelman B, 1996, PEDIATR RES, V39, P692, DOI 10.1203/00006450-199604000-00022; Herter JM, 2014, J THROMB HAEMOST, V12, P1764, DOI 10.1111/jth.12730; HOCKLEY DJ, 1988, J GEN VIROL, V69, P2455, DOI 10.1099/0022-1317-69-10-2455; Iba T, 2022, TRENDS CARDIOVAS MED, V32, P1, DOI 10.1016/j.tcm.2021.08.012; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Jing HJ, 2021, AM J TRANSL RES, V13, P8575; Kazemi E, 2021, ANN CLIN MICROB ANTI, V20, DOI 10.1186/s12941-021-00420-3; Khalifa ARM, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13125; Kholmukhamedov A, 2018, J THROMB HAEMOST, V16, P2315, DOI 10.1111/jth.14284; Vajari MK, 2021, CELL BIOL INT, V45, P1832, DOI 10.1002/cbin.11623; Koupenova M, 2018, CIRC RES, V122, P337, DOI 10.1161/CIRCRESAHA.117.310795; Koupenova M, 2014, BLOOD, V124, P791, DOI 10.1182/blood-2013-11-536003; Kulkarni PP, 2022, HAEMATOLOGICA, V107, P1209, DOI 10.3324/haematol.2021.279847; Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9; Lin WY, 2021, AGING-US, V13, P17253, DOI 10.18632/aging.203205; Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763; Lu QJ, 2011, ARTIF ORGANS, V35, P137, DOI 10.1111/j.1525-1594.2010.01051.x; Machin SJ, 2010, J THROMB HAEMOST, V8, P146, DOI 10.1111/j.1538-7836.2009.03673.x; Marcoux G, 2021, PLATELETS, V32, P340, DOI 10.1080/09537104.2020.1786043; Masselli E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144866; Matarrese P, 2009, FEBS J, V276, P845, DOI 10.1111/j.1742-4658.2008.06829.x; Melchinger H, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00153; Ngo ATP, 2020, PLATELETS, V31, P68, DOI 10.1080/09537104.2019.1573314; O'Dell BL, 2013, ADV NUTR, V4, P287, DOI 10.3945/an.112.003624; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Phillips N, 2021, NATURE, V590, P382, DOI 10.1038/d41586-021-00396-2; Ramirez GA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02491; Ravi S, 2015, BBA-MOL BASIS DIS, V1852, P2525, DOI 10.1016/j.bbadis.2015.08.026; Ravi S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123597; Rezel-Potts Emma, 2022, PLoS Med, V19, pe1004052, DOI 10.1371/journal.pmed.1004052; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Slavka G, 2011, ARTERIOSCL THROM VAS, V31, P1215, DOI 10.1161/ATVBAHA.110.221788; Soslau G, 2020, J EXP ZOOL PART B, V334, P113, DOI 10.1002/jez.b.22922; Sumbalova Z, 2022, BRATISL MED J, V123, P9, DOI 10.4149/BLL_2022_002; Thomas MR, 2015, THROMB HAEMOSTASIS, V114, P449, DOI 10.1160/TH14-12-1067; Xu WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132007; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yun SH, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9060143; Zamora C, 2018, INFLAMM BOWEL DIS, V24, P818, DOI 10.1093/ibd/izx106; Zhang YF, 2020, LIVER INT, V40, P2095, DOI 10.1111/liv.14455; Zheng Y, 2020, J ZHEJIANG UNIV-SC B, V21, P378, DOI 10.1631/jzus.B2000174	62	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1022401	10.3389/fimmu.2022.1022401	http://dx.doi.org/10.3389/fimmu.2022.1022401			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T6SP	36479107	gold, Green Published			2022-12-18	WOS:000893807900001
J	Zhang, CJ; Li, YF; Qian, JQ; Zhu, ZP; Huang, C; He, ZS; Zhou, LQ; Gong, YQ				Zhang, Cuijian; Li, Yifan; Qian, Jinqin; Zhu, Zhenpeng; Huang, Cong; He, Zhisong; Zhou, Liqun; Gong, Yanqing			Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy	FRONTIERS IN IMMUNOLOGY			English	Article						clear cell renal cell carcinoma (ccRCC); claudin; tumor microenvironment; immunity; prognosis; immune checkpoint inhibitor (ICI)	TUMOR MICROENVIRONMENT; EXPRESSION; SURVIVAL	BackgroundIn bladder and breast cancer, the claudin-low subtype is widely identified, revealing a distinct tumor microenvironment (TME) and immunological feature. Although we have previously identified individual claudin members as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC), the existence of an intrinsic claudin-low subtype and its interplay with TME and clinical outcomes remains unclear. MethodsTranscriptomic and clinical data from The Cancer Genome Atlas (TCGA)- kidney clear cell carcinoma (KIRC) cohort and E-MTAB-1980 were derived as the training and validation cohorts, respectively. In addition, GSE40435, GSE53757, International Cancer Genome Consortium (ICGC) datasets, and RNA-sequencing data from local ccRCC patients were utilized as validation cohorts for claudin clustering based on silhouette scores. Using weighted correlation network analysis (WGCNA) and multiple machine learning algorithms, including least absolute shrinkage and selection operator (LASSO), CoxBoost, and random forest, we constructed a claudin-TME related (CTR) risk signature. Furthermore, the CTR associated genomic characteristics, immunity, and treatment sensitivity were evaluated. ResultsA claudin-low phenotype was identified and associated with an inferior survival and distinct TME and cancer immunity characteristics. Based on its interaction with TME, a risk signature was developed with robust prognostic prediction accuracy. Moreover, we found its association with a claudin-low, stem-like phenotype and advanced clinicopathological features. Intriguingly, it was also effective in kidney chromophobe and renal papillary cell carcinoma. The high CTR group exhibited genomic characteristics similar to those of claudin-low phenotype, including increased chromosomal instability (such as deletions at 9p) and risk genomic alterations (especially BAP1 and SETD2). In addition, a higher abundance of CD8 T cells and overexpression of immune checkpoints, such as LAG3, CTLA4 and PDCD1, were identified in the high CTR group. Notably, ccRCC patients with high CTR were potentially more sensitive to immune checkpoint inhibitors; their counterparts could have more clinical benefits when treated with antiangiogenic drugs, mTOR, or HIF inhibitors. ConclusionWe comprehensively evaluated the expression features of claudin genes and identified a claudin-low phenotype in ccRCC. In addition, its related signature could robustly predict the prognosis and provide guide for personalizing management strategies.	[Zhang, Cuijian; Li, Yifan; Qian, Jinqin; Zhu, Zhenpeng; Huang, Cong; He, Zhisong; Zhou, Liqun; Gong, Yanqing] Peking Univ First Hosp, Dept Urol, Beijing, Peoples R China; [Zhang, Cuijian; Li, Yifan; Qian, Jinqin; Zhu, Zhenpeng; Huang, Cong; He, Zhisong; Zhou, Liqun; Gong, Yanqing] Peking Univ, Inst Urol, Beijing, Peoples R China; [Zhang, Cuijian; Li, Yifan; Qian, Jinqin; Zhu, Zhenpeng; Huang, Cong; He, Zhisong; Zhou, Liqun; Gong, Yanqing] Peking Univ First Hosp, Natl Urol Canc Ctr, Beijing, Peoples R China	Peking University; Peking University	Gong, YQ (corresponding author), Peking Univ First Hosp, Dept Urol, Beijing, Peoples R China.; Gong, YQ (corresponding author), Peking Univ, Inst Urol, Beijing, Peoples R China.; Gong, YQ (corresponding author), Peking Univ First Hosp, Natl Urol Canc Ctr, Beijing, Peoples R China.	yqgongbjmu@163.com			National Key R&D Program of China; National Natural Science Foundation of China;  [2019YFA0906001];  [82273347]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; 	Funding The present study was funded by The National Key R&D Program of China (grant no. 2019YFA0906001) and National Natural Science Foundation of China (No. 82273347).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bandini M, 2020, ANN ONCOL, V31, P1755, DOI 10.1016/j.annonc.2020.09.011; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Beuselinck B, 2018, ACTA ONCOL, V57, P498, DOI 10.1080/0284186X.2017.1388927; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Braun DA, 2020, NAT MED, V26, P909, DOI 10.1038/s41591-020-0839-y; Chen J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.700084; Chen YP, 2017, THERANOSTICS, V7, P3585, DOI 10.7150/thno.21471; Choueiri TK, 2021, NAT MED, V27, P802, DOI 10.1038/s41591-021-01324-7; Fallah J, 2022, CLIN CANCER RES, V28, P4843, DOI 10.1158/1078-0432.CCR-22-1054; Fougner C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15574-5; Hu J, 2021, THERANOSTICS, V11, P3089, DOI 10.7150/thno.53649; Ingels A, 2022, NAT REV UROL, V19, P391, DOI 10.1038/s41585-022-00592-3; Jiang Aimin, 2021, Front Oncol, V11, P755212, DOI 10.3389/fonc.2021.755212; Jonasch E, 2021, NAT REV NEPHROL, V17, P245, DOI 10.1038/s41581-020-00359-2; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; Kardos J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85902; Kumar B, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01870-5; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; Li KP, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.853088; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li YF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0924-y; Liu LX, 2021, J INFLAMM RES, V14, P4969, DOI 10.2147/JIR.S334041; Liu YN, 2021, GENOMICS, V113, P1816, DOI 10.1016/j.ygeno.2021.04.005; Ljungberg Borje, 2022, Eur Urol, V82, P399, DOI 10.1016/j.eururo.2022.03.006; Lv ZT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.633950; Ma Q, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100929; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Mason JM, 2017, P NATL ACAD SCI USA, V114, P3127, DOI 10.1073/pnas.1700234114; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Owari T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218340; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pommier RM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17249-7; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Pusztai L, 2021, CANCER CELL, V39, P989, DOI 10.1016/j.ccell.2021.05.009; Rosiello G, 2022, UROL ONCOL-SEMIN ORI, V40, DOI 10.1016/j.urolonc.2021.12.010; Sansregret L, 2018, NAT REV CLIN ONCOL, V15, P139, DOI 10.1038/nrclinonc.2017.198; Santaguida S, 2017, DEV CELL, V41, P638, DOI 10.1016/j.devcel.2017.05.022; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Sun H, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29277-6; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tabaries S, 2017, ONCOGENE, V36, P1176, DOI 10.1038/onc.2016.289; Tang G, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.816024; Taylor NA, 2017, J CLIN INVEST, V127, P3478, DOI 10.1172/JCI90499; Bui TO, 2022, EUR UROL, V81, P349, DOI 10.1016/j.eururo.2021.12.010; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Vick SC, 2021, J IMMUNOL, V207, P2598, DOI 10.4049/jimmunol.2001334; Wu JY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.815223; Wu Y, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9939331; Wu Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.684643; Wu Y, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6648093; Yin XM, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1933332; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zheng B, 2021, AGING-US, V13, P19789, DOI 10.18632/aging.203390; Zhu ZP, 2020, ONCOTARGETS THER, V13, P9135, DOI 10.2147/OTT.S266846	55	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1020729	10.3389/fimmu.2022.1020729	http://dx.doi.org/10.3389/fimmu.2022.1020729			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S9EZ	36479115	gold, Green Published			2022-12-18	WOS:000893287100001
J	Zhang, LY; Qin, QY; Xu, C; Zhang, NY; Zhao, TY				Zhang, Liyuan; Qin, Qiyuan; Xu, Chen; Zhang, Ningyi; Zhao, Tianyi			Identification of immune cell function in breast cancer by integrating multiple single-cell data	FRONTIERS IN IMMUNOLOGY			English	Article						scRNA-seq; integration analysis; immune cells; T cell; functional analysis	GENES	Breast cancer has now become the most commonly diagnosed cancer worldwide. It is a highly complex and heterogeneous disease that comprises distinct histological features and treatment response. With the development of molecular biology and immunology, immunotherapy has become a new field of breast cancer treatment. Identifying cell-type-specific genes critical to the immune microenvironment contributes to breast cancer treatment. Single-cell RNA sequencing (scRNA-seq) technology could serve as a powerful tool to analyze cellular genetic information at single-cell resolution and to uncover the gene expression status of each cell, thus allowing comprehensive assessment of intercellular heterogeneity. Because of the influence of sample size and sequencing depth, the specificity of genes in different cell types for breast cancer cannot be fully revealed. Therefore, the present study integrated two public breast cancer scRNA-seq datasets aiming to investigate the functions of different type of immune cells in tumor microenvironment. We identified total five significant differential expressed genes of B cells, T cells and macrophage and explored their functions and immune mechanisms in breast cancer. Finally, we performed functional annotation analyses using the top fifteen differentially expressed genes in each immune cell type to discover the immune-related pathways and gene ontology (GO) terms.	[Zhang, Liyuan; Zhang, Ningyi] Harbin Inst Technol, Dept Comp Sci, Harbin, Peoples R China; [Qin, Qiyuan] Sun Yat sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Peoples R China; [Xu, Chen] Harbin Inst Technol, Ctr Bioinformat, Sch Comp Sci & Technol, Harbin, Peoples R China; [Zhao, Tianyi] Harbin Inst Technol, Sch Med & Hlth, Harbin, Peoples R China	Harbin Institute of Technology; Sun Yat Sen University; Harbin Institute of Technology; Harbin Institute of Technology	Zhao, TY (corresponding author), Harbin Inst Technol, Sch Med & Hlth, Harbin, Peoples R China.	zty2009@hit.edu.cn			National Key Research and Development Program of China; Natural Science Foundation of China; Interdisciplinary Research Foundation of HIT;  [2021YFF1200105];  [62102116]	National Key Research and Development Program of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Interdisciplinary Research Foundation of HIT; ; 	Funding This work has been supported by the National Key Research and Development Program of China (No: 2021YFF1200105), the Natural Science Foundation of China (No: 62102116) and Interdisciplinary Research Foundation of HIT.	Akram M, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0140-9; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Burger JA, 2018, NAT REV CANCER, V18, P148, DOI 10.1038/nrc.2017.121; Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173; Cheng NT, 2022, CURR GENE THER, V22, P439, DOI 10.2174/1566523222666220324110914; Chung W, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15081; Cimino-Mathews A, 2015, ONCOLOGY-NY, V29, P375; De Laurentiis M, 2010, CANCER TREAT REV, V36, pS80, DOI 10.1016/S0305-7372(10)70025-6; Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588; Fisler DA, 2018, ONCOL LETT, V16, P2757, DOI 10.3892/ol.2018.8957; Gu Y, 2019, NAT MED, V25, P312, DOI 10.1038/s41591-018-0309-y; Heiskala M, 2019, VIRCHOWS ARCH, V474, P3, DOI 10.1007/s00428-018-2461-7; Hong CC, 2013, BREAST CANCER RES TR, V139, P477, DOI 10.1007/s10549-013-2549-3; Hu QT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22300-2; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Khan JS, 2020, DRUGS, V80, P23, DOI 10.1007/s40265-019-01227-5; Kobak D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13056-x; Kuipers J, 2017, BBA-REV CANCER, V1867, P127, DOI 10.1016/j.bbcan.2017.02.001; Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008; Li MO, 2016, NAT REV IMMUNOL, V16, P220, DOI 10.1038/nri.2016.26; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408; Martelotto LG, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3658; Noel G, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139905; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Roedig H, 2020, SEMIN CANCER BIOL, V62, P31, DOI 10.1016/j.semcancer.2019.07.026; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Shapiro RS, 2011, AM J HEMATOL, V86, P48, DOI 10.1002/ajh.21903; Vonderheide RH, 2017, CLIN CANCER RES, V23, P2640, DOI 10.1158/1078-0432.CCR-16-2569; Weigelt B, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2734; Yin L, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01296-5; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zhang XY, 2016, CANCER RES, V76, P1305, DOI 10.1158/0008-5472.CAN-15-1907; Zhao TY, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab014	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1058239	10.3389/fimmu.2022.1058239	http://dx.doi.org/10.3389/fimmu.2022.1058239			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6T0BN	36479102	Green Published, gold			2022-12-18	WOS:000893348100001
J	Zhang, S; Sun, ZY; Jiang, X; Lu, ZM; Ding, L; Li, CZ; Tian, XW; Wang, QL				Zhang, Sen; Sun, Zhiyuan; Jiang, Xing; Lu, Zhimin; Ding, Ling; Li, Chengzhi; Tian, Xuewen; Wang, Qinglu			Ferroptosis increases obesity: Crosstalk between adipocytes and the neuroimmune system	FRONTIERS IN IMMUNOLOGY			English	Review						ferroptosis pathway; obesity; neurological dysfunction; inflammatory response; metabolic disorders	POSTPRANDIAL INSULIN-RESISTANCE; GLUTATHIONE-PEROXIDASE 4; SATELLITE GLIAL-CELLS; REGULATORY T-CELLS; ADIPOSE-TISSUE; OXIDATIVE STRESS; B-CELLS; LIPID-PEROXIDATION; VAGUS NERVE; FATTY-ACIDS	Ferroptosis requires not only the accumulation of iron ions, but also changes in many ferroptosis-related regulators, including a decrease in GPX4 and inhibition of SLC7A11 for classical ferroptosis, a deletion of FSP1 or GCH1. Surprisingly, adipose tissue (AT) in the obesity conditions is also accompanied by iron buildup, decreased GSH, and increased ROS. On the neurological side, the pro-inflammatory factor released by AT may have first caused ferroptosis in the vagus nerve by inhibiting of the NRF2-GPX4 pathway, resulting in disorders of the autonomic nervous system. On the immune side, obesity may cause M2 macrophages ferroptosis due to damage to iron-rich ATMs (MFehi) and antioxidant ATMs (Mox), and lead to Treg cells ferroptosis through reductions in NRF2, GPX4, and GCH1 levels. At the same time, the reduction in GPX4 may also trigger the ferroptosis of B1 cells. In addition, some studies have also found the role of GPX4 in neutrophil autophagy, which is also worth pondering whether there is a connection with ferroptosis. In conclusion, this review summarizes the associations between neuroimmune regulation associated with obesity and ferroptosis, and on the basis of this, highlights their potential molecular mechanisms, proposing that ferroptosis in one or more cells in a multicellular tissue changes the fate of that tissue.	[Zhang, Sen; Sun, Zhiyuan; Jiang, Xing; Lu, Zhimin; Ding, Ling; Li, Chengzhi; Tian, Xuewen; Wang, Qinglu] Shandong Sport Univ, Coll Sport & Hlth, Jinan, Shandong, Peoples R China	Shandong Sport University	Tian, XW; Wang, QL (corresponding author), Shandong Sport Univ, Coll Sport & Hlth, Jinan, Shandong, Peoples R China.	xuewentian1978@163.com; wql_zcq@126.com			Taishan Scholars Program of Shandong Province [tsqn201909148]; central government guides local science and technology development funds [YDZX2022091]; technology research and integrated application of scientific fitness smart chip and cloud service platform [2020CXGC010902]	Taishan Scholars Program of Shandong Province; central government guides local science and technology development funds; technology research and integrated application of scientific fitness smart chip and cloud service platform	This work was supported by grants from the Taishan Scholars Program of Shandong Province (tsqn201909148), the central government guides local science and technology development funds (YDZX2022091), and the technology research and integrated application of scientific fitness smart chip and cloud service platform (2020CXGC010902).	Abbaspour N, 2014, J RES MED SCI, V19, P164; Afonso RA, 2010, BRIT J NUTR, V104, P1450, DOI 10.1017/S0007114510002400; Agashe Shruti, 2018, Methodist Debakey Cardiovasc J, V14, P251, DOI 10.14797/mdcj-14-4-251; Ahmed B, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111315; Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Arner E, 2010, DIABETES, V59, P105, DOI 10.2337/db09-0942; Arner P, 2013, J CLIN ENDOCR METAB, V98, pE897, DOI 10.1210/jc.2012-4106; Balbo SL, 2016, J PHYSIOL BIOCHEM, V72, P625, DOI 10.1007/s13105-016-0501-9; Balcioglu AS, 2015, WORLD J DIABETES, V6, P80, DOI 10.4239/wjd.v6.i1.80; Bandeira SD, 2013, INT J MOL SCI, V14, P3265, DOI 10.3390/ijms14023265; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; Belgardt BF, 2009, J PHYSIOL-LONDON, V587, P5305, DOI 10.1113/jphysiol.2009.179192; Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2; Berthoud HR, 2006, AM J PHYSIOL-REG I, V291, pR1240, DOI 10.1152/ajpregu.00428.2006; Bohm A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69016-9; Browning KN, 2017, GASTROENTEROLOGY, V152, P730, DOI 10.1053/j.gastro.2016.10.046; Cadenas Enrique, 2004, Molecular Aspects of Medicine, V25, P17, DOI 10.1016/j.mam.2004.02.005; Cao WN, 2017, ONCOTARGET, V8, P40872, DOI 10.18632/oncotarget.16606; Cao Y, 2018, MOL METAB, V14, P71, DOI 10.1016/j.molmet.2018.06.004; Caslin HL, 2020, IMMUNOL REV, V295, P101, DOI 10.1111/imr.12853; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen LJ, 2015, J BIOL CHEM, V290, P28097, DOI 10.1074/jbc.M115.680090; Cinkajzlova A, 2022, J ENDOCRINOL, V252, pR1, DOI 10.1530/JOE-21-0159; Cinkajzlova A, 2017, PROTOPLASMA, V254, P1219, DOI 10.1007/s00709-017-1082-3; Cobley JN, 2018, REDOX BIOL, V15, P490, DOI 10.1016/j.redox.2018.01.008; Cohen M, 2013, EUR J ENDOCRINOL, V168, P845, DOI 10.1530/EJE-12-1082; Collins Sheila, 2011, Front Endocrinol (Lausanne), V2, P102, DOI 10.3389/fendo.2011.00102; Conrad M, 2019, NAT CHEM BIOL, V15, P1137, DOI 10.1038/s41589-019-0408-1; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; Corna G, 2010, HAEMATOL-HEMATOL J, V95, P1814, DOI 10.3324/haematol.2010.023879; Lopes FNC, 2022, LIFE SCI, V295, DOI 10.1016/j.lfs.2022.120405; Cronin SJF, 2018, NATURE, V563, P564, DOI 10.1038/s41586-018-0701-2; de Lartigue G, 2016, J PHYSIOL-LONDON, V594, P5791, DOI 10.1113/JP271538; de Mello AH, 2018, LIFE SCI, V192, P26, DOI 10.1016/j.lfs.2017.11.019; DeFuria J, 2013, P NATL ACAD SCI USA, V110, P5133, DOI 10.1073/pnas.1215840110; del Paso GAR, 1999, APPL PSYCHOPHYS BIOF, V24, P67, DOI 10.1023/A:1022899115220; Denis RGP, 2014, DIABETES METAB, V40, P191, DOI 10.1016/j.diabet.2013.11.002; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]; Dorneles GP, 2019, SCAND J MED SCI SPOR, V29, P1755, DOI 10.1111/sms.13506; Du HJ, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/1052699; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5; Galaris D, 2008, CRIT REV CL LAB SCI, V45, P1, DOI [10.1080/10408360701713104, 10.1080/10408360701713104 ]; Ganz T, 2012, J INNATE IMMUN, V4, P446, DOI 10.1159/000336423; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Garretson JT, 2016, MOL METAB, V5, P626, DOI 10.1016/j.molmet.2016.06.013; Ghosh MK, 1997, MOL CELL BIOCHEM, V166, P35, DOI 10.1023/A:1006841228483; Giordano A, 2006, AM J PHYSIOL-REG I, V291, pR1243, DOI 10.1152/ajpregu.00679.2005; Gonzalez-Dominguez A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155529; Guilherme A, 2019, NAT REV ENDOCRINOL, V15, P207, DOI 10.1038/s41574-019-0165-y; Hall JE, 2010, J BIOL CHEM, V285, P17271, DOI 10.1074/jbc.R110.113175; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hampton RF, 2022, DIABETOLOGIA, V65, P1069, DOI 10.1007/s00125-022-05691-9; Han F, 2021, BIOENGINEERED, V12, P5279, DOI 10.1080/21655979.2021.1964158; Hanani M, 2005, BRAIN RES REV, V48, P457, DOI 10.1016/j.brainresrev.2004.09.001; Hanani M, 2010, BRAIN RES REV, V64, P304, DOI 10.1016/j.brainresrev.2010.04.009; Harmon DB, 2016, ARTERIOSCL THROM VAS, V36, P682, DOI 10.1161/ATVBAHA.116.307166; Harris RBS, 2018, PHYSIOL BEHAV, V190, P3, DOI 10.1016/j.physbeh.2017.07.008; Hirooka Y, 2011, AM J PHYSIOL-REG I, V300, pR818, DOI 10.1152/ajpregu.00426.2010; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; Hotamisligil GS, 2003, INT J OBESITY, V27, pS53, DOI 10.1038/sj.ijo.0802502; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hu XL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.705786; Huang LL, 2019, J CELL MOL MED, V23, P4153, DOI 10.1111/jcmm.14302; Imai J, 2022, INT IMMUNOL, V34, P67, DOI 10.1093/intimm/dxab023; Jakaria M, 2021, J NEUROCHEM, V159, P804, DOI 10.1111/jnc.15519; Jheng HF, 2012, MOL CELL BIOL, V32, P309, DOI 10.1128/MCB.05603-11; Jiang JW, 2020, AM J PHYSIOL-HEART C, V319, pH1069, DOI 10.1152/ajpheart.00411.2020; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Jung HS, 2020, J LIPID RES, V61, P33, DOI 10.1194/jlr.RA119000256; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]; Kanamori Y, 2019, VITAM HORM, V110, P143, DOI 10.1016/bs.vh.2019.01.007; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Kobayashi H, 2009, AM J PHYSIOL-ENDOC M, V296, pE1326, DOI 10.1152/ajpendo.90921.2008; Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238-020-00789-5; Koppula P, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0288-x; Kosaraju R, 2017, J IMMUNOL, V198, P4738, DOI 10.4049/jimmunol.1601031; Kraft VAN, 2020, ACS CENTRAL SCI, V6, P41, DOI 10.1021/acscentsci.9b01063; Kuchler JC, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.672027; Kuhn H, 2015, BBA-MOL CELL BIOL L, V1851, P308, DOI 10.1016/j.bbalip.2014.10.002; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; Lee N, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020317; Li B, 2020, PROG LIPID RES, V77, DOI 10.1016/j.plipres.2019.101020; Li PC, 2021, NAT IMMUNOL, V22, P1107, DOI 10.1038/s41590-021-00993-3; Li YJ, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-01342-3; Lieu Pauline T., 2001, Molecular Aspects of Medicine, V22, P1, DOI 10.1016/S0098-2997(00)00006-6; Lin J, 2019, J CELL PHYSIOL, V234, P21199, DOI 10.1002/jcp.28726; Liu R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01587; Long EK, 2013, FREE RADICAL BIO MED, V63, P390, DOI 10.1016/j.freeradbiomed.2013.05.030; Luo C, 2016, NANO LETT, V16, P5401, DOI 10.1021/acs.nanolett.6b01632; Ma XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179889; Macedo MP, 2014, REV ENDOCR METAB DIS, V15, P67, DOI 10.1007/s11154-013-9281-5; Maj T, 2017, NAT IMMUNOL, V18, P1332, DOI 10.1038/ni.3868; Merkofer M, 2006, CHEM RES TOXICOL, V19, P1263, DOI 10.1021/tx060101w; Metzger JM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226999; Roman-Pintos LM, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3425617; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; Muri J, 2021, NAT REV IMMUNOL, V21, P363, DOI 10.1038/s41577-020-00478-8; Muri J, 2019, CELL REP, V29, P2731, DOI 10.1016/j.celrep.2019.10.070; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nosalski R, 2017, BRIT J PHARMACOL, V174, P3496, DOI 10.1111/bph.13705; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Orr JS, 2014, DIABETES, V63, P421, DOI 10.2337/db13-0213; Pandolfi J, 2015, J LEUKOCYTE BIOL, V97, P941, DOI 10.1189/jlb.3A1214-626R; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Peterson CY, 2012, ARCH SURG-CHICAGO, V147, P76, DOI 10.1001/archsurg.2011.237; Piattini F, 2021, EUR J IMMUNOL, V51, P2417, DOI 10.1002/eji.202049114; Pietrangelo A, 2016, LIVER INT, V36, P116, DOI 10.1111/liv.13020; Prasun P, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165838; Putti R, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00109; Ruperez AI, 2014, J NUTRIGENET NUTRIGE, V7, P130, DOI 10.1159/000368833; Ryu V, 2015, J NEUROSCI, V35, P2181, DOI 10.1523/JNEUROSCI.3306-14.2015; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Schriever SC, 2017, NEUROSCIENCE, V357, P241, DOI 10.1016/j.neuroscience.2017.05.050; Schwarzler J, 2022, INT J OBESITY, V46, P951, DOI 10.1038/s41366-022-01064-9; Sears B, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0123-1; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Serbulea V, 2018, MOL METAB, V7, P23, DOI 10.1016/j.molmet.2017.11.002; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Song XH, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00267; Soula M, 2020, NAT CHEM BIOL, V16, P1351, DOI 10.1038/s41589-020-0613-y; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; Sui SY, 2022, PHARMACOL THERAPEUT, V232, DOI 10.1016/j.pharmthera.2021.107992; Sun XY, 2020, GASTRIC CANCER, V23, P241, DOI 10.1007/s10120-019-01004-z; Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011; Talukdar S, 2012, NAT MED, V18, P1407, DOI 10.1038/nm.2885; Tang G, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.873090; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Thorp AA, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/341583; Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529; Tu H, 2021, EUR J PHARMACOL, V898, DOI 10.1016/j.ejphar.2021.173999; Villette S, 2002, BLOOD CELL MOL DIS, V29, P174, DOI 10.1006/bcmd.2002.0556; Wang B, 2014, CELL IMMUNOL, V288, P39, DOI 10.1016/j.cellimm.2014.02.003; Wang CY, 2016, CURR OPIN HEMATOL, V23, P189, DOI 10.1097/MOH.0000000000000236; Wang Q, 2021, ADIPOCYTE, V10, P435, DOI 10.1080/21623945.2021.1965314; Wang Q, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02509; Wang Y, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/9911167; Wang ZL, 2022, TRENDS MOL MED, V28, P258, DOI 10.1016/j.molmed.2022.02.003; Watanabe Y, 2019, FASEB J, V33, P11821, DOI 10.1096/fj.201900477RR; Wei YP, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2020.129539; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wen Y, 2021, FREE RADICAL BIO MED, V173, P41, DOI 10.1016/j.freeradbiomed.2021.07.019; Winer DA, 2011, NAT MED, V17, P610, DOI 10.1038/nm.2353; Witko-Sarsat V, 2011, TRENDS IMMUNOL, V32, P117, DOI 10.1016/j.it.2011.01.001; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Xia HY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1079129; Xie BS, 2019, CNS NEUROSCI THER, V25, P465, DOI 10.1111/cns.13069; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Xie YZ, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01297-1; Xiong YY, 2021, INNATE IMMUN-LONDON, V27, P31, DOI 10.1177/1753425920951985; Xu CX, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109235; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yan RH, 2022, CELL RES, V32, P687, DOI 10.1038/s41422-022-00642-w; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Ying W, 2017, J CLIN INVEST, V127, P1019, DOI 10.1172/JCI90350; Ying W, 2016, SCI REP-UK, V6, DOI 10.1038/srep20176; Yuan YJ, 2019, CLIN SCI, V133, P1759, DOI 10.1042/CS20190672; Zhang B, 2021, J PERIODONTAL RES, V56, P991, DOI 10.1111/jre.12912; Zhang YG, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.832432; Zheng JS, 2020, CELL METAB, V32, P920, DOI 10.1016/j.cmet.2020.10.011; Zhou HY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01961; Zorzano A, 2009, INT J BIOCHEM CELL B, V41, P1846, DOI 10.1016/j.biocel.2009.02.004; Zou YL, 2020, NAT CHEM BIOL, V16, P302, DOI 10.1038/s41589-020-0472-6; Zou Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09277-9	172	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 21	2022	13								1049936	10.3389/fimmu.2022.1049936	http://dx.doi.org/10.3389/fimmu.2022.1049936			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6U3ET	36479119	Green Published, gold			2022-12-18	WOS:000894251600001
J	Ferreira, BL; Sousa, MB; Leite, GGF; Brunialti, MKC; Nishiduka, ES; Tashima, AK; van der Poll, T; Salomao, R				Ferreira, Bianca Lima; Sousa, Monica Braganca; Leite, Giuseppe Gianini Figueiredo; Brunialti, Milena Karina Colo; Nishiduka, Erika Sayuri; Tashima, Alexandre Keiji; van der Poll, Tom; Salomao, Reinaldo			Glucose metabolism is upregulated in the mononuclear cell proteome during sepsis and supports endotoxin-tolerant cell function	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; immunometabolism; PBMCs; endotoxin-tolerance; LPS; glycolysis; pentose phosphate pathway	MACROPHAGES; EXPRESSION; PHAGOCYTOSIS; LEUKOCYTES	Metabolic adaptations shape immune cell function. In the acute response, a metabolic switch towards glycolysis is necessary for mounting a proinflammatory response. During the clinical course of sepsis, both suppression and activation of immune responses take place simultaneously. Leukocytes from septic patients present inhibition of cytokine production while other functions such as phagocytosis and production of reactive oxygen species (ROS) are preserved, similarly to the in vitro endotoxin tolerance model, where a first stimulation with lipopolysaccharide (LPS) affects the response to a second stimulus. Here, we sought to investigate how cellular metabolism is related to the modulation of immune responses in sepsis and endotoxin tolerance. Proteomic analysis in peripheral blood mononuclear cells (PBMCs) from septic patients obtained at intensive care unit admission showed an upregulation of proteins related to glycolysis, the pentose phosphate pathway (PPP), production of ROS and nitric oxide, and downregulation of proteins in the tricarboxylic acid cycle and oxidative phosphorylation compared to healthy volunteers. Using the endotoxin-tolerance model in PBMCs from healthy subjects, we observed increased lactate production in control cells upon LPS stimulation, while endotoxin-tolerant cells presented inhibited tumor necrosis factor-alpha and lactate production along with preserved phagocytic capacity. Inhibition of glycolysis and PPP led to impairment of phagocytosis and cytokine production both in control and in endotoxin-tolerant cells. These data indicate that glucose metabolism supports leukocyte functions even in a condition of endotoxin tolerance.	[Ferreira, Bianca Lima; Sousa, Monica Braganca; Leite, Giuseppe Gianini Figueiredo; Brunialti, Milena Karina Colo; Salomao, Reinaldo] Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, Sao Paulo, Brazil; [Nishiduka, Erika Sayuri; Tashima, Alexandre Keiji] Univ Fed Sao Paulo, Dept Biochem, Escola Paulista Med, Sao Paulo, Brazil; [van der Poll, Tom] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Ctr Expt & Mol Med, Amsterdam, Netherlands; [van der Poll, Tom] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Div Infect Dis, Amsterdam, Netherlands	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); University of Amsterdam; University of Amsterdam	Salomao, R (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, Sao Paulo, Brazil.	rsalomao@unifesp.br			FAPESP [2017/21052-0, 2016/13855-2, 2020/05077-5, 2019/20532-3]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by FAPESP (2017/21052-0). BF and MS received scholarships from FAPESP (2016/13855-2, 2020/05077-5). GL has a scholarship from FAPESP (2019/20532-3).	Ahl PJ, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1027-9; Alves-Januzzi AB, 2017, CYTOM PART B-CLIN CY, V92, P192, DOI 10.1002/cyto.b.21321; Arts RJW, 2017, J LEUKOCYTE BIOL, V101, P151, DOI 10.1189/jlb.4MR0216-066R; Baardman J, 2018, CELL REP, V25, P2044, DOI 10.1016/j.celrep.2018.10.092; Belikova I, 2007, CRIT CARE MED, V35, P2702, DOI 10.1097/01.CCM.0000295593.25106.C4; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Britt EC, 2022, NAT METAB, V4, P389, DOI 10.1038/s42255-022-00550-8; Cheng SC, 2016, NAT IMMUNOL, V17, P406, DOI 10.1038/ni.3398; Darden DB, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081742; Rodrigues PMD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94474-0; Fernandes ML, 2010, BRAZ J MED BIOL RES, V43, P860, DOI 10.1590/S0100-879X2010000900008; Ferreira BL, 2021, SHOCK, V56, P80, DOI 10.1097/SHK.0000000000001694; da Mota NVF, 2018, SHOCK, V50, P293, DOI 10.1097/SHK.0000000000001078; Leite GGF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744799; Garrabou G, 2012, J INFECT DIS, V205, P392, DOI 10.1093/infdis/jir764; Gillen J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020164; Graham DB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8838; Grondman I, 2019, J LEUKOCYTE BIOL, V106, P11, DOI 10.1002/JLB.5HI0119-018R; Haschemi A, 2012, CELL METAB, V15, P813, DOI 10.1016/j.cmet.2012.04.023; Jones N, 2015, CLIN EXP IMMUNOL, V182, P69, DOI 10.1111/cei.12662; King ZA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004321; Koo SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00202; Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796; Liu TF, 2012, J BIOL CHEM, V287, P25758, DOI 10.1074/jbc.M112.362343; MICHL J, 1976, J EXP MED, V144, P1465, DOI 10.1084/jem.144.6.1465; Nucci LA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172024; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Rodriguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Sadiku P, 2021, CELL METAB, V33, DOI [10.1016/j.cmet.2021.03.018, 10.1016/j.cmet.2020.11.016]; Salomao R, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431x20198595, 10.1590/1414-431X20198595]; Santos Sidneia S, 2016, Intensive Care Med Exp, V4, P5, DOI 10.1186/s40635-016-0078-1; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Singer M, 2014, VIRULENCE, V5, P66, DOI 10.4161/viru.26907; SPEERT DP, 1992, J CLIN INVEST, V90, P1085, DOI 10.1172/JCI115924; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; van der Poll T, 2021, IMMUNITY, V54, P2450, DOI 10.1016/j.immuni.2021.10.012; Venter G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096786; Vogel C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009217; Widdrington JD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02217	42	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1051514	10.3389/fimmu.2022.1051514	http://dx.doi.org/10.3389/fimmu.2022.1051514			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6UZ	36466921	gold, Green Published			2022-12-18	WOS:000893121300001
J	Gao, F; Yu, B; Rao, BC; Sun, Y; Yu, J; Wang, DM; Cui, GY; Ren, ZG				Gao, Feng; Yu, Bo; Rao, Benchen; Sun, Ying; Yu, Jia; Wang, Daming; Cui, Guangying; Ren, Zhigang			The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment	FRONTIERS IN IMMUNOLOGY			English	Review						intratumoral microbiome; tumor; inflammation; immune; genetic engineering; treatment	CYTOLETHAL DISTENDING TOXIN; ENTEROTOXIGENIC BACTEROIDES-FRAGILIS; DOUBLE-STRAND BREAKS; NUCLEATUM PROMOTES CHEMORESISTANCE; FUSOBACTERIUM-NUCLEATUM; INTESTINAL INFLAMMATION; GENOMIC INSTABILITY; COLORECTAL-CANCER; LUNG MICROBIOTA; IMMUNITY	In the past few decades, great progress has been achieved in the understanding of microbiome-cancer interactions. However, most of the studies have focused on the gut microbiome, ignoring how other microbiomes interact with tumors. Emerging evidence suggests that in many types of cancers, such as lung cancer, pancreatic cancer, and colorectal cancer, the intratumoral microbiome plays a significant role. In addition, accumulating evidence suggests that intratumoral microbes have multiple effects on the biological behavior of tumors, for example, regulating tumor initiation and progression and altering the tumor response to chemotherapy and immunotherapy. However, to fully understand the role of the intratumoral microbiome in cancer, further investigation of the effects and mechanisms is still needed. This review discusses the role of intratumoral bacteria in tumorigenesis and tumor progression, recurrence and metastasis, as well as their effect on cancer prognosis and treatment outcome, and summarizes the relevant mechanisms.	[Gao, Feng; Rao, Benchen; Sun, Ying; Yu, Jia; Wang, Daming; Cui, Guangying; Ren, Zhigang] Zhengzhou Univ, Dept Infect Dis, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Gao, Feng; Rao, Benchen; Sun, Ying; Yu, Jia; Wang, Daming; Cui, Guangying; Ren, Zhigang] Jinan Microecol Biomed Shandong Lab, Jinan, Peoples R China; [Gao, Feng; Rao, Benchen; Sun, Ying; Yu, Jia; Wang, Daming; Cui, Guangying; Ren, Zhigang] Zhengzhou Univ, Gene Hosp Henan Prov, Precis Med Ctr, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Yu, Bo] Zhengzhou Univ, Sch Agr Sci, Henan Key Lab Ion beam Bioengn, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University	Cui, GY; Ren, ZG (corresponding author), Zhengzhou Univ, Dept Infect Dis, Affiliated Hosp 1, Zhengzhou, Peoples R China.; Cui, GY; Ren, ZG (corresponding author), Jinan Microecol Biomed Shandong Lab, Jinan, Peoples R China.; Cui, GY; Ren, ZG (corresponding author), Zhengzhou Univ, Gene Hosp Henan Prov, Precis Med Ctr, Affiliated Hosp 1, Zhengzhou, Peoples R China.	fcccuigy@zzu.edu.cn; fccrenzg@zzu.edu.cn			National Key Research and Development Program of China; Research Project of Jinan Microecological Biomedicine Shandong Laboratory; National Natural Science Foundation of China;  [2018YFC2000500];  [2022YFC2303103];  [JNL-2022015B];  [JNL-2022001A];  [U2004121]	National Key Research and Development Program of China; Research Project of Jinan Microecological Biomedicine Shandong Laboratory; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; ; ; ; 	Funding This study was sponsored by grants from the National Key Research and Development Program of China (2018YFC2000500 and 2022YFC2303103), Research Project of Jinan Microecological Biomedicine Shandong Laboratory (JNL-2022015B and JNL-2022001A), and National Natural Science Foundation of China (U2004121).	Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Aykut B, 2019, NATURE, V574, P264, DOI 10.1038/s41586-019-1608-2; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Banerjee S, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04092-x; Banerjee S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00951; Banerjee S, 2017, ONCOTARGET, V8, P36225, DOI 10.18632/oncotarget.16717; Barrett M, 2020, TRENDS CANCER, V6, P277, DOI 10.1016/j.trecan.2020.01.019; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Belkaid Y, 2013, NAT IMMUNOL, V14, P646, DOI 10.1038/ni.2604; Bezine E, 2016, SCI REP-UK, V6, DOI 10.1038/srep36022; Bi H, 2019, J MED MICROBIOL, V68, P1471, DOI 10.1099/jmm.0.001058; Boleij A, 2015, CLIN INFECT DIS, V60, P208, DOI 10.1093/cid/ciu787; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Cameron SJS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177062; Cao YY, 2021, GASTROENTEROLOGY, V161, P1552, DOI 10.1053/j.gastro.2021.08.003; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Chen JX, 2017, THERANOSTICS, V7, P2250, DOI 10.7150/thno.18816; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng WT, 2020, MALAYS J MED SCI, V27, P9, DOI 10.21315/mjms2020.27.4.2; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cogdill AP, 2018, TRENDS IMMUNOL, V39, P900, DOI 10.1016/j.it.2018.09.007; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107; Daisley BA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18649-5; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Dejea CM, 2018, SCIENCE, V359, P592, DOI 10.1126/science.aah3648; Dickson RP, 2015, ANN AM THORAC SOC, V12, P821, DOI 10.1513/AnnalsATS.201501-029OC; Domenis R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44949-y; Dzutsev A, 2017, ANNU REV IMMUNOL, V35, P199, DOI 10.1146/annurev-immunol-051116-052133; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Fedor Y, 2013, CELL MICROBIOL, V15, P1, DOI 10.1111/cmi.12028; Fessler J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0574-4; Flemer B, 2017, GUT, V66, P633, DOI 10.1136/gutjnl-2015-309595; Frisan T, 2003, CELL MICROBIOL, V5, P695, DOI 10.1046/j.1462-5822.2003.00311.x; Fu AK, 2022, CELL, V185, P1356, DOI 10.1016/j.cell.2022.02.027; Garrett WS, 2019, SCIENCE, V364, P1133, DOI 10.1126/science.aaw2367; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gomes S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49195-w; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Greathouse KL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1501-6; Guerra L, 2011, FEBS J, V278, P4577, DOI 10.1111/j.1742-4658.2011.08125.x; Guo SH, 2021, GUT, V70, P1507, DOI 10.1136/gutjnl-2020-321187; Guo YX, 2020, CANCER LETT, V469, P102, DOI 10.1016/j.canlet.2019.10.033; Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010; Gustafson AM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000251; Han YY, 2020, AM J CANCER RES, V10, P727; Hieken TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep30751; Huffnagle GB, 2017, MUCOSAL IMMUNOL, V10, P299, DOI 10.1038/mi.2016.108; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040; Jin M, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.727937; Jinadasa RN, 2011, MICROBIOL-SGM, V157, P1851, DOI 10.1099/mic.0.049536-0; Kadosh E, 2020, NATURE, V586, P133, DOI 10.1038/s41586-020-2541-0; Kalaora S, 2021, NATURE, V592, P138, DOI 10.1038/s41586-021-03368-8; Kim DH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0295-2; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Kovacs T, 2021, CANCER METAST REV, V40, P1223, DOI 10.1007/s10555-021-10013-3; Lambin P, 1998, ANAEROBE, V4, P183, DOI 10.1006/anae.1998.0161; Lara-Tejero M, 2001, INFECT IMMUN, V69, P4358, DOI 10.1128/IAI.69.7.4358-4365.2001; Le Noci V, 2018, CELL REP, V24, P3528, DOI 10.1016/j.celrep.2018.08.090; Lee SH, 2016, LUNG CANCER, V102, P89, DOI 10.1016/j.lungcan.2016.10.016; Lehouritis P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14554; Lewis DA, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00041; Li S, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0363-6; Liang K, 2019, CANCER LETT, V448, P168, DOI 10.1016/j.canlet.2019.01.037; Liang YR, 2020, SEMIN CANCER BIOL, V60, P14, DOI 10.1016/j.semcancer.2019.08.012; Liu HX, 2018, INT J CANCER, V142, P769, DOI 10.1002/ijc.31098; Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011; Lloyd CM, 2017, IMMUNITY, V46, P549, DOI 10.1016/j.immuni.2017.04.005; Lu R, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.20; Ma JY, 2020, CANCERS, V12, DOI 10.3390/cancers12092524; Marchesi JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020447; Mrazek J, 2019, FOLIA MICROBIOL, V64, P435, DOI 10.1007/s12223-018-00670-3; Nakatsuji T, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao4502; Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189; Nemunaitis J, 2003, CANCER GENE THER, V10, P737, DOI 10.1038/sj.cgt.7700634; Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059; O'Donnell JS, 2017, CANCER TREAT REV, V52, P71, DOI 10.1016/j.ctrv.2016.11.007; Oliva M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031446; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Parhi L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16967-2; Pilette C, 2001, EUR RESPIR J, V18, P571, DOI 10.1183/09031936.01.00228801; Popovic VB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29054-w; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Putze J, 2009, INFECT IMMUN, V77, P4696, DOI 10.1128/IAI.00522-09; Qiao H, 2022, JAMA ONCOL, V8, P1301, DOI 10.1001/jamaoncol.2022.2810; Qu DD, 2022, HEPATOL COMMUN, V6, P1741, DOI 10.1002/hep4.1908; Ramirez-Labrada AG, 2020, TRENDS CANCER, V6, P86, DOI 10.1016/j.trecan.2019.12.007; Riquelme E, 2019, CELL, V178, P795, DOI 10.1016/j.cell.2019.07.008; Robles AI, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001016; Rubinstein MR, 2019, EMBO REP, V20, DOI 10.15252/embr.201847638; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Salehan MR, 2013, BRIT J BIOMED SCI, V70, P31, DOI 10.1080/09674845.2013.11669927; Sears CL, 2009, CLIN MICROBIOL REV, V22, P349, DOI 10.1128/CMR.00053-08; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Sevcikova A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010488; Shalapour S, 2020, ANNU REV IMMUNOL, V38, P649, DOI 10.1146/annurev-immunol-082019-081656; Shi YY, 2020, J EXP MED, V217, DOI 10.1084/jem.20192282; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sommariva M, 2020, CELL MOL LIFE SCI, V77, P2739, DOI 10.1007/s00018-020-03452-8; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tenaillon O, 2010, NAT REV MICROBIOL, V8, P207, DOI 10.1038/nrmicro2298; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tong Y, 2021, THERANOSTICS, V11, P5889, DOI 10.7150/thno.56157; Tsay JCJ, 2018, AM J RESP CRIT CARE, V198, P1188, DOI 10.1164/rccm.201710-2118OC; Tzeng A, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00874-2; Urbaniak C, 2014, APPL ENVIRON MICROB, V80, P3007, DOI 10.1128/AEM.00242-14; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Walther-Antonio MRS, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0368-y; Wang JP, 2021, J CANCER RES CLIN, V147, P481, DOI 10.1007/s00432-020-03462-w; Wang YY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.754788; Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785; Wong-Rolle A, 2021, PROTEIN CELL, V12, P426, DOI 10.1007/s13238-020-00813-8; Wu SG, 2003, GASTROENTEROLOGY, V124, P392, DOI 10.1053/gast.2003.50047; Xu SH, 2020, GUT PATHOG, V12, DOI 10.1186/s13099-020-00368-3; Yamamura K, 2016, CLIN CANCER RES, V22, P5574, DOI 10.1158/1078-0432.CCR-16-1786; Yan XM, 2015, AM J CANCER RES, V5, P3111; Yu GQ, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1021-1; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zhang L, 2007, CANCER RES, V67, P5859, DOI 10.1158/0008-5472.CAN-07-0098; Zhang N, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01221-6; Zhang S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0985-y; Zhao KM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00244-1; Zhao XY, 2018, CANCER LETT, V428, P34, DOI 10.1016/j.canlet.2018.04.026; Zhong GH, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.859721; Zhou SB, 2018, NAT REV CANCER, V18, P727, DOI 10.1038/s41568-018-0070-z	135	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1051987	10.3389/fimmu.2022.1051987	http://dx.doi.org/10.3389/fimmu.2022.1051987			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6HL	36466871	gold, Green Published			2022-12-18	WOS:000893085800001
J	Hameed, M; Geerling, E; Pinto, AK; Miraj, I; Weger-Lucarelli, J				Hameed, Muddassar; Geerling, Elizabeth; Pinto, Amelia K. K.; Miraj, Iqra; Weger-Lucarelli, James			Immune response to arbovirus infection in obesity	FRONTIERS IN IMMUNOLOGY			English	Review						obesity; arboviruses; adipocytes; cytokines; interferons	DIET-INDUCED OBESITY; ADIPOSE-TISSUE INFLAMMATION; DENGUE HEMORRHAGIC-FEVER; DENDRITIC CELL-FUNCTION; NATURAL-KILLER NK; WEST NILE VIRUS; T-CELLS; TELOMERE LENGTH; RISK-FACTORS; MICE	Obesity is a global health problem that affects 650 million people worldwide and leads to diverse changes in host immunity. Individuals with obesity experience an increase in the size and the number of adipocytes, which function as an endocrine organ and release various adipocytokines such as leptin and adiponectin that exert wide ranging effects on other cells. In individuals with obesity, macrophages account for up to 40% of adipose tissue (AT) cells, three times more than in adipose tissue (10%) of healthy weight individuals and secrete several cytokines and chemokines such as interleukin (IL)-1 beta, chemokine C-C ligand (CCL)-2, IL-6, CCL5, and tumor necrosis factor (TNF)-alpha, leading to the development of inflammation. Overall, obesity-derived cytokines strongly affect immune responses and make patients with obesity more prone to severe symptoms than patients with a healthy weight. Several epidemiological studies reported a strong association between obesity and severe arthropod-borne virus (arbovirus) infections such as dengue virus (DENV), chikungunya virus (CHIKV), West Nile virus (WNV), and Sindbis virus (SINV). Recently, experimental investigations found that DENV, WNV, CHIKV and Mayaro virus (MAYV) infections cause worsened disease outcomes in infected diet induced obese (DIO) mice groups compared to infected healthy-weight animals. The mechanisms leading to higher susceptibility to severe infections in individuals with obesity remain unknown, though a better understanding of the causes will help scientists and clinicians develop host directed therapies to treat severe disease. In this review article, we summarize the effects of obesity on the host immune response in the context of arboviral infections. We have outlined that obesity makes the host more susceptible to infectious agents, likely by disrupting the functions of innate and adaptive immune cells. We have also discussed the immune response of DIO mouse models against some important arboviruses such as CHIKV, MAYV, DENV, and WNV. We can speculate that obesity-induced disruption of innate and adaptive immune cell function in arboviral infections ultimately affects the course of arboviral disease. Therefore, further studies are needed to explore the cellular and molecular aspects of immunity that are compromised in obesity during arboviral infections or vaccination, which will be helpful in developing specific therapeutic/prophylactic interventions to prevent immunopathology and disease progression in individuals with obesity.	[Hameed, Muddassar; Weger-Lucarelli, James] Virginia Tech, VA MD Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA; [Geerling, Elizabeth; Pinto, Amelia K. K.] St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO USA; [Miraj, Iqra] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou, Peoples R China	Virginia Polytechnic Institute & State University; Saint Louis University; Zhejiang University	Hameed, M; Weger-Lucarelli, J (corresponding author), Virginia Tech, VA MD Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.	muddassarh@vt.edu; weger@vt.edu						Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x; Adams LE, 2022, JAMA-J AM MED ASSOC, V327, P817, DOI 10.1001/jama.2021.23466; Ahlm C, 2014, EPIDEMIOL INFECT, V142, P1559, DOI 10.1017/S0950268813002239; Almond MH, 2013, THORAX, V68, P684, DOI 10.1136/thoraxjnl-2012-203009; Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207; Rojas-Osornio SA, 2019, OBES RES CLIN PRACT, V13, P419, DOI 10.1016/j.orcp.2019.05.003; Apostolopoulos V, 2016, MOL NUTR FOOD RES, V60, P43, DOI 10.1002/mnfr.201500272; Baldeon RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115209; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; Bertola A, 2012, DIABETES, V61, P2238, DOI 10.2337/db11-1274; Bhargavi BS, 2020, GLOBAL BIOSECUR, V2, DOI [10.31646/GBIO.83, DOI 10.31646/GBIO.83, 10.31646/gbio.83]; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; BROWN RE, 1966, TROP GEOGR MED, V18, P125; Calamusa G, 2012, J INFECTION, V64, P212, DOI 10.1016/j.jinf.2011.11.012; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Catoi AF, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091199; Catrysse L, 2018, CELL IMMUNOL, V330, P114, DOI 10.1016/j.cellimm.2018.03.001; Cerny D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004548; Cheung KP, 2012, IMMUNOL RES, V52, P182, DOI 10.1007/s12026-011-8261-7; Chuong C, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00828-x; Cinti S., 2019, CURR OPIN ENDOCRINE, V4, P29, DOI [10.1016/j.coemr.2018.07.003, DOI 10.1016/J.COEMR.2018.07.003]; Conroy AL, 2015, INT J INFECT DIS, V40, P45, DOI 10.1016/j.ijid.2015.07.027; Costanzo AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120918; Daryabor G, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12747; David S, 2016, INFECT DIS-NOR, V48, P571, DOI 10.3109/23744235.2016.1164890; Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X; Diaz E, 2011, CHEST, V139, P382, DOI 10.1378/chest.10-1160; Divella R, 2016, J CANCER, V7, P2346, DOI 10.7150/jca.16884; Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137; Eliakim A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326; Engin AB, 2017, ADV EXP MED BIOL, V960, P327, DOI 10.1007/978-3-319-48382-5_14; Fain JN, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/513948; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Frasca D, 2017, CLIN EXP IMMUNOL, V187, P64, DOI 10.1111/cei.12824; Frasca D, 2017, MECH AGEING DEV, V162, P91, DOI 10.1016/j.mad.2017.01.004; Frierson J. Gordon, 2010, Yale Journal of Biology and Medicine, V83, P77; Gallagher P, 2020, J INFECTION, V81, P10, DOI 10.1016/j.jinf.2020.04.039; Ge Q, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/987285; Geerling E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.739025; Gerardin P, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-99; Goldstein N, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061508; Gornicka A, 2012, AM J PHYSIOL-ENDOC M, V303, pE597, DOI 10.1152/ajpendo.00022.2012; Green WD, 2017, ANN AM THORAC SOC, V14, pS406, DOI 10.1513/AnnalsATS.201706-447AW; Green WD, 2017, CURR OPIN IMMUNOL, V46, P1, DOI 10.1016/j.coi.2017.03.008; Guzik TJ, 2017, CARDIOVASC RES, V113, P1009, DOI 10.1093/cvr/cvx108; Hammarstedt A, 2018, PHYSIOL REV, V98, P1911, DOI 10.1152/physrev.00034.2017; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Henegar C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r14; Honce R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01071; Huang Y, 2020, METABOLISM, V113, DOI 10.1016/j.metabol.2020.154378; Huh JY, 2014, MOL CELLS, V37, P365, DOI 10.14348/molcells.2014.0074; Jackson-Morris AM, 2020, GLOBAL HEALTH ACTION, V13, DOI 10.1080/16549716.2020.1804700; Jacobsen MJ, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/8539057; James BR, 2012, J IMMUNOL, V189, P1311, DOI 10.4049/jimmunol.1100587; Jean-Baptiste E, 2016, AM J TROP MED HYG, V95, P1345, DOI 10.4269/ajtmh.16-0320; Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81; de Oya NJ, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.00360-18, 10.1128/AAC.00360-18]; Jung YS, 2018, YONSEI MED J, V59, P554, DOI 10.3349/ymj.2018.59.4.554; Kalayanarooj Siripen, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P378; Kanneganti TD, 2012, NAT IMMUNOL, V13, P707, DOI 10.1038/ni.2343; Karlsson EA, 2016, MBIO, V7, DOI 10.1128/mBio.01144-16; Karlsson EA, 2010, EXP BIOL MED, V235, P1412, DOI 10.1258/ebm.2010.010227; Kaushik Prashant, 2016, BioMolecular Concepts, V7, P145, DOI 10.1515/bmc-2016-0010; Kim SM, 2009, CANCER EPIDEM BIOMAR, V18, P816, DOI 10.1158/1055-9965.EPI-08-0935; Kim YH, 2012, J INFECT DIS, V205, P244, DOI 10.1093/infdis/jir731; Kinlen D, 2018, QJM-INT J MED, V111, P437, DOI 10.1093/qjmed/hcx152; Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013; Koenig SM, 2001, AM J MED SCI, V321, P249, DOI 10.1097/00000441-200104000-00006; Kramer LD, 2019, J MED ENTOMOL, V56, P1448, DOI 10.1093/jme/tjz151; Kyle JL, 2007, J INFECT DIS, V195, P1808, DOI 10.1086/518007; Lam QLK, 2007, CELL MOL IMMUNOL, V4, P1; Landrier JF, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080859; Lee BC, 2014, BBA-MOL BASIS DIS, V1842, P446, DOI 10.1016/j.bbadis.2013.05.017; Lee M, 2011, AM J HUM BIOL, V23, P100, DOI 10.1002/ajhb.21109; Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415; Linton PJ, 2004, NAT IMMUNOL, V5, P133, DOI 10.1038/ni1033; Liu YX, 2020, MOL IMMUNOL, V117, P139, DOI 10.1016/j.molimm.2019.11.002; Luft VC, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-31; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; Lynch L, 2012, IMMUNITY, V37, P574, DOI 10.1016/j.immuni.2012.06.016; Macia L, 2006, J IMMUNOL, V177, P5997, DOI 10.4049/jimmunol.177.9.5997; Malik P, 2021, J MED VIROL, V93, P1188, DOI 10.1002/jmv.26555; Marques RE, 2015, IMMUNOLOGY, V145, P583, DOI 10.1111/imm.12476; Mauro C, 2017, CELL METAB, V25, P593, DOI 10.1016/j.cmet.2017.01.008; Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7; Milner JJ, 2015, J IMMUNOL, V194, P4846, DOI 10.4049/jimmunol.1402295; Milner JJ, 2013, J IMMUNOL, V191, P2474, DOI 10.4049/jimmunol.1202429; Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014; Monteiro R, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/289645; Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011; Moser JAS, 2019, INFLUENZA OTHER RESP, V13, P3, DOI 10.1111/irv.12618; Mundstock E, 2015, OBESITY, V23, P2165, DOI 10.1002/oby.21183; Namkoong H, 2019, BIOCHEM BIOPH RES CO, V513, P405, DOI 10.1016/j.bbrc.2019.03.211; Nave H, 2008, ENDOCRINOLOGY, V149, P3370, DOI 10.1210/en.2007-1516; Naylor C, 2016, TRENDS MOL MED, V22, P88, DOI 10.1016/j.molmed.2015.12.001; Nevalainen T, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-016-0301-7; Vuong NL, 2022, J INFECT DIS, V226, P1338, DOI 10.1093/infdis/jiac093; Nguyen NM., 2020, WELLCOME OPEN RES, V5, P160, DOI [10.12688/wellcomeopenres.16053.1, DOI 10.12688/WELLCOMEOPENRES.16053.1]; Nicolaidis S, 2019, METABOLISM, V100, DOI 10.1016/j.metabol.2019.07.006; Noor FM, 2020, J COMMUN HEALTH, V45, P1270, DOI 10.1007/s10900-020-00920-x; Nsoesie EO, 2016, EUROSURVEILLANCE, V21, P7, DOI 10.2807/1560-7917.ES.2016.21.20.30234; O'Shea D, 2013, INT J OBESITY, V37, P1510, DOI 10.1038/ijo.2013.16; O'Shea D, 2019, CANCERS, V11, DOI 10.3390/cancers11040573; Ong SWX, 2020, CLIN INFECT DIS, V71, P2300, DOI 10.1093/cid/ciaa548; Ornellas F, 2016, PHYSIOL BEHAV, V153, P47, DOI 10.1016/j.physbeh.2015.10.019; Padmakumar B, 2010, SE ASIAN J TROP MED, V41, P85; Palmer AK, 2019, AGING CELL, V18, DOI 10.1111/acel.12950; Pan XX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.637424; Park HL, 2014, HUM VACC IMMUNOTHER, V10, P1181, DOI 10.4161/hv.28332; Paz-Bailey G, 2021, MMWR RECOMM REP, V70, P1, DOI 10.15585/mmwr.rr7006a1; Pellegrinelli V, 2015, DIABETES, V64, P3121, DOI 10.2337/db14-0796; Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105; Pereira S, 2014, NUTRITION, V30, P784, DOI 10.1016/j.nut.2013.11.023; Petersen LR, 2013, EPIDEMIOL INFECT, V141, P591, DOI 10.1017/S0950268812001070; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Pichainarong Natchaporn, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P283; Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y; R. Pellini, 2021, medRxiv, DOI 10.1101/2021.02.24.21251664; Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215; Rebello CJ, 2020, INT J OBESITY, V44, P1810, DOI 10.1038/s41366-020-0640-5; Renner K, 2015, EUR J IMMUNOL, V45, P2504, DOI 10.1002/eji.201545473; Revelo X, 2014, ENDOCR PATHOL, V25, P93, DOI 10.1007/s12022-013-9288-1; Rivino L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0526; Ronca SE, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009190; Roos J, 2016, SCI REP-UK, V6, DOI 10.1038/srep38339; Satchidanandam V, 2020, CURR TREAT OPT INFEC, V12, P375, DOI 10.1007/s40506-020-00242-5; Schwarz NG, 2012, EMERG INFECT DIS, V18, P1780, DOI 10.3201/eid1811.111036; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Shin SK, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101749; Shirakawa K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092435; Simar D, 2014, METABOLISM, V63, P1188, DOI 10.1016/j.metabol.2014.05.014; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Smith AG, 2007, J NUTR, V137, P1236, DOI 10.1093/jn/137.5.1236; Smith AG, 2009, IMMUNOLOGY, V126, P268, DOI 10.1111/j.1365-2567.2008.02895.x; Snyder Thomas M, 2020, medRxiv, DOI 10.1101/2020.07.31.20165647; Soe HJ, 2017, J GEN VIROL, V98, P2993, DOI 10.1099/jgv.0.000981; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Soto-Acosta R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006257; Spencer M, 2011, J CLIN ENDOCR METAB, V96, pE1990, DOI 10.1210/jc.2011-1567; Spielmann G, 2014, CLIN EXP IMMUNOL, V176, P246, DOI 10.1111/cei.12267; St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x; St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108; Su YP, 2020, CELL, V183, P1479, DOI 10.1016/j.cell.2020.10.037; Suganami T, 2010, J LEUKOCYTE BIOL, V88, P33, DOI 10.1189/jlb.0210072; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Sun K, 2010, RES PERSPECT END INT, P67, DOI 10.1007/978-3-642-13517-0_6; Sun Y, 2016, INFECT DIS-NOR, V48, P813, DOI 10.1080/23744235.2016.1201721; Tagliabue C, 2016, EUR J CLIN MICROBIOL, V35, P325, DOI 10.1007/s10096-015-2558-8; Tan VPK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200698; Teran-Cabanillas E, 2017, INFLAMMATION, V40, P58, DOI 10.1007/s10753-016-0452-x; Teran-Cabanillas E, 2014, CLIN NUTR, V33, P922, DOI 10.1016/j.clnu.2013.10.011; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tobin LM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94939; Travers RL, 2015, INT J OBESITY, V39, P762, DOI 10.1038/ijo.2014.195; Ulbert S, 2019, HUM VACC IMMUNOTHER, V15, P2337, DOI 10.1080/21645515.2019.1621149; Vairo F, 2019, INFECT DIS CLIN N AM, V33, P1003, DOI 10.1016/j.idc.2019.08.006; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Viel S, 2017, CLIN IMMUNOL, V177, P12, DOI 10.1016/j.clim.2016.01.007; Wang Q, 2021, ADIPOCYTE, V10, P435, DOI 10.1080/21623945.2021.1965314; Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002; Wang XL, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-87; Wang ZM, 2019, NAT MED, V25, P141, DOI 10.1038/s41591-018-0221-5; Watanabe M, 2022, DIABETES-METAB RES, V38, DOI 10.1002/dmrr.3465; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; Weger-Lucarelli J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008089; Weger-Lucarelli J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006247; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weitman ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070703; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yactayo S, 2016, J INFECT DIS, V214, pS441, DOI 10.1093/infdis/jiw390; Yan TT, 2021, THERANOSTICS, V11, P8234, DOI 10.7150/thno.59293; Yang HW, 2010, J IMMUNOL, V185, P1836, DOI 10.4049/jimmunol.1000021; Yang H, 2009, BLOOD, V114, P3803, DOI 10.1182/blood-2009-03-213595; Yang J, 2021, J MED VIROL, V93, P2662, DOI 10.1002/jmv.26677; Yang RH, 2007, CIRC RES, V101, P545, DOI 10.1161/CIRCRESAHA.107.156596; Zatterale F, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01607; Zhang AJX, 2013, J INFECT DIS, V207, P1270, DOI 10.1093/infdis/jit031	185	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								968582	10.3389/fimmu.2022.968582	http://dx.doi.org/10.3389/fimmu.2022.968582			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6VJ	36466818	Green Published, gold			2022-12-18	WOS:000893122300001
J	He, Y; Liang, B; Hung, SW; Zhang, RZ; Xu, H; Chung, JPW; Wang, CC				He, Ying; Liang, Bo; Hung, Sze Wan; Zhang, Ruizhe; Xu, Hui; Chung, Jacqueline Pui Wah; Wang, Chi Chiu			Re-evaluation of mouse models of endometriosis for pathological and immunological research	FRONTIERS IN IMMUNOLOGY			English	Article						endometriosis; animal models; pathology; immunology; surgical transplantation	NATURAL-KILLER ACTIVITY; ESTROUS-CYCLE; MURINE MODEL; PERITONEAL-MACROPHAGES; LESION GROWTH; CELLS; MICE; ANGIOGENESIS; WOMEN; ESTABLISHMENT	Endometriosis is an estrogen-dependent gynecological disease with chronic pelvic inflammation. In order to study the pathophysiology of endometriosis and examine the therapeutic effects of new pharmaceuticals for endometriosis treatment, different animal models had been developed in the last two decades, especially mouse models. However, no study evaluated the effects of various modeling approaches on pathology and immunology in endometriosis. This study aimed to compare endometriotic lesion development and immune profiles under different methods of establishing endometriosis models in mice, including estrus synchronization (ovariectomy with estrogen supplement versus male urine-soaked transfer bedding), endometrium preparations (whole uterus including endometrium and myometrium fragments versus solely endometrium fragments), and surgical transplantation (subcutaneous transplantation versus intraperitoneal injection). Our results showed that lesion growth under estrus synchronization by ovariectomy with estrogen supplement had a higher success rate and more proliferative endometrium, apart from higher body weight gain. Immune responses in peripheral blood were similar in the whole uterus and solely endometrium fragments and in intraperitoneal injection and subcutaneous transplantation, but a more innate immune response in the peritoneal microenvironment was found in solely endometrium fragments and intraperitoneal injection than counterparts. In conclusion, different endometriosis modeling methods result in different pathological and immunological features. Ovariectomy with estrogen supplement, solely endometrium fragments, and intraperitoneal injection are more suitable for both pathological and immunological studies of endometriosis in mice, which are important for mechanistic studies and immunotherapy development.	[He, Ying; Liang, Bo; Hung, Sze Wan; Zhang, Ruizhe; Xu, Hui; Chung, Jacqueline Pui Wah; Wang, Chi Chiu] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Peoples R China; [He, Ying] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Gynecol Oncol, Shenzhen, Peoples R China; [He, Ying] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Joint Lab Reprod Med, Sichuan Univ, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Sichuan University	Wang, CC (corresponding author), Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Peoples R China.; Wang, CC (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.; Wang, CC (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.; Wang, CC (corresponding author), Chinese Univ Hong Kong, Joint Lab Reprod Med, Sichuan Univ, Hong Kong, Peoples R China.	ccwang@cuhk.edu.hk			Food and Health Bureau [08190886]; Hong Kong Society of Obstetricians and Gynaecologists, and Academic Equipment Grant [3029876]; Chinese University of Hong Kong [2017.044]	Food and Health Bureau; Hong Kong Society of Obstetricians and Gynaecologists, and Academic Equipment Grant; Chinese University of Hong Kong(Chinese University of Hong Kong)	This research was supported by the Health and Medical Research Fund (08190886) from the Food and Health Bureau, The Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from the Hong Kong Society of Obstetricians and Gynaecologists, and Academic Equipment Grant (3029876) and Direct Grant (2017.044) from The Chinese University of Hong Kong.	Ahn SH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/795976; Andres MP, 2020, J MINIM INVAS GYN, V27, P373, DOI 10.1016/j.jmig.2019.10.004; Bacci M, 2009, AM J PATHOL, V175, P547, DOI 10.2353/ajpath.2009.081011; Bayne Lauren J, 2013, Cold Spring Harb Protoc, V2013, P955, DOI 10.1101/pdb.prot077198; Berbic M, 2010, HUM REPROD, V25, P900, DOI 10.1093/humrep/deq020; Braun DP, 1998, CURR OPIN OBSTET GYN, V10, P365, DOI 10.1097/00001703-199810000-00003; Burns KA, 2018, ENDOCRINOLOGY, V159, P103, DOI 10.1210/en.2017-00562; Burns KA, 2012, ENDOCRINOLOGY, V153, P3960, DOI 10.1210/en.2012-1294; Butcher MJ, 2011, JOVE-J VIS EXP, DOI 10.3791/2848; Cao X, 2004, FERTIL STERIL, V82, P999, DOI 10.1016/j.fertnstert.2004.04.040; Chen Y, 2019, REPROD SCI, V26, P1130, DOI 10.1177/1933719118808923; Cheng CW, 2011, J PATHOL, V224, P261, DOI 10.1002/path.2852; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; CUMMINGS AM, 1995, REPROD TOXICOL, V9, P233, DOI 10.1016/0890-6238(95)00004-T; Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899; DHooghe TM, 1996, ACTA OBSTET GYN SCAN, V75, P98, DOI 10.3109/00016349609033298; Dodds KN, 2017, BIOL REPROD, V97, P810, DOI 10.1093/biolre/iox132; Ekambaram G, 2017, J CLIN DIAGN RES, V11, pAC5, DOI 10.7860/JCDR/2017/23977.9148; Fainaru O, 2008, FASEB J, V22, P522, DOI 10.1096/fj.07-9034com; Fang ZJ, 2004, FERTIL STERIL, V82, P673, DOI 10.1016/j.fertnstert.2004.01.048; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERDES J, 1984, J IMMUNOL, V133, P1710; Greaves E, 2014, AM J PATHOL, V184, P1930, DOI 10.1016/j.ajpath.2014.03.011; Grummer R, 2006, HUM REPROD UPDATE, V12, P641, DOI 10.1093/humupd/dml026; Guo PP, 2019, REPROD BIOMED ONLINE, V39, P704, DOI 10.1016/j.rbmo.2019.05.014; HALME J, 1984, AM J OBSTET GYNECOL, V148, P85, DOI 10.1016/S0002-9378(84)80037-X; Herington JL, 2011, EXPERT REV CLIN IMMU, V7, P611, DOI [10.1586/ECI.11.53, 10.1586/eci.11.53]; Hirata T, 2005, HUM REPROD, V20, P2092, DOI 10.1093/humrep/dei012; Holoch KJ, 2010, CLIN OBSTET GYNECOL, V53, P429, DOI 10.1097/GRF.0b013e3181db7d71; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; Jiang HH, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106352; Lin YJ, 2006, ENDOCRINOLOGY, V147, P1278, DOI 10.1210/en.2005-0790; Lv LT, 2014, J CELL BIOCHEM, V115, P81, DOI 10.1002/jcb.24635; Macer ML, 2012, OBSTET GYN CLIN N AM, V39, P535, DOI 10.1016/j.ogc.2012.10.002; McLean AC, 2012, JOVE-J VIS EXP, DOI 10.3791/4389; OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45; OOSTERLYNCK DJ, 1992, FERTIL STERIL, V58, P290; Pelch KE, 2012, JOVE-J VIS EXP, DOI 10.3791/3396; Rana N, 1996, FERTIL STERIL, V65, P925, DOI 10.1016/S0015-0282(16)58262-4; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Rossi AGZ, 2002, GYNECOL OBSTET INVES, V54, P185, DOI 10.1159/000068380; Somigliana E, 1999, HUM REPROD, V14, P2944, DOI 10.1093/humrep/14.12.2944; Styer AK, 2008, ENDOCRINOLOGY, V149, P506, DOI 10.1210/en.2007-1225; Tirado-Gonzalez I, 2010, J REPROD IMMUNOL, V86, P141, DOI 10.1016/j.jri.2010.05.001; Wang CC, 2013, ANGIOGENESIS, V16, P59, DOI 10.1007/s10456-012-9299-4; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; WHITTEN WK, 1956, J ENDOCRINOL, V13, P399, DOI 10.1677/joe.0.0130399; Zhang T, 2018, EUR J IMMUNOL, V48, P1059, DOI 10.1002/eji.201747417	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								986202	10.3389/fimmu.2022.986202	http://dx.doi.org/10.3389/fimmu.2022.986202			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6VC	36466829	Green Published, gold			2022-12-18	WOS:000893121600001
J	Hong, CH; Pyo, HS; Baek, IC; Kim, TG				Hong, Cheol-Hwa; Pyo, Hong-Seon; Baek, In-Cheol; Kim, Tai-Gyu			Rapid identification of CMV-specific TCRs via reverse TCR cloning system based on bulk TCR repertoire data	FRONTIERS IN IMMUNOLOGY			English	Article						CMV; TCR; T cell receptor; NGS; next generation sequencing; reverse TCR cloning; artificial APC	T-CELL-RECEPTOR; BLOOD-LYMPHOCYTES; REACTIVE TCR; HLA-B; EXPRESSION; SELECTION; AFFINITY; PEPTIDE; CONFERS; GENES	Advances in next-generation sequencing (NGS) have improved the resolution of T-cell receptor (TCR) repertoire analysis, and recent single-cell sequencing has made it possible to obtain information about TCR pairs. In our previous study, cytomegalovirus (CMV) pp65-specific T-cell response restricted by a single human leukocyte antigen (HLA) class I allotype was observed in an individual. Therefore, to effectively clone an antigen-specific TCR from these T cells, we developed a TCR cloning system that does not require a single cell level. First, we established the improved Jurkat reporter cell line, which was TCR alpha beta double knock-out and expressed CD8 alpha beta molecules. Furthermore, functional TCRs were directly obtained by reverse TCR cloning using unique CDR3-specific PCR primers after bulk TCR sequencing of activation marker-positive CD8 T cells by NGS. A total of 15 TCR alpha and 14 TCR beta strands were successfully amplified by PCR from cDNA of 4-1BB-positive CD8 T cells restricted by HLA-A*02:01, HLA-A*02:06, HLA-B*07:02, and HLA-B*40:06. The panels with combinations of TCR alpha and TCR beta genes were investigated using Jurkat reporter cell line and artificial antigen-presenting cells (APCs). In two TCR pairs restricted by HLA-A*02:01, one TCR pair by HLA-A*02:06, four TCR pairs by HLA-B*07:02, and one TCR pair by HLA-B*40:06, their specificity and affinity were confirmed. The TCR pair of A*02:01/1-1 showed alloreactivity to HLA-A*02:06. The one TCR pair showed a higher response to the naturally processed antigen than that of the peptide pool. This reverse TCR cloning system will not only provide functional information to TCR repertoire analysis by NGS but also help in the development of TCR-T therapy.	[Hong, Cheol-Hwa; Pyo, Hong-Seon] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, Seoul, South Korea; [Hong, Cheol-Hwa; Pyo, Hong-Seon; Kim, Tai-Gyu] Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul, South Korea; [Hong, Cheol-Hwa; Baek, In-Cheol; Kim, Tai-Gyu] Catholic Univ Korea, Coll Med, Catholic Hematopoiet Stem Cell Bank, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Kim, TG (corresponding author), Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul, South Korea.; Kim, TG (corresponding author), Catholic Univ Korea, Coll Med, Catholic Hematopoiet Stem Cell Bank, Seoul, South Korea.	kimtg@catholic.ac.kr			BK21 program; Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea;  [HI14C3417]	BK21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea; 	Funding This research was supported by the BK21 program and a grant from the Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI14C3417).	Aarnoudse CA, 2002, INT J CANCER, V99, P7, DOI 10.1002/ijc.10317; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Arnaud M, 2022, NAT BIOTECHNOL, V40, P656, DOI 10.1038/s41587-021-01072-6; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Baek IC, 2021, HLA, V97, P112, DOI 10.1111/tan.14134; Bendle GM, 2010, NAT MED, V16, P565, DOI 10.1038/nm.2128; Bethune MT, 2018, P NATL ACAD SCI USA, V115, pE10702, DOI 10.1073/pnas.1810653115; Bunse M, 2014, MOL THER, V22, P1983, DOI 10.1038/mt.2014.142; Chelvanayagam G, 1996, IMMUNOGENETICS, V45, P15, DOI 10.1007/s002510050162; Chiffelle J, 2020, CURR OPIN BIOTECH, V65, P284, DOI 10.1016/j.copbio.2020.07.010; Cho HI, 2018, BRIT J CANCER, V118, P534, DOI 10.1038/bjc.2017.475; Clay TM, 1999, J IMMUNOL, V163, P507; Cooper LJN, 2000, J VIROL, V74, P8207, DOI 10.1128/JVI.74.17.8207-8212.2000; Daniels MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; De Simone M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01638; Djaoud Z, 2020, ANNU REV BIOCHEM, V89, P717, DOI [10.1146/annurev-biochem-011520-102754, 10.1146/annurev-biochem-011520102754]; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Felix NJ, 2007, NAT REV IMMUNOL, V7, P942, DOI 10.1038/nri2200; Friedman J, 2022, BMC IMMUNOL, V23, DOI 10.1186/s12865-022-00478-4; Govers C, 2014, J IMMUNOL, V193, P5315, DOI 10.4049/jimmunol.1302074; Hamana H, 2016, BIOCHEM BIOPH RES CO, V474, P709, DOI 10.1016/j.bbrc.2016.05.015; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Hong CH, 2017, J IMMUNOTHER, V40, P201, DOI 10.1097/CJI.0000000000000176; Huth A, 2019, J IMMUNOL, V202, P979, DOI 10.4049/jimmunol.1801401; Hyun SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01591; Johnson LA, 2006, J IMMUNOL, V177, P6548, DOI 10.4049/jimmunol.177.9.6548; Jutz S, 2016, J IMMUNOL METHODS, V430, P10, DOI 10.1016/j.jim.2016.01.007; Kobayashi E, 2013, NAT MED, V19, P1542, DOI 10.1038/nm.3358; La Gruta NL, 2018, NAT REV IMMUNOL, V18, P467, DOI 10.1038/s41577-018-0007-5; Legut M, 2018, BLOOD, V131, P311, DOI 10.1182/blood-2017-05-787598; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; Morton LT, 2020, MOL THER, V28, P64, DOI 10.1016/j.ymthe.2019.10.001; Muller TR, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100374; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Nesterenko PA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021190118; Pai JA, 2021, NAT METHODS, V18, P881, DOI 10.1038/s41592-021-01201-8; Paria BC, 2021, J IMMUNOTHER, V44, P1, DOI 10.1097/CJI.0000000000000342; Polz MF, 1998, APPL ENVIRON MICROB, V64, P3724; RIDDELL SR, 1992, SCIENCE, V257, P238; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Schub A, 2009, J IMMUNOL, V183, P6819, DOI 10.4049/jimmunol.0902233; Simon P, 2014, CANCER IMMUNOL RES, V2, P1230, DOI 10.1158/2326-6066.CIR-14-0108; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Trautmann L, 2005, J IMMUNOL, V175, P6123, DOI 10.4049/jimmunol.175.9.6123; van Loenen MM, 2010, P NATL ACAD SCI USA, V107, P10972, DOI 10.1073/pnas.1005802107; Wang Y, 2017, P NATL ACAD SCI USA, V114, pE4792, DOI 10.1073/pnas.1700459114; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wolfl M, 2008, CYTOM PART A, V73A, P1043, DOI 10.1002/cyto.a.20594; Wu JH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01631; Yang S, 2008, GENE THER, V15, P1411, DOI 10.1038/gt.2008.90; Zajac P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085270; Zhang W, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf5835	53	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1021067	10.3389/fimmu.2022.1021067	http://dx.doi.org/10.3389/fimmu.2022.1021067			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6IK	36466875	gold, Green Published			2022-12-18	WOS:000893088500001
J	Kanchan, K; Shankar, G; Huffaker, MF; Bahnson, HT; Chinthrajah, RS; Sanda, S; Manohar, M; Ling, H; Paschall, JE; Toit, GD; Ruczinski, I; Togias, A; Lack, G; Nadeau, KC; Jones, SM; Nepom, GT; Mathias, RA				Kanchan, Kanika; Shankar, Gautam; Huffaker, Michelle F. F.; Bahnson, Henry T. T.; Chinthrajah, R. Sharon; Sanda, Srinath; Manohar, Monali; Ling, Hua; Paschall, Justin E. E.; Toit, George Du; Ruczinski, Ingo; Togias, Alkis; Lack, Gideon; Nadeau, Kari C. C.; Jones, Stacie M. M.; Nepom, Gerald T. T.; Mathias, Rasika A. A.			HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success	FRONTIERS IN IMMUNOLOGY			English	Article						peanut allergy; oral immunotherapy; HLA; desensitization; remission; tolerance	ALLERGEN; DISEASE; RISK; AGE	RationalePrevious studies identified an interaction between HLA and oral peanut exposure. HLA-DQA1*01:02 had a protective role with the induction of Ara h 2 epitope-specific IgG4 associated with peanut consumption during the LEAP clinical trial for prevention of peanut allergy, while it was a risk allele for peanut allergy in the peanut avoidance group. We have now evaluated this gene-environment interaction in two subsequent peanut oral immunotherapy (OIT) trials - IMPACT and POISED - to better understand the potential for the HLA-DQA1*01:02 allele as an indicator of higher likelihood of desensitization, sustained unresponsiveness, and peanut allergy remission. MethodsWe determined HLA-DQA1*01:02 carrier status using genome sequencing from POISED (N=118, age: 7-55yr) and IMPACT (N=126, age: 12-<48mo). We tested for association with remission, sustained unresponsiveness (SU), and desensitization in the OIT groups, as well as peanut component specific IgG4 (psIgG4) using generalized linear models and adjusting for relevant covariates and ancestry. ResultsWhile not quite statistically significant, a higher proportion of HLA-DQA1*01:02 carriers receiving OIT in IMPACT were desensitized (93%) compared to non-carriers (78%); odds ratio (OR)=5.74 (p=0.06). In this sample we also observed that a higher proportion of carriers achieved remission (35%) compared to non-carriers (22%); OR=1.26 (p=0.80). In POISED, carriers more frequently attained continued desensitization (80% versus 61% among non-carriers; OR=1.28, p=0.86) and achieved SU (52% versus 31%; OR=2.32, p=0.19). psIgG4 associations with HLA-DQA1*01:02 in the OIT arm of IMPACT which included younger study subjects recapitulated patterns noted in LEAP, but no associations of note were observed in the older POISED study subjects. ConclusionsFindings across three clinical trials show a pattern of a gene environment interaction between HLA and oral peanut exposure. Age, and prior sensitization contribute additional determinants of outcomes, consistent with a mechanism of restricted antigen recognition fundamental to driving protective immune responses to OIT.	[Kanchan, Kanika; Shankar, Gautam; Mathias, Rasika A. A.] Johns Hopkins Univ, Div Allergy & Clin Immunol, Dept Med, Sch Med, Baltimore, MD 21218 USA; [Huffaker, Michelle F. F.; Sanda, Srinath] Immune Tolerance Network, San Francisco, CA USA; [Bahnson, Henry T. T.; Nepom, Gerald T. T.] Immune Tolerance Network, Seattle, WA USA; [Bahnson, Henry T. T.; Nepom, Gerald T. T.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA; [Chinthrajah, R. Sharon; Manohar, Monali; Nadeau, Kari C. C.] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Palo Alto, CA USA; [Ling, Hua; Paschall, Justin E. E.] Johns Hopkins Univ, Inst Genet Med, Sch Med, Dept Med, Baltimore, MD USA; [Toit, George Du; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Ruczinski, Ingo] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, Rockville, MD USA; [Jones, Stacie M. M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR USA; [Jones, Stacie M. M.] Arkansas Childrens Hosp, Little Rock, AR USA	Johns Hopkins University; Immune Tolerance Network; Immune Tolerance Network; Benaroya Research Institute; Virginia Mason Medical Center; Stanford University; Johns Hopkins University; University of London; King's College London; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Mathias, RA (corresponding author), Johns Hopkins Univ, Div Allergy & Clin Immunol, Dept Med, Sch Med, Baltimore, MD 21218 USA.	rmathias@jhmi.edu			National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) [UM1AI109565]; NIH-NIAID [UM1AI109565, UM2AI117870]; National Center for Research Resources supported Clinical Translational Science Awards and Clinical Research Centers [TR003107, TR001111, TR003142, TR000067, TR000424]; NIAID [AADCRC U19AI104209]; Sean N Parker Center for Allergy and Asthma Research at Stanford University; Myra Reinhard Family Foundation; Food Allergy Research & Education Center of Excellence; End Allergies Together; TripAdvisor Charitable Foundation; Crown Family Philanthropies	National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources supported Clinical Translational Science Awards and Clinical Research Centers; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Sean N Parker Center for Allergy and Asthma Research at Stanford University; Myra Reinhard Family Foundation; Food Allergy Research & Education Center of Excellence; End Allergies Together; TripAdvisor Charitable Foundation; Crown Family Philanthropies	This research was performed as a project of the Immune Tolerance Network, an international clinical research consortium headquartered at the Benaroya Research Institute and supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award no. UM1AI109565. IMPACT trial was funded through NIH-NIAID under Award Number UM1AI109565 and UM2AI117870. Other sources of support include the National Center for Research Resources supported Clinical Translational Science Awards and Clinical Research Centers TR003107 (University of Arkansas for Medical Sciences), TR001111 (University of North Carolina), TR003142 (Stanford University), TR000067 (Mount Sinai University), and TR000424 (Johns Hopkins University School of Medicine). POISED trial was supported by the NIAID grant AADCRC U19AI104209, the Sean N Parker Center for Allergy and Asthma Research at Stanford University, the Myra Reinhard Family Foundation, Food Allergy Research & Education Center of Excellence, End Allergies Together, TripAdvisor Charitable Foundation, and Crown Family Philanthropies.	Arevalo M, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1724-7; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Chinthrajah RS, 2019, LANCET, V394, P1437, DOI 10.1016/S0140-6736(19)31793-3; Conomos MP, 2015, GENET EPIDEMIOL, V39, P276, DOI 10.1002/gepi.21896; Dominguez D, 2021, J RHEUMATOL, V48, P852, DOI 10.3899/jrheum.200002; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Hemmings O, 2020, J ALLERGY CLIN IMMUN, V146, P621, DOI 10.1016/j.jaci.2020.03.026; Inshaw JRJ, 2020, DIABETES CARE, V43, P169, DOI 10.2337/dc19-0803; Inshaw JRJ, 2018, DIABETOLOGIA, V61, P147, DOI 10.1007/s00125-017-4440-y; James LK, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0600-2; Jimenez-Saiz R, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0819-1; Jones SM, 2022, LANCET, V399, P359, DOI 10.1016/S0140-6736(21)02390-4; Kanchan K, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI152070; Kanchan K, 2021, J ALLERGY CLIN IMMUN, V147, P15, DOI 10.1016/j.jaci.2020.10.039; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; Lane LC, 2020, J CLIN ENDOCR METAB, V105, pE3277, DOI 10.1210/clinem/dgaa347; Misicka E, 2022, MULT SCLER J, V28, P1189, DOI 10.1177/13524585211053155; Raczy C, 2013, BIOINFORMATICS, V29, P2041, DOI 10.1093/bioinformatics/btt314; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Tada K, 2022, MOD RHEUMATOL, DOI 10.1093/mr/roac008; Watanabe M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79833-7; Winters A, 2019, J ALLERGY CLIN IMMUN, V143, P2326, DOI 10.1016/j.jaci.2019.02.016	23	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								941839	10.3389/fimmu.2022.941839	http://dx.doi.org/10.3389/fimmu.2022.941839			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S7IU	36466872	gold, Green Published			2022-12-18	WOS:000893157200001
J	Koutsogiannaki, S; Hou, LF; Okuno, T; Shibamura-Fujiogi, M; Luo, HR; Yuki, K				Koutsogiannaki, Sophia; Hou, Lifei; Okuno, Toshiaki; Shibamura-Fujiogi, Miho; Luo, Hongbo R. R.; Yuki, Koichi			alpha D beta 2 as a novel target of experimental polymicrobial sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						integrin; aDb2; sepsis; cell death; phagocytosis	HEMATOPOIETIC STEM; SPINAL-CORD; BETA 2; INTEGRINS; APOPTOSIS; INJURY; INFLAMMATION; CD11B/CD18; DEFICIENCY; LIGATION	Since sepsis was defined three decades ago, it has been a target of intensive study. However, there is no specific sepsis treatment available, with its high mortality and morbidity. alpha D beta 2 (CD11d/CD18) is one of the four beta 2 integrin members. Its role in sepsis has been limitedly studied. Using an experimental polymicrobial sepsis model, we found that the deficiency of alpha D beta 2 was associated with less lung injury and better outcome, which was in sharp contrast to other beta 2 integrin member alpha L beta 2 (CD11a/CD18), and alpha M beta 2 (CD11b/CD18). This phenotype was supported by a reduction of bacterial loads in alpha D beta 2 knockout mice. Further analysis showed that the deficiency of alpha D beta 2 led to a reduction of neutrophil cell death as well as an increase in neutrophil phagocytosis in both murine and human systems. Our data showed a unique role of alpha D beta 2 among the beta 2 integrin members, which would serve as a potential target to improve the outcome of sepsis.	[Koutsogiannaki, Sophia; Hou, Lifei; Shibamura-Fujiogi, Miho; Yuki, Koichi] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Cardiac Anesthesia Div, Boston, MA 02115 USA; [Koutsogiannaki, Sophia; Hou, Lifei; Shibamura-Fujiogi, Miho; Yuki, Koichi] Harvard Med Sch, Dept Anaesthesia, Boston, MA 02115 USA; [Koutsogiannaki, Sophia; Hou, Lifei; Shibamura-Fujiogi, Miho; Yuki, Koichi] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA; [Okuno, Toshiaki] Juntendo Univ, Dept Biochem, Fac Med, Tokyo, Japan; [Luo, Hongbo R. R.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Juntendo University; Harvard University; Boston Children's Hospital	Yuki, K (corresponding author), Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Cardiac Anesthesia Div, Boston, MA 02115 USA.; Yuki, K (corresponding author), Harvard Med Sch, Dept Anaesthesia, Boston, MA 02115 USA.; Yuki, K (corresponding author), Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA.	koichi.yuki@childrens.harvard.edu			 [R21HD099194]		Funding This study was in part supported by R21HD099194 (KY, SK).	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Aziz MH, 2017, J IMMUNOL, V198, P4855, DOI 10.4049/jimmunol.1602175; Bak RO, 2018, NAT PROTOC, V13, P358, DOI 10.1038/nprot.2017.143; Bao EL, 2020, NATURE, V586, DOI 10.1038/s41586-020-2786-7; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; de Azevedo-Quintanilha IG, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1447-7; Ding ZM, 1999, J IMMUNOL, V163, P5029; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf; Evans R, 2009, J CELL SCI, V122, P215, DOI 10.1242/jcs.019117; Geremia NM, 2017, EXP NEUROL, V295, P125, DOI 10.1016/j.expneurol.2017.06.002; Guo RF, 2002, J IMMUNOL, V169, P307, DOI 10.4049/jimmunol.169.1.307; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hou LF, 2020, BLOOD ADV, V4, P6086, DOI 10.1182/bloodadvances.2020002504; Kessel JM, 2006, J ALLERGY CLIN IMMUN, V118, P831, DOI 10.1016/j.jaci.2006.05.026; Kishimoto T K, 1989, Curr Probl Dermatol, V18, P106; Koutsogiannaki S, 2019, FASEB J, V33, P12668, DOI 10.1096/fj.201901360R; Koutsogiannaki S, 2019, J SURG RES, V233, P323, DOI 10.1016/j.jss.2018.07.075; Koutsogiannaki S, 2017, TOXICOL SCI, V156, P402, DOI 10.1093/toxsci/kfw261; Liu JR, 2015, WORLD J CLIN CASES, V3, P793, DOI 10.12998/wjcc.v3.i9.793; Liu JR, 2014, SHOCK, V42, P532, DOI 10.1097/SHK.0000000000000250; Mayadas TN, 2005, TRENDS IMMUNOL, V26, P388, DOI 10.1016/j.it.2005.05.002; Miyazaki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112770; Okuno T, 2019, FASEB J, V33, P14528, DOI 10.1096/fj.201901570R; Osaka M, 2016, SCI REP-UK, V6, DOI 10.1038/srep21391; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Schmid MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07387-4; SEEKAMP A, 1993, AM J PATHOL, V143, P464; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI [10.1056/NEJMra1608077, 10.1056/NEJMc1711824]; Vaidyanathan S, 2020, CELL STEM CELL, V26, P161, DOI 10.1016/j.stem.2019.11.002; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Weiss SL, 2020, PEDIATR CRIT CARE ME, V21, pE52, DOI [10.1097/PCC.0000000000002198, 10.1007/s00134-019-05878-6]; Wu HZ, 2004, J IMMUNOL, V173, P297, DOI 10.4049/jimmunol.173.1.297; Yakubenko VP, 2018, BLOOD, V132, P78, DOI 10.1182/blood-2017-10-810176; Zhang QQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15948	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1059996	10.3389/fimmu.2022.1059996	http://dx.doi.org/10.3389/fimmu.2022.1059996			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6HJ	36466931	Green Published, gold			2022-12-18	WOS:000893085600001
J	Li, WL; Dong, YZ; Liu, WC; Tang, ZR; Sun, CY; Lowe, S; Chen, SY; Bentley, R; Zhou, Q; Xu, C; Li, WY; Wang, B; Wang, HS; Dong, ST; Hu, ZH; Liu, Q; Cai, XT; Feng, XW; Zhao, W; Yin, CL				Li, Wenle; Dong, Youzheng; Liu, Wencai; Tang, Zhiri; Sun, Chenyu; Lowe, Scott; Chen, Shuya; Bentley, Rachel; Zhou, Qin; Xu, Chan; Li, Wanying; Wang, Bing; Wang, Haosheng; Dong, Shengtao; Hu, Zhaohui; Liu, Qiang; Cai, Xintian; Feng, Xiaowei; Zhao, Wei; Yin, Chengliang			A deep belief network-based clinical decision system for patients with osteosarcoma	FRONTIERS IN IMMUNOLOGY			English	Article						Osteosarcoma; lung metastasis; deep belief networks; prognosis; clinical decision	HIGH-GRADE OSTEOSARCOMA; LEARNING ALGORITHM; PROGNOSTIC-FACTORS; EXTREMITIES; METADATA; SARCOMA; IMAGES	Osteosarcoma was the most frequent type of malignant primary bone tumor with a poor survival rate mainly occurring in children and adolescents. For precision treatment, an accurate individualized prognosis for Osteosarcoma patients is highly desired. In recent years, many machine learning-based approaches have been used to predict distant metastasis and overall survival based on available individual information. In this study, we compared the performance of the deep belief networks (DBN) algorithm with six other machine learning algorithms, including Random Forest, XGBoost, Decision Tree, Gradient Boosting Machine, Logistic Regression, and Naive Bayes Classifier, to predict lung metastasis for Osteosarcoma patients. Therefore the DBN-based lung metastasis prediction model was integrated as a parameter into the Cox proportional hazards model to predict the overall survival of Osteosarcoma patients. The accuracy, precision, recall, and F1 score of the DBN algorithm were 0.917/0.888, 0.896/0.643, 0.956/0.900, and 0.925/0.750 in the training/validation sets, respectively, which were better than the other six machine-learning algorithms. For the performance of the DBN survival Cox model, the areas under the curve (AUCs) for the 1-, 3- and 5-year survival in the training set were 0.851, 0.806 and 0.793, respectively, indicating good discrimination, and the calibration curves showed good agreement between the prediction and actual observations. The DBN survival Cox model also demonstrated promising performance in the validation set. In addition, a nomogram integrating the DBN output was designed as a tool to aid clinical decision-making.	[Li, Wenle; Zhao, Wei] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Orthopaed Surg, Urumqi, Xinjiang, Peoples R China; [Li, Wenle] Xiamen Univ, Ctr Mol Imaging & Translat Med, Xiamen, Peoples R China; [Dong, Youzheng] Second Affiliated Hosp Nanchang Univ, Key Lab Mol Med, Nanchang, Peoples R China; [Liu, Wencai] First Affiliated Hosp Nanchang Univ, Dept Orthopaed Surg, Nanchang, Peoples R China; [Tang, Zhiri] Wuhan Univ, Sch Phys & Technol, Wuhan, Peoples R China; [Sun, Chenyu] AMITA Hlth St Joseph Hosp Chicago, Chicago, IL USA; [Lowe, Scott; Bentley, Rachel] Kansas City Univ, Coll Osteopath Med, Kansas City, MO USA; [Chen, Shuya] Newham Univ Hosp, Fdn Program, London, England; [Zhou, Qin] Mayo Clin, Radiat Oncol, Rochester, MN USA; [Xu, Chan; Li, Wanying; Wang, Bing; Liu, Qiang] Xianyang Cent Hosp, Clin Med Res Ctr, Xianyang, Peoples R China; [Wang, Haosheng] Second Hosp Jilin Univ, Dept Orthopaed, Changchun, Peoples R China; [Dong, Shengtao] Affiliated Hosp Dalian Med Univ 2, Dept Spine Surg, Dalian, Peoples R China; [Hu, Zhaohui] Liuzhou Peoples Hosp, Dept Spine Surg, Liuzhou, Peoples R China; [Cai, Xintian] Xinjiang Med Univ, Grad Sch, Urumqi, Xinjiang, Peoples R China; [Feng, Xiaowei] Shaanxi Prov Rehabil Hosp, Dept Neuro Rehabil, Xian, Peoples R China; [Yin, Chengliang] Macau Univ Sci & Technol, Fac Med, Macau, Peoples R China	Xiamen University; Wuhan University; Mayo Clinic; Jilin University; Xinjiang Medical University; Macau University of Science & Technology	Zhao, W (corresponding author), Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Orthopaed Surg, Urumqi, Xinjiang, Peoples R China.; Feng, XW (corresponding author), Shaanxi Prov Rehabil Hosp, Dept Neuro Rehabil, Xian, Peoples R China.; Yin, CL (corresponding author), Macau Univ Sci & Technol, Fac Med, Macau, Peoples R China.	fxw600@qq.com; 34302603@qq.com; chengliangyin@163.com		Lowe, Scott/0000-0002-3325-6438				Alba AC, 2017, JAMA-J AM MED ASSOC, V318, P1377, DOI 10.1001/jama.2017.12126; Augsburger M, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02728-4; Bacci G, 2008, J SURG ONCOL, V98, P415, DOI 10.1002/jso.21140; Bengio Y., 2007, LARGE SCALE KERNEL M, V34, P1, DOI [DOI 10.1038/NATURE14539, 10.1016/j.asoc.2014.05.028, DOI 10.1016/J.ASOC.2014.05.028]; Bengio Y, 2009, FOUND TRENDS MACH LE, V2, P1, DOI 10.1561/2200000006; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Brendlin AS, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003261; Cerentini A, 2017, STUD HEALTH TECHNOL, V245, P318, DOI 10.3233/978-1-61499-830-3-318; Chi SQ, 2017, CANCER MED-US, V6, P1882, DOI 10.1002/cam4.1116; Cik I., 2021, 2021 IEEE 19 WORLD S, DOI [10.1109/SAMI50585.2021.9378686, DOI 10.1109/SAMI50585.2021.9378686]; Corbin D, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-09719-3; Dancsok AR, 2017, ONCOTARGET, V8, P7068, DOI 10.18632/oncotarget.12548; El Beaino M, 2017, ANN SURG ONCOL, V24, P2145, DOI 10.1245/s10434-017-5855-x; Fayaz Begum S., 2021, ICCCE, P431, DOI [10.1007/978-981-15-7961-5_43, DOI 10.1007/978-981-15-7961-5_43]; Fessler J, 2020, J HEART LUNG TRANSPL, V39, pS385; Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705; Gronchi A, 2017, FUTURE ONCOL, V13, P13, DOI 10.2217/fon-2016-0499; Harting Matthew T, 2006, Semin Pediatr Surg, V15, P25, DOI 10.1053/j.sempedsurg.2005.11.005; Hassan MR, 2022, FUTURE GENER COMP SY, V127, P462, DOI 10.1016/j.future.2021.09.030; Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527; Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895; Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050; Joensuu H, 2012, LANCET ONCOL, V13, P265, DOI 10.1016/S1470-2045(11)70299-6; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kager L, 2017, FUTURE ONCOL, V13, P357, DOI 10.2217/fon-2016-0261; Kaur A., 2021, INT C ARTIFICIAL INT, P62, DOI [10.1007/978-3-030-95711-7_6, DOI 10.1007/978-3-030-95711-7_6]; Kawakami E, 2019, CLIN CANCER RES, V25, P3006, DOI 10.1158/1078-0432.CCR-18-3378; Kocher M, 2020, STRAHLENTHER ONKOL, V196, P856, DOI 10.1007/s00066-020-01626-8; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Lee GW, 2022, BMC NEUROL, V22, DOI 10.1186/s12883-022-02670-w; Lei T, 2021, CANCER SCI, V112, P4785, DOI 10.1111/cas.15131; Ma RZ, 2020, CURR OPIN UROL, V30, P808, DOI 10.1097/MOU.0000000000000816; Mao B, 2021, EUR RADIOL, V31, P4576, DOI 10.1007/s00330-020-07562-6; Misaghi A, 2018, SICOT-J, V4, DOI 10.1051/sicotj/2017028; Pacheco AGC, 2021, IEEE J BIOMED HEALTH, V25, P3554, DOI 10.1109/JBHI.2021.3062002; Pan LR, 2022, HEALTH INF SCI SYST, V10, DOI 10.1007/s13755-022-00174-y; Prentice RL, 2021, J AM STAT ASSOC, V116, P1330, DOI 10.1080/01621459.2020.1713792; Rainusso N, 2013, CURR ONCOL REP, V15, P296, DOI 10.1007/s11912-013-0321-9; Rusk N, 2016, NAT METHODS, V13, P35, DOI 10.1038/nmeth.3707; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Steyerberg EW, 2014, EUR HEART J, V35, P1925, DOI 10.1093/eurheartj/ehu207; Tahmassebi A, 2019, INVEST RADIOL, V54, P110, DOI 10.1097/RLI.0000000000000518; Tang Zhiri, 2021, IEEE J Biomed Health Inform, VPP, DOI 10.1109/JBHI.2021.3130028; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Wolbers M, 2009, EPIDEMIOLOGY, V20, P555, DOI 10.1097/EDE.0b013e3181a39056; Wu EQ, 2021, IEEE T COGN DEV SYST, V13, P575, DOI 10.1109/TCDS.2019.2963476; Xu YY, 2021, J MAGN RESON IMAGING, V54, P571, DOI 10.1002/jmri.27536	47	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1003347	10.3389/fimmu.2022.1003347	http://dx.doi.org/10.3389/fimmu.2022.1003347			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6WJ	36466868	Green Published, gold			2022-12-18	WOS:000893124900001
J	Li, YW; Zhu, MM; Liu, YF; Luo, BY; Cui, J; Huang, LQ; Chen, KJ; Liu, Y				Li, Yiwen; Zhu, Mengmeng; Liu, Yanfei; Luo, Binyu; Cui, Jing; Huang, Luqi; Chen, Keji; Liu, Yue			The oral microbiota and cardiometabolic health: A comprehensive review and emerging insights	FRONTIERS IN IMMUNOLOGY			English	Review						oral microbiome; cardiovascular disease; microbial metabolites; oral microbiota transplantation; periodontal disease	CHAIN FATTY-ACIDS; ACUTE MYOCARDIAL-INFARCTION; NITRIC-OXIDE; PERIODONTAL-DISEASE; GUT MICROBIOTA; PORPHYROMONAS-GINGIVALIS; DIETARY NITRATE; RECEPTOR; METABOLISM; BUTYRATE	There is mounting evidence demonstrating that oral dysbiosis causes periodontal disease and promotes the development of cardiovascular disease. The advancement of omics techniques has driven the optimization of oral microbiota species analysis and has provided a deeper understanding of oral pathogenic bacteria. A bi-directional relationship exists between the oral microbiota and the host, and oral-gut microbiota transfer is known to alter the composition of the gut microbiota and may cause local metabolic disorders. Furthermore, cardiovascular health can also be highly affected by oral microbiota functions and metabolites, including short-chain fatty acids (SCFAs), nitric oxide (NO), hydrogen sulfide (H2S), and some lipid metabolites. Studies have found that trimethylamine oxide (TMAO) may have adverse effects on cardiovascular health, whereas SCFAs, NO, and H2S have cardioprotective effects. SCFAs and H2S exert varying oral and cardiovascular effects, however reports on this specific topic remain controversial. Previous evidences are accustomed to summarizing the functions of oral microbiota in the context of periodontitis. The direct relationship between oral microbiota and cardiovascular diseases is insufficient. By systematically summarizing the methods associated with oral microbiota transplantation (OMT), this review facilitates an investigation into the causal links between oral microbiota and cardiovascular disease. The concomitant development of omics, bioinformatics, bacterial culture techniques, and microbiota transplantation techniques is required to gain a deeper understanding of the relationship between oral microbiota and cardiovascular disease occurrence.	[Li, Yiwen; Zhu, Mengmeng; Luo, Binyu; Cui, Jing; Chen, Keji; Liu, Yue] Chinese Acad Chinese Med Sci, Xiyuan Hosp, Natl Clin Res Ctr Chinese Med Cardiol, Beijing, Peoples R China; [Liu, Yanfei] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gerontol 2, Beijing, Peoples R China; [Huang, Luqi] China Acad Chinese Med Sci, China Ctr Evidence Based Med Tradit Chinese Med TC, Beijing, Peoples R China	Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences	Liu, Y (corresponding author), Chinese Acad Chinese Med Sci, Xiyuan Hosp, Natl Clin Res Ctr Chinese Med Cardiol, Beijing, Peoples R China.	liuyueheart@hotmail.com			National Natural Science Foundation of China;  [82022076]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	Funding This work was supported by the National Natural Science Foundation of China (82022076).	Abusleme L, 2013, ISME J, V7, P1016, DOI 10.1038/ismej.2012.174; Aguilar EC, 2014, NUTR METAB CARDIOVAS, V24, P606, DOI 10.1016/j.numecd.2014.01.002; Aguilar EC, 2018, NUTRITION, V47, P75, DOI 10.1016/j.nut.2017.10.007; Akamatsu Y, 2011, ARCH ORAL BIOL, V56, P1290, DOI 10.1016/j.archoralbio.2011.05.012; Atarashi K, 2017, SCIENCE, V358, P359, DOI 10.1126/science.aan4526; Authimoolam SP, 2014, BIOMACROMOLECULES, V15, P3099, DOI 10.1021/bm5006917; Lourenco TGB, 2014, J CLIN PERIODONTOL, V41, P1027, DOI 10.1111/jcpe.12302; Bai L, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.842845; Barr LA, 2015, NITRIC OXIDE-BIOL CH, V46, P145, DOI 10.1016/j.niox.2014.12.013; Basic A, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2019.1617015; Beck JD, 2020, J PERIODONTOL, V91, P1409, DOI 10.1002/JPER.19-0723; Bescos R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61912-4; Blasco-Baque V, 2017, GUT, V66, P872, DOI 10.1136/gutjnl-2015-309897; Blasco-Baque V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048220; Bochenek G, 2013, HUM MOL GENET, V22, P4516, DOI 10.1093/hmg/ddt299; Bondonno CP, 2018, MOL ASPECTS MED, V61, P83, DOI 10.1016/j.mam.2017.08.001; Bondonno CP, 2016, CRIT REV FOOD SCI, V56, P2036, DOI 10.1080/10408398.2013.811212; Campbell K, 2021, NATURE, V598, DOI 10.1038/d41586-021-02920-w; Carda-Dieguez M, 2022, MICROBIOME, V10, DOI 10.1186/s40168-022-01338-4; Cardinale JP, 2010, HYPERTENSION, V56, P437, DOI 10.1161/HYPERTENSIONAHA.110.154567; Casarin RCV, 2013, J PERIODONTAL RES, V48, P30, DOI 10.1111/j.1600-0765.2012.01498.x; Chaban B, 2015, SEMIN CELL DEV BIOL, V46, P91, DOI 10.1016/j.semcdb.2015.10.032; CHAO CK, 1990, J NUTR BIOCHEM, V1, P89, DOI 10.1016/0955-2863(90)90055-P; Chattopadhyay I, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819867354; Chauhan N, 2019, J ENDODONT, V45, P681, DOI 10.1016/j.joen.2019.03.003; Cheung MK, 2022, MICROBIOL SPECTR, V10, DOI 10.1128/spectrum.02410-21; Chhibber-Goel J, 2016, NPJ BIOFILMS MICROBI, V2, DOI 10.1038/s41522-016-0009-7; Chukkapalli SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143291; Chukkapalli SS, 2014, INFECT IMMUN, V82, P1959, DOI 10.1128/IAI.01511-14; Coggins MP, 2007, ARTERIOSCL THROM VAS, V27, P1877, DOI 10.1161/ATVBAHA.107.142943; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Cui JX, 2019, PROTEIN CELL, V10, P496, DOI 10.1007/s13238-018-0596-6; Curtis MA, 2014, J DENT RES, V93, P840, DOI 10.1177/0022034514542469; Czesnikiewicz-Guzik M, 2019, EUR HEART J, V40, P3459, DOI 10.1093/eurheartj/ehz646; de Oliveira C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2451; Dewhirst FE, 2010, J BACTERIOL, V192, P5002, DOI 10.1128/JB.00542-10; Dilek N, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105119; Divaris K, 2012, J DENT RES, V91, pS21, DOI 10.1177/0022034512447951; Dong JL, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109886; Donia MS, 2014, CELL, V158, P1402, DOI 10.1016/j.cell.2014.08.032; Donnarumma E, 2017, COMPR PHYSIOL, V7, P583, DOI 10.1002/cphy.c160023; Earl JP, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0569-2; Eisenstein Michael, 2021, Nature, DOI 10.1038/d41586-021-02918-4; Costa MJF, 2021, CLIN ORAL INVEST, V25, P797, DOI 10.1007/s00784-020-03764-w; Ford PJ, 2005, ORAL MICROBIOL IMMUN, V20, P296, DOI 10.1111/j.1399-302X.2005.00230.x; Frenkel ES, 2017, ISME J, V11, P1286, DOI 10.1038/ismej.2016.200; Gabanyi I, 2022, SCIENCE, V376, P263, DOI 10.1126/science.abj3986; Gangula P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129885; Gorini F, 2020, SCI TOTAL ENVIRON, V743, DOI 10.1016/j.scitotenv.2020.140818; Griffen AL, 2012, ISME J, V6, P1176, DOI 10.1038/ismej.2011.191; Gurav AN, 2014, EUR J CLIN INVEST, V44, P1000, DOI 10.1111/eci.12322; Hajishengallis G, 2012, MOL ORAL MICROBIOL, V27, P409, DOI 10.1111/j.2041-1014.2012.00663.x; Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001; Hajishengallis G, 2013, SEMIN IMMUNOL, V25, P65, DOI 10.1016/j.smim.2013.04.004; Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006; Hajishengallis G, 2011, NAT REV IMMUNOL, V11, P187, DOI 10.1038/nri2918; Hampelska K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082484; Han YW, 2013, J DENT RES, V92, P485, DOI 10.1177/0022034513487559; Hansson GC, 2020, ANNU REV BIOCHEM, V89, P769, DOI [10.1146/annurev-biochem-011520-105053, 10.1146/annurev-biochem-011520105053]; Hayashi C, 2010, J INNATE IMMUN, V2, P334, DOI 10.1159/000314686; Hayashi K, 2019, EXP GERONTOL, V120, P1, DOI 10.1016/j.exger.2019.02.007; Hezel MP, 2015, ORAL DIS, V21, P7, DOI 10.1111/odi.12157; Holmlund A, 2017, J DENT RES, V96, P768, DOI 10.1177/0022034517701901; Holmlund A, 2017, ATHEROSCLEROSIS, V262, P101, DOI 10.1016/j.atherosclerosis.2017.05.009; Hsu CN, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202001116; Hyde ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088645; Inui T, 2015, APPL ENVIRON MICROB, V81, P5471, DOI 10.1128/AEM.01180-15; Ishai A, 2019, JACC-CARDIOVASC IMAG, V12, P2271, DOI 10.1016/j.jcmg.2019.05.015; Isola G, 2021, MOLECULES, V26, DOI 10.3390/molecules26061777; Jones AM, 2021, MED SCI SPORT EXER, V53, P280, DOI 10.1249/MSS.0000000000002470; Kameda M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00479; Karpinski TM, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7010020; Kato T, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00460-18; Kim MH, 2013, GASTROENTEROLOGY, V145, P396, DOI 10.1053/j.gastro.2013.04.056; Kim-Shapiro DB, 2014, NITRIC OXIDE-BIOL CH, V38, P58, DOI 10.1016/j.niox.2013.11.002; Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38; Koch CD, 2017, FREE RADICAL BIO MED, V105, P48, DOI 10.1016/j.freeradbiomed.2016.12.015; Koren O, 2011, P NATL ACAD SCI USA, V108, P4592, DOI 10.1073/pnas.1011383107; Kumar PS, 2005, J CLIN MICROBIOL, V43, P3944, DOI 10.1128/JCM.43.8.3944-3955.2005; Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x; Lee YL, 2015, CLIN INTERV AGING, V10, P175, DOI 10.2147/CIA.S67854; Li GF, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1968257; Li P, 2020, NAT REV CARDIOL, V17, P96, DOI 10.1038/s41569-019-0235-9; Li Y, 2014, ISME J, V8, P1879, DOI 10.1038/ismej.2014.28; Liccardo D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061414; Liu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037919; Liu H, 2018, ADV NUTR, V9, P21, DOI 10.1093/advances/nmx009; Liu XM, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00356-0; Lonn J, 2018, J PERIODONTAL RES, V53, P403, DOI 10.1111/jre.12527; Louis P, 2017, ENVIRON MICROBIOL, V19, P29, DOI 10.1111/1462-2920.13589; Lu H., 2022, IMETA, V1, pe23, DOI [10.1002/imt2.23, DOI 10.1002/IMT2.23]; Lucchese A, 2017, AUTOIMMUN REV, V16, P456, DOI 10.1016/j.autrev.2017.03.009; Lundberg JO, 2015, NAT REV DRUG DISCOV, V14, P623, DOI 10.1038/nrd4623; Magne F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051474; Magrin GL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144895; Magrin GL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051679; Manome A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01099; Manrique P, 2013, MOL ORAL MICROBIOL, V28, P404, DOI 10.1111/omi.12033; Marchesan J, 2018, NAT PROTOC, V13, P2247, DOI 10.1038/s41596-018-0035-4; Morrison DJ, 2016, GUT MICROBES, V7, P189, DOI 10.1080/19490976.2015.1134082; Mukherjee C, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0535-z; Munz M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31980-8; Murugesan S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02291-2; Nakajima M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134234; Nascimento MM, 2014, MOL ORAL MICROBIOL, V29, P45, DOI 10.1111/omi.12044; Nearing JT, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00451-20; Nguyen K, 2020, J CARDIOVASC PHARM T, V25, P472, DOI 10.1177/1074248420923542; Norimatsu Y, 2015, MICROBIOL IMMUNOL, V59, P501, DOI 10.1111/1348-0421.12283; Nyvad B, 2020, J ORAL MICROBIOL, V12, DOI 10.1080/20002297.2019.1710953; Oliveira-Paula GH, 2019, CURR DRUG TARGETS, V20, P431, DOI 10.2174/1389450119666180816120816; Pan C, 2014, ORAL DIS, V20, P100, DOI 10.1111/odi.12081; Park SY, 2019, EUR HEART J, V40, P1138, DOI 10.1093/eurheartj/ehy836; Pignatelli P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207538; Plachokova AS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115876; Pluznick JL, 2014, GUT MICROBES, V5, P202, DOI 10.4161/gmic.27492; Pluznick JL, 2013, P NATL ACAD SCI USA, V110, P4410, DOI 10.1073/pnas.1215927110; Proctor LM, 2019, NATURE, V569, P641, DOI 10.1038/s41586-019-1238-8; Proctor LM, 2014, CELL HOST MICROBE, V16, P276, DOI 10.1016/j.chom.2014.08.014; Qiao CM, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111772; Ramos HC, 2004, TRENDS MICROBIOL, V12, P509, DOI 10.1016/j.tim.2004.09.002; Horliana ACRT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098271; Robertsson C, 2021, J ORAL MICROBIOL, V13, DOI 10.1080/20002297.2021.1967636; Salhi L, 2020, J PERIODONTOL, V91, P1453, DOI 10.1002/JPER.19-0671; Sanders ME, 2019, NAT REV GASTRO HEPAT, V16, P605, DOI 10.1038/s41575-019-0173-3; Sanz M, 2020, J CLIN PERIODONTOL, V47, P268, DOI 10.1111/jcpe.13189; Schenkein HA, 2020, PERIODONTOL 2000, V83, P90, DOI 10.1111/prd.12304; Schincaglia GP, 2017, J DENT RES, V96, P47, DOI 10.1177/0022034516668847; Schmidt TSB, 2019, ELIFE, V8, DOI 10.7554/eLife.42693; Segata N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r42; Sharma M, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01329; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sobko T, 2005, NITRIC OXIDE-BIOL CH, V13, P272, DOI 10.1016/j.niox.2005.08.002; Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x; Spychala MS, 2018, ANN NEUROL, V84, P23, DOI 10.1002/ana.25250; Stinson MW, 2003, INFECT IMMUN, V71, P2365, DOI 10.1128/IAI.71.5.2365-2372.2003; Takahashi N, 2015, J DENT RES, V94, P1628, DOI 10.1177/0022034515606045; Takahashi N, 2011, J DENT RES, V90, P1463, DOI 10.1177/0022034511423395; Takahashi N, 2011, J DENT RES, V90, P294, DOI 10.1177/0022034510379602; Tang G, 2022, BRIT J PHARMACOL, V179, P159, DOI 10.1111/bph.15693; Tian DY, 2017, FREE RADICAL BIO MED, V110, P291, DOI 10.1016/j.freeradbiomed.2017.06.016; Travers JG, 2021, CIRCULATION, V143, P1874, DOI 10.1161/CIRCULATIONAHA.120.046462; Tsai HJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082679; Usami M, 2015, WORLD J GASTROENTERO, V21, P11597, DOI 10.3748/wjg.v21.i41.11597; Verhaar BJH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102982; Wang JW, 2019, J FORMOS MED ASSOC, V118, pS23, DOI 10.1016/j.jfma.2018.08.011; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Werlang CA, 2021, NAT MICROBIOL, V6, P574, DOI 10.1038/s41564-021-00876-1; Witkowski M, 2020, CIRC RES, V127, P553, DOI 10.1161/CIRCRESAHA.120.316242; WITTER JP, 1979, APPL ENVIRON MICROB, V38, P870, DOI 10.1128/AEM.38.5.870-878.1979; Wu L, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00558-19; Xiao E, 2017, CELL HOST MICROBE, V22, P120, DOI 10.1016/j.chom.2017.06.014; Xiao HW, 2021, COMPUT STRUCT BIOTEC, V19, P5898, DOI 10.1016/j.csbj.2021.10.028; Xie LP, 2016, DIABETES, V65, P3171, DOI 10.2337/db16-0020; Xie MR, 2020, CIRC RES, V126, pE15, DOI 10.1161/CIRCRESAHA.119.315502; Yang SF, 2022, J DENT RES, V101, P590, DOI 10.1177/00220345211051967; Yang T, 2015, HYPERTENSION, V65, P1331, DOI 10.1161/HYPERTENSIONAHA.115.05315; Zhang S, 2016, ONCOL REP, V35, P2825, DOI 10.3892/or.2016.4691; Zhang X, 2015, NAT MED, V21, P895, DOI 10.1038/nm.3914; Zhang YH, 2018, BIOMED PHARMACOTHER, V99, P883, DOI 10.1016/j.biopha.2018.01.146; Zhao YQ, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/8124593; Zheng X, 2015, J DENT RES, V94, P344, DOI 10.1177/0022034514561259; Zhuang P, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01126-6; Zindel J, 2020, ANNU REV PATHOL-MECH, V15, P493, DOI 10.1146/annurev-pathmechdis-012419-032847	163	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1010368	10.3389/fimmu.2022.1010368	http://dx.doi.org/10.3389/fimmu.2022.1010368			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6JJ	36466857	gold, Green Published			2022-12-18	WOS:000893091100001
J	Niu, Q; Gao, JF; Wang, L; Liu, JX; Zhang, LY				Niu, Qing; Gao, Jinfang; Wang, Lei; Liu, Jiaxi; Zhang, Liyun			Regulation of differentiation and generation of osteoclasts in rheumatoid arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						osteoclasts; rheumatoid arthritis; bone destruction; regulation of formation and differentiation; targeted therapy	RECEPTOR TYROSINE KINASE; BONE-MINERAL DENSITY; CITRULLINATED PROTEIN ANTIBODIES; ARYL-HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR; INFLAMMATORY ARTHRITIS; NEGATIVE REGULATION; MICRORNAS MODULATE; STRUCTURAL DAMAGE; RAW264.7 CELLS	Introduction: Rheumatoid arthritis (RA), which affects nearly 1% of the world's population, is a debilitating autoimmune disease. Bone erosion caused by periarticular osteopenia and synovial pannus formation is the most destructive pathological changes of RA, also leads to joint deformity and loss of function, and ultimately affects the quality of life of patients. Osteoclasts (OCs) are the only known bone resorption cells and their abnormal differentiation and production play an important role in the occurrence and development of RA bone destruction; this remains the main culprit behind RA. Method: Based on the latest published literature and research progress at home and abroad, this paper reviews the abnormal regulation mechanism of OC generation and differentiation in RA and the possible targeted therapy. Result: OC-mediated bone destruction is achieved through the regulation of a variety of cytokines and cell-to-cell interactions, including gene transcription, epigenetics and environmental factors. At present, most methods for the treatment of RA are based on the regulation of inflammation, the inhibition of bone injury and joint deformities remains unexplored. Discussion: This article will review the mechanism of abnormal differentiation of OC in RA, and summarise the current treatment oftargeting cytokines in the process of OC generation and differentiation to reduce bone destruction in patients with RA, which isexpected to become a valuable treatment choice to inhibit bone destruction in RA.	[Niu, Qing] Shanxi Med Univ, Sch Basic Med Sci, Taiyuan, Peoples R China; [Gao, Jinfang; Wang, Lei; Liu, Jiaxi; Zhang, Liyun] Shanxi Med Univ, Hosp 3, Tongji Shanxi Hosp, Shanxi Bethune Hosp,Shanxi Acad Med Sci, Taiyuan, Peoples R China	Shanxi Medical University; Shanxi Medical University	Zhang, LY (corresponding author), Shanxi Med Univ, Hosp 3, Tongji Shanxi Hosp, Shanxi Bethune Hosp,Shanxi Acad Med Sci, Taiyuan, Peoples R China.	1315710223@qq.com			National Natural Science Foundation of China; Shanxi Provincial Key Research and Development Project; applied basic research project of Shanxi Science and Technology Department;  [81202356];  [81771768];  [81771292];  [201803D31136];  [201901D111416]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanxi Provincial Key Research and Development Project; applied basic research project of Shanxi Science and Technology Department; ; ; ; ; 	Funding Financial support for this research was provided by the National Natural Science Foundation of China (81202356, 81771768 and 81771292), Shanxi Provincial Key Research and Development Project (201803D31136), and the applied basic research project of Shanxi Science and Technology Department (201901D111416).	Abdollahi-Roodsaz S, 2008, ARTHRITIS RHEUM, V58, P3753, DOI 10.1002/art.24127; Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198; Al-Bogami M, 2021, RHEUMATOLOGY, V60, P947, DOI 10.1093/rheumatology/keaa551; Alzabin S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3875; Andersen M, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4557; Andersson A, 2016, ENDOCRINOLOGY, V157, P1013, DOI 10.1210/en.2015-1820; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105-2896.2009.00859.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brzustewicz E, 2015, CYTOKINE, V76, P527, DOI 10.1016/j.cyto.2015.08.260; Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267; Carey HA, 2019, ISCIENCE, V11, P238, DOI 10.1016/j.isci.2018.12.018; Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chiou WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089159; Chiplunkar AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054891; Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417; Cong Q, 2017, SCI REP-UK, V7, DOI 10.1038/srep45964; Coxon FP, 2008, SEMIN CELL DEV BIOL, V19, P424, DOI 10.1016/j.semcdb.2008.08.004; Cuda CM, 2016, NAT REV RHEUMATOL, V12, P543, DOI 10.1038/nrrheum.2016.132; Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis-2014-207137; Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103; Das M, 2012, CURR MOL MED, V12, P113, DOI 10.2174/156652412798889090; Das M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080908; Das M, 2019, J CELL MOL MED, V23, P1386, DOI 10.1111/jcmm.14041; Degboe Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00003; Delgado-Calle J, 2012, EPIGENETICS-US, V7, P83, DOI 10.4161/epi.7.1.18753; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004; Donate PB, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017120118; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Du NC, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106387; Duffau P, 2015, ARTHRITIS RHEUMATOL, V67, P3146, DOI 10.1002/art.39321; Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824; Feng X, 2011, ANNU REV PATHOL-MECH, V6, P121, DOI 10.1146/annurev-pathol-011110-130203; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gigliotti CL, 2016, J IMMUNOL, V197, P3905, DOI 10.4049/jimmunol.1600424; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Gravallese EM, 1998, AM J PATHOL, V152, P943; Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001; Guo YY, 2015, J THORAC DIS, V7, P471, DOI 10.3978/j.issn.2072-1439.2015.02.11; Guo YC, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3712083; Hafstrom I, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1833-y; Hah YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087733; Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651; Harre U, 2012, AUTOIMMUNITY, V45, P612, DOI 10.3109/08916934.2012.719950; Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304; Hong MH, 2000, J BONE MINER RES, V15, P911, DOI 10.1359/jbmr.2000.15.5.911; Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915; Ilvesaro J, 2005, LIFE SCI, V77, P1351, DOI 10.1016/j.lfs.2005.01.027; Iqbal J, 2013, P NATL ACAD SCI USA, V110, P11115, DOI 10.1073/pnas.1220919110; Izawa N, 2019, J BONE MINER RES, V34, P1143, DOI 10.1002/jbmr.3689; Ji JD, 2009, J IMMUNOL, V183, P7223, DOI 10.4049/jimmunol.0900072; Joosten LAB, 2000, J IMMUNOL, V165, P6553, DOI 10.4049/jimmunol.165.11.6553; Joosten LAB, 2008, ARTHRITIS RHEUM-US, V58, P98, DOI 10.1002/art.23152; Jung YH, 2007, BLOOD, V110, P82, DOI 10.1182/blood-2006-05-021352; Kagiya T, 2013, J PERIODONTAL RES, V48, P373, DOI 10.1111/jre.12017; Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200; Kawaguchi Hiroshi, 2004, Mod Rheumatol, V14, P1, DOI 10.1007/s10165-003-0257-2; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kim HB, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0762-7; Kim JH, 2018, BONE, V107, P188, DOI 10.1016/j.bone.2017.12.005; Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233; Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062; Kim KW, 2019, J BIOCHEM, V166, P259, DOI 10.1093/jb/mvz033; Kim MJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168888; Kim SJ, 2014, J IMMUNOL, V193, P3902, DOI 10.4049/jimmunol.1302998; Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046; Komatsu N, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143060; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis-2015-208093; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314; Lemke G, 2017, TRENDS BIOCHEM SCI, V42, P738, DOI 10.1016/j.tibs.2017.06.004; Li CW, 2022, CELL DEATH DIFFER, V29, P1123, DOI 10.1038/s41418-021-00904-x; Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood-2009-11-255026; Li QW, 2020, J BONE MINER RES, V35, P1597, DOI 10.1002/jbmr.4015; Li T, 2010, NAT IMMUNOL, V11, P799, DOI 10.1038/ni.1918; Li XN, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-018-0134-6; Li YN, 2022, BONE RES, V10, DOI 10.1038/s41413-022-00218-9; Li YT, 2012, ARTHRITIS RHEUM-US, V64, P3240, DOI 10.1002/art.34550; Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis-2012-201671; Liu X, 2019, INT J MOL MED, V43, P2329, DOI 10.3892/ijmm.2019.4171; Lu DZ, 2020, MOL CELL ENDOCRINOL, V508, DOI 10.1016/j.mce.2020.110791; Lu Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.684976; Lu SY, 2014, EXP CELL RES, V328, P32, DOI 10.1016/j.yexcr.2014.08.018; Lu SY, 2010, MOL BIOL CELL, V21, P1763, DOI 10.1091/mbc.E09-07-0584; Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489; Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715; Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282; Moura RA, 2013, J RHEUMATOL, V40, P1293, DOI 10.3899/jrheum.121110; Mukherjee PM, 2010, AM J ORTHOD DENTOFAC, V138, P140, DOI 10.1016/j.ajodo.2010.04.004; Mulari M, 2003, MICROSC RES TECHNIQ, V61, P496, DOI 10.1002/jemt.10371; Nakamura YS, 1998, STEM CELLS, V16, P229, DOI 10.1002/stem.160229; Nanke Y, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4874195; Negishi-Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637; Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774; Nomura K, 2008, BIOCHEM BIOPH RES CO, V367, P881, DOI 10.1016/j.bbrc.2008.01.023; O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002-9440(10)65369-2; Occhi G, 2015, ONCOTARGET, V6, P32104, DOI 10.18632/oncotarget.5194; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016; Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418-018-1636-2; Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914-017-0381-0; Onuora Sarah, 2012, Nat Rev Rheumatol, V8, P633, DOI 10.1038/nrrheum.2012.171; Orsolini G, 2017, CALCIFIED TISSUE INT, V101, P17, DOI 10.1007/s00223-017-0253-8; Ospelt C, 2008, ARTHRITIS RHEUM-US, V58, P3684, DOI 10.1002/art.24140; Ovrevik J, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0048-8; Pagani S, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/1614627; Palacios BS, 2015, J PATHOL, V235, P515, DOI 10.1002/path.4466; Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200; Park KH, 2017, AM J CHINESE MED, V45, P1725, DOI 10.1142/S0192415X17500938; Park R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102294; Parmar KM, 2005, J BIOL CHEM, V280, P26714, DOI 10.1074/jbc.C500144200; Peeters MJW, 2020, CANCER IMMUNOL IMMUN, V69, P237, DOI 10.1007/s00262-019-02421-w; Perpetuo IP, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2690402; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Presumey J, 2013, ANN RHEUM DIS, V72, P1717, DOI 10.1136/annrheumdis-2012-202403; Qin JC, 2020, PATHOL ONCOL RES, V26, P2023, DOI 10.1007/s12253-019-00663-8; Qu B, 2015, EXP CELL RES, V338, P89, DOI 10.1016/j.yexcr.2015.07.023; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Rietjens IMCM, 2013, MOL NUTR FOOD RES, V57, P100, DOI 10.1002/mnfr.201200439; Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood-2004-01-0041; Rolph D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00937; Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014; Rothlin CV, 2015, ANNU REV IMMUNOL, V33, P355, DOI 10.1146/annurev-immunol-032414-112103; Rothlin CV, 2010, CURR OPIN IMMUNOL, V22, P740, DOI 10.1016/j.coi.2010.10.001; Ruiz-Heiland G, 2014, ANN RHEUM DIS, V73, P771, DOI 10.1136/annrheumdis-2012-202907; Sargin G, 2019, EUR J RHEUMATOL, V6, P29, DOI 10.5152/eurjrheum.2018.18099; Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5; Scherer HU, 2010, ARTHRITIS RHEUM-US, V62, P1620, DOI 10.1002/art.27414; Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153; Schneider AJ, 2014, INT J MOL SCI, V15, P17852, DOI 10.3390/ijms151017852; Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110; Seibl R, 2003, AM J PATHOL, V162, P1221, DOI 10.1016/S0002-9440(10)63918-1; Self-Fordham JB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01062; Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713; Shalev M, 2021, FEBS J, V288, P4702, DOI 10.1111/febs.15778; Smart SK, 2018, CANCERS, V10, DOI 10.3390/cancers10120474; Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65; Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takeuchi T, 2017, BIOL PHARM BULL, V40, P352, DOI 10.1248/bpb.b16-00877; Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis-2018-214827; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; van de Laar L, 2016, IMMUNITY, V44, P755, DOI 10.1016/j.immuni.2016.02.017; Vomero M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01577; Voronov I, 2008, BIOCHEM PHARMACOL, V75, P2034, DOI 10.1016/j.bcp.2008.02.025; Voronov I, 2005, BIOCHEM PHARMACOL, V70, P300, DOI 10.1016/j.bcp.2005.04.028; Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847; Wang Q, 2016, TOXICOL SCI, V149, P346, DOI 10.1093/toxsci/kfv246; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599; Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/NCHEMBIO.1403, 10.1038/nchembio.1403]; Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH-22.443; Xue JM, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02308-7; Yamakawa T, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115494; Yamanaka S, 2020, BIOCHEM BIOPH RES CO, V524, P1, DOI 10.1016/j.bbrc.2019.12.049; Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310; Yudoh K, 2000, ARTHRITIS RHEUM, V43, P617, DOI 10.1002/1529-0131(200003)43:3<617::AID-ANR19>3.0.CO;2-B; Zhang LQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.132; Zhang Li Qin, 2011, J Bioanal Biomed, V3, P13; Zhang X, 2019, CLIN CHIM ACTA, V496, P76, DOI 10.1016/j.cca.2019.06.026; Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205; Zhao GJ, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6848430; Zizzo G, 2012, J IMMUNOL, V189, P3508, DOI 10.4049/jimmunol.1200662	175	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1034050	10.3389/fimmu.2022.1034050	http://dx.doi.org/10.3389/fimmu.2022.1034050			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S7KD	36466887	Green Published, gold			2022-12-18	WOS:000893160700001
J	Song, YC; Guo, WC; Li, ZP; Guo, D; Li, Z; Li, Y				Song, Yancheng; Guo, Wencong; Li, Zhaopeng; Guo, Dong; Li, Zhao; Li, Yu			Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015-2018	FRONTIERS IN IMMUNOLOGY			English	Article						systemic immune-inflammation index (SII); hepatic steatosis; non-alcoholic fatty liver disease; bariatric surgery; NHANES	FATTY LIVER; PROGNOSIS; OBESITY	BackgroundAs a novel inflammatory marker, Systemic Immune-Inflammation Index (SII) has not been studied with hepatic steatosis. The aim of this study was to investigate the possible relationship between SII and hepatic steatosis. MethodsIn the cross-sectional investigation, adults having complete information on SII, hepatic steatosis, and bariatric surgery from the 2015-2018 National Health and Nutrition Examination Survey (NHANES) were included. Hepatic steatosis was evaluated with heaptic steatosis index (HSI). The platelet count x neutrophil count/lymphocyte count was used to compute SII. We investigated the independent interaction between SII and hepatic steatosis using weighted multivariable regression analysis and subgroup analysis. To explore the potential relationship between SII, bariatric surgery and hepatic steatosis by controlling potential confounders by propensity score matching. ResultsThe study involved 10505 participants in total, 5937 (56.5%) of whom had hepatic steatosis according to the diagnosis. After adjusted for covariates, multivariable logistic regression revealed that high SII level was an independent risk factor for hepatic steatosis (OR = 1.30, 95% CI: 1.10-1.52, P 0.01). Unexpectedly, bariatric surgery reduced SII even after PSM corrected for differences of BMI and HSI. ConclusionsIn US adults, SII was positively correlated with an increase in hepatic steatosis. The SII may be a simple and affordable way to identify hepatic steatosis. Bariatric surgery may reduce SII without resorting to weight loss. This needs to be verified in additional prospective research.	[Song, Yancheng; Li, Zhaopeng; Guo, Dong; Li, Zhao; Li, Yu] Qingdao Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Qingdao, Peoples R China; [Guo, Wencong] Qingdao Univ, Affiliated Qingdao Municipal Hosp, Lab Nephrol, Qingdao, Shandong, Peoples R China; [Guo, Wencong] Qingdao Univ, Affiliated Qingdao Municipal Hosp, Dept Nephrol, Qingdao, Shandong, Peoples R China	Qingdao University; Qingdao University; Qingdao University	Li, Y (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Qingdao, Peoples R China.	liyu11920@hotmail.com						Angulo P, 2007, NUTR REV, V65, pS57, DOI 10.1301/nr.2007.jun.S57-S63; Barrea L, 2018, CRIT REV FOOD SCI, V58, P3141, DOI 10.1080/10408398.2017.1353479; Brunner KT, 2019, CURR OBES REP, V8, P220, DOI 10.1007/s13679-019-00345-1; Casagrande BP, 2020, J ENDOCRINOL, V245, P369, DOI 10.1530/JOE-20-0073; Chen JH, 2017, WORLD J GASTROENTERO, V23, P6261, DOI 10.3748/wjg.v23.i34.6261; Eren C, 2020, J PAK MED ASSOC, V70, P1746, DOI 10.5455/JPMA.27772; Ezquerro S, 2020, INT J OBESITY, V44, P475, DOI 10.1038/s41366-019-0420-2; Festi D, 2004, Obes Rev, V5, P27, DOI 10.1111/j.1467-789X.2004.00126.x; Fu HY, 2018, CELL PHYSIOL BIOCHEM, V47, P293, DOI 10.1159/000489807; Gao Y, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.640448; Hasan I, 2022, J GASTROINTEST CANC, DOI 10.1007/s12029-021-00796-7; Hu B, 2014, CLIN CANCER RES, V20, P6212, DOI 10.1158/1078-0432.CCR-14-0442; Jin WY, 2022, TURK J GASTROENTEROL, V33, P53, DOI 10.5152/tjg.2022.20715; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Lassailly G, 2020, GASTROENTEROLOGY, V159, P1290, DOI 10.1053/j.gastro.2020.06.006; Lee JH, 2010, DIGEST LIVER DIS, V42, P503, DOI 10.1016/j.dld.2009.08.002; Lieber CS, 2004, ALCOHOL, V34, P9, DOI 10.1016/j.alcohol.2004.07.008; Lu Y, 2019, ONCOTARGETS THER, V12, P7791, DOI 10.2147/OTT.S223419; Miao Y, 2016, CANCER BIOMARK, V17, P33, DOI 10.3233/CBM-160614; Qin Z, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.863640; Ren A, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/6656996; Schuster S, 2018, NAT REV GASTRO HEPAT, V15, P349, DOI 10.1038/s41575-018-0009-6; Shih KL, 2016, SCI REP-UK, V6, DOI 10.1038/srep24031; Song YC, 2022, OBES SURG, V32, P3811, DOI 10.1007/s11695-022-06284-6; Song YC, 2022, THER ADV GASTROINTES, V15, DOI 10.1177/26317745221111944; Song YC, 2021, ADIPOCYTE, V10, P424, DOI 10.1080/21623945.2021.1970341; Thavaraputta Subhanudh, 2020, Proc (Bayl Univ Med Cent), V34, P17, DOI 10.1080/08998280.2020.1799482; Tosu Aydin Rodi, 2021, Arch Med Sci Atheroscler Dis, V6, pe152, DOI 10.5114/amsad.2021.109253; Wang BL, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018571; Wang J, 2021, CLIN INTERV AGING, V16, P97, DOI 10.2147/CIA.S285000; Zhang XY, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/4369329; Zhang Z, 2022, ANN VASC SURG, V84, P322, DOI 10.1016/j.avsg.2021.12.011	32	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2022	13								1058779	10.3389/fimmu.2022.1058779	http://dx.doi.org/10.3389/fimmu.2022.1058779			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6S6UE	36466832	Green Published, gold			2022-12-18	WOS:000893119200001
